{"cfd6f06653c31766de27f2b499d1557c82ba1733": [["On March 25, 2015, the Wisconsin Division of Public Health was notified of a possible respiratory syncytial virus (RSV) infection outbreak among infants hospitalized in a neonatal intensive care unit (NICU).", [["respiratory syncytial virus (RSV) infection", "DISEASE", 86, 129], ["respiratory syncytial virus", "ORGANISM", 86, 113], ["RSV", "ORGANISM", 115, 118], ["infants", "ORGANISM", 145, 152], ["infants", "SPECIES", 145, 152], ["respiratory syncytial virus", "SPECIES", 86, 113], ["RSV", "SPECIES", 115, 118], ["respiratory syncytial virus", "PROBLEM", 86, 113], ["syncytial virus", "OBSERVATION", 98, 113]]], ["On March 23, the index patient (neonate A), aged 3 days, had feeding intolerance and apnea.", [["feeding intolerance", "DISEASE", 61, 80], ["apnea", "DISEASE", 85, 90], ["patient", "ORGANISM", 23, 30], ["patient", "SPECIES", 23, 30], ["feeding intolerance", "PROBLEM", 61, 80], ["apnea", "PROBLEM", 85, 90], ["feeding intolerance", "OBSERVATION", 61, 80]]], ["A nasopharyngeal swab specimen collected from neonate A was tested using a single-manufacturer rapid RSV antigen detection test (RRADT) at the hospital laboratory; the result was positive.", [["nasopharyngeal swab specimen", "ANATOMY", 2, 30], ["RSV antigen", "CHEMICAL", 101, 112], ["nasopharyngeal swab specimen", "CANCER", 2, 30], ["RSV", "ORGANISM", 101, 104], ["RSV", "SPECIES", 101, 104], ["A nasopharyngeal swab specimen", "TEST", 0, 30], ["nasopharyngeal", "ANATOMY", 2, 16], ["positive", "OBSERVATION", 179, 187]]], ["The following day, because of concern about the possibility of more widespread RSV infection, RRADT was used to test nasopharyngeal swab specimens from neonate B, aged 1 month, who had resided in a different hospital room in the NICU and had developed an increased oxygen requirement, apnea, and poor feeding that day, as well as from two asymptomatic neonates who were hospitalized in the same room with neonate A; all three were positive.", [["nasopharyngeal swab specimens", "ANATOMY", 117, 146], ["RSV infection", "DISEASE", 79, 92], ["oxygen", "CHEMICAL", 265, 271], ["apnea", "DISEASE", 285, 290], ["oxygen", "CHEMICAL", 265, 271], ["RSV", "ORGANISM", 79, 82], ["nasopharyngeal swab specimens", "ORGANISM_SUBSTANCE", 117, 146], ["oxygen", "SIMPLE_CHEMICAL", 265, 271], ["neonates", "ORGANISM", 352, 360], ["RSV", "SPECIES", 79, 82], ["more widespread RSV infection", "PROBLEM", 63, 92], ["test nasopharyngeal swab specimens", "TEST", 112, 146], ["an increased oxygen requirement", "PROBLEM", 252, 283], ["apnea", "PROBLEM", 285, 290], ["widespread", "OBSERVATION_MODIFIER", 68, 78], ["RSV", "OBSERVATION_MODIFIER", 79, 82], ["infection", "OBSERVATION", 83, 92], ["increased", "OBSERVATION_MODIFIER", 255, 264], ["oxygen requirement", "OBSERVATION", 265, 283]]], ["Later that day, nasopharyngeal swab specimens from the remaining 16 asymptomatic NICU patients were tested using the same RRADT; seven tests were positive, making a total of 11 positives.", [["nasopharyngeal swab specimens", "ANATOMY", 16, 45], ["nasopharyngeal swab specimens", "CANCER", 16, 45], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["nasopharyngeal swab specimens", "TEST", 16, 45], ["seven tests", "TEST", 129, 140], ["nasopharyngeal", "ANATOMY", 16, 30]]]], "PMC7481476": [["BackgroundDepression and coronary heart disease (CHD) are both common conditions and often occur together.", [["coronary", "ANATOMY", 25, 33], ["heart", "ANATOMY", 34, 39], ["BackgroundDepression", "DISEASE", 0, 20], ["coronary heart disease", "DISEASE", 25, 47], ["CHD", "DISEASE", 49, 52], ["coronary heart", "MULTI-TISSUE_STRUCTURE", 25, 39], ["BackgroundDepression", "PROBLEM", 0, 20], ["coronary heart disease", "PROBLEM", 25, 47], ["CHD", "PROBLEM", 49, 52], ["coronary heart", "ANATOMY", 25, 39], ["disease", "OBSERVATION", 40, 47]]], ["There is a complex inter-relationship between depression and CHD, where depressive illness results in cardiovascular disease and in turn heart disease causes depression (Goldston and Baillie, 2008; Seymour and Benning, 2009).", [["cardiovascular", "ANATOMY", 102, 116], ["heart", "ANATOMY", 137, 142], ["depression", "DISEASE", 46, 56], ["CHD", "DISEASE", 61, 64], ["depressive illness", "DISEASE", 72, 90], ["cardiovascular disease", "DISEASE", 102, 124], ["heart disease", "DISEASE", 137, 150], ["depression", "DISEASE", 158, 168], ["cardiovascular", "ANATOMICAL_SYSTEM", 102, 116], ["heart", "ORGAN", 137, 142], ["depression", "PROBLEM", 46, 56], ["CHD", "PROBLEM", 61, 64], ["depressive illness", "PROBLEM", 72, 90], ["cardiovascular disease", "PROBLEM", 102, 124], ["heart disease", "PROBLEM", 137, 150], ["depression", "PROBLEM", 158, 168], ["complex", "OBSERVATION_MODIFIER", 11, 18], ["depression", "OBSERVATION", 46, 56], ["cardiovascular disease", "OBSERVATION", 102, 124], ["heart", "ANATOMY", 137, 142], ["disease", "OBSERVATION", 143, 150]]], ["Increasing evidence has shown that depression can be linked to an increased risk of CHD in an independent manner, and patients with CHD and depression exhibit a higher morbidity and mortality compared with those with CHD only (Nemeroff and Goldschmidt-Clermont, 2012; Headrick et al., 2017).", [["depression", "DISEASE", 35, 45], ["CHD", "DISEASE", 84, 87], ["CHD", "DISEASE", 132, 135], ["depression", "DISEASE", 140, 150], ["CHD", "DISEASE", 217, 220], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["depression", "PROBLEM", 35, 45], ["CHD", "PROBLEM", 84, 87], ["CHD", "PROBLEM", 132, 135], ["depression", "PROBLEM", 140, 150], ["a higher morbidity", "PROBLEM", 159, 177], ["depression", "OBSERVATION", 35, 45], ["increased", "OBSERVATION_MODIFIER", 66, 75], ["CHD", "OBSERVATION", 84, 87], ["higher", "OBSERVATION_MODIFIER", 161, 167], ["morbidity", "OBSERVATION", 168, 177]]], ["As the classical emergent manifestation of CHD, acute myocardial ischemia (MI) is associated with an increased mortality risk (Wang et al., 2014).", [["myocardial", "ANATOMY", 54, 64], ["CHD", "DISEASE", 43, 46], ["acute myocardial ischemia", "DISEASE", 48, 73], ["MI", "DISEASE", 75, 77], ["myocardial", "MULTI-TISSUE_STRUCTURE", 54, 64], ["CHD", "PROBLEM", 43, 46], ["acute myocardial ischemia", "PROBLEM", 48, 73], ["MI", "PROBLEM", 75, 77], ["an increased mortality risk", "PROBLEM", 98, 125], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["myocardial", "ANATOMY", 54, 64], ["ischemia", "OBSERVATION", 65, 73], ["increased", "OBSERVATION_MODIFIER", 101, 110], ["mortality", "OBSERVATION", 111, 120]]], ["Depression is an important clinical issue in MI patients due to its extreme commonness, and the comorbidity complicates the depression treatment and worsens the cardiovascular prognosis (Shapiro, 2015).", [["cardiovascular", "ANATOMY", 161, 175], ["Depression", "DISEASE", 0, 10], ["MI", "DISEASE", 45, 47], ["depression", "DISEASE", 124, 134], ["patients", "ORGANISM", 48, 56], ["cardiovascular", "ANATOMICAL_SYSTEM", 161, 175], ["patients", "SPECIES", 48, 56], ["Depression", "PROBLEM", 0, 10], ["its extreme commonness", "PROBLEM", 64, 86], ["the comorbidity", "PROBLEM", 92, 107], ["the depression treatment", "TREATMENT", 120, 144]]], ["Although many therapeutic strategies have been used to treat CHD or MI patients with depression (Colquhoun et al., 2013), such as psychological therapy (cognitive-behavioral therapy and interpersonal psychotherapy) and pharmacological therapy (fluoxetine, sertraline, citalopram, and mirtazapine), clinical outcomes remain unsatisfied, which can be mainly attributed to the unavoidable adverse effects of these treatments.", [["CHD", "DISEASE", 61, 64], ["MI", "DISEASE", 68, 70], ["depression", "DISEASE", 85, 95], ["fluoxetine", "CHEMICAL", 244, 254], ["sertraline", "CHEMICAL", 256, 266], ["citalopram", "CHEMICAL", 268, 278], ["mirtazapine", "CHEMICAL", 284, 295], ["fluoxetine", "CHEMICAL", 244, 254], ["sertraline", "CHEMICAL", 256, 266], ["citalopram", "CHEMICAL", 268, 278], ["mirtazapine", "CHEMICAL", 284, 295], ["patients", "ORGANISM", 71, 79], ["fluoxetine", "SIMPLE_CHEMICAL", 244, 254], ["sertraline", "SIMPLE_CHEMICAL", 256, 266], ["citalopram", "SIMPLE_CHEMICAL", 268, 278], ["mirtazapine", "SIMPLE_CHEMICAL", 284, 295], ["patients", "SPECIES", 71, 79], ["CHD", "PROBLEM", 61, 64], ["MI", "PROBLEM", 68, 70], ["depression", "PROBLEM", 85, 95], ["psychological therapy", "TREATMENT", 130, 151], ["behavioral therapy", "TREATMENT", 163, 181], ["interpersonal psychotherapy", "TREATMENT", 186, 213], ["pharmacological therapy", "TREATMENT", 219, 242], ["fluoxetine", "TREATMENT", 244, 254], ["sertraline", "TREATMENT", 256, 266], ["citalopram", "TREATMENT", 268, 278], ["mirtazapine", "TREATMENT", 284, 295], ["these treatments", "TREATMENT", 405, 421]]], ["Therefore, a great deal of efforts have been made to develop efficient therapies based on traditional Chinese medicine (TCM), which is a crucial part of complementary and alternative medicines (Francis et al., 2015), and in some parts, its multi-components with the multi-target characteristics may contribute to complex somatopsychic illness (Wang et al., 2012).", [["somatopsychic illness", "DISEASE", 321, 342], ["efficient therapies", "TREATMENT", 61, 80], ["traditional Chinese medicine", "TREATMENT", 90, 118], ["complex somatopsychic illness", "PROBLEM", 313, 342]]], ["The TCM Kai-Xin-San (KXS) is composed of ginseng (Panax ginseng C.A. Meyer), hoelen (Poria cocos F.A. Wolf), polygala (Polygala tenuifolia Willd), and acorus (Acorus calamus var. angustatus Besser syn.", [["ginseng", "ORGANISM", 41, 48], ["Polygala tenuifolia Willd", "ORGANISM", 119, 144], ["acorus", "ORGANISM", 151, 157], ["Acorus calamus", "ORGANISM", 159, 173], ["var", "ORGANISM", 174, 177], ["ginseng", "SPECIES", 41, 48], ["Panax ginseng", "SPECIES", 50, 63], ["hoelen", "SPECIES", 77, 83], ["Poria cocos", "SPECIES", 85, 96], ["Polygala tenuifolia", "SPECIES", 119, 138], ["Acorus calamus", "SPECIES", 159, 173], ["Panax ginseng C.A. Meyer)", "SPECIES", 50, 75], ["Poria cocos", "SPECIES", 85, 96], ["Polygala tenuifolia", "SPECIES", 119, 138], ["Acorus calamus", "SPECIES", 159, 173], ["The TCM", "TEST", 0, 7], ["polygala (Polygala tenuifolia Willd", "TREATMENT", 109, 144], ["acorus (Acorus calamus var", "TREATMENT", 151, 177], ["acorus", "ANATOMY", 151, 157], ["Acorus calamus", "ANATOMY", 159, 173]]], ["Acorus tatarinowii Schott) with a ratio of 3:3:2:2 (Hu et al., 2013a; Hu et al., 2013b), which was first recorded in Thousand Formulae for Emergency (Bei Ji Qian Jin Yao Fang) by Sun Si Miao.", [["Acorus tatarinowii", "SPECIES", 0, 18], ["Acorus tatarinowii", "SPECIES", 0, 18], ["Bei Ji Qian Jin Yao Fang", "SPECIES", 150, 174], ["a ratio", "TEST", 32, 39]]], ["This formula is widely used in Asia, especially in China, and KXS is effective in treating depression-associated deficits of learning and memory.", [["KXS", "CHEMICAL", 62, 65], ["depression", "DISEASE", 91, 101], ["deficits of learning and memory", "DISEASE", 113, 144], ["depression", "PROBLEM", 91, 101]]], ["In our previous studies, we have proved its antidepressive effect using different animal models, such as the chronic mild stress (CMS) challenge, tail-suspension test, and forced swim test (Cao et al., 2012; Zhou et al., 2012; Dong et al., 2013).", [["its antidepressive effect", "PROBLEM", 40, 65], ["the chronic mild stress (CMS) challenge", "PROBLEM", 105, 144], ["tail-suspension test", "TEST", 146, 166], ["forced swim test", "TEST", 172, 188], ["chronic", "OBSERVATION_MODIFIER", 109, 116], ["mild", "OBSERVATION_MODIFIER", 117, 121], ["stress", "OBSERVATION", 122, 128]]], ["KXS is effective in improving behavior disorders by activating TrkB/ERK/CREB/BDNF and TrkB/PI3 K/CREB/BDNF pathways and influencing various inflammatory pathways, such as IL-6 and TNF-\u03b1 (Dong et al., 2016).", [["KXS", "CHEMICAL", 0, 3], ["KXS", "SIMPLE_CHEMICAL", 0, 3], ["TrkB", "GENE_OR_GENE_PRODUCT", 63, 67], ["ERK", "GENE_OR_GENE_PRODUCT", 68, 71], ["CREB", "GENE_OR_GENE_PRODUCT", 72, 76], ["BDNF", "GENE_OR_GENE_PRODUCT", 77, 81], ["TrkB", "GENE_OR_GENE_PRODUCT", 86, 90], ["PI3 K", "GENE_OR_GENE_PRODUCT", 91, 96], ["CREB", "GENE_OR_GENE_PRODUCT", 97, 101], ["BDNF", "GENE_OR_GENE_PRODUCT", 102, 106], ["IL-6", "GENE_OR_GENE_PRODUCT", 171, 175], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 180, 185], ["TrkB", "PROTEIN", 63, 67], ["ERK", "PROTEIN", 68, 71], ["CREB", "PROTEIN", 72, 76], ["BDNF", "PROTEIN", 77, 81], ["TrkB", "PROTEIN", 86, 90], ["PI3 K", "PROTEIN", 91, 96], ["CREB", "PROTEIN", 97, 101], ["BDNF", "PROTEIN", 102, 106], ["IL-6", "PROTEIN", 171, 175], ["TNF", "PROTEIN", 180, 183], ["improving behavior disorders", "PROBLEM", 20, 48], ["CREB/BDNF", "TEST", 72, 81], ["TrkB", "TEST", 86, 90], ["CREB/BDNF pathways", "TEST", 97, 115], ["influencing various inflammatory pathways", "PROBLEM", 120, 161], ["IL", "TEST", 171, 173], ["inflammatory", "OBSERVATION_MODIFIER", 140, 152]]], ["In the present study, we further explored Shen-Zhi-Ling (SZL) tablets, which are the proprietary Chinese medicines based on KXS decoction, and verified its safety and efficacy in patients with depression (unpublished data).", [["depression", "DISEASE", 193, 203], ["SZL", "SIMPLE_CHEMICAL", 57, 60], ["patients", "ORGANISM", 179, 187], ["patients", "SPECIES", 179, 187], ["Shen-Zhi-Ling (SZL) tablets", "TREATMENT", 42, 69], ["Chinese medicines", "TREATMENT", 97, 114], ["KXS decoction", "TREATMENT", 124, 137], ["depression", "PROBLEM", 193, 203]]], ["Huang YF (Huang et al., 2000) et al. have found the protective effect of KXS on kidney in rats using ischemia-reperfusion injury model.", [["kidney", "ANATOMY", 80, 86], ["KXS", "CHEMICAL", 73, 76], ["ischemia-reperfusion injury", "DISEASE", 101, 128], ["KXS", "CHEMICAL", 73, 76], ["KXS", "SIMPLE_CHEMICAL", 73, 76], ["kidney", "ORGAN", 80, 86], ["rats", "ORGANISM", 90, 94], ["rats", "SPECIES", 90, 94], ["KXS on kidney in rats", "TREATMENT", 73, 94], ["ischemia-reperfusion injury model", "PROBLEM", 101, 134], ["kidney", "ANATOMY", 80, 86], ["ischemia-reperfusion injury", "OBSERVATION", 101, 128]]], ["KXS can increase SOD and NO activities, decrease MDA content and improve kidney tissues.", [["kidney tissues", "ANATOMY", 73, 87], ["KXS", "CHEMICAL", 0, 3], ["NO", "CHEMICAL", 25, 27], ["MDA", "CHEMICAL", 49, 52], ["NO", "CHEMICAL", 25, 27], ["MDA", "CHEMICAL", 49, 52], ["KXS", "SIMPLE_CHEMICAL", 0, 3], ["SOD", "SIMPLE_CHEMICAL", 17, 20], ["NO", "SIMPLE_CHEMICAL", 25, 27], ["MDA", "SIMPLE_CHEMICAL", 49, 52], ["kidney tissues", "TISSUE", 73, 87], ["SOD", "PROTEIN", 17, 20], ["kidney tissues", "ANATOMY", 73, 87]]], ["These finding suggest that KXS can protect the blood vessels effectively.", [["blood vessels", "ANATOMY", 47, 60], ["KXS", "CHEMICAL", 27, 30], ["KXS", "SIMPLE_CHEMICAL", 27, 30], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 47, 60], ["blood vessels", "ANATOMY", 47, 60]]], ["Here, we hypothesized that KXS might balance psychosomatic status and effectively relieve symptoms of CHD with depression.", [["KXS", "CHEMICAL", 27, 30], ["CHD", "DISEASE", 102, 105], ["depression", "DISEASE", 111, 121], ["symptoms", "PROBLEM", 90, 98], ["CHD", "PROBLEM", 102, 105], ["depression", "PROBLEM", 111, 121]]], ["In this study, we investigated whether KXS possessed both antidepressive effects and cardioprotective functions.Preparation of KXS ::: MethodsKXS, supplied in the form of a powdered herbal extract, was obtained from Beijing Tongrentang Drug Store (Beijing, China).", [["extract", "ANATOMY", 189, 196], ["KXS", "CHEMICAL", 39, 42], ["MethodsKXS", "CHEMICAL", 135, 145], ["KXS", "SIMPLE_CHEMICAL", 39, 42], ["MethodsKXS", "SIMPLE_CHEMICAL", 135, 145], ["this study", "TEST", 3, 13], ["KXS", "TEST", 39, 42], ["MethodsKXS", "TREATMENT", 135, 145], ["a powdered herbal extract", "TREATMENT", 171, 196]]], ["All KXS formulations were provided by the Chengdu Luye Medicinal Material Plantation Co., Chengdu, China.", [["All KXS formulations", "TREATMENT", 0, 20]]], ["The voucher specimens of the four plants, identified by Professor Ping Liu and registered under the numbers NU\u221290111, NU\u221282003, NU\u221279015 and NU\u221280617, respectively, were preserved at the pharmacy of the Herbarium of Traditional Chinese Medicinal (TCM), Chinese People\u2019s Liberation Army (PLA) General Hospital (Beijing, China).", [["specimens", "ANATOMY", 12, 21], ["NU\u221290111", "CHEMICAL", 108, 116], ["NU\u221282003", "CHEMICAL", 118, 126], ["NU\u221279015", "CHEMICAL", 128, 136], ["NU\u221280617", "CHEMICAL", 141, 149], ["NU\u221282003", "CHEMICAL", 118, 126], ["NU\u221279015", "CHEMICAL", 128, 136], ["NU\u221280617", "CHEMICAL", 141, 149], ["NU\u221282003", "CELL", 118, 126], ["NU\u221279015", "CELL", 128, 136], ["NU\u221280617", "CELL", 141, 149], ["People", "SPECIES", 261, 267], ["NU", "TEST", 118, 120]]], ["The total extract was prepared as previously reported (Cao et al., 2012).", [["extract", "ANATOMY", 10, 17]]], ["Averagely, 1 g yielded KXS powder equaled to 4.83 g total herbs.", [["KXS", "CHEMICAL", 23, 26], ["KXS powder", "TREATMENT", 23, 33]]], ["The standardization of KXS was ensured by determining its chemical fingerprinting according to our previous study (Hu Y. et al., 2014).", [["KXS", "DNA", 23, 26], ["The standardization of KXS", "TEST", 0, 26], ["our previous study", "TEST", 95, 113]]], ["Thin-layer chromatography (TLC) of the total extract and each herb showed in supplement 1.Animals ::: MethodsMale Sprague-Dawley (SD) rats, weighing 250\u2013270 g, were used for the experimental procedures.", [["extract", "ANATOMY", 45, 52], ["Sprague-Dawley (SD) rats", "ORGANISM", 114, 138], ["rats", "SPECIES", 134, 138], ["Thin-layer chromatography", "TEST", 0, 25], ["the total extract", "TREATMENT", 35, 52], ["the experimental procedures", "TREATMENT", 174, 201]]], ["Rats were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. and given 3 days to acclimate to the housing facility.", [["Rats", "ORGANISM", 0, 4], ["Rats", "SPECIES", 0, 4]]], ["Animals were housed in 475 \u00d7 345 \u00d7 200 mm cages and given free access to food and water.", [["Animals", "ORGANISM", 0, 7]]], ["A total of 50 SD rats were randomly and evenly divided into five groups (n=10) as follows: normal control (control group), isopropyl adrenaline (ISO) model (MI group), CMS model (depression group), MI+ depression (model group) and MI+ depression treated with intragastric administration of 1,785 mg total herbs/kg KXS (about 370 mg/kg KXS, KXS group), and the antidepressive effect of KXS at such dosage has been proved in several previous studies (Hu et al., 2013a; Dong et al., 2016).", [["adrenaline", "CHEMICAL", 133, 143], ["ISO", "CHEMICAL", 145, 148], ["depression", "DISEASE", 179, 189], ["MI", "DISEASE", 198, 200], ["depression", "DISEASE", 202, 212], ["MI", "DISEASE", 231, 233], ["depression", "DISEASE", 235, 245], ["KXS", "CHEMICAL", 314, 317], ["KXS", "CHEMICAL", 385, 388], ["isopropyl adrenaline", "CHEMICAL", 123, 143], ["ISO", "CHEMICAL", 145, 148], ["rats", "ORGANISM", 17, 21], ["isopropyl adrenaline", "SIMPLE_CHEMICAL", 123, 143], ["KXS", "SIMPLE_CHEMICAL", 385, 388], ["rats", "SPECIES", 17, 21], ["isopropyl adrenaline (ISO) model (MI group)", "TREATMENT", 123, 166], ["CMS model (depression group)", "PROBLEM", 168, 196], ["MI", "PROBLEM", 198, 200], ["depression", "PROBLEM", 202, 212], ["MI", "PROBLEM", 231, 233], ["depression", "PROBLEM", 235, 245], ["intragastric administration", "TREATMENT", 259, 286], ["KXS", "TREATMENT", 314, 317], ["KXS", "TREATMENT", 385, 388], ["depression", "OBSERVATION", 202, 212], ["depression", "OBSERVATION", 235, 245]]], ["Except for the KXS group, other groups were given the same volume of saline by intragastric administration.", [["saline", "SIMPLE_CHEMICAL", 69, 75], ["intragastric", "IMMATERIAL_ANATOMICAL_ENTITY", 79, 91], ["the same volume of saline", "TREATMENT", 50, 75], ["intragastric administration", "TREATMENT", 79, 106]]], ["Rats in all other groups were challenged with the same CMS for 49 days, except for the control group.", [["Rats", "ORGANISM", 0, 4], ["Rats", "SPECIES", 0, 4]]], ["Behavioral tests, including open-field and sucrose preference tests, were performed during the experiment.", [["sucrose", "CHEMICAL", 43, 50], ["sucrose", "CHEMICAL", 43, 50], ["Behavioral tests", "TEST", 0, 16], ["open-field and sucrose preference tests", "TEST", 28, 67]]], ["For the KXS group, rats were administered by gavage with KXS dissolved in distilled water once a day for 21 days after 28 days of CMS challenge, and meanwhile, the rats were continuously challenged with CMS.", [["KXS", "CHEMICAL", 57, 60], ["KXS", "SIMPLE_CHEMICAL", 8, 11], ["rats", "ORGANISM", 19, 23], ["KXS", "SIMPLE_CHEMICAL", 57, 60], ["rats", "ORGANISM", 164, 168], ["rats", "SPECIES", 19, 23], ["rats", "SPECIES", 164, 168], ["KXS", "TREATMENT", 57, 60], ["CMS challenge", "TREATMENT", 130, 143]]], ["In order to establish MI and MI+ depression models, rats were fixed in the supine position, and 85 mg/kg ISO (Sigma-Aldrich, St. Louis, MO, USA) was subcutaneously injected on the limb roots and back in three consecutive days (Cheng et al., 2013).", [["subcutaneously", "ANATOMY", 149, 163], ["limb roots", "ANATOMY", 180, 190], ["MI", "DISEASE", 22, 24], ["MI", "DISEASE", 29, 31], ["depression", "DISEASE", 33, 43], ["ISO", "CHEMICAL", 105, 108], ["ISO", "CHEMICAL", 105, 108], ["rats", "ORGANISM", 52, 56], ["limb roots", "ORGANISM_SUBDIVISION", 180, 190], ["rats", "SPECIES", 52, 56], ["MI", "PROBLEM", 22, 24], ["MI", "PROBLEM", 29, 31], ["depression models", "PROBLEM", 33, 50], ["St. Louis, MO, USA)", "TREATMENT", 125, 144], ["limb roots", "ANATOMY", 180, 190], ["back", "ANATOMY", 195, 199]]], ["The MI model was verified by echocardiography as well as the levels of serum creatine kinase MB (CK-MB) and lactate dehydrogenase (LDH).", [["serum", "ANATOMY", 71, 76], ["MI", "DISEASE", 4, 6], ["creatine", "CHEMICAL", 77, 85], ["lactate", "CHEMICAL", 108, 115], ["creatine", "CHEMICAL", 77, 85], ["lactate", "CHEMICAL", 108, 115], ["serum", "ORGANISM_SUBSTANCE", 71, 76], ["creatine kinase MB", "GENE_OR_GENE_PRODUCT", 77, 95], ["CK-MB", "GENE_OR_GENE_PRODUCT", 97, 102], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 108, 129], ["LDH", "GENE_OR_GENE_PRODUCT", 131, 134], ["serum creatine kinase MB", "PROTEIN", 71, 95], ["CK", "PROTEIN", 97, 99], ["lactate dehydrogenase", "PROTEIN", 108, 129], ["LDH", "PROTEIN", 131, 134], ["The MI model", "TEST", 0, 12], ["echocardiography", "TEST", 29, 45], ["the levels", "TEST", 57, 67], ["serum creatine kinase MB", "TEST", 71, 95], ["CK-MB", "TEST", 97, 102], ["lactate dehydrogenase", "TEST", 108, 129], ["LDH", "TEST", 131, 134]]], ["At the end of the trial, the rats were sacrificed by cervical dislocation.", [["cervical", "ANATOMY", 53, 61], ["cervical dislocation", "DISEASE", 53, 73], ["rats", "ORGANISM", 29, 33], ["cervical", "ORGAN", 53, 61], ["rats", "SPECIES", 29, 33], ["cervical dislocation", "PROBLEM", 53, 73], ["cervical", "ANATOMY", 53, 61], ["dislocation", "OBSERVATION", 62, 73]]], ["At day 49, the rats were anesthetized rats (10% chloral hydrate, 350 mg/kg) and sacrificed by cervical dislocation.", [["cervical", "ANATOMY", 94, 102], ["chloral hydrate", "CHEMICAL", 48, 63], ["cervical dislocation", "DISEASE", 94, 114], ["chloral hydrate", "CHEMICAL", 48, 63], ["rats", "ORGANISM", 15, 19], ["rats", "ORGANISM", 38, 42], ["chloral hydrate", "SIMPLE_CHEMICAL", 48, 63], ["cervical", "ORGAN", 94, 102], ["rats", "SPECIES", 15, 19], ["rats", "SPECIES", 38, 42], ["anesthetized rats", "TREATMENT", 25, 42], ["10% chloral hydrate", "TREATMENT", 44, 63], ["cervical dislocation", "PROBLEM", 94, 114], ["cervical", "ANATOMY", 94, 102], ["dislocation", "OBSERVATION", 103, 114]]], ["Rats no exhibited signs of peritonitis after the administration of 10% chloral hydrate.CMS Model ::: MethodsIn the present study, the CMS model was employed as a validated animal model of depression (Wang et al.).", [["peritonitis", "DISEASE", 27, 38], ["chloral hydrate", "CHEMICAL", 71, 86], ["depression", "DISEASE", 188, 198], ["chloral hydrate", "CHEMICAL", 71, 86], ["Rats", "ORGANISM", 0, 4], ["chloral hydrate", "SIMPLE_CHEMICAL", 71, 86], ["Rats", "SPECIES", 0, 4], ["peritonitis", "PROBLEM", 27, 38], ["10% chloral hydrate", "TREATMENT", 67, 86], ["Methods", "TREATMENT", 101, 108], ["the present study", "TEST", 111, 128], ["depression", "PROBLEM", 188, 198], ["peritonitis", "OBSERVATION", 27, 38]]], ["All rats were challenged with the following stressors (Hu et al., 2013a), including repeated confinement to a small (38 \u00d7 20 \u00d7 16 cm) cage, restraint (1 h), water deprivation (24 h), food deprivation (24 h), isolation (24 h), flashing light (3 h), forced cold-water swimming (10 min) or group-housed in a soiled cage overnight.", [["rats", "ORGANISM", 4, 8], ["rats", "SPECIES", 4, 8], ["restraint", "TREATMENT", 140, 149]]], ["Above-mentioned stressors were given every day for 49 days in a random and unpredictable order.Open-Field Test and Sucrose Consumption Test ::: MethodsThe open-field test (Yan et al.) and sucrose consumption test (Dang et al., 2009) were employed to assess the behavior and anhedonic-like state of all rats.", [["sucrose", "CHEMICAL", 188, 195], ["Sucrose", "CHEMICAL", 115, 122], ["sucrose", "CHEMICAL", 188, 195], ["sucrose", "SIMPLE_CHEMICAL", 188, 195], ["rats", "ORGANISM", 302, 306], ["rats", "SPECIES", 302, 306], ["Open-Field Test", "TEST", 95, 110], ["The open-field test", "TEST", 151, 170], ["sucrose consumption test", "TEST", 188, 212]]], ["These tests were performed on day 0, 28 and 49 during the experiment.", [["These tests", "TEST", 0, 11]]], ["For open-field test, the emotional state, including assessment of horizontal movements (the total number of crossing squares) and vertical movements (grooming and rearing), during a period of 5 min was recorded as the behavioral response to a new environment.", [["open-field test", "TEST", 4, 19], ["horizontal movements", "PROBLEM", 66, 86]]], ["A special white square consisting of 25 sectors with black stripes on the ground was used (80 \u00d7 80 \u00d7 40 cm) in the test.", [["black stripes", "TREATMENT", 53, 66], ["the test", "TEST", 111, 119]]], ["Animals were individually placed in the same central sector, and a video camera was used to record their activity during a period of 5 min.", [["Animals", "ORGANISM", 0, 7], ["a video camera", "TEST", 65, 79]]], ["Subsequently, the results of video tapes were analyzed by observers (ANYmaze, Stoelting Co., USA).Open-Field Test and Sucrose Consumption Test ::: MethodsSucrose consumption test is a trial reflecting the anhedonic-like state of animals.", [["Sucrose", "CHEMICAL", 118, 125], ["MethodsSucrose", "SIMPLE_CHEMICAL", 147, 161], ["video tapes", "TEST", 29, 40], ["MethodsSucrose consumption test", "TEST", 147, 178]]], ["Rats were deprived of food and water for 24 h prior to sucrose consumption test, and then they were fed with two pre-weighted bottles containing either 1% sucrose solution or water for 1 h.", [["sucrose", "CHEMICAL", 55, 62], ["sucrose", "CHEMICAL", 155, 162], ["sucrose", "CHEMICAL", 55, 62], ["sucrose", "CHEMICAL", 155, 162], ["Rats", "ORGANISM", 0, 4], ["sucrose", "SIMPLE_CHEMICAL", 55, 62], ["sucrose", "SIMPLE_CHEMICAL", 155, 162], ["Rats", "SPECIES", 0, 4], ["sucrose consumption test", "TEST", 55, 79], ["two pre-weighted bottles", "TREATMENT", 109, 133], ["1% sucrose solution", "TREATMENT", 152, 171]]], ["Water intake was determined by weighing the bottles before and after each test.", [["each test", "TEST", 69, 78]]], ["All tests were carried out in the home cage, by which the extraneous novelty and disturbance were minimized.", [["All tests", "TEST", 0, 9]]], ["The sucrose preference was calculated as sucrose intake/total water intake (sucrose intake+water intake)(Chen et al.).Echocardiographic Determination ::: MethodsThe hairs on the chest of anesthetized rats were removed with depilatory paste (Strep Co., Milan, Italy).", [["hairs", "ANATOMY", 165, 170], ["chest", "ANATOMY", 178, 183], ["sucrose", "CHEMICAL", 4, 11], ["sucrose", "CHEMICAL", 41, 48], ["sucrose", "CHEMICAL", 76, 83], ["sucrose", "CHEMICAL", 4, 11], ["sucrose", "CHEMICAL", 41, 48], ["sucrose", "CHEMICAL", 76, 83], ["sucrose", "SIMPLE_CHEMICAL", 4, 11], ["sucrose", "SIMPLE_CHEMICAL", 41, 48], ["water", "SIMPLE_CHEMICAL", 62, 67], ["sucrose", "SIMPLE_CHEMICAL", 76, 83], ["hairs", "MULTI-TISSUE_STRUCTURE", 165, 170], ["chest", "ORGANISM_SUBDIVISION", 178, 183], ["rats", "ORGANISM", 200, 204], ["rats", "SPECIES", 200, 204], ["The sucrose preference", "TREATMENT", 0, 22], ["anesthetized rats", "TREATMENT", 187, 204], ["depilatory paste", "TREATMENT", 223, 239], ["chest", "ANATOMY", 178, 183]]], ["Subsequently, rats were placed on the scanning platform of a high-resolution ultrasound system in the supine position (VisualSonics Corporation Vero 770, Canada).", [["rats", "ORGANISM", 14, 18], ["rats", "SPECIES", 14, 18]]], ["The chest of each rat was covered with a layer of ultrasonic coupling agent.", [["chest", "ANATOMY", 4, 9], ["chest", "ORGAN", 4, 9], ["rat", "ORGANISM", 18, 21], ["rat", "SPECIES", 18, 21], ["rat", "SPECIES", 18, 21], ["a layer of ultrasonic coupling agent", "TREATMENT", 39, 75], ["chest", "ANATOMY", 4, 9]]], ["M-mode echocardiography was conducted to determine cardiac parameters, including length of left ventricular internal diameter at end-diastole (LVIDd), length of left ventricular internal diameter at end-systole (LVIDs), ratio of stoke volume at left ventricular end diastolic volume (ejection fraction, EF), and (LVIDd-LVIDs)/LVIDs (fractional shortening, FS)Measurement of Cardiac Marker Enzymes ::: MethodsAfter the ECG detection, arterial blood samples were collected and centrifuged at 3,000 rpm for 15 min, and serum was collected and then stored at \u221280\u00b0C. Serum samples were thawed at room temperature before analysis.", [["cardiac", "ANATOMY", 51, 58], ["left ventricular", "ANATOMY", 91, 107], ["left ventricular", "ANATOMY", 161, 177], ["left ventricular", "ANATOMY", 245, 261], ["arterial blood samples", "ANATOMY", 433, 455], ["serum", "ANATOMY", 516, 521], ["Serum samples", "ANATOMY", 562, 575], ["cardiac", "ORGAN", 51, 58], ["ventricular internal", "MULTI-TISSUE_STRUCTURE", 96, 116], ["ventricular internal", "MULTI-TISSUE_STRUCTURE", 166, 186], ["ventricular", "MULTI-TISSUE_STRUCTURE", 250, 261], ["arterial blood samples", "ORGANISM_SUBSTANCE", 433, 455], ["serum", "ORGANISM_SUBSTANCE", 516, 521], ["Serum samples", "ORGANISM_SUBSTANCE", 562, 575], ["M-mode echocardiography", "TEST", 0, 23], ["cardiac parameters", "TEST", 51, 69], ["length", "TEST", 151, 157], ["ratio", "TEST", 220, 225], ["stoke volume", "TEST", 229, 241], ["left ventricular end diastolic volume", "TEST", 245, 282], ["ejection fraction", "TEST", 284, 301], ["EF", "TEST", 303, 305], ["LVIDd", "TEST", 313, 318], ["LVIDs", "TEST", 319, 324], ["LVIDs", "TEST", 326, 331], ["fractional shortening", "PROBLEM", 333, 354], ["FS", "TEST", 356, 358], ["Cardiac Marker Enzymes", "TEST", 374, 396], ["the ECG detection", "TEST", 414, 431], ["arterial blood samples", "TEST", 433, 455], ["serum", "TEST", 516, 521], ["Serum samples", "TEST", 562, 575], ["analysis", "TEST", 615, 623], ["left ventricular", "ANATOMY", 91, 107], ["internal", "ANATOMY_MODIFIER", 108, 116], ["diameter", "OBSERVATION_MODIFIER", 117, 125], ["diastole", "OBSERVATION", 133, 141], ["length", "OBSERVATION_MODIFIER", 151, 157], ["left ventricular", "ANATOMY", 161, 177], ["internal", "ANATOMY_MODIFIER", 178, 186], ["diameter", "OBSERVATION_MODIFIER", 187, 195], ["systole", "ANATOMY_MODIFIER", 203, 210], ["stoke volume", "OBSERVATION", 229, 241], ["left ventricular", "ANATOMY", 245, 261], ["diastolic volume", "OBSERVATION", 266, 282], ["ejection fraction", "OBSERVATION", 284, 301], ["arterial", "ANATOMY", 433, 441]]], ["The serum levels of CK-MB and LDH were determined by commercial kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) to evaluate the myocardial damage according to the manufacturer\u2019s instructions.Measurement of Antioxidant Enzymes and Inflammation Assay ::: MethodsActivities of SOD, MDA, CAT, and GSH-Px in myocardial tissue were determined using commercial kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) according to the manufacturer\u2019s instructions.", [["serum", "ANATOMY", 4, 9], ["myocardial", "ANATOMY", 146, 156], ["myocardial tissue", "ANATOMY", 321, 338], ["myocardial damage", "DISEASE", 146, 163], ["GSH", "CHEMICAL", 311, 314], ["MDA", "CHEMICAL", 297, 300], ["GSH", "CHEMICAL", 311, 314], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["CK-MB", "GENE_OR_GENE_PRODUCT", 20, 25], ["LDH", "SIMPLE_CHEMICAL", 30, 33], ["myocardial", "MULTI-TISSUE_STRUCTURE", 146, 156], ["SOD", "SIMPLE_CHEMICAL", 292, 295], ["MDA", "SIMPLE_CHEMICAL", 297, 300], ["CAT", "SIMPLE_CHEMICAL", 302, 305], ["GSH-Px", "SIMPLE_CHEMICAL", 311, 317], ["myocardial tissue", "TISSUE", 321, 338], ["CK", "PROTEIN", 20, 22], ["LDH", "PROTEIN", 30, 33], ["SOD", "PROTEIN", 292, 295], ["MDA", "PROTEIN", 297, 300], ["CAT", "PROTEIN", 302, 305], ["The serum levels", "TEST", 0, 16], ["CK-MB", "TEST", 20, 25], ["LDH", "TEST", 30, 33], ["the myocardial damage", "PROBLEM", 142, 163], ["Antioxidant Enzymes", "TEST", 224, 243], ["Inflammation Assay", "TEST", 248, 266], ["MethodsActivities", "TEST", 271, 288], ["SOD", "PROBLEM", 292, 295], ["MDA", "TEST", 297, 300], ["CAT", "TEST", 302, 305], ["GSH", "TEST", 311, 314], ["myocardial tissue", "PROBLEM", 321, 338], ["myocardial", "ANATOMY", 146, 156], ["damage", "OBSERVATION", 157, 163], ["myocardial tissue", "ANATOMY", 321, 338]]], ["Levels of CRP, IL-6 and TNF-\u03b1 in myocardial tissue were determined by ELISA kits using specific antibodies (Antix Biotech China Co., Ltd., Changsha, China) according to the manufacturer\u2019s instructions.", [["myocardial tissue", "ANATOMY", 33, 50], ["CRP", "GENE_OR_GENE_PRODUCT", 10, 13], ["IL-6", "GENE_OR_GENE_PRODUCT", 15, 19], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 24, 29], ["myocardial tissue", "TISSUE", 33, 50], ["CRP", "PROTEIN", 10, 13], ["IL-6", "PROTEIN", 15, 19], ["TNF-\u03b1", "PROTEIN", 24, 29], ["specific antibodies", "PROTEIN", 87, 106], ["Levels", "TEST", 0, 6], ["CRP", "TEST", 10, 13], ["IL", "TEST", 15, 17], ["TNF", "TEST", 24, 27], ["myocardial tissue", "PROBLEM", 33, 50], ["ELISA kits", "TEST", 70, 80], ["myocardial tissue", "ANATOMY", 33, 50]]], ["Absorbance at a wavelength of 450 nm was determined on a microtiter plate reader (PerkinElmer, Inc., Waltham, MA, USA), and results were expressed as ng/L.Histological Studies ::: MethodsThe freshly dissected heart tissues were fixed in 10% formalin solution.", [["heart tissues", "ANATOMY", 209, 222], ["formalin", "CHEMICAL", 241, 249], ["formalin", "CHEMICAL", 241, 249], ["heart tissues", "TISSUE", 209, 222], ["formalin", "SIMPLE_CHEMICAL", 241, 249], ["a microtiter plate", "TREATMENT", 55, 73], ["Methods", "TREATMENT", 180, 187], ["10% formalin solution", "TREATMENT", 237, 258], ["freshly", "OBSERVATION_MODIFIER", 191, 198], ["dissected", "OBSERVATION", 199, 208], ["heart tissues", "ANATOMY", 209, 222], ["fixed", "OBSERVATION_MODIFIER", 228, 233]]], ["The sectioning and staining of heart tissue were performed according to previously established protocols.", [["heart tissue", "ANATOMY", 31, 43], ["heart tissue", "TISSUE", 31, 43], ["The sectioning", "TEST", 0, 14], ["staining of heart tissue", "TEST", 19, 43], ["heart tissue", "ANATOMY", 31, 43]]], ["Sections (5 mm, Leica RM 2125, Germany) from the left ventricle were stained with hematoxylin and eosin (H&E) and examined by light microscopy (Nikon, Tokyo, Japan) at a magnification of 200 \u00d7.Statistical Analysis ::: MethodsResults were expressed as means \u00b1 SD.", [["left ventricle", "ANATOMY", 49, 63], ["hematoxylin", "CHEMICAL", 82, 93], ["eosin", "CHEMICAL", 98, 103], ["left ventricle", "MULTI-TISSUE_STRUCTURE", 49, 63], ["hematoxylin", "SIMPLE_CHEMICAL", 82, 93], ["Sections", "TEST", 0, 8], ["Leica RM", "TEST", 16, 24], ["hematoxylin", "TREATMENT", 82, 93], ["left ventricle", "ANATOMY", 49, 63]]], ["Statistical analysis was performed using the one-way ANOVA, followed by Dunnett\u2019s t test.", [["Statistical analysis", "TEST", 0, 20]]], ["P < 0.05 was considered as statistically significant.Behavioral Analysis ::: ResultsTable 1 displays the fluid intake during the sucrose consumption test and the changes of open-field test scores, which were used to define anhedonia in five experimental groups.", [["fluid", "ANATOMY", 105, 110], ["sucrose", "CHEMICAL", 129, 136], ["anhedonia", "DISEASE", 223, 232], ["sucrose", "CHEMICAL", 129, 136], ["fluid", "ORGANISM_SUBSTANCE", 105, 110], ["sucrose", "SIMPLE_CHEMICAL", 129, 136], ["the fluid intake", "TEST", 101, 117], ["the sucrose consumption test", "TEST", 125, 153], ["open-field test scores", "TEST", 173, 195], ["anhedonia", "PROBLEM", 223, 232]]], ["There were no differences in sucrose intake test and open-field test scores among various groups at the baseline.", [["sucrose", "CHEMICAL", 29, 36], ["sucrose", "CHEMICAL", 29, 36], ["sucrose", "SIMPLE_CHEMICAL", 29, 36], ["sucrose intake test", "TEST", 29, 48], ["open-field test scores", "TEST", 53, 75], ["no", "UNCERTAINTY", 11, 13]]], ["However, after 28 days, the sucrose consumption and open-field test scores were significantly reduced in the depression and model groups (data not shown), and such results were consistent with previous study (Dong et al., 2016).", [["sucrose", "CHEMICAL", 28, 35], ["depression", "DISEASE", 109, 119], ["sucrose", "CHEMICAL", 28, 35], ["sucrose", "SIMPLE_CHEMICAL", 28, 35], ["the sucrose consumption", "TREATMENT", 24, 47], ["open-field test scores", "TEST", 52, 74], ["the depression and model groups", "PROBLEM", 105, 136], ["previous study", "TEST", 193, 207]]], ["After 49 days, the sucrose consumption and open-field test scores were significantly reduced in the MI group, depression group, and model group.", [["sucrose", "CHEMICAL", 19, 26], ["MI", "DISEASE", 100, 102], ["depression", "DISEASE", 110, 120], ["sucrose", "CHEMICAL", 19, 26], ["sucrose", "SIMPLE_CHEMICAL", 19, 26], ["the sucrose consumption", "TREATMENT", 15, 38], ["open-field test scores", "TEST", 43, 65], ["depression group, and model group", "PROBLEM", 110, 143]]], ["For these three injured groups, the levels of sucrose consumption and open-field test score were similar between the model and depression groups, while higher levels were observed in the MI group.", [["sucrose", "CHEMICAL", 46, 53], ["depression", "DISEASE", 127, 137], ["MI", "DISEASE", 187, 189], ["sucrose", "CHEMICAL", 46, 53], ["sucrose", "SIMPLE_CHEMICAL", 46, 53], ["sucrose consumption", "TREATMENT", 46, 65], ["open-field test score", "TEST", 70, 91], ["the model and depression groups", "PROBLEM", 113, 144], ["depression", "OBSERVATION", 127, 137]]], ["Collectively, KXS administration could significantly improve sucrose consumption and open-field test scores (vs. model, P < 0.01).The Effect of KXS on Myocardial Injury ::: ResultsFigure 2A shows that the myocardial cells exhibited uniform HE staining, and striated filaments of cardiac myocytes were neatly arranged with clear cell boundaries.", [["Myocardial", "ANATOMY", 151, 161], ["myocardial cells", "ANATOMY", 205, 221], ["striated filaments", "ANATOMY", 257, 275], ["cardiac myocytes", "ANATOMY", 279, 295], ["cell", "ANATOMY", 328, 332], ["KXS", "CHEMICAL", 14, 17], ["sucrose", "CHEMICAL", 61, 68], ["Myocardial Injury", "DISEASE", 151, 168], ["sucrose", "CHEMICAL", 61, 68], ["KXS", "SIMPLE_CHEMICAL", 14, 17], ["sucrose", "SIMPLE_CHEMICAL", 61, 68], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 151, 161], ["myocardial cells", "CELL", 205, 221], ["striated filaments", "CELLULAR_COMPONENT", 257, 275], ["cardiac myocytes", "CELL", 279, 295], ["cell", "CELL", 328, 332], ["ResultsFigure 2A", "PROTEIN", 173, 189], ["myocardial cells", "CELL_TYPE", 205, 221], ["KXS administration", "TREATMENT", 14, 32], ["sucrose consumption", "TREATMENT", 61, 80], ["open-field test scores", "TEST", 85, 107], ["model", "TEST", 113, 118], ["Myocardial Injury", "PROBLEM", 151, 168], ["the myocardial cells", "PROBLEM", 201, 221], ["striated filaments of cardiac myocytes", "PROBLEM", 257, 295], ["Myocardial", "ANATOMY", 151, 161], ["Injury", "OBSERVATION", 162, 168], ["myocardial cells", "ANATOMY", 205, 221], ["uniform", "OBSERVATION_MODIFIER", 232, 239], ["cardiac myocytes", "ANATOMY", 279, 295], ["clear cell boundaries", "OBSERVATION", 322, 343]]], ["In the control group, typical normal cardiac myocytes were observed.", [["cardiac myocytes", "ANATOMY", 37, 53], ["cardiac myocytes", "CELL", 37, 53], ["typical", "OBSERVATION_MODIFIER", 22, 29], ["normal", "OBSERVATION", 30, 36], ["cardiac myocytes", "ANATOMY", 37, 53]]], ["Only minor infiltration of inflammatory cells was detected, and no apparent fibrosis was found.", [["inflammatory cells", "ANATOMY", 27, 45], ["fibrosis", "DISEASE", 76, 84], ["inflammatory cells", "CELL", 27, 45], ["inflammatory cells", "CELL_TYPE", 27, 45], ["minor infiltration of inflammatory cells", "PROBLEM", 5, 45], ["apparent fibrosis", "PROBLEM", 67, 84], ["minor", "OBSERVATION_MODIFIER", 5, 10], ["infiltration", "OBSERVATION", 11, 23], ["inflammatory cells", "OBSERVATION", 27, 45], ["no apparent", "UNCERTAINTY", 64, 75], ["fibrosis", "OBSERVATION", 76, 84]]], ["Compared with the control group, fibrotic tissues were slightly increased, and the gaps of myocardial fibers became wider in the depression group.", [["fibrotic tissues", "ANATOMY", 33, 49], ["myocardial fibers", "ANATOMY", 91, 108], ["depression", "DISEASE", 129, 139], ["fibrotic tissues", "TISSUE", 33, 49], ["myocardial fibers", "TISSUE", 91, 108], ["fibrotic tissues", "PROBLEM", 33, 49], ["myocardial fibers", "PROBLEM", 91, 108], ["the depression group", "PROBLEM", 125, 145], ["fibrotic", "OBSERVATION", 33, 41], ["slightly", "OBSERVATION_MODIFIER", 55, 63], ["increased", "OBSERVATION_MODIFIER", 64, 73], ["gaps", "OBSERVATION_MODIFIER", 83, 87], ["myocardial", "ANATOMY", 91, 101], ["fibers", "OBSERVATION_MODIFIER", 102, 108], ["wider", "OBSERVATION_MODIFIER", 116, 121], ["depression", "OBSERVATION", 129, 139]]], ["In the MI and model groups, myocardial fibers were thicker and disordered, the gaps were wider, and extensive cardiomyocyte injury and necrosis were observed, indicating increased infiltration of inflammatory cells.", [["myocardial fibers", "ANATOMY", 28, 45], ["cardiomyocyte", "ANATOMY", 110, 123], ["inflammatory cells", "ANATOMY", 196, 214], ["MI", "DISEASE", 7, 9], ["necrosis", "DISEASE", 135, 143], ["myocardial fibers", "CELL", 28, 45], ["cardiomyocyte", "CELL", 110, 123], ["cells", "CELL", 209, 214], ["inflammatory cells", "CELL_TYPE", 196, 214], ["the gaps", "TEST", 75, 83], ["extensive cardiomyocyte injury", "PROBLEM", 100, 130], ["necrosis", "PROBLEM", 135, 143], ["increased infiltration of inflammatory cells", "PROBLEM", 170, 214], ["MI", "ANATOMY", 7, 9], ["myocardial fibers", "ANATOMY", 28, 45], ["wider", "OBSERVATION_MODIFIER", 89, 94], ["extensive", "OBSERVATION_MODIFIER", 100, 109], ["cardiomyocyte", "ANATOMY", 110, 123], ["injury", "OBSERVATION", 124, 130], ["necrosis", "OBSERVATION", 135, 143], ["increased", "OBSERVATION_MODIFIER", 170, 179], ["infiltration", "OBSERVATION", 180, 192], ["inflammatory cells", "OBSERVATION", 196, 214]]], ["Compared with the model group, less infiltration of inflammatory cells was observed in the KXS group, fibrous tissues were significantly decreased, and only fewer disordered cells were detected.", [["inflammatory cells", "ANATOMY", 52, 70], ["KXS", "ANATOMY", 91, 94], ["fibrous tissues", "ANATOMY", 102, 117], ["cells", "ANATOMY", 174, 179], ["inflammatory cells", "CELL", 52, 70], ["KXS", "CANCER", 91, 94], ["fibrous tissues", "TISSUE", 102, 117], ["cells", "CELL", 174, 179], ["inflammatory cells", "CELL_TYPE", 52, 70], ["inflammatory cells", "PROBLEM", 52, 70], ["fibrous tissues", "PROBLEM", 102, 117], ["fewer disordered cells", "PROBLEM", 157, 179], ["less", "OBSERVATION_MODIFIER", 31, 35], ["infiltration", "OBSERVATION", 36, 48], ["inflammatory cells", "OBSERVATION", 52, 70], ["fibrous tissues", "OBSERVATION", 102, 117], ["significantly", "OBSERVATION_MODIFIER", 123, 136], ["decreased", "OBSERVATION_MODIFIER", 137, 146], ["fewer", "OBSERVATION_MODIFIER", 157, 162], ["disordered cells", "OBSERVATION", 163, 179]]], ["Figure 2B reveals that EF and FS were decreased in the MI group, depression group, and model group compared with the control group (P < 0.01 or P < 0.05).", [["MI", "DISEASE", 55, 57], ["depression", "DISEASE", 65, 75], ["EF", "PROTEIN", 23, 25], ["EF", "TEST", 23, 25], ["FS", "TEST", 30, 32], ["depression group", "PROBLEM", 65, 81], ["decreased", "OBSERVATION_MODIFIER", 38, 47]]], ["Compared with the model group, levels of EF and FS were significantly increased in the KXS group (P < 0.05).", [["KXS", "ANATOMY", 87, 90], ["KXS", "CANCER", 87, 90], ["EF", "PROTEIN", 41, 43], ["EF", "TEST", 41, 43], ["FS", "TEST", 48, 50], ["significantly", "OBSERVATION_MODIFIER", 56, 69], ["increased", "OBSERVATION_MODIFIER", 70, 79]]], ["Figure 2C shows that the levels of CK-MB and LDH were higher in the MI group, depression group, and model group compared with the control group (P < 0.01 or P<0.05).", [["MI", "DISEASE", 68, 70], ["depression", "DISEASE", 78, 88], ["CK-MB", "GENE_OR_GENE_PRODUCT", 35, 40], ["LDH", "GENE_OR_GENE_PRODUCT", 45, 48], ["CK", "PROTEIN", 35, 37], ["LDH", "PROTEIN", 45, 48], ["Figure 2C", "TEST", 0, 9], ["the levels", "TEST", 21, 31], ["CK-MB", "TEST", 35, 40], ["LDH", "TEST", 45, 48], ["depression group", "PROBLEM", 78, 94], ["LDH", "ANATOMY", 45, 48], ["higher", "OBSERVATION_MODIFIER", 54, 60]]], ["Moreover, the levels of CK-MB and LDH were significantly decreased in the KXS group compared with the model group (P < 0.01 or P<0.05).The Effect of KXS on Antioxidant Enzymes and Inflammation Index ::: ResultsFigure 3 indicates that the MDA activity was significantly increased, while the activities of SOD, CAT, and GSH-Px were significantly decreased in other groups compared with the control group (P < 0.01).", [["KXS", "ANATOMY", 74, 77], ["KXS", "CHEMICAL", 149, 152], ["GSH", "CHEMICAL", 318, 321], ["MDA", "CHEMICAL", 238, 241], ["GSH", "CHEMICAL", 318, 321], ["CK-MB", "GENE_OR_GENE_PRODUCT", 24, 29], ["LDH", "GENE_OR_GENE_PRODUCT", 34, 37], ["KXS", "CANCER", 74, 77], ["KXS", "SIMPLE_CHEMICAL", 149, 152], ["MDA", "SIMPLE_CHEMICAL", 238, 241], ["SOD", "GENE_OR_GENE_PRODUCT", 304, 307], ["CAT", "GENE_OR_GENE_PRODUCT", 309, 312], ["GSH-Px", "GENE_OR_GENE_PRODUCT", 318, 324], ["CK", "PROTEIN", 24, 26], ["LDH", "PROTEIN", 34, 37], ["SOD", "PROTEIN", 304, 307], ["CAT", "PROTEIN", 309, 312], ["the levels", "TEST", 10, 20], ["CK-MB", "TEST", 24, 29], ["LDH", "TEST", 34, 37], ["P", "TEST", 127, 128], ["KXS", "TEST", 149, 152], ["Antioxidant Enzymes", "TEST", 156, 175], ["Inflammation Index", "TEST", 180, 198], ["the MDA activity", "TEST", 234, 250], ["CAT", "TEST", 309, 312], ["GSH", "TEST", 318, 321], ["significantly", "OBSERVATION_MODIFIER", 43, 56], ["decreased", "OBSERVATION_MODIFIER", 57, 66], ["increased", "OBSERVATION_MODIFIER", 269, 278], ["decreased", "OBSERVATION_MODIFIER", 344, 353]]], ["Moreover, the highest MDA activity was found in the model group.", [["MDA", "CHEMICAL", 22, 25], ["MDA", "SIMPLE_CHEMICAL", 22, 25], ["MDA", "PROTEIN", 22, 25], ["the highest MDA activity", "PROBLEM", 10, 34], ["highest", "OBSERVATION_MODIFIER", 14, 21], ["MDA activity", "OBSERVATION", 22, 34]]], ["Compared with the control group, the levels of CRP, IL-6 and TNF-\u03b1 were significantly increased in other groups (P < 0.01).", [["CRP", "GENE_OR_GENE_PRODUCT", 47, 50], ["IL-6", "GENE_OR_GENE_PRODUCT", 52, 56], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 61, 66], ["CRP", "PROTEIN", 47, 50], ["IL-6", "PROTEIN", 52, 56], ["TNF", "PROTEIN", 61, 64], ["CRP", "TEST", 47, 50], ["IL", "TEST", 52, 54], ["TNF", "TEST", 61, 64], ["significantly", "OBSERVATION_MODIFIER", 72, 85], ["increased", "OBSERVATION_MODIFIER", 86, 95]]], ["The activities of antioxidant enzymes and levels of inflammatory factors were similar between the MI and model groups.", [["MI", "DISEASE", 98, 100], ["antioxidant enzymes", "GENE_OR_GENE_PRODUCT", 18, 37], ["antioxidant enzymes", "PROTEIN", 18, 37], ["inflammatory factors", "PROTEIN", 52, 72], ["antioxidant enzymes", "TEST", 18, 37], ["inflammatory factors", "PROBLEM", 52, 72], ["inflammatory", "OBSERVATION", 52, 64]]], ["Compared with these two groups, higher levels of SOD, CAT, and GSH-Px but lower levels of CRP, IL-6 and TNF-\u03b1 were observed in the depression group.", [["GSH", "CHEMICAL", 63, 66], ["depression", "DISEASE", 131, 141], ["GSH", "CHEMICAL", 63, 66], ["SOD", "GENE_OR_GENE_PRODUCT", 49, 52], ["CAT", "GENE_OR_GENE_PRODUCT", 54, 57], ["GSH-Px", "GENE_OR_GENE_PRODUCT", 63, 69], ["CRP", "GENE_OR_GENE_PRODUCT", 90, 93], ["IL-6", "GENE_OR_GENE_PRODUCT", 95, 99], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 104, 109], ["SOD", "PROTEIN", 49, 52], ["CAT", "PROTEIN", 54, 57], ["CRP", "PROTEIN", 90, 93], ["IL-6", "PROTEIN", 95, 99], ["TNF", "PROTEIN", 104, 107], ["CAT", "TEST", 54, 57], ["GSH", "TEST", 63, 66], ["CRP", "TEST", 90, 93], ["IL", "TEST", 95, 97], ["TNF", "TEST", 104, 107], ["the depression group", "PROBLEM", 127, 147], ["depression", "OBSERVATION", 131, 141]]], ["After KXS treatment, the activity of MDA was significantly decreased (P < 0.01), while the activities of SOD, CAT, and GSH-Px were significantly increased compared with the model group (P < 0.01).", [["KXS", "CHEMICAL", 6, 9], ["MDA", "CHEMICAL", 37, 40], ["GSH", "CHEMICAL", 119, 122], ["KXS", "CHEMICAL", 6, 9], ["MDA", "CHEMICAL", 37, 40], ["GSH", "CHEMICAL", 119, 122], ["KXS", "SIMPLE_CHEMICAL", 6, 9], ["MDA", "SIMPLE_CHEMICAL", 37, 40], ["SOD", "GENE_OR_GENE_PRODUCT", 105, 108], ["CAT", "GENE_OR_GENE_PRODUCT", 110, 113], ["GSH-Px", "GENE_OR_GENE_PRODUCT", 119, 125], ["SOD", "PROTEIN", 105, 108], ["CAT", "PROTEIN", 110, 113], ["KXS treatment", "TREATMENT", 6, 19], ["the activity of MDA", "TEST", 21, 40], ["CAT", "TEST", 110, 113], ["GSH", "TEST", 119, 122], ["decreased", "OBSERVATION_MODIFIER", 59, 68], ["increased", "OBSERVATION_MODIFIER", 145, 154]]], ["In addition, the levels of CRP, IL-6 and TNF-\u03b1 were significantly decreased in the KXS group compared with the model group (P < 0.01).DiscussionGenerally speaking, comorbid depression occurs in 9.3-23% of individuals with one or more chronic physical diseases (Moussavi et al., 2007).", [["KXS", "ANATOMY", 83, 86], ["KXS", "CHEMICAL", 83, 86], ["depression", "DISEASE", 173, 183], ["chronic physical diseases", "DISEASE", 234, 259], ["CRP", "GENE_OR_GENE_PRODUCT", 27, 30], ["IL-6", "GENE_OR_GENE_PRODUCT", 32, 36], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 41, 46], ["KXS", "CANCER", 83, 86], ["CRP", "PROTEIN", 27, 30], ["IL-6", "PROTEIN", 32, 36], ["TNF", "PROTEIN", 41, 44], ["the levels", "TEST", 13, 23], ["CRP", "TEST", 27, 30], ["IL", "TEST", 32, 34], ["TNF", "TEST", 41, 44], ["comorbid depression", "PROBLEM", 164, 183], ["more chronic physical diseases", "PROBLEM", 229, 259], ["significantly", "OBSERVATION_MODIFIER", 52, 65], ["decreased", "OBSERVATION_MODIFIER", 66, 75], ["chronic", "OBSERVATION_MODIFIER", 234, 241]]], ["Similarly, the prevalence of depressive disorder is 15%\u201330% in MI patients, which is about five times higher compared with the general population.", [["depressive disorder", "DISEASE", 29, 48], ["MI", "DISEASE", 63, 65], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["depressive disorder", "PROBLEM", 29, 48], ["depressive disorder", "OBSERVATION", 29, 48]]], ["A meta-analysis indicates that the risk of cardiac mortality and new cardiovascular events is increased by 2.4-fold and 2-fold under the conditions of post-MI depression, respectively (Meijer et al., 2013).", [["cardiac", "ANATOMY", 43, 50], ["cardiovascular", "ANATOMY", 69, 83], ["depression", "DISEASE", 159, 169], ["cardiac", "ORGAN", 43, 50], ["cardiovascular", "ANATOMICAL_SYSTEM", 69, 83], ["A meta-analysis", "TEST", 0, 15], ["cardiac mortality", "PROBLEM", 43, 60], ["new cardiovascular events", "PROBLEM", 65, 90], ["post-MI depression", "PROBLEM", 151, 169], ["cardiac", "ANATOMY", 43, 50], ["mortality", "OBSERVATION", 51, 60], ["new", "OBSERVATION_MODIFIER", 65, 68], ["cardiovascular", "OBSERVATION", 69, 83], ["increased", "OBSERVATION_MODIFIER", 94, 103]]], ["In the present study, lower levels of EF and FS but higher levels of CK-MB and LDH were observed compared with normal rats, indicating the myocardial injury in depressive rats.", [["myocardial", "ANATOMY", 139, 149], ["myocardial injury", "DISEASE", 139, 156], ["depressive", "DISEASE", 160, 170], ["CK-MB", "GENE_OR_GENE_PRODUCT", 69, 74], ["LDH", "GENE_OR_GENE_PRODUCT", 79, 82], ["rats", "ORGANISM", 118, 122], ["myocardial", "MULTI-TISSUE_STRUCTURE", 139, 149], ["rats", "ORGANISM", 171, 175], ["EF", "PROTEIN", 38, 40], ["CK", "PROTEIN", 69, 71], ["LDH", "PROTEIN", 79, 82], ["rats", "SPECIES", 118, 122], ["rats", "SPECIES", 171, 175], ["the present study", "TEST", 3, 20], ["EF", "TEST", 38, 40], ["FS", "TEST", 45, 47], ["CK-MB", "TEST", 69, 74], ["LDH", "TEST", 79, 82], ["the myocardial injury in depressive rats", "PROBLEM", 135, 175], ["myocardial", "ANATOMY", 139, 149], ["injury", "OBSERVATION", 150, 156]]], ["Moreover, rats in the MI group showed depression-like behaviors.", [["MI", "DISEASE", 22, 24], ["depression", "DISEASE", 38, 48], ["rats", "ORGANISM", 10, 14], ["rats", "SPECIES", 10, 14], ["depression", "PROBLEM", 38, 48], ["depression", "OBSERVATION", 38, 48]]], ["These results verified the relationship between depression and MI.", [["depression", "DISEASE", 48, 58], ["MI", "DISEASE", 63, 65], ["depression", "PROBLEM", 48, 58], ["MI", "PROBLEM", 63, 65]]], ["Although many therapeutic strategies have been used to treat MI, the outcomes remain unsatisfied.", [["MI", "DISEASE", 61, 63], ["many therapeutic strategies", "TREATMENT", 9, 36], ["MI", "PROBLEM", 61, 63]]], ["Therefore, it is urgently necessary to develop an alternative medicine for MI treatment and to investigate its potential mechanism.DiscussionOur previous study has shown the anti-depressive effect of KXS in several depression models (Dang et al., 2009; Yan et al., 2016).", [["MI", "DISEASE", 75, 77], ["KXS", "CHEMICAL", 200, 203], ["depression", "DISEASE", 215, 225], ["KXS", "SIMPLE_CHEMICAL", 200, 203], ["an alternative medicine", "TREATMENT", 47, 70], ["MI treatment", "TREATMENT", 75, 87], ["previous study", "TEST", 145, 159], ["the anti-depressive effect of KXS", "PROBLEM", 170, 203], ["several depression models", "PROBLEM", 207, 232]]], ["In this study, in order to investigate whether KXS possessed both antidepressive effects and cardioprotective functions, we first established a rat model of MI with depression.", [["KXS", "CHEMICAL", 47, 50], ["MI", "DISEASE", 157, 159], ["depression", "DISEASE", 165, 175], ["KXS", "SIMPLE_CHEMICAL", 47, 50], ["rat", "ORGANISM", 144, 147], ["rat", "SPECIES", 144, 147], ["this study", "TEST", 3, 13], ["KXS", "TEST", 47, 50], ["MI", "PROBLEM", 157, 159], ["depression", "PROBLEM", 165, 175]]], ["The model was established using CMS-challenged rats, followed by ISO-triggered induction of MI.", [["ISO", "CHEMICAL", 65, 68], ["MI", "DISEASE", 92, 94], ["ISO", "CHEMICAL", 65, 68], ["rats", "ORGANISM", 47, 51], ["rats", "SPECIES", 47, 51], ["ISO", "TEST", 65, 68], ["MI", "PROBLEM", 92, 94]]], ["ISO is a synthetic catecholamine and \u03b2-adrenergic agonist, and it triggers necrosis, hypoxia, hyperplasia, and MI at high doses (Abbas, 2016; Zhang et al., 2017).", [["ISO", "CHEMICAL", 0, 3], ["catecholamine", "CHEMICAL", 19, 32], ["necrosis", "DISEASE", 75, 83], ["hypoxia", "DISEASE", 85, 92], ["hyperplasia", "DISEASE", 94, 105], ["MI", "DISEASE", 111, 113], ["ISO", "CHEMICAL", 0, 3], ["catecholamine", "CHEMICAL", 19, 32], ["catecholamine", "SIMPLE_CHEMICAL", 19, 32], ["\u03b2-adrenergic", "SIMPLE_CHEMICAL", 37, 49], ["a synthetic catecholamine and \u03b2-adrenergic agonist", "TREATMENT", 7, 57], ["necrosis", "PROBLEM", 75, 83], ["hypoxia", "PROBLEM", 85, 92], ["hyperplasia", "PROBLEM", 94, 105], ["MI", "PROBLEM", 111, 113], ["necrosis", "OBSERVATION", 75, 83], ["hypoxia", "OBSERVATION_MODIFIER", 85, 92], ["hyperplasia", "OBSERVATION", 94, 105]]], ["In our current study, MI model was established in rats by intraperitoneal administration of ISO for three successive days with a dose of 85 mg/kg and a 24-h interval between the applications.", [["intraperitoneal", "ANATOMY", 58, 73], ["MI", "DISEASE", 22, 24], ["ISO", "CHEMICAL", 92, 95], ["ISO", "CHEMICAL", 92, 95], ["rats", "ORGANISM", 50, 54], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 58, 73], ["rats", "SPECIES", 50, 54], ["our current study", "TEST", 3, 20], ["MI model", "TEST", 22, 30], ["intraperitoneal administration of ISO", "TREATMENT", 58, 95], ["the applications", "TREATMENT", 174, 190]]], ["Then the model was tested by depression-like behavior and myocardial injury.", [["myocardial", "ANATOMY", 58, 68], ["depression", "DISEASE", 29, 39], ["myocardial injury", "DISEASE", 58, 75], ["myocardial", "MULTI-TISSUE_STRUCTURE", 58, 68], ["depression", "PROBLEM", 29, 39], ["myocardial injury", "PROBLEM", 58, 75], ["myocardial", "ANATOMY", 58, 68], ["injury", "OBSERVATION", 69, 75]]], ["For the determination of depression-like behavior, we found that sucrose intake and open-field test scores were significantly reduced in rats exposed to CMS.", [["depression", "DISEASE", 25, 35], ["sucrose", "CHEMICAL", 65, 72], ["sucrose", "CHEMICAL", 65, 72], ["sucrose", "SIMPLE_CHEMICAL", 65, 72], ["rats", "ORGANISM", 137, 141], ["rats", "SPECIES", 137, 141], ["depression", "PROBLEM", 25, 35], ["sucrose intake", "TEST", 65, 79], ["open-field test scores", "TEST", 84, 106], ["depression", "OBSERVATION", 25, 35]]], ["For myocardial injury, we tested it by echocardiography and cardiac markers.", [["myocardial", "ANATOMY", 4, 14], ["cardiac", "ANATOMY", 60, 67], ["myocardial injury", "DISEASE", 4, 21], ["myocardial", "MULTI-TISSUE_STRUCTURE", 4, 14], ["myocardial injury", "PROBLEM", 4, 21], ["echocardiography", "TEST", 39, 55], ["cardiac markers", "TEST", 60, 75], ["myocardial", "ANATOMY", 4, 14], ["injury", "OBSERVATION", 15, 21]]], ["MI leads to significantly decreased contractile and diastolic forces of the heart, especially in the region of the MI.", [["heart", "ANATOMY", 76, 81], ["MI", "DISEASE", 0, 2], ["MI", "DISEASE", 115, 117], ["heart", "ORGAN", 76, 81], ["MI", "PROBLEM", 0, 2], ["significantly decreased contractile and diastolic forces of the heart", "PROBLEM", 12, 81], ["the MI", "PROBLEM", 111, 117], ["significantly", "OBSERVATION_MODIFIER", 12, 25], ["decreased", "OBSERVATION_MODIFIER", 26, 35], ["contractile", "OBSERVATION", 36, 47], ["diastolic forces", "OBSERVATION", 52, 68], ["heart", "ANATOMY", 76, 81], ["region", "ANATOMY_MODIFIER", 101, 107], ["MI", "ANATOMY", 115, 117]]], ["These alterations can be attributed to ischemia in the ventricular walls, limiting the movement.", [["ventricular walls", "ANATOMY", 55, 72], ["ischemia", "DISEASE", 39, 47], ["ventricular walls", "MULTI-TISSUE_STRUCTURE", 55, 72], ["ischemia in the ventricular walls", "PROBLEM", 39, 72], ["can be attributed to", "UNCERTAINTY", 18, 38], ["ischemia", "OBSERVATION", 39, 47], ["ventricular", "ANATOMY", 55, 66], ["walls", "ANATOMY_MODIFIER", 67, 72], ["movement", "OBSERVATION_MODIFIER", 87, 95]]], ["Previous studies have reported that lesion severity and left ventricular function determine the prognosis of MI.", [["lesion", "ANATOMY", 36, 42], ["left ventricular", "ANATOMY", 56, 72], ["MI", "DISEASE", 109, 111], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 56, 72], ["Previous studies", "TEST", 0, 16], ["lesion severity", "PROBLEM", 36, 51], ["left ventricular function", "TEST", 56, 81], ["MI", "PROBLEM", 109, 111], ["lesion", "OBSERVATION", 36, 42], ["left ventricular", "ANATOMY", 56, 72]]], ["Therefore, left ventricular function plays a crucial role in evaluating treatment effect (Wang et al., 2015).", [["left ventricular", "ANATOMY", 11, 27], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 11, 27], ["left ventricular function", "TEST", 11, 36], ["left ventricular", "ANATOMY", 11, 27]]], ["Echocardiography is a useful tool to determine the cardiac function and assess the changes in left ventricular function by EF and FS, which can accurately diagnose MI in animals (Xu et al., 2018).", [["cardiac", "ANATOMY", 51, 58], ["left ventricular", "ANATOMY", 94, 110], ["MI", "DISEASE", 164, 166], ["cardiac", "ORGAN", 51, 58], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 94, 110], ["Echocardiography", "TEST", 0, 16], ["the cardiac function", "TEST", 47, 67], ["EF", "TEST", 123, 125], ["FS", "TEST", 130, 132], ["left ventricular", "ANATOMY", 94, 110]]], ["CK-MB and LDH, related to the cellular damage and loss of functional integrity, are important myocardial enzymes in the evaluation of myocardial injury and congestive heart failure, and these markers have also been used to diagnose MI (Dhivya et al., 2017; Lin et al., 2017).", [["cellular", "ANATOMY", 30, 38], ["myocardial", "ANATOMY", 94, 104], ["myocardial", "ANATOMY", 134, 144], ["heart", "ANATOMY", 167, 172], ["myocardial injury", "DISEASE", 134, 151], ["congestive heart failure", "DISEASE", 156, 180], ["MI", "DISEASE", 232, 234], ["CK-MB", "GENE_OR_GENE_PRODUCT", 0, 5], ["LDH", "GENE_OR_GENE_PRODUCT", 10, 13], ["cellular", "CELL", 30, 38], ["myocardial", "MULTI-TISSUE_STRUCTURE", 94, 104], ["myocardial", "MULTI-TISSUE_STRUCTURE", 134, 144], ["heart", "ORGAN", 167, 172], ["CK", "PROTEIN", 0, 2], ["myocardial enzymes", "PROTEIN", 94, 112], ["CK-MB", "TEST", 0, 5], ["LDH", "TEST", 10, 13], ["the cellular damage", "PROBLEM", 26, 45], ["loss of functional integrity", "PROBLEM", 50, 78], ["myocardial enzymes", "TEST", 94, 112], ["the evaluation", "TEST", 116, 130], ["myocardial injury", "PROBLEM", 134, 151], ["congestive heart failure", "PROBLEM", 156, 180], ["MI", "PROBLEM", 232, 234], ["cellular damage", "OBSERVATION", 30, 45], ["loss", "OBSERVATION_MODIFIER", 50, 54], ["functional integrity", "OBSERVATION", 58, 78], ["myocardial", "ANATOMY", 134, 144], ["injury", "OBSERVATION", 145, 151], ["congestive", "OBSERVATION_MODIFIER", 156, 166], ["heart", "ANATOMY", 167, 172], ["failure", "OBSERVATION", 173, 180]]], ["In this work, the levels of EF and FS were significantly decreased, while the levels of plasma CK-MB and LDH were increased in the MI and model groups compared with the control group.", [["plasma", "ANATOMY", 88, 94], ["MI", "DISEASE", 131, 133], ["plasma", "ORGANISM_SUBSTANCE", 88, 94], ["CK-MB", "GENE_OR_GENE_PRODUCT", 95, 100], ["LDH", "GENE_OR_GENE_PRODUCT", 105, 108], ["EF", "PROTEIN", 28, 30], ["CK", "PROTEIN", 95, 97], ["LDH", "PROTEIN", 105, 108], ["the levels", "TEST", 14, 24], ["EF", "TEST", 28, 30], ["FS", "TEST", 35, 37], ["the levels", "TEST", 74, 84], ["plasma CK", "TEST", 88, 97], ["MB", "TEST", 98, 100], ["LDH", "TEST", 105, 108], ["LDH", "ANATOMY", 105, 108], ["increased", "OBSERVATION_MODIFIER", 114, 123]]], ["The above-mentioned findings indicated that an MI+ depression model was successfully established.", [["MI", "DISEASE", 47, 49], ["depression", "DISEASE", 51, 61], ["an MI+ depression model", "PROBLEM", 44, 67], ["depression", "OBSERVATION", 51, 61]]], ["In addition, such model showed similar results to those of the depression group in behavioral test, including open-field test and sucrose consumption.", [["depression", "DISEASE", 63, 73], ["sucrose", "CHEMICAL", 130, 137], ["sucrose", "CHEMICAL", 130, 137], ["sucrose", "SIMPLE_CHEMICAL", 130, 137], ["the depression group", "PROBLEM", 59, 79], ["behavioral test", "TEST", 83, 98], ["open-field test", "TEST", 110, 125]]], ["Moreover, the MI+ depression model also exhibited similar results to those of the IM group in terms of echocardiography (EF and FS), cardiac markers (CK-MB and LDH), antioxidants (SOD, GSH-Px, and CAT) and inflammatory factors (CRP, IL-6, and TNF-\u03b1).DiscussionAfter KXS treatment, open-field test scores were increased, and the sucrose consumption was also elevated, suggesting the antidepressive effects of KXS, that consisted with our previous studies (Hu et al., 2011; Dong et al., 2016).", [["cardiac", "ANATOMY", 133, 140], ["MI", "DISEASE", 14, 16], ["depression", "DISEASE", 18, 28], ["GSH", "CHEMICAL", 185, 188], ["KXS", "CHEMICAL", 266, 269], ["sucrose", "CHEMICAL", 328, 335], ["KXS", "CHEMICAL", 408, 411], ["GSH", "CHEMICAL", 185, 188], ["sucrose", "CHEMICAL", 328, 335], ["cardiac", "ORGAN", 133, 140], ["CK-MB", "GENE_OR_GENE_PRODUCT", 150, 155], ["LDH", "SIMPLE_CHEMICAL", 160, 163], ["SOD", "SIMPLE_CHEMICAL", 180, 183], ["GSH-Px", "GENE_OR_GENE_PRODUCT", 185, 191], ["CAT", "GENE_OR_GENE_PRODUCT", 197, 200], ["CRP", "GENE_OR_GENE_PRODUCT", 228, 231], ["IL-6", "GENE_OR_GENE_PRODUCT", 233, 237], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 243, 248], ["KXS", "SIMPLE_CHEMICAL", 266, 269], ["sucrose", "SIMPLE_CHEMICAL", 328, 335], ["KXS", "SIMPLE_CHEMICAL", 408, 411], ["CK", "PROTEIN", 150, 152], ["LDH", "PROTEIN", 160, 163], ["SOD", "PROTEIN", 180, 183], ["CAT", "PROTEIN", 197, 200], ["inflammatory factors", "PROTEIN", 206, 226], ["CRP", "PROTEIN", 228, 231], ["IL-6", "PROTEIN", 233, 237], ["TNF", "PROTEIN", 243, 246], ["the MI+ depression model", "PROBLEM", 10, 34], ["echocardiography", "TEST", 103, 119], ["EF", "TEST", 121, 123], ["FS", "TEST", 128, 130], ["cardiac markers", "TEST", 133, 148], ["CK", "TEST", 150, 152], ["MB", "TEST", 153, 155], ["LDH", "TEST", 160, 163], ["antioxidants", "TEST", 166, 178], ["SOD", "TEST", 180, 183], ["GSH", "TEST", 185, 188], ["Px", "TEST", 189, 191], ["CAT", "TEST", 197, 200], ["inflammatory factors", "PROBLEM", 206, 226], ["CRP", "TEST", 228, 231], ["IL", "TEST", 233, 235], ["TNF", "TEST", 243, 246], ["KXS treatment", "TREATMENT", 266, 279], ["open-field test scores", "TEST", 281, 303], ["the sucrose consumption", "TEST", 324, 347], ["depression", "OBSERVATION", 18, 28], ["cardiac", "ANATOMY", 133, 140], ["LDH", "ANATOMY", 160, 163], ["inflammatory", "OBSERVATION_MODIFIER", 206, 218]]], ["KXS could partially increase the levels of EF and FS and decrease the serum levels of CK-MB and LDH, indicating that KXS could not only improve the depression-like behavior of rats in the model group but also improve the cell functional integrity and restrict the leakage of these enzymes into circulation.", [["serum", "ANATOMY", 70, 75], ["cell", "ANATOMY", 221, 225], ["KXS", "CHEMICAL", 0, 3], ["KXS", "CHEMICAL", 117, 120], ["depression", "DISEASE", 148, 158], ["KXS", "SIMPLE_CHEMICAL", 0, 3], ["serum", "ORGANISM_SUBSTANCE", 70, 75], ["CK-MB", "GENE_OR_GENE_PRODUCT", 86, 91], ["LDH", "GENE_OR_GENE_PRODUCT", 96, 99], ["KXS", "SIMPLE_CHEMICAL", 117, 120], ["rats", "ORGANISM", 176, 180], ["cell", "CELL", 221, 225], ["EF", "PROTEIN", 43, 45], ["CK", "PROTEIN", 86, 88], ["enzymes", "PROTEIN", 281, 288], ["rats", "SPECIES", 176, 180], ["EF", "TEST", 43, 45], ["FS", "TEST", 50, 52], ["the serum levels", "TEST", 66, 82], ["CK-MB", "TEST", 86, 91], ["LDH", "TEST", 96, 99], ["KXS", "TEST", 117, 120], ["the depression", "PROBLEM", 144, 158], ["these enzymes", "TEST", 275, 288], ["increase", "OBSERVATION_MODIFIER", 20, 28], ["depression", "OBSERVATION", 148, 158]]], ["In addition, HE staining is another method frequently used in evaluation of myocardial injury (Zhang et al., 2014; Lin et al., 2017).", [["myocardial", "ANATOMY", 76, 86], ["myocardial injury", "DISEASE", 76, 93], ["myocardial", "MULTI-TISSUE_STRUCTURE", 76, 86], ["evaluation", "TEST", 62, 72], ["myocardial injury", "PROBLEM", 76, 93], ["myocardial", "ANATOMY", 76, 86], ["injury", "OBSERVATION", 87, 93]]], ["In the current study, the cardioprotective effects of KXS were further validated by the significantly improved histological results.", [["KXS", "CHEMICAL", 54, 57], ["KXS", "CHEMICAL", 54, 57], ["KXS", "SIMPLE_CHEMICAL", 54, 57], ["the current study", "TEST", 3, 20], ["KXS", "TEST", 54, 57]]], ["The histopathological changes were significantly restored by KXS treatment, and less area of degeneration was found in the heart tissue sections of the KXS group compared with the model group.", [["heart tissue sections", "ANATOMY", 123, 144], ["KXS", "ANATOMY", 152, 155], ["KXS", "CHEMICAL", 61, 64], ["KXS", "CHEMICAL", 61, 64], ["KXS", "SIMPLE_CHEMICAL", 61, 64], ["heart tissue sections", "MULTI-TISSUE_STRUCTURE", 123, 144], ["KXS", "CANCER", 152, 155], ["The histopathological changes", "PROBLEM", 0, 29], ["KXS treatment", "TREATMENT", 61, 74], ["degeneration", "PROBLEM", 93, 105], ["less", "OBSERVATION_MODIFIER", 80, 84], ["area", "OBSERVATION_MODIFIER", 85, 89], ["degeneration", "OBSERVATION", 93, 105], ["heart", "ANATOMY", 123, 128], ["tissue", "ANATOMY_MODIFIER", 129, 135]]], ["These findings also provided convincing evidence that KXS exerted cardioprotective effects against ISO-induced myocardial injury.DiscussionAccording to published many literatures about KXS antidepressant mechanism, such as Dong XZ (Dong et al., 2017) and Wang S (Wang et al., 2016).", [["myocardial", "ANATOMY", 111, 121], ["KXS", "CHEMICAL", 54, 57], ["ISO", "CHEMICAL", 99, 102], ["myocardial injury", "DISEASE", 111, 128], ["antidepressant", "CHEMICAL", 189, 203], ["KXS", "CHEMICAL", 54, 57], ["ISO", "CHEMICAL", 99, 102], ["KXS", "SIMPLE_CHEMICAL", 54, 57], ["ISO", "SIMPLE_CHEMICAL", 99, 102], ["myocardial", "MULTI-TISSUE_STRUCTURE", 111, 121], ["KXS", "SIMPLE_CHEMICAL", 185, 188], ["ISO", "PROBLEM", 99, 102], ["myocardial injury", "PROBLEM", 111, 128], ["KXS antidepressant mechanism", "TREATMENT", 185, 213], ["myocardial", "ANATOMY", 111, 121], ["injury", "OBSERVATION", 122, 128]]], ["Therefore, we believed antioxidant enzymes and inflammation index are related with depression.", [["depression", "DISEASE", 83, 93], ["antioxidant enzymes", "PROTEIN", 23, 42], ["antioxidant enzymes", "TEST", 23, 42], ["inflammation index", "PROBLEM", 47, 65], ["depression", "PROBLEM", 83, 93], ["inflammation", "OBSERVATION", 47, 59]]], ["At the same time, antioxidant enzymes and inflammation index are more related with CHD, so we hypothesized the antioxidant enzymes and inflammation index might be the co-morbid condition of heart disease and depression.", [["heart", "ANATOMY", 190, 195], ["CHD", "DISEASE", 83, 86], ["inflammation", "DISEASE", 135, 147], ["heart disease", "DISEASE", 190, 203], ["depression", "DISEASE", 208, 218], ["heart", "ORGAN", 190, 195], ["antioxidant enzymes", "PROTEIN", 18, 37], ["antioxidant enzymes", "PROTEIN", 111, 130], ["antioxidant enzymes", "TEST", 18, 37], ["inflammation index", "PROBLEM", 42, 60], ["CHD", "PROBLEM", 83, 86], ["the antioxidant enzymes", "TEST", 107, 130], ["inflammation index", "PROBLEM", 135, 153], ["heart disease", "PROBLEM", 190, 203], ["depression", "PROBLEM", 208, 218], ["inflammation", "OBSERVATION", 42, 54], ["heart", "ANATOMY", 190, 195], ["disease", "OBSERVATION", 196, 203]]], ["The status of oxidative stress was assessed by determining the MDA activity and activities of several endogenous antioxidants.", [["MDA", "CHEMICAL", 63, 66], ["MDA", "SIMPLE_CHEMICAL", 63, 66], ["oxidative stress", "PROBLEM", 14, 30], ["several endogenous antioxidants", "TREATMENT", 94, 125], ["oxidative stress", "OBSERVATION", 14, 30]]], ["MDA [a reactive oxygen species (ROS)] as well as SOD, GSH, and CAT (antioxidants) are important markers of myocardial oxidative damages (Hu X. et al., 2014; Yang et al., 2014).", [["myocardial", "ANATOMY", 107, 117], ["MDA", "CHEMICAL", 0, 3], ["oxygen", "CHEMICAL", 16, 22], ["ROS", "CHEMICAL", 32, 35], ["GSH", "CHEMICAL", 54, 57], ["myocardial oxidative damages", "DISEASE", 107, 135], ["MDA", "CHEMICAL", 0, 3], ["oxygen", "CHEMICAL", 16, 22], ["GSH", "CHEMICAL", 54, 57], ["MDA", "SIMPLE_CHEMICAL", 0, 3], ["reactive oxygen species", "SIMPLE_CHEMICAL", 7, 30], ["ROS", "SIMPLE_CHEMICAL", 32, 35], ["SOD", "SIMPLE_CHEMICAL", 49, 52], ["GSH", "SIMPLE_CHEMICAL", 54, 57], ["CAT", "SIMPLE_CHEMICAL", 63, 66], ["myocardial", "MULTI-TISSUE_STRUCTURE", 107, 117], ["SOD", "PROTEIN", 49, 52], ["CAT", "PROTEIN", 63, 66], ["a reactive oxygen species", "PROBLEM", 5, 30], ["SOD", "PROBLEM", 49, 52], ["CAT (antioxidants", "TREATMENT", 63, 80], ["myocardial oxidative damages", "PROBLEM", 107, 135], ["reactive", "OBSERVATION_MODIFIER", 7, 15], ["oxygen species", "OBSERVATION", 16, 30], ["myocardial", "ANATOMY", 107, 117], ["oxidative damages", "OBSERVATION", 118, 135]]], ["Antioxidants can scavenge free radicals under pathologic conditions, and excessive ROS disturbs the existing balance of antioxidant system (Hu et al., 2016).", [["ROS", "CHEMICAL", 83, 86], ["free radicals", "SIMPLE_CHEMICAL", 26, 39], ["ROS", "SIMPLE_CHEMICAL", 83, 86], ["Antioxidants", "TREATMENT", 0, 12], ["excessive ROS", "PROBLEM", 73, 86]]], ["KXS treatment reduced the MDA activity, and the activities of SOD, GSH, and CAT were restored by KXS treatment compared with the MI rats.", [["KXS", "CHEMICAL", 0, 3], ["GSH", "CHEMICAL", 67, 70], ["KXS", "CHEMICAL", 97, 100], ["KXS", "CHEMICAL", 0, 3], ["MDA", "CHEMICAL", 26, 29], ["GSH", "CHEMICAL", 67, 70], ["KXS", "CHEMICAL", 97, 100], ["KXS", "SIMPLE_CHEMICAL", 0, 3], ["MDA", "SIMPLE_CHEMICAL", 26, 29], ["SOD", "GENE_OR_GENE_PRODUCT", 62, 65], ["GSH", "SIMPLE_CHEMICAL", 67, 70], ["CAT", "GENE_OR_GENE_PRODUCT", 76, 79], ["KXS", "SIMPLE_CHEMICAL", 97, 100], ["rats", "ORGANISM", 132, 136], ["SOD", "PROTEIN", 62, 65], ["CAT", "PROTEIN", 76, 79], ["rats", "SPECIES", 132, 136], ["KXS treatment", "TREATMENT", 0, 13], ["the MDA activity", "TREATMENT", 22, 38], ["GSH", "TEST", 67, 70], ["CAT", "TREATMENT", 76, 79], ["KXS treatment", "TREATMENT", 97, 110]]], ["The over-production of pro-inflammatory cytokines, including IL-6, CRP, and TNF-\u03b1, can be induced by excessive oxidative stress.", [["IL-6", "GENE_OR_GENE_PRODUCT", 61, 65], ["CRP", "GENE_OR_GENE_PRODUCT", 67, 70], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 76, 81], ["pro-inflammatory cytokines", "PROTEIN", 23, 49], ["IL-6", "PROTEIN", 61, 65], ["CRP", "PROTEIN", 67, 70], ["TNF-\u03b1", "PROTEIN", 76, 81], ["pro-inflammatory cytokines", "PROBLEM", 23, 49], ["IL", "TEST", 61, 63], ["CRP", "TEST", 67, 70], ["TNF", "TEST", 76, 79], ["excessive oxidative stress", "PROBLEM", 101, 127], ["pro-inflammatory cytokines", "OBSERVATION", 23, 49], ["oxidative stress", "OBSERVATION", 111, 127]]], ["Many studies have linked the elevated levels of inflammatory markers to ischemia (Willerson and Ridker, 2004).", [["ischemia", "DISEASE", 72, 80], ["inflammatory markers", "PROTEIN", 48, 68], ["Many studies", "TEST", 0, 12], ["the elevated levels of inflammatory markers", "PROBLEM", 25, 68], ["ischemia", "PROBLEM", 72, 80], ["elevated", "OBSERVATION_MODIFIER", 29, 37], ["levels", "OBSERVATION_MODIFIER", 38, 44], ["inflammatory", "OBSERVATION_MODIFIER", 48, 60], ["ischemia", "OBSERVATION", 72, 80]]], ["KXS treatment decreased the contents of pro-inflammatory cytokines, suggesting that its cardioprotective effects were partially attributed to its anti-inflammatory properties.", [["KXS", "CHEMICAL", 0, 3], ["KXS", "CHEMICAL", 0, 3], ["KXS", "SIMPLE_CHEMICAL", 0, 3], ["pro-inflammatory cytokines", "PROTEIN", 40, 66], ["KXS treatment", "TREATMENT", 0, 13], ["pro-inflammatory cytokines", "PROBLEM", 40, 66], ["its anti-inflammatory properties", "TREATMENT", 142, 174], ["pro-inflammatory cytokines", "OBSERVATION", 40, 66], ["anti-inflammatory properties", "OBSERVATION", 146, 174]]], ["These findings were consistent with previous data that KXS treatment can modulate the disturbance of cytokines induced by chronic fatigue syndrome (Cao et al., 2012).", [["KXS", "CHEMICAL", 55, 58], ["chronic fatigue syndrome", "DISEASE", 122, 146], ["KXS", "CHEMICAL", 55, 58], ["KXS", "SIMPLE_CHEMICAL", 55, 58], ["cytokines", "PROTEIN", 101, 110], ["KXS treatment", "TREATMENT", 55, 68], ["the disturbance of cytokines", "PROBLEM", 82, 110], ["chronic fatigue syndrome", "PROBLEM", 122, 146], ["consistent with", "UNCERTAINTY", 20, 35], ["chronic", "OBSERVATION_MODIFIER", 122, 129], ["fatigue syndrome", "OBSERVATION", 130, 146]]], ["In addition, these results were consistent with the histological evaluation of inflammatory cellular infiltration in myocardial tissues.DiscussionA randomized, double-blind, positive-drug, parallel-controlled clinical trial has been conducted to evaluate the efficacy and safety of KXS in treatment of mild/moderate depression since 2015.", [["cellular", "ANATOMY", 92, 100], ["myocardial tissues", "ANATOMY", 117, 135], ["KXS", "CHEMICAL", 282, 285], ["depression", "DISEASE", 316, 326], ["cellular", "CELL", 92, 100], ["myocardial tissues", "TISSUE", 117, 135], ["KXS", "SIMPLE_CHEMICAL", 282, 285], ["the histological evaluation", "TEST", 48, 75], ["inflammatory cellular infiltration in myocardial tissues", "PROBLEM", 79, 135], ["KXS", "TREATMENT", 282, 285], ["treatment", "TREATMENT", 289, 298], ["mild/moderate depression", "PROBLEM", 302, 326], ["consistent with", "UNCERTAINTY", 32, 47], ["inflammatory", "OBSERVATION_MODIFIER", 79, 91], ["cellular", "OBSERVATION_MODIFIER", 92, 100], ["infiltration", "OBSERVATION", 101, 113], ["myocardial tissues", "ANATOMY", 117, 135], ["mild", "OBSERVATION_MODIFIER", 302, 306], ["moderate", "OBSERVATION_MODIFIER", 307, 315], ["depression", "OBSERVATION", 316, 326]]], ["Pharmacologically, KXS with its active compounds may exert its effects on mental illness mainly through adjusting the adrenergic activation, HPA axis dysfunction and immuno-inflammation (Hu et al., 2011; Cao et al., 2012; Hu et al., 2013a), which are the co-mechanisms in psycho-cardiology (Headrick et al., 2017).", [["KXS", "CHEMICAL", 19, 22], ["illness", "DISEASE", 81, 88], ["KXS", "SIMPLE_CHEMICAL", 19, 22], ["its active compounds", "PROBLEM", 28, 48], ["mental illness", "PROBLEM", 74, 88], ["the adrenergic activation", "PROBLEM", 114, 139], ["HPA axis dysfunction", "PROBLEM", 141, 161], ["immuno-inflammation", "PROBLEM", 166, 185]]], ["In the present study, we demonstrated that KXS had beneficial effects on cardiac function in MI rats.", [["cardiac", "ANATOMY", 73, 80], ["KXS", "CHEMICAL", 43, 46], ["MI", "DISEASE", 93, 95], ["KXS", "CHEMICAL", 43, 46], ["KXS", "SIMPLE_CHEMICAL", 43, 46], ["cardiac", "ORGAN", 73, 80], ["rats", "ORGANISM", 96, 100], ["rats", "SPECIES", 96, 100], ["the present study", "TEST", 3, 20], ["KXS", "TEST", 43, 46], ["cardiac function", "TEST", 73, 89]]], ["Moreover, KXS treatment showed remarkable anti-depression and cardioprotective effects in an MI rat model with depression.", [["KXS", "CHEMICAL", 10, 13], ["MI", "DISEASE", 93, 95], ["depression", "DISEASE", 111, 121], ["KXS", "CHEMICAL", 10, 13], ["KXS", "SIMPLE_CHEMICAL", 10, 13], ["rat", "ORGANISM", 96, 99], ["rat", "SPECIES", 96, 99], ["KXS treatment", "TREATMENT", 10, 23], ["remarkable anti-depression", "PROBLEM", 31, 57], ["cardioprotective effects", "PROBLEM", 62, 86], ["depression", "PROBLEM", 111, 121], ["cardioprotective effects", "OBSERVATION", 62, 86], ["depression", "OBSERVATION", 111, 121]]], ["The cardioprotective function of KXS might be associated with its ability to attenuate oxidative stress, leading to reduced myocardial damage.", [["myocardial", "ANATOMY", 124, 134], ["KXS", "CHEMICAL", 33, 36], ["myocardial damage", "DISEASE", 124, 141], ["KXS", "SIMPLE_CHEMICAL", 33, 36], ["myocardial", "MULTI-TISSUE_STRUCTURE", 124, 134], ["oxidative stress", "PROBLEM", 87, 103], ["reduced myocardial damage", "PROBLEM", 116, 141], ["myocardial", "ANATOMY", 124, 134], ["damage", "OBSERVATION", 135, 141]]], ["Taken together, our findings supported that KXS had therapeutic effects on patients with cardiovascular disease.", [["cardiovascular", "ANATOMY", 89, 103], ["KXS", "CHEMICAL", 44, 47], ["cardiovascular disease", "DISEASE", 89, 111], ["KXS", "SIMPLE_CHEMICAL", 44, 47], ["patients", "ORGANISM", 75, 83], ["cardiovascular", "ANATOMICAL_SYSTEM", 89, 103], ["patients", "SPECIES", 75, 83], ["KXS", "TEST", 44, 47], ["cardiovascular disease", "PROBLEM", 89, 111], ["cardiovascular disease", "OBSERVATION", 89, 111]]], ["However, such beneficial effects of KXS were only verified by behavior and biochemical tests.", [["KXS", "CHEMICAL", 36, 39], ["KXS", "SIMPLE_CHEMICAL", 36, 39], ["KXS", "TEST", 36, 39], ["biochemical tests", "TEST", 75, 92]]], ["Therefore, further studies are required to reveal its underlying mechanisms.DiscussionIn the present study, we found that KXS had antidepressive effect and cardioprotective function by a rat model of MI with depression.", [["KXS", "CHEMICAL", 122, 125], ["MI", "DISEASE", 200, 202], ["depression", "DISEASE", 208, 218], ["KXS", "CHEMICAL", 122, 125], ["KXS", "SIMPLE_CHEMICAL", 122, 125], ["rat", "ORGANISM", 187, 190], ["rat", "SPECIES", 187, 190], ["further studies", "TEST", 11, 26], ["KXS", "TEST", 122, 125], ["antidepressive effect", "PROBLEM", 130, 151], ["MI", "PROBLEM", 200, 202], ["depression", "PROBLEM", 208, 218], ["depression", "OBSERVATION", 208, 218]]], ["After KXS treatment, open-field test scores, and sucrose consumption, which are indicators for evaluating depression-like behaviors, were significantly increased compared with the model group.", [["KXS", "CHEMICAL", 6, 9], ["sucrose", "CHEMICAL", 49, 56], ["depression", "DISEASE", 106, 116], ["sucrose", "CHEMICAL", 49, 56], ["sucrose", "SIMPLE_CHEMICAL", 49, 56], ["KXS treatment", "TREATMENT", 6, 19], ["open-field test scores", "TEST", 21, 43], ["sucrose consumption", "TEST", 49, 68], ["depression", "PROBLEM", 106, 116], ["significantly", "OBSERVATION_MODIFIER", 138, 151], ["increased", "OBSERVATION_MODIFIER", 152, 161]]], ["For cardioprotective effects, KXS treatment could improve the EF and FS, down-regulate CK-MB, LDH, and MDA, and up-regulate SOD, GSH-PX, and CAT.", [["KXS", "CHEMICAL", 30, 33], ["MDA", "CHEMICAL", 103, 106], ["GSH", "CHEMICAL", 129, 132], ["KXS", "CHEMICAL", 30, 33], ["MDA", "CHEMICAL", 103, 106], ["GSH", "CHEMICAL", 129, 132], ["KXS", "SIMPLE_CHEMICAL", 30, 33], ["CK-MB", "GENE_OR_GENE_PRODUCT", 87, 92], ["LDH", "SIMPLE_CHEMICAL", 94, 97], ["MDA", "SIMPLE_CHEMICAL", 103, 106], ["SOD", "GENE_OR_GENE_PRODUCT", 124, 127], ["GSH-PX", "GENE_OR_GENE_PRODUCT", 129, 135], ["CAT", "GENE_OR_GENE_PRODUCT", 141, 144], ["CK", "PROTEIN", 87, 89], ["SOD", "PROTEIN", 124, 127], ["PX", "PROTEIN", 133, 135], ["CAT", "PROTEIN", 141, 144], ["cardioprotective effects", "TREATMENT", 4, 28], ["KXS treatment", "TREATMENT", 30, 43], ["the EF", "TEST", 58, 64], ["FS", "TEST", 69, 71], ["CK", "TEST", 87, 89], ["MB", "TEST", 90, 92], ["LDH", "TEST", 94, 97], ["MDA", "TEST", 103, 106], ["GSH", "TEST", 129, 132], ["LDH", "ANATOMY", 94, 97]]], ["Meanwhile, KXS treatment reduced the levels of CRP, IL-6, and TNF-\u03b1 in myocardial tissue compared with the model group.Data Availability StatementThe raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.Ethics StatementAll animal related experiments were approved by the Animal Experimentation Ethics Committee of Chinese PLA General Hospital (number: 2017-x15-23).", [["myocardial tissue", "ANATOMY", 71, 88], ["KXS", "CHEMICAL", 11, 14], ["KXS", "CHEMICAL", 11, 14], ["KXS", "SIMPLE_CHEMICAL", 11, 14], ["CRP", "GENE_OR_GENE_PRODUCT", 47, 50], ["IL-6", "GENE_OR_GENE_PRODUCT", 52, 56], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 62, 67], ["myocardial tissue", "TISSUE", 71, 88], ["CRP", "PROTEIN", 47, 50], ["IL-6", "PROTEIN", 52, 56], ["TNF-\u03b1", "PROTEIN", 62, 67], ["KXS treatment", "TREATMENT", 11, 24], ["CRP", "TEST", 47, 50], ["IL", "TEST", 52, 54], ["TNF", "TEST", 62, 65], ["myocardial tissue", "ANATOMY", 71, 88]]], ["All animal handling procedures were carried out in compliance with the \u2018Principles of Laboratory Animal Care\u2019 and the Chinese legislation for the use and care of laboratory animals.Author ContributionsYH, XL, PL, and YC contributed to study design, trial, and writing of this study.", [["All animal handling procedures", "TREATMENT", 0, 30], ["this study", "TEST", 271, 281], ["PL", "ANATOMY", 209, 211]]], ["TYZ, CC, and XZD contributed to the trial.FundingFinancial support was provided by National Natural Science Foundation of China (No 81573876 and 81973520) for the study and collection, analysis, interpretation of data and in writing the manuscript, and Clinical Research Support Funding of PLA General Hospital (2016FS-TSYS-2045) for the study and analysis.Conflict of InterestThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [["TYZ", "CHEMICAL", 0, 3], ["CC", "CHEMICAL", 5, 7], ["XZD", "CHEMICAL", 13, 16], ["2016FS-TSYS-2045", "CHEMICAL", 312, 328], ["TYZ", "SIMPLE_CHEMICAL", 0, 3], ["XZD", "PROBLEM", 13, 16], ["the study", "TEST", 159, 168], ["collection, analysis", "TEST", 173, 193], ["the study", "TEST", 334, 343], ["analysis", "TEST", 348, 356]]]], "PMC7306943": [["For example, the initiation of social distancing, self-isolation and lockdowns limits face-to-face social contact with others; a model of interaction known to reduce the risk of Depressive disorder.9Impact on the General Public ::: Mental Health Impact of COVID-19Social connection is vital to well-being in humans10, and whilst internet-based media and applications such as Zoom, Skype, WhatsApp and FaceTime may allow for social interactions to continue, they do not replace the need for in-person human contact.", [["Depressive disorder", "DISEASE", 178, 197], ["humans", "ORGANISM", 308, 314], ["human", "ORGANISM", 500, 505], ["humans", "SPECIES", 308, 314], ["human", "SPECIES", 500, 505], ["humans", "SPECIES", 308, 314], ["human", "SPECIES", 500, 505], ["self-isolation", "TREATMENT", 50, 64], ["Depressive disorder", "PROBLEM", 178, 197], ["COVID", "TREATMENT", 256, 261]]], ["It is possible that people may begin to experience transient mild to moderate depressive symptoms in the current circumstances.", [["depressive symptoms", "DISEASE", 78, 97], ["people", "ORGANISM", 20, 26], ["people", "SPECIES", 20, 26], ["transient mild to moderate depressive symptoms", "PROBLEM", 51, 97], ["mild", "OBSERVATION_MODIFIER", 61, 65], ["moderate", "OBSERVATION_MODIFIER", 69, 77], ["depressive", "OBSERVATION_MODIFIER", 78, 88], ["symptoms", "OBSERVATION", 89, 97]]], ["Additionally, there is likely to be increased vigilance towards cleanliness and hygiene, which when coupled with fears of infection and disease may lead to feeling more anxious than usual, and in persons with pre-existing psychiatric vulnerabilities it may manifest as the development of anxiety disorders.Impact on the General Public ::: Mental Health Impact of COVID-19In addition to heightened risk of Depression and Anxiety for the general public, it has been predicted that the COVID-19 pandemic is likely to increase rates of substance use, loneliness, domestic violence and child abuse11.", [["infection", "DISEASE", 122, 131], ["psychiatric vulnerabilities", "DISEASE", 222, 249], ["anxiety disorders", "DISEASE", 288, 305], ["Depression", "DISEASE", 405, 415], ["Anxiety", "DISEASE", 420, 427], ["loneliness", "DISEASE", 547, 557], ["domestic violence", "DISEASE", 559, 576], ["abuse", "DISEASE", 587, 592], ["persons", "SPECIES", 196, 203], ["increased vigilance", "PROBLEM", 36, 55], ["infection", "PROBLEM", 122, 131], ["disease", "PROBLEM", 136, 143], ["feeling more anxious", "PROBLEM", 156, 176], ["pre-existing psychiatric vulnerabilities", "PROBLEM", 209, 249], ["anxiety disorders", "PROBLEM", 288, 305], ["COVID", "TREATMENT", 363, 368], ["Depression", "PROBLEM", 405, 415], ["Anxiety", "PROBLEM", 420, 427], ["likely to be", "UNCERTAINTY", 23, 35], ["increased", "OBSERVATION_MODIFIER", 36, 45], ["vigilance", "OBSERVATION_MODIFIER", 46, 55], ["infection", "OBSERVATION", 122, 131], ["Depression", "OBSERVATION", 405, 415]]], ["Substance use may increase for those seeking recreation, thrill-seeking or as a way of self-medicating for stress and anxiety.", [["anxiety", "DISEASE", 118, 125], ["stress", "PROBLEM", 107, 113], ["anxiety", "PROBLEM", 118, 125]]], ["Domestic violence and child abuse may increase due to isolation and lockdowns whereby abusers and victims will be in close proximity without much possibility of escape.", [["Domestic violence", "DISEASE", 0, 17], ["child abuse", "DISEASE", 22, 33]]], ["These are all factors known to contribute to the development and worsening of psychiatric disorders.Impact on Patients of COVID-19 ::: Mental Health Impact of COVID-19This is an area for further research.", [["psychiatric disorders", "DISEASE", 78, 99], ["Patients", "ORGANISM", 110, 118], ["Patients", "SPECIES", 110, 118], ["psychiatric disorders", "PROBLEM", 78, 99], ["COVID", "TREATMENT", 159, 164], ["worsening", "OBSERVATION_MODIFIER", 65, 74]]], ["As yet there are no empirical data available relating to the mental health impact of contracting COVID-19.", [["COVID-19", "CHEMICAL", 97, 105], ["empirical data", "TEST", 20, 34], ["contracting COVID", "TEST", 85, 102]]], ["However, lessons from previous pandemic situations indicate that there is likely to be a risk of COVID-19 patients, who recover, developing symptoms of PTSD or Depression.7 This is likely to be moderated by personal traits such as resilience, availability and quality of social support and the patient\u2019s own worries related to the illness and recovery.8Impact on Healthcare Workers ::: Mental Health Impact of COVID-19Whilst healthcare workers reported increased psychological distress during the SARS pandemic, perception of risk and perceptions of own health mediated the development of psychiatric morbidity.12 Those who perceived themselves to be at risk, were without protective gear and felt their own health to be sub-optimal, were more likely to develop psychiatric morbidity as compared to those who volunteered to work on SARS wards.13 This indicates the importance of organisational and governmental support for healthcare workers in terms of provision of suitable equipment, protective measures and working conditions to ensure minimal mental health difficulties.", [["PTSD", "DISEASE", 152, 156], ["Depression", "DISEASE", 160, 170], ["illness", "DISEASE", 331, 338], ["psychological distress", "DISEASE", 463, 485], ["SARS", "DISEASE", 497, 501], ["psychiatric", "DISEASE", 589, 600], ["psychiatric", "DISEASE", 762, 773], ["SARS", "DISEASE", 832, 836], ["patients", "ORGANISM", 106, 114], ["patient", "ORGANISM", 294, 301], ["patients", "SPECIES", 106, 114], ["patient", "SPECIES", 294, 301], ["previous pandemic situations", "PROBLEM", 22, 50], ["symptoms", "PROBLEM", 140, 148], ["PTSD", "PROBLEM", 152, 156], ["Depression", "PROBLEM", 160, 170], ["social support", "TREATMENT", 271, 285], ["the illness", "PROBLEM", 327, 338], ["increased psychological distress", "PROBLEM", 453, 485], ["psychiatric morbidity", "PROBLEM", 589, 610], ["psychiatric morbidity", "PROBLEM", 762, 783], ["organisational and governmental support", "TREATMENT", 879, 918], ["suitable equipment", "TREATMENT", 967, 985], ["protective measures", "TREATMENT", 987, 1006], ["working conditions", "TREATMENT", 1011, 1029], ["minimal mental health difficulties", "PROBLEM", 1040, 1074], ["likely to be", "UNCERTAINTY", 74, 86], ["likely to be", "UNCERTAINTY", 181, 193], ["minimal", "OBSERVATION_MODIFIER", 1040, 1047]]], ["It also indicates that pre-existing factors such as psychological resilience, emotional resources such as social/familial support and preparedness may improve mental health outcomes for healthcare workers.Impact on Persons with Pre-Existing Mental Health Difficulties ::: Mental Health Impact of COVID-19Mental health conditions are chronic health co-morbidities that are often overlooked and considered comparatively unimportant as compared to medical co-morbidities like diabetes, hypertension etc. However, people suffering from mental health conditions already experience poverty, chronic medical problems and social disparity.", [["diabetes", "DISEASE", 473, 481], ["hypertension", "DISEASE", 483, 495], ["poverty", "DISEASE", 576, 583], ["people", "ORGANISM", 510, 516], ["Persons", "SPECIES", 215, 222], ["people", "SPECIES", 510, 516], ["pre-existing factors", "PROBLEM", 23, 43], ["emotional resources", "TREATMENT", 78, 97], ["social/familial support", "TREATMENT", 106, 129], ["chronic health co-morbidities", "PROBLEM", 333, 362], ["diabetes", "PROBLEM", 473, 481], ["hypertension etc", "PROBLEM", 483, 499], ["mental health conditions", "PROBLEM", 532, 556], ["chronic medical problems", "PROBLEM", 585, 609], ["social disparity", "PROBLEM", 614, 630], ["chronic", "OBSERVATION_MODIFIER", 333, 340], ["diabetes", "OBSERVATION", 473, 481], ["hypertension", "OBSERVATION", 483, 495], ["chronic", "OBSERVATION_MODIFIER", 585, 592]]], ["Needless to say, COVID-19 is likely to adversely affect this population more acutely than the rest.14Impact on Persons with Pre-Existing Mental Health Difficulties ::: Mental Health Impact of COVID-19For persons with pre-existing psychiatric disorders, the main concern is the worsening of symptoms; for those with pre-existing vulnerabilities, it is the onset of psychiatric symptoms that is the primary concern.", [["psychiatric disorders", "DISEASE", 230, 251], ["psychiatric", "DISEASE", 364, 375], ["persons", "ORGANISM", 204, 211], ["Persons", "SPECIES", 111, 118], ["persons", "SPECIES", 204, 211], ["COVID", "TEST", 17, 22], ["COVID", "TREATMENT", 192, 197], ["pre-existing psychiatric disorders", "PROBLEM", 217, 251], ["the worsening of symptoms", "PROBLEM", 273, 298], ["psychiatric symptoms", "PROBLEM", 364, 384], ["worsening", "OBSERVATION_MODIFIER", 277, 286]]], ["Stress is a well-established contributor to development, onset and severity of mental health disorders.15 Anxiety and Depression are on the rise in the general population, with one in three people experiencing anxiety and one in five sleep disturbance and depressive symptoms.16 Sufferers of generalised anxiety and health anxiety may find increase in their symptoms during pandemic.", [["Anxiety", "DISEASE", 106, 113], ["Depression", "DISEASE", 118, 128], ["anxiety", "DISEASE", 210, 217], ["sleep disturbance", "DISEASE", 234, 251], ["depressive symptoms", "DISEASE", 256, 275], ["anxiety", "DISEASE", 304, 311], ["anxiety", "DISEASE", 323, 330], ["people", "ORGANISM", 190, 196], ["people", "SPECIES", 190, 196], ["mental health disorders", "PROBLEM", 79, 102], ["Anxiety", "PROBLEM", 106, 113], ["Depression", "PROBLEM", 118, 128], ["anxiety", "PROBLEM", 210, 217], ["five sleep disturbance", "PROBLEM", 229, 251], ["depressive symptoms", "PROBLEM", 256, 275], ["generalised anxiety", "PROBLEM", 292, 311], ["health anxiety", "PROBLEM", 316, 330], ["their symptoms", "PROBLEM", 352, 366], ["pandemic", "PROBLEM", 374, 382], ["Depression", "OBSERVATION", 118, 128]]], ["Depressive symptoms may worsen with increased low mood, decreased energy, and limited interest in day-to-day activities.", [["Depressive symptoms", "DISEASE", 0, 19], ["low mood", "DISEASE", 46, 54], ["Depressive symptoms", "PROBLEM", 0, 19], ["increased low mood", "PROBLEM", 36, 54], ["decreased energy", "PROBLEM", 56, 72]]], ["In crises, fear intensifies symptoms in people with pre-existing mental health disorders.17 For instance, stress is a well-documented factor in the worsening of symptoms of people with Schizophrenia and Bipolar Affective Disorder.", [["Schizophrenia", "DISEASE", 185, 198], ["Bipolar Affective Disorder", "DISEASE", 203, 229], ["people", "ORGANISM", 40, 46], ["people", "ORGANISM", 173, 179], ["people", "SPECIES", 40, 46], ["people", "SPECIES", 173, 179], ["fear intensifies symptoms", "PROBLEM", 11, 36], ["pre-existing mental health disorders", "PROBLEM", 52, 88], ["symptoms", "PROBLEM", 161, 169], ["Schizophrenia", "PROBLEM", 185, 198], ["Bipolar Affective Disorder", "PROBLEM", 203, 229], ["worsening", "OBSERVATION_MODIFIER", 148, 157], ["Schizophrenia", "OBSERVATION", 185, 198], ["Bipolar Affective", "OBSERVATION", 203, 220]]], ["In the aftermath of a natural disaster, patients suffering from Schizophrenia show the highest avoidance and have low approach coping, followed by patients suffering from Bipolar Disorder.18 It is possible that those with Obsessive-Compulsive Disorder (OCD) with pre-occupations of contamination and cleanliness may experience increased frequency and intensity of obsessive thoughts.", [["Schizophrenia", "DISEASE", 64, 77], ["Bipolar Disorder", "DISEASE", 171, 187], ["Obsessive-Compulsive Disorder", "DISEASE", 222, 251], ["OCD", "DISEASE", 253, 256], ["obsessive thoughts", "DISEASE", 364, 382], ["patients", "ORGANISM", 40, 48], ["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 147, 155], ["Schizophrenia", "PROBLEM", 64, 77], ["Bipolar Disorder", "PROBLEM", 171, 187], ["Obsessive-Compulsive Disorder", "PROBLEM", 222, 251], ["OCD", "PROBLEM", 253, 256], ["pre-occupations of contamination", "PROBLEM", 263, 295], ["increased frequency", "PROBLEM", 327, 346], ["obsessive thoughts", "PROBLEM", 364, 382], ["Bipolar Disorder", "OBSERVATION", 171, 187]]], ["The emphasis on frequent hand washing and the risk of infection after touching objects and meeting people as a part of COVID-19 preventions, as propagated by the government, media and social media, enhances the risk of relapse in persons with OCD.19Possible General Interventions ::: Mental Health Impact of COVID-19In the current era of international travel, any outbreak of infection has the potential to become a pandemic, leading to consequences for world health, economics and politics.", [["hand", "ANATOMY", 25, 29], ["infection", "DISEASE", 54, 63], ["OCD", "DISEASE", 243, 246], ["infection", "DISEASE", 376, 385], ["hand", "ORGANISM_SUBDIVISION", 25, 29], ["people", "ORGANISM", 99, 105], ["persons", "ORGANISM", 230, 237], ["people", "SPECIES", 99, 105], ["persons", "SPECIES", 230, 237], ["frequent hand washing", "TREATMENT", 16, 37], ["infection", "PROBLEM", 54, 63], ["OCD", "PROBLEM", 243, 246], ["COVID", "TREATMENT", 308, 313], ["infection", "PROBLEM", 376, 385], ["a pandemic", "PROBLEM", 414, 424], ["infection", "OBSERVATION", 54, 63], ["infection", "OBSERVATION", 376, 385]]], ["Pandemics create a burden on healthcare professionals because of increased workload, high absenteeism, high mortality rates, lack of personal protective equipment, risk of infection and transmitting infection to loved ones, and ethical dilemmas of providing care to people.20Resilience Training ::: Mental Health Impact of COVID-19As seen in previous such crises (SARS 2003, Influenza 2009), healthcare workers who were adequately trained to deal with disaster situations reported better coping and no long term psychiatric problems as compared to people with no prior training.21 Therefore, the introduction of resilience training for healthcare professionals may be beneficial.", [["infection", "DISEASE", 172, 181], ["infection", "DISEASE", 199, 208], ["SARS", "DISEASE", 364, 368], ["psychiatric", "DISEASE", 512, 523], ["people", "ORGANISM", 266, 272], ["people", "ORGANISM", 548, 554], ["people", "SPECIES", 266, 272], ["people", "SPECIES", 548, 554], ["Pandemics", "PROBLEM", 0, 9], ["increased workload", "PROBLEM", 65, 83], ["high absenteeism", "PROBLEM", 85, 101], ["high mortality rates", "PROBLEM", 103, 123], ["personal protective equipment", "TREATMENT", 133, 162], ["infection", "PROBLEM", 172, 181], ["transmitting infection", "PROBLEM", 186, 208], ["long term psychiatric problems", "PROBLEM", 502, 532], ["resilience training", "TREATMENT", 612, 631], ["healthcare professionals", "TREATMENT", 636, 660], ["burden", "OBSERVATION_MODIFIER", 19, 25], ["increased", "OBSERVATION_MODIFIER", 65, 74], ["infection", "OBSERVATION", 172, 181]]], ["Resilience training leads to professionals being better able to cope with highly stressful situations.22Resilience Training ::: Mental Health Impact of COVID-19Resilience training has 10 steps: 1-Family-work balance, 2.", [["Resilience training", "TREATMENT", 0, 19]]], ["Antiviral prophylaxis, 3.", [["Antiviral prophylaxis", "TREATMENT", 0, 21]]], ["Need for ongoing resilience training.22Social Media Use ::: Mental Health Impact of COVID-19As fear is usually higher than risk of infection23, it is important for people to maintain a sense of normalcy in times of social distancing and quarantine.", [["people", "ORGANISM", 164, 170], ["people", "SPECIES", 164, 170], ["ongoing resilience training", "TREATMENT", 9, 36], ["COVID", "TREATMENT", 84, 89], ["infection23", "PROBLEM", 131, 142]]], ["Any news, verified or not, via social media and television adds to the panic and fears of the public.", [["panic", "DISEASE", 71, 76]]], ["In order to mitigate this, the public should be encouraged to decrease or minimise excess exposure to social media.", [["social media", "TREATMENT", 102, 114]]], ["Beneficial use of social media such as to communicate with loved ones, provide support and reassurance, provide practical advice and to seek help in case of a mental health difficulty can be used to support the public and pre-empt panic.23Social Connection & Individual Actions ::: Mental Health Impact of COVID-19Due to mass quarantine and social distancing, to prevent a sense of disconnection, people are advised to communicate with loved ones, reduce exposure to the news, maintain a positive attitude, take good care of their health, be aware of their own emotions and talk to someone if feeling sad or anxious.", [["panic", "DISEASE", 231, 236], ["people", "ORGANISM", 397, 403], ["people", "SPECIES", 397, 403], ["social media", "TREATMENT", 18, 30], ["reassurance", "TREATMENT", 91, 102], ["a mental health difficulty", "PROBLEM", 157, 183], ["panic", "PROBLEM", 231, 236], ["COVID", "TREATMENT", 306, 311], ["anxious", "PROBLEM", 608, 615]]], ["It is also advisable to rely on official news outlets and government guidelines regarding the pandemic.24Tele-Health ::: Mental Health Impact of COVID-19It has been suggested that psychiatric morbidities in developing countries may be mitigated by the provision of tele-health services, task-sharing amongst professionals and guidance and advice from professionals in more development nations.25 Whilst these measures would offer some respite, there are certain caveats such as limited internet access for many, the limited number of mental health professionals available in non-urban areas, and privacy, confidentiality and risk management issues with tele-health.Possible Mental Health Specific Interventions ::: Mental Health Impact of COVID-19In order to address mental health distress, steps may be taken to ensure psychological and emotional wellbeing.", [["psychiatric morbidities", "DISEASE", 180, 203], ["the pandemic", "PROBLEM", 90, 102], ["COVID", "TREATMENT", 145, 150], ["psychiatric morbidities", "PROBLEM", 180, 203], ["COVID", "TREATMENT", 739, 744], ["mental health distress", "PROBLEM", 767, 789]]], ["This will allow the incorporation of psychiatric interventions in the management of patients with coronavirus and their families.20,26 Clear and consistent information regarding the disease and management plan should be provided to everyone so as to avoid panic and confusion.27 As we try to limit exposure for the public and healthcare workers, the already strained frontline workers are left to deal with the psychological stress of patients.", [["psychiatric", "DISEASE", 37, 48], ["coronavirus", "DISEASE", 98, 109], ["panic", "DISEASE", 256, 261], ["confusion", "DISEASE", 266, 275], ["patients", "ORGANISM", 84, 92], ["coronavirus", "ORGANISM", 98, 109], ["patients", "ORGANISM", 435, 443], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 435, 443], ["psychiatric interventions", "TREATMENT", 37, 62], ["the management", "TREATMENT", 66, 80], ["coronavirus", "PROBLEM", 98, 109], ["the disease", "PROBLEM", 178, 189], ["management plan", "TREATMENT", 194, 209], ["panic", "PROBLEM", 256, 261], ["confusion", "PROBLEM", 266, 275]]], ["It is essential to offer tele-psychiatry in all medical settings to deal with the psychological burden of the disease.25 Furthermore, institutional guidelines need to be created to address how to deal with mental health difficulties in patients, healthcare workers and the general population, and to ensure the availability of specialist care.26Possible Mental Health Specific Interventions ::: Mental Health Impact of COVID-19Telemedicine services are readily available to anyone owning a telephone or a computer28,25 and can be provided through video calls, phone call, text messaging and online forums.", [["patients", "ORGANISM", 236, 244], ["patients", "SPECIES", 236, 244], ["the disease", "PROBLEM", 106, 117], ["disease", "OBSERVATION", 110, 117]]], ["In China, the government has set up telemedicine units to give appropriate guidance, spread awareness and provide psychological counselling to those in need of it in order to prevent the long term effects of mental health distress.27,25Psychological First Aid ::: Mental Health Impact of COVID-19Psychological First Aid is a psychological intervention offered to survivors of disasters or disease outbreaks such as that of COVID-19.", [["psychological counselling", "TREATMENT", 114, 139], ["mental health distress", "PROBLEM", 208, 230], ["a psychological intervention", "TREATMENT", 323, 351], ["disease outbreaks", "PROBLEM", 389, 406], ["COVID", "TEST", 423, 428], ["long term", "OBSERVATION_MODIFIER", 187, 196]]], ["It emphasises compassion for survivors, the provision of informational care and creating space for listening to their stories, in order to ease their early rehabilitation.29 In crises, it is important to provide safety, adequate information, basic needs and comfort.29 In the current circumstances, where fear, anxiety or \u2018pandemic anxiety\u2019 may make one feel out of control, psychological first aid can be a helpful way to aid people in managing their experiences and emotions.Authors\u2019 Contribution ::: CONCLUSIONSIIH: Conceived the review, initiated the literature search, contributed to its draft and coordination.Authors\u2019 Contribution ::: CONCLUSIONSFT: Conducted literature review, contributed to writing & reviewing the manuscript.Authors\u2019 Contribution ::: CONCLUSIONSSMT: Conducted literature review, and contributed to write-up & critical revision.Authors\u2019 Contribution ::: CONCLUSIONSAll authors read and approved the final manuscript.", [["anxiety", "DISEASE", 311, 318], ["anxiety", "DISEASE", 332, 339], ["people", "ORGANISM", 427, 433], ["people", "SPECIES", 427, 433], ["informational care", "TREATMENT", 57, 75], ["fear", "PROBLEM", 305, 309], ["anxiety", "PROBLEM", 311, 318], ["\u2018pandemic anxiety", "PROBLEM", 322, 339], ["critical revision", "TREATMENT", 837, 854], ["revision", "OBSERVATION", 846, 854]]]], "PMC7184975": [["En Argentina, no hay registros confiables con anterioridad al siglo xx, pero se supone que durante aquel per\u00edodo la EVN registr\u00f3 pocos cambios, manteni\u00e9ndose en alrededor de 30 a\u00f1os.", [["no", "UNCERTAINTY", 14, 16]]], ["Luego comenz\u00f3 a incrementarse y, seg\u00fan datos del INDEC3, ya en 1905 alcanzaba los 40 a\u00f1os y en 1947 llegaba casi a 60 a\u00f1os.", [["seg\u00fan datos del INDEC3, ya en 1905 alcanzaba los 40 a\u00f1os y en 1947 llegaba casi", "SPECIES", 33, 112]]], ["Desde entonces, la EVN registra un crecimiento constante, con pendientes de aproximadamente un a\u00f1o de incremento cada 2,5 a\u00f1os calendario en el per\u00edodo 1880-1965 y de un a\u00f1o de incremento cada 5 a\u00f1os calendario en el per\u00edodo 1965-2010 (fig. 1A).", [["incremento cada 2,5 a\u00f1os calendario en el per\u00edodo 1880-1965 y de un a\u00f1o de incremento cada 5 a\u00f1os calendario en el per\u00edodo 1965-2010 (fig. 1A", "SPECIES", 102, 243]]], ["Estos datos se corroboran en una serie hist\u00f3rica 1960-2017 publicada por el Banco Mundial1, en la cual, si se compara la curva de EVN de Argentina con las del mundo, la regi\u00f3n y Noruega \u2014el pa\u00eds con mayor \u00edndice de desarrollo humano\u2014, puede observarse, por un lado, que a menor EVN, mayor tiende a ser su tasa de incremento anual y, por otro lado, que posibilitando el acceso a mejores condiciones de vida para toda nuestra poblaci\u00f3n, esta podr\u00eda vivir 6 a\u00f1os m\u00e1s, en promedio (fig. 1B).", [["Estos datos se corroboran en una serie hist\u00f3rica 1960-2017 publicada por el Banco Mundial1, en la cual", "SPECIES", 0, 102], ["hist\u00f3rica", "TEST", 39, 48], ["publicada", "TEST", 59, 68], ["Mundial1", "TEST", 82, 90]]]], "fe45dd208c3a4a741b6b7b861c3e282b9adbc496": [["I. INTRODUCTIONWitnessing an alarmingly large number of novel pandemics in this century such as SARS, Swine Flue, MERS, Ebola, and Zika, there has been growing concerns on the ''next big one'' [1] .", [["SARS", "DISEASE", 96, 100], ["Ebola", "DISEASE", 120, 125], ["Zika", "DISEASE", 131, 135], ["SARS", "PROBLEM", 96, 100]]], ["Consequently, there are calls for technology-based preparedness [3] , especially in the areas of infection prevention, case finding, case investigation, and contact tracing [4] .", [["infection", "DISEASE", 97, 106], ["infection prevention", "TREATMENT", 97, 117], ["infection", "OBSERVATION", 97, 106]]], ["In this paper, we tackle one of the areas that need the technological revamping: contact tracing.I. INTRODUCTIONOn the brink of an infectious disease epidemic, the most urgent task is to trace those who possibly made contacts with the infected person(s), in order to cut the chain of infection and prevent it from growing into a wider epidemic.", [["infectious disease", "DISEASE", 131, 149], ["infection", "DISEASE", 284, 293], ["person", "SPECIES", 244, 250], ["contact tracing", "TEST", 81, 96], ["an infectious disease epidemic", "PROBLEM", 128, 158], ["infection", "PROBLEM", 284, 293], ["infectious", "OBSERVATION", 131, 141], ["infection", "OBSERVATION", 284, 293]]], ["Meanwhile, recent outbreaks have been fundamentally different from those of the past -highly mobile populations [6] and the spread into densely populated cities [2] -which exacerbate the problem with the traditional contact tracing approach.I. INTRODUCTIONWhen there are many potential contacts that an infected person cannot identify or recollect as in our typical urban life, a potent tool we can marshal is the mobile devices such as smartphones.", [["person", "SPECIES", 312, 318], ["fundamentally", "OBSERVATION_MODIFIER", 38, 51], ["different", "OBSERVATION_MODIFIER", 52, 61], ["densely", "OBSERVATION_MODIFIER", 136, 143]]], ["The mobile-based epidemic monitoring is nothing but a logical next step because only the mobile devices that move with people can keep up with the contacts they make.", [["people", "ORGANISM", 119, 125], ["people", "SPECIES", 119, 125], ["the mobile devices", "TREATMENT", 85, 103], ["mobile", "OBSERVATION_MODIFIER", 4, 10]]], ["Indeed, there have been increasing number of proposals for smartphone-based contact tracing.", [["increasing", "OBSERVATION_MODIFIER", 24, 34], ["number", "OBSERVATION_MODIFIER", 35, 41]]], ["The employed technologies range from similar Global Positioning System (GPS) positions [7] , similar Wi-Fi fingerprints [8] , Bluetooth peer discovery [9] , and identical cells in mobile communication [10] .", [["cells", "ANATOMY", 171, 176], ["cells", "CELL", 171, 176]]], ["Unfortunately, they either provide position information too coarse to be used for infectious contact detection [11] (GPS, cellular/Wi-Fi fingerprinting), require the infrastructure nearby (cellular/Wi-Fi), cannot be used indoors (GPS), consumes too much power for extended monitoring use (GPS) [12] , or could compromise privacy by exposing the identity of the device and eventually its owner (Bluetooth beacons).I. INTRODUCTIONHowever, some recent works including our earlier pilot study [11] , [13] present a new possibility by demonstrating that a magnetometer traces-based approach can detect close contacts.", [["cellular", "ANATOMY", 122, 130], ["cellular", "ANATOMY", 189, 197], ["cellular", "CELL", 122, 130], ["cellular", "CELL", 189, 197], ["infectious contact detection", "TEST", 82, 110], ["cellular/Wi-Fi fingerprinting", "TREATMENT", 122, 151], ["the device", "TREATMENT", 357, 367], ["our earlier pilot study", "TEST", 465, 488], ["a magnetometer traces", "TEST", 549, 570]]], ["They exploit the fact that the magnetic field strength is rich in spatial features (e.g. 1 m \u22121 to 0.01 m \u22121 ) [14] due to various distortions by ferromagnetic materials used in buildings such as reinforced concrete and metal doors.", [["various distortions", "PROBLEM", 123, 142], ["ferromagnetic materials", "TREATMENT", 146, 169]]], ["The magnetometer-based approach overcomes most of the aforementioned issues.", [["The magnetometer-based approach", "TREATMENT", 0, 31]]], ["Second, it offers better privacy protection by not revealing any identity of the device or the location of the trace generation.", [["the device", "TREATMENT", 77, 87], ["trace generation", "OBSERVATION", 111, 127]]], ["The lowpower smartphone magnetometers can only be affected by ferromagnetic structures within a few meters [15] , [16] .", [["The lowpower smartphone magnetometers", "TREATMENT", 0, 37]]], ["This last characteristics is especially important as many infectious disease transmissions occur in close distances.", [["many infectious disease transmissions", "PROBLEM", 53, 90], ["especially important", "UNCERTAINTY", 29, 49], ["infectious", "OBSERVATION_MODIFIER", 58, 68]]], ["Public health policies for tracing close contacts or infection control guidance often use a distance of up to 2 meters or 6 feet [18] .I. INTRODUCTIONWhen the disease control authority performs an epidemiological investigation, they can use the smartphone magnetometer traces of the person confirmed infected and of the one suspected of a contact with the infected, in a system depicted in Fig. 1 .", [["infection", "DISEASE", 53, 62], ["person", "SPECIES", 283, 289], ["infection control guidance", "TREATMENT", 53, 79], ["an epidemiological investigation", "TEST", 194, 226], ["infected", "OBSERVATION", 300, 308], ["infected", "OBSERVATION", 356, 364]]], ["When people make contacts, they are recorded in their individual phones in the form of similar magnetometer readings.", [["people", "ORGANISM", 5, 11], ["people", "SPECIES", 5, 11]]], ["When they want to check if they could have met an infected person, they can ask the system to compare their traces with that of the infected person.", [["person", "SPECIES", 59, 65], ["person", "SPECIES", 141, 147], ["infected", "OBSERVATION", 50, 58], ["infected", "OBSERVATION", 132, 140]]], ["Since it is a pairwise comparison, it works for the case many people gather at a location.", [["people", "ORGANISM", 62, 68], ["people", "SPECIES", 62, 68]]], ["In this paper, we assume that it is an emergency situation, and people are cooperating with the disease control authority by downloading an application that records the magnetometer readings and submits it through the phone's cellular connection if necessary.", [["cellular", "ANATOMY", 226, 234], ["people", "ORGANISM", 64, 70], ["cellular", "CELL", 226, 234], ["people", "SPECIES", 64, 70], ["the magnetometer readings", "TEST", 165, 190]]], ["In this effort by British Broadcasting Corporation (BBC), people are encouraged to download an app and activate it for helping model the spreading dynamics in future pandemics.", [["people", "ORGANISM", 58, 64], ["people", "SPECIES", 58, 64]]], ["Considering this precedent, our own system model in Fig. 1 is not excessively unrealistic.", [["not", "UNCERTAINTY", 62, 65], ["excessively", "OBSERVATION_MODIFIER", 66, 77], ["unrealistic", "OBSERVATION", 78, 89]]], ["Under the depicted scenario, not only the disease control authority but also each individual user can check herself whether or not there has been close contact with an infected person.", [["person", "SPECIES", 177, 183], ["infected", "OBSERVATION", 168, 176]]], ["Indeed, World Health Organization (WHO) strongly recommends that disease control authorities ensure at-risk populations have the information they need, thereby minimizing social and economic disruption [21] .I. INTRODUCTIONAlthough the existing magnetometer-based works have confirmed the feasibility of the idea, they are a far cry from a serious alternative to the traditional contact tracing method.", [["disease control", "TREATMENT", 65, 80]]], ["However, when two people, possibly strangers, make a contact, its duration can be very small compared to the entire span of comparison (which can match the most active transmission period of the disease).", [["people", "ORGANISM", 18, 24], ["people", "SPECIES", 18, 24], ["small", "OBSERVATION_MODIFIER", 87, 92]]], ["In Fig. 2 , if the infected person A was confirmed infected at time t and the disease transmissible duration is l tx , the similarity measure between the traces R A and R B can be computed low if the duration of contact l 2 l tx .", [["person", "ORGANISM", 28, 34], ["R B", "GENE_OR_GENE_PRODUCT", 169, 172], ["person", "SPECIES", 28, 34], ["l tx", "TREATMENT", 112, 116], ["contact l 2 l tx", "TREATMENT", 212, 228]]], ["Therefore, we need to define the window of comparison T W that we slide over the entire trace pair to find any contact (i.e., the similarity measure over a threshold) to make it a valid test method.", [["T W", "GENE_OR_GENE_PRODUCT", 54, 57], ["a valid test method", "TEST", 178, 197]]], ["Second, when new diagnostic tests are introduced, it is necessary to evaluate the comparative diagnostic accuracy and feasibility of this new test in comparison to the existing tests or the gold standard [22] .", [["new diagnostic tests", "TEST", 13, 33], ["this new test", "TEST", 133, 146], ["the existing tests", "TEST", 164, 182]]], ["This ability and diagnostic accuracy can be quantified by calculating various measures such as sensitivity and specificity, positive and negative likelihood ratios, diagnostic odds ratio,etc. In this paper, we address these issues by defining the desirable length of T W , the decision threshold \u03b8 c , and by evaluating the quality of the contact diagnosis under these parameter values.I. INTRODUCTIONAs to the nature of the technology we propose in this paper, one can argue that it is only supplementary.", [["T W", "GENE_OR_GENE_PRODUCT", 267, 270], ["diagnostic accuracy", "TEST", 17, 36], ["sensitivity", "TEST", 95, 106], ["specificity", "TEST", 111, 122]]], ["In that we believe that the final confirmation about the infection event should be always made by human experts, it is true to a certain degree.", [["infection", "DISEASE", 57, 66], ["human", "ORGANISM", 98, 103], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 98, 103], ["the infection event", "PROBLEM", 53, 72], ["infection", "OBSERVATION", 57, 66]]], ["It can be used to quickly identify possible contacts with relatively high accuracy, so that the human experts can focus on the most likely ones that have been identified by technology.", [["human", "ORGANISM", 96, 101], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 96, 101]]], ["In largescale epidemics, the technology can quickly pan out even such contacts that cannot be recovered from the memory of the infected person.", [["person", "SPECIES", 136, 142], ["largescale", "OBSERVATION_MODIFIER", 3, 13], ["epidemics", "OBSERVATION", 14, 23], ["infected", "OBSERVATION", 127, 135]]], ["Then we identify the parameters that determine the performance of the magnetometer-based contact test, and discuss how we will measure it.", [["the magnetometer", "TEST", 66, 82], ["contact test", "TEST", 89, 101]]], ["In Section IV, we evaluate the performance of the test using a set of real-life smartphone magnetometer traces.", [["the test", "TEST", 46, 54]]], ["Finally, we conclude the paper in Section V.I. INTRODUCTIONBefore delving into the discussion, we list the acronyms used throughout the paper in Table 1 .II. RELATED WORKThere is rich literature on co-presence detection or its use on epidemiology and social studies.", [["social studies", "TEST", 251, 265]]], ["We summarize them below, with brief remarks on their relevance to our problem or the relation to our approach.A. GPSAlthough the disease transmissibility check in contact tracing needs not necessarily absolute but relative coordinates (i.e., relative to the infected person), one may well consider using GPS trajectories to determine the distance of contact.", [["person", "SPECIES", 267, 273], ["the disease transmissibility", "PROBLEM", 125, 153], ["contact tracing", "TEST", 163, 178], ["disease", "OBSERVATION", 129, 136]]], ["For instance, Qi et al. use GPS to track and visualize space-time activities for a flu transmission study [23] .", [["a flu transmission study", "TEST", 81, 105]]], ["Unfortunately, GPS is a power-inefficient sensor.", [["GPS", "TEST", 15, 18]]], ["As we need to amplify the signal and achieve a high processing gain due to the small received power, a significant reduction in battery time is inevitable.", [["a high processing gain", "PROBLEM", 45, 67], ["a significant reduction in battery time", "TREATMENT", 101, 140], ["small", "OBSERVATION_MODIFIER", 79, 84], ["significant", "OBSERVATION_MODIFIER", 103, 114], ["reduction", "OBSERVATION_MODIFIER", 115, 124]]], ["For instance, it can drain a smartphone battery in much less than a typical charge interval even with minimal activity [24] , [25] .", [["a smartphone battery", "TEST", 27, 47]]], ["In attempts to mitigate the problem, we could activate GPS only when user movement exceeds the accuracy bound, or turn it off indoors by detecting the condition through other means such as the received signal strength (RSS) fingerprints of cell towers.", [["cell", "ANATOMY", 240, 244], ["cell", "CELL", 240, 244], ["cell towers", "OBSERVATION", 240, 251]]], ["Even if the power issue is resolved, however, problems remain.", [["resolved", "OBSERVATION_MODIFIER", 27, 35]]], ["First, the distance estimate between two GPS sensors may include a large error because each can have an average error over 10 meters, when a few meters matter in disease transmissibility check.", [["a large error", "PROBLEM", 65, 78], ["disease transmissibility check", "TEST", 162, 192], ["large", "OBSERVATION_MODIFIER", 67, 72], ["error", "OBSERVATION", 73, 78]]], ["Second, and more importantly, GPS is incapable of checking for possible infection events indoors.B. RFID AND SENSOR NETWORKMany studies have used radio frequency identification (RFID) or sensor network technologies to understand infection and to prevent it in hospitals [26] and in schools [27] .", [["infection", "DISEASE", 72, 81], ["infection", "DISEASE", 229, 238], ["infection events", "PROBLEM", 72, 88], ["SENSOR NETWORKMany studies", "TEST", 109, 135], ["radio frequency identification", "TEST", 146, 176], ["infection", "PROBLEM", 229, 238], ["infection", "OBSERVATION", 72, 81]]], ["Isella et al. use active tags to track contacts that take place in a pediatric ward for analyzing the structure of the contact data, it identifies the central groups that need close attention to prevent nosocomial infection prevention.", [["nosocomial infection", "DISEASE", 203, 223], ["nosocomial infection prevention", "TREATMENT", 203, 234], ["nosocomial", "OBSERVATION_MODIFIER", 203, 213], ["infection", "OBSERVATION", 214, 223]]], ["Salathe et al. use TelosB motes carried by students in a school to obtain close proximity interactions data and develop a more effective vaccination strategy.", [["a more effective vaccination strategy", "TREATMENT", 120, 157]]], ["It finds the small world phenomenon, and suggests a vaccination strategy based on the structure that is more effective than random vaccination.", [["the small world phenomenon", "PROBLEM", 9, 35], ["a vaccination strategy", "TREATMENT", 50, 72], ["small", "OBSERVATION_MODIFIER", 13, 18], ["world phenomenon", "OBSERVATION", 19, 35], ["more effective", "OBSERVATION_MODIFIER", 104, 118]]], ["It is also used in social studies [28] and for security based on proximity [29] .B. RFID AND SENSOR NETWORKShafagh and Hithnawi [29] use ambient radio signals to detect other nodes in close proximity, for authentication between IoT devices before they connect.", [["ambient radio signals", "TEST", 137, 158], ["other nodes", "PROBLEM", 169, 180], ["IoT devices", "TREATMENT", 228, 239], ["nodes", "OBSERVATION", 175, 180]]], ["Boli\u0107 et al. use an enhanced RFID tags to mutually detect proximity to track.", [["an enhanced RFID tags", "TEST", 17, 38]]], ["When attached to people, it can be applied for tracking interactions at social events [28] .", [["people", "ORGANISM", 17, 23], ["people", "SPECIES", 17, 23]]], ["But the biggest drawback of these approaches is that today's smartphones hardly support RFID or personal area network (PAN) technologies other than Bluetooth.", [["area network", "MULTI-TISSUE_STRUCTURE", 105, 117]]], ["Due to the lack of deployment base among general public, they do not serve our purpose of massive mutual contact monitoring between strangers.C. SOCIAL MEDIA AND SEARCH RECORDSRecently, there have been efforts to introduce social media such as Twitter to epidemic monitoring, for early detection, management, and control of epidemic outbreaks [30] - [33] .", [["C.", "SPECIES", 142, 144], ["C.", "SPECIES", 142, 144], ["epidemic monitoring", "TEST", 255, 274], ["management", "TREATMENT", 297, 307], ["epidemic outbreaks", "PROBLEM", 324, 342]]], ["In particular, participatory surveillance using social networks to collect symptom reports to detect infectious disease outbreaks has been tried.", [["infectious disease outbreaks", "DISEASE", 101, 129], ["symptom", "PROBLEM", 75, 82], ["infectious disease outbreaks", "PROBLEM", 101, 129]]], ["However, most studies limit their scope to common and seasonally recurring health events such as Influenza due to the noisy nature of Twitter [34] .", [["Influenza", "DISEASE", 97, 106], ["Influenza", "PROBLEM", 97, 106]]], ["Moreover, this post-symptomatic reporting can take long time because some diseases go through long incubation period (e.g. 3 weeks in Middle East Respiratory Syndrome (MERS) [35] ).", [["Respiratory Syndrome", "DISEASE", 146, 166], ["some diseases", "PROBLEM", 69, 82], ["Middle East Respiratory Syndrome", "PROBLEM", 134, 166], ["Respiratory Syndrome", "OBSERVATION", 146, 166]]], ["Moreover, subjective symptom reports do not provide information specific enough for disease control authorities to construct contact traces and obtain contact contexts.", [["subjective symptom", "PROBLEM", 10, 28]]], ["Also, it gives us only collective statistics at coarse granularities, while contact tracing requires information on person-to-person interactions.", [["person", "SPECIES", 116, 122], ["coarse granularities", "PROBLEM", 48, 68], ["contact tracing", "TEST", 76, 91]]], ["In the same vein, search-based global disease trend tracking services [36] are not directly helpful to contact tracing in emergency response.D. WI-FIFor its prevalence, Wi-Fi is extremely popular for indoor localization.", [["vein", "ANATOMY", 12, 16], ["vein", "MULTI-TISSUE_STRUCTURE", 12, 16], ["search-based global disease", "PROBLEM", 18, 45], ["vein", "ANATOMY", 12, 16], ["global", "OBSERVATION_MODIFIER", 31, 37], ["disease", "OBSERVATION", 38, 45]]], ["Again, as in GPS, we could consider using Wi-Fi assisted location information to determine the distance of contact, although the disease transmissibility check in contact tracing needs not necessarily absolute but relative coordinates.", [["the disease transmissibility", "PROBLEM", 125, 153], ["contact tracing", "TEST", 163, 178]]], ["Existing works based on Wi-Fi are mostly centered around proximity detection and its applications.", [["Wi-Fi", "DNA", 24, 29]]], ["Carreras et al. [38] use Wi-Fi to mutually discover smartphones in proximity and determine the distance using received signal strength indication (RSSI).", [["signal strength indication", "TREATMENT", 119, 145]]], ["As to the closeness estimation, most previous works rely on RSSI [39] - [41] .", [["RSSI", "TEST", 60, 64]]], ["In particular, Nguyen et al. [8] show that the co-presence in disease transmissible distance can be determined through RSSI signatures from public Wi-Fi access points.", [["the co-presence in disease transmissible distance", "PROBLEM", 43, 92], ["RSSI signatures", "TEST", 119, 134], ["disease", "OBSERVATION", 62, 69]]], ["A drawback of using Wi-Fi is that access points may be unavailable or prove insufficient to fix positions with a consistent precision.", [["Wi-Fi", "PROTEIN", 20, 25], ["Wi-Fi", "TREATMENT", 20, 25]]], ["Also, the technology is not stellar in energy efficiency, especially for long and continual monitoring.E. BLUETOOTHFor proximity detection, Bluetooth is a popular technology for its relatively high precision in short distances [9] .", [["continual monitoring", "TEST", 82, 102], ["not", "UNCERTAINTY", 24, 27], ["stellar", "OBSERVATION_MODIFIER", 28, 35], ["energy efficiency", "OBSERVATION", 39, 56]]], ["Liu et al. [9] show that Bluetooth can be used to detect face-to-face interaction within 1.5 m by mapping Bluetooth RSSI to distance.", [["Bluetooth RSSI", "PROTEIN", 106, 120], ["Bluetooth", "TREATMENT", 25, 34]]], ["Compared with Wi-Fi and cellular location, they show that Bluetooth can provide an order of magnitude more precise proximity detection.", [["cellular", "ANATOMY", 24, 32], ["cellular", "CELL", 24, 32]]], ["Montanari [42] proposes to use Bluetooth Low Energy (BLE) to measure the duration and the proximity of social contact using BLE-enabled wearables.", [["BLE", "SIMPLE_CHEMICAL", 124, 127]]], ["It has been also used to measure, understand, and predict how individuals change their social behavior in response to infectious diseases [7] .", [["infectious diseases", "DISEASE", 118, 137]]], ["Yoneki [7] uses Bluetooth to collect proximity devices data to measure, understand, and predict how individuals change their social behavior in response to infectious disease.", [["infectious disease", "DISEASE", 156, 174], ["Bluetooth", "TREATMENT", 16, 25], ["infectious disease", "PROBLEM", 156, 174]]], ["Jamil et al. [43] use BLE tags and smartphones to track group dynamics in a massive religious gathering.", [["BLE tags", "TEST", 22, 30], ["smartphones", "TREATMENT", 35, 46]]], ["It investigates the best configurations for the BLE tags and the scan durations for smartphones.", [["BLE tags", "DNA", 48, 56], ["the BLE tags", "TEST", 44, 56], ["the scan durations", "TEST", 61, 79], ["smartphones", "TEST", 84, 95]]], ["Compared with the infection study, the group dynamics study requires detection in farther distances at more than 10 m.", [["infection", "DISEASE", 18, 27], ["the infection study", "TEST", 14, 33], ["the group dynamics study", "TEST", 35, 59]]], ["Also, the tags unilaterally advertise, and the smartphones unilaterally scan.", [["the smartphones unilaterally scan", "TEST", 43, 76]]], ["It also does 10% duty cycling, with 5 minutes of hibernation between 30 seconds scans.", [["scans", "TEST", 80, 85]]], ["Therefore, this does not fit with the continuous monitoring need for infectious contacts that could happen any time.", [["infectious contacts", "PROBLEM", 69, 88]]], ["A recent study also points out the inefficiency of the Bluetooth (LE) protocol in connectionbased interactions when there are hundreds or even thousands of BLE devices in the communication range of each other [44] .", [["A recent study", "TEST", 0, 14], ["the Bluetooth (LE) protocol", "TREATMENT", 51, 78], ["BLE devices", "TREATMENT", 156, 167]]], ["Harris et al. [44] consider the dense BLE deployment scenario where hundreds or even thousands of tags interact with a large number of scanning devices such as smartphones.", [["the dense BLE deployment scenario", "PROBLEM", 28, 61], ["scanning devices", "TREATMENT", 135, 151]]], ["It raises the message collision and consequent energy waste issues of the BLE active scanning mode, and proposes an optimization scheme to solve them.", [["the BLE active scanning mode", "TREATMENT", 70, 98], ["an optimization scheme", "TREATMENT", 113, 135]]], ["The beacons can reveal the identity of the transmitting device, threatening the privacy of the user.F. CELLULAR NETWORKCommunication traces obtained by mobile phones are known to be good proxies for the physical interaction network, and they may provide a valuable tool for contact tracing.", [["the transmitting device", "TREATMENT", 39, 62]]], ["For example, calls and messaging activities were used to construct human contact networks [45] .", [["human", "ORGANISM", 67, 72], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 67, 72]]], ["Mobile network data or call detail records (CDRs) have also been used to model population flows, major mobility hubs, and movement typologies, and how they change as the Ebola outbreak unfolds [46] .", [["Ebola", "DISEASE", 170, 175]]], ["We could even use two phones attaching to an identical cell as a signal for a possible physical contact.", [["cell", "ANATOMY", 55, 59], ["cell", "CELL", 55, 59]]], ["However, the coverage of a single cell tower is at least a few hundred meters in radius, so it would be too coarse to identify infectious physical contact events within a few meters [18] .G. ACCELEROMETEROne important instance of the mix encounters with strangers is public transport such as train or bus, which people can share for long enough time to enable several modes of disease transmission.", [["cell", "ANATOMY", 34, 38], ["cell", "CELL", 34, 38], ["people", "ORGANISM", 312, 318], ["people", "SPECIES", 312, 318], ["a single cell tower", "TREATMENT", 25, 44], ["ACCELEROMETEROne", "TREATMENT", 191, 207], ["disease transmission", "PROBLEM", 377, 397], ["few", "OBSERVATION_MODIFIER", 59, 62], ["radius", "ANATOMY", 81, 87], ["infectious", "OBSERVATION_MODIFIER", 127, 137], ["disease", "OBSERVATION", 377, 384]]], ["For example, an infected person openly coughing in the bus can infect fellow riders in case of aerosol or droplet transmission diseases.", [["person", "SPECIES", 25, 31], ["coughing", "PROBLEM", 39, 47], ["aerosol", "TREATMENT", 95, 102], ["droplet transmission diseases", "PROBLEM", 106, 135], ["infected", "OBSERVATION_MODIFIER", 16, 24]]], ["These devices can be leveraged to detect co-location, which can be a good proxy for the physical contacts.", [["These devices", "TREATMENT", 0, 13]]], ["But on a multi-car vehicle, a more relevant question in the context of epidemic infection is whether two passengers are on the same car or on different cars.", [["infection", "DISEASE", 80, 89], ["epidemic infection", "PROBLEM", 71, 89], ["epidemic", "OBSERVATION_MODIFIER", 71, 79], ["infection", "OBSERVATION", 80, 89]]], ["Our study reveals that accelerometer readings during train stop and start events tend to be characteristic of different car positions, so they can be used to generate a strong co-location signature on the car level.", [["Our study", "TEST", 0, 9], ["accelerometer readings", "TEST", 23, 45]]], ["Thanks to the movements of the train, it does not require a complex communication infrastructure on the train for classification [41] , but an accelerometer.H. AMBIENT SOUND SENSORCommon ambient sound detection using the microphone sensor [47] - [49] can be a technology of choice.", [["ambient sound detection", "TEST", 187, 210], ["the microphone sensor", "TEST", 217, 238]]], ["But using the microphone sensor has its own issues.", [["the microphone sensor", "TREATMENT", 10, 31]]], ["First, the number of samples at its typically high sampling frequencies (e.g. 44.1 KHz) is too large for continuous and indefinitely long monitoring required for detecting contacts that can happen at any time.", [["samples", "ANATOMY", 21, 28], ["KHz", "TEST", 83, 86], ["large", "OBSERVATION_MODIFIER", 95, 100]]], ["Finally, there is the possibility of false detection.", [["false detection", "PROBLEM", 37, 52], ["possibility of", "UNCERTAINTY", 22, 36], ["false detection", "OBSERVATION", 37, 52]]], ["For example, two people watching the same TV channel or listening to other broadcast sounds in different places can be classified as coexistent.I. MAGNETOMETERThe smartphone magnetometer has been extensively used for indoor localization and tracking (but not much for coexistence detection).", [["people", "ORGANISM", 17, 23], ["people", "SPECIES", 17, 23], ["MAGNETOMETERThe smartphone magnetometer", "TREATMENT", 147, 186], ["coexistent", "OBSERVATION", 133, 143]]], ["Moreover, the field is stable over long periods of time [50] - [52] .", [["stable", "OBSERVATION_MODIFIER", 23, 29]]], ["The richness and the stability of the magnetic field enables mapping (a.k.a. fingerprinting) and magnetic map-based applications.", [["magnetic map-based applications", "TREATMENT", 97, 128], ["richness", "OBSERVATION_MODIFIER", 4, 12], ["stability", "OBSERVATION_MODIFIER", 21, 30]]], ["Chung et al. [15] showed that the geomagnetic anomaly can provide signatures for indoor locations that can be leveraged for sub-meter-level location accuracy.", [["the geomagnetic anomaly", "PROBLEM", 30, 53]]], ["Frassl et al. [14] used magnetic maps with centimeterlevel accuracy to localize a human or robot.", [["human", "ORGANISM", 82, 87], ["human", "SPECIES", 82, 87], ["human", "SPECIES", 82, 87], ["magnetic maps", "TEST", 24, 37]]], ["Li et al. [52] discussed possible issues that can affect the precision and the feasibility of the fingerprinting approach for indoor location.", [["Li", "CHEMICAL", 0, 2], ["the fingerprinting approach", "TREATMENT", 94, 121]]], ["Angermann et al. [50] found that the use of all three field components provides good resolution of ambiguities in a small indoor area.", [["good", "OBSERVATION_MODIFIER", 80, 84], ["resolution", "OBSERVATION_MODIFIER", 85, 95], ["small", "OBSERVATION_MODIFIER", 116, 121]]], ["Carrillo et al. [53] used the three components of the measured magnetic field by smartphone magnetometers instead of just the intensity to improve accuracy.", [["smartphone magnetometers", "TREATMENT", 81, 105], ["accuracy", "TEST", 147, 155]]], ["Brzozowski and Kazmierczak [54] discussed ways of recording, visualizing, and mapping local magnetic field changes in 3D that can be used as a support for indoor navigation systems for unmanned aerial vehicles (UAVs).", [["indoor navigation systems", "TREATMENT", 155, 180]]], ["Riehle et al. [55] considered a leader-follower style navigation application for visually impaired people where there is time gap between traversals, without relying on expensive indoor magnetic fingerprinting.", [["people", "ORGANISM", 99, 105], ["people", "SPECIES", 99, 105], ["style navigation application", "TREATMENT", 48, 76], ["visually impaired people", "PROBLEM", 81, 105]]], ["Nguyen et al. [13] used only smartphone magnetometers to detect co-location of passengers in public transport.", [["smartphone magnetometers", "TREATMENT", 29, 53]]], ["They exploited the fact that the passengers share the trajectory between at least two consecutive stations, and the magnetometer traces exhibit high similarity, which was measured by the distance in Derivative Dynamic Time Warping (DDTW).", [["the magnetometer traces", "TEST", 112, 135], ["high similarity", "OBSERVATION", 144, 159]]], ["Kuk et al. [11] showed that even in outdoors the magnetometer traces can be compared to detect contacts within a few meters where the current GPS can have an order-ofmagnitude larger errors.", [["larger errors", "PROBLEM", 176, 189]]], ["Kuk et al. showed that they could lower the frequency to 1 Hz without significantly harming the detection performance, but increasing the battery life significantly.I. MAGNETOMETERThe smartphone magnetometer overcomes undesirable properties of other technological alternatives.", [["the detection performance", "TEST", 92, 117], ["MAGNETOMETERThe smartphone magnetometer", "TREATMENT", 168, 207]]], ["It can detect contacts within very short distances that fit infectious disease transmissions monitoring, and it can work indoors.", [["infectious disease transmissions monitoring", "TEST", 60, 103]]], ["It consumes relatively small power compared with other sensors, and has little privacy concerns.", [["relatively", "OBSERVATION_MODIFIER", 12, 22], ["small", "OBSERVATION_MODIFIER", 23, 28], ["power", "OBSERVATION_MODIFIER", 29, 34]]], ["In this paper, therefore, we focus on the contact detection on smartphone magnetometers and explore their potential to provide a diagnostic tool for potentially infectious contacts made between smartphone holders.I. MAGNETOMETERAs to the privacy concern of some of the technologies above, it may not an issue in the event of an epidemic.", [["smartphone magnetometers", "TREATMENT", 63, 87], ["an epidemic", "PROBLEM", 325, 336], ["infectious", "OBSERVATION", 161, 171], ["epidemic", "OBSERVATION", 328, 336]]], ["Authorities may legally have purpose-based access to the phone data of the infected or so suspected person, or rather, 20738 VOLUME 7, 2019 users may voluntarily give consent to the authority to use their trajectory data.", [["person", "SPECIES", 100, 106], ["infected", "OBSERVATION", 75, 83]]], ["Indeed, we assume such model in subsequent discussions.I. MAGNETOMETERFinally, it is worthwhile to mention that any combination of the magnetometer-based method proposed in this paper with other technologies is possible.", [["the magnetometer-based method", "TREATMENT", 131, 160]]], ["For instance, the cost of comparing two traces for checking close contacts could be avoided if their GPS coordinates or cellular attachments show totally different values.", [["cellular", "ANATOMY", 120, 128], ["cellular", "CELL", 120, 128]]], ["Many valuable combinations could be conceived, but in this paper, we focus on the smartphone magnetometer-based method first so that it can be used in such combination in a more intelligent way.III. A MAGNETOMETER-BASED DIAGNOSTIC TESTIn this section, we discuss how we measure the similarity of two magnetometer traces.", [["the smartphone magnetometer", "TREATMENT", 78, 105]]], ["It is a good measure of linear correlation, which fits the linear correlation that two magnetometers in close proximity show in their ambient magnetic field strength readings.", [["good", "OBSERVATION_MODIFIER", 8, 12]]], ["Fig. 3 shows real traces generated by two phones held by the people walking side-by-side through a corridor in a university campus building.", [["people", "ORGANISM", 61, 67], ["people", "SPECIES", 61, 67]]], ["In (a), the horizontal axis is the sample number of measured magnetometer values, and the vertical axis is the strength of the magnetic field vector perpendicular to the ground.", [["magnetometer values", "TEST", 61, 80], ["vertical axis", "OBSERVATION", 90, 103]]], ["The fluctuations are the results of the magnetic distortions to the geomagnetic field by ferromagnetic materials such as steel doors, pillars, and rebars among others in the building the smartphone users are passing by.", [["the magnetic distortions", "PROBLEM", 36, 60]]], ["Therefore, when each phone records such trace while the user moves around in daily life, we can let the users or the disease control authority later check for possible contacts with an infected person using the strength of the linear correlation.", [["person", "SPECIES", 194, 200]]], ["For example, as in Fig. 1 , a susceptible user can check if her smartphone has a trace segment that computes a high correlation with an infected person's trace that can be provided by the disease control authority.A. SIMILARITY MEASURE: PEARSON'S RIn order to compute the similarity of two smartphone magnetometer traces, we need to use a similarity measure.", [["person", "SPECIES", 145, 151], ["A.", "SPECIES", 214, 216], ["a trace segment", "PROBLEM", 79, 94], ["infected", "OBSERVATION", 136, 144]]], ["There are numerous similarity measures, but some popular ones in the literature are cosine similarity, Dynamic Time Warping (DTW) distance, Euclidean distance, Kullback-Liebler distance, Jaccard similarity, Pearson correlation, among others [56] .", [["numerous", "OBSERVATION_MODIFIER", 10, 18], ["similarity", "OBSERVATION_MODIFIER", 19, 29], ["measures", "OBSERVATION_MODIFIER", 30, 38], ["some", "OBSERVATION_MODIFIER", 44, 48], ["popular", "OBSERVATION_MODIFIER", 49, 56]]], ["In the areas of epidemiology and psychology, however, the measure of association is frequently analyzed by correlation analysis and regression analysis [57] .", [["correlation analysis", "TEST", 107, 127], ["regression analysis", "TEST", 132, 151], ["areas", "OBSERVATION_MODIFIER", 7, 12]]], ["In this paper, we use the correlation analysis.", [["the correlation analysis", "TEST", 22, 46]]], ["Given T W and the magnetometer sampling rate f s , the Pearson correlation coefficient for the samples in the window 1 N W = T W \u00b7 f s starting from the k th sample is defined to be:A. SIMILARITY MEASURE: PEARSON'S Rwhere A k+i and B k+i are (k + i) th individual magnetometer readings from phones A and B, respectively. \u00b5 and \u03c3 are the mean and the standard deviation of the measured values in two phone's compared traces in the inspection window.A. SIMILARITY MEASURE: PEARSON'S RRecollect that the existing works [11] , [13] compute the similarity over the entire span of samples L = l tx \u00b7 f s , essentially making N W = L. Unfortunately, at an arbitrary length L, we cannot control the false detection possibilities at all, whether positive or negative.", [["T W", "GENE_OR_GENE_PRODUCT", 6, 9], ["\u03c3", "GENE_OR_GENE_PRODUCT", 327, 328], ["T W", "TREATMENT", 6, 9], ["the magnetometer sampling rate", "TEST", 14, 44], ["the samples", "TEST", 91, 102], ["T W \u00b7 f s", "TEST", 125, 134], ["the k th sample", "TEST", 149, 164], ["A k", "TEST", 222, 225], ["B k", "TEST", 232, 235], ["l tx \u00b7 f s", "TEST", 587, 597], ["negative", "OBSERVATION", 749, 757]]], ["Therefore, we will use a window N W L to slide over the compared traces to find any interval for which \u03c1 k (A, B) > \u03b8 c , 0 \u2264 k < L \u2212 N W + 1, where \u03b8 c is the cutoff threshold for the contact decision.A. SIMILARITY MEASURE: PEARSON'S RWhen l tx significantly increases, there are two aspects we need to consider: memory to store a trace (at smartphones) and correlation computation (at contact tracing check server).", [["\u03b8 c", "GENE_OR_GENE_PRODUCT", 149, 152], ["\u03b8 c", "PROTEIN", 149, 152], ["a window N W L to slide", "TREATMENT", 23, 46], ["k", "TEST", 105, 106], ["c", "TEST", 118, 119], ["k", "TEST", 126, 127], ["l tx", "TREATMENT", 241, 245], ["correlation computation", "TEST", 359, 382]]], ["First, in terms of memory, the smartphones should keep the samples collected during the long transmissible duration.", [["samples", "ANATOMY", 59, 66], ["the samples", "TEST", 55, 66]]], ["In our implementation, each magnetometer measurement sample is a vector, whose size is 50 bytes.", [["each magnetometer measurement sample", "TEST", 23, 59], ["size", "OBSERVATION_MODIFIER", 79, 83]]], ["Modern smartphones typically have a few tens of gigabytes of memory, so it will not be an excessive burden, especially in the emergency situation (i.e., infectious epidemic).", [["Modern smartphones", "PROBLEM", 0, 18], ["an excessive burden", "PROBLEM", 87, 106], ["few", "OBSERVATION_MODIFIER", 36, 39], ["tens", "OBSERVATION_MODIFIER", 40, 44], ["excessive", "OBSERVATION_MODIFIER", 90, 99], ["burden", "OBSERVATION", 100, 106], ["infectious", "OBSERVATION_MODIFIER", 153, 163]]], ["In terms of computation, the trace comparison is performed not on the smartphones but on a server to which the traces are submitted by users who want to check if they were in a close distance with the infected person.", [["person", "SPECIES", 210, 216], ["trace", "OBSERVATION_MODIFIER", 29, 34], ["infected", "OBSERVATION", 201, 209]]], ["But the computation itself is not extremely heavy.", [["not extremely", "UNCERTAINTY", 30, 43], ["heavy", "OBSERVATION", 44, 49]]], ["We tested the correlation computation with the sliding inspection window of 10 seconds over two continuous traces of 56,600 samples collected at 10 Hz (or l tx = 5,660 seconds or 94 minutes).", [["samples", "ANATOMY", 124, 131]]], ["It takes approximately 6.7 seconds on a server that has an i7-7700K processor with the clock speed of 4.2 GHz, using only a single core.", [["K processor", "TREATMENT", 66, 77]]], ["This contact type is more common in infectious disease transmissions than the 'same-place-different-time' (SPDT) type [59] .", [["infectious disease transmissions", "PROBLEM", 36, 68], ["more common", "OBSERVATION_MODIFIER", 21, 32], ["infectious", "OBSERVATION", 36, 46]]], ["Finally, we focus on the contacts made in the indoor contexts, because urban life is 90% indoors [61] , and indoors is where most infection events take place.B. PARAMETERS FOR CONTACT DECISIONAs the length of the traces L over which the search is performed should be defined by the given disease of concern, e.g. by its incubation period [62] or the duration of active transmission, we do not consider this parameter further in this paper.", [["infection", "DISEASE", 130, 139], ["most infection events", "PROBLEM", 125, 146], ["infection", "OBSERVATION", 130, 139]]], ["As for the window size N W , it should be long enough to find the contacts of the critical duration that can enable the transmission.", [["the window size N W", "TREATMENT", 7, 26]]], ["However, it is hard to definitely characterize the duration as it will be disease-specific.", [["disease", "PROBLEM", 74, 81]]], ["Namely, we investigate the minimum window size that we can effectively use for the comparison, which will be equivalent to defining the granularity of inspection that smartphone magnetometers can offer.", [["smartphone magnetometers", "TREATMENT", 167, 191]]], ["Specifically, the required sample size N W over which the correlation is computed can be estimated as a function of the targeted cutoff \u03b8 c .", [["sample", "ANATOMY", 27, 33], ["\u03b8 c", "PROTEIN", 136, 139], ["sample size N W", "TREATMENT", 27, 42], ["size", "OBSERVATION_MODIFIER", 34, 38]]], ["In particular, N W decreases as \u03b8 c or the confidence interval increases.", [["\u03b8 c", "GENE_OR_GENE_PRODUCT", 32, 35], ["\u03b8 c", "PROTEIN", 32, 35], ["decreases", "OBSERVATION_MODIFIER", 19, 28], ["increases", "OBSERVATION_MODIFIER", 63, 72]]], ["Without the stationarity of the magnetometer values in our environment, we cannot analytically derive the window size but turn to the measurement-based approach to estimate N W to meet the given \u03b8 c .C. PERFORMANCE MEASURESIn order to see whether we can use the similarity check of the smartphone magnetometer traces as a diagnostic test, we evaluate its discriminative and predictive power.", [["\u03b8 c", "PROTEIN", 195, 198], ["the magnetometer values", "TEST", 28, 51], ["a diagnostic test", "TEST", 320, 337]]], ["In particular, we need to evaluate it under different choices of N W and \u03b8 c .", [["\u03b8 c", "GENE_OR_GENE_PRODUCT", 73, 76]]], ["In clinical studies, numerous metrics are used to evaluate the quality of a diagnostic test.", [["clinical studies", "TEST", 3, 19], ["a diagnostic test", "TEST", 74, 91]]], ["Some of them are: sensitivity, specificity, accuracy, positive and negative likelihood ratio, positive and negative predictive value, odds ratio, relative risk, risk difference, number needed to treat, etc. Among these, we will use the ones that are not affected by the prevalence, which can only be artificial in our setting.C. PERFORMANCE MEASURESGiven the ground truth (contact vs. no contact) and the decision using the smartphone magnetometer traces, there can be four cases among which true positive (TP) and true negative (TN) are desirable, and false positive (FP) and false negative (FN) should be minimized ( Table 3) .", [["TP", "GENE_OR_GENE_PRODUCT", 507, 509], ["TN", "PROTEIN", 530, 532], ["FN", "PROTEIN", 593, 595], ["accuracy", "TEST", 44, 52], ["likelihood ratio", "TEST", 76, 92], ["the smartphone magnetometer traces", "TEST", 420, 454], ["true positive (TP) and true negative (TN)", "PROBLEM", 492, 533], ["false positive (FP", "PROBLEM", 553, 571]]], ["As in any other accuracy assessment of diagnostic tests, we use the 2\u00d72 table.C. PERFORMANCE MEASURESAs to how the false detections (FP and FN) arise in our setting, we can consider two possibilities.", [["any other accuracy assessment", "TEST", 6, 35], ["diagnostic tests", "TEST", 39, 55], ["the false detections", "TEST", 111, 131]]], ["Suppose the length of the contact duration represented in the traces is T c , and the number of samples generated during the duration L c = T c \u00b7 f s .", [["T c", "GENE_OR_GENE_PRODUCT", 72, 75], ["length", "OBSERVATION_MODIFIER", 12, 18]]], ["Then, let us consider Fig. 5 , where two people move indoors with the smartphone magnetometers measuring the ambient field strength at 10 Hz.", [["people", "ORGANISM", 41, 47], ["people", "SPECIES", 41, 47], ["the smartphone magnetometers", "TREATMENT", 66, 94]]], ["The two people come from different places (A 1 vs. B 1 ), meet in the middle, and move together in the region labeled ''A 2 + B 2 '' for T c = 90 seconds, and then part and return to their initial locations (A 3 vs. B 3 ).", [["people", "ORGANISM", 8, 14], ["T c", "GENE_OR_GENE_PRODUCT", 137, 140], ["people", "SPECIES", 8, 14], ["T c", "TEST", 137, 140], ["middle", "ANATOMY_MODIFIER", 70, 76]]], ["The shaded region represents the duration of contact.", [["shaded", "OBSERVATION_MODIFIER", 4, 10]]], ["It is approximately from samples 1,600 through 2,400 in both graphs.", [["approximately", "OBSERVATION_MODIFIER", 6, 19]]], ["There are two subcases in this case.", [["two", "OBSERVATION_MODIFIER", 10, 13], ["subcases", "OBSERVATION", 14, 22]]], ["First, if N W is very small, it can cause many spurious contact detections since coincidental high correlations may not be sufficiently averaged out.", [["very small", "PROBLEM", 17, 27], ["many spurious contact detections", "PROBLEM", 42, 74], ["very small", "OBSERVATION_MODIFIER", 17, 27]]], ["For example, with N W = 100 and 1,200, Fig. 6 (a) and (b) show their Pearson correlation coefficients, respectively.", [["N W", "TEST", 18, 21]]], ["The circles in Fig. 6(a) show that two spurious detection events are possible for N W = 100 and \u03b8 c = 0.8.", [["two spurious detection events", "PROBLEM", 35, 64], ["N W", "TEST", 82, 85], ["circles", "OBSERVATION_MODIFIER", 4, 11]]], ["Second, even if N W is large there are still chances for false detections, but only negative.", [["false detections", "TEST", 57, 73], ["large", "OBSERVATION", 23, 28]]], ["It is because increasing N W decreases \u03c1 k (A, B) as a consequence of the non-stationarity of the magnetic field strength distribution [13] , when the human smartphone holder moves through space.", [["human", "ORGANISM", 151, 156], ["human", "SPECIES", 151, 156], ["human", "SPECIES", 151, 156], ["increasing N W decreases", "PROBLEM", 14, 38], ["the human smartphone holder", "TREATMENT", 147, 174], ["increasing", "OBSERVATION_MODIFIER", 14, 24], ["decreases", "OBSERVATION_MODIFIER", 29, 38]]], ["Using our coexistent trace pairs, we indeed confirm that the larger window sizes significantly reduce the correlation coefficient (Fig. 7) .2) COMPARISON WINDOW IS WIDER THAN THE CONTACT DURATION (N W > L C )In this case, a possible consequence is that the adjacent measurement samples outside the coexistence duration that happen to be included in the window decreases the cross correlation, possibly leading to a false negative decision depending on \u03b8 c .", [["\u03b8 c", "GENE_OR_GENE_PRODUCT", 452, 455], ["\u03b8 c", "PROTEIN", 452, 455], ["our coexistent trace pairs", "PROBLEM", 6, 32], ["the larger window sizes", "PROBLEM", 57, 80], ["larger", "OBSERVATION_MODIFIER", 61, 67], ["sizes", "OBSERVATION_MODIFIER", 75, 80]]], ["Observe that for high cutoff thresholds such as \u03b8 c > 0.8, Fig. 6 (b) will falsely determine that there was no contact, whereas the former will correctly detect the contact.2) COMPARISON WINDOW IS WIDER THAN THE CONTACT DURATION (N W > L C )Either way, these problems can lead to false decisions about the contact, so it is clear that we need to determine FIGURE 7.", [["high cutoff thresholds", "PROBLEM", 17, 39]]], ["Pearson correlation coefficient \u03c1 k with 95% confidence interval, for a large number coexistent trace pairs. the appropriate window size N W as well as the cutoff threshold \u03b8 c .IV. EVALUATIONFor our measurement-based study, we use indoor magnetometer traces collected in the Korea University campus in Seoul, Korea.", [["a large number coexistent trace pairs", "PROBLEM", 70, 107], ["the appropriate window size N W", "TREATMENT", 109, 140], ["IV", "TREATMENT", 178, 180], ["our measurement-based study", "TEST", 196, 223], ["indoor magnetometer traces", "TEST", 232, 258], ["large", "OBSERVATION_MODIFIER", 72, 77], ["trace pairs", "OBSERVATION", 96, 107], ["window", "OBSERVATION_MODIFIER", 125, 131], ["size", "OBSERVATION_MODIFIER", 132, 136]]], ["Then we evaluate the smartphone magnetometerbased contact detection using the measures mentioned in Section III-C.A. MAGNETOMETER TRACE COLLECTIONTo collect the magnetometer traces, we developed and installed a magnetometer sensing app for Android smartphones, Samsung Galaxy S5, S6, S8 and LG G3 and G4.", [["Samsung Galaxy S5, S6, S8 and LG G3", "PROTEIN", 261, 296], ["G4", "PROTEIN", 301, 303], ["LG G3", "ANATOMY", 291, 296]]], ["Among the phones, we used two Galaxy S5's to collect the traces used in this section.", [["this section", "TREATMENT", 72, 84]]], ["We collect the magnetometer traces in five different buildings in the campus.", [["the magnetometer traces", "TREATMENT", 11, 34], ["campus", "ANATOMY", 70, 76]]], ["At each place, we repeated the trace collection six times along the same walking path.", [["the trace collection", "PROBLEM", 27, 47], ["trace", "OBSERVATION_MODIFIER", 31, 36], ["collection", "OBSERVATION", 37, 47]]], ["So, in total, there are 90 traces, and each trace is 300 seconds long.", [["90 traces", "OBSERVATION_MODIFIER", 24, 33], ["300 seconds", "OBSERVATION_MODIFIER", 53, 64]]], ["There are C(6, 2) = 15 pairs of traces per place to be judged co-existent.", [["C", "TEST", 10, 11], ["co-existent", "OBSERVATION", 62, 73]]], ["Since there are 15 different places from which the traces were collected, we have 15 \u00b7 C(6, 2) = 225 co-existent trace pairs in total.", [["15 different", "OBSERVATION_MODIFIER", 16, 28], ["trace pairs", "OBSERVATION", 113, 124]]], ["On the other hand, there are C(15, 2) \u00b7 C(6, 1) \u00b7 C(6, 1) = 15 \u00b7 7 \u00b7 6 \u00b7 6 = 3, 780 non-coexistent pairs.A. MAGNETOMETER TRACE COLLECTIONWe measured the magnetic field strengths at the default sampling frequency of 10 Hz, a popular magnetometer sensing rate in the literature [17] .", [["C(15, 2) \u00b7 C(6, 1) \u00b7 C(6, 1)", "SIMPLE_CHEMICAL", 29, 57], ["C", "TEST", 29, 30], ["C", "TEST", 40, 41], ["C", "TEST", 50, 51], ["a popular magnetometer sensing rate", "TEST", 222, 257], ["hand", "ANATOMY", 13, 17]]], ["The magnetometer readings are obtained in three phone-specific axes: X, Y, and Z. In order to simulate typical indoor walking dynamics, we let the smartphone holders walk approximately at the 'preferred' walking speed [64] .", [["The magnetometer readings", "TEST", 0, 25]]], ["It is known that people prefer to walk at approximately 1.4 m/s (or 5.0 km/h) irrespective of cultures, as they find slower or faster speed uncomfortable.", [["people", "ORGANISM", 17, 23], ["people", "SPECIES", 17, 23], ["cultures", "TEST", 94, 102]]], ["Each trace was produced in narrow corridors, and we saw to it that the traces do not deviate from each other more than an 'arm's length' to simulate the typical personal gap [65] .A. MAGNETOMETER TRACE COLLECTIONAs the smartphones can have arbitrary attitudes when and while the contact is made, the measured magnetic strengths in their X, Y, and Z axes will generally be misaligned.", [["narrow", "OBSERVATION_MODIFIER", 27, 33], ["corridors", "OBSERVATION_MODIFIER", 34, 43]]], ["For this, we use Android getRotationMatrix() method to translate the phonespecific coordinates to the absolute coordinate (i.e., North, East, etc).", [["Android getRotationMatrix() method", "TREATMENT", 17, 51]]], ["As to the robustness of the method against the accumulation of errors over a long duration of continuous operation, it is a research issue of its own [66] .", [["the accumulation of errors", "PROBLEM", 43, 69], ["continuous operation", "TREATMENT", 94, 114]]], ["In this paper, we assume that such calibration is being done to maintain the precision of the magnetometers.", [["such calibration", "TREATMENT", 30, 46], ["the magnetometers", "TREATMENT", 90, 107]]], ["Fig. 8 illustrates the alignment operation in our measurement system.", [["the alignment operation", "TREATMENT", 19, 42], ["alignment operation", "OBSERVATION", 23, 42]]], ["Finally, the EAST is simply the cross product of the two vectors NORTH and UP, so it is redundant.", [["NORTH", "GENE_OR_GENE_PRODUCT", 65, 70], ["EAST", "PROTEIN", 13, 17], ["NORTH", "PROTEIN", 65, 70], ["redundant", "OBSERVATION", 88, 97]]], ["Thus in our implementation, we choose whichever axis between NORTH and UP that shows the highest correlation in the decision.B. RESULTSHere, we compute the evaluation measures for the combinations of the window size and the decision threshold.", [["NORTH", "GENE_OR_GENE_PRODUCT", 61, 66], ["NORTH", "DNA", 61, 66], ["the evaluation measures", "TEST", 152, 175], ["size", "OBSERVATION_MODIFIER", 211, 215]]], ["In particular, we will compute them for the first N W samples from each trace pair, i.e., k = 0 in (1).", [["the first N W samples", "TREATMENT", 40, 61]]], ["But first, there is a caveat.1) ON PREVALENCE AND ITS DEPENDENT MEASURESIn total, there are 3, 780 and 225 non-coexistent and co-existent trace pairs in our data set, totaling at 4, 005.", [["caveat", "OBSERVATION", 22, 28], ["trace pairs", "OBSERVATION", 138, 149]]], ["However, this is artificial -we could have made it higher or lower by producing more of coexistent or noncoexistent traces, respectively.", [["higher", "OBSERVATION_MODIFIER", 51, 57], ["lower", "OBSERVATION_MODIFIER", 61, 66], ["coexistent", "OBSERVATION_MODIFIER", 88, 98], ["noncoexistent", "OBSERVATION_MODIFIER", 102, 115], ["traces", "OBSERVATION_MODIFIER", 116, 122]]], ["Naturally, it is meaningless to calculate the measures affected by the prevalence, where the prevalence of disease is artificially controlled [22] .", [["disease", "PROBLEM", 107, 114], ["disease", "OBSERVATION", 107, 114]]], ["Sensitivity and specificity are not generally related to the prevalence of the disease in the population considered, since these are properties of the diagnostic tool.", [["Sensitivity", "TEST", 0, 11], ["the disease", "PROBLEM", 75, 86], ["disease", "OBSERVATION", 79, 86]]], ["Unlike sensitivity and specificity, measures such as predictive values, accuracy, relative risk and risk difference are affected by the prevalence.", [["predictive values", "TEST", 53, 70], ["accuracy", "TEST", 72, 80]]], ["Therefore, we exclude them, and use the measures that are not affected by the prevalence to evaluate the magnetometerbased contact test.2) SENSITIVITY AND SPECIFICITYSensitivity is expressed as the proportion of correctly classified as true positives among the total contacts TP/(TP + FN ).", [["TP", "GENE_OR_GENE_PRODUCT", 276, 278], ["TP + FN", "GENE_OR_GENE_PRODUCT", 280, 287], ["FN", "PROTEIN", 285, 287], ["the magnetometerbased contact test", "TEST", 101, 135], ["SENSITIVITY", "TEST", 139, 150], ["true positives", "PROBLEM", 236, 250]]], ["In other words, it is the ability of the magnetometer-based test to correctly identify the trace pairs with a real contact.", [["the magnetometer", "TEST", 37, 53]]], ["A highly sensitive test is useful, when we do not want to miss a contact (with an infected person) in screening the population.", [["person", "SPECIES", 91, 97]]], ["The specificity is the ability to identify the no contacts, expressed as TN /(TN + FP).", [["TN + FP", "GENE_OR_GENE_PRODUCT", 78, 85], ["TN", "PROTEIN", 73, 75], ["TN", "PROTEIN", 78, 80]]], ["A specific test will rarely misclassify the trace pairs without a contact as having made a contact.", [["A specific test", "TEST", 0, 15]]], ["The sensitivity and specificity show the discriminative powers of a diagnostic test.", [["The sensitivity", "TEST", 0, 15], ["a diagnostic test", "TEST", 66, 83]]], ["Fig. 9 shows the sensitivity and the specificity of our smartphone magnetometer-based test, as functions of N W and \u03b8 c .", [["\u03b8 c", "GENE_OR_GENE_PRODUCT", 116, 119], ["\u03b8 c", "PROTEIN", 116, 119], ["our smartphone magnetometer", "TEST", 52, 79], ["based test", "TEST", 80, 90]]], ["We first find that larger N W does not necessarily mean the higher sensitivity.", [["larger", "OBSERVATION_MODIFIER", 19, 25]]], ["Although happening at different values of N W (50| \u03b8 c =0.9 \u223c 200| \u03b8 c =0.1 ), the sensitivity begins to decrease beyond a certain N W at each cutoff threshold.", [["the sensitivity", "TEST", 79, 94]]], ["It implies that the correlation decreases when computed for an excessively long trace segment used as the inspection window.", [["an excessively long trace segment", "PROBLEM", 60, 93], ["the inspection window", "TEST", 102, 123]]], ["The specificity, on the other hand, steadily increases as we use larger N W .", [["The specificity", "TEST", 0, 15], ["larger N W", "TREATMENT", 65, 75]]], ["The lesson here is that when we use the magnetometer-based diagnostic test, we need to examine the similarity of the two traces using the time window of N W = 50 \u223c 200 to achieve the highest sensitivity.", [["the magnetometer", "TEST", 36, 52], ["diagnostic test", "TEST", 59, 74], ["N W", "TREATMENT", 153, 156]]], ["Then, the choice of the exact cutoff threshold will depend on the target specificity.2) SENSITIVITY AND SPECIFICITYAlso, we find in Fig. 9 that the sensitivity is higher with lower cutoff values, whereas the specificity is higher with higher cutoff values.", [["the sensitivity", "TEST", 144, 159], ["the specificity", "TEST", 204, 219], ["higher", "OBSERVATION_MODIFIER", 163, 169], ["higher", "OBSERVATION_MODIFIER", 223, 229]]], ["This tension is natural, and can be summarized in the Receiver Operating Characteristic (ROC) curve.", [["tension", "OBSERVATION", 5, 12], ["natural", "OBSERVATION_MODIFIER", 16, 23]]], ["Fig. 10 shows the ROC curves for different parameter combinations.", [["the ROC curves", "TEST", 14, 28], ["different parameter combinations", "TREATMENT", 33, 65]]], ["Although we cannot show the area under curve (AUC) itself due to the absence of very low specificity data points, it is clear that the AUC's for various N W are very high.", [["AUC", "TEST", 46, 49], ["very low specificity data points", "PROBLEM", 80, 112], ["the AUC's", "TEST", 131, 140], ["various N W", "TREATMENT", 145, 156]]], ["Namely, the magnetometer-based test is of high diagnostic quality.", [["the magnetometer-based test", "TEST", 8, 35]]], ["Among the inspection sample window sizes, very small N W (50, 70) and very large N W (1,500) lead to poorer AUC than those in the middle (N W = 100 \u223c 900) as shown in Fig. 10(b) .", [["the inspection sample window sizes", "TEST", 6, 40], ["very small N W", "PROBLEM", 42, 56], ["very large N W", "PROBLEM", 70, 84], ["sizes", "OBSERVATION_MODIFIER", 35, 40], ["very", "OBSERVATION_MODIFIER", 42, 46], ["small", "OBSERVATION_MODIFIER", 47, 52], ["large", "OBSERVATION_MODIFIER", 75, 80], ["middle", "ANATOMY_MODIFIER", 130, 136]]], ["N W = 300 achieves the best overall AUC.2) SENSITIVITY AND SPECIFICITYIn order to obtain the cutoff value \u03b8 c that achieves the highest AUC for a given N W , we can compute the shortest distance VOLUME 7, 20193) LIKELIHOOD RATIOSLikelihood ratio (LR) is the mostly widely applied measure of diagnostic accuracy.", [["the cutoff value", "TEST", 89, 105], ["the shortest distance VOLUME", "TEST", 173, 201], ["LIKELIHOOD RATIOSLikelihood ratio", "TEST", 212, 245], ["diagnostic accuracy", "TEST", 291, 310]]], ["When both probabilities are equal (i.e., LR = 1), such test is of no value.", [["LR", "TEST", 41, 43], ["such test", "TEST", 50, 59]]], ["The LR for positive test results (LR+) is defined as TP TP+FN / FP TN +FP .", [["TP TP", "GENE_OR_GENE_PRODUCT", 53, 58], ["FN", "PROTEIN", 59, 61], ["TN", "PROTEIN", 67, 69], ["LR", "TEST", 34, 36], ["TP TP", "TEST", 53, 58], ["FN", "TEST", 59, 61], ["FP", "TEST", 71, 73]]], ["The higher the LR+, the more indicative the test is of the contact.", [["LR", "PROTEIN", 15, 17], ["higher", "OBSERVATION_MODIFIER", 4, 10]]], ["Good diagnostic tests have LR+ > 10 and their positive result has a significant contribution to the diagnosis [67] .", [["LR", "TEST", 27, 29]]], ["On the other hand, the LR for negative test result (LR\u2212) is defined as FN TP+FN / TN TN +FP , and it represents the ratio of the probability that a negative result will occur in trace pairs with the contact to the probability that the same result will occur in trace pairs without the contact.", [["FN TP", "GENE_OR_GENE_PRODUCT", 71, 76], ["FN", "PROTEIN", 71, 73], ["FN", "PROTEIN", 77, 79], ["TN", "PROTEIN", 82, 84], ["TN", "PROTEIN", 85, 87], ["the LR", "TEST", 19, 25], ["LR", "TEST", 52, 54], ["FN TP", "TEST", 71, 76], ["FN", "TEST", 77, 79], ["FP", "TEST", 89, 91], ["trace pairs", "PROBLEM", 178, 189]]], ["Good diagnostic tests have LR\u2212 < 0.1 [67] .", [["LR", "TEST", 27, 29]]], ["The lower the LR\u2212, the more significant contribution of the test is in ruling-out.", [["the test", "TEST", 56, 64], ["lower", "ANATOMY_MODIFIER", 4, 9], ["significant", "OBSERVATION_MODIFIER", 28, 39]]], ["LR's do not depend on prevalence of disease of population, as only sensitivity and specificity values are used to calculate them.", [["LR's", "TREATMENT", 0, 4], ["disease of population", "PROBLEM", 36, 57], ["specificity values", "TEST", 83, 101], ["disease", "OBSERVATION", 36, 43]]], ["As a result the LR's of one study could be used in another setting with the condition that the definition of contact is not changed.3) LIKELIHOOD RATIOSThe likelihood ratios of the smartphone magnetometerbased contact test are shown in Fig. 11 .", [["the LR's", "TREATMENT", 12, 20], ["one study", "TEST", 24, 33], ["the smartphone magnetometerbased contact test", "TEST", 177, 222]]], ["The criterion LR+ > 10 tells us that the positive likelihoods can be a significant contribution to the diagnosis.", [["The criterion LR", "TEST", 0, 16], ["the positive likelihoods", "PROBLEM", 37, 61]]], ["We also note that we do not need large N W to have LR+ > 10, especially when we use higher cutoff thresholds of \u03b8 c \u2265 0.6.", [["large N W", "TREATMENT", 33, 42], ["LR", "TEST", 51, 53], ["higher cutoff thresholds", "TEST", 84, 108]]], ["Less than 100 measurement samples at 10 Hz, or equivalently 10 seconds, is enough to qualify for a good test for positive identification of contacts.", [["samples", "ANATOMY", 26, 33], ["a good test", "TEST", 97, 108]]], ["On the other hand, Fig. 11 (b) shows that the higher cutoff thresholds cannot achieve LR\u2212 < 0.1 regardless of N W .", [["the higher cutoff thresholds", "PROBLEM", 42, 70], ["LR", "TEST", 86, 88]]], ["It implies that using the higher cutoffs can produce a high fraction of false negatives.", [["the higher cutoffs", "PROBLEM", 22, 40], ["false negatives", "OBSERVATION", 72, 87]]], ["For example, in Fig. 6(a) , hundreds of adjacent positive decisions will occur as we slide up k in (1).", [["positive", "OBSERVATION", 49, 57]]], ["Interspersed false negatives will less affect the final decision then.4) DIAGNOSTIC ODDS RATIODiagnostic odds ratio (DOR) is a relative measure for diagnostic accuracy, used for the estimation of discriminative power of diagnostic procedures [67] .", [["Interspersed false negatives", "PROBLEM", 0, 28], ["diagnostic accuracy", "TEST", 148, 167], ["diagnostic procedures", "TEST", 220, 241], ["false negatives", "OBSERVATION", 13, 28]]], ["DOR of a test is the ratio of the odds of positivity in traces with the contact relative to the odds in traces without contact.", [["a test", "TEST", 7, 13], ["positivity", "OBSERVATION", 42, 52]]], ["It is calculated according to the formula: DOR = (TP/FN )/(FP/TN ).", [["FN", "PROTEIN", 53, 55], ["TN", "PROTEIN", 62, 64], ["DOR", "TEST", 43, 46]]], ["DOR depends significantly on the sensitivity and specificity of a test.", [["the sensitivity", "TEST", 29, 44], ["a test", "TEST", 64, 70]]], ["A test with high specificity and sensitivity with low rate of false positives and false negatives has high DOR.", [["DOR", "PROTEIN", 107, 110], ["A test", "TEST", 0, 6], ["sensitivity", "TEST", 33, 44], ["false positives", "TEST", 62, 77], ["false negatives", "TEST", 82, 97], ["high DOR", "PROBLEM", 102, 110], ["false positives", "OBSERVATION", 62, 77]]], ["With the same sensitivity of the test, DOR increases with the increase of the test specificity.", [["DOR", "SIMPLE_CHEMICAL", 39, 42], ["the test", "TEST", 29, 37], ["DOR", "PROBLEM", 39, 42], ["the test specificity", "TEST", 74, 94]]], ["For example, a test with sensitivity > 90% and specificity of 99% has a DOR greater than 500.", [["a test", "TEST", 13, 19], ["sensitivity", "TEST", 25, 36], ["specificity", "TEST", 47, 58], ["a DOR", "TEST", 70, 75]]], ["The diagnostic odds ratio ranges from zero to infinity, although for useful tests it is greater than one, and higher diagnostic odds ratios are indicative of better test performance.", [["useful tests", "TEST", 69, 81], ["indicative of", "UNCERTAINTY", 144, 157]]], ["Fig. 12 shows that the DOR of the smartphone magnetometer-based contact test is much larger than one for most N W values.", [["the smartphone magnetometer", "TEST", 30, 57], ["based contact test", "TEST", 58, 76]]], ["So, this measure also confirms that the magnetometer-based test is useful.", [["the magnetometer-based test", "TEST", 36, 63]]], ["If we use OR = 500 as the example criterion, the figure tells us that higher cutoff thresholds qualify with less measurement samples N W to look at (\u03b8 c = 0.9 has FN = 0 at N W = 100, so it should qualify although we cannot plot it).", [["higher cutoff thresholds", "PROBLEM", 70, 94], ["FN", "TEST", 163, 165]]], ["For these higher cutoffs, less than 300 samples (or equivalently 30 seconds) or less is enough to achieve the high DOR.C. SUMMARY OF RESULTS AND RECOMMENDATIONSAbove, we evaluated the quality of the smartphone magnetometer traces comparison as a clinical test for potential (infectious) contact.", [["these higher cutoffs", "PROBLEM", 4, 24], ["a clinical test", "TEST", 244, 259], ["higher", "OBSERVATION_MODIFIER", 10, 16], ["cutoffs", "OBSERVATION", 17, 24]]], ["All evaluation metrics that we used for the evaluation, namely sensitivity, specificity, likelihood ratio, and diagnostic odds ratio, point to the fact that the number of magnetometer readings to be compared between two traces (N W ) can be small.", [["All evaluation metrics", "TEST", 0, 22], ["the evaluation", "TEST", 40, 54], ["likelihood ratio", "TEST", 89, 105], ["magnetometer readings", "TEST", 171, 192], ["small", "OBSERVATION_MODIFIER", 241, 246]]], ["These metrics produce slightly different optimal numbers for the required readings, but if we need one good number to apply in real-life cases, it is 100 samples (or equivalently 10 seconds at the 10 Hz sampling frequency).", [["slightly", "OBSERVATION_MODIFIER", 22, 30]]], ["It leads to the best or close-to-thebest performance in all the evaluation measures.", [["all the evaluation measures", "TEST", 56, 83]]], ["One further recommendation is that the correlation coefficient value used as the decision threshold can be high.", [["the correlation coefficient value", "TEST", 35, 68]]], ["Note that these two numbers N W and \u03b8 c to produce the most precise decision are closely related, and other combinations than (100, 0.6) can be inferred from the results in the previous section.V. CONCLUSIONWhen a large-scale epidemic crisis unfolds in the highly urbanized society today, the traditional contact tracing method of medical personnel interviewing the infected persons will become highly costly, slow, and ineffective.", [["\u03b8 c", "GENE_OR_GENE_PRODUCT", 36, 39], ["persons", "ORGANISM", 375, 382], ["persons", "SPECIES", 375, 382], ["a large-scale epidemic crisis", "PROBLEM", 212, 241], ["large", "OBSERVATION_MODIFIER", 214, 219], ["-scale", "OBSERVATION_MODIFIER", 219, 225], ["epidemic", "OBSERVATION_MODIFIER", 226, 234], ["crisis", "OBSERVATION", 235, 241]]], ["In this paper, we discuss how smartphones carried by most people can be harnessed to automatize the contact tracing in such situation.", [["people", "ORGANISM", 58, 64], ["people", "SPECIES", 58, 64]]], ["We exploit the fact that smartphone magnetometers show high linear correlation when two phones coexist within a short, disease-contractible distances, such as less than two meters.", [["smartphone magnetometers", "TEST", 25, 49], ["a short, disease-contractible distances", "PROBLEM", 110, 149]]], ["Our evaluation reveals that the magnetometer-based method qualifies for a valid clinical test, if used with certain parameter values in the correlation computation.", [["Our evaluation", "TEST", 0, 14], ["a valid clinical test", "TEST", 72, 93], ["the correlation computation", "TEST", 136, 163]]], ["First, the size of the sliding window of trace section to be compared is best to be what corresponds to 10 seconds of samples.", [["the sliding window of trace section", "TREATMENT", 19, 54], ["samples", "TEST", 118, 125], ["size", "OBSERVATION_MODIFIER", 11, 15], ["sliding window", "OBSERVATION", 23, 37]]], ["Second, the decision threshold that matches the comparison window size is 0.6, for the most precise contact decision.", [["size", "OBSERVATION_MODIFIER", 66, 70]]], ["These two parameters are inversely related with respect to the precision of the contact detection, and other combinations around the recommended values are also possible.", [["the contact detection", "TEST", 76, 97]]], ["In future, we will further test the reliability of the proposed method with the recommended and other parameter settings in more extensive real-life environments, for instance with different smartphone movement speeds, with obstacles, people or objects between or around the smartphone holders, and with interferences such as power lines close to the smartphones.", [["people", "ORGANISM", 235, 241], ["people", "SPECIES", 235, 241], ["other parameter settings", "TREATMENT", 96, 120], ["power lines", "TREATMENT", 326, 337]]], ["The artificial traces that we generated in a controlled environment could have biased our experiment results and our conclusion.", [["artificial traces", "OBSERVATION", 4, 21]]]], "PMC7149483": [], "a3dd274bc9a9d46c96dca3d140b5bc75ab1547c2": [["Evidence before this studyThe interaction between current smoking and COVID-19 is unclear.", [["smoking", "CHEMICAL", 58, 65], ["COVID-19", "CHEMICAL", 70, 78], ["COVID-19", "CHEMICAL", 70, 78], ["COVID-19", "GENE_OR_GENE_PRODUCT", 70, 78], ["this study", "TEST", 16, 26], ["COVID", "TREATMENT", 70, 75]]], ["Smoking is known to increase susceptibility to viral infections and appears to be associated with worse outcomes in people admitted to hospital with COVID-19.", [["Smoking", "DISEASE", 0, 7], ["viral infections", "DISEASE", 47, 63], ["people", "ORGANISM", 116, 122], ["people", "SPECIES", 116, 122], ["viral infections", "PROBLEM", 47, 63], ["COVID", "TEST", 149, 154], ["viral infections", "OBSERVATION", 47, 63]]], ["However, case series have reported relatively low levels of current smoking among individuals admitted to hospital with the condition, raising the possibility that smoking has a protective effect against the disease.Added value of this studyData from a large UK population who are users of a symptom reporting app during the pandemic supports the hypothesis that smokers are more likely to develop symptoms consistent with COVID-19 and that they have an increased symptom burden.Implications of all the available evidenceThese population data, combined with evidence of a worse outcome in smokers hospitalised with the condition, support the contention that smoking increases individual risk from COVID- 19 .", [["smoking", "CHEMICAL", 68, 75], ["smoking", "CHEMICAL", 164, 171], ["smoking", "CHEMICAL", 658, 665], ["COVID- 19", "CHEMICAL", 697, 706], ["smokers", "ORGANISM", 363, 370], ["the disease", "PROBLEM", 204, 215], ["this study", "TEST", 231, 241], ["a symptom", "PROBLEM", 290, 299], ["symptoms", "PROBLEM", 398, 406], ["COVID", "TEST", 423, 428], ["an increased symptom burden", "PROBLEM", 451, 478], ["COVID", "TEST", 697, 702], ["disease", "OBSERVATION", 208, 215], ["large", "OBSERVATION_MODIFIER", 253, 258], ["increased", "OBSERVATION_MODIFIER", 454, 463], ["symptom", "OBSERVATION", 464, 471]]], ["Support to help people to quit smoking should therefore form part of efforts to deal with the pandemic.Implications of all the available evidence.", [["people", "ORGANISM", 16, 22], ["people", "SPECIES", 16, 22], ["the pandemic", "PROBLEM", 90, 102]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 21, 2020. .INTRODUCTIONAlthough in many people infection with SARS-CoV-2 causes no or only minor symptoms, in a proportion who develop COVID-19 there is progressive lung involvement with respiratory failure and widespread systemic consequences 1, 2 .The risk of severe complications is higher in older people and those with long term medical conditions including cardiovascular disease, diabetes and COPD.", [["lung", "ANATOMY", 429, 433], ["respiratory", "ANATOMY", 451, 462], ["cardiovascular", "ANATOMY", 627, 641], ["CC", "CHEMICAL", 0, 2], ["infection", "DISEASE", 311, 320], ["SARS", "DISEASE", 326, 330], ["COVID", "DISEASE", 399, 404], ["respiratory failure", "DISEASE", 451, 470], ["cardiovascular disease", "DISEASE", 627, 649], ["diabetes", "DISEASE", 651, 659], ["COPD", "DISEASE", 664, 668], ["people", "ORGANISM", 304, 310], ["SARS-CoV-2", "ORGANISM", 326, 336], ["lung", "ORGAN", 429, 433], ["people", "ORGANISM", 566, 572], ["cardiovascular", "ANATOMICAL_SYSTEM", 627, 641], ["people", "SPECIES", 304, 310], ["people", "SPECIES", 566, 572], ["SARS-CoV", "SPECIES", 326, 334], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["many people infection", "PROBLEM", 299, 320], ["SARS", "PROBLEM", 326, 330], ["minor symptoms", "PROBLEM", 355, 369], ["COVID", "TEST", 399, 404], ["progressive lung involvement", "PROBLEM", 417, 445], ["respiratory failure", "PROBLEM", 451, 470], ["widespread systemic consequences", "PROBLEM", 475, 507], ["severe complications", "PROBLEM", 526, 546], ["long term medical conditions", "PROBLEM", 588, 616], ["cardiovascular disease", "PROBLEM", 627, 649], ["diabetes", "PROBLEM", 651, 659], ["COPD", "PROBLEM", 664, 668], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["infection", "OBSERVATION", 311, 320], ["progressive", "OBSERVATION_MODIFIER", 417, 428], ["lung", "ANATOMY", 429, 433], ["involvement", "OBSERVATION", 434, 445], ["respiratory failure", "OBSERVATION", 451, 470], ["widespread", "OBSERVATION_MODIFIER", 475, 485], ["systemic", "OBSERVATION_MODIFIER", 486, 494], ["severe", "OBSERVATION_MODIFIER", 526, 532], ["complications", "OBSERVATION", 533, 546], ["higher", "OBSERVATION_MODIFIER", 550, 556], ["cardiovascular", "ANATOMY", 627, 641], ["disease", "OBSERVATION", 642, 649], ["COPD", "OBSERVATION", 664, 668]]], ["[3] [4] [5] Tobacco smoking is a significant risk factor for both viral and bacterial infections of the respiratory system 6, 7 , with smokers five times as likely to develop influenza and twice as likely to have pneumonia 8 .", [["viral and bacterial infections", "DISEASE", 66, 96], ["influenza", "DISEASE", 175, 184], ["pneumonia", "DISEASE", 213, 222], ["[3] [4] [5]", "SIMPLE_CHEMICAL", 0, 11], ["Tobacco", "ORGANISM", 12, 19], ["a significant risk factor", "PROBLEM", 31, 56], ["both viral and bacterial infections of the respiratory system", "PROBLEM", 61, 122], ["influenza", "PROBLEM", 175, 184], ["pneumonia", "PROBLEM", 213, 222], ["viral", "OBSERVATION", 66, 71], ["bacterial infections", "OBSERVATION", 76, 96], ["respiratory system", "ANATOMY", 104, 122], ["influenza", "OBSERVATION", 175, 184], ["pneumonia", "OBSERVATION", 213, 222]]], ["It may therefore be an important factor worsening the impact of COVID-19.", [["COVID-19", "CHEMICAL", 64, 72], ["COVID", "TEST", 64, 69], ["worsening", "OBSERVATION_MODIFIER", 40, 49]]], ["There is evidence from case series that smoking is associated with more severe disease, a greater risk of ITU admission and excess mortality in people with COVID-19 admitted to hospital 3, [9] [10] [11] [12] .", [["smoking", "CHEMICAL", 40, 47], ["people", "ORGANISM", 144, 150], ["[9] [10] [11] [12]", "SIMPLE_CHEMICAL", 189, 207], ["people", "SPECIES", 144, 150], ["more severe disease", "PROBLEM", 67, 86], ["severe", "OBSERVATION_MODIFIER", 72, 78], ["disease", "OBSERVATION", 79, 86]]], ["However some reports have suggested that although smoking related disease is common in patients with COVID-19, current smoking rates in hospitalised patients are lower than would be expected from population smoking prevalence.", [["smoking", "CHEMICAL", 50, 57], ["smoking", "CHEMICAL", 119, 126], ["smoking", "CHEMICAL", 207, 214], ["patients", "ORGANISM", 87, 95], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 87, 95], ["patients", "SPECIES", 149, 157], ["disease", "PROBLEM", 66, 73], ["COVID", "TEST", 101, 106]]], ["While some studies have looked specifically at current smoking [10] [11] [12] others combined current and exsmokers 3, 9 , and smoking prevalence in these samples suggest data may have been incomplete.", [["smoking", "CHEMICAL", 55, 62], ["samples", "CANCER", 155, 162], ["some studies", "TEST", 6, 18]]], ["A potential protective effect of nicotine has been suggested 13 .INTRODUCTIONIt has been reported that smoking is associated with upregulation of ACE2 [14] [15] [16] , the receptor for the SARS-CoV-2 virus 17 in the lung, though a recent meta-analysis suggests divergent effects with upregulation in epithelial cells and downregulation in alveolar type 2 cells 18 .", [["lung", "ANATOMY", 216, 220], ["epithelial cells", "ANATOMY", 300, 316], ["alveolar type 2 cells", "ANATOMY", 339, 360], ["nicotine", "CHEMICAL", 33, 41], ["smoking", "CHEMICAL", 103, 110], ["nicotine", "CHEMICAL", 33, 41], ["nicotine", "SIMPLE_CHEMICAL", 33, 41], ["ACE2 [14] [15] [16]", "GENE_OR_GENE_PRODUCT", 146, 165], ["SARS-CoV-2 virus 17", "ORGANISM", 189, 208], ["lung", "ORGAN", 216, 220], ["epithelial cells", "CELL", 300, 316], ["alveolar type 2 cells", "CELL", 339, 360], ["ACE2", "PROTEIN", 146, 150], ["epithelial cells", "CELL_TYPE", 300, 316], ["alveolar type 2 cells", "CELL_TYPE", 339, 360], ["CoV-2 virus", "SPECIES", 194, 205], ["SARS-CoV-2 virus", "SPECIES", 189, 205], ["nicotine", "TREATMENT", 33, 41], ["upregulation of ACE2", "TREATMENT", 130, 150], ["the receptor", "TEST", 168, 180], ["the SARS", "TEST", 185, 193], ["CoV", "TEST", 194, 197], ["a recent meta-analysis", "TEST", 229, 251], ["divergent effects", "PROBLEM", 261, 278], ["upregulation in epithelial cells", "PROBLEM", 284, 316], ["downregulation in alveolar type 2 cells", "PROBLEM", 321, 360], ["lung", "ANATOMY", 216, 220], ["divergent effects", "OBSERVATION", 261, 278], ["epithelial cells", "OBSERVATION", 300, 316], ["alveolar", "ANATOMY_MODIFIER", 339, 347]]], ["The situation is further complicated by the possibility that internalisation of ACE2 due to viral infection leads to unopposed ACEI activity and high angiotensin II levels, contributing to endothelial damage and the coagulopathy and microthrombosis seen in severe COVID-19 1,2 .INTRODUCTIONSmoking itself causes vascular endothelial damage 19 , a prominent feature in the pathophysiology of severe COVID-19.INTRODUCTION. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)In order to establish the impact of current smoking more accurately, we analysed data from a population COVID-19 symptom reporting app, the COVID Symptom Study, developed by Zoe in collaboration with KCL and MGH.", [["endothelial", "ANATOMY", 189, 200], ["vascular endothelial", "ANATOMY", 312, 332], ["viral infection", "DISEASE", 92, 107], ["angiotensin II", "CHEMICAL", 150, 164], ["endothelial damage", "DISEASE", 189, 207], ["coagulopathy", "DISEASE", 216, 228], ["microthrombosis", "DISEASE", 233, 248], ["COVID", "DISEASE", 398, 403], ["CC", "CHEMICAL", 421, 423], ["COVID-19", "CHEMICAL", 398, 406], ["ACE2", "GENE_OR_GENE_PRODUCT", 80, 84], ["ACEI", "SIMPLE_CHEMICAL", 127, 131], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 150, 164], ["endothelial", "TISSUE", 189, 200], ["vascular endothelial", "TISSUE", 312, 332], ["MGH", "CANCER", 830, 833], ["ACE2", "PROTEIN", 80, 84], ["angiotensin II", "PROTEIN", 150, 164], ["internalisation of ACE2", "PROBLEM", 61, 84], ["viral infection", "PROBLEM", 92, 107], ["unopposed ACEI activity", "PROBLEM", 117, 140], ["high angiotensin II levels", "PROBLEM", 145, 171], ["endothelial damage", "PROBLEM", 189, 207], ["the coagulopathy", "PROBLEM", 212, 228], ["microthrombosis", "PROBLEM", 233, 248], ["severe COVID", "PROBLEM", 257, 269], ["vascular endothelial damage", "TEST", 312, 339], ["severe COVID", "PROBLEM", 391, 403], ["CC", "TEST", 421, 423], ["ND", "PROBLEM", 430, 432], ["the COVID Symptom Study", "TEST", 758, 781], ["KCL", "TREATMENT", 822, 825], ["viral", "OBSERVATION_MODIFIER", 92, 97], ["infection", "OBSERVATION", 98, 107], ["endothelial damage", "OBSERVATION", 189, 207], ["coagulopathy", "OBSERVATION", 216, 228], ["severe", "OBSERVATION_MODIFIER", 257, 263], ["vascular endothelial", "ANATOMY", 312, 332], ["prominent", "OBSERVATION_MODIFIER", 347, 356], ["severe", "OBSERVATION_MODIFIER", 391, 397], ["NC", "ANATOMY", 427, 429], ["med", "ANATOMY", 526, 529]]], ["We hypothesised that current smokers would be at increased risk of developing COVID-19 symptoms and would experience a higher symptom burden.", [["COVID", "DISEASE", 78, 83], ["smokers", "ORGANISM", 29, 36], ["developing COVID-19 symptoms", "PROBLEM", 67, 95], ["a higher symptom burden", "PROBLEM", 117, 140]]], ["To provide additional mechanistic data we analysed the relationship between smoking and ACE2 gene expression in adipose tissue samples from mono-and dizygotic twins from the TwinsUK cohort 20 as well as investigating the relationship between ACE2 expression in lung and adipose tissue in samples from the Genotype-Tissue Expression (GTEx) resource 21 .Data and analysisAdult members of the public were invited to download the COVID Symptom Study App after launch on radio, TV and via social media.", [["adipose tissue samples", "ANATOMY", 112, 134], ["lung", "ANATOMY", 261, 265], ["adipose tissue", "ANATOMY", 270, 284], ["samples", "ANATOMY", 288, 295], ["smoking", "CHEMICAL", 76, 83], ["ACE2", "GENE_OR_GENE_PRODUCT", 88, 92], ["adipose tissue samples", "TISSUE", 112, 134], ["ACE2", "GENE_OR_GENE_PRODUCT", 242, 246], ["lung", "ORGAN", 261, 265], ["adipose tissue", "TISSUE", 270, 284], ["Tissue", "TISSUE", 314, 320], ["ACE2", "PROTEIN", 88, 92], ["ACE2", "PROTEIN", 242, 246], ["ACE2 gene expression", "TREATMENT", 88, 108], ["adipose tissue samples", "TEST", 112, 134], ["mono", "TEST", 140, 144], ["ACE2 expression in lung and adipose tissue", "PROBLEM", 242, 284], ["lung", "ANATOMY", 261, 265], ["adipose tissue", "ANATOMY", 270, 284]]], ["On first use, the app records self-reported location, age, and core health risk factors, including height, weight, smoking and common disease (e.g, diabetes, heart disease, lung disease) status, some medication use, as well as whether they thought that they had already had COVID-19 22 .", [["heart", "ANATOMY", 158, 163], ["lung", "ANATOMY", 173, 177], ["diabetes", "DISEASE", 148, 156], ["heart disease", "DISEASE", 158, 171], ["lung disease", "DISEASE", 173, 185], ["heart", "ORGAN", 158, 163], ["lung", "ORGAN", 173, 177], ["height", "TEST", 99, 105], ["common disease (e.g", "PROBLEM", 127, 146], ["diabetes", "PROBLEM", 148, 156], ["heart disease", "PROBLEM", 158, 171], ["lung disease)", "PROBLEM", 173, 186], ["COVID", "TEST", 274, 279], ["heart", "ANATOMY", 158, 163], ["disease", "OBSERVATION", 164, 171], ["lung", "ANATOMY", 173, 177], ["disease", "OBSERVATION", 178, 185]]], ["With continued use, participants can provide daily updates on whether they have been tested for SARS-CoV-2 and if they \"feel physically normal\".", [["SARS", "DISEASE", 96, 100], ["participants", "SPECIES", 20, 32], ["SARS", "PROBLEM", 96, 100]]], ["If not, they can record the presence of 14 COVID-19 related symptoms (i.e., abdominal pain, chest pain, delirium, diarrhoea, fatigue, fever, headache, hoarse voice, loss of smell, persistent cough, shortness of breath, skipped meals, sore throat, unusual muscle pains) and whether they had attended hospital.", [["abdominal", "ANATOMY", 76, 85], ["chest", "ANATOMY", 92, 97], ["muscle", "ANATOMY", 255, 261], ["abdominal pain", "DISEASE", 76, 90], ["chest pain", "DISEASE", 92, 102], ["delirium", "DISEASE", 104, 112], ["diarrhoea", "DISEASE", 114, 123], ["fatigue", "DISEASE", 125, 132], ["fever", "DISEASE", 134, 139], ["headache", "DISEASE", 141, 149], ["loss of smell", "DISEASE", 165, 178], ["cough", "DISEASE", 191, 196], ["shortness of breath", "DISEASE", 198, 217], ["sore throat", "DISEASE", 234, 245], ["muscle pains", "DISEASE", 255, 267], ["abdominal", "ORGANISM_SUBDIVISION", 76, 85], ["chest", "ORGANISM_SUBDIVISION", 92, 97], ["throat", "ORGANISM_SUBDIVISION", 239, 245], ["muscle", "ORGAN", 255, 261], ["COVID", "TEST", 43, 48], ["related symptoms", "PROBLEM", 52, 68], ["abdominal pain", "PROBLEM", 76, 90], ["chest pain", "PROBLEM", 92, 102], ["delirium", "PROBLEM", 104, 112], ["diarrhoea", "PROBLEM", 114, 123], ["fatigue", "PROBLEM", 125, 132], ["fever", "PROBLEM", 134, 139], ["headache", "PROBLEM", 141, 149], ["hoarse voice", "PROBLEM", 151, 163], ["loss of smell", "PROBLEM", 165, 178], ["persistent cough", "PROBLEM", 180, 196], ["shortness of breath", "PROBLEM", 198, 217], ["skipped meals", "PROBLEM", 219, 232], ["sore throat", "PROBLEM", 234, 245], ["unusual muscle pains", "PROBLEM", 247, 267], ["abdominal", "ANATOMY", 76, 85], ["chest", "ANATOMY", 92, 97], ["muscle", "ANATOMY", 255, 261]]], ["Fatigue and shortness of breath were graded by symptom severity, ranging from mild to severe.Data and analysisThe study has been approved by the King's College London Research Ethics Committee REMAS ID 18210, review reference LRS-19/20-18210 and all subscribers provided informed consent.Data and analysis.", [["Fatigue", "DISEASE", 0, 7], ["shortness of breath", "DISEASE", 12, 31], ["LRS-19/20-18210", "CHEMICAL", 226, 241], ["Fatigue", "PROBLEM", 0, 7], ["shortness of breath", "PROBLEM", 12, 31], ["symptom severity", "PROBLEM", 47, 63], ["mild to severe", "PROBLEM", 78, 92], ["Data and analysis", "TEST", 93, 110], ["The study", "TEST", 110, 119], ["Data and analysis", "TEST", 288, 305], ["mild", "OBSERVATION_MODIFIER", 78, 82], ["to severe", "OBSERVATION_MODIFIER", 83, 92]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Study PopulationThe study population comprised individuals resident in the UK who had entered data via the app between 24th March and 23rd April 2020, meeting the following criteria: age 16 to 90 years; BMI (kg/m 2 ) between 15 and 55.", [["CC", "CHEMICAL", 0, 2], ["individuals", "ORGANISM", 249, 260], ["ND", "PROBLEM", 9, 11], ["BMI", "TEST", 405, 408], ["med", "ANATOMY", 105, 108]]], ["For this analysis we removed individuals with inconsistent SARS-CoV-2 test results (i.e., people reporting testing both positive and negative for SARS-CoV-2), and inconsistent assessments (e.g. where the body temperature, when logged, was outside the range of 35 to 43\u00b0 C or where they reported feeling unwell but had no symptoms).", [["body", "ANATOMY", 204, 208], ["people", "ORGANISM", 90, 96], ["body", "ORGANISM_SUBDIVISION", 204, 208], ["people", "SPECIES", 90, 96], ["this analysis", "TEST", 4, 17], ["inconsistent SARS", "PROBLEM", 46, 63], ["CoV-2 test results", "TEST", 64, 82], ["testing", "TEST", 107, 114], ["SARS", "PROBLEM", 146, 150], ["CoV", "TEST", 151, 154], ["inconsistent assessments", "TEST", 163, 187], ["the body temperature", "TEST", 200, 220], ["unwell", "PROBLEM", 303, 309], ["symptoms", "PROBLEM", 321, 329]]], ["We also excluded women who declared themselves to be pregnant (n=8,680).Study PopulationWe collected all symptoms declared by each participant during the period which they engaged with the app (median [IQR] number of days of 14 ).", [["women", "ORGANISM", 17, 22], ["women", "SPECIES", 17, 22], ["participant", "SPECIES", 131, 142], ["all symptoms", "PROBLEM", 101, 113]]], ["While the response option for the majority of symptoms was yes/no, fatigue and shortness of breath were considered present if any level of severity was reported.Statistical analysisStatistical analyses were carried out using R (v. 3.6.0).", [["fatigue", "DISEASE", 67, 74], ["shortness of breath", "DISEASE", 79, 98], ["symptoms", "PROBLEM", 46, 54], ["fatigue", "PROBLEM", 67, 74], ["shortness of breath", "PROBLEM", 79, 98], ["Statistical analysisStatistical analyses", "TEST", 161, 201]]], ["Association between smoking status and binary variables, (i.e., presence/absence of one or more symptoms, self-assessed COVID-19 status or results from testing for SARS-CoV-2) was carried out through multivariate logistic regression using the R stats package, and including age, sex and BMI as covariates.Statistical analysisThe Bonferroni-adjusted threshold for statistical significance was calculated by dividing a conventional alpha value of 0.05 by the number of tested groups and the effective number of .", [["more symptoms", "PROBLEM", 91, 104], ["COVID", "TEST", 120, 125], ["testing", "TEST", 152, 159], ["SARS", "PROBLEM", 164, 168], ["the R stats package", "TREATMENT", 239, 258], ["Statistical analysis", "TEST", 305, 325], ["The Bonferroni-adjusted threshold", "TREATMENT", 325, 358], ["a conventional alpha value", "TEST", 415, 441]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Statistical analysisThe copyright holder for this preprint this version posted May 21, 2020. . independent symptoms, which were estimated based on their pairwise polychoric correlation coefficients (polycor R package, v. 0.7-10), using the Li's method 23 .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["Statistical analysis", "TEST", 202, 222], ["The copyright holder", "TREATMENT", 222, 242], ["independent symptoms", "PROBLEM", 297, 317], ["the Li's method", "TEST", 438, 453], ["med", "ANATOMY", 105, 108]]], ["The resulting p-value threshold was 0.05/4/11 = 1.14x10 -3 .", [["The resulting p-value threshold", "TEST", 0, 31]]], ["Association p-values lower than this threshold were considered to be statistically significant.Statistical analysisIn order to assess if smokers were characterised by specific patterns of co-occurring symptoms, we built distinct symptom correlation matrices in smokers and non-smokers based on the pairwise polychoric correlations between symptoms.", [["smokers", "ORGANISM", 137, 144], ["Association p-values", "TEST", 0, 20], ["co-occurring symptoms", "PROBLEM", 188, 209], ["symptoms", "PROBLEM", 339, 347]]], ["Subsequently, we tested the correlation between the two matrices using the Mantel test, as implemented in the vegan R package (v. 2.5-6).", [["the Mantel test", "TEST", 71, 86]]], ["The empirical p-value was given as the proportion of 1000 random permutations of the correlation matrices that had test statistic greater than or equal to the observed one.Statistical analysisWe further explored the effect of smoking on COVID-19 severity among Standard Users (i.e., subjects neither tested for SARS-CoV-2 nor self-reporting prior suspected COVID-19 infection at the time of registration) by seeking association between smoking status and the development of a greater symptom burden.", [["smoking", "CHEMICAL", 226, 233], ["SARS", "DISEASE", 311, 315], ["infection", "DISEASE", 366, 375], ["smoking", "CHEMICAL", 436, 443], ["The empirical p-value", "TEST", 0, 21], ["the correlation matrices", "TEST", 81, 105], ["test statistic", "TEST", 115, 129], ["COVID", "TREATMENT", 237, 242], ["SARS", "PROBLEM", 311, 315], ["prior suspected COVID-19 infection", "PROBLEM", 341, 375], ["a greater symptom burden", "PROBLEM", 474, 498]]], ["Tested logistic regression models included: i) presence of all classic COVID-19 related symptoms (i.e., fever, persistent cough and shortness of breath), ii) presence of more than 5 symptoms and iii) presence of more than 10 symptoms.", [["fever", "DISEASE", 104, 109], ["cough", "DISEASE", 122, 127], ["shortness of breath", "DISEASE", 132, 151], ["all classic COVID", "PROBLEM", 59, 76], ["related symptoms", "PROBLEM", 80, 96], ["fever", "PROBLEM", 104, 109], ["persistent cough", "PROBLEM", 111, 127], ["shortness of breath", "PROBLEM", 132, 151], ["5 symptoms", "PROBLEM", 180, 190], ["10 symptoms", "PROBLEM", 222, 233], ["persistent", "OBSERVATION_MODIFIER", 111, 121], ["cough", "OBSERVATION", 122, 127]]], ["Age, sex and BMI were included as covariates.Statistical analysisWith continued use of the app, visits to hospitals were recorded through user updates on their location following suspected COVID-19 (i.e., \"home\", \"hospital\", or \"back from hospital\").Statistical analysisWe treated hospital attendance as an additional proxy for COVID-19 symptom severity, and therefore tested by logistic regression its association with smoking in individuals testing .", [["smoking", "CHEMICAL", 420, 427], ["COVID", "TEST", 328, 333], ["symptom severity", "PROBLEM", 337, 353], ["individuals testing", "TEST", 431, 450]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 21, 2020. . positive for SARS-CoV-2.", [["CC", "CHEMICAL", 0, 2], ["SARS", "DISEASE", 289, 293], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 289, 299], ["SARS-CoV", "SPECIES", 289, 297], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["SARS", "PROBLEM", 289, 293], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Age, sex, BMI and presence of comorbidities (i.e., diabetes, lung disease, kidney disease, cancer and heart disease) or comorbidity-related treatments (i.e., blood pressure medications and immunosuppressants) were included as covariates in the model.", [["lung", "ANATOMY", 61, 65], ["kidney", "ANATOMY", 75, 81], ["cancer", "ANATOMY", 91, 97], ["heart", "ANATOMY", 102, 107], ["blood", "ANATOMY", 158, 163], ["diabetes", "DISEASE", 51, 59], ["lung disease", "DISEASE", 61, 73], ["kidney disease", "DISEASE", 75, 89], ["cancer", "DISEASE", 91, 97], ["heart disease", "DISEASE", 102, 115], ["lung", "ORGAN", 61, 65], ["kidney", "ORGAN", 75, 81], ["cancer", "CANCER", 91, 97], ["heart", "ORGAN", 102, 107], ["blood", "ORGANISM_SUBSTANCE", 158, 163], ["comorbidities", "PROBLEM", 30, 43], ["diabetes", "PROBLEM", 51, 59], ["lung disease", "PROBLEM", 61, 73], ["kidney disease", "PROBLEM", 75, 89], ["cancer", "PROBLEM", 91, 97], ["heart disease)", "PROBLEM", 102, 116], ["comorbidity", "PROBLEM", 120, 131], ["related treatments", "TREATMENT", 132, 150], ["blood pressure medications", "TREATMENT", 158, 184], ["immunosuppressants", "TREATMENT", 189, 207], ["comorbidities", "OBSERVATION", 30, 43], ["lung", "ANATOMY", 61, 65], ["disease", "OBSERVATION", 66, 73], ["kidney", "ANATOMY", 75, 81], ["disease", "OBSERVATION", 82, 89], ["cancer", "OBSERVATION", 91, 97], ["heart", "ANATOMY", 102, 107], ["disease", "OBSERVATION", 108, 115]]], ["As part of a sensitivity analysis, we also assessed the association between smoking status and hospital attendance (including age, sex and BMI as covariates) only in those subjects not reporting any comorbidities or treatments, in order to reduce the possible confounding effect of pre-existing health conditions.ACE2 expression analysesSubcutaneous adipose tissue gene expression, measured by RNASeq, was available in 541 female subjects who were participants in the TwinsUK cohort 20 .", [["Subcutaneous adipose tissue", "ANATOMY", 337, 364], ["smoking", "CHEMICAL", 76, 83], ["ACE2", "GENE_OR_GENE_PRODUCT", 313, 317], ["Subcutaneous adipose tissue", "TISSUE", 337, 364], ["ACE2", "PROTEIN", 313, 317], ["participants", "SPECIES", 448, 460], ["a sensitivity analysis", "TEST", 11, 33], ["treatments", "TREATMENT", 216, 226], ["pre-existing health conditions", "PROBLEM", 282, 312], ["ACE2 expression analyses", "TREATMENT", 313, 337], ["Subcutaneous adipose tissue gene expression", "PROBLEM", 337, 380], ["Subcutaneous adipose", "ANATOMY", 337, 357]]], ["Association of ACE2 expression in adipose tissue with smoking status was assessed using multivariate linear mixed effects models adjusting for RNASeq technical covariates, i.e. age, BMI, type 2 diabetes status, and family structure.ACE2 expression analysesFurther details of these analyses are available in the Online Supplement.Assessment of ACE2 expression in adipose tissue and lung samples from the GTEx resourceThe data used for the analyses described in this manuscript were obtained from the GTEx .", [["adipose tissue", "ANATOMY", 34, 48], ["adipose tissue", "ANATOMY", 362, 376], ["lung samples", "ANATOMY", 381, 393], ["type 2 diabetes", "DISEASE", 187, 202], ["ACE2", "GENE_OR_GENE_PRODUCT", 15, 19], ["adipose tissue", "TISSUE", 34, 48], ["ACE2", "GENE_OR_GENE_PRODUCT", 232, 236], ["ACE2", "GENE_OR_GENE_PRODUCT", 343, 347], ["adipose tissue", "TISSUE", 362, 376], ["lung samples", "CANCER", 381, 393], ["ACE2", "PROTEIN", 15, 19], ["ACE2", "PROTEIN", 232, 236], ["ACE2", "PROTEIN", 343, 347], ["ACE2 expression in adipose tissue", "PROBLEM", 15, 48], ["multivariate linear mixed effects models", "TREATMENT", 88, 128], ["RNASeq technical covariates", "TREATMENT", 143, 170], ["type 2 diabetes status", "PROBLEM", 187, 209], ["these analyses", "TEST", 275, 289], ["ACE2 expression in adipose tissue", "PROBLEM", 343, 376], ["lung samples", "TEST", 381, 393], ["the analyses", "TEST", 434, 446], ["ACE2 expression", "OBSERVATION", 15, 30], ["adipose tissue", "ANATOMY", 34, 48], ["adipose tissue", "ANATOMY", 362, 376], ["lung", "ANATOMY", 381, 385]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 21, 2020. .RESULTSOverall, 2,401,982 UK residents, a majority female (63.3%), entered data via the app between 24th March 2020 and 22nd April 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["During this period, 834,437 individuals (35%) reported that they \"did not feel physically normal\" and entered at least one COVID-19 related symptom.", [["related symptom", "PROBLEM", 132, 147]]], ["The 2,401,982 participants were classified into the following categories: tested SARS-CoV-2 positive (SC2P; n=7,123); tested SARS-CoV-2 negative (SC2N; n=16,759); subjects self-reporting COVID-19 (SC2S; n=157,406) who believed, based on symptoms, that they had already had COVID-19 at the time of registration; the remaining 2,221,088 were defined as \"StandardRESULTSUsers\" (Table 1) The overall smoking rate in this sample was 11.0%.", [["participants", "ORGANISM", 14, 26], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 81, 91], ["participants", "SPECIES", 14, 26], ["SARS-CoV", "SPECIES", 125, 133], ["tested SARS", "TEST", 74, 85], ["CoV", "TEST", 86, 89], ["SC2P", "TEST", 102, 106], ["tested SARS", "TEST", 118, 129], ["CoV", "TEST", 130, 133], ["COVID", "TEST", 187, 192], ["symptoms", "PROBLEM", 237, 245], ["COVID", "TEST", 273, 278], ["registration", "TEST", 297, 309]]], ["Smoking prevalence in the overall population and in any age and sex strata was lower compared to the general UK population (NHS report, 2018; Table 1 ).", [["Smoking", "DISEASE", 0, 7]]], ["This difference may be due to sampling bias, reflecting the demographics of this sample, as smoking rates are lower in wealthier groups 25 who may also have been more likely to be able to make use of a smartphone app.", [["sampling bias", "TEST", 30, 43], ["may be due to", "UNCERTAINTY", 16, 29], ["lower", "OBSERVATION_MODIFIER", 110, 115]]], ["We noted a higher p=8.00x10 -187 ; greater than 10 symptoms OR=1.50[1.42 to 1.58]; p=3.46x10 -48 ) (Figure 1) .RESULTS. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 21, 2020. .Smoking was strongly associated with having most COVID-19 symptoms among StandardUsers and SC2S (p< 1.14x10 -3 ; see Methods; Among subjects who reported not feeling well, the incidence of all COVID-19 related symptoms, with the exception of delirium and sore throat, was higher in the SC2P group as compared to the other categories (Chi-squared test p<1.27x10 -6 ; Figure 2) .", [["CC", "CHEMICAL", 120, 122], ["Smoking", "DISEASE", 395, 402], ["delirium", "DISEASE", 637, 645], ["sore throat", "DISEASE", 650, 661], ["SC2P", "CANCER", 681, 685], ["symptoms", "TEST", 51, 59], ["p", "TEST", 83, 84], ["CC", "TEST", 120, 122], ["ND", "PROBLEM", 129, 131], ["The copyright holder", "TREATMENT", 321, 341], ["most COVID-19 symptoms", "PROBLEM", 439, 461], ["all COVID-19 related symptoms", "PROBLEM", 584, 613], ["delirium", "PROBLEM", 637, 645], ["sore throat", "PROBLEM", 650, 661], ["Chi-squared test p", "TEST", 729, 747], ["NC", "ANATOMY", 126, 128], ["med", "ANATOMY", 225, 228]]], ["We did not observe any specific pattern of co-occurring symptoms distinguishing smokers from nonsmokers, with symptom correlation matrices showing significant inter-correlation in all four user categories (lowest Mantel's test r 2 = 0.54; p = 0.001; Figure 3 ).Smoking was strongly associated with having most COVID-19 symptoms among StandardTo explore differences in COVID-19 disease course between smokers and non-smokers, we used the number of reported COVID-19 symptoms as a proxy for disease severity, with the assumption that a higher symptom burden was suggestive of more severe disease.", [["Smoking", "DISEASE", 261, 268], ["co-occurring symptoms", "PROBLEM", 43, 64], ["symptom correlation matrices", "TEST", 110, 138], ["Mantel's test", "TEST", 213, 226], ["most COVID-19 symptoms", "PROBLEM", 305, 327], ["19 symptoms", "PROBLEM", 462, 473], ["disease severity", "PROBLEM", 489, 505], ["a higher symptom burden", "PROBLEM", 532, 555], ["more severe disease", "PROBLEM", 574, 593], ["suggestive of", "UNCERTAINTY", 560, 573], ["more severe", "OBSERVATION_MODIFIER", 574, 585], ["disease", "OBSERVATION", 586, 593]]], ["Indeed, individuals reporting hospital attendance reported experiencing a higher number of cooccurring symptoms than those who did not attend hospital (OR 1.32[1.31 to 1.33]; P<2.22 x10 -16 ).Smoking was strongly associated with having most COVID-19 symptoms among StandardWe observed a shift in the symptom burden distribution towards an increasing number of symptoms across groups, with the lowest average symptom burden in the Standard Users .", [["Smoking", "DISEASE", 192, 199], ["cooccurring symptoms", "PROBLEM", 91, 111], ["most COVID-19 symptoms", "PROBLEM", 236, 258], ["a shift in the symptom burden distribution", "PROBLEM", 285, 327], ["symptoms across groups", "PROBLEM", 360, 382], ["the lowest average symptom burden", "PROBLEM", 389, 422], ["shift", "OBSERVATION_MODIFIER", 287, 292], ["increasing", "OBSERVATION_MODIFIER", 339, 349], ["number", "OBSERVATION_MODIFIER", 350, 356]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 21, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Figure 4 ).Characteristics of SARS-CoV-2 tested individualsAs expected, the group who reported that they had undergone testing (n=26,918 1.1% of app users) differed in a number of ways from the general study population ( Table 1 ).", [["SARS", "DISEASE", 30, 34], ["individuals", "ORGANISM", 48, 59], ["SARS-CoV", "SPECIES", 30, 38], ["SARS", "TEST", 30, 34], ["CoV", "TEST", 35, 38], ["testing", "TEST", 119, 126], ["SARS", "OBSERVATION", 30, 34]]], ["In particular, 20% of those tested were healthcare workers (HCW) compared to 3.4% in the whole population and 31% of those testing positive were HCW.", [["those testing", "TEST", 117, 130]]], ["Smoking rates among tested individuals were lower compared to all users of the app (8.9% vs 11.0%).", [["the app", "TEST", 75, 82]]], ["Smoking rates were lower in those who had tested positive for SARS-CoV-2 compared to those testing negative (7.4% vs 9.3%), as were rates of cancer, heart disease and lung disease.", [["cancer", "ANATOMY", 141, 147], ["heart", "ANATOMY", 149, 154], ["lung", "ANATOMY", 167, 171], ["SARS", "DISEASE", 62, 66], ["cancer", "DISEASE", 141, 147], ["heart disease", "DISEASE", 149, 162], ["lung disease", "DISEASE", 167, 179], ["SARS-CoV-2", "ORGANISM", 62, 72], ["cancer", "CANCER", 141, 147], ["heart", "ORGAN", 149, 154], ["lung", "ORGAN", 167, 171], ["SARS-CoV", "SPECIES", 62, 70], ["SARS", "PROBLEM", 62, 66], ["CoV", "TEST", 67, 70], ["those testing", "TEST", 85, 98], ["cancer", "PROBLEM", 141, 147], ["heart disease", "PROBLEM", 149, 162], ["lung disease", "PROBLEM", 167, 179], ["cancer", "OBSERVATION", 141, 147], ["heart", "ANATOMY", 149, 154], ["disease", "OBSERVATION", 155, 162], ["lung", "ANATOMY", 167, 171], ["disease", "OBSERVATION", 172, 179]]], ["Although p=9.49x10 -9 ), we also found that symptom burden was higher in smokers who tested positive for SARS-CoV-2 as compared to non-smokers.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 105, 115], ["SARS-CoV", "SPECIES", 105, 113], ["p", "TEST", 9, 10], ["symptom burden", "PROBLEM", 44, 58], ["SARS", "PROBLEM", 105, 109], ["CoV", "TEST", 110, 113]]], ["In addition, current smokers who tested positive had a higher risk of attending hospital due to COVID-19 (OR 2.11 [1.41 to 3.11] (p=1.99x10 -4 )).", [["smokers", "ORGANISM", 21, 28], ["COVID", "TEST", 96, 101]]], ["This association remained significant when subjects reporting the presence of comorbidities were removed from the analysis (OR 1.87 [1.15 to 2.95]; p=9.02x10 -3 ).ACE2 expression in GTEx lung and adipose tissueWe examined ACE2 expression in publicly-available gene expression data measured by RNASeq in the GTEx project 24 .", [["GTEx lung", "ANATOMY", 182, 191], ["adipose tissueWe", "ANATOMY", 196, 212], ["ACE2", "GENE_OR_GENE_PRODUCT", 163, 167], ["GTEx lung", "TISSUE", 182, 191], ["adipose tissueWe", "TISSUE", 196, 212], ["ACE2", "GENE_OR_GENE_PRODUCT", 222, 226], ["ACE2", "PROTEIN", 163, 167], ["ACE2", "PROTEIN", 222, 226], ["comorbidities", "PROBLEM", 78, 91], ["the analysis", "TEST", 110, 122], ["p", "TEST", 148, 149], ["ACE2 expression", "TEST", 163, 178], ["adipose tissueWe", "TEST", 196, 212], ["ACE2 expression", "TEST", 222, 237], ["gene expression data", "TEST", 260, 280], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["GTEx", "ANATOMY_MODIFIER", 182, 186], ["lung", "ANATOMY", 187, 191], ["adipose", "ANATOMY", 196, 203]]], ["In this sample, median ACE2 gene expression in .", [["sample", "ANATOMY", 8, 14], ["ACE2", "GENE_OR_GENE_PRODUCT", 23, 27], ["ACE2", "PROTEIN", 23, 27], ["median ACE2 gene expression", "TREATMENT", 16, 43]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 21, 2020. . subcutaneous adipose tissue was higher than in lung samples (Supplementary figure E2) .(which was not certified by peer review)ACE2 expression levels were positively correlated between adipose and lung tissue from the same subjects (Spearman's rho=0.25; p=1.57x10 -7 ; Supplementary Figure E3 ).Association of ACE2 expression with smoking in TwinsUKWe explored the relationship between ACE2 expression in adipose tissue and smoking status in gene expression data measured by RNASeq in female twins from the TwinsUK cohort 1 .", [["subcutaneous adipose tissue", "ANATOMY", 276, 303], ["lung samples", "ANATOMY", 323, 335], ["adipose", "ANATOMY", 461, 468], ["lung tissue", "ANATOMY", 473, 484], ["adipose tissue", "ANATOMY", 681, 695], ["CC", "CHEMICAL", 0, 2], ["smoking", "CHEMICAL", 607, 614], ["smoking", "CHEMICAL", 700, 707], ["subcutaneous adipose tissue", "TISSUE", 276, 303], ["lung samples", "TISSUE", 323, 335], ["ACE2", "GENE_OR_GENE_PRODUCT", 403, 407], ["adipose", "TISSUE", 461, 468], ["lung tissue", "TISSUE", 473, 484], ["E3", "GENE_OR_GENE_PRODUCT", 566, 568], ["ACE2", "GENE_OR_GENE_PRODUCT", 586, 590], ["ACE2", "GENE_OR_GENE_PRODUCT", 662, 666], ["adipose tissue", "TISSUE", 681, 695], ["ACE2", "PROTEIN", 403, 407], ["ACE2", "PROTEIN", 586, 590], ["ACE2", "PROTEIN", 662, 666], ["RNASeq", "PROTEIN", 751, 757], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["subcutaneous adipose tissue", "PROBLEM", 276, 303], ["ACE2 expression levels", "TEST", 403, 425], ["Spearman's rho", "TEST", 509, 523], ["p", "TEST", 530, 531], ["ACE2 expression", "PROBLEM", 586, 601], ["ACE2 expression in adipose tissue", "PROBLEM", 662, 695], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["adipose", "ANATOMY", 289, 296], ["tissue", "OBSERVATION", 297, 303], ["higher", "OBSERVATION_MODIFIER", 308, 314], ["lung", "ANATOMY", 323, 327], ["lung", "ANATOMY", 473, 477], ["tissue", "ANATOMY_MODIFIER", 478, 484], ["ACE2 expression", "OBSERVATION", 586, 601], ["adipose tissue", "ANATOMY", 681, 695]]], ["In this sample, smokers were found to have reduced ACE2 expression in adipose tissue compared to non-smokers (Beta(SE)= -0.395(0.149); p=7.01x10 -3 ).", [["adipose tissue", "ANATOMY", 70, 84], ["smokers", "ORGANISM", 16, 23], ["ACE2", "GENE_OR_GENE_PRODUCT", 51, 55], ["adipose tissue", "TISSUE", 70, 84], ["ACE2", "PROTEIN", 51, 55], ["reduced ACE2 expression in adipose tissue", "PROBLEM", 43, 84], ["Beta(SE)", "TEST", 110, 118], ["ACE2 expression", "OBSERVATION", 51, 66], ["adipose tissue", "OBSERVATION", 70, 84]]], ["This association was robust to sensitivity analyses excluding subjects with type 2 diabetes, and to the inclusion of past smokers in the dataset ( Figure 5 Table E1 ).DISCUSSIONThe main finding of this study from a large prospective population cohort was that current smoking was associated with a substantially increased risk of developing symptoms suggestive of COVID-19.", [["type 2 diabetes", "DISEASE", 76, 91], ["smoking", "CHEMICAL", 268, 275], ["COVID-19", "CHEMICAL", 364, 372], ["sensitivity analyses", "TEST", 31, 51], ["type 2 diabetes", "PROBLEM", 76, 91], ["this study", "TEST", 197, 207], ["developing symptoms", "PROBLEM", 330, 349], ["COVID", "TEST", 364, 369], ["diabetes", "OBSERVATION", 83, 91], ["main", "OBSERVATION_MODIFIER", 181, 185], ["large", "OBSERVATION_MODIFIER", 215, 220], ["increased", "OBSERVATION_MODIFIER", 312, 321]]], ["In addition, current smoking was associated with a greater symptom burden, indicating an impact on disease severity and smokers testing positive for SARS-CoV-2 were more likely to attend hospital.", [["smoking", "CHEMICAL", 21, 28], ["SARS", "DISEASE", 149, 153], ["SARS-CoV", "SPECIES", 149, 157], ["a greater symptom burden", "PROBLEM", 49, 73], ["disease severity", "PROBLEM", 99, 115], ["smokers testing", "TEST", 120, 135], ["SARS", "PROBLEM", 149, 153]]], ["ACE2 expression in adipose tissue was noted to be lower which may have an impact on mechanisms of disease severity.Significance of findingsThe COVID-19 pandemic spreads continues to threaten to overwhelm the capacity of health systems, especially as communities prepare for a release from social distancing after the first wave of the pandemic.", [["adipose tissue", "ANATOMY", 19, 33], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["adipose tissue", "TISSUE", 19, 33], ["ACE2", "PROTEIN", 0, 4], ["ACE2 expression in adipose tissue", "PROBLEM", 0, 33], ["disease severity", "PROBLEM", 98, 114], ["The COVID-19 pandemic spreads", "TREATMENT", 139, 168], ["the pandemic", "PROBLEM", 331, 343], ["adipose tissue", "OBSERVATION", 19, 33], ["disease", "OBSERVATION", 98, 105]]], ["There is a need for strategies to mitigate this, which includes preventing or delaying transmission of the virus to \"flatten the curve\", as well as any measures that might reduce the severity of the condition.", [["strategies", "TREATMENT", 20, 30], ["the virus", "PROBLEM", 103, 112], ["the severity of the condition", "PROBLEM", 179, 208]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 21, 2020. . https://doi.org/10.1101/2020.05.18.20105288 doi: medRxiv preprint to increase health system capacity and reduce health system demand from other sources.(which was not certified by peer review)The present data suggest that smoking cessation should be considered as an element in strategies to address COVID-19, as smoking increases both the likelihood of symptomatic disease defined according to the presence of \"classic\" symptoms of fever, cough and breathlessness and the severity of disease, defined based on the number of symptoms.(which was not certified by peer review)Combined with this, a reduction in population smoking rates is likely to reduce the health system burden from other conditions that require hospitalisation such as acute vascular events and exacerbations of lung disease 8 as well as improving resilience by reducing overall sickness absence among key-workers 26 .(which was not certified by peer review)In addition to an increase in individual susceptibility to developing COVID-19 following viral infection, smoking might also be expected to increase the risk of infection because of the repeated hand to mouth movements that smoking entails.", [["vascular", "ANATOMY", 1020, 1028], ["lung", "ANATOMY", 1057, 1061], ["hand", "ANATOMY", 1398, 1402], ["mouth", "ANATOMY", 1406, 1411], ["CC", "CHEMICAL", 0, 2], ["smoking", "CHEMICAL", 498, 505], ["smoking", "CHEMICAL", 589, 596], ["fever", "DISEASE", 709, 714], ["cough", "DISEASE", 716, 721], ["breathlessness", "DISEASE", 726, 740], ["smoking", "CHEMICAL", 896, 903], ["lung disease", "DISEASE", 1057, 1069], ["sickness absence", "DISEASE", 1124, 1140], ["COVID-19", "CHEMICAL", 1273, 1281], ["viral infection", "DISEASE", 1292, 1307], ["smoking", "CHEMICAL", 1309, 1316], ["infection", "DISEASE", 1364, 1373], ["mouth movements", "DISEASE", 1406, 1421], ["smoking", "CHEMICAL", 1427, 1434], ["vascular", "MULTI-TISSUE_STRUCTURE", 1020, 1028], ["lung", "ORGAN", 1057, 1061], ["COVID-19", "GENE_OR_GENE_PRODUCT", 1273, 1281], ["hand", "ORGANISM_SUBDIVISION", 1398, 1402], ["mouth", "ORGANISM_SUBDIVISION", 1406, 1411], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv", "TREATMENT", 325, 332], ["smoking cessation", "TREATMENT", 498, 515], ["COVID", "TEST", 576, 581], ["symptomatic disease", "PROBLEM", 630, 649], ["\"classic\" symptoms", "PROBLEM", 687, 705], ["fever", "PROBLEM", 709, 714], ["cough", "PROBLEM", 716, 721], ["breathlessness", "PROBLEM", 726, 740], ["the severity of disease", "PROBLEM", 745, 768], ["symptoms", "PROBLEM", 801, 809], ["a reduction in population smoking rates", "TREATMENT", 870, 909], ["other conditions", "PROBLEM", 960, 976], ["acute vascular events", "PROBLEM", 1014, 1035], ["exacerbations of lung disease", "PROBLEM", 1040, 1069], ["individual susceptibility", "PROBLEM", 1233, 1258], ["COVID", "TEST", 1273, 1278], ["viral infection", "PROBLEM", 1292, 1307], ["infection", "PROBLEM", 1364, 1373], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["symptomatic", "OBSERVATION_MODIFIER", 630, 641], ["disease", "OBSERVATION", 642, 649], ["fever", "OBSERVATION", 709, 714], ["disease", "OBSERVATION", 761, 768], ["reduction", "OBSERVATION_MODIFIER", 872, 881], ["vascular", "ANATOMY", 1020, 1028], ["lung", "ANATOMY", 1057, 1061], ["disease", "OBSERVATION", 1062, 1069], ["increase", "OBSERVATION_MODIFIER", 1221, 1229], ["infection", "OBSERVATION", 1298, 1307], ["infection", "OBSERVATION", 1364, 1373]]], ["The increase in severity that we found associated with smoking suggests that the whole curve of disease is shifted as opposed to just the chance of infection.", [["smoking", "CHEMICAL", 55, 62], ["infection", "DISEASE", 148, 157], ["The increase in severity", "PROBLEM", 0, 24], ["the whole curve of disease", "PROBLEM", 77, 103], ["infection", "PROBLEM", 148, 157], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["disease", "OBSERVATION", 96, 103], ["infection", "OBSERVATION", 148, 157]]], ["Importantly, although the number and degree of symptoms was higher in smokers the pattern of symptoms did not differ, indicating that the phenomenon that we observed was not caused by the presence of symptoms related directly to smoking itself.(which was not certified by peer review)We found that adipose tissue ACE2 expression levels were reduced in smokers compared to non-smokers in TwinsUK.", [["adipose tissue", "ANATOMY", 298, 312], ["smoking", "CHEMICAL", 229, 236], ["adipose tissue", "TISSUE", 298, 312], ["ACE2", "GENE_OR_GENE_PRODUCT", 313, 317], ["ACE2", "PROTEIN", 313, 317], ["symptoms", "PROBLEM", 47, 55], ["symptoms", "PROBLEM", 93, 101], ["the phenomenon", "PROBLEM", 134, 148], ["symptoms", "PROBLEM", 200, 208], ["adipose tissue ACE2 expression levels", "PROBLEM", 298, 335], ["adipose tissue", "OBSERVATION", 298, 312], ["reduced", "OBSERVATION_MODIFIER", 341, 348]]], ["The contribution of ACE2 expression levels to Sars-CoV-2 infection and disease severity is a matter of intense interest 27 .", [["infection", "DISEASE", 57, 66], ["ACE2", "GENE_OR_GENE_PRODUCT", 20, 24], ["Sars-CoV-2", "ORGANISM", 46, 56], ["ACE2", "PROTEIN", 20, 24], ["Sars-CoV-2", "SPECIES", 46, 56], ["ACE2 expression levels", "PROBLEM", 20, 42], ["Sars-CoV-2 infection", "PROBLEM", 46, 66], ["disease severity", "PROBLEM", 71, 87], ["ACE2 expression", "OBSERVATION", 20, 35], ["infection", "OBSERVATION", 57, 66]]], ["It has been hypothesised that ACE2 internalisation after viral infection causes a reduction in ACE2 activity leading to increased Angiotensin II levels which contribute to the widespread endothelial damage, microthrombosis and coagulopathy observed in severe COVID-19 1,2 .", [["endothelial", "ANATOMY", 187, 198], ["viral infection", "DISEASE", 57, 72], ["Angiotensin II", "CHEMICAL", 130, 144], ["endothelial damage", "DISEASE", 187, 205], ["microthrombosis", "DISEASE", 207, 222], ["coagulopathy", "DISEASE", 227, 239], ["ACE2", "GENE_OR_GENE_PRODUCT", 30, 34], ["ACE2", "GENE_OR_GENE_PRODUCT", 95, 99], ["Angiotensin II", "GENE_OR_GENE_PRODUCT", 130, 144], ["endothelial", "TISSUE", 187, 198], ["ACE2", "PROTEIN", 30, 34], ["ACE2", "PROTEIN", 95, 99], ["Angiotensin II", "PROTEIN", 130, 144], ["ACE2 internalisation", "PROBLEM", 30, 50], ["viral infection", "PROBLEM", 57, 72], ["a reduction in ACE2 activity", "PROBLEM", 80, 108], ["increased Angiotensin II levels", "PROBLEM", 120, 151], ["the widespread endothelial damage", "PROBLEM", 172, 205], ["microthrombosis", "PROBLEM", 207, 222], ["coagulopathy", "PROBLEM", 227, 239], ["severe COVID", "PROBLEM", 252, 264], ["viral", "OBSERVATION_MODIFIER", 57, 62], ["infection", "OBSERVATION", 63, 72], ["reduction", "OBSERVATION_MODIFIER", 82, 91], ["ACE2 activity", "OBSERVATION", 95, 108], ["increased", "OBSERVATION_MODIFIER", 120, 129], ["Angiotensin", "OBSERVATION", 130, 141], ["widespread", "OBSERVATION_MODIFIER", 176, 186], ["endothelial damage", "OBSERVATION", 187, 205], ["coagulopathy", "OBSERVATION", 227, 239], ["severe", "OBSERVATION_MODIFIER", 252, 258]]], ["It has also been hypothesised that reduced ACE2 levels may offer some protection against initial infection, but once infected, as is highly likely to occur at some stage in a pandemic setting, low ACE2 levels may contribute to increased disease severity 28 .", [["infection", "DISEASE", 97, 106], ["ACE2", "GENE_OR_GENE_PRODUCT", 43, 47], ["ACE2", "GENE_OR_GENE_PRODUCT", 197, 201], ["ACE2", "PROTEIN", 43, 47], ["ACE2", "PROTEIN", 197, 201], ["reduced ACE2 levels", "PROBLEM", 35, 54], ["initial infection", "PROBLEM", 89, 106], ["infected", "PROBLEM", 117, 125], ["low ACE2 levels", "PROBLEM", 193, 208], ["increased disease severity", "PROBLEM", 227, 253], ["infection", "OBSERVATION", 97, 106], ["highly likely", "UNCERTAINTY", 133, 146], ["increased", "OBSERVATION_MODIFIER", 227, 236], ["disease", "OBSERVATION", 237, 244]]], ["Our data from TwinsUK showing that .", [["Our data", "TEST", 0, 8]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 21, 2020. . https://doi.org/10.1101/2020.05.18.20105288 doi: medRxiv preprint ACE2 expression is lower in adipose tissue of smokers may explain some of the increased risk of systemic disease in smokers with COVID-19.", [["adipose tissue", "ANATOMY", 370, 384], ["CC", "CHEMICAL", 0, 2], ["systemic disease", "DISEASE", 438, 454], ["COVID-19", "CHEMICAL", 471, 479], ["medRxiv preprint ACE2", "GENE_OR_GENE_PRODUCT", 325, 346], ["adipose tissue", "TISSUE", 370, 384], ["ACE2", "PROTEIN", 342, 346], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint ACE2 expression", "TREATMENT", 325, 357], ["systemic disease", "PROBLEM", 438, 454], ["COVID", "TEST", 471, 476], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["lower", "OBSERVATION_MODIFIER", 361, 366], ["increased", "OBSERVATION_MODIFIER", 420, 429], ["systemic", "OBSERVATION_MODIFIER", 438, 446], ["disease", "OBSERVATION", 447, 454]]], ["The GTEx data indicate a weak correlation between adipose and lung ACE2 expression.", [["adipose", "ANATOMY", 50, 57], ["lung", "ANATOMY", 62, 66], ["adipose", "TISSUE", 50, 57], ["lung", "ORGAN", 62, 66], ["ACE2", "GENE_OR_GENE_PRODUCT", 67, 71], ["GTEx", "PROTEIN", 4, 8], ["ACE2", "PROTEIN", 67, 71], ["The GTEx data", "TEST", 0, 13], ["a weak correlation between adipose and lung ACE2 expression", "PROBLEM", 23, 82], ["lung", "ANATOMY", 62, 66], ["ACE2 expression", "OBSERVATION", 67, 82]]], ["This could suggest that ACE2 expression may also be reduced in smokers' lungs.", [["lungs", "ANATOMY", 72, 77], ["ACE2", "GENE_OR_GENE_PRODUCT", 24, 28], ["lungs", "ORGAN", 72, 77], ["ACE2", "PROTEIN", 24, 28], ["ACE2 expression", "PROBLEM", 24, 39], ["may also be", "UNCERTAINTY", 40, 51], ["reduced", "OBSERVATION_MODIFIER", 52, 59], ["lungs", "ANATOMY", 72, 77]]], ["However, there have also been recent studies showing the opposite effect [14] [15] [16] .", [["[14] [15] [16]", "SIMPLE_CHEMICAL", 73, 87], ["recent studies", "TEST", 30, 44]]], ["To further complicate matters, single cell-type data suggest that in smokers ACE2 is upregulated in epithelial cells but down-regulated in Type 2 alveolar cells 18 .(which was not certified by peer review)Data were also available for a limited number of individuals who reported the results of PCR tests performed to identify the presence of SARs-CoV-2.", [["cell", "ANATOMY", 38, 42], ["epithelial cells", "ANATOMY", 100, 116], ["Type 2 alveolar cells", "ANATOMY", 139, 160], ["cell", "CELL", 38, 42], ["ACE2", "GENE_OR_GENE_PRODUCT", 77, 81], ["epithelial cells", "CELL", 100, 116], ["Type 2 alveolar cells", "CELL", 139, 160], ["SARs-CoV-2", "GENE_OR_GENE_PRODUCT", 342, 352], ["ACE2", "PROTEIN", 77, 81], ["epithelial cells", "CELL_TYPE", 100, 116], ["Type 2 alveolar cells", "CELL_TYPE", 139, 160], ["epithelial cells", "PROBLEM", 100, 116], ["PCR tests", "TEST", 294, 303], ["SARs", "PROBLEM", 342, 346], ["CoV", "TEST", 347, 350], ["epithelial cells", "OBSERVATION", 100, 116], ["alveolar cells", "ANATOMY", 146, 160]]], ["Only 1% of the study population had undergone testing and this group was heavily selected because of testing policies which focused on healthcare workers and others interacting with healthcare.", [["the study population", "TEST", 11, 31], ["testing", "TEST", 46, 53]]], ["Smoking prevalence was lower in the tested group, 8.9% vs 11.0%, both values substantially below the UK population average and smoking prevalence was lower in those testing positive than those testing negative (7.4% vs 9.3%).", [["Smoking", "DISEASE", 0, 7], ["smoking", "CHEMICAL", 127, 134], ["those testing", "TEST", 187, 200]]], ["Firstly, it may be that smoking does reduce susceptibility to infection with SARS-CoV-2, though the likelihood of developing symptoms and severity of disease in current smokers remains higher, according both to the whole population data and the fact that smokers testing positive were more likely to report hospital attendance.", [["smoking", "CHEMICAL", 24, 31], ["infection", "DISEASE", 62, 71], ["SARS", "DISEASE", 77, 81], ["SARS-CoV-2", "ORGANISM", 77, 87], ["smokers", "ORGANISM", 255, 262], ["SARS-CoV", "SPECIES", 77, 85], ["susceptibility to infection", "PROBLEM", 44, 71], ["SARS", "PROBLEM", 77, 81], ["CoV", "TEST", 82, 85], ["developing symptoms", "PROBLEM", 114, 133], ["disease", "PROBLEM", 150, 157], ["smokers testing", "TEST", 255, 270], ["infection", "OBSERVATION", 62, 71]]], ["Data from a multinational study of 8,910 hospitalised COVID-19 patients indicate that smokers experience more severe disease and have worse outcomes, including an increased risk of death (9.4%, vs. 5.6% among former smokers or non-smokers; OR [95% CI] 1.79 [1.29 to 2.47]) 4 .", [["death", "DISEASE", 181, 186], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["a multinational study", "TEST", 10, 31], ["more severe disease", "PROBLEM", 105, 124], ["an increased risk of death", "PROBLEM", 160, 186], ["CI", "TEST", 248, 250], ["severe", "OBSERVATION_MODIFIER", 110, 116], ["disease", "OBSERVATION", 117, 124], ["increased", "OBSERVATION_MODIFIER", 163, 172]]], ["Alternatively, our finding may represent sampling bias.(which was not certified by peer review)Among those tested, a negative PCR result was also associated with a higher rate of heart disease, cancer and respiratory disease, all factors associated with worse outcomes in people with COVID-19 but unlikely to be protective against infection.", [["heart", "ANATOMY", 179, 184], ["cancer", "ANATOMY", 194, 200], ["respiratory", "ANATOMY", 205, 216], ["heart disease", "DISEASE", 179, 192], ["cancer", "DISEASE", 194, 200], ["respiratory disease", "DISEASE", 205, 224], ["COVID-19", "CHEMICAL", 284, 292], ["infection", "DISEASE", 331, 340], ["heart", "ORGAN", 179, 184], ["cancer", "CANCER", 194, 200], ["people", "ORGANISM", 272, 278], ["people", "SPECIES", 272, 278], ["a negative PCR", "TEST", 115, 129], ["heart disease", "PROBLEM", 179, 192], ["cancer", "PROBLEM", 194, 200], ["respiratory disease", "PROBLEM", 205, 224], ["COVID", "TEST", 284, 289], ["infection", "PROBLEM", 331, 340], ["may represent", "UNCERTAINTY", 27, 40], ["heart", "ANATOMY", 179, 184], ["disease", "OBSERVATION", 185, 192], ["cancer", "OBSERVATION", 194, 200], ["respiratory disease", "OBSERVATION", 205, 224], ["infection", "OBSERVATION", 331, 340]]], ["The use of swab testing for PCR diagnosis of viral infection has limitations with a significant false negative rate.", [["viral infection", "DISEASE", 45, 60], ["swab testing", "TEST", 11, 23], ["PCR", "TEST", 28, 31], ["viral infection", "PROBLEM", 45, 60], ["viral", "OBSERVATION_MODIFIER", 45, 50], ["infection", "OBSERVATION", 51, 60], ["negative rate", "OBSERVATION", 102, 115]]], ["It is possible that non-random differences in the way that tests were conducted (e.g.(which was not certified by peer review).", [["non-random", "OBSERVATION_MODIFIER", 20, 30], ["differences", "OBSERVATION_MODIFIER", 31, 42]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 21, 2020. . https://doi.org/10.1101/2020.05.18.20105288 doi: medRxiv preprint nasopharyngeal or oropharyngeal swabs) or the temporal relation of testing to the development of symptoms (likely more rapid for healthcare workers for example) could have influenced results 29, 30 .", [["nasopharyngeal", "ANATOMY", 342, 356], ["oropharyngeal swabs", "ANATOMY", 360, 379], ["CC", "CHEMICAL", 0, 2], ["nasopharyngeal", "CANCER", 342, 356], ["oropharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 360, 379], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv", "TREATMENT", 325, 332], ["oropharyngeal swabs", "TREATMENT", 360, 379], ["symptoms", "PROBLEM", 439, 447], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["In due course, the question of relative infectivity may be answered based either on surveillance screening or widespread antibody testing.Methodological issuesThere are some limitations in what can be inferred from these data.", [["relative infectivity", "PROBLEM", 31, 51], ["surveillance screening", "TEST", 84, 106], ["widespread antibody testing", "TEST", 110, 137], ["Methodological issues", "PROBLEM", 138, 159], ["these data", "TEST", 215, 225]]], ["The study uses the development of symptoms to define COVID-19, but it is possible that some of these represented conditions other than COVID-19.", [["COVID-19", "CHEMICAL", 135, 143], ["The study", "TEST", 0, 9], ["symptoms", "PROBLEM", 34, 42], ["COVID", "TEST", 53, 58], ["COVID", "TEST", 135, 140]]], ["Behavioural factors or individual prior expectations may have played a role.", [["Behavioural factors", "PROBLEM", 0, 19]]], ["Thus smokers may have felt themselves to be at a higher risk of developing COVID-19 making them more likely to report symptoms, thus exaggerating the apparent impact of smoking.", [["smoking", "CHEMICAL", 169, 176], ["symptoms", "PROBLEM", 118, 126]]], ["Alternatively, non-smokers being in general healthier, might be expected to be more sensitive to changes in their wellbeing making them more likely to report symptoms, thus underestimating the impact of smoking.", [["smoking", "CHEMICAL", 203, 210], ["symptoms", "PROBLEM", 158, 166]]], ["Participants in the study were self-selected, having chosen to register to use the app.", [["Participants", "SPECIES", 0, 12], ["the study", "TEST", 16, 25]]], ["Smoking rates were also lower in the study than in the general population and there were relatively fewer people in the older age groups who are most susceptible to the condition.Methodological issuesOur analyses of ACE2 expression in adipose tissue in TwinsUK were limited by the small sample size of subjects with smoking data available.", [["adipose tissue", "ANATOMY", 235, 249], ["people", "ORGANISM", 106, 112], ["ACE2", "GENE_OR_GENE_PRODUCT", 216, 220], ["adipose tissue", "TISSUE", 235, 249], ["ACE2", "PROTEIN", 216, 220], ["people", "SPECIES", 106, 112], ["ACE2 expression in adipose tissue", "PROBLEM", 216, 249], ["lower", "OBSERVATION_MODIFIER", 24, 29], ["ACE2 expression", "OBSERVATION", 216, 231], ["adipose tissue", "OBSERVATION", 235, 249], ["small", "OBSERVATION_MODIFIER", 281, 286], ["size", "OBSERVATION_MODIFIER", 294, 298]]], ["The expression dataset is also a female-only sample, which, given the sex differences observed in COVID-19 disease progression, limits inferences that can be drawn.", [["COVID", "TEST", 98, 103]]], ["Furthermore, previously noted differences in ACE2 expression across tissues, and resultant associations, make extrapolation from adipose tissue challenging.Conclusion.", [["tissues", "ANATOMY", 68, 75], ["adipose tissue", "ANATOMY", 129, 143], ["ACE2", "GENE_OR_GENE_PRODUCT", 45, 49], ["tissues", "TISSUE", 68, 75], ["adipose tissue", "TISSUE", 129, 143], ["ACE2", "PROTEIN", 45, 49], ["ACE2 expression across tissues", "PROBLEM", 45, 75], ["adipose tissue challenging", "TREATMENT", 129, 155], ["adipose tissue", "OBSERVATION", 129, 143]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 21, 2020. . https://doi.org/10.1101/2020.05.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["18.20105288 doi: medRxiv preprint At current trajectories, smoking will kill around one billion people in the 21 st century.", [["smoking", "CHEMICAL", 59, 66], ["people", "ORGANISM", 96, 102], ["people", "SPECIES", 96, 102]]], ["31 Evidence that current smoking increases individual and thus health system risk from COVID-19 is a strong argument for governments to accelerate rather than pause measures to deliver on tobacco control plans.", [["smoking", "CHEMICAL", 25, 32], ["tobacco", "ORGANISM", 188, 195], ["tobacco", "SPECIES", 188, 195], ["COVID", "TEST", 87, 92], ["pause measures", "TREATMENT", 159, 173], ["tobacco control plans", "TREATMENT", 188, 209]]], ["32 These should include options such as polluter-pays levies on tobacco transnationals that will continue, through the pandemic, to be highly profitable as well as enormously damaging 33 .(which was not certified by peer review)Our results provide compelling evidence for an association between current smoking and individual risk from COVID-19, including symptom burden and risk of attending hospital.(which was not certified by peer review)Smoking cessation should be incorporated into public health campaigns and other efforts to address the COVID-19 pandemic.DATA SHARINGAnonymised research data will be shared with third parties via the centre for Health Data MF is the guarantor.DATA SHARING.", [["smoking", "CHEMICAL", 303, 310], ["tobacco", "ORGANISM", 64, 71], ["tobacco", "SPECIES", 64, 71], ["COVID", "TEST", 336, 341], ["symptom burden", "PROBLEM", 356, 370], ["the COVID", "TEST", 541, 550], ["pandemic", "PROBLEM", 554, 562]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 21, 2020.TRANSPARENCY DECLARATIONMario Falchi, the manuscript's guarantor affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.TRANSPARENCY DECLARATION.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["the study", "TEST", 417, 426], ["the study", "TEST", 472, 481], ["the study", "TEST", 533, 542], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 21, 2020. . is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 21, 2020.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["The copyright holder", "TREATMENT", 410, 430], ["med", "ANATOMY", 105, 108], ["med", "ANATOMY", 314, 317]]], ["The plot shows the OR [95% CI] for smokers from the Standard Users category of presenting with COVID-19 classic symptoms (i.e., all three of cough, fever and breathlessness) or a higher symptom burden (i.e., more than five or more than ten symptoms).", [["cough", "DISEASE", 141, 146], ["fever", "DISEASE", 148, 153], ["breathlessness", "DISEASE", 158, 172], ["The plot", "TEST", 0, 8], ["COVID", "TEST", 95, 100], ["classic symptoms", "PROBLEM", 104, 120], ["cough", "PROBLEM", 141, 146], ["fever", "PROBLEM", 148, 153], ["breathlessness", "PROBLEM", 158, 172], ["a higher symptom burden", "PROBLEM", 177, 200]]]], "a481a287c867b1cb003d5394ebc7cec749aa8182": [["Introduction:The relationship between systemic glycocalyx degradation markers and regional glycocalyx thickness in non-septic critically ill patients is unclear.", [["glycocalyx", "ANATOMY", 91, 101], ["critically ill", "DISEASE", 126, 140], ["glycocalyx", "MULTI-TISSUE_STRUCTURE", 47, 57], ["glycocalyx", "TISSUE", 91, 101], ["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 141, 149], ["systemic glycocalyx degradation markers", "TREATMENT", 38, 77], ["regional glycocalyx thickness", "TREATMENT", 82, 111], ["regional", "OBSERVATION_MODIFIER", 82, 90], ["glycocalyx", "OBSERVATION_MODIFIER", 91, 101], ["thickness", "OBSERVATION_MODIFIER", 102, 111], ["non-septic", "OBSERVATION_MODIFIER", 115, 125], ["critically ill", "OBSERVATION_MODIFIER", 126, 140]]], ["Conjunctival sidestream dark fieldimaging for the purpose of glycocalyx thickness estimation has never been performed.", [["Conjunctival", "ANATOMY", 0, 12], ["glycocalyx", "ANATOMY", 61, 71], ["glycocalyx", "TISSUE", 61, 71], ["Conjunctival sidestream dark fieldimaging", "TEST", 0, 41], ["glycocalyx thickness estimation", "TEST", 61, 92]]], ["We aimed to investigate whether changes in glycocalyx thickness in conjunctival and sublingual mucosa are associated with global glycocalyx shedding markers.", [["glycocalyx", "ANATOMY", 43, 53], ["conjunctival", "ANATOMY", 67, 79], ["sublingual mucosa", "ANATOMY", 84, 101], ["glycocalyx", "ANATOMY", 129, 139], ["glycocalyx", "TISSUE", 43, 53], ["conjunctival", "TISSUE", 67, 79], ["sublingual mucosa", "MULTI-TISSUE_STRUCTURE", 84, 101], ["changes in glycocalyx thickness in conjunctival and sublingual mucosa", "PROBLEM", 32, 101], ["global glycocalyx shedding markers", "PROBLEM", 122, 156], ["glycocalyx thickness", "OBSERVATION", 43, 63], ["conjunctival", "ANATOMY", 67, 79], ["sublingual mucosa", "ANATOMY", 84, 101]]], ["Methods: In this single-centre prospective observational study, using techniques for direct in-vivo observation of the microcirculation, we performed a single measurement of glycocalyx thickness in both ocular conjunctiva and sublingual mucosa in mixed cardio surgical (n=18) and neurocritical patients (n=27) and compared these data with age-matched healthy controls (n=20).", [["glycocalyx", "ANATOMY", 174, 184], ["ocular conjunctiva", "ANATOMY", 203, 221], ["sublingual mucosa", "ANATOMY", 226, 243], ["glycocalyx", "TISSUE", 174, 184], ["ocular conjunctiva", "TISSUE", 203, 221], ["sublingual mucosa", "MULTI-TISSUE_STRUCTURE", 226, 243], ["patients", "ORGANISM", 294, 302], ["patients", "SPECIES", 294, 302], ["glycocalyx thickness", "TREATMENT", 174, 194], ["mixed cardio surgical", "TREATMENT", 247, 268], ["these data", "TEST", 323, 333], ["glycocalyx thickness", "OBSERVATION", 174, 194], ["both", "ANATOMY_MODIFIER", 198, 202], ["ocular conjunctiva", "ANATOMY", 203, 221], ["sublingual mucosa", "ANATOMY", 226, 243], ["cardio", "ANATOMY", 253, 259]]], ["In addition we measured systemic syndecan-1 levels Results: In the sublingual and conjunctival region we observed a significant increase of the perfused boundary region (PBR) in both neuro critical and cardiac surgical ICU patients, compared to controls (2.20 7 ], p<0,05).", [["sublingual", "ANATOMY", 67, 77], ["conjunctival region", "ANATOMY", 82, 101], ["cardiac", "ANATOMY", 202, 209], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 33, 43], ["sublingual", "MULTI-TISSUE_STRUCTURE", 67, 77], ["conjunctival", "ORGAN", 82, 94], ["patients", "ORGANISM", 223, 231], ["syndecan", "PROTEIN", 33, 41], ["patients", "SPECIES", 223, 231], ["systemic syndecan", "TEST", 24, 41], ["the perfused boundary region", "PROBLEM", 140, 168], ["conjunctival", "ANATOMY", 82, 94], ["significant", "OBSERVATION_MODIFIER", 116, 127], ["increase", "OBSERVATION_MODIFIER", 128, 136], ["perfused boundary", "OBSERVATION", 144, 161], ["cardiac", "ANATOMY", 202, 209]]], ["We detected a weak correlation between syndecan-1 and sublingual PBR(r=0.40, p=0.002) but no correlations between global glycocalyx damage markers and conjuctival glycocalyx thickness.", [["sublingual", "ANATOMY", 54, 64], ["glycocalyx", "ANATOMY", 121, 131], ["conjuctival glycocalyx", "ANATOMY", 151, 173], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 39, 49], ["sublingual PBR", "GENE_OR_GENE_PRODUCT", 54, 68], ["glycocalyx", "TISSUE", 121, 131], ["conjuctival glycocalyx", "TISSUE", 151, 173], ["syndecan", "PROTEIN", 39, 47], ["syndecan", "TEST", 39, 47], ["sublingual PBR", "TEST", 54, 68], ["global glycocalyx damage markers", "TEST", 114, 146], ["glycocalyx", "ANATOMY_MODIFIER", 121, 131], ["damage", "OBSERVATION", 132, 138], ["glycocalyx thickness", "OBSERVATION", 163, 183]]], ["Conclusions: Conjunctival glycocalyx thickness evaluation using SDF videomicroscopy is suitable and is impaired in non-septic ICU patients but only measurements in sublingual mucosa are correlating with systemic glycocalyx shedding markers.", [["Conjunctival glycocalyx", "ANATOMY", 13, 36], ["sublingual mucosa", "ANATOMY", 164, 181], ["glycocalyx", "ANATOMY", 212, 222], ["Conjunctival glycocalyx", "TISSUE", 13, 36], ["patients", "ORGANISM", 130, 138], ["sublingual mucosa", "MULTI-TISSUE_STRUCTURE", 164, 181], ["patients", "SPECIES", 130, 138], ["Conjunctival glycocalyx thickness evaluation", "TEST", 13, 57], ["SDF videomicroscopy", "TEST", 64, 83], ["systemic glycocalyx shedding markers", "TREATMENT", 203, 239], ["Conjunctival glycocalyx", "ANATOMY", 13, 36], ["impaired", "OBSERVATION_MODIFIER", 103, 111], ["sublingual mucosa", "ANATOMY", 164, 181]]], ["Global glycocalyx damage is more severe in cardiac comparing to neuro critical patients.", [["glycocalyx", "ANATOMY", 7, 17], ["cardiac", "ANATOMY", 43, 50], ["glycocalyx damage", "DISEASE", 7, 24], ["cardiac", "ORGAN", 43, 50], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["Global glycocalyx damage", "PROBLEM", 0, 24], ["glycocalyx", "ANATOMY_MODIFIER", 7, 17], ["damage", "OBSERVATION", 18, 24], ["more severe", "OBSERVATION_MODIFIER", 28, 39], ["cardiac", "ANATOMY", 43, 50]]], ["Introduction: Endothelial dysfunction plays a major role in the sepsis related organ dysfunction, and is featured by vascular leakage.", [["Endothelial", "ANATOMY", 14, 25], ["organ", "ANATOMY", 79, 84], ["vascular", "ANATOMY", 117, 125], ["Endothelial dysfunction", "DISEASE", 14, 37], ["sepsis", "DISEASE", 64, 70], ["organ dysfunction", "DISEASE", 79, 96], ["Endothelial", "CELL", 14, 25], ["organ", "ORGAN", 79, 84], ["vascular", "MULTI-TISSUE_STRUCTURE", 117, 125], ["Endothelial dysfunction", "PROBLEM", 14, 37], ["the sepsis related organ dysfunction", "PROBLEM", 60, 96], ["vascular leakage", "PROBLEM", 117, 133], ["Endothelial", "ANATOMY", 14, 25], ["dysfunction", "OBSERVATION", 26, 37], ["sepsis", "OBSERVATION", 64, 70], ["organ", "ANATOMY", 79, 84], ["dysfunction", "OBSERVATION", 85, 96], ["vascular", "ANATOMY", 117, 125], ["leakage", "OBSERVATION", 126, 133]]], ["AMP-activated protein kinase (AMPK) is known to regulate actin cytoskeleton organization and interendothelial junctions (IEJs), contributing to endothelial barrier integrity.", [["cytoskeleton", "ANATOMY", 63, 75], ["interendothelial junctions", "ANATOMY", 93, 119], ["IEJs", "ANATOMY", 121, 125], ["endothelial barrier", "ANATOMY", 144, 163], ["AMP", "CHEMICAL", 0, 3], ["AMP", "CHEMICAL", 0, 3], ["AMP-activated protein kinase", "GENE_OR_GENE_PRODUCT", 0, 28], ["AMPK", "GENE_OR_GENE_PRODUCT", 30, 34], ["actin", "GENE_OR_GENE_PRODUCT", 57, 62], ["cytoskeleton", "CELLULAR_COMPONENT", 63, 75], ["interendothelial junctions", "CELLULAR_COMPONENT", 93, 119], ["IEJs", "CELLULAR_COMPONENT", 121, 125], ["endothelial barrier", "TISSUE", 144, 163], ["AMP-activated protein kinase", "PROTEIN", 0, 28], ["AMPK", "PROTEIN", 30, 34], ["actin", "PROTEIN", 57, 62], ["AMP", "TEST", 0, 3], ["activated protein kinase", "TEST", 4, 28], ["AMPK", "TEST", 30, 34], ["endothelial barrier integrity", "TREATMENT", 144, 173], ["actin cytoskeleton organization", "OBSERVATION", 57, 88], ["interendothelial junctions", "OBSERVATION", 93, 119], ["endothelial", "ANATOMY", 144, 155], ["barrier integrity", "OBSERVATION", 156, 173]]], ["We have already demonstrated its role in defence against sepsis induced hyperpermeability [1] , but the underlying mechanisms remain unknown.", [["sepsis", "DISEASE", 57, 63], ["sepsis induced hyperpermeability", "PROBLEM", 57, 89], ["hyperpermeability", "OBSERVATION", 72, 89]]], ["This project aims to identify molecular targets involved in the beneficial action of AMPK against endothelial barrier dysfunction.", [["endothelial barrier", "ANATOMY", 98, 117], ["AMPK", "GENE_OR_GENE_PRODUCT", 85, 89], ["endothelial barrier", "TISSUE", 98, 117], ["AMPK", "PROTEIN", 85, 89], ["endothelial barrier dysfunction", "PROBLEM", 98, 129]]], ["Methods: Experiments have been performed in human microvascular dermal endothelial cells. \u03b11AMPK activity has been modulated via the use of a specific siRNA or treatment by two pharmacological AMPK activators (AICAr, 991).", [["microvascular dermal endothelial cells", "ANATOMY", 50, 88], ["human", "ORGANISM", 44, 49], ["microvascular dermal endothelial cells", "CELL", 50, 88], ["\u03b11AMPK", "GENE_OR_GENE_PRODUCT", 90, 96], ["AMPK", "GENE_OR_GENE_PRODUCT", 193, 197], ["human microvascular dermal endothelial cells", "CELL_TYPE", 44, 88], ["1AMPK", "PROTEIN", 91, 96], ["AMPK", "PROTEIN", 193, 197], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 44, 49], ["a specific siRNA", "TREATMENT", 140, 156], ["treatment", "TREATMENT", 160, 169], ["AICAr", "TEST", 210, 215], ["microvascular", "ANATOMY", 50, 63], ["dermal endothelial cells", "OBSERVATION", 64, 88]]], ["We have investigated the effect of this modulation on the expression/phosphorylation of Connexin 43 (Cx43) and Heat shock protein 27 (HSP27), two proteins playing a key role in maintenance of IEJs and actin dynamics respectively.", [["IEJs", "ANATOMY", 192, 196], ["Connexin 43", "GENE_OR_GENE_PRODUCT", 88, 99], ["Cx43", "GENE_OR_GENE_PRODUCT", 101, 105], ["Heat shock protein 27", "GENE_OR_GENE_PRODUCT", 111, 132], ["HSP27", "GENE_OR_GENE_PRODUCT", 134, 139], ["IEJs", "GENE_OR_GENE_PRODUCT", 192, 196], ["actin", "GENE_OR_GENE_PRODUCT", 201, 206], ["Connexin 43", "PROTEIN", 88, 99], ["Cx43", "PROTEIN", 101, 105], ["Heat shock protein 27", "PROTEIN", 111, 132], ["HSP27", "PROTEIN", 134, 139], ["IEJs", "PROTEIN", 192, 196], ["actin", "PROTEIN", 201, 206], ["this modulation", "TREATMENT", 35, 50], ["the expression/phosphorylation of Connexin", "TREATMENT", 54, 96], ["Heat shock protein", "TEST", 111, 129], ["HSP27", "TEST", 134, 139]]], ["Results: We show that \u03b11AMPK is required to sustain the level of Cx43 expression as it was drastically reduced in cells transfected with a siRNA targeting specifically \u03b11AMPK.", [["cells", "ANATOMY", 114, 119], ["\u03b11AMPK", "GENE_OR_GENE_PRODUCT", 22, 28], ["Cx43", "GENE_OR_GENE_PRODUCT", 65, 69], ["cells", "CELL", 114, 119], ["\u03b11AMPK", "GENE_OR_GENE_PRODUCT", 168, 174], ["\u03b11AMPK", "PROTEIN", 22, 28], ["Cx43", "PROTEIN", 65, 69], ["\u03b11AMPK", "PROTEIN", 168, 174], ["drastically reduced in cells", "PROBLEM", 91, 119], ["a siRNA", "TREATMENT", 137, 144]]], ["Regarding HSP27, its expression level was not affected by \u03b11AMPK deletion.", [["HSP27", "GENE_OR_GENE_PRODUCT", 10, 15], ["\u03b11AMPK", "GENE_OR_GENE_PRODUCT", 58, 64], ["HSP27", "PROTEIN", 10, 15], ["1AMPK", "PROTEIN", 59, 64], ["HSP27", "TEST", 10, 15]]], ["However, both AMPK activators increased its phosphorylation on Ser82, in a \u03b11AMPKdependent manner, while they had no effect on Cx43.", [["AMPK", "GENE_OR_GENE_PRODUCT", 14, 18], ["Ser82", "GENE_OR_GENE_PRODUCT", 63, 68], ["Cx43", "GENE_OR_GENE_PRODUCT", 127, 131], ["AMPK", "PROTEIN", 14, 18], ["Ser82", "PROTEIN", 63, 68], ["Cx43", "PROTEIN", 127, 131], ["Cx43", "TEST", 127, 131], ["increased", "OBSERVATION_MODIFIER", 30, 39]]], ["Our results also reveal that HSP27 phosphorylation concurred with the appearance of actin stress fibers at the periphery of cells, suggesting a beneficial role for pHSP27 as well as F-actin stress fibers in vascular barrier function through reinforcing the endothelial tethering.", [["stress fibers", "ANATOMY", 90, 103], ["cells", "ANATOMY", 124, 129], ["F-actin stress fibers", "ANATOMY", 182, 203], ["vascular barrier", "ANATOMY", 207, 223], ["endothelial", "ANATOMY", 257, 268], ["HSP27", "GENE_OR_GENE_PRODUCT", 29, 34], ["actin", "GENE_OR_GENE_PRODUCT", 84, 89], ["stress fibers", "CELLULAR_COMPONENT", 90, 103], ["cells", "CELL", 124, 129], ["pHSP27", "GENE_OR_GENE_PRODUCT", 164, 170], ["F-actin", "GENE_OR_GENE_PRODUCT", 182, 189], ["stress fibers", "CELLULAR_COMPONENT", 190, 203], ["vascular barrier", "MULTI-TISSUE_STRUCTURE", 207, 223], ["endothelial", "CELL", 257, 268], ["HSP27", "PROTEIN", 29, 34], ["actin", "PROTEIN", 84, 89], ["pHSP27", "PROTEIN", 164, 170], ["F-actin", "PROTEIN", 182, 189], ["HSP27 phosphorylation", "TEST", 29, 50], ["actin stress fibers", "PROBLEM", 84, 103], ["pHSP27", "TREATMENT", 164, 170], ["F-actin stress fibers", "TREATMENT", 182, 203], ["vascular barrier function", "TREATMENT", 207, 232], ["the endothelial tethering", "PROBLEM", 253, 278], ["actin stress fibers", "OBSERVATION", 84, 103], ["F-actin", "OBSERVATION", 182, 189], ["stress fibers", "OBSERVATION", 190, 203], ["vascular", "ANATOMY", 207, 215], ["barrier function", "OBSERVATION", 216, 232], ["endothelial tethering", "OBSERVATION", 257, 278]]], ["Conclusions: Our work identifies the regulation of Cx43 expression and HSP27 phosphorylation as potential protective responses underlying the beneficial action of AMPK against endothelial barrier dysfunction.", [["endothelial barrier", "ANATOMY", 176, 195], ["Cx43", "GENE_OR_GENE_PRODUCT", 51, 55], ["HSP27", "GENE_OR_GENE_PRODUCT", 71, 76], ["AMPK", "GENE_OR_GENE_PRODUCT", 163, 167], ["endothelial barrier", "TISSUE", 176, 195], ["Cx43", "PROTEIN", 51, 55], ["HSP27", "PROTEIN", 71, 76], ["AMPK", "PROTEIN", 163, 167], ["Cx43 expression", "TREATMENT", 51, 66], ["HSP27 phosphorylation", "TREATMENT", 71, 92], ["AMPK", "TREATMENT", 163, 167], ["endothelial barrier dysfunction", "PROBLEM", 176, 207]]], ["AMPK could consequently represent a new therapeutic target during sepsis.Introduction:Introduction: Sepsis Induced Cardiomyopathy (SIC) is a serious condition during sepsis with a mortality rate up to 70% (1) .", [["sepsis", "DISEASE", 66, 72], ["Sepsis", "DISEASE", 100, 106], ["Cardiomyopathy", "DISEASE", 115, 129], ["SIC", "DISEASE", 131, 134], ["sepsis", "DISEASE", 166, 172], ["AMPK", "GENE_OR_GENE_PRODUCT", 0, 4], ["AMPK", "PROTEIN", 0, 4], ["AMPK", "TREATMENT", 0, 4], ["sepsis", "PROBLEM", 66, 72], ["Sepsis Induced Cardiomyopathy", "PROBLEM", 100, 129], ["a serious condition", "PROBLEM", 139, 158], ["sepsis", "PROBLEM", 166, 172], ["a mortality rate", "TEST", 178, 194], ["could consequently represent", "UNCERTAINTY", 5, 33], ["new", "OBSERVATION_MODIFIER", 36, 39], ["therapeutic", "OBSERVATION_MODIFIER", 40, 51], ["target", "OBSERVATION_MODIFIER", 52, 58], ["sepsis", "OBSERVATION", 66, 72], ["Sepsis", "OBSERVATION", 100, 106], ["Cardiomyopathy", "OBSERVATION", 115, 129], ["sepsis", "OBSERVATION", 166, 172]]], ["SIC is clinically manifested with left ventricle impaired contractility (2) .", [["left ventricle", "ANATOMY", 34, 48], ["SIC", "DISEASE", 0, 3], ["ventricle", "MULTI-TISSUE_STRUCTURE", 39, 48], ["left ventricle impaired contractility", "PROBLEM", 34, 71], ["left ventricle", "ANATOMY", 34, 48], ["impaired", "OBSERVATION", 49, 57], ["contractility", "OBSERVATION_MODIFIER", 58, 71]]], ["Melusin is a muscle-specific protein involved in sustaining cardiomyocyte survival thorough the activation of AKT signaling pathways (3) .", [["muscle", "ANATOMY", 13, 19], ["cardiomyocyte", "ANATOMY", 60, 73], ["Melusin", "CHEMICAL", 0, 7], ["Melusin", "GENE_OR_GENE_PRODUCT", 0, 7], ["muscle", "ORGAN", 13, 19], ["cardiomyocyte", "CELL", 60, 73], ["AKT", "GENE_OR_GENE_PRODUCT", 110, 113], ["Melusin", "PROTEIN", 0, 7], ["muscle-specific protein", "PROTEIN", 13, 36], ["AKT", "PROTEIN", 110, 113], ["muscle", "ANATOMY", 13, 19], ["cardiomyocyte", "ANATOMY", 60, 73]]], ["PI3K-AKT signaling pathway plays a pivotal role in regulating calcium channel activity (4) .", [["calcium", "CHEMICAL", 62, 69], ["calcium", "CHEMICAL", 62, 69], ["PI3K", "GENE_OR_GENE_PRODUCT", 0, 4], ["AKT", "GENE_OR_GENE_PRODUCT", 5, 8], ["calcium", "SIMPLE_CHEMICAL", 62, 69], ["PI3K", "PROTEIN", 0, 4], ["AKT", "PROTEIN", 5, 8], ["PI3K", "TEST", 0, 4]]], ["We hypothesized that Melusin overexpression could exert a protective effect on cardiac function during septic injury.", [["cardiac", "ANATOMY", 79, 86], ["Melusin", "CHEMICAL", 21, 28], ["septic injury", "DISEASE", 103, 116], ["Melusin", "GENE_OR_GENE_PRODUCT", 21, 28], ["cardiac", "ORGAN", 79, 86], ["Melusin overexpression", "TREATMENT", 21, 43], ["septic injury", "PROBLEM", 103, 116], ["septic injury", "OBSERVATION", 103, 116]]], ["Methods: Animals were treated with an intraperitoneal injection of lipopolysaccharide (LPS) at 12 mg/kg.", [["intraperitoneal", "ANATOMY", 38, 53], ["lipopolysaccharide", "CHEMICAL", 67, 85], ["LPS", "CHEMICAL", 87, 90], ["Animals", "ORGANISM", 9, 16], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 38, 53], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 67, 85], ["LPS", "SIMPLE_CHEMICAL", 87, 90], ["an intraperitoneal injection of lipopolysaccharide (LPS)", "TREATMENT", 35, 91]]], ["SV129 strain Knockout mice (KO) for Melusin gene and FVB strain with cardiac-specific overexpression (OV) of Melusin were compared.", [["cardiac", "ANATOMY", 69, 76], ["SV129 strain Knockout mice", "ORGANISM", 0, 26], ["Melusin", "GENE_OR_GENE_PRODUCT", 36, 43], ["FVB strain", "ORGANISM", 53, 63], ["cardiac", "ORGAN", 69, 76], ["Melusin", "GENE_OR_GENE_PRODUCT", 109, 116], ["Melusin gene", "DNA", 36, 48], ["mice", "SPECIES", 22, 26], ["mice", "SPECIES", 22, 26], ["Melusin gene", "TREATMENT", 36, 48], ["FVB strain", "PROBLEM", 53, 63], ["Melusin", "TREATMENT", 109, 116], ["cardiac", "ANATOMY", 69, 76]]], ["Hemocardiac parameters were studied at 0 hour and 6 hours through echocardiography.", [["Hemocardiac parameters", "TEST", 0, 22], ["echocardiography", "TEST", 66, 82]]], ["Another cohort of animals was sacrificed 6 hours after 20 mg/kg LPS treatment and cardiac tissues and blood sample were harvested for Wb analysis to quantify the expression of AKT, P-AKT and CACNA1C and Elisa analysis for Troponin levels.", [["cardiac tissues", "ANATOMY", 82, 97], ["blood sample", "ANATOMY", 102, 114], ["LPS", "CHEMICAL", 64, 67], ["animals", "ORGANISM", 18, 25], ["LPS", "SIMPLE_CHEMICAL", 64, 67], ["cardiac tissues", "TISSUE", 82, 97], ["blood sample", "ORGANISM_SUBSTANCE", 102, 114], ["AKT", "GENE_OR_GENE_PRODUCT", 176, 179], ["P-AKT", "GENE_OR_GENE_PRODUCT", 181, 186], ["CACNA1C", "GENE_OR_GENE_PRODUCT", 191, 198], ["Troponin", "GENE_OR_GENE_PRODUCT", 222, 230], ["AKT", "PROTEIN", 176, 179], ["P", "PROTEIN", 181, 182], ["AKT", "PROTEIN", 183, 186], ["CACNA1C", "PROTEIN", 191, 198], ["Troponin", "PROTEIN", 222, 230], ["LPS treatment", "TREATMENT", 64, 77], ["cardiac tissues", "TEST", 82, 97], ["blood sample", "TEST", 102, 114], ["Wb analysis", "TEST", 134, 145], ["AKT", "TEST", 176, 179], ["P", "TEST", 181, 182], ["CACNA1C", "TEST", 191, 198], ["Elisa analysis", "TEST", 203, 217], ["Troponin levels", "TEST", 222, 237], ["cardiac tissues", "ANATOMY", 82, 97]]], ["Results: SV129 WT, KO Melusin and FVB WT mice groups, fractional shortening (FS) was significantly impaired after LPS challenge and was associated with compensatory tachycardia (Fig. 1) .", [["LPS", "CHEMICAL", 114, 117], ["tachycardia", "DISEASE", 165, 176], ["SV129 WT", "ORGANISM", 9, 17], ["KO Melusin", "ORGANISM", 19, 29], ["FVB WT mice", "ORGANISM", 34, 45], ["LPS", "SIMPLE_CHEMICAL", 114, 117], ["mice", "SPECIES", 41, 45], ["mice", "SPECIES", 41, 45], ["WT", "TEST", 15, 17], ["Melusin", "TEST", 22, 29], ["fractional shortening", "PROBLEM", 54, 75], ["FS", "TEST", 77, 79], ["LPS challenge", "TEST", 114, 127], ["compensatory tachycardia", "PROBLEM", 152, 176]]], ["FVB OV mice group didn't show decrease in FS.", [["FVB OV mice", "ORGANISM", 0, 11], ["mice", "SPECIES", 7, 11], ["decrease in FS", "PROBLEM", 30, 44], ["decrease", "OBSERVATION_MODIFIER", 30, 38]]], ["Consistent with the increased AKT phosphorylation observed in OV mice, the expression of CACNA1C was also significantly higher both at basal levels and after LPS treatment in OV mice compared to WT mice (Fig. 2) .", [["LPS", "CHEMICAL", 158, 161], ["AKT", "GENE_OR_GENE_PRODUCT", 30, 33], ["OV mice", "ORGANISM", 62, 69], ["CACNA1C", "GENE_OR_GENE_PRODUCT", 89, 96], ["LPS", "SIMPLE_CHEMICAL", 158, 161], ["OV mice", "ORGANISM", 175, 182], ["WT mice", "ORGANISM", 195, 202], ["AKT", "PROTEIN", 30, 33], ["CACNA1C", "PROTEIN", 89, 96], ["mice", "SPECIES", 65, 69], ["mice", "SPECIES", 178, 182], ["mice", "SPECIES", 198, 202], ["mice", "SPECIES", 65, 69], ["mice", "SPECIES", 178, 182], ["mice", "SPECIES", 198, 202], ["the increased AKT phosphorylation", "PROBLEM", 16, 49], ["CACNA1C", "PROBLEM", 89, 96], ["LPS treatment", "TREATMENT", 158, 171], ["OV mice", "TREATMENT", 175, 182], ["increased", "OBSERVATION_MODIFIER", 20, 29], ["AKT phosphorylation", "OBSERVATION", 30, 49]]], ["Troponin levels didn't differ between mice groups after LPS treatment Conclusion: Melusin has protective role in LPS induced cardiomyopathy, likely through Akt phosphorylation controlling the CACNA1C protein density.Introduction:Introduction: Liver dysfunction is frequent in sepsis, but its pathophysiology remains incompletely understood.", [["Liver", "ANATOMY", 243, 248], ["LPS", "CHEMICAL", 56, 59], ["Melusin", "CHEMICAL", 82, 89], ["LPS", "CHEMICAL", 113, 116], ["cardiomyopathy", "DISEASE", 125, 139], ["Liver dysfunction", "DISEASE", 243, 260], ["sepsis", "DISEASE", 276, 282], ["Troponin", "GENE_OR_GENE_PRODUCT", 0, 8], ["mice", "ORGANISM", 38, 42], ["LPS", "SIMPLE_CHEMICAL", 56, 59], ["Melusin", "GENE_OR_GENE_PRODUCT", 82, 89], ["LPS", "SIMPLE_CHEMICAL", 113, 116], ["Akt", "GENE_OR_GENE_PRODUCT", 156, 159], ["CACNA1C", "GENE_OR_GENE_PRODUCT", 192, 199], ["Liver", "ORGAN", 243, 248], ["Troponin", "PROTEIN", 0, 8], ["Akt", "PROTEIN", 156, 159], ["CACNA1C", "PROTEIN", 192, 199], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 38, 42], ["Troponin levels", "TEST", 0, 15], ["LPS treatment", "TREATMENT", 56, 69], ["Melusin", "TREATMENT", 82, 89], ["LPS induced cardiomyopathy", "PROBLEM", 113, 139], ["Akt phosphorylation", "PROBLEM", 156, 175], ["the CACNA1C protein density", "PROBLEM", 188, 215], ["Liver dysfunction", "PROBLEM", 243, 260], ["sepsis", "PROBLEM", 276, 282], ["LPS induced", "OBSERVATION_MODIFIER", 113, 124], ["cardiomyopathy", "OBSERVATION", 125, 139], ["likely", "UNCERTAINTY", 141, 147], ["CACNA1C protein density", "OBSERVATION", 192, 215], ["Liver", "ANATOMY", 243, 248], ["dysfunction", "OBSERVATION", 249, 260], ["sepsis", "OBSERVATION", 276, 282]]], ["Since altered liver function has also been described in ICU patients without sepsis [1, 2] , the influence of sepsis may be overestimated.", [["liver", "ANATOMY", 14, 19], ["sepsis", "DISEASE", 77, 83], ["sepsis", "DISEASE", 110, 116], ["liver", "ORGAN", 14, 19], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["altered liver function", "PROBLEM", 6, 28], ["sepsis", "PROBLEM", 77, 83], ["sepsis", "PROBLEM", 110, 116], ["liver", "ANATOMY", 14, 19], ["sepsis", "OBSERVATION", 77, 83], ["sepsis", "OBSERVATION", 110, 116], ["may be", "UNCERTAINTY", 117, 123]]], ["We hypothesized that sedation and prolonged mechanical ventilation after abdominal surgery is associated with impaired liver function independent of sepsis.", [["abdominal", "ANATOMY", 73, 82], ["liver", "ANATOMY", 119, 124], ["impaired liver function", "DISEASE", 110, 133], ["sepsis", "DISEASE", 149, 155], ["abdominal", "ORGANISM_SUBDIVISION", 73, 82], ["liver", "ORGAN", 119, 124], ["sedation", "TREATMENT", 21, 29], ["prolonged mechanical ventilation", "TREATMENT", 34, 66], ["abdominal surgery", "TREATMENT", 73, 90], ["impaired liver function", "PROBLEM", 110, 133], ["sepsis", "PROBLEM", 149, 155], ["mechanical ventilation", "OBSERVATION", 44, 66], ["abdominal", "ANATOMY", 73, 82], ["surgery", "OBSERVATION", 83, 90], ["liver", "ANATOMY", 119, 124], ["sepsis", "OBSERVATION", 149, 155]]], ["Methods: Sedated and mechanically ventilated pigs underwent abdominal surgery for regional hemodynamic monitoring and were subsequently randomized to fecal peritonitis and controls, respectively (n=4, each), followed by 80 h observation.", [["abdominal", "ANATOMY", 60, 69], ["fecal", "ANATOMY", 150, 155], ["peritonitis", "DISEASE", 156, 167], ["pigs", "ORGANISM", 45, 49], ["abdominal", "ORGANISM_SUBDIVISION", 60, 69], ["pigs", "SPECIES", 45, 49], ["Sedated", "TREATMENT", 9, 16], ["mechanically ventilated pigs", "TREATMENT", 21, 49], ["abdominal surgery", "TREATMENT", 60, 77], ["regional hemodynamic monitoring", "TEST", 82, 113], ["fecal peritonitis", "PROBLEM", 150, 167], ["abdominal", "ANATOMY", 60, 69], ["fecal", "ANATOMY", 150, 155], ["peritonitis", "OBSERVATION", 156, 167]]], ["Indocyanine green (ICG) retention rate 15 minutes after injection of 0.25mg/kg ICG (ICG R15) was determined at baseline, and 11, 32 and 80 h after sepsis induction (SI), and at the same time points in controls.", [["Indocyanine green", "CHEMICAL", 0, 17], ["ICG", "CHEMICAL", 19, 22], ["ICG", "CHEMICAL", 79, 82], ["sepsis", "DISEASE", 147, 153], ["Indocyanine green", "CHEMICAL", 0, 17], ["ICG", "CHEMICAL", 19, 22], ["ICG", "CHEMICAL", 79, 82], ["ICG", "CHEMICAL", 84, 87], ["Indocyanine green", "SIMPLE_CHEMICAL", 0, 17], ["ICG", "SIMPLE_CHEMICAL", 19, 22], ["ICG", "SIMPLE_CHEMICAL", 79, 82], ["ICG", "SIMPLE_CHEMICAL", 84, 87], ["Indocyanine green (ICG) retention rate", "TREATMENT", 0, 38], ["sepsis induction", "TREATMENT", 147, 163], ["sepsis", "OBSERVATION", 147, 153]]], ["Concurrent with ICG R15, plasma volume, total hepatic perfusion (ultrasound transit time), and bilirubin and liver enzymes were measured.", [["plasma", "ANATOMY", 25, 31], ["hepatic", "ANATOMY", 46, 53], ["liver", "ANATOMY", 109, 114], ["bilirubin", "CHEMICAL", 95, 104], ["bilirubin", "CHEMICAL", 95, 104], ["ICG", "SIMPLE_CHEMICAL", 16, 19], ["plasma", "ORGANISM_SUBSTANCE", 25, 31], ["hepatic", "MULTI-TISSUE_STRUCTURE", 46, 53], ["bilirubin", "SIMPLE_CHEMICAL", 95, 104], ["liver", "ORGAN", 109, 114], ["bilirubin", "PROTEIN", 95, 104], ["liver enzymes", "PROTEIN", 109, 122], ["ICG R15", "TEST", 16, 23], ["plasma volume", "TEST", 25, 38], ["total hepatic perfusion", "TEST", 40, 63], ["ultrasound transit time", "TEST", 65, 88], ["bilirubin", "TEST", 95, 104], ["liver enzymes", "TEST", 109, 122], ["hepatic", "ANATOMY", 46, 53], ["liver", "ANATOMY", 109, 114]]], ["ANOVA for non-parametric repeated measurements was performed in both groups separately.", [["non-parametric repeated measurements", "TEST", 10, 46]]], ["Results: ICG R15 increased over time without significant differences between groups (Table 1 ).", [["ICG R15", "SIMPLE_CHEMICAL", 9, 16], ["ICG R15", "TEST", 9, 16]]], ["There was a parallel increase in bilirubin in septic but not control animals.", [["bilirubin", "CHEMICAL", 33, 42], ["septic", "DISEASE", 46, 52], ["bilirubin", "CHEMICAL", 33, 42], ["bilirubin", "SIMPLE_CHEMICAL", 33, 42], ["a parallel increase in bilirubin in septic", "PROBLEM", 10, 52], ["parallel", "OBSERVATION_MODIFIER", 12, 20], ["increase", "OBSERVATION_MODIFIER", 21, 29], ["bilirubin", "OBSERVATION_MODIFIER", 33, 42], ["septic", "OBSERVATION", 46, 52]]], ["The other measured parameters were similar in both groups at the end of the experiment.", [["similar", "OBSERVATION_MODIFIER", 35, 42]]], ["Conclusion: Liver function was impaired under sedation and prolonged mechanical ventilation after abdominal surgery, even in animals without sepsis.", [["Liver", "ANATOMY", 12, 17], ["abdominal", "ANATOMY", 98, 107], ["sepsis", "DISEASE", 141, 147], ["Liver", "ORGAN", 12, 17], ["abdominal", "ORGANISM_SUBDIVISION", 98, 107], ["sedation", "TREATMENT", 46, 54], ["prolonged mechanical ventilation", "TREATMENT", 59, 91], ["abdominal surgery", "TREATMENT", 98, 115], ["sepsis", "PROBLEM", 141, 147], ["Liver", "ANATOMY", 12, 17], ["mechanical ventilation", "OBSERVATION", 69, 91], ["abdominal", "ANATOMY", 98, 107], ["surgery", "OBSERVATION", 108, 115], ["without", "UNCERTAINTY", 133, 140], ["sepsis", "OBSERVATION", 141, 147]]], ["The underlying reasons should be further explored.Introduction:Introduction: Previous work has shown the cytoprotective properties of antithrombin-affinity depleted heparin (AADH), by neutralization of cytotoxic extracellular histones [1] , major mediators of death in sepsis [2, 3] .", [["extracellular", "ANATOMY", 212, 225], ["heparin", "CHEMICAL", 165, 172], ["AADH", "CHEMICAL", 174, 178], ["death", "DISEASE", 260, 265], ["sepsis", "DISEASE", 269, 275], ["antithrombin-affinity depleted heparin", "SIMPLE_CHEMICAL", 134, 172], ["AADH", "SIMPLE_CHEMICAL", 174, 178], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 212, 225], ["antithrombin", "PROTEIN", 134, 146], ["cytotoxic extracellular histones", "PROTEIN", 202, 234], ["antithrombin", "TREATMENT", 134, 146], ["heparin (AADH)", "TREATMENT", 165, 179], ["cytotoxic extracellular histones", "TREATMENT", 202, 234], ["death", "PROBLEM", 260, 265], ["sepsis", "PROBLEM", 269, 275], ["sepsis", "OBSERVATION", 269, 275]]], ["AADH was produced from clinical grade heparin, resulting in preparations that have lost >99,5% of their anticoagulant activity.", [["AADH", "CHEMICAL", 0, 4], ["heparin", "CHEMICAL", 38, 45], ["AADH", "SIMPLE_CHEMICAL", 0, 4], ["heparin", "SIMPLE_CHEMICAL", 38, 45], ["clinical grade heparin", "TREATMENT", 23, 45]]], ["To gain insight into the mechanisms and the basic pharmacological aspects of AADH protective properties, we performed a systematic analysis of how AADH is tolerated in mice and ascertained its effects in three different in vivo models of inflammation and infection.", [["AADH", "CHEMICAL", 147, 151], ["inflammation", "DISEASE", 238, 250], ["infection", "DISEASE", 255, 264], ["AADH", "CHEMICAL", 147, 151], ["AADH", "SIMPLE_CHEMICAL", 77, 81], ["AADH", "SIMPLE_CHEMICAL", 147, 151], ["mice", "ORGANISM", 168, 172], ["mice", "SPECIES", 168, 172], ["mice", "SPECIES", 168, 172], ["a systematic analysis", "TEST", 118, 139], ["inflammation", "PROBLEM", 238, 250], ["infection", "PROBLEM", 255, 264], ["inflammation", "OBSERVATION", 238, 250], ["infection", "OBSERVATION", 255, 264]]], ["Methods: Dose ranging studies, short term and medium term, were performed in C57BL/6 mice.", [["C57BL/6 mice", "ORGANISM", 77, 89], ["mice", "SPECIES", 85, 89], ["mice", "SPECIES", 85, 89], ["Dose ranging studies", "TEST", 9, 29]]], ["The effects of i.v. administration of extracellular histones in the presence or absence of AADH were assessed in mice.", [["extracellular", "ANATOMY", 38, 51], ["AADH", "CHEMICAL", 91, 95], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 38, 51], ["histones", "GENE_OR_GENE_PRODUCT", 52, 60], ["AADH", "GENE_OR_GENE_PRODUCT", 91, 95], ["mice", "ORGANISM", 113, 117], ["extracellular histones", "PROTEIN", 38, 60], ["AADH", "PROTEIN", 91, 95], ["mice", "SPECIES", 113, 117], ["mice", "SPECIES", 113, 117], ["i.v. administration", "TREATMENT", 15, 34], ["extracellular histones", "TREATMENT", 38, 60], ["extracellular histones", "OBSERVATION", 38, 60]]], ["We further analysed the effect of AADH in models of Concanavalin A-and MRSA-mediated lethality.", [["AADH", "CHEMICAL", 34, 38], ["Concanavalin A-", "CHEMICAL", 52, 67], ["MRSA", "CHEMICAL", 71, 75], ["AADH", "SIMPLE_CHEMICAL", 34, 38], ["Concanavalin A-", "SIMPLE_CHEMICAL", 52, 67], ["MRSA", "SIMPLE_CHEMICAL", 71, 75], ["MRSA", "SPECIES", 71, 75], ["AADH", "TREATMENT", 34, 38], ["Concanavalin A-", "TREATMENT", 52, 67], ["MRSA", "PROBLEM", 71, 75], ["lethality", "PROBLEM", 85, 94], ["MRSA", "OBSERVATION", 71, 75], ["lethality", "OBSERVATION", 85, 94]]], ["In all studies we assessed clinical signs, lab parameters and histology.", [["all studies", "TEST", 3, 14], ["clinical signs", "TEST", 27, 41], ["lab parameters", "TEST", 43, 57], ["histology", "TEST", 62, 71]]], ["Results: AADH was well tolerated in both short term and intermediate term (till 7 days) experiments in mice, in the absence of any signs of tissue bleeding.", [["tissue", "ANATOMY", 140, 146], ["AADH", "CHEMICAL", 9, 13], ["bleeding", "DISEASE", 147, 155], ["AADH", "SIMPLE_CHEMICAL", 9, 13], ["mice", "ORGANISM", 103, 107], ["tissue", "TISSUE", 140, 146], ["mice", "SPECIES", 103, 107], ["mice", "SPECIES", 103, 107], ["AADH", "TEST", 9, 13], ["tissue bleeding", "PROBLEM", 140, 155], ["tissue", "ANATOMY", 140, 146], ["bleeding", "OBSERVATION", 147, 155]]], ["AADH was able to revert the cytotoxic properties of i.v. administered histones.", [["AADH", "CHEMICAL", 0, 4], ["AADH", "SIMPLE_CHEMICAL", 0, 4], ["histones", "PROTEIN", 70, 78], ["i.v. administered histones", "TREATMENT", 52, 78]]], ["In a Concanavalin A mediated model of sterile inflammation, we confirmed that AADH has protective properties that counteract the cytotoxic effects of extracellular histones.", [["extracellular", "ANATOMY", 150, 163], ["inflammation", "DISEASE", 46, 58], ["AADH", "CHEMICAL", 78, 82], ["Concanavalin A", "SIMPLE_CHEMICAL", 5, 19], ["AADH", "SIMPLE_CHEMICAL", 78, 82], ["extracellular histones", "CELLULAR_COMPONENT", 150, 172], ["extracellular histones", "PROTEIN", 150, 172], ["sterile inflammation", "PROBLEM", 38, 58], ["protective properties", "TREATMENT", 87, 108], ["extracellular histones", "PROBLEM", 150, 172], ["inflammation", "OBSERVATION", 46, 58], ["cytotoxic", "OBSERVATION_MODIFIER", 129, 138], ["extracellular histones", "OBSERVATION", 150, 172]]], ["In an in vivo lethal MRSA model, for the first time, AADH was shown to induce a survivalbenefit.", [["AADH", "CHEMICAL", 53, 57], ["AADH", "SIMPLE_CHEMICAL", 53, 57], ["AADH", "PROTEIN", 53, 57], ["MRSA", "SPECIES", 21, 25], ["MRSA", "OBSERVATION", 21, 25]]], ["Conclusions: We conclude that AADH contributes to the overall increased survival by means of neutralization of extracellular histones and represents a promising product for further development into a drug for the treatment of inflammatory diseases and sepsis.Introduction:Introduction: Urokinase (UK) and tissue plasminogen activator (tPA) mediate thrombolytic actions by activating endogenous plasminogen.", [["extracellular", "ANATOMY", 111, 124], ["AADH", "CHEMICAL", 30, 34], ["inflammatory diseases", "DISEASE", 226, 247], ["sepsis", "DISEASE", 252, 258], ["AADH", "SIMPLE_CHEMICAL", 30, 34], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 111, 124], ["histones", "GENE_OR_GENE_PRODUCT", 125, 133], ["Urokinase", "GENE_OR_GENE_PRODUCT", 286, 295], ["UK", "GENE_OR_GENE_PRODUCT", 297, 299], ["tissue plasminogen activator", "GENE_OR_GENE_PRODUCT", 305, 333], ["PA", "GENE_OR_GENE_PRODUCT", 336, 338], ["plasminogen", "GENE_OR_GENE_PRODUCT", 394, 405], ["extracellular histones", "PROTEIN", 111, 133], ["Urokinase", "PROTEIN", 286, 295], ["UK", "PROTEIN", 297, 299], ["endogenous plasminogen", "PROTEIN", 383, 405], ["neutralization of extracellular histones", "TREATMENT", 93, 133], ["a drug", "TREATMENT", 198, 204], ["inflammatory diseases", "PROBLEM", 226, 247], ["sepsis", "PROBLEM", 252, 258], ["Urokinase (UK)", "TREATMENT", 286, 300], ["tissue plasminogen activator (tPA) mediate thrombolytic actions", "TREATMENT", 305, 368], ["activating endogenous plasminogen", "TREATMENT", 372, 405], ["increased", "OBSERVATION_MODIFIER", 62, 71], ["extracellular histones", "OBSERVATION", 111, 133], ["inflammatory", "OBSERVATION", 226, 238], ["sepsis", "OBSERVATION", 252, 258]]], ["Thrombomodulin (TM) complexes with thrombin to activate Protein C and thrombin activatable fibrinolysis inhibitor (TAFI).", [["Thrombomodulin", "SIMPLE_CHEMICAL", 0, 14], ["thrombin", "GENE_OR_GENE_PRODUCT", 35, 43], ["Protein C", "GENE_OR_GENE_PRODUCT", 56, 65], ["thrombin activatable fibrinolysis inhibitor", "GENE_OR_GENE_PRODUCT", 70, 113], ["TAFI", "GENE_OR_GENE_PRODUCT", 115, 119], ["Thrombomodulin (TM) complexes", "PROTEIN", 0, 29], ["thrombin", "PROTEIN", 35, 43], ["Protein C", "PROTEIN", 56, 65], ["thrombin", "PROTEIN", 70, 78], ["TAFI", "PROTEIN", 115, 119], ["Thrombomodulin (TM) complexes", "TREATMENT", 0, 29], ["thrombin", "TREATMENT", 35, 43], ["Protein C", "PROBLEM", 56, 65], ["thrombin activatable fibrinolysis inhibitor", "TREATMENT", 70, 113], ["TAFI", "TEST", 115, 119]]], ["Activated Protein C (APC) modulates coagulation by digesting factors V and VIII and activates fibrinolysis by decreasing PAI-1 functionality.", [["Protein C", "GENE_OR_GENE_PRODUCT", 10, 19], ["APC", "GENE_OR_GENE_PRODUCT", 21, 24], ["factors V", "GENE_OR_GENE_PRODUCT", 61, 70], ["VIII", "GENE_OR_GENE_PRODUCT", 75, 79], ["PAI-1", "GENE_OR_GENE_PRODUCT", 121, 126], ["Protein C", "PROTEIN", 10, 19], ["APC", "PROTEIN", 21, 24], ["digesting factors V and VIII", "PROTEIN", 51, 79], ["PAI", "PROTEIN", 121, 124], ["Activated Protein C (APC) modulates coagulation", "TREATMENT", 0, 47], ["VIII", "TREATMENT", 75, 79], ["activates fibrinolysis", "TREATMENT", 84, 106], ["decreasing PAI", "PROBLEM", 110, 124]]], ["Methods: The purpose of this study is to compare the effects of rTM and APC on urokinase and tPA mediated thrombolysis utilizing thromboelastography.", [["APC", "CHEMICAL", 72, 75], ["rTM", "SIMPLE_CHEMICAL", 64, 67], ["APC", "GENE_OR_GENE_PRODUCT", 72, 75], ["urokinase", "GENE_OR_GENE_PRODUCT", 79, 88], ["tPA", "GENE_OR_GENE_PRODUCT", 93, 96], ["APC", "CELL_TYPE", 72, 75], ["urokinase", "PROTEIN", 79, 88], ["tPA", "PROTEIN", 93, 96], ["this study", "TEST", 24, 34], ["rTM and APC", "TREATMENT", 64, 75], ["urokinase", "TREATMENT", 79, 88], ["tPA mediated thrombolysis", "TREATMENT", 93, 118], ["thromboelastography", "TEST", 129, 148]]], ["Results: Native whole blood was activated using a diluted intrinsic activator (APTT reagent, Triniclot).", [["whole blood", "ANATOMY", 16, 27], ["blood", "ORGANISM_SUBSTANCE", 22, 27], ["Triniclot", "SIMPLE_CHEMICAL", 93, 102], ["a diluted intrinsic activator (APTT reagent", "TREATMENT", 48, 91], ["Triniclot", "TREATMENT", 93, 102]]], ["The modulation of thrombolysis by tPA and UK (Abbott, Chicago, USA) was studied by supplementing these agents to whole blood and monitoring TEG profiles.", [["whole blood", "ANATOMY", 113, 124], ["tPA", "GENE_OR_GENE_PRODUCT", 34, 37], ["UK", "GENE_OR_GENE_PRODUCT", 42, 44], ["blood", "ORGANISM_SUBSTANCE", 119, 124], ["TEG", "PROTEIN", 140, 143], ["thrombolysis", "TREATMENT", 18, 30], ["tPA", "TREATMENT", 34, 37], ["whole blood", "TEST", 113, 124], ["monitoring TEG profiles", "TEST", 129, 152], ["thrombolysis", "OBSERVATION", 18, 30]]], ["APC (Haematologic Technologies, VT, USA) and rTM (Asahi Kasai Pharma, Tokyo, Japan) were supplemented to the activated blood at 0.02 -3.0 ug/ml.", [["blood", "ANATOMY", 119, 124], ["APC", "CHEMICAL", 0, 3], ["APC", "GENE_OR_GENE_PRODUCT", 0, 3], ["blood", "ORGANISM_SUBSTANCE", 119, 124], ["APC", "CELL_TYPE", 0, 3], ["APC", "PROBLEM", 0, 3], ["Haematologic Technologies", "TEST", 5, 30], ["VT", "TEST", 32, 34], ["rTM (Asahi Kasai Pharma", "TREATMENT", 45, 68]]], ["The modulation of tPA and UK induced thrombolysis by APC and rTM was studied in terms of thromboelastograph patterns.", [["APC", "CHEMICAL", 53, 56], ["tPA", "GENE_OR_GENE_PRODUCT", 18, 21], ["UK", "GENE_OR_GENE_PRODUCT", 26, 28], ["APC", "GENE_OR_GENE_PRODUCT", 53, 56], ["tPA", "PROTEIN", 18, 21], ["APC", "CELL_TYPE", 53, 56], ["tPA", "TREATMENT", 18, 21], ["UK induced thrombolysis", "TREATMENT", 26, 49], ["APC and rTM", "TREATMENT", 53, 64], ["thrombolysis", "OBSERVATION", 37, 49]]], ["The effect of both APC and rTM on plasma based systems supplemented with tPA was also investigated.", [["plasma", "ANATOMY", 34, 40], ["rTM", "CHEMICAL", 27, 30], ["APC", "CHEMICAL", 19, 22], ["APC", "GENE_OR_GENE_PRODUCT", 19, 22], ["rTM", "SIMPLE_CHEMICAL", 27, 30], ["plasma", "ORGANISM_SUBSTANCE", 34, 40], ["tPA", "GENE_OR_GENE_PRODUCT", 73, 76], ["APC", "CELL_TYPE", 19, 22], ["tPA", "PROTEIN", 73, 76], ["both APC", "TREATMENT", 14, 22], ["plasma based systems", "TREATMENT", 34, 54], ["tPA", "TREATMENT", 73, 76]]], ["Patients treated with antibiotic therapy were eligible for inclusion.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["antibiotic therapy", "TREATMENT", 22, 40]]], ["The plausibility of infection (definite, probable, possible, none) was determined based on the Centers for Diseases Control (CDC) criteria.", [["infection", "DISEASE", 20, 29], ["infection", "PROBLEM", 20, 29], ["infection", "OBSERVATION", 20, 29]]], ["Patients with sepsis (definite/probable/possible infection and a SOFA score increase of >=2) were screened for death within 60 days and secondary infections 48 h to 60 days after ICU admission, using the CDC criteria.", [["sepsis", "DISEASE", 14, 20], ["infection", "DISEASE", 49, 58], ["death", "DISEASE", 111, 116], ["infections", "DISEASE", 146, 156], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["sepsis", "PROBLEM", 14, 20], ["infection", "PROBLEM", 49, 58], ["a SOFA score", "TEST", 63, 75], ["death", "PROBLEM", 111, 116], ["secondary infections", "PROBLEM", 136, 156], ["sepsis", "OBSERVATION", 14, 20], ["probable/possible", "UNCERTAINTY", 31, 48], ["infection", "OBSERVATION", 49, 58]]], ["HLA-DRA and CD74 mRNA expressions were determined by reverse transcription quantitative PCR.Introduction:Results: Among 579 ICU admissions, a blood sample for RNA analysis was collected in 551 cases.", [["blood sample", "ANATOMY", 142, 154], ["HLA-DRA", "GENE_OR_GENE_PRODUCT", 0, 7], ["CD74", "GENE_OR_GENE_PRODUCT", 12, 16], ["blood", "ORGANISM_SUBSTANCE", 142, 147], ["HLA-DRA and CD74 mRNA", "RNA", 0, 21], ["HLA", "TEST", 0, 3], ["CD74 mRNA expressions", "TEST", 12, 33], ["a blood sample", "TEST", 140, 154], ["RNA analysis", "TEST", 159, 171]]], ["Two hundred fifty-seven patients met the inclusion criteria and provided written informed consent.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32]]], ["Sepsis was noted in 134 patients.", [["Sepsis", "DISEASE", 0, 6], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["Sepsis", "PROBLEM", 0, 6]]], ["The sepsis patients experienced death in 36 cases (27%), secondary infection in 32 cases (24%), and death and/or secondary infection in 60 cases (45%).", [["sepsis", "DISEASE", 4, 10], ["death", "DISEASE", 32, 37], ["infection", "DISEASE", 67, 76], ["death", "DISEASE", 100, 105], ["infection", "DISEASE", 123, 132], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["The sepsis", "PROBLEM", 0, 10], ["death", "PROBLEM", 32, 37], ["secondary infection in 32 cases", "PROBLEM", 57, 88], ["death", "PROBLEM", 100, 105], ["secondary infection", "PROBLEM", 113, 132], ["sepsis", "OBSERVATION", 4, 10], ["infection", "OBSERVATION", 67, 76], ["secondary", "OBSERVATION_MODIFIER", 113, 122], ["infection", "OBSERVATION", 123, 132]]], ["Table 1 shows the results of HLA-DRA and CD74 expression related to death and secondary infections.Introduction:Conclusions: The mRNA expression of HLA-DRA on ICU admission was significantly decreased in patients with sepsis who died or contracted secondary infections within 60 days.", [["death", "DISEASE", 68, 73], ["infections", "DISEASE", 88, 98], ["sepsis", "DISEASE", 218, 224], ["infections", "DISEASE", 258, 268], ["HLA-DRA", "GENE_OR_GENE_PRODUCT", 29, 36], ["CD74", "GENE_OR_GENE_PRODUCT", 41, 45], ["HLA-DRA", "GENE_OR_GENE_PRODUCT", 148, 155], ["patients", "ORGANISM", 204, 212], ["CD74", "PROTEIN", 41, 45], ["HLA-DRA", "DNA", 148, 155], ["patients", "SPECIES", 204, 212], ["HLA", "TEST", 29, 32], ["CD74 expression", "PROBLEM", 41, 56], ["death", "PROBLEM", 68, 73], ["secondary infections", "PROBLEM", 78, 98], ["sepsis", "PROBLEM", 218, 224], ["contracted secondary infections", "PROBLEM", 237, 268], ["secondary", "OBSERVATION_MODIFIER", 78, 87], ["infections", "OBSERVATION", 88, 98], ["decreased", "OBSERVATION_MODIFIER", 191, 200], ["sepsis", "OBSERVATION", 218, 224]]], ["CD74 expression was not significantly decreased in patients with negative outcome.", [["CD74", "GENE_OR_GENE_PRODUCT", 0, 4], ["patients", "ORGANISM", 51, 59], ["CD74", "PROTEIN", 0, 4], ["patients", "SPECIES", 51, 59], ["CD74 expression", "TEST", 0, 15], ["not", "UNCERTAINTY", 20, 23], ["significantly", "OBSERVATION_MODIFIER", 24, 37], ["decreased", "OBSERVATION_MODIFIER", 38, 47]]], ["Introduction: Acid-base disturbances are common in patients with infection admitted to the intensive care unit (ICU).", [["infection", "DISEASE", 65, 74], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["Acid-base disturbances", "PROBLEM", 14, 36], ["infection", "PROBLEM", 65, 74], ["base", "ANATOMY_MODIFIER", 19, 23], ["infection", "OBSERVATION", 65, 74]]], ["More attention is given to hyperlactatemia in this patient population as a prognostic factor, although other acid-base disturbances may also have an impact on patient outcomes.", [["hyperlactatemia", "DISEASE", 27, 42], ["patient", "ORGANISM", 51, 58], ["patient", "ORGANISM", 159, 166], ["patient", "SPECIES", 51, 58], ["patient", "SPECIES", 159, 166], ["hyperlactatemia", "PROBLEM", 27, 42], ["a prognostic factor", "PROBLEM", 73, 92], ["other acid-base disturbances", "PROBLEM", 103, 131]]], ["Our objective is to describe the acid-base profile of this patient population and determine the association between different acid-base abnormalities and ICU mortality.", [["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66], ["different acid-base abnormalities", "PROBLEM", 116, 149], ["ICU mortality", "PROBLEM", 154, 167]]], ["Methods: Retrospective cohort of patients admitted with infection to an intensive care unit.", [["infection", "DISEASE", 56, 65], ["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["infection", "PROBLEM", 56, 65], ["infection", "OBSERVATION", 56, 65]]], ["Patients were stratified according to pH (<7.35; 7.35 -7.45; > 7.45) and, then, according to the standard base excess (SBE) (< -2; -2 -+2; > +2).", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["pH", "TEST", 38, 40], ["SBE", "TEST", 119, 122]]], ["In each of these strata and the whole population, the proportions of acid-base disturbances were quantified during the first 24 hours of ICU admission.", [["acid-base disturbances", "PROBLEM", 69, 91], ["base disturbances", "OBSERVATION", 74, 91]]], ["To assess the association between acid-base disturbances and outcome, a logistic regression model was fit, adjusting for age, sex and SAPS 3 score.Introduction:Results: 605 patients were analysed.", [["patients", "ORGANISM", 173, 181], ["patients", "SPECIES", 173, 181], ["acid-base disturbances", "PROBLEM", 34, 56], ["base", "ANATOMY_MODIFIER", 39, 43]]], ["304 (50%) patients were acidemic and 244 (40%) presented with a normal pH.", [["acidemic", "DISEASE", 24, 32], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["acidemic", "TEST", 24, 32], ["normal", "OBSERVATION", 64, 70]]], ["Metabolic acidosis (as assessed by SBE) was observed in all subgroups, regardless of pH levels (pH < 7 ).", [["Metabolic acidosis", "DISEASE", 0, 18], ["Metabolic acidosis", "PROBLEM", 0, 18], ["SBE", "TEST", 35, 38], ["pH levels", "TEST", 85, 94], ["pH", "TEST", 96, 98], ["acidosis", "OBSERVATION", 10, 18]]], ["Lactic acidosis was observed in 71% of the whole population; SIG (Strong ion gap) acidosis, in 75%; SID (hyperchloremic) acidosis, in 58%; metabolic alkalosis, in 7%; and respiratory acidosis, in 13% of the patients.", [["respiratory", "ANATOMY", 171, 182], ["Lactic acidosis", "DISEASE", 0, 15], ["acidosis", "DISEASE", 82, 90], ["acidosis", "DISEASE", 121, 129], ["metabolic alkalosis", "DISEASE", 139, 158], ["respiratory acidosis", "DISEASE", 171, 191], ["patients", "ORGANISM", 207, 215], ["patients", "SPECIES", 207, 215], ["Lactic acidosis", "PROBLEM", 0, 15], ["Strong ion gap) acidosis", "PROBLEM", 66, 90], ["SID (hyperchloremic) acidosis", "PROBLEM", 100, 129], ["metabolic alkalosis", "PROBLEM", 139, 158], ["respiratory acidosis", "PROBLEM", 171, 191], ["acidosis", "OBSERVATION", 7, 15], ["acidosis", "OBSERVATION", 82, 90], ["hyperchloremic", "OBSERVATION", 105, 119], ["acidosis", "OBSERVATION", 121, 129], ["metabolic alkalosis", "OBSERVATION", 139, 158], ["respiratory acidosis", "OBSERVATION", 171, 191]]], ["Introduction: Sepsis-induced brain dysfunction has been neglected until recently due to the absence of specific clinical or biological markers.", [["brain", "ANATOMY", 29, 34], ["brain dysfunction", "DISEASE", 29, 46], ["brain", "ORGAN", 29, 34], ["Sepsis-induced brain dysfunction", "PROBLEM", 14, 46], ["Sepsis-induced", "OBSERVATION", 14, 28], ["brain", "ANATOMY", 29, 34], ["dysfunction", "OBSERVATION", 35, 46]]], ["There is increasing evidence that sepsis may pose substantial risks for long term cognitive impairment.Introduction:Methods: To find out clinical and inflammatory factors associated with acute sepsis-induced brain dysfunction (SIBD) serum levels of cytokines, complement breakdown products and neurodegeneration markers were measured by ELISA in sera of 86 SIBD patients and 33 healthy controls.", [["brain", "ANATOMY", 208, 213], ["serum", "ANATOMY", 233, 238], ["sera", "ANATOMY", 346, 350], ["SIBD", "ANATOMY", 357, 361], ["sepsis", "DISEASE", 34, 40], ["cognitive impairment", "DISEASE", 82, 102], ["sepsis", "DISEASE", 193, 199], ["brain dysfunction", "DISEASE", 208, 225], ["SIBD", "DISEASE", 227, 231], ["SIBD", "DISEASE", 357, 361], ["brain", "ORGAN", 208, 213], ["serum", "ORGANISM_SUBSTANCE", 233, 238], ["sera", "ORGANISM_SUBSTANCE", 346, 350], ["patients", "ORGANISM", 362, 370], ["inflammatory factors", "PROTEIN", 150, 170], ["cytokines", "PROTEIN", 249, 258], ["complement breakdown products", "PROTEIN", 260, 289], ["neurodegeneration markers", "PROTEIN", 294, 319], ["patients", "SPECIES", 362, 370], ["sepsis", "PROBLEM", 34, 40], ["long term cognitive impairment", "PROBLEM", 72, 102], ["clinical and inflammatory factors", "PROBLEM", 137, 170], ["acute sepsis", "PROBLEM", 187, 199], ["induced brain dysfunction", "PROBLEM", 200, 225], ["serum levels", "TEST", 233, 245], ["cytokines", "PROBLEM", 249, 258], ["complement breakdown products", "PROBLEM", 260, 289], ["neurodegeneration markers", "PROBLEM", 294, 319], ["ELISA in sera", "TEST", 337, 350], ["increasing", "OBSERVATION_MODIFIER", 9, 19], ["sepsis", "OBSERVATION", 34, 40], ["long term", "OBSERVATION_MODIFIER", 72, 81], ["inflammatory", "OBSERVATION", 150, 162], ["acute", "OBSERVATION_MODIFIER", 187, 192], ["sepsis", "OBSERVATION", 193, 199], ["brain", "ANATOMY", 208, 213], ["dysfunction", "OBSERVATION", 214, 225], ["breakdown", "OBSERVATION_MODIFIER", 271, 280]]], ["Association between these biological markers and cognitive test results was investigated.Introduction:Results: SIBD patients showed significantly increased IL-6, IL-8, IL-10 and C4d levels and decreased TNF-\u03b1, IL-12, C5a and iC3b levels than healthy controls.", [["SIBD", "ORGANISM", 111, 115], ["patients", "ORGANISM", 116, 124], ["IL-6", "GENE_OR_GENE_PRODUCT", 156, 160], ["IL-8", "GENE_OR_GENE_PRODUCT", 162, 166], ["IL-10", "GENE_OR_GENE_PRODUCT", 168, 173], ["C4d", "GENE_OR_GENE_PRODUCT", 178, 181], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 203, 208], ["IL-12", "GENE_OR_GENE_PRODUCT", 210, 215], ["C5a", "GENE_OR_GENE_PRODUCT", 217, 220], ["iC3b", "GENE_OR_GENE_PRODUCT", 225, 229], ["C4d", "PROTEIN", 178, 181], ["TNF", "PROTEIN", 203, 206], ["C5a", "PROTEIN", 217, 220], ["iC3b", "PROTEIN", 225, 229], ["patients", "SPECIES", 116, 124], ["these biological markers", "TEST", 20, 44], ["cognitive test results", "TEST", 49, 71], ["significantly increased IL", "PROBLEM", 132, 158], ["IL", "TEST", 162, 164], ["IL", "TEST", 168, 170], ["C4d levels", "TEST", 178, 188], ["TNF", "TEST", 203, 206], ["IL", "TEST", 210, 212], ["C5a", "TEST", 217, 220], ["iC3b levels", "TEST", 225, 236], ["decreased", "OBSERVATION_MODIFIER", 193, 202], ["TNF", "ANATOMY", 203, 206]]], ["No significant alteration was observed in neuronal loss and neurodegeneration marker (neuron specific enolase (NSE), amyloid \u03b2, tau) levels.", [["neuronal", "ANATOMY", 42, 50], ["neuronal loss", "DISEASE", 42, 55], ["neurodegeneration", "DISEASE", 60, 77], ["neuronal", "CELL", 42, 50], ["neuron specific enolase", "GENE_OR_GENE_PRODUCT", 86, 109], ["NSE", "GENE_OR_GENE_PRODUCT", 111, 114], ["amyloid \u03b2", "GENE_OR_GENE_PRODUCT", 117, 126], ["tau", "GENE_OR_GENE_PRODUCT", 128, 131], ["neuron specific enolase", "PROTEIN", 86, 109], ["NSE", "PROTEIN", 111, 114], ["amyloid \u03b2", "PROTEIN", 117, 126], ["tau", "PROTEIN", 128, 131], ["significant alteration", "PROBLEM", 3, 25], ["neuronal loss", "PROBLEM", 42, 55], ["neurodegeneration marker", "TEST", 60, 84], ["neuron specific enolase", "TEST", 86, 109], ["amyloid \u03b2, tau) levels", "TEST", 117, 139], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["alteration", "OBSERVATION", 15, 25], ["neuronal loss", "OBSERVATION", 42, 55]]], ["Increased IL-1\u03b2, IL-6, IL-8, IL-10, TNF-\u03b1 and decreased C4d, C5a and iC3b levels were associated with septic shock, coma and mortality.", [["septic shock", "DISEASE", 102, 114], ["coma", "DISEASE", 116, 120], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 10, 15], ["IL-6", "GENE_OR_GENE_PRODUCT", 17, 21], ["IL-8", "GENE_OR_GENE_PRODUCT", 23, 27], ["IL-10", "GENE_OR_GENE_PRODUCT", 29, 34], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 36, 41], ["C4d", "GENE_OR_GENE_PRODUCT", 56, 59], ["C5a", "GENE_OR_GENE_PRODUCT", 61, 64], ["iC3b", "GENE_OR_GENE_PRODUCT", 69, 73], ["IL", "PROTEIN", 10, 12], ["TNF", "PROTEIN", 36, 39], ["C4d", "PROTEIN", 56, 59], ["C5a", "PROTEIN", 61, 64], ["iC3b", "PROTEIN", 69, 73], ["Increased IL", "TEST", 0, 12], ["IL", "TEST", 17, 19], ["IL", "TEST", 23, 25], ["IL", "TEST", 29, 31], ["TNF", "TEST", 36, 39], ["C5a", "TEST", 61, 64], ["iC3b levels", "TEST", 69, 80], ["septic shock", "PROBLEM", 102, 114], ["coma", "PROBLEM", 116, 120], ["decreased", "OBSERVATION_MODIFIER", 46, 55], ["C4d", "OBSERVATION", 56, 59], ["septic shock", "OBSERVATION", 102, 114]]], ["Transient mild cognitive impairment was observed in 7 of 21 patients who underwent neuropsychological assessment.", [["cognitive impairment", "DISEASE", 15, 35], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["Transient mild cognitive impairment", "PROBLEM", 0, 35], ["neuropsychological assessment", "TEST", 83, 112], ["mild", "OBSERVATION_MODIFIER", 10, 14], ["cognitive", "OBSERVATION", 15, 24]]], ["Cognitive dysfunction and neuronal loss were associated with increased duration of septic shock and delirium but not baseline serum levels of inflammation and neurodegeneration markers.Introduction:Conclusions: Increased cytokine levels, decreased complement activity and increased neuronal loss are indicators of poor prognosis and adverse events in SIBD.", [["neuronal", "ANATOMY", 26, 34], ["serum", "ANATOMY", 126, 131], ["neuronal", "ANATOMY", 282, 290], ["SIBD", "ANATOMY", 351, 355], ["Cognitive dysfunction", "DISEASE", 0, 21], ["neuronal loss", "DISEASE", 26, 39], ["septic shock", "DISEASE", 83, 95], ["delirium", "DISEASE", 100, 108], ["inflammation", "DISEASE", 142, 154], ["neurodegeneration", "DISEASE", 159, 176], ["neuronal loss", "DISEASE", 282, 295], ["SIBD", "DISEASE", 351, 355], ["neuronal", "CELL", 26, 34], ["serum", "ORGANISM_SUBSTANCE", 126, 131], ["neuronal", "CELL", 282, 290], ["SIBD", "CANCER", 351, 355], ["neurodegeneration markers", "PROTEIN", 159, 184], ["cytokine", "PROTEIN", 221, 229], ["Cognitive dysfunction", "PROBLEM", 0, 21], ["neuronal loss", "PROBLEM", 26, 39], ["septic shock", "PROBLEM", 83, 95], ["delirium", "PROBLEM", 100, 108], ["serum levels", "TEST", 126, 138], ["inflammation", "PROBLEM", 142, 154], ["neurodegeneration markers", "PROBLEM", 159, 184], ["Increased cytokine levels", "PROBLEM", 211, 236], ["decreased complement activity", "PROBLEM", 238, 267], ["increased neuronal loss", "PROBLEM", 272, 295], ["poor prognosis", "PROBLEM", 314, 328], ["adverse events in SIBD", "PROBLEM", 333, 355], ["neuronal loss", "OBSERVATION", 26, 39], ["increased", "OBSERVATION_MODIFIER", 61, 70], ["septic shock", "OBSERVATION", 83, 95], ["delirium", "OBSERVATION", 100, 108], ["inflammation", "OBSERVATION", 142, 154], ["neurodegeneration markers", "OBSERVATION", 159, 184], ["Increased", "OBSERVATION_MODIFIER", 211, 220], ["cytokine levels", "OBSERVATION", 221, 236], ["decreased", "OBSERVATION_MODIFIER", 238, 247], ["activity", "OBSERVATION_MODIFIER", 259, 267], ["increased", "OBSERVATION_MODIFIER", 272, 281], ["neuronal loss", "OBSERVATION", 282, 295]]], ["Cognitive dysfunction and neuronal destruction in SIBD do not seem to be associated with systemic inflammation factors and Alzheimer disease-type neurodegeneration but rather with increased duration of neuronal dysfunction and enhanced exposure of the brain to sepsisinducing pathogens.", [["neuronal", "ANATOMY", 26, 34], ["neuronal", "ANATOMY", 202, 210], ["brain", "ANATOMY", 252, 257], ["Cognitive dysfunction", "DISEASE", 0, 21], ["neuronal destruction", "DISEASE", 26, 46], ["SIBD", "DISEASE", 50, 54], ["inflammation", "DISEASE", 98, 110], ["Alzheimer disease-type neurodegeneration", "DISEASE", 123, 163], ["neuronal dysfunction", "DISEASE", 202, 222], ["neuronal", "CELL", 26, 34], ["neuronal", "CELL", 202, 210], ["brain", "ORGAN", 252, 257], ["Cognitive dysfunction", "PROBLEM", 0, 21], ["neuronal destruction in SIBD", "PROBLEM", 26, 54], ["systemic inflammation factors", "PROBLEM", 89, 118], ["Alzheimer disease", "PROBLEM", 123, 140], ["type neurodegeneration", "PROBLEM", 141, 163], ["neuronal dysfunction", "PROBLEM", 202, 222], ["enhanced exposure of the brain", "PROBLEM", 227, 257], ["sepsisinducing pathogens", "PROBLEM", 261, 285], ["neuronal destruction", "OBSERVATION", 26, 46], ["not seem to be associated with", "UNCERTAINTY", 58, 88], ["systemic", "OBSERVATION_MODIFIER", 89, 97], ["inflammation", "OBSERVATION", 98, 110], ["Alzheimer disease", "OBSERVATION", 123, 140], ["neuronal dysfunction", "OBSERVATION", 202, 222], ["brain", "ANATOMY", 252, 257]]], ["Introduction: High levels of some aromatic microbial metabolites (AMM) in serum are related to the severity and mortality of critically ill patients [1] .", [["serum", "ANATOMY", 74, 79], ["critically ill", "DISEASE", 125, 139], ["serum", "ORGANISM_SUBSTANCE", 74, 79], ["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148], ["some aromatic microbial metabolites (AMM) in serum", "PROBLEM", 29, 79], ["High levels", "OBSERVATION_MODIFIER", 14, 25]]], ["Several studies have discussed the imbalance and loss of the diversity of gut microbiota but there are practically no data on the gut microbial metabolites in critical conditions, only a little -in healthy people [2, 3] .", [["gut microbiota", "ANATOMY", 74, 88], ["gut", "ANATOMY", 130, 133], ["gut", "ORGANISM_SUBDIVISION", 74, 77], ["gut", "ORGANISM_SUBDIVISION", 130, 133], ["people", "SPECIES", 206, 212], ["Several studies", "TEST", 0, 15], ["the imbalance", "PROBLEM", 31, 44]]], ["The aim of this work is to analyze the connection between serum and fecal levels of AMM in ICU patients.", [["serum", "ANATOMY", 58, 63], ["fecal", "ANATOMY", 68, 73], ["serum", "ORGANISM_SUBSTANCE", 58, 63], ["fecal", "ORGANISM_SUBSTANCE", 68, 73], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["fecal", "ANATOMY", 68, 73]]], ["Methods: 13 simultaneously serum and fecal samples (SFS) from ICU patients with nosocomial pneumonia (group I), 21 SFS from ICU neurorehabilitation patients (group II) and 5 SFS from healthy people were taken for GC/MS analyses.", [["serum", "ANATOMY", 27, 32], ["fecal samples", "ANATOMY", 37, 50], ["nosocomial pneumonia", "DISEASE", 80, 100], ["serum", "ORGANISM_SUBSTANCE", 27, 32], ["fecal samples", "ORGANISM_SUBSTANCE", 37, 50], ["patients", "ORGANISM", 66, 74], ["patients", "ORGANISM", 148, 156], ["people", "ORGANISM", 191, 197], ["patients", "SPECIES", 66, 74], ["patients", "SPECIES", 148, 156], ["people", "SPECIES", 191, 197], ["Methods", "TEST", 0, 7], ["simultaneously serum", "TEST", 12, 32], ["fecal samples", "TEST", 37, 50], ["nosocomial pneumonia", "PROBLEM", 80, 100], ["GC/MS analyses", "TEST", 213, 227], ["fecal", "ANATOMY", 37, 42], ["pneumonia", "OBSERVATION", 91, 100]]], ["The following AMM were measured: phenylpropionic (PhPA), phenyllactic (PhLA), p-hydroxybenzoic (p-HBA), p-hydroxyphenyllactic (p-HPhLA), p-hydroxyphenylacetic (HPhAA), p-hydroxyphenylpropionic (p-HPhPA) and homovanillic (HVA) acids.", [["phenylpropionic", "CHEMICAL", 33, 48], ["PhPA", "CHEMICAL", 50, 54], ["phenyllactic", "CHEMICAL", 57, 69], ["PhLA", "CHEMICAL", 71, 75], ["p-hydroxybenzoic", "CHEMICAL", 78, 94], ["p-HBA", "CHEMICAL", 96, 101], ["p-hydroxyphenyllactic", "CHEMICAL", 104, 125], ["p-HPhLA", "CHEMICAL", 127, 134], ["p-hydroxyphenylacetic", "CHEMICAL", 137, 158], ["HPhAA", "CHEMICAL", 160, 165], ["p-hydroxyphenylpropionic", "CHEMICAL", 168, 192], ["p-HPhPA", "CHEMICAL", 194, 201], ["homovanillic", "CHEMICAL", 207, 219], ["HVA", "CHEMICAL", 221, 224], ["phenylpropionic", "CHEMICAL", 33, 48], ["PhPA", "CHEMICAL", 50, 54], ["phenyllactic", "CHEMICAL", 57, 69], ["PhLA", "CHEMICAL", 71, 75], ["p-hydroxybenzoic (p-HBA", "CHEMICAL", 78, 101], ["p-hydroxyphenyllactic", "CHEMICAL", 104, 125], ["p-HPhLA", "CHEMICAL", 127, 134], ["p-hydroxyphenylacetic", "CHEMICAL", 137, 158], ["HPhAA", "CHEMICAL", 160, 165], ["p-hydroxyphenylpropionic", "CHEMICAL", 168, 192], ["p-HPhPA", "CHEMICAL", 194, 201], ["homovanillic", "CHEMICAL", 207, 219], ["HVA", "CHEMICAL", 221, 224], ["phenylpropionic", "SIMPLE_CHEMICAL", 33, 48], ["PhPA", "SIMPLE_CHEMICAL", 50, 54], ["phenyllactic", "SIMPLE_CHEMICAL", 57, 69], ["PhLA", "SIMPLE_CHEMICAL", 71, 75], ["p-hydroxybenzoic (p-HBA", "SIMPLE_CHEMICAL", 78, 101], ["p-hydroxyphenyllactic", "SIMPLE_CHEMICAL", 104, 125], ["p-HPhLA", "SIMPLE_CHEMICAL", 127, 134], ["p-hydroxyphenylacetic", "SIMPLE_CHEMICAL", 137, 158], ["HPhAA", "SIMPLE_CHEMICAL", 160, 165], ["p-hydroxyphenylpropionic", "SIMPLE_CHEMICAL", 168, 192], ["p-HPhPA", "SIMPLE_CHEMICAL", 194, 201], ["homovanillic (HVA) acids", "SIMPLE_CHEMICAL", 207, 231], ["phenylpropionic (PhPA", "TREATMENT", 33, 54], ["phenyllactic (PhLA)", "TREATMENT", 57, 76], ["p-hydroxybenzoic (p-HBA)", "TREATMENT", 78, 102], ["p-hydroxyphenyllactic (p-HPhLA)", "TREATMENT", 104, 135], ["p-hydroxyphenylacetic (HPhAA)", "TREATMENT", 137, 166], ["p-hydroxyphenylpropionic (p-HPhPA)", "TREATMENT", 168, 202], ["homovanillic (HVA) acids", "TREATMENT", 207, 231]]], ["Data were presented as medians with interquartile range (IR, 25-75%) using STATISTICA 10.Introduction:Results: The sum of the level of 4 most relevant metabolites (4AMM) -PhLA, p-HPhLA, p-HPhAA, and HVA -in serum samples from group I and group II were equal to 0.9 (0.6-9.6) \u03bc M and 0.7 (0.5-1.0) \u03bc M, respectively, and were higher than in healthy people -0.4 (0.4-0.6) \u03bc M (p<0.05).", [["serum samples", "ANATOMY", 207, 220], ["HVA", "CHEMICAL", 199, 202], ["PhLA", "CHEMICAL", 171, 175], ["p-HPhLA", "CHEMICAL", 177, 184], ["p-HPhAA", "CHEMICAL", 186, 193], ["HVA", "CHEMICAL", 199, 202], ["4AMM) -PhLA", "SIMPLE_CHEMICAL", 164, 175], ["p-HPhLA", "SIMPLE_CHEMICAL", 177, 184], ["p-HPhAA", "SIMPLE_CHEMICAL", 186, 193], ["HVA", "SIMPLE_CHEMICAL", 199, 202], ["serum samples", "ORGANISM_SUBSTANCE", 207, 220], ["people", "ORGANISM", 348, 354], ["people", "SPECIES", 348, 354], ["IR", "TEST", 57, 59], ["PhLA", "TEST", 171, 175], ["p", "TEST", 177, 178], ["HPhLA", "TEST", 179, 184], ["p", "TEST", 186, 187], ["HPhAA", "TEST", 188, 193], ["HVA", "TEST", 199, 202], ["serum samples", "TEST", 207, 220], ["group I", "TEST", 226, 233], ["M", "TEST", 277, 278], ["higher", "OBSERVATION_MODIFIER", 325, 331]]], ["We suppose the presence of the correlation of AMM profile in blood and intestine.", [["blood", "ANATOMY", 61, 66], ["intestine", "ANATOMY", 71, 80], ["blood", "ORGANISM_SUBSTANCE", 61, 66], ["intestine", "ORGAN", 71, 80], ["AMM profile in blood and intestine", "PROBLEM", 46, 80], ["intestine", "ANATOMY", 71, 80]]], ["Particularly, SFS of healthy people are characterized by the prevalence of PhPA; AMM are not detected in feces of non-survivors but only HVA dominates in their serum in the absence of other (Fig. 1) .Introduction:Conclusions: The AMM profiles in gut and serum are interrelated; AMM in serum probably reflect the violation and loss of biodiversity of the gut microbiota in critically ill patients.Introduction:Introduction: Since nitrogen oxide (NO) is an essential component of the immune system, the dynamics of plasma NO concentration was studied in order to predict the development of sepsis [1, 2] .", [["feces", "ANATOMY", 105, 110], ["serum", "ANATOMY", 160, 165], ["gut", "ANATOMY", 246, 249], ["serum", "ANATOMY", 254, 259], ["serum", "ANATOMY", 285, 290], ["gut microbiota", "ANATOMY", 354, 368], ["immune system", "ANATOMY", 482, 495], ["plasma", "ANATOMY", 513, 519], ["HVA", "CHEMICAL", 137, 140], ["critically ill", "DISEASE", 372, 386], ["nitrogen oxide", "CHEMICAL", 429, 443], ["NO", "CHEMICAL", 445, 447], ["NO", "CHEMICAL", 520, 522], ["sepsis", "DISEASE", 588, 594], ["HVA", "CHEMICAL", 137, 140], ["nitrogen oxide", "CHEMICAL", 429, 443], ["NO", "CHEMICAL", 445, 447], ["NO", "CHEMICAL", 520, 522], ["people", "ORGANISM", 29, 35], ["PhPA", "GENE_OR_GENE_PRODUCT", 75, 79], ["feces", "ORGANISM_SUBDIVISION", 105, 110], ["HVA", "SIMPLE_CHEMICAL", 137, 140], ["serum", "ORGANISM_SUBSTANCE", 160, 165], ["gut", "ORGANISM_SUBDIVISION", 246, 249], ["serum", "ORGANISM_SUBSTANCE", 254, 259], ["serum", "ORGANISM_SUBSTANCE", 285, 290], ["gut", "ORGANISM_SUBDIVISION", 354, 357], ["patients", "ORGANISM", 387, 395], ["nitrogen oxide", "SIMPLE_CHEMICAL", 429, 443], ["NO", "SIMPLE_CHEMICAL", 445, 447], ["immune system", "ANATOMICAL_SYSTEM", 482, 495], ["plasma", "ORGANISM_SUBSTANCE", 513, 519], ["NO", "SIMPLE_CHEMICAL", 520, 522], ["people", "SPECIES", 29, 35], ["patients", "SPECIES", 387, 395], ["HVA", "TEST", 137, 140], ["their serum", "TEST", 154, 165], ["The AMM profiles", "TEST", 226, 242], ["AMM in serum", "TEST", 278, 290], ["the violation", "PROBLEM", 308, 321], ["nitrogen oxide", "TREATMENT", 429, 443], ["sepsis", "PROBLEM", 588, 594], ["gut", "ANATOMY", 246, 249], ["violation", "OBSERVATION", 312, 321], ["loss", "OBSERVATION_MODIFIER", 326, 330], ["biodiversity", "OBSERVATION_MODIFIER", 334, 346], ["gut", "ANATOMY", 354, 357], ["sepsis", "OBSERVATION", 588, 594]]], ["Methods: With the permission of the Ethics Committee included the 200 full-term newborns with respiratory diseases on a ventilator, retrospectively divided into two groups (I, n=46 -sepsis 4-5 days; II, n=154 without sepsis), at 1, 3-5, 20 days was studied by ELISA the plasma concentration of NO, NOS-2, NOS-3, ADMA (Multilabel Coulter Victor-21420, Finland).", [["respiratory", "ANATOMY", 94, 105], ["plasma", "ANATOMY", 270, 276], ["respiratory diseases", "DISEASE", 94, 114], ["sepsis", "DISEASE", 182, 188], ["sepsis", "DISEASE", 217, 223], ["NO", "CHEMICAL", 294, 296], ["ADMA", "CHEMICAL", 312, 316], ["NO", "CHEMICAL", 294, 296], ["newborns", "ORGANISM", 80, 88], ["plasma", "ORGANISM_SUBSTANCE", 270, 276], ["NO", "SIMPLE_CHEMICAL", 294, 296], ["NOS-2", "GENE_OR_GENE_PRODUCT", 298, 303], ["NOS-3", "GENE_OR_GENE_PRODUCT", 305, 310], ["ADMA", "SIMPLE_CHEMICAL", 312, 316], ["NOS", "PROTEIN", 298, 301], ["NOS", "PROTEIN", 305, 308], ["respiratory diseases", "PROBLEM", 94, 114], ["a ventilator", "TREATMENT", 118, 130], ["sepsis", "PROBLEM", 182, 188], ["sepsis", "PROBLEM", 217, 223], ["ELISA the plasma concentration", "TEST", 260, 290], ["NOS", "TEST", 298, 301], ["NOS", "TEST", 305, 308], ["ADMA", "TEST", 312, 316], ["respiratory diseases", "OBSERVATION", 94, 114]]], ["To select points \"Cut-Off\" used the method of ROC-Lines.Introduction:Results: The statistical power of the study was 86.7% (\u00ce\u00b1<0.05).", [["the study", "TEST", 103, 112]]], ["At admission in patients of groups I and II decrease the concentration of NO and increased ADMA in plasma (p<0.05) relative to healthy newborns.", [["plasma", "ANATOMY", 99, 105], ["NO", "CHEMICAL", 74, 76], ["ADMA", "CHEMICAL", 91, 95], ["NO", "CHEMICAL", 74, 76], ["patients", "ORGANISM", 16, 24], ["NO", "SIMPLE_CHEMICAL", 74, 76], ["ADMA", "SIMPLE_CHEMICAL", 91, 95], ["plasma", "ORGANISM_SUBSTANCE", 99, 105], ["newborns", "ORGANISM", 135, 143], ["patients", "SPECIES", 16, 24], ["increased ADMA in plasma", "PROBLEM", 81, 105], ["increased", "OBSERVATION_MODIFIER", 81, 90], ["ADMA", "OBSERVATION", 91, 95]]], ["After 3-5 days, relatively in patients of groups Introduction: Sepsis-associated disseminated intravascular coagulation (SAC) is associated with decreased platelet counts and formation.", [["intravascular", "ANATOMY", 94, 107], ["platelet", "ANATOMY", 155, 163], ["Sepsis", "DISEASE", 63, 69], ["disseminated intravascular coagulation", "DISEASE", 81, 119], ["SAC", "DISEASE", 121, 124], ["patients", "ORGANISM", 30, 38], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 94, 107], ["platelet", "CELL", 155, 163], ["patients", "SPECIES", 30, 38], ["Sepsis", "PROBLEM", 63, 69], ["disseminated intravascular coagulation", "PROBLEM", 81, 119], ["decreased platelet counts", "PROBLEM", 145, 170], ["Sepsis", "OBSERVATION", 63, 69], ["disseminated", "OBSERVATION_MODIFIER", 81, 93], ["intravascular coagulation", "OBSERVATION", 94, 119], ["decreased", "OBSERVATION_MODIFIER", 145, 154], ["platelet counts", "OBSERVATION", 155, 170]]], ["The widespread activation of platelets contribute to vascular occlusions, fibrin deposition, multi-organ dysfunction, contributing to a two-fold increase in mortality.", [["platelets", "ANATOMY", 29, 38], ["vascular", "ANATOMY", 53, 61], ["multi-organ", "ANATOMY", 93, 104], ["vascular occlusions", "DISEASE", 53, 72], ["multi-organ dysfunction", "DISEASE", 93, 116], ["platelets", "CELL", 29, 38], ["vascular", "MULTI-TISSUE_STRUCTURE", 53, 61], ["fibrin", "GENE_OR_GENE_PRODUCT", 74, 80], ["platelets", "CELL_TYPE", 29, 38], ["The widespread activation of platelets", "PROBLEM", 0, 38], ["vascular occlusions", "PROBLEM", 53, 72], ["fibrin deposition", "PROBLEM", 74, 91], ["multi-organ dysfunction", "PROBLEM", 93, 116], ["a two-fold increase in mortality", "PROBLEM", 134, 166], ["widespread", "OBSERVATION_MODIFIER", 4, 14], ["activation", "OBSERVATION", 15, 25], ["platelets", "OBSERVATION", 29, 38], ["vascular", "ANATOMY", 53, 61], ["occlusions", "OBSERVATION", 62, 72], ["fibrin deposition", "OBSERVATION", 74, 91], ["multi-organ dysfunction", "OBSERVATION", 93, 116], ["two-fold", "OBSERVATION_MODIFIER", 136, 144], ["increase", "OBSERVATION_MODIFIER", 145, 153], ["mortality", "OBSERVATION", 157, 166]]], ["The purpose was to measure markers of platelet function in the plasma of patients with clinically established SAC and to determine association to disease severity and outcome.Introduction:Methods: Plasma samples from 103 adult intensive care unit (ICU) patients with sepsis and suspected SAC were collected at baseline and on days 4 and 8.", [["platelet", "ANATOMY", 38, 46], ["plasma", "ANATOMY", 63, 69], ["Plasma samples", "ANATOMY", 197, 211], ["sepsis", "DISEASE", 267, 273], ["platelet", "CELL", 38, 46], ["plasma", "ORGANISM_SUBSTANCE", 63, 69], ["patients", "ORGANISM", 73, 81], ["patients", "ORGANISM", 253, 261], ["patients", "SPECIES", 73, 81], ["patients", "SPECIES", 253, 261], ["platelet function", "TEST", 38, 55], ["disease severity", "PROBLEM", 146, 162], ["sepsis", "PROBLEM", 267, 273], ["suspected SAC", "PROBLEM", 278, 291], ["sepsis", "OBSERVATION", 267, 273], ["SAC", "ANATOMY", 288, 291]]], ["DIC scores were calculated using platelet count, D-Dimer, INR, and fibrinogen.", [["platelet", "ANATOMY", 33, 41], ["platelet", "CELL", 33, 41], ["D-Dimer", "SIMPLE_CHEMICAL", 49, 56], ["INR", "SIMPLE_CHEMICAL", 58, 61], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 67, 77], ["Dimer", "PROTEIN", 51, 56], ["INR", "PROTEIN", 58, 61], ["fibrinogen", "PROTEIN", 67, 77], ["DIC scores", "TEST", 0, 10], ["platelet count", "TEST", 33, 47], ["D-Dimer", "TEST", 49, 56], ["INR", "TEST", 58, 61], ["fibrinogen", "TEST", 67, 77]]], ["Patients were categorized as having no DIC, non-overt DIC, or overt DIC.", [["DIC", "DISEASE", 39, 42], ["DIC", "DISEASE", 54, 57], ["DIC", "DISEASE", 68, 71], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["DIC", "PROBLEM", 39, 42], ["non-overt DIC", "PROBLEM", 44, 57], ["overt DIC", "PROBLEM", 62, 71]]], ["Plasma levels of CD40L, von Willebrand Factor (vWF), platelet factor-4 (PF-4), and microparticles (MP) were quantified using commercially available ELISA methods.Introduction:Results: Markers of platelet activation were significantly elevated in patients with sepsis alone and with suspected DIC compared to normal healthy individuals on ICU day 0 (p<0.001).", [["platelet", "ANATOMY", 195, 203], ["sepsis", "DISEASE", 260, 266], ["DIC", "DISEASE", 292, 295], ["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["CD40L", "GENE_OR_GENE_PRODUCT", 17, 22], ["von Willebrand Factor", "GENE_OR_GENE_PRODUCT", 24, 45], ["vWF", "GENE_OR_GENE_PRODUCT", 47, 50], ["platelet factor-4", "GENE_OR_GENE_PRODUCT", 53, 70], ["PF-4", "GENE_OR_GENE_PRODUCT", 72, 76], ["microparticles", "GENE_OR_GENE_PRODUCT", 83, 97], ["MP", "GENE_OR_GENE_PRODUCT", 99, 101], ["platelet", "CELL", 195, 203], ["patients", "ORGANISM", 246, 254], ["CD40L", "PROTEIN", 17, 22], ["von Willebrand Factor", "PROTEIN", 24, 45], ["vWF", "PROTEIN", 47, 50], ["platelet factor-4", "PROTEIN", 53, 70], ["PF", "PROTEIN", 72, 74], ["patients", "SPECIES", 246, 254], ["Plasma levels", "TEST", 0, 13], ["CD40L", "TEST", 17, 22], ["von Willebrand Factor (vWF)", "TEST", 24, 51], ["platelet factor", "TEST", 53, 68], ["PF", "TEST", 72, 74], ["platelet activation", "TEST", 195, 214], ["significantly elevated", "PROBLEM", 220, 242], ["sepsis", "PROBLEM", 260, 266], ["suspected DIC", "PROBLEM", 282, 295], ["CD40L", "ANATOMY", 17, 22], ["sepsis", "OBSERVATION", 260, 266]]], ["Levels of platelet-associated biomarkers were compared between survivors and non-survivors.", [["platelet", "ANATOMY", 10, 18], ["platelet", "CELL", 10, 18], ["Levels", "TEST", 0, 6], ["platelet", "TEST", 10, 18], ["biomarkers", "TEST", 30, 40], ["non-survivors", "PROBLEM", 77, 90]]], ["PF-4 was significantly decreased in non-survivors compared to survivors (p = 0.0156).", [["PF-4", "GENE_OR_GENE_PRODUCT", 0, 4], ["PF", "TEST", 0, 2], ["decreased", "OBSERVATION_MODIFIER", 23, 32]]], ["Patients were stratified based on platelet count and levels of markers were compared between groups.Introduction:CD40L, vWF, PF4, and MP showed significant variation based on platelet count, with all markers exhibiting stepwise elevation with increasing platelet count.Introduction:Conclusions: Markers of platelet activation were significantly elevated in patients with SAC compared to healthy individuals.", [["platelet", "ANATOMY", 34, 42], ["platelet", "ANATOMY", 175, 183], ["platelet", "ANATOMY", 254, 262], ["platelet", "ANATOMY", 306, 314], ["SAC", "CHEMICAL", 371, 374], ["Patients", "ORGANISM", 0, 8], ["platelet", "CELL", 34, 42], ["CD40L", "GENE_OR_GENE_PRODUCT", 113, 118], ["vWF", "GENE_OR_GENE_PRODUCT", 120, 123], ["PF4", "GENE_OR_GENE_PRODUCT", 125, 128], ["MP", "GENE_OR_GENE_PRODUCT", 134, 136], ["platelet", "CELL", 175, 183], ["platelet", "CELL", 254, 262], ["platelet", "CELL", 306, 314], ["patients", "ORGANISM", 357, 365], ["CD40L", "PROTEIN", 113, 118], ["WF", "PROTEIN", 121, 123], ["PF4", "PROTEIN", 125, 128], ["MP", "PROTEIN", 134, 136], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 357, 365], ["platelet count", "TEST", 34, 48], ["levels of markers", "TEST", 53, 70], ["PF4", "TEST", 125, 128], ["MP", "TEST", 134, 136], ["significant variation", "PROBLEM", 144, 165], ["platelet count", "TEST", 175, 189], ["all markers", "TEST", 196, 207], ["stepwise elevation", "PROBLEM", 219, 237], ["increasing platelet count", "PROBLEM", 243, 268], ["platelet activation", "TEST", 306, 325], ["significantly elevated", "PROBLEM", 331, 353], ["SAC", "PROBLEM", 371, 374], ["significant", "OBSERVATION", 144, 155], ["platelet count", "OBSERVATION", 175, 189], ["increasing", "OBSERVATION_MODIFIER", 243, 253], ["platelet count", "OBSERVATION", 254, 268], ["SAC", "ANATOMY", 371, 374]]], ["PF4 levels showed significant difference based on DIC score or mortality, and differentiated the non-survivors compared to survivors.", [["PF4", "GENE_OR_GENE_PRODUCT", 0, 3], ["PF4", "PROTEIN", 0, 3], ["PF4 levels", "TEST", 0, 10], ["significant difference", "PROBLEM", 18, 40], ["DIC score", "TEST", 50, 59], ["significant", "OBSERVATION_MODIFIER", 18, 29], ["difference", "OBSERVATION_MODIFIER", 30, 40]]], ["CD40L, vWF, PF4, and MP showed significant association with platelet count, increasing in a stepwise manner with increases in platelet count (Table 1) .P024Prognostic value of mean platelet volume in septic patients: a prospective study A Chaari King Hamad University Hospital, Bussaiteen, Bahrain Critical Care 2018, 22(Suppl 1):P024P024Introduction: Mean Platelet Volume (MPV) has been reported as a valuable marker of inflammatory diseases.", [["platelet", "ANATOMY", 60, 68], ["platelet", "ANATOMY", 126, 134], ["platelet", "ANATOMY", 181, 189], ["Platelet", "ANATOMY", 357, 365], ["septic", "DISEASE", 200, 206], ["CD40L", "GENE_OR_GENE_PRODUCT", 0, 5], ["vWF", "GENE_OR_GENE_PRODUCT", 7, 10], ["PF4", "GENE_OR_GENE_PRODUCT", 12, 15], ["MP", "GENE_OR_GENE_PRODUCT", 21, 23], ["platelet", "CELL", 60, 68], ["platelet", "CELL", 126, 134], ["platelet", "CELL", 181, 189], ["patients", "ORGANISM", 207, 215], ["CD40L", "PROTEIN", 0, 5], ["WF", "PROTEIN", 8, 10], ["PF4", "PROTEIN", 12, 15], ["MP", "PROTEIN", 21, 23], ["patients", "SPECIES", 207, 215], ["PF4", "TEST", 12, 15], ["MP", "TEST", 21, 23], ["platelet count", "TEST", 60, 74], ["platelet count", "TEST", 126, 140], ["Prognostic value", "TEST", 156, 172], ["mean platelet volume", "TEST", 176, 196], ["Mean Platelet Volume", "TEST", 352, 372], ["MPV", "TEST", 374, 377], ["inflammatory diseases", "PROBLEM", 421, 442], ["platelet count", "OBSERVATION", 60, 74], ["increases", "OBSERVATION_MODIFIER", 113, 122], ["platelet count", "OBSERVATION", 126, 140], ["septic", "OBSERVATION_MODIFIER", 200, 206], ["inflammatory", "OBSERVATION", 421, 433]]], ["The aim of the current study is to assess the prognostic value of MPV in septic patients.", [["septic", "DISEASE", 73, 79], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["the current study", "TEST", 11, 28], ["septic patients", "OBSERVATION", 73, 88]]], ["Methods: Prospective study including all patients admitted to the intensive care unit (ICU) with sepsis or septic shock.", [["sepsis", "DISEASE", 97, 103], ["septic shock", "DISEASE", 107, 119], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["Prospective study", "TEST", 9, 26], ["sepsis", "PROBLEM", 97, 103], ["septic shock", "PROBLEM", 107, 119], ["sepsis", "OBSERVATION", 97, 103], ["septic shock", "OBSERVATION", 107, 119]]], ["Demographic, clinical and laboratory data were collected.", [["laboratory data", "TEST", 26, 41]]], ["The MPV was checked on admission and on day 3.", [["MPV", "PROTEIN", 4, 7], ["The MPV", "TEST", 0, 7], ["MPV", "ANATOMY", 4, 7]]], ["[3] [4] [5] [6] [7] [8] [9] [10] [11] [12] days in survivors and 8.5 [3.5-12] days in non-survivors (p=0.623).P024Conclusions: The decrease of the platelet count but not the increase of the MPV was associated with increased mortality in critically-ill septic patients.P025Endotoxin activity assay levels measured within 24 hours after ICU admission affected patients' severity assessments A Kodaira 1 , T Ikeda 2 , S Ono 2 , S Suda 2 , T Nagura 2 1 Tokyo Medical University, Tokyo, Japan, 2 Introduction: Sepsis profoundly alters immune homeostasis by inducing first a systemic pro-inflammatory, then an anti-inflammatory state.", [["platelet", "ANATOMY", 147, 155], ["critically-ill", "DISEASE", 237, 251], ["septic", "DISEASE", 252, 258], ["Sepsis", "DISEASE", 505, 511], ["platelet", "CELL", 147, 155], ["patients", "ORGANISM", 259, 267], ["P025", "GENE_OR_GENE_PRODUCT", 268, 272], ["Endotoxin", "GENE_OR_GENE_PRODUCT", 272, 281], ["patients", "ORGANISM", 358, 366], ["P025", "PROTEIN", 268, 272], ["patients", "SPECIES", 259, 267], ["patients", "SPECIES", 358, 366], ["survivors", "TEST", 51, 60], ["the platelet count", "TEST", 143, 161], ["the MPV", "TEST", 186, 193], ["increased mortality", "PROBLEM", 214, 233], ["critically-ill septic patients", "PROBLEM", 237, 267], ["Endotoxin activity assay levels", "TEST", 272, 303], ["severity assessments", "TEST", 368, 388], ["A Kodaira", "TREATMENT", 389, 398], ["T Ikeda", "TREATMENT", 403, 410], ["Sepsis", "PROBLEM", 505, 511], ["immune homeostasis", "PROBLEM", 530, 548], ["a systemic pro-inflammatory", "PROBLEM", 567, 594], ["an anti-inflammatory state", "TREATMENT", 601, 627], ["decrease", "OBSERVATION_MODIFIER", 131, 139], ["platelet count", "OBSERVATION", 147, 161], ["increased", "OBSERVATION_MODIFIER", 214, 223], ["mortality", "OBSERVATION", 224, 233], ["Sepsis", "OBSERVATION", 505, 511]]], ["We evaluate the prognostic value of ex vivo lipopolysaccharide (LPS) stimulation of whole blood in septic patients, at day 1 and 7 after intensive care unit (ICU) admission.P025Methods: This prospective cohort study included patients with severe sepsis or septic shock admitted to a surgical ICU of a university hospital.", [["whole blood", "ANATOMY", 84, 95], ["lipopolysaccharide", "CHEMICAL", 44, 62], ["LPS", "CHEMICAL", 64, 67], ["septic", "DISEASE", 99, 105], ["sepsis", "DISEASE", 246, 252], ["septic shock", "DISEASE", 256, 268], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 44, 62], ["LPS", "SIMPLE_CHEMICAL", 64, 67], ["blood", "ORGANISM_SUBSTANCE", 90, 95], ["patients", "ORGANISM", 106, 114], ["patients", "ORGANISM", 225, 233], ["patients", "SPECIES", 106, 114], ["patients", "SPECIES", 225, 233], ["ex vivo lipopolysaccharide (LPS)", "TREATMENT", 36, 68], ["whole blood in septic patients", "PROBLEM", 84, 114], ["This prospective cohort study", "TEST", 186, 215], ["severe sepsis", "PROBLEM", 239, 252], ["septic shock", "PROBLEM", 256, 268], ["septic", "OBSERVATION", 99, 105], ["severe", "OBSERVATION_MODIFIER", 239, 245], ["sepsis", "OBSERVATION", 246, 252], ["septic shock", "OBSERVATION", 256, 268]]], ["Blood was drawn on day 1 and day 7, and stimulated ex vivo with LPS for 24 hours.", [["Blood", "ANATOMY", 0, 5], ["LPS", "CHEMICAL", 64, 67], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["LPS", "SIMPLE_CHEMICAL", 64, 67], ["Blood", "TEST", 0, 5]]], ["Tumor necrosis factor alpha (TNF), interleukin (IL) 1, IL6 and IL10 were measured.", [["necrosis", "DISEASE", 6, 14], ["Tumor necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 0, 27], ["TNF", "GENE_OR_GENE_PRODUCT", 29, 32], ["interleukin (IL) 1", "GENE_OR_GENE_PRODUCT", 35, 53], ["IL6", "GENE_OR_GENE_PRODUCT", 55, 58], ["IL10", "GENE_OR_GENE_PRODUCT", 63, 67], ["Tumor necrosis factor alpha", "PROTEIN", 0, 27], ["TNF", "PROTEIN", 29, 32], ["interleukin (IL) 1", "PROTEIN", 35, 53], ["IL6", "PROTEIN", 55, 58], ["IL10", "PROTEIN", 63, 67], ["Tumor necrosis factor alpha", "PROBLEM", 0, 27], ["TNF", "TEST", 29, 32], ["interleukin (IL)", "TREATMENT", 35, 51], ["IL6 and IL10", "TREATMENT", 55, 67], ["necrosis", "OBSERVATION", 6, 14], ["alpha", "OBSERVATION_MODIFIER", 22, 27]]], ["Twenty-three healthy adults served as controls.", [["adults", "ORGANISM", 21, 27]]], ["Outcomes were ventilator and ICU-free days, SOFA score at day 1 and 7, and need for dialysis during the course of sepsis.", [["sepsis", "DISEASE", 114, 120], ["ventilator", "TREATMENT", 14, 24], ["SOFA score", "TEST", 44, 54], ["dialysis", "TREATMENT", 84, 92], ["sepsis", "PROBLEM", 114, 120], ["sepsis", "OBSERVATION", 114, 120]]], ["Results: Forty-nine patients were included (mean age 62 \u00b1 15 years).", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28]]], ["The blood of septic patients was less responsive to ex vivo stimulation with LPS than that of healthy controls, as demonstrated by lower TNF, IL1, IL6 and IL10 release ( Fig. 1 ).", [["blood", "ANATOMY", 4, 9], ["septic", "DISEASE", 13, 19], ["LPS", "CHEMICAL", 77, 80], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["patients", "ORGANISM", 20, 28], ["LPS", "SIMPLE_CHEMICAL", 77, 80], ["TNF", "GENE_OR_GENE_PRODUCT", 137, 140], ["IL1", "GENE_OR_GENE_PRODUCT", 142, 145], ["IL6", "GENE_OR_GENE_PRODUCT", 147, 150], ["IL10", "GENE_OR_GENE_PRODUCT", 155, 159], ["TNF", "PROTEIN", 137, 140], ["IL6", "PROTEIN", 147, 150], ["IL10", "PROTEIN", 155, 159], ["patients", "SPECIES", 20, 28], ["septic patients", "PROBLEM", 13, 28], ["ex vivo stimulation", "TREATMENT", 52, 71], ["LPS", "TREATMENT", 77, 80], ["IL1, IL6 and IL10 release", "TREATMENT", 142, 167], ["septic", "OBSERVATION", 13, 19], ["lower TNF", "ANATOMY", 131, 140]]], ["At day 1, patients above the 50th percentile of IL10 release had significantly fewer ventilator and ICU-free days than those in the lower 50th percentile (Fig. 2) .", [["patients", "ORGANISM", 10, 18], ["IL10", "GENE_OR_GENE_PRODUCT", 48, 52], ["IL10", "PROTEIN", 48, 52], ["patients", "SPECIES", 10, 18], ["IL10 release", "TREATMENT", 48, 60]]], ["In contrast, patients in whom IL10 release increased between day 1 and day 7 had significantly lower SOFA scores at day 1 and 7 and need for dialysis, and more ICU-free days than patients in whom IL10 release decreased (Table 1) .P025Conclusions: Greater LPS-stimulated IL10 release in septic patients at day 1 was associated with poorer clinical outcomes and may reflect the severity of the forthcoming immunoparalysis.", [["LPS", "CHEMICAL", 255, 258], ["septic", "DISEASE", 286, 292], ["immunoparalysis", "DISEASE", 404, 419], ["patients", "ORGANISM", 13, 21], ["IL10", "GENE_OR_GENE_PRODUCT", 30, 34], ["patients", "ORGANISM", 179, 187], ["IL10", "GENE_OR_GENE_PRODUCT", 196, 200], ["LPS", "SIMPLE_CHEMICAL", 255, 258], ["IL10", "GENE_OR_GENE_PRODUCT", 270, 274], ["patients", "ORGANISM", 293, 301], ["IL10", "PROTEIN", 30, 34], ["IL10", "PROTEIN", 196, 200], ["IL10", "PROTEIN", 270, 274], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 179, 187], ["patients", "SPECIES", 293, 301], ["significantly lower SOFA scores", "PROBLEM", 81, 112], ["dialysis", "TREATMENT", 141, 149], ["Greater LPS", "TREATMENT", 247, 258], ["septic patients", "PROBLEM", 286, 301], ["the forthcoming immunoparalysis", "PROBLEM", 388, 419], ["septic", "OBSERVATION_MODIFIER", 286, 292]]], ["However, an increase in IL10 release between day 1 and day 7 was associated with favorable outcomes, perhaps signaling immune restoration.", [["IL10", "GENE_OR_GENE_PRODUCT", 24, 28], ["IL10", "PROTEIN", 24, 28], ["an increase in IL10 release", "TREATMENT", 9, 36], ["signaling immune restoration", "PROBLEM", 109, 137], ["increase", "OBSERVATION_MODIFIER", 12, 20], ["immune restoration", "OBSERVATION", 119, 137]]], ["Introduction: Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery (HIPEC-CRS) is a curative treatment modality for peritoneal carcinomatosis.", [["Intraperitoneal", "ANATOMY", 27, 42], ["peritoneal carcinomatosis", "ANATOMY", 132, 157], ["peritoneal carcinomatosis", "DISEASE", 132, 157], ["peritoneal carcinomatosis", "CANCER", 132, 157], ["Hyperthermic Intraperitoneal Chemotherapy", "TREATMENT", 14, 55], ["Cytoreductive Surgery", "TREATMENT", 61, 82], ["HIPEC-CRS", "TREATMENT", 84, 93], ["a curative treatment modality", "TREATMENT", 98, 127], ["peritoneal carcinomatosis", "PROBLEM", 132, 157], ["peritoneal", "ANATOMY", 132, 142], ["carcinomatosis", "OBSERVATION", 143, 157]]], ["Extensive debulking surgery, peritoneal stripping and multiple visceral resections followed by intraperitoneal installation of heated high-dose chemotherapeutic agents, a process leads to a 'high-inflammatory' syndrome.", [["peritoneal", "ANATOMY", 29, 39], ["visceral", "ANATOMY", 63, 71], ["intraperitoneal", "ANATOMY", 95, 110], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 29, 39], ["visceral", "ORGAN", 63, 71], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 95, 110], ["Extensive debulking surgery", "TREATMENT", 0, 27], ["peritoneal stripping", "TREATMENT", 29, 49], ["multiple visceral resections", "TREATMENT", 54, 82], ["intraperitoneal installation", "TREATMENT", 95, 123], ["heated high-dose chemotherapeutic agents", "TREATMENT", 127, 167], ["a 'high-inflammatory' syndrome", "PROBLEM", 188, 218], ["debulking", "OBSERVATION", 10, 19], ["peritoneal", "ANATOMY", 29, 39], ["stripping", "OBSERVATION", 40, 49], ["multiple", "OBSERVATION_MODIFIER", 54, 62], ["visceral", "ANATOMY", 63, 71], ["resections", "OBSERVATION", 72, 82], ["high-dose", "OBSERVATION_MODIFIER", 134, 143], ["chemotherapeutic agents", "OBSERVATION", 144, 167], ["inflammatory' syndrome", "OBSERVATION", 196, 218]]], ["Serum procalcitonin (PCT), a biomarker for bacterial sepsis, in the heightened inflammatory state after HIPEC-CRS might be of limited utility.", [["Serum", "ANATOMY", 0, 5], ["bacterial sepsis", "DISEASE", 43, 59], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 6, 19], ["PCT", "GENE_OR_GENE_PRODUCT", 21, 24], ["Serum procalcitonin", "PROTEIN", 0, 19], ["PCT", "PROTEIN", 21, 24], ["Serum procalcitonin", "TEST", 0, 19], ["PCT", "TEST", 21, 24], ["a biomarker", "TEST", 27, 38], ["bacterial sepsis", "PROBLEM", 43, 59], ["the heightened inflammatory state", "PROBLEM", 64, 97], ["HIPEC", "TREATMENT", 104, 109], ["CRS", "PROBLEM", 110, 113], ["bacterial", "OBSERVATION_MODIFIER", 43, 52], ["sepsis", "OBSERVATION", 53, 59], ["heightened", "OBSERVATION_MODIFIER", 68, 78], ["inflammatory", "OBSERVATION_MODIFIER", 79, 91]]], ["Our aim is to determine the trends of PCT in the early postoperative phase of HIPEC-CRS and to identify trends in patients with and without bacterial sepsis Methods: In a case-control design, we reviewed all patients undergoing HIPEC-CRS over a 24-month period (2015) (2016) (2017) .", [["CRS", "DISEASE", 84, 87], ["bacterial sepsis", "DISEASE", 140, 156], ["patients", "ORGANISM", 114, 122], ["patients", "ORGANISM", 208, 216], ["patients", "SPECIES", 114, 122], ["patients", "SPECIES", 208, 216], ["PCT", "TEST", 38, 41], ["HIPEC", "TREATMENT", 78, 83], ["CRS", "PROBLEM", 84, 87], ["bacterial sepsis", "PROBLEM", 140, 156], ["HIPEC", "TREATMENT", 228, 233], ["CRS", "TREATMENT", 234, 237], ["sepsis", "OBSERVATION", 150, 156]]], ["Patients were divided into 2 groups based on whether they developed bacterial sepsis in the first 5 days after surgery (infected v/s non-infected).", [["bacterial sepsis", "DISEASE", 68, 84], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["bacterial sepsis", "PROBLEM", 68, 84], ["surgery", "TREATMENT", 111, 118], ["infected v/s non-infected", "PROBLEM", 120, 145], ["bacterial", "OBSERVATION_MODIFIER", 68, 77], ["sepsis", "OBSERVATION", 78, 84]]], ["Two-tailed nonparametric tests were performed and considered significant at p values of less than 0.05 Results: 82 patients' data was analyzed.", [["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["Two-tailed nonparametric tests", "TEST", 0, 30], ["patients' data", "TEST", 115, 129]]], ["Infections developed in 16% (13 patients) with Escherichia coli as the predominant pathogen isolated (36% isolates).", [["Infections", "DISEASE", 0, 10], ["patients", "ORGANISM", 32, 40], ["Escherichia coli", "ORGANISM", 47, 63], ["patients", "SPECIES", 32, 40], ["Escherichia coli", "SPECIES", 47, 63], ["Escherichia coli", "SPECIES", 47, 63], ["Infections", "PROBLEM", 0, 10], ["Escherichia coli", "PROBLEM", 47, 63], ["the predominant pathogen", "PROBLEM", 67, 91], ["Escherichia coli", "OBSERVATION", 47, 63]]], ["PCT levels (ngm/ml) were elevated postoperatively in both infected and non-infected patients; Day 1 infected 0.97 (IQR 0.", [["PCT", "GENE_OR_GENE_PRODUCT", 0, 3], ["patients", "ORGANISM", 84, 92], ["PCT", "PROTEIN", 0, 3], ["patients", "SPECIES", 84, 92], ["PCT levels", "TEST", 0, 10], ["elevated", "PROBLEM", 25, 33], ["infected", "OBSERVATION_MODIFIER", 58, 66]]], ["5 Introduction: Early outcome in cardiac surgery has been an area of growing interest where the given risks raise several predictive models for assessment of postoperative outcome [1] .", [["cardiac", "ANATOMY", 33, 40], ["cardiac", "ORGAN", 33, 40], ["cardiac surgery", "TREATMENT", 33, 48], ["assessment", "TEST", 144, 154]]], ["Procacitonin (PCT) emerges as a possible predictive tool in cardiothoracic intensive care unit (CTICU).We aim at testing the predictive power of PCT for early morbidity, prolonged ventilation, ICU and hospital stay, in patients developing early fever after cardiac surgery Methods: A retrospective descriptive study done in tertiary cardiac center, enrolling patients who stayed for more than 24 hours post-operatively in the CTICU Risk stratification included additive Euro score and PCT immunoluminometricaly prior to surgery and every 48 hours in response to onset of fever.", [["cardiac", "ANATOMY", 257, 264], ["Procacitonin", "CHEMICAL", 0, 12], ["PCT", "CHEMICAL", 14, 17], ["fever", "DISEASE", 245, 250], ["fever", "DISEASE", 571, 576], ["Procacitonin", "CHEMICAL", 0, 12], ["PCT", "CHEMICAL", 14, 17], ["Procacitonin", "SIMPLE_CHEMICAL", 0, 12], ["patients", "ORGANISM", 219, 227], ["patients", "ORGANISM", 359, 367], ["patients", "SPECIES", 219, 227], ["patients", "SPECIES", 359, 367], ["Procacitonin (PCT)", "TREATMENT", 0, 18], ["PCT", "TEST", 145, 148], ["early morbidity", "PROBLEM", 153, 168], ["prolonged ventilation", "TREATMENT", 170, 191], ["early fever", "PROBLEM", 239, 250], ["cardiac surgery", "TREATMENT", 257, 272], ["A retrospective descriptive study", "TEST", 282, 315], ["PCT immunoluminometricaly", "TREATMENT", 485, 510], ["surgery", "TREATMENT", 520, 527], ["fever", "PROBLEM", 571, 576], ["early", "OBSERVATION_MODIFIER", 239, 244], ["fever", "OBSERVATION", 245, 250], ["cardiac", "ANATOMY", 257, 264], ["surgery", "OBSERVATION", 265, 272], ["fever", "OBSERVATION", 571, 576]]], ["Results: We screened 501 consecutive patients who underwent open heart cardiac, of which 119 patients were enrolled in the study.", [["heart", "ANATOMY", 65, 70], ["patients", "ORGANISM", 37, 45], ["heart", "ORGAN", 65, 70], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 93, 101], ["open heart cardiac", "TEST", 60, 78], ["the study", "TEST", 119, 128], ["heart", "ANATOMY", 65, 70], ["cardiac", "ANATOMY", 71, 78]]], ["Patients were divided into two groups based on the level of PCT, those with value > 2 ng/ml (Group 1) and those with level < 2 ng/ml (Group 2).", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["PCT", "TEST", 60, 63], ["value", "TEST", 76, 81]]], ["Patients in group 1 as compared to Group 2, over the postoperative course was associated with prolonged ICU stay (P=0.04), length of mechanical ventilation (P=0.05), length of hospitalization (p=0.05), acute kidney injury (P=0.04) and culture positivity (P=0.02).", [["kidney", "ANATOMY", 208, 214], ["acute kidney injury", "DISEASE", 202, 221], ["Patients", "ORGANISM", 0, 8], ["kidney", "ORGAN", 208, 214], ["Patients", "SPECIES", 0, 8], ["mechanical ventilation", "TREATMENT", 133, 155], ["acute kidney injury", "PROBLEM", 202, 221], ["P", "TEST", 223, 224], ["culture positivity", "TEST", 235, 253], ["P", "TEST", 255, 256], ["mechanical ventilation", "OBSERVATION", 133, 155], ["acute", "OBSERVATION_MODIFIER", 202, 207], ["kidney", "ANATOMY", 208, 214], ["injury", "OBSERVATION", 215, 221]]], ["Multivariate analysis showed that PCT >2ng/ml was was significantly associated with positive cultures. (p=0.023) Conclusions: A rise of serum PCT carries the signals of early ICU morbidity and lengths of ventilation, ICU stay and hospital stay Methods: 42 patients aged 153 (44-252) days (4-360 days) underwent cardiac surgery with cardiopulmonary bypass for severe congenital heart disease.", [["serum", "ANATOMY", 136, 141], ["cardiac", "ANATOMY", 311, 318], ["cardiopulmonary", "ANATOMY", 332, 347], ["heart", "ANATOMY", 377, 382], ["congenital heart disease", "DISEASE", 366, 390], ["serum", "ORGANISM_SUBSTANCE", 136, 141], ["patients", "ORGANISM", 256, 264], ["cardiac", "ORGAN", 311, 318], ["heart", "ORGAN", 377, 382], ["patients", "SPECIES", 256, 264], ["Multivariate analysis", "TEST", 0, 21], ["PCT", "TEST", 34, 37], ["positive cultures", "PROBLEM", 84, 101], ["serum PCT", "TEST", 136, 145], ["ventilation", "TREATMENT", 204, 215], ["cardiac surgery", "TREATMENT", 311, 326], ["cardiopulmonary bypass", "TREATMENT", 332, 354], ["severe congenital heart disease", "PROBLEM", 359, 390], ["cardiac", "ANATOMY", 311, 318], ["surgery", "OBSERVATION", 319, 326], ["cardiopulmonary", "ANATOMY", 332, 347], ["bypass", "OBSERVATION", 348, 354], ["severe", "OBSERVATION_MODIFIER", 359, 365], ["congenital", "OBSERVATION", 366, 376], ["heart", "ANATOMY", 377, 382], ["disease", "OBSERVATION", 383, 390]]], ["In the dynamics levels of PCT, MR-proADM, CT-proAVP and MR-proANP were measured before surgery and on the 1, 2, 3 and 6 days after the operation with the Kryptor compact plus analyzer.", [["PCT", "SIMPLE_CHEMICAL", 26, 29], ["MR-proADM", "SIMPLE_CHEMICAL", 31, 40], ["CT-proAVP", "SIMPLE_CHEMICAL", 42, 51], ["MR-proANP", "SIMPLE_CHEMICAL", 56, 65], ["PCT", "PROTEIN", 26, 29], ["MR", "PROTEIN", 31, 33], ["proADM", "PROTEIN", 34, 40], ["CT", "PROTEIN", 42, 44], ["proAVP", "PROTEIN", 45, 51], ["MR", "PROTEIN", 56, 58], ["proANP", "PROTEIN", 59, 65], ["PCT", "TEST", 26, 29], ["MR", "TEST", 31, 33], ["CT", "TEST", 42, 44], ["MR", "TEST", 56, 58], ["proANP", "TEST", 59, 65], ["surgery", "TREATMENT", 87, 94], ["the operation", "TREATMENT", 131, 144]]], ["The Mann-Whitney U-test was used to compare the data.", [["The Mann-Whitney U-test", "TEST", 0, 23], ["the data", "TEST", 44, 52]]], ["Values of p <0.05 were statistically significant.P025Results: 24 patients (57%) required ALV for more than 72 hours.", [["patients", "ORGANISM", 65, 73], ["ALV", "ORGANISM", 89, 92], ["patients", "SPECIES", 65, 73], ["Values", "TEST", 0, 6], ["p", "TEST", 10, 11], ["ALV", "TREATMENT", 89, 92], ["significant", "OBSERVATION_MODIFIER", 37, 48]]], ["In this group statistically significant higher levels of PCT, MR-proADM and MR-proANP were found throughout the period ( Table 1 ).", [["PCT", "SIMPLE_CHEMICAL", 57, 60], ["MR-proADM", "SIMPLE_CHEMICAL", 62, 71], ["MR-proANP", "GENE_OR_GENE_PRODUCT", 76, 85], ["PCT", "PROTEIN", 57, 60], ["MR", "PROTEIN", 62, 64], ["proADM", "PROTEIN", 65, 71], ["MR", "PROTEIN", 76, 78], ["proANP", "PROTEIN", 79, 85], ["PCT", "TEST", 57, 60], ["MR", "TEST", 62, 64], ["MR", "TEST", 76, 78], ["proANP", "TEST", 79, 85], ["significant", "OBSERVATION_MODIFIER", 28, 39], ["higher", "OBSERVATION_MODIFIER", 40, 46]]], ["The level of CT-proAVP had increased to statistical significance since the 3 day after the operation.", [["CT-proAVP", "GENE_OR_GENE_PRODUCT", 13, 22], ["CT", "PROTEIN", 13, 15], ["proAVP", "PROTEIN", 16, 22], ["CT", "TEST", 13, 15], ["the operation", "TREATMENT", 87, 100]]], ["23 patients were in the ICU for more than 168 hours.", [["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11]]], ["In this group statistically significant higher levels of PCT, MR-proADM were found throughout the whole period ( Table 2 ).", [["PCT", "SIMPLE_CHEMICAL", 57, 60], ["MR-proADM", "GENE_OR_GENE_PRODUCT", 62, 71], ["PCT", "PROTEIN", 57, 60], ["MR", "PROTEIN", 62, 64], ["proADM", "PROTEIN", 65, 71], ["PCT", "TEST", 57, 60], ["MR", "TEST", 62, 64], ["significant", "OBSERVATION_MODIFIER", 28, 39], ["higher", "OBSERVATION_MODIFIER", 40, 46]]], ["The higher level of MR-proANP was statistically significant on the 1st and 6th days after surgery, MR-proANP had a tendency of increasing values on 2nd and 3rd days.", [["MR-proANP", "GENE_OR_GENE_PRODUCT", 20, 29], ["MR-proANP", "SIMPLE_CHEMICAL", 99, 108], ["MR", "PROTEIN", 20, 22], ["MR", "PROTEIN", 99, 101], ["MR", "TEST", 20, 22], ["proANP", "TEST", 23, 29], ["surgery", "TREATMENT", 90, 97], ["MR", "TEST", 99, 101], ["proANP", "TEST", 102, 108], ["increasing values", "PROBLEM", 127, 144], ["significant", "OBSERVATION_MODIFIER", 48, 59], ["tendency", "OBSERVATION_MODIFIER", 115, 123], ["increasing", "OBSERVATION_MODIFIER", 127, 137], ["values", "OBSERVATION_MODIFIER", 138, 144]]], ["CT-proAVP increased to statistical significance since the 2nd day after the operation and persisted throughout the studied period.P025Conclusions: PCT, MR-proADM and MR-proANP can be used as predictors of prolonged ALV for children of the first year of life after cardiac surgery with cardiopulmonary bypass.", [["cardiac", "ANATOMY", 264, 271], ["cardiopulmonary", "ANATOMY", 285, 300], ["MR-proADM", "SIMPLE_CHEMICAL", 152, 161], ["MR-proANP", "SIMPLE_CHEMICAL", 166, 175], ["ALV", "ORGANISM", 215, 218], ["children", "ORGANISM", 223, 231], ["cardiac", "ORGAN", 264, 271], ["PCT", "PROTEIN", 147, 150], ["MR", "PROTEIN", 152, 154], ["MR", "PROTEIN", 166, 168], ["proANP", "PROTEIN", 169, 175], ["children", "SPECIES", 223, 231], ["ALV", "SPECIES", 215, 218], ["CT", "TEST", 0, 2], ["the operation", "TREATMENT", 72, 85], ["PCT", "TEST", 147, 150], ["MR", "TEST", 152, 154], ["MR", "TEST", 166, 168], ["proANP", "TEST", 169, 175], ["cardiac surgery", "TREATMENT", 264, 279], ["cardiopulmonary bypass", "TREATMENT", 285, 307], ["operation", "OBSERVATION", 76, 85], ["cardiac", "ANATOMY", 264, 271], ["surgery", "OBSERVATION", 272, 279], ["cardiopulmonary", "ANATOMY", 285, 300], ["bypass", "OBSERVATION", 301, 307]]], ["The level of CT-proAVP can be considered since the 3 day after surgery.", [["CT-proAVP", "GENE_OR_GENE_PRODUCT", 13, 22], ["CT", "PROTEIN", 13, 15], ["proAVP", "PROTEIN", 16, 22], ["CT-proAVP", "TREATMENT", 13, 22], ["surgery", "TREATMENT", 63, 70]]], ["PCT and MR-proADM may be used to predict the LOS in the ICU.", [["MR-proADM", "SIMPLE_CHEMICAL", 8, 17], ["PCT", "PROTEIN", 0, 3], ["MR", "PROTEIN", 8, 10], ["PCT", "TEST", 0, 3], ["MR", "TEST", 8, 10]]], ["MR-proANP and CT-proAVP can be considered since the 1 and 2 days after surgery respectively.P025Introduction: Early prediction of the risk of death among patients admitted at the Emergency Department (ED) remains an unmet need.", [["MR-proANP", "CHEMICAL", 0, 9], ["death", "DISEASE", 142, 147], ["MR-proANP", "SIMPLE_CHEMICAL", 0, 9], ["CT-proAVP", "SIMPLE_CHEMICAL", 14, 23], ["patients", "ORGANISM", 154, 162], ["MR", "PROTEIN", 0, 2], ["CT", "PROTEIN", 14, 16], ["proAVP", "PROTEIN", 17, 23], ["patients", "SPECIES", 154, 162], ["MR", "TEST", 0, 2], ["proANP", "TEST", 3, 9], ["CT", "TEST", 14, 16], ["surgery", "TREATMENT", 71, 78]]], ["The prognostic performance of HBP that is secreted by neutrophils was prospectively validated in a series of sequential ED admissions.", [["neutrophils", "ANATOMY", 54, 65], ["HBP", "SIMPLE_CHEMICAL", 30, 33], ["neutrophils", "CELL", 54, 65], ["HBP", "PROTEIN", 30, 33], ["neutrophils", "CELL_TYPE", 54, 65], ["HBP", "TEST", 30, 33]]], ["Methods: HBP and elements of qSOFA were analyzed prospectively in 310 serial ED admissions (main reasons for admission: acute abdominal pain 28.4%; fever 24.5%; vomiting/diarrhea 23.9%; dyspnea 22.3%; neurologic signs 11.3%; non-specific complaints 38.1%; most patients admitted for more than one reasons).", [["abdominal", "ANATOMY", 126, 135], ["neurologic", "ANATOMY", 201, 211], ["abdominal pain", "DISEASE", 126, 140], ["fever", "DISEASE", 148, 153], ["vomiting", "DISEASE", 161, 169], ["diarrhea", "DISEASE", 170, 178], ["dyspnea", "DISEASE", 186, 193], ["abdominal", "ORGANISM_SUBDIVISION", 126, 135], ["patients", "ORGANISM", 261, 269], ["patients", "SPECIES", 261, 269], ["qSOFA", "TEST", 29, 34], ["acute abdominal pain", "PROBLEM", 120, 140], ["fever", "PROBLEM", 148, 153], ["vomiting", "PROBLEM", 161, 169], ["diarrhea", "PROBLEM", 170, 178], ["dyspnea", "PROBLEM", 186, 193], ["neurologic signs", "TEST", 201, 217], ["non-specific complaints", "PROBLEM", 225, 248], ["abdominal", "ANATOMY", 126, 135]]], ["Upon ED admission patients were scored as low-risk, intermediate-risk and high-risk at the discretion of the physician.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26]]], ["HBP was measured in blood samples upon admission by an enzyme immunosorbent assay.", [["blood samples", "ANATOMY", 20, 33], ["HBP", "SIMPLE_CHEMICAL", 0, 3], ["blood samples", "ORGANISM_SUBSTANCE", 20, 33], ["HBP", "PROTEIN", 0, 3], ["HBP", "TEST", 0, 3], ["blood samples", "TEST", 20, 33], ["an enzyme immunosorbent assay", "TEST", 52, 81]]], ["Results: HBP was significantly greater among patients who died very early (Fig. 1 ).", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["HBP", "TEST", 9, 12]]], ["In five out of six of patients dying early HBP was greater than 15 ng/ml.", [["patients", "ORGANISM", 22, 30], ["HBP", "GENE_OR_GENE_PRODUCT", 43, 46], ["patients", "SPECIES", 22, 30], ["HBP", "TEST", 43, 46]]], ["We combined HBP more than 15 ng/ml and the presence of one sign of qSOFA into a new score; this had 82.4% sensitivity to predict 30-day mortality.", [["HBP", "SIMPLE_CHEMICAL", 12, 15], ["HBP", "TEST", 12, 15], ["qSOFA", "TEST", 67, 72]]], ["The respective sensitivity of two signs of qSOFA was 23.5% (p: 0.002).", [["qSOFA", "DISEASE", 43, 48], ["The respective sensitivity", "TEST", 0, 26], ["qSOFA", "TEST", 43, 48]]], ["The use of this new score allowed better stratification of patients originally considered at the triage as low-risk into high-risk (Fig. 2) .", [["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67]]], ["Conclusions: We propose HBP more than 15 ng/ml and one qSOFA sign as an early score for 30-day mortality at the ED.", [["HBP", "SIMPLE_CHEMICAL", 24, 27], ["HBP", "TEST", 24, 27], ["qSOFA sign", "TEST", 55, 65]]], ["Introduction: Despite of our growing knowledge in pathophysiology of septic shock still remain one of the most important factors of hospital mortality.", [["septic shock", "DISEASE", 69, 81], ["septic shock", "PROBLEM", 69, 81], ["septic shock", "OBSERVATION", 69, 81]]], ["It is thought that early diagnosis and treatment at early stage of septic shock would decrease its mortality.", [["septic shock", "DISEASE", 67, 79], ["treatment", "TREATMENT", 39, 48], ["septic shock", "PROBLEM", 67, 79], ["thought that", "UNCERTAINTY", 6, 18], ["early", "OBSERVATION_MODIFIER", 19, 24], ["septic shock", "OBSERVATION", 67, 79]]], ["There have been on-going studies in recent years which research the usability of Heparin Binding Protein (HBP) in early diagnosis of sepsis [1] .", [["sepsis", "DISEASE", 133, 139], ["Heparin Binding Protein", "GENE_OR_GENE_PRODUCT", 81, 104], ["Heparin Binding Protein", "PROTEIN", 81, 104], ["HBP", "PROTEIN", 106, 109], ["Heparin Binding Protein", "TREATMENT", 81, 104], ["sepsis", "PROBLEM", 133, 139], ["sepsis", "OBSERVATION", 133, 139]]], ["To seek the usability of C-reactive protein (C-RP), procalcitonin (PCT) and HBP biomarker combination in early diagnosis of septic shock.", [["septic shock", "DISEASE", 124, 136], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 25, 43], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 52, 65], ["HBP", "SIMPLE_CHEMICAL", 76, 79], ["C-reactive protein", "PROTEIN", 25, 43], ["C", "PROTEIN", 45, 46], ["procalcitonin", "PROTEIN", 52, 65], ["PCT", "PROTEIN", 67, 70], ["C-reactive protein", "TEST", 25, 43], ["procalcitonin", "TEST", 52, 65], ["PCT", "TEST", 67, 70], ["HBP biomarker", "TEST", 76, 89], ["septic shock", "PROBLEM", 124, 136], ["septic shock", "OBSERVATION", 124, 136]]], ["Methods: 30 patients, who have the diagnosis of septic shock, that are expected to stay in intensive care unit more than 24 hours, and aged between 22-75 are included in the study.", [["septic shock", "DISEASE", 48, 60], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["septic shock", "PROBLEM", 48, 60], ["the study", "TEST", 170, 179], ["septic shock", "OBSERVATION", 48, 60]]], ["Data are collected from the patients' blood samples that are drawn on admission, on the 24th hour, and on the day of discharge or death.P025Results: It has been found in our study that, best \"cut-off\" value 124 ng/mL, specificity 0.82 and sensitivity 0.77 for HBP.", [["blood samples", "ANATOMY", 38, 51], ["death", "DISEASE", 130, 135], ["patients", "ORGANISM", 28, 36], ["blood samples", "ORGANISM_SUBSTANCE", 38, 51], ["patients", "SPECIES", 28, 36], ["blood samples", "TEST", 38, 51], ["death", "PROBLEM", 130, 135], ["our study", "TEST", 170, 179], ["specificity", "TEST", 218, 229], ["sensitivity", "TEST", 239, 250], ["HBP", "TEST", 260, 263]]], ["Compared with other biomarkers, HBP was the best predictor of progression to organ dysfunction (area under the receiver operating characteristic curve (AUC) = 0.801).P025Conclusions: Although there have been many biomarkers for early diagnose of septic shock, C-RP and PCT are the most common used markers in nowadays' clinical practice.", [["organ", "ANATOMY", 77, 82], ["organ dysfunction", "DISEASE", 77, 94], ["septic shock", "DISEASE", 246, 258], ["HBP", "SIMPLE_CHEMICAL", 32, 35], ["organ", "ORGAN", 77, 82], ["C-RP", "GENE_OR_GENE_PRODUCT", 260, 264], ["other biomarkers", "TEST", 14, 30], ["HBP", "TEST", 32, 35], ["organ dysfunction", "PROBLEM", 77, 94], ["AUC", "TEST", 152, 155], ["many biomarkers", "TEST", 208, 223], ["septic shock", "PROBLEM", 246, 258], ["PCT", "TEST", 269, 272], ["organ", "ANATOMY", 77, 82], ["dysfunction", "OBSERVATION", 83, 94], ["septic shock", "OBSERVATION", 246, 258]]], ["The usability of HBP in early diagnosis of sepsis is still being researched.", [["sepsis", "DISEASE", 43, 49], ["HBP", "SIMPLE_CHEMICAL", 17, 20], ["HBP", "PROBLEM", 17, 20], ["sepsis", "PROBLEM", 43, 49], ["sepsis", "OBSERVATION", 43, 49]]], ["We concluded that PCT, C-RP and HBP biomarker combination is usable to diagnose septic shock at the end of our study.P025Introduction: Reduced ADAMTS-13 and increased von Willebrand Factor (vWF)/ADAMTS-13 ratio have been observed in sepsis and are associated with the severity of the disease [1, 2] .", [["septic shock", "DISEASE", 80, 92], ["sepsis", "DISEASE", 233, 239], ["C-RP", "SIMPLE_CHEMICAL", 23, 27], ["HBP", "SIMPLE_CHEMICAL", 32, 35], ["ADAMTS-13", "GENE_OR_GENE_PRODUCT", 143, 152], ["von Willebrand Factor", "GENE_OR_GENE_PRODUCT", 167, 188], ["vWF", "GENE_OR_GENE_PRODUCT", 190, 193], ["ADAMTS-13", "GENE_OR_GENE_PRODUCT", 195, 204], ["ADAMTS-13", "PROTEIN", 143, 152], ["vWF", "PROTEIN", 190, 193], ["ADAMTS-13", "PROTEIN", 195, 204], ["PCT", "TEST", 18, 21], ["C-RP", "PROBLEM", 23, 27], ["HBP biomarker", "TEST", 32, 45], ["septic shock", "PROBLEM", 80, 92], ["our study", "TEST", 107, 116], ["Reduced ADAMTS", "PROBLEM", 135, 149], ["ADAMTS", "TEST", 195, 201], ["sepsis", "PROBLEM", 233, 239], ["the disease", "PROBLEM", 280, 291], ["sepsis", "OBSERVATION", 233, 239], ["disease", "OBSERVATION", 284, 291]]], ["However, their change during the septic episode and in the event of a change in the clinical status of the septic patients has not been investigated.", [["septic", "DISEASE", 33, 39], ["septic", "DISEASE", 107, 113], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["the septic episode", "PROBLEM", 29, 47], ["a change", "PROBLEM", 68, 76], ["the septic patients", "PROBLEM", 103, 122], ["change", "OBSERVATION_MODIFIER", 15, 21], ["septic episode", "OBSERVATION", 33, 47], ["change", "OBSERVATION_MODIFIER", 70, 76], ["septic", "OBSERVATION", 107, 113]]], ["The aim of the study was to assess the variation of these hemostatic parameters in critically ill patients during the course of a septic episode.", [["critically ill", "DISEASE", 83, 97], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["the study", "TEST", 11, 20], ["these hemostatic parameters", "TEST", 52, 79], ["a septic episode", "PROBLEM", 128, 144], ["hemostatic", "OBSERVATION", 58, 68], ["septic", "OBSERVATION", 130, 136]]], ["Methods: We monitored 34 septic patients admitted in the Intensive Care Unit (ICU).", [["septic", "DISEASE", 25, 31], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40]]], ["23 improved (group A) while 11 deteriorated (group B).", [["improved", "OBSERVATION_MODIFIER", 3, 11]]], ["We assessed vWF, ADAMTS-13 and the vWF/ADAMTS-13 ratio on admission in ICU (time point 0) and at the time of a change in patients' clinical condition (remission or deterioration, time point 1).", [["vWF", "GENE_OR_GENE_PRODUCT", 12, 15], ["ADAMTS-13", "GENE_OR_GENE_PRODUCT", 17, 26], ["vWF", "GENE_OR_GENE_PRODUCT", 35, 38], ["ADAMTS-13", "GENE_OR_GENE_PRODUCT", 39, 48], ["patients", "ORGANISM", 121, 129], ["vWF", "PROTEIN", 12, 15], ["ADAMTS-13", "PROTEIN", 17, 26], ["vWF", "PROTEIN", 35, 38], ["ADAMTS-13", "PROTEIN", 39, 48], ["patients", "SPECIES", 121, 129], ["vWF", "TEST", 12, 15], ["ADAMTS", "TEST", 17, 23], ["the vWF/ADAMTS", "TEST", 31, 45], ["a change in patients' clinical condition", "PROBLEM", 109, 149], ["deterioration", "PROBLEM", 164, 177]]], ["Results: In group A, ADAMTS-13 and the vWF/ADAMTS-13 ratio did not significantly change (567.0\u00b1296.0 vs 670.7\u00b1534.", [["ADAMTS-13", "GENE_OR_GENE_PRODUCT", 21, 30], ["vWF", "GENE_OR_GENE_PRODUCT", 39, 42], ["ADAMTS-13", "GENE_OR_GENE_PRODUCT", 43, 52], ["ADAMTS-13", "PROTEIN", 21, 30], ["vWF", "PROTEIN", 39, 42], ["ADAMTS", "PROTEIN", 43, 49], ["ADAMTS", "TEST", 21, 27], ["the vWF/ADAMTS", "TEST", 35, 49], ["vs", "TEST", 101, 103]]], ["5 Conclusions: Hemostatic disorders, as assessed by vWF and ADAMTS-13 levels were detected in septic patients, while their changes differed according to the evolution of the septic episode.", [["Hemostatic disorders", "DISEASE", 15, 35], ["septic", "DISEASE", 94, 100], ["septic", "DISEASE", 174, 180], ["vWF", "GENE_OR_GENE_PRODUCT", 52, 55], ["ADAMTS-13", "GENE_OR_GENE_PRODUCT", 60, 69], ["patients", "ORGANISM", 101, 109], ["vWF", "PROTEIN", 52, 55], ["ADAMTS-13", "PROTEIN", 60, 69], ["patients", "SPECIES", 101, 109], ["Hemostatic disorders", "PROBLEM", 15, 35], ["vWF", "TEST", 52, 55], ["ADAMTS", "TEST", 60, 66], ["the septic episode", "PROBLEM", 170, 188], ["septic", "OBSERVATION_MODIFIER", 94, 100], ["septic", "OBSERVATION", 174, 180]]], ["ADAMTS-13 changes may be associated with outcome.", [["ADAMTS-13", "GENE_OR_GENE_PRODUCT", 0, 9], ["ADAMTS-13", "PROTEIN", 0, 9]]], ["Methods: 100 adult patients with at least one sign of qSOFA and infection or acute pancreatitis or after operation were prospectively followed-up.", [["qSOFA", "DISEASE", 54, 59], ["infection", "DISEASE", 64, 73], ["pancreatitis", "DISEASE", 83, 95], ["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["qSOFA", "PROBLEM", 54, 59], ["infection", "PROBLEM", 64, 73], ["acute pancreatitis", "PROBLEM", 77, 95], ["operation", "TREATMENT", 105, 114], ["infection", "OBSERVATION", 64, 73], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["pancreatitis", "OBSERVATION", 83, 95]]], ["Blood was sampled the first 24 hours; those with HIV infection, neutropenia and multiple injuries were excluded.", [["Blood", "ANATOMY", 0, 5], ["HIV infection", "DISEASE", 49, 62], ["neutropenia", "DISEASE", 64, 75], ["multiple injuries", "DISEASE", 80, 97], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["HIV", "SPECIES", 49, 52], ["HIV", "SPECIES", 49, 52], ["Blood", "TEST", 0, 5], ["HIV infection", "PROBLEM", 49, 62], ["neutropenia", "PROBLEM", 64, 75], ["multiple injuries", "PROBLEM", 80, 97], ["HIV", "OBSERVATION_MODIFIER", 49, 52], ["infection", "OBSERVATION", 53, 62], ["neutropenia", "OBSERVATION", 64, 75], ["multiple", "OBSERVATION_MODIFIER", 80, 88], ["injuries", "OBSERVATION", 89, 97]]], ["Sepsis was diagnosed using the Sepsis-3 criteria.", [["Sepsis", "DISEASE", 0, 6], ["Sepsis", "DISEASE", 31, 37], ["Sepsis", "PROBLEM", 0, 6], ["the Sepsis", "TEST", 27, 37], ["Sepsis", "OBSERVATION", 31, 37]]], ["Soluble urokinase plasminogen activator receptor (suPAR) was measured by an enzyme immunoassay.P025Results: Sixty patients were classified with sepsis using the Sepsis-3 definitions.", [["sepsis", "DISEASE", 144, 150], ["Sepsis", "DISEASE", 161, 167], ["urokinase plasminogen activator receptor", "GENE_OR_GENE_PRODUCT", 8, 48], ["suPAR", "GENE_OR_GENE_PRODUCT", 50, 55], ["patients", "ORGANISM", 114, 122], ["Soluble urokinase plasminogen activator receptor", "PROTEIN", 0, 48], ["suPAR", "PROTEIN", 50, 55], ["patients", "SPECIES", 114, 122], ["Soluble urokinase plasminogen activator receptor", "TREATMENT", 0, 48], ["an enzyme immunoassay", "TEST", 73, 94], ["sepsis", "PROBLEM", 144, 150], ["the Sepsis", "PROBLEM", 157, 167], ["sepsis", "OBSERVATION", 144, 150], ["Sepsis", "OBSERVATION", 161, 167]]], ["Presence of at least two signs of qSOFA had 56.7% sensitivity, 95.0% specificity, 92.8% positive predictive value and 38.0% negative predictive value for the diagnosis of sepsis.", [["sepsis", "DISEASE", 171, 177], ["qSOFA", "TEST", 34, 39], ["sensitivity", "TEST", 50, 61], ["specificity", "TEST", 69, 80], ["sepsis", "PROBLEM", 171, 177], ["at least", "OBSERVATION_MODIFIER", 12, 20], ["sepsis", "OBSERVATION", 171, 177]]], ["The integration of qSOFA signs and suPAR improved the diagnostic performance ( Fig. 1) .P025Conclusions: Conclusions Two signs of qSOFA have significant positive prognostic value for sepsis but low sensitivity.", [["sepsis", "DISEASE", 183, 189], ["suPAR", "GENE_OR_GENE_PRODUCT", 35, 40], ["qSOFA", "GENE_OR_GENE_PRODUCT", 130, 135], ["suPAR", "PROTEIN", 35, 40], ["qSOFA signs", "TEST", 19, 30], ["suPAR", "TEST", 35, 40], ["qSOFA", "TEST", 130, 135], ["significant positive prognostic value", "PROBLEM", 141, 178], ["sepsis", "PROBLEM", 183, 189], ["low sensitivity", "PROBLEM", 194, 209]]], ["This is improved after integration with suPAR.", [["suPAR", "GENE_OR_GENE_PRODUCT", 40, 45], ["suPAR", "PROTEIN", 40, 45], ["suPAR", "TREATMENT", 40, 45], ["improved", "OBSERVATION_MODIFIER", 8, 16]]], ["The INTELLIGENCE-1 study is supported by the European Commission through the Seventh Framework Programme (FP7) HemoSpec.P025Introduction: Sepsis is a frequent reason for admission in the Emergency Department (ED) and its prognostic mainly relies on early diagnosis.", [["Sepsis", "DISEASE", 138, 144], ["The INTELLIGENCE-1 study", "TEST", 0, 24], ["Sepsis", "PROBLEM", 138, 144], ["Sepsis", "OBSERVATION", 138, 144]]], ["In addition, no validated prognostic tool is currently available.", [["no", "UNCERTAINTY", 13, 15]]], ["Therefore, identification of patients at high risk of worsening in the ED is key.", [["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["worsening", "OBSERVATION_MODIFIER", 54, 63]]], ["The TRIAGE objective was to assess the prognostic value of a blood marker panel to predict early clinical worsening of patients admitted in the ED with suspected sepsis.", [["blood", "ANATOMY", 61, 66], ["sepsis", "DISEASE", 162, 168], ["blood", "ORGANISM_SUBSTANCE", 61, 66], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["a blood marker panel", "TEST", 59, 79], ["sepsis", "PROBLEM", 162, 168], ["sepsis", "OBSERVATION", 162, 168]]], ["Methods: TRIAGE was a prospective, multicenter (11 sites in France and Belgium) study on biological samples conducted in partnership with bioMerieux S.A. Patients admitted in the ED with suspected or confirmed community-acquired infection for less than 72h were included.", [["infection", "DISEASE", 229, 238], ["Patients", "ORGANISM", 154, 162], ["Patients", "SPECIES", 154, 162], ["biological samples", "TEST", 89, 107], ["community-acquired infection", "PROBLEM", 210, 238], ["infection", "OBSERVATION", 229, 238]]], ["Exclusion criteria were: admission in the ED for more than 12 hours, septic shock at admission, immunodepression, sepsis syndrome 30 days prior to admission.", [["septic shock", "DISEASE", 69, 81], ["immunodepression", "DISEASE", 96, 112], ["sepsis", "DISEASE", 114, 120], ["septic shock", "PROBLEM", 69, 81], ["immunodepression", "PROBLEM", 96, 112], ["sepsis syndrome", "PROBLEM", 114, 129], ["septic shock", "OBSERVATION", 69, 81], ["sepsis", "OBSERVATION", 114, 120]]], ["The protocol included 5 clinical and biological time points (H0, H6, H24, H72, D28).", [["The protocol", "TREATMENT", 0, 12]]], ["Patients were classified in 3 groups at admission (infection, sepsis, severe sepsis) and divided into 2 evolution/prognosis groups depending on worsening or not from their initial condition to severe sepsis or septic shock and SOFA score's evolution.", [["infection", "DISEASE", 51, 60], ["sepsis", "DISEASE", 62, 68], ["sepsis", "DISEASE", 77, 83], ["sepsis", "DISEASE", 200, 206], ["septic shock", "DISEASE", 210, 222], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["infection", "PROBLEM", 51, 60], ["sepsis", "PROBLEM", 62, 68], ["severe sepsis", "PROBLEM", 70, 83], ["prognosis groups", "PROBLEM", 114, 130], ["severe sepsis", "PROBLEM", 193, 206], ["septic shock", "PROBLEM", 210, 222], ["SOFA score's evolution", "PROBLEM", 227, 249], ["infection", "OBSERVATION", 51, 60], ["sepsis", "OBSERVATION", 62, 68], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["sepsis", "OBSERVATION", 77, 83], ["severe", "OBSERVATION_MODIFIER", 193, 199], ["sepsis", "OBSERVATION", 200, 206], ["septic shock", "OBSERVATION", 210, 222]]], ["The evolution criteria were centrally evaluated by an independent adjudication committee of sepsis experts including emergency physicians and intensivists.", [["sepsis", "DISEASE", 92, 98], ["sepsis", "PROBLEM", 92, 98], ["sepsis", "OBSERVATION", 92, 98]]], ["Patients were followed up to day 28 for mortality.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Results: The study duration was 3 years with 600 patients included (102 excluded).", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57]]], ["The centralized analysis is in progress to select the combination of biomarkers with the best prognostic performance comparing both evolution/prognosis groups.", [["The centralized analysis", "TEST", 0, 24], ["biomarkers", "TEST", 69, 79]]], ["Currently, 125 patients have been classified as worsening and some results will be available in 2018.P025Conclusions: TRIAGE is the largest prospective multicenter study assessing the prognostic value of a panel of blood markers in EDs which could help identification of septic patient at risk of worsening at time of admission in the ED and develop specific management.P025Introduction: Immune status characterization in Intensive Care Unit (ICU) patients presents a major challenge due to the heterogeneity of response.", [["blood", "ANATOMY", 215, 220], ["septic", "DISEASE", 271, 277], ["patients", "ORGANISM", 15, 23], ["blood", "ORGANISM_SUBSTANCE", 215, 220], ["patient", "ORGANISM", 278, 285], ["patients", "ORGANISM", 448, 456], ["patients", "SPECIES", 15, 23], ["patient", "SPECIES", 278, 285], ["patients", "SPECIES", 448, 456], ["blood markers", "TEST", 215, 228], ["septic patient", "PROBLEM", 271, 285], ["specific management", "TREATMENT", 350, 369], ["worsening", "OBSERVATION_MODIFIER", 48, 57], ["septic", "OBSERVATION", 271, 277], ["worsening", "OBSERVATION_MODIFIER", 297, 306]]], ["In this study, the FilmArray\u00ae system was used with customized gene assays to assess the immune profile of critically-ill ICU patients compared to healthy volunteers; from within the REALISM cohort.", [["critically-ill", "DISEASE", 106, 120], ["patients", "ORGANISM", 125, 133], ["volunteers", "ORGANISM", 154, 164], ["patients", "SPECIES", 125, 133], ["this study", "TEST", 3, 13], ["customized gene assays", "TEST", 51, 73]]], ["Methods: A customized FilmArray\u00ae pouch containing 24 assays was designed; 16 target and 8 reference genes.", [["16 target and 8 reference genes", "DNA", 74, 105], ["A customized FilmArray\u00ae pouch", "TREATMENT", 9, 38]]], ["Detection and semiquantification of assays from whole blood collected in PAXgene tubes occurs in the device within 1 hour.", [["whole blood", "ANATOMY", 48, 59], ["blood", "ORGANISM_SUBSTANCE", 54, 59], ["PAXgene tubes", "MULTI-TISSUE_STRUCTURE", 73, 86], ["Detection", "TEST", 0, 9], ["assays", "TEST", 36, 42], ["whole blood", "TEST", 48, 59], ["PAXgene tubes", "TREATMENT", 73, 86], ["tubes", "OBSERVATION", 81, 86]]], ["A total of 20 subjects from the REALISM cohort were tested in duplicates: 1 trauma, 5 septic shock and 5 surgery patients, along with 9 healthy volunteers.", [["trauma", "DISEASE", 76, 82], ["septic shock", "DISEASE", 86, 98], ["patients", "ORGANISM", 113, 121], ["volunteers", "ORGANISM", 144, 154], ["patients", "SPECIES", 113, 121], ["1 trauma", "PROBLEM", 74, 82], ["5 septic shock", "PROBLEM", 84, 98], ["5 surgery", "TREATMENT", 103, 112], ["total", "OBSERVATION_MODIFIER", 2, 7], ["septic shock", "OBSERVATION", 86, 98]]], ["The patients' selection was based on HLA-DR expression on monocytes, and PHA-(Phytohaemagglutinin) stimulated T-cell proliferation assay, to have various immune profiles.P025Results: Quantification cycle values of the target genes were normalized by the geometrical mean of reference genes to account for the different cell counts among specimens.", [["monocytes", "ANATOMY", 58, 67], ["T-cell", "ANATOMY", 110, 116], ["cell", "ANATOMY", 319, 323], ["specimens", "ANATOMY", 337, 346], ["patients", "ORGANISM", 4, 12], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 37, 43], ["monocytes", "CELL", 58, 67], ["PHA", "SIMPLE_CHEMICAL", 73, 76], ["Phytohaemagglutinin", "SIMPLE_CHEMICAL", 78, 97], ["T-cell", "CELL", 110, 116], ["cell", "CELL", 319, 323], ["monocytes", "CELL_TYPE", 58, 67], ["PHA", "PROTEIN", 73, 76], ["target genes", "DNA", 218, 230], ["reference genes", "DNA", 274, 289], ["patients", "SPECIES", 4, 12], ["HLA", "TEST", 37, 40], ["monocytes", "TEST", 58, 67], ["PHA", "TEST", 73, 76], ["Phytohaemagglutinin", "TEST", 78, 97], ["stimulated T-cell proliferation assay", "TEST", 99, 136], ["Quantification cycle values", "TEST", 183, 210], ["the different cell counts", "TEST", 305, 330], ["monocytes", "ANATOMY", 58, 67]]], ["The number of the CD3+ cells and HLA-DR, determined by flow cytometry, showed good correlation to CD3D and CD74 gene expression, respectively.", [["CD3+ cells", "ANATOMY", 18, 28], ["CD3", "GENE_OR_GENE_PRODUCT", 18, 21], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 33, 39], ["CD3D", "GENE_OR_GENE_PRODUCT", 98, 102], ["CD74", "GENE_OR_GENE_PRODUCT", 107, 111], ["CD3", "PROTEIN", 18, 21], ["HLA-DR", "PROTEIN", 33, 39], ["CD74", "PROTEIN", 107, 111], ["HLA", "TEST", 33, 36], ["flow cytometry", "TEST", 55, 69], ["CD3D", "TEST", 98, 102], ["CD3+ cells", "OBSERVATION", 18, 28], ["flow cytometry", "OBSERVATION", 55, 69]]], ["Seven genes showed significant differences in expression levels between the healthy volunteers and patient groups: CD3D, CD74, CTLA4 & CX3CR1 were down-regulated, while IL-10, IL1RN and S100A9 were up-regulated in the patient populations.", [["volunteers", "ORGANISM", 84, 94], ["patient", "ORGANISM", 99, 106], ["CD3D", "GENE_OR_GENE_PRODUCT", 115, 119], ["CD74", "GENE_OR_GENE_PRODUCT", 121, 125], ["CTLA4", "GENE_OR_GENE_PRODUCT", 127, 132], ["CX3CR1", "GENE_OR_GENE_PRODUCT", 135, 141], ["IL-10", "GENE_OR_GENE_PRODUCT", 169, 174], ["IL1RN", "GENE_OR_GENE_PRODUCT", 176, 181], ["S100A9", "GENE_OR_GENE_PRODUCT", 186, 192], ["patient", "ORGANISM", 218, 225], ["CD3D", "PROTEIN", 115, 119], ["CD74", "PROTEIN", 121, 125], ["CTLA4", "PROTEIN", 127, 132], ["CX3CR1", "PROTEIN", 135, 141], ["IL-10", "PROTEIN", 169, 174], ["IL1RN", "PROTEIN", 176, 181], ["S100A9", "PROTEIN", 186, 192], ["patient", "SPECIES", 99, 106], ["patient", "SPECIES", 218, 225], ["significant differences in expression levels", "PROBLEM", 19, 63], ["CTLA4", "TEST", 127, 132], ["CX3CR1", "TEST", 135, 141], ["IL", "TEST", 169, 171], ["IL1RN", "TEST", 176, 181], ["S100A9", "TEST", 186, 192], ["significant", "OBSERVATION_MODIFIER", 19, 30], ["differences", "OBSERVATION_MODIFIER", 31, 42]]], ["The use of relative quantitative difference of some markers was able to distinguish and Introduction: Early, rapid diagnosis is integral to the efficient effective treatment of sepsis; however, there is no gold standard for diagnosis, and biochemical surrogates are of limited and controversial utility.", [["sepsis", "DISEASE", 177, 183], ["sepsis", "PROBLEM", 177, 183], ["biochemical surrogates", "TEST", 239, 261], ["sepsis", "OBSERVATION", 177, 183], ["no", "UNCERTAINTY", 203, 205]]], ["The CytoVale system measures biophysical properties of cells by imaging thousands of single cells per second as they are hydrodynamically stretched in a microfluidic channel.", [["cells", "ANATOMY", 55, 60], ["cells", "ANATOMY", 92, 97], ["cells", "CELL", 55, 60], ["cells", "CELL", 92, 97], ["single cells", "CELL_TYPE", 85, 97], ["The CytoVale system", "TREATMENT", 0, 19], ["imaging", "TEST", 64, 71], ["hydrodynamically", "OBSERVATION_MODIFIER", 121, 137], ["stretched", "OBSERVATION", 138, 147], ["microfluidic channel", "OBSERVATION", 153, 173]]], ["This platform has been shown to measure dozens of mechanical, morphological, and cell surface biomarkers of WBC activation simultaneously [1, 2] .", [["cell surface", "ANATOMY", 81, 93], ["WBC", "ANATOMY", 108, 111], ["cell", "CELL", 81, 85], ["WBC", "CELL", 108, 111], ["WBC activation", "TEST", 108, 122]]], ["In this study, we show the performance of the CytoVale system in measuring biophysical markers for sepsis detection in the emergency department (ED).", [["sepsis", "DISEASE", 99, 105], ["this study", "TEST", 3, 13], ["the CytoVale system", "TEST", 42, 61], ["sepsis detection", "TEST", 99, 115], ["sepsis", "OBSERVATION", 99, 105]]], ["Methods: We conducted an IRB-approved prospective cohort study of Emergency Department (ED) patients with 2+ SIRS criteria and evidence of organ dysfunction.", [["organ", "ANATOMY", 139, 144], ["SIRS", "DISEASE", 109, 113], ["organ dysfunction", "DISEASE", 139, 156], ["patients", "ORGANISM", 92, 100], ["organ", "ORGAN", 139, 144], ["patients", "SPECIES", 92, 100], ["organ dysfunction", "PROBLEM", 139, 156], ["organ", "ANATOMY", 139, 144], ["dysfunction", "OBSERVATION", 145, 156]]], ["307 patients were included for analysis.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["analysis", "TEST", 31, 39]]], ["Blood samples for the Cytovale assay were collected in the ED, and the diagnosis of sepsis was adjudicated by blinded clinician review of the medical record.", [["Blood samples", "ANATOMY", 0, 13], ["sepsis", "DISEASE", 84, 90], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["Blood samples", "TEST", 0, 13], ["the Cytovale assay", "TEST", 18, 36], ["sepsis", "PROBLEM", 84, 90], ["sepsis", "OBSERVATION", 84, 90]]], ["Captured imaging data were analyzed using computer vision to quantify mechanical parameters per cell, and a logistic model was trained to discriminate patients who had sepsis from those who did not.", [["cell", "ANATOMY", 96, 100], ["sepsis", "DISEASE", 168, 174], ["cell", "CELL", 96, 100], ["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 151, 159], ["Captured imaging data", "TEST", 0, 21], ["sepsis", "PROBLEM", 168, 174], ["sepsis", "OBSERVATION", 168, 174]]], ["Results: We found substantial biophysical differences between cells from septic and non-septic patients as observed at both the single cell level (Fig. 1) and when looking at the overall leukocyte populations (Fig. 2) .", [["cells", "ANATOMY", 62, 67], ["cell", "ANATOMY", 135, 139], ["leukocyte", "ANATOMY", 187, 196], ["septic", "DISEASE", 73, 79], ["cells", "CELL", 62, 67], ["patients", "ORGANISM", 95, 103], ["cell", "CELL", 135, 139], ["leukocyte", "CELL", 187, 196], ["leukocyte populations", "CELL_TYPE", 187, 208], ["patients", "SPECIES", 95, 103], ["substantial biophysical differences between cells", "PROBLEM", 18, 67], ["septic and non-septic patients", "PROBLEM", 73, 103], ["substantial", "OBSERVATION_MODIFIER", 18, 29], ["septic", "OBSERVATION_MODIFIER", 73, 79], ["non-septic", "OBSERVATION", 84, 94], ["leukocyte", "ANATOMY", 187, 196]]], ["A multiparameter classification algorithm to discriminate septic from non-septic patients based on biophysical markers currently yields a sensitivity of 88% with a negative predictive value of 95%.", [["septic", "DISEASE", 58, 64], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["A multiparameter classification algorithm", "TEST", 0, 41], ["septic from non-septic patients", "PROBLEM", 58, 89], ["biophysical markers", "TEST", 99, 118], ["a sensitivity", "TEST", 136, 149], ["septic", "OBSERVATION_MODIFIER", 58, 64], ["non-septic", "OBSERVATION", 70, 80]]], ["Conclusions: In patients presenting to the ED with 2 of 4 SIRS criteria and evidence of organ dysfunction, the CytoVale system provides a potentially viable means for the early diagnosis of sepsis via the quantification of biophysical properties of leukocytes.P040Oxidative stress and other biomarkers to predict the presence of sepsis in ICU patients V Tsolaki, M Karapetsa, G Ganeli, E Zakynthinos ICU, Larissa, Greece Critical Care 2018, 22(Suppl 1):P040P040Introduction: Early identification of sepsis adds a survival benefit in ICU patients.", [["organ", "ANATOMY", 88, 93], ["leukocytes", "ANATOMY", 249, 259], ["SIRS", "DISEASE", 58, 62], ["organ dysfunction", "DISEASE", 88, 105], ["sepsis", "DISEASE", 190, 196], ["sepsis", "DISEASE", 329, 335], ["sepsis", "DISEASE", 499, 505], ["patients", "ORGANISM", 16, 24], ["organ", "ORGAN", 88, 93], ["leukocytes", "CELL", 249, 259], ["P040", "SIMPLE_CHEMICAL", 260, 264], ["patients", "ORGANISM", 343, 351], ["patients", "ORGANISM", 537, 545], ["leukocytes", "CELL_TYPE", 249, 259], ["P040", "PROTEIN", 260, 264], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 343, 351], ["patients", "SPECIES", 537, 545], ["4 SIRS criteria", "PROBLEM", 56, 71], ["organ dysfunction", "PROBLEM", 88, 105], ["the CytoVale system", "TREATMENT", 107, 126], ["sepsis", "PROBLEM", 190, 196], ["leukocytes", "PROBLEM", 249, 259], ["Oxidative stress", "TEST", 264, 280], ["other biomarkers", "TEST", 285, 301], ["sepsis", "PROBLEM", 329, 335], ["sepsis", "PROBLEM", 499, 505], ["evidence of", "UNCERTAINTY", 76, 87], ["organ dysfunction", "OBSERVATION", 88, 105], ["sepsis", "OBSERVATION", 190, 196], ["leukocytes", "OBSERVATION", 249, 259], ["sepsis", "OBSERVATION", 329, 335], ["sepsis", "OBSERVATION", 499, 505]]], ["Several biomarkers have been evaluated, yet an optimal marker is still lacking [1] .", [["Several biomarkers", "TEST", 0, 18]]], ["Methods: We prospectively determined oxidative status in patients admitted in a general Intensive Care Unit of the University Hospital of Larisa.", [["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65]]], ["Oxidative status was determined measuring the novel static (sORP) and capacity (cORP) oxidation-reduction potential markers.", [["Oxidative status", "PROBLEM", 0, 16], ["capacity (cORP) oxidation", "TREATMENT", 70, 95]]], ["Other biomarkers (BNP, presepsin, CRP) were measured, and the discriminative properties for the detection of sepsis were evaluated.", [["sepsis", "DISEASE", 109, 115], ["BNP", "GENE_OR_GENE_PRODUCT", 18, 21], ["presepsin", "GENE_OR_GENE_PRODUCT", 23, 32], ["CRP", "GENE_OR_GENE_PRODUCT", 34, 37], ["BNP", "PROTEIN", 18, 21], ["presepsin", "PROTEIN", 23, 32], ["CRP", "PROTEIN", 34, 37], ["Other biomarkers", "TEST", 0, 16], ["BNP", "TEST", 18, 21], ["presepsin", "TEST", 23, 32], ["CRP", "TEST", 34, 37], ["sepsis", "PROBLEM", 109, 115], ["sepsis", "OBSERVATION", 109, 115]]], ["Results: Oxidative status was evaluated in a hundred and fifty two consecutive patients.", [["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87]]], ["Patients with severe sepsis and septic shock had significantly higher sORP values than patients without sepsis ( Introduction: C-reactive protein (CRP), is reported to be an effective marker for the assessment of vascular inflammation activity and acute coronary events prediction [1] .We hypothesized that preoperative CRP elevation is related to the occurrence of postoperative adverse cardiovascular outcomes.", [["vascular", "ANATOMY", 213, 221], ["coronary", "ANATOMY", 254, 262], ["cardiovascular", "ANATOMY", 388, 402], ["sepsis", "DISEASE", 21, 27], ["septic shock", "DISEASE", 32, 44], ["sepsis", "DISEASE", 104, 110], ["inflammation", "DISEASE", 222, 234], ["Patients", "ORGANISM", 0, 8], ["sORP", "GENE_OR_GENE_PRODUCT", 70, 74], ["patients", "ORGANISM", 87, 95], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 127, 145], ["CRP", "GENE_OR_GENE_PRODUCT", 147, 150], ["vascular", "MULTI-TISSUE_STRUCTURE", 213, 221], ["coronary", "MULTI-TISSUE_STRUCTURE", 254, 262], ["CRP", "GENE_OR_GENE_PRODUCT", 320, 323], ["sORP", "PROTEIN", 70, 74], ["C-reactive protein", "PROTEIN", 127, 145], ["CRP", "PROTEIN", 147, 150], ["CRP", "PROTEIN", 320, 323], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 87, 95], ["severe sepsis", "PROBLEM", 14, 27], ["septic shock", "PROBLEM", 32, 44], ["significantly higher sORP values", "PROBLEM", 49, 81], ["sepsis", "PROBLEM", 104, 110], ["C-reactive protein", "TEST", 127, 145], ["CRP", "TEST", 147, 150], ["the assessment", "TEST", 195, 209], ["vascular inflammation activity", "PROBLEM", 213, 243], ["acute coronary events prediction", "PROBLEM", 248, 280], ["preoperative CRP elevation", "PROBLEM", 307, 333], ["postoperative adverse cardiovascular outcomes", "PROBLEM", 366, 411], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["sepsis", "OBSERVATION", 21, 27], ["septic shock", "OBSERVATION", 32, 44], ["without", "UNCERTAINTY", 96, 103], ["sepsis", "OBSERVATION", 104, 110], ["vascular", "ANATOMY", 213, 221], ["inflammation", "OBSERVATION", 222, 234], ["acute", "OBSERVATION_MODIFIER", 248, 253], ["coronary", "ANATOMY", 254, 262], ["postoperative", "OBSERVATION", 366, 379]]], ["Methods: We prospectively included patients scheduled to undergo different vascular surgeries from december 2016 to september 2017. we assessed demographic data, comorbidities, revised cardiac risk index (RCRI) and biomarkers (CRP, cardiac troponin high sensitive Ths, creatinine and urea) in the preoperative period. we also noted type and duration of surgery, intraoperative blood loss, ICU stay and mortality. we evaluated CRP as a predictive marker of major cardiovascular events defined as chest pain, Ths elevation, electrocardiogram changes, arrhythmia, pulmonary embolism, stroke occuring within postoperative 3 months.P040Results: During our study, 30 patients were scheduled to undergo vascular surgeries.", [["vascular", "ANATOMY", 75, 83], ["cardiac", "ANATOMY", 185, 192], ["cardiac", "ANATOMY", 232, 239], ["blood", "ANATOMY", 377, 382], ["cardiovascular", "ANATOMY", 462, 476], ["chest", "ANATOMY", 495, 500], ["pulmonary", "ANATOMY", 561, 570], ["vascular", "ANATOMY", 696, 704], ["creatinine", "CHEMICAL", 269, 279], ["urea", "CHEMICAL", 284, 288], ["intraoperative blood loss", "DISEASE", 362, 387], ["chest pain", "DISEASE", 495, 505], ["arrhythmia", "DISEASE", 549, 559], ["pulmonary embolism", "DISEASE", 561, 579], ["stroke", "DISEASE", 581, 587], ["creatinine", "CHEMICAL", 269, 279], ["urea", "CHEMICAL", 284, 288], ["patients", "ORGANISM", 35, 43], ["vascular", "MULTI-TISSUE_STRUCTURE", 75, 83], ["cardiac", "ORGAN", 185, 192], ["CRP", "GENE_OR_GENE_PRODUCT", 227, 230], ["cardiac troponin", "GENE_OR_GENE_PRODUCT", 232, 248], ["creatinine", "SIMPLE_CHEMICAL", 269, 279], ["urea", "SIMPLE_CHEMICAL", 284, 288], ["blood", "ORGANISM_SUBSTANCE", 377, 382], ["CRP", "GENE_OR_GENE_PRODUCT", 426, 429], ["cardiovascular", "ANATOMICAL_SYSTEM", 462, 476], ["chest", "ORGANISM_SUBDIVISION", 495, 500], ["pulmonary", "ORGAN", 561, 570], ["patients", "ORGANISM", 661, 669], ["vascular", "MULTI-TISSUE_STRUCTURE", 696, 704], ["CRP", "PROTEIN", 227, 230], ["CRP", "PROTEIN", 426, 429], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 661, 669], ["different vascular surgeries", "TREATMENT", 65, 93], ["demographic data", "TEST", 144, 160], ["comorbidities", "PROBLEM", 162, 175], ["cardiac risk index", "TEST", 185, 203], ["RCRI", "TEST", 205, 209], ["biomarkers", "TEST", 215, 225], ["CRP", "TEST", 227, 230], ["cardiac troponin", "TEST", 232, 248], ["creatinine", "TEST", 269, 279], ["urea", "TEST", 284, 288], ["surgery", "TREATMENT", 353, 360], ["intraoperative blood loss", "PROBLEM", 362, 387], ["CRP", "TEST", 426, 429], ["major cardiovascular events", "PROBLEM", 456, 483], ["chest pain", "PROBLEM", 495, 505], ["Ths elevation", "PROBLEM", 507, 520], ["electrocardiogram changes", "PROBLEM", 522, 547], ["arrhythmia", "PROBLEM", 549, 559], ["pulmonary embolism", "PROBLEM", 561, 579], ["stroke", "PROBLEM", 581, 587], ["our study", "TEST", 647, 656], ["vascular surgeries", "TREATMENT", 696, 714], ["vascular", "ANATOMY", 75, 83], ["chest", "ANATOMY", 495, 500], ["arrhythmia", "OBSERVATION", 549, 559], ["pulmonary", "ANATOMY", 561, 570], ["embolism", "OBSERVATION", 571, 579], ["stroke", "OBSERVATION", 581, 587], ["vascular", "ANATOMY", 696, 704], ["surgeries", "OBSERVATION", 705, 714]]], ["From the 30 patients, 66% developed adverse cardiac events (Table 1) .", [["cardiac", "ANATOMY", 44, 51], ["adverse cardiac events", "DISEASE", 36, 58], ["patients", "ORGANISM", 12, 20], ["cardiac", "ORGAN", 44, 51], ["patients", "SPECIES", 12, 20], ["adverse cardiac events", "PROBLEM", 36, 58]]], ["We showed the predictive value of CRP in major cardiovascular event in a ROC analysis (Fig. 1) .", [["cardiovascular", "ANATOMY", 47, 61], ["CRP", "GENE_OR_GENE_PRODUCT", 34, 37], ["cardiovascular", "ANATOMICAL_SYSTEM", 47, 61], ["CRP", "PROTEIN", 34, 37], ["CRP", "TEST", 34, 37], ["a ROC analysis", "TEST", 71, 85], ["cardiovascular", "ANATOMY", 47, 61]]], ["The cuttoff value of CPR was 54 giving 85% of sensitivity and 82% of specificity.", [["The cuttoff value", "TEST", 0, 17], ["CPR", "TEST", 21, 24], ["sensitivity", "TEST", 46, 57], ["specificity", "TEST", 69, 80]]], ["Conclusions: Our study pointed out that CRP preoperative elevation could have a very strong predictive value of post-operative cardiovascular events in vascular surgery, this is in line with results showed by previous studies [1] .P040Introduction: Elderly are particularly susceptible to bacterial infections and sepsis, and they comprise an increasing proportion of intensive care unit (ICU) admissions.", [["cardiovascular", "ANATOMY", 127, 141], ["vascular", "ANATOMY", 152, 160], ["bacterial infections", "DISEASE", 289, 309], ["sepsis", "DISEASE", 314, 320], ["CRP", "GENE_OR_GENE_PRODUCT", 40, 43], ["cardiovascular", "ANATOMICAL_SYSTEM", 127, 141], ["vascular", "MULTI-TISSUE_STRUCTURE", 152, 160], ["CRP", "PROTEIN", 40, 43], ["Our study", "TEST", 13, 22], ["CRP preoperative elevation", "PROBLEM", 40, 66], ["post-operative cardiovascular events", "PROBLEM", 112, 148], ["vascular surgery", "TREATMENT", 152, 168], ["previous studies", "TEST", 209, 225], ["bacterial infections", "PROBLEM", 289, 309], ["sepsis", "PROBLEM", 314, 320], ["vascular", "ANATOMY", 152, 160], ["surgery", "OBSERVATION", 161, 168], ["bacterial", "OBSERVATION_MODIFIER", 289, 298], ["infections", "OBSERVATION", 299, 309], ["sepsis", "OBSERVATION", 314, 320]]], ["Our aim was to evaluate the impact of age on critically ill infected patients.", [["critically ill infected", "DISEASE", 45, 68], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77]]], ["Methods: We performed a post-hoc analysis of all infected patients admitted to ICU enrolled in a 1-year prospective, observational, multicenter study involving 14 ICUs.", [["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["a post-hoc analysis", "TEST", 22, 41], ["multicenter study", "TEST", 132, 149]]], ["Patients aged <65, 65-74 and >=75 years were compared (group A, B, and C).", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Multidrug-resistance (MDR) was defined as acquired non-susceptibility to at least one agent within three or more antimicrobial categories.", [["Multidrug-resistance (MDR", "PROBLEM", 0, 25], ["resistance", "OBSERVATION", 10, 20], ["antimicrobial categories", "OBSERVATION", 113, 137]]], ["Results: Of the 3766 patients analyzed, 1652 (43.9%) were infected on ICU admission.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29]]], ["Of these, 828 (50%) belonged to group A, 434 (23%) to group B and 440 (27%) to group C. Group C were more dependent, had higher SAPS II and Charlson scores (p<0.05).", [["group B", "TEST", 54, 61], ["group C. Group C", "TEST", 79, 95], ["Charlson scores", "TEST", 140, 155], ["more dependent", "OBSERVATION_MODIFIER", 101, 115]]], ["Microorganism isolation and bacteremia were higher in group B (53% and 24%, respectively) than groups A (45% and 19%, respectively) and C (47% and 17%, respectively; p<0.05).", [["bacteremia", "DISEASE", 28, 38], ["Microorganism isolation", "PROBLEM", 0, 23], ["bacteremia", "PROBLEM", 28, 38], ["A", "TEST", 102, 103], ["C", "TEST", 136, 137], ["p", "TEST", 166, 167], ["bacteremia", "OBSERVATION", 28, 38], ["higher", "OBSERVATION_MODIFIER", 44, 50]]], ["Septic shock was present in 58% of patients and was more frequent in groups B (55%) and C (55%) than group A (48%).", [["Septic shock", "DISEASE", 0, 12], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["Septic shock", "PROBLEM", 0, 12], ["C", "TEST", 88, 89], ["group A", "TEST", 101, 108], ["shock", "OBSERVATION", 7, 12]]], ["The most common sources of infections were respiratory and intra-abdominal.", [["respiratory", "ANATOMY", 43, 54], ["intra-abdominal", "ANATOMY", 59, 74], ["infections", "DISEASE", 27, 37], ["infections", "PROBLEM", 27, 37], ["intra-abdominal", "PROBLEM", 59, 74], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["infections", "OBSERVATION", 27, 37], ["intra-abdominal", "ANATOMY", 59, 74]]], ["Isolation of gram-negative bacteria was significantly increased in group B and C (p=0.034).", [["gram-negative bacteria", "PROBLEM", 13, 35], ["gram", "OBSERVATION_MODIFIER", 13, 17], ["negative bacteria", "OBSERVATION_MODIFIER", 18, 35], ["significantly", "OBSERVATION_MODIFIER", 40, 53], ["increased", "OBSERVATION_MODIFIER", 54, 63]]], ["The most common isolated bacteria were Escherichia coli (17%), Staphylococcus aureus (15%) and Pseudomonas aeruginosa (8%) for all groups.", [["Escherichia coli", "DISEASE", 39, 55], ["Staphylococcus aureus", "DISEASE", 63, 84], ["Pseudomonas aeruginosa", "DISEASE", 95, 117], ["Escherichia coli", "ORGANISM", 39, 55], ["Staphylococcus aureus", "ORGANISM", 63, 84], ["Pseudomonas aeruginosa", "ORGANISM", 95, 117], ["Escherichia coli", "SPECIES", 39, 55], ["Staphylococcus aureus", "SPECIES", 63, 84], ["Pseudomonas aeruginosa", "SPECIES", 95, 117], ["Escherichia coli", "SPECIES", 39, 55], ["Staphylococcus aureus", "SPECIES", 63, 84], ["Pseudomonas aeruginosa", "SPECIES", 95, 117], ["The most common isolated bacteria", "PROBLEM", 0, 33], ["Escherichia coli", "TEST", 39, 55], ["Staphylococcus aureus", "TEST", 63, 84], ["Pseudomonas aeruginosa", "PROBLEM", 95, 117], ["bacteria", "OBSERVATION", 25, 33], ["Escherichia coli", "OBSERVATION", 39, 55]]], ["In total, 151 isolates (22%) corresponded to MDR bacteria, of which 57% were Staphylococcus aureus.", [["Staphylococcus aureus", "DISEASE", 77, 98], ["Staphylococcus aureus", "ORGANISM", 77, 98], ["Staphylococcus aureus", "SPECIES", 77, 98], ["Staphylococcus aureus", "SPECIES", 77, 98], ["isolates", "TEST", 14, 22], ["MDR bacteria", "PROBLEM", 45, 57], ["Staphylococcus aureus", "PROBLEM", 77, 98], ["Staphylococcus aureus", "OBSERVATION", 77, 98]]], ["Age was not a risk factor for infection by MDR.", [["infection", "DISEASE", 30, 39], ["MDR", "DISEASE", 43, 46], ["infection", "PROBLEM", 30, 39], ["MDR", "PROBLEM", 43, 46], ["infection", "OBSERVATION", 30, 39]]], ["All-cause mortality in ICU and hospital was: 23% and 30%; 29% and 40%; 36% and 53% -respectively for groups A, B, and C (p < 0.001).P040Conclusions: Old patients (65-74 years) were more prone to present with bacteremia, which could account for the increased severity of sepsis and higher all-cause mortality.", [["bacteremia", "DISEASE", 208, 218], ["sepsis", "DISEASE", 270, 276], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 153, 161], ["groups", "TEST", 101, 107], ["A", "TEST", 108, 109], ["B", "TEST", 111, 112], ["bacteremia", "PROBLEM", 208, 218], ["the increased severity of sepsis", "PROBLEM", 244, 276], ["bacteremia", "OBSERVATION", 208, 218], ["increased", "OBSERVATION_MODIFIER", 248, 257], ["severity", "OBSERVATION_MODIFIER", 258, 266], ["sepsis", "OBSERVATION", 270, 276]]], ["Age was not a risk factor for MDR infection.P040Introduction: The rapid identification of pathogens using patient samples is crucial.", [["samples", "ANATOMY", 114, 121], ["infection", "DISEASE", 34, 43], ["patient", "ORGANISM", 106, 113], ["patient", "SPECIES", 106, 113], ["MDR infection", "PROBLEM", 30, 43], ["pathogens", "PROBLEM", 90, 99], ["infection", "OBSERVATION", 34, 43]]], ["Delays in this can potentially have serious implications for patients and infection prevention/control [1] .", [["infection", "DISEASE", 74, 83], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["infection prevention", "TREATMENT", 74, 94]]], ["The aim of this project was to identify the number of microbiology samples sent, the number rejected and reasons for rejection, with the intention to reduce such instances.", [["microbiology samples", "TEST", 54, 74], ["rejection", "PROBLEM", 117, 126]]], ["Patients were identified and data collected using the Intensive Care National Audit and Research Centre (ICNARC) database and from electronic patient records.", [["Patients", "ORGANISM", 0, 8], ["patient", "ORGANISM", 142, 149], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 142, 149]]], ["Data collected included: demographics, length of stay, microbiology samples sent and details on the rejected samples.P040Results: 530 patients were identified with a total of 4725 (median: 4 samples/patient) samples sent to microbiology.", [["samples", "ANATOMY", 109, 116], ["samples", "ANATOMY", 208, 215], ["patients", "ORGANISM", 134, 142], ["patient", "ORGANISM", 199, 206], ["samples", "CANCER", 208, 215], ["patients", "SPECIES", 134, 142], ["patient", "SPECIES", 199, 206], ["microbiology samples", "TEST", 55, 75], ["the rejected samples", "TEST", 96, 116], ["samples", "TEST", 208, 215]]], ["100 (18%) patients had at least 1 sample rejected.", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18]]], ["The median number of samples rejected per patient was 1 (Range: 1-10).", [["samples", "ANATOMY", 21, 28], ["patient", "ORGANISM", 42, 49], ["patient", "SPECIES", 42, 49], ["median", "OBSERVATION_MODIFIER", 4, 10]]], ["The area under the curve for CRP elevation is 0.891 most common samples rejected were urine (22%), blood (20%), faeces (19%) and sputum (8%).", [["samples", "ANATOMY", 64, 71], ["urine", "ANATOMY", 86, 91], ["blood", "ANATOMY", 99, 104], ["faeces", "ANATOMY", 112, 118], ["sputum", "ANATOMY", 129, 135], ["CRP", "GENE_OR_GENE_PRODUCT", 29, 32], ["samples", "CANCER", 64, 71], ["urine", "ORGANISM_SUBSTANCE", 86, 91], ["blood", "ORGANISM_SUBSTANCE", 99, 104], ["faeces", "ORGANISM_SUBSTANCE", 112, 118], ["CRP", "PROTEIN", 29, 32], ["the curve", "TEST", 15, 24], ["CRP elevation", "TEST", 29, 42], ["urine", "TEST", 86, 91], ["blood", "TEST", 99, 104], ["faeces", "TEST", 112, 118], ["sputum", "TEST", 129, 135]]], ["69 (48%) of the samples were resent for testing (median 1 day; range 0-20).", [["samples", "ANATOMY", 16, 23], ["samples", "CANCER", 16, 23], ["the samples", "TEST", 12, 23], ["testing", "TEST", 40, 47]]], ["Reasons for sample rejection are shown in Table 1 .", [["sample", "ANATOMY", 12, 18], ["sample rejection", "PROBLEM", 12, 28], ["rejection", "OBSERVATION", 19, 28]]], ["Most rejections occurred within 48-hours of admission ( Fig. 1) .P040Conclusions: This study confirms a high number of samples are sent to microbiology.", [["samples", "ANATOMY", 119, 126], ["samples", "CANCER", 119, 126], ["Most rejections", "PROBLEM", 0, 15], ["This study", "TEST", 82, 92], ["rejections", "OBSERVATION", 5, 15]]], ["Although a few are rejected, overall this represents a large number, with most occurring during the first days of admission.", [["few", "OBSERVATION_MODIFIER", 11, 14], ["rejected", "OBSERVATION", 19, 27], ["large", "OBSERVATION_MODIFIER", 55, 60], ["number", "OBSERVATION_MODIFIER", 61, 67]]], ["Reasons for sample rejection are remedial through improved training and vigilance.", [["sample", "ANATOMY", 12, 18], ["sample rejection", "PROBLEM", 12, 28], ["rejection", "OBSERVATION", 19, 28]]], ["A bespoke guide to sample collection for microbiology coupled with a training program for healthcare professionals has been introduced with the aim to reduce sample rejections from 3% to 0.5%.P040Introduction: Careful hand hygiene of health-care workers (HCWs) is recommended to reduce transmission of pathogenic microorganisms to patients [1] .", [["sample", "ANATOMY", 19, 25], ["hand", "ANATOMY", 218, 222], ["hand", "ORGANISM_SUBDIVISION", 218, 222], ["patients", "ORGANISM", 331, 339], ["patients", "SPECIES", 331, 339], ["a training program", "TREATMENT", 67, 85], ["healthcare professionals", "TREATMENT", 90, 114], ["sample rejections", "PROBLEM", 158, 175], ["pathogenic microorganisms", "PROBLEM", 302, 327]]], ["The purpose of this study was to assess the colonization rate of ICU HCWs' mobile phones before and after work shifts.", [["this study", "TEST", 15, 25]]], ["Methods: Prospective observational study conducted in an academic, tertiary-level ICU.", [["Prospective observational study", "TEST", 9, 40]]], ["Samples were taken with eSwab in a standardized modality and seeded on Columbia Agar plus 5% sheep blood.", [["Samples", "ANATOMY", 0, 7], ["blood", "ANATOMY", 99, 104], ["sheep", "ORGANISM", 93, 98], ["blood", "ORGANISM_SUBSTANCE", 99, 104], ["sheep", "SPECIES", 93, 98], ["sheep", "SPECIES", 93, 98], ["Samples", "TEST", 0, 7], ["eSwab", "TREATMENT", 24, 29], ["Columbia Agar", "TEST", 71, 84]]], ["A semiquantitative growth evaluation was performed at 24 and 48 hours after incubation at 35\u00b0C. Results: Fifty HCWs participated in the study (91% of department staff).", [["A semiquantitative growth evaluation", "TEST", 0, 36], ["the study", "TEST", 132, 141]]], ["One hundred swabs were taken from 50 mobile phones.", [["swabs", "ANATOMY", 12, 17]]], ["Fortythree HCWs (86%) reported a habitual use of their phones during the work shift, and 38 of them (88.4%) usually kept their mobiles in the uniform pocket.", [["uniform", "OBSERVATION_MODIFIER", 142, 149], ["pocket", "OBSERVATION", 150, 156]]], ["All phones (100%) were positive for bacteria.", [["bacteria", "PROBLEM", 36, 44]]], ["The most frequently isolated bacteria were Coagulase Negative Staphylococcus, Bacillus sp. and MRSA (97%, 56%, 17%, respectively).", [["MRSA", "DISEASE", 95, 99], ["Bacillus sp", "ORGANISM", 78, 89], ["MRSA", "SPECIES", 95, 99], ["The most frequently isolated bacteria", "PROBLEM", 0, 37], ["Coagulase", "TEST", 43, 52], ["Staphylococcus", "PROBLEM", 62, 76], ["MRSA", "TEST", 95, 99], ["bacteria", "OBSERVATION_MODIFIER", 29, 37], ["Staphylococcus", "OBSERVATION_MODIFIER", 62, 76], ["MRSA", "OBSERVATION", 95, 99]]], ["No patient admitted to the ICU during the study period was positive for bacteria found of HCWs' mobile phones.", [["patient", "ORGANISM", 3, 10], ["patient", "SPECIES", 3, 10], ["the study", "TEST", 38, 47], ["bacteria", "PROBLEM", 72, 80]]], ["No difference in bacteria types and burden was found between the beginning and the end of work shifts.P040Conclusions: HCWs' mobile phones are always colonized mainly by flora resident on HCW's hands, even before the work shift and irrespective of the microbiological patients' flora.", [["HCWs", "ORGANISM", 119, 123], ["hands", "ORGANISM_SUBDIVISION", 194, 199], ["patients", "ORGANISM", 268, 276], ["patients", "SPECIES", 268, 276], ["difference in bacteria types", "PROBLEM", 3, 31], ["burden", "PROBLEM", 36, 42], ["difference", "OBSERVATION_MODIFIER", 3, 13], ["bacteria types", "OBSERVATION_MODIFIER", 17, 31]]], ["Further studies are warranted to investigate the role of mobile phones' bacterial colonization in the ICU setting and to determine whether routine cleaning of HCWs' mobile phones may reduce the rate of infection transmission in critical patients.", [["infection", "DISEASE", 202, 211], ["patients", "ORGANISM", 237, 245], ["patients", "SPECIES", 237, 245], ["Further studies", "TEST", 0, 15], ["bacterial colonization", "PROBLEM", 72, 94], ["HCWs' mobile phones", "TREATMENT", 159, 178], ["infection transmission", "PROBLEM", 202, 224], ["infection", "OBSERVATION", 202, 211]]], ["Methods: Sixty samples were collected from AICU (n=25), PICU (n=15) and OR (n=20) during August to September 2017.", [["samples", "ANATOMY", 15, 22]]], ["Samples were randomly selected and taken at the end of the HCWs duty with a sterile swab covering all MP surfaces.", [["swab", "ANATOMY", 84, 88], ["Samples", "TEST", 0, 7], ["a sterile swab", "TREATMENT", 74, 88]]], ["The inoculation was made into blood sheep and eosyn methilene blue agar for culture.", [["blood", "ANATOMY", 30, 35], ["eosyn methilene blue", "CHEMICAL", 46, 66], ["methilene blue", "CHEMICAL", 52, 66], ["blood", "ORGANISM_SUBSTANCE", 30, 35], ["sheep", "ORGANISM_SUBSTANCE", 36, 41], ["sheep", "SPECIES", 36, 41], ["sheep", "SPECIES", 36, 41], ["The inoculation", "TREATMENT", 0, 15], ["blood sheep", "TEST", 30, 41], ["culture", "TEST", 76, 83]]], ["Isolated bacteria were identified according to standard microbiological techniques.", [["Isolated bacteria", "PROBLEM", 0, 17], ["standard microbiological techniques", "TEST", 47, 82], ["bacteria", "OBSERVATION", 9, 17]]], ["Antibiotic sensitivity testing was performed using disc diffusion method.P040Results: Overall MP bacterial colonization rate was 95%.", [["MP", "DISEASE", 94, 96], ["Antibiotic sensitivity testing", "TEST", 0, 30], ["disc diffusion method", "TEST", 51, 72], ["Overall MP bacterial colonization rate", "TEST", 86, 124], ["bacterial colonization", "OBSERVATION", 97, 119]]], ["Most common non pathogenic bacteria was Staphylococcus epidermidis n=18 (90%).", [["Staphylococcus epidermidis", "DISEASE", 40, 66], ["Staphylococcus epidermidis", "ORGANISM", 40, 66], ["Staphylococcus epidermidis", "SPECIES", 40, 66], ["Staphylococcus epidermidis n=18", "SPECIES", 40, 71], ["Most common non pathogenic bacteria", "PROBLEM", 0, 35], ["Staphylococcus epidermidis n", "TEST", 40, 68], ["pathogenic", "OBSERVATION_MODIFIER", 16, 26], ["bacteria", "OBSERVATION", 27, 35], ["Staphylococcus epidermidis", "OBSERVATION", 40, 66]]], ["Isolated pathogenic bacteria Conclusions: We found high rates of MP colonization with pathogenic bacteria.", [["MP", "DISEASE", 65, 67], ["MP", "GENE_OR_GENE_PRODUCT", 65, 67], ["Isolated pathogenic bacteria", "PROBLEM", 0, 28], ["MP colonization", "PROBLEM", 65, 80], ["pathogenic bacteria", "PROBLEM", 86, 105], ["pathogenic", "OBSERVATION_MODIFIER", 9, 19], ["bacteria", "OBSERVATION", 20, 28], ["high rates", "OBSERVATION_MODIFIER", 51, 61], ["MP colonization", "OBSERVATION_MODIFIER", 65, 80], ["pathogenic bacteria", "OBSERVATION", 86, 105]]], ["An educational program is necessary to reduce the contamination and transmission of these high risk microorganisms.P040Introduction: The objective of this study was to evaluate the variability in the dynamics and levels of airborne contamination within a hospital Intensive Care Unit in order to establish an improved understanding of the extent to which airborne bioburden contributes to cross-infection of patients.", [["patients", "ORGANISM", 408, 416], ["patients", "SPECIES", 408, 416], ["An educational program", "TREATMENT", 0, 22], ["the contamination", "PROBLEM", 46, 63], ["these high risk microorganisms", "PROBLEM", 84, 114], ["this study", "TEST", 150, 160], ["airborne bioburden", "PROBLEM", 355, 373], ["airborne bioburden", "OBSERVATION", 355, 373]]], ["Microorganisms from the respiratory tract or skin can become airborne by coughing, sneezing and periods of increased activity such as bed changes and staff rounds.", [["respiratory tract", "ANATOMY", 24, 41], ["skin", "ANATOMY", 45, 49], ["respiratory tract", "ORGANISM_SUBDIVISION", 24, 41], ["skin", "ORGAN", 45, 49], ["Microorganisms from the respiratory tract", "PROBLEM", 0, 41], ["coughing", "PROBLEM", 73, 81], ["sneezing", "PROBLEM", 83, 91], ["increased activity", "PROBLEM", 107, 125], ["respiratory tract", "ANATOMY", 24, 41], ["skin", "ANATOMY", 45, 49]]], ["Current knowledge of the clinical microflora is limited however it is estimated that 10-33% of nosocomial infections are transmitted via air.", [["infections", "DISEASE", 106, 116], ["nosocomial infections", "PROBLEM", 95, 116], ["nosocomial", "OBSERVATION_MODIFIER", 95, 105], ["infections", "OBSERVATION", 106, 116]]], ["Methods: Environmental air monitoring was conducted in Glasgow Royal Infirmary ICU, in the open ward and in patient isolation rooms.", [["patient", "ORGANISM", 108, 115], ["patient", "SPECIES", 108, 115]]], ["A sieve impactor air sampler was used to collect 500 L air samples every 15 minutes over 10 hour (08:00-18:00 h) and 24 hour (08:00-08:00 h) periods.", [["A sieve impactor air sampler", "TREATMENT", 0, 28]]], ["Samples were collected, room activity logged and the bacterial contamination levels were recorded as CFU/m 3 of air.P040Results: A high degree of variability in levels of airborne contamination was observed over the course of a 10 hour day and a 24 period in a hospital ICU.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["the bacterial contamination levels", "TEST", 49, 83], ["A high degree of variability", "PROBLEM", 129, 157], ["airborne contamination", "PROBLEM", 171, 193], ["high degree", "OBSERVATION_MODIFIER", 131, 142], ["variability", "OBSERVATION_MODIFIER", 146, 157], ["airborne contamination", "OBSERVATION", 171, 193]]], ["Counts ranged from 12-510 CFU/m 3 over 24 hours in an isolation room occupied for 10 days by a patient with C. difficile infection.", [["C. difficile infection", "DISEASE", 108, 130], ["patient", "ORGANISM", 95, 102], ["C. difficile", "ORGANISM", 108, 120], ["patient", "SPECIES", 95, 102], ["C. difficile", "SPECIES", 108, 120], ["C. difficile", "SPECIES", 108, 120], ["Counts", "TEST", 0, 6], ["C. difficile infection", "PROBLEM", 108, 130], ["difficile", "OBSERVATION_MODIFIER", 111, 120], ["infection", "OBSERVATION", 121, 130]]], ["Contamination levels were found to be lowest during the night and in unoccupied rooms, with an average value of 20 CFU/m 3 .", [["Contamination levels", "TEST", 0, 20], ["an average value", "TEST", 92, 108]]], ["Peaks in airborne contamination showed a direct relation to increased room activity.P040Conclusions: This study demonstrates the degree of airborne contamination that can occur in an ICU over a 24 hour period.", [["Peaks in airborne contamination", "PROBLEM", 0, 31], ["increased room activity", "PROBLEM", 60, 83], ["This study", "TEST", 101, 111], ["airborne contamination", "PROBLEM", 139, 161], ["airborne contamination", "OBSERVATION", 9, 31], ["increased", "OBSERVATION_MODIFIER", 60, 69], ["room activity", "OBSERVATION", 70, 83], ["airborne contamination", "OBSERVATION", 139, 161]]], ["Numerous factors were found to contribute to microbial air contamination and consideration should be given to potential improved infection control strategies and decontamination technologies which could be deployed within the clinical environment to reduce the airborne contamination levels, with the ultimate aim of reducing healthcareassociated infections from environmental sources.P047New practice of fixing the venous catheter of the jugular on the thorax and its impact on the infection F Goldstein, C Carius, A Coscia QuintaD'or, Rio de Janeiro, Brazil Critical Care 2018, 22(Suppl 1):P047P047Introduction: Central Line-associated Bloodstream Infection (CLABSI) is an important concern in the ICU, mainly in those with a high density of use of central venous catheter.", [["venous", "ANATOMY", 416, 422], ["jugular", "ANATOMY", 439, 446], ["thorax", "ANATOMY", 454, 460], ["venous", "ANATOMY", 759, 765], ["infection", "DISEASE", 129, 138], ["infections", "DISEASE", 347, 357], ["infection", "DISEASE", 483, 492], ["Bloodstream Infection", "DISEASE", 638, 659], ["CLABSI", "DISEASE", 661, 667], ["venous catheter", "MULTI-TISSUE_STRUCTURE", 416, 431], ["jugular", "MULTI-TISSUE_STRUCTURE", 439, 446], ["thorax", "ORGAN", 454, 460], ["central venous catheter", "MULTI-TISSUE_STRUCTURE", 751, 774], ["Numerous factors", "PROBLEM", 0, 16], ["microbial air contamination", "PROBLEM", 45, 72], ["potential improved infection control strategies", "PROBLEM", 110, 157], ["decontamination technologies", "TREATMENT", 162, 190], ["the airborne contamination levels", "TEST", 257, 290], ["reducing healthcareassociated infections", "PROBLEM", 317, 357], ["the venous catheter", "TREATMENT", 412, 431], ["Central Line-associated Bloodstream Infection", "PROBLEM", 614, 659], ["central venous catheter", "TREATMENT", 751, 774], ["air contamination", "OBSERVATION", 55, 72], ["improved", "OBSERVATION_MODIFIER", 120, 128], ["infection", "OBSERVATION", 129, 138], ["infections", "OBSERVATION", 347, 357], ["venous", "ANATOMY", 416, 422], ["catheter", "OBSERVATION", 423, 431], ["jugular", "ANATOMY", 439, 446], ["thorax", "ANATOMY", 454, 460], ["infection", "OBSERVATION", 483, 492], ["Central Line", "OBSERVATION", 614, 626], ["Bloodstream", "OBSERVATION_MODIFIER", 638, 649], ["Infection", "OBSERVATION", 650, 659], ["high density", "OBSERVATION_MODIFIER", 728, 740], ["central", "ANATOMY_MODIFIER", 751, 758], ["venous", "ANATOMY", 759, 765], ["catheter", "OBSERVATION", 766, 774]]], ["Any measures that may have an impact on the reduction of CLABSI are important in reducing morbidity and mortality of hospitalized patients.", [["CLABSI", "DISEASE", 57, 63], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["CLABSI", "PROBLEM", 57, 63], ["impact", "OBSERVATION_MODIFIER", 30, 36], ["reduction", "OBSERVATION_MODIFIER", 44, 53], ["CLABSI", "OBSERVATION", 57, 63]]], ["Therefore we present a retrospective study comparing the fixation site (neck vs. thorax) of the catheters implanted in the jugular vein, guided by ultrasonography and evaluating its impact on the incidence of CLABSI.", [["neck", "ANATOMY", 72, 76], ["thorax", "ANATOMY", 81, 87], ["jugular vein", "ANATOMY", 123, 135], ["CLABSI", "DISEASE", 209, 215], ["neck", "ORGANISM_SUBDIVISION", 72, 76], ["thorax", "ORGAN", 81, 87], ["jugular vein", "MULTI-TISSUE_STRUCTURE", 123, 135], ["a retrospective study", "TEST", 21, 42], ["the fixation site (neck vs. thorax", "TREATMENT", 53, 87], ["the catheters", "TREATMENT", 92, 105], ["ultrasonography", "TEST", 147, 162], ["CLABSI", "PROBLEM", 209, 215], ["neck", "ANATOMY", 72, 76], ["thorax", "ANATOMY", 81, 87], ["catheters", "OBSERVATION", 96, 105], ["jugular vein", "ANATOMY", 123, 135], ["CLABSI", "OBSERVATION", 209, 215]]], ["The purpose of our study was to identify if there is any positive impact on the reduction of CLABSI when the catheter is fixated on the thorax.", [["thorax", "ANATOMY", 136, 142], ["CLABSI", "DISEASE", 93, 99], ["thorax", "ORGAN", 136, 142], ["our study", "TEST", 15, 24], ["the reduction of CLABSI", "TREATMENT", 76, 99], ["the catheter", "TREATMENT", 105, 117], ["CLABSI", "OBSERVATION", 93, 99], ["catheter", "OBSERVATION", 109, 117], ["fixated", "OBSERVATION", 121, 128], ["thorax", "ANATOMY", 136, 142]]], ["Methods: A retrospective unicentric study comparing the infection rates between the year of 2012, when the traditional technique of catheter fixation on the neck was used, and 2015, when 100% of the catheters were fixated on the thoracic region.", [["neck", "ANATOMY", 157, 161], ["thoracic region", "ANATOMY", 229, 244], ["infection", "DISEASE", 56, 65], ["neck", "ORGANISM_SUBDIVISION", 157, 161], ["thoracic region", "MULTI-TISSUE_STRUCTURE", 229, 244], ["A retrospective unicentric study", "TEST", 9, 41], ["the infection rates", "PROBLEM", 52, 71], ["the traditional technique of catheter fixation", "TREATMENT", 103, 149], ["the catheters", "TREATMENT", 195, 208], ["infection", "OBSERVATION", 56, 65], ["catheter fixation", "OBSERVATION", 132, 149], ["neck", "ANATOMY", 157, 161], ["catheters", "OBSERVATION", 199, 208], ["thoracic", "ANATOMY", 229, 237], ["region", "ANATOMY_MODIFIER", 238, 244]]], ["The criteria for CLABSI were defined by the Infection Commission of QuintaD`or Hospital and the data on CLABSI were provided by the same commission.", [["CLABSI", "PROBLEM", 17, 23], ["CLABSI", "TREATMENT", 104, 110], ["Infection", "OBSERVATION", 44, 53]]], ["During this period there were no changes in the team of our unit and the patient's profile was the same.", [["patient", "ORGANISM", 73, 80], ["patient", "SPECIES", 73, 80], ["the patient's profile", "TEST", 69, 90], ["no", "UNCERTAINTY", 30, 32]]], ["No deep vein catheter impregnated with antibiotics were used in the patients included in the study.", [["deep vein", "ANATOMY", 3, 12], ["deep vein", "MULTI-TISSUE_STRUCTURE", 3, 12], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["deep vein catheter", "TREATMENT", 3, 21], ["antibiotics", "TREATMENT", 39, 50], ["the study", "TEST", 89, 98], ["deep", "ANATOMY_MODIFIER", 3, 7], ["vein", "ANATOMY", 8, 12], ["catheter", "OBSERVATION", 13, 21]]], ["The comparison used Fisher\u0301s test as a tool.", [["Fisher\u0301s test", "TEST", 20, 33]]], ["All the patients hospitalized in the intensive care unit with indication of the central venous catheter of short permanence in the internal jugular vein were included.", [["venous", "ANATOMY", 88, 94], ["internal jugular vein", "ANATOMY", 131, 152], ["patients", "ORGANISM", 8, 16], ["central venous", "MULTI-TISSUE_STRUCTURE", 80, 94], ["internal jugular vein", "MULTI-TISSUE_STRUCTURE", 131, 152], ["patients", "SPECIES", 8, 16], ["the central venous catheter of short permanence", "TREATMENT", 76, 123], ["central", "ANATOMY_MODIFIER", 80, 87], ["venous", "ANATOMY", 88, 94], ["catheter", "OBSERVATION", 95, 103], ["short permanence", "OBSERVATION", 107, 123], ["internal jugular vein", "ANATOMY", 131, 152]]], ["Patients with the central venous catheter of short permanence in other topographies, patients with hemodialysis catheter or with PICC were excluded.P047Results: During the year of 2012, 98 internal jugular vein catheters were installed in our unit using the traditional technique, fixing the catheter on the neck.", [["venous", "ANATOMY", 26, 32], ["internal jugular vein", "ANATOMY", 189, 210], ["neck", "ANATOMY", 308, 312], ["Patients", "ORGANISM", 0, 8], ["central venous", "MULTI-TISSUE_STRUCTURE", 18, 32], ["patients", "ORGANISM", 85, 93], ["jugular vein", "MULTI-TISSUE_STRUCTURE", 198, 210], ["neck", "ORGANISM_SUBDIVISION", 308, 312], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 85, 93], ["the central venous catheter", "TREATMENT", 14, 41], ["hemodialysis catheter", "TREATMENT", 99, 120], ["PICC", "TREATMENT", 129, 133], ["internal jugular vein catheters", "TREATMENT", 189, 220], ["the traditional technique", "TREATMENT", 254, 279], ["the catheter on the neck", "TREATMENT", 288, 312], ["central", "ANATOMY_MODIFIER", 18, 25], ["venous", "ANATOMY", 26, 32], ["catheter", "OBSERVATION", 33, 41], ["short", "OBSERVATION_MODIFIER", 45, 50], ["hemodialysis catheter", "OBSERVATION", 99, 120], ["internal", "ANATOMY", 189, 197], ["jugular vein", "ANATOMY", 198, 210], ["catheters", "OBSERVATION", 211, 220], ["catheter", "OBSERVATION", 292, 300], ["neck", "ANATOMY", 308, 312]]], ["In this period, 6 cases of CLABSI were detected.", [["CLABSI", "DISEASE", 27, 33], ["CLABSI", "CANCER", 27, 33], ["CLABSI", "PROBLEM", 27, 33], ["CLABSI", "OBSERVATION", 27, 33]]], ["On the other hand, in the year of 2015, 127 internal jugular vein catheters were installed in the same unit, all of them, using the thorax as the point of fixation.", [["internal jugular vein", "ANATOMY", 44, 65], ["thorax", "ANATOMY", 132, 138], ["jugular vein", "MULTI-TISSUE_STRUCTURE", 53, 65], ["thorax", "ORGAN", 132, 138], ["internal jugular vein catheters", "TREATMENT", 44, 75], ["fixation", "TREATMENT", 155, 163], ["internal", "ANATOMY", 44, 52], ["jugular vein", "ANATOMY", 53, 65], ["catheters", "OBSERVATION", 66, 75], ["thorax", "ANATOMY", 132, 138], ["fixation", "OBSERVATION", 155, 163]]], ["Although the number of catheters installed this year was higher, there was no case of CLABSI.", [["CLABSI", "DISEASE", 86, 92], ["catheters", "TREATMENT", 23, 32], ["CLABSI", "PROBLEM", 86, 92], ["catheters", "OBSERVATION", 23, 32], ["no case of", "UNCERTAINTY", 75, 85], ["CLABSI", "OBSERVATION", 86, 92]]], ["It appears that this position, provides a better fixation of the catheter, avoiding that the bandage gets uncovered.P047Conclusions: During the year of 2015, though there were more patients using deep vein catheters of short permanence, we had less CLABSI events on our unity compared to the year of 2012.P047Fisher's exact test identified a p-value of this association of 0.476.", [["vein", "ANATOMY", 201, 205], ["patients", "ORGANISM", 181, 189], ["deep vein", "MULTI-TISSUE_STRUCTURE", 196, 205], ["patients", "SPECIES", 181, 189], ["a better fixation of the catheter", "TREATMENT", 40, 73], ["the bandage", "TREATMENT", 89, 100], ["deep vein catheters", "TREATMENT", 196, 215], ["less CLABSI events", "PROBLEM", 244, 262], ["P047Fisher's exact test", "TEST", 305, 328], ["catheter", "OBSERVATION", 65, 73], ["bandage", "OBSERVATION", 93, 100], ["deep", "ANATOMY_MODIFIER", 196, 200], ["vein", "ANATOMY", 201, 205]]], ["Fixation of the internal jugular vein catheter in the thorax seems to contribute to the prevention of CLABSI.", [["internal jugular vein", "ANATOMY", 16, 37], ["thorax", "ANATOMY", 54, 60], ["CLABSI", "DISEASE", 102, 108], ["internal jugular vein", "MULTI-TISSUE_STRUCTURE", 16, 37], ["thorax", "ORGAN", 54, 60], ["Fixation", "TREATMENT", 0, 8], ["the internal jugular vein catheter", "TREATMENT", 12, 46], ["CLABSI", "PROBLEM", 102, 108], ["internal jugular vein", "ANATOMY", 16, 37], ["catheter", "OBSERVATION", 38, 46], ["thorax", "ANATOMY", 54, 60], ["CLABSI", "OBSERVATION", 102, 108]]], ["Further prospective and randomized studies are required to evaluate the contribution of fixation of the jugular vein catheter in the thorax in the CLABSI prevention.", [["jugular vein", "ANATOMY", 104, 116], ["thorax", "ANATOMY", 133, 139], ["jugular vein", "MULTI-TISSUE_STRUCTURE", 104, 116], ["thorax", "ORGAN", 133, 139], ["randomized studies", "TEST", 24, 42], ["fixation", "TREATMENT", 88, 96], ["the jugular vein catheter", "TREATMENT", 100, 125], ["the CLABSI prevention", "TREATMENT", 143, 164], ["fixation", "OBSERVATION", 88, 96], ["jugular vein", "ANATOMY", 104, 116], ["catheter", "OBSERVATION", 117, 125], ["thorax", "ANATOMY", 133, 139], ["CLABSI", "OBSERVATION", 147, 153]]], ["Introduction: The oral cavity of a patient who has been hospitalized presents a different flora from normal healthy people.", [["oral cavity", "ANATOMY", 18, 29], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 18, 29], ["patient", "ORGANISM", 35, 42], ["people", "ORGANISM", 116, 122], ["patient", "SPECIES", 35, 42], ["people", "SPECIES", 116, 122]]], ["After 48h hours of hospital stay, the flora presents a bigger number of microorganisms that can be responsible for secondary infections, like pneumonia, because of their growth and proliferation.", [["infections", "DISEASE", 125, 135], ["pneumonia", "DISEASE", 142, 151], ["the flora", "PROBLEM", 34, 43], ["microorganisms", "PROBLEM", 72, 86], ["secondary infections", "PROBLEM", 115, 135], ["pneumonia", "PROBLEM", 142, 151], ["their growth", "PROBLEM", 164, 176], ["proliferation", "PROBLEM", 181, 194], ["can be responsible for", "UNCERTAINTY", 92, 114], ["secondary", "OBSERVATION_MODIFIER", 115, 124], ["infections", "OBSERVATION", 125, 135], ["pneumonia", "OBSERVATION", 142, 151], ["growth", "OBSERVATION_MODIFIER", 170, 176], ["proliferation", "OBSERVATION_MODIFIER", 181, 194]]], ["The objective of our study was to assess the dental plaque index on patients on admission to an Intensive Care Unit, and reassess 7 days later, to evaluate the efficacy of oral hygiene.", [["plaque", "ANATOMY", 52, 58], ["oral", "ANATOMY", 172, 176], ["patients", "ORGANISM", 68, 76], ["oral", "ORGANISM_SUBDIVISION", 172, 176], ["patients", "SPECIES", 68, 76], ["our study", "TEST", 17, 26], ["the dental plaque index", "PROBLEM", 41, 64], ["oral hygiene", "TREATMENT", 172, 184]]], ["Methods: Prospective, descriptive and observational study in an Intensive Care Unit of the CHP.", [["observational study", "TEST", 38, 57]]], ["Demographic, admission motive, hospital length of stay, feeding protocol, respiratory support need and oral hygiene protocol data was collected.", [["oral", "ANATOMY", 103, 107], ["oral", "ORGANISM_SUBDIVISION", 103, 107], ["feeding protocol", "TREATMENT", 56, 72], ["respiratory support", "TREATMENT", 74, 93], ["oral hygiene protocol data", "TEST", 103, 129]]], ["The Greene & Vermillion Simplified Oral Hygiene Index (IHO-S) was used as the assessment tool on the first 24h and on 7th day.", [["The Greene & Vermillion", "TREATMENT", 0, 23], ["the assessment tool", "TEST", 74, 93]]], ["Results: 74 patients were evaluated, 42 of which were excluded for not meeting the minimal dentition.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["32 patients had a mean age of 60,53 \u00b1 14,44 years, 53,1% were males and most of medical and surgical scope (37,5% each).", [["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["surgical scope", "TEST", 92, 106]]], ["The majority of patients were sedated (75%), under ventilator support (81,3%) and with enteric nutritional support, under nasogastric tube feeding.", [["tube", "ANATOMY", 134, 138], ["patients", "ORGANISM", 16, 24], ["nasogastric tube", "MULTI-TISSUE_STRUCTURE", 122, 138], ["patients", "SPECIES", 16, 24], ["sedated", "TREATMENT", 30, 37], ["ventilator support", "TREATMENT", 51, 69], ["enteric nutritional support", "TREATMENT", 87, 114], ["nasogastric tube feeding", "TREATMENT", 122, 146], ["nasogastric tube", "OBSERVATION", 122, 138]]], ["Initial IHO-S score was 0,67\u00b10,45, rising to 1,04\u00b10,51 (p<0,05) 7 days later.P047Conclusions: Various studies have proven the importance of a good oral hygiene to avoid bacterial growth and reduce the risk for nosocomial infections.", [["oral", "ANATOMY", 147, 151], ["nosocomial infections", "DISEASE", 210, 231], ["oral", "ORGANISM_SUBDIVISION", 147, 151], ["Initial IHO-S score", "TEST", 0, 19], ["Various studies", "TEST", 94, 109], ["bacterial growth", "PROBLEM", 169, 185], ["nosocomial infections", "PROBLEM", 210, 231], ["nosocomial", "OBSERVATION_MODIFIER", 210, 220], ["infections", "OBSERVATION", 221, 231]]], ["In this study, we've observed a significant worsening of oral hygiene one week after admission.", [["oral", "ANATOMY", 57, 61], ["oral", "ORGANISM_SUBDIVISION", 57, 61], ["this study", "TEST", 3, 13], ["oral hygiene", "TREATMENT", 57, 69], ["significant", "OBSERVATION_MODIFIER", 32, 43], ["worsening", "OBSERVATION_MODIFIER", 44, 53]]], ["Although this could be unimportant for a one week staying patient, it could indicate an increased risk for nosocomial infections for longer staying patients, which could benefit from a more efficient oral hygiene protocol.P049Positive pocket cultures and infection risk after cardiac electronic device implantation-a retrospective observational single-center cohort study P Peki\u0107 1 Methods: We performed a retrospective observational single-center cohort study on 251 patients who received de novo implantation of pacemaker, cardioverter-defibrillator or cardiac resynchronization therapy device in a two-year period.", [["oral", "ANATOMY", 200, 204], ["cardiac", "ANATOMY", 276, 283], ["cardiac", "ANATOMY", 555, 562], ["infections", "DISEASE", 118, 128], ["infection", "DISEASE", 255, 264], ["patient", "ORGANISM", 58, 65], ["patients", "ORGANISM", 148, 156], ["oral", "ORGANISM_SUBDIVISION", 200, 204], ["patients", "ORGANISM", 468, 476], ["P049Positive pocket cultures", "CELL_LINE", 222, 250], ["patient", "SPECIES", 58, 65], ["patients", "SPECIES", 148, 156], ["patients", "SPECIES", 468, 476], ["nosocomial infections", "PROBLEM", 107, 128], ["a more efficient oral hygiene protocol", "TREATMENT", 183, 221], ["pocket cultures", "TEST", 235, 250], ["infection risk", "PROBLEM", 255, 269], ["cardiac electronic device implantation", "TREATMENT", 276, 314], ["cohort study", "TEST", 448, 460], ["de novo implantation of pacemaker", "TREATMENT", 490, 523], ["cardioverter", "TREATMENT", 525, 537], ["defibrillator", "TREATMENT", 538, 551], ["cardiac resynchronization therapy device", "TREATMENT", 555, 595], ["increased", "OBSERVATION_MODIFIER", 88, 97], ["nosocomial", "OBSERVATION_MODIFIER", 107, 117], ["infections", "OBSERVATION", 118, 128], ["infection", "OBSERVATION", 255, 264], ["pacemaker", "OBSERVATION", 514, 523], ["cardiac", "ANATOMY", 555, 562], ["resynchronization therapy", "OBSERVATION", 563, 588]]], ["Each patient was implanted using standard aseptic procedure according to local protocol and antibiotic (cefazolin) prophylaxis before the procedure.", [["cefazolin", "CHEMICAL", 104, 113], ["cefazolin", "CHEMICAL", 104, 113], ["patient", "ORGANISM", 5, 12], ["cefazolin", "SIMPLE_CHEMICAL", 104, 113], ["patient", "SPECIES", 5, 12], ["standard aseptic procedure", "TREATMENT", 33, 59], ["local protocol", "TREATMENT", 73, 87], ["antibiotic (cefazolin) prophylaxis", "TREATMENT", 92, 126], ["the procedure", "TREATMENT", 134, 147]]], ["Pocket aspirate was taken after irrigating the wound with normal saline just before device placement.", [["wound", "ANATOMY", 47, 52], ["wound", "PATHOLOGICAL_FORMATION", 47, 52], ["saline", "SIMPLE_CHEMICAL", 65, 71], ["Pocket aspirate", "TEST", 0, 15], ["the wound", "PROBLEM", 43, 52], ["normal saline", "TREATMENT", 58, 71], ["device placement", "TREATMENT", 84, 100], ["aspirate", "OBSERVATION", 7, 15], ["wound", "ANATOMY", 47, 52]]], ["Results: We analyzed 251 patients (58.6% male, 41.4% female).", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33]]], ["The most often implanted device was a DDD pacemaker followed by a VVI pacemaker.", [["The most often implanted device", "TREATMENT", 0, 31], ["a DDD pacemaker", "TREATMENT", 36, 51], ["a VVI pacemaker", "TREATMENT", 64, 79], ["pacemaker", "OBSERVATION", 42, 51], ["VVI pacemaker", "OBSERVATION", 66, 79]]], ["Mean length of hospital stay was 12.02\u00b18.34 days.", [["length", "OBSERVATION_MODIFIER", 5, 11]]], ["There were 54 (21.5%) positive cultures with overall 3 (1.19%) clinically apparent infections which required prolonged iv antibiotics, removal of device and reimplantation after infection resolution.", [["infections", "DISEASE", 83, 93], ["infection", "DISEASE", 178, 187], ["positive cultures", "TEST", 22, 39], ["clinically apparent infections", "PROBLEM", 63, 93], ["prolonged iv antibiotics", "TREATMENT", 109, 133], ["removal of device", "TREATMENT", 135, 152], ["reimplantation", "TREATMENT", 157, 171], ["infection resolution", "PROBLEM", 178, 198], ["infections", "OBSERVATION", 83, 93], ["reimplantation", "OBSERVATION", 157, 171], ["infection", "OBSERVATION", 178, 187]]], ["In regard to microbiology, S. epidermidis (48.2%) and coagulase negative Staphylococcus (29.6%) were the most often finding which is in contrast to the cultures described in the literature.", [["S. epidermidis", "DISEASE", 27, 41], ["coagulase negative Staphylococcus", "DISEASE", 54, 87], ["S. epidermidis", "ORGANISM", 27, 41], ["coagulase negative Staphylococcus", "GENE_OR_GENE_PRODUCT", 54, 87], ["S. epidermidis", "SPECIES", 27, 41], ["S. epidermidis", "SPECIES", 27, 41], ["microbiology", "TEST", 13, 25], ["S. epidermidis", "TEST", 27, 41], ["coagulase negative Staphylococcus", "PROBLEM", 54, 87], ["the cultures", "TEST", 148, 160], ["epidermidis", "OBSERVATION", 30, 41], ["Staphylococcus", "OBSERVATION_MODIFIER", 73, 87]]], ["The only statistically significant risk factor for positive pocket culture was male sex and presence of a urinary catheter.", [["urinary", "ANATOMY", 106, 113], ["urinary", "ORGANISM_SUBDIVISION", 106, 113], ["positive pocket culture", "PROBLEM", 51, 74], ["a urinary catheter", "TREATMENT", 104, 122], ["significant", "OBSERVATION_MODIFIER", 23, 34], ["pocket", "OBSERVATION_MODIFIER", 60, 66], ["urinary", "ANATOMY", 106, 113], ["catheter", "OBSERVATION", 114, 122]]], ["Invasive vascular devices, previous intrahospital infection, and diabetes were not found to increase the likelihood of positive pocket culture.", [["vascular", "ANATOMY", 9, 17], ["intrahospital infection", "DISEASE", 36, 59], ["diabetes", "DISEASE", 65, 73], ["vascular", "MULTI-TISSUE_STRUCTURE", 9, 17], ["Invasive vascular devices", "TREATMENT", 0, 25], ["previous intrahospital infection", "PROBLEM", 27, 59], ["diabetes", "PROBLEM", 65, 73], ["positive pocket culture", "PROBLEM", 119, 142], ["vascular", "ANATOMY", 9, 17], ["devices", "OBSERVATION", 18, 25], ["intrahospital", "OBSERVATION_MODIFIER", 36, 49], ["infection", "OBSERVATION", 50, 59], ["diabetes", "OBSERVATION", 65, 73], ["positive pocket", "OBSERVATION", 119, 134]]], ["Conclusions: Positive pocket cultures after CIED implant are a frequent finding mostly due to contamination and colonisation.", [["Positive pocket cultures", "PROBLEM", 13, 37], ["CIED implant", "TREATMENT", 44, 56], ["a frequent finding", "PROBLEM", 61, 79], ["contamination", "PROBLEM", 94, 107], ["colonisation", "PROBLEM", 112, 124], ["Positive", "OBSERVATION_MODIFIER", 13, 21], ["pocket", "OBSERVATION_MODIFIER", 22, 28], ["colonisation", "OBSERVATION", 112, 124]]], ["The risk factors for such a finding differ from the usual and expected clinical circumstances.", [["The risk factors", "PROBLEM", 0, 16]]], ["Our results are consistent with those in the literature.", [["consistent with", "UNCERTAINTY", 16, 31]]], ["It turns out that the most important preventive measure in CIED implantation is strict aseptic procedure.", [["CIED implantation", "TREATMENT", 59, 76], ["strict aseptic procedure", "TREATMENT", 80, 104], ["aseptic procedure", "OBSERVATION", 87, 104]]], ["Introduction: Intensive care patients are in constant risk of contamination due to suppression of their immune system, use of invasive procedures and medical equipment and health associated infections (HAI).", [["infections", "DISEASE", 190, 200], ["HAI", "DISEASE", 202, 205], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["contamination", "PROBLEM", 62, 75], ["invasive procedures", "TREATMENT", 126, 145], ["medical equipment", "TREATMENT", 150, 167], ["health associated infections", "PROBLEM", 172, 200], ["infections", "OBSERVATION", 190, 200]]], ["Chlorhexidine Gluconate (CHG) is an antiseptic and disinfectant product.", [["Chlorhexidine Gluconate", "CHEMICAL", 0, 23], ["CHG", "CHEMICAL", 25, 28], ["Chlorhexidine Gluconate", "CHEMICAL", 0, 23], ["CHG", "CHEMICAL", 25, 28], ["Chlorhexidine Gluconate", "SIMPLE_CHEMICAL", 0, 23], ["CHG", "SIMPLE_CHEMICAL", 25, 28], ["Chlorhexidine Gluconate (CHG)", "TREATMENT", 0, 29], ["an antiseptic", "TREATMENT", 33, 46], ["disinfectant product", "TREATMENT", 51, 71]]], ["In medical research it has been found that daily CHG bathing is affective in reducing levels of skin and central line related infections (Climo, 2013) .", [["skin", "ANATOMY", 96, 100], ["central line", "ANATOMY", 105, 117], ["CHG", "CHEMICAL", 49, 52], ["infections", "DISEASE", 126, 136], ["CHG", "CHEMICAL", 49, 52], ["CHG", "SIMPLE_CHEMICAL", 49, 52], ["skin", "ORGAN", 96, 100], ["daily CHG bathing", "TREATMENT", 43, 60], ["central line related infections", "PROBLEM", 105, 136], ["skin", "ANATOMY", 96, 100], ["central line", "OBSERVATION", 105, 117]]], ["It is also referred to in the recommendations of the ministry of health \"prevention of septicemia due to central lines\" (2011).", [["central lines", "ANATOMY", 105, 118], ["septicemia", "DISEASE", 87, 97], ["central lines", "CELL", 105, 118], ["septicemia", "PROBLEM", 87, 97], ["central lines", "TREATMENT", 105, 118], ["septicemia", "OBSERVATION", 87, 97], ["central lines", "OBSERVATION", 105, 118]]], ["Methods: Unit guide lines for patient Dry Bathing were written in May 2015 and thereafter began the implementation and instruction of nursing staff.", [["patient", "ORGANISM", 30, 37], ["patient", "SPECIES", 30, 37], ["Unit guide lines", "TREATMENT", 9, 25]]], ["There was a 15 phase questioner that included several categories such as: preparation of the CHG solution, staff protection actions, infusions and surgical wound dressings, bathing performance and documentation.P049Results: A gradual rise of 97%was observed in theperformance ofdry bathing according to the unit guidelines Conclusions: 97% of observed dry baths where performed according to the guide lines.", [["wound", "ANATOMY", 156, 161], ["CHG", "CHEMICAL", 93, 96], ["CHG", "SIMPLE_CHEMICAL", 93, 96], ["wound", "PATHOLOGICAL_FORMATION", 156, 161], ["the CHG solution", "TREATMENT", 89, 105], ["staff protection actions", "TREATMENT", 107, 131], ["infusions", "TREATMENT", 133, 142], ["surgical wound dressings", "TREATMENT", 147, 171], ["bathing performance", "TREATMENT", 173, 192], ["observed dry baths", "TREATMENT", 343, 361], ["gradual", "OBSERVATION_MODIFIER", 226, 233], ["rise", "OBSERVATION_MODIFIER", 234, 238]]], ["Points for improvement: Correct care of infusions and surgical wound dressing and verify use of separate wipes for each body part.", [["wound", "ANATOMY", 63, 68], ["body", "ANATOMY", 120, 124], ["wound", "PATHOLOGICAL_FORMATION", 63, 68], ["body", "ORGANISM_SUBDIVISION", 120, 124], ["infusions", "TREATMENT", 40, 49], ["surgical wound dressing", "TREATMENT", 54, 77], ["separate wipes", "TREATMENT", 96, 110]]], ["Next we will examine the correlation between the use of dry baths and theextent of infections in the unit.", [["infections", "DISEASE", 83, 93], ["dry baths", "TREATMENT", 56, 65], ["infections", "PROBLEM", 83, 93], ["infections", "OBSERVATION", 83, 93]]], ["Dry Baths are nowconsidered an integralpart of the daily nursing routine.", [["Baths", "OBSERVATION", 4, 9]]], ["They have no substantial costs, help prevent complications from infection and add to the patient's safety.P049Introduction: Despite reductions in mortality reported with SDD, concerns about bacterial resistance and alteration of microbiome limit use.", [["infection", "DISEASE", 64, 73], ["patient", "ORGANISM", 89, 96], ["patient", "SPECIES", 89, 96], ["complications", "PROBLEM", 45, 58], ["infection", "PROBLEM", 64, 73], ["SDD", "PROBLEM", 170, 173], ["bacterial resistance", "PROBLEM", 190, 210], ["no", "UNCERTAINTY", 10, 12], ["substantial", "OBSERVATION_MODIFIER", 13, 24], ["costs", "OBSERVATION", 25, 30], ["infection", "OBSERVATION", 64, 73], ["bacterial resistance", "OBSERVATION", 190, 210]]], ["A retrospective observational study was conducted into the effect of local SDD protocols on VAP rates and resistance patterns.", [["VAP", "DISEASE", 92, 95], ["A retrospective observational study", "TEST", 0, 35], ["local SDD protocols", "TREATMENT", 69, 88], ["VAP rates", "TEST", 92, 101]]], ["Over a 2-year period, 2 regimens were used dependent on drug availability and hospital antibiotic stewardship concerns.", [["2 regimens", "TREATMENT", 22, 32], ["hospital antibiotic stewardship", "TREATMENT", 78, 109]]], ["The study was designed to review practice and identify any risks of partial implementation.P049Methods: Patients ventilated on a general intensive care were identified via clinical information systems.", [["Patients", "ORGANISM", 104, 112], ["Patients", "SPECIES", 104, 112], ["The study", "TEST", 0, 9], ["a general intensive care", "TREATMENT", 127, 151]]], ["Three periods were reviewed for adherence to SDD protocols, Pre SDD (Jan -Feb 14), Full (July -Sept 15) and Partial (July -Sept 16).", [["SDD protocols", "TREATMENT", 45, 58]]], ["High-risk patients during both SDD periods also received IV antibiotics for 96 hours.", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["IV antibiotics", "TREATMENT", 57, 71]]], ["Patients admitted with pneumonia or tuberculosis were excluded from VAP analysis.", [["pneumonia", "DISEASE", 23, 32], ["tuberculosis", "DISEASE", 36, 48], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["pneumonia", "PROBLEM", 23, 32], ["tuberculosis", "PROBLEM", 36, 48], ["VAP analysis", "TEST", 68, 80], ["pneumonia", "OBSERVATION", 23, 32], ["tuberculosis", "OBSERVATION", 36, 48]]], ["Remaining patients' records were reviewed and the Clinical Pulmonary Infection Score (CPIS) calculated for each ventilated day to identify VAP rates.", [["Pulmonary", "ANATOMY", 59, 68], ["Pulmonary Infection", "DISEASE", 59, 78], ["VAP", "DISEASE", 139, 142], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["the Clinical Pulmonary Infection Score", "PROBLEM", 46, 84], ["CPIS", "TEST", 86, 90], ["VAP rates", "TEST", 139, 148], ["Pulmonary", "ANATOMY", 59, 68], ["Infection", "OBSERVATION", 69, 78]]], ["Positive respiratory microbiological results for all patients admitted to the ICU during each time period were reviewed to assess for wider changes in local resistance patterns.", [["respiratory", "ANATOMY", 9, 20], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["wider changes in local resistance patterns", "PROBLEM", 134, 176], ["respiratory", "ANATOMY", 9, 20], ["local resistance", "OBSERVATION", 151, 167]]], ["Results: Protocol adherence was assessed in 71 patients during the full SDD period and 70 during the partial ( Table 1 ).", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55]]], ["The number of patients included for analysis of VAP rates during each period was 38 pre SDD, 50 during full SDD and 37 during partial SDD.", [["VAP", "DISEASE", 48, 51], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["analysis", "TEST", 36, 44], ["VAP rates", "PROBLEM", 48, 57]]], ["There were no significant changes in resistance patterns or Clostridium difficule rates (Table 2) .P049Conclusions: Compliance with the available enteral antibiotics was reasonable but with IV antibiotics was poor.", [["Clostridium difficule", "SPECIES", 60, 81], ["significant changes in resistance patterns", "PROBLEM", 14, 56], ["Clostridium difficule rates", "PROBLEM", 60, 87], ["the available enteral antibiotics", "TREATMENT", 132, 165], ["IV antibiotics", "TREATMENT", 190, 204], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["changes", "OBSERVATION", 26, 33], ["resistance", "OBSERVATION", 37, 47], ["Clostridium", "OBSERVATION_MODIFIER", 60, 71]]], ["It is accepted that alterations and non-adherence to protocols risk development of resistant bacterial strains.", [["resistant bacterial strains", "PROBLEM", 83, 110], ["resistant", "OBSERVATION_MODIFIER", 83, 92], ["bacterial strains", "OBSERVATION", 93, 110]]], ["Within our unit no decrease in VAP rates was seen but reassuringly no increased rates of extended bacterial resistance were identified during the treatment periods.", [["VAP", "DISEASE", 31, 34], ["decrease in VAP rates", "PROBLEM", 19, 40], ["increased rates", "PROBLEM", 70, 85], ["extended bacterial resistance", "PROBLEM", 89, 118], ["the treatment periods", "TREATMENT", 142, 163], ["decrease", "OBSERVATION_MODIFIER", 19, 27], ["VAP", "OBSERVATION", 31, 34], ["increased", "OBSERVATION_MODIFIER", 70, 79], ["bacterial resistance", "OBSERVATION", 98, 118]]], ["Introduction: Arterial catheters are commonly used in Intensive Care Units (ICU) and are among the most frequently manipulated vascular access devices.", [["Arterial", "ANATOMY", 14, 22], ["vascular", "ANATOMY", 127, 135], ["Arterial catheters", "MULTI-TISSUE_STRUCTURE", 14, 32], ["vascular", "MULTI-TISSUE_STRUCTURE", 127, 135], ["Arterial catheters", "TREATMENT", 14, 32], ["manipulated vascular access devices", "TREATMENT", 115, 150], ["Arterial", "ANATOMY", 14, 22], ["catheters", "OBSERVATION", 23, 32], ["vascular", "ANATOMY", 127, 135]]], ["Our aim was to evaluate the rate of arterial catheterrelated bloodstream infection and colonization.P049Methods: This was a 12-month, prospective and monocentric cohort study, performed in a multipurpose ICU.", [["arterial", "ANATOMY", 36, 44], ["bloodstream", "ANATOMY", 61, 72], ["bloodstream infection", "DISEASE", 61, 82], ["arterial", "MULTI-TISSUE_STRUCTURE", 36, 44], ["arterial catheterrelated bloodstream infection", "PROBLEM", 36, 82], ["colonization", "PROBLEM", 87, 99], ["monocentric cohort study", "TEST", 150, 174], ["arterial", "ANATOMY", 36, 44], ["bloodstream", "OBSERVATION_MODIFIER", 61, 72], ["infection", "OBSERVATION", 73, 82]]], ["All arterial catheters, inserted in or presented to the ICU, were cultured and assessed for colonization or catheter-related bloodstream infection (CRBI).", [["arterial", "ANATOMY", 4, 12], ["bloodstream", "ANATOMY", 125, 136], ["bloodstream infection", "DISEASE", 125, 146], ["CRBI", "DISEASE", 148, 152], ["arterial catheters", "MULTI-TISSUE_STRUCTURE", 4, 22], ["All arterial catheters", "TREATMENT", 0, 22], ["colonization", "PROBLEM", 92, 104], ["catheter", "TREATMENT", 108, 116], ["bloodstream infection", "PROBLEM", 125, 146], ["arterial", "ANATOMY", 4, 12], ["catheters", "OBSERVATION", 13, 22], ["catheter", "OBSERVATION", 108, 116], ["bloodstream", "OBSERVATION_MODIFIER", 125, 136], ["infection", "OBSERVATION", 137, 146]]], ["Results: We enrolled 119 patients (63.8% males, average age 59\u00b117 years, SAPS 2 42\u00b121) of whom a total of 141 arterial catheters were analyzed for a total of 1552 catheter-days.", [["arterial", "ANATOMY", 110, 118], ["patients", "ORGANISM", 25, 33], ["arterial catheters", "MULTI-TISSUE_STRUCTURE", 110, 128], ["patients", "SPECIES", 25, 33], ["SAPS", "TEST", 73, 77], ["141 arterial catheters", "TREATMENT", 106, 128], ["arterial", "ANATOMY", 110, 118], ["catheters", "OBSERVATION", 119, 128]]], ["Radial arterial catheters were inserted in 88.7% (n=125), femoral arterial catheters in 7.8% (n=11) and other arterial catheters in 3.5% (n=5).", [["arterial", "ANATOMY", 7, 15], ["femoral arterial", "ANATOMY", 58, 74], ["arterial", "ANATOMY", 110, 118], ["Radial arterial catheters", "MULTI-TISSUE_STRUCTURE", 0, 25], ["femoral arterial", "MULTI-TISSUE_STRUCTURE", 58, 74], ["arterial catheters", "MULTI-TISSUE_STRUCTURE", 110, 128], ["Radial arterial catheters", "TREATMENT", 0, 25], ["femoral arterial catheters", "TREATMENT", 58, 84], ["other arterial catheters", "TREATMENT", 104, 128], ["arterial", "ANATOMY", 7, 15], ["catheters", "OBSERVATION", 16, 25], ["femoral", "ANATOMY_MODIFIER", 58, 65], ["arterial", "ANATOMY", 66, 74], ["catheters", "OBSERVATION", 75, 84], ["arterial", "ANATOMY", 110, 118], ["catheters", "OBSERVATION", 119, 128]]], ["Signs of dysfunction were found in 28.8% and 45.5%, respectively.", [["dysfunction", "PROBLEM", 9, 20], ["dysfunction", "OBSERVATION", 9, 20]]], ["Radial arterial catheters colonization (n=5) and CRBI (n=1) occurred at a rate of 3.0 and 0.8/ 1000 catheter-days.", [["arterial", "ANATOMY", 7, 15], ["CRBI", "DISEASE", 49, 53], ["Radial arterial catheters", "MULTI-TISSUE_STRUCTURE", 0, 25], ["Radial arterial catheters colonization", "TREATMENT", 0, 38], ["CRBI", "TEST", 49, 53], ["a rate", "TEST", 72, 78], ["arterial", "ANATOMY", 7, 15], ["catheters", "OBSERVATION", 16, 25], ["colonization", "OBSERVATION_MODIFIER", 26, 38]]], ["Femoral arterial catheters colonization (n=2) and CRBI (n=1) occurred at a rate of 10.8 and 5.4/1000 catheter-days, respectively.", [["Femoral arterial", "ANATOMY", 0, 16], ["CRBI", "DISEASE", 50, 54], ["Femoral arterial", "MULTI-TISSUE_STRUCTURE", 0, 16], ["Femoral arterial catheters colonization", "TREATMENT", 0, 39], ["CRBI", "TEST", 50, 54], ["a rate", "TEST", 73, 79], ["arterial", "ANATOMY", 8, 16], ["catheters", "OBSERVATION", 17, 26], ["colonization", "OBSERVATION_MODIFIER", 27, 39]]], ["Mean catheter time insertion was significantly higher in colonized catheters/CRBI (21\u00b18 days; 95% CI: 14-28) when compared to arterial catheters with negative cultures (10\u00b18 days; 95% CI: 9-12); p = 0.002).", [["arterial", "ANATOMY", 126, 134], ["arterial", "MULTI-TISSUE_STRUCTURE", 126, 134], ["Mean catheter time insertion", "TREATMENT", 0, 28], ["colonized catheters/CRBI", "TREATMENT", 57, 81], ["CI", "TEST", 98, 100], ["arterial catheters", "TEST", 126, 144], ["CI", "TEST", 184, 186], ["p", "TEST", 195, 196], ["catheter", "OBSERVATION", 5, 13], ["significantly", "OBSERVATION_MODIFIER", 33, 46], ["higher", "OBSERVATION_MODIFIER", 47, 53], ["colonized catheters", "OBSERVATION", 57, 76], ["arterial", "ANATOMY", 126, 134], ["catheters", "OBSERVATION", 135, 144]]], ["Colonized lines showed Acinetobacter baumannii (n=3), Staphylococcus epidermidis (n=1), Enterococcus spp (n=1) and Pseudomonas aeruginosa (n=1).", [["lines", "ANATOMY", 10, 15], ["Acinetobacter baumannii", "DISEASE", 23, 46], ["Staphylococcus epidermidis", "DISEASE", 54, 80], ["Enterococcus spp", "DISEASE", 88, 104], ["Pseudomonas aeruginosa", "DISEASE", 115, 137], ["Acinetobacter baumannii", "ORGANISM", 23, 46], ["Staphylococcus epidermidis", "ORGANISM", 54, 80], ["Enterococcus spp", "ORGANISM", 88, 104], ["Pseudomonas aeruginosa", "ORGANISM", 115, 137], ["Acinetobacter baumannii", "SPECIES", 23, 46], ["Staphylococcus epidermidis", "SPECIES", 54, 80], ["Enterococcus spp", "SPECIES", 88, 104], ["Pseudomonas aeruginosa", "SPECIES", 115, 137], ["Acinetobacter baumannii", "SPECIES", 23, 46], ["Staphylococcus epidermidis", "SPECIES", 54, 80], ["Enterococcus spp (n=1", "SPECIES", 88, 109], ["Pseudomonas aeruginosa", "SPECIES", 115, 137], ["Colonized lines", "TEST", 0, 15], ["Acinetobacter baumannii", "PROBLEM", 23, 46], ["Staphylococcus epidermidis", "PROBLEM", 54, 80], ["Enterococcus spp", "PROBLEM", 88, 104], ["Pseudomonas aeruginosa", "PROBLEM", 115, 137], ["Acinetobacter baumannii", "OBSERVATION", 23, 46], ["Staphylococcus epidermidis", "OBSERVATION", 54, 80]]], ["CRBI were caused by Staphylococcus epidermidis (n=1) and Staphylococcus haemolyticus (n=1).P049Conclusions: The incidence of radial arterial catheters colonization and CRBI were lower than reported rates in literature.", [["radial arterial", "ANATOMY", 125, 140], ["CRBI", "DISEASE", 0, 4], ["Staphylococcus epidermidis", "DISEASE", 20, 46], ["Staphylococcus haemolyticus", "DISEASE", 57, 84], ["Staphylococcus epidermidis", "ORGANISM", 20, 46], ["Staphylococcus haemolyticus", "ORGANISM", 57, 84], ["radial arterial", "MULTI-TISSUE_STRUCTURE", 125, 140], ["Staphylococcus epidermidis", "SPECIES", 20, 46], ["Staphylococcus haemolyticus", "SPECIES", 57, 84], ["Staphylococcus epidermidis", "SPECIES", 20, 46], ["Staphylococcus haemolyticus", "SPECIES", 57, 84], ["CRBI", "TEST", 0, 4], ["Staphylococcus epidermidis", "PROBLEM", 20, 46], ["Staphylococcus haemolyticus", "PROBLEM", 57, 84], ["radial arterial catheters colonization", "TREATMENT", 125, 163], ["CRBI", "TREATMENT", 168, 172], ["Staphylococcus epidermidis", "OBSERVATION", 20, 46], ["Staphylococcus haemolyticus", "OBSERVATION", 57, 84], ["radial", "ANATOMY_MODIFIER", 125, 131], ["arterial", "ANATOMY", 132, 140], ["catheters colonization", "OBSERVATION", 141, 163]]], ["Colonization and CRBI rates were higher in femoral catheters.", [["femoral", "ANATOMY", 43, 50], ["femoral catheters", "MULTI-TISSUE_STRUCTURE", 43, 60], ["Colonization", "PROBLEM", 0, 12], ["CRBI rates", "TEST", 17, 27], ["femoral catheters", "TREATMENT", 43, 60], ["higher", "OBSERVATION_MODIFIER", 33, 39], ["femoral", "ANATOMY", 43, 50], ["catheters", "OBSERVATION", 51, 60]]], ["Femoral catheters showed dysfunction more frequently.", [["Femoral", "ANATOMY", 0, 7], ["Femoral catheters", "MULTI-TISSUE_STRUCTURE", 0, 17], ["Femoral catheters", "TREATMENT", 0, 17], ["dysfunction", "PROBLEM", 25, 36], ["catheters", "OBSERVATION", 8, 17], ["dysfunction", "OBSERVATION", 25, 36]]], ["Prolonged catheterization was associated with colonization and CRBI.P053A multimodality approach to decreasing ICU infections by hydrogen peroxide, silver cations and compartmentalization and applying acinetobacter as infection marker Introduction: Nosocomial infections at the intensive care unit (ICU) represent a substantial health threat [1, 2] .", [["CRBI", "DISEASE", 63, 67], ["infections", "DISEASE", 115, 125], ["hydrogen peroxide", "CHEMICAL", 129, 146], ["silver cations", "CHEMICAL", 148, 162], ["acinetobacter", "CHEMICAL", 201, 214], ["infection", "DISEASE", 218, 227], ["Nosocomial infections", "DISEASE", 249, 270], ["hydrogen peroxide", "CHEMICAL", 129, 146], ["silver", "CHEMICAL", 148, 154], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 129, 146], ["silver cations", "SIMPLE_CHEMICAL", 148, 162], ["Prolonged catheterization", "TREATMENT", 0, 25], ["colonization", "PROBLEM", 46, 58], ["CRBI", "TREATMENT", 63, 67], ["decreasing ICU infections", "PROBLEM", 100, 125], ["hydrogen peroxide", "TREATMENT", 129, 146], ["silver cations", "TREATMENT", 148, 162], ["acinetobacter", "PROBLEM", 201, 214], ["Nosocomial infections", "PROBLEM", 249, 270], ["catheterization", "OBSERVATION", 10, 25], ["associated with", "UNCERTAINTY", 30, 45], ["colonization", "OBSERVATION", 46, 58]]], ["ICU infections are mainly attributed to the extended hospital delay which results in high morbidities and mortalities.", [["infections", "DISEASE", 4, 14], ["ICU infections", "PROBLEM", 0, 14], ["high morbidities and mortalities", "PROBLEM", 85, 117], ["infections", "OBSERVATION", 4, 14], ["high morbidities", "OBSERVATION", 85, 101]]], ["Methods: A cross sectional study was conducted at the Intensive Care Unit, Aseer Central Hospital, Saudi Arabia over 13 months period (2014) (2015) .", [["A cross sectional study", "TEST", 9, 32]]], ["The intervention program included the application of mist of hydrogen peroxide and silver cations, physical separation and compartmentalization of the intensive care unit.", [["hydrogen peroxide", "CHEMICAL", 61, 78], ["silver cations", "CHEMICAL", 83, 97], ["hydrogen peroxide", "CHEMICAL", 61, 78], ["silver", "CHEMICAL", 83, 89], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 61, 78], ["silver cations", "SIMPLE_CHEMICAL", 83, 97], ["hydrogen peroxide", "TREATMENT", 61, 78], ["silver cations", "TREATMENT", 83, 97], ["physical separation", "TREATMENT", 99, 118]]], ["The GLOSAIR\u2122 400 System was used to deliver a mist of hydrogen peroxide and silver cations.", [["hydrogen peroxide", "CHEMICAL", 54, 71], ["silver cations", "CHEMICAL", 76, 90], ["hydrogen peroxide", "CHEMICAL", 54, 71], ["silver", "CHEMICAL", 76, 82], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 54, 71], ["silver cations", "SIMPLE_CHEMICAL", 76, 90], ["The GLOSAIR\u2122 400 System", "TREATMENT", 0, 23], ["a mist of hydrogen peroxide and silver cations", "TREATMENT", 44, 90]]], ["Hydrogen peroxide is an oxidizing agent, which kills microorganisms.P053Results: A total of 103 strains of Acinetobacter species were identified from the patients over the 13 months period (Fig. 1) .", [["Hydrogen peroxide", "CHEMICAL", 0, 17], ["Hydrogen peroxide", "CHEMICAL", 0, 17], ["Hydrogen peroxide", "SIMPLE_CHEMICAL", 0, 17], ["Acinetobacter species", "ORGANISM", 107, 128], ["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 154, 162], ["Hydrogen peroxide", "TREATMENT", 0, 17], ["an oxidizing agent", "TREATMENT", 21, 39], ["Acinetobacter species", "PROBLEM", 107, 128], ["Acinetobacter", "OBSERVATION", 107, 120]]], ["The mean infection rates decreased from 14.3 in the first three months of the program to 4 in the last three month after continuous.P053Conclusions: The program using the three procedures offered a significant decrease in infections at the ICU as measured by Acinetobacter count, which is one of the most hazardous nosocomial pathogens.", [["infection", "DISEASE", 9, 18], ["infections", "DISEASE", 222, 232], ["The mean infection rates", "TEST", 0, 24], ["the three procedures", "TREATMENT", 167, 187], ["a significant decrease in infections", "PROBLEM", 196, 232], ["Acinetobacter count", "TEST", 259, 278], ["the most hazardous nosocomial pathogens", "PROBLEM", 296, 335], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["infection", "OBSERVATION", 9, 18], ["rates", "OBSERVATION_MODIFIER", 19, 24], ["decreased", "OBSERVATION_MODIFIER", 25, 34], ["significant", "OBSERVATION_MODIFIER", 198, 209], ["decrease", "OBSERVATION_MODIFIER", 210, 218], ["infections", "OBSERVATION", 222, 232], ["hazardous", "OBSERVATION_MODIFIER", 305, 314], ["nosocomial", "OBSERVATION_MODIFIER", 315, 325], ["pathogens", "OBSERVATION", 326, 335]]], ["Introduction: The efficacy of \u00df lactam antibiotics is related to the time above MIC.", [["\u00df lactam", "CHEMICAL", 30, 38], ["\u00df lactam", "CHEMICAL", 30, 38], ["\u00df lactam", "SIMPLE_CHEMICAL", 30, 38], ["\u00df lactam antibiotics", "TREATMENT", 30, 50]]], ["Continuous or extended infusions can be used to increase the time above MIC, especially in patients with normal or increased drug clearance.", [["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["Continuous or extended infusions", "TREATMENT", 0, 32], ["increased drug clearance", "PROBLEM", 115, 139], ["increased", "OBSERVATION_MODIFIER", 115, 124], ["drug clearance", "OBSERVATION", 125, 139]]], ["Administering antibiotics by continuous infusion is not a new concept.", [["antibiotics", "TREATMENT", 14, 25], ["continuous infusion", "TREATMENT", 29, 48]]], ["A review in 1992 looks at the outcomes of continuous infusions [1] .", [["continuous infusions", "TREATMENT", 42, 62]]], ["More recently an improvement in mortality has been demonstrated [2] .", [["improvement", "OBSERVATION_MODIFIER", 17, 28]]], ["Our perception was that uptake of this low cost intervention was not common, so we undertook a survey to determine how commonly continuous infusions are used in England.P053Methods: A telephone survey of all intensive care units in England was undertaken.", [["this low cost intervention", "TREATMENT", 34, 60], ["continuous infusions", "TREATMENT", 128, 148]]], ["Questions included: -Are you using continuous or extended antibiotic infusions? -Which antibiotics are you using for continuous or extended infusions? -If not currently using has it been considered?P053Data was collected over a week in June 2017.", [["P053Data", "GENE_OR_GENE_PRODUCT", 198, 206], ["P053Data", "PROTEIN", 198, 206], ["extended antibiotic infusions", "TREATMENT", 49, 78], ["antibiotics", "TREATMENT", 87, 98], ["continuous or extended infusions", "TREATMENT", 117, 149]]], ["73 (44.5%) of the units continuously infuse some antibiotics, however 71.2% of those only infuse vancomycin and not \u00df lactams.", [["vancomycin", "CHEMICAL", 97, 107], ["\u00df lactams", "CHEMICAL", 116, 125], ["vancomycin", "CHEMICAL", 97, 107], ["\u00df lactams", "CHEMICAL", 116, 125], ["vancomycin", "SIMPLE_CHEMICAL", 97, 107], ["\u00df lactams", "SIMPLE_CHEMICAL", 116, 125], ["some antibiotics", "TREATMENT", 44, 60], ["vancomycin", "TREATMENT", 97, 107], ["lactams", "TREATMENT", 118, 125]]], ["Only 21 of the total responders (12.8%) infuse antibiotics other than vancomycin (i.e. \u00df lactams).", [["vancomycin", "CHEMICAL", 70, 80], ["\u00df lactams", "CHEMICAL", 87, 96], ["vancomycin", "CHEMICAL", 70, 80], ["\u00df lactams", "CHEMICAL", 87, 96], ["vancomycin", "SIMPLE_CHEMICAL", 70, 80], ["\u00df lactams", "SIMPLE_CHEMICAL", 87, 96], ["antibiotics", "TREATMENT", 47, 58], ["vancomycin", "TREATMENT", 70, 80], ["lactams", "TREATMENT", 89, 96]]], ["Conclusions: The theoretical advantage of continuous infusion of \u00df lactam antibiotics has been described for over 20 years.", [["\u00df lactam", "CHEMICAL", 65, 73], ["\u00df lactam", "CHEMICAL", 65, 73], ["\u00df lactam", "SIMPLE_CHEMICAL", 65, 73], ["continuous infusion of \u00df lactam antibiotics", "TREATMENT", 42, 85]]], ["Despite this, uptake in England has been slow.P053Introduction: Infections contribute to a significant proportion of morbidity and mortality worldwide.", [["P053Introduction", "CHEMICAL", 46, 62], ["Infections", "DISEASE", 64, 74], ["Infections", "PROBLEM", 64, 74], ["morbidity", "PROBLEM", 117, 126], ["slow", "OBSERVATION_MODIFIER", 41, 45], ["Infections", "OBSERVATION", 64, 74], ["morbidity", "OBSERVATION", 117, 126]]], ["While many infections are successfully managed with antimicrobial therapy, rates of antimicrobial resistance (AMR) are increasing.", [["infections", "DISEASE", 11, 21], ["AMR", "DISEASE", 110, 113], ["many infections", "PROBLEM", 6, 21], ["antimicrobial therapy", "TREATMENT", 52, 73], ["antimicrobial resistance", "TREATMENT", 84, 108], ["infections", "OBSERVATION", 11, 21], ["antimicrobial resistance", "OBSERVATION", 84, 108], ["increasing", "OBSERVATION_MODIFIER", 119, 129]]], ["Certain patient populations such as those admitted to intensive care units (ICU) are at high risk.", [["patient", "ORGANISM", 8, 15], ["patient", "SPECIES", 8, 15]]], ["Methods: We conducted a retrospective, observational study of all ICU patients at a tertiary referral hospital in Rwanda from January 2015 through December 2016 We collected data on diagnosis, ICU length of stay, mortality and hospital length of stay, as well as microorganism, site of culture, AMR and antibiotics prescribe.", [["AMR", "DISEASE", 295, 298], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["observational study", "TEST", 39, 58], ["microorganism", "PROBLEM", 263, 276], ["culture", "TEST", 286, 293], ["AMR", "PROBLEM", 295, 298], ["antibiotics prescribe", "TREATMENT", 303, 324]]], ["Results: Overall, 331 patients were admitted to the ICU.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30]]], ["Most patients were admitted from the main operating theater (n=150, 45%).The most common admitting diagnoses were sepsis (n=113, 34%), head trauma (n= 90, 27%).", [["head", "ANATOMY", 135, 139], ["sepsis", "DISEASE", 114, 120], ["head trauma", "DISEASE", 135, 146], ["patients", "ORGANISM", 5, 13], ["head", "ORGANISM_SUBDIVISION", 135, 139], ["patients", "SPECIES", 5, 13], ["sepsis", "PROBLEM", 114, 120], ["head trauma", "PROBLEM", 135, 146], ["sepsis", "OBSERVATION", 114, 120], ["head", "ANATOMY", 135, 139]]], ["A total of 268 samples were collected from 331 patients.", [["samples", "ANATOMY", 15, 22], ["samples", "CANCER", 15, 22], ["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55]]], ["The samples were from blood (n=110, 33%), tracheal aspirate (n=22, 7%),.", [["samples", "ANATOMY", 4, 11], ["blood", "ANATOMY", 22, 27], ["tracheal aspirate", "ANATOMY", 42, 59], ["blood", "ORGANISM_SUBSTANCE", 22, 27], ["tracheal aspirate", "MULTI-TISSUE_STRUCTURE", 42, 59], ["The samples", "TEST", 0, 11], ["blood", "TEST", 22, 27], ["tracheal aspirate", "TEST", 42, 59], ["tracheal", "ANATOMY", 42, 50], ["aspirate", "OBSERVATION", 51, 59]]], ["The most common organisms isolated were Klebsiella (n=30, 29%), Acinetobacter (n=20, 19%), E.coli (n=16, 15%), Proteus (n=15, 14%), Citrobacter (n=8, 8%), S aureus (n=7, 7%), Pseudomonas (n=5, 5%), and other (n=9, 9%).", [["Acinetobacter", "DISEASE", 64, 77], ["Proteus", "DISEASE", 111, 118], ["S aureus", "DISEASE", 155, 163], ["S aureus", "ORGANISM", 155, 163], ["S aureus", "SPECIES", 155, 163], ["S aureus", "SPECIES", 155, 163], ["The most common organisms", "PROBLEM", 0, 25], ["Klebsiella", "PROBLEM", 40, 50], ["Acinetobacter", "TEST", 64, 77], ["E.coli", "TEST", 91, 97], ["Proteus", "TEST", 111, 118], ["Citrobacter", "TEST", 132, 143], ["S aureus", "TEST", 155, 163], ["Pseudomonas", "PROBLEM", 175, 186], ["Klebsiella", "OBSERVATION_MODIFIER", 40, 50], ["E.coli", "ANATOMY", 91, 97], ["aureus", "OBSERVATION", 157, 163]]], ["Of Klebsiella isolates, 100% and 76% were resistant to ceftriaxone and cefotaxime, respectively.", [["ceftriaxone", "CHEMICAL", 55, 66], ["cefotaxime", "CHEMICAL", 71, 81], ["ceftriaxone", "CHEMICAL", 55, 66], ["cefotaxime", "CHEMICAL", 71, 81], ["ceftriaxone", "SIMPLE_CHEMICAL", 55, 66], ["cefotaxime", "SIMPLE_CHEMICAL", 71, 81], ["Klebsiella isolates", "PROBLEM", 3, 22], ["ceftriaxone", "TREATMENT", 55, 66], ["cefotaxime", "TREATMENT", 71, 81], ["Klebsiella isolates", "OBSERVATION", 3, 22]]], ["Of E.coli isolates, 86% and 71% were resistant to ceftriaxone and cefotaxime, respectively.", [["ceftriaxone", "CHEMICAL", 50, 61], ["cefotaxime", "CHEMICAL", 66, 76], ["ceftriaxone", "CHEMICAL", 50, 61], ["cefotaxime", "CHEMICAL", 66, 76], ["ceftriaxone", "SIMPLE_CHEMICAL", 50, 61], ["cefotaxime", "SIMPLE_CHEMICAL", 66, 76], ["E.coli isolates", "TEST", 3, 18], ["ceftriaxone", "TREATMENT", 50, 61], ["cefotaxime", "TREATMENT", 66, 76], ["E.coli", "OBSERVATION", 3, 9]]], ["All Acinetobacter isolates were resistant to ceftriaxone and cefotaxime.", [["ceftriaxone", "CHEMICAL", 45, 56], ["cefotaxime", "CHEMICAL", 61, 71], ["ceftriaxone", "CHEMICAL", 45, 56], ["cefotaxime", "CHEMICAL", 61, 71], ["ceftriaxone", "SIMPLE_CHEMICAL", 45, 56], ["cefotaxime", "SIMPLE_CHEMICAL", 61, 71], ["All Acinetobacter isolates", "PROBLEM", 0, 26], ["ceftriaxone", "TREATMENT", 45, 56], ["cefotaxime", "TREATMENT", 61, 71], ["Acinetobacter", "OBSERVATION", 4, 17]]], ["Conclusions: There is an alarming rate of antimicrobial resistance to commonly used antibiotics in the ICU.", [["antimicrobial resistance", "TREATMENT", 42, 66], ["antibiotics", "TREATMENT", 84, 95], ["antimicrobial resistance", "OBSERVATION", 42, 66]]], ["Expanding antibiotic options and strengthening antimicrobial stewardship are critical for patient care.P056The last three days G Latten 1 , P Stassen 2 1 Zuyderland MC, Sittard-Geleen, Netherlands, 2 Introduction: This study provides an overview of the prehospital course of patients with a (suspected) infection in the emergency department (ED).", [["infection", "DISEASE", 303, 312], ["patient", "ORGANISM", 90, 97], ["patients", "ORGANISM", 275, 283], ["patient", "SPECIES", 90, 97], ["patients", "SPECIES", 275, 283], ["Expanding antibiotic options", "TREATMENT", 0, 28], ["strengthening antimicrobial stewardship", "TREATMENT", 33, 72], ["This study", "TEST", 214, 224], ["a (suspected) infection", "PROBLEM", 289, 312], ["infection", "OBSERVATION", 303, 312]]], ["Most research on serious infections and sepsis has focused on the hospital environment, while potentially most delay, and therefore possibly the best opportunity to improve treatment, lies in the prehospital setting.", [["infections", "DISEASE", 25, 35], ["sepsis", "DISEASE", 40, 46], ["serious infections", "PROBLEM", 17, 35], ["sepsis", "PROBLEM", 40, 46], ["treatment", "TREATMENT", 173, 182], ["serious", "OBSERVATION_MODIFIER", 17, 24], ["infections", "OBSERVATION", 25, 35], ["sepsis", "OBSERVATION", 40, 46]]], ["Methods: Patients were included in this prospective observational study during a 4 week period in 2017.", [["Patients", "ORGANISM", 9, 17], ["Patients", "SPECIES", 9, 17], ["this prospective observational study", "TEST", 35, 71]]], ["All patients aged 18 years or older with a suspected or proven infection were included.", [["infection", "DISEASE", 63, 72], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["proven infection", "PROBLEM", 56, 72], ["infection", "OBSERVATION", 63, 72]]], ["Results: In total, 2452 patients visited the ED during the study period, of whom 440 (17.9%) patients had a (suspected) infection.", [["infection", "DISEASE", 120, 129], ["patients", "ORGANISM", 24, 32], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 93, 101], ["the study", "TEST", 55, 64], ["a (suspected) infection", "PROBLEM", 106, 129], ["infection", "OBSERVATION", 120, 129]]], ["(Fig. 1 ) Median duration of symptoms before ED visit was 3 days (IQR 1-7 days), with 23.9% of patients using antibiotics before arrival in the ED.", [["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["symptoms", "PROBLEM", 29, 37], ["antibiotics", "TREATMENT", 110, 121]]], ["Most patients (83%) had been referred by a general practicioner (GP), while 41.1% of patients had visited their GP previously during the current disease episode.", [["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 85, 93], ["the current disease episode", "PROBLEM", 133, 160]]], ["Twenty-two patients (5.0%) experienced an adverse outcome (ICU admission and/or 30-day all-cause mortality): these patients were less often referred by a general practicioner (GP) (59.1 vs. 84.2%, p=0.001) and were considered more urgent both by EMS and in the ED.", [["patients", "ORGANISM", 11, 19], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 115, 123], ["p", "TEST", 197, 198]]], ["Conclusions: The prehospital phase of patients with an infection provides a window of opportunity for improvement of care.", [["infection", "DISEASE", 55, 64], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["an infection", "PROBLEM", 52, 64], ["infection", "OBSERVATION", 55, 64]]], ["Patients become ill 3 days before the ED visit and 41.1% already visited their GP previously during the current disease episode, while 23.9% is currently using antibiotics.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["the current disease episode", "PROBLEM", 100, 127], ["antibiotics", "TREATMENT", 160, 171], ["ill", "OBSERVATION_MODIFIER", 16, 19]]], ["Future research should focus on quality improvement programs in the prehospital setting, targeting patients and/or primary care professionals.", [["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107]]], ["Introduction: Worldwide, the prevalence of tetanus has decreased.-However, even if progress has been made in the combat to eradicate tetanus it may be a cause of admission to intensive care.The objectives of our study are to determine epidemiological,clinical and prognostic characteristics for severe tetanus in our unit.", [["tetanus", "DISEASE", 43, 50], ["tetanus", "DISEASE", 133, 140], ["tetanus", "DISEASE", 302, 309], ["tetanus", "PROBLEM", 43, 50], ["tetanus", "TREATMENT", 133, 140], ["our study", "TEST", 208, 217], ["severe tetanus", "PROBLEM", 295, 309], ["decreased", "OBSERVATION_MODIFIER", 55, 64]]], ["Methods: We conducted a retrospective study in the medical intensive care unit of Ibn Rushd hospital in Casablanca in Morocco from 2010 to 2016.We studied the epidemiological,clinical and prognostic characteristics of the patients who were admitted for severe tetanus.", [["tetanus", "DISEASE", 260, 267], ["patients", "ORGANISM", 222, 230], ["patients", "SPECIES", 222, 230], ["a retrospective study", "TEST", 22, 43], ["severe tetanus", "PROBLEM", 253, 267]]], ["Results: The incidence of severe tetanus was 2.04% affecting male in 100%.41.9% were aged between 31 and 40 years old.", [["tetanus", "DISEASE", 33, 40], ["severe tetanus", "PROBLEM", 26, 40], ["severe", "OBSERVATION_MODIFIER", 26, 32], ["tetanus", "OBSERVATION", 33, 40]]], ["In 85.7% there were a integumentary portal of entry.", [["integumentary", "ANATOMY_MODIFIER", 22, 35], ["portal", "ANATOMY", 36, 42]]], ["Contractures were present in 69%of the cases.", [["Contractures", "PROBLEM", 0, 12]]], ["At intensive care unit admission, 21.4% of the patients were sedated.", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["sedated", "TREATMENT", 61, 68]]], ["The anti-tetanus vaccination was never updated.", [["The anti-tetanus vaccination", "TREATMENT", 0, 28]]], ["According to the Dakar score 28.6% of the patients were listed Dakar 1, 54.8% Dakar 2 and 16.6% Dakar 3.", [["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50]]], ["For the Mollaret score, the crude form was found in 44.2%, the acute generalized form was found in 32.6% and the severe form in 20.9% of the cases.Mechanical ventilation was necessary in 83.3%.", [["Mechanical ventilation", "TREATMENT", 147, 169], ["acute", "OBSERVATION_MODIFIER", 63, 68], ["severe", "OBSERVATION_MODIFIER", 113, 119]]], ["Diazepam and baclofen were used in 92.9%, phenobarbital in76.2% and propofol in 42.85%.", [["Diazepam", "CHEMICAL", 0, 8], ["baclofen", "CHEMICAL", 13, 21], ["phenobarbital", "CHEMICAL", 42, 55], ["propofol", "CHEMICAL", 68, 76], ["Diazepam", "CHEMICAL", 0, 8], ["baclofen", "CHEMICAL", 13, 21], ["phenobarbital", "CHEMICAL", 42, 55], ["propofol", "CHEMICAL", 68, 76], ["Diazepam", "SIMPLE_CHEMICAL", 0, 8], ["baclofen", "SIMPLE_CHEMICAL", 13, 21], ["phenobarbital", "SIMPLE_CHEMICAL", 42, 55], ["propofol", "SIMPLE_CHEMICAL", 68, 76], ["Diazepam", "TREATMENT", 0, 8], ["baclofen", "TREATMENT", 13, 21], ["phenobarbital", "TREATMENT", 42, 55], ["propofol", "TREATMENT", 68, 76]]], ["A serotherapy was used for all the patients and a preliminary vaccination dose for 26.9%.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["A serotherapy", "TREATMENT", 0, 13], ["a preliminary vaccination dose", "TREATMENT", 48, 78]]], ["All the patients received antibiotics, penicillin G 33.33% and metronidazole 76.2%.", [["penicillin", "CHEMICAL", 39, 49], ["metronidazole", "CHEMICAL", 63, 76], ["penicillin G", "CHEMICAL", 39, 51], ["metronidazole", "CHEMICAL", 63, 76], ["patients", "ORGANISM", 8, 16], ["penicillin G", "SIMPLE_CHEMICAL", 39, 51], ["metronidazole", "SIMPLE_CHEMICAL", 63, 76], ["patients", "SPECIES", 8, 16], ["antibiotics", "TREATMENT", 26, 37], ["penicillin G", "TREATMENT", 39, 51], ["metronidazole", "TREATMENT", 63, 76]]], ["The mortality was 61.9%.", [["The mortality", "TEST", 0, 13]]], ["The length of intensive care stay was significantly higher.", [["length", "OBSERVATION_MODIFIER", 4, 10]]], ["The need for an intubation,its duration and the occurrence of autonomic dysfunction have significantly influenced the mortality.", [["autonomic dysfunction", "DISEASE", 62, 83], ["an intubation", "TREATMENT", 13, 26], ["autonomic dysfunction", "PROBLEM", 62, 83], ["autonomic dysfunction", "OBSERVATION", 62, 83]]], ["Conclusions: To improve the prognosis in these serious forms of tetanus,it is highly important to identify the warning signs and refer patients in intensive care for early and appropriate management in intensive care.", [["tetanus", "DISEASE", 64, 71], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["tetanus", "PROBLEM", 64, 71], ["intensive care", "TREATMENT", 202, 216]]], ["Introduction: Bloodstream infections (BSIs) are associated with increased mortality in the ICU.", [["Bloodstream", "ANATOMY", 14, 25], ["Bloodstream infections", "DISEASE", 14, 36], ["BSIs", "DISEASE", 38, 42], ["Bloodstream infections (BSIs", "PROBLEM", 14, 42], ["increased mortality", "PROBLEM", 64, 83], ["Bloodstream", "ANATOMY", 14, 25], ["infections", "OBSERVATION", 26, 36], ["increased", "OBSERVATION_MODIFIER", 64, 73], ["mortality", "OBSERVATION", 74, 83]]], ["The aim of the study was to evaluate the epidemiology and resistance patterns during the period 2013 to 2017.", [["the study", "TEST", 11, 20]]], ["Methods: Bacteria and fungi isolated from the blood of patients hospitalized in a mixed ICU during the study period were retrospectively analyzed.", [["blood", "ANATOMY", 46, 51], ["Bacteria", "CELL", 9, 17], ["blood", "ORGANISM_SUBSTANCE", 46, 51], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["Bacteria", "PROBLEM", 9, 17], ["fungi", "PROBLEM", 22, 27], ["the study", "TEST", 99, 108], ["Bacteria", "OBSERVATION", 9, 17]]], ["Sensitivity testing was performed with disk diffusion (Kirby-Bauer) and Microscan Walkaway 96 plus for minimal inhibitory concentrations.", [["Sensitivity testing", "TEST", 0, 19], ["disk diffusion", "TEST", 39, 53], ["minimal inhibitory concentrations", "TREATMENT", 103, 136]]], ["Results: During the study period 1198 patients were hospitalized in the ICU.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46]]], ["BSIs were diagnosed in 284 cases (23.7%).", [["BSIs", "DISEASE", 0, 4], ["BSIs", "TEST", 0, 4]]], ["The isolated microorganisms were Acinetobacter baumannii (29%), Klebsiella pneumoniae (15%), other Enterobacteriaceae (8%), Pseudomonas aeruginosa (6%), Stenotrophomonas maltophilia (1%), enterococci (20%), staphylococci (8%) and Candida spp.", [["Acinetobacter baumannii", "DISEASE", 33, 56], ["Klebsiella pneumoniae", "DISEASE", 64, 85], ["Pseudomonas aeruginosa", "DISEASE", 124, 146], ["Stenotrophomonas maltophilia", "DISEASE", 153, 181], ["staphylococci", "DISEASE", 207, 220], ["Candida spp", "DISEASE", 230, 241], ["Acinetobacter baumannii", "ORGANISM", 33, 56], ["Klebsiella pneumoniae", "ORGANISM", 64, 85], ["Pseudomonas aeruginosa", "ORGANISM", 124, 146], ["Stenotrophomonas maltophilia", "ORGANISM", 153, 181], ["enterococci", "CANCER", 188, 199], ["Candida spp", "ORGANISM", 230, 241], ["Acinetobacter baumannii", "SPECIES", 33, 56], ["Klebsiella pneumoniae", "SPECIES", 64, 85], ["Pseudomonas aeruginosa", "SPECIES", 124, 146], ["Stenotrophomonas maltophilia", "SPECIES", 153, 181], ["Acinetobacter baumannii", "SPECIES", 33, 56], ["Klebsiella pneumoniae", "SPECIES", 64, 85], ["Pseudomonas aeruginosa", "SPECIES", 124, 146], ["Stenotrophomonas maltophilia", "SPECIES", 153, 181], ["The isolated microorganisms", "TEST", 0, 27], ["Acinetobacter baumannii", "PROBLEM", 33, 56], ["Klebsiella pneumoniae", "PROBLEM", 64, 85], ["other Enterobacteriaceae", "TEST", 93, 117], ["Pseudomonas aeruginosa", "PROBLEM", 124, 146], ["Stenotrophomonas maltophilia", "PROBLEM", 153, 181], ["enterococci", "TEST", 188, 199], ["staphylococci", "TEST", 207, 220], ["Candida spp", "PROBLEM", 230, 241], ["microorganisms", "OBSERVATION_MODIFIER", 13, 27], ["Klebsiella pneumoniae", "OBSERVATION", 64, 85], ["Candida spp", "OBSERVATION", 230, 241]]], ["Of the A. baumannii isolates, 97% were resistant to carbapenems, 9.6% to colistin, and 31% to tigecycline.", [["carbapenems", "CHEMICAL", 52, 63], ["colistin", "CHEMICAL", 73, 81], ["tigecycline", "CHEMICAL", 94, 105], ["carbapenems", "CHEMICAL", 52, 63], ["colistin", "CHEMICAL", 73, 81], ["tigecycline", "CHEMICAL", 94, 105], ["A. baumannii", "ORGANISM", 7, 19], ["carbapenems", "SIMPLE_CHEMICAL", 52, 63], ["colistin", "SIMPLE_CHEMICAL", 73, 81], ["tigecycline", "SIMPLE_CHEMICAL", 94, 105], ["A. baumannii", "SPECIES", 7, 19], ["A. baumannii", "SPECIES", 7, 19], ["the A. baumannii isolates", "TEST", 3, 28], ["carbapenems", "TREATMENT", 52, 63], ["colistin", "TREATMENT", 73, 81], ["tigecycline", "TREATMENT", 94, 105]]], ["Of the K. pneumoniae isolates 80% were resistant to carbapenems, 70% to colistin, and 4.5% to tigecycline.", [["carbapenems", "CHEMICAL", 52, 63], ["colistin", "CHEMICAL", 72, 80], ["tigecycline", "CHEMICAL", 94, 105], ["carbapenems", "CHEMICAL", 52, 63], ["colistin", "CHEMICAL", 72, 80], ["tigecycline", "CHEMICAL", 94, 105], ["K. pneumoniae", "ORGANISM", 7, 20], ["carbapenems", "SIMPLE_CHEMICAL", 52, 63], ["colistin", "SIMPLE_CHEMICAL", 72, 80], ["tigecycline", "SIMPLE_CHEMICAL", 94, 105], ["K. pneumoniae", "SPECIES", 7, 20], ["K. pneumoniae", "SPECIES", 7, 20], ["the K. pneumoniae isolates", "TEST", 3, 29], ["carbapenems", "TREATMENT", 52, 63], ["colistin", "TREATMENT", 72, 80], ["tigecycline", "TREATMENT", 94, 105], ["pneumoniae", "OBSERVATION", 10, 20]]], ["Of the P. aeruginosa species 44% were resistant to carbapenems and they were all susceptible to colistin.", [["carbapenems", "CHEMICAL", 51, 62], ["colistin", "CHEMICAL", 96, 104], ["carbapenems", "CHEMICAL", 51, 62], ["colistin", "CHEMICAL", 96, 104], ["P. aeruginosa species", "ORGANISM", 7, 28], ["carbapenems", "SIMPLE_CHEMICAL", 51, 62], ["colistin", "SIMPLE_CHEMICAL", 96, 104], ["P. aeruginosa", "SPECIES", 7, 20], ["P. aeruginosa", "SPECIES", 7, 20], ["the P. aeruginosa species", "TEST", 3, 28], ["carbapenems", "TREATMENT", 51, 62], ["colistin", "TREATMENT", 96, 104], ["aeruginosa", "OBSERVATION_MODIFIER", 10, 20]]], ["The rate of resistance to vancomycin was 56% for the E. faecium isolates, 5.5% for the E. faecalis, while the resistance to methicillin of the coagulase negative staphylococci was 90%.", [["vancomycin", "CHEMICAL", 26, 36], ["methicillin", "CHEMICAL", 124, 135], ["staphylococci", "DISEASE", 162, 175], ["vancomycin", "CHEMICAL", 26, 36], ["methicillin", "CHEMICAL", 124, 135], ["vancomycin", "SIMPLE_CHEMICAL", 26, 36], ["E. faecium", "ORGANISM", 53, 63], ["E. faecalis", "ORGANISM", 87, 98], ["methicillin", "SIMPLE_CHEMICAL", 124, 135], ["E. faecium", "SPECIES", 53, 63], ["E. faecalis", "SPECIES", 87, 98], ["E. faecium", "SPECIES", 53, 63], ["E. faecalis", "SPECIES", 87, 98], ["vancomycin", "TREATMENT", 26, 36], ["the E. faecium isolates", "TEST", 49, 72], ["the E. faecalis", "PROBLEM", 83, 98], ["methicillin", "TEST", 124, 135], ["the coagulase", "TEST", 139, 152], ["staphylococci", "PROBLEM", 162, 175]]], ["The most commonly isolate species of Candida was C. albicans.P056Conclusions: Multi-drug resistant isolates, especially A. baumannii and Enterobacteriaceae, are a serious problem in our ICU.", [["Candida", "ORGANISM", 37, 44], ["C. albicans", "ORGANISM", 49, 60], ["A. baumannii", "ORGANISM", 120, 132], ["C. albicans", "SPECIES", 49, 60], ["A. baumannii", "SPECIES", 120, 132], ["C. albicans", "SPECIES", 49, 60], ["A. baumannii", "SPECIES", 120, 132], ["Candida", "PROBLEM", 37, 44], ["C. albicans", "PROBLEM", 49, 60], ["Multi-drug resistant isolates", "PROBLEM", 78, 107], ["A. baumannii", "PROBLEM", 120, 132], ["Enterobacteriaceae", "PROBLEM", 137, 155], ["most commonly", "OBSERVATION_MODIFIER", 4, 17], ["Multi-drug resistant", "OBSERVATION_MODIFIER", 78, 98], ["Enterobacteriaceae", "OBSERVATION", 137, 155]]], ["Gram positive bacteria are less common, but the resistance of enterococci to vancomycin is significant.", [["vancomycin", "CHEMICAL", 77, 87], ["vancomycin", "CHEMICAL", 77, 87], ["enterococci", "CANCER", 62, 73], ["vancomycin", "SIMPLE_CHEMICAL", 77, 87], ["Gram positive bacteria", "PROBLEM", 0, 22], ["enterococci", "PROBLEM", 62, 73], ["vancomycin", "TREATMENT", 77, 87], ["positive bacteria", "OBSERVATION", 5, 22], ["less common", "OBSERVATION_MODIFIER", 27, 38], ["enterococci", "OBSERVATION", 62, 73]]], ["Antibiotic stewardship and infection control measures should be applied in a more strict way.P059Nosocomial sinusitis in intensive care unit patients I Titov 1 Introduction: Nosocomial sinusitis (NS) is a complication of critically ill patients which develops 48-72 h after admission and is mostly linked but not limited to such invasive procedures as nasotracheal intubation and nasogastric tube placement.", [["nasotracheal", "ANATOMY", 352, 364], ["nasogastric tube", "ANATOMY", 380, 396], ["infection", "DISEASE", 27, 36], ["sinusitis", "DISEASE", 108, 117], ["Nosocomial sinusitis", "DISEASE", 174, 194], ["NS", "DISEASE", 196, 198], ["critically ill", "DISEASE", 221, 235], ["patients", "ORGANISM", 141, 149], ["patients", "ORGANISM", 236, 244], ["nasogastric tube", "MULTI-TISSUE_STRUCTURE", 380, 396], ["patients", "SPECIES", 141, 149], ["patients", "SPECIES", 236, 244], ["Antibiotic stewardship", "TREATMENT", 0, 22], ["infection control measures", "TREATMENT", 27, 53], ["P059Nosocomial sinusitis", "PROBLEM", 93, 117], ["Nosocomial sinusitis", "PROBLEM", 174, 194], ["such invasive procedures", "TREATMENT", 324, 348], ["nasotracheal intubation", "TREATMENT", 352, 375], ["nasogastric tube placement", "TREATMENT", 380, 406], ["infection", "OBSERVATION", 27, 36], ["sinusitis", "OBSERVATION", 108, 117], ["sinusitis", "OBSERVATION", 185, 194], ["nasogastric tube", "OBSERVATION", 380, 396]]], ["NS is often overlooked as a source of pyrexia of unknown origin, meningeal manifestations, sepsis and ventilator associated pneumonia in ICU patients.", [["meningeal", "ANATOMY", 65, 74], ["pyrexia", "DISEASE", 38, 45], ["sepsis", "DISEASE", 91, 97], ["pneumonia", "DISEASE", 124, 133], ["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 141, 149], ["NS", "TREATMENT", 0, 2], ["pyrexia", "PROBLEM", 38, 45], ["meningeal manifestations", "PROBLEM", 65, 89], ["sepsis", "PROBLEM", 91, 97], ["ventilator associated pneumonia", "PROBLEM", 102, 133], ["pyrexia", "OBSERVATION", 38, 45], ["meningeal", "ANATOMY", 65, 74], ["sepsis", "OBSERVATION", 91, 97], ["ventilator associated", "OBSERVATION_MODIFIER", 102, 123], ["pneumonia", "OBSERVATION", 124, 133]]], ["CT scanning and sinus puncture are used to confirm the inflammatory process and identify the pathogen behind it.", [["sinus", "ANATOMY", 16, 21], ["sinus puncture", "MULTI-TISSUE_STRUCTURE", 16, 30], ["CT scanning", "TEST", 0, 11], ["sinus puncture", "TEST", 16, 30], ["the inflammatory process", "PROBLEM", 51, 75], ["the pathogen", "PROBLEM", 89, 101], ["sinus", "ANATOMY", 16, 21], ["inflammatory", "OBSERVATION", 55, 67]]], ["Methods: A retrospective case study of 6.479 ICU patients for a period of 2012-2016 was performed.", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["A retrospective case study", "TEST", 9, 35]]], ["We have analysed data from the CT scans of paranasal sinuses and bacteriological findings of samples obtained from sinus puncture.", [["paranasal sinuses", "ANATOMY", 43, 60], ["samples", "ANATOMY", 93, 100], ["sinus", "ANATOMY", 115, 120], ["paranasal sinuses", "PATHOLOGICAL_FORMATION", 43, 60], ["sinus puncture", "MULTI-TISSUE_STRUCTURE", 115, 129], ["the CT scans of paranasal sinuses", "TEST", 27, 60], ["bacteriological findings", "TEST", 65, 89], ["sinus puncture", "TEST", 115, 129], ["paranasal sinuses", "ANATOMY", 43, 60], ["sinus", "ANATOMY", 115, 120]]], ["Results: 644 (9.9%) patients were suspected of NS on the 5-7th day of stay in the ICU.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["NS", "TREATMENT", 47, 49]]], ["The CT scan confirmed pathological changes in 464 patients (7.1%).", [["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["The CT scan", "TEST", 0, 11], ["pathological changes", "PROBLEM", 22, 42], ["pathological", "OBSERVATION", 22, 34]]], ["Hemisinusitis was detected in 422 patients (90.9%) and pansinusitis in 41 patients (8.8%).", [["Hemisinusitis", "DISEASE", 0, 13], ["pansinusitis", "DISEASE", 55, 67], ["patients", "ORGANISM", 34, 42], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 34, 42], ["patients", "SPECIES", 74, 82], ["Hemisinusitis", "TEST", 0, 13], ["pansinusitis", "TEST", 55, 67]]], ["There was also an isolated case of maxillary sinusitis in 1 patient (0.2%).", [["maxillary sinusitis", "ANATOMY", 35, 54], ["maxillary sinusitis", "DISEASE", 35, 54], ["maxillary", "ORGAN", 35, 44], ["patient", "ORGANISM", 60, 67], ["patient", "SPECIES", 60, 67], ["maxillary sinusitis", "PROBLEM", 35, 54], ["maxillary", "ANATOMY", 35, 44], ["sinusitis", "OBSERVATION", 45, 54]]], ["The pathogenic culture was identified only in 297 (64%) samples, 34.6% of which revealed isolated bacteria and 65.4% a polymicrobial association.", [["samples", "ANATOMY", 56, 63], ["polymicrobial", "DISEASE", 119, 132], ["samples", "CANCER", 56, 63], ["The pathogenic culture", "TEST", 0, 22], ["samples", "TEST", 56, 63], ["isolated bacteria", "PROBLEM", 89, 106], ["a polymicrobial association", "PROBLEM", 117, 144], ["bacteria", "OBSERVATION_MODIFIER", 98, 106], ["polymicrobial", "OBSERVATION", 119, 132]]], ["Gram positive bacteria were detected in 16.1% of cases and Gram negative in 49.5%.", [["Gram", "GENE_OR_GENE_PRODUCT", 0, 4], ["Gram positive bacteria", "PROBLEM", 0, 22], ["cases", "TEST", 49, 54], ["Gram", "TEST", 59, 63], ["positive bacteria", "OBSERVATION", 5, 22]]], ["Most cases revealed multiple antibiotic resistance.", [["multiple antibiotic resistance", "TREATMENT", 20, 50], ["multiple", "OBSERVATION_MODIFIER", 20, 28], ["antibiotic resistance", "OBSERVATION", 29, 50]]], ["NS has proved to be largely caused by Gram negative bacteria and polymicrobial associations.", [["NS", "TREATMENT", 0, 2], ["Gram negative bacteria", "PROBLEM", 38, 60], ["polymicrobial associations", "PROBLEM", 65, 91], ["negative bacteria", "OBSERVATION", 43, 60], ["polymicrobial", "OBSERVATION", 65, 78]]], ["The use of broad spectrum antibiotics in ICU may justify the presence of sterile cultures.", [["broad spectrum antibiotics", "TREATMENT", 11, 37], ["sterile cultures", "TEST", 73, 89]]], ["2.Early identification of risk patients in ICU as well as the use of screening CT scan may benefit timely diagnosis and adequate treatment of patients.", [["patients", "ORGANISM", 31, 39], ["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 142, 150], ["screening CT scan", "TEST", 69, 86]]], ["3 .Preventive considerations include: patient's bed head elevation, the use of oral gastric tube in sedated and coma patients on ventilation, nasotracheal intubation only if indicated, removal of nasogastric tube at night, proper hygiene.P059Conclusions: Only 78 of 4,011 TB patients (2%) required critical care intervention (Table 1) .", [["head", "ANATOMY", 52, 56], ["oral gastric tube", "ANATOMY", 79, 96], ["nasotracheal", "ANATOMY", 142, 154], ["nasogastric tube", "ANATOMY", 196, 212], ["coma", "DISEASE", 112, 116], ["TB", "DISEASE", 272, 274], ["patient", "ORGANISM", 38, 45], ["head", "ORGANISM_SUBDIVISION", 52, 56], ["oral", "ORGANISM_SUBDIVISION", 79, 83], ["gastric tube", "MULTI-TISSUE_STRUCTURE", 84, 96], ["patients", "ORGANISM", 117, 125], ["nasogastric tube", "MULTI-TISSUE_STRUCTURE", 196, 212], ["patients", "ORGANISM", 275, 283], ["patient", "SPECIES", 38, 45], ["patients", "SPECIES", 117, 125], ["patients", "SPECIES", 275, 283], ["patient's bed head elevation", "PROBLEM", 38, 66], ["oral gastric tube", "TREATMENT", 79, 96], ["sedated", "TREATMENT", 100, 107], ["ventilation", "TREATMENT", 129, 140], ["nasotracheal intubation", "TREATMENT", 142, 165], ["removal", "TREATMENT", 185, 192], ["nasogastric tube", "TREATMENT", 196, 212], ["critical care intervention", "TREATMENT", 298, 324], ["gastric", "ANATOMY", 84, 91], ["tube", "OBSERVATION", 92, 96], ["nasogastric tube", "OBSERVATION", 196, 212]]], ["Those admitted to ICU were older and more likely to have pulmonary, CNS, miliary or abdominal TB (Table 2) .", [["pulmonary", "ANATOMY", 57, 66], ["CNS", "ANATOMY", 68, 71], ["abdominal", "ANATOMY", 84, 93], ["pulmonary, CNS, miliary or abdominal TB", "DISEASE", 57, 96], ["pulmonary", "ORGAN", 57, 66], ["CNS", "ANATOMICAL_SYSTEM", 68, 71], ["pulmonary, CNS, miliary or abdominal TB", "PROBLEM", 57, 96], ["pulmonary", "ANATOMY", 57, 66], ["CNS", "ANATOMY", 68, 71], ["miliary", "OBSERVATION", 73, 80], ["abdominal", "ANATOMY", 84, 93], ["TB", "OBSERVATION", 94, 96]]], ["Mortality was high despite critical care input in a unit familiar with managing TB, and 24 hour access to Infectious Diseases advice within the trust, likely due to overwhelming organ dysfunction, patient frailty and advanced TB infection.", [["organ", "ANATOMY", 178, 183], ["TB", "DISEASE", 80, 82], ["organ dysfunction", "DISEASE", 178, 195], ["frailty", "DISEASE", 205, 212], ["TB infection", "DISEASE", 226, 238], ["organ", "ORGAN", 178, 183], ["patient", "ORGANISM", 197, 204], ["patient", "SPECIES", 197, 204], ["overwhelming organ dysfunction", "PROBLEM", 165, 195], ["patient frailty", "PROBLEM", 197, 212], ["advanced TB infection", "PROBLEM", 217, 238], ["likely due to", "UNCERTAINTY", 151, 164], ["dysfunction", "OBSERVATION", 184, 195], ["advanced", "OBSERVATION_MODIFIER", 217, 225], ["TB", "OBSERVATION_MODIFIER", 226, 228], ["infection", "OBSERVATION", 229, 238]]], ["Rates of drug resistant TB were low and comparable to UK-wide rates over that period (5% mono-drug resistant, 2% MDR) thus less likely a contributory factor to the majority of deaths.P061Short term antibiotics prevent early VAP in patients treated with mild therapeutic hypothermia after cardiac arrest T Daix 1 , A Cariou 2 , F Meziani 3 , PF Dequin 4 , C Guitton 5 , N Deye 6 , G Plantef\u00e8ve 7 , JP Quenot 8 , A Desachy 9 , T Kamel 10 , S Bedon-Carte 11 , JL Diehl 12 , N Chudeau 13 , E Karam 14 , F Renon-Carron 1 , A Hernandez Padilla 1 , P Vignon 1 , A Le Gouge 4 Introduction: Patients treated with mild therapeutic hypothermia after cardiac arrests with shockable rhythm are at high risk of ventilator-associated pneumonia (VAP) [1] .", [["cardiac", "ANATOMY", 288, 295], ["cardiac", "ANATOMY", 639, 646], ["TB", "DISEASE", 24, 26], ["deaths", "DISEASE", 176, 182], ["VAP", "DISEASE", 224, 227], ["hypothermia", "DISEASE", 270, 281], ["cardiac arrest", "DISEASE", 288, 302], ["hypothermia", "DISEASE", 621, 632], ["cardiac arrests", "DISEASE", 639, 654], ["pneumonia", "DISEASE", 719, 728], ["VAP", "DISEASE", 730, 733], ["patients", "ORGANISM", 231, 239], ["Patients", "ORGANISM", 582, 590], ["patients", "SPECIES", 231, 239], ["Patients", "SPECIES", 582, 590], ["drug resistant TB", "PROBLEM", 9, 26], ["Short term antibiotics", "TREATMENT", 187, 209], ["early VAP", "PROBLEM", 218, 227], ["mild therapeutic hypothermia", "PROBLEM", 253, 281], ["cardiac arrest", "PROBLEM", 288, 302], ["Meziani", "TREATMENT", 329, 336], ["Guitton", "TEST", 357, 364], ["Deye", "TEST", 371, 375], ["Plantef\u00e8ve", "TEST", 382, 392], ["JP Quenot", "TEST", 397, 406], ["A Desachy", "TEST", 411, 420], ["Kamel", "TEST", 427, 432], ["Carte", "TEST", 446, 451], ["Chudeau", "TEST", 473, 480], ["mild therapeutic hypothermia", "PROBLEM", 604, 632], ["cardiac arrests", "PROBLEM", 639, 654], ["shockable rhythm", "TREATMENT", 660, 676], ["ventilator-associated pneumonia (VAP)", "PROBLEM", 697, 734], ["drug", "OBSERVATION_MODIFIER", 9, 13], ["resistant", "OBSERVATION_MODIFIER", 14, 23], ["TB", "OBSERVATION", 24, 26], ["mild", "OBSERVATION_MODIFIER", 253, 257], ["therapeutic", "OBSERVATION_MODIFIER", 258, 269], ["hypothermia", "OBSERVATION", 270, 281], ["cardiac", "ANATOMY", 288, 295], ["arrest", "OBSERVATION", 296, 302], ["JP", "ANATOMY", 397, 399], ["mild", "OBSERVATION_MODIFIER", 604, 608], ["therapeutic", "OBSERVATION_MODIFIER", 609, 620], ["hypothermia", "OBSERVATION", 621, 632], ["cardiac", "ANATOMY", 639, 646], ["arrests", "OBSERVATION", 647, 654], ["ventilator", "OBSERVATION", 697, 707], ["pneumonia", "OBSERVATION", 719, 728]]], ["Despite retrospective trials suggesting a benefit of short-term (48h) antibiotics in this setting [2] , it is not recommended.", [["retrospective trials", "TREATMENT", 8, 28], ["short-term (48h) antibiotics", "TREATMENT", 53, 81]]], ["The primary objective was to demonstrate that systematic antibiotic prophylaxis can reduce incidence of early VAP (<7 days).", [["VAP", "DISEASE", 110, 113], ["systematic antibiotic prophylaxis", "TREATMENT", 46, 79], ["early VAP", "PROBLEM", 104, 113], ["early", "OBSERVATION_MODIFIER", 104, 109], ["VAP", "OBSERVATION", 110, 113]]], ["The impact on incidence of late VAP and on Day 28 mortality was also assessed.P061Methods: Multicenter, placebo-controlled, double-blinded, randomized trial.", [["VAP", "DISEASE", 32, 35], ["late VAP", "PROBLEM", 27, 35], ["placebo", "TREATMENT", 104, 111], ["late", "OBSERVATION_MODIFIER", 27, 31], ["VAP", "OBSERVATION", 32, 35]]], ["ICU patients >18 years, mechanically ventilated after out-of-hospital resuscitated cardiac arrest related to initial shockable rhythm and treated with mild therapeutic hypothermia were included.", [["cardiac", "ANATOMY", 83, 90], ["cardiac arrest", "DISEASE", 83, 97], ["hypothermia", "DISEASE", 168, 179], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["mechanically ventilated", "PROBLEM", 24, 47], ["cardiac arrest", "PROBLEM", 83, 97], ["initial shockable rhythm", "PROBLEM", 109, 133], ["mild therapeutic hypothermia", "PROBLEM", 151, 179], ["cardiac", "ANATOMY", 83, 90], ["arrest", "OBSERVATION", 91, 97], ["mild", "OBSERVATION_MODIFIER", 151, 155], ["therapeutic", "OBSERVATION_MODIFIER", 156, 167], ["hypothermia", "OBSERVATION", 168, 179]]], ["Moribund patients and those requiring extracorporeal life supports, with ongoing antibiotic therapy, known chronic colonization with multiresistant bacteria or known allergy to beta-lactam antibiotics were excluded.", [["allergy", "DISEASE", 166, 173], ["beta-lactam", "CHEMICAL", 177, 188], ["beta-lactam", "CHEMICAL", 177, 188], ["patients", "ORGANISM", 9, 17], ["beta-lactam antibiotics", "SIMPLE_CHEMICAL", 177, 200], ["patients", "SPECIES", 9, 17], ["extracorporeal life supports", "TREATMENT", 38, 66], ["ongoing antibiotic therapy", "TREATMENT", 73, 99], ["known chronic colonization", "PROBLEM", 101, 127], ["multiresistant bacteria", "PROBLEM", 133, 156], ["known allergy", "PROBLEM", 160, 173], ["beta-lactam antibiotics", "TREATMENT", 177, 200], ["chronic", "OBSERVATION_MODIFIER", 107, 114], ["colonization", "OBSERVATION", 115, 127], ["multiresistant bacteria", "OBSERVATION", 133, 156]]], ["Either IV injection of amoxicillin-clavulanic acid (1g/200mg) or placebo was administered 3 times a day for 2 days.", [["amoxicillin-clavulanic acid", "CHEMICAL", 23, 50], ["amoxicillin-clavulanic acid", "CHEMICAL", 23, 50], ["amoxicillin-clavulanic acid", "SIMPLE_CHEMICAL", 23, 50], ["IV injection", "TREATMENT", 7, 19], ["amoxicillin-clavulanic acid", "TREATMENT", 23, 50], ["placebo", "TREATMENT", 65, 72]]], ["All pulmonary infections were recorded and blindly confirmed by an adjudication committee.", [["pulmonary", "ANATOMY", 4, 13], ["pulmonary infections", "DISEASE", 4, 24], ["pulmonary", "ORGAN", 4, 13], ["All pulmonary infections", "PROBLEM", 0, 24], ["pulmonary", "ANATOMY", 4, 13], ["infections", "OBSERVATION", 14, 24]]], ["Results: In intention to treat analysis, 196 patients were analyzed, (treatment group n=99; mean age 60.5\u00b114.4 years, sex ratio=4, SOFA score 8.7\u00b13.1).", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["analysis", "TEST", 31, 39], ["sex ratio", "TEST", 118, 127], ["SOFA score", "TEST", 131, 141]]], ["Global characteristics of cardiac arrest were similar (no flow= 3.5min vs 3.8min, low-flow= 21.8min vs 18.2min).", [["cardiac", "ANATOMY", 26, 33], ["cardiac arrest", "DISEASE", 26, 40], ["cardiac", "ORGAN", 26, 33], ["cardiac arrest", "PROBLEM", 26, 40], ["flow", "TEST", 58, 62], ["cardiac", "ANATOMY", 26, 33], ["arrest", "OBSERVATION", 34, 40]]], ["60 VAP were confirmed incl.", [["VAP", "DISEASE", 3, 6], ["VAP", "PROBLEM", 3, 6]]], ["51 early VAP, 19 in treatment group vs 32 in placebo group (HR=0.546; IC 95%=[0.315; 0.946]) (Fig. 1) .", [["VAP", "DISEASE", 9, 12], ["early VAP", "PROBLEM", 3, 12], ["HR", "TEST", 60, 62], ["IC", "TEST", 70, 72], ["VAP", "OBSERVATION", 9, 12]]], ["Occurrence of late VAP (4% vs 5.1%) and Day 28 mortality (41.4% vs 37.5%) was not affected by the study procedure.", [["VAP", "DISEASE", 19, 22], ["late VAP", "PROBLEM", 14, 22], ["the study procedure", "TEST", 94, 113], ["late", "OBSERVATION_MODIFIER", 14, 18], ["VAP", "OBSERVATION", 19, 22]]], ["Conclusions: Short-term antibiotic prophylaxis significantly decreases incidence of early VAP in patients treated with mild therapeutic hypothermia after out-of-hospital cardiac arrest related to shockable rhythm and should be recommended.", [["cardiac", "ANATOMY", 170, 177], ["VAP", "DISEASE", 90, 93], ["hypothermia", "DISEASE", 136, 147], ["cardiac arrest", "DISEASE", 170, 184], ["patients", "ORGANISM", 97, 105], ["cardiac", "ORGAN", 170, 177], ["patients", "SPECIES", 97, 105], ["Short-term antibiotic prophylaxis", "TREATMENT", 13, 46], ["early VAP", "PROBLEM", 84, 93], ["mild therapeutic hypothermia", "PROBLEM", 119, 147], ["hospital cardiac arrest", "TREATMENT", 161, 184], ["shockable rhythm", "PROBLEM", 196, 212], ["Short-", "OBSERVATION_MODIFIER", 13, 19], ["early", "OBSERVATION_MODIFIER", 84, 89], ["VAP", "OBSERVATION", 90, 93], ["mild", "OBSERVATION_MODIFIER", 119, 123], ["therapeutic", "OBSERVATION_MODIFIER", 124, 135], ["hypothermia", "OBSERVATION", 136, 147], ["cardiac", "ANATOMY", 170, 177], ["arrest", "OBSERVATION", 178, 184]]], ["Introduction: Antibiotics are the most commonly prescribed drugs in ICU.In the era of antibiotic resistance it is difficult to choose antibiotics during septic episode.The choice antibiotics mainly depends on clinical diagnosis,culture sensitivity and local flora.", [["Antibiotics", "TREATMENT", 14, 25], ["antibiotic resistance", "TREATMENT", 86, 107], ["antibiotics", "TREATMENT", 134, 145], ["septic episode", "PROBLEM", 153, 167], ["The choice antibiotics", "TREATMENT", 168, 190], ["clinical diagnosis", "TEST", 209, 227], ["culture sensitivity", "TEST", 228, 247], ["local flora", "PROBLEM", 252, 263], ["antibiotic resistance", "OBSERVATION", 86, 107], ["local flora", "OBSERVATION", 252, 263]]], ["Whether severity of illness really maters is not well known.", [["illness", "DISEASE", 20, 27], ["illness", "PROBLEM", 20, 27], ["illness", "OBSERVATION", 20, 27]]], ["To study antibiotic prescription pattern and whether the choice of antibiotic varies according to hemodynamic stability in patients admitted in ICU.To study of microbiological isolates and their variability according to hamodynamic stability in ICU patients.", [["patients", "ORGANISM", 123, 131], ["patients", "ORGANISM", 249, 257], ["patients", "SPECIES", 123, 131], ["patients", "SPECIES", 249, 257], ["study antibiotic prescription pattern", "TREATMENT", 3, 40], ["antibiotic", "TREATMENT", 67, 77], ["microbiological isolates", "TEST", 160, 184]]], ["Methods: All ICU patients of more than 18 years age who received antibiotics and where cultures had been sent were included in the study.Patients discharged against medical advice and where treatment had been withdrawn were excluded in this study.", [["patients", "ORGANISM", 17, 25], ["Patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 17, 25], ["Patients", "SPECIES", 137, 145], ["antibiotics", "TREATMENT", 65, 76], ["cultures", "TEST", 87, 95], ["the study", "TEST", 127, 136], ["treatment", "TREATMENT", 190, 199], ["this study", "TEST", 236, 246]]], ["This prospective observational study was conducted between July 2016 to March 2017.Patients were divided into stable and unstable group according to hemodynamic parameter and usage of antibiotics and microbiological isolated were correlated.", [["Patients", "ORGANISM", 83, 91], ["Patients", "SPECIES", 83, 91], ["This prospective observational study", "TEST", 0, 36], ["hemodynamic parameter", "TEST", 149, 170], ["antibiotics", "TREATMENT", 184, 195], ["stable", "OBSERVATION_MODIFIER", 110, 116]]], ["ICU mortality and length of stay were correlated between hemodynamically stable and unstable group.", [["stable", "OBSERVATION_MODIFIER", 73, 79], ["unstable", "OBSERVATION", 84, 92]]], ["Results: 786 sepsis episode were analysed.", [["sepsis", "DISEASE", 13, 19], ["sepsis episode", "PROBLEM", 13, 27], ["sepsis", "OBSERVATION", 13, 19]]], ["Mean age was 65 years, male predominant, and average APACHE IV score was 58(SD25).", [["average APACHE IV score", "TEST", 45, 68], ["predominant", "OBSERVATION_MODIFIER", 28, 39]]], ["We had 444 patients in unstable group of which 71% patients got discharged and 86% of patients got discharged in stable group.", [["patients", "ORGANISM", 11, 19], ["patients", "ORGANISM", 51, 59], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 51, 59], ["patients", "SPECIES", 86, 94], ["stable", "OBSERVATION_MODIFIER", 113, 119]]], ["Antibiotic combination therapy was used more in hemodynamically unstsble patients(p 0.3).", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["Antibiotic combination therapy", "TREATMENT", 0, 30]]], ["BLBLI was used more in stable group.", [["stable", "OBSERVATION_MODIFIER", 23, 29]]], ["Drug resistance in microbiological isolates did not reveal any statistically significant difference among stable or unstable group.", [["Drug resistance in microbiological isolates", "PROBLEM", 0, 43], ["stable", "OBSERVATION_MODIFIER", 106, 112], ["unstable", "OBSERVATION_MODIFIER", 116, 124]]], ["Conclusions: There is a tendency to administer combination antibiotics in sicker group of patients with hemodynamic instability.", [["hemodynamic instability", "DISEASE", 104, 127], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["a tendency", "PROBLEM", 22, 32], ["combination antibiotics", "TREATMENT", 47, 70], ["hemodynamic instability", "PROBLEM", 104, 127], ["hemodynamic instability", "OBSERVATION", 104, 127]]], ["Prevalence of microbial flora did not show any statistical difference. outcome is worse in hemodynamically unstable patients.P065The clinical significance of Candida score in critically ill patients with candida infection H Al-Dorzi 1 , R Khan 1 , T Aldabbagh 1 , A Toledo 1 , S Al Johani 1 , A Almutairi 2 , S Khalil 2 , F Siddiqui 2 , Y Arabi 3 1 King Abdulaziz Medical City, Riyadh, Saudi Arabia, 2 MSD, Riyadh, Saudi Arabia, 3 King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia Critical Care 2018, 22(Suppl 1):P065 Introduction: Candida score (CS) is used to identify patients with invasive candidiasis in the ICU, but its clinical use has not become widespread.", [["critically ill", "DISEASE", 175, 189], ["candida infection", "DISEASE", 204, 221], ["candidiasis", "DISEASE", 621, 632], ["patients", "ORGANISM", 116, 124], ["P065", "GENE_OR_GENE_PRODUCT", 125, 129], ["patients", "ORGANISM", 190, 198], ["patients", "ORGANISM", 598, 606], ["patients", "SPECIES", 116, 124], ["patients", "SPECIES", 190, 198], ["patients", "SPECIES", 598, 606], ["microbial flora", "PROBLEM", 14, 29], ["Candida score", "PROBLEM", 158, 171], ["candida infection", "PROBLEM", 204, 221], ["S Al Johani", "TREATMENT", 277, 288], ["A Almutairi 2", "TREATMENT", 293, 306], ["invasive candidiasis", "PROBLEM", 612, 632], ["worse", "OBSERVATION_MODIFIER", 82, 87], ["invasive", "OBSERVATION_MODIFIER", 612, 620], ["candidiasis", "OBSERVATION", 621, 632], ["widespread", "OBSERVATION_MODIFIER", 681, 691]]], ["Our objective was to evaluate the clinical significance of CS in a mixed population of ICU patients.", [["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99]]], ["Methods: This was a prospective observational study of critically ill patients who had Candida species growth during their stay in any of six different ICUs of a tertiary-care center.", [["critically ill", "DISEASE", 55, 69], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["a prospective observational study", "TEST", 18, 51], ["Candida species growth", "PROBLEM", 87, 109]]], ["Two intensivists classified patients as having Candida colonization or invasive candidiasis according to predefined criteria.", [["Candida colonization", "DISEASE", 47, 67], ["invasive candidiasis", "DISEASE", 71, 91], ["patients", "ORGANISM", 28, 36], ["candidiasis", "CANCER", 80, 91], ["patients", "SPECIES", 28, 36], ["Candida colonization", "PROBLEM", 47, 67], ["invasive candidiasis", "PROBLEM", 71, 91], ["invasive", "OBSERVATION_MODIFIER", 71, 79], ["candidiasis", "OBSERVATION", 80, 91]]], ["CS was calculated for each patient on the day of Candida species growth as follows: 1 .", [["patient", "ORGANISM", 27, 34], ["patient", "SPECIES", 27, 34], ["CS", "TEST", 0, 2], ["Candida species growth", "PROBLEM", 49, 71]]], ["See text for description point for parenteral nutrition + 1 point for surgery + 1 point for multifocal Candida colonization + 2 points for severe sepsis.", [["sepsis", "DISEASE", 146, 152], ["parenteral nutrition", "TREATMENT", 35, 55], ["surgery", "TREATMENT", 70, 77], ["multifocal Candida colonization", "PROBLEM", 92, 123], ["severe sepsis", "PROBLEM", 139, 152], ["severe", "OBSERVATION_MODIFIER", 139, 145], ["sepsis", "OBSERVATION", 146, 152]]], ["The Receiver Operating Characteristic (ROC) curve was plotted to assess CS ability to discriminate between invasive candidiasis and Candida colonization.", [["invasive candidiasis", "ANATOMY", 107, 127], ["candidiasis", "DISEASE", 116, 127], ["candidiasis", "CANCER", 116, 127], ["Characteristic (ROC) curve", "TEST", 23, 49], ["CS ability", "PROBLEM", 72, 82], ["invasive candidiasis", "PROBLEM", 107, 127], ["Candida colonization", "PROBLEM", 132, 152], ["invasive", "OBSERVATION_MODIFIER", 107, 115], ["candidiasis", "OBSERVATION", 116, 127], ["Candida colonization", "OBSERVATION", 132, 152]]], ["Results: CS was 1.6\u00b10.9 in patients with Candida colonization (N=261) and 2.4\u00b10.9 in those with invasive candidiasis (N=120) (p<0.001).", [["invasive candidiasis", "ANATOMY", 96, 116], ["Candida colonization", "DISEASE", 41, 61], ["invasive candidiasis", "DISEASE", 96, 116], ["patients", "ORGANISM", 27, 35], ["candidiasis", "PATHOLOGICAL_FORMATION", 105, 116], ["patients", "SPECIES", 27, 35], ["CS", "TEST", 9, 11], ["Candida colonization", "PROBLEM", 41, 61], ["invasive candidiasis", "PROBLEM", 96, 116], ["invasive", "OBSERVATION_MODIFIER", 96, 104], ["candidiasis", "OBSERVATION", 105, 116]]], ["However, only 38.7% of invasive candidiasis cases had CS >= 3 (compared with 8.0% of Candida colonization cases; p<0.001).", [["candidiasis", "DISEASE", 32, 43], ["candidiasis", "PATHOLOGICAL_FORMATION", 32, 43], ["invasive candidiasis cases", "PROBLEM", 23, 49], ["CS", "TEST", 54, 56], ["Candida colonization cases", "PROBLEM", 85, 111], ["invasive", "OBSERVATION_MODIFIER", 23, 31], ["candidiasis", "OBSERVATION", 32, 43]]], ["The ROC curve (Fig. 1) showed that CS had fair ability to discriminate between invasive candidiasis and Candida colonization (area under the curve 0.71, 95% confidence interval 0.65 to 0.77; p<0.001).", [["invasive candidiasis", "ANATOMY", 79, 99], ["candidiasis", "DISEASE", 88, 99], ["candidiasis", "PATHOLOGICAL_FORMATION", 88, 99], ["The ROC curve (Fig. 1)", "TEST", 0, 22], ["CS", "PROBLEM", 35, 37], ["invasive candidiasis", "PROBLEM", 79, 99], ["Candida colonization", "PROBLEM", 104, 124], ["the curve", "TEST", 137, 146], ["invasive", "OBSERVATION_MODIFIER", 79, 87], ["candidiasis", "OBSERVATION", 88, 99], ["Candida colonization", "OBSERVATION", 104, 124]]], ["In patients with invasive candidiasis, CS was similar in hospital survivors and nonsurvivors (2.2\u00b10.9 and 2.5\u00b10.8, respectively; p=0.13).", [["invasive candidiasis", "ANATOMY", 17, 37], ["candidiasis", "DISEASE", 26, 37], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["invasive candidiasis", "PROBLEM", 17, 37], ["nonsurvivors", "TEST", 80, 92], ["invasive", "OBSERVATION_MODIFIER", 17, 25], ["candidiasis", "OBSERVATION", 26, 37]]], ["CS did not discriminate between survivors and nonsurvivors (area under the ROC curve 0.61, 95% confidence interval 0.46 to 0.75; p<0.15).", [["the ROC curve", "TEST", 71, 84]]], ["Conclusions: CS was higher in patients with invasive candidiasis than those with Candida Colonization.", [["invasive candidiasis", "ANATOMY", 44, 64], ["candidiasis", "DISEASE", 53, 64], ["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["CS", "TEST", 13, 15], ["invasive candidiasis", "PROBLEM", 44, 64], ["Candida Colonization", "PROBLEM", 81, 101], ["invasive", "OBSERVATION_MODIFIER", 44, 52], ["candidiasis", "OBSERVATION", 53, 64], ["Candida Colonization", "OBSERVATION", 81, 101]]], ["However, its ability to discriminate between these patients was only fair.", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59]]], ["CS was not associated with hospital mortality.P066Poor reliability of creatinine clearance estimates in predicting fluconazole exposure in liver transplant patients M Lugano, P Cojutti, F Pea ASUIUD, Udine, Italy Critical Care 2018, 22(Suppl 1):P066 Introduction: Invasive candidiasis (IC) is a frequent complication in liver transplant (LT) recipients, especially during the first 1-3 months after LT.", [["liver", "ANATOMY", 139, 144], ["Invasive candidiasis", "ANATOMY", 264, 284], ["liver transplant", "ANATOMY", 320, 336], ["creatinine", "CHEMICAL", 70, 80], ["fluconazole", "CHEMICAL", 115, 126], ["Invasive candidiasis", "DISEASE", 264, 284], ["IC", "DISEASE", 286, 288], ["creatinine", "CHEMICAL", 70, 80], ["fluconazole", "CHEMICAL", 115, 126], ["creatinine", "SIMPLE_CHEMICAL", 70, 80], ["fluconazole", "SIMPLE_CHEMICAL", 115, 126], ["liver", "ORGAN", 139, 144], ["patients", "ORGANISM", 156, 164], ["candidiasis", "PATHOLOGICAL_FORMATION", 273, 284], ["liver", "ORGAN", 320, 325], ["patients", "SPECIES", 156, 164], ["creatinine clearance", "TEST", 70, 90], ["fluconazole exposure", "TREATMENT", 115, 135], ["Invasive candidiasis", "PROBLEM", 264, 284], ["a frequent complication", "PROBLEM", 293, 316], ["liver transplant", "TREATMENT", 320, 336], ["not associated with", "UNCERTAINTY", 7, 26], ["liver", "ANATOMY", 139, 144], ["Invasive", "OBSERVATION_MODIFIER", 264, 272], ["candidiasis", "OBSERVATION", 273, 284], ["frequent", "OBSERVATION_MODIFIER", 295, 303], ["complication", "OBSERVATION", 304, 316], ["liver", "ANATOMY", 320, 325], ["transplant", "OBSERVATION", 326, 336]]], ["Fluconazole is a triazole antifungal used for prophylaxis and treatment of IC.", [["Fluconazole", "CHEMICAL", 0, 11], ["triazole", "CHEMICAL", 17, 25], ["Fluconazole", "CHEMICAL", 0, 11], ["triazole", "CHEMICAL", 17, 25], ["Fluconazole", "SIMPLE_CHEMICAL", 0, 11], ["triazole", "SIMPLE_CHEMICAL", 17, 25], ["Fluconazole", "TREATMENT", 0, 11], ["a triazole antifungal", "TREATMENT", 15, 36], ["prophylaxis", "TREATMENT", 46, 57], ["treatment of IC", "TREATMENT", 62, 77]]], ["Due to its renal elimination, dose adjustments are usually based on estimated creatinine clearance (eCrCL).", [["renal", "ANATOMY", 11, 16], ["creatinine", "CHEMICAL", 78, 88], ["creatinine", "CHEMICAL", 78, 88], ["renal", "ORGAN", 11, 16], ["creatinine", "SIMPLE_CHEMICAL", 78, 88], ["dose adjustments", "TREATMENT", 30, 46], ["estimated creatinine clearance", "TEST", 68, 98], ["renal", "ANATOMY", 11, 16], ["elimination", "OBSERVATION", 17, 28]]], ["However, the reliability of eCrCL in predicting fluconazole clearance has never been investigated in this population.", [["fluconazole", "CHEMICAL", 48, 59], ["fluconazole", "CHEMICAL", 48, 59], ["eCrCL", "GENE_OR_GENE_PRODUCT", 28, 33], ["fluconazole", "SIMPLE_CHEMICAL", 48, 59], ["eCrCL", "PROTEIN", 28, 33], ["eCrCL", "PROBLEM", 28, 33], ["predicting fluconazole clearance", "TREATMENT", 37, 69]]], ["The aim of this study was to conduct a population pharmacokinetic (popPK) analysis in a cohort of LT patients who underwent therapeutic drug monitoring (TDM) in order to find out which covariates may influence fluconazole pharmacokinetics (PKs).", [["fluconazole", "CHEMICAL", 210, 221], ["fluconazole", "CHEMICAL", 210, 221], ["patients", "ORGANISM", 101, 109], ["fluconazole", "SIMPLE_CHEMICAL", 210, 221], ["patients", "SPECIES", 101, 109], ["this study", "TEST", 11, 21], ["therapeutic drug monitoring", "TEST", 124, 151], ["fluconazole pharmacokinetics", "TREATMENT", 210, 238]]], ["Methods: This retrospective study included LT patients who were admitted to the intensive care unit of our University Hospital between December 2007 and May 2016, and who were treated with intravenous fluconazole in the first months after LT.", [["intravenous", "ANATOMY", 189, 200], ["fluconazole", "CHEMICAL", 201, 212], ["fluconazole", "CHEMICAL", 201, 212], ["patients", "ORGANISM", 46, 54], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 189, 200], ["fluconazole", "SIMPLE_CHEMICAL", 201, 212], ["patients", "SPECIES", 46, 54], ["This retrospective study", "TEST", 9, 33], ["intravenous fluconazole", "TREATMENT", 189, 212]]], ["TDM of fluconazole was performed with the intent of attaining the efficacy pharmacodynamic target (AUC24h/MIC > 55.2).", [["fluconazole", "CHEMICAL", 7, 18], ["fluconazole", "CHEMICAL", 7, 18], ["fluconazole", "SIMPLE_CHEMICAL", 7, 18], ["fluconazole", "TREATMENT", 7, 18], ["AUC24h/MIC", "TEST", 99, 109]]], ["The tested covariates were: age, gender, CKD-EPI eCrCL, time from LT, serum albumin and transaminases, SAPS II score.", [["serum", "ANATOMY", 70, 75], ["CKD", "DISEASE", 41, 44], ["serum", "ORGANISM_SUBSTANCE", 70, 75], ["albumin", "GENE_OR_GENE_PRODUCT", 76, 83], ["transaminases", "SIMPLE_CHEMICAL", 88, 101], ["LT", "PROTEIN", 66, 68], ["serum albumin", "PROTEIN", 70, 83], ["SAPS II", "PROTEIN", 103, 110], ["CKD", "PROBLEM", 41, 44], ["EPI eCrCL", "TEST", 45, 54], ["LT", "TEST", 66, 68], ["serum albumin", "TEST", 70, 83], ["transaminases", "TEST", 88, 101], ["SAPS II score", "TEST", 103, 116], ["LT", "ANATOMY", 66, 68]]], ["PopPK was carried out with Pmetrics software.", [["PopPK", "TEST", 0, 5]]], ["Results: Nineteen patients (mean\u00b1SD age, weight and serum creatinine of 60\u00b18.4 years, 75\u00b116.8 kg, 1.0\u00b10.62 mg/dL, respectively) with a total of 89 fluconazole trough plasma concentrations were included in the popPK analysis.", [["serum", "ANATOMY", 52, 57], ["plasma", "ANATOMY", 166, 172], ["creatinine", "CHEMICAL", 58, 68], ["fluconazole", "CHEMICAL", 147, 158], ["creatinine", "CHEMICAL", 58, 68], ["fluconazole", "CHEMICAL", 147, 158], ["patients", "ORGANISM", 18, 26], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["fluconazole", "SIMPLE_CHEMICAL", 147, 158], ["plasma", "ORGANISM_SUBSTANCE", 166, 172], ["patients", "SPECIES", 18, 26], ["weight", "TEST", 41, 47], ["serum creatinine", "TEST", 52, 68], ["fluconazole trough plasma concentrations", "TEST", 147, 187], ["the popPK analysis", "TEST", 205, 223]]], ["Mean\u00b1SD fluconazole distribution volume (Vd) and clearance (CL) were 27.02\u00b110.78 L and 0.55\u00b10.19 L/h.", [["fluconazole", "CHEMICAL", 8, 19], ["fluconazole", "CHEMICAL", 8, 19], ["fluconazole", "SIMPLE_CHEMICAL", 8, 19], ["Mean\u00b1SD fluconazole", "TREATMENT", 0, 19], ["clearance", "TEST", 49, 58]]], ["Age and time from LT were the only clinical covariates significantly correlated with fluconazole Vd and CL, respectively.", [["fluconazole", "CHEMICAL", 85, 96], ["fluconazole", "CHEMICAL", 85, 96], ["fluconazole", "SIMPLE_CHEMICAL", 85, 96], ["CL", "MULTI-TISSUE_STRUCTURE", 104, 106], ["fluconazole Vd", "TREATMENT", 85, 99]]], ["Conversely, CKD-EPI eCLCr was unable to predict fluconazole CL.", [["CKD", "DISEASE", 12, 15], ["fluconazole", "CHEMICAL", 48, 59], ["fluconazole", "CHEMICAL", 48, 59], ["fluconazole CL", "SIMPLE_CHEMICAL", 48, 62], ["CKD", "PROBLEM", 12, 15], ["EPI eCLCr", "PROBLEM", 16, 25], ["fluconazole CL", "TREATMENT", 48, 62], ["CKD", "OBSERVATION", 12, 15]]], ["Conclusions: CKD-EPI eCLCr is unreliable in predicting fluconazole exposure in LT recipients.", [["CKD", "DISEASE", 13, 16], ["fluconazole", "CHEMICAL", 55, 66], ["fluconazole", "CHEMICAL", 55, 66], ["fluconazole", "SIMPLE_CHEMICAL", 55, 66], ["LT recipients", "ORGANISM", 79, 92], ["CKD", "PROBLEM", 13, 16], ["EPI eCLCr", "TEST", 17, 26], ["fluconazole exposure", "TREATMENT", 55, 75], ["LT recipients", "TREATMENT", 79, 92], ["CKD", "OBSERVATION", 13, 16], ["LT", "ANATOMY", 79, 81]]], ["Consistently, in this population adaptation of fluconazole dose should be based on measured CrCL, and TDM may be helpful in optimizing drug exposure.P067Outcomes of a candidiasis screening protocol in a medical ICU M Boujelb\u00e8n 1 , I Fathallah 1 , H Kallel 1 , D Sakis 1 , M Tobich 1 , S Habacha 1 , N Ben Salah 1 , M Bouchekoua 2 , S Trabelsi 2 , S Khaled 2 , N Kouraichi 1 Introduction: The aim is to determine the incidence, characteristics and risk factors of invasive candidiasis (IC) in critically ill patients by using a weekly screening protocol.", [["fluconazole", "CHEMICAL", 47, 58], ["candidiasis", "DISEASE", 167, 178], ["candidiasis", "DISEASE", 472, 483], ["IC", "DISEASE", 485, 487], ["critically ill", "DISEASE", 492, 506], ["fluconazole", "CHEMICAL", 47, 58], ["fluconazole", "SIMPLE_CHEMICAL", 47, 58], ["CrCL", "SIMPLE_CHEMICAL", 92, 96], ["candidiasis", "PATHOLOGICAL_FORMATION", 472, 483], ["patients", "ORGANISM", 507, 515], ["patients", "SPECIES", 507, 515], ["fluconazole dose", "TREATMENT", 47, 63], ["CrCL", "TEST", 92, 96], ["TDM", "TREATMENT", 102, 105], ["a candidiasis screening protocol", "TREATMENT", 165, 197], ["N Ben Salah", "TREATMENT", 299, 310], ["invasive candidiasis", "PROBLEM", 463, 483], ["a weekly screening protocol", "TREATMENT", 525, 552], ["candidiasis", "OBSERVATION", 167, 178], ["invasive", "OBSERVATION_MODIFIER", 463, 471], ["candidiasis", "OBSERVATION", 472, 483]]], ["Methods: A 9 months' prospective study was conducted in a 6-bed MICU.", [["prospective study", "TEST", 21, 38]]], ["The candidiasis screening consisted of the culture of plastic swabs (from different body sites), urine and respiratory tract samples.It was conducted upon admission and on weekly basis for all the patients.", [["swabs", "ANATOMY", 62, 67], ["body sites", "ANATOMY", 84, 94], ["urine", "ANATOMY", 97, 102], ["respiratory tract samples", "ANATOMY", 107, 132], ["candidiasis", "DISEASE", 4, 15], ["body sites", "MULTI-TISSUE_STRUCTURE", 84, 94], ["urine", "ORGANISM_SUBSTANCE", 97, 102], ["respiratory tract samples", "CANCER", 107, 132], ["patients", "ORGANISM", 197, 205], ["patients", "SPECIES", 197, 205], ["The candidiasis screening", "TEST", 0, 25], ["the culture", "TEST", 39, 50], ["plastic swabs", "TEST", 54, 67], ["urine and respiratory tract samples", "TEST", 97, 132], ["candidiasis", "OBSERVATION", 4, 15], ["respiratory tract", "ANATOMY", 107, 124]]], ["Results: 97 patients were included.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["The colonization rate with Candida spp was 28.8%(n=28).", [["Candida spp", "DISEASE", 27, 38], ["Candida spp", "ORGANISM", 27, 38], ["The colonization rate", "TEST", 0, 21], ["Candida spp", "TEST", 27, 38]]], ["415 screening samples were collected with a positivity rate at 27.9%(n=118).", [["samples", "ANATOMY", 14, 21], ["samples", "CANCER", 14, 21], ["screening samples", "TEST", 4, 21], ["a positivity rate", "TEST", 42, 59]]], ["Table 1 describes the isolated Candida species by site.", [["the isolated Candida species", "PROBLEM", 18, 46], ["Candida species", "OBSERVATION", 31, 46]]], ["Antifungal resistance was tested in 72(62%) species.", [["Antifungal resistance", "TEST", 0, 21]]], ["The resistance rate to fluconazole was 13.8%(n=10).", [["fluconazole", "CHEMICAL", 23, 34], ["fluconazole", "CHEMICAL", 23, 34], ["fluconazole", "SIMPLE_CHEMICAL", 23, 34], ["The resistance rate", "TREATMENT", 0, 19], ["fluconazole", "TREATMENT", 23, 34]]], ["The antifungal resistance of Candida albicans is detailed in Table 2 .", [["Candida albicans", "DISEASE", 29, 45], ["Candida albicans", "ORGANISM", 29, 45], ["Candida albicans", "SPECIES", 29, 45], ["Candida albicans", "SPECIES", 29, 45], ["The antifungal resistance of", "TREATMENT", 0, 28], ["Candida albicans", "PROBLEM", 29, 45], ["antifungal resistance", "OBSERVATION", 4, 25], ["Candida albicans", "OBSERVATION", 29, 45]]], ["14(14.4%) patients presented an IC with a mean age and mean SAPS II at 54.3 \u00b1 18 years and 48\u00b118.7 respectively.", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["mean SAPS II", "TEST", 55, 67]]], ["7(50%) presented acute renal failure upon admission.", [["renal", "ANATOMY", 23, 28], ["acute renal failure", "DISEASE", 17, 36], ["renal", "ORGAN", 23, 28], ["acute renal failure", "PROBLEM", 17, 36], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["renal", "ANATOMY", 23, 28], ["failure", "OBSERVATION", 29, 36]]], ["85.7% (n=12) of the patients needed mechanical ventilation.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["mechanical ventilation", "TREATMENT", 36, 58], ["mechanical ventilation", "OBSERVATION", 36, 58]]], ["The median length of stay was 29 days [18.5-62.5] and the mortality rate was 42.9%(n=6).", [["the mortality rate", "TEST", 54, 72], ["median", "OBSERVATION_MODIFIER", 4, 10], ["length", "OBSERVATION_MODIFIER", 11, 17]]], ["The mean SOFA score upon infection was 8.5\u00b12.79.", [["infection", "DISEASE", 25, 34], ["The mean SOFA score", "TEST", 0, 19], ["infection", "PROBLEM", 25, 34], ["infection", "OBSERVATION", 25, 34]]], ["The candida score was >= 2.5 and the colonization index was >= 0.5 in Fig. 1 (abstract P065).", [["candida", "DISEASE", 4, 11], ["The candida score", "TEST", 0, 17], ["the colonization index", "TEST", 33, 55], ["candida", "OBSERVATION_MODIFIER", 4, 11]]], ["ROC curve for Candida score discrimintaing between invasive candidiasis and Candida colonization 92.8%(n=13) and 78.5%(n=11) of the patients respectively.", [["invasive candidiasis", "ANATOMY", 51, 71], ["invasive candidiasis", "DISEASE", 51, 71], ["candidiasis", "CANCER", 60, 71], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["ROC curve", "TEST", 0, 9], ["Candida score", "TEST", 14, 27], ["invasive candidiasis", "PROBLEM", 51, 71], ["Candida colonization", "TEST", 76, 96], ["invasive", "OBSERVATION_MODIFIER", 51, 59], ["candidiasis", "OBSERVATION", 60, 71]]], ["Only one patient had a positive blood culture.", [["blood", "ANATOMY", 32, 37], ["patient", "ORGANISM", 9, 16], ["blood", "ORGANISM_SUBSTANCE", 32, 37], ["patient", "SPECIES", 9, 16], ["a positive blood culture", "PROBLEM", 21, 45]]], ["Mannan antigen and anti-mannan antibodies were screened only in five patients with a positivity rate at 100%(n=5).", [["Mannan antigen", "GENE_OR_GENE_PRODUCT", 0, 14], ["anti-mannan antibodies", "GENE_OR_GENE_PRODUCT", 19, 41], ["patients", "ORGANISM", 69, 77], ["Mannan antigen", "PROTEIN", 0, 14], ["anti-mannan antibodies", "PROTEIN", 19, 41], ["patients", "SPECIES", 69, 77], ["Mannan antigen", "TEST", 0, 14], ["anti-mannan antibodies", "TEST", 19, 41], ["a positivity rate", "TEST", 83, 100]]], ["The most isolated species was: Candida albicans 64.3%(n=9).", [["Candida albicans", "DISEASE", 31, 47], ["Candida albicans", "ORGANISM", 31, 47], ["Candida albicans", "SPECIES", 31, 47], ["Candida albicans", "SPECIES", 31, 47], ["Candida albicans", "TEST", 31, 47]]], ["Multivariate analysis showed that prior use of Imipinem more than 6 days was a risk factor for IC (OR=9.37, CI95[1.15 ; 75.8], p=0.03).P067Conclusions: This study showed the ecology and epidemiology of Candida species in our MICU with an increased IC rate and high mortality.", [["Imipinem", "CHEMICAL", 47, 55], ["Imipinem", "CHEMICAL", 47, 55], ["Candida species", "ORGANISM", 202, 217], ["Multivariate analysis", "TEST", 0, 21], ["Imipinem", "TREATMENT", 47, 55], ["CI95", "TEST", 108, 112], ["p", "TEST", 127, 128], ["This study", "TEST", 152, 162], ["Candida species", "PROBLEM", 202, 217], ["an increased IC rate", "PROBLEM", 235, 255], ["high mortality", "PROBLEM", 260, 274], ["Candida species", "OBSERVATION", 202, 217], ["increased", "OBSERVATION_MODIFIER", 238, 247], ["high mortality", "OBSERVATION", 260, 274]]], ["Prior Imipinem use was a risk factor for IC.", [["Imipinem", "CHEMICAL", 6, 14], ["Imipinem", "CHEMICAL", 6, 14], ["Imipinem", "SIMPLE_CHEMICAL", 6, 14], ["Prior Imipinem", "TREATMENT", 0, 14]]], ["Introduction: ICU-acquired infection is as high as 42.7 episodes per 1000 patient-days in lower-middle income countries like India (WHO).", [["infection", "DISEASE", 27, 36], ["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 74, 81], ["acquired infection", "PROBLEM", 18, 36], ["infection", "OBSERVATION", 27, 36]]], ["Candida Infection is the 3rd most commonly acquired nosocomial infection in India burdening the debilitated patient with longer ICU stay [2] .", [["Candida Infection", "DISEASE", 0, 17], ["nosocomial infection", "DISEASE", 52, 72], ["patient", "ORGANISM", 108, 115], ["patient", "SPECIES", 108, 115], ["Candida Infection", "PROBLEM", 0, 17], ["acquired nosocomial infection", "PROBLEM", 43, 72], ["Infection", "OBSERVATION", 8, 17], ["nosocomial", "OBSERVATION_MODIFIER", 52, 62], ["infection", "OBSERVATION", 63, 72]]], ["There are no definite guidelines on whether & when to start antifungal treatment, specific to India where IFI risk is high and diagnostic facilities are limited.", [["IFI", "DISEASE", 106, 109], ["antifungal treatment", "TREATMENT", 60, 80], ["IFI risk", "TEST", 106, 114], ["no definite", "UNCERTAINTY", 10, 21]]], ["Currently, the Intensivists across India are using antifungals, according to their clinical experience and selective application of international guidelines leading to non-uniformity of patient outcomes.Methods:In an endeavour to synchronize anti-fungal therapy and educate intensivists from small cities of India, 2 Intensivists and 1 Infectious Disease specialist of international repute were approached to design a module on 'Invasive Fungal Infections -When to Start Anti-fungals in ICU [ Fig. 1 ].", [["Fungal Infections", "DISEASE", 438, 455], ["patient", "ORGANISM", 186, 193], ["patient", "SPECIES", 186, 193], ["antifungals", "TREATMENT", 51, 62], ["international guidelines", "TREATMENT", 132, 156], ["synchronize anti-fungal therapy", "TREATMENT", 230, 261], ["a module on 'Invasive Fungal Infections", "PROBLEM", 416, 455], ["small", "OBSERVATION_MODIFIER", 292, 297]]], ["The IFI in India was summarised into a compact 1 hour session for dissemination of knowledge using IDSA 2016 as a reference guideline.", [["IFI", "DISEASE", 4, 7], ["IFI", "OBSERVATION", 4, 7]]], ["The module was rolled out to Intensivists and Pulmonologists focussing particularly on the tier-2 & tier -3 cities where avenues for learning are limited [ Fig. 2 Introduction: Trichosporon species are fungi found in nature and human normal flora but they can be an opportunistic pathogen, Introduction: This study assessed whether empiric combination antibiotic therapy directed against Gram-negative bacteria is associated with lower intensive care unit (ICU) mortality compared to single antibiotic therapy.", [["Trichosporon species", "ORGANISM", 177, 197], ["human", "ORGANISM", 228, 233], ["human", "SPECIES", 228, 233], ["human", "SPECIES", 228, 233], ["Trichosporon species", "PROBLEM", 177, 197], ["fungi", "PROBLEM", 202, 207], ["This study", "TEST", 304, 314], ["empiric combination antibiotic therapy", "TREATMENT", 332, 370], ["Gram-negative bacteria", "PROBLEM", 388, 410], ["single antibiotic therapy", "TREATMENT", 484, 509], ["negative bacteria", "OBSERVATION", 393, 410]]], ["Methods: Retrospective cohort study on prospectively collected data conducted in the ICU of a tertiary care hospital in India between July2016 to March2017.", [["Retrospective cohort study", "TEST", 9, 35], ["prospectively collected data", "TEST", 39, 67]]], ["All consecutive infection episodes treated with empiric antibiotic therapy and with subsequent positive culture for Gram-negative bacteria were included.", [["infection", "DISEASE", 16, 25], ["All consecutive infection episodes", "PROBLEM", 0, 34], ["empiric antibiotic therapy", "TREATMENT", 48, 74], ["Gram-negative bacteria", "PROBLEM", 116, 138], ["consecutive", "OBSERVATION_MODIFIER", 4, 15], ["infection", "OBSERVATION", 16, 25], ["negative bacteria", "OBSERVATION_MODIFIER", 121, 138]]], ["Outcomes were compared between infection episodes treated with single vs.combination antibiotic therapy.", [["infection", "DISEASE", 31, 40], ["infection episodes", "PROBLEM", 31, 49], ["single vs.combination antibiotic therapy", "TREATMENT", 63, 103]]], ["Results: Of total 214 episodes of gram-negative infections 66.4% received combination-antibiotic therapy.", [["infections", "DISEASE", 48, 58], ["gram-negative infections", "PROBLEM", 34, 58], ["antibiotic therapy", "TREATMENT", 86, 104]]], ["Baseline demographic and clinical characteristics between single vs. combination therapy groups were similar (mean age: p=0.07; sex: p=0.3; mean APACHE IV score: p=0.07).", [["combination therapy groups", "TREATMENT", 69, 95], ["mean APACHE IV score", "TEST", 140, 160], ["p", "TEST", 162, 163]]], ["Overall ICU mortality did not significantly differ between single and combination antibiotic groups (30.2% vs. 27%; p=0.7).", [["combination antibiotic groups", "TREATMENT", 70, 99], ["p", "TEST", 116, 117]]], ["In single antibiotic group, ICU mortality was significantly higher for antibiotic-resistant compared to antibiotic-sensitive bacteria (77.8% vs. 18.5%, p=0.0002).", [["single antibiotic group", "TREATMENT", 3, 26], ["antibiotic", "TREATMENT", 71, 81], ["antibiotic", "TEST", 104, 114], ["sensitive bacteria", "PROBLEM", 115, 133], ["p", "TEST", 152, 153]]], ["In combination group, significantly lower ICU mortality was noted if bacteria was sensitive to even one antibiotic compared to pan-resistant bacteria (21.4% vs. 63.6%, p=0.0001).", [["significantly lower ICU mortality", "PROBLEM", 22, 55], ["bacteria", "PROBLEM", 69, 77], ["one antibiotic", "TREATMENT", 100, 114], ["pan-resistant bacteria", "PROBLEM", 127, 149], ["p", "TEST", 168, 169]]], ["ICU LOS was similar between antibiotic-sensitive bacteria and antibiotic-resistant bacteria, both in single and combination therapy groups (single, antibiotic-sensitive vs. antibiotic-resistant: mean LOS\u00b1SD 14.6\u00b112.7 vs.12.8\u00b111days; p=0.6; combination, antibioticsensitive vs. antibiotic-resistant: 15.5\u00b113.3 vs.11.2 days; p=0.1).", [["ICU LOS", "TEST", 0, 7], ["antibiotic", "TREATMENT", 28, 38], ["sensitive bacteria", "PROBLEM", 39, 57], ["antibiotic", "TREATMENT", 62, 72], ["resistant bacteria", "PROBLEM", 73, 91], ["combination therapy groups", "TREATMENT", 112, 138], ["antibiotic", "TREATMENT", 148, 158], ["antibiotic", "TREATMENT", 173, 183], ["SD", "TEST", 204, 206], ["vs", "TEST", 217, 219], ["p", "TEST", 233, 234], ["antibiotic", "TREATMENT", 277, 287], ["vs", "TEST", 309, 311], ["p", "TEST", 323, 324], ["resistant bacteria", "OBSERVATION", 73, 91]]], ["Conclusions: Irrespective of the number of antibiotics prescribed as empiric therapy, outcome of patients solely depends on the sensitivity pattern of the bacteria isolated.P073Pharmacokinetics of trimethoprim and sulfametrole in critically ill patients on continuous haemofiltration R Welte 1 , J Hotter 1 , T Gasperetti 1 , R Beyer 1 , R Introduction: The combination of trimethoprim and sulfametrole (TMP-SMT, Rokiprim\u00ae) is active against multi-drug resistant bacteria and Pneumocystis jirovecii.", [["trimethoprim", "CHEMICAL", 197, 209], ["sulfametrole", "CHEMICAL", 214, 226], ["critically ill", "DISEASE", 230, 244], ["trimethoprim", "CHEMICAL", 373, 385], ["sulfametrole", "CHEMICAL", 390, 402], ["TMP-SMT", "CHEMICAL", 404, 411], ["Rokiprim\u00ae", "CHEMICAL", 413, 422], ["Pneumocystis jirovecii", "DISEASE", 476, 498], ["trimethoprim", "CHEMICAL", 197, 209], ["sulfametrole", "CHEMICAL", 214, 226], ["trimethoprim", "CHEMICAL", 373, 385], ["sulfametrole", "CHEMICAL", 390, 402], ["TMP-SMT", "CHEMICAL", 404, 411], ["Rokiprim\u00ae", "CHEMICAL", 413, 422], ["patients", "ORGANISM", 97, 105], ["trimethoprim", "SIMPLE_CHEMICAL", 197, 209], ["sulfametrole", "SIMPLE_CHEMICAL", 214, 226], ["patients", "ORGANISM", 245, 253], ["trimethoprim", "SIMPLE_CHEMICAL", 373, 385], ["sulfametrole", "SIMPLE_CHEMICAL", 390, 402], ["TMP-SMT", "SIMPLE_CHEMICAL", 404, 411], ["Rokiprim\u00ae", "SIMPLE_CHEMICAL", 413, 422], ["Pneumocystis jirovecii", "ORGANISM", 476, 498], ["patients", "SPECIES", 97, 105], ["patients", "SPECIES", 245, 253], ["Pneumocystis jirovecii", "SPECIES", 476, 498], ["Pneumocystis jirovecii", "SPECIES", 476, 498], ["antibiotics", "TREATMENT", 43, 54], ["empiric therapy", "TREATMENT", 69, 84], ["the bacteria", "PROBLEM", 151, 163], ["trimethoprim", "TREATMENT", 197, 209], ["sulfametrole", "TREATMENT", 214, 226], ["continuous haemofiltration R Welte", "TREATMENT", 257, 291], ["Gasperetti", "TEST", 311, 321], ["trimethoprim", "TREATMENT", 373, 385], ["sulfametrole", "TREATMENT", 390, 402], ["TMP-SMT, Rokiprim\u00ae)", "TREATMENT", 404, 423], ["multi-drug resistant bacteria", "PROBLEM", 442, 471], ["Pneumocystis jirovecii", "PROBLEM", 476, 498], ["bacteria", "OBSERVATION", 155, 163], ["Pneumocystis jirovecii", "OBSERVATION", 476, 498]]], ["In critically ill patients undergoing continuous veno-venous haemofiltration (CVVH), however, its use is limited because of lacking pharmacokinetic data.", [["critically ill", "DISEASE", 3, 17], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["continuous veno-venous haemofiltration", "TREATMENT", 38, 76], ["CVVH", "TREATMENT", 78, 82], ["veno-venous haemofiltration", "OBSERVATION", 49, 76]]], ["Methods: Pharmacokinetics of both drugs were determined after standard doses in patients on CVVH and in critically ill patients with approximately normal renal function.", [["renal", "ANATOMY", 154, 159], ["critically ill", "DISEASE", 104, 118], ["patients", "ORGANISM", 80, 88], ["patients", "ORGANISM", 119, 127], ["renal", "ORGAN", 154, 159], ["patients", "SPECIES", 80, 88], ["patients", "SPECIES", 119, 127], ["both drugs", "TREATMENT", 29, 39], ["CVVH", "TREATMENT", 92, 96], ["renal", "ANATOMY", 154, 159], ["function", "OBSERVATION", 160, 168]]], ["Quantification of TMP and SMT was done by high pressure liquid chromatography (HPLC) and UV detection after pre-purification by solid phase extraction.", [["TMP", "CHEMICAL", 18, 21], ["TMP", "CHEMICAL", 18, 21], ["TMP", "SIMPLE_CHEMICAL", 18, 21], ["SMT", "SIMPLE_CHEMICAL", 26, 29], ["TMP and SMT", "TEST", 18, 29], ["high pressure liquid chromatography", "TEST", 42, 77], ["HPLC", "TEST", 79, 83], ["UV detection", "TEST", 89, 101], ["solid phase extraction", "TREATMENT", 128, 150], ["solid phase", "OBSERVATION", 128, 139]]], ["The total clearance (CLtot) was estimated from arterial plasma levels and the haemofilter clearance (CLHF) from plasma and ultrafiltrate concentrations.", [["arterial plasma", "ANATOMY", 47, 62], ["plasma", "ANATOMY", 112, 118], ["arterial", "MULTI-TISSUE_STRUCTURE", 47, 55], ["plasma", "ORGANISM_SUBSTANCE", 56, 62], ["haemofilter", "SIMPLE_CHEMICAL", 78, 89], ["plasma", "ORGANISM_SUBSTANCE", 112, 118], ["ultrafiltrate", "ORGANISM_SUBSTANCE", 123, 136], ["The total clearance (CLtot)", "TREATMENT", 0, 27], ["arterial plasma levels", "TEST", 47, 69], ["the haemofilter clearance", "TEST", 74, 99], ["plasma and ultrafiltrate concentrations", "TREATMENT", 112, 151], ["total", "OBSERVATION_MODIFIER", 4, 9]]], ["Results: Six patients on CVVH (3 after the first dose, 3 at steady state) and nine patients off CVVH have been enrolled (4 after first dose, 7 at steady state).", [["patients", "ORGANISM", 13, 21], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 83, 91], ["CVVH", "TREATMENT", 25, 29], ["CVVH", "TREATMENT", 96, 100]]], ["After a single dose, CLtot of SMT was 3.5 (1.8-3.8, median [range]) and 1.7 (1.1-2.7) L/h on and off CVVH, respectively.", [["CLtot of SMT", "TEST", 21, 33], ["CVVH", "TREATMENT", 101, 105]]], ["At steady state, we observed a CLtot of 1.0 (0.5-1.0) and 0.3 (0.2-0.9) L/h, respectively, on and off CVVH.", [["a CLtot", "TEST", 29, 36], ["CVVH", "TREATMENT", 102, 106]]], ["Steady state trough levels (Cmin) of SMT amounted to 52-113 mg/L in patients on CVVH and 18-145 in patients off CVVH.", [["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 99, 107], ["trough levels", "TEST", 13, 26], ["Cmin", "TEST", 28, 32], ["SMT", "TEST", 37, 40], ["CVVH", "TREATMENT", 80, 84], ["CVVH", "TREATMENT", 112, 116]]], ["CLtot of TMP was 4.4 (2.5-5.", [["TMP", "CHEMICAL", 9, 12], ["TMP", "CHEMICAL", 9, 12], ["TMP", "SIMPLE_CHEMICAL", 9, 12], ["CLtot", "TEST", 0, 5], ["TMP", "TEST", 9, 12]]], ["3) L/h on CVVH and 5.4 (3.2-9.9) L/h off CVVH after the first dose.", [["CVVH", "TREATMENT", 10, 14], ["CVVH", "TREATMENT", 41, 45]]], ["At steady state, its CLtot amounted to 0.8 (0.4-0.8) and 1.0 (0.6-1.9) L/h on and off CVVH, respectively.", [["its CLtot", "TEST", 17, 26], ["CVVH", "TREATMENT", 86, 90]]], ["Cmin was 4-12 mg/L on CVVH and 3-9 mg/L in patients off CVVH.", [["Cmin", "CHEMICAL", 0, 4], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["Cmin", "TEST", 0, 4], ["CVVH", "TREATMENT", 22, 26], ["CVVH", "TREATMENT", 56, 60]]], ["CLHF accounted for 22-68% of CLtot of SMT and 28-72% of CLtot TMP.", [["CLHF", "DISEASE", 0, 4], ["TMP", "CHEMICAL", 62, 65], ["TMP", "CHEMICAL", 62, 65], ["CLtot TMP", "SIMPLE_CHEMICAL", 56, 65], ["CLHF", "TEST", 0, 4], ["CLtot", "TEST", 29, 34], ["SMT", "TEST", 38, 41], ["CLtot TMP", "TREATMENT", 56, 65]]], ["Conclusions: Exposure to both antimicrobial agents is highly variable, but comparable in patients on and off CVVH.", [["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["both antimicrobial agents", "TREATMENT", 25, 50], ["CVVH", "TREATMENT", 109, 113], ["antimicrobial agents", "OBSERVATION", 30, 50]]], ["As considerable amounts of SMT and TMP are eliminated by CVVH, no excessive accumulation appears to take place during treatment with standard doses.P074The positive impact of meropenem stewardship intervention at a Brazilian intensive care unit W Freitas 1 Introduction: Loss of colistin as a clinical option has profound public health implications.", [["SMT", "CHEMICAL", 27, 30], ["TMP", "CHEMICAL", 35, 38], ["P074", "CHEMICAL", 148, 152], ["meropenem", "CHEMICAL", 175, 184], ["colistin", "CHEMICAL", 279, 287], ["SMT", "CHEMICAL", 27, 30], ["TMP", "CHEMICAL", 35, 38], ["P074", "CHEMICAL", 148, 152], ["meropenem", "CHEMICAL", 175, 184], ["colistin", "CHEMICAL", 279, 287], ["SMT", "SIMPLE_CHEMICAL", 27, 30], ["TMP", "SIMPLE_CHEMICAL", 35, 38], ["P074", "GENE_OR_GENE_PRODUCT", 148, 152], ["meropenem", "SIMPLE_CHEMICAL", 175, 184], ["colistin", "SIMPLE_CHEMICAL", 279, 287], ["P074", "PROTEIN", 148, 152], ["SMT and TMP", "TREATMENT", 27, 38], ["CVVH", "TREATMENT", 57, 61], ["excessive accumulation", "PROBLEM", 66, 88], ["treatment", "TREATMENT", 118, 127], ["meropenem stewardship intervention", "TREATMENT", 175, 209], ["colistin", "TREATMENT", 279, 287], ["amounts", "OBSERVATION_MODIFIER", 16, 23], ["SMT", "OBSERVATION_MODIFIER", 27, 30], ["no", "UNCERTAINTY", 63, 65], ["excessive", "OBSERVATION_MODIFIER", 66, 75], ["accumulation", "OBSERVATION", 76, 88], ["positive", "OBSERVATION_MODIFIER", 156, 164]]], ["Widespread use of colistin in agriculture and humans has seen the emergence of Mcr-1 mediated resistance amongst South African patients [1] .", [["colistin", "CHEMICAL", 18, 26], ["colistin", "CHEMICAL", 18, 26], ["colistin", "SIMPLE_CHEMICAL", 18, 26], ["humans", "ORGANISM", 46, 52], ["Mcr-1", "GENE_OR_GENE_PRODUCT", 79, 84], ["patients", "ORGANISM", 127, 135], ["humans", "SPECIES", 46, 52], ["patients", "SPECIES", 127, 135], ["humans", "SPECIES", 46, 52], ["colistin", "TREATMENT", 18, 26]]], ["We sought to describe the trends of colistin minimum inhibitory concentrations (MIC) over two years using data collected by SMART.", [["colistin", "CHEMICAL", 36, 44], ["colistin", "CHEMICAL", 36, 44], ["colistin", "SIMPLE_CHEMICAL", 36, 44], ["colistin minimum inhibitory concentrations", "TREATMENT", 36, 78]]], ["Methods: SMART monitors the in vitro susceptibility of clinical aerobic and facultative gram-negative bacterial isolates to selected antimicrobials of importance, enabling longitudinal analyses to determine changes over time.", [["SMART monitors", "TEST", 9, 23], ["clinical aerobic", "TEST", 55, 71], ["facultative gram", "TEST", 76, 92], ["negative bacterial isolates", "PROBLEM", 93, 120], ["longitudinal analyses", "TEST", 172, 193]]], ["The dataset comprised bacterial isolates from four different South African private pathology laboratories and one public sector pathology laboratory from 2015 -2016.", [["bacterial isolates", "PROBLEM", 22, 40], ["bacterial isolates", "OBSERVATION", 22, 40]]], ["The methods used in the study have been described elsewhere [2] .", [["The methods", "TREATMENT", 0, 11], ["the study", "TEST", 20, 29]]], ["Isolate proportions between years were compared using the chisquared test with Yates' continuity correction.", [["the chisquared test", "TEST", 54, 73], ["Yates' continuity correction", "TREATMENT", 79, 107]]], ["(2) (3) (4) (5) days]; 4 patients underwent renal replacement therapy.", [["renal", "ANATOMY", 44, 49], ["patients", "ORGANISM", 25, 33], ["renal", "ORGAN", 44, 49], ["patients", "SPECIES", 25, 33], ["renal replacement therapy", "TREATMENT", 44, 69], ["renal", "ANATOMY", 44, 49], ["replacement", "OBSERVATION", 50, 61]]], ["The median treatment duration (IQR) was 14 (13-14) days.", [["The median treatment duration", "TREATMENT", 0, 29]]], ["In 41.6% of cases, antibiotic-therapy therapy combination (phosphomycin and colistin) was chosen.", [["phosphomycin", "CHEMICAL", 59, 71], ["colistin", "CHEMICAL", 76, 84], ["phosphomycin", "CHEMICAL", 59, 71], ["colistin", "CHEMICAL", 76, 84], ["phosphomycin", "SIMPLE_CHEMICAL", 59, 71], ["colistin", "SIMPLE_CHEMICAL", 76, 84], ["antibiotic-therapy therapy", "TREATMENT", 19, 45], ["phosphomycin", "TREATMENT", 59, 71], ["colistin", "TREATMENT", 76, 84]]], ["All the patients experienced a clinical response by 72/96 hours from the ceftazidime/avibactam commencing.", [["ceftazidime", "CHEMICAL", 73, 84], ["avibactam", "CHEMICAL", 85, 94], ["ceftazidime", "CHEMICAL", 73, 84], ["avibactam", "CHEMICAL", 85, 94], ["patients", "ORGANISM", 8, 16], ["ceftazidime", "SIMPLE_CHEMICAL", 73, 84], ["avibactam", "SIMPLE_CHEMICAL", 85, 94], ["patients", "SPECIES", 8, 16], ["the ceftazidime/avibactam", "TREATMENT", 69, 94]]], ["In 8/ 9 bacteraemic patients negativization of blood culture occurred by 96 hours as well as of the rectal swab in 5/14 patients.", [["blood", "ANATOMY", 47, 52], ["rectal swab", "ANATOMY", 100, 111], ["patients", "ORGANISM", 20, 28], ["blood", "ORGANISM_SUBSTANCE", 47, 52], ["rectal swab", "MULTI-TISSUE_STRUCTURE", 100, 111], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 120, 128], ["blood culture", "TEST", 47, 60], ["the rectal swab", "TEST", 96, 111], ["rectal", "ANATOMY", 100, 106]]], ["A (B) recurred and a second treatment was given.", [["B", "CANCER", 3, 4], ["a second treatment", "TREATMENT", 19, 37]]], ["11/14 (78.5%) patients survived, whereas death was caused by multi-organ failure.", [["multi-organ", "ANATOMY", 61, 72], ["death", "DISEASE", 41, 46], ["multi-organ failure", "DISEASE", 61, 80], ["patients", "ORGANISM", 14, 22], ["multi-organ", "ORGAN", 61, 72], ["patients", "SPECIES", 14, 22], ["multi-organ failure", "PROBLEM", 61, 80], ["multi-organ", "ANATOMY", 61, 72], ["failure", "OBSERVATION", 73, 80]]], ["The susceptibility test of strains showed sensitivity to ceftazidime/avibactam, whereas 100% of resistance to carbapenems, quinolones and III/IV generation cephalosporin, tigecycline and piperacillin/tazobactam; 62.5% of susceptibility to fosfomycin and colistin; (v) less than 50% of suceptibility to aminoglicosides.", [["ceftazidime", "CHEMICAL", 57, 68], ["avibactam", "CHEMICAL", 69, 78], ["carbapenems", "CHEMICAL", 110, 121], ["quinolones", "CHEMICAL", 123, 133], ["cephalosporin", "CHEMICAL", 156, 169], ["tigecycline", "CHEMICAL", 171, 182], ["piperacillin/tazobactam", "CHEMICAL", 187, 210], ["fosfomycin", "CHEMICAL", 239, 249], ["colistin", "CHEMICAL", 254, 262], ["aminoglicosides", "CHEMICAL", 302, 317], ["ceftazidime", "CHEMICAL", 57, 68], ["avibactam", "CHEMICAL", 69, 78], ["carbapenems", "CHEMICAL", 110, 121], ["quinolones", "CHEMICAL", 123, 133], ["cephalosporin", "CHEMICAL", 156, 169], ["tigecycline", "CHEMICAL", 171, 182], ["piperacillin", "CHEMICAL", 187, 199], ["tazobactam", "CHEMICAL", 200, 210], ["fosfomycin", "CHEMICAL", 239, 249], ["colistin", "CHEMICAL", 254, 262], ["aminoglicosides", "CHEMICAL", 302, 317], ["ceftazidime", "SIMPLE_CHEMICAL", 57, 68], ["avibactam", "SIMPLE_CHEMICAL", 69, 78], ["carbapenems", "SIMPLE_CHEMICAL", 110, 121], ["quinolones", "SIMPLE_CHEMICAL", 123, 133], ["IV generation cephalosporin", "SIMPLE_CHEMICAL", 142, 169], ["tigecycline", "SIMPLE_CHEMICAL", 171, 182], ["piperacillin/tazobactam", "SIMPLE_CHEMICAL", 187, 210], ["fosfomycin", "SIMPLE_CHEMICAL", 239, 249], ["colistin", "SIMPLE_CHEMICAL", 254, 262], ["aminoglicosides", "SIMPLE_CHEMICAL", 302, 317], ["The susceptibility test", "TEST", 0, 23], ["strains", "PROBLEM", 27, 34], ["sensitivity", "PROBLEM", 42, 53], ["ceftazidime", "TREATMENT", 57, 68], ["avibactam", "TREATMENT", 69, 78], ["carbapenems", "TREATMENT", 110, 121], ["quinolones", "TREATMENT", 123, 133], ["III/IV generation cephalosporin", "TREATMENT", 138, 169], ["tigecycline", "TREATMENT", 171, 182], ["piperacillin", "TREATMENT", 187, 199], ["tazobactam", "TREATMENT", 200, 210], ["fosfomycin", "TREATMENT", 239, 249], ["colistin", "TREATMENT", 254, 262]]], ["Conclusions: The 14 strains of KP-cp were susceptible to ceftazidimeavibactam despite the high carbapenem-resistance recorded in our ICU, because od rare identification of KP-cp VIM/NDL +.", [["KP", "CHEMICAL", 31, 33], ["ceftazidimeavibactam", "CHEMICAL", 57, 77], ["carbapenem", "CHEMICAL", 95, 105], ["ceftazidimeavibactam", "CHEMICAL", 57, 77], ["carbapenem", "CHEMICAL", 95, 105], ["KP-cp", "ORGANISM", 31, 36], ["ceftazidimeavibactam", "SIMPLE_CHEMICAL", 57, 77], ["VIM", "GENE_OR_GENE_PRODUCT", 178, 181], ["NDL", "GENE_OR_GENE_PRODUCT", 182, 185], ["VIM", "PROTEIN", 178, 181], ["NDL", "PROTEIN", 182, 185], ["KP-cp", "SPECIES", 31, 36], ["KP-cp", "PROBLEM", 31, 36], ["ceftazidimeavibactam", "TREATMENT", 57, 77], ["the high carbapenem", "TREATMENT", 86, 105], ["KP", "TEST", 172, 174], ["high carbapenem", "OBSERVATION", 90, 105]]], ["The preliminary data seems to confirm the efficacy and clinical utility of this antibiotic for the critically ill patients.", [["critically ill", "DISEASE", 99, 113], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["The preliminary data", "TEST", 0, 20], ["this antibiotic", "TREATMENT", 75, 90]]], ["Introduction: Multidrug resistant bacteria (MDR) are an increasing problem on intensive care units.", [["Multidrug resistant bacteria", "PROBLEM", 14, 42], ["an increasing problem", "PROBLEM", 53, 74], ["intensive care units", "TREATMENT", 78, 98], ["Multidrug resistant", "OBSERVATION_MODIFIER", 14, 33], ["increasing", "OBSERVATION_MODIFIER", 56, 66]]], ["Lung infections caused by Acinetobacter baumannii are frequently difficult to treat.", [["Lung", "ANATOMY", 0, 4], ["Lung infections", "DISEASE", 0, 15], ["Acinetobacter baumannii", "DISEASE", 26, 49], ["Lung", "ORGAN", 0, 4], ["Acinetobacter baumannii", "ORGANISM", 26, 49], ["Acinetobacter baumannii", "SPECIES", 26, 49], ["Acinetobacter baumannii", "SPECIES", 26, 49], ["Lung infections", "PROBLEM", 0, 15], ["Acinetobacter baumannii", "PROBLEM", 26, 49], ["infections", "OBSERVATION", 5, 15], ["Acinetobacter baumannii", "OBSERVATION", 26, 49]]], ["Phages have regained attention as treatment option for bacterial infections due to their specificity and effectivity in lysis.", [["bacterial infections", "DISEASE", 55, 75], ["Phages", "TREATMENT", 0, 6], ["treatment option", "TREATMENT", 34, 50], ["bacterial infections", "PROBLEM", 55, 75], ["lysis", "TREATMENT", 120, 125]]], ["The aim of this preclinical study was to determine efficacy and safety of a novel phage preparation in mice.", [["mice", "ORGANISM", 103, 107], ["mice", "SPECIES", 103, 107], ["mice", "SPECIES", 103, 107], ["this preclinical study", "TEST", 11, 33], ["a novel phage preparation", "TREATMENT", 74, 99]]], ["Methods: Mice were transnasally infected with a MDR A. baumannii strain [1] and 12 hours later treated intratracheally with a specific phage or solvent.", [["intratracheally", "ANATOMY", 103, 118], ["Mice", "ORGANISM", 9, 13], ["A. baumannii", "ORGANISM", 52, 64], ["Mice", "SPECIES", 9, 13], ["A. baumannii", "SPECIES", 52, 64], ["A. baumannii", "SPECIES", 52, 64], ["a MDR A. baumannii strain", "TREATMENT", 46, 71], ["a specific phage or solvent", "TREATMENT", 124, 151]]], ["Phage Acibel004 [2] was produced as suspension including efficient depletion of endotoxins.", [["Acibel004 [2]", "CHEMICAL", 6, 19], ["Phage Acibel004", "TREATMENT", 0, 15], ["endotoxins", "PROBLEM", 80, 90], ["depletion", "OBSERVATION", 67, 76], ["endotoxins", "OBSERVATION", 80, 90]]], ["At defined time points, clinical parameters, bacterial burden in lung and bronchoalveolar lavage fluid (BALF) and cell influx were determined.", [["lung", "ANATOMY", 65, 69], ["bronchoalveolar lavage fluid", "ANATOMY", 74, 102], ["BALF", "ANATOMY", 104, 108], ["cell", "ANATOMY", 114, 118], ["lung", "ORGAN", 65, 69], ["bronchoalveolar lavage fluid", "ORGANISM_SUBSTANCE", 74, 102], ["BALF", "ORGANISM_SUBSTANCE", 104, 108], ["cell", "CELL", 114, 118], ["clinical parameters", "TEST", 24, 43], ["bacterial burden in lung", "PROBLEM", 45, 69], ["bronchoalveolar lavage fluid (BALF", "TEST", 74, 108], ["cell influx", "PROBLEM", 114, 125], ["bacterial", "OBSERVATION_MODIFIER", 45, 54], ["burden", "OBSERVATION_MODIFIER", 55, 61], ["lung", "ANATOMY", 65, 69], ["bronchoalveolar lavage", "OBSERVATION", 74, 96], ["cell influx", "OBSERVATION", 114, 125]]], ["Further, lung permeability and cytokine release were quantified and histopathological examination was performed.", [["lung", "ANATOMY", 9, 13], ["lung", "ORGAN", 9, 13], ["cytokine", "PROTEIN", 31, 39], ["cytokine release", "TEST", 31, 47], ["histopathological examination", "TEST", 68, 97], ["lung", "ANATOMY", 9, 13], ["permeability", "OBSERVATION", 14, 26]]], ["Results: Mice treated with phages recovered faster from infectionassociated hypothermia.", [["hypothermia", "DISEASE", 76, 87], ["Mice", "ORGANISM", 9, 13], ["Mice", "SPECIES", 9, 13], ["phages", "TREATMENT", 27, 33], ["infectionassociated hypothermia", "PROBLEM", 56, 87], ["hypothermia", "OBSERVATION", 76, 87]]], ["48 hours after infection, phage treatment led to a reduction in bacterial loads in lungs and BALF.", [["lungs", "ANATOMY", 83, 88], ["BALF", "ANATOMY", 93, 97], ["infection", "DISEASE", 15, 24], ["lungs", "ORGAN", 83, 88], ["BALF", "ORGANISM_SUBSTANCE", 93, 97], ["BALF", "CELL_TYPE", 93, 97], ["infection", "PROBLEM", 15, 24], ["phage treatment", "TREATMENT", 26, 41], ["a reduction in bacterial loads in lungs and BALF", "PROBLEM", 49, 97], ["infection", "OBSERVATION", 15, 24], ["reduction", "OBSERVATION_MODIFIER", 51, 60], ["bacterial loads", "OBSERVATION", 64, 79], ["lungs", "ANATOMY", 83, 88], ["BALF", "ANATOMY", 93, 97]]], ["In addition, lung permeability and cytokine production were reduced in phagetreated mice.", [["lung", "ANATOMY", 13, 17], ["lung", "ORGAN", 13, 17], ["mice", "ORGANISM", 84, 88], ["cytokine", "PROTEIN", 35, 43], ["mice", "SPECIES", 84, 88], ["mice", "SPECIES", 84, 88], ["lung permeability", "TEST", 13, 30], ["cytokine production", "TEST", 35, 54], ["lung", "ANATOMY", 13, 17], ["permeability", "OBSERVATION", 18, 30], ["cytokine production", "OBSERVATION", 35, 54]]], ["Histopathological examination of the lungs showed less spreading of bacteria to the periphery in phage-treated mice, whereas cellular recruitment into the lung was unaffected.", [["lungs", "ANATOMY", 37, 42], ["periphery", "ANATOMY", 84, 93], ["cellular", "ANATOMY", 125, 133], ["lung", "ANATOMY", 155, 159], ["lungs", "ORGAN", 37, 42], ["mice", "ORGANISM", 111, 115], ["cellular", "CELL", 125, 133], ["lung", "ORGAN", 155, 159], ["mice", "SPECIES", 111, 115], ["mice", "SPECIES", 111, 115], ["Histopathological examination of the lungs", "TEST", 0, 42], ["bacteria", "PROBLEM", 68, 76], ["lungs", "ANATOMY", 37, 42], ["less", "OBSERVATION_MODIFIER", 50, 54], ["spreading", "OBSERVATION_MODIFIER", 55, 64], ["bacteria", "OBSERVATION", 68, 76], ["periphery", "OBSERVATION_MODIFIER", 84, 93], ["cellular recruitment", "OBSERVATION", 125, 145], ["lung", "ANATOMY", 155, 159], ["unaffected", "OBSERVATION", 164, 174]]], ["No adverse effects were observed.", [["adverse effects", "PROBLEM", 3, 18], ["adverse effects", "OBSERVATION", 3, 18]]], ["Conclusions: For the first time a highly purified phage against A. baumannii was successfully used in vivo.", [["A. baumannii", "ORGANISM", 64, 76], ["A. baumannii", "SPECIES", 64, 76], ["A. baumannii", "SPECIES", 64, 76], ["a highly purified phage", "TREATMENT", 32, 55], ["A. baumannii", "TREATMENT", 64, 76]]], ["The current preclinical data support the concept of a phage-based therapy against pulmonary A. baumannii infections.P077Introduction: VAP is common in critically ill patients and associated with high morbidity and mortality, especially when caused by antibiotic resistant bacteria.", [["pulmonary A. baumannii infections", "DISEASE", 82, 115], ["P077Introduction", "CHEMICAL", 116, 132], ["VAP", "DISEASE", 134, 137], ["critically ill", "DISEASE", 151, 165], ["pulmonary A. baumannii", "ORGANISM", 82, 104], ["patients", "ORGANISM", 166, 174], ["A. baumannii", "SPECIES", 92, 104], ["patients", "SPECIES", 166, 174], ["A. baumannii", "SPECIES", 92, 104], ["a phage-based therapy", "TREATMENT", 52, 73], ["pulmonary A. baumannii infections", "PROBLEM", 82, 115], ["VAP", "PROBLEM", 134, 137], ["high morbidity", "PROBLEM", 195, 209], ["antibiotic resistant bacteria", "PROBLEM", 251, 280], ["pulmonary", "ANATOMY", 82, 91], ["baumannii", "OBSERVATION", 95, 104], ["VAP", "OBSERVATION", 134, 137]]], ["Recently, phage therapy has emerged as a promising non-antibiotic based treatment of antibiotic resistant bacterial infections.", [["bacterial infections", "DISEASE", 106, 126], ["phage therapy", "TREATMENT", 10, 23], ["a promising non-antibiotic based treatment", "TREATMENT", 39, 81], ["antibiotic resistant bacterial infections", "PROBLEM", 85, 126], ["bacterial", "OBSERVATION_MODIFIER", 106, 115], ["infections", "OBSERVATION", 116, 126]]], ["However, proof-of-concept experimental and clinical studies are missing before its wider use in clinical medicine.", [["clinical studies", "TEST", 43, 59], ["clinical medicine", "TREATMENT", 96, 113]]], ["The goal of this experimental study was to compare the efficacy of phage therapy versus antibiotics for the treatment of MRSA in a rat model of VAP.", [["MRSA", "DISEASE", 121, 125], ["VAP", "DISEASE", 144, 147], ["rat", "ORGANISM", 131, 134], ["MRSA", "SPECIES", 121, 125], ["rat", "SPECIES", 131, 134], ["MRSA", "SPECIES", 121, 125], ["rat", "SPECIES", 131, 134], ["this experimental study", "TEST", 12, 35], ["phage therapy", "TREATMENT", 67, 80], ["antibiotics", "TREATMENT", 88, 99], ["the treatment", "TREATMENT", 104, 117], ["MRSA", "PROBLEM", 121, 125], ["VAP", "PROBLEM", 144, 147], ["MRSA", "OBSERVATION", 121, 125]]], ["Methods: Four hours after intubation and protective ventilation, rats were inoculated via the endotracheal tube with 6-9 x 10 9 CFU (LD100) of the MRSA clinical isolate AW7.", [["endotracheal tube", "ANATOMY", 94, 111], ["rats", "ORGANISM", 65, 69], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 94, 111], ["rats", "SPECIES", 65, 69], ["MRSA", "SPECIES", 147, 151], ["intubation", "TREATMENT", 26, 36], ["protective ventilation", "TREATMENT", 41, 63], ["the endotracheal tube", "TREATMENT", 90, 111], ["endotracheal tube", "OBSERVATION", 94, 111]]], ["The animals were subsequently extubated.", [["animals", "ORGANISM", 4, 11]]], ["Two hours after bacterial challenge, rats were randomised to receive intravenously either teicoplanin (n= 8), a cocktail of 4 lytic anti-S. aureus bacteriophages (n=9) or combination of both (n=6).", [["intravenously", "ANATOMY", 69, 82], ["teicoplanin", "CHEMICAL", 90, 101], ["teicoplanin", "CHEMICAL", 90, 101], ["rats", "ORGANISM", 37, 41], ["teicoplanin", "SIMPLE_CHEMICAL", 90, 101], ["anti-S. aureus", "ORGANISM", 132, 146], ["rats", "SPECIES", 37, 41], ["anti-S. aureus", "SPECIES", 132, 146], ["anti-S. aureus", "SPECIES", 132, 146], ["bacterial challenge", "TREATMENT", 16, 35], ["intravenously either teicoplanin", "TREATMENT", 69, 101], ["4 lytic anti-S. aureus bacteriophages", "PROBLEM", 124, 161]]], ["5 animals served as control (no treatment).", [["treatment", "TREATMENT", 32, 41]]], ["Secondary outcomes were bacterial count in lungs, spleen and blood.", [["lungs", "ANATOMY", 43, 48], ["spleen", "ANATOMY", 50, 56], ["blood", "ANATOMY", 61, 66], ["lungs", "ORGAN", 43, 48], ["spleen", "ORGAN", 50, 56], ["blood", "ORGANISM_SUBSTANCE", 61, 66], ["Secondary outcomes", "PROBLEM", 0, 18], ["bacterial count in lungs, spleen and blood", "PROBLEM", 24, 66], ["bacterial count", "OBSERVATION", 24, 39], ["lungs", "ANATOMY", 43, 48], ["spleen", "ANATOMY", 50, 56], ["blood", "ANATOMY", 61, 66]]], ["Kaplan-Meier estimates of survival were done and multiple comparisons of survival rates performed using the Holm-Sidak method.", [["survival rates", "TEST", 73, 87], ["the Holm-Sidak method", "TREATMENT", 104, 125]]], ["Results: Treatment with either phages, antibiotics or combination of both significantly increased survival (66%, 50%, 50% respectively, compared to 0% survival for controls, p<0.05).", [["either phages", "TREATMENT", 24, 37], ["antibiotics", "TREATMENT", 39, 50]]], ["There were no statistical differences in survival rates between either forms of treatment ( Fig. 1) .", [["statistical differences in survival rates", "PROBLEM", 14, 55], ["treatment ( Fig", "TREATMENT", 80, 95], ["no", "UNCERTAINTY", 11, 13]]], ["Treatments hinder the systemic extension of the infection into the blood and spleen without impacting bacterial counts within the lungs, but the numbers are too small to perform statistical tests (Table 1) Introduction: The aim of the study was comparative evaluation of the clinical and microbiological efficacy of combination of amikacin thru nebuliser Aeroneb Pro and standard antimicrobal therapy (AMTcomb) with standard antimicrobal therapy (AMTst) in treatment of ventilator-associated pneumonia (VAP) and ventilator-associated tracheobronchitis (VAT) caused by multi-drug resistant gram-negative bacteria.", [["blood", "ANATOMY", 67, 72], ["spleen", "ANATOMY", 77, 83], ["lungs", "ANATOMY", 130, 135], ["VAT", "ANATOMY", 553, 556], ["infection", "DISEASE", 48, 57], ["amikacin", "CHEMICAL", 331, 339], ["Aeroneb Pro", "CHEMICAL", 355, 366], ["ventilator-associated pneumonia", "DISEASE", 470, 501], ["VAP", "DISEASE", 503, 506], ["ventilator-associated tracheobronchitis", "DISEASE", 512, 551], ["VAT", "DISEASE", 553, 556], ["amikacin", "CHEMICAL", 331, 339], ["blood", "ORGANISM_SUBSTANCE", 67, 72], ["spleen", "ORGAN", 77, 83], ["lungs", "ORGAN", 130, 135], ["amikacin", "SIMPLE_CHEMICAL", 331, 339], ["Aeroneb Pro", "SIMPLE_CHEMICAL", 355, 366], ["VAT", "TISSUE", 553, 556], ["Treatments", "TREATMENT", 0, 10], ["the infection into the blood and spleen", "PROBLEM", 44, 83], ["impacting bacterial counts within the lungs", "PROBLEM", 92, 135], ["statistical tests", "TEST", 178, 195], ["the study", "TEST", 231, 240], ["comparative evaluation", "TEST", 245, 267], ["amikacin", "TREATMENT", 331, 339], ["nebuliser Aeroneb Pro", "TREATMENT", 345, 366], ["standard antimicrobal therapy (AMTcomb)", "TREATMENT", 371, 410], ["standard antimicrobal therapy", "TREATMENT", 416, 445], ["AMTst)", "TREATMENT", 447, 453], ["ventilator-associated pneumonia", "PROBLEM", 470, 501], ["VAP", "PROBLEM", 503, 506], ["ventilator-associated tracheobronchitis", "PROBLEM", 512, 551], ["multi-drug resistant gram-negative bacteria", "PROBLEM", 568, 611], ["systemic", "OBSERVATION_MODIFIER", 22, 30], ["infection", "OBSERVATION", 48, 57], ["blood", "ANATOMY", 67, 72], ["spleen", "ANATOMY", 77, 83], ["without", "UNCERTAINTY", 84, 91], ["bacterial counts", "OBSERVATION", 102, 118], ["lungs", "ANATOMY", 130, 135], ["pneumonia", "OBSERVATION", 492, 501], ["tracheobronchitis", "OBSERVATION", 534, 551], ["negative bacteria", "OBSERVATION", 594, 611]]], ["Methods: In prospective two-center study with retrospective control included patients with VAP and VAT.", [["VAP", "DISEASE", 91, 94], ["patients", "ORGANISM", 77, 85], ["VAT", "TISSUE", 99, 102], ["patients", "SPECIES", 77, 85], ["retrospective control", "TREATMENT", 46, 67], ["VAP", "PROBLEM", 91, 94], ["VAT", "TREATMENT", 99, 102]]], ["In AMTst group (retrospective, n=25) we used combination of meropenem 1 g every 8h iv as continuous infusion, cefoperazon/sulbactam 4 g every 12 h iv as continuous infusion and amikacin 1 g iv every 24 h.", [["meropenem", "CHEMICAL", 60, 69], ["cefoperazon", "CHEMICAL", 110, 121], ["sulbactam", "CHEMICAL", 122, 131], ["amikacin", "CHEMICAL", 177, 185], ["meropenem", "CHEMICAL", 60, 69], ["cefoperazon", "CHEMICAL", 110, 121], ["sulbactam", "CHEMICAL", 122, 131], ["amikacin", "CHEMICAL", 177, 185], ["AMTst", "SIMPLE_CHEMICAL", 3, 8], ["meropenem", "SIMPLE_CHEMICAL", 60, 69], ["cefoperazon", "SIMPLE_CHEMICAL", 110, 121], ["sulbactam", "SIMPLE_CHEMICAL", 122, 131], ["amikacin", "SIMPLE_CHEMICAL", 177, 185], ["meropenem", "TREATMENT", 60, 69], ["cefoperazon", "TREATMENT", 110, 121], ["sulbactam", "TREATMENT", 122, 131], ["amikacin", "TREATMENT", 177, 185]]], ["In AMTcomb group (prospective, n=25) we used combination of AMTst and amikacin inhalation 500 mg every 12 h thru nebuliser Aeroneb Pro.", [["AMTst", "CHEMICAL", 60, 65], ["amikacin", "CHEMICAL", 70, 78], ["amikacin", "CHEMICAL", 70, 78], ["AMTcomb", "SIMPLE_CHEMICAL", 3, 10], ["AMTst", "SIMPLE_CHEMICAL", 60, 65], ["amikacin", "SIMPLE_CHEMICAL", 70, 78], ["AMTst", "TREATMENT", 60, 65], ["amikacin inhalation", "TREATMENT", 70, 89]]], ["Results: In AMTcomb clinical cure rate was 84%, while in AMTst 29.2% (p<0.001), Clinical Pulmonary Infection Score (CPIS) on day 7 was 6 (4-7) points in AMTst and 2 (0-4) points in AMTcomb (p<0.001).", [["Pulmonary", "ANATOMY", 89, 98], ["Pulmonary Infection", "DISEASE", 89, 108], ["Pulmonary", "ORGAN", 89, 98], ["AMTst", "TEST", 57, 62], ["Clinical Pulmonary Infection Score", "PROBLEM", 80, 114], ["CPIS", "TEST", 116, 120], ["AMTst", "TEST", 153, 158], ["Pulmonary", "ANATOMY", 89, 98], ["Infection", "OBSERVATION", 99, 108]]], ["Recurrence of VAP/VAT was 29.2% in AMTst and 12.5% in AMTcomb (p=0.008).", [["VAP", "DISEASE", 14, 17], ["AMTst", "DISEASE", 35, 40], ["VAP", "PROBLEM", 14, 17], ["VAT", "TEST", 18, 21], ["AMTst", "TEST", 35, 40], ["VAP", "OBSERVATION", 14, 17]]], ["On day 7 infectious agent titer in tracheal aspirate was 10 7 (10 3 -10 8 ) CFU/ml in AMTst group, while 10 3 (no growth-10 6 ) CFU/ml in AMTcomb (p=0.016).", [["tracheal aspirate", "ANATOMY", 35, 52], ["tracheal aspirate", "MULTI-TISSUE_STRUCTURE", 35, 52], ["AMTst", "CANCER", 86, 91], ["infectious agent", "TREATMENT", 9, 25], ["tracheal aspirate", "TEST", 35, 52], ["growth", "TEST", 114, 120], ["tracheal", "ANATOMY", 35, 43], ["aspirate", "OBSERVATION", 44, 52]]], ["Microbiological eradication observed in 13 patients in AMTcomb vs in 1 patient in AMTst and microbiological persistance observed in 6 patients in AMTcomb vs 17 patients in AMTst (p=0.002).", [["patients", "ORGANISM", 43, 51], ["patient", "ORGANISM", 71, 78], ["AMTst", "CANCER", 82, 87], ["patients", "ORGANISM", 134, 142], ["patients", "ORGANISM", 160, 168], ["patients", "SPECIES", 43, 51], ["patient", "SPECIES", 71, 78], ["patients", "SPECIES", 134, 142], ["patients", "SPECIES", 160, 168], ["Microbiological eradication", "TEST", 0, 27]]], ["In AMTcomb on 3rd day sputum was less purulent (p=0.016).", [["sputum", "ANATOMY", 22, 28], ["sputum", "TEST", 22, 28], ["purulent", "PROBLEM", 38, 46], ["less", "OBSERVATION_MODIFIER", 33, 37], ["purulent", "OBSERVATION", 38, 46]]], ["Amikacin nebulisation didn't led to deterioration of organ dysfunction: on day 7 there was no difference in platelet count, creatinine and bilirubin levels as compared to day 0 (p=0.102; p=0.297, p=0.532, respectively).", [["organ", "ANATOMY", 53, 58], ["platelet", "ANATOMY", 108, 116], ["Amikacin", "CHEMICAL", 0, 8], ["organ dysfunction", "DISEASE", 53, 70], ["creatinine", "CHEMICAL", 124, 134], ["bilirubin", "CHEMICAL", 139, 148], ["Amikacin", "CHEMICAL", 0, 8], ["creatinine", "CHEMICAL", 124, 134], ["bilirubin", "CHEMICAL", 139, 148], ["Amikacin", "SIMPLE_CHEMICAL", 0, 8], ["organ", "ORGAN", 53, 58], ["platelet", "CELL", 108, 116], ["creatinine", "SIMPLE_CHEMICAL", 124, 134], ["bilirubin", "SIMPLE_CHEMICAL", 139, 148], ["Amikacin nebulisation", "TREATMENT", 0, 21], ["organ dysfunction", "PROBLEM", 53, 70], ["platelet count", "TEST", 108, 122], ["creatinine", "TEST", 124, 134], ["bilirubin levels", "TEST", 139, 155], ["p", "TEST", 187, 188], ["p", "TEST", 196, 197], ["organ", "ANATOMY", 53, 58], ["dysfunction", "OBSERVATION", 59, 70], ["no", "UNCERTAINTY", 91, 93], ["platelet count", "OBSERVATION", 108, 122]]], ["Conclusions: Addition of amikacin inhalation 500 mg every 12 h thru Aeroneb Pro nebuliser in patients with VAP and VAT was more efficacious than intravenous standard antimicrobal treatment with comparable safety profile.", [["intravenous", "ANATOMY", 145, 156], ["amikacin", "CHEMICAL", 25, 33], ["VAP", "DISEASE", 107, 110], ["amikacin", "CHEMICAL", 25, 33], ["amikacin", "SIMPLE_CHEMICAL", 25, 33], ["patients", "ORGANISM", 93, 101], ["VAT", "TISSUE", 115, 118], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 145, 156], ["patients", "SPECIES", 93, 101], ["amikacin inhalation", "TREATMENT", 25, 44], ["Aeroneb Pro nebuliser", "TREATMENT", 68, 89], ["VAP", "PROBLEM", 107, 110], ["VAT", "TREATMENT", 115, 118], ["intravenous standard antimicrobal treatment", "TREATMENT", 145, 188]]], ["Introduction: The aim of the study was to assess the effectiveness of inhaled colistin (IC) as an adjunct to systemic antibiotics in the treatment of ventilator-associated pneumonia (VAP).", [["colistin", "CHEMICAL", 78, 86], ["IC", "CHEMICAL", 88, 90], ["ventilator-associated pneumonia", "DISEASE", 150, 181], ["VAP", "DISEASE", 183, 186], ["colistin", "CHEMICAL", 78, 86], ["colistin", "SIMPLE_CHEMICAL", 78, 86], ["IC", "SIMPLE_CHEMICAL", 88, 90], ["the study", "TEST", 25, 34], ["inhaled colistin (IC)", "TREATMENT", 70, 91], ["systemic antibiotics", "TREATMENT", 109, 129], ["ventilator-associated pneumonia", "PROBLEM", 150, 181], ["VAP", "PROBLEM", 183, 186], ["pneumonia", "OBSERVATION", 172, 181]]], ["Methods: 110 ICU patients with VAP were enrolled in this observational study.", [["VAP", "DISEASE", 31, 34], ["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["VAP", "PROBLEM", 31, 34], ["this observational study", "TEST", 52, 76]]], ["Resolution of VAP was assessed as primary endpoint; eradication of pathogens in sputum, weaning time, duration of ICU stay and mortality were assessed as secondary outcomes.", [["sputum", "ANATOMY", 80, 86], ["VAP", "DISEASE", 14, 17], ["VAP", "PROBLEM", 14, 17], ["pathogens in sputum", "PROBLEM", 67, 86], ["VAP", "OBSERVATION", 14, 17]]], ["Patients were split into 2 groups: Gr.1 (n = 60) -addition of IC to systemic antibiotics without changing the basic regimen; Gr.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["IC to systemic antibiotics", "TREATMENT", 62, 88], ["changing the basic regimen", "TREATMENT", 97, 123]]], ["2 (n = 50) -change in systemic antibiotics according to sensitivity.", [["systemic antibiotics", "TREATMENT", 22, 42], ["sensitivity", "TEST", 56, 67]]], ["IC was administered in a dose of 2 million IU TID (Xselia Pharmaceuticals ApS, Denmark).", [["TID", "CHEMICAL", 46, 49], ["IC", "TREATMENT", 0, 2]]], ["Statistical analysis was performed using Statistica 7.0 (M, \u03c3, Newman-Keuls test; p <0.05).", [["Statistical analysis", "TEST", 0, 20], ["Statistica", "TEST", 41, 51]]], ["Results: VAP resolution rate was 77% in Gr.1 (vs. 50% in Gr.", [["VAP", "DISEASE", 9, 12], ["VAP resolution rate", "TEST", 9, 28]]], ["2, p = 0.0295); eradication of pathogens from sputum by the 7th day. treatment was achieved in 80% of Gr.", [["sputum", "ANATOMY", 46, 52], ["sputum", "ORGANISM_SUBSTANCE", 46, 52], ["Gr.", "ORGANISM", 102, 105], ["pathogens", "PROBLEM", 31, 40], ["sputum", "TEST", 46, 52], ["treatment", "TREATMENT", 69, 78]]], ["1 and 60% in the Gr.", [["Gr.", "ORGANISM", 17, 20]]], ["2 (n = 12) (p> 0.05); in Gr.", [["Gr.", "ORGANISM", 25, 28]]], ["1 weaning from ventilation was possible earlier than in Gr.", [["ventilation", "TREATMENT", 15, 26]]], ["2 -7.8\u00b11.3 days. in Gr.", [["Gr.", "ORGANISM", 20, 23]]], ["1 vs. 10.9\u00b14.5 days. in Gr.", [["Gr.", "ORGANISM", 24, 27]]], ["2 (p = 0.0000); in Gr.", [["Gr.", "ORGANISM", 19, 22]]], ["2 -11.5\u00b13.2 days vs. 17.1\u00b12.3 days. in Gr.", [["Gr.", "ORGANISM", 39, 42]]], ["No mortality differences were detected.", [["mortality differences", "PROBLEM", 3, 24], ["mortality", "OBSERVATION", 3, 12]]], ["Conclusions: Administration of inhaled colistin 2 million IU TID is effective as an adjunct to systemic antibiotics in the treatment of VAP.", [["colistin", "CHEMICAL", 39, 47], ["TID", "CHEMICAL", 61, 64], ["VAP", "DISEASE", 136, 139], ["colistin", "CHEMICAL", 39, 47], ["TID", "CHEMICAL", 61, 64], ["colistin", "SIMPLE_CHEMICAL", 39, 47], ["TID", "SIMPLE_CHEMICAL", 61, 64], ["inhaled colistin", "TREATMENT", 31, 47], ["systemic antibiotics", "TREATMENT", 95, 115], ["VAP", "PROBLEM", 136, 139], ["VAP", "OBSERVATION", 136, 139]]], ["This modified treatment promotes a more rapid resolution of VAP, earlier weaning from ventilator, reduction of the duration of ICU stay, with no impact on mortality.", [["VAP", "DISEASE", 60, 63], ["This modified treatment", "TREATMENT", 0, 23], ["VAP", "PROBLEM", 60, 63], ["ventilator", "TREATMENT", 86, 96], ["VAP", "OBSERVATION", 60, 63]]], ["The addition of IC to systemic antibiotics should be considered as second-line regimen in VAP patients.P081Factors associated with no de-escalation of empirical antimicrobial therapy in ICU settings with high rate of multi-drug resistant bacteria C Routsi 1 Introduction: De-escalation is recommended in the management of antimicrobial therapy in ICU patients [1] .", [["VAP", "DISEASE", 90, 93], ["patients", "ORGANISM", 94, 102], ["patients", "ORGANISM", 351, 359], ["patients", "SPECIES", 94, 102], ["patients", "SPECIES", 351, 359], ["IC to systemic antibiotics", "TREATMENT", 16, 42], ["second-line regimen", "TREATMENT", 67, 86], ["VAP patients", "TREATMENT", 90, 102], ["empirical antimicrobial therapy", "TREATMENT", 151, 182], ["multi-drug resistant bacteria C Routsi", "TREATMENT", 217, 255], ["De-escalation", "TREATMENT", 272, 285], ["antimicrobial therapy", "TREATMENT", 322, 343]]], ["However, this strategy has not been adequately evaluated in the presence of increased prevalence of multidrug-resistant (MDR) bacteria.", [["multidrug-resistant (MDR) bacteria", "DISEASE", 100, 134], ["multidrug-resistant (MDR) bacteria", "PROBLEM", 100, 134], ["increased", "OBSERVATION_MODIFIER", 76, 85]]], ["The aim of this study was to identify factors associated with no de-escalation in ICUs with high rate of MDR bacteria [2] .", [["this study", "TEST", 11, 21], ["MDR bacteria", "PROBLEM", 105, 117]]], ["Methods: Prospective, multicenter study conducted in 12 Greek ICUs over a 1-year period.", [["multicenter study", "TEST", 22, 39]]], ["Patients with laboratory confirmed infections were included.", [["infections", "DISEASE", 35, 45], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["infections", "PROBLEM", 35, 45], ["infections", "OBSERVATION", 35, 45]]], ["SOFA score on admission, on septic episode and thereafter every 24 h over 14 days, infection site(s), culture results, antimicrobial therapy, and mortality were recorded.", [["infection", "DISEASE", 83, 92], ["SOFA score", "TEST", 0, 10], ["septic episode", "PROBLEM", 28, 42], ["infection site", "PROBLEM", 83, 97], ["culture", "TEST", 102, 109], ["antimicrobial therapy", "TREATMENT", 119, 140], ["septic", "OBSERVATION", 28, 34]]], ["Only the first septic episode was analyzed.", [["septic", "DISEASE", 15, 21], ["the first septic episode", "PROBLEM", 5, 29], ["septic", "OBSERVATION_MODIFIER", 15, 21], ["episode", "OBSERVATION", 22, 29]]], ["In order to assess the factors associated with no de-escalation, a multivariate analysis was performed.", [["de-escalation", "TREATMENT", 50, 63], ["a multivariate analysis", "TEST", 65, 88]]], ["Results: A total of 211 patients (admission SOFA score 10\u00b13) were analyzed.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["SOFA score", "TEST", 44, 54]]], ["43% of those had septic episode on ICU admission; 57% patients had an ICU-acquired.", [["septic", "DISEASE", 17, 23], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["septic episode", "PROBLEM", 17, 31], ["septic", "OBSERVATION", 17, 23]]], ["De-escalation was applied to 44 (21%) patients whereas it was not feasible in 75 patients (44 %) due to the recovery of MDR pathogens or it was not applied, although the microbiology results allowed it, in 92 patients (56 %).", [["patients", "ORGANISM", 38, 46], ["patients", "ORGANISM", 81, 89], ["patients", "ORGANISM", 209, 217], ["patients", "SPECIES", 38, 46], ["patients", "SPECIES", 81, 89], ["patients", "SPECIES", 209, 217], ["De-escalation", "TREATMENT", 0, 13], ["MDR pathogens", "PROBLEM", 120, 133], ["the microbiology", "TEST", 166, 182]]], ["Septic shock on the day of septic episode was present in 67% and 79% of patients with and without de-escalation, respectively, p=0.072).", [["shock", "DISEASE", 7, 12], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["Septic shock", "PROBLEM", 0, 12], ["septic episode", "PROBLEM", 27, 41], ["de-escalation", "TEST", 98, 111], ["shock", "OBSERVATION", 7, 12]]], ["Compared to no de-escalation, de-escalation strategy was associated with a shorter duration of shock (4 \u00b15 vs. 9\u00b17 days, p<0.001) and all-cause mortality (15.4% vs. 46.4%, p<0.001).", [["shock", "DISEASE", 95, 100], ["de-escalation", "TREATMENT", 15, 28], ["de-escalation strategy", "TREATMENT", 30, 52], ["shock", "PROBLEM", 95, 100], ["mortality", "TEST", 144, 153], ["shock", "OBSERVATION", 95, 100]]], ["Multivariate analysis showed that the variables associated with no de-escalation were: a deteriorating clinical course as indicated by an increasing SOFA score (OR 14.7, p<0.001) and a lack of de-escalation possibility due to recovery of MDR pathogens (OR 27.3, p=0.008).", [["Multivariate analysis", "TEST", 0, 21], ["an increasing SOFA score", "PROBLEM", 135, 159], ["MDR pathogens", "PROBLEM", 238, 251]]], ["Conclusions: Deteriorating clinical course and MDR pathogens are independently associated with no de-escalation strategy in critically ill patients.", [["critically ill", "DISEASE", 124, 138], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["MDR pathogens", "PROBLEM", 47, 60], ["de-escalation strategy", "TREATMENT", 98, 120]]], ["Conclusions: The qSOFA scale in the prognosis of sepsis does not differ significantly from the SIRS criteria, but in the prognosis of mortality is significantly better than SIRS. qSOFA significantly worse in the prognosis of sepsis and death than the SOFA scale.", [["sepsis", "DISEASE", 49, 55], ["SIRS", "DISEASE", 95, 99], ["SIRS", "DISEASE", 173, 177], ["sepsis", "DISEASE", 225, 231], ["death", "DISEASE", 236, 241], ["The qSOFA scale", "TEST", 13, 28], ["sepsis", "PROBLEM", 49, 55], ["SIRS", "PROBLEM", 173, 177], ["qSOFA", "PROBLEM", 179, 184], ["sepsis", "PROBLEM", 225, 231], ["death", "PROBLEM", 236, 241], ["the SOFA scale", "TEST", 247, 261], ["sepsis", "OBSERVATION", 49, 55], ["worse", "OBSERVATION_MODIFIER", 199, 204], ["sepsis", "OBSERVATION", 225, 231]]], ["The international task force of Sepsis-3 introduced the quick Sequential Failure Assessment (qSOFA) score to supersede the systemic inflammatory response syndrome (SIRS) score as the screen tool for sepsis.", [["Sepsis", "DISEASE", 32, 38], ["systemic inflammatory response syndrome", "DISEASE", 123, 162], ["SIRS", "DISEASE", 164, 168], ["sepsis", "DISEASE", 199, 205], ["Sepsis", "PROBLEM", 32, 38], ["the systemic inflammatory response syndrome", "PROBLEM", 119, 162], ["the screen tool", "TEST", 179, 194], ["sepsis", "PROBLEM", 199, 205], ["Sepsis", "OBSERVATION", 32, 38], ["systemic", "OBSERVATION_MODIFIER", 123, 131], ["inflammatory response syndrome", "OBSERVATION", 132, 162], ["sepsis", "OBSERVATION", 199, 205]]], ["The objective of this study is to prospectively access the diagnostic value of qSOFA and SIRS among patients with infection in general wards.", [["SIRS", "DISEASE", 89, 93], ["infection", "DISEASE", 114, 123], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["this study", "TEST", 17, 27], ["qSOFA", "TEST", 79, 84], ["SIRS", "PROBLEM", 89, 93], ["infection", "PROBLEM", 114, 123], ["infection", "OBSERVATION", 114, 123]]], ["Methods: A prospective cohort study conducted in ten general wards of a tertiary teaching hospital.", [["A prospective cohort study", "TEST", 9, 35]]], ["For a half-year period, consecutive patients who were admitted with infection or developed infection during hospital stay were included.", [["infection", "DISEASE", 68, 77], ["infection", "DISEASE", 91, 100], ["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["infection", "PROBLEM", 68, 77], ["infection", "PROBLEM", 91, 100], ["infection", "OBSERVATION", 68, 77], ["infection", "OBSERVATION", 91, 100]]], ["Demographic data and all variables for qSOFA, SIRS and SOFA scores were collected.", [["SIRS", "DISEASE", 46, 50], ["Demographic data", "TEST", 0, 16], ["qSOFA", "TEST", 39, 44], ["SIRS", "PROBLEM", 46, 50], ["SOFA scores", "TEST", 55, 66]]], ["We recorded daily qSOFA, SIRS and SOFA scores until hospital discharge, death, or day 28, whichever occurred earlier.", [["SIRS", "DISEASE", 25, 29], ["death", "DISEASE", 72, 77], ["SIRS", "PROBLEM", 25, 29], ["SOFA scores", "TEST", 34, 45]]], ["The primary outcome was sepsis at 28 days.", [["sepsis", "DISEASE", 24, 30], ["sepsis", "PROBLEM", 24, 30], ["sepsis", "OBSERVATION", 24, 30]]], ["Discrimination was assessed using the area under the receiver operating characteristic curve (AUROC) and sensitivities or specificities with a conventional cutoff value of 2.", [["a conventional cutoff value", "TEST", 141, 168]]], ["Results: Of 409 patients (median age, 55 years [IQR, 40-67]; male, 225[55%]; most common diagnosis pneumonia, 234[57%]) who were identified with infection in general wards, 229(56%) developed sepsis at a median of 0 (IQR, 0-1) day, 146 patients (36%) and 371 patients (91%) met qSOFA and SIRS criteria at a median of 1 (IQR, 0-5) and 0 (IQR, 0-0) day, respectively.", [["pneumonia", "DISEASE", 99, 108], ["infection", "DISEASE", 145, 154], ["sepsis", "DISEASE", 192, 198], ["SIRS", "DISEASE", 288, 292], ["patients", "ORGANISM", 16, 24], ["patients", "ORGANISM", 236, 244], ["patients", "ORGANISM", 259, 267], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 236, 244], ["patients", "SPECIES", 259, 267], ["IQR", "TEST", 48, 51], ["pneumonia", "PROBLEM", 99, 108], ["infection", "PROBLEM", 145, 154], ["sepsis", "PROBLEM", 192, 198], ["qSOFA", "TEST", 278, 283], ["SIRS criteria", "TEST", 288, 301], ["pneumonia", "OBSERVATION", 99, 108], ["infection", "OBSERVATION", 145, 154], ["sepsis", "OBSERVATION", 192, 198]]], ["The qSOFA performed better than SIRS in diagnosing sepsis, with an AUROC of 0.75 (95% CI, 0.71-0.79) vs 0.69(95% CI, 0.64-0.74).", [["SIRS", "DISEASE", 32, 36], ["sepsis", "DISEASE", 51, 57], ["The qSOFA", "TEST", 0, 9], ["SIRS", "PROBLEM", 32, 36], ["sepsis", "PROBLEM", 51, 57], ["an AUROC", "TEST", 64, 72], ["CI", "TEST", 86, 88], ["vs", "TEST", 101, 103], ["CI", "TEST", 113, 115], ["sepsis", "OBSERVATION", 51, 57]]], ["With a conventional cutoff value of 2, qSOFA had lower sensitivity (53% [95% CI, 47%-60%] vs. 98% [95% CI, 95%-99%], p < 0.001) and higher specificity (87% [95% CI, 81%-91%] vs. 18% [95% CI, 13%-23%], p < 0.001) than SIRS (Table 1) .", [["SIRS", "DISEASE", 217, 221], ["a conventional cutoff value", "TEST", 5, 32], ["qSOFA", "TEST", 39, 44], ["lower sensitivity", "PROBLEM", 49, 66], ["CI", "TEST", 77, 79], ["%", "TEST", 83, 84], ["CI", "TEST", 103, 105], ["p", "TEST", 117, 118], ["specificity", "TEST", 139, 150], ["CI", "TEST", 161, 163], ["%", "TEST", 167, 168], ["CI", "TEST", 187, 189], ["p", "TEST", 201, 202], ["SIRS", "TEST", 217, 221]]], ["Conclusions: Among patients with infection in general wards, the use of qSOFA resulted in greater diagnostic accuracy for sepsis than SIRS during hospitalization. qSOFA and SIRS scores can predict the occurrence of sepsis with high specificity and high sensitivity, respectively.P086Prognostic accuracy of quick sequential organ failure assessment (qSOFA) score for mortality: systematic review and meta-analysis Introduction: The purpose of this study was to summarize the evidence assessing the qSOFA [1] , calculated in admission of the patient in emergency department (ED) or intensive care unit (ICU), as a predictor of mortality.", [["organ", "ANATOMY", 323, 328], ["infection", "DISEASE", 33, 42], ["qSOFA", "CHEMICAL", 72, 77], ["sepsis", "DISEASE", 122, 128], ["SIRS", "DISEASE", 134, 138], ["SIRS", "DISEASE", 173, 177], ["sepsis", "DISEASE", 215, 221], ["patients", "ORGANISM", 19, 27], ["organ", "ORGAN", 323, 328], ["patient", "ORGANISM", 540, 547], ["patients", "SPECIES", 19, 27], ["patient", "SPECIES", 540, 547], ["infection", "PROBLEM", 33, 42], ["qSOFA", "TEST", 72, 77], ["sepsis", "PROBLEM", 122, 128], ["SIRS", "PROBLEM", 134, 138], ["qSOFA", "TEST", 163, 168], ["SIRS scores", "PROBLEM", 173, 184], ["sepsis", "PROBLEM", 215, 221], ["quick sequential organ failure assessment", "TEST", 306, 347], ["this study", "TEST", 442, 452], ["the qSOFA", "TEST", 493, 502], ["infection", "OBSERVATION", 33, 42], ["sepsis", "OBSERVATION", 122, 128], ["sepsis", "OBSERVATION", 215, 221]]], ["Methods: Systematic review and meta-analysis of studies assessing qSOFA as prediction tool for mortality found on PubMed, OVID, EMBASE, SCOPUS and EBSCO database from inception until November 2017.", [["studies", "TEST", 48, 55], ["qSOFA", "TEST", 66, 71]]], ["Studies reporting sensitivity and specificity of the qSOFA making it possible to create a 2x2 table were included.", [["sensitivity", "TEST", 18, 29], ["the qSOFA", "TEST", 49, 58], ["a 2x2 table", "TREATMENT", 88, 99]]], ["The diagnostic odds ratio (LnDOR) was summarized following the approach of DerSimonian and Laird using the software R ('mada' package).", [["the software R ('mada' package", "TREATMENT", 103, 133]]], ["The summary ROC curve was created using the Reistma model (bivariate model).", [["The summary ROC curve", "TEST", 0, 21], ["the Reistma model (bivariate model", "TREATMENT", 40, 74]]], ["Of 134 unique citations, 48 met the inclusion criteria (426,618 patients).", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72]]], ["The sensitivity and specificity from each study are shown in Fig. 1 .", [["The sensitivity", "TEST", 0, 15], ["each study", "TEST", 37, 47]]], ["The meta-analysis of the DOR was 4.838 (95% confidence interval (CI): 3.808 -6.146) and of the LnDOR was 1.576 (95% IC: 1.337 -1.816) (Fig. 2) .", [["the DOR", "TEST", 21, 28], ["CI", "TEST", 65, 67], ["the LnDOR", "TEST", 91, 100]]], ["The pooled area under the summary receiver operating characteristic (SROC) curve was 0.717.", [["SROC) curve", "TEST", 69, 80]]], ["The summary estimative of the sensitivity was 0.55 and the false positive rate was 0.209, by bivariate diagnostic random-effects metaanalysis.", [["the sensitivity", "TEST", 26, 41], ["the false positive rate", "TEST", 55, 78]]], ["The Chi-square goodness of fit test rejects the assumption of homogeneity, and the fit of the model for heterogeneity was better (p-value = 0.3661).", [["fit test", "TEST", 27, 35], ["p-value", "TEST", 130, 137]]], ["Conclusions: The qSOFA has a poor performance to predict mortality in patients admitted to the ED or ICU.", [["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78]]], ["Introduction: Sepsis and septic shock patients are the most common cause of death in intensive care units.", [["Sepsis", "DISEASE", 14, 20], ["septic shock", "DISEASE", 25, 37], ["death", "DISEASE", 76, 81], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["Sepsis", "PROBLEM", 14, 20], ["septic shock", "PROBLEM", 25, 37], ["Sepsis", "OBSERVATION", 14, 20], ["septic shock", "OBSERVATION", 25, 37], ["most common", "OBSERVATION_MODIFIER", 55, 66]]], ["[1] The aim of this study is to quantify the relationship between 72 hours sequential organ failure assessment (SOFA) scores change and in-hospital mortality as a treatment outcome in sepsis and septic shock patients.", [["organ", "ANATOMY", 86, 91], ["organ failure", "DISEASE", 86, 99], ["sepsis", "DISEASE", 184, 190], ["septic shock", "DISEASE", 195, 207], ["organ", "ORGAN", 86, 91], ["patients", "ORGANISM", 208, 216], ["patients", "SPECIES", 208, 216], ["this study", "TEST", 15, 25], ["sequential organ failure assessment", "TEST", 75, 110], ["SOFA) scores change", "PROBLEM", 112, 131], ["sepsis", "PROBLEM", 184, 190], ["septic shock patients", "PROBLEM", 195, 216], ["failure", "OBSERVATION", 92, 99], ["sepsis", "OBSERVATION", 184, 190], ["septic shock", "OBSERVATION", 195, 207]]], ["Introduction: An Outreach Team, akin to a Rapid Response Team, is made up of healthcare professionals assembled together for quick and effective reviews in managing of rapidly deteriorating or gravely deteriorated patients [1] .", [["patients", "ORGANISM", 214, 222], ["patients", "SPECIES", 214, 222]]], ["This study aimed to look at the variety of patient referrals in terms of their severity, patient dynamics, reasons for referral and their subsequent dispositions.", [["patient", "ORGANISM", 43, 50], ["patient", "ORGANISM", 89, 96], ["patient", "SPECIES", 43, 50], ["patient", "SPECIES", 89, 96], ["This study", "TEST", 0, 10]]], ["Methods: 258 patient records were randomly reviewed retrospectively from July to October 2017.", [["patient", "ORGANISM", 13, 20], ["patient", "SPECIES", 13, 20]]], ["Results: From the 258 referrals, the severity criteria was done by calculating the National Early Warning Score (NEWS).", [["the severity criteria", "TEST", 33, 54]]], ["It was found that 51% patients had a score of 0-4, 23% had a score of 5-6, and 26% scored more or equal to 7.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["a score", "TEST", 35, 42]]], ["50% of patients were in the age range 61-70 years old.", [["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15]]], ["78% referrals came from the Emergency Department (ED) where a consultant was involved in the decision of the referral; of this, 46% were referred during office hours of 8AM to 5PM where there was greater manpower to aid management.", [["aid management", "TREATMENT", 216, 230]]], ["For reasons for referrals and disposition decisions, see Fig. 1 .P086Conclusions: Despite having no set criteria for Outreach Team referrals, the accuracy rate was nearly 65% admissions to IC/HD based on clinician concerns.", [["the accuracy rate", "TEST", 142, 159], ["IC/HD", "TREATMENT", 189, 194]]], ["There was only 1% re-admission rate having been re-reviewed when the patients had not been deemed suitable for IC/HD admission initially.", [["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["IC/HD admission", "TREATMENT", 111, 126]]], ["Introduction: Prompt recognition of patient deterioration allows early initiation of medical intervention with reduction in morbidity and mortality.", [["patient", "ORGANISM", 36, 43], ["patient", "SPECIES", 36, 43], ["patient deterioration", "PROBLEM", 36, 57], ["medical intervention", "TREATMENT", 85, 105], ["reduction in morbidity", "TREATMENT", 111, 133]]], ["This digital era provides an opportunity to harness the power of machine learning algorithms to process and analyze big data, automatically acquired from the electronic medical records.", [["big data", "TEST", 116, 124]]], ["Intensix (Netanya, Israel) has developed a novel predictive model that detects early signs of patient deterioration and alerts physicians.", [["patient", "ORGANISM", 94, 101], ["patient", "SPECIES", 94, 101], ["patient deterioration", "PROBLEM", 94, 115]]], ["In this study we prospectively validated the ability of the model to detect patient deterioration in real time.", [["patient", "ORGANISM", 76, 83], ["patient", "SPECIES", 76, 83], ["this study", "TEST", 3, 13], ["patient deterioration", "PROBLEM", 76, 97]]], ["Methods: The model was developed and validated using a retrospective cohort of 9246 consecutive patients admitted to the Intensive Care Unit in the Tel-Aviv Sourasky medical centera tertiary care facility in Israel, between January 2007 and December 2015.", [["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104]]], ["In this study, we tested model performance in real time, on a cohort of 333 patients admitted to the same ICU between June 2016 and August 2017.", [["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["this study", "TEST", 3, 13]]], ["Significant events that lead to major interventions (e.g. intubation, initiation of treatment for sepsis or shock, etc.) were tagged upon medical case review by a senior intensivist, blinded to model alerts.", [["sepsis", "DISEASE", 98, 104], ["shock", "DISEASE", 108, 113], ["Significant events", "PROBLEM", 0, 18], ["major interventions", "TREATMENT", 32, 51], ["intubation", "TREATMENT", 58, 68], ["treatment", "TREATMENT", 84, 93], ["sepsis", "PROBLEM", 98, 104], ["shock", "PROBLEM", 108, 113]]], ["These tags were then compared with model alerts.", [["These tags", "TEST", 0, 10]]], ["[3] [4] [5] [6] .", [["[3] [4] [5] [6]", "SIMPLE_CHEMICAL", 0, 15]]], ["RRT review led to CC admission in 315 (31.2%) cases; median [IQR] NEWS 5 [3] [4] [5] [6] [7] [8] .", [["CC", "CHEMICAL", 18, 20], ["[IQR] NEWS 5 [3] [4] [5] [6] [7]", "CHEMICAL", 60, 92]]], ["Probability of admission increased with higher NEWS (Fig. 1 ), however 82 admissions had 'low NEWS'.", [["increased", "OBSERVATION_MODIFIER", 25, 34]]], ["The remaining 31 (9.8%) represented genuine low NEWS cases; age 54 [36-64], 50% male, admission APACHE II 12 [8-17] and day 1 SOFA 2 [1] [2] [3] [4] [5] .", [["admission APACHE II", "TEST", 86, 105], ["SOFA", "TEST", 126, 130]]], ["No low NEWS patients with sepsis were qSOFA positive.", [["sepsis", "DISEASE", 26, 32], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["sepsis", "PROBLEM", 26, 32], ["qSOFA", "TEST", 38, 43], ["low", "OBSERVATION_MODIFIER", 3, 6], ["sepsis", "OBSERVATION", 26, 32]]], ["CC length of stay was 2 [1] [2] [3] [4] days and ICU mortality was 9.6%.", [["CC", "CHEMICAL", 0, 2], ["ICU mortality", "TEST", 49, 62]]], ["Conclusions: A high proportion of RRT activity occurs at low levels of abnormal physiology.", [["RRT activity", "PROBLEM", 34, 46], ["abnormal physiology", "PROBLEM", 71, 90], ["RRT activity", "OBSERVATION", 34, 46], ["low levels", "OBSERVATION_MODIFIER", 57, 67], ["abnormal physiology", "OBSERVATION", 71, 90]]], ["Despite an association between NEWS and CC admission, NEWS fails to trigger for approximately one in ten admitted cases.", [["CC", "CHEMICAL", 40, 42]]], ["Clinical concern remains an important component of the escalation of acutely ill patients.", [["acutely ill", "DISEASE", 69, 80], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89]]], ["Meanwhile, novel markers of deterioration should be sought and validated.", [["deterioration", "PROBLEM", 28, 41]]], ["Introduction: Although rapid response systems are known to reduce in-hospital cardiac arrest rate, their effect on mortality remains debated.", [["cardiac", "ANATOMY", 78, 85], ["cardiac arrest", "DISEASE", 78, 92], ["cardiac", "ORGAN", 78, 85], ["rapid response systems", "PROBLEM", 23, 45], ["cardiac", "ANATOMY", 78, 85], ["arrest", "OBSERVATION", 86, 92]]], ["The Rapid Response Call (RRC) is a system designed to escalate care to a specialised team in response to the detection of patient deterioration.", [["patient", "ORGANISM", 122, 129], ["patient", "SPECIES", 122, 129], ["patient deterioration", "PROBLEM", 122, 143]]], ["There are diurnal variations in hospital staffing levels that can influence the performance of rapid response systems and patient outcomes.", [["patient", "ORGANISM", 122, 129], ["patient", "SPECIES", 122, 129], ["diurnal variations in hospital staffing levels", "PROBLEM", 10, 56], ["rapid response systems", "PROBLEM", 95, 117], ["diurnal variations", "OBSERVATION", 10, 28]]], ["The objective of this study was to examine the relationship between the time of RRC activations and patient outcome.", [["patient", "ORGANISM", 100, 107], ["patient", "SPECIES", 100, 107], ["this study", "TEST", 17, 27]]], ["All patients with medical emergency team activation were included.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["Results: Between January 2015 and October 2017 there were 209 RRC.", [["RRC", "DISEASE", 62, 65], ["RRC", "CANCER", 62, 65]]], ["The trigger for RRCs activation was nurse concern (101; 38.3%), modified early warning score (80; 28.3%) and cardiac arrest (28; 13.4%).", [["cardiac", "ANATOMY", 109, 116], ["cardiac arrest", "DISEASE", 109, 123], ["cardiac", "ORGAN", 109, 116], ["cardiac arrest", "TEST", 109, 123], ["cardiac", "ANATOMY", 109, 116], ["arrest", "OBSERVATION", 117, 123]]], ["44 RRCs were \"out of hours\" being the main activation trigger a modified warning score > 5.", [["RRCs", "ANATOMY", 3, 7], ["RRCs", "CANCER", 3, 7]]], ["\"Out of hours\" patients had higher ICU admissions (31.7% versus 20%) and were more likely to have an inhospital cardiopulmonary arrest (OR=1.4, p<0.002).", [["inhospital cardiopulmonary arrest", "DISEASE", 101, 134], ["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["an inhospital cardiopulmonary arrest", "PROBLEM", 98, 134], ["cardiopulmonary", "ANATOMY", 112, 127], ["arrest", "OBSERVATION", 128, 134]]], ["Conclusions: The diurnal timing of RRCs appears to have significant implications for patient outcomes.", [["RRCs", "CANCER", 35, 39], ["patient", "ORGANISM", 85, 92], ["patient", "SPECIES", 85, 92]]], ["This finding has implications for staffing and resource allocation. and septic shock) and severe sepsis (incl. septic shock) using ICD-10 codes coded as primary and secondary discharge diagnoses and procedural OPS codes.", [["septic shock", "DISEASE", 72, 84], ["sepsis", "DISEASE", 97, 103], ["septic shock", "DISEASE", 111, 123], ["septic shock", "PROBLEM", 72, 84], ["severe sepsis", "PROBLEM", 90, 103], ["septic shock", "PROBLEM", 111, 123], ["ICD", "TREATMENT", 131, 134], ["septic shock", "OBSERVATION", 72, 84], ["severe", "OBSERVATION_MODIFIER", 90, 96], ["sepsis", "OBSERVATION", 97, 103], ["shock", "OBSERVATION", 118, 123]]], ["Results: Incidences, mortalities and discharge disposition comparing 2010 and 2015 and the mean annual increase in incidence rates are reported in Tables 1 and 2 .P086Conclusions: The annual increase in standardized sepsis incidence rates is greater than in infections, but similar to the increase in infectious disease patients with organ dysfunction, which are less prone to coding incentives than sepsis codes.", [["organ", "ANATOMY", 334, 339], ["sepsis", "DISEASE", 216, 222], ["infections", "DISEASE", 258, 268], ["infectious disease", "DISEASE", 301, 319], ["organ dysfunction", "DISEASE", 334, 351], ["sepsis", "DISEASE", 400, 406], ["patients", "ORGANISM", 320, 328], ["organ", "ORGAN", 334, 339], ["patients", "SPECIES", 320, 328], ["incidence rates", "PROBLEM", 115, 130], ["The annual increase", "PROBLEM", 180, 199], ["standardized sepsis incidence rates", "PROBLEM", 203, 238], ["infections", "PROBLEM", 258, 268], ["infectious disease", "PROBLEM", 301, 319], ["organ dysfunction", "PROBLEM", 334, 351], ["sepsis codes", "PROBLEM", 400, 412], ["increase", "OBSERVATION_MODIFIER", 103, 111], ["increase", "OBSERVATION_MODIFIER", 191, 199], ["sepsis", "OBSERVATION", 216, 222], ["greater", "OBSERVATION_MODIFIER", 242, 249], ["infections", "OBSERVATION", 258, 268], ["increase", "OBSERVATION_MODIFIER", 289, 297], ["infectious", "OBSERVATION", 301, 311], ["organ", "ANATOMY", 334, 339], ["dysfunction", "OBSERVATION", 340, 351]]], ["An increasing number of patients is discharged to nursing homes and hospice.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["hospice", "TREATMENT", 68, 75], ["increasing", "OBSERVATION_MODIFIER", 3, 13], ["number", "OBSERVATION_MODIFIER", 14, 20]]], ["Given the alarming increase in sepsis cases and deaths, this analysis confirms sepsis as a key priority for health care systems.", [["sepsis", "DISEASE", 31, 37], ["deaths", "DISEASE", 48, 54], ["sepsis", "DISEASE", 79, 85], ["sepsis cases", "PROBLEM", 31, 43], ["this analysis", "TEST", 56, 69], ["sepsis", "PROBLEM", 79, 85], ["health care systems", "TREATMENT", 108, 127], ["sepsis", "OBSERVATION", 31, 37], ["sepsis", "OBSERVATION", 79, 85]]], ["Introduction: Patients with urgent admissions to the hospital on weekends may be subjected to a higher risk of worse outcomes, which may be due to differences in compliance to established processes.", [["Patients", "ORGANISM", 14, 22], ["Patients", "SPECIES", 14, 22], ["may be due to", "UNCERTAINTY", 133, 146]]], ["Because delays to antibiotic administration is an important measure of sepsis protocol efficiency and has been associated to worse outcomes, we aimed to assess the association of the weekend effect (admissions on weekend) with timing to antibiotic administration.", [["sepsis", "DISEASE", 71, 77], ["antibiotic administration", "TREATMENT", 18, 43], ["sepsis protocol efficiency", "TREATMENT", 71, 97], ["antibiotic administration", "TREATMENT", 237, 262], ["sepsis", "OBSERVATION", 71, 77]]], ["Methods: Patients included in the sepsis protocol in the emergency department (ED) of Hospital Sao Rafael, from January 2016 to July 2017 were retrospectively evaluated.", [["sepsis", "DISEASE", 34, 40], ["Patients", "ORGANISM", 9, 17], ["Patients", "SPECIES", 9, 17], ["sepsis", "OBSERVATION", 34, 40]]], ["Sepsis protocol is supposed to be activated to every patient with a suspected sepsis diagnosis in the ED.", [["Sepsis", "DISEASE", 0, 6], ["sepsis", "DISEASE", 78, 84], ["patient", "ORGANISM", 53, 60], ["patient", "SPECIES", 53, 60], ["Sepsis protocol", "TREATMENT", 0, 15], ["a suspected sepsis", "PROBLEM", 66, 84], ["sepsis", "OBSERVATION", 78, 84]]], ["We evaluated the association of weekend (saturday or sunday) admission with timing to antibiotic administration.", [["antibiotic administration", "TREATMENT", 86, 111]]], ["Introduction: Current sepsis guidelines emphasize resuscitation of hypotension to a mean arterial pressure (MAP) of at least 65 mmHg [1] .", [["arterial", "ANATOMY", 89, 97], ["sepsis", "DISEASE", 22, 28], ["hypotension", "DISEASE", 67, 78], ["arterial", "MULTI-TISSUE_STRUCTURE", 89, 97], ["Current sepsis guidelines", "TREATMENT", 14, 39], ["resuscitation", "TREATMENT", 50, 63], ["hypotension", "PROBLEM", 67, 78], ["a mean arterial pressure", "TEST", 82, 106], ["MAP", "TEST", 108, 111]]], ["A MAP less than 90 mmHg appears to be associated with poor outcomes in postoperative patients in the intensive care unit (ICU) [2] .", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["A MAP", "TEST", 0, 5]]], ["However, extent of hypotension in critically ill septic patients during ICU stay and its relationship with adverse outcomes is poorly defined.", [["hypotension", "DISEASE", 19, 30], ["critically ill", "DISEASE", 34, 48], ["septic", "DISEASE", 49, 55], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["hypotension", "PROBLEM", 19, 30], ["critically ill septic patients", "PROBLEM", 34, 64], ["adverse outcomes", "PROBLEM", 107, 123], ["hypotension", "OBSERVATION", 19, 30], ["critically", "OBSERVATION_MODIFIER", 34, 44], ["ill", "OBSERVATION_MODIFIER", 45, 48], ["septic", "OBSERVATION", 49, 55], ["poorly defined", "OBSERVATION_MODIFIER", 127, 141]]], ["We determined the magnitude of hypotension in ICU patients with a diagnosis of sepsis and its association with major complications.", [["hypotension", "DISEASE", 31, 42], ["sepsis", "DISEASE", 79, 85], ["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["hypotension", "PROBLEM", 31, 42], ["sepsis", "PROBLEM", 79, 85], ["major complications", "PROBLEM", 111, 130], ["hypotension", "OBSERVATION", 31, 42], ["sepsis", "OBSERVATION", 79, 85]]], ["Conclusions: Reduced mortality may be supposed to be correlated to a quicker recovery of organ damage sepsis related.", [["organ", "ANATOMY", 89, 94], ["organ damage", "DISEASE", 89, 101], ["sepsis", "DISEASE", 102, 108], ["organ", "ORGAN", 89, 94], ["Reduced mortality", "PROBLEM", 13, 30], ["organ damage sepsis", "PROBLEM", 89, 108], ["damage", "OBSERVATION_MODIFIER", 95, 101], ["sepsis", "OBSERVATION", 102, 108]]], ["PCRTs should be warranted in the future to corroborate these preliminary data.MethodsIntroduction: The PD-1/PD-L1 immune checkpoint pathway is involved in sepsis-associated immunopathy.", [["sepsis", "DISEASE", 155, 161], ["immunopathy", "DISEASE", 173, 184], ["PD-1", "GENE_OR_GENE_PRODUCT", 103, 107], ["PD-L1", "GENE_OR_GENE_PRODUCT", 108, 113], ["PCRTs", "TREATMENT", 0, 5], ["these preliminary data", "TEST", 55, 77], ["The PD", "TREATMENT", 99, 105], ["PD-L1 immune checkpoint pathway", "TREATMENT", 108, 139], ["sepsis", "PROBLEM", 155, 161], ["associated immunopathy", "PROBLEM", 162, 184], ["sepsis", "OBSERVATION", 155, 161]]], ["We assessed the safety of anti-PD-L1 (BMS-936559, Bristol-Myers Squibb) and its effect on immune biomarkers and exploratory clinical outcomes in participants with sepsis-associated immunopathy.", [["anti-PD-L1", "CHEMICAL", 26, 36], ["BMS-936559", "CHEMICAL", 38, 48], ["Bristol-Myers Squibb", "CHEMICAL", 50, 70], ["sepsis", "DISEASE", 163, 169], ["immunopathy", "DISEASE", 181, 192], ["BMS-936559", "CHEMICAL", 38, 48], ["anti-PD-L1", "SIMPLE_CHEMICAL", 26, 36], ["BMS-936559", "SIMPLE_CHEMICAL", 38, 48], ["Bristol-Myers Squibb", "SIMPLE_CHEMICAL", 50, 70], ["participants", "SPECIES", 145, 157], ["anti-PD", "TEST", 26, 33], ["BMS", "TEST", 38, 41], ["immune biomarkers", "TEST", 90, 107], ["sepsis", "PROBLEM", 163, 169], ["associated immunopathy", "PROBLEM", 170, 192], ["L1", "ANATOMY", 34, 36], ["sepsis", "OBSERVATION", 163, 169]]], ["Methods: Participants with sepsis/septic shock and absolute lymphocyte count <=1100 cells/\u03bc L received BMS-936559 i.v.", [["lymphocyte", "ANATOMY", 60, 70], ["cells", "ANATOMY", 84, 89], ["sepsis", "DISEASE", 27, 33], ["septic shock", "DISEASE", 34, 46], ["BMS-936559", "CHEMICAL", 103, 113], ["BMS-936559", "CHEMICAL", 103, 113], ["lymphocyte", "CELL", 60, 70], ["BMS-936559", "SIMPLE_CHEMICAL", 103, 113], ["Participants", "SPECIES", 9, 21], ["sepsis", "PROBLEM", 27, 33], ["septic shock", "PROBLEM", 34, 46], ["absolute lymphocyte count", "TEST", 51, 76], ["cells", "TEST", 84, 89], ["BMS", "TEST", 103, 106], ["sepsis", "OBSERVATION", 27, 33], ["septic shock", "OBSERVATION", 34, 46]]], ["(10-900mg; n=20) or placebo (PBO; n=4) + standard of care and were followed for 90d.", [["PBO", "CHEMICAL", 29, 32], ["PBO", "CHEMICAL", 29, 32], ["placebo (PBO", "TREATMENT", 20, 32]]], ["Primary endpoints were death and adverse events (AEs); secondary endpoints were monocyte (m)HLA-DR levels and clinical outcomes.", [["monocyte", "ANATOMY", 80, 88], ["death", "DISEASE", 23, 28], ["monocyte", "CELL", 80, 88], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 92, 98], ["death", "PROBLEM", 23, 28], ["adverse events", "PROBLEM", 33, 47], ["secondary endpoints", "PROBLEM", 55, 74], ["monocyte", "TEST", 80, 88], ["HLA", "TEST", 92, 95], ["DR levels", "TEST", 96, 105]]], ["Methods: This observational study was performed using a prospective, multi-center registry of septic shock.", [["septic shock", "DISEASE", 94, 106], ["This observational study", "TEST", 9, 33], ["septic shock", "PROBLEM", 94, 106], ["septic shock", "OBSERVATION", 94, 106]]], ["We compared the 28-day mortality between patients who were excluded from the new definition (defined as <2 mmol/L after volume resuscitation) and those who were not (lactate level >=2 mmol/L after volume resuscitation), from among a cohort of patients with refractory hypotension, and requiring the use of vasopressors.MethodsResults: Of 567 patients with refractory hypotension, requiring the use of vasopressors, 435 had elevated lactate levels, while 83 did not have elevated lactate levels (neither initially nor after volume resuscitation), and 49 (8.2%) had elevated lactate levels initially, which normalized after fluid resuscitation (Fig. 1 ).", [["fluid", "ANATOMY", 622, 627], ["lactate", "CHEMICAL", 166, 173], ["hypotension", "DISEASE", 268, 279], ["hypotension", "DISEASE", 367, 378], ["lactate", "CHEMICAL", 432, 439], ["lactate", "CHEMICAL", 479, 486], ["lactate", "CHEMICAL", 573, 580], ["lactate", "CHEMICAL", 166, 173], ["lactate", "CHEMICAL", 432, 439], ["lactate", "CHEMICAL", 479, 486], ["lactate", "CHEMICAL", 573, 580], ["patients", "ORGANISM", 41, 49], ["lactate", "SIMPLE_CHEMICAL", 166, 173], ["patients", "ORGANISM", 243, 251], ["patients", "ORGANISM", 342, 350], ["lactate", "SIMPLE_CHEMICAL", 432, 439], ["lactate", "SIMPLE_CHEMICAL", 479, 486], ["lactate", "SIMPLE_CHEMICAL", 573, 580], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 243, 251], ["patients", "SPECIES", 342, 350], ["volume resuscitation", "TREATMENT", 120, 140], ["lactate level", "TEST", 166, 179], ["volume resuscitation", "TREATMENT", 197, 217], ["refractory hypotension", "PROBLEM", 257, 279], ["vasopressors", "TREATMENT", 306, 318], ["refractory hypotension", "PROBLEM", 356, 378], ["vasopressors", "TREATMENT", 401, 413], ["elevated lactate levels", "PROBLEM", 423, 446], ["elevated lactate levels", "PROBLEM", 470, 493], ["volume resuscitation", "TEST", 523, 543], ["elevated lactate levels", "PROBLEM", 564, 587], ["fluid resuscitation", "TREATMENT", 622, 641], ["refractory", "OBSERVATION_MODIFIER", 257, 267], ["hypotension", "OBSERVATION", 268, 279], ["refractory", "OBSERVATION_MODIFIER", 356, 366], ["hypotension", "OBSERVATION", 367, 378], ["elevated", "OBSERVATION", 470, 478]]], ["Thus, these 49 patients were excluded by the new definition of septic shock.", [["septic shock", "DISEASE", 63, 75], ["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["septic shock", "PROBLEM", 63, 75], ["septic shock", "OBSERVATION", 63, 75]]], ["Significantly lower 28-day mortality was observed in these patients than in those who had not been excluded (8.2% vs 25.5%, p=0.02).MethodsConclusions: It seems reasonable for septic shock to be defined by the lactate levels after volume resuscitation, however due to small sample size further large scale study is needed.", [["septic shock", "DISEASE", 176, 188], ["lactate", "CHEMICAL", 210, 217], ["lactate", "CHEMICAL", 210, 217], ["patients", "ORGANISM", 59, 67], ["lactate", "SIMPLE_CHEMICAL", 210, 217], ["patients", "SPECIES", 59, 67], ["p", "TEST", 124, 125], ["septic shock", "PROBLEM", 176, 188], ["the lactate levels", "TEST", 206, 224], ["volume resuscitation", "TREATMENT", 231, 251], ["small sample size", "PROBLEM", 268, 285], ["large scale study", "TEST", 294, 311], ["small", "OBSERVATION_MODIFIER", 268, 273], ["size", "OBSERVATION_MODIFIER", 281, 285]]], ["Results: Significant downregulation (p<0.01) of about 30 pro-and anti-inflammatory cytokines, including IL-6, IP-10, TNF-a, MIP-1a, MIP-1\u00df, IL-10, was documented.", [["IL-6", "GENE_OR_GENE_PRODUCT", 104, 108], ["IP-10", "GENE_OR_GENE_PRODUCT", 110, 115], ["TNF-a", "GENE_OR_GENE_PRODUCT", 117, 122], ["MIP-1a", "GENE_OR_GENE_PRODUCT", 124, 130], ["MIP-1\u00df", "GENE_OR_GENE_PRODUCT", 132, 138], ["IL-10", "GENE_OR_GENE_PRODUCT", 140, 145], ["anti-inflammatory cytokines", "PROTEIN", 65, 92], ["IL-6", "PROTEIN", 104, 108], ["TNF", "PROTEIN", 117, 120], ["MIP", "PROTEIN", 124, 127], ["MIP", "PROTEIN", 132, 135], ["IL", "PROTEIN", 140, 142], ["Significant downregulation", "PROBLEM", 9, 35], ["anti-inflammatory cytokines", "TEST", 65, 92], ["IL", "TEST", 104, 106], ["IP", "TEST", 110, 112], ["TNF", "TEST", 117, 120], ["MIP", "TEST", 124, 127], ["MIP", "TEST", 132, 135], ["IL", "TEST", 140, 142], ["Significant", "OBSERVATION_MODIFIER", 9, 20], ["downregulation", "OBSERVATION_MODIFIER", 21, 35], ["anti-inflammatory cytokines", "OBSERVATION", 65, 92]]], ["IFN-g effect on macrophages and dendritic cells was inhibited at the level of phosphorylated STAT1.", [["macrophages", "ANATOMY", 16, 27], ["dendritic cells", "ANATOMY", 32, 47], ["IFN-g", "GENE_OR_GENE_PRODUCT", 0, 5], ["macrophages", "CELL", 16, 27], ["dendritic cells", "CELL", 32, 47], ["STAT1", "GENE_OR_GENE_PRODUCT", 93, 98], ["IFN", "PROTEIN", 0, 3], ["macrophages", "CELL_TYPE", 16, 27], ["dendritic cells", "CELL_TYPE", 32, 47], ["phosphorylated STAT1", "PROTEIN", 78, 98], ["IFN", "PROBLEM", 0, 3], ["macrophages", "PROBLEM", 16, 27], ["dendritic cells", "PROBLEM", 32, 47], ["g effect", "OBSERVATION_MODIFIER", 4, 12], ["macrophages", "OBSERVATION", 16, 27], ["dendritic cells", "OBSERVATION", 32, 47], ["phosphorylated STAT1", "OBSERVATION", 78, 98]]], ["IFN-ginduced expression of CXCL10 and CXCL9 in macrophages was reduced.", [["macrophages", "ANATOMY", 47, 58], ["IFN", "GENE_OR_GENE_PRODUCT", 0, 3], ["CXCL10", "GENE_OR_GENE_PRODUCT", 27, 33], ["CXCL9", "GENE_OR_GENE_PRODUCT", 38, 43], ["macrophages", "CELL", 47, 58], ["IFN", "PROTEIN", 0, 3], ["CXCL10", "PROTEIN", 27, 33], ["CXCL9", "PROTEIN", 38, 43], ["macrophages", "CELL_TYPE", 47, 58], ["IFN", "TEST", 0, 3], ["CXCL10", "TEST", 27, 33], ["CXCL9 in macrophages", "TEST", 38, 58], ["macrophages", "ANATOMY", 47, 58], ["reduced", "OBSERVATION_MODIFIER", 63, 70]]], ["Patients treated in vivo with higher dosages of apoptotic cells had lower cytokine/chemokine levels compared to those treated with lower levels, and in inverse correlation to aGVHD staging.", [["cells", "ANATOMY", 58, 63], ["aGVHD", "DISEASE", 175, 180], ["Patients", "ORGANISM", 0, 8], ["cells", "CELL", 58, 63], ["apoptotic cells", "CELL_TYPE", 48, 63], ["cytokine", "PROTEIN", 74, 82], ["chemokine", "PROTEIN", 83, 92], ["Patients", "SPECIES", 0, 8], ["apoptotic cells", "TREATMENT", 48, 63], ["lower cytokine/chemokine levels", "PROBLEM", 68, 99], ["aGVHD staging", "TEST", 175, 188], ["apoptotic cells", "OBSERVATION", 48, 63]]], ["In vitro binding of apoptotic cells to LPS was documented.MethodsConclusions: The cytokine storm is significantly modified towards homeostasis following apoptotic cell treatment.", [["cells", "ANATOMY", 30, 35], ["cell", "ANATOMY", 163, 167], ["LPS", "CHEMICAL", 39, 42], ["cells", "CELL", 30, 35], ["LPS", "SIMPLE_CHEMICAL", 39, 42], ["cell", "CELL", 163, 167], ["apoptotic cells", "CELL_TYPE", 20, 35], ["cytokine", "PROTEIN", 82, 90], ["apoptotic cells", "PROBLEM", 20, 35], ["LPS", "TEST", 39, 42], ["The cytokine storm", "TREATMENT", 78, 96], ["apoptotic cell treatment", "TREATMENT", 153, 177], ["apoptotic cells", "OBSERVATION", 20, 35], ["apoptotic cell treatment", "OBSERVATION", 153, 177]]], ["The mechanism is multifactorial and was shown to include TAM receptor triggering, NFkb inhibition, and LPS binding.", [["TAM", "CHEMICAL", 57, 60], ["LPS", "CHEMICAL", 103, 106], ["TAM", "CHEMICAL", 57, 60], ["TAM receptor", "GENE_OR_GENE_PRODUCT", 57, 69], ["NFkb", "GENE_OR_GENE_PRODUCT", 82, 86], ["LPS", "SIMPLE_CHEMICAL", 103, 106], ["NFkb", "PROTEIN", 82, 86], ["NFkb inhibition", "PROBLEM", 82, 97], ["LPS binding", "PROBLEM", 103, 114]]], ["These results together with previous studies showing significantly higher murine survival in sepsis models of LPS and cecal ligation puncture suggest that apoptotic cells may be used to treat patients with sepsis.", [["cecal", "ANATOMY", 118, 123], ["cells", "ANATOMY", 165, 170], ["sepsis", "DISEASE", 93, 99], ["LPS", "CHEMICAL", 110, 113], ["sepsis", "DISEASE", 206, 212], ["murine", "ORGANISM", 74, 80], ["LPS", "SIMPLE_CHEMICAL", 110, 113], ["cells", "CELL", 165, 170], ["patients", "ORGANISM", 192, 200], ["apoptotic cells", "CELL_TYPE", 155, 170], ["murine", "SPECIES", 74, 80], ["patients", "SPECIES", 192, 200], ["previous studies", "TEST", 28, 44], ["sepsis models of LPS", "PROBLEM", 93, 113], ["cecal ligation puncture", "TREATMENT", 118, 141], ["apoptotic cells", "PROBLEM", 155, 170], ["sepsis", "PROBLEM", 206, 212], ["sepsis", "OBSERVATION", 93, 99], ["cecal", "ANATOMY", 118, 123], ["ligation", "OBSERVATION", 124, 132], ["apoptotic cells", "OBSERVATION", 155, 170], ["sepsis", "OBSERVATION", 206, 212]]], ["A multicenter clinical trial in septic patients is planned in 2018.", [["septic", "DISEASE", 32, 38], ["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47]]], ["Moreover, the urine output significantly increased in survival group.MethodsConclusions: The present study suggests that cytokine-oriented critical care using PMMA-CHDF might be effective the treatment of sepsis and ARDS, particularly,in the treatment of ARDS associated with aspiration pneumonia in elderly patients.P111The polymyxin b immobilized fiber column direct hemoperfusion has an effect for septic shock but has no effect on sepsis: a cohort study and propensity-matched analysis K Hoshino 1 Introduction: Overwhelming cytokine release often referred to as \"cytokine storm\" is a common feature of septic shock, resulting in multiple organ dysfunction and early death.", [["urine", "ANATOMY", 14, 19], ["organ", "ANATOMY", 643, 648], ["PMMA-CHDF", "CHEMICAL", 159, 168], ["sepsis", "DISEASE", 205, 211], ["ARDS", "DISEASE", 216, 220], ["ARDS", "DISEASE", 255, 259], ["aspiration pneumonia", "DISEASE", 276, 296], ["polymyxin", "CHEMICAL", 325, 334], ["septic shock", "DISEASE", 401, 413], ["sepsis", "DISEASE", 435, 441], ["septic shock", "DISEASE", 607, 619], ["organ dysfunction", "DISEASE", 643, 660], ["death", "DISEASE", 671, 676], ["PMMA-CHDF", "CHEMICAL", 159, 168], ["polymyxin", "CHEMICAL", 325, 334], ["urine", "ORGANISM_SUBSTANCE", 14, 19], ["PMMA-CHDF", "SIMPLE_CHEMICAL", 159, 168], ["patients", "ORGANISM", 308, 316], ["P111", "SIMPLE_CHEMICAL", 317, 321], ["polymyxin b", "SIMPLE_CHEMICAL", 325, 336], ["organ", "ORGAN", 643, 648], ["cytokine", "PROTEIN", 121, 129], ["cytokine", "PROTEIN", 529, 537], ["cytokine", "PROTEIN", 568, 576], ["patients", "SPECIES", 308, 316], ["the urine output", "TEST", 10, 26], ["The present study", "TEST", 89, 106], ["cytokine-oriented critical care", "TREATMENT", 121, 152], ["PMMA-CHDF", "TREATMENT", 159, 168], ["sepsis", "PROBLEM", 205, 211], ["ARDS", "PROBLEM", 216, 220], ["ARDS", "PROBLEM", 255, 259], ["aspiration pneumonia", "PROBLEM", 276, 296], ["The polymyxin b immobilized fiber column direct hemoperfusion", "TREATMENT", 321, 382], ["septic shock", "PROBLEM", 401, 413], ["sepsis", "PROBLEM", 435, 441], ["a cohort study", "TEST", 443, 457], ["Overwhelming cytokine release", "PROBLEM", 516, 545], ["septic shock", "PROBLEM", 607, 619], ["multiple organ dysfunction", "PROBLEM", 634, 660], ["early death", "PROBLEM", 665, 676], ["urine", "OBSERVATION", 14, 19], ["output", "OBSERVATION_MODIFIER", 20, 26], ["significantly", "OBSERVATION_MODIFIER", 27, 40], ["increased", "OBSERVATION_MODIFIER", 41, 50], ["sepsis", "OBSERVATION", 205, 211], ["ARDS", "OBSERVATION", 216, 220], ["ARDS", "OBSERVATION", 255, 259], ["aspiration", "OBSERVATION", 276, 286], ["septic shock", "OBSERVATION", 401, 413], ["no", "UNCERTAINTY", 422, 424], ["sepsis", "OBSERVATION", 435, 441], ["septic shock", "OBSERVATION", 607, 619], ["multiple", "OBSERVATION_MODIFIER", 634, 642], ["organ", "ANATOMY", 643, 648], ["dysfunction", "OBSERVATION", 649, 660], ["early", "OBSERVATION_MODIFIER", 665, 670], ["death", "OBSERVATION", 671, 676]]], ["Attenuating this cytokine storm early by eliminating cytokines may have some pathophysiological rationale.", [["cytokine", "PROTEIN", 17, 25], ["cytokines", "PROTEIN", 53, 62], ["cytokine storm", "OBSERVATION", 17, 31]]], ["Our aim was to investigate the effects of extracorporeal cytokine removal (CytoSorb) therapy on organ dysfunction and inflammatory response within the first 48 hours from the onset of septic shock.", [["extracorporeal", "ANATOMY", 42, 56], ["organ", "ANATOMY", 96, 101], ["CytoSorb", "CHEMICAL", 75, 83], ["organ dysfunction", "DISEASE", 96, 113], ["septic shock", "DISEASE", 184, 196], ["CytoSorb", "SIMPLE_CHEMICAL", 75, 83], ["organ", "ORGAN", 96, 101], ["extracorporeal cytokine", "PROTEIN", 42, 65], ["extracorporeal cytokine removal", "TREATMENT", 42, 73], ["CytoSorb) therapy", "TREATMENT", 75, 92], ["organ dysfunction", "PROBLEM", 96, 113], ["inflammatory response", "PROBLEM", 118, 139], ["septic shock", "PROBLEM", 184, 196], ["inflammatory", "OBSERVATION_MODIFIER", 118, 130], ["septic shock", "OBSERVATION", 184, 196]]], ["Methods: Patients with: sepsis of medical origin, on mechanical ventilation, noradrenaline >10mg/min, procalcitonin >3ng/mL and no need for renal replacement therapy, were randomized into CytoSorb and Control groups.", [["renal", "ANATOMY", 140, 145], ["sepsis", "DISEASE", 24, 30], ["noradrenaline", "CHEMICAL", 77, 90], ["noradrenaline", "CHEMICAL", 77, 90], ["Patients", "ORGANISM", 9, 17], ["noradrenaline", "SIMPLE_CHEMICAL", 77, 90], ["renal", "ORGAN", 140, 145], ["Patients", "SPECIES", 9, 17], ["sepsis of medical origin", "PROBLEM", 24, 48], ["mechanical ventilation", "TREATMENT", 53, 75], ["noradrenaline", "TREATMENT", 77, 90], ["procalcitonin", "TREATMENT", 102, 115], ["renal replacement therapy", "TREATMENT", 140, 165], ["sepsis", "OBSERVATION", 24, 30], ["renal", "ANATOMY", 140, 145], ["replacement", "OBSERVATION", 146, 157]]], ["CytoSorb therapy lasted for 24 hours.", [["CytoSorb", "CHEMICAL", 0, 8], ["CytoSorb", "SIMPLE_CHEMICAL", 0, 8], ["CytoSorb therapy", "TREATMENT", 0, 16]]], ["In addition to detailed clinical data collection, blood samples were taken to determine IL-1, IL-1ra, IL-6, IL-8, IL-10, TNF-\u03b1, PCT, CRP levels.", [["blood samples", "ANATOMY", 50, 63], ["blood samples", "ORGANISM_SUBSTANCE", 50, 63], ["IL-1", "GENE_OR_GENE_PRODUCT", 88, 92], ["IL-1ra", "GENE_OR_GENE_PRODUCT", 94, 100], ["IL-6", "GENE_OR_GENE_PRODUCT", 102, 106], ["IL-8", "GENE_OR_GENE_PRODUCT", 108, 112], ["IL-10", "GENE_OR_GENE_PRODUCT", 114, 119], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 121, 126], ["PCT", "GENE_OR_GENE_PRODUCT", 128, 131], ["CRP", "GENE_OR_GENE_PRODUCT", 133, 136], ["TNF", "PROTEIN", 121, 124], ["PCT", "PROTEIN", 128, 131], ["CRP", "PROTEIN", 133, 136], ["blood samples", "TEST", 50, 63], ["IL", "TEST", 88, 90], ["IL", "TEST", 94, 96], ["IL", "TEST", 102, 104], ["IL", "TEST", 108, 110], ["IL", "TEST", 114, 116], ["TNF", "TEST", 121, 124], ["PCT", "TEST", 128, 131], ["CRP levels", "TEST", 133, 143]]], ["Introduction: Blind pericardiocentesis leading to low success rate and high complication rates such as ventricular wall or oesophageal perforations, pneumothorax or upper abdominal organ injury.Real time needle visualisation is allowing us to avoid this major complication [1] .", [["ventricular wall", "ANATOMY", 103, 119], ["oesophageal", "ANATOMY", 123, 134], ["abdominal organ", "ANATOMY", 171, 186], ["ventricular wall or oesophageal perforations", "DISEASE", 103, 147], ["pneumothorax", "DISEASE", 149, 161], ["abdominal organ injury", "DISEASE", 171, 193], ["ventricular wall", "MULTI-TISSUE_STRUCTURE", 103, 119], ["oesophageal", "ORGAN", 123, 134], ["organ", "ORGAN", 181, 186], ["Blind pericardiocentesis", "TREATMENT", 14, 38], ["low success rate", "PROBLEM", 50, 66], ["high complication rates", "PROBLEM", 71, 94], ["ventricular wall or oesophageal perforations", "PROBLEM", 103, 147], ["pneumothorax", "PROBLEM", 149, 161], ["upper abdominal organ injury", "PROBLEM", 165, 193], ["Real time needle visualisation", "TEST", 194, 224], ["this major complication", "PROBLEM", 249, 272], ["ventricular", "ANATOMY", 103, 114], ["wall", "ANATOMY_MODIFIER", 115, 119], ["oesophageal", "ANATOMY", 123, 134], ["perforations", "OBSERVATION", 135, 147], ["pneumothorax", "OBSERVATION", 149, 161], ["upper", "ANATOMY_MODIFIER", 165, 170], ["abdominal organ", "ANATOMY", 171, 186], ["injury", "OBSERVATION", 187, 193]]], ["Methods: We presented 2 cases of acute traumatic cardiac tamponade secondary to severe chest injury.", [["cardiac", "ANATOMY", 49, 56], ["chest", "ANATOMY", 87, 92], ["cardiac tamponade", "DISEASE", 49, 66], ["chest injury", "DISEASE", 87, 99], ["cardiac", "ORGAN", 49, 56], ["chest", "ORGANISM_SUBDIVISION", 87, 92], ["acute traumatic cardiac tamponade", "PROBLEM", 33, 66], ["severe chest injury", "PROBLEM", 80, 99], ["acute", "OBSERVATION_MODIFIER", 33, 38], ["traumatic", "OBSERVATION_MODIFIER", 39, 48], ["cardiac", "ANATOMY", 49, 56], ["tamponade", "OBSERVATION", 57, 66], ["severe", "OBSERVATION_MODIFIER", 80, 86], ["chest", "ANATOMY", 87, 92], ["injury", "OBSERVATION", 93, 99]]], ["Both patients presented with haemodynamic instability and echocardiographic features of pericardial tamponade.", [["pericardial", "ANATOMY", 88, 99], ["haemodynamic instability", "DISEASE", 29, 53], ["pericardial tamponade", "DISEASE", 88, 109], ["patients", "ORGANISM", 5, 13], ["pericardial", "ORGAN", 88, 99], ["patients", "SPECIES", 5, 13], ["haemodynamic instability", "PROBLEM", 29, 53], ["pericardial tamponade", "PROBLEM", 88, 109], ["haemodynamic instability", "OBSERVATION", 29, 53], ["pericardial", "ANATOMY", 88, 99], ["tamponade", "OBSERVATION", 100, 109]]], ["Pericardiocentesis under ultrasound guidance at left parasternal area with needle directed from medial to lateral technique were performed (Fig. 1) .", [["left parasternal area", "ANATOMY", 48, 69], ["parasternal area", "MULTI-TISSUE_STRUCTURE", 53, 69], ["Pericardiocentesis", "TREATMENT", 0, 18], ["needle", "TREATMENT", 75, 81], ["left", "ANATOMY_MODIFIER", 48, 52], ["parasternal", "ANATOMY", 53, 64]]], ["Real time needle tip visualisation done throughout the procedure (Fig. 2a) .", [["Real time needle tip visualisation", "TEST", 0, 34], ["the procedure", "TREATMENT", 51, 64]]], ["Needle placement in pericardial space was confirmed with agitated saline and guidewire visualisation (Fig. 2b) .", [["pericardial space", "ANATOMY", 20, 37], ["Needle placement in pericardial space", "TREATMENT", 0, 37], ["agitated saline", "TREATMENT", 57, 72], ["guidewire visualisation", "TEST", 77, 100], ["pericardial", "ANATOMY", 20, 31]]], ["Pigtail catheter was inserted and blood was aspirated until the patient were haemodynamically improved.", [["blood", "ANATOMY", 34, 39], ["blood", "ORGANISM_SUBSTANCE", 34, 39], ["patient", "ORGANISM", 64, 71], ["patient", "SPECIES", 64, 71], ["Pigtail catheter", "TREATMENT", 0, 16], ["catheter", "OBSERVATION", 8, 16], ["haemodynamically", "OBSERVATION_MODIFIER", 77, 93], ["improved", "OBSERVATION", 94, 102]]], ["Repeated ultrasound was done to confirm the absence of ultrasonographic features of tamponade and complications.", [["tamponade", "DISEASE", 84, 93], ["Repeated ultrasound", "TEST", 0, 19], ["tamponade", "PROBLEM", 84, 93], ["complications", "PROBLEM", 98, 111], ["tamponade", "OBSERVATION", 84, 93]]], ["Results: We demonstrated a successful real time needle visualisation ultrasound guided pericardiocentesis in 2 cases acute traumatic pericardial tamponade.", [["pericardial", "ANATOMY", 133, 144], ["traumatic pericardial tamponade", "DISEASE", 123, 154], ["pericardial", "ORGAN", 133, 144], ["a successful real time needle visualisation ultrasound", "TEST", 25, 79], ["pericardiocentesis", "TREATMENT", 87, 105], ["acute traumatic pericardial tamponade", "PROBLEM", 117, 154], ["pericardiocentesis", "OBSERVATION", 87, 105], ["acute", "OBSERVATION_MODIFIER", 117, 122], ["traumatic", "OBSERVATION_MODIFIER", 123, 132], ["pericardial", "ANATOMY", 133, 144], ["tamponade", "OBSERVATION", 145, 154]]], ["Procedural time (time from needle piercing the skin to time needle entering the pericardium) in both cases were less than 1 minute.", [["skin", "ANATOMY", 47, 51], ["pericardium", "ANATOMY", 80, 91], ["skin", "ORGAN", 47, 51], ["pericardium", "ORGAN", 80, 91], ["needle piercing the skin to time needle entering the pericardium", "TREATMENT", 27, 91], ["skin", "ANATOMY", 47, 51], ["pericardium", "ANATOMY", 80, 91]]], ["Post procedural ultrasound confirmed no major complications.", [["Post procedural ultrasound", "TEST", 0, 26], ["major complications", "PROBLEM", 40, 59], ["no", "UNCERTAINTY", 37, 39], ["major", "OBSERVATION_MODIFIER", 40, 45], ["complications", "OBSERVATION", 46, 59]]], ["Conclusions: The real time needle visualisation using ultrasound was important to reduce major complications during pericardiocentesis.", [["The real time needle visualisation", "TEST", 13, 47], ["ultrasound", "TEST", 54, 64], ["major complications", "PROBLEM", 89, 108], ["pericardiocentesis", "TREATMENT", 116, 134], ["pericardiocentesis", "OBSERVATION", 116, 134]]], ["The safety of the highly invasive procedure can be improved with real time needle visualisation.ReferenceOsman A et al. Eur J Emerg Med (in press), 2017 Introduction: Diagnosis of cardiac tamponade post continuous-flow left ventricle assist devices (cf-LVADs) is challenging due to missing pulsatility.", [["cardiac", "ANATOMY", 180, 187], ["left ventricle", "ANATOMY", 219, 233], ["cardiac tamponade", "DISEASE", 180, 197], ["cardiac", "ORGAN", 180, 187], ["ventricle", "MULTI-TISSUE_STRUCTURE", 224, 233], ["the highly invasive procedure", "TREATMENT", 14, 43], ["real time needle visualisation", "TEST", 65, 95], ["cardiac tamponade", "PROBLEM", 180, 197], ["continuous-flow left ventricle assist devices", "TREATMENT", 203, 248], ["cf-LVADs", "TREATMENT", 250, 258], ["missing pulsatility", "PROBLEM", 282, 301], ["Med", "ANATOMY", 132, 135], ["cardiac", "ANATOMY", 180, 187], ["tamponade", "OBSERVATION", 188, 197], ["left ventricle", "ANATOMY", 219, 233]]], ["Recent case study of sublingually microcirculation with incident dark-field imaging (IDF) provide a new improved imaging for clinical assessment of cardiac tamponade in a patient with cf-LVAD.", [["cardiac", "ANATOMY", 148, 155], ["cardiac tamponade", "DISEASE", 148, 165], ["cardiac", "ORGAN", 148, 155], ["patient", "ORGANISM", 171, 178], ["patient", "SPECIES", 171, 178], ["Recent case study", "TEST", 0, 17], ["dark-field imaging", "TEST", 65, 83], ["a new improved imaging", "TEST", 98, 120], ["clinical assessment", "TEST", 125, 144], ["cardiac tamponade", "PROBLEM", 148, 165], ["LVAD", "TREATMENT", 187, 191], ["cardiac", "ANATOMY", 148, 155], ["tamponade", "OBSERVATION", 156, 165], ["LVAD", "OBSERVATION", 187, 191]]], ["We sought to examine the changes in microvascular flow index (MFI) as a sign of cardiac tamponade following LVAD implantation.", [["microvascular", "ANATOMY", 36, 49], ["cardiac", "ANATOMY", 80, 87], ["cardiac tamponade", "DISEASE", 80, 97], ["microvascular", "TISSUE", 36, 49], ["cardiac", "ORGAN", 80, 87], ["microvascular flow index", "TEST", 36, 60], ["cardiac tamponade", "PROBLEM", 80, 97], ["LVAD implantation", "TREATMENT", 108, 125], ["microvascular", "ANATOMY", 36, 49], ["flow index", "OBSERVATION", 50, 60], ["cardiac", "ANATOMY", 80, 87], ["tamponade", "OBSERVATION", 88, 97], ["LVAD implantation", "OBSERVATION", 108, 125]]], ["Methods: Off-site quantitative analysis of sublingual microcirculation clips with Automated Vascular Analyses software (AVA; MicroVision Medical\u00a9), and the velocity distributions followed during admission till discharge in patients with end-stage heart failure treated with cf-LVAD complicated by cardiac tamponade.ReferenceResults: Eleven out of thirty LVAD implantations, 9 males, mean age 58 \u00b1 10 years, April 2015 to January 2017, ((8 Heart Mate 3 (HM 3) and 3 HeartMate II (HM II) (Thoratec Corp., CA)), were complicated by rethoracotomy due to early postoperative cardiac tamponade within 1 week.", [["sublingual", "ANATOMY", 43, 53], ["Vascular", "ANATOMY", 92, 100], ["heart", "ANATOMY", 247, 252], ["cardiac", "ANATOMY", 297, 304], ["cardiac", "ANATOMY", 570, 577], ["heart failure", "DISEASE", 247, 260], ["cardiac tamponade", "DISEASE", 297, 314], ["rethoracotomy", "DISEASE", 529, 542], ["postoperative cardiac tamponade", "DISEASE", 556, 587], ["Vascular", "MULTI-TISSUE_STRUCTURE", 92, 100], ["patients", "ORGANISM", 223, 231], ["heart", "ORGAN", 247, 252], ["cardiac", "ORGAN", 297, 304], ["cardiac", "ORGAN", 570, 577], ["patients", "SPECIES", 223, 231], ["sublingual microcirculation clips", "TREATMENT", 43, 76], ["the velocity distributions", "PROBLEM", 152, 178], ["end-stage heart failure", "PROBLEM", 237, 260], ["cf-LVAD", "TREATMENT", 274, 281], ["cardiac tamponade", "PROBLEM", 297, 314], ["thirty LVAD implantations", "TREATMENT", 347, 372], ["early postoperative cardiac tamponade", "PROBLEM", 550, 587], ["microcirculation clips", "OBSERVATION", 54, 76], ["Vascular", "ANATOMY", 92, 100], ["velocity", "OBSERVATION_MODIFIER", 156, 164], ["heart", "ANATOMY", 247, 252], ["failure", "OBSERVATION", 253, 260], ["LVAD", "OBSERVATION", 277, 281], ["cardiac", "ANATOMY", 297, 304], ["tamponade", "OBSERVATION", 305, 314], ["Heart", "ANATOMY", 439, 444], ["early", "OBSERVATION_MODIFIER", 550, 555], ["postoperative", "OBSERVATION_MODIFIER", 556, 569], ["cardiac", "ANATOMY", 570, 577], ["tamponade", "OBSERVATION", 578, 587]]], ["There sublingual microcirculation was examined by a novel incident dark-field imaging (IDF) before and daily post-LVAD implantation.", [["sublingual", "ANATOMY", 6, 16], ["sublingual microcirculation", "MULTI-TISSUE_STRUCTURE", 6, 33], ["dark-field imaging", "TEST", 67, 85], ["LVAD implantation", "TREATMENT", 114, 131], ["LVAD implantation", "OBSERVATION", 114, 131]]], ["Pre-LVAD microcirculation was typical for heart failure, characterized by slowly, sludging movement of red blood cells (RBCs), (Fig. 1A arrows) .", [["heart", "ANATOMY", 42, 47], ["red blood cells", "ANATOMY", 103, 118], ["RBCs", "ANATOMY", 120, 124], ["heart failure", "DISEASE", 42, 55], ["heart", "ORGAN", 42, 47], ["red blood cells", "CELL", 103, 118], ["RBCs", "CELL", 120, 124], ["red blood cells", "CELL_TYPE", 103, 118], ["RBCs", "CELL_TYPE", 120, 124], ["heart failure", "PROBLEM", 42, 55], ["red blood cells", "TEST", 103, 118], ["RBCs", "TEST", 120, 124], ["heart", "ANATOMY", 42, 47], ["failure", "OBSERVATION", 48, 55], ["slowly", "OBSERVATION_MODIFIER", 74, 80]]], ["Directly after implantation, a normal microcirculatory flow was seen with a high RBCs velocity (Fig. 1B) .", [["microcirculatory", "ANATOMY", 38, 54], ["RBCs", "ANATOMY", 81, 85], ["microcirculatory", "MULTI-TISSUE_STRUCTURE", 38, 54], ["RBCs", "CELL", 81, 85], ["implantation", "TREATMENT", 15, 27], ["a high RBCs velocity", "PROBLEM", 74, 94], ["implantation", "OBSERVATION", 15, 27], ["normal", "OBSERVATION", 31, 37], ["microcirculatory flow", "OBSERVATION", 38, 59], ["high RBCs velocity", "OBSERVATION", 76, 94]]], ["On the day of tamponade the patients were stable except for severe failure of microcirculation as reflected by drop in MFI (Fig. 1C ) and congestion in venules (* in Fig. 1C ).", [["venules", "ANATOMY", 152, 159], ["patients", "ORGANISM", 28, 36], ["venules", "MULTI-TISSUE_STRUCTURE", 152, 159], ["patients", "SPECIES", 28, 36], ["tamponade", "PROBLEM", 14, 23], ["severe failure of microcirculation", "PROBLEM", 60, 94], ["drop in MFI", "PROBLEM", 111, 122], ["congestion in venules", "PROBLEM", 138, 159], ["tamponade", "OBSERVATION", 14, 23], ["stable", "OBSERVATION_MODIFIER", 42, 48], ["severe", "OBSERVATION_MODIFIER", 60, 66], ["failure", "OBSERVATION", 67, 74], ["drop", "OBSERVATION_MODIFIER", 111, 115], ["congestion", "OBSERVATION", 138, 148], ["venules", "ANATOMY", 152, 159]]], ["In 8 out of 11 patients there was a significant drop in MFI before tamponade was clinically recognized (p<0.05).", [["tamponade", "DISEASE", 67, 76], ["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["a significant drop in MFI", "PROBLEM", 34, 59], ["tamponade", "PROBLEM", 67, 76], ["significant", "OBSERVATION_MODIFIER", 36, 47], ["drop", "OBSERVATION_MODIFIER", 48, 52], ["tamponade", "OBSERVATION", 67, 76]]], ["Shortly after rethoracotomy a quick restoration of microcirculatory flow has been found.", [["microcirculatory", "ANATOMY", 51, 67], ["microcirculatory", "MULTI-TISSUE_STRUCTURE", 51, 67], ["rethoracotomy", "TREATMENT", 14, 27], ["microcirculatory flow", "PROBLEM", 51, 72], ["microcirculatory flow", "OBSERVATION", 51, 72]]], ["Conclusions: Sublingual microcirculation imaging is a simple and sensitive non-invasive tool in early detection of cardiac tamponade.P121Survey on the use of cardiovascular drugs in shock (ucards) - Results: A total of 827 physicians responded.", [["Sublingual", "ANATOMY", 13, 23], ["cardiac", "ANATOMY", 115, 122], ["cardiovascular", "ANATOMY", 158, 172], ["cardiac tamponade", "DISEASE", 115, 132], ["shock", "DISEASE", 182, 187], ["cardiac", "ORGAN", 115, 122], ["Sublingual microcirculation imaging", "TEST", 13, 48], ["cardiac tamponade", "PROBLEM", 115, 132], ["cardiovascular drugs", "TREATMENT", 158, 178], ["cardiac", "ANATOMY", 115, 122], ["tamponade", "OBSERVATION", 123, 132]]], ["As detailed in Table 1 , the respondents think that dobutamine is first-line inotrope to increase cardiac pump function (N=695, 84%) and should be started when signs of hypoperfusion or hyperlactatemia despite adequate use of fluids and vasopressors in the context of low left ventricular ejection fraction are present (N=359, 43%).", [["cardiac", "ANATOMY", 98, 105], ["left ventricular", "ANATOMY", 272, 288], ["dobutamine", "CHEMICAL", 52, 62], ["hypoperfusion", "DISEASE", 169, 182], ["hyperlactatemia", "DISEASE", 186, 201], ["dobutamine", "CHEMICAL", 52, 62], ["dobutamine", "SIMPLE_CHEMICAL", 52, 62], ["cardiac", "ORGAN", 98, 105], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 272, 288], ["dobutamine", "TREATMENT", 52, 62], ["first-line inotrope", "TREATMENT", 66, 85], ["cardiac pump function", "TEST", 98, 119], ["hypoperfusion", "PROBLEM", 169, 182], ["hyperlactatemia", "PROBLEM", 186, 201], ["fluids", "TREATMENT", 226, 232], ["vasopressors", "TREATMENT", 237, 249], ["low left ventricular ejection fraction", "PROBLEM", 268, 306], ["hypoperfusion", "OBSERVATION", 169, 182], ["hyperlactatemia", "OBSERVATION", 186, 201], ["low", "OBSERVATION_MODIFIER", 268, 271], ["left ventricular", "ANATOMY", 272, 288], ["ejection fraction", "OBSERVATION", 289, 306]]], ["The most accepted target was an adequate cardiac output (N=369, 45%).", [["cardiac", "ANATOMY", 41, 48], ["cardiac", "ORGAN", 41, 48], ["output", "OBSERVATION_MODIFIER", 49, 55]]], ["The combination of noradrenaline and dobutamine was preferred to single treatment with adrenaline mainly due to possibility to titrate individually (N=366, 44%).", [["noradrenaline", "CHEMICAL", 19, 32], ["dobutamine", "CHEMICAL", 37, 47], ["adrenaline", "CHEMICAL", 87, 97], ["noradrenaline", "CHEMICAL", 19, 32], ["dobutamine", "CHEMICAL", 37, 47], ["adrenaline", "CHEMICAL", 87, 97], ["noradrenaline", "SIMPLE_CHEMICAL", 19, 32], ["dobutamine", "SIMPLE_CHEMICAL", 37, 47], ["adrenaline", "SIMPLE_CHEMICAL", 87, 97], ["noradrenaline", "TREATMENT", 19, 32], ["dobutamine", "TREATMENT", 37, 47], ["adrenaline", "TREATMENT", 87, 97]]], ["The main reason for adding another inotrope was to use synergistic effects of two different mechanisms of action (N=229, 27%).", [["another inotrope", "TREATMENT", 27, 43], ["synergistic effects", "TREATMENT", 55, 74], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["According to respondents, phosphodiesterase-inhibitors should be used in the treatment of predominant right heart failure because of prominent vasodilatory effect on the pulmonary circulation (N=360, 44%).", [["right heart", "ANATOMY", 102, 113], ["pulmonary", "ANATOMY", 170, 179], ["heart failure", "DISEASE", 108, 121], ["heart", "ORGAN", 108, 113], ["pulmonary", "ORGAN", 170, 179], ["phosphodiesterase-inhibitors", "TREATMENT", 26, 54], ["predominant right heart failure", "PROBLEM", 90, 121], ["prominent vasodilatory effect on the pulmonary circulation", "PROBLEM", 133, 191], ["right", "ANATOMY_MODIFIER", 102, 107], ["heart", "ANATOMY", 108, 113], ["failure", "OBSERVATION", 114, 121], ["prominent", "OBSERVATION_MODIFIER", 133, 142], ["vasodilatory effect", "OBSERVATION", 143, 162], ["pulmonary circulation", "ANATOMY", 170, 191]]], ["They also believe levosimendan is the only inotrope that does not increase myocardial oxygen demand (N=350, 42%).", [["myocardial", "ANATOMY", 75, 85], ["levosimendan", "CHEMICAL", 18, 30], ["oxygen", "CHEMICAL", 86, 92], ["levosimendan", "CHEMICAL", 18, 30], ["oxygen", "CHEMICAL", 86, 92], ["levosimendan", "SIMPLE_CHEMICAL", 18, 30], ["myocardial", "MULTI-TISSUE_STRUCTURE", 75, 85], ["oxygen", "SIMPLE_CHEMICAL", 86, 92], ["levosimendan", "TREATMENT", 18, 30], ["inotrope", "TREATMENT", 43, 51], ["myocardial oxygen demand", "PROBLEM", 75, 99], ["oxygen demand", "OBSERVATION", 86, 99]]], ["Vasodilators are used in cardiogenic shock to decrease left ventricular afterload (N=244, 30%).", [["left ventricular", "ANATOMY", 55, 71], ["cardiogenic shock", "DISEASE", 25, 42], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 55, 71], ["Vasodilators", "TREATMENT", 0, 12], ["cardiogenic shock", "PROBLEM", 25, 42], ["left ventricular afterload", "TEST", 55, 81], ["cardiogenic shock", "OBSERVATION", 25, 42], ["left ventricular", "ANATOMY", 55, 71], ["afterload", "OBSERVATION", 72, 81]]], ["There is no experience or no opinion about the use of \u00df-blockers in shock states (N=268, 32%).P121Conclusions: This web-based survey provided latest trends on inotrope use in shock states which showed considerable diversity among respondents in opinions about its use.", [["shock", "DISEASE", 68, 73], ["inotrope", "CHEMICAL", 159, 167], ["shock", "DISEASE", 175, 180], ["\u00df-blockers", "SIMPLE_CHEMICAL", 54, 64], ["\u00df-blockers", "TREATMENT", 54, 64], ["inotrope", "TREATMENT", 159, 167], ["no", "UNCERTAINTY", 9, 11]]], ["Introduction: Recent literature data clearly indicated that in patients with shock the resuscitation of macro-circulation often does not match with microcirculation and tissue perfusion improvement.", [["tissue", "ANATOMY", 169, 175], ["shock", "DISEASE", 77, 82], ["patients", "ORGANISM", 63, 71], ["tissue", "TISSUE", 169, 175], ["patients", "SPECIES", 63, 71], ["Recent literature data", "TEST", 14, 36], ["shock the resuscitation", "TREATMENT", 77, 100], ["macro-circulation", "TREATMENT", 104, 121]]], ["Unfortunately, the bed-side assessment of regional perfusion remains difficult, particulary in critically ill patients.", [["critically ill", "DISEASE", 95, 109], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["the bed-side assessment", "TEST", 15, 38]]], ["In the last years thermography has been used in different medical fields but no studies have been performed on the use of this technique in critically ill patients.", [["critically ill", "DISEASE", 140, 154], ["patients", "ORGANISM", 155, 163], ["patients", "SPECIES", 155, 163], ["thermography", "TEST", 18, 30], ["studies", "TEST", 80, 87], ["this technique", "TREATMENT", 122, 136]]], ["The aim of this study was to evaluate whether thermography is feasible and may provide useful data during resuscitation of patients with septic shock.", [["septic shock", "DISEASE", 137, 149], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["this study", "TEST", 11, 21], ["thermography", "TEST", 46, 58], ["resuscitation", "TREATMENT", 106, 119], ["septic shock", "PROBLEM", 137, 149], ["septic shock", "OBSERVATION", 137, 149]]], ["Methods: In 4 patients with septic shock we collected central systemic temperature and infrared images (FLIR-T640 digital camera) of limbs at 0, 3, 6 and 24 hours after shock occurrence.", [["limbs", "ANATOMY", 133, 138], ["septic shock", "DISEASE", 28, 40], ["shock", "DISEASE", 169, 174], ["patients", "ORGANISM", 14, 22], ["limbs", "ORGANISM_SUBDIVISION", 133, 138], ["patients", "SPECIES", 14, 22], ["septic shock", "PROBLEM", 28, 40], ["central systemic temperature", "TEST", 54, 82], ["infrared images", "TEST", 87, 102], ["FLIR", "TEST", 104, 108], ["shock occurrence", "PROBLEM", 169, 185], ["septic shock", "OBSERVATION", 28, 40], ["limbs", "ANATOMY", 133, 138]]], ["Thermal pattern distribution of the limbs was obtained by a specific analysis of the images (ThermaCAM\u2122Researcher P).", [["limbs", "ANATOMY", 36, 41], ["limbs", "ORGAN", 36, 41], ["a specific analysis", "TEST", 58, 77], ["the images", "TEST", 81, 91], ["limbs", "ANATOMY", 36, 41]]], ["A systemic to peripheral temperature gradient called \"\u0394 systemic-limb temperature\" was calculated for each single temperature data collected.P121Results: Macrocirculatory and perfusion parameters improved in all the patients throughout the study period: mean values of noradrenaline dose decreased from 0.21 to 0.13 \u03b3/kg/min, mean MAP increased from 65 to 81 mmHg and mean blood lactate decreased from 6.6 to 4.2 mMol/L. The \"\u0394 systemic-limb temperature\" pattern showed an heterogenous time course in the 4 patients with a mean overall increase at 6 and 24 hours (Fig. 1) .P121Conclusions: As expected, the regional data obtained by thermography did not match with macrocirculatory and systemic perfusion parameters.", [["limb", "ANATOMY", 65, 69], ["blood", "ANATOMY", 373, 378], ["limb", "ANATOMY", 437, 441], ["noradrenaline", "CHEMICAL", 269, 282], ["lactate", "CHEMICAL", 379, 386], ["noradrenaline", "CHEMICAL", 269, 282], ["lactate", "CHEMICAL", 379, 386], ["limb", "ORGANISM_SUBDIVISION", 65, 69], ["patients", "ORGANISM", 216, 224], ["noradrenaline", "SIMPLE_CHEMICAL", 269, 282], ["blood", "ORGANISM_SUBSTANCE", 373, 378], ["lactate", "SIMPLE_CHEMICAL", 379, 386], ["limb", "ORGANISM_SUBDIVISION", 437, 441], ["patients", "ORGANISM", 507, 515], ["patients", "SPECIES", 216, 224], ["patients", "SPECIES", 507, 515], ["peripheral temperature gradient", "TEST", 14, 45], ["each single temperature data", "TEST", 102, 130], ["perfusion parameters", "TEST", 175, 195], ["mean values", "TEST", 254, 265], ["noradrenaline dose", "TREATMENT", 269, 287], ["mean MAP", "TEST", 326, 334], ["mean blood lactate", "TEST", 368, 386], ["The \"\u0394 systemic-limb temperature", "TEST", 421, 453], ["the regional data", "TEST", 603, 620], ["thermography", "TEST", 633, 645], ["systemic perfusion parameters", "TEST", 686, 715], ["systemic", "OBSERVATION", 2, 10], ["limb", "ANATOMY", 65, 69], ["limb", "ANATOMY", 437, 441], ["heterogenous", "OBSERVATION", 473, 485], ["increase", "OBSERVATION_MODIFIER", 536, 544]]], ["The significance and the relationship between treatments and data observed will be investigated by appropriate studies.P123Regional differences in the treatment of refractory septic shockan analysis of the ATHOS-3 data Introduction: Vasodilatory shock is a common syndrome with high mortality.", [["Vasodilatory shock", "DISEASE", 233, 251], ["treatments", "TREATMENT", 46, 56], ["appropriate studies", "TEST", 99, 118], ["refractory septic shockan analysis", "PROBLEM", 164, 198], ["Vasodilatory shock", "PROBLEM", 233, 251], ["a common syndrome", "PROBLEM", 255, 272], ["high mortality", "PROBLEM", 278, 292], ["refractory", "OBSERVATION_MODIFIER", 164, 174], ["septic", "OBSERVATION", 175, 181], ["Vasodilatory shock", "OBSERVATION", 233, 251], ["high mortality", "OBSERVATION", 278, 292]]], ["Despite established care protocols, regional differences in treatment remain.", [["established care protocols", "TREATMENT", 8, 34], ["treatment", "TREATMENT", 60, 69], ["regional", "OBSERVATION_MODIFIER", 36, 44], ["differences", "OBSERVATION_MODIFIER", 45, 56]]], ["Methods: Individual patient data were analyzed at baseline and at 48h for regional differences in demographics, clinical characteristics, and treatment patterns, and grouped according to four geographical areas: the United States (US), Canada (CA), Europe (EU) and Australasia (AU).", [["patient", "ORGANISM", 20, 27], ["patient", "SPECIES", 20, 27], ["Individual patient data", "TEST", 9, 32]]], ["P-values were calculated by Kruskal-Wallis tests for continuous data and chi-square tests for categorical data.", [["P", "DNA", 0, 1], ["Wallis tests", "TEST", 36, 48], ["continuous data", "TEST", 53, 68], ["chi-square tests", "TEST", 73, 89], ["categorical data", "TEST", 94, 110]]], ["Subsequent temporal analysis compared changes in the treatment of shock, indexed by changes in patient acuity level.", [["shock", "DISEASE", 66, 71], ["patient", "ORGANISM", 95, 102], ["patient", "SPECIES", 95, 102], ["Subsequent temporal analysis", "TEST", 0, 28], ["shock", "PROBLEM", 66, 71], ["changes in patient acuity level", "PROBLEM", 84, 115], ["shock", "OBSERVATION", 66, 71]]], ["Results: Regional differences existed with respect to BMI (p=0.0076), albumin (p<0.0001), CVP (p=0.0383), MELD score (p=0.0191), APACHE II score (p=0.0007) and SOFA score (p=0.0076).", [["albumin", "GENE_OR_GENE_PRODUCT", 70, 77], ["BMI", "TEST", 54, 57], ["albumin", "TEST", 70, 77], ["CVP", "TEST", 90, 93], ["MELD score", "TEST", 106, 116], ["APACHE II score", "TEST", 129, 144], ["SOFA score", "TEST", 160, 170]]], ["Baseline norepinephrine (NE) and NE equivalent doses were significantly higher in EU (p<0.0001 and p=0.0494, respectively), and utilization of vasopressin was correspondingly lower (p<0.0001).", [["norepinephrine", "CHEMICAL", 9, 23], ["NE", "CHEMICAL", 25, 27], ["NE", "CHEMICAL", 33, 35], ["vasopressin", "CHEMICAL", 143, 154], ["norepinephrine", "CHEMICAL", 9, 23], ["vasopressin", "CHEMICAL", 143, 154], ["norepinephrine", "SIMPLE_CHEMICAL", 9, 23], ["NE", "SIMPLE_CHEMICAL", 25, 27], ["NE", "SIMPLE_CHEMICAL", 33, 35], ["vasopressin", "GENE_OR_GENE_PRODUCT", 143, 154], ["NE", "PROTEIN", 33, 35], ["Baseline norepinephrine (NE)", "TREATMENT", 0, 28], ["NE equivalent doses", "TREATMENT", 33, 52], ["vasopressin", "TREATMENT", 143, 154], ["lower", "OBSERVATION_MODIFIER", 175, 180]]], ["At baseline, stress dose steroids were utilized to a greater extent in the US and CA (p=0.0011).", [["steroids", "CHEMICAL", 25, 33], ["steroids", "CHEMICAL", 25, 33], ["stress dose steroids", "TREATMENT", 13, 33], ["the US", "TEST", 71, 77], ["CA", "TEST", 82, 84], ["greater extent", "OBSERVATION_MODIFIER", 53, 67]]], ["Temporal analysis revealed differences in the utilization of vasopressin and steroids with changes in patient acuity: in EU, increasing acuity was associated with a lower utilization of vasopressin, and in CA, increased acuity was associated with a lower utilization of steroids.", [["vasopressin", "CHEMICAL", 61, 72], ["steroids", "CHEMICAL", 77, 85], ["vasopressin", "CHEMICAL", 186, 197], ["steroids", "CHEMICAL", 270, 278], ["vasopressin", "CHEMICAL", 61, 72], ["steroids", "CHEMICAL", 77, 85], ["steroids", "CHEMICAL", 270, 278], ["vasopressin", "SIMPLE_CHEMICAL", 61, 72], ["steroids", "SIMPLE_CHEMICAL", 77, 85], ["patient", "ORGANISM", 102, 109], ["vasopressin", "GENE_OR_GENE_PRODUCT", 186, 197], ["CA", "GENE_OR_GENE_PRODUCT", 206, 208], ["steroids", "SIMPLE_CHEMICAL", 270, 278], ["patient", "SPECIES", 102, 109], ["Temporal analysis", "TEST", 0, 17], ["vasopressin", "TREATMENT", 61, 72], ["steroids", "TREATMENT", 77, 85], ["changes in patient acuity", "PROBLEM", 91, 116], ["increasing acuity", "PROBLEM", 125, 142], ["vasopressin", "TREATMENT", 186, 197], ["increased acuity", "PROBLEM", 210, 226], ["steroids", "TREATMENT", 270, 278], ["increased", "OBSERVATION_MODIFIER", 210, 219], ["acuity", "OBSERVATION", 220, 226]]], ["Steroid utilization was higher with increased level of acuity in AU and the US.P123Conclusions: Significant differences in the treatment of vasodilitory shock exist globally, with important implications: (a) there are Introduction: Levosimendan is a calcium sensitizer and KATP-channel opener exerting sustained hemodynamic and symptomatic effects.", [["shock", "DISEASE", 153, 158], ["Levosimendan", "CHEMICAL", 232, 244], ["calcium", "CHEMICAL", 250, 257], ["Steroid", "CHEMICAL", 0, 7], ["Levosimendan", "CHEMICAL", 232, 244], ["calcium", "CHEMICAL", 250, 257], ["Steroid", "SIMPLE_CHEMICAL", 0, 7], ["Levosimendan", "SIMPLE_CHEMICAL", 232, 244], ["calcium", "SIMPLE_CHEMICAL", 250, 257], ["KATP-channel", "SIMPLE_CHEMICAL", 273, 285], ["Steroid utilization", "TREATMENT", 0, 19], ["the US", "TEST", 72, 78], ["vasodilitory shock", "PROBLEM", 140, 158], ["Levosimendan", "TREATMENT", 232, 244], ["a calcium sensitizer", "TREATMENT", 248, 268], ["KATP-channel opener", "TREATMENT", 273, 292], ["symptomatic effects", "PROBLEM", 328, 347], ["Significant", "OBSERVATION_MODIFIER", 96, 107], ["differences", "OBSERVATION_MODIFIER", 108, 119]]], ["In the past fifteen years, levosimendan has been used in clinical practice also to stabilize at-risk patients undergoing cardiac surgery.", [["cardiac", "ANATOMY", 121, 128], ["levosimendan", "CHEMICAL", 27, 39], ["levosimendan", "CHEMICAL", 27, 39], ["levosimendan", "SIMPLE_CHEMICAL", 27, 39], ["patients", "ORGANISM", 101, 109], ["cardiac", "ORGAN", 121, 128], ["patients", "SPECIES", 101, 109], ["levosimendan", "TREATMENT", 27, 39], ["cardiac surgery", "TREATMENT", 121, 136], ["cardiac", "ANATOMY", 121, 128], ["surgery", "OBSERVATION", 129, 136]]], ["Recently, the three randomized, placebo-controlled, multicenter studies LICORN [1] , CHEETAH [2] and LEVO-CTS [3] have been testing the peri-operative use of levosimendan in patients with compromised cardiac ventricular function.", [["cardiac ventricular", "ANATOMY", 200, 219], ["CTS", "DISEASE", 106, 109], ["levosimendan", "CHEMICAL", 158, 170], ["levosimendan", "CHEMICAL", 158, 170], ["levosimendan", "SIMPLE_CHEMICAL", 158, 170], ["patients", "ORGANISM", 174, 182], ["cardiac ventricular", "MULTI-TISSUE_STRUCTURE", 200, 219], ["patients", "SPECIES", 174, 182], ["placebo", "TREATMENT", 32, 39], ["LEVO", "TREATMENT", 101, 105], ["levosimendan", "TREATMENT", 158, 170], ["cardiac ventricular", "ANATOMY", 200, 219]]], ["Over 40 smaller trials conducted in the past [4] suggested beneficial outcomes with levosimendan in peri-operative settings.", [["levosimendan", "CHEMICAL", 84, 96], ["levosimendan", "CHEMICAL", 84, 96], ["levosimendan", "SIMPLE_CHEMICAL", 84, 96], ["levosimendan", "TREATMENT", 84, 96], ["peri-operative settings", "TREATMENT", 100, 123]]], ["In contrast, the latest three studies were neutral or inconclusive.", [["the latest three studies", "TEST", 13, 37]]], ["We aim to understand the reasons for such dissimilarity.", [["such dissimilarity", "PROBLEM", 37, 55]]], ["Methods: We re-analyzed the results of the latest trials in the light of the previous literature to find sub-settings in which levosimendan can be demonstrated harmful or beneficious.P123Results: None of the three latest studies raised any safety concern, which is consistent with the findings of the previous smaller studies.P123In LEVO-CTS, mortality was significantly lower in the levosimendan arm than in the placebo arm in the subgroup of isolated CABG patients ( Fig. 1 ) [3] .", [["levosimendan", "CHEMICAL", 127, 139], ["CTS", "DISEASE", 338, 341], ["levosimendan", "CHEMICAL", 384, 396], ["levosimendan", "CHEMICAL", 127, 139], ["levosimendan", "CHEMICAL", 384, 396], ["levosimendan", "SIMPLE_CHEMICAL", 127, 139], ["patients", "ORGANISM", 458, 466], ["patients", "SPECIES", 458, 466], ["levosimendan", "TREATMENT", 127, 139], ["the three latest studies", "TEST", 204, 228], ["the previous smaller studies", "TEST", 297, 325], ["LEVO", "TREATMENT", 333, 337], ["CTS", "TREATMENT", 338, 341], ["isolated CABG", "TREATMENT", 444, 457], ["consistent with", "UNCERTAINTY", 265, 280], ["levosimendan arm", "ANATOMY", 384, 400], ["CABG", "OBSERVATION", 453, 457]]], ["The trend towards both hemodynamic and long term mortality benefits is maintained in recent meta-analyses [5, 6] including the three larger recent studies.P123Conclusions: Despite the fact that the null hypothesis could not be ruled out in the recent trials, we conclude that levosimendan can still Results: 27 patients were included in levosimendan group and 36 in control group.", [["levosimendan", "CHEMICAL", 276, 288], ["levosimendan", "CHEMICAL", 337, 349], ["levosimendan", "CHEMICAL", 276, 288], ["levosimendan", "CHEMICAL", 337, 349], ["levosimendan", "SIMPLE_CHEMICAL", 276, 288], ["patients", "ORGANISM", 311, 319], ["levosimendan", "SIMPLE_CHEMICAL", 337, 349], ["patients", "SPECIES", 311, 319], ["the null hypothesis", "PROBLEM", 194, 213], ["levosimendan", "TREATMENT", 276, 288], ["levosimendan group", "TREATMENT", 337, 355], ["long term", "OBSERVATION_MODIFIER", 39, 48], ["could not be", "UNCERTAINTY", 214, 226]]], ["In the whole population, weaning failure incidence and mortality was comparable between the 2 groups (respectively 24% vs 20%, Pr 0, 34 and 36% vs 38%, Pr=0,6).", [["weaning failure incidence", "PROBLEM", 25, 50], ["Pr", "TEST", 127, 129], ["vs", "TEST", 144, 146], ["Pr", "TEST", 152, 154]]], ["Higher assistance duration, longer stay under mechanical ventilation and longer duration of stay in critical care unit were observed in Levosimendan group.", [["Levosimendan", "CHEMICAL", 136, 148], ["Levosimendan", "CHEMICAL", 136, 148], ["Levosimendan", "SIMPLE_CHEMICAL", 136, 148], ["mechanical ventilation", "TREATMENT", 46, 68], ["Levosimendan group", "TREATMENT", 136, 154], ["mechanical ventilation", "OBSERVATION", 46, 68]]], ["In the post-cardiotomy sub-group (Table 1) , weaning failure was lower in levosimendan group (12% vs 29%, Pr 0,9) and levosimendan was an independent protective factor from weaning failure (OR 0,073, Pr 0,92).", [["levosimendan", "CHEMICAL", 74, 86], ["levosimendan", "CHEMICAL", 118, 130], ["weaning failure", "DISEASE", 173, 188], ["levosimendan", "CHEMICAL", 74, 86], ["levosimendan", "CHEMICAL", 118, 130], ["levosimendan", "SIMPLE_CHEMICAL", 74, 86], ["levosimendan", "SIMPLE_CHEMICAL", 118, 130], ["weaning failure", "PROBLEM", 45, 60], ["Pr", "TEST", 106, 108], ["levosimendan", "TREATMENT", 118, 130], ["an independent protective factor", "PROBLEM", 135, 167], ["weaning failure", "PROBLEM", 173, 188]]], ["Positive impact of levosimendan may be explained in part by his calcium sensitizer effect and by facilitating recovery of myocardial calcium homeostasis in postcardiotomy cardiac stunning.", [["myocardial", "ANATOMY", 122, 132], ["cardiac", "ANATOMY", 171, 178], ["levosimendan", "CHEMICAL", 19, 31], ["calcium", "CHEMICAL", 64, 71], ["calcium", "CHEMICAL", 133, 140], ["cardiac stunning", "DISEASE", 171, 187], ["levosimendan", "CHEMICAL", 19, 31], ["calcium", "CHEMICAL", 64, 71], ["calcium", "CHEMICAL", 133, 140], ["levosimendan", "SIMPLE_CHEMICAL", 19, 31], ["calcium", "SIMPLE_CHEMICAL", 64, 71], ["myocardial", "MULTI-TISSUE_STRUCTURE", 122, 132], ["calcium", "SIMPLE_CHEMICAL", 133, 140], ["cardiac", "ORGAN", 171, 178], ["levosimendan", "TREATMENT", 19, 31], ["his calcium sensitizer effect", "PROBLEM", 60, 89], ["myocardial calcium homeostasis", "PROBLEM", 122, 152], ["postcardiotomy cardiac stunning", "TREATMENT", 156, 187], ["levosimendan", "OBSERVATION", 19, 31], ["may be explained", "UNCERTAINTY", 32, 48], ["myocardial", "ANATOMY", 122, 132], ["calcium homeostasis", "OBSERVATION", 133, 152], ["cardiac", "ANATOMY", 171, 178], ["stunning", "OBSERVATION", 179, 187]]], ["Conclusions: Levosimendan failed to reduce the incidence of ECMO weaning failure, except for post-cardiotomy population.P129Renal outcomes of vasopressin and its analogues in distributive shock: a systematic review and meta-analysis of randomized trials Introduction: Venous return (VR) is driven by the difference between mean systemic filling pressure (MSFP) and right atrial pressure (RAP) and determines the maximum ECMO flow.", [["Venous", "ANATOMY", 268, 274], ["right atrial", "ANATOMY", 365, 377], ["Levosimendan", "CHEMICAL", 13, 25], ["weaning failure", "DISEASE", 65, 80], ["vasopressin", "CHEMICAL", 142, 153], ["shock", "DISEASE", 188, 193], ["Levosimendan", "CHEMICAL", 13, 25], ["vasopressin", "CHEMICAL", 142, 153], ["Levosimendan", "SIMPLE_CHEMICAL", 13, 25], ["vasopressin", "SIMPLE_CHEMICAL", 142, 153], ["Venous", "MULTI-TISSUE_STRUCTURE", 268, 274], ["atrial", "MULTI-TISSUE_STRUCTURE", 371, 377], ["Levosimendan", "TREATMENT", 13, 25], ["ECMO weaning failure", "TREATMENT", 60, 80], ["post-cardiotomy population", "TREATMENT", 93, 119], ["vasopressin", "TREATMENT", 142, 153], ["its analogues", "TREATMENT", 158, 171], ["randomized trials", "TREATMENT", 236, 253], ["mean systemic filling pressure", "TEST", 323, 353], ["MSFP", "TEST", 355, 359], ["right atrial pressure", "TEST", 365, 386], ["the maximum ECMO flow", "TEST", 408, 429], ["ECMO", "OBSERVATION", 60, 64], ["cardiotomy", "OBSERVATION", 98, 108], ["distributive shock", "OBSERVATION", 175, 193], ["Venous", "ANATOMY", 268, 274], ["filling pressure", "OBSERVATION", 337, 353], ["right atrial", "ANATOMY", 365, 377], ["pressure", "OBSERVATION_MODIFIER", 378, 386], ["maximum", "OBSERVATION_MODIFIER", 412, 419], ["ECMO flow", "OBSERVATION", 420, 429]]], ["MSFP depends on stressed volume and vascular compliance.", [["vascular", "ANATOMY", 36, 44], ["vascular", "MULTI-TISSUE_STRUCTURE", 36, 44], ["stressed volume", "OBSERVATION", 16, 31], ["vascular", "ANATOMY", 36, 44]]], ["It can be modified by absolute blood volume changes and shifts between stressed and unstressed volume.", [["blood", "ANATOMY", 31, 36], ["blood", "ORGANISM_SUBSTANCE", 31, 36], ["absolute blood volume changes", "TREATMENT", 22, 51], ["absolute blood volume", "OBSERVATION", 22, 43], ["unstressed volume", "OBSERVATION", 84, 101]]], ["Norepinephrine (NE) may increase stressed volume by constriction of venous capacitance and at the same time increase the resistance to systemic flow.", [["venous", "ANATOMY", 68, 74], ["Norepinephrine", "CHEMICAL", 0, 14], ["NE", "CHEMICAL", 16, 18], ["Norepinephrine", "CHEMICAL", 0, 14], ["Norepinephrine", "SIMPLE_CHEMICAL", 0, 14], ["NE", "SIMPLE_CHEMICAL", 16, 18], ["venous", "MULTI-TISSUE_STRUCTURE", 68, 74], ["Norepinephrine (NE)", "TREATMENT", 0, 19], ["constriction of venous capacitance", "TREATMENT", 52, 86], ["systemic flow", "TEST", 135, 148], ["constriction", "OBSERVATION", 52, 64], ["venous capacitance", "OBSERVATION", 68, 86], ["resistance", "OBSERVATION", 121, 131], ["systemic flow", "OBSERVATION", 135, 148]]], ["We therefore studied the effects of NE on MSFP, maximum ECMO flow and the ECMO pressure head (MAP-RAP).", [["head", "ANATOMY", 88, 92], ["NE", "CHEMICAL", 36, 38], ["NE", "SIMPLE_CHEMICAL", 36, 38], ["MSFP", "SIMPLE_CHEMICAL", 42, 46], ["head", "ORGANISM_SUBDIVISION", 88, 92], ["NE", "PROTEIN", 36, 38], ["NE", "TREATMENT", 36, 38], ["MSFP", "TREATMENT", 42, 46], ["maximum ECMO flow", "TREATMENT", 48, 65], ["the ECMO pressure head", "TEST", 70, 92], ["MAP", "TEST", 94, 97]]], ["Methods: MSFP was measured with blood volume at Euvolemia and NE 1 to 3 (0.05, 0.125 and 0.2\u03bcg/kg/h) in a closed-chest porcine VA-ECMO model (n=9, central cannulation with left atrial vent and avshunt) in ventricular fibrillation.", [["blood", "ANATOMY", 32, 37], ["left atrial", "ANATOMY", 172, 183], ["ventricular", "ANATOMY", 205, 216], ["ventricular fibrillation", "DISEASE", 205, 229], ["MSFP", "SIMPLE_CHEMICAL", 9, 13], ["blood", "ORGANISM_SUBSTANCE", 32, 37], ["atrial", "MULTI-TISSUE_STRUCTURE", 177, 183], ["ventricular", "MULTI-TISSUE_STRUCTURE", 205, 216], ["blood volume at Euvolemia", "TREATMENT", 32, 57], ["a closed-chest porcine VA", "TREATMENT", 104, 129], ["ECMO model", "TREATMENT", 130, 140], ["central cannulation", "TREATMENT", 147, 166], ["left atrial vent", "TREATMENT", 172, 188], ["ventricular fibrillation", "PROBLEM", 205, 229], ["chest", "ANATOMY", 113, 118], ["left atrial", "ANATOMY", 172, 183], ["ventricular", "ANATOMY", 205, 216], ["fibrillation", "OBSERVATION", 217, 229]]], ["The responses of RAP and VR (measured as ECMO flow, QECMO) were studied at variable pump speeds including maximum possible speed without clinically apparent vessel collapse at constant airway pressure.", [["vessel", "ANATOMY", 157, 163], ["airway", "ANATOMY", 185, 191], ["RAP", "CHEMICAL", 17, 20], ["vessel", "MULTI-TISSUE_STRUCTURE", 157, 163], ["airway", "MULTI-TISSUE_STRUCTURE", 185, 191], ["RAP", "TEST", 17, 20], ["VR", "TEST", 25, 27], ["ECMO flow", "TEST", 41, 50], ["clinically apparent vessel collapse", "PROBLEM", 137, 172], ["RAP", "OBSERVATION_MODIFIER", 17, 20], ["vessel", "ANATOMY", 157, 163], ["collapse", "OBSERVATION", 164, 172], ["airway pressure", "OBSERVATION", 185, 200]]], ["Results: The ECMO pump speed and QECMO showed a strictly linear relationship (r 2 0.95 to 0.995, range over all conditions) despite increased pressure head, indicating that the maximum QECMO was determined by VR alone.", [["head", "ANATOMY", 151, 155], ["head", "ORGANISM_SUBDIVISION", 151, 155], ["The ECMO pump speed", "TREATMENT", 9, 28], ["increased pressure head", "PROBLEM", 132, 155], ["the maximum QECMO", "TEST", 173, 190]]], ["NE led to both increases in MSFP and QECMO in a dose dependent way, indicating a rightward shift in the VR plot ( Fig. 1 ) via recruitment of stressed from unstressed volume ( Table 1 , Fig. 2 ).", [["NE", "CHEMICAL", 0, 2], ["MSFP", "CHEMICAL", 28, 32], ["NE", "SIMPLE_CHEMICAL", 0, 2], ["MSFP", "SIMPLE_CHEMICAL", 28, 32], ["NE", "PROTEIN", 0, 2], ["MSFP", "TREATMENT", 28, 32], ["QECMO", "TREATMENT", 37, 42], ["a rightward shift", "PROBLEM", 79, 96], ["the VR plot", "TEST", 100, 111], ["both", "OBSERVATION_MODIFIER", 10, 14], ["increases", "OBSERVATION_MODIFIER", 15, 24], ["rightward shift", "OBSERVATION", 81, 96]]], ["This resulted in an increased MSFP during NE despite decreased absolute blood volume (3.9\u00b10.4 L vs. 3.3\u00b10.3L, p=0.009).", [["blood", "ANATOMY", 72, 77], ["NE", "CHEMICAL", 42, 44], ["decreased absolute blood volume", "DISEASE", 53, 84], ["MSFP", "SIMPLE_CHEMICAL", 30, 34], ["NE", "SIMPLE_CHEMICAL", 42, 44], ["blood", "ORGANISM_SUBSTANCE", 72, 77], ["MSFP", "PROTEIN", 30, 34], ["NE", "PROTEIN", 42, 44], ["an increased MSFP", "PROBLEM", 17, 34], ["decreased absolute blood volume", "PROBLEM", 53, 84], ["p", "TEST", 110, 111], ["increased", "OBSERVATION_MODIFIER", 20, 29], ["MSFP", "OBSERVATION", 30, 34]]], ["The reduced blood volume was associated with hemoconcentration suggesting plasma leakage.", [["blood", "ANATOMY", 12, 17], ["plasma", "ANATOMY", 74, 80], ["hemoconcentration", "DISEASE", 45, 62], ["blood", "ORGANISM_SUBSTANCE", 12, 17], ["plasma", "ORGANISM_SUBSTANCE", 74, 80], ["The reduced blood volume", "PROBLEM", 0, 24], ["hemoconcentration", "PROBLEM", 45, 62], ["plasma leakage", "PROBLEM", 74, 88], ["reduced", "OBSERVATION_MODIFIER", 4, 11], ["blood volume", "OBSERVATION", 12, 24], ["hemoconcentration", "OBSERVATION", 45, 62], ["plasma leakage", "OBSERVATION", 74, 88]]], ["Conclusions: NE shifts the VR curve to the right, allowing a higher maximum ECMO flow.", [["NE", "SIMPLE_CHEMICAL", 13, 15], ["NE", "PROTEIN", 13, 15], ["the VR curve", "TEST", 23, 35], ["a higher maximum ECMO flow", "TREATMENT", 59, 85], ["NE shifts", "OBSERVATION", 13, 22], ["right", "ANATOMY_MODIFIER", 43, 48], ["higher", "OBSERVATION_MODIFIER", 61, 67], ["maximum", "OBSERVATION_MODIFIER", 68, 75], ["ECMO flow", "OBSERVATION", 76, 85]]], ["The NE induced increase in MSFP results from recruitment of unstressed volume to stressed volume, which may be modified by changes in vascular compliance.", [["vascular", "ANATOMY", 134, 142], ["NE", "CHEMICAL", 4, 6], ["NE", "SIMPLE_CHEMICAL", 4, 6], ["MSFP", "SIMPLE_CHEMICAL", 27, 31], ["vascular", "MULTI-TISSUE_STRUCTURE", 134, 142], ["NE", "PROTEIN", 4, 6], ["MSFP", "PROTEIN", 27, 31], ["unstressed volume", "PROBLEM", 60, 77], ["stressed volume", "PROBLEM", 81, 96], ["NE induced", "OBSERVATION_MODIFIER", 4, 14], ["increase", "OBSERVATION_MODIFIER", 15, 23], ["unstressed volume", "OBSERVATION", 60, 77], ["may be", "UNCERTAINTY", 104, 110], ["vascular", "ANATOMY", 134, 142]]], ["The effects on pump afterload were not limiting.", [["pump afterload", "TREATMENT", 15, 29]]], ["Introduction: To locate vessels for percutaneous central venous catheterizations, it may be helpful to apply not only real-time ultrasound (US) guidance but also US-assistance vein prelocation.", [["vessels", "ANATOMY", 24, 31], ["percutaneous", "ANATOMY", 36, 48], ["venous", "ANATOMY", 57, 63], ["vein", "ANATOMY", 176, 180], ["vessels", "MULTI-TISSUE_STRUCTURE", 24, 31], ["central venous", "MULTI-TISSUE_STRUCTURE", 49, 63], ["vein", "MULTI-TISSUE_STRUCTURE", 176, 180], ["percutaneous central venous catheterizations", "TREATMENT", 36, 80], ["ultrasound", "TEST", 128, 138], ["US", "TEST", 162, 164], ["vessels", "ANATOMY", 24, 31], ["venous", "ANATOMY", 57, 63], ["catheterizations", "OBSERVATION", 64, 80], ["vein", "ANATOMY", 176, 180]]], ["The aim of this study was to evaluate the superiority of two US methods compared to surface landmark methods by reviewing randomized control trials (RCTs).", [["surface", "ANATOMY", 84, 91], ["this study", "TEST", 11, 21], ["two US methods", "TEST", 57, 71]]], ["We included RCTs which compared the failure rates of internal jugular or femoral venous cannulations among 1) real-time US guidance, 2) US-assistance vein prelocation and 3) surface landmark methods.", [["internal jugular", "ANATOMY", 53, 69], ["femoral venous", "ANATOMY", 73, 87], ["vein", "ANATOMY", 150, 154], ["surface", "ANATOMY", 174, 181], ["internal jugular", "MULTI-TISSUE_STRUCTURE", 53, 69], ["femoral venous", "MULTI-TISSUE_STRUCTURE", 73, 87], ["vein", "MULTI-TISSUE_STRUCTURE", 150, 154], ["RCTs", "TREATMENT", 12, 16], ["internal jugular", "TREATMENT", 53, 69], ["femoral venous cannulations", "TREATMENT", 73, 100], ["US", "TEST", 136, 138], ["internal jugular", "ANATOMY", 53, 69], ["femoral venous", "ANATOMY", 73, 87], ["vein", "ANATOMY", 150, 154]]], ["A frequentist network meta-analysis was conducted using the netmeta package on R.P129Results: Out of 1395 citations, 11 RCTs (935 patients) were eligible.", [["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138]]], ["The number of studies comparing outcomes between real-time US guidance vs. surface landmark methods, US-assistance vein prelocation vs surface landmark methods and real-time US guidance vs US-assistance vein prelocation was 7, 3 and 1.", [["surface", "ANATOMY", 75, 82], ["vein", "ANATOMY", 115, 119], ["surface", "ANATOMY", 135, 142], ["vein", "ANATOMY", 203, 207], ["vein", "MULTI-TISSUE_STRUCTURE", 115, 119], ["vein", "MULTI-TISSUE_STRUCTURE", 203, 207], ["surface landmark methods", "TEST", 75, 99], ["US", "TEST", 101, 103], ["US", "TEST", 189, 191], ["assistance vein prelocation", "TEST", 192, 219], ["vein", "ANATOMY", 115, 119], ["vein", "ANATOMY", 203, 207]]], ["Regarding cannulation failure rate, network meta-analysis in a fix-effect model showed that a p-score was lower in the real-time US guidance than US-assistance vein prelocation (0.61 vs. 0.88), by reference to surface landmark methods, and also regarding arterial punctures, a p-score was lower in the real-time US guidance than US-assistance vein prelocation (0.64 vs. 0.83).P129Conclusions: Based on the present network meta-analysis of RCTs, pscores of cannulation failure and arterial puncture were lower in the real-time US guidance, suggesting that the US-assistance vein prelocation is superior than the real-time US guidance, both of which achieve lower rates of failure and arterial puncture compared to the landmark methods.", [["vein", "ANATOMY", 160, 164], ["surface", "ANATOMY", 210, 217], ["arterial", "ANATOMY", 255, 263], ["vein", "ANATOMY", 343, 347], ["arterial", "ANATOMY", 480, 488], ["vein", "ANATOMY", 573, 577], ["arterial", "ANATOMY", 683, 691], ["cannulation failure", "DISEASE", 456, 475], ["vein", "MULTI-TISSUE_STRUCTURE", 160, 164], ["arterial punctures", "MULTI-TISSUE_STRUCTURE", 255, 273], ["vein", "MULTI-TISSUE_STRUCTURE", 343, 347], ["arterial puncture", "MULTI-TISSUE_STRUCTURE", 480, 497], ["vein", "MULTI-TISSUE_STRUCTURE", 573, 577], ["arterial", "MULTI-TISSUE_STRUCTURE", 683, 691], ["cannulation failure rate", "PROBLEM", 10, 34], ["a p-score", "TEST", 92, 101], ["US", "TEST", 146, 148], ["assistance vein prelocation", "TEST", 149, 176], ["arterial punctures", "TEST", 255, 273], ["a p-score", "TEST", 275, 284], ["US", "TEST", 329, 331], ["assistance vein prelocation", "TEST", 332, 359], ["RCTs", "TEST", 439, 443], ["cannulation failure", "PROBLEM", 456, 475], ["arterial puncture", "TEST", 480, 497], ["the US", "TEST", 555, 561], ["failure", "PROBLEM", 671, 678], ["arterial puncture", "TEST", 683, 700], ["vein", "ANATOMY", 160, 164], ["arterial", "ANATOMY", 255, 263], ["punctures", "OBSERVATION", 264, 273], ["vein", "ANATOMY", 343, 347], ["cannulation failure", "OBSERVATION", 456, 475], ["arterial", "ANATOMY", 480, 488], ["puncture", "OBSERVATION", 489, 497], ["vein", "ANATOMY", 573, 577], ["failure", "OBSERVATION", 671, 678], ["arterial", "ANATOMY", 683, 691], ["puncture", "OBSERVATION", 692, 700]]], ["We speculates that the inferiority of real-time guidance is associated with difficulties in manipulating the needle together with an echo probe in targeting relatively smaller veins in children.", [["veins", "ANATOMY", 176, 181], ["veins", "MULTI-TISSUE_STRUCTURE", 176, 181], ["children", "ORGANISM", 185, 193], ["children", "SPECIES", 185, 193], ["an echo probe", "TEST", 130, 143], ["smaller", "OBSERVATION_MODIFIER", 168, 175], ["veins", "ANATOMY", 176, 181]]], ["Introduction: We present a case report of 'Shoshin beriberi' in a young female who was 'fussy with food' that developed an acutely progressive metabolic acidosis and multi-organ failure requiring intensive care support.", [["multi-organ", "ANATOMY", 166, 177], ["Shoshin beriberi", "DISEASE", 43, 59], ["metabolic acidosis", "DISEASE", 143, 161], ["multi-organ failure", "DISEASE", 166, 185], ["female", "ORGANISM", 72, 78], ["an acutely progressive metabolic acidosis", "PROBLEM", 120, 161], ["multi-organ failure", "PROBLEM", 166, 185], ["intensive care support", "TREATMENT", 196, 218], ["acutely", "OBSERVATION_MODIFIER", 123, 130], ["progressive", "OBSERVATION_MODIFIER", 131, 142], ["metabolic acidosis", "OBSERVATION", 143, 161], ["multi-organ failure", "OBSERVATION", 166, 185]]], ["Methods: Our patient was a 36-year-old British woman who presented to the emergency department (ED) with a ten-day history of diarrhea, vomiting and increasing fatigue.", [["diarrhea", "DISEASE", 126, 134], ["vomiting", "DISEASE", 136, 144], ["fatigue", "DISEASE", 160, 167], ["patient", "ORGANISM", 13, 20], ["woman", "ORGANISM", 47, 52], ["patient", "SPECIES", 13, 20], ["woman", "SPECIES", 47, 52], ["diarrhea", "PROBLEM", 126, 134], ["vomiting", "PROBLEM", 136, 144], ["increasing fatigue", "PROBLEM", 149, 167], ["diarrhea", "OBSERVATION", 126, 134], ["increasing", "OBSERVATION_MODIFIER", 149, 159], ["fatigue", "OBSERVATION", 160, 167]]], ["She had a past medical history of gastroparesis, polycystic ovary syndrome (on metformin), laparoscopic cholecystectomy and hysteropexy.", [["polycystic ovary", "ANATOMY", 49, 65], ["gastroparesis", "DISEASE", 34, 47], ["polycystic ovary syndrome", "DISEASE", 49, 74], ["metformin", "CHEMICAL", 79, 88], ["metformin", "CHEMICAL", 79, 88], ["ovary", "ORGAN", 60, 65], ["metformin", "SIMPLE_CHEMICAL", 79, 88], ["gastroparesis", "PROBLEM", 34, 47], ["polycystic ovary syndrome", "PROBLEM", 49, 74], ["metformin", "TREATMENT", 79, 88], ["laparoscopic cholecystectomy", "TREATMENT", 91, 119], ["hysteropexy", "TREATMENT", 124, 135], ["gastroparesis", "OBSERVATION", 34, 47], ["polycystic ovary syndrome", "OBSERVATION", 49, 74], ["laparoscopic", "OBSERVATION_MODIFIER", 91, 103], ["cholecystectomy", "OBSERVATION", 104, 119]]], ["She lived with her husband and two children who had viral gastroenteritis two weeks previously.", [["viral gastroenteritis", "DISEASE", 52, 73], ["children", "ORGANISM", 35, 43], ["children", "SPECIES", 35, 43], ["viral gastroenteritis", "PROBLEM", 52, 73], ["gastroenteritis", "OBSERVATION", 58, 73]]], ["Results: The patient had a metabolic acidosis (pH 6.9) with raised lactate (>16) on initial blood gas in the ED.", [["blood", "ANATOMY", 92, 97], ["metabolic acidosis", "DISEASE", 27, 45], ["lactate", "CHEMICAL", 67, 74], ["lactate", "CHEMICAL", 67, 74], ["patient", "ORGANISM", 13, 20], ["lactate", "SIMPLE_CHEMICAL", 67, 74], ["blood", "ORGANISM_SUBSTANCE", 92, 97], ["patient", "SPECIES", 13, 20], ["a metabolic acidosis", "PROBLEM", 25, 45], ["pH", "TEST", 47, 49], ["raised lactate", "TEST", 60, 74], ["initial blood gas", "TEST", 84, 101], ["metabolic acidosis", "OBSERVATION", 27, 45]]], ["A 1.26% sodium bicarbonate infusion and hemofiltration were commenced overnight.", [["sodium bicarbonate", "CHEMICAL", 8, 26], ["sodium bicarbonate", "CHEMICAL", 8, 26], ["sodium bicarbonate", "SIMPLE_CHEMICAL", 8, 26], ["A 1.26% sodium bicarbonate infusion", "TREATMENT", 0, 35], ["hemofiltration", "TREATMENT", 40, 54]]], ["The patient's pH and lactate remained static with an increasing work of breathing over this period.", [["lactate", "CHEMICAL", 21, 28], ["lactate", "CHEMICAL", 21, 28], ["patient", "ORGANISM", 4, 11], ["lactate", "SIMPLE_CHEMICAL", 21, 28], ["patient", "SPECIES", 4, 11], ["The patient's pH", "TEST", 0, 16], ["lactate", "TEST", 21, 28], ["an increasing work of breathing", "PROBLEM", 50, 81], ["increasing", "OBSERVATION_MODIFIER", 53, 63], ["work of breathing", "OBSERVATION", 64, 81]]], ["By morning she developed flash pulmonary oedema and hypotension, the first signs of acute cardiac failure.", [["pulmonary", "ANATOMY", 31, 40], ["cardiac", "ANATOMY", 90, 97], ["pulmonary oedema", "DISEASE", 31, 47], ["hypotension", "DISEASE", 52, 63], ["acute cardiac failure", "DISEASE", 84, 105], ["pulmonary", "ORGAN", 31, 40], ["cardiac", "ORGAN", 90, 97], ["flash pulmonary oedema", "PROBLEM", 25, 47], ["hypotension", "PROBLEM", 52, 63], ["acute cardiac failure", "PROBLEM", 84, 105], ["flash", "OBSERVATION_MODIFIER", 25, 30], ["pulmonary", "ANATOMY", 31, 40], ["oedema", "OBSERVATION", 41, 47], ["hypotension", "OBSERVATION", 52, 63], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["cardiac", "ANATOMY", 90, 97], ["failure", "OBSERVATION", 98, 105]]], ["An echocardiogram displayed severely impaired left ventricular function with ejection fraction of 17%.", [["left ventricular", "ANATOMY", 46, 62], ["impaired left ventricular function", "DISEASE", 37, 71], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 46, 62], ["An echocardiogram", "TEST", 0, 17], ["severely impaired left ventricular function", "PROBLEM", 28, 71], ["ejection fraction", "TEST", 77, 94], ["severely", "OBSERVATION_MODIFIER", 28, 36], ["impaired", "OBSERVATION", 37, 45], ["left ventricular", "ANATOMY", 46, 62], ["ejection fraction", "OBSERVATION", 77, 94]]], ["The patient was intubated and inotropic support was commenced.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["intubated", "TREATMENT", 16, 25], ["inotropic support", "TREATMENT", 30, 47]]], ["It was thought that a micronutrient deficiency may have caused a rapid onset cardiac failure.", [["cardiac", "ANATOMY", 77, 84], ["micronutrient deficiency", "DISEASE", 22, 46], ["cardiac failure", "DISEASE", 77, 92], ["cardiac", "ORGAN", 77, 84], ["a micronutrient deficiency", "PROBLEM", 20, 46], ["a rapid onset cardiac failure", "PROBLEM", 63, 92], ["micronutrient deficiency", "OBSERVATION", 22, 46], ["rapid", "OBSERVATION_MODIFIER", 65, 70], ["onset", "OBSERVATION_MODIFIER", 71, 76], ["cardiac", "ANATOMY", 77, 84], ["failure", "OBSERVATION", 85, 92]]], ["Pabrinex (containing 250ml of Thiamine Hydrochloride) was commenced and within 9 hours the patient's metabolic acidosis markedly improved ( Fig. 1 ).", [["Pabrinex", "CHEMICAL", 0, 8], ["Thiamine Hydrochloride", "CHEMICAL", 30, 52], ["metabolic acidosis", "DISEASE", 101, 119], ["Pabrinex", "CHEMICAL", 0, 8], ["Thiamine Hydrochloride", "CHEMICAL", 30, 52], ["Pabrinex", "SIMPLE_CHEMICAL", 0, 8], ["Thiamine Hydrochloride", "SIMPLE_CHEMICAL", 30, 52], ["patient", "ORGANISM", 91, 98], ["patient", "SPECIES", 91, 98], ["Pabrinex", "TREATMENT", 0, 8], ["Thiamine Hydrochloride", "TREATMENT", 30, 52], ["the patient's metabolic acidosis", "PROBLEM", 87, 119], ["metabolic acidosis", "OBSERVATION", 101, 119], ["markedly", "OBSERVATION_MODIFIER", 120, 128], ["improved", "OBSERVATION_MODIFIER", 129, 137]]], ["Complete reversal of the cardiac failure occurred over 96 hours.P129Conclusions: Shoshin is a rare clinical manifestation of thiamine deficiency [1] .", [["cardiac", "ANATOMY", 25, 32], ["cardiac failure", "DISEASE", 25, 40], ["thiamine", "CHEMICAL", 125, 133], ["thiamine", "CHEMICAL", 125, 133], ["cardiac", "ORGAN", 25, 32], ["Shoshin", "GENE_OR_GENE_PRODUCT", 81, 88], ["thiamine", "SIMPLE_CHEMICAL", 125, 133], ["the cardiac failure", "PROBLEM", 21, 40], ["thiamine deficiency", "PROBLEM", 125, 144], ["reversal", "OBSERVATION_MODIFIER", 9, 17], ["cardiac", "ANATOMY", 25, 32], ["failure", "OBSERVATION", 33, 40], ["thiamine deficiency", "OBSERVATION", 125, 144]]], ["It is an important differential diagnosis to bear in mind after excluding more common aetiologies of heart failure.", [["heart", "ANATOMY", 101, 106], ["heart failure", "DISEASE", 101, 114], ["heart", "ORGAN", 101, 106], ["heart failure", "PROBLEM", 101, 114], ["heart", "ANATOMY", 101, 106], ["failure", "OBSERVATION", 107, 114]]], ["Especially in this case as our patient had no obvious risk factors at the time of presentation.", [["patient", "ORGANISM", 31, 38], ["patient", "SPECIES", 31, 38], ["obvious risk factors", "PROBLEM", 46, 66]]], ["We suggest empiric use of thiamine should be considered in treatment algorithms for young patients presenting with acute cardiac failure.", [["cardiac", "ANATOMY", 121, 128], ["thiamine", "CHEMICAL", 26, 34], ["acute cardiac failure", "DISEASE", 115, 136], ["thiamine", "CHEMICAL", 26, 34], ["thiamine", "SIMPLE_CHEMICAL", 26, 34], ["patients", "ORGANISM", 90, 98], ["cardiac", "ORGAN", 121, 128], ["patients", "SPECIES", 90, 98], ["thiamine", "TREATMENT", 26, 34], ["treatment algorithms", "TREATMENT", 59, 79], ["acute cardiac failure", "PROBLEM", 115, 136], ["acute", "OBSERVATION_MODIFIER", 115, 120], ["cardiac", "ANATOMY", 121, 128], ["failure", "OBSERVATION", 129, 136]]], ["Introduction: Takotsubo syndrome (TS) is known to be an acute transient cardiac condition accompanied with acute heart failure.", [["cardiac", "ANATOMY", 72, 79], ["heart", "ANATOMY", 113, 118], ["Takotsubo syndrome", "DISEASE", 14, 32], ["TS", "DISEASE", 34, 36], ["cardiac condition", "DISEASE", 72, 89], ["acute heart failure", "DISEASE", 107, 126], ["cardiac", "ORGAN", 72, 79], ["heart", "ORGAN", 113, 118], ["Takotsubo syndrome", "PROBLEM", 14, 32], ["an acute transient cardiac condition", "PROBLEM", 53, 89], ["acute heart failure", "PROBLEM", 107, 126], ["Takotsubo syndrome", "OBSERVATION", 14, 32], ["known to be", "UNCERTAINTY", 41, 52], ["acute", "OBSERVATION_MODIFIER", 56, 61], ["transient", "OBSERVATION", 62, 71], ["cardiac", "ANATOMY", 72, 79], ["condition", "OBSERVATION", 80, 89], ["acute", "OBSERVATION_MODIFIER", 107, 112], ["heart", "ANATOMY", 113, 118], ["failure", "OBSERVATION", 119, 126]]], ["TS is often triggered by critical illness but that has been rarely studied in ICU practice.Therefore, it is known, that the use of catecholamines can directly induce TS, worsen LVOT obstruction, and delay spontaneous recovery in TS patients, it is nearly impossible to avoid their administration in critically ill [1] .", [["TS", "DISEASE", 0, 2], ["catecholamines", "CHEMICAL", 131, 145], ["LVOT obstruction", "DISEASE", 177, 193], ["critically ill", "DISEASE", 299, 313], ["catecholamines", "CHEMICAL", 131, 145], ["catecholamines", "SIMPLE_CHEMICAL", 131, 145], ["patients", "ORGANISM", 232, 240], ["patients", "SPECIES", 232, 240], ["catecholamines", "TREATMENT", 131, 145], ["LVOT obstruction", "PROBLEM", 177, 193], ["obstruction", "OBSERVATION", 182, 193]]], ["Methods: We have analyzed medical records from 23 patients with TS, that were revealed during year 2017 in our hospital.", [["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58]]], ["TS was defined due to Mayo criteria, including transient regional wall motion abnormalities, mildly elevated troponin level and no signs of obstructive CAD on coronary angiography.", [["wall", "ANATOMY", 66, 70], ["coronary", "ANATOMY", 159, 167], ["obstructive CAD", "DISEASE", 140, 155], ["wall", "MULTI-TISSUE_STRUCTURE", 66, 70], ["troponin", "GENE_OR_GENE_PRODUCT", 109, 117], ["coronary", "MULTI-TISSUE_STRUCTURE", 159, 167], ["troponin", "PROTEIN", 109, 117], ["transient regional wall motion abnormalities", "PROBLEM", 47, 91], ["mildly elevated troponin level", "PROBLEM", 93, 123], ["obstructive CAD", "PROBLEM", 140, 155], ["coronary angiography", "TEST", 159, 179], ["regional", "ANATOMY_MODIFIER", 57, 65], ["wall", "ANATOMY_MODIFIER", 66, 70], ["motion abnormalities", "OBSERVATION", 71, 91], ["mildly", "OBSERVATION_MODIFIER", 93, 99], ["elevated", "OBSERVATION", 100, 108], ["no signs of", "UNCERTAINTY", 128, 139], ["obstructive", "OBSERVATION_MODIFIER", 140, 151], ["CAD", "OBSERVATION", 152, 155], ["coronary", "ANATOMY", 159, 167]]], ["Results: Out of 23 patients who developed TS in ICU or ICCU, hemodynamic instability occurred in acute phase of TS in 12 (52%) cases.", [["TS", "DISEASE", 42, 44], ["hemodynamic instability", "DISEASE", 61, 84], ["TS", "DISEASE", 112, 114], ["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["TS", "PROBLEM", 42, 44], ["hemodynamic instability", "PROBLEM", 61, 84], ["hemodynamic instability", "OBSERVATION", 61, 84], ["acute phase", "OBSERVATION_MODIFIER", 97, 108]]], ["9 (39%) of patients were admitted to ICU in due to septic shock (2 patients), major bleeding (1), cerebral mass lesion (1) and ARDS (2) and required treatment with catecholamines.", [["cerebral mass lesion", "ANATOMY", 98, 118], ["septic shock", "DISEASE", 51, 63], ["bleeding", "DISEASE", 84, 92], ["cerebral mass lesion", "DISEASE", 98, 118], ["ARDS", "DISEASE", 127, 131], ["catecholamines", "CHEMICAL", 164, 178], ["catecholamines", "CHEMICAL", 164, 178], ["patients", "ORGANISM", 11, 19], ["patients", "ORGANISM", 67, 75], ["cerebral", "PATHOLOGICAL_FORMATION", 98, 106], ["catecholamines", "SIMPLE_CHEMICAL", 164, 178], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 67, 75], ["septic shock", "PROBLEM", 51, 63], ["major bleeding", "PROBLEM", 78, 92], ["cerebral mass lesion", "PROBLEM", 98, 118], ["ARDS", "PROBLEM", 127, 131], ["treatment", "TREATMENT", 149, 158], ["catecholamines", "TREATMENT", 164, 178], ["septic shock", "OBSERVATION", 51, 63], ["major", "OBSERVATION_MODIFIER", 78, 83], ["bleeding", "OBSERVATION", 84, 92], ["cerebral", "ANATOMY", 98, 106], ["mass", "OBSERVATION", 107, 111], ["ARDS", "OBSERVATION", 127, 131]]], ["General mortality rate in TS patients was 7 (30%), and 5 (55%) in critically ill TS patients.", [["critically ill TS", "DISEASE", 66, 83], ["patients", "ORGANISM", 29, 37], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 29, 37], ["patients", "SPECIES", 84, 92], ["General mortality rate", "TEST", 0, 22]]], ["Mean duration of noradrenalin infusion was 7,2 days, dobutamine infusion 4,3 days.", [["noradrenalin", "CHEMICAL", 17, 29], ["dobutamine", "CHEMICAL", 53, 63], ["noradrenalin", "CHEMICAL", 17, 29], ["dobutamine", "CHEMICAL", 53, 63], ["noradrenalin", "SIMPLE_CHEMICAL", 17, 29], ["noradrenalin infusion", "TREATMENT", 17, 38], ["dobutamine infusion", "TREATMENT", 53, 72]]], ["Patients with TS needed more ICU resources and longer ICU-stay.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Mortality rate was higher in TS patients (55%) vs the ICU-population (28%), p = 0.02.", [["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["Mortality rate", "TEST", 0, 14], ["higher", "OBSERVATION_MODIFIER", 19, 25]]], ["Conclusions: TS seems to be an often cause of LV dysfunction and acute heart failure in critically ill.", [["LV", "ANATOMY", 46, 48], ["heart", "ANATOMY", 71, 76], ["LV dysfunction", "DISEASE", 46, 60], ["heart failure", "DISEASE", 71, 84], ["critically ill", "DISEASE", 88, 102], ["LV", "MULTI-TISSUE_STRUCTURE", 46, 48], ["heart", "ORGAN", 71, 76], ["LV dysfunction", "PROBLEM", 46, 60], ["acute heart failure", "PROBLEM", 65, 84], ["critically ill", "PROBLEM", 88, 102], ["LV", "ANATOMY", 46, 48], ["dysfunction", "OBSERVATION", 49, 60], ["acute", "OBSERVATION_MODIFIER", 65, 70], ["heart", "ANATOMY", 71, 76], ["failure", "OBSERVATION", 77, 84]]], ["It seems that TS could be a predictor of worse prognosis in critically ill patients.", [["critically ill", "DISEASE", 60, 74], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83]]], ["Although catecholamine administration may worsen the patient prognosis and induce further AHF in critically ill patients it rearely can be avoided.", [["catecholamine", "CHEMICAL", 9, 22], ["AHF", "DISEASE", 90, 93], ["critically ill", "DISEASE", 97, 111], ["catecholamine", "CHEMICAL", 9, 22], ["catecholamine", "SIMPLE_CHEMICAL", 9, 22], ["patient", "ORGANISM", 53, 60], ["patients", "ORGANISM", 112, 120], ["patient", "SPECIES", 53, 60], ["patients", "SPECIES", 112, 120], ["catecholamine administration", "TREATMENT", 9, 37], ["further AHF", "PROBLEM", 82, 93]]], ["Introduction: Previous studies on readmission following LVAD implantation have focused on hospital readmission after dismissal from the index hospitalization.", [["Previous studies", "TEST", 14, 30], ["LVAD implantation", "TREATMENT", 56, 73]]], ["Since there are very little data existing, the purpose of this study was to examine intensive care unit (ICU) readmission in patients during their initial hospitalization for LVAD implantation to determine reasons for, factors associated with, and mortality following ICU readmission.", [["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["this study", "TEST", 58, 68], ["LVAD implantation", "TREATMENT", 175, 192]]], ["Methods: This was a retrospective, single center, cohort study in an academic tertiary referral center.", [["cohort study", "TEST", 50, 62]]], ["All patients at our institution undergoing first time LVAD implantation from February 2007 to March 2015 were included.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["LVAD implantation", "TREATMENT", 54, 71]]], ["Patients dismissed from the ICU who then required ICU readmission prior to hospital dismissal were compared to those not requiring ICU readmission prior to hospital dismissal.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Results: Among 266 LVAD patients, 45 (16.9%) required ICU readmission.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["LVAD", "TEST", 19, 23]]], ["The most common reasons for admission were bleeding and respiratory failure (Fig. 1) .", [["respiratory", "ANATOMY", 56, 67], ["bleeding", "DISEASE", 43, 51], ["respiratory failure", "DISEASE", 56, 75], ["bleeding", "PROBLEM", 43, 51], ["respiratory failure", "PROBLEM", 56, 75], ["bleeding", "OBSERVATION", 43, 51], ["respiratory failure", "OBSERVATION", 56, 75]]], ["Factors found to be significantly associated with ICU readmission were preoperative hemoglobin level of less than 10 g/dL, preoperative estimated glomerular filtration rate <35mL/min/1.73m2, preoperative atrial fibrillation, preoperative dialysis, longer cardiopulmonary bypass times, and higher intraoperative allogeneic blood transfusion requirements.", [["glomerular", "ANATOMY", 146, 156], ["atrial", "ANATOMY", 204, 210], ["cardiopulmonary", "ANATOMY", 255, 270], ["blood", "ANATOMY", 322, 327], ["atrial fibrillation", "DISEASE", 204, 223], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 84, 94], ["glomerular", "TISSUE", 146, 156], ["atrial", "MULTI-TISSUE_STRUCTURE", 204, 210], ["blood", "ORGANISM_SUBSTANCE", 322, 327], ["hemoglobin", "PROTEIN", 84, 94], ["preoperative hemoglobin level", "TEST", 71, 100], ["preoperative estimated glomerular filtration rate", "TEST", 123, 172], ["preoperative atrial fibrillation", "PROBLEM", 191, 223], ["preoperative dialysis", "TREATMENT", 225, 246], ["longer cardiopulmonary bypass times", "TREATMENT", 248, 283], ["higher intraoperative allogeneic blood transfusion requirements", "TREATMENT", 289, 352], ["glomerular", "ANATOMY", 146, 156], ["atrial", "ANATOMY", 204, 210], ["fibrillation", "OBSERVATION", 211, 223], ["bypass", "OBSERVATION", 271, 277], ["allogeneic blood transfusion", "OBSERVATION", 311, 339]]], ["Mortality at 1 year was 30.2% in patients requiring ICU readmission vs. 11.9% in those not requiring ICU readmission (age-adjusted OR=3.0, 95% CI 1.4 to 6.6, p=0.005).", [["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["CI", "TEST", 143, 145], ["p", "TEST", 158, 159]]], ["Conclusions: ICU readmission following LVAD implantation occurred relatively frequently and was associated with significant one-year mortality.", [["LVAD implantation", "TREATMENT", 39, 56], ["LVAD", "OBSERVATION", 39, 43]]], ["These data can be used to identify LVAD patients at risk for ICU readmission and implement practice changes to mitigate ICU readmission.", [["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["ICU readmission", "TREATMENT", 61, 76], ["practice changes", "TREATMENT", 91, 107], ["ICU readmission", "TREATMENT", 120, 135]]], ["Future larger and prospective studies are warranted.P140Atrial fibrillation and infection among acute patients in the emergency department: a multicentre cohort study of prevalence and prognosis T Graversgaard Odense University Hospital, Odense, Denmark Critical Care 2018, 22(Suppl 1):P140 Introduction: Patients with infection presenting with atrial fibrillation (AF) are frequent in emergency departments (ED).", [["atrial", "ANATOMY", 345, 351], ["Atrial fibrillation", "DISEASE", 56, 75], ["infection", "DISEASE", 80, 89], ["infection", "DISEASE", 319, 328], ["atrial fibrillation", "DISEASE", 345, 364], ["AF", "DISEASE", 366, 368], ["patients", "ORGANISM", 102, 110], ["Patients", "ORGANISM", 305, 313], ["patients", "SPECIES", 102, 110], ["Patients", "SPECIES", 305, 313], ["Future larger and prospective studies", "TEST", 0, 37], ["Atrial fibrillation", "PROBLEM", 56, 75], ["infection", "PROBLEM", 80, 89], ["infection", "PROBLEM", 319, 328], ["atrial fibrillation", "PROBLEM", 345, 364], ["AF", "PROBLEM", 366, 368], ["larger", "OBSERVATION_MODIFIER", 7, 13], ["Atrial", "ANATOMY", 56, 62], ["fibrillation", "OBSERVATION", 63, 75], ["infection", "OBSERVATION", 80, 89], ["acute", "OBSERVATION_MODIFIER", 96, 101], ["infection", "OBSERVATION", 319, 328], ["atrial", "ANATOMY", 345, 351], ["fibrillation", "OBSERVATION", 352, 364]]], ["This combination is probably related to a poor prognosis compared to lone AF or infection, but existing data are scarce.", [["AF", "DISEASE", 74, 76], ["infection", "DISEASE", 80, 89], ["a poor prognosis", "PROBLEM", 40, 56], ["lone AF", "PROBLEM", 69, 76], ["infection", "PROBLEM", 80, 89], ["probably related to", "UNCERTAINTY", 20, 39], ["infection", "OBSERVATION", 80, 89]]], ["Aim: to describe the prevalence and prognosis for AF and infection individually and concomitantly in an ED setting.", [["AF", "DISEASE", 50, 52], ["infection", "DISEASE", 57, 66], ["AF", "PROBLEM", 50, 52], ["infection", "PROBLEM", 57, 66], ["infection", "OBSERVATION", 57, 66]]], ["Introduction: Its afterload reducing effects make PEEP the treatment of choice for cardiogenic pulmonary edema.", [["pulmonary", "ANATOMY", 95, 104], ["cardiogenic pulmonary edema", "DISEASE", 83, 110], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 95, 110], ["Its afterload reducing effects", "TREATMENT", 14, 44], ["PEEP", "TREATMENT", 50, 54], ["cardiogenic pulmonary edema", "PROBLEM", 83, 110], ["pulmonary", "ANATOMY", 95, 104], ["edema", "OBSERVATION", 105, 110]]], ["Studies indicate that PEEP may lower coronary blood flow.", [["coronary", "ANATOMY", 37, 45], ["blood", "ANATOMY", 46, 51], ["coronary", "MULTI-TISSUE_STRUCTURE", 37, 45], ["blood", "ORGANISM_SUBSTANCE", 46, 51], ["Studies", "TEST", 0, 7], ["PEEP", "TEST", 22, 26], ["lower coronary blood flow", "PROBLEM", 31, 56], ["PEEP", "OBSERVATION", 22, 26], ["lower", "ANATOMY_MODIFIER", 31, 36], ["coronary blood", "ANATOMY", 37, 51], ["flow", "OBSERVATION_MODIFIER", 52, 56]]], ["Its effects on left ventricular contractility is unclear.", [["left ventricular", "ANATOMY", 15, 31], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 15, 31], ["left ventricular", "ANATOMY", 15, 31], ["contractility", "OBSERVATION", 32, 45]]], ["Most of the surrogate measures for cardiac contractility are dependent on afterload and contractility assessment under PEEP may therefore be biased.", [["cardiac", "ANATOMY", 35, 42], ["cardiac", "ORGAN", 35, 42], ["afterload", "TEST", 74, 83], ["contractility assessment", "TEST", 88, 112], ["PEEP", "TREATMENT", 119, 123], ["contractility", "OBSERVATION", 43, 56]]], ["We have investigated cardiac contractility under PEEP with the endsystolic pressure volume relationship (ESPVR) as a load-independent measure of contractility.", [["cardiac", "ANATOMY", 21, 28], ["cardiac", "ORGAN", 21, 28], ["PEEP", "TREATMENT", 49, 53], ["the endsystolic pressure volume", "TEST", 59, 90], ["a load", "TEST", 115, 121], ["cardiac", "ANATOMY", 21, 28], ["contractility", "OBSERVATION", 29, 42]]], ["Methods: 23 patients scheduled for coronary angiography were ventilated with CPAP and a full face mask at three levels of PEEP (0, 5 and 10 cmH2O) in random order.", [["coronary", "ANATOMY", 35, 43], ["patients", "ORGANISM", 12, 20], ["coronary", "MULTI-TISSUE_STRUCTURE", 35, 43], ["patients", "SPECIES", 12, 20], ["coronary angiography", "TEST", 35, 55], ["CPAP", "TREATMENT", 77, 81], ["a full face mask", "TREATMENT", 86, 102], ["PEEP", "TREATMENT", 122, 126], ["coronary", "ANATOMY", 35, 43]]], ["Structural cardiac pathologies were excluded with echocardiography.", [["cardiac", "ANATOMY", 11, 18], ["cardiac pathologies", "DISEASE", 11, 30], ["cardiac", "ORGAN", 11, 18], ["Structural cardiac pathologies", "PROBLEM", 0, 30], ["echocardiography", "TEST", 50, 66], ["cardiac", "ANATOMY", 11, 18], ["pathologies", "OBSERVATION", 19, 30]]], ["At every PEEP level, left ventricular pressure volume loops (Millar conductance catheter with INCA System, Leycom, Netherlands) were obtained.", [["left ventricular", "ANATOMY", 21, 37], ["ventricular", "MULTI-TISSUE_STRUCTURE", 26, 37], ["PEEP level", "TEST", 9, 19], ["left ventricular pressure volume", "TEST", 21, 53], ["Millar conductance catheter", "TREATMENT", 61, 88], ["INCA System", "TREATMENT", 94, 105], ["left ventricular", "ANATOMY", 21, 37], ["pressure", "OBSERVATION_MODIFIER", 38, 46], ["volume loops", "OBSERVATION", 47, 59], ["conductance catheter", "OBSERVATION", 68, 88]]], ["The endsystolic elastance was derived from a PV-loop family under preload reduction with an Amplatzer sizing balloon in the inferior caval vein.", [["inferior caval vein", "ANATOMY", 124, 143], ["inferior caval vein", "MULTI-TISSUE_STRUCTURE", 124, 143], ["PV-loop family", "PROTEIN", 45, 59], ["The endsystolic elastance", "TEST", 0, 25], ["preload reduction", "TREATMENT", 66, 83], ["an Amplatzer sizing balloon", "TREATMENT", 89, 116], ["elastance", "OBSERVATION", 16, 25], ["preload reduction", "OBSERVATION", 66, 83], ["Amplatzer", "OBSERVATION", 92, 101], ["sizing", "OBSERVATION_MODIFIER", 102, 108], ["balloon", "OBSERVATION", 109, 116], ["inferior caval vein", "ANATOMY", 124, 143]]], ["All participants gave written informed consent.", [["participants", "SPECIES", 4, 16]]], ["The study was approved by the Bernese ethics committee.", [["The study", "TEST", 0, 9]]], ["Results: 5 women and 18 men with an age 59\u00b16 years were studied.", [["women", "ORGANISM", 11, 16], ["men", "ORGANISM", 24, 27], ["women", "SPECIES", 11, 16], ["men", "SPECIES", 24, 27]]], ["Ejection fraction was 70\u00b18 % at baseline.", [["Ejection fraction", "TEST", 0, 17]]], ["Mean ESPVR at PEEP levels of 0, 5 and 10 were 2.64\u00b11.3, 2.56\u00b1 1.18 and 2.33\u00b10.88 mmHg/mL (p = 0.318, repeated measurements ANOVA). dP/dt and ejection fraction did not differ between the PEEP levels (p=0.138 and 0.48).", [["Mean ESPVR", "TEST", 0, 10], ["PEEP levels", "TEST", 14, 25], ["p", "TEST", 90, 91], ["dP/dt", "TEST", 131, 136], ["ejection fraction", "TEST", 141, 158], ["the PEEP levels", "TEST", 182, 197], ["p", "TEST", 199, 200], ["ejection fraction", "OBSERVATION", 141, 158]]], ["Conclusions: Moderate levels of PEEP did not influence endsystolic elastance.", [["PEEP", "TREATMENT", 32, 36], ["Moderate", "OBSERVATION_MODIFIER", 13, 21]]], ["Higher PEEP and patients in cardiogenic shock should be investigated.", [["cardiogenic shock", "DISEASE", 28, 45], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["Higher PEEP", "TREATMENT", 0, 11], ["cardiogenic shock", "PROBLEM", 28, 45], ["cardiogenic shock", "OBSERVATION", 28, 45]]], ["Introduction: We sought to assess the feasibility of 3D volumetric analysis with transthoracic echocardiography in critically ill patients.", [["critically ill", "DISEASE", 115, 129], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["3D volumetric analysis", "TEST", 53, 75], ["transthoracic echocardiography", "TEST", 81, 111]]], ["We choose a cohort typical of ICU where accurate volumetric analysis is important: hypoxic, mechanically ventilated patients.", [["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 116, 124], ["accurate volumetric analysis", "TEST", 40, 68], ["hypoxic", "PROBLEM", 83, 90], ["hypoxic", "OBSERVATION_MODIFIER", 83, 90], ["mechanically ventilated", "OBSERVATION", 92, 115]]], ["3D analysis is enticing in simplicity and wealth of data available.", [["3D analysis", "TEST", 0, 11]]], ["It is accurate in cardiology patients [1] but has not been assessed in the ICU.", [["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37]]], ["Methods: Patients were imaged within 24 hours of admission.", [["Patients", "ORGANISM", 9, 17], ["Patients", "SPECIES", 9, 17]]], ["Inclusion criteria: adult, hypoxic (P:F <300), mechanically ventilated, Doppler stroke volume (SV) assessment possible.", [["stroke", "DISEASE", 80, 86], ["hypoxic", "PROBLEM", 27, 34], ["mechanically ventilated", "TREATMENT", 47, 70], ["Doppler stroke volume", "TEST", 72, 93], ["SV) assessment", "TEST", 95, 109], ["hypoxic", "OBSERVATION_MODIFIER", 27, 34], ["ventilated", "OBSERVATION", 60, 70]]], ["Echocardiography: Seimens SC2000 real-time volumetric analysis with standard B-mode and Doppler assessment.", [["Echocardiography", "TEST", 0, 16], ["Seimens", "TEST", 18, 25], ["volumetric analysis", "TEST", 43, 62], ["Doppler assessment", "TEST", 88, 106]]], ["Images unacceptable if >2 segments unable to be seen in 2 volumetric planes.", [["Images", "TEST", 0, 6]]], ["3D Left ventricle (LV) and right ventricle (RV) analysis with Tomtec Imaging and Seimens Acuson respectively and compared to Doppler derived SV.", [["Left ventricle", "ANATOMY", 3, 17], ["LV", "ANATOMY", 19, 21], ["right ventricle", "ANATOMY", 27, 42], ["Left ventricle", "MULTI-TISSUE_STRUCTURE", 3, 17], ["LV", "MULTI-TISSUE_STRUCTURE", 19, 21], ["ventricle", "MULTI-TISSUE_STRUCTURE", 33, 42], ["RV", "MULTI-TISSUE_STRUCTURE", 44, 46], ["3D Left ventricle (LV) and right ventricle (RV) analysis", "TEST", 0, 56], ["Tomtec Imaging", "TEST", 62, 76], ["Seimens Acuson", "TEST", 81, 95], ["Doppler", "TEST", 125, 132], ["Left ventricle", "ANATOMY", 3, 17], ["LV", "ANATOMY", 19, 21], ["right ventricle", "ANATOMY", 27, 42], ["RV", "ANATOMY", 44, 46]]], ["Imaging was optimised for volumetric analysis (20-45 vols/sec).", [["Imaging", "TEST", 0, 7], ["volumetric analysis", "TEST", 26, 45], ["vols/sec", "TEST", 53, 61]]], ["Results: 92 patients, 83 in sinus, 9 in AF.", [["sinus", "ANATOMY", 28, 33], ["AF", "DISEASE", 40, 42], ["patients", "ORGANISM", 12, 20], ["sinus", "MULTI-TISSUE_STRUCTURE", 28, 33], ["patients", "SPECIES", 12, 20], ["AF", "PROBLEM", 40, 42], ["sinus", "ANATOMY", 28, 33], ["AF", "OBSERVATION", 40, 42]]], ["No significant difference seen between Doppler vs 2D Simpson's biplane, 3D LV or 3D RV SV estimation.", [["LV", "MULTI-TISSUE_STRUCTURE", 75, 77], ["significant difference", "PROBLEM", 3, 25], ["Doppler", "TEST", 39, 46], ["3D LV", "TEST", 72, 77], ["3D RV SV estimation", "TEST", 81, 100], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION", 15, 25], ["LV", "ANATOMY", 75, 77], ["RV SV", "ANATOMY", 84, 89]]], ["Feasibility, SV values and bias are reported in Table 1 and Fig. 1 .", [["SV values", "TEST", 13, 22], ["bias", "TEST", 27, 31]]], ["Limit of agreement for corrected Doppler vs LV 3D SV = -48% to 55%; RV 3D SV = -62.7% to 84.3%.", [["corrected Doppler", "TEST", 23, 40], ["LV", "TEST", 44, 46], ["SV", "TEST", 50, 52], ["RV", "TEST", 68, 70], ["SV", "TEST", 74, 76]]], ["Conclusions: 3D LV and RV volumetric analysis is feasible in majority of patients requiring mechanical ventilation, however lacks agreement with Doppler derived stroke volume assessment.", [["LV", "ANATOMY", 16, 18], ["stroke", "DISEASE", 161, 167], ["LV", "MULTI-TISSUE_STRUCTURE", 16, 18], ["RV", "MULTI-TISSUE_STRUCTURE", 23, 25], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["3D LV", "TEST", 13, 18], ["RV volumetric analysis", "TEST", 23, 45], ["mechanical ventilation", "TREATMENT", 92, 114], ["Doppler derived stroke volume assessment", "TEST", 145, 185], ["RV", "ANATOMY", 23, 25], ["mechanical ventilation", "OBSERVATION", 92, 114]]], ["Although images may appear sufficient, the semi-automated software appears to underestimate stroke volume.", [["stroke", "DISEASE", 92, 98], ["images", "TEST", 9, 15], ["underestimate stroke volume", "PROBLEM", 78, 105], ["stroke", "OBSERVATION", 92, 98]]], ["Further larger studies using thermodilution are warranted.", [["Further larger studies", "TEST", 0, 22], ["thermodilution", "TREATMENT", 29, 43]]], ["Introduction: Body position changes such as leg raising are used to determine fluid responsiveness.", [["Body", "ANATOMY", 14, 18], ["leg", "ANATOMY", 44, 47], ["fluid", "ANATOMY", 78, 83], ["leg", "ORGANISM_SUBDIVISION", 44, 47], ["Body position changes", "TREATMENT", 14, 35], ["fluid responsiveness", "TEST", 78, 98], ["leg", "ANATOMY", 44, 47]]], ["We hypothesized that the Trendelenburg position increases resistance to venous return.", [["venous", "ANATOMY", 72, 78], ["venous", "MULTI-TISSUE_STRUCTURE", 72, 78], ["the Trendelenburg position", "TREATMENT", 21, 47], ["Trendelenburg position", "OBSERVATION", 25, 47], ["venous", "ANATOMY", 72, 78]]], ["Together with abolishment of the hepatic vascular waterfall, this may limit the increase in regional blood flow.", [["hepatic vascular", "ANATOMY", 33, 49], ["blood", "ANATOMY", 101, 106], ["hepatic vascular", "MULTI-TISSUE_STRUCTURE", 33, 49], ["blood", "ORGANISM_SUBSTANCE", 101, 106], ["the hepatic vascular waterfall", "PROBLEM", 29, 59], ["the increase in regional blood flow", "PROBLEM", 76, 111], ["hepatic", "ANATOMY", 33, 40], ["vascular waterfall", "ANATOMY", 41, 59], ["increase", "OBSERVATION_MODIFIER", 80, 88], ["regional blood flow", "OBSERVATION", 92, 111]]], ["Methods: Inferior vena cava (IVC), portal vein (PV), hepatic, superior mesenteric (SMA) and carotid artery blood flows and arterial, right atrial (RA) and hepatic (HV) and portal venous blood pressures were measured in anesthetized and mechanically ventilated pigs in supine and 30\u00b0Trendelenburg positions.", [["Inferior vena cava", "ANATOMY", 9, 27], ["IVC", "ANATOMY", 29, 32], ["portal vein", "ANATOMY", 35, 46], ["PV", "ANATOMY", 48, 50], ["hepatic", "ANATOMY", 53, 60], ["superior mesenteric", "ANATOMY", 62, 81], ["carotid artery blood", "ANATOMY", 92, 112], ["arterial", "ANATOMY", 123, 131], ["right atrial", "ANATOMY", 133, 145], ["RA", "ANATOMY", 147, 149], ["hepatic", "ANATOMY", 155, 162], ["portal venous", "ANATOMY", 172, 185], ["blood", "ANATOMY", 186, 191], ["Inferior vena cava", "MULTI-TISSUE_STRUCTURE", 9, 27], ["IVC", "MULTI-TISSUE_STRUCTURE", 29, 32], ["portal vein", "MULTI-TISSUE_STRUCTURE", 35, 46], ["PV", "MULTI-TISSUE_STRUCTURE", 48, 50], ["hepatic", "MULTI-TISSUE_STRUCTURE", 53, 60], ["mesenteric", "MULTI-TISSUE_STRUCTURE", 71, 81], ["SMA", "MULTI-TISSUE_STRUCTURE", 83, 86], ["carotid artery", "MULTI-TISSUE_STRUCTURE", 92, 106], ["blood", "ORGANISM_SUBSTANCE", 107, 112], ["arterial", "MULTI-TISSUE_STRUCTURE", 123, 131], ["right atrial", "MULTI-TISSUE_STRUCTURE", 133, 145], ["hepatic", "MULTI-TISSUE_STRUCTURE", 155, 162], ["portal venous", "MULTI-TISSUE_STRUCTURE", 172, 185], ["blood", "ORGANISM_SUBSTANCE", 186, 191], ["pigs", "ORGANISM", 260, 264], ["pigs", "SPECIES", 260, 264], ["PV", "SPECIES", 48, 50], ["portal venous blood pressures", "TEST", 172, 201], ["mechanically ventilated pigs", "TREATMENT", 236, 264], ["Inferior vena cava", "ANATOMY", 9, 27], ["IVC", "ANATOMY", 29, 32], ["portal vein", "ANATOMY", 35, 46], ["hepatic", "ANATOMY", 53, 60], ["superior mesenteric", "ANATOMY", 62, 81], ["SMA", "ANATOMY", 83, 86], ["carotid artery", "ANATOMY", 92, 106], ["arterial", "ANATOMY", 123, 131], ["right atrial", "ANATOMY", 133, 145], ["RA", "ANATOMY", 147, 149], ["hepatic", "ANATOMY", 155, 162], ["portal venous", "ANATOMY", 172, 185], ["pressures", "OBSERVATION_MODIFIER", 192, 201], ["mechanically", "OBSERVATION_MODIFIER", 236, 248], ["ventilated pigs", "OBSERVATION", 249, 264]]], ["All hemodynamic parameters were measured during end-expiration at 5 cmH2O PEEP, and at inspiratory hold with increasing airway pressures (AWP) of 15, 20, 25 and 30 cmH2O, respectively.", [["airway", "ANATOMY", 120, 126], ["airway", "MULTI-TISSUE_STRUCTURE", 120, 126], ["All hemodynamic parameters", "TEST", 0, 26], ["PEEP", "TREATMENT", 74, 78], ["increasing airway pressures", "TREATMENT", 109, 136], ["airway pressures", "OBSERVATION", 120, 136]]], ["Paired t test was used to compare pressures and flows in different positions during end-expiration.", [["Paired t test", "TEST", 0, 13], ["pressures", "TEST", 34, 43], ["flows", "OBSERVATION_MODIFIER", 48, 53], ["different", "OBSERVATION_MODIFIER", 57, 66], ["positions", "OBSERVATION_MODIFIER", 67, 76]]], ["Repeated measures ANOVA was performed to evaluate the effects of AWP on hemodynamic parameters.", [["AWP", "CHEMICAL", 65, 68], ["AWP", "SIMPLE_CHEMICAL", 65, 68], ["Repeated measures ANOVA", "TEST", 0, 23], ["hemodynamic parameters", "TEST", 72, 94]]], ["Results: Trendelenburg position significantly increased RA, HV and PV blood pressures at end-expiration, while Qpv and Qsma remained unchanged, Qha increased and Qivc showed a trend to decrease (Table 1 ).", [["blood", "ANATOMY", 70, 75], ["blood", "ORGANISM_SUBSTANCE", 70, 75], ["Qsma", "PROTEIN", 119, 123], ["PV", "SPECIES", 67, 69], ["Trendelenburg position", "TEST", 9, 31], ["HV", "TEST", 60, 62], ["PV blood pressures", "TEST", 67, 85], ["Qpv", "TEST", 111, 114], ["Qsma", "TEST", 119, 123], ["increased", "OBSERVATION_MODIFIER", 46, 55], ["pressures", "OBSERVATION_MODIFIER", 76, 85], ["unchanged", "OBSERVATION_MODIFIER", 133, 142]]], ["In both positions, all blood flows decreased with increasing AWP, and the difference between Ppv and Qsma became smaller, indicating splanchnic blood pooling ( Table 2 ).", [["blood", "ANATOMY", 23, 28], ["splanchnic blood", "ANATOMY", 133, 149], ["blood", "ORGANISM_SUBSTANCE", 23, 28], ["AWP", "SIMPLE_CHEMICAL", 61, 64], ["blood", "ORGANISM_SUBSTANCE", 144, 149], ["Ppv", "PROTEIN", 93, 96], ["all blood flows", "TEST", 19, 34], ["increasing AWP", "TREATMENT", 50, 64], ["Ppv", "TEST", 93, 96], ["splanchnic blood pooling", "PROBLEM", 133, 157], ["both", "ANATOMY_MODIFIER", 3, 7], ["positions", "OBSERVATION_MODIFIER", 8, 17], ["blood", "OBSERVATION_MODIFIER", 23, 28], ["flows", "OBSERVATION_MODIFIER", 29, 34], ["decreased", "OBSERVATION_MODIFIER", 35, 44], ["increasing", "OBSERVATION_MODIFIER", 50, 60], ["smaller", "OBSERVATION_MODIFIER", 113, 120], ["splanchnic", "ANATOMY", 133, 143], ["blood pooling", "OBSERVATION", 144, 157]]], ["In the Trendelenburg position, splanchnic blood pooling was less severe compared to supine position.", [["splanchnic blood", "ANATOMY", 31, 47], ["splanchnic blood", "MULTI-TISSUE_STRUCTURE", 31, 47], ["splanchnic blood pooling", "PROBLEM", 31, 55], ["Trendelenburg", "ANATOMY", 7, 20], ["splanchnic", "ANATOMY", 31, 41], ["blood pooling", "OBSERVATION", 42, 55], ["less", "OBSERVATION_MODIFIER", 60, 64], ["severe", "OBSERVATION_MODIFIER", 65, 71]]], ["Conclusions: Trendelenburg position tended to decrease venous return from inferior vena cava.", [["venous", "ANATOMY", 55, 61], ["inferior vena cava", "ANATOMY", 74, 92], ["venous", "MULTI-TISSUE_STRUCTURE", 55, 61], ["inferior vena cava", "MULTI-TISSUE_STRUCTURE", 74, 92], ["Trendelenburg position", "TREATMENT", 13, 35], ["Trendelenburg position", "OBSERVATION", 13, 35], ["venous", "ANATOMY", 55, 61], ["inferior vena cava", "ANATOMY", 74, 92]]], ["Further increases in RAP by augmenting AWP led to a decrease in all flows and signs of abolished hepatic vascular waterfall.", [["hepatic vascular", "ANATOMY", 97, 113], ["AWP", "CHEMICAL", 39, 42], ["RAP", "CHEMICAL", 21, 24], ["RAP", "GENE_OR_GENE_PRODUCT", 21, 24], ["AWP", "SIMPLE_CHEMICAL", 39, 42], ["hepatic vascular", "MULTI-TISSUE_STRUCTURE", 97, 113], ["RAP", "PROTEIN", 21, 24], ["a decrease in all flows", "PROBLEM", 50, 73], ["abolished hepatic vascular waterfall", "PROBLEM", 87, 123], ["increases", "OBSERVATION_MODIFIER", 8, 17], ["decrease", "OBSERVATION_MODIFIER", 52, 60], ["hepatic", "ANATOMY", 97, 104], ["vascular", "ANATOMY", 105, 113], ["waterfall", "OBSERVATION", 114, 123]]], ["Passive manoeuvers to assess fluid responsiveness evoke complex hemodynamic reactions which are not fully understood.", [["fluid", "ANATOMY", 29, 34], ["Passive manoeuvers", "TREATMENT", 0, 18], ["fluid responsiveness", "TEST", 29, 49], ["complex hemodynamic reactions", "PROBLEM", 56, 85]]], ["Introduction: Despite of preventive measures, the incidence of deep venous thrombosis (DVT) in ICU patients is estimated to range from 5-31%.", [["deep venous", "ANATOMY", 63, 74], ["deep venous thrombosis", "DISEASE", 63, 85], ["DVT", "DISEASE", 87, 90], ["deep venous", "MULTI-TISSUE_STRUCTURE", 63, 74], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["preventive measures", "TREATMENT", 25, 44], ["deep venous thrombosis", "PROBLEM", 63, 85], ["DVT", "PROBLEM", 87, 90], ["deep", "ANATOMY_MODIFIER", 63, 67], ["venous", "ANATOMY", 68, 74], ["thrombosis", "OBSERVATION", 75, 85], ["DVT", "OBSERVATION", 87, 90]]], ["While clinical diagnostics is unreliable, ultrasound compression test (UCT) has proven to be a highly sensitive and specific modality for the recognition of lower extremity DVT [1] .", [["lower extremity DVT", "ANATOMY", 157, 176], ["DVT", "DISEASE", 173, 176], ["clinical diagnostics", "TEST", 6, 26], ["ultrasound compression test", "TEST", 42, 69], ["lower extremity DVT", "PROBLEM", 157, 176], ["lower extremity", "ANATOMY", 157, 172], ["DVT", "OBSERVATION", 173, 176]]], ["Delegating this competence to ICU nurses can increase UCT availability and enable preventive DVT screening.", [["DVT", "DISEASE", 93, 96], ["preventive DVT screening", "TEST", 82, 106], ["DVT", "OBSERVATION", 93, 96]]], ["Therefore, we decided to conduct a clinical study to evaluate the sensitivity and specificity of UCT performed by general ICU nurse in ICU patients compared to an investigation by ICU physician certified in ultrasound.P140Methods: Prior to the study, each nurse participating in the study completed one-hour training in UCT and examined 5 patients under supervision.", [["patients", "ORGANISM", 139, 147], ["patients", "ORGANISM", 339, 347], ["patients", "SPECIES", 139, 147], ["patients", "SPECIES", 339, 347], ["a clinical study", "TEST", 33, 49], ["ultrasound", "TEST", 207, 217], ["the study", "TEST", 240, 249], ["the study", "TEST", 279, 288]]], ["Then, ICU patients without known DVT underwent UCT in the femoral and popliteal region of both lower extremities performed by trained general ICU nurse.", [["femoral", "ANATOMY", 58, 65], ["popliteal region", "ANATOMY", 70, 86], ["lower extremities", "ANATOMY", 95, 112], ["DVT", "DISEASE", 33, 36], ["patients", "ORGANISM", 10, 18], ["femoral", "MULTI-TISSUE_STRUCTURE", 58, 65], ["popliteal region", "MULTI-TISSUE_STRUCTURE", 70, 86], ["lower extremities", "ORGANISM_SUBDIVISION", 95, 112], ["patients", "SPECIES", 10, 18], ["known DVT", "PROBLEM", 27, 36], ["DVT", "OBSERVATION", 33, 36], ["femoral", "ANATOMY", 58, 65], ["popliteal", "ANATOMY", 70, 79], ["region", "ANATOMY_MODIFIER", 80, 86], ["both", "ANATOMY_MODIFIER", 90, 94], ["lower extremities", "ANATOMY", 95, 112]]], ["On the same day, the examination was repeated by an ICU physician.", [["the examination", "TEST", 17, 32]]], ["The results of the examinations of each patient were blinded to each other for both investigators until both tests were performed.", [["patient", "ORGANISM", 40, 47], ["patient", "SPECIES", 40, 47], ["the examinations", "TEST", 15, 31], ["both tests", "TEST", 104, 114]]], ["The sensitivity and specificity of the test performed by general nurse was calculated in comparison with the examination by a specialist.P140Results: A total of 80 patients were examined.", [["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 164, 172], ["The sensitivity", "TEST", 0, 15], ["the test", "TEST", 35, 43], ["the examination", "TEST", 105, 120]]], ["Both lower extremities were examined in all patients.", [["lower extremities", "ANATOMY", 5, 22], ["lower extremities", "ORGANISM_SUBDIVISION", 5, 22], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["lower extremities", "ANATOMY", 5, 22]]], ["The prevalence of DVT of 11,25% has been found.", [["DVT", "DISEASE", 18, 21], ["DVT", "PROBLEM", 18, 21], ["DVT", "OBSERVATION", 18, 21]]], ["The overall sensitivity of the examination performed by general nurse was 90.0%, the specificity 100% with negative predictive value of 98.61%, positive predictive value of 100% and accuracy of 98.77%.Conclusions:The results of our study have shown that general ICU nurses are able to perform bedside screening of DVT by compression ultrasound test with a high degree of reliability after a brief training.", [["DVT", "DISEASE", 314, 317], ["the examination", "TEST", 27, 42], ["the specificity", "TEST", 81, 96], ["accuracy", "TEST", 182, 190], ["our study", "TEST", 228, 237], ["bedside screening", "TEST", 293, 310], ["DVT", "PROBLEM", 314, 317], ["compression ultrasound test", "TEST", 321, 348], ["a brief training", "TREATMENT", 389, 405], ["DVT", "OBSERVATION", 314, 317]]], ["Methods: A Cytosorb\u00ae (Cytosorbents, New Jersey, USA) HA device was inserted within the CPB circuit in ten patients undergoing elective cardiac surgery.", [["cardiac", "ANATOMY", 135, 142], ["patients", "ORGANISM", 106, 114], ["cardiac", "ORGAN", 135, 142], ["patients", "SPECIES", 106, 114], ["A Cytosorb\u00ae (Cytosorbents", "TREATMENT", 9, 34], ["New Jersey, USA) HA device", "TREATMENT", 36, 62], ["the CPB circuit", "TREATMENT", 83, 98], ["elective cardiac surgery", "TREATMENT", 126, 150], ["CPB", "ANATOMY", 87, 90], ["cardiac", "ANATOMY", 135, 142], ["surgery", "OBSERVATION", 143, 150]]], ["One hour after CPB onset, the activity of coagulation factors (Antithrombin (AT), von Willebrand Factor (vWF), factors II, V, VIII, IX, XI, and XII) were measured before and after the device.", [["coagulation factors", "GENE_OR_GENE_PRODUCT", 42, 61], ["Antithrombin", "GENE_OR_GENE_PRODUCT", 63, 75], ["AT", "GENE_OR_GENE_PRODUCT", 77, 79], ["von Willebrand Factor", "GENE_OR_GENE_PRODUCT", 82, 103], ["vWF", "GENE_OR_GENE_PRODUCT", 105, 108], ["factors II", "GENE_OR_GENE_PRODUCT", 111, 121], ["V", "GENE_OR_GENE_PRODUCT", 123, 124], ["VIII", "GENE_OR_GENE_PRODUCT", 126, 130], ["IX", "GENE_OR_GENE_PRODUCT", 132, 134], ["XI", "GENE_OR_GENE_PRODUCT", 136, 138], ["XII", "GENE_OR_GENE_PRODUCT", 144, 147], ["coagulation factors", "PROTEIN", 42, 61], ["Antithrombin", "PROTEIN", 63, 75], ["AT", "PROTEIN", 77, 79], ["von Willebrand Factor", "PROTEIN", 82, 103], ["vWF", "PROTEIN", 105, 108], ["factors II", "PROTEIN", 111, 121], ["V", "PROTEIN", 123, 124], ["VIII", "PROTEIN", 126, 130], ["IX", "PROTEIN", 132, 134], ["XI", "PROTEIN", 136, 138], ["XII", "PROTEIN", 144, 147], ["CPB", "TREATMENT", 15, 18], ["coagulation factors", "PROBLEM", 42, 61], ["Antithrombin (AT)", "TREATMENT", 63, 80], ["the device", "TREATMENT", 180, 190], ["XII", "ANATOMY", 144, 147]]], ["Pre and post device measurements were compared using student ttest, a p value <0.05 was considered statistically significant.", [["post device measurements", "TEST", 8, 32], ["student ttest", "TEST", 53, 66], ["a p value", "TEST", 68, 77]]], ["Results: Patients' mean age was 60.6 \u00b1 21.4 years, 20% were female, the mean EuroSCORE II was 6.2 \u00b1 8.1.", [["Patients", "ORGANISM", 9, 17], ["Patients", "SPECIES", 9, 17], ["the mean EuroSCORE II", "TEST", 68, 89]]], ["Procedures were: coronary artery bypass graft (CABG) (2/10), aortic root replacement (6/10) and CABG combined with aortic valve replacement (2/10).", [["coronary artery", "ANATOMY", 17, 32], ["aortic root", "ANATOMY", 61, 72], ["aortic valve", "ANATOMY", 115, 127], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 17, 32], ["graft", "TISSUE", 40, 45], ["aortic root", "MULTI-TISSUE_STRUCTURE", 61, 72], ["aortic valve", "MULTI-TISSUE_STRUCTURE", 115, 127], ["coronary artery bypass graft", "TREATMENT", 17, 45], ["CABG", "TREATMENT", 47, 51], ["aortic root replacement", "TREATMENT", 61, 84], ["CABG", "TREATMENT", 96, 100], ["aortic valve replacement", "TREATMENT", 115, 139], ["coronary artery", "ANATOMY", 17, 32], ["bypass graft", "OBSERVATION", 33, 45], ["aortic", "ANATOMY", 61, 67], ["root replacement", "OBSERVATION", 68, 84], ["CABG", "OBSERVATION", 96, 100], ["aortic valve", "ANATOMY", 115, 127], ["replacement", "OBSERVATION", 128, 139]]], ["Mean CPB duration was 161.8 \u00b1 52.3 min.", [["Mean CPB duration", "TEST", 0, 17]]], ["Pre and post HA measurements of coagulation factors activity are presented in Fig. 1 .", [["coagulation factors", "GENE_OR_GENE_PRODUCT", 32, 51], ["coagulation factors", "PROTEIN", 32, 51], ["HA measurements", "TEST", 13, 28], ["coagulation factors activity", "PROBLEM", 32, 60]]], ["Post-device AT and FII activity was significantly lower (respectively from 70.4 to 66.6, p=0.01 and from 61.5 to 57.1, p=0.03) compared to predevice measurement.", [["FII", "GENE_OR_GENE_PRODUCT", 19, 22], ["FII", "PROTEIN", 19, 22], ["Post-device AT and FII activity", "TEST", 0, 31], ["predevice measurement", "TEST", 139, 160]]], ["There was no statistically significant difference between pre-and post-HA measurements for all other coagulation parameters Conclusions: Pre and post HA Cytosorb\u00ae measurements for coagulation factor activity were not different except for a small decrease in AT and FII activity.", [["coagulation factor", "GENE_OR_GENE_PRODUCT", 180, 198], ["FII", "GENE_OR_GENE_PRODUCT", 265, 268], ["coagulation factor", "PROTEIN", 180, 198], ["FII", "PROTEIN", 265, 268], ["statistically significant difference", "PROBLEM", 13, 49], ["-HA measurements", "TEST", 70, 86], ["all other coagulation parameters", "TEST", 91, 123], ["Pre and post HA Cytosorb\u00ae measurements", "TEST", 137, 175], ["coagulation factor activity", "TEST", 180, 207], ["a small decrease in AT", "PROBLEM", 238, 260], ["no", "UNCERTAINTY", 10, 12], ["statistically", "OBSERVATION_MODIFIER", 13, 26], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["difference", "OBSERVATION", 39, 49], ["small", "OBSERVATION_MODIFIER", 240, 245], ["decrease", "OBSERVATION", 246, 254]]], ["This might be related with intra-device consumption or adsorption.", [["intra-device consumption", "TREATMENT", 27, 51]]], ["Further analyses accounting for CPB fluid balance, the entire study population and timepoints are pending.", [["Further analyses", "TEST", 0, 16], ["CPB fluid balance", "TEST", 32, 49], ["the entire study population", "TEST", 51, 78]]], ["Introduction: The aim of this study is to evaluate changes in hemodynamics and microvascular perfusion during extracorporeal blood purification with Cytosorb in patients with septic shock requiring renal replacement therapy.", [["microvascular", "ANATOMY", 79, 92], ["extracorporeal blood", "ANATOMY", 110, 130], ["renal", "ANATOMY", 198, 203], ["Cytosorb", "CHEMICAL", 149, 157], ["septic shock", "DISEASE", 175, 187], ["microvascular", "TISSUE", 79, 92], ["blood", "ORGANISM_SUBSTANCE", 125, 130], ["Cytosorb", "SIMPLE_CHEMICAL", 149, 157], ["patients", "ORGANISM", 161, 169], ["renal", "ORGAN", 198, 203], ["patients", "SPECIES", 161, 169], ["this study", "TEST", 25, 35], ["changes in hemodynamics", "PROBLEM", 51, 74], ["microvascular perfusion", "TEST", 79, 102], ["extracorporeal blood purification", "TREATMENT", 110, 143], ["Cytosorb", "TREATMENT", 149, 157], ["septic shock", "PROBLEM", 175, 187], ["renal replacement therapy", "TREATMENT", 198, 223], ["microvascular perfusion", "OBSERVATION", 79, 102], ["septic shock", "OBSERVATION", 175, 187], ["renal", "ANATOMY", 198, 203], ["replacement", "OBSERVATION", 204, 215]]], ["Methods: Eight adult patients with septic shock requiring continuous renal replacement therapy for acute renal failure were enrolled and underwent a 24-hour treatment with the emodasorption cartridge Cytosorb.", [["renal", "ANATOMY", 69, 74], ["renal", "ANATOMY", 105, 110], ["septic shock", "DISEASE", 35, 47], ["acute renal failure", "DISEASE", 99, 118], ["patients", "ORGANISM", 21, 29], ["renal", "ORGAN", 69, 74], ["renal", "ORGAN", 105, 110], ["patients", "SPECIES", 21, 29], ["septic shock", "PROBLEM", 35, 47], ["continuous renal replacement therapy", "TREATMENT", 58, 94], ["acute renal failure", "PROBLEM", 99, 118], ["a 24-hour treatment", "TREATMENT", 147, 166], ["the emodasorption cartridge Cytosorb", "TREATMENT", 172, 208], ["septic shock", "OBSERVATION", 35, 47], ["renal", "ANATOMY", 69, 74], ["replacement", "OBSERVATION", 75, 86], ["acute", "OBSERVATION_MODIFIER", 99, 104], ["renal", "ANATOMY", 105, 110], ["failure", "OBSERVATION", 111, 118]]], ["Measurements were taken at baseline before starting Cytosorb, after 6h (t1) and 24h (t2) and included: blood gases, macrohemodynamic parameters (Picco2), vasopressor and inotropic dose, plasma levels of cytokines (interleukin [IL]-1, IL6, IL8, IL10, tumor necrosis factor alpha) and parameters of microvascular density and perfusion (sublingual sidestream dark field videomicroscopy).", [["blood", "ANATOMY", 103, 108], ["plasma", "ANATOMY", 186, 192], ["microvascular", "ANATOMY", 297, 310], ["necrosis", "DISEASE", 256, 264], ["blood", "ORGANISM_SUBSTANCE", 103, 108], ["Picco2", "SIMPLE_CHEMICAL", 145, 151], ["plasma", "ORGANISM_SUBSTANCE", 186, 192], ["interleukin [IL]-1", "GENE_OR_GENE_PRODUCT", 214, 232], ["IL6", "GENE_OR_GENE_PRODUCT", 234, 237], ["IL8", "GENE_OR_GENE_PRODUCT", 239, 242], ["IL10", "GENE_OR_GENE_PRODUCT", 244, 248], ["tumor necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 250, 277], ["microvascular", "TISSUE", 297, 310], ["cytokines", "PROTEIN", 203, 212], ["interleukin [IL]-1", "PROTEIN", 214, 232], ["IL6", "PROTEIN", 234, 237], ["IL8", "PROTEIN", 239, 242], ["IL10", "PROTEIN", 244, 248], ["tumor necrosis factor alpha", "PROTEIN", 250, 277], ["Measurements", "TEST", 0, 12], ["Cytosorb", "TREATMENT", 52, 60], ["blood gases", "TEST", 103, 114], ["macrohemodynamic parameters", "TEST", 116, 143], ["Picco2)", "TREATMENT", 145, 152], ["vasopressor", "TREATMENT", 154, 165], ["inotropic dose", "TREATMENT", 170, 184], ["plasma levels", "TEST", 186, 199], ["cytokines", "TEST", 203, 212], ["interleukin [IL]", "TEST", 214, 230], ["IL6", "PROBLEM", 234, 237], ["IL8", "TREATMENT", 239, 242], ["IL10", "TREATMENT", 244, 248], ["tumor necrosis factor alpha", "TEST", 250, 277], ["microvascular density", "TEST", 297, 318], ["perfusion", "TEST", 323, 332], ["sublingual sidestream dark field videomicroscopy", "TEST", 334, 382], ["IL10", "ANATOMY", 244, 248], ["tumor", "OBSERVATION_MODIFIER", 250, 255], ["necrosis", "OBSERVATION", 256, 264], ["microvascular density", "OBSERVATION", 297, 318]]], ["Procalcitonin was measured at baseline and after 24h of treatment.Conclusions:Results: A non-significant decrease in plasma levels of cytokines was observed over time.", [["plasma", "ANATOMY", 117, 123], ["Procalcitonin", "GENE_OR_GENE_PRODUCT", 0, 13], ["plasma", "ORGANISM_SUBSTANCE", 117, 123], ["cytokines", "PROTEIN", 134, 143], ["Procalcitonin", "TEST", 0, 13], ["treatment", "TREATMENT", 56, 65], ["A non-significant decrease in plasma levels of cytokines", "PROBLEM", 87, 143], ["decrease", "OBSERVATION_MODIFIER", 105, 113], ["cytokines", "OBSERVATION", 134, 143]]], ["Hemodynamic parameters and vasopressor requirement remained stable.", [["Hemodynamic parameters", "TEST", 0, 22], ["vasopressor requirement", "TEST", 27, 50], ["vasopressor requirement", "OBSERVATION", 27, 50], ["stable", "OBSERVATION_MODIFIER", 60, 66]]], ["The microvascular flow index increased significantly at t2, total vessel density and perfused vessel density increased at t1 and t2 ( Introduction: Objective renal replacement therapy (RRT) with the OXIRIS filter is used in sepsis septic shock with AKI, but few clinical studies compare the adsorbing effect of Oxiris filter on the inflammatory mediators to RRT.", [["microvascular", "ANATOMY", 4, 17], ["vessel", "ANATOMY", 66, 72], ["vessel", "ANATOMY", 94, 100], ["renal", "ANATOMY", 158, 163], ["sepsis", "DISEASE", 224, 230], ["septic shock", "DISEASE", 231, 243], ["AKI", "DISEASE", 249, 252], ["microvascular", "MULTI-TISSUE_STRUCTURE", 4, 17], ["vessel", "MULTI-TISSUE_STRUCTURE", 66, 72], ["vessel", "MULTI-TISSUE_STRUCTURE", 94, 100], ["renal", "ORGAN", 158, 163], ["Oxiris", "SIMPLE_CHEMICAL", 311, 317], ["inflammatory mediators", "PROTEIN", 332, 354], ["The microvascular flow index", "TEST", 0, 28], ["total vessel density and perfused vessel density", "PROBLEM", 60, 108], ["Objective renal replacement therapy", "TREATMENT", 148, 183], ["RRT", "TREATMENT", 185, 188], ["the OXIRIS filter", "TREATMENT", 195, 212], ["sepsis septic shock", "PROBLEM", 224, 243], ["AKI", "PROBLEM", 249, 252], ["clinical studies", "TEST", 262, 278], ["Oxiris filter", "TREATMENT", 311, 324], ["the inflammatory mediators", "TREATMENT", 328, 354], ["microvascular", "ANATOMY", 4, 17], ["flow index", "OBSERVATION", 18, 28], ["total", "OBSERVATION_MODIFIER", 60, 65], ["vessel", "ANATOMY", 66, 72], ["density", "OBSERVATION", 73, 80], ["perfused", "ANATOMY_MODIFIER", 85, 93], ["vessel", "ANATOMY", 94, 100], ["density", "OBSERVATION_MODIFIER", 101, 108], ["increased", "OBSERVATION_MODIFIER", 109, 118], ["renal", "ANATOMY", 158, 163], ["replacement", "OBSERVATION", 164, 175], ["sepsis", "OBSERVATION_MODIFIER", 224, 230], ["septic shock", "OBSERVATION", 231, 243], ["AKI", "OBSERVATION", 249, 252], ["Oxiris filter", "OBSERVATION", 311, 324], ["inflammatory", "OBSERVATION_MODIFIER", 332, 344]]], ["The aim of this study is 1-to confirm whether oxiris decreases cytokines and procalcitonin in sepsis septic shock.2-This effect is superior to RRT.3-This translates in a better cardio renal response.", [["cardio renal", "ANATOMY", 177, 189], ["oxiris", "CHEMICAL", 46, 52], ["sepsis", "DISEASE", 94, 100], ["septic shock", "DISEASE", 101, 113], ["oxiris", "SIMPLE_CHEMICAL", 46, 52], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 77, 90], ["renal", "ORGAN", 184, 189], ["cytokines", "PROTEIN", 63, 72], ["procalcitonin", "PROTEIN", 77, 90], ["this study", "TEST", 11, 21], ["oxiris decreases cytokines", "PROBLEM", 46, 72], ["procalcitonin", "TEST", 77, 90], ["sepsis septic shock", "PROBLEM", 94, 113], ["sepsis", "OBSERVATION_MODIFIER", 94, 100], ["septic shock", "OBSERVATION", 101, 113], ["renal", "ANATOMY", 184, 189]]], ["Methods: A coohort study and a propensity-matched analysis included 73 patients admitted to three Intensive Care (Aurelia Hospital, European Hospital, Tor Vergata -Rome) with a diagnosis of septic shock.50 patients were submitted to RRT with oxiris filter and 23 patients to RRT.Il 6, Procalcitonin, the cardiorenal indices and SOFA score were compared before (T0) and at the end of the treatments (T1).", [["septic shock", "DISEASE", 190, 202], ["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 206, 214], ["patients", "ORGANISM", 263, 271], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 206, 214], ["patients", "SPECIES", 263, 271], ["A coohort study", "TEST", 9, 24], ["septic shock", "PROBLEM", 190, 202], ["oxiris filter", "TREATMENT", 242, 255], ["RRT.Il", "TREATMENT", 275, 281], ["Procalcitonin", "TREATMENT", 285, 298], ["the cardiorenal indices", "TEST", 300, 323], ["SOFA score", "TEST", 328, 338], ["septic shock", "OBSERVATION", 190, 202], ["cardiorenal", "ANATOMY", 304, 315], ["SOFA score", "OBSERVATION", 328, 338]]], ["Results: Of 50 patients submitted to RRT with the oXiris filter 32 could be matched to 22 septic patients who received RRT.", [["septic", "DISEASE", 90, 96], ["patients", "ORGANISM", 15, 23], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 97, 105], ["RRT", "TREATMENT", 37, 40], ["the oXiris filter", "TREATMENT", 46, 63], ["RRT", "TREATMENT", 119, 122]]], ["IL6 and Procalcitonin decreased in the Oxiris group (p< 0.01) but not in the RRT group.-MAP increased (p< 0.01) and noradrenaline dosage decreased in oxiris group (p< 0.01), but non in RRT group.", [["noradrenaline", "CHEMICAL", 116, 129], ["noradrenaline", "CHEMICAL", 116, 129], ["IL6", "GENE_OR_GENE_PRODUCT", 0, 3], ["Procalcitonin", "GENE_OR_GENE_PRODUCT", 8, 21], ["-MAP", "GENE_OR_GENE_PRODUCT", 87, 91], ["noradrenaline", "SIMPLE_CHEMICAL", 116, 129], ["oxiris", "SIMPLE_CHEMICAL", 150, 156], ["IL6", "PROTEIN", 0, 3], ["IL6", "TEST", 0, 3], ["Procalcitonin", "TEST", 8, 21], ["MAP", "TEST", 88, 91], ["noradrenaline dosage", "TREATMENT", 116, 136]]], ["Also PaO2/FIO2 ratio, diuresis, SOFA improved only in the in the oxiris group (p<0.05).", [["PaO2", "SIMPLE_CHEMICAL", 5, 9], ["PaO2", "TEST", 5, 9], ["FIO2 ratio", "TEST", 10, 20], ["diuresis", "TREATMENT", 22, 30], ["SOFA", "TEST", 32, 36]]], ["Conclusions: In sepsis/septic shock patients with AKI, IL6 and procalcitonin decrease more in the oXirs group then in the RRT group.This is associated with an improvement of the cardio -renal function and the clinical condition.The study confirms that RRT with oXiris filter may be useful in sepsis/septic shock when other convective/diffusive techinques fail.", [["renal", "ANATOMY", 186, 191], ["sepsis", "DISEASE", 16, 22], ["septic shock", "DISEASE", 23, 35], ["AKI", "DISEASE", 50, 53], ["sepsis", "DISEASE", 292, 298], ["septic shock", "DISEASE", 299, 311], ["patients", "ORGANISM", 36, 44], ["IL6", "GENE_OR_GENE_PRODUCT", 55, 58], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 63, 76], ["oXirs", "CANCER", 98, 103], ["renal", "ORGAN", 186, 191], ["IL6", "PROTEIN", 55, 58], ["patients", "SPECIES", 36, 44], ["sepsis", "PROBLEM", 16, 22], ["septic shock", "PROBLEM", 23, 35], ["AKI", "PROBLEM", 50, 53], ["IL6", "TREATMENT", 55, 58], ["procalcitonin decrease", "PROBLEM", 63, 85], ["The study", "TEST", 228, 237], ["RRT with oXiris filter", "TREATMENT", 252, 274], ["sepsis", "PROBLEM", 292, 298], ["septic shock", "PROBLEM", 299, 311], ["other convective/diffusive techinques fail", "PROBLEM", 317, 359], ["sepsis", "OBSERVATION", 16, 22], ["septic shock", "OBSERVATION", 23, 35], ["AKI", "OBSERVATION", 50, 53], ["improvement", "OBSERVATION_MODIFIER", 159, 170], ["cardio", "ANATOMY", 178, 184], ["renal", "ANATOMY", 186, 191], ["function", "OBSERVATION", 192, 200], ["sepsis", "OBSERVATION", 292, 298], ["septic shock", "OBSERVATION", 299, 311]]], ["Introduction: ADVOS (Hepa Wash GmbH, Munich, Germany) is a recently developed CE-certified albumin-based hemodialysis procedure for the treatment of critically ill patients.", [["critically ill", "DISEASE", 149, 163], ["albumin", "SIMPLE_CHEMICAL", 91, 98], ["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 164, 172], ["CE", "TEST", 78, 80], ["certified albumin", "TREATMENT", 81, 98], ["hemodialysis procedure", "TREATMENT", 105, 127]]], ["In addition to the removal of water-soluble and albumin-bound substances, acid-base imbalances can be corrected thanks to an automatically regulated dialysate pH ranging 7.2 to 9.5.", [["albumin", "SIMPLE_CHEMICAL", 48, 55], ["acid", "SIMPLE_CHEMICAL", 74, 78], ["the removal of water-soluble and albumin-bound substances", "TREATMENT", 15, 72], ["acid-base imbalances", "PROBLEM", 74, 94], ["dialysate pH", "TEST", 149, 161]]], ["Methods: Patients treated with the ADVOS procedure between in the Department of Intensive Care Medicine of the University Medical Center Hamburg-Eppendorf were retrospectively analyzed.", [["Patients", "ORGANISM", 9, 17], ["Patients", "SPECIES", 9, 17], ["the ADVOS procedure", "TREATMENT", 31, 50]]], ["Overall 102 treatments in 34 critically ill patients (Mean SOFA Score 16) were evaluated.", [["critically ill", "DISEASE", 29, 43], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["Mean SOFA Score", "TEST", 54, 69]]], ["Additionally, subgroup analysis for hyperbilirubinemia, respiratory acidosis and non-respiratory acidosis were conducted.", [["respiratory", "ANATOMY", 56, 67], ["hyperbilirubinemia", "DISEASE", 36, 54], ["respiratory acidosis", "DISEASE", 56, 76], ["acidosis", "DISEASE", 97, 105], ["subgroup analysis", "TEST", 14, 31], ["hyperbilirubinemia", "PROBLEM", 36, 54], ["respiratory acidosis", "PROBLEM", 56, 76], ["non-respiratory acidosis", "PROBLEM", 81, 105], ["hyperbilirubinemia", "OBSERVATION", 36, 54], ["respiratory acidosis", "OBSERVATION", 56, 76], ["non-respiratory acidosis", "OBSERVATION", 81, 105]]], ["Results: Severe hyperbilirubinemia (>6 mg/dl) was present in 60 treatments, while 26 and 14 treatments were performed to treat respiratory (PaCO2>45 mmHg) and non-respiratory (PaCO2<45 mmHg) acidosis (pH<7.35), respectively.", [["respiratory", "ANATOMY", 127, 138], ["hyperbilirubinemia", "DISEASE", 16, 34], ["acidosis", "DISEASE", 191, 199], ["Severe hyperbilirubinemia", "PROBLEM", 9, 34], ["respiratory", "TEST", 127, 138], ["PaCO2", "TEST", 140, 145], ["non-respiratory", "TEST", 159, 174], ["PaCO2", "TEST", 176, 181], ["acidosis", "TEST", 191, 199], ["pH", "TEST", 201, 203], ["Severe", "OBSERVATION_MODIFIER", 9, 15], ["hyperbilirubinemia", "OBSERVATION", 16, 34]]], ["Mean treatment duration was 16 h.", [["Mean treatment duration", "TREATMENT", 0, 23]]], ["ADVOS procedure was able to correct acidosis and reduce bilirubin, BUN and creatinine levels significantly.", [["acidosis", "DISEASE", 36, 44], ["bilirubin", "CHEMICAL", 56, 65], ["creatinine", "CHEMICAL", 75, 85], ["bilirubin", "CHEMICAL", 56, 65], ["creatinine", "CHEMICAL", 75, 85], ["bilirubin", "SIMPLE_CHEMICAL", 56, 65], ["BUN", "SIMPLE_CHEMICAL", 67, 70], ["creatinine", "SIMPLE_CHEMICAL", 75, 85], ["ADVOS procedure", "TREATMENT", 0, 15], ["acidosis", "PROBLEM", 36, 44], ["bilirubin", "TEST", 56, 65], ["BUN", "TEST", 67, 70], ["creatinine levels", "TEST", 75, 92], ["acidosis", "OBSERVATION", 36, 44]]], ["The subgroup analysis shows an average bilirubin reduction of 21% per ADVOS multi treatment in the hyperbilirubinemia group (15.24mg/dL vs 11.77mg/dL, p<0.05).", [["bilirubin", "CHEMICAL", 39, 48], ["hyperbilirubinemia", "DISEASE", 99, 117], ["bilirubin", "CHEMICAL", 39, 48], ["bilirubin", "SIMPLE_CHEMICAL", 39, 48], ["The subgroup analysis", "TEST", 0, 21], ["an average bilirubin reduction", "TEST", 28, 58], ["multi treatment", "TREATMENT", 76, 91], ["the hyperbilirubinemia", "PROBLEM", 95, 117], ["p", "TEST", 151, 152], ["average", "OBSERVATION_MODIFIER", 31, 38], ["bilirubin", "OBSERVATION_MODIFIER", 39, 48], ["reduction", "OBSERVATION_MODIFIER", 49, 58], ["hyperbilirubinemia", "OBSERVATION", 99, 117]]], ["Moreover, pH (7.23 vs. 7.35, p<0.001) and PaCO2 (65.88 vs. 53.61 mmHg, p<0.001) were corrected in the respiratory acidosis group, while in the non-respiratory acidosis group, an improvement in pH (7.19 vs. 7.37, p<0.001), HCO3 (15.21 vs. 20.48, p=0.002) and base excess (-12.69 vs. -5.10, p=0.004) could be observed.", [["respiratory", "ANATOMY", 102, 113], ["respiratory acidosis", "DISEASE", 102, 122], ["acidosis", "DISEASE", 159, 167], ["HCO3", "CHEMICAL", 222, 226], ["HCO3", "SIMPLE_CHEMICAL", 222, 226], ["pH", "TEST", 10, 12], ["p", "TEST", 29, 30], ["PaCO2", "TEST", 42, 47], ["mmHg", "TEST", 65, 69], ["p", "TEST", 71, 72], ["the respiratory acidosis group", "PROBLEM", 98, 128], ["the non-respiratory acidosis group", "PROBLEM", 139, 173], ["pH", "TEST", 193, 195], ["p", "TEST", 212, 213], ["HCO3", "TEST", 222, 226], ["p", "TEST", 245, 246], ["base excess", "TEST", 258, 269], ["respiratory", "ANATOMY", 102, 113], ["acidosis", "OBSERVATION", 114, 122], ["non-respiratory acidosis", "OBSERVATION", 143, 167], ["improvement", "OBSERVATION_MODIFIER", 178, 189]]], ["There were no treatment-related adverse events during therapy.", [["treatment", "TREATMENT", 14, 23], ["related adverse events", "PROBLEM", 24, 46], ["therapy", "TREATMENT", 54, 61], ["no", "UNCERTAINTY", 11, 13]]], ["Conclusions: ADVOS is a safe and effective hemodialysis procedure, which is able to remove water soluble and protein bound markers and correct severe acidosis in critically ill patients.P150Score for timely prescribing (STOP) renal replacement therapy in intensive care unit -preliminary study of a mneumonic approach Introduction: The moment of initiation of renal replacement therapy (RRT) in critically ill patients and a reason for debate, without having objective criteria that indicate it.", [["renal", "ANATOMY", 226, 231], ["renal", "ANATOMY", 360, 365], ["acidosis", "DISEASE", 150, 158], ["critically ill", "DISEASE", 162, 176], ["critically ill", "DISEASE", 395, 409], ["patients", "ORGANISM", 177, 185], ["renal", "ORGAN", 226, 231], ["renal", "ORGAN", 360, 365], ["patients", "ORGANISM", 410, 418], ["protein bound markers", "PROTEIN", 109, 130], ["patients", "SPECIES", 177, 185], ["patients", "SPECIES", 410, 418], ["effective hemodialysis procedure", "TREATMENT", 33, 65], ["water soluble", "TREATMENT", 91, 104], ["protein bound markers", "TEST", 109, 130], ["severe acidosis", "PROBLEM", 143, 158], ["renal replacement therapy", "TREATMENT", 226, 251], ["preliminary study", "TEST", 276, 293], ["a mneumonic approach", "TREATMENT", 297, 317], ["renal replacement therapy", "TREATMENT", 360, 385], ["RRT", "TREATMENT", 387, 390], ["severe", "OBSERVATION_MODIFIER", 143, 149], ["acidosis", "OBSERVATION", 150, 158], ["critically ill", "OBSERVATION_MODIFIER", 162, 176], ["renal", "ANATOMY", 226, 231], ["replacement", "OBSERVATION", 232, 243], ["renal", "ANATOMY", 360, 365], ["replacement", "OBSERVATION", 366, 377]]], ["The objective of this study was to propose a score to help identify the ideal time for the initiation of RRT, and if there is correlation between this score and Intensive Care Unit length of stay and mortality.", [["this study", "TEST", 17, 27], ["RRT", "TREATMENT", 105, 108]]], ["Methods: patients admitted to the Intensive Care Unit, > 18-yearsold, to whom RRT were indicated by the intensivist.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17]]], ["The study protocol was approved by the Hospital das For\u00e7as Armadas Ethical Committe, and written informed consent was obtained from all patients.", [["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144], ["The study protocol", "TEST", 0, 18]]], ["The STOP was assigned according to the presence or not of each of the items (Fig. 1 ).", [["STOP", "DNA", 4, 8]]], ["Results: 80 patients admitted to ICU in the period, 2 excluded for limitation of therapeutic efforts.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["78 were admitted to the study, with the mean age of 75.2 years; 64,1% males (n=50).", [["the study", "TEST", 20, 29]]], ["Distribution among the groups: A1 (n=1, 1.2%), A2 (31, 39.7%), A3 (5, 6.4%), B1 (6, 7.6%), B2 (35, 44.8%) e B3 (no patients).", [["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["A1", "TEST", 31, 33], ["A2", "TEST", 47, 49], ["A3", "TEST", 63, 65], ["B1", "TEST", 77, 79], ["B2", "TEST", 91, 93], ["A1", "ANATOMY", 31, 33]]], ["There were statistically significant correlation between group change and mortality (p 0.02), and between the STOP and nephrologist agreement (p 0.01).", [["significant", "OBSERVATION_MODIFIER", 25, 36]]], ["The group change was correlated to increased mortality, in the study population.", [["increased mortality", "PROBLEM", 35, 54], ["the study population", "TEST", 59, 79], ["increased", "OBSERVATION_MODIFIER", 35, 44], ["mortality", "OBSERVATION", 45, 54]]], ["The significance of STOP as a tool in determining the moment of initiation of renal replacement therapy remains a work in progress.", [["renal", "ANATOMY", 78, 83], ["STOP", "GENE_OR_GENE_PRODUCT", 20, 24], ["renal", "ORGAN", 78, 83], ["STOP", "DNA", 20, 24], ["renal replacement therapy", "TREATMENT", 78, 103], ["renal", "ANATOMY", 78, 83], ["replacement", "OBSERVATION", 84, 95]]], ["Introduction: Liver transplant (LT) in patients with renal dysfunction presents intraoperative challenges and portends postoperative morbidity.", [["Liver", "ANATOMY", 14, 19], ["renal", "ANATOMY", 53, 58], ["renal dysfunction", "DISEASE", 53, 70], ["Liver", "ORGAN", 14, 19], ["patients", "ORGANISM", 39, 47], ["renal", "ORGAN", 53, 58], ["patients", "SPECIES", 39, 47], ["Liver transplant (LT)", "TREATMENT", 14, 35], ["renal dysfunction", "PROBLEM", 53, 70], ["intraoperative challenges", "TREATMENT", 80, 105], ["portends postoperative morbidity", "TREATMENT", 110, 142], ["Liver", "ANATOMY", 14, 19], ["transplant", "OBSERVATION", 20, 30], ["renal", "ANATOMY", 53, 58], ["dysfunction", "OBSERVATION", 59, 70]]], ["Continuous renal replacement therapy (CRRT) is increasingly used for intraoperative support; however, there is a paucity of data to support this practice.", [["renal", "ANATOMY", 11, 16], ["renal", "ORGAN", 11, 16], ["Continuous renal replacement therapy", "TREATMENT", 0, 36], ["CRRT", "TREATMENT", 38, 42], ["intraoperative support", "TREATMENT", 69, 91], ["this practice", "TREATMENT", 140, 153], ["renal", "ANATOMY", 11, 16], ["replacement", "OBSERVATION", 17, 28]]], ["Methods: Pilot randomized open-label controlled trial in adults receiving cadaveric LT with a Modification of End-Stage Liver Disease (MELD) score >=25 and preoperative acute kidney injury (KDIGO stage 1) and/or estimated glomerular filtration rate <60 mL/min/1.73m2.", [["Liver", "ANATOMY", 120, 125], ["kidney", "ANATOMY", 175, 181], ["glomerular", "ANATOMY", 222, 232], ["Modification of End-Stage Liver Disease", "DISEASE", 94, 133], ["acute kidney injury", "DISEASE", 169, 188], ["adults", "ORGANISM", 57, 63], ["Liver", "ORGAN", 120, 125], ["kidney", "ORGAN", 175, 181], ["glomerular", "TISSUE", 222, 232], ["Pilot randomized open", "TREATMENT", 9, 30], ["cadaveric LT", "TREATMENT", 74, 86], ["a Modification", "TREATMENT", 92, 106], ["End-Stage Liver Disease", "PROBLEM", 110, 133], ["MELD) score", "TEST", 135, 146], ["preoperative acute kidney injury", "PROBLEM", 156, 188], ["KDIGO stage", "TEST", 190, 201], ["estimated glomerular filtration rate", "TEST", 212, 248], ["Liver", "ANATOMY", 120, 125], ["Disease", "OBSERVATION", 126, 133], ["acute", "OBSERVATION_MODIFIER", 169, 174], ["kidney", "ANATOMY", 175, 181], ["injury", "OBSERVATION", 182, 188], ["glomerular", "ANATOMY", 222, 232]]], ["Patients were randomized to intraoperative CRRT (iCRRT) or standard of care.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["intraoperative CRRT", "TREATMENT", 28, 47], ["iCRRT", "TREATMENT", 49, 54], ["standard of care", "TREATMENT", 59, 75]]], ["Primary endpoints were feasibility and adverse events.", [["adverse events", "PROBLEM", 39, 53]]], ["Secondary endpoints were changes in intraoperative fluid balance, complications, and hospital mortality.", [["fluid", "ANATOMY", 51, 56], ["Secondary endpoints", "PROBLEM", 0, 19], ["intraoperative fluid balance", "TEST", 36, 64], ["complications", "PROBLEM", 66, 79], ["fluid balance", "OBSERVATION", 51, 64]]], ["Analysis was intention-to-treat.", [["Analysis", "TEST", 0, 8]]], ["Results: Sixty patients were enrolled, 32 (53%) were randomized (17 to iCRRT; 15 to control).", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["iCRRT", "TEST", 71, 76]]], ["Mean (SD) was age 49 (13) years, MELD was 36 (8), 75% (n=24) had cirrhosis; 63% (n=20) received preoperative RRT; and 66% (n=21) were transplanted from ICU.", [["cirrhosis", "DISEASE", 65, 74], ["Mean", "TEST", 0, 4], ["MELD", "TEST", 33, 37], ["cirrhosis", "PROBLEM", 65, 74], ["preoperative RRT", "TEST", 96, 112], ["cirrhosis", "OBSERVATION", 65, 74]]], ["One patient allocated to iCRRT did not receive LT.", [["patient", "ORGANISM", 4, 11], ["LT", "PROTEIN", 47, 49], ["patient", "SPECIES", 4, 11], ["LT", "TREATMENT", 47, 49]]], ["Seven (41%) allocated to control crossed over intraoperatively iCRRT ( (137) min, with only 3 interruptions (all due to access). iCRRT fluid removal was 2.8L (range 0-14.5).", [["iCRRT fluid removal", "TREATMENT", 129, 148]]], ["Fluid balance was 5.3L (2.9) for iCRRT vs. 4.3L (6.1) for control (p=0.57).", [["Fluid balance", "TEST", 0, 13], ["iCRRT", "TEST", 33, 38]]], ["Postoperative CRRT was similar (77% vs. 50%, p=0.25).", [["Postoperative CRRT", "TREATMENT", 0, 18], ["p", "TEST", 45, 46]]], ["There were no differences in reexploration (p=0.36), mechanical ventilation time (p=0.87), reintubation (p=0.18), sepsis (p=0.56), or mortality (p=0.16).", [["sepsis", "DISEASE", 114, 120], ["reexploration", "TEST", 29, 42], ["mechanical ventilation time", "TREATMENT", 53, 80], ["reintubation", "TREATMENT", 91, 103], ["sepsis", "PROBLEM", 114, 120], ["no", "UNCERTAINTY", 11, 13], ["reexploration", "OBSERVATION", 29, 42]]], ["Conclusions: In this pilot trial of high acuity LT patients, iCRRT was feasible and safe.", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["iCRRT", "TREATMENT", 61, 66]]], ["These data will inform the design of a large trial to define the role of iCRRT during LT.ReferencesClinicalTrials.gov: NCT01575015.P152The uptake of citrate anticoagulation for continuous renal replacement therapy in intensive care units across the Introduction: The purpose of this descriptive study is to report the trend of citrate anticoagulation uptake, used for continuous renal replacement therapy (CRRT), in intensive care units (ICUs) across the United Kingdom (UK).", [["renal", "ANATOMY", 188, 193], ["renal", "ANATOMY", 379, 384], ["P152", "CHEMICAL", 131, 135], ["citrate", "CHEMICAL", 149, 156], ["citrate", "CHEMICAL", 327, 334], ["citrate", "CHEMICAL", 149, 156], ["citrate", "CHEMICAL", 327, 334], ["iCRRT", "SIMPLE_CHEMICAL", 73, 78], ["P152", "GENE_OR_GENE_PRODUCT", 131, 135], ["citrate", "SIMPLE_CHEMICAL", 149, 156], ["renal", "ORGAN", 188, 193], ["citrate", "SIMPLE_CHEMICAL", 327, 334], ["renal", "ORGAN", 379, 384], ["LT", "PROTEIN", 86, 88], ["P152", "PROTEIN", 131, 135], ["citrate anticoagulation", "TREATMENT", 149, 172], ["continuous renal replacement therapy", "TREATMENT", 177, 213], ["this descriptive study", "TEST", 278, 300], ["citrate anticoagulation uptake", "TREATMENT", 327, 357], ["continuous renal replacement therapy", "TREATMENT", 368, 404], ["CRRT", "TREATMENT", 406, 410], ["renal", "ANATOMY", 188, 193], ["replacement", "OBSERVATION", 194, 205], ["renal", "ANATOMY", 379, 384], ["replacement", "OBSERVATION", 385, 396]]], ["Citrate anticoagulation has been used in the UK since 2008, but its uptake since then is unknown [1] .", [["Citrate", "CHEMICAL", 0, 7], ["Citrate", "CHEMICAL", 0, 7], ["Citrate", "SIMPLE_CHEMICAL", 0, 7], ["Citrate anticoagulation", "TREATMENT", 0, 23]]], ["Methods: A survey questionnaire targeted pharmacists working in UK adult ICUs providing CRRT.", [["CRRT", "TREATMENT", 88, 92]]], ["Basic demographic data, ICU specifications, the citrate system in use and implementation details were sought.", [["citrate", "CHEMICAL", 48, 55], ["citrate", "CHEMICAL", 48, 55], ["citrate", "SIMPLE_CHEMICAL", 48, 55], ["the citrate system", "TREATMENT", 44, 62]]], ["A descriptive statistical analysis ensued.", [["A descriptive statistical analysis", "TEST", 0, 34]]], ["Results: 70 responses were received of which 67 were analysed after duplication removal.", [["duplication removal", "TREATMENT", 68, 87]]], ["45 trusts, encompassing a total 67 units, in the UK confirmed use of citrate anticoagulation for CRRT.", [["citrate", "CHEMICAL", 69, 76], ["citrate", "CHEMICAL", 69, 76], ["citrate", "SIMPLE_CHEMICAL", 69, 76], ["citrate anticoagulation", "TREATMENT", 69, 92], ["CRRT", "TREATMENT", 97, 101]]], ["Units reported a mean of 71 days to implement a citrate system (range 0 to 645 days).", [["citrate", "CHEMICAL", 48, 55], ["citrate", "CHEMICAL", 48, 55], ["citrate", "SIMPLE_CHEMICAL", 48, 55], ["a citrate system", "TREATMENT", 46, 62]]], ["Prismaflex\u00ae (Baxter) and Multifiltrate (Fresenius) were reported as the most commonly used citrate systems; 32 (47.8%) and 28 (41.8%) units respectively.P152Conclusions: There are 279 ICUs in the UK [2] .", [["Prismaflex\u00ae", "CHEMICAL", 0, 11], ["citrate", "CHEMICAL", 91, 98], ["citrate", "CHEMICAL", 91, 98], ["Prismaflex\u00ae", "SIMPLE_CHEMICAL", 0, 11], ["Multifiltrate", "SIMPLE_CHEMICAL", 25, 38], ["citrate", "SIMPLE_CHEMICAL", 91, 98], ["Prismaflex\u00ae (Baxter)", "TREATMENT", 0, 20], ["Multifiltrate (Fresenius", "TREATMENT", 25, 49], ["citrate systems", "TEST", 91, 106]]], ["We conclude that a minimum of 67 units (24%) use citrate anticoagulation for CRRT in UK critical care centres.", [["citrate", "CHEMICAL", 49, 56], ["citrate", "CHEMICAL", 49, 56], ["citrate", "SIMPLE_CHEMICAL", 49, 56], ["citrate anticoagulation", "TREATMENT", 49, 72], ["CRRT", "TREATMENT", 77, 81]]], ["Citrate systems of anticoagulation are becoming an increasing popular choice for regional anticoagulation, falling in line with international guidance [3] .", [["Citrate", "CHEMICAL", 0, 7], ["Citrate", "CHEMICAL", 0, 7], ["Citrate", "SIMPLE_CHEMICAL", 0, 7], ["Citrate systems", "TREATMENT", 0, 15], ["anticoagulation", "TREATMENT", 19, 34], ["regional anticoagulation", "TREATMENT", 81, 105]]], ["Introduction: Patients requiring renal replacement therapy (RRT) whilst on significant doses of vasoactive medications have often been deemed unsuitable to undergo ultrafiltration (UF).", [["renal", "ANATOMY", 33, 38], ["Patients", "ORGANISM", 14, 22], ["renal", "ORGAN", 33, 38], ["Patients", "SPECIES", 14, 22], ["renal replacement therapy", "TREATMENT", 33, 58], ["RRT", "TREATMENT", 60, 63], ["vasoactive medications", "TREATMENT", 96, 118], ["ultrafiltration (UF", "TREATMENT", 164, 183], ["renal", "ANATOMY", 33, 38], ["replacement", "OBSERVATION", 39, 50]]], ["However with better understanding of the pathophysiology of renal injury [1] in intensive care patients we hypothesise that vasopressor/inotrope requirement will not significantly increase with UF or with a more negative fluid balance (FB).", [["renal", "ANATOMY", 60, 65], ["fluid", "ANATOMY", 221, 226], ["renal injury", "DISEASE", 60, 72], ["renal", "ORGAN", 60, 65], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["renal injury", "PROBLEM", 60, 72], ["vasopressor/inotrope requirement", "TREATMENT", 124, 156], ["UF", "TREATMENT", 194, 196], ["renal", "ANATOMY", 60, 65], ["injury", "OBSERVATION", 66, 72]]], ["Methods: Data was retrospectively collected in a general ICU/HDU of adult patients requiring acute RRT for acute kidney injury.", [["kidney", "ANATOMY", 113, 119], ["acute kidney injury", "DISEASE", 107, 126], ["patients", "ORGANISM", 74, 82], ["kidney", "ORGAN", 113, 119], ["patients", "SPECIES", 74, 82], ["acute RRT", "TREATMENT", 93, 102], ["acute kidney injury", "PROBLEM", 107, 126], ["acute", "OBSERVATION_MODIFIER", 107, 112], ["kidney", "ANATOMY", 113, 119], ["injury", "OBSERVATION", 120, 126]]], ["Patients on chronic dialysis were excluded.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["chronic dialysis", "TREATMENT", 12, 28], ["chronic", "OBSERVATION_MODIFIER", 12, 19], ["dialysis", "OBSERVATION", 20, 28]]], ["Percentage change in vasopressor index and mean arterial pressure were combined to form the Combined Percentage Change (CPC) which we used as an index of patient stability.", [["arterial", "ANATOMY", 48, 56], ["arterial", "MULTI-TISSUE_STRUCTURE", 48, 56], ["patient", "ORGANISM", 154, 161], ["patient", "SPECIES", 154, 161], ["Percentage change", "PROBLEM", 0, 17], ["vasopressor index", "TEST", 21, 38], ["mean arterial pressure", "TEST", 43, 65], ["the Combined Percentage Change (CPC)", "TREATMENT", 88, 124], ["vasopressor index", "OBSERVATION", 21, 38], ["mean arterial pressure", "OBSERVATION", 43, 65], ["stability", "OBSERVATION_MODIFIER", 162, 171]]], ["Results: 38 patients were assessed undergoing a total of 206 RRT sessions.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["a total of 206 RRT sessions", "TREATMENT", 46, 73]]], ["Mean FB for the 24 hours from start of RRT was +651mls (range -2317 to +14850mls).", [["FB", "MULTI-TISSUE_STRUCTURE", 5, 7], ["Mean FB", "TEST", 0, 7], ["RRT", "TEST", 39, 42]]], ["Using a model to correct for significant covariates and plotting 24 hour FB against CPC we found no significant effect of FB on stability p=0.98 (Fig. 1 ).", [["significant covariates", "PROBLEM", 29, 51], ["CPC", "TEST", 84, 87], ["no", "UNCERTAINTY", 97, 99], ["significant", "OBSERVATION_MODIFIER", 100, 111]]], ["Mean UF volume was 880mls (range 0-3009mls).", [["Mean UF volume", "TEST", 0, 14]]], ["There was a non linear relationship between UF and stability with moderate volumes improving but larger volumes worsening stability (Fig. 2 ).", [["moderate volumes", "PROBLEM", 66, 82], ["larger volumes worsening stability", "PROBLEM", 97, 131], ["non linear", "OBSERVATION_MODIFIER", 12, 22], ["stability", "OBSERVATION_MODIFIER", 51, 60], ["moderate", "OBSERVATION_MODIFIER", 66, 74], ["volumes", "OBSERVATION_MODIFIER", 75, 82], ["improving", "OBSERVATION_MODIFIER", 83, 92], ["larger", "OBSERVATION_MODIFIER", 97, 103], ["volumes", "OBSERVATION_MODIFIER", 104, 111], ["worsening", "OBSERVATION_MODIFIER", 112, 121], ["stability", "OBSERVATION_MODIFIER", 122, 131]]], ["Conclusions: Fluid balance has no effect on cardiovascular stability during RRT in our cohort but there may be a varying effect of UF depending on volume.", [["cardiovascular", "ANATOMY", 44, 58], ["cardiovascular", "ANATOMICAL_SYSTEM", 44, 58], ["Fluid balance", "TEST", 13, 26], ["RRT", "TREATMENT", 76, 79], ["UF", "TREATMENT", 131, 133], ["volume", "TEST", 147, 153], ["Fluid balance", "OBSERVATION", 13, 26], ["no", "UNCERTAINTY", 31, 33], ["effect", "OBSERVATION_MODIFIER", 34, 40], ["stability", "OBSERVATION", 59, 68], ["varying", "OBSERVATION_MODIFIER", 113, 120], ["effect", "OBSERVATION_MODIFIER", 121, 127]]], ["Introduction: Exposure of blood to a foreign surface such as a continuous renal replacement therapy (CRRT) filter could lead to activation of platelets (plt) and fibrinogen (fib) trapping.", [["blood", "ANATOMY", 26, 31], ["surface", "ANATOMY", 45, 52], ["renal", "ANATOMY", 74, 79], ["platelets", "ANATOMY", 142, 151], ["blood", "ORGANISM_SUBSTANCE", 26, 31], ["renal", "ORGAN", 74, 79], ["platelets", "CELL", 142, 151], ["plt", "GENE_OR_GENE_PRODUCT", 153, 156], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 162, 172], ["fib", "GENE_OR_GENE_PRODUCT", 174, 177], ["platelets", "CELL_TYPE", 142, 151], ["plt", "PROTEIN", 153, 156], ["fibrinogen", "PROTEIN", 162, 172], ["fib", "PROTEIN", 174, 177], ["a foreign surface", "TREATMENT", 35, 52], ["a continuous renal replacement therapy", "TREATMENT", 61, 99], ["CRRT) filter", "TREATMENT", 101, 113], ["platelets", "TEST", 142, 151], ["plt", "TEST", 153, 156], ["fibrinogen (fib) trapping", "PROBLEM", 162, 187], ["renal", "ANATOMY", 74, 79], ["replacement", "OBSERVATION", 80, 91]]], ["Thrombocytopenia has been reported in adults on CRRT but data in pediatrics are scarce.", [["Thrombocytopenia", "DISEASE", 0, 16], ["Thrombocytopenia", "PROBLEM", 0, 16], ["CRRT", "TREATMENT", 48, 52]]], ["Our institution uses regional citrate anticoagulation (RCA) as standard of care with prefilter hemodilution and HF1000 filters (polysulfone, surface area (SA) 1.1 m2) regardless of patients' (pts) age and size.", [["surface area", "ANATOMY", 141, 153], ["citrate", "CHEMICAL", 30, 37], ["citrate", "CHEMICAL", 30, 37], ["polysulfone", "CHEMICAL", 128, 139], ["citrate", "SIMPLE_CHEMICAL", 30, 37], ["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 181, 189], ["regional citrate anticoagulation (RCA", "TREATMENT", 21, 58], ["prefilter hemodilution", "TREATMENT", 85, 107], ["HF1000 filters (polysulfone, surface area (SA)", "TREATMENT", 112, 158], ["size", "OBSERVATION_MODIFIER", 205, 209]]], ["As filter SA is relatively larger in younger pts, we aimed to investigate the impact of CRRT filter change on hemostasis parameters in infants on CRRT in up to first three filter changes.", [["infants", "ORGANISM", 135, 142], ["infants", "SPECIES", 135, 142], ["CRRT filter change", "TREATMENT", 88, 106], ["hemostasis parameters", "TREATMENT", 110, 131], ["CRRT", "TREATMENT", 146, 150], ["relatively", "OBSERVATION_MODIFIER", 16, 26], ["larger", "OBSERVATION_MODIFIER", 27, 33], ["CRRT filter", "OBSERVATION", 88, 99], ["filter", "OBSERVATION", 172, 178]]], ["Methods: Retrospective chart review Results: 30 patients < 10 kg were included, age 4.3 (0.5-8) months, weight 5.4+2.4 kg, with 88 filters.", [["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["age", "TEST", 80, 83], ["weight", "TEST", 104, 110]]], ["Metabolic disease was the most common principal diagnosis (7/30, 23%), liver failure (LF) was the most common comorbidity (12/30, 40%).", [["liver", "ANATOMY", 71, 76], ["Metabolic disease", "DISEASE", 0, 17], ["liver failure", "DISEASE", 71, 84], ["liver", "ORGAN", 71, 76], ["Metabolic disease", "PROBLEM", 0, 17], ["liver failure", "PROBLEM", 71, 84], ["disease", "OBSERVATION", 10, 17], ["liver", "ANATOMY", 71, 76], ["failure", "OBSERVATION", 77, 84]]], ["All patients received prefilter continuous venovenous hemodiafiltration with minimum dose of 2000 ml/1.73m2/h.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["prefilter continuous venovenous hemodiafiltration", "TREATMENT", 22, 71]]], ["Thrombocytopenia was common at CRRT start (28/30, 93%).", [["Thrombocytopenia", "DISEASE", 0, 16], ["Thrombocytopenia", "PROBLEM", 0, 16]]], ["Plts decreased in 74% filter changes (65/88) by 15+70% (pre vs post plt 71 (44-111) vs 50(30-83), p<0.001).", [["Plts", "GENE_OR_GENE_PRODUCT", 0, 4], ["Plts", "TEST", 0, 4], ["filter changes", "TEST", 22, 36], ["plt", "TEST", 68, 71], ["vs", "TEST", 84, 86], ["decreased", "OBSERVATION_MODIFIER", 5, 14]]], ["Fibrinogen also decreased from 201 (152-261) to 170 (134-210), p<0.001; there was no change in PTT, PT, or INR values before and after filter changes.", [["Fibrinogen", "GENE_OR_GENE_PRODUCT", 0, 10], ["Fibrinogen", "PROTEIN", 0, 10], ["INR", "PROTEIN", 107, 110], ["Fibrinogen", "TEST", 0, 10], ["change in PTT", "PROBLEM", 85, 98], ["PT", "TEST", 100, 102], ["INR values", "TEST", 107, 117], ["filter changes", "TEST", 135, 149], ["decreased", "OBSERVATION_MODIFIER", 16, 25], ["no", "UNCERTAINTY", 82, 84], ["change", "OBSERVATION_MODIFIER", 85, 91]]], ["Bleeding events were seen in 13/30 (43%) of pts (8/12 of LF pts vs 5/ 18 others, p=0.04), but were not more common in pts who had decrease in plts or fib with filter changes (41% with drop in plts vs 57% without, p=0.66; 47% with drop in fib vs 75% without, p=0.58).", [["Bleeding", "DISEASE", 0, 8], ["Bleeding events", "PROBLEM", 0, 15], ["decrease in plts", "PROBLEM", 130, 146], ["fib", "PROBLEM", 150, 153], ["filter changes", "TEST", 159, 173], ["drop", "TEST", 184, 188], ["plts vs", "TEST", 192, 199], ["p", "TEST", 213, 214], ["fib", "TEST", 238, 241], ["filter", "OBSERVATION", 159, 165]]], ["Conclusions: Thrombocytopenia is common in infants on CRRT.", [["Thrombocytopenia", "DISEASE", 13, 29], ["infants", "ORGANISM", 43, 50], ["infants", "SPECIES", 43, 50], ["Thrombocytopenia", "PROBLEM", 13, 29], ["CRRT", "TREATMENT", 54, 58], ["Thrombocytopenia", "OBSERVATION", 13, 29]]], ["Further decreases in plt and fibrinogen can be seen in with CRRT filter changes if the filters are relatively large compared to patient size.", [["plt", "SIMPLE_CHEMICAL", 21, 24], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 29, 39], ["patient", "ORGANISM", 128, 135], ["fibrinogen", "PROTEIN", 29, 39], ["patient", "SPECIES", 128, 135], ["Further decreases", "PROBLEM", 0, 17], ["plt", "TEST", 21, 24], ["fibrinogen", "TEST", 29, 39], ["CRRT filter changes", "TREATMENT", 60, 79], ["the filters", "TREATMENT", 83, 94], ["decreases", "OBSERVATION_MODIFIER", 8, 17], ["plt", "OBSERVATION", 21, 24], ["fibrinogen", "OBSERVATION", 29, 39], ["filter", "OBSERVATION", 65, 71], ["filters", "OBSERVATION", 87, 94], ["relatively", "OBSERVATION_MODIFIER", 99, 109], ["large", "OBSERVATION", 110, 115], ["size", "OBSERVATION_MODIFIER", 136, 140]]], ["Bleeding events seems more related to underlying comorbidity, and less to changes in hemostatis parameters observed with filter change but would need to be confirmed with further studies.P155Intensive monitoring of post filter ionized calcium concentrations during CVVHD with regional citrate anticoagulation: is it still required?", [["Bleeding", "DISEASE", 0, 8], ["calcium", "CHEMICAL", 235, 242], ["citrate", "CHEMICAL", 285, 292], ["calcium", "CHEMICAL", 235, 242], ["citrate", "CHEMICAL", 285, 292], ["calcium", "SIMPLE_CHEMICAL", 235, 242], ["citrate", "SIMPLE_CHEMICAL", 285, 292], ["Bleeding events", "PROBLEM", 0, 15], ["underlying comorbidity", "PROBLEM", 38, 60], ["changes in hemostatis parameters", "PROBLEM", 74, 106], ["filter change", "TREATMENT", 121, 134], ["further studies", "TEST", 171, 186], ["Intensive monitoring", "TEST", 191, 211], ["post filter ionized calcium concentrations", "TREATMENT", 215, 257], ["CVVHD", "TREATMENT", 265, 270], ["regional citrate anticoagulation", "TREATMENT", 276, 308], ["comorbidity", "OBSERVATION", 49, 60], ["filter", "OBSERVATION", 121, 127]]], ["Introduction: The aim of the present study was to evaluate the role of postfilter calcium concentrations (pfCa) in terms of safety and efficacy in large retrospective cohort of patients treated with CVVHD and regional citrate anticoagulation.", [["calcium", "CHEMICAL", 82, 89], ["citrate", "CHEMICAL", 218, 225], ["calcium", "CHEMICAL", 82, 89], ["citrate", "CHEMICAL", 218, 225], ["calcium", "SIMPLE_CHEMICAL", 82, 89], ["pfCa", "SIMPLE_CHEMICAL", 106, 110], ["patients", "ORGANISM", 177, 185], ["citrate", "SIMPLE_CHEMICAL", 218, 225], ["patients", "SPECIES", 177, 185], ["the present study", "TEST", 25, 42], ["postfilter calcium concentrations", "TREATMENT", 71, 104], ["pfCa", "TREATMENT", 106, 110], ["CVVHD", "TREATMENT", 199, 204], ["regional citrate anticoagulation", "TREATMENT", 209, 241], ["large", "OBSERVATION_MODIFIER", 147, 152]]], ["Methods: Retrospective, observational study at a university hospital with 6 ICUs.", [["observational study", "TEST", 24, 43]]], ["All patients treated with RCA-CRRT were included in the study.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["RCA-CRRT", "TREATMENT", 26, 34], ["the study", "TEST", 52, 61]]], ["Results: Among 1070 patients treated with RCA-CVVH pfCa at the start of the CVVHD was available in 987 pts.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["RCA-CVVH pfCa", "TREATMENT", 42, 55], ["the CVVHD", "TREATMENT", 72, 81]]], ["The pfCa concentrations were in target range (0.25-0.35 mmol/L) in the majority of patients (70%), whereas 17% and 13% of patients had the pfCa below or above the target range, respectively.", [["pfCa", "CHEMICAL", 4, 8], ["pfCa", "GENE_OR_GENE_PRODUCT", 4, 8], ["patients", "ORGANISM", 83, 91], ["patients", "ORGANISM", 122, 130], ["pfCa", "GENE_OR_GENE_PRODUCT", 139, 143], ["pfCa", "PROTEIN", 4, 8], ["pfCa", "PROTEIN", 139, 143], ["patients", "SPECIES", 83, 91], ["patients", "SPECIES", 122, 130], ["The pfCa concentrations", "TEST", 0, 23], ["the pfCa", "TEST", 135, 143]]], ["In the further 72h of CVVHD treatment the propotion of patients with targeted pfCa increased to 86% and remained stable.", [["CVVHD", "DISEASE", 22, 27], ["CVVHD", "CHEMICAL", 22, 27], ["patients", "ORGANISM", 55, 63], ["pfCa", "GENE_OR_GENE_PRODUCT", 78, 82], ["pfCa", "PROTEIN", 78, 82], ["patients", "SPECIES", 55, 63], ["CVVHD treatment", "TREATMENT", 22, 37], ["targeted pfCa", "TREATMENT", 69, 82], ["stable", "OBSERVATION_MODIFIER", 113, 119]]], ["At the start of the RCA-CVVHD there was a significant but weak correlation between the pfCa and ionized systemic Ca (iCa) with a Spearman rank-order correlation coefficient (rho) of 0.374 (p < 0.001).", [["CVVHD", "DISEASE", 24, 29], ["Ca", "CHEMICAL", 113, 115], ["Ca (iCa)", "CHEMICAL", 113, 121], ["pfCa", "SIMPLE_CHEMICAL", 87, 91], ["pfCa", "PROTEIN", 87, 91], ["the RCA-CVVHD", "TREATMENT", 16, 29], ["the pfCa", "TEST", 83, 91], ["ionized systemic Ca", "TEST", 96, 115], ["a Spearman rank", "TEST", 127, 142], ["rho", "TEST", 174, 177], ["significant", "OBSERVATION_MODIFIER", 42, 53]]], ["The coefficient of variation of pfCa concentraions was significantly higher if compared to the coefficient of variation of iCa concentration.", [["iCa", "CHEMICAL", 123, 126], ["pfCa", "GENE_OR_GENE_PRODUCT", 32, 36], ["iCa", "SIMPLE_CHEMICAL", 123, 126], ["pfCa", "PROTEIN", 32, 36], ["iCa", "PROTEIN", 123, 126], ["pfCa concentraions", "PROBLEM", 32, 50], ["coefficient", "OBSERVATION_MODIFIER", 4, 15]]], ["Using per protocol adaptations the incidence of a severe hypocalcemia (<0.9 mmol/L) was low and present only at first 12 hours of therapy: 4% and 2% of patients with pfCa below the target range and 0.7% and 0.4% of patients with pfCa in target range, at 0h and 12h respectively (p<0.001).", [["hypocalcemia", "DISEASE", 57, 69], ["patients", "ORGANISM", 152, 160], ["patients", "ORGANISM", 215, 223], ["patients", "SPECIES", 152, 160], ["patients", "SPECIES", 215, 223], ["a severe hypocalcemia", "PROBLEM", 48, 69], ["therapy", "TREATMENT", 130, 137], ["pfCa", "TEST", 166, 170], ["pfCa", "TEST", 229, 233], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["hypocalcemia", "OBSERVATION", 57, 69]]], ["There was no correlation between pfCa concentrations and filter lifetime.Conclusions:The results of the present study support the previous reports about higher measurements variation of pfCa compared to systemic iCa (1).", [["pfCa", "CHEMICAL", 33, 37], ["pfCa", "SIMPLE_CHEMICAL", 33, 37], ["pfCa", "GENE_OR_GENE_PRODUCT", 186, 190], ["pfCa", "PROTEIN", 33, 37], ["pfCa", "PROTEIN", 186, 190], ["the present study", "TEST", 100, 117], ["higher measurements variation of pfCa", "PROBLEM", 153, 190], ["systemic iCa", "TEST", 203, 215], ["no", "UNCERTAINTY", 10, 12]]], ["Nevertheless due to the weak correlation of iCa and pfCa as well as a low number of patients with a severe metabolic complication, the results of our study question the necessity of intensive pfCa monitoring during RCA-CRRT.", [["iCa", "GENE_OR_GENE_PRODUCT", 44, 47], ["pfCa", "GENE_OR_GENE_PRODUCT", 52, 56], ["patients", "ORGANISM", 84, 92], ["pfCa", "SIMPLE_CHEMICAL", 192, 196], ["iCa", "PROTEIN", 44, 47], ["pfCa", "PROTEIN", 52, 56], ["patients", "SPECIES", 84, 92], ["the weak correlation of iCa and pfCa", "PROBLEM", 20, 56], ["a severe metabolic complication", "PROBLEM", 98, 129], ["our study", "TEST", 146, 155], ["intensive pfCa monitoring", "TREATMENT", 182, 207], ["RCA-CRRT", "TREATMENT", 215, 223], ["severe", "OBSERVATION_MODIFIER", 100, 106], ["metabolic complication", "OBSERVATION", 107, 129]]], ["Introduction: In critically ill patients, occurrence of pain is frequent and usually correlates with worse outcomes, such as prolonged ICU length of stay (LOS) and mechanical ventilation.", [["critically ill", "DISEASE", 17, 31], ["pain", "DISEASE", 56, 60], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["pain", "PROBLEM", 56, 60], ["mechanical ventilation", "TREATMENT", 164, 186], ["pain", "OBSERVATION", 56, 60], ["mechanical ventilation", "OBSERVATION", 164, 186]]], ["In this regard, pain leads to sympathetic activation, inflammatory mediators and therefore, potentially to organic dysfunction.", [["pain", "DISEASE", 16, 20], ["organic dysfunction", "DISEASE", 107, 126], ["inflammatory mediators", "PROTEIN", 54, 76], ["pain", "PROBLEM", 16, 20], ["sympathetic activation", "PROBLEM", 30, 52], ["inflammatory mediators", "PROBLEM", 54, 76], ["organic dysfunction", "PROBLEM", 107, 126]]], ["The aim of this study is to evaluate the relationship between acute pain in critically ill patients and their association with acute kidney injury (AKI).", [["kidney", "ANATOMY", 133, 139], ["acute pain", "DISEASE", 62, 72], ["critically ill", "DISEASE", 76, 90], ["acute kidney injury", "DISEASE", 127, 146], ["AKI", "DISEASE", 148, 151], ["patients", "ORGANISM", 91, 99], ["kidney", "ORGAN", 133, 139], ["patients", "SPECIES", 91, 99], ["this study", "TEST", 11, 21], ["acute pain", "PROBLEM", 62, 72], ["acute kidney injury", "PROBLEM", 127, 146], ["AKI", "PROBLEM", 148, 151], ["acute", "OBSERVATION_MODIFIER", 62, 67], ["pain", "OBSERVATION", 68, 72], ["acute", "OBSERVATION_MODIFIER", 127, 132], ["kidney", "ANATOMY", 133, 139], ["injury", "OBSERVATION", 140, 146], ["AKI", "OBSERVATION", 148, 151]]], ["Methods: Retrospective cohort with 6345 adults patients admitted between June 2013 and June 2016, from the ICU of Hospital S\u00edrio Liban\u00eas Hospital in Sao Paulo (Brazil).", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55]]], ["Main exclusion criteria were: length of stay < 48h, coma and previous AKI.", [["coma", "DISEASE", 52, 56], ["AKI", "DISEASE", 70, 73], ["coma", "PROBLEM", 52, 56], ["previous AKI", "PROBLEM", 61, 73], ["AKI", "OBSERVATION", 70, 73]]], ["The predictor pain was obtained through daily electronic records according to numerical verbal scale (0-10).", [["pain", "DISEASE", 14, 18], ["The predictor pain", "PROBLEM", 0, 18], ["numerical verbal scale", "TEST", 78, 100]]], ["The outcome was defined as serum creatinine elevation equal to or greater than 0.3mg/dl and/or greater than 50% increase at any time after the first 48 hours in the ICU.", [["serum", "ANATOMY", 27, 32], ["creatinine", "CHEMICAL", 33, 43], ["creatinine", "CHEMICAL", 33, 43], ["serum", "ORGANISM_SUBSTANCE", 27, 32], ["creatinine", "SIMPLE_CHEMICAL", 33, 43], ["serum creatinine elevation", "TEST", 27, 53]]], ["The multivariate analysis was performed by Binary Logistic Regression through distinct groups of early or late predictive factors in relation to AKI.", [["AKI", "DISEASE", 145, 148], ["The multivariate analysis", "TEST", 0, 25], ["AKI", "PROBLEM", 145, 148], ["AKI", "OBSERVATION", 145, 148]]], ["Results: After the exclusion of 3220 patients, the incidence of pain with numerical verbal scale equal to or greater than 3 points was 23.6%.", [["pain", "DISEASE", 64, 68], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["pain", "PROBLEM", 64, 68], ["numerical verbal scale", "TEST", 74, 96]]], ["In the binary regression, using the more early predictive factors, sex and pain presented independent relation with the outcome -adjusted OR 1.24 (1.12-1.36) and 1.63 (1.34-1.98), respectively (p <0.001).", [["pain", "DISEASE", 75, 79], ["pain", "PROBLEM", 75, 79]]], ["In the analysis Conclusions: Poor management of ICU pain is associated to worse outcomes, including increased risk to AKI.", [["ICU pain", "DISEASE", 48, 56], ["AKI", "DISEASE", 118, 121], ["ICU pain", "PROBLEM", 48, 56], ["AKI", "PROBLEM", 118, 121], ["AKI", "OBSERVATION", 118, 121]]], ["The search for a better pain management strategy in the ICU scenario should therefore be reinforced.", [["pain", "DISEASE", 24, 28], ["a better pain management", "TREATMENT", 15, 39]]], ["Introduction: Acute Kidney Injury (AKI) is a common complication in hospitalised patients, strongly associated with adverse outcomes [1] .", [["Kidney", "ANATOMY", 20, 26], ["Kidney Injury", "DISEASE", 20, 33], ["AKI", "DISEASE", 35, 38], ["Kidney", "ORGAN", 20, 26], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["Acute Kidney Injury", "PROBLEM", 14, 33], ["AKI", "PROBLEM", 35, 38], ["a common complication", "PROBLEM", 43, 64], ["adverse outcomes", "PROBLEM", 116, 132], ["Acute", "OBSERVATION_MODIFIER", 14, 19], ["Kidney", "ANATOMY", 20, 26], ["Injury", "OBSERVATION", 27, 33], ["AKI", "OBSERVATION", 35, 38]]], ["A lack of baseline incidence and outcome data limits our ability to assess local strategies aimed at improving AKI care.", [["AKI", "DISEASE", 111, 114], ["outcome data", "TEST", 33, 45], ["local strategies", "TREATMENT", 75, 91], ["AKI care", "TREATMENT", 111, 119]]], ["Methods: In an audit in three linked inner London hospitals we interrogated our electronic patient data warehouse (Cerner Millennium power insight electronic data warehouse) with a specially written query to identify cases of AKI, defined by KDIGO creatinine criteria, in patients aged over 18y admitted for >24h during January to June 2016.", [["AKI", "DISEASE", 226, 229], ["creatinine", "CHEMICAL", 248, 258], ["creatinine", "CHEMICAL", 248, 258], ["patient", "ORGANISM", 91, 98], ["patients", "ORGANISM", 272, 280], ["patient", "SPECIES", 91, 98], ["patients", "SPECIES", 272, 280], ["AKI", "PROBLEM", 226, 229], ["KDIGO creatinine criteria", "TEST", 242, 267], ["AKI", "OBSERVATION", 226, 229]]], ["We excluded palliative care and obstetric patients.", [["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["palliative care", "TREATMENT", 12, 27]]], ["In the absence of premorbid baseline (median 7-365d pre-admission) the admission creatinine value was used.", [["creatinine", "CHEMICAL", 81, 91], ["creatinine", "CHEMICAL", 81, 91], ["creatinine", "SIMPLE_CHEMICAL", 81, 91], ["the admission creatinine value", "TEST", 67, 97]]], ["End stage renal disease (ESRD) and primary sepsis diagnosis was obtained from ICD10 coding.", [["renal", "ANATOMY", 10, 15], ["End stage renal disease", "DISEASE", 0, 23], ["ESRD", "DISEASE", 25, 29], ["primary sepsis", "DISEASE", 35, 49], ["renal", "ORGAN", 10, 15], ["ICD10 coding", "DNA", 78, 90], ["End stage renal disease", "PROBLEM", 0, 23], ["ESRD", "PROBLEM", 25, 29], ["primary sepsis", "PROBLEM", 35, 49], ["stage", "OBSERVATION_MODIFIER", 4, 9], ["renal", "ANATOMY", 10, 15], ["disease", "OBSERVATION", 16, 23], ["primary", "OBSERVATION_MODIFIER", 35, 42], ["sepsis", "OBSERVATION", 43, 49]]], ["Results: Of 28872 admissions, we excluded 1052 with pre-existing ESRD (Hospital mortality 6.0%) and 8833 with fewer than one creatinine result who could not be assigned AKI status (mortality 1.1%).", [["ESRD", "DISEASE", 65, 69], ["creatinine", "CHEMICAL", 125, 135], ["AKI", "DISEASE", 169, 172], ["creatinine", "CHEMICAL", 125, 135], ["pre-existing ESRD", "PROBLEM", 52, 69], ["Hospital mortality", "TEST", 71, 89], ["AKI status", "TEST", 169, 179], ["mortality", "TEST", 181, 190]]], ["Of the remaining 18987 there were 3145 with AKI (16.6%), with mortality increasing from No AKI group (2.4%), to AKI stage 1 (12.6%), and a further increase to AKI stages 2-3 (22.4%) (p<0.001) ( Table 1) .", [["AKI", "DISEASE", 44, 47], ["AKI", "DISEASE", 91, 94], ["AKI", "DISEASE", 112, 115], ["AKI", "DISEASE", 159, 162], ["AKI", "TEST", 44, 47], ["mortality", "TEST", 62, 71], ["AKI group", "PROBLEM", 91, 100], ["AKI stage", "TEST", 112, 121], ["AKI stages", "TEST", 159, 169], ["AKI", "OBSERVATION", 44, 47], ["No", "UNCERTAINTY", 88, 90], ["AKI", "OBSERVATION", 91, 94], ["increase", "OBSERVATION_MODIFIER", 147, 155], ["AKI", "OBSERVATION", 159, 162]]], ["Patients with AKI were older (p<0.001), more likely to be medical than surgical (p<0.001), more likely to have a primary sepsis diagnosis (p<0.001) and had higher baseline creatinine (median 91 vs 79 p<0.001).", [["AKI", "DISEASE", 14, 17], ["sepsis", "DISEASE", 121, 127], ["creatinine", "CHEMICAL", 172, 182], ["creatinine", "CHEMICAL", 172, 182], ["Patients", "ORGANISM", 0, 8], ["creatinine", "SIMPLE_CHEMICAL", 172, 182], ["Patients", "SPECIES", 0, 8], ["AKI", "PROBLEM", 14, 17], ["a primary sepsis diagnosis", "PROBLEM", 111, 137], ["creatinine", "TEST", 172, 182], ["AKI", "OBSERVATION", 14, 17], ["primary", "OBSERVATION_MODIFIER", 113, 120], ["sepsis", "OBSERVATION", 121, 127]]], ["No known baseline was found in 29.7% of patients with AKI, but their mortality did not significantly differ to those with a baseline (14.2% vs 16.6%, p=0.093).", [["AKI", "DISEASE", 54, 57], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["AKI", "PROBLEM", 54, 57], ["p", "TEST", 150, 151], ["AKI", "OBSERVATION", 54, 57]]], ["Conclusions: An electronic query identified the local burden of AKI and it's associated hospital-mortality; such baseline data is essential to assess the effect of Quality Improvement interventions in AKI prevention and care.", [["AKI", "DISEASE", 64, 67], ["AKI", "DISEASE", 201, 204], ["AKI", "PROBLEM", 64, 67], ["baseline data", "TEST", 113, 126], ["AKI prevention", "TREATMENT", 201, 215], ["local", "OBSERVATION_MODIFIER", 48, 53], ["burden", "OBSERVATION_MODIFIER", 54, 60], ["AKI", "OBSERVATION", 64, 67]]], ["Introduction: Acute kidney injury (AKI) is a common condition in critically ill patients [1, 2] .", [["kidney", "ANATOMY", 20, 26], ["Acute kidney injury", "DISEASE", 14, 33], ["AKI", "DISEASE", 35, 38], ["critically ill", "DISEASE", 65, 79], ["kidney", "ORGAN", 20, 26], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["Acute kidney injury", "PROBLEM", 14, 33], ["AKI", "PROBLEM", 35, 38], ["Acute", "OBSERVATION_MODIFIER", 14, 19], ["kidney", "ANATOMY", 20, 26], ["injury", "OBSERVATION", 27, 33], ["AKI", "OBSERVATION", 35, 38]]], ["Loop diuretics are generally used as first line treatment.", [["Loop diuretics", "TREATMENT", 0, 14], ["first line treatment", "TREATMENT", 37, 57], ["diuretics", "OBSERVATION", 5, 14]]], ["We ought to search systematically and realize a metaanalysis on the matter.", [["a metaanalysis on the matter", "PROBLEM", 46, 74]]], ["Methods: An electronic search of randomized clinical trials in adult patient treated with diuretics for AKI compared with standard treatment or a control group was conducted.", [["AKI", "DISEASE", 104, 107], ["patient", "ORGANISM", 69, 76], ["patient", "SPECIES", 69, 76], ["diuretics", "TREATMENT", 90, 99], ["AKI", "PROBLEM", 104, 107], ["standard treatment", "TREATMENT", 122, 140]]], ["The primary objective of the analysis was to assess recovery of renal function.", [["renal", "ANATOMY", 64, 69], ["renal", "ORGAN", 64, 69], ["the analysis", "TEST", 25, 37], ["renal", "ANATOMY", 64, 69]]], ["Secondary endpoints included time to recovery of renal function, need for Renal Replacement Therapy (RRT), mortality in the Intensive Care Unit (ICU) and complications.", [["renal", "ANATOMY", 49, 54], ["Renal", "ANATOMY", 74, 79], ["renal", "ORGAN", 49, 54], ["Renal", "ORGAN", 74, 79], ["Secondary endpoints", "PROBLEM", 0, 19], ["renal function", "PROBLEM", 49, 63], ["Renal Replacement Therapy", "TREATMENT", 74, 99], ["complications", "PROBLEM", 154, 167], ["renal", "ANATOMY", 49, 54], ["Renal", "ANATOMY", 74, 79], ["Replacement", "OBSERVATION", 80, 91]]], ["Introduction: Increased venous pressure is one of the mechanism leading to acute kidney injury (AKI) after cardiac surgery.", [["venous", "ANATOMY", 24, 30], ["kidney", "ANATOMY", 81, 87], ["cardiac", "ANATOMY", 107, 114], ["acute kidney injury", "DISEASE", 75, 94], ["AKI", "DISEASE", 96, 99], ["venous", "MULTI-TISSUE_STRUCTURE", 24, 30], ["kidney", "ORGAN", 81, 87], ["cardiac", "ORGAN", 107, 114], ["Increased venous pressure", "TREATMENT", 14, 39], ["acute kidney injury", "PROBLEM", 75, 94], ["AKI", "PROBLEM", 96, 99], ["cardiac surgery", "TREATMENT", 107, 122], ["Increased venous pressure", "OBSERVATION", 14, 39], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["kidney", "ANATOMY", 81, 87], ["injury", "OBSERVATION", 88, 94], ["AKI", "OBSERVATION", 96, 99], ["cardiac", "ANATOMY", 107, 114], ["surgery", "OBSERVATION", 115, 122]]], ["Portal flow pulsatility and discontinuous intra-renal venous flow are potential ultrasound markers of the impact of venous hypertension on organs.Conclusions:The main objective of this study was to describe these signs after cardiac surgery and to determine if they are associated with AKI.Conclusions:Methods: This single center prospective cohort study (NCT02831907) recruited adult patients able to give consent.", [["Portal", "ANATOMY", 0, 6], ["intra-renal venous", "ANATOMY", 42, 60], ["venous", "ANATOMY", 116, 122], ["organs", "ANATOMY", 139, 145], ["cardiac", "ANATOMY", 225, 232], ["hypertension", "DISEASE", 123, 135], ["AKI", "DISEASE", 286, 289], ["venous", "MULTI-TISSUE_STRUCTURE", 54, 60], ["venous", "MULTI-TISSUE_STRUCTURE", 116, 122], ["organs", "ORGAN", 139, 145], ["cardiac", "ORGAN", 225, 232], ["patients", "ORGANISM", 385, 393], ["patients", "SPECIES", 385, 393], ["Portal flow pulsatility", "TEST", 0, 23], ["discontinuous intra-renal venous flow", "PROBLEM", 28, 65], ["ultrasound markers", "TEST", 80, 98], ["venous hypertension on organs", "PROBLEM", 116, 145], ["this study", "TEST", 180, 190], ["these signs", "TEST", 207, 218], ["cardiac surgery", "TREATMENT", 225, 240], ["AKI", "PROBLEM", 286, 289], ["cohort study", "TEST", 342, 354], ["flow pulsatility", "OBSERVATION", 7, 23], ["discontinuous", "OBSERVATION_MODIFIER", 28, 41], ["intra-renal", "ANATOMY_MODIFIER", 42, 53], ["venous", "ANATOMY", 54, 60], ["flow", "OBSERVATION", 61, 65], ["venous", "ANATOMY", 116, 122], ["hypertension", "OBSERVATION", 123, 135], ["organs", "ANATOMY", 139, 145], ["main", "OBSERVATION_MODIFIER", 162, 166], ["AKI", "OBSERVATION", 286, 289]]], ["Ultrasound studies were performed before cardiac surgery and repeated on post-operative day (POD) 0, 1, 2 and 3.", [["cardiac", "ANATOMY", 41, 48], ["Ultrasound studies", "TEST", 0, 18], ["cardiac surgery", "TREATMENT", 41, 56]]], ["Abnormal portal and renal venous flow patterns are defined in Fig. 1 .", [["portal", "ANATOMY", 9, 15], ["renal venous", "ANATOMY", 20, 32], ["portal", "MULTI-TISSUE_STRUCTURE", 9, 15], ["renal venous", "MULTI-TISSUE_STRUCTURE", 20, 32], ["Abnormal portal and renal venous flow patterns", "PROBLEM", 0, 46], ["portal", "ANATOMY", 9, 15], ["renal venous", "ANATOMY", 20, 32], ["flow patterns", "OBSERVATION", 33, 46], ["Fig", "OBSERVATION_MODIFIER", 62, 65]]], ["The association between the studied markers and the risk of new onset of AKI in the following 24 hours period following an assessment was tested using logistic regression with a 95% confidence interval.", [["AKI", "DISEASE", 73, 76], ["AKI", "PROBLEM", 73, 76], ["an assessment", "TEST", 120, 133], ["new", "OBSERVATION_MODIFIER", 60, 63], ["AKI", "OBSERVATION", 73, 76]]], ["Clinical variables associated with the detection of the signs were tested using generalized estimating equation models.", [["the signs", "TEST", 52, 61], ["generalized estimating equation models", "TEST", 80, 118]]], ["This study was approved by the local ethics committee.Conclusions:Results: During the study period, 145 patients were included.", [["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["This study", "TEST", 0, 10], ["the study", "TEST", 82, 91]]], ["The presence of the studied ultrasound signs is presented in Fig. 2 .", [["the studied ultrasound signs", "TEST", 16, 44]]], ["During the week following cardiac surgery, 49 patients (33.8%) developed AKI, most often on POD 1 (71.4%).", [["cardiac", "ANATOMY", 26, 33], ["AKI", "DISEASE", 73, 76], ["cardiac", "ORGAN", 26, 33], ["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["cardiac surgery", "TREATMENT", 26, 41], ["AKI", "PROBLEM", 73, 76], ["cardiac", "ANATOMY", 26, 33], ["surgery", "OBSERVATION", 34, 41], ["AKI", "OBSERVATION", 73, 76]]], ["The detection of portal flow pulsatility and severe alterations in renal venous flow (Pattern 3) at ICU admission (POD 0) were associated with AKI in the subsequent 24 hours period and was independently associated with AKI in multivariable models including EUROSCORE II and baseline creatinine ( Table 1 ).", [["portal", "ANATOMY", 17, 23], ["renal venous", "ANATOMY", 67, 79], ["AKI", "DISEASE", 143, 146], ["AKI", "DISEASE", 219, 222], ["creatinine", "CHEMICAL", 283, 293], ["creatinine", "CHEMICAL", 283, 293], ["portal", "MULTI-TISSUE_STRUCTURE", 17, 23], ["renal venous", "MULTI-TISSUE_STRUCTURE", 67, 79], ["portal flow pulsatility", "PROBLEM", 17, 40], ["severe alterations in renal venous flow", "PROBLEM", 45, 84], ["AKI", "PROBLEM", 143, 146], ["AKI", "PROBLEM", 219, 222], ["baseline creatinine", "TEST", 274, 293], ["portal", "ANATOMY", 17, 23], ["flow pulsatility", "OBSERVATION", 24, 40], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["alterations", "OBSERVATION", 52, 63], ["renal venous", "ANATOMY", 67, 79], ["flow", "ANATOMY_MODIFIER", 80, 84], ["AKI", "OBSERVATION", 143, 146], ["AKI", "OBSERVATION", 219, 222]]], ["The variables associated with the detection of abnormal portal and renal patterns were associated with lower perfusion pressure, higher NT-pro-BNP and inferior vena cava measurements (Table 2) .", [["portal", "ANATOMY", 56, 62], ["renal", "ANATOMY", 67, 72], ["inferior vena cava", "ANATOMY", 151, 169], ["portal", "MULTI-TISSUE_STRUCTURE", 56, 62], ["renal", "ORGAN", 67, 72], ["NT-pro-BNP", "GENE_OR_GENE_PRODUCT", 136, 146], ["inferior vena cava", "MULTI-TISSUE_STRUCTURE", 151, 169], ["abnormal portal and renal patterns", "PROBLEM", 47, 81], ["lower perfusion pressure", "TEST", 103, 127], ["inferior vena cava measurements", "TEST", 151, 182], ["abnormal", "OBSERVATION", 47, 55], ["portal", "ANATOMY", 56, 62], ["renal", "ANATOMY", 67, 72], ["lower", "ANATOMY_MODIFIER", 103, 108], ["perfusion pressure", "OBSERVATION", 109, 127], ["inferior vena cava", "ANATOMY", 151, 169]]], ["Conclusions: Abnormal portal and intra-renal venous patterns are associated with early AKI after cardiac surgery.", [["portal", "ANATOMY", 22, 28], ["intra-renal venous", "ANATOMY", 33, 51], ["cardiac", "ANATOMY", 97, 104], ["AKI", "DISEASE", 87, 90], ["portal", "MULTI-TISSUE_STRUCTURE", 22, 28], ["intra-renal venous", "MULTI-TISSUE_STRUCTURE", 33, 51], ["cardiac", "ORGAN", 97, 104], ["Abnormal portal and intra-renal venous patterns", "PROBLEM", 13, 60], ["early AKI", "PROBLEM", 81, 90], ["cardiac surgery", "TREATMENT", 97, 112], ["Abnormal", "OBSERVATION", 13, 21], ["portal", "ANATOMY", 22, 28], ["intra-renal venous", "ANATOMY", 33, 51], ["early", "OBSERVATION_MODIFIER", 81, 86], ["AKI", "OBSERVATION", 87, 90], ["cardiac", "ANATOMY", 97, 104], ["surgery", "OBSERVATION", 105, 112]]], ["These Doppler features must be further studied as potential treatment targets to personalize management.", [["These Doppler features", "TEST", 0, 22], ["potential treatment targets", "TREATMENT", 50, 77], ["personalize management", "TREATMENT", 81, 103]]], ["Introduction: Acute kidney injury (AKI) is very prevalent after cardiac surgery in children, and associated with poor outcomes [1] .", [["kidney", "ANATOMY", 20, 26], ["cardiac", "ANATOMY", 64, 71], ["Acute kidney injury", "DISEASE", 14, 33], ["AKI", "DISEASE", 35, 38], ["kidney", "ORGAN", 20, 26], ["cardiac", "ORGAN", 64, 71], ["children", "ORGANISM", 83, 91], ["children", "SPECIES", 83, 91], ["Acute kidney injury", "PROBLEM", 14, 33], ["AKI", "PROBLEM", 35, 38], ["cardiac surgery", "TREATMENT", 64, 79], ["Acute", "OBSERVATION_MODIFIER", 14, 19], ["kidney", "ANATOMY", 20, 26], ["injury", "OBSERVATION", 27, 33], ["AKI", "OBSERVATION", 35, 38], ["surgery", "OBSERVATION", 72, 79]]], ["The present study is a preplanned sub-analysis of a prospective blinded observational study on the clinical value of the Foresight nearinfrared spectroscopy (NIRS) monitor [2] .", [["a prospective blinded observational study", "TEST", 50, 91]]], ["The purpose of this subanalysis was to develop a clinical prediction model for severe AKI (sAKI) in the first week of PICU stay.", [["AKI", "DISEASE", 86, 89], ["AKI", "DISEASE", 92, 95], ["severe AKI", "PROBLEM", 79, 89], ["AKI", "PROBLEM", 92, 95], ["severe", "OBSERVATION_MODIFIER", 79, 85], ["AKI", "OBSERVATION", 86, 89]]], ["Methods: sAKI was defined as serum creatinine (SCr) >/= 2 times the baseline, or urine output < 0.5 ml/kg/h for >/= 12h.", [["serum", "ANATOMY", 29, 34], ["urine", "ANATOMY", 81, 86], ["creatinine", "CHEMICAL", 35, 45], ["creatinine", "CHEMICAL", 35, 45], ["serum", "ORGANISM_SUBSTANCE", 29, 34], ["creatinine", "SIMPLE_CHEMICAL", 35, 45], ["SCr", "SIMPLE_CHEMICAL", 47, 50], ["urine", "ORGANISM_SUBSTANCE", 81, 86], ["serum creatinine", "TEST", 29, 45], ["SCr", "TEST", 47, 50], ["urine output", "TEST", 81, 93]]], ["Predictive models were built using multivariable logistic regression.", [["Predictive models", "TEST", 0, 17], ["multivariable logistic regression", "PROBLEM", 35, 68]]], ["Data collected during surgery, upon PICU admission, as well as monitoring and lab data until 6h before sAKI onset, were used as predictors.", [["lab data", "TEST", 78, 86]]], ["Accuracy of the models was tested using bootstraps, by AUROC and decision curves.", [["the models", "TEST", 12, 22], ["bootstraps", "TREATMENT", 40, 50]]], ["Results: 177 children were enrolled, admitted to the PICU of the Leuven University Hospitals after cardiac surgery, between October 2012 and November 2015.", [["cardiac", "ANATOMY", 99, 106], ["children", "ORGANISM", 13, 21], ["cardiac", "ORGAN", 99, 106], ["children", "SPECIES", 13, 21], ["cardiac surgery", "TREATMENT", 99, 114], ["cardiac", "ANATOMY", 99, 106], ["surgery", "OBSERVATION", 107, 114]]], ["5 patients were excluded.", [["patients", "ORGANISM", 2, 10], ["patients", "SPECIES", 2, 10]]], ["70 children (40.7%) developed sAKI in the first week of PICU stay.", [["sAKI", "DISEASE", 30, 34], ["children", "ORGANISM", 3, 11], ["children", "SPECIES", 3, 11], ["sAKI", "PROBLEM", 30, 34]]], ["A multivariate model with 5 admission parameters (maximum lactate during surgery, duration of CPB, baseline sCr, RACHS1 and PIM2 scores), and 4 postoperative measurements (average heart rate, average blood pressure, hemoglobin, lactate), was most predictive for sAKI ( Fig. 1) .Conclusions:Conclusions: The risk of sAKI in children after congenital cardiac surgery could be predicted with high accuracy.", [["heart", "ANATOMY", 180, 185], ["blood", "ANATOMY", 200, 205], ["cardiac", "ANATOMY", 349, 356], ["lactate", "CHEMICAL", 58, 65], ["lactate", "CHEMICAL", 228, 235], ["sAKI", "DISEASE", 315, 319], ["lactate", "CHEMICAL", 58, 65], ["lactate", "CHEMICAL", 228, 235], ["lactate", "SIMPLE_CHEMICAL", 58, 65], ["heart", "ORGAN", 180, 185], ["blood", "ORGANISM_SUBSTANCE", 200, 205], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 216, 226], ["lactate", "SIMPLE_CHEMICAL", 228, 235], ["sAKI", "CANCER", 315, 319], ["children", "ORGANISM", 323, 331], ["cardiac", "ORGAN", 349, 356], ["PIM2", "PROTEIN", 124, 128], ["hemoglobin", "PROTEIN", 216, 226], ["children", "SPECIES", 323, 331], ["5 admission parameters", "TEST", 26, 48], ["maximum lactate", "TEST", 50, 65], ["surgery", "TREATMENT", 73, 80], ["CPB", "TREATMENT", 94, 97], ["baseline sCr", "TEST", 99, 111], ["RACHS1", "TEST", 113, 119], ["PIM2 scores", "TEST", 124, 135], ["average heart rate", "TEST", 172, 190], ["blood pressure", "TEST", 200, 214], ["hemoglobin", "TEST", 216, 226], ["lactate", "TEST", 228, 235], ["sAKI", "PROBLEM", 262, 266], ["congenital cardiac surgery", "TREATMENT", 338, 364], ["cardiac", "ANATOMY", 349, 356], ["surgery", "OBSERVATION", 357, 364]]], ["Future models will also include medication data.", [["medication data", "TEST", 32, 47]]], ["These models will be compared against and combined with NIRS oximetry data to investigate the independent and added predictive value of the Foresight monitor.", [["NIRS oximetry data", "TEST", 56, 74], ["the Foresight monitor", "TEST", 136, 157]]], ["Introduction: Acute kidney injury (AKI) occurs in over 50% of the patients in the intensive care unit (ICU).", [["kidney", "ANATOMY", 20, 26], ["Acute kidney injury", "DISEASE", 14, 33], ["AKI", "DISEASE", 35, 38], ["kidney", "ORGAN", 20, 26], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["Acute kidney injury", "PROBLEM", 14, 33], ["AKI", "PROBLEM", 35, 38], ["Acute", "OBSERVATION_MODIFIER", 14, 19], ["kidney", "ANATOMY", 20, 26], ["injury", "OBSERVATION", 27, 33], ["AKI", "OBSERVATION", 35, 38]]], ["The predominantly ethiology of AKI is septic shock, the most common diagnosis in the ICU.", [["AKI", "DISEASE", 31, 34], ["septic shock", "DISEASE", 38, 50], ["AKI", "PROBLEM", 31, 34], ["septic shock", "PROBLEM", 38, 50], ["predominantly", "OBSERVATION_MODIFIER", 4, 17], ["AKI", "OBSERVATION", 31, 34], ["septic shock", "OBSERVATION", 38, 50], ["most common", "OBSERVATION_MODIFIER", 56, 67]]], ["AKI significantly increases the risk of both morbidity and mortality [1] .", [["AKI", "DISEASE", 0, 3], ["AKI", "PROBLEM", 0, 3]]], ["Methods: 8 ICU patients with septic shock was studied within 24 hrs from admission.", [["septic shock", "DISEASE", 29, 41], ["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["septic shock", "PROBLEM", 29, 41], ["septic shock", "OBSERVATION", 29, 41]]], ["58 patients after cardiac surgery served as control group.", [["cardiac", "ANATOMY", 18, 25], ["patients", "ORGANISM", 3, 11], ["cardiac", "ORGAN", 18, 25], ["patients", "SPECIES", 3, 11], ["cardiac surgery", "TREATMENT", 18, 33], ["cardiac", "ANATOMY", 18, 25], ["surgery", "OBSERVATION", 26, 33]]], ["All patients were sedated and mechanically ventilated.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["sedated", "TREATMENT", 18, 25], ["mechanically ventilated", "TREATMENT", 30, 53], ["mechanically ventilated", "OBSERVATION", 30, 53]]], ["Renal blood flow (RBF) and glomerular filtration rate (GFR) were obtained by the infusion clearance of paraaminohippuric acid (PAH) and by extraction of 51Cr-ethylenediamine (51Cr-EDTA).", [["Renal", "ANATOMY", 0, 5], ["blood", "ANATOMY", 6, 11], ["glomerular", "ANATOMY", 27, 37], ["paraaminohippuric acid", "CHEMICAL", 103, 125], ["PAH", "CHEMICAL", 127, 130], ["51Cr-ethylenediamine", "CHEMICAL", 153, 173], ["51Cr-EDTA", "CHEMICAL", 175, 184], ["paraaminohippuric acid", "CHEMICAL", 103, 125], ["PAH", "CHEMICAL", 127, 130], ["51Cr-ethylenediamine", "CHEMICAL", 153, 173], ["51Cr", "CHEMICAL", 175, 179], ["EDTA", "CHEMICAL", 180, 184], ["Renal blood", "MULTI-TISSUE_STRUCTURE", 0, 11], ["glomerular", "TISSUE", 27, 37], ["paraaminohippuric acid", "SIMPLE_CHEMICAL", 103, 125], ["PAH", "SIMPLE_CHEMICAL", 127, 130], ["51Cr-ethylenediamine", "SIMPLE_CHEMICAL", 153, 173], ["51Cr-EDTA", "SIMPLE_CHEMICAL", 175, 184], ["Renal blood flow", "TEST", 0, 16], ["RBF", "TEST", 18, 21], ["glomerular filtration rate", "TEST", 27, 53], ["GFR", "TEST", 55, 58], ["the infusion clearance of paraaminohippuric acid", "TREATMENT", 77, 125], ["ethylenediamine", "TREATMENT", 158, 173], ["blood", "ANATOMY", 6, 11], ["flow", "OBSERVATION", 12, 16], ["glomerular", "ANATOMY", 27, 37]]], ["N-acetyl-\u03b2 -D-glucosaminidase (NAG), was measured.Conclusions:Results: RBF was 19% lower, renal vascular resistance 19% higher and the relation of RBF to cardiac index was 29% lower in patients with septic shock compared to the control group.", [["renal vascular", "ANATOMY", 90, 104], ["cardiac", "ANATOMY", 154, 161], ["N-acetyl-\u03b2 -D-glucosaminidase", "CHEMICAL", 0, 29], ["septic shock", "DISEASE", 199, 211], ["N-acetyl-\u03b2 -D-glucosaminidase", "CHEMICAL", 0, 29], ["N-acetyl-\u03b2 -D-glucosaminidase", "SIMPLE_CHEMICAL", 0, 29], ["NAG", "SIMPLE_CHEMICAL", 31, 34], ["renal vascular", "MULTI-TISSUE_STRUCTURE", 90, 104], ["cardiac", "ORGAN", 154, 161], ["patients", "ORGANISM", 185, 193], ["patients", "SPECIES", 185, 193], ["acetyl", "TREATMENT", 2, 8], ["D-glucosaminidase (NAG)", "TREATMENT", 12, 35], ["RBF", "TEST", 71, 74], ["renal vascular resistance", "TEST", 90, 115], ["cardiac index", "TEST", 154, 167], ["septic shock", "PROBLEM", 199, 211], ["renal vascular", "ANATOMY", 90, 104], ["cardiac", "ANATOMY", 154, 161], ["index", "OBSERVATION_MODIFIER", 162, 167], ["septic shock", "OBSERVATION", 199, 211]]], ["GFR (32%, p=0.006) and renal oxygen delivery (RDO2) (24%) where both significantly lower in the study group (Table 1) .", [["renal", "ANATOMY", 23, 28], ["oxygen", "CHEMICAL", 29, 35], ["oxygen", "CHEMICAL", 29, 35], ["renal", "ORGAN", 23, 28], ["oxygen", "SIMPLE_CHEMICAL", 29, 35], ["GFR", "TEST", 0, 3], ["p", "TEST", 10, 11], ["renal oxygen delivery", "TREATMENT", 23, 44], ["RDO2", "TEST", 46, 50], ["renal", "ANATOMY", 23, 28], ["oxygen", "OBSERVATION", 29, 35], ["significantly", "OBSERVATION_MODIFIER", 69, 82], ["lower", "OBSERVATION_MODIFIER", 83, 88]]], ["There was no difference between the groups in renal oxygen consumption (RVO2) but Renal oxygen delivery was almost 30% lower in septic shock patients.", [["renal", "ANATOMY", 46, 51], ["Renal", "ANATOMY", 82, 87], ["oxygen", "CHEMICAL", 52, 58], ["oxygen", "CHEMICAL", 88, 94], ["septic shock", "DISEASE", 128, 140], ["oxygen", "CHEMICAL", 52, 58], ["oxygen", "CHEMICAL", 88, 94], ["renal", "ORGAN", 46, 51], ["oxygen", "SIMPLE_CHEMICAL", 52, 58], ["Renal", "ORGAN", 82, 87], ["oxygen", "SIMPLE_CHEMICAL", 88, 94], ["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 141, 149], ["renal oxygen consumption", "TREATMENT", 46, 70], ["Renal oxygen delivery", "TREATMENT", 82, 103], ["septic shock patients", "TREATMENT", 128, 149], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23], ["renal", "ANATOMY", 46, 51], ["oxygen consumption", "OBSERVATION", 52, 70], ["Renal", "ANATOMY", 82, 87], ["oxygen", "OBSERVATION_MODIFIER", 88, 94], ["septic shock", "OBSERVATION", 128, 140]]], ["Renal oxygen extraction was significantly higher in the study group than in the control group.", [["Renal", "ANATOMY", 0, 5], ["oxygen", "CHEMICAL", 6, 12], ["oxygen", "CHEMICAL", 6, 12], ["Renal", "ORGAN", 0, 5], ["oxygen", "SIMPLE_CHEMICAL", 6, 12], ["Renal oxygen extraction", "TREATMENT", 0, 23], ["oxygen extraction", "OBSERVATION", 6, 23], ["significantly", "OBSERVATION_MODIFIER", 28, 41], ["higher", "OBSERVATION_MODIFIER", 42, 48]]], ["In the study group, NAG was 5.4 \u00b1 3.4 units/mikromol creatinine more, i.e 5 times the value in patients undergoing cardiac surgery [2] .", [["cardiac", "ANATOMY", 115, 122], ["creatinine", "CHEMICAL", 53, 63], ["creatinine", "CHEMICAL", 53, 63], ["NAG", "SIMPLE_CHEMICAL", 20, 23], ["mikromol", "SIMPLE_CHEMICAL", 44, 52], ["creatinine", "SIMPLE_CHEMICAL", 53, 63], ["patients", "ORGANISM", 95, 103], ["cardiac", "ORGAN", 115, 122], ["patients", "SPECIES", 95, 103], ["NAG", "TEST", 20, 23], ["mikromol creatinine", "TEST", 44, 63], ["cardiac surgery", "TREATMENT", 115, 130], ["cardiac", "ANATOMY", 115, 122], ["surgery", "OBSERVATION", 123, 130]]], ["Conclusions: Sepsis related AKI is caused by a renal afferent vasoconstriction resulting in a reduced RBF and lowered RDO2 In combination with an anchanged RVO2, this results in a renal oxygen supply/ demand mismatch.", [["renal afferent", "ANATOMY", 47, 61], ["renal", "ANATOMY", 180, 185], ["Sepsis", "DISEASE", 13, 19], ["AKI", "DISEASE", 28, 31], ["oxygen", "CHEMICAL", 186, 192], ["oxygen", "CHEMICAL", 186, 192], ["renal afferent", "MULTI-TISSUE_STRUCTURE", 47, 61], ["RVO2", "SIMPLE_CHEMICAL", 156, 160], ["renal", "ORGAN", 180, 185], ["oxygen", "SIMPLE_CHEMICAL", 186, 192], ["RDO2", "PROTEIN", 118, 122], ["Sepsis", "PROBLEM", 13, 19], ["AKI", "PROBLEM", 28, 31], ["a renal afferent vasoconstriction", "PROBLEM", 45, 78], ["a reduced RBF", "PROBLEM", 92, 105], ["lowered RDO2", "PROBLEM", 110, 122], ["a renal oxygen supply", "TREATMENT", 178, 199], ["demand mismatch", "PROBLEM", 201, 216], ["Sepsis", "OBSERVATION", 13, 19], ["AKI", "OBSERVATION", 28, 31], ["renal", "ANATOMY", 47, 52], ["afferent vasoconstriction", "OBSERVATION", 53, 78], ["reduced RBF", "OBSERVATION", 94, 105], ["renal", "ANATOMY", 180, 185], ["oxygen supply", "OBSERVATION", 186, 199], ["demand mismatch", "OBSERVATION", 201, 216]]], ["Introduction: The primary aim was to determine if the addition of daily creatine kinase (CK) measurement was usefully guiding decision making in intensive care units within Greater Glasgow and Clyde.", [["creatine", "CHEMICAL", 72, 80], ["creatine", "CHEMICAL", 72, 80], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 72, 87], ["CK", "GENE_OR_GENE_PRODUCT", 89, 91], ["creatine kinase", "PROTEIN", 72, 87], ["CK", "PROTEIN", 89, 91], ["daily creatine kinase", "TEST", 66, 87], ["CK) measurement", "TEST", 89, 104]]], ["Methods: After a change to the daily blood ordering schedule to include CK, a retrospective audit was carried out covering a 5-month period within 3 intensive care units.", [["blood", "ANATOMY", 37, 42], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["CK", "GENE_OR_GENE_PRODUCT", 72, 74], ["CK", "PROTEIN", 72, 74], ["the daily blood ordering schedule", "TREATMENT", 27, 60], ["CK", "TEST", 72, 74]]], ["All patients with CK >870 units/ litre were included.", [["patients", "ORGANISM", 4, 12], ["CK", "PROTEIN", 18, 20], ["patients", "SPECIES", 4, 12], ["CK", "TEST", 18, 20]]], ["Basic demographics, APACHE 2 score and admitting diagnosis were recorded.", [["APACHE", "TEST", 20, 26], ["admitting diagnosis", "TEST", 39, 58]]], ["Utility of CK was assessed by determining the associated diagnosis and whether the diagnosis was first considered (diagnostic trigger) due to CK level, clinical suspicion or haematuria.", [["haematuria", "DISEASE", 174, 184], ["CK", "GENE_OR_GENE_PRODUCT", 11, 13], ["CK", "GENE_OR_GENE_PRODUCT", 142, 144], ["CK", "PROTEIN", 11, 13], ["CK", "PROTEIN", 142, 144], ["CK", "TEST", 11, 13], ["CK level", "TEST", 142, 150], ["haematuria", "PROBLEM", 174, 184], ["haematuria", "OBSERVATION", 174, 184]]], ["Additionally, it was determined if and what actions had been taken based on the raised CK and associated diagnoses.", [["CK", "GENE_OR_GENE_PRODUCT", 87, 89], ["CK", "PROTEIN", 87, 89], ["the raised CK", "TEST", 76, 89]]], ["276 patients were captured with CK >870 units/litre from an average combined admission rate of 200 patients/month [1] .", [["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 99, 107], ["CK", "PROTEIN", 32, 34], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 99, 107], ["CK", "TEST", 32, 34]]], ["Total male patients 191 (69.2%) and female 85 (30.8%).", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19]]], ["Age range 17 to 95 years (mean 54.7).", [["mean", "TEST", 26, 30]]], ["APACHE 2 score range 0 to 45 (mean 20.9) with estimated mean mortality of 36.7%.", [["APACHE", "TEST", 0, 6], ["mean", "TEST", 30, 34], ["estimated mean mortality", "TEST", 46, 70]]], ["176 patients (63.8%) had associated diagnoses with elevated CK including: burns 2 (0.7%), compartment syndrome 7 (2.5%), myocardial infarction 20 (7.2%), myositis/myocarditis 2 (0.7%), neuroleptic malignant syndrome 1 (0.4%), rhabdomyolysis 61 (22.1%), serotonin syndrome 7 (2.5%), surgical procedure 76 (27.5%).", [["myocardial", "ANATOMY", 121, 131], ["burns", "DISEASE", 74, 79], ["compartment syndrome", "DISEASE", 90, 110], ["myocardial infarction", "DISEASE", 121, 142], ["myositis", "DISEASE", 154, 162], ["myocarditis", "DISEASE", 163, 174], ["neuroleptic malignant syndrome", "DISEASE", 185, 215], ["rhabdomyolysis", "DISEASE", 226, 240], ["serotonin", "CHEMICAL", 253, 262], ["serotonin", "CHEMICAL", 253, 262], ["patients", "ORGANISM", 4, 12], ["CK", "GENE_OR_GENE_PRODUCT", 60, 62], ["myocardial", "MULTI-TISSUE_STRUCTURE", 121, 131], ["CK", "PROTEIN", 60, 62], ["patients", "SPECIES", 4, 12], ["elevated CK", "PROBLEM", 51, 62], ["burns", "TEST", 74, 79], ["compartment syndrome", "PROBLEM", 90, 110], ["myocardial infarction", "PROBLEM", 121, 142], ["myositis", "PROBLEM", 154, 162], ["myocarditis", "PROBLEM", 163, 174], ["neuroleptic malignant syndrome", "PROBLEM", 185, 215], ["rhabdomyolysis", "PROBLEM", 226, 240], ["serotonin syndrome", "PROBLEM", 253, 271], ["surgical procedure", "TREATMENT", 282, 300], ["compartment syndrome", "ANATOMY", 90, 110], ["myocardial", "ANATOMY", 121, 131], ["infarction", "OBSERVATION", 132, 142], ["myositis", "OBSERVATION", 154, 162], ["myocarditis", "OBSERVATION", 163, 174], ["neuroleptic malignant syndrome", "OBSERVATION", 185, 215], ["serotonin syndrome", "OBSERVATION", 253, 271]]], ["As outlined in Fig. 1 the diagnostic trigger was the routine CK measurement in 65 patients (23.6%), prior clinical suspicion 108 (39.1%), haematuria 1 (0.4%) and unclear in 102 (36.9%).", [["haematuria", "DISEASE", 138, 148], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["the routine CK measurement", "TEST", 49, 75], ["prior clinical suspicion", "TEST", 100, 124], ["haematuria", "TEST", 138, 148]]], ["Action was The correlation analysis showed the eGFRs from every formula could all to some extent reflect the glomerular function or GFR accurately.", [["glomerular", "ANATOMY", 109, 119], ["glomerular", "TISSUE", 109, 119], ["The correlation analysis", "TEST", 11, 35], ["the eGFRs", "TEST", 43, 52], ["glomerular", "OBSERVATION", 109, 119]]], ["The GFR (Scys) formula was a quickly and accurate method for estimating GFR and may apply clinically in critically ill patients.P165Perioperative chloride levels and acute kidney injury after liver transplantation: a retrospective observational study S Choi 1 Introduction: The risk of developing acute kidney injury (AKI) after liver transplantation in the immediate postoperative period ranges between 17 to 95%.", [["kidney", "ANATOMY", 172, 178], ["liver", "ANATOMY", 192, 197], ["kidney", "ANATOMY", 303, 309], ["liver", "ANATOMY", 329, 334], ["critically ill", "DISEASE", 104, 118], ["P165Perioperative chloride", "CHEMICAL", 128, 154], ["acute kidney injury", "DISEASE", 166, 185], ["acute kidney injury", "DISEASE", 297, 316], ["AKI", "DISEASE", 318, 321], ["P165Perioperative chloride", "CHEMICAL", 128, 154], ["patients", "ORGANISM", 119, 127], ["P165Perioperative chloride", "SIMPLE_CHEMICAL", 128, 154], ["kidney", "ORGAN", 172, 178], ["liver", "ORGAN", 192, 197], ["kidney", "ORGAN", 303, 309], ["liver", "ORGAN", 329, 334], ["patients", "SPECIES", 119, 127], ["The GFR (Scys) formula", "TEST", 0, 22], ["estimating GFR", "TEST", 61, 75], ["P165Perioperative chloride levels", "TEST", 128, 161], ["acute kidney injury", "PROBLEM", 166, 185], ["liver transplantation", "TREATMENT", 192, 213], ["acute kidney injury", "PROBLEM", 297, 316], ["AKI", "PROBLEM", 318, 321], ["liver transplantation", "TREATMENT", 329, 350], ["acute", "OBSERVATION_MODIFIER", 166, 171], ["kidney", "ANATOMY", 172, 178], ["injury", "OBSERVATION", 179, 185], ["liver", "ANATOMY", 192, 197], ["transplantation", "OBSERVATION", 198, 213], ["acute", "OBSERVATION_MODIFIER", 297, 302], ["kidney", "ANATOMY", 303, 309], ["injury", "OBSERVATION", 310, 316], ["AKI", "OBSERVATION", 318, 321], ["liver", "ANATOMY", 329, 334], ["transplantation", "OBSERVATION", 335, 350]]], ["Most studies in critically ill and surgical patients evaluated the link between chloride-rich resuscitation fluids, not serum chloride levels, and the incidence of AKI.", [["serum", "ANATOMY", 120, 125], ["critically ill", "DISEASE", 16, 30], ["chloride", "CHEMICAL", 80, 88], ["chloride", "CHEMICAL", 126, 134], ["AKI", "DISEASE", 164, 167], ["chloride", "CHEMICAL", 80, 88], ["chloride", "CHEMICAL", 126, 134], ["patients", "ORGANISM", 44, 52], ["chloride", "SIMPLE_CHEMICAL", 80, 88], ["serum", "ORGANISM_SUBSTANCE", 120, 125], ["chloride", "SIMPLE_CHEMICAL", 126, 134], ["patients", "SPECIES", 44, 52], ["Most studies", "TEST", 0, 12], ["chloride-rich resuscitation fluids", "TREATMENT", 80, 114], ["serum chloride levels", "TEST", 120, 141], ["AKI", "PROBLEM", 164, 167], ["AKI", "OBSERVATION", 164, 167]]], ["The association between preoperative chloride level or difference in perioperative chloride levels and the incidence of postoperative AKI after liver transplantation were evaluated.", [["liver", "ANATOMY", 144, 149], ["chloride", "CHEMICAL", 37, 45], ["chloride", "CHEMICAL", 83, 91], ["AKI", "DISEASE", 134, 137], ["chloride", "CHEMICAL", 37, 45], ["chloride", "CHEMICAL", 83, 91], ["chloride", "SIMPLE_CHEMICAL", 37, 45], ["chloride", "SIMPLE_CHEMICAL", 83, 91], ["liver", "ORGAN", 144, 149], ["preoperative chloride level", "TEST", 24, 51], ["perioperative chloride levels", "TEST", 69, 98], ["postoperative AKI", "PROBLEM", 120, 137], ["liver transplantation", "TREATMENT", 144, 165], ["postoperative AKI", "OBSERVATION", 120, 137], ["liver", "ANATOMY", 144, 149], ["transplantation", "OBSERVATION", 150, 165]]], ["Methods: Adult patients (>=18 years old) who underwent liver transplantation at Seoul National University Hospital between 2004 and 2015 were included in the retrospective analysis.", [["liver", "ANATOMY", 55, 60], ["patients", "ORGANISM", 15, 23], ["liver", "ORGAN", 55, 60], ["patients", "SPECIES", 15, 23], ["liver transplantation", "TREATMENT", 55, 76], ["the retrospective analysis", "TEST", 154, 180], ["liver", "ANATOMY", 55, 60], ["transplantation", "OBSERVATION", 61, 76]]], ["The difference between preoperative serum chloride level and the immediate postoperative serum chloride level was defined as intraoperative chloride loading.", [["serum", "ANATOMY", 36, 41], ["serum", "ANATOMY", 89, 94], ["chloride", "CHEMICAL", 42, 50], ["chloride", "CHEMICAL", 95, 103], ["chloride", "CHEMICAL", 140, 148], ["chloride", "CHEMICAL", 42, 50], ["chloride", "CHEMICAL", 95, 103], ["chloride", "CHEMICAL", 140, 148], ["serum", "ORGANISM_SUBSTANCE", 36, 41], ["chloride", "SIMPLE_CHEMICAL", 42, 50], ["serum", "ORGANISM_SUBSTANCE", 89, 94], ["chloride", "SIMPLE_CHEMICAL", 95, 103], ["chloride", "SIMPLE_CHEMICAL", 140, 148], ["preoperative serum chloride level", "TEST", 23, 56], ["the immediate postoperative serum chloride level", "TEST", 61, 109], ["intraoperative chloride loading", "TREATMENT", 125, 156]]], ["Postoperative AKI within 7 days of liver transplantation was diagnosed according to the RIFLE criteria.", [["liver", "ANATOMY", 35, 40], ["AKI", "DISEASE", 14, 17], ["liver", "ORGAN", 35, 40], ["Postoperative AKI", "PROBLEM", 0, 17], ["liver transplantation", "TREATMENT", 35, 56], ["AKI", "OBSERVATION", 14, 17], ["liver", "ANATOMY", 35, 40], ["transplantation", "OBSERVATION", 41, 56]]], ["Patients were divided into normochloremia group (96-106 mEq/L), hypochloremia group (<96 mEq/L), or hyperchloremia group (>106 mEq/L) according to their preoperative chloride level.", [["normochloremia", "DISEASE", 27, 41], ["hypochloremia", "DISEASE", 64, 77], ["hyperchloremia", "DISEASE", 100, 114], ["chloride", "CHEMICAL", 166, 174], ["chloride", "CHEMICAL", 166, 174], ["Patients", "ORGANISM", 0, 8], ["chloride", "SIMPLE_CHEMICAL", 166, 174], ["Patients", "SPECIES", 0, 8], ["hypochloremia", "PROBLEM", 64, 77], ["hyperchloremia", "PROBLEM", 100, 114], ["their preoperative chloride level", "TEST", 147, 180]]], ["Intraoperative chloride loading was defined as the difference between preoperative serum chloride level and immediate postoperative serum chloride level. .03) compared to patients with preoperative normochloremia.", [["serum", "ANATOMY", 83, 88], ["serum", "ANATOMY", 132, 137], ["chloride", "CHEMICAL", 15, 23], ["chloride", "CHEMICAL", 89, 97], ["chloride", "CHEMICAL", 138, 146], ["normochloremia", "DISEASE", 198, 212], ["chloride", "CHEMICAL", 15, 23], ["chloride", "CHEMICAL", 89, 97], ["chloride", "CHEMICAL", 138, 146], ["chloride", "SIMPLE_CHEMICAL", 15, 23], ["serum", "ORGANISM_SUBSTANCE", 83, 88], ["chloride", "SIMPLE_CHEMICAL", 89, 97], ["serum", "ORGANISM_SUBSTANCE", 132, 137], ["chloride", "SIMPLE_CHEMICAL", 138, 146], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["Intraoperative chloride loading", "TREATMENT", 0, 31], ["preoperative serum chloride level", "TEST", 70, 103], ["immediate postoperative serum chloride level", "TEST", 108, 152], ["preoperative normochloremia", "PROBLEM", 185, 212], ["normochloremia", "OBSERVATION", 198, 212]]], ["MELD scores > 11 and age >56 years were also associated with increased risk of AKI.", [["AKI", "DISEASE", 79, 82], ["MELD scores", "TEST", 0, 11], ["AKI", "PROBLEM", 79, 82], ["AKI", "OBSERVATION", 79, 82]]], ["Intraoperative chloride loading was not a significant risk factor for AKI after liver transplantation.P165Conclusions: Preoperative hyperchloremia and hypochloremia were both associated with an increased risk of developing AKI in the immediate postoperative period after liver transplantation.", [["liver", "ANATOMY", 80, 85], ["liver", "ANATOMY", 271, 276], ["chloride", "CHEMICAL", 15, 23], ["AKI", "DISEASE", 70, 73], ["hyperchloremia", "DISEASE", 132, 146], ["hypochloremia", "DISEASE", 151, 164], ["AKI", "DISEASE", 223, 226], ["chloride", "CHEMICAL", 15, 23], ["chloride", "SIMPLE_CHEMICAL", 15, 23], ["liver", "ORGAN", 80, 85], ["liver", "ORGAN", 271, 276], ["Intraoperative chloride loading", "TREATMENT", 0, 31], ["AKI", "PROBLEM", 70, 73], ["liver transplantation", "TREATMENT", 80, 101], ["Preoperative hyperchloremia", "PROBLEM", 119, 146], ["hypochloremia", "PROBLEM", 151, 164], ["developing AKI", "PROBLEM", 212, 226], ["liver transplantation", "TREATMENT", 271, 292], ["AKI", "OBSERVATION", 70, 73], ["liver", "ANATOMY", 80, 85], ["transplantation", "OBSERVATION", 86, 101], ["increased", "OBSERVATION_MODIFIER", 194, 203], ["AKI", "OBSERVATION", 223, 226], ["liver", "ANATOMY", 271, 276], ["transplantation", "OBSERVATION", 277, 292]]], ["Introduction: Perioperative Acute Kidney Injury (AKI) is associated with significant morbidity and mortality [1] .", [["Kidney", "ANATOMY", 34, 40], ["Acute Kidney Injury", "DISEASE", 28, 47], ["AKI", "DISEASE", 49, 52], ["Kidney", "ORGAN", 34, 40], ["Perioperative Acute Kidney Injury", "PROBLEM", 14, 47], ["AKI", "PROBLEM", 49, 52], ["significant morbidity", "PROBLEM", 73, 94], ["Acute", "OBSERVATION_MODIFIER", 28, 33], ["Kidney", "ANATOMY", 34, 40], ["Injury", "OBSERVATION", 41, 47], ["AKI", "OBSERVATION", 49, 52], ["significant", "OBSERVATION_MODIFIER", 73, 84], ["morbidity", "OBSERVATION", 85, 94]]], ["Certain urinary biochemical parameters seem to have a standardized behavior during AKI development and may act as surrogates of decreased glomerular filtration rate (GFR) aiding in early AKI diagnosis [2] .", [["urinary", "ANATOMY", 8, 15], ["glomerular", "ANATOMY", 138, 148], ["AKI", "DISEASE", 83, 86], ["AKI", "DISEASE", 187, 190], ["urinary", "ORGANISM_SUBSTANCE", 8, 15], ["glomerular", "TISSUE", 138, 148], ["Certain urinary biochemical parameters", "PROBLEM", 0, 38], ["AKI development", "PROBLEM", 83, 98], ["decreased glomerular filtration rate", "PROBLEM", 128, 164]]], ["Aim of this prospective observational study was the evaluation of urinary biochemical parameters as early indicators of AKI in a cohort of major surgery patients.", [["urinary", "ANATOMY", 66, 73], ["AKI", "DISEASE", 120, 123], ["urinary", "ORGANISM_SUBSTANCE", 66, 73], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 153, 161], ["this prospective observational study", "TEST", 7, 43], ["the evaluation", "TEST", 48, 62], ["urinary biochemical parameters", "TEST", 66, 96], ["AKI", "PROBLEM", 120, 123], ["major surgery", "TREATMENT", 139, 152], ["AKI", "OBSERVATION", 120, 123]]], ["Methods: 68 patients were studied.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["AKI was defined according to AKIN criteria within 48 hrs after surgery [3] .", [["AKI", "DISEASE", 0, 3], ["AKI", "PROBLEM", 0, 3], ["surgery", "TREATMENT", 63, 70]]], ["At pre-defined time points (preoperatively, recovery room [RR] and on postoperative days [POD] 1 to 3) simultaneous serum and urine samples were analyzed Additional studies must confirm these findings and reevaluate these simple parameters as potential AKI monitoring tools.P168Urinary liver-type fatty acid-binding protein is the novel biomarker for diagnosis of acute kidney injury secondary to sepsis T Komuro, T Ota Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan Critical Care 2018, 22(Suppl 1):P168P168Introduction: Acute kidney injury (AKI) is the predictor of poor prognosis for the patient with sepsis and septic shock.", [["serum", "ANATOMY", 116, 121], ["urine samples", "ANATOMY", 126, 139], ["kidney", "ANATOMY", 370, 376], ["kidney", "ANATOMY", 540, 546], ["AKI", "DISEASE", 253, 256], ["acute kidney injury", "DISEASE", 364, 383], ["sepsis", "DISEASE", 397, 403], ["Acute kidney injury", "DISEASE", 534, 553], ["AKI", "DISEASE", 555, 558], ["sepsis", "DISEASE", 616, 622], ["septic shock", "DISEASE", 627, 639], ["fatty acid-", "CHEMICAL", 297, 308], ["serum", "ORGANISM_SUBSTANCE", 116, 121], ["urine samples", "ORGANISM_SUBSTANCE", 126, 139], ["liver", "ORGAN", 286, 291], ["fatty acid-binding protein", "GENE_OR_GENE_PRODUCT", 297, 323], ["kidney", "ORGAN", 370, 376], ["kidney", "ORGAN", 540, 546], ["patient", "ORGANISM", 603, 610], ["P168Urinary liver-type fatty acid-binding protein", "PROTEIN", 274, 323], ["patient", "SPECIES", 603, 610], ["RR", "TEST", 59, 61], ["simultaneous serum", "TEST", 103, 121], ["urine samples", "TEST", 126, 139], ["Additional studies", "TEST", 154, 172], ["these findings", "TEST", 186, 200], ["these simple parameters", "TEST", 216, 239], ["AKI monitoring tools", "TEST", 253, 273], ["P168Urinary liver", "TEST", 274, 291], ["type fatty acid-binding protein", "PROBLEM", 292, 323], ["acute kidney injury", "PROBLEM", 364, 383], ["sepsis", "PROBLEM", 397, 403], ["Acute kidney injury", "PROBLEM", 534, 553], ["sepsis", "PROBLEM", 616, 622], ["septic shock", "PROBLEM", 627, 639], ["liver", "ANATOMY", 286, 291], ["acute", "OBSERVATION_MODIFIER", 364, 369], ["kidney", "ANATOMY", 370, 376], ["injury", "OBSERVATION", 377, 383], ["sepsis", "OBSERVATION", 397, 403], ["Acute", "OBSERVATION_MODIFIER", 534, 539], ["kidney", "ANATOMY", 540, 546], ["injury", "OBSERVATION", 547, 553], ["sepsis", "OBSERVATION", 616, 622], ["septic shock", "OBSERVATION", 627, 639]]], ["Several diagnostic criteria for AKI is used on clinical settings, but useful biomarker is not known yet.", [["AKI", "DISEASE", 32, 35], ["AKI", "PROBLEM", 32, 35], ["useful biomarker", "TEST", 70, 86], ["AKI", "OBSERVATION", 32, 35]]], ["Urinary liver-type fatty acid-binding protein(L-FABP) is associated with kidney function and AKI [1] , But that is not still discussed about AKI secondary to sepsis.", [["Urinary", "ANATOMY", 0, 7], ["kidney", "ANATOMY", 73, 79], ["AKI", "DISEASE", 93, 96], ["AKI", "DISEASE", 141, 144], ["sepsis", "DISEASE", 158, 164], ["liver-type fatty acid-binding protein", "GENE_OR_GENE_PRODUCT", 8, 45], ["L-FABP", "GENE_OR_GENE_PRODUCT", 46, 52], ["kidney", "ORGAN", 73, 79], ["Urinary liver-type fatty acid-binding protein", "PROTEIN", 0, 45], ["L", "PROTEIN", 46, 47], ["FABP", "PROTEIN", 48, 52], ["Urinary liver", "TEST", 0, 13], ["type fatty acid-binding protein", "PROBLEM", 14, 45], ["kidney function", "PROBLEM", 73, 88], ["AKI", "PROBLEM", 93, 96], ["AKI", "PROBLEM", 141, 144], ["sepsis", "PROBLEM", 158, 164], ["liver", "ANATOMY", 8, 13], ["fatty acid-binding", "OBSERVATION", 19, 37], ["kidney", "ANATOMY", 73, 79], ["AKI", "OBSERVATION", 93, 96], ["sepsis", "OBSERVATION", 158, 164]]], ["Thus, we conducted the study of the association between urine L-FABP and AKI with secondary to sepsis.", [["urine", "ANATOMY", 56, 61], ["AKI", "DISEASE", 73, 76], ["sepsis", "DISEASE", 95, 101], ["urine", "ORGANISM_SUBSTANCE", 56, 61], ["L-FABP", "GENE_OR_GENE_PRODUCT", 62, 68], ["urine L-FABP", "PROTEIN", 56, 68], ["the study", "TEST", 19, 28], ["urine L-FABP", "TEST", 56, 68], ["AKI", "PROBLEM", 73, 76], ["sepsis", "PROBLEM", 95, 101], ["AKI", "OBSERVATION", 73, 76], ["sepsis", "OBSERVATION", 95, 101]]], ["The cut-off line of L-FABP was 95.71\u03bcg/g Cr.", [["L-", "CHEMICAL", 20, 22], ["L-FABP", "GENE_OR_GENE_PRODUCT", 20, 26], ["L-FABP", "TEST", 20, 26]]], ["Conclusions: L-FABP can be the novel biomarker for diagnosis of AKI.", [["AKI", "DISEASE", 64, 67], ["L-FABP", "GENE_OR_GENE_PRODUCT", 13, 19], ["L-FABP", "PROTEIN", 13, 19], ["AKI", "PROBLEM", 64, 67], ["AKI", "OBSERVATION", 64, 67]]], ["Further investigation need for diagnostic value of L-FABP and usefulness of early intervention for AKI used by L-FABP.", [["AKI", "DISEASE", 99, 102], ["L-FABP", "GENE_OR_GENE_PRODUCT", 51, 57], ["L-FABP", "GENE_OR_GENE_PRODUCT", 111, 117], ["L-FABP", "PROTEIN", 51, 57], ["L-FABP", "PROTEIN", 111, 117], ["Further investigation", "TEST", 0, 21], ["diagnostic value", "TEST", 31, 47], ["L-FABP", "TEST", 51, 57], ["early intervention", "TREATMENT", 76, 94], ["AKI", "PROBLEM", 99, 102], ["AKI", "OBSERVATION", 99, 102]]], ["Introduction: Biotransformation of 25-hydroxyvitamin D to active 1,25(OH) 2 D occurs primarily in the kidney.", [["kidney", "ANATOMY", 102, 108], ["25-hydroxyvitamin D", "CHEMICAL", 35, 54], ["1,25(OH) 2 D", "CHEMICAL", 65, 77], ["25-hydroxyvitamin D", "CHEMICAL", 35, 54], ["1,25(OH) 2 D", "CHEMICAL", 65, 77], ["25-hydroxyvitamin D", "SIMPLE_CHEMICAL", 35, 54], ["1,25(OH) 2 D", "SIMPLE_CHEMICAL", 65, 77], ["kidney", "ORGAN", 102, 108], ["kidney", "ANATOMY", 102, 108]]], ["Our aim was to explore whether this process was altered in patients with acute kidney injury (AKI).", [["kidney", "ANATOMY", 79, 85], ["acute kidney injury", "DISEASE", 73, 92], ["AKI", "DISEASE", 94, 97], ["patients", "ORGANISM", 59, 67], ["kidney", "ORGAN", 79, 85], ["patients", "SPECIES", 59, 67], ["acute kidney injury", "PROBLEM", 73, 92], ["AKI", "PROBLEM", 94, 97], ["acute", "OBSERVATION_MODIFIER", 73, 78], ["kidney", "ANATOMY", 79, 85], ["injury", "OBSERVATION", 86, 92], ["AKI", "OBSERVATION", 94, 97]]], ["Methods: Consecutive patients admitted to critical care at a tertiary hospital were recruited.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29]]], ["The AKI group comprised patients with KDIGO stage II or stage III AKI; the non-AKI group were patients requiring cardiovascular or respiratory support, but with no AKI.", [["cardiovascular", "ANATOMY", 113, 127], ["respiratory", "ANATOMY", 131, 142], ["AKI", "DISEASE", 4, 7], ["AKI", "DISEASE", 66, 69], ["AKI", "DISEASE", 164, 167], ["patients", "ORGANISM", 24, 32], ["non-AKI", "CANCER", 75, 82], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 94, 102], ["KDIGO stage II", "PROBLEM", 38, 52], ["stage III AKI", "PROBLEM", 56, 69], ["cardiovascular or respiratory support", "TREATMENT", 113, 150], ["AKI", "PROBLEM", 164, 167], ["AKI", "OBSERVATION", 4, 7], ["stage III", "OBSERVATION_MODIFIER", 56, 65], ["AKI", "OBSERVATION", 66, 69], ["no", "UNCERTAINTY", 161, 163], ["AKI", "OBSERVATION", 164, 167]]], ["Vitamin D metabolite concentrations were measured on days 0, 2 and 5.", [["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["Vitamin D metabolite concentrations", "TEST", 0, 35]]], ["Statistical analysis included comparison between groups at each time point, and longitudinal profiles of vitamin D metabolites.P168Results: Interim analysis of 55 participants (44% of the recruitment target) showed that 1,25(OH) 2 D concentrations were significantly lower in patients with AKI at day 2 and day 5.", [["vitamin D", "CHEMICAL", 105, 114], ["1,25", "CHEMICAL", 220, 224], ["OH) 2 D", "CHEMICAL", 225, 232], ["AKI", "DISEASE", 290, 293], ["vitamin D", "CHEMICAL", 105, 114], ["1,25(OH) 2 D", "CHEMICAL", 220, 232], ["vitamin D", "SIMPLE_CHEMICAL", 105, 114], ["1,25(OH) 2 D", "SIMPLE_CHEMICAL", 220, 232], ["patients", "ORGANISM", 276, 284], ["participants", "SPECIES", 163, 175], ["patients", "SPECIES", 276, 284], ["Statistical analysis", "TEST", 0, 20], ["vitamin D metabolites", "TREATMENT", 105, 126], ["Interim analysis", "TEST", 140, 156], ["the recruitment target", "TEST", 184, 206], ["1,25(OH) 2 D concentrations", "TEST", 220, 247], ["AKI", "PROBLEM", 290, 293], ["lower", "OBSERVATION_MODIFIER", 267, 272], ["AKI", "OBSERVATION", 290, 293]]], ["Considering longitudinal changes, 25-hydroxyvitamin D profiles were not different between the groups ( Fig. 1 ) but there was a trend towards a longitudinal increase in 1,25(OH) 2 D in patients without AKI, which was not seen in AKI patients (Fig. 2) .P168Conclusions: Interim analysis indicates significant differences in concentrations of 1,25(OH) 2 D, but not 25(OH)D, in critically ill patients with AKI.", [["25-hydroxyvitamin D", "CHEMICAL", 34, 53], ["1,25(OH) 2 D", "CHEMICAL", 169, 181], ["AKI", "DISEASE", 202, 205], ["AKI", "DISEASE", 229, 232], ["1,25", "CHEMICAL", 341, 345], ["OH) 2 D", "CHEMICAL", 346, 353], ["25(OH)D", "CHEMICAL", 363, 370], ["critically ill", "DISEASE", 375, 389], ["AKI", "DISEASE", 404, 407], ["25-hydroxyvitamin D", "CHEMICAL", 34, 53], ["1,25(OH) 2 D", "CHEMICAL", 169, 181], ["1,25(OH) 2 D", "CHEMICAL", 341, 353], ["25(OH)D", "CHEMICAL", 363, 370], ["25-hydroxyvitamin D", "SIMPLE_CHEMICAL", 34, 53], ["1,25(OH) 2 D", "SIMPLE_CHEMICAL", 169, 181], ["patients", "ORGANISM", 185, 193], ["patients", "ORGANISM", 233, 241], ["1,25(OH) 2 D", "SIMPLE_CHEMICAL", 341, 353], ["25(OH)D", "SIMPLE_CHEMICAL", 363, 370], ["patients", "ORGANISM", 390, 398], ["patients", "SPECIES", 185, 193], ["patients", "SPECIES", 233, 241], ["patients", "SPECIES", 390, 398], ["longitudinal changes", "PROBLEM", 12, 32], ["hydroxyvitamin D profiles", "TEST", 37, 62], ["a longitudinal increase", "PROBLEM", 142, 165], ["AKI", "PROBLEM", 202, 205], ["Interim analysis", "TEST", 269, 285], ["significant differences in concentrations", "PROBLEM", 296, 337], ["AKI", "PROBLEM", 404, 407], ["without", "UNCERTAINTY", 194, 201], ["AKI", "OBSERVATION", 202, 205], ["significant", "OBSERVATION_MODIFIER", 296, 307], ["differences", "OBSERVATION_MODIFIER", 308, 319], ["AKI", "OBSERVATION", 404, 407]]], ["Introduction: Acute renal failure affects from 1% to 25% of patients in the intensive care units (ICUs)1 and it is associated with excess mortality.", [["renal", "ANATOMY", 20, 25], ["Acute renal failure", "DISEASE", 14, 33], ["renal", "ORGAN", 20, 25], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["Acute renal failure", "PROBLEM", 14, 33], ["excess mortality", "PROBLEM", 131, 147], ["Acute", "OBSERVATION_MODIFIER", 14, 19], ["renal", "ANATOMY", 20, 25], ["failure", "OBSERVATION", 26, 33]]], ["Hydratation is a useful preventive measure but it is often controindicated in critically ill patients who, on the contrary, often benefit by a strictly conservative strategy of fluid management.", [["fluid", "ANATOMY", 177, 182], ["Hydratation", "DISEASE", 0, 11], ["critically ill", "DISEASE", 78, 92], ["patients", "ORGANISM", 93, 101], ["fluid", "ORGANISM_SUBSTANCE", 177, 182], ["patients", "SPECIES", 93, 101], ["fluid management", "TREATMENT", 177, 193], ["fluid management", "OBSERVATION", 177, 193]]], ["Fenoldopam, a selective dopamine 1-receptor agonist, increases renal blood flow and glomerular filtration rate by vasodilating selectively the afferent arteriole of renal glomerulus.", [["renal", "ANATOMY", 63, 68], ["blood", "ANATOMY", 69, 74], ["glomerular", "ANATOMY", 84, 94], ["afferent arteriole", "ANATOMY", 143, 161], ["renal glomerulus", "ANATOMY", 165, 181], ["Fenoldopam", "CHEMICAL", 0, 10], ["dopamine", "CHEMICAL", 24, 32], ["Fenoldopam", "CHEMICAL", 0, 10], ["dopamine", "CHEMICAL", 24, 32], ["Fenoldopam", "SIMPLE_CHEMICAL", 0, 10], ["dopamine 1-receptor", "GENE_OR_GENE_PRODUCT", 24, 43], ["renal", "MULTI-TISSUE_STRUCTURE", 63, 68], ["blood", "ORGANISM_SUBSTANCE", 69, 74], ["glomerular", "TISSUE", 84, 94], ["afferent arteriole", "MULTI-TISSUE_STRUCTURE", 143, 161], ["renal glomerulus", "TISSUE", 165, 181], ["Fenoldopam", "TREATMENT", 0, 10], ["a selective dopamine", "TREATMENT", 12, 32], ["renal blood flow", "TREATMENT", 63, 79], ["glomerular filtration rate", "TEST", 84, 110], ["renal", "ANATOMY", 63, 68], ["blood flow", "OBSERVATION", 69, 79], ["glomerular filtration", "OBSERVATION", 84, 105], ["afferent", "ANATOMY_MODIFIER", 143, 151], ["arteriole", "ANATOMY_MODIFIER", 152, 161], ["renal", "ANATOMY", 165, 170], ["glomerulus", "ANATOMY_MODIFIER", 171, 181]]], ["The aim of our study is to compare renal effects of fenoldopam and placebo in critically ill patients undergoing a restrictive fluid management.", [["renal", "ANATOMY", 35, 40], ["fluid", "ANATOMY", 127, 132], ["fenoldopam", "CHEMICAL", 52, 62], ["critically ill", "DISEASE", 78, 92], ["fenoldopam", "CHEMICAL", 52, 62], ["renal", "ORGAN", 35, 40], ["fenoldopam", "SIMPLE_CHEMICAL", 52, 62], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["our study", "TEST", 11, 20], ["fenoldopam", "TREATMENT", 52, 62], ["placebo", "TREATMENT", 67, 74], ["a restrictive fluid management", "TREATMENT", 113, 143], ["renal", "ANATOMY", 35, 40], ["restrictive", "OBSERVATION_MODIFIER", 115, 126], ["fluid management", "OBSERVATION", 127, 143]]], ["Methods: We enrolled 130 patients admitted to our ICU.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33]]], ["Patients were assigned by randomization to study groups: fenoldopam (n=64) and placebo (n=66).", [["fenoldopam", "CHEMICAL", 57, 67], ["fenoldopam", "CHEMICAL", 57, 67], ["Patients", "ORGANISM", 0, 8], ["fenoldopam", "SIMPLE_CHEMICAL", 57, 67], ["Patients", "SPECIES", 0, 8], ["fenoldopam", "TREATMENT", 57, 67]]], ["Fenoldopam was infused continuously at 0,1 mcg/Kg/ min and equivalent volume for placebo during a period of seven days.", [["Fenoldopam", "CHEMICAL", 0, 10], ["Fenoldopam", "CHEMICAL", 0, 10], ["Fenoldopam", "SIMPLE_CHEMICAL", 0, 10], ["Fenoldopam", "TREATMENT", 0, 10], ["placebo", "TREATMENT", 81, 88]]], ["Creatinine, cystatin C and creatinine clearance were daily measured as markers of renal function.", [["renal", "ANATOMY", 82, 87], ["Creatinine", "CHEMICAL", 0, 10], ["creatinine", "CHEMICAL", 27, 37], ["Creatinine", "CHEMICAL", 0, 10], ["creatinine", "CHEMICAL", 27, 37], ["Creatinine", "SIMPLE_CHEMICAL", 0, 10], ["cystatin C", "GENE_OR_GENE_PRODUCT", 12, 22], ["creatinine", "SIMPLE_CHEMICAL", 27, 37], ["renal", "ORGAN", 82, 87], ["Creatinine", "TEST", 0, 10], ["cystatin C", "TEST", 12, 22], ["creatinine clearance", "TEST", 27, 47], ["renal", "ANATOMY", 82, 87]]], ["The incidence of AKI according to RIFLE criteria (Risk, Injury, Failure, Loss, End Stage kidney disease) was also calculated.P168Results: Patients with a negative fluid balance at the end of the week (~-5000 ml, p=0,0001) were included in the analysis, 32 in the placebo group and 38 in the fenoldopam group.", [["kidney", "ANATOMY", 89, 95], ["fluid", "ANATOMY", 163, 168], ["AKI", "DISEASE", 17, 20], ["Injury, Failure, Loss, End Stage kidney disease", "DISEASE", 56, 103], ["fenoldopam", "CHEMICAL", 291, 301], ["fenoldopam", "CHEMICAL", 291, 301], ["kidney", "ORGAN", 89, 95], ["Patients", "ORGANISM", 138, 146], ["fenoldopam", "SIMPLE_CHEMICAL", 291, 301], ["Patients", "SPECIES", 138, 146], ["AKI", "PROBLEM", 17, 20], ["RIFLE criteria", "TEST", 34, 48], ["Injury", "PROBLEM", 56, 62], ["Failure, Loss", "PROBLEM", 64, 77], ["End Stage kidney disease", "PROBLEM", 79, 103], ["fluid balance", "TEST", 163, 176], ["the analysis", "TEST", 239, 251], ["AKI", "OBSERVATION", 17, 20], ["Failure", "OBSERVATION", 64, 71], ["kidney", "ANATOMY", 89, 95], ["disease", "OBSERVATION", 96, 103]]], ["There were not significant differences in the trend of creatinine, creatinine clearance, cystatin C and in the incidence of AKI between the groups during the week of infusion.P168Conclusions: A continuous infusion of fenoldopam at 0,1 mcg/kg/ min does not improve renal function and does not prevent AKI in critically ill patients undergoing a strictly conservative strategy of fluid management.", [["renal", "ANATOMY", 264, 269], ["fluid", "ANATOMY", 378, 383], ["creatinine", "CHEMICAL", 55, 65], ["creatinine", "CHEMICAL", 67, 77], ["AKI", "DISEASE", 124, 127], ["fenoldopam", "CHEMICAL", 217, 227], ["AKI", "DISEASE", 300, 303], ["critically ill", "DISEASE", 307, 321], ["creatinine", "CHEMICAL", 55, 65], ["creatinine", "CHEMICAL", 67, 77], ["fenoldopam", "CHEMICAL", 217, 227], ["creatinine", "SIMPLE_CHEMICAL", 55, 65], ["creatinine", "SIMPLE_CHEMICAL", 67, 77], ["cystatin C", "GENE_OR_GENE_PRODUCT", 89, 99], ["fenoldopam", "SIMPLE_CHEMICAL", 217, 227], ["renal", "ORGAN", 264, 269], ["patients", "ORGANISM", 322, 330], ["fluid", "ORGANISM_SUBSTANCE", 378, 383], ["cystatin C", "PROTEIN", 89, 99], ["patients", "SPECIES", 322, 330], ["creatinine", "TEST", 55, 65], ["creatinine clearance", "TEST", 67, 87], ["cystatin C", "TEST", 89, 99], ["AKI", "PROBLEM", 124, 127], ["infusion", "TREATMENT", 166, 174], ["A continuous infusion of fenoldopam", "TREATMENT", 192, 227], ["AKI", "PROBLEM", 300, 303], ["a strictly conservative strategy of fluid management", "TREATMENT", 342, 394], ["not", "UNCERTAINTY", 11, 14], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["differences", "OBSERVATION_MODIFIER", 27, 38], ["AKI", "OBSERVATION", 124, 127], ["renal", "ANATOMY", 264, 269], ["function", "OBSERVATION", 270, 278], ["fluid management", "OBSERVATION", 378, 394]]], ["Introduction: This study aims to evaluate the efficacy of a protocol implemented for dysphagia risk factors [1] in hospitalized patients in a CICU (Coronary Intensive Care Unit).", [["dysphagia", "DISEASE", 85, 94], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["This study", "TEST", 14, 24], ["a protocol", "TREATMENT", 58, 68], ["dysphagia risk factors", "PROBLEM", 85, 107], ["Coronary", "ANATOMY", 148, 156]]], ["Methods: Patients hospitalized in the CICU of a medium-sized hospital in Presidente Prudente, SP, Brazil, were subjected to a survey that screened for dysphagia during the period from January of 2016 to September of 2017.", [["dysphagia", "DISEASE", 151, 160], ["Patients", "ORGANISM", 9, 17], ["Patients", "SPECIES", 9, 17], ["dysphagia", "PROBLEM", 151, 160]]], ["Patients with at least one risk factor for dysphagia were evaluated by a phonoaudiologist and are the subject of this study.", [["dysphagia", "DISEASE", 43, 52], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["dysphagia", "PROBLEM", 43, 52], ["this study", "TEST", 113, 123]]], ["The information was statistically analyzed using EPI INFO, version 7.2.2.2 software.", [["EPI INFO", "TREATMENT", 49, 57], ["version", "TEST", 59, 66]]], ["Considering significant P <0.05 two-tailed, for logistic regressions multivariate estimated in the sample.", [["logistic regressions multivariate", "PROBLEM", 48, 81]]], ["Results: For this study 1018 patients were selected, of which 57.41% were male and the mean age was 71.77 \u00b1 10.96 years.", [["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["this study", "TEST", 13, 23]]], ["A higher incidence of dysphagia was observed among patients who had at least one of the following risk factors: stroke (Odds Ratio 9.58 p<0.001); brain tumor (OR 4.49 p=0.0013); chronic obstructive pulmonary disease (COPD) (OR 3.45 p=0.023); degenerative diseases (OR 16.76 p<0.001); lower level of consciousness (OR 13.62 p<0.001); ataxic respiration (OR 2.24 p<0.001); aspiration pneumonia (OR 7.04 p<0.001); orotracheal intubation >48h (OR 13.35 p<0.001); tracheostomy (OR 12.99 p<0.001); airway secretion (OR 24.91 p<0.001); nasoenteral tube (OR 14.9 p<0.001); gastrostomy (OR 4.58 p=0.030).", [["brain tumor", "ANATOMY", 146, 157], ["pulmonary", "ANATOMY", 198, 207], ["orotracheal", "ANATOMY", 411, 422], ["airway", "ANATOMY", 492, 498], ["nasoenteral tube", "ANATOMY", 529, 545], ["dysphagia", "DISEASE", 22, 31], ["stroke", "DISEASE", 112, 118], ["brain tumor", "DISEASE", 146, 157], ["chronic obstructive pulmonary disease", "DISEASE", 178, 215], ["COPD", "DISEASE", 217, 221], ["degenerative diseases", "DISEASE", 242, 263], ["ataxic respiration", "DISEASE", 333, 351], ["aspiration pneumonia", "DISEASE", 371, 391], ["patients", "ORGANISM", 51, 59], ["brain tumor", "CANCER", 146, 157], ["pulmonary", "ORGAN", 198, 207], ["airway", "MULTI-TISSUE_STRUCTURE", 492, 498], ["nasoenteral tube", "MULTI-TISSUE_STRUCTURE", 529, 545], ["patients", "SPECIES", 51, 59], ["dysphagia", "PROBLEM", 22, 31], ["stroke", "PROBLEM", 112, 118], ["Ratio", "TEST", 125, 130], ["brain tumor", "PROBLEM", 146, 157], ["chronic obstructive pulmonary disease (COPD)", "PROBLEM", 178, 222], ["degenerative diseases", "PROBLEM", 242, 263], ["lower level of consciousness", "PROBLEM", 284, 312], ["ataxic respiration", "PROBLEM", 333, 351], ["aspiration pneumonia", "PROBLEM", 371, 391], ["orotracheal intubation", "TREATMENT", 411, 433], ["tracheostomy", "TREATMENT", 459, 471], ["airway secretion", "TEST", 492, 508], ["nasoenteral tube", "TREATMENT", 529, 545], ["gastrostomy", "TREATMENT", 565, 576], ["higher", "OBSERVATION_MODIFIER", 2, 8], ["dysphagia", "OBSERVATION", 22, 31], ["stroke", "OBSERVATION", 112, 118], ["brain", "ANATOMY", 146, 151], ["tumor", "OBSERVATION", 152, 157], ["chronic", "OBSERVATION_MODIFIER", 178, 185], ["obstructive", "OBSERVATION_MODIFIER", 186, 197], ["pulmonary", "ANATOMY", 198, 207], ["disease", "OBSERVATION", 208, 215], ["COPD", "OBSERVATION", 217, 221], ["degenerative", "OBSERVATION_MODIFIER", 242, 254], ["diseases", "OBSERVATION", 255, 263], ["pneumonia", "OBSERVATION", 382, 391], ["orotracheal", "ANATOMY", 411, 422], ["airway", "ANATOMY", 492, 498], ["tube", "OBSERVATION", 541, 545]]], ["There was no statistical significance for age >60, traumatic brain injury, oropharyngeal surgery and unfavorable dentition.", [["brain", "ANATOMY", 61, 66], ["oropharyngeal", "ANATOMY", 75, 88], ["traumatic brain injury", "DISEASE", 51, 73], ["brain", "ORGAN", 61, 66], ["oropharyngeal", "ORGANISM_SUBDIVISION", 75, 88], ["traumatic brain injury", "PROBLEM", 51, 73], ["oropharyngeal surgery", "TREATMENT", 75, 96], ["unfavorable dentition", "PROBLEM", 101, 122], ["no", "UNCERTAINTY", 10, 12], ["traumatic", "OBSERVATION_MODIFIER", 51, 60], ["brain", "ANATOMY", 61, 66], ["injury", "OBSERVATION", 67, 73], ["oropharyngeal", "ANATOMY", 75, 88], ["surgery", "OBSERVATION", 89, 96], ["unfavorable dentition", "OBSERVATION", 101, 122]]], ["Four factors appeared less than 3 times and could not be analyzed (chagas disease, human immunodeficiency virus (HIV), orofacial burn and excess saliva).", [["orofacial", "ANATOMY", 119, 128], ["chagas disease", "DISEASE", 67, 81], ["human immunodeficiency virus (HIV), orofacial burn", "DISEASE", 83, 133], ["human immunodeficiency virus", "ORGANISM", 83, 111], ["HIV", "ORGANISM", 113, 116], ["orofacial", "ORGANISM_SUBDIVISION", 119, 128], ["saliva", "ORGANISM_SUBSTANCE", 145, 151], ["human immunodeficiency virus", "SPECIES", 83, 111], ["HIV", "SPECIES", 113, 116], ["human immunodeficiency virus", "SPECIES", 83, 111], ["HIV", "SPECIES", 113, 116], ["chagas disease", "PROBLEM", 67, 81], ["human immunodeficiency virus (HIV)", "PROBLEM", 83, 117], ["orofacial burn", "PROBLEM", 119, 133], ["excess saliva", "PROBLEM", 138, 151], ["orofacial", "ANATOMY", 119, 128]]], ["Conclusions: We concluded that the dysphagia triage protocol insertion was effective to identify dysphagic patients and can be used as an additional tool in the intensive care risk management. physiological bases of this age old concept, more recently applied to endotracheal intubation, have never been confirmed by current methods.", [["endotracheal", "ANATOMY", 263, 275], ["dysphagia", "DISEASE", 35, 44], ["dysphagic", "DISEASE", 97, 106], ["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["the dysphagia triage protocol insertion", "TREATMENT", 31, 70], ["dysphagic patients", "PROBLEM", 97, 115], ["the intensive care risk management", "TREATMENT", 157, 191], ["endotracheal intubation", "TREATMENT", 263, 286], ["bases", "ANATOMY_MODIFIER", 207, 212], ["endotracheal intubation", "OBSERVATION", 263, 286]]], ["We therefore decided to study the effects of an apnea oxygenation period under HFNC oxygen therapy by means of a novel modelization of the respiratory system.", [["respiratory system", "ANATOMY", 139, 157], ["apnea", "DISEASE", 48, 53], ["oxygen", "CHEMICAL", 84, 90], ["oxygen", "CHEMICAL", 84, 90], ["oxygen", "SIMPLE_CHEMICAL", 84, 90], ["an apnea oxygenation period", "TREATMENT", 45, 72], ["HFNC oxygen therapy", "TREATMENT", 79, 98], ["a novel modelization of the respiratory system", "TREATMENT", 111, 157], ["apnea", "OBSERVATION", 48, 53], ["oxygen therapy", "OBSERVATION", 84, 98], ["respiratory system", "ANATOMY", 139, 157]]], ["Methods: Firstly, an airway model was built with anatomical, physical and physiological attributes similar to that of a healthy subject (Fig. 1) .", [["airway", "ANATOMY", 21, 27], ["airway", "MULTI-TISSUE_STRUCTURE", 21, 27], ["airway", "ANATOMY", 21, 27]]], ["This system reproduces the physiological evolution of intrapulmonary gases during apnea by progressively increasing CO 2 levels after having cut off previous O 2 supplies (FIO 2 21%).", [["intrapulmonary", "ANATOMY", 54, 68], ["apnea", "DISEASE", 82, 87], ["CO 2", "CHEMICAL", 116, 120], ["O 2", "CHEMICAL", 158, 161], ["intrapulmonary gases", "PROBLEM", 54, 74], ["apnea", "PROBLEM", 82, 87], ["progressively increasing CO 2 levels", "PROBLEM", 91, 127], ["FIO", "TEST", 172, 175], ["intrapulmonary gases", "OBSERVATION", 54, 74]]], ["Secondly, the effects of a HFNC apnea oxygenation of 50l/min with an FIO 2 of 100% were analyzed by collecting intrapulmonary gas samples at regular intervals (Fig. 2) .", [["intrapulmonary gas samples", "ANATOMY", 111, 137], ["apnea", "DISEASE", 32, 37], ["a HFNC apnea oxygenation", "TREATMENT", 25, 49], ["an FIO", "TREATMENT", 66, 72], ["collecting intrapulmonary gas samples", "TEST", 100, 137], ["HFNC apnea", "OBSERVATION", 27, 37], ["intrapulmonary", "ANATOMY", 111, 125]]], ["Results: After 1 minute of apnea oxygenation, intrapulmonary oxygen levels remain stable at 21%.", [["intrapulmonary", "ANATOMY", 46, 60], ["apnea", "DISEASE", 27, 32], ["oxygen", "CHEMICAL", 61, 67], ["oxygen", "CHEMICAL", 61, 67], ["intrapulmonary", "MULTI-TISSUE_STRUCTURE", 46, 60], ["oxygen", "SIMPLE_CHEMICAL", 61, 67], ["apnea oxygenation", "TEST", 27, 44], ["intrapulmonary oxygen levels", "TEST", 46, 74], ["intrapulmonary", "ANATOMY", 46, 60], ["oxygen levels", "OBSERVATION", 61, 74], ["stable", "OBSERVATION_MODIFIER", 82, 88]]], ["After 5 minutes, oxygen fraction reaches 33%, and increases up to 45% in 10 minutes.", [["oxygen", "CHEMICAL", 17, 23], ["oxygen", "CHEMICAL", 17, 23], ["oxygen", "SIMPLE_CHEMICAL", 17, 23], ["oxygen fraction", "TEST", 17, 32]]], ["Regarding CO 2 levels, no significant modifications were observed.", [["CO 2", "CHEMICAL", 10, 14], ["CO 2", "GENE_OR_GENE_PRODUCT", 10, 14], ["CO 2 levels", "TEST", 10, 21], ["significant modifications", "PROBLEM", 26, 51], ["no", "UNCERTAINTY", 23, 25], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["modifications", "OBSERVATION", 38, 51]]], ["Conclusions: A novel experimental and physiological model of the respiratory system has been developed and confirms the existence of an alveolar oxygen supply as well as the lack of a CO 2 washout during HFNC apnea oxygenation.", [["respiratory system", "ANATOMY", 65, 83], ["alveolar", "ANATOMY", 136, 144], ["oxygen", "CHEMICAL", 145, 151], ["apnea", "DISEASE", 209, 214], ["oxygen", "CHEMICAL", 145, 151], ["CO 2", "CHEMICAL", 184, 188], ["alveolar", "TISSUE", 136, 144], ["oxygen", "SIMPLE_CHEMICAL", 145, 151], ["an alveolar oxygen supply", "TREATMENT", 133, 158], ["a CO 2 washout", "TREATMENT", 182, 196], ["HFNC apnea oxygenation", "TREATMENT", 204, 226], ["respiratory system", "ANATOMY", 65, 83], ["alveolar", "OBSERVATION", 136, 144], ["oxygen supply", "OBSERVATION", 145, 158], ["apnea oxygenation", "OBSERVATION", 209, 226]]], ["Therefore, the clinical interests of this technique to reduce apnea-induced desaturation during intubation of a hypoxemic patient in the ICU seem limited without adequate preoxygenation.", [["desaturation", "DISEASE", 76, 88], ["patient", "ORGANISM", 122, 129], ["patient", "SPECIES", 122, 129], ["this technique", "TREATMENT", 37, 51], ["apnea-induced desaturation", "PROBLEM", 62, 88], ["intubation", "TREATMENT", 96, 106], ["a hypoxemic", "PROBLEM", 110, 121]]], ["Combination of both preoxygenation and apnea oxygenation by HFNC can most likely explain positive results observed in other clinical studies.P173Effect of 4% nebulized lignocaine versus 2% nebulized lignocaine for awake fibreoptic nasotracheal intubation in maxillofacial injuries in emergency department H Abbas, L Kumar King George's Medical University,Lucknow,India, Lucknow, India Critical Care 2018, 22(Suppl 1):P173 Introduction: Topical lignocaine is most commonly used pharmacological agent for anaesthetizing upper airway during fibreoptic bronchoscopy.", [["maxillofacial", "ANATOMY", 258, 271], ["upper airway", "ANATOMY", 518, 530], ["apnea", "DISEASE", 39, 44], ["HFNC", "CHEMICAL", 60, 64], ["lignocaine", "CHEMICAL", 168, 178], ["lignocaine", "CHEMICAL", 199, 209], ["maxillofacial injuries", "DISEASE", 258, 280], ["lignocaine", "CHEMICAL", 444, 454], ["lignocaine", "CHEMICAL", 168, 178], ["lignocaine", "CHEMICAL", 199, 209], ["lignocaine", "CHEMICAL", 444, 454], ["HFNC", "SIMPLE_CHEMICAL", 60, 64], ["lignocaine", "SIMPLE_CHEMICAL", 168, 178], ["lignocaine", "SIMPLE_CHEMICAL", 199, 209], ["lignocaine", "SIMPLE_CHEMICAL", 444, 454], ["upper airway", "MULTI-TISSUE_STRUCTURE", 518, 530], ["both preoxygenation", "TREATMENT", 15, 34], ["apnea oxygenation", "PROBLEM", 39, 56], ["HFNC", "TREATMENT", 60, 64], ["other clinical studies", "TEST", 118, 140], ["4% nebulized lignocaine", "TREATMENT", 155, 178], ["2% nebulized lignocaine", "TREATMENT", 186, 209], ["fibreoptic nasotracheal intubation", "TREATMENT", 220, 254], ["Topical lignocaine", "TREATMENT", 436, 454], ["pharmacological agent", "TREATMENT", 477, 498], ["anaesthetizing upper airway", "TREATMENT", 503, 530], ["fibreoptic bronchoscopy", "TEST", 538, 561], ["both preoxygenation", "OBSERVATION", 15, 34], ["apnea oxygenation", "OBSERVATION", 39, 56], ["maxillofacial", "ANATOMY", 258, 271], ["upper", "ANATOMY_MODIFIER", 518, 523], ["airway", "ANATOMY", 524, 530]]], ["We compare the effectiveness of two different concentrations, 2% lignocaine and 4% lignocaine, in nebulised form for airway anaesthesia during awake fibreoptic nasotracheal intubation in terms of patient's comfort and optimal intubating conditions, intubation time.", [["airway", "ANATOMY", 117, 123], ["nasotracheal", "ANATOMY", 160, 172], ["lignocaine", "CHEMICAL", 65, 75], ["lignocaine", "CHEMICAL", 83, 93], ["lignocaine", "CHEMICAL", 65, 75], ["lignocaine", "CHEMICAL", 83, 93], ["lignocaine", "SIMPLE_CHEMICAL", 65, 75], ["lignocaine", "SIMPLE_CHEMICAL", 83, 93], ["airway", "MULTI-TISSUE_STRUCTURE", 117, 123], ["patient", "ORGANISM", 196, 203], ["patient", "SPECIES", 196, 203], ["two different concentrations", "TREATMENT", 32, 60], ["2% lignocaine", "TREATMENT", 62, 75], ["4% lignocaine", "TREATMENT", 80, 93], ["airway anaesthesia", "TREATMENT", 117, 135], ["awake fibreoptic nasotracheal intubation", "TREATMENT", 143, 183], ["patient's comfort", "TREATMENT", 196, 213], ["optimal intubating conditions", "TREATMENT", 218, 247], ["intubation", "TREATMENT", 249, 259], ["airway", "ANATOMY", 117, 123]]], ["Methods: Institutional Ethics Committee approved the study and written informed consent obtained; patients of either sex, between 18-55 years age with anticipated difficult airway planned for intubation were included for this study.", [["airway", "ANATOMY", 173, 179], ["patients", "ORGANISM", 98, 106], ["airway", "MULTI-TISSUE_STRUCTURE", 173, 179], ["patients", "SPECIES", 98, 106], ["intubation", "TREATMENT", 192, 202], ["this study", "TEST", 221, 231]]], ["Patients were randomly allocated into two groups (A and B) based on sealed envelope method; patients and observers were blinded by using prefilled syringes of lignocaine.One group was nebulized with 10ml of 4% lignocaine(Group A) and other with 10 ml of 2% lignocaine(Group B) in coded syringes via ultrasonic nebuliser for 10 minutes followed by Inj midazolam 0.05 mg/kg IV and Inj Fentanyl 1 microgram/kg IV just before the procedure.", [["lignocaine", "CHEMICAL", 159, 169], ["lignocaine", "CHEMICAL", 210, 220], ["lignocaine", "CHEMICAL", 257, 267], ["midazolam", "CHEMICAL", 351, 360], ["Fentanyl", "CHEMICAL", 383, 391], ["lignocaine", "CHEMICAL", 159, 169], ["lignocaine", "CHEMICAL", 210, 220], ["lignocaine", "CHEMICAL", 257, 267], ["midazolam", "CHEMICAL", 351, 360], ["Fentanyl", "CHEMICAL", 383, 391], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 92, 100], ["lignocaine", "SIMPLE_CHEMICAL", 159, 169], ["lignocaine", "SIMPLE_CHEMICAL", 210, 220], ["lignocaine", "SIMPLE_CHEMICAL", 257, 267], ["midazolam", "SIMPLE_CHEMICAL", 351, 360], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 92, 100], ["lignocaine", "TREATMENT", 159, 169], ["4% lignocaine(Group A)", "TREATMENT", 207, 229], ["2% lignocaine(Group B)", "TREATMENT", 254, 276], ["ultrasonic nebuliser", "TREATMENT", 299, 319], ["Inj midazolam", "TREATMENT", 347, 360], ["Inj Fentanyl", "TREATMENT", 379, 391], ["the procedure", "TREATMENT", 422, 435]]], ["The fibreoptic broncoscope was introduced via nostril and the other nostril was used for oxygen insufflation (3-4 L/min).", [["nostril", "ANATOMY", 46, 53], ["nostril", "ANATOMY", 68, 75], ["oxygen", "CHEMICAL", 89, 95], ["oxygen", "CHEMICAL", 89, 95], ["nostril", "ORGAN", 46, 53], ["nostril", "ORGAN", 68, 75], ["oxygen", "SIMPLE_CHEMICAL", 89, 95], ["The fibreoptic broncoscope", "TREATMENT", 0, 26], ["nostril", "TREATMENT", 46, 53], ["the other nostril", "TREATMENT", 58, 75], ["oxygen insufflation", "TREATMENT", 89, 108], ["oxygen insufflation", "OBSERVATION", 89, 108]]], ["The fibroscope was introduced through the glottic opening and visualising tracheal rings and carina.The endotracheal tube railroaded over the fiberscope and cuff inflated.", [["glottic", "ANATOMY", 42, 49], ["tracheal rings", "ANATOMY", 74, 88], ["endotracheal tube", "ANATOMY", 104, 121], ["fiberscope", "ANATOMY", 142, 152], ["glottic", "ORGAN", 42, 49], ["tracheal rings", "MULTI-TISSUE_STRUCTURE", 74, 88], ["carina", "MULTI-TISSUE_STRUCTURE", 93, 99], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 104, 121], ["The fibroscope", "TREATMENT", 0, 14], ["The endotracheal tube", "TREATMENT", 100, 121], ["the fiberscope", "TREATMENT", 138, 152], ["cuff inflated", "TREATMENT", 157, 170], ["fibroscope", "OBSERVATION", 4, 14], ["glottic opening", "OBSERVATION", 42, 57], ["tracheal rings", "ANATOMY", 74, 88], ["carina", "ANATOMY", 93, 99], ["endotracheal tube", "OBSERVATION", 104, 121], ["cuff inflated", "OBSERVATION", 157, 170]]], ["Results: The primary outcome measure was patient's comfort during awake fibreoptic nasotracheal intubation.", [["patient", "ORGANISM", 41, 48], ["patient", "SPECIES", 41, 48], ["awake fibreoptic nasotracheal intubation", "TREATMENT", 66, 106], ["nasotracheal intubation", "OBSERVATION", 83, 106]]], ["The mean patient comfort Puchner scale score of Group A was 1.30 \u00b1 0.08 and of Group B was 2.23 \u00b1 0.12.", [["patient", "ORGANISM", 9, 16], ["patient", "SPECIES", 9, 16], ["The mean patient comfort Puchner scale score", "TEST", 0, 44], ["Group A", "TEST", 48, 55], ["Group B", "TEST", 79, 86]]], ["The mean value of Puchner scale of Group B was significantly higher.The mean procedural time of Group B was significantly higher (15.1%) as compared to Group A (p<0.001).", [["The mean value", "TEST", 0, 14], ["Group B", "TEST", 96, 103], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["mean", "OBSERVATION_MODIFIER", 72, 76]]], ["The no of intubations attempts did not differ between the two groups.", [["intubations", "TREATMENT", 10, 21], ["no", "UNCERTAINTY", 4, 6]]], ["Conclusions: 4% nebulised lidocaine provided adequate airway anaesthesia and optimal intubating conditions, patient comfort, stable hemodynamics.", [["airway", "ANATOMY", 54, 60], ["lidocaine", "CHEMICAL", 26, 35], ["lidocaine", "CHEMICAL", 26, 35], ["lidocaine", "SIMPLE_CHEMICAL", 26, 35], ["airway", "MULTI-TISSUE_STRUCTURE", 54, 60], ["patient", "ORGANISM", 108, 115], ["patient", "SPECIES", 108, 115], ["nebulised lidocaine", "TREATMENT", 16, 35], ["adequate airway anaesthesia", "TREATMENT", 45, 72], ["optimal intubating conditions", "TREATMENT", 77, 106], ["airway", "ANATOMY", 54, 60]]], ["Introduction: This systematic review and meta-analysis aims to investigate whether video laryngoscopy (VL) improves the success of orotracheal intubation, when compared with direct laryngoscopy (DL).", [["orotracheal", "ANATOMY", 131, 142], ["video laryngoscopy", "TEST", 83, 101], ["orotracheal intubation", "TREATMENT", 131, 153], ["direct laryngoscopy", "TEST", 174, 193], ["orotracheal intubation", "OBSERVATION", 131, 153]]], ["Methods: A systematic search of Pubmed, Embase, and CENTRAL databases was performed to identify studies comparing VL and DL for emergency orotracheal intubations outside the operating room.", [["orotracheal", "ANATOMY", 138, 149], ["studies", "TEST", 96, 103], ["emergency orotracheal intubations", "TREATMENT", 128, 161]]], ["The primary outcome was rate of first pass intubation.", [["first pass intubation", "TREATMENT", 32, 53]]], ["The secondary outcome was rate of complications.", [["complications", "PROBLEM", 34, 47]]], ["Results: The search identified 32 studies with 15,064 emergency intubations.", [["32 studies", "TEST", 31, 41], ["emergency intubations", "TREATMENT", 54, 75]]], ["There was no overall difference in first-pass intubation with VL compared to DL.", [["no", "UNCERTAINTY", 10, 12], ["overall", "OBSERVATION_MODIFIER", 13, 20], ["difference", "OBSERVATION_MODIFIER", 21, 31]]], ["Subgroup analysis showed first-pass intubations were increased with VL in the intensive care unit (ICU) (2.02 (1.43-2.85); p<0.01), but not in the emergency department or pre-hospital setting.", [["Subgroup analysis", "TEST", 0, 17]]], ["Rate of first-pass intubations were similar with Glidescope\u00ae and DL, but improved with the CMAC\u00ae (1.32(1.08-1.62); p=0.007).", [["intubations", "TREATMENT", 19, 30], ["the CMAC", "TEST", 87, 95], ["DL", "ANATOMY", 65, 67]]], ["There was greater first-pass intubation with VL than DL among novice/trainee clinicians (OR=1.95 (1.45-2.64); p<0.001), but not among experienced clinicians or paramedics/nurses.", [["greater", "OBSERVATION_MODIFIER", 10, 17]]], ["There was no difference in first-pass intubation with VL and DL during cardiopulmonary resuscitation or trauma.", [["cardiopulmonary", "ANATOMY", 71, 86], ["trauma", "DISEASE", 104, 110], ["VL", "TREATMENT", 54, 56], ["cardiopulmonary resuscitation", "TREATMENT", 71, 100], ["trauma", "PROBLEM", 104, 110], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23], ["cardiopulmonary", "ANATOMY", 71, 86], ["resuscitation", "OBSERVATION", 87, 100]]], ["VL was associated with fewer oesophageal intubations than DL (OR=0.31 (0.14-0.69); p=0.004), but more arterial hypotension (OR=1.49 (1.00-2.23); p=0.05).", [["oesophageal", "ANATOMY", 29, 40], ["arterial", "ANATOMY", 102, 110], ["arterial hypotension", "DISEASE", 102, 122], ["oesophageal", "ORGAN", 29, 40], ["arterial", "MULTI-TISSUE_STRUCTURE", 102, 110], ["VL", "TEST", 0, 2], ["fewer oesophageal intubations", "PROBLEM", 23, 52], ["more arterial hypotension", "PROBLEM", 97, 122], ["fewer", "OBSERVATION_MODIFIER", 23, 28], ["oesophageal", "ANATOMY", 29, 40], ["intubations", "OBSERVATION", 41, 52], ["arterial", "ANATOMY", 102, 110], ["hypotension", "OBSERVATION", 111, 122]]], ["Conclusions: In summary, compared to DL, VL is associated with greater first-pass emergency intubation in the ICU and among less experienced clinicians.", [["emergency intubation", "TREATMENT", 82, 102], ["greater", "OBSERVATION_MODIFIER", 63, 70]]], ["VL is associated with reduced oesophageal intubations but a greater incidence of arterial hypotension.P175Compared success rate between direct laryngoscope and video laryngoscope for emergency intubation, in Emergency Department: Randomized Control Trial P Sanguanwit, N Laowattana Ramathibodi Hospital, Bangkok, Thailand Critical Care 2018, 22(Suppl 1):P175 Introduction: Video Laryngoscope was used as an alternative to intubate in the Emergency room, designed for tracheal intubation more success [1, 2] .", [["oesophageal", "ANATOMY", 30, 41], ["arterial", "ANATOMY", 81, 89], ["tracheal", "ANATOMY", 467, 475], ["VL", "DISEASE", 0, 2], ["arterial hypotension", "DISEASE", 81, 101], ["oesophageal", "ORGAN", 30, 41], ["arterial", "MULTI-TISSUE_STRUCTURE", 81, 89], ["tracheal", "ORGAN", 467, 475], ["reduced oesophageal intubations", "PROBLEM", 22, 53], ["arterial hypotension", "PROBLEM", 81, 101], ["direct laryngoscope", "TREATMENT", 136, 155], ["video laryngoscope", "TREATMENT", 160, 178], ["emergency intubation", "TREATMENT", 183, 203], ["Video Laryngoscope", "TREATMENT", 373, 391], ["tracheal intubation", "TREATMENT", 467, 486], ["associated with", "UNCERTAINTY", 6, 21], ["reduced", "OBSERVATION_MODIFIER", 22, 29], ["oesophageal intubations", "OBSERVATION", 30, 53], ["greater", "OBSERVATION_MODIFIER", 60, 67], ["arterial", "ANATOMY", 81, 89], ["hypotension", "OBSERVATION", 90, 101], ["tracheal", "ANATOMY", 467, 475]]], ["Methods: We performed a prospective randomized controlled trial study of 158 patients who had sign of respiratory failure or met indication for intubation from July 2015 to June 2016.", [["respiratory", "ANATOMY", 102, 113], ["respiratory failure", "DISEASE", 102, 121], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["respiratory failure", "PROBLEM", 102, 121], ["intubation", "TREATMENT", 144, 154], ["respiratory", "ANATOMY", 102, 113], ["failure", "OBSERVATION", 114, 121]]], ["Patients were randomly by SNOSE technique; assigned to Video laryngoscope first or Direct laryngoscope first.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["Video laryngoscope", "TEST", 55, 73], ["Direct laryngoscope", "TREATMENT", 83, 102]]], ["We collect the Demographics, Difficult Intubation Predictor, Rapid Sequence Intubation, attempt, Cormack-Lehane view and immediate complication.", [["Rapid Sequence Intubation", "TREATMENT", 61, 86], ["Cormack", "TEST", 97, 104], ["immediate complication", "PROBLEM", 121, 143], ["complication", "OBSERVATION", 131, 143]]], ["Primary outcome was first attempt success rate of intubation.", [["intubation", "TREATMENT", 50, 60]]], ["Results: First attempt success rate of Video laryngoscope was 73.1% trend to better than Direct laryngoscope was 58.8%, (P=0.06), Good Glottic view (Cormack-Lehane view 1-2) of Video laryngoscope was 88.5% better than Direct laryngoscope 71.3%, and statistically significant (P=0.03), no statistical significant in immediate serious complication between Direct laryngoscope or Video laryngoscope.", [["Video laryngoscope", "TEST", 39, 57], ["Direct laryngoscope", "TEST", 89, 108], ["P", "TEST", 121, 122], ["Good Glottic view", "TEST", 130, 147], ["Cormack", "TEST", 149, 156], ["Lehane view", "TEST", 157, 168], ["Video laryngoscope", "TEST", 177, 195], ["Direct laryngoscope", "TEST", 218, 237], ["P", "TEST", 276, 277], ["statistical significant in immediate serious complication", "PROBLEM", 288, 345], ["Direct laryngoscope", "TREATMENT", 354, 373], ["Video laryngoscope", "TREATMENT", 377, 395], ["significant", "OBSERVATION_MODIFIER", 263, 274], ["significant", "OBSERVATION_MODIFIER", 300, 311]]], ["Conclusions: Compared to the success rate between using Video laryngoscope or Direct laryngoscope for intubation, Video laryngoscope trend to better success rate, and better glottic view.P17610-year cohort of prehospital intubations and rescue airway techniques by helicopter emergency medical service physicians: a retrospective database study P De Jong, C Slagt, N Hoogerwerf Radboudumc, Nijmegen, Netherlands Critical Care 2018, 22(Suppl 1):P176 Introduction: In the Netherlands the pre-hospital Helicopter Emergency Medical Service (HEMS) is physician based and an adjunct to ambulance services.", [["glottic", "ANATOMY", 174, 181], ["airway", "ANATOMY", 244, 250], ["airway", "MULTI-TISSUE_STRUCTURE", 244, 250], ["Video laryngoscope", "TEST", 56, 74], ["Direct laryngoscope", "TREATMENT", 78, 97], ["intubation", "TREATMENT", 102, 112], ["Video laryngoscope", "TEST", 114, 132], ["prehospital intubations", "TREATMENT", 209, 232], ["airway", "ANATOMY", 244, 250]]], ["In many dispatches the added value is airway related [1] .", [["airway", "ANATOMY", 38, 44], ["airway", "MULTI-TISSUE_STRUCTURE", 38, 44], ["airway", "ANATOMY", 38, 44]]], ["As part of our quality control cycle, all airway related procedures were analysed.", [["airway", "ANATOMY", 42, 48], ["airway", "MULTI-TISSUE_STRUCTURE", 42, 48], ["all airway related procedures", "TREATMENT", 38, 67], ["airway", "ANATOMY", 42, 48]]], ["High quality airway management is characterized by high overall and first pass endotracheal intubation (ETI) success [2] .", [["airway", "ANATOMY", 13, 19], ["endotracheal", "ANATOMY", 79, 91], ["airway", "MULTI-TISSUE_STRUCTURE", 13, 19], ["High quality airway management", "TREATMENT", 0, 30], ["first pass endotracheal intubation", "TREATMENT", 68, 102], ["airway", "ANATOMY", 13, 19], ["high", "OBSERVATION_MODIFIER", 51, 55]]], ["Methods: The HEMS database was analysed for all patients in whom prehospital advanced airway management was performed in the period 2007-2017.", [["airway", "ANATOMY", 86, 92], ["patients", "ORGANISM", 48, 56], ["airway", "MULTI-TISSUE_STRUCTURE", 86, 92], ["patients", "SPECIES", 48, 56], ["prehospital advanced airway management", "TREATMENT", 65, 103], ["airway", "ANATOMY", 86, 92]]], ["Balloon/mask ventilation, supraglottic airway (SGA) devices, total intubation attempts, Cormack & Lehane (C&L) intubation grades, successful ETI, primary and rescue surgical airway procedures and professional background were reviewed.", [["Balloon", "ANATOMY", 0, 7], ["supraglottic airway", "ANATOMY", 26, 45], ["airway", "ANATOMY", 174, 180], ["supraglottic airway", "MULTI-TISSUE_STRUCTURE", 26, 45], ["airway", "MULTI-TISSUE_STRUCTURE", 174, 180], ["Balloon/mask ventilation", "TREATMENT", 0, 24], ["supraglottic airway (SGA) devices", "TREATMENT", 26, 59], ["total intubation attempts", "TREATMENT", 61, 86], ["Cormack & Lehane (C&L) intubation", "TREATMENT", 88, 121], ["successful ETI", "TREATMENT", 130, 144], ["rescue surgical airway procedures", "TREATMENT", 158, 191], ["mask ventilation", "OBSERVATION", 8, 24], ["supraglottic airway", "ANATOMY", 26, 45], ["airway", "ANATOMY", 174, 180]]], ["In total 8127 patients were treated in the prehospital setting by our HEMS.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["Of those, 3233 required a secured airway.", [["airway", "ANATOMY", 34, 40], ["airway", "MULTI-TISSUE_STRUCTURE", 34, 40], ["a secured airway", "TREATMENT", 24, 40], ["airway", "ANATOMY", 34, 40]]], ["ETI was successful in 3078 of 3148 (97.8%).", [["ETI", "TEST", 0, 3]]], ["In the remaining 70 patients ( Fig. 1 ) an alternative airway was needed.", [["airway", "ANATOMY", 55, 61], ["patients", "ORGANISM", 20, 28], ["airway", "MULTI-TISSUE_STRUCTURE", 55, 61], ["patients", "SPECIES", 20, 28], ["an alternative airway", "TREATMENT", 40, 61], ["airway", "ANATOMY", 55, 61]]], ["Rescue surgical airway was performed in 1.4%, 0.5 % received a rescue SGA, rescue balloon/mask ventilation was applied in 0.2% of cases, 1 was allowed to regain spontaneous ventilation and in 0.1% of patients all airway management failed.", [["airway", "ANATOMY", 16, 22], ["airway", "ANATOMY", 213, 219], ["SGA", "DISEASE", 70, 73], ["airway", "MULTI-TISSUE_STRUCTURE", 16, 22], ["patients", "ORGANISM", 200, 208], ["airway", "MULTI-TISSUE_STRUCTURE", 213, 219], ["patients", "SPECIES", 200, 208], ["Rescue surgical airway", "TREATMENT", 0, 22], ["a rescue SGA", "TREATMENT", 61, 73], ["rescue balloon/mask ventilation", "TREATMENT", 75, 106], ["spontaneous ventilation", "TREATMENT", 161, 184], ["patients all airway management", "TREATMENT", 200, 230], ["airway", "ANATOMY", 16, 22], ["airway", "ANATOMY", 213, 219]]], ["HEMS physicians, ambulance paramedics, HEMS paramedics and others (e.g. German emergency physicians) had ETI first pass success rates of 83.4%, 59.6%, 62.4% and 84.5% respectively (Fig. 2) .", [["success rates", "TEST", 120, 133]]], ["Difficult laryngoscopy (no epiglottis visible) was reported in 2.2% of patients (Table 1) .", [["epiglottis", "ANATOMY", 27, 37], ["epiglottis", "ORGAN", 27, 37], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["Difficult laryngoscopy", "TEST", 0, 22], ["epiglottis", "PROBLEM", 27, 37], ["no", "UNCERTAINTY", 24, 26], ["epiglottis", "ANATOMY", 27, 37]]], ["Conclusions: Our data show that airway management performed by a physician based HEMS operation is safe and has a high overall ETI success rate of 97.8%.", [["airway", "ANATOMY", 32, 38], ["airway", "MULTI-TISSUE_STRUCTURE", 32, 38], ["Our data", "TEST", 13, 21], ["airway management", "TREATMENT", 32, 49], ["airway", "ANATOMY", 32, 38]]], ["Introduction: Incidences associated with endotracheal tubes are frequent during mechanical ventilation (MV) of intensive care unit (ICU) patients and can be associated with poor outcomes for patients and detrimental effects on health care facilities.", [["endotracheal tubes", "ANATOMY", 41, 59], ["endotracheal tubes", "MULTI-TISSUE_STRUCTURE", 41, 59], ["patients", "ORGANISM", 137, 145], ["patients", "ORGANISM", 191, 199], ["patients", "SPECIES", 137, 145], ["patients", "SPECIES", 191, 199], ["MV", "SPECIES", 104, 106], ["endotracheal tubes", "TREATMENT", 41, 59], ["mechanical ventilation", "TREATMENT", 80, 102], ["endotracheal tubes", "OBSERVATION", 41, 59]]], ["Here, we aimed to identify factors associated with Event occurrence due to Unsafe Management of Endotracheal Tubes (E-UMET).", [["Endotracheal Tubes", "TREATMENT", 96, 114], ["Endotracheal Tubes", "OBSERVATION", 96, 114]]], ["Methods: A retrospective observational study was conducted in three ICUs: one surgical ICU, one stroke ICU, and one emergency department, at a tertiary hospital in Japan from 1 April 2016 to 31 March 2017.", [["stroke", "DISEASE", 96, 102], ["A retrospective observational study", "TEST", 9, 44]]], ["Patients requiring MV and oral intubation during their ICU stay were included.", [["oral", "ANATOMY", 26, 30], ["Patients", "ORGANISM", 0, 8], ["oral", "ORGANISM_SUBDIVISION", 26, 30], ["Patients", "SPECIES", 0, 8], ["MV", "SPECIES", 19, 21], ["MV", "TREATMENT", 19, 21], ["oral intubation", "TREATMENT", 26, 41]]], ["The primary finding was the incidence rate of E-UMET (biting, unplanned extubations, and/or displacement of the endotracheal tube).", [["endotracheal tube", "ANATOMY", 112, 129], ["E-UMET", "SIMPLE_CHEMICAL", 46, 52], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 112, 129], ["unplanned extubations", "TREATMENT", 62, 83], ["the endotracheal tube", "TREATMENT", 108, 129], ["endotracheal tube", "OBSERVATION", 112, 129]]], ["The patients were divided into two groups: with or without E-UMET.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["To investigate E-UMET, potential factors possibly related to its occurrence were obtained from electronic medical records.", [["E-UMET", "GENE_OR_GENE_PRODUCT", 15, 21], ["E-UMET", "DNA", 15, 21]]], ["We conducted univariable and multivariable analyses to investigate E-UMET factors.", [["E-UMET factors", "GENE_OR_GENE_PRODUCT", 67, 81], ["UMET factors", "PROTEIN", 69, 81], ["multivariable analyses", "TEST", 29, 51]]], ["Results: Of 410 patients, E-UMET occurred in 112 (27.3%).", [["patients", "ORGANISM", 16, 24], ["E-UMET", "SIMPLE_CHEMICAL", 26, 32], ["patients", "SPECIES", 16, 24], ["E", "TEST", 26, 27]]], ["The mean and standard deviation for age and Acute Physiology and Chronic Health Evaluation (APACHE) II score were 66 (17) and 25 (7), respectively.", [["Acute Physiology", "PROBLEM", 44, 60], ["Chronic Health Evaluation", "TEST", 65, 90], ["APACHE) II score", "TEST", 92, 108], ["standard deviation", "OBSERVATION", 13, 31], ["Acute", "OBSERVATION_MODIFIER", 44, 49], ["Chronic", "OBSERVATION_MODIFIER", 65, 72]]], ["According to a multivariate logistic-regression analysis, significant risk factors associated with E-UMET included patients of neurosurgery (odds ratio (OR) 3.3; 95% CI, 1.51-7.46; p=0.003), sedative administration (OR 2.9; 95% CI, 1.63-5.32; p<0.001), and higher Richmond Agitation-Sedation Scale (RASS) scores (OR 1.4; 95% CI, 1.24-1.77; p<0.001).", [["Agitation", "DISEASE", 273, 282], ["E-UMET", "SIMPLE_CHEMICAL", 99, 105], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["significant risk factors", "PROBLEM", 58, 82], ["CI", "TEST", 166, 168], ["p", "TEST", 181, 182], ["sedative administration", "TREATMENT", 191, 214], ["CI", "TEST", 228, 230], ["p", "TEST", 243, 244], ["higher Richmond Agitation", "PROBLEM", 257, 282], ["Sedation Scale", "TREATMENT", 283, 297], ["scores", "TEST", 305, 311], ["CI", "TEST", 325, 327]]], ["The use of a restraint (OR 0.4; 95% CI, 0.22-0.95; p=0.003) was an independent factor associated with a lower probability of E-UMET.P176Conclusions: This study suggests that risk factors associated with E-UMET include neurosurgery, higher RASS scores, and the administration of sedatives.", [["a restraint (OR", "TREATMENT", 11, 26], ["CI", "TEST", 36, 38], ["an independent factor", "PROBLEM", 64, 85], ["This study", "TEST", 149, 159], ["risk factors", "PROBLEM", 174, 186], ["the administration of sedatives", "TREATMENT", 256, 287]]], ["Patients with these factors and longer oral intubation periods might require extra care.", [["oral", "ANATOMY", 39, 43], ["Patients", "ORGANISM", 0, 8], ["oral", "ORGANISM_SUBDIVISION", 39, 43], ["Patients", "SPECIES", 0, 8], ["these factors", "PROBLEM", 14, 27], ["longer oral intubation periods", "TREATMENT", 32, 62], ["extra care", "TREATMENT", 77, 87]]], ["Introduction: The use of nasal high flow (NHF) as a respiratory support therapy post-extubation has become increasingly more common.", [["nasal", "ANATOMY", 25, 30], ["respiratory", "ANATOMY", 52, 63], ["nasal high flow (NHF", "TREATMENT", 25, 45], ["a respiratory support therapy", "TREATMENT", 50, 79]]], ["NHF has been shown to be non-inferior to NIV and reduces escalation needs compared to conventional oxygen therapy.", [["NHF", "CHEMICAL", 0, 3], ["oxygen", "CHEMICAL", 99, 105], ["NHF", "CHEMICAL", 0, 3], ["NIV", "CHEMICAL", 41, 44], ["oxygen", "CHEMICAL", 99, 105], ["NHF", "SIMPLE_CHEMICAL", 0, 3], ["oxygen", "SIMPLE_CHEMICAL", 99, 105], ["NIV", "TREATMENT", 41, 44], ["escalation needs", "TREATMENT", 57, 73], ["conventional oxygen therapy", "TREATMENT", 86, 113], ["NIV", "OBSERVATION", 41, 44], ["escalation", "OBSERVATION_MODIFIER", 57, 67], ["oxygen therapy", "OBSERVATION", 99, 113]]], ["Clinical outcomes using NHF in patients with Type II Respiratory Failure (RF) is less well understood.", [["NHF", "DISEASE", 24, 27], ["Type II Respiratory Failure", "DISEASE", 45, 72], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["NHF", "TREATMENT", 24, 27], ["Type II Respiratory Failure", "PROBLEM", 45, 72], ["Respiratory", "ANATOMY", 53, 64], ["Failure", "OBSERVATION", 65, 72]]], ["Our aim was to determine if NHF can be used successfully when extubating Type II RF patients compared to Type I RF.", [["NHF", "CHEMICAL", 28, 31], ["NHF", "SIMPLE_CHEMICAL", 28, 31], ["patients", "ORGANISM", 84, 92], ["Type I RF", "PROTEIN", 105, 114], ["patients", "SPECIES", 84, 92], ["Type I", "SPECIES", 105, 111], ["NHF", "PROBLEM", 28, 31], ["Type I RF", "PROBLEM", 105, 114]]], ["Methods: We conducted a retrospective observational study on the use of NHF as an extubation respiratory support in 56 (n=56) consecutive patients in ICU over a 12-month period.", [["respiratory", "ANATOMY", 93, 104], ["NHF", "CHEMICAL", 72, 75], ["NHF", "CHEMICAL", 72, 75], ["NHF", "SIMPLE_CHEMICAL", 72, 75], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["NHF", "TREATMENT", 72, 75], ["an extubation respiratory support", "TREATMENT", 79, 112]]], ["Primary outcome was the need for escalation in therapy (NIV, Intubation and Palliation) post extubation.", [["escalation in therapy", "TREATMENT", 33, 54], ["NIV", "TREATMENT", 56, 59], ["Intubation", "TREATMENT", 61, 71], ["Palliation", "TREATMENT", 76, 86], ["extubation", "TREATMENT", 93, 103]]], ["Patients were categorised as high risk if they scored >=1 from: Age>=75 years, BMI>=30 and >=1 medical comorbidity.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["BMI", "TEST", 79, 82]]], ["Results: Analysis was conducted on all fifty-six (n=56) patients.", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["Analysis", "TEST", 9, 17]]], ["Type I RF group was composed of 25 (n=25) patients with a mean age of 62.7 (\u00b1SD) years.", [["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["Type I RF group", "PROBLEM", 0, 15]]], ["Type II RF group had 31 (n=31) patients with a mean age of 65.5 (\u00b1SD) years.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["Type II RF group", "PROBLEM", 0, 16]]], ["In Type I RF 22 patients (88%) were successfully extubated with NHF compared to 21 patients (67.7%) in Type II.", [["NHF", "DISEASE", 64, 67], ["patients", "ORGANISM", 16, 24], ["NHF", "CANCER", 64, 67], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 83, 91], ["NHF", "PROBLEM", 64, 67]]], ["In Type II RF the outcomes were more variable with a greater requirement for NIV.", [["NIV", "TREATMENT", 77, 80]]], ["Of these patients 16% required NIV, 3.2% required intubation and 12.9% received NHF therapy for palliation.", [["NHF", "CHEMICAL", 80, 83], ["patients", "ORGANISM", 9, 17], ["NHF", "SIMPLE_CHEMICAL", 80, 83], ["patients", "SPECIES", 9, 17], ["NIV", "TREATMENT", 31, 34], ["intubation", "TREATMENT", 50, 60], ["NHF therapy", "TREATMENT", 80, 91], ["palliation", "TREATMENT", 96, 106]]], ["A higher average BMI (30.32 vs 27.16 kg/m2) was found in unsuccessfully vs successfully extubated patients in Type II RF.", [["patients", "ORGANISM", 98, 106], ["Type II RF", "PROTEIN", 110, 120], ["patients", "SPECIES", 98, 106], ["A higher average BMI", "PROBLEM", 0, 20], ["Type II RF", "PROBLEM", 110, 120]]], ["In Type I RF escalation of therapy was equally distributed with 4% in each category.", [["therapy", "TREATMENT", 27, 34]]], ["Conclusions: The use of NHF for respiratory support post-extubation may become standard practice for Type I RF in critical care settings.", [["respiratory", "ANATOMY", 32, 43], ["NHF", "CHEMICAL", 24, 27], ["NHF", "SIMPLE_CHEMICAL", 24, 27], ["NHF", "TREATMENT", 24, 27], ["respiratory support post-extubation", "TREATMENT", 32, 67], ["Type I RF", "PROBLEM", 101, 110]]], ["Our data suggests that NHF can be used but with caution in Type II RF and clinicians should risk stratify patients to identify those at risk of re-intubation and post-extubation respiratory failure.", [["respiratory", "ANATOMY", 178, 189], ["NHF", "CHEMICAL", 23, 26], ["re-intubation", "DISEASE", 144, 157], ["respiratory failure", "DISEASE", 178, 197], ["NHF", "SIMPLE_CHEMICAL", 23, 26], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["Our data", "TEST", 0, 8], ["NHF", "PROBLEM", 23, 26], ["re-intubation", "TREATMENT", 144, 157], ["post-extubation respiratory failure", "PROBLEM", 162, 197], ["NHF", "OBSERVATION", 23, 26], ["re-intubation", "OBSERVATION", 144, 157], ["respiratory failure", "OBSERVATION", 178, 197]]], ["Introduction: Pathogenesis of ventilator-associated pneumonia (VAP) relies on colonization and microaspiration.", [["ventilator-associated pneumonia", "DISEASE", 30, 61], ["VAP", "DISEASE", 63, 66], ["ventilator-associated pneumonia (VAP)", "PROBLEM", 30, 67], ["colonization", "PROBLEM", 78, 90], ["microaspiration", "PROBLEM", 95, 110], ["ventilator", "OBSERVATION", 30, 40], ["pneumonia", "OBSERVATION", 52, 61]]], ["Oral topical decontamination reduced the VAP incidence from 18 to 13% [1] .", [["Oral", "ANATOMY", 0, 4], ["VAP", "DISEASE", 41, 44], ["Oral", "ORGANISM_SUBDIVISION", 0, 4], ["Oral topical decontamination", "TREATMENT", 0, 28]]], ["The persistence of antiseptic effect in the oral cavity is questionable; we hypothesize that continuous oral antiseptic infusion may offer a better decontamination.", [["oral cavity", "ANATOMY", 44, 55], ["oral", "ANATOMY", 104, 108], ["oral cavity", "ORGANISM_SUBDIVISION", 44, 55], ["oral", "ORGANISM_SUBDIVISION", 104, 108], ["antiseptic effect in the oral cavity", "PROBLEM", 19, 55], ["continuous oral antiseptic infusion", "TREATMENT", 93, 128], ["a better decontamination", "TREATMENT", 139, 163], ["persistence", "OBSERVATION_MODIFIER", 4, 15], ["antiseptic effect", "OBSERVATION", 19, 36], ["oral cavity", "ANATOMY", 44, 55]]], ["Aim of the work: We developed endotracheal tube that allows continuous oral infusion of chlorhexidine (CHX), and we want to test the technique versus the conventional on bacterial colonization.", [["endotracheal tube", "ANATOMY", 30, 47], ["oral", "ANATOMY", 71, 75], ["chlorhexidine", "CHEMICAL", 88, 101], ["CHX", "CHEMICAL", 103, 106], ["chlorhexidine", "CHEMICAL", 88, 101], ["CHX", "CHEMICAL", 103, 106], ["endotracheal tube", "TISSUE", 30, 47], ["oral", "ORGANISM_SUBDIVISION", 71, 75], ["chlorhexidine", "SIMPLE_CHEMICAL", 88, 101], ["CHX", "SIMPLE_CHEMICAL", 103, 106], ["endotracheal tube", "TREATMENT", 30, 47], ["continuous oral infusion of chlorhexidine (CHX", "TREATMENT", 60, 106], ["the technique", "TREATMENT", 129, 142], ["bacterial colonization", "PROBLEM", 170, 192], ["endotracheal tube", "OBSERVATION", 30, 47], ["bacterial colonization", "OBSERVATION", 170, 192]]], ["(Provisional patent: 62359944) Methods: A two identical bio models for the upper airways were manufactured by (3DX Diagnostics, USA) to adapt the modified and the ordinary endotracheal tubes (ETT).", [["upper airways", "ANATOMY", 75, 88], ["upper airways", "MULTI-TISSUE_STRUCTURE", 75, 88], ["endotracheal tubes", "MULTI-TISSUE_STRUCTURE", 172, 190], ["the ordinary endotracheal tubes (ETT", "TREATMENT", 159, 195], ["patent", "OBSERVATION", 13, 19], ["upper", "ANATOMY_MODIFIER", 75, 80], ["airways", "ANATOMY", 81, 88], ["endotracheal tubes", "OBSERVATION", 172, 190]]], ["The two techniques tested were using six hourly disinfection with CHX (group A) versus disinfection through the 24 hours infusion technique (Group B).", [["CHX", "CHEMICAL", 66, 69], ["CHX", "CHEMICAL", 66, 69], ["CHX", "SIMPLE_CHEMICAL", 66, 69], ["CHX", "TREATMENT", 66, 69], ["disinfection", "TREATMENT", 87, 99], ["the 24 hours infusion technique", "TREATMENT", 108, 139]]], ["Five microorganisms plus mixed bacteria were used and each was tested for five times.", [["Five microorganisms", "PROBLEM", 0, 19], ["mixed bacteria", "PROBLEM", 25, 39], ["mixed", "OBSERVATION_MODIFIER", 25, 30], ["bacteria", "OBSERVATION", 31, 39]]], ["Normal saline was used constantly to irrigate the biomodels and Ten ml aliquot was collected by the procedure end.", [["saline", "SIMPLE_CHEMICAL", 7, 13], ["Normal saline", "TREATMENT", 0, 13], ["the biomodels", "TREATMENT", 46, 59], ["Ten ml aliquot", "TREATMENT", 64, 78], ["saline", "OBSERVATION", 7, 13]]], ["Culturing of the aliquots from decanted broth pre and post disinfection was performed.", [["disinfection", "TREATMENT", 59, 71]]], ["The time to apply CHX by practitioner was also compared.P176Results: There was a trend towards lower bacterial growth in group A in 5 experiments which reach statistical significance only with Pseudomonas aeruginosa (p=0.045).", [["CHX", "CHEMICAL", 18, 21], ["CHX", "CHEMICAL", 18, 21], ["CHX", "SIMPLE_CHEMICAL", 18, 21], ["Pseudomonas aeruginosa", "ORGANISM", 193, 215], ["Pseudomonas aeruginosa", "SPECIES", 193, 215], ["Pseudomonas aeruginosa", "SPECIES", 193, 215], ["CHX", "TREATMENT", 18, 21], ["lower bacterial growth", "PROBLEM", 95, 117], ["Pseudomonas aeruginosa", "PROBLEM", 193, 215], ["bacterial", "OBSERVATION_MODIFIER", 101, 110], ["growth", "OBSERVATION_MODIFIER", 111, 117]]], ["In one experiment the growth was lower in group B (Fig. 1) .", [["growth", "OBSERVATION_MODIFIER", 22, 28], ["lower", "OBSERVATION_MODIFIER", 33, 38]]], ["Monitoring airways non invasive online analysing different particle flow from the airways is never done before.", [["airways", "ANATOMY", 11, 18], ["airways", "ANATOMY", 82, 89], ["airways", "MULTI-TISSUE_STRUCTURE", 11, 18], ["airways", "MULTI-TISSUE_STRUCTURE", 82, 89], ["airways", "ANATOMY", 11, 18], ["invasive", "OBSERVATION", 23, 31], ["particle flow", "OBSERVATION", 59, 72], ["airways", "ANATOMY", 82, 89]]], ["In the present study we use a new technology for airway monitoring using mass spectrometric analysis of particle flow and their size distribution (PExA Particles in Expired Air).", [["airway", "ANATOMY", 49, 55], ["airway", "MULTI-TISSUE_STRUCTURE", 49, 55], ["airway monitoring", "TEST", 49, 66], ["mass spectrometric analysis", "TEST", 73, 100], ["airway", "ANATOMY", 49, 55], ["particle flow", "OBSERVATION", 104, 117], ["size", "OBSERVATION_MODIFIER", 128, 132], ["distribution", "OBSERVATION_MODIFIER", 133, 145]]], ["The exhaled particles are collected onto a substrate and possible for subsequent chemical analysis for biomarkers.", [["subsequent chemical analysis", "TEST", 70, 98], ["biomarkers", "TEST", 103, 113], ["exhaled particles", "OBSERVATION", 4, 21]]], ["Our hypothesis was that by analysing the particle flow online, we could optimise the mechanical ventilation.P176Our hypothesis was that a small particle flow would probably be more gentle for the lung than a large particle flow when the lung is squeezed out and the majority of all small airways are open.P176Methods: In the present study we analyse the particle flow from the airways in vivo, post mortem and during ex vivo lung perfusion using different ventilation modes; Volume Controlled Ventilation (VCV) and Pressure Controlled Ventilation (PCV) comparing small tidal volumes(1) versus big tidal volumes(2) at different PEEP (Positive End-Expiratory Pressure) and after distribution of different drugs in six domestic pigs.", [["lung", "ANATOMY", 196, 200], ["lung", "ANATOMY", 237, 241], ["airways", "ANATOMY", 288, 295], ["airways", "ANATOMY", 377, 384], ["lung", "ANATOMY", 425, 429], ["lung", "ORGAN", 196, 200], ["lung", "ORGAN", 237, 241], ["airways", "MULTI-TISSUE_STRUCTURE", 288, 295], ["airways", "MULTI-TISSUE_STRUCTURE", 377, 384], ["lung", "ORGAN", 425, 429], ["pigs", "ORGANISM", 725, 729], ["pigs", "SPECIES", 725, 729], ["pigs", "SPECIES", 725, 729], ["the mechanical ventilation", "TREATMENT", 81, 107], ["a small particle flow", "PROBLEM", 136, 157], ["ex vivo lung perfusion", "TREATMENT", 417, 439], ["different ventilation modes", "TREATMENT", 446, 473], ["Volume Controlled Ventilation", "TREATMENT", 475, 504], ["Pressure Controlled Ventilation", "TREATMENT", 515, 546], ["PCV", "TEST", 548, 551], ["small tidal volumes", "TEST", 563, 582], ["big tidal volumes", "TEST", 593, 610], ["PEEP", "TEST", 627, 631], ["End-Expiratory Pressure", "TEST", 642, 665], ["different drugs", "TREATMENT", 693, 708], ["mechanical ventilation", "OBSERVATION", 85, 107], ["small", "OBSERVATION_MODIFIER", 138, 143], ["particle flow", "OBSERVATION", 144, 157], ["lung", "ANATOMY", 196, 200], ["large", "OBSERVATION_MODIFIER", 208, 213], ["particle", "OBSERVATION_MODIFIER", 214, 222], ["flow", "OBSERVATION", 223, 227], ["lung", "ANATOMY", 237, 241], ["squeezed", "OBSERVATION", 245, 253], ["majority", "OBSERVATION_MODIFIER", 266, 274], ["all", "OBSERVATION_MODIFIER", 278, 281], ["small", "OBSERVATION_MODIFIER", 282, 287], ["airways", "ANATOMY", 288, 295], ["airways", "ANATOMY", 377, 384], ["lung", "ANATOMY", 425, 429], ["ventilation modes", "OBSERVATION", 456, 473], ["small", "OBSERVATION_MODIFIER", 563, 568], ["tidal volumes", "OBSERVATION", 569, 582]]], ["Results: We found that VCV resulted in a significant lower particle flow than PCV in vivo but in ex vivo settings the opposite was found (Fig. 1 ).", [["VCV", "SPECIES", 23, 26], ["VCV", "TEST", 23, 26], ["a significant lower particle flow", "PROBLEM", 39, 72], ["PCV", "TREATMENT", 78, 81], ["VCV", "OBSERVATION", 23, 26], ["significant", "OBSERVATION_MODIFIER", 41, 52], ["lower", "OBSERVATION_MODIFIER", 53, 58], ["particle flow", "OBSERVATION", 59, 72]]], ["In both in vivo and ex vivo settings we found that big tidal volume resulted in a larger particle flow than small tidal volumes.air.Conclusions:The opening and the closure of the small airways reflect the particle flow from the airways.", [["airways", "ANATOMY", 185, 192], ["particle", "ANATOMY", 205, 213], ["airways", "ANATOMY", 228, 235], ["airways", "MULTI-TISSUE_STRUCTURE", 185, 192], ["airways", "MULTI-TISSUE_STRUCTURE", 228, 235], ["big tidal volume", "TEST", 51, 67], ["a larger particle flow", "PROBLEM", 80, 102], ["The opening", "TREATMENT", 144, 155], ["tidal volume", "OBSERVATION", 55, 67], ["larger", "OBSERVATION_MODIFIER", 82, 88], ["particle", "OBSERVATION_MODIFIER", 89, 97], ["flow", "OBSERVATION", 98, 102], ["tidal volumes", "OBSERVATION", 114, 127], ["closure", "OBSERVATION", 164, 171], ["small", "OBSERVATION_MODIFIER", 179, 184], ["airways", "ANATOMY", 185, 192], ["particle flow", "OBSERVATION", 205, 218], ["airways", "ANATOMY", 228, 235]]], ["We found that different ventilation modes resulted in different particle flow from the airways.", [["airways", "ANATOMY", 87, 94], ["airways", "MULTI-TISSUE_STRUCTURE", 87, 94], ["different ventilation modes", "TREATMENT", 14, 41], ["different", "OBSERVATION_MODIFIER", 14, 23], ["ventilation modes", "OBSERVATION", 24, 41], ["different", "OBSERVATION_MODIFIER", 54, 63], ["particle flow", "OBSERVATION", 64, 77], ["airways", "ANATOMY", 87, 94]]], ["We believe this technology will be useful for monitoring mechanical ventilated patients to optimise ventilation and preserve the lung quality and has a high potential to detect new biomarkers in exhaled air.", [["lung", "ANATOMY", 129, 133], ["patients", "ORGANISM", 79, 87], ["lung", "ORGAN", 129, 133], ["patients", "SPECIES", 79, 87], ["mechanical ventilated", "TREATMENT", 57, 78], ["ventilation", "TREATMENT", 100, 111], ["new biomarkers in exhaled air", "PROBLEM", 177, 206], ["lung", "ANATOMY", 129, 133], ["exhaled air", "OBSERVATION", 195, 206]]], ["Introduction: Malaria is a common problem in underdeveloped countries, with an estimated mortality of more than one million people per year.", [["Malaria", "DISEASE", 14, 21], ["people", "ORGANISM", 124, 130], ["people", "SPECIES", 124, 130], ["Malaria", "PROBLEM", 14, 21], ["Malaria", "OBSERVATION", 14, 21]]], ["Pulmonary involvement is one of the most serious manifestations of Plasmodium falciparum malaria.", [["Pulmonary", "ANATOMY", 0, 9], ["Plasmodium falciparum malaria", "DISEASE", 67, 96], ["Pulmonary", "ORGAN", 0, 9], ["Plasmodium falciparum", "ORGANISM", 67, 88], ["Plasmodium falciparum", "SPECIES", 67, 88], ["Plasmodium falciparum", "SPECIES", 67, 88], ["Pulmonary involvement", "PROBLEM", 0, 21], ["Plasmodium falciparum malaria", "PROBLEM", 67, 96], ["involvement", "OBSERVATION", 10, 21], ["most serious", "OBSERVATION_MODIFIER", 36, 48], ["Plasmodium falciparum malaria", "OBSERVATION", 67, 96]]], ["Non-invasive ventilation (NIV) decreases muscular works and improves gas exchange by recruitment of hypoventilated alveolus.", [["muscular", "ANATOMY", 41, 49], ["alveolus", "ANATOMY", 115, 123], ["muscular", "ORGAN", 41, 49], ["alveolus", "ORGAN", 115, 123], ["Non-invasive ventilation (NIV", "TREATMENT", 0, 29], ["hypoventilated alveolus", "PROBLEM", 100, 123], ["ventilation", "OBSERVATION", 13, 24], ["hypoventilated alveolus", "OBSERVATION", 100, 123]]], ["In this context, we analyze the impact of the use of non-invasive ventilation in malaria with pulmonary dysfunction.", [["pulmonary", "ANATOMY", 94, 103], ["malaria", "DISEASE", 81, 88], ["pulmonary dysfunction", "DISEASE", 94, 115], ["pulmonary", "ORGAN", 94, 103], ["non-invasive ventilation", "TREATMENT", 53, 77], ["malaria", "PROBLEM", 81, 88], ["pulmonary dysfunction", "PROBLEM", 94, 115], ["malaria", "OBSERVATION", 81, 88], ["pulmonary", "ANATOMY", 94, 103], ["dysfunction", "OBSERVATION", 104, 115]]], ["Methods: It's a retrospective cohort study.", [["a retrospective cohort study", "TEST", 14, 42]]], ["We analyzed electronic records of patients who were diagnosed with malaria, with acute respiratory failure, who underwent respiratory therapy with NIV between 2015-2016 within the intensive care unit (ICU).", [["respiratory", "ANATOMY", 87, 98], ["respiratory", "ANATOMY", 122, 133], ["malaria", "DISEASE", 67, 74], ["acute respiratory failure", "DISEASE", 81, 106], ["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["malaria", "PROBLEM", 67, 74], ["acute respiratory failure", "PROBLEM", 81, 106], ["respiratory therapy", "TREATMENT", 122, 141], ["NIV", "TREATMENT", 147, 150], ["malaria", "OBSERVATION", 67, 74], ["acute", "OBSERVATION_MODIFIER", 81, 86], ["respiratory failure", "OBSERVATION", 87, 106], ["respiratory therapy", "OBSERVATION", 122, 141]]], ["The study variables were: ICU mortality, length of hospital stay, NIV time and outcome groups.", [["NIV", "TREATMENT", 66, 69]]], ["Statistical analysis was performed with the Pearson correlation coefficient, with significance level of p <0.01.", [["Statistical analysis", "TEST", 0, 20]]], ["The statistics were performed using the BioEstat 3.0 program.", [["the BioEstat 3.0 program", "TREATMENT", 36, 60]]], ["Results: Thirty-one patients were included in the study.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["the study", "TEST", 46, 55]]], ["94% of the patients were discharged from the hospital.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19]]], ["Pearson's correlation coefficient analysis showed statistical significance in the Group (NIV/Discharge) in the analysis of patients hospitalized versus NIV (95% CI = 0.24 to 0.83 <(p) = 0.0036).Conclusions:Conclusions: The use of NIV was positive in patients using this resource as first-line treatment of malaria in the fight against respiratory decompensation, with improvement of symptoms.", [["respiratory", "ANATOMY", 335, 346], ["malaria", "DISEASE", 306, 313], ["respiratory decompensation", "DISEASE", 335, 361], ["NIV", "CHEMICAL", 230, 233], ["patients", "ORGANISM", 123, 131], ["patients", "ORGANISM", 250, 258], ["patients", "SPECIES", 123, 131], ["patients", "SPECIES", 250, 258], ["Pearson's correlation coefficient analysis", "TEST", 0, 42], ["NIV", "TEST", 152, 155], ["CI", "TEST", 161, 163], ["NIV", "TREATMENT", 230, 233], ["this resource", "TREATMENT", 265, 278], ["first-line treatment", "TREATMENT", 282, 302], ["malaria", "PROBLEM", 306, 313], ["respiratory decompensation", "PROBLEM", 335, 361], ["symptoms", "PROBLEM", 383, 391], ["malaria", "OBSERVATION", 306, 313], ["respiratory decompensation", "OBSERVATION", 335, 361]]], ["Introduction: CPAP is used to improve oxygenation in patient with ARF.", [["ARF", "DISEASE", 66, 69], ["CPAP", "CHEMICAL", 14, 18], ["patient", "ORGANISM", 53, 60], ["ARF", "GENE_OR_GENE_PRODUCT", 66, 69], ["patient", "SPECIES", 53, 60], ["CPAP", "TREATMENT", 14, 18], ["ARF", "PROBLEM", 66, 69], ["ARF", "OBSERVATION", 66, 69]]], ["We aimed to determine non-inferiority (NI) of helmet CPAP to facemask in ARF based on physiological (heart rate (HR) and respiratory rate (RR)) and blood gas parameters (PaO2 and PaCO2).", [["heart", "ANATOMY", 101, 106], ["blood", "ANATOMY", 148, 153], ["ARF", "DISEASE", 73, 76], ["heart", "ORGAN", 101, 106], ["blood", "ORGANISM_SUBSTANCE", 148, 153], ["helmet CPAP", "TREATMENT", 46, 57], ["facemask", "TREATMENT", 61, 69], ["ARF", "PROBLEM", 73, 76], ["heart rate", "TEST", 101, 111], ["HR", "TEST", 113, 115], ["respiratory rate", "TEST", 121, 137], ["RR", "TEST", 139, 141], ["blood gas parameters", "TEST", 148, 168], ["PaO2", "TEST", 170, 174], ["PaCO2", "TEST", 179, 184], ["ARF", "OBSERVATION", 73, 76]]], ["We also compared patients' perception in dyspnea improvement after CPAP using dyspnea scale (visual analogue scale (VAS)) and Likert score.", [["dyspnea", "DISEASE", 41, 48], ["dyspnea", "DISEASE", 78, 85], ["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["dyspnea", "PROBLEM", 41, 48], ["CPAP", "TREATMENT", 67, 71], ["dyspnea scale", "TREATMENT", 78, 91], ["visual analogue scale (VAS)", "TREATMENT", 93, 120], ["Likert score", "TEST", 126, 138]]], ["Methods: We randomized 123 patients to helmet (n=64) and facemask (n=59) with 71.7% of ARF was due to acute pulmonary edema.", [["pulmonary", "ANATOMY", 108, 117], ["ARF", "DISEASE", 87, 90], ["acute pulmonary edema", "DISEASE", 102, 123], ["patients", "ORGANISM", 27, 35], ["ARF", "GENE_OR_GENE_PRODUCT", 87, 90], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 108, 123], ["patients", "SPECIES", 27, 35], ["facemask", "TREATMENT", 57, 65], ["ARF", "PROBLEM", 87, 90], ["acute pulmonary edema", "PROBLEM", 102, 123], ["ARF", "OBSERVATION", 87, 90], ["acute", "OBSERVATION_MODIFIER", 102, 107], ["pulmonary", "ANATOMY", 108, 117], ["edema", "OBSERVATION", 118, 123]]], ["CPAP was applied for 60 minutes.", [["CPAP", "CHEMICAL", 0, 4], ["CPAP", "TREATMENT", 0, 4]]], ["Patients' physiological and blood gas parameters were recorded before and after intervention.", [["blood", "ANATOMY", 28, 33], ["Patients", "ORGANISM", 0, 8], ["blood", "ORGANISM_SUBSTANCE", 28, 33], ["Patients", "SPECIES", 0, 8], ["blood gas parameters", "TEST", 28, 48], ["intervention", "TREATMENT", 80, 92]]], ["Patients then marked on dyspnea scale and Likert score.", [["dyspnea", "DISEASE", 24, 31], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["dyspnea scale", "PROBLEM", 24, 37], ["Likert score", "TEST", 42, 54], ["marked", "OBSERVATION_MODIFIER", 14, 20]]], ["NI of helmet would be declared if confidence interval (CI) of mean difference between groups (helmet's mean minus facemask's mean) in improving physiological, blood gas parameters and dyspnea scale was no worse than predetermined non-inferiority margin (NIM).", [["blood", "ANATOMY", 159, 164], ["dyspnea", "DISEASE", 184, 191], ["blood", "ORGANISM_SUBSTANCE", 159, 164], ["helmet", "TREATMENT", 6, 12], ["CI", "TEST", 55, 57], ["mean difference between groups", "PROBLEM", 62, 92], ["helmet", "TEST", 94, 100], ["blood gas parameters", "TEST", 159, 179], ["dyspnea scale", "PROBLEM", 184, 197], ["helmet", "OBSERVATION", 6, 12], ["no", "UNCERTAINTY", 202, 204]]], ["Secondary outcome was to compare incidence of discomfort and mucosal dryness between groups.", [["mucosal", "ANATOMY", 61, 68], ["mucosal", "ORGANISM_SUBDIVISION", 61, 68], ["discomfort", "PROBLEM", 46, 56], ["mucosal dryness between groups", "PROBLEM", 61, 91], ["discomfort", "OBSERVATION", 46, 56], ["mucosal", "ANATOMY", 61, 68], ["dryness", "OBSERVATION", 69, 76]]], ["Methods: This is a single center retrospective study performed in the ICU of Tel Aviv Medical Center, Israel, a tertiary academic referral hospital.", [["retrospective study", "TEST", 33, 52]]], ["Using the electronic medical record system and Intensix predictive critical care system for analysis, all patients admitted to the ICU between 1.2007 and 12.2014 were assessed.", [["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["analysis", "TEST", 92, 100]]], ["Respiratory deterioration in MV patients was defined as acute adjustment of FiO2 increase >20% or PEEP increase > 5 cmH2O that persisted for at least 2 hours.", [["Respiratory", "ANATOMY", 0, 11], ["Respiratory deterioration", "DISEASE", 0, 25], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["MV", "SPECIES", 29, 31], ["Respiratory deterioration", "PROBLEM", 0, 25], ["FiO2 increase", "TREATMENT", 76, 89], ["PEEP", "TREATMENT", 98, 102], ["deterioration", "OBSERVATION", 12, 25], ["acute", "OBSERVATION_MODIFIER", 56, 61]]], ["A Chi square test for trends was used for the significance of mortality data and a one way ANOVA test for LOS.", [["Chi square test", "TEST", 2, 17]]], ["Results: 5376 MV patients were admitted to the ICU with an overall mortality of 16.5%.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["MV", "SPECIES", 14, 16]]], ["Mortality and LOS were tripled in patients who experienced at least one respiratory deterioration when compared to no events (33.8% vs. 9.9 %, p<0.0001 and 10.7 vs. 2.2 days, p<0.0001 respectively) (Fig. 1) .", [["respiratory", "ANATOMY", 72, 83], ["respiratory deterioration", "DISEASE", 72, 97], ["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["one respiratory deterioration", "PROBLEM", 68, 97], ["events", "PROBLEM", 118, 124], ["p", "TEST", 143, 144], ["LOS", "OBSERVATION_MODIFIER", 14, 17], ["respiratory", "ANATOMY", 72, 83], ["deterioration", "OBSERVATION", 84, 97]]], ["Increased events of respiratory deteriorations showed significant trend of increased mortality (p<0.0001).", [["respiratory", "ANATOMY", 20, 31], ["respiratory deteriorations", "DISEASE", 20, 46], ["Increased events", "PROBLEM", 0, 16], ["respiratory deteriorations", "PROBLEM", 20, 46], ["increased mortality", "PROBLEM", 75, 94], ["respiratory deteriorations", "OBSERVATION", 20, 46], ["significant", "OBSERVATION_MODIFIER", 54, 65], ["trend", "OBSERVATION_MODIFIER", 66, 71], ["increased", "OBSERVATION_MODIFIER", 75, 84], ["mortality", "OBSERVATION_MODIFIER", 85, 94]]], ["Conclusions: In MV patients, a single respiratory deterioration event carries a 3 times higher mortality rate and Length Of Stay (LOS).", [["respiratory", "ANATOMY", 38, 49], ["respiratory deterioration", "DISEASE", 38, 63], ["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["MV", "SPECIES", 16, 18], ["a single respiratory deterioration event", "PROBLEM", 29, 69], ["deterioration", "OBSERVATION", 50, 63]]], ["Any additional event further increases both parameters.P191Association of lung ultrasound score with mortality in mechanically ventilated patients J Taculod, JT Sahagun, Y Tan, V Ong, K See National University Hospital Singapore, Singapore, Singapore Critical Care 2018, 22(Suppl 1):P191 Introduction: Lung ultrasound is an important part of the evaluation of critically ill patients.", [["lung", "ANATOMY", 74, 78], ["Lung", "ANATOMY", 302, 306], ["critically ill", "DISEASE", 360, 374], ["lung", "ORGAN", 74, 78], ["patients", "ORGANISM", 138, 146], ["Lung", "ORGAN", 302, 306], ["patients", "ORGANISM", 375, 383], ["patients", "SPECIES", 138, 146], ["patients", "SPECIES", 375, 383], ["lung ultrasound score", "TEST", 74, 95], ["Lung ultrasound", "TEST", 302, 317], ["the evaluation", "TEST", 342, 356], ["lung", "ANATOMY", 74, 78], ["Lung", "ANATOMY", 302, 306]]], ["It has been shown to predict recruitability in acute respiratory distress syndrome.", [["respiratory", "ANATOMY", 53, 64], ["acute respiratory distress syndrome", "DISEASE", 47, 82], ["acute respiratory distress syndrome", "PROBLEM", 47, 82], ["acute", "OBSERVATION_MODIFIER", 47, 52], ["respiratory distress", "OBSERVATION", 53, 73], ["syndrome", "OBSERVATION", 74, 82]]], ["However, little is known about the application of lung ultrasound in predicting mortality in mechanically ventilated patients.", [["lung", "ANATOMY", 50, 54], ["lung", "ORGAN", 50, 54], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["lung ultrasound", "TEST", 50, 65], ["lung", "ANATOMY", 50, 54], ["mechanically ventilated", "OBSERVATION", 93, 116]]], ["Methods: Observational study of mechanically ventilated patients admitted to the medical intensive care unit (ICU) of a tertiary hospital (National University Hospital, Singapore) in 2015 and 2016.", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["Observational study", "TEST", 9, 28]]], ["Only the first ICU admissions of these patients were studied.", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47]]], ["Lung ultrasound was done at six points per hemithorax and scored according to Soummer (Crit Care Med 2012): normal aeration = 0; multiple, well-defined B lines =1; multiple coalescent B lines = 2; lung consolidation = 3.", [["Lung", "ANATOMY", 0, 4], ["hemithorax", "ANATOMY", 43, 53], ["lung", "ANATOMY", 197, 201], ["Lung", "ORGAN", 0, 4], ["hemithorax", "ORGAN", 43, 53], ["B lines", "CELL", 152, 159], ["lung", "ORGAN", 197, 201], ["B lines", "CELL_LINE", 152, 159], ["multiple coalescent B lines", "CELL_LINE", 164, 191], ["Lung ultrasound", "TEST", 0, 15], ["multiple coalescent B lines", "PROBLEM", 164, 191], ["lung consolidation", "PROBLEM", 197, 215], ["hemithorax", "ANATOMY", 43, 53], ["aeration", "OBSERVATION_MODIFIER", 115, 123], ["multiple", "OBSERVATION_MODIFIER", 164, 172], ["coalescent", "OBSERVATION_MODIFIER", 173, 183], ["B lines", "OBSERVATION", 184, 191], ["lung", "ANATOMY", 197, 201], ["consolidation", "OBSERVATION", 202, 215]]], ["The Lung Ultrasound (LUS) score was calculated as the sum of points (score range 0-36).", [["Lung", "ANATOMY", 4, 8], ["Lung", "ORGAN", 4, 8], ["The Lung Ultrasound (LUS) score", "TEST", 0, 31], ["Lung", "ANATOMY", 4, 8]]], ["We analysed the association of LUS score with ICU/hospital mortality, using logistic regression, adjusted for age and Acute Physiology and Chronic Health Evaluation (APACHE) II score.", [["Acute Physiology", "PROBLEM", 118, 134], ["Chronic Health Evaluation", "TEST", 139, 164], ["Acute", "OBSERVATION_MODIFIER", 118, 123], ["Chronic", "OBSERVATION_MODIFIER", 139, 146]]], ["Results: 247 patients were included (age 62.0 \u00b1 16.2 years; 89 female [36.0%]; APACHE II 29.7 \u00b1 7.9; 88 sepsis diagnosis [35.6%]).", [["sepsis", "DISEASE", 104, 110], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["APACHE II", "TEST", 79, 88], ["sepsis diagnosis", "TEST", 104, 120]]], ["LUS score was associated with increased ICU (OR 1.04, 95% CI 1.00-1.09, P=0.07) and hospital (OR 1.04, 95% CI 1.00-1.08, P=0.045) mortality, adjusted for age and APACHE II score.", [["LUS score", "TEST", 0, 9], ["CI", "TEST", 58, 60], ["P", "TEST", 72, 73], ["CI", "TEST", 107, 109], ["P", "TEST", 121, 122], ["APACHE II score", "TEST", 162, 177]]], ["Conclusions: LUS score was associated with increased ICU/hospital mortality and may be useful for risk stratification of mechanically ventilated patients admitted to ICU.", [["LUS", "MULTI-TISSUE_STRUCTURE", 13, 16], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 145, 153], ["LUS score", "TEST", 13, 22], ["mechanically ventilated", "TREATMENT", 121, 144]]], ["Introduction: Ventilator asynchrony results in morbidities and mortality.", [["Ventilator asynchrony", "TREATMENT", 14, 35]]], ["The aim of this study was to explore whether and how physicians used patient-ventilator interactions(PVI) to set mechanical ventilators(MV) in Thailand.", [["patient", "ORGANISM", 69, 76], ["patient", "SPECIES", 69, 76], ["MV", "SPECIES", 136, 138], ["this study", "TEST", 11, 21], ["ventilator interactions", "TREATMENT", 77, 100], ["PVI", "TREATMENT", 101, 104], ["mechanical ventilators", "TREATMENT", 113, 135]]], ["Methods: Thai physicians treating MV patients were asked to respond to questionnaires distributed in conferences and to e-mails sent.", [["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["MV", "SPECIES", 34, 36], ["MV patients", "TREATMENT", 34, 45]]], ["Types of asynchronies encountered and frequency of MV adjustment guided by PVI were evaluated.", [["MV", "SPECIES", 51, 53], ["asynchronies", "PROBLEM", 9, 21], ["MV adjustment", "TREATMENT", 51, 64], ["PVI", "TREATMENT", 75, 78], ["asynchronies", "OBSERVATION", 9, 21]]], ["In addition, correlations between physician's knowledge and 1)confidence to manage asynchronies and 2)their experience were analyzed.", [["asynchronies", "PROBLEM", 83, 95]]], ["82% of them set and adjusted MV by asynchrony guidance and the majority used waveform analysis to more than a half of their patients.", [["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["MV", "SPECIES", 29, 31], ["MV", "TREATMENT", 29, 31], ["asynchrony guidance", "TREATMENT", 35, 54], ["waveform analysis", "TEST", 77, 94]]], ["The most and the least common asynchronies encountered were double triggering and reverse triggering, respectively, while the most difficult-to-manage and the most easily managed asynchronies were periodic/?A3B2 show $132#?>unstable breathing and flow starvation, respectively.", [["asynchronies", "DISEASE", 179, 191], ["A3B2", "SIMPLE_CHEMICAL", 207, 211], ["A3B2", "PROTEIN", 207, 211], ["unstable breathing and flow starvation", "PROBLEM", 224, 262], ["least", "OBSERVATION_MODIFIER", 17, 22], ["common", "OBSERVATION_MODIFIER", 23, 29], ["asynchronies", "OBSERVATION", 30, 42], ["unstable", "OBSERVATION_MODIFIER", 224, 232], ["breathing", "OBSERVATION", 233, 242], ["flow starvation", "OBSERVATION", 247, 262]]], ["Lack of confidence and knowledge of PVI were the major reasons of physicians who did not perform asynchrony assessment.", [["PVI", "PROBLEM", 36, 39], ["asynchrony assessment", "TEST", 97, 118]]], ["For knowledge evaluation, more than 50% of physicians incorrectly managed asynchrony.", [["knowledge evaluation", "TEST", 4, 24]]], ["Chest and ICU fellows had the greatest skills in waveform interpretation and asynchrony management with the mean score of 2.62 from the total 5, compared with specialist(2.58), medical residents(1.85), internists(1.84) and general practitioner(0.85).", [["waveform interpretation", "TEST", 49, 72], ["asynchrony management", "TREATMENT", 77, 98], ["the mean score", "TEST", 104, 118]]], ["There were poor correlations between years' experience in MV management and the skill in waveform interpretation (r = 0.15, p=0.034) and between physician's confidence in PVI management and the clinical skill (r = 0.27, p<0.001) Conclusions: The majority of Thai physicians realized the importance of PVI, but the skill in asynchrony management was moderate.", [["MV", "SPECIES", 58, 60], ["MV management", "TREATMENT", 58, 71], ["waveform interpretation", "TEST", 89, 112], ["PVI management", "TREATMENT", 171, 185], ["the clinical skill", "TEST", 190, 208], ["PVI", "TREATMENT", 301, 304], ["asynchrony management", "TREATMENT", 323, 344], ["moderate", "OBSERVATION_MODIFIER", 349, 357]]], ["Intensive programs should be provided to improve their clinical performance.", [["Intensive programs", "TREATMENT", 0, 18]]], ["Methods: Six deeply anesthetized swine underwent tracheostomy, thoracostomy and experimental PLEF with 10 ml/kg of radiopaque saline randomly instilled into either pleural space.", [["pleural space", "ANATOMY", 164, 177], ["PLEF", "CHEMICAL", 93, 97], ["swine", "ORGANISM", 33, 38], ["pleural space", "MULTI-TISSUE_STRUCTURE", 164, 177], ["swine", "SPECIES", 33, 38], ["swine", "SPECIES", 33, 38], ["tracheostomy", "TREATMENT", 49, 61], ["thoracostomy", "TREATMENT", 63, 75], ["experimental PLEF", "TREATMENT", 80, 97], ["radiopaque saline", "TREATMENT", 115, 132], ["tracheostomy", "OBSERVATION", 49, 61], ["thoracostomy", "OBSERVATION", 63, 75], ["pleural", "ANATOMY", 164, 171]]], ["Animals were ventilated at VT=10ml/kg, frequency=15bpm, I/E=1:2, PEEP=1cmH2O, and FIO2=0.5.", [["Animals", "ORGANISM", 0, 7], ["VT", "TEST", 27, 29], ["frequency", "TEST", 39, 48], ["I/E", "TEST", 56, 59], ["PEEP", "TEST", 65, 69], ["FIO2", "TEST", 82, 86]]], ["Quantitative lung computed tomographic (CT) analysis of regional aeration and global FRC measurements by nitrogen wash-in/wash-out technique were performed in each of these randomly applied positions: semi-Fowler's (inclined 30\u00b0from horizontal in the sagittal plane); prone, supine, and lateral positions with dependent PLEF and non-dependent PLEF (Fig. 1) .P191Results: No significant differences in FRC were observed among the horizontal positions, either at baseline (p=0.9037) or with PLEF (p=0.58) ( Fig. 2A) .", [["lung", "ANATOMY", 13, 17], ["nitrogen", "CHEMICAL", 105, 113], ["nitrogen", "CHEMICAL", 105, 113], ["lung", "ORGAN", 13, 17], ["non-dependent PLEF", "PROTEIN", 329, 347], ["Quantitative lung computed tomographic (CT) analysis", "TEST", 0, 52], ["regional aeration", "TEST", 56, 73], ["global FRC measurements", "TEST", 78, 101], ["nitrogen wash", "TEST", 105, 118], ["semi-Fowler's", "TREATMENT", 201, 214], ["dependent PLEF", "PROBLEM", 310, 324], ["significant differences in FRC", "PROBLEM", 374, 404], ["PLEF", "TEST", 489, 493], ["lung", "ANATOMY", 13, 17], ["regional", "OBSERVATION_MODIFIER", 56, 64], ["aeration", "OBSERVATION_MODIFIER", 65, 73], ["non-dependent", "OBSERVATION_MODIFIER", 329, 342], ["PLEF", "OBSERVATION", 343, 347], ["No", "UNCERTAINTY", 371, 373], ["significant", "OBSERVATION_MODIFIER", 374, 385], ["differences", "OBSERVATION", 386, 397]]], ["However, component sector total gas volume in each phase of the tidal cycle were different within all studied positions with and without PLEF (p=<.01).", [["component sector total gas volume", "PROBLEM", 9, 42], ["PLEF", "TEST", 137, 141], ["component", "OBSERVATION_MODIFIER", 9, 18], ["sector", "OBSERVATION_MODIFIER", 19, 25], ["total", "OBSERVATION_MODIFIER", 26, 31], ["gas volume", "OBSERVATION", 32, 42], ["tidal cycle", "OBSERVATION", 64, 75]]], ["Compared to other positions, prone and lateral position with non-dependent PLEF had a more homogenous VT distribution among quadrants (p=.051, Fig. 2B ).", [["non-dependent", "OBSERVATION_MODIFIER", 61, 74], ["PLEF", "OBSERVATION", 75, 79], ["more", "OBSERVATION_MODIFIER", 86, 90], ["homogenous", "OBSERVATION_MODIFIER", 91, 101], ["VT", "OBSERVATION", 102, 104]]], ["Supine was associated with most dependent collapse (Fig. 2C ) and greatest tendency for tidal recruitment (48% vs~22%, p=0.0073, Fig. 2D ).P191Conclusions: Changes in body position in the setting of effusioncaused chest asymmetry markedly affected the internal distributions of gas volume, collapse, ventilation, and tidal recruitment, even when commonly used global FRC measurements provided little indication of these important positional changes.", [["body", "ANATOMY", 167, 171], ["chest", "ANATOMY", 214, 219], ["body", "ORGANISM_SUBDIVISION", 167, 171], ["chest", "ORGANISM_SUBDIVISION", 214, 219], ["most dependent collapse", "PROBLEM", 27, 50], ["greatest tendency", "PROBLEM", 66, 83], ["tidal recruitment", "TEST", 88, 105], ["p", "TEST", 119, 120], ["effusioncaused chest asymmetry", "PROBLEM", 199, 229], ["gas volume", "PROBLEM", 278, 288], ["collapse", "PROBLEM", 290, 298], ["ventilation", "TREATMENT", 300, 311], ["tidal recruitment", "TREATMENT", 317, 334], ["global FRC measurements", "TEST", 360, 383], ["most dependent", "OBSERVATION_MODIFIER", 27, 41], ["collapse", "OBSERVATION", 42, 50], ["greatest", "OBSERVATION_MODIFIER", 66, 74], ["tendency", "OBSERVATION_MODIFIER", 75, 83], ["tidal recruitment", "OBSERVATION", 88, 105], ["body position", "OBSERVATION", 167, 180], ["chest", "ANATOMY", 214, 219], ["asymmetry", "OBSERVATION", 220, 229], ["internal", "OBSERVATION_MODIFIER", 252, 260], ["distributions", "OBSERVATION_MODIFIER", 261, 274], ["gas volume", "OBSERVATION", 278, 288], ["collapse", "OBSERVATION", 290, 298], ["ventilation", "OBSERVATION_MODIFIER", 300, 311], ["tidal recruitment", "OBSERVATION", 317, 334]]], ["Of the respondents, 80% were affiliated with multidisciplinary ICUs, 14% with thoracic and/or cardiac ICUs and 6% with neuro-ICUs.", [["thoracic", "ANATOMY", 78, 86], ["cardiac", "ANATOMY", 94, 101], ["thoracic and/or cardiac ICUs", "DISEASE", 78, 106], ["thoracic", "ORGAN", 78, 86], ["thoracic", "ANATOMY", 78, 86], ["cardiac", "ANATOMY", 94, 101]]], ["Overall, arterial oxygen tension (PaO 2 ) was the preferred parameter for the evaluation of oxygenation (Fig. 1 ).", [["arterial", "ANATOMY", 9, 17], ["oxygen", "CHEMICAL", 18, 24], ["oxygen", "CHEMICAL", 18, 24], ["arterial", "MULTI-TISSUE_STRUCTURE", 9, 17], ["oxygen", "SIMPLE_CHEMICAL", 18, 24], ["arterial oxygen tension (PaO", "TREATMENT", 9, 37], ["the evaluation", "TEST", 74, 88], ["arterial", "ANATOMY", 9, 17], ["oxygen tension", "OBSERVATION", 18, 32]]], ["The proportions of doctors' preferences for increasing, decreasing or not changing an FiO 2 of 0.50 in two (out of six) patient categories at different PaO 2 levels are presented in Table 1 and Table 2 .P191Conclusions: This is the largest survey of the preferred oxygenation targets among ICU doctors.", [["patient", "ORGANISM", 120, 127], ["patient", "SPECIES", 120, 127], ["an FiO", "TREATMENT", 83, 89]]], ["PaO 2 seems to be the preferred parameter for evaluating oxygenation.", [["PaO 2", "CHEMICAL", 0, 5], ["PaO 2", "GENE_OR_GENE_PRODUCT", 0, 5], ["PaO", "TEST", 0, 3], ["evaluating oxygenation", "TEST", 46, 68]]], ["The characterisation of PaO 2 target levels in various clinical scenarios provide valuable information for future clinical trials on oxygenation targets in critically ill ICU patients.", [["critically ill", "DISEASE", 156, 170], ["PaO 2", "CHEMICAL", 24, 29], ["PaO 2", "GENE_OR_GENE_PRODUCT", 24, 29], ["patients", "ORGANISM", 175, 183], ["PaO 2", "PROTEIN", 24, 29], ["patients", "SPECIES", 175, 183], ["PaO 2 target levels", "TEST", 24, 43], ["oxygenation targets", "TREATMENT", 133, 152]]], ["Introduction: Sonographic assessment of diaphragmatic excursion and muscle thickening fraction have been suggested to evaluate diaphragm function during weaning trial [1] .", [["diaphragmatic", "ANATOMY", 40, 53], ["muscle", "ANATOMY", 68, 74], ["diaphragm", "ANATOMY", 127, 136], ["diaphragmatic", "ORGAN", 40, 53], ["muscle", "ORGAN", 68, 74], ["diaphragm", "ORGAN", 127, 136], ["Sonographic assessment", "TEST", 14, 36], ["diaphragmatic excursion", "PROBLEM", 40, 63], ["muscle thickening fraction", "PROBLEM", 68, 94], ["diaphragmatic", "ANATOMY", 40, 53], ["muscle", "ANATOMY", 68, 74], ["thickening", "OBSERVATION", 75, 85], ["diaphragm", "ANATOMY", 127, 136]]], ["The purpose of this study is to compare these two parameters to predict extubation success.P191Methods: This prospective study was carried out during 9 months from March to November 2017.", [["this study", "TEST", 15, 25], ["This prospective study", "TEST", 104, 126]]], ["We enrolled patients who were mechanically ventilated for more than 48h and met all criteria for extubation.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["mechanically ventilated", "TREATMENT", 30, 53], ["extubation", "TREATMENT", 97, 107]]], ["The non inclusion criteria were: age < 18 years, history of neuromuscular disease or severe chronic respiratory failure.", [["neuromuscular", "ANATOMY", 60, 73], ["respiratory", "ANATOMY", 100, 111], ["neuromuscular disease", "DISEASE", 60, 81], ["chronic respiratory failure", "DISEASE", 92, 119], ["neuromuscular disease", "PROBLEM", 60, 81], ["severe chronic respiratory failure", "PROBLEM", 85, 119], ["neuromuscular", "ANATOMY", 60, 73], ["disease", "OBSERVATION", 74, 81], ["severe", "OBSERVATION_MODIFIER", 85, 91], ["chronic", "OBSERVATION_MODIFIER", 92, 99], ["respiratory failure", "OBSERVATION", 100, 119]]], ["We excluded subjects who needed reintubation for upper airway obstruction, neurological or hemodynamic alteration.P191The scenario involves a patient expected to receive mechanical ventilation for at least 24 hours in the ICU.", [["airway", "ANATOMY", 55, 61], ["neurological", "ANATOMY", 75, 87], ["airway obstruction", "DISEASE", 55, 73], ["upper airway", "ORGANISM_SUBDIVISION", 49, 61], ["P191", "GENE_OR_GENE_PRODUCT", 114, 118], ["patient", "ORGANISM", 142, 149], ["P191", "PROTEIN", 114, 118], ["patient", "SPECIES", 142, 149], ["reintubation", "TREATMENT", 32, 44], ["upper airway obstruction", "PROBLEM", 49, 73], ["neurological or hemodynamic alteration", "PROBLEM", 75, 113], ["mechanical ventilation", "TREATMENT", 170, 192], ["upper", "ANATOMY_MODIFIER", 49, 54], ["airway", "ANATOMY", 55, 61], ["obstruction", "OBSERVATION", 62, 73], ["hemodynamic alteration", "OBSERVATION", 91, 113]]], ["All proportions are percentages of respondents with 95% confidence intervals. blood flow (Eq.1) CO2 molar volume at 25\u00b0C [l/mol] = 24; solubility of CO2 at 37\u00b0C = 0.03 mmol/(lp-value<0.001, *p-value<0.01 Fig. 1 (abstract P351) .", [["blood", "ANATOMY", 78, 83], ["CO2", "CHEMICAL", 96, 99], ["CO2", "CHEMICAL", 149, 152], ["CO2", "CHEMICAL", 96, 99], ["CO2", "CHEMICAL", 149, 152], ["blood", "ORGANISM_SUBSTANCE", 78, 83], ["CO2", "SIMPLE_CHEMICAL", 149, 152], ["blood flow", "TEST", 78, 88], ["CO2 molar volume", "TEST", 96, 112], ["l/mol", "TEST", 122, 127], ["CO2", "TEST", 149, 152], ["lp", "TEST", 174, 176], ["value", "TEST", 177, 182], ["*p", "TEST", 190, 192]]], ["Longitudinal change in 28-day mortality for cancer patients (yes) compared with controls (no) over the 10-year study period.", [["cancer", "ANATOMY", 44, 50], ["cancer", "DISEASE", 44, 50], ["cancer", "CANCER", 44, 50], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["Longitudinal change", "PROBLEM", 0, 19], ["cancer", "PROBLEM", 44, 50], ["28-", "OBSERVATION_MODIFIER", 23, 26], ["cancer", "OBSERVATION", 44, 50]]], ["Mortality in the cancer group decreased from 36% to 25% (-30%), while mortality in the control group decreased from 14 to 12% (-21%).P353Enoxaparin pharmacokinetics in patients with augmented renal clearance, preliminary results of a single center study Introduction: Augmented renal clearance (ARC) has being described in some groups of critically ill patients.", [["cancer", "ANATOMY", 17, 23], ["renal", "ANATOMY", 192, 197], ["renal", "ANATOMY", 278, 283], ["cancer", "DISEASE", 17, 23], ["Enoxaparin", "CHEMICAL", 137, 147], ["critically ill", "DISEASE", 338, 352], ["Enoxaparin", "CHEMICAL", 137, 147], ["cancer", "CANCER", 17, 23], ["P353", "SIMPLE_CHEMICAL", 133, 137], ["Enoxaparin", "SIMPLE_CHEMICAL", 137, 147], ["patients", "ORGANISM", 168, 176], ["renal", "ORGAN", 192, 197], ["renal", "ORGAN", 278, 283], ["patients", "ORGANISM", 353, 361], ["patients", "SPECIES", 168, 176], ["patients", "SPECIES", 353, 361], ["Enoxaparin pharmacokinetics", "TREATMENT", 137, 164], ["Augmented renal clearance (ARC)", "TREATMENT", 268, 299], ["cancer", "OBSERVATION", 17, 23], ["decreased", "OBSERVATION_MODIFIER", 30, 39], ["renal", "ANATOMY", 192, 197], ["renal", "ANATOMY", 278, 283]]], ["The aim was to investigate the impact of ARC on the pharmacokinetics of enoxaparin.", [["enoxaparin", "CHEMICAL", 72, 82], ["enoxaparin", "CHEMICAL", 72, 82], ["ARC", "SIMPLE_CHEMICAL", 41, 44], ["enoxaparin", "SIMPLE_CHEMICAL", 72, 82], ["enoxaparin", "TREATMENT", 72, 82]]], ["Methods: This is a prospective study in a surgical and medical intensive care unit (ICU) carried out from August to November 2017.", [["a prospective study", "TEST", 17, 36]]], ["Patients <65 years old, under prophylactic treatment with enoxaparin and normal plasma creatinine, were included.", [["plasma", "ANATOMY", 80, 86], ["enoxaparin", "CHEMICAL", 58, 68], ["creatinine", "CHEMICAL", 87, 97], ["enoxaparin", "CHEMICAL", 58, 68], ["creatinine", "CHEMICAL", 87, 97], ["Patients", "ORGANISM", 0, 8], ["enoxaparin", "SIMPLE_CHEMICAL", 58, 68], ["plasma", "ORGANISM_SUBSTANCE", 80, 86], ["creatinine", "SIMPLE_CHEMICAL", 87, 97], ["Patients", "SPECIES", 0, 8], ["prophylactic treatment", "TREATMENT", 30, 52], ["enoxaparin", "TREATMENT", 58, 68], ["normal plasma creatinine", "TEST", 73, 97]]], ["Anti-Xa activity was measured at second day under treatment.", [["Anti-Xa", "GENE_OR_GENE_PRODUCT", 0, 7], ["Xa", "PROTEIN", 5, 7], ["treatment", "TREATMENT", 50, 59]]], ["Creatinine clearance was calculated from urine sample collected during 24-hours.", [["urine sample", "ANATOMY", 41, 53], ["Creatinine", "CHEMICAL", 0, 10], ["Creatinine", "CHEMICAL", 0, 10], ["Creatinine", "SIMPLE_CHEMICAL", 0, 10], ["urine", "ORGANISM_SUBSTANCE", 41, 46], ["Creatinine clearance", "TEST", 0, 20], ["urine sample", "TEST", 41, 53]]], ["ARC was defined by a creatinine clearance >=130 mL/min/1.73 m2.", [["creatinine", "CHEMICAL", 21, 31], ["creatinine", "CHEMICAL", 21, 31], ["ARC", "SIMPLE_CHEMICAL", 0, 3], ["creatinine", "SIMPLE_CHEMICAL", 21, 31], ["a creatinine clearance", "TEST", 19, 41]]], ["Results: Thirteen patients aged 43 years old (\u00b116.4) were included.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26]]], ["Six patients developed ARC and 5 of them were in therapeutic range.", [["patients", "ORGANISM", 4, 12], ["ARC", "CANCER", 23, 26], ["patients", "SPECIES", 4, 12], ["ARC", "PROBLEM", 23, 26], ["ARC", "OBSERVATION_MODIFIER", 23, 26]]], ["Seven patients did not develop ARC and 6 of them were in therapeutic range.", [["ARC", "DISEASE", 31, 34], ["patients", "ORGANISM", 6, 14], ["ARC", "CANCER", 31, 34], ["patients", "SPECIES", 6, 14], ["ARC", "TEST", 31, 34]]], ["There was no differences between the two groups in achieving therapeutic range (Fisher test, p=0.5).", [["Fisher test", "TEST", 80, 91], ["no", "UNCERTAINTY", 10, 12]]], ["We did not observe thromboembolic events.", [["thromboembolic", "DISEASE", 19, 33], ["thromboembolic events", "PROBLEM", 19, 40], ["thromboembolic", "OBSERVATION", 19, 33]]], ["Conclusions: We found no relationship between ARC and therapeutic failure in patients under prophylactic treatment with enoxaparin.", [["enoxaparin", "CHEMICAL", 120, 130], ["enoxaparin", "CHEMICAL", 120, 130], ["ARC", "GENE_OR_GENE_PRODUCT", 46, 49], ["patients", "ORGANISM", 77, 85], ["enoxaparin", "SIMPLE_CHEMICAL", 120, 130], ["patients", "SPECIES", 77, 85], ["relationship between ARC", "PROBLEM", 25, 49], ["therapeutic failure", "PROBLEM", 54, 73], ["prophylactic treatment", "TREATMENT", 92, 114], ["enoxaparin", "TREATMENT", 120, 130], ["therapeutic", "OBSERVATION_MODIFIER", 54, 65], ["failure", "OBSERVATION", 66, 73]]], ["Introduction: This study reviewed argatroban use in patients in a tertiary hospital critical care unit.", [["argatroban", "CHEMICAL", 34, 44], ["argatroban", "CHEMICAL", 34, 44], ["argatroban", "SIMPLE_CHEMICAL", 34, 44], ["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["This study", "TEST", 14, 24], ["argatroban", "TREATMENT", 34, 44]]], ["Argatroban is a direct thrombin inhibitor approved for use in proven or suspected heparin-induced thrombocytopenia (HIT) in patients with renal dysfunction.", [["renal", "ANATOMY", 138, 143], ["Argatroban", "CHEMICAL", 0, 10], ["heparin", "CHEMICAL", 82, 89], ["thrombocytopenia", "DISEASE", 98, 114], ["HIT", "DISEASE", 116, 119], ["renal dysfunction", "DISEASE", 138, 155], ["Argatroban", "CHEMICAL", 0, 10], ["Argatroban", "SIMPLE_CHEMICAL", 0, 10], ["thrombin", "GENE_OR_GENE_PRODUCT", 23, 31], ["heparin-induced thrombocytopenia", "SIMPLE_CHEMICAL", 82, 114], ["patients", "ORGANISM", 124, 132], ["renal", "ORGAN", 138, 143], ["patients", "SPECIES", 124, 132], ["Argatroban", "TREATMENT", 0, 10], ["a direct thrombin inhibitor", "TREATMENT", 14, 41], ["heparin", "TREATMENT", 82, 89], ["thrombocytopenia", "PROBLEM", 98, 114], ["HIT", "PROBLEM", 116, 119], ["renal dysfunction", "PROBLEM", 138, 155], ["thrombocytopenia", "OBSERVATION", 98, 114], ["renal", "ANATOMY", 138, 143], ["dysfunction", "OBSERVATION", 144, 155]]], ["Methods: This was a retrospective cohort study in a medical and surgical ICU in a tertiary teaching hospital.", [["a retrospective cohort study", "TEST", 18, 46]]], ["Data was collected for adult patients treated with argatroban for proven or suspected HIT April-August 2016, excluding patients requiring ECMO.", [["argatroban", "CHEMICAL", 51, 61], ["HIT", "DISEASE", 86, 89], ["argatroban", "CHEMICAL", 51, 61], ["patients", "ORGANISM", 29, 37], ["argatroban", "SIMPLE_CHEMICAL", 51, 61], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 29, 37], ["patients", "SPECIES", 119, 127], ["argatroban", "TREATMENT", 51, 61], ["ECMO", "TREATMENT", 138, 142]]], ["We scored patients using the 4T score and compared this to an ELISA immunoassay optical density score which quantifies the PF4/H antibody level.", [["patients", "ORGANISM", 10, 18], ["PF4", "GENE_OR_GENE_PRODUCT", 123, 126], ["H antibody", "GENE_OR_GENE_PRODUCT", 127, 137], ["PF4", "PROTEIN", 123, 126], ["H antibody", "PROTEIN", 127, 137], ["patients", "SPECIES", 10, 18], ["the 4T score", "TEST", 25, 37], ["an ELISA immunoassay optical density score", "TEST", 59, 101], ["the PF4/H antibody level", "TEST", 119, 143]]], ["Also noted was use of continuous haemodialysis and organ failure using the Sequential Organ Failure Assessment (SOFA), scoring >=3 defines failure.", [["organ", "ANATOMY", 51, 56], ["organ failure", "DISEASE", 51, 64], ["organ", "ORGAN", 51, 56], ["continuous haemodialysis", "TREATMENT", 22, 46], ["organ failure", "PROBLEM", 51, 64], ["the Sequential Organ Failure Assessment", "TEST", 71, 110], ["failure", "PROBLEM", 139, 146], ["organ", "ANATOMY", 51, 56], ["failure", "OBSERVATION", 57, 64], ["failure", "OBSERVATION", 139, 146]]], ["Results: 16 patients were treated with argatroban for proven or suspected HIT.", [["argatroban", "CHEMICAL", 39, 49], ["HIT", "DISEASE", 74, 77], ["argatroban", "CHEMICAL", 39, 49], ["patients", "ORGANISM", 12, 20], ["argatroban", "SIMPLE_CHEMICAL", 39, 49], ["patients", "SPECIES", 12, 20], ["argatroban", "TREATMENT", 39, 49], ["HIT", "PROBLEM", 74, 77], ["HIT", "OBSERVATION", 74, 77]]], ["15/16 patients had a positive ELISA.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["a positive ELISA", "PROBLEM", 19, 35]]], ["There was no relationship between 4T score and ELISA optical density (Fig. 1) .", [["no", "UNCERTAINTY", 10, 12], ["optical density", "OBSERVATION", 53, 68]]], ["Infusions were commenced at either the manufacturer recommended dose of 2 \u03bcg/kg/min or a reduced dose of 0.5 \u03bcg/kg/min.", [["Infusions", "TREATMENT", 0, 9]]], ["Patients receiving the reduced dose had a median of 2 organs failing compared to 1 in the standard regimen.", [["organs", "ANATOMY", 54, 60], ["Patients", "ORGANISM", 0, 8], ["organs", "ORGAN", 54, 60], ["Patients", "SPECIES", 0, 8], ["the standard regimen", "TREATMENT", 86, 106]]], ["The time taken to the first APTR in range was longer with the reduced dose regimen, however, the time to a stable APTR was less (Table 1 ).", [["the reduced dose regimen", "TREATMENT", 58, 82], ["stable", "OBSERVATION_MODIFIER", 107, 113]]], ["In 2 patients the dose of argatroban never stabilised.", [["argatroban", "CHEMICAL", 26, 36], ["argatroban", "CHEMICAL", 26, 36], ["patients", "ORGANISM", 5, 13], ["argatroban", "SIMPLE_CHEMICAL", 26, 36], ["patients", "SPECIES", 5, 13], ["argatroban", "TREATMENT", 26, 36]]], ["1 died and 1 was very sensitive to argatroban and required cessation of the infusion for interventions.", [["argatroban", "CHEMICAL", 35, 45], ["argatroban", "CHEMICAL", 35, 45], ["argatroban", "SIMPLE_CHEMICAL", 35, 45], ["argatroban", "TREATMENT", 35, 45], ["the infusion", "TREATMENT", 72, 84], ["interventions", "TREATMENT", 89, 102]]], ["In the reduced regimen group, there were 2 episodes of bleeding, 1 minor PR bleed in a patient with 3 organs failure and 1 upper GI bleed.", [["organs", "ANATOMY", 102, 108], ["GI", "ANATOMY", 129, 131], ["bleeding", "DISEASE", 55, 63], ["organs failure", "DISEASE", 102, 116], ["patient", "ORGANISM", 87, 94], ["organs", "ORGAN", 102, 108], ["upper GI", "ORGANISM_SUBDIVISION", 123, 131], ["patient", "SPECIES", 87, 94], ["bleeding", "PROBLEM", 55, 63], ["1 minor PR bleed", "PROBLEM", 65, 81], ["3 organs failure", "PROBLEM", 100, 116], ["1 upper GI bleed", "PROBLEM", 121, 137], ["bleeding", "OBSERVATION", 55, 63], ["bleed", "OBSERVATION", 76, 81], ["organs", "ANATOMY", 102, 108], ["failure", "OBSERVATION", 109, 116], ["upper", "ANATOMY_MODIFIER", 123, 128], ["GI", "ANATOMY", 129, 131], ["bleed", "OBSERVATION", 132, 137]]], ["Conclusions: In this population of ICU patients the 4T score did not correlate with the ELISA optical density score, as found previously.", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["the 4T score", "TEST", 48, 60], ["the ELISA optical density score", "PROBLEM", 84, 115], ["density", "OBSERVATION", 102, 109]]], ["Patients with multi-organ failure mostly received the reduced starting dose.", [["multi-organ", "ANATOMY", 14, 25], ["multi-organ failure", "DISEASE", 14, 33], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["multi-organ failure", "PROBLEM", 14, 33], ["multi-organ", "ANATOMY", 14, 25], ["failure", "OBSERVATION", 26, 33]]], ["However, the bleeding events were still confined to this group.", [["bleeding", "DISEASE", 13, 21], ["the bleeding events", "PROBLEM", 9, 28], ["bleeding", "OBSERVATION", 13, 21]]], ["This correlates with previous studies that organ dysfunction necessitates a dose reduction for argatroban.", [["organ", "ANATOMY", 43, 48], ["organ dysfunction", "DISEASE", 43, 60], ["argatroban", "CHEMICAL", 95, 105], ["argatroban", "CHEMICAL", 95, 105], ["organ", "ORGAN", 43, 48], ["argatroban", "SIMPLE_CHEMICAL", 95, 105], ["previous studies", "TEST", 21, 37], ["organ dysfunction", "PROBLEM", 43, 60], ["a dose reduction", "TREATMENT", 74, 90], ["argatroban", "TREATMENT", 95, 105]]], ["The effects of TPE on standard coagulation were increased aPTT (24\u00b12 to 36 \u00b1 6 s, p=0.005) and decreased fibrinogen levels (286\u00b176 to 242 \u00b148 mg/dL, p=0.008).", [["TPE", "CHEMICAL", 15, 18], ["TPE", "SIMPLE_CHEMICAL", 15, 18], ["aPTT", "GENE_OR_GENE_PRODUCT", 58, 62], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 105, 115], ["fibrinogen", "PROTEIN", 105, 115], ["TPE", "PROBLEM", 15, 18], ["standard coagulation", "TEST", 22, 42], ["aPTT", "TEST", 58, 62], ["p", "TEST", 82, 83], ["decreased fibrinogen levels", "PROBLEM", 95, 122], ["p", "TEST", 149, 150]]], ["A non-significant decrease in platelet count was observed (160333\u00b123091 to 151133\u00b122244/mm 3 , p=0.662).", [["platelet", "ANATOMY", 30, 38], ["platelet", "CELL", 30, 38], ["A non-significant decrease", "PROBLEM", 0, 26], ["platelet count", "TEST", 30, 44], ["non-significant", "OBSERVATION_MODIFIER", 2, 17], ["decrease", "OBSERVATION_MODIFIER", 18, 26], ["platelet count", "OBSERVATION", 30, 44]]], ["On ROTEM parameters TPE was associated with increased CT in ExTEM (57\u00b18 to 73\u00b112 s, p=0.030) and InTEM (156\u00b115 to 194 \u00b152 s, p=0.003) and increased MaxVt on ExTEM (90\u00b1 27 to 128 \u00b1 37 s, p=0.031) and InTEM (177\u00b117 to 225\u00b171 s, p=0.003).", [["ROTEM parameters", "TEST", 3, 19], ["increased CT in ExTEM", "PROBLEM", 44, 65], ["p", "TEST", 84, 85], ["InTEM", "TEST", 97, 102], ["p", "TEST", 125, 126], ["increased MaxVt", "PROBLEM", 138, 153], ["ExTEM", "TEST", 157, 162], ["p", "TEST", 186, 187], ["InTEM", "TEST", 199, 204], ["p", "TEST", 226, 227]]], ["All other ROTEM parameters changed non-significantly.", [["All other ROTEM parameters", "TEST", 0, 26], ["ROTEM parameters", "OBSERVATION", 10, 26]]], ["The decrease observed in fibrinogen levels was not associated with a decrease in FibTEM MCF (15\u00b12 to 14\u00b12 mm, p=0.414).P353Conclusions: Our results demonstrate that TPE is associated with minimum changes in clot kinetics initiation that do not result in either pro-or anti-coagulant changes.", [["FibTEM MCF", "ANATOMY", 81, 91], ["clot", "ANATOMY", 207, 211], ["MCF", "DISEASE", 88, 91], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 25, 35], ["FibTEM MCF", "CANCER", 81, 91], ["clot", "ORGANISM_SUBSTANCE", 207, 211], ["fibrinogen", "PROTEIN", 25, 35], ["The decrease", "PROBLEM", 0, 12], ["fibrinogen levels", "TEST", 25, 42], ["a decrease in FibTEM MCF", "PROBLEM", 67, 91], ["p", "TEST", 110, 111], ["TPE", "PROBLEM", 165, 168], ["minimum changes", "PROBLEM", 188, 203], ["clot kinetics initiation", "TREATMENT", 207, 231], ["decrease", "OBSERVATION_MODIFIER", 4, 12], ["fibrinogen levels", "OBSERVATION", 25, 42], ["not associated with", "UNCERTAINTY", 47, 66], ["decrease", "OBSERVATION_MODIFIER", 69, 77], ["FibTEM MCF", "OBSERVATION", 81, 91], ["TPE", "OBSERVATION", 165, 168], ["clot", "OBSERVATION", 207, 211], ["anti-coagulant", "OBSERVATION", 268, 282]]], ["Therefore, TPE with fresh frozen plasma can be safely used in normal subjects.", [["plasma", "ANATOMY", 33, 39], ["TPE", "SIMPLE_CHEMICAL", 11, 14], ["plasma", "ORGANISM_SUBSTANCE", 33, 39], ["TPE", "TEST", 11, 14], ["fresh frozen plasma", "TREATMENT", 20, 39]]], ["Introduction: Acutely ill patients are prone to critical illness anaemia, a multifactorial condition with potential contribution of iatrogenic anaemia defined as lowered Hb due to large/frequent venepunctions.", [["Acutely ill", "DISEASE", 14, 25], ["anaemia", "DISEASE", 65, 72], ["anaemia", "DISEASE", 143, 150], ["venepunctions", "DISEASE", 195, 208], ["patients", "ORGANISM", 26, 34], ["Hb", "GENE_OR_GENE_PRODUCT", 170, 172], ["Hb", "PROTEIN", 170, 172], ["patients", "SPECIES", 26, 34], ["critical illness anaemia", "PROBLEM", 48, 72], ["a multifactorial condition", "PROBLEM", 74, 100], ["iatrogenic anaemia", "PROBLEM", 132, 150], ["lowered Hb", "PROBLEM", 162, 172], ["large/frequent venepunctions", "PROBLEM", 180, 208], ["iatrogenic", "OBSERVATION_MODIFIER", 132, 142], ["anaemia", "OBSERVATION", 143, 150], ["large", "OBSERVATION_MODIFIER", 180, 185]]], ["Decline in Hb is most pronounced in the first 3 days of ICU stay.", [["Hb", "GENE_OR_GENE_PRODUCT", 11, 13], ["Hb", "PROTEIN", 11, 13], ["Decline in Hb", "PROBLEM", 0, 13], ["Hb", "OBSERVATION", 11, 13], ["most pronounced", "OBSERVATION_MODIFIER", 17, 32]]], ["It correlates with the need for RBC transfusion, but the impact on patient outcome is uncertain.", [["RBC", "ANATOMY", 32, 35], ["RBC", "CELL", 32, 35], ["patient", "ORGANISM", 67, 74], ["patient", "SPECIES", 67, 74], ["RBC transfusion", "TREATMENT", 32, 47]]], ["The aim of this study was to determine impact of phlebotomy on change in Hb (\u0394Hb), and correlation of \u0394Hb with need for transfusion, presence of central venous catheter (CVC) and patient outcome.", [["central venous catheter", "ANATOMY", 145, 168], ["Hb", "SIMPLE_CHEMICAL", 73, 75], ["central venous", "MULTI-TISSUE_STRUCTURE", 145, 159], ["patient", "ORGANISM", 179, 186], ["Hb", "PROTEIN", 73, 75], ["patient", "SPECIES", 179, 186], ["this study", "TEST", 11, 21], ["phlebotomy", "TREATMENT", 49, 59], ["transfusion", "TREATMENT", 120, 131], ["central venous catheter (CVC", "TREATMENT", 145, 173], ["phlebotomy", "OBSERVATION", 49, 59], ["Hb", "ANATOMY", 73, 75], ["central", "ANATOMY_MODIFIER", 145, 152], ["venous", "ANATOMY", 153, 159], ["catheter", "OBSERVATION", 160, 168]]], ["Conclusions: Critical illness anaemia is an unexplained phenomenon.", [["anaemia", "DISEASE", 30, 37], ["Critical illness anaemia", "PROBLEM", 13, 37], ["an unexplained phenomenon", "PROBLEM", 41, 66], ["illness anaemia", "OBSERVATION", 22, 37], ["unexplained", "OBSERVATION_MODIFIER", 44, 55], ["phenomenon", "OBSERVATION", 56, 66]]], ["Impact of phlebotomy is hard to unequivocally determine since there are many confounders.", [["phlebotomy", "TREATMENT", 10, 20], ["phlebotomy", "OBSERVATION", 10, 20]]], ["The change in Hb levels during ICU stay correlates with the need for transfusion that could cause immunomodulation and potentially adverse outcome.", [["Hb", "GENE_OR_GENE_PRODUCT", 14, 16], ["Hb", "PROTEIN", 14, 16], ["The change in Hb levels", "PROBLEM", 0, 23], ["transfusion", "TREATMENT", 69, 80], ["immunomodulation", "PROBLEM", 98, 114], ["potentially adverse outcome", "PROBLEM", 119, 146], ["change", "OBSERVATION_MODIFIER", 4, 10], ["Hb", "ANATOMY", 14, 16]]], ["Every effort should be made to maintain adequate Hb levels and lower the risk of iatrogenic anemia.", [["anemia", "DISEASE", 92, 98], ["Hb", "GENE_OR_GENE_PRODUCT", 49, 51], ["Hb", "PROTEIN", 49, 51], ["Hb levels", "TEST", 49, 58], ["iatrogenic anemia", "PROBLEM", 81, 98], ["lower", "OBSERVATION_MODIFIER", 63, 68], ["iatrogenic", "OBSERVATION_MODIFIER", 81, 91], ["anemia", "OBSERVATION", 92, 98]]], ["Introduction: Anemia is prevalent in critically ill traumatic brain injury (TBI) patients and red blood cell (RBC) transfusions are often required.", [["brain", "ANATOMY", 62, 67], ["red blood cell", "ANATOMY", 94, 108], ["RBC", "ANATOMY", 110, 113], ["Anemia", "DISEASE", 14, 20], ["critically ill", "DISEASE", 37, 51], ["traumatic brain injury", "DISEASE", 52, 74], ["TBI", "DISEASE", 76, 79], ["brain", "ORGAN", 62, 67], ["patients", "ORGANISM", 81, 89], ["red blood cell", "CELL", 94, 108], ["RBC", "CELL", 110, 113], ["red blood cell", "CELL_TYPE", 94, 108], ["patients", "SPECIES", 81, 89], ["Anemia", "PROBLEM", 14, 20], ["critically ill traumatic brain injury", "PROBLEM", 37, 74], ["red blood cell (RBC) transfusions", "TREATMENT", 94, 127], ["Anemia", "OBSERVATION", 14, 20], ["brain", "ANATOMY", 62, 67], ["injury", "OBSERVATION", 68, 74]]], ["Over the years, restrictive transfusion strategies have been advocated in the general critically ill population.", [["critically ill", "DISEASE", 86, 100], ["restrictive transfusion strategies", "TREATMENT", 16, 50], ["restrictive", "OBSERVATION_MODIFIER", 16, 27], ["transfusion", "OBSERVATION", 28, 39]]], ["However, considerable uncertainty exists regarding optimal transfusion thresholds in critically ill TBI patients due to the susceptibility of the injured brain to hypoxemic damages.", [["brain", "ANATOMY", 154, 159], ["critically ill", "DISEASE", 85, 99], ["TBI", "DISEASE", 100, 103], ["hypoxemic damages", "DISEASE", 163, 180], ["patients", "ORGANISM", 104, 112], ["brain", "ORGAN", 154, 159], ["patients", "SPECIES", 104, 112], ["optimal transfusion thresholds", "TREATMENT", 51, 81], ["critically ill TBI patients", "TREATMENT", 85, 112], ["the injured brain", "PROBLEM", 142, 159], ["hypoxemic damages", "PROBLEM", 163, 180], ["injured", "OBSERVATION", 146, 153], ["brain", "ANATOMY", 154, 159], ["hypoxemic damages", "OBSERVATION", 163, 180]]], ["Methods: We conducted an electronic self-administered survey targeting all intensivists and neurosurgeons from Canada, Australia and the United Kingdom working caring for TBI patients.", [["TBI", "DISEASE", 171, 174], ["patients", "ORGANISM", 175, 183], ["patients", "SPECIES", 175, 183], ["TBI patients", "TREATMENT", 171, 183]]], ["The questionnaire was developed using a structured process of domains/items generation and reduction with a panel of experts.", [["domains/items generation", "TREATMENT", 62, 86]]], ["It was validated for clinical sensibility, reliability and content validity.", [["clinical sensibility", "TEST", 21, 41]]], ["Results: The response rate was 28.6% (217/760).", [["The response rate", "TEST", 9, 26]]], ["When presented with a scenario of a young patient with severe TBI, a wide range of transfusion practices was noted among respondents, with 47% favoring RBC transfusion at a hemoglobin level of 7g/dL or less in the acute phase of care, while 73% would use this trigger in the plateau phase.", [["RBC", "ANATOMY", 152, 155], ["TBI", "DISEASE", 62, 65], ["patient", "ORGANISM", 42, 49], ["RBC", "CELL", 152, 155], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 173, 183], ["hemoglobin", "PROTEIN", 173, 183], ["patient", "SPECIES", 42, 49], ["severe TBI", "PROBLEM", 55, 65], ["transfusion practices", "TREATMENT", 83, 104], ["RBC transfusion", "TREATMENT", 152, 167], ["a hemoglobin level", "TEST", 171, 189], ["severe", "OBSERVATION_MODIFIER", 55, 61], ["TBI", "OBSERVATION", 62, 65], ["acute phase", "OBSERVATION_MODIFIER", 214, 225], ["plateau", "ANATOMY", 275, 282]]], ["Multiple trauma, neuromonitoring data, hemorrhagic shock and planned surgeries were the most important factors thought to influence the need for transfusion.", [["trauma", "DISEASE", 9, 15], ["hemorrhagic shock", "DISEASE", 39, 56], ["Multiple trauma", "PROBLEM", 0, 15], ["neuromonitoring data", "TEST", 17, 37], ["hemorrhagic shock", "PROBLEM", 39, 56], ["planned surgeries", "TREATMENT", 61, 78], ["transfusion", "TREATMENT", 145, 156], ["trauma", "OBSERVATION", 9, 15], ["hemorrhagic", "OBSERVATION_MODIFIER", 39, 50], ["shock", "OBSERVATION", 51, 56]]], ["The level of evidence was the main reason mentioned to explain the uncertainty regarding RBC transfusion strategies.", [["RBC", "ANATOMY", 89, 92], ["RBC", "CELL", 89, 92], ["RBC transfusion strategies", "TREATMENT", 89, 115]]], ["Conclusions: In critically ill TBI patients, transfusion practices and hemoglobin thresholds for transfusion are said to be influenced by patients' characteristics and the use of neuromonitoring in critical care physicians and neurosurgeons from Canada, Australia and the UK.", [["critically ill TBI", "DISEASE", 16, 34], ["patients", "ORGANISM", 35, 43], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 71, 81], ["patients", "ORGANISM", 138, 146], ["hemoglobin", "PROTEIN", 71, 81], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 138, 146], ["transfusion practices", "TREATMENT", 45, 66], ["hemoglobin thresholds", "TEST", 71, 92], ["transfusion", "TREATMENT", 97, 108], ["neuromonitoring", "TREATMENT", 179, 194]]], ["Equipoise regarding optimal transfusion strategy is manifest, mainly attributed to lack of clear evidences and clinical guidelines (1-year) .", [["optimal transfusion strategy", "TREATMENT", 20, 48]]], ["No significant associations were found between FFP:RBC ratio and mortality rates.", [["RBC", "ANATOMY", 51, 54], ["FFP", "SIMPLE_CHEMICAL", 47, 50], ["RBC", "CELL", 51, 54], ["FFP", "TEST", 47, 50], ["RBC ratio", "TEST", 51, 60], ["mortality rates", "TEST", 65, 80], ["significant", "OBSERVATION_MODIFIER", 3, 14]]], ["Patients with higher APACHE II score received more platelet transfusions and mortality rates were higher in those who received Platelets:RBC ratio >1.", [["platelet", "ANATOMY", 51, 59], ["Platelets", "ANATOMY", 127, 136], ["RBC", "ANATOMY", 137, 140], ["Patients", "ORGANISM", 0, 8], ["platelet", "CELL", 51, 59], ["Platelets", "CELL", 127, 136], ["RBC", "CELL", 137, 140], ["APACHE II", "PROTEIN", 21, 30], ["Patients", "SPECIES", 0, 8], ["higher APACHE II score", "PROBLEM", 14, 36], ["platelet transfusions", "TREATMENT", 51, 72], ["mortality rates", "TEST", 77, 92], ["Platelets", "TEST", 127, 136], ["RBC ratio", "TEST", 137, 146]]], ["On multivariate analysis, higher APA-CHE II score was an independent predictor of increased mortality.P353Conclusions: The compliance with the recommended 1:1:1 ratio of blood products was poor.", [["blood", "ANATOMY", 170, 175], ["APA-CHE II", "GENE_OR_GENE_PRODUCT", 33, 43], ["blood", "ORGANISM_SUBSTANCE", 170, 175], ["multivariate analysis", "TEST", 3, 24], ["increased mortality", "PROBLEM", 82, 101], ["1:1:1 ratio of blood products", "TREATMENT", 155, 184], ["increased", "OBSERVATION_MODIFIER", 82, 91], ["mortality", "OBSERVATION", 92, 101]]], ["There was no association between transfusion ratios and mortality after adjusting for APACHE II score.", [["transfusion ratios", "TEST", 33, 51], ["APACHE II score", "TEST", 86, 101], ["no association between", "UNCERTAINTY", 10, 32]]], ["Introduction: The lack of evidence-based medicine supporting the transfusion decision is illustrated by the wide range of blood product use during first-time coronary artery bypass grafting (CABG).", [["blood", "ANATOMY", 122, 127], ["coronary artery", "ANATOMY", 158, 173], ["blood", "ORGANISM_SUBSTANCE", 122, 127], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 158, 173], ["the transfusion decision", "TREATMENT", 61, 85], ["blood product", "TREATMENT", 122, 135], ["coronary artery bypass grafting", "TREATMENT", 158, 189], ["CABG", "TREATMENT", 191, 195], ["coronary artery", "ANATOMY", 158, 173], ["bypass grafting", "OBSERVATION", 174, 189]]], ["Use of red blood cells (RBC) ranges from 3 to 83 percent, while the use of platelets range from 0 to 40 [1] .", [["red blood cells", "ANATOMY", 7, 22], ["RBC", "ANATOMY", 24, 27], ["platelets", "ANATOMY", 75, 84], ["red blood cells", "CELL", 7, 22], ["RBC", "CELL", 24, 27], ["platelets", "CELL", 75, 84], ["red blood cells", "CELL_TYPE", 7, 22], ["RBC", "CELL_TYPE", 24, 27], ["platelets", "CELL_TYPE", 75, 84], ["red blood cells", "TEST", 7, 22], ["RBC", "TEST", 24, 27], ["platelets", "TEST", 75, 84]]], ["Approximately 20 percent of CABG patients suffer abnormal bleeding, with platelet dysfunction thought to be the most common culprit [2] .", [["platelet", "ANATOMY", 73, 81], ["abnormal bleeding", "DISEASE", 49, 66], ["platelet dysfunction", "DISEASE", 73, 93], ["patients", "ORGANISM", 33, 41], ["platelet", "CELL", 73, 81], ["patients", "SPECIES", 33, 41], ["CABG", "TREATMENT", 28, 32], ["abnormal bleeding", "PROBLEM", 49, 66], ["platelet dysfunction", "PROBLEM", 73, 93], ["abnormal", "OBSERVATION_MODIFIER", 49, 57], ["bleeding", "OBSERVATION", 58, 66], ["platelet dysfunction", "OBSERVATION", 73, 93]]], ["Methods: The objective of this study was to evaluate the use of allogeneic blood and blood products among patients undergoing first-time CABG over the past 15years.", [["blood", "ANATOMY", 75, 80], ["blood", "ANATOMY", 85, 90], ["blood", "ORGANISM_SUBSTANCE", 75, 80], ["blood", "ORGANISM_SUBSTANCE", 85, 90], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["this study", "TEST", 26, 36], ["allogeneic blood and blood products", "TREATMENT", 64, 99], ["first-time CABG", "TREATMENT", 126, 141]]], ["The first 50 patients who underwent CABG (on-pump and off-pump) from 1 st of March each year were included for analysis.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["CABG", "TREATMENT", 36, 40], ["pump", "TREATMENT", 45, 49], ["pump", "TREATMENT", 58, 62], ["analysis", "TEST", 111, 119], ["CABG", "OBSERVATION", 36, 40]]], ["The percentage of patients receiving RBC, fresh frozen plasma (FFP), platelet and cryoprecipitate during the first 48 hours intra-and postoperatively were analysed.", [["RBC", "ANATOMY", 37, 40], ["frozen plasma", "ANATOMY", 48, 61], ["platelet", "ANATOMY", 69, 77], ["patients", "ORGANISM", 18, 26], ["RBC", "CELL", 37, 40], ["plasma", "ORGANISM_SUBSTANCE", 55, 61], ["FFP", "SIMPLE_CHEMICAL", 63, 66], ["platelet", "CELL", 69, 77], ["cryoprecipitate", "ORGANISM_SUBSTANCE", 82, 97], ["RBC", "CELL_TYPE", 37, 40], ["platelet", "CELL_TYPE", 69, 77], ["cryoprecipitate", "PROTEIN", 82, 97], ["patients", "SPECIES", 18, 26], ["RBC", "TEST", 37, 40], ["fresh frozen plasma (FFP", "TREATMENT", 42, 66], ["platelet", "TREATMENT", 69, 77], ["cryoprecipitate", "TREATMENT", 82, 97], ["percentage", "OBSERVATION_MODIFIER", 4, 14]]], ["Linear regression analysis was performed in each group.P353Results: Our analysis shows that the use of RBC decreased over the last 15 years, in contrast to the use of the other 3 investigated products. (see Fig. 1 ) The increase of platelets was the most pronounced with a direction coefficient of 0.022 and had the least variability (r 2 =0.59). (see Fig. 2 ) The decrease in RBC was less obvious than the rise in platelet use (direction coefficient of 0.015) and had a higher variability (r 2 =0.32).", [["RBC", "ANATOMY", 103, 106], ["platelets", "ANATOMY", 232, 241], ["RBC", "ANATOMY", 377, 380], ["platelet", "ANATOMY", 415, 423], ["RBC", "CELL", 103, 106], ["platelets", "CELL", 232, 241], ["RBC", "CELL", 377, 380], ["platelet", "CELL", 415, 423], ["RBC", "CELL_TYPE", 103, 106], ["platelets", "CELL_TYPE", 232, 241], ["RBC", "CELL_TYPE", 377, 380], ["Linear regression analysis", "TEST", 0, 26], ["Our analysis", "TEST", 68, 80], ["RBC", "TEST", 103, 106], ["the other 3 investigated products", "TREATMENT", 167, 200], ["The increase of platelets", "PROBLEM", 216, 241], ["The decrease in RBC", "PROBLEM", 361, 380], ["a higher variability", "PROBLEM", 469, 489], ["decreased", "OBSERVATION_MODIFIER", 107, 116], ["increase", "OBSERVATION_MODIFIER", 220, 228], ["platelets", "OBSERVATION", 232, 241], ["most pronounced", "OBSERVATION_MODIFIER", 250, 265], ["least", "OBSERVATION_MODIFIER", 316, 321], ["variability", "OBSERVATION_MODIFIER", 322, 333], ["decrease", "OBSERVATION_MODIFIER", 365, 373], ["less obvious", "OBSERVATION_MODIFIER", 385, 397], ["rise", "OBSERVATION_MODIFIER", 407, 411], ["higher", "OBSERVATION_MODIFIER", 471, 477], ["variability", "OBSERVATION_MODIFIER", 478, 489]]], ["The consumption of FFP and cryoprecipitate stayed constant (direction coefficient of 0.004 and 0.001 respectively).Conclusions:The higher incidence of semi-urgent CABG in recent years, which involves continuation of anti-platelet therapy until the day before surgery, can be an explanation for our observed increased use of platelets.", [["platelets", "ANATOMY", 324, 333], ["FFP", "SIMPLE_CHEMICAL", 19, 22], ["cryoprecipitate", "ORGANISM_SUBSTANCE", 27, 42], ["platelets", "CELL", 324, 333], ["FFP", "PROTEIN", 19, 22], ["cryoprecipitate", "PROTEIN", 27, 42], ["platelets", "CELL_TYPE", 324, 333], ["FFP", "TREATMENT", 19, 22], ["cryoprecipitate", "TREATMENT", 27, 42], ["semi-urgent CABG", "TREATMENT", 151, 167], ["anti-platelet therapy", "TREATMENT", 216, 237], ["surgery", "TREATMENT", 259, 266], ["platelets", "TREATMENT", 324, 333], ["CABG", "OBSERVATION", 163, 167], ["anti-platelet therapy", "OBSERVATION", 216, 237]]], ["The observed decrease in RBC transfusion over the past 15 years might be due to rising awareness of complications associated with red cell transfusion.Conclusions:Introduction: Red blood cells (RBC) transfusion is frequently required in cardiac surgery and is associated with increased morbidity and mortality rates.", [["RBC", "ANATOMY", 25, 28], ["red cell", "ANATOMY", 130, 138], ["Red blood cells", "ANATOMY", 177, 192], ["RBC", "ANATOMY", 194, 197], ["cardiac", "ANATOMY", 237, 244], ["RBC", "CELL", 25, 28], ["red cell", "CELL", 130, 138], ["Red blood cells", "CELL", 177, 192], ["RBC", "CELL", 194, 197], ["cardiac", "ORGAN", 237, 244], ["RBC", "CELL_TYPE", 25, 28], ["Red blood cells", "CELL_TYPE", 177, 192], ["RBC", "CELL_TYPE", 194, 197], ["RBC transfusion", "TREATMENT", 25, 40], ["rising awareness of complications", "PROBLEM", 80, 113], ["red cell transfusion", "TREATMENT", 130, 150], ["Red blood cells", "TEST", 177, 192], ["RBC) transfusion", "TREATMENT", 194, 210], ["cardiac surgery", "TREATMENT", 237, 252], ["increased morbidity", "PROBLEM", 276, 295], ["mortality rates", "PROBLEM", 300, 315], ["decrease", "OBSERVATION_MODIFIER", 13, 21], ["RBC transfusion", "OBSERVATION", 25, 40], ["red cell transfusion", "OBSERVATION", 130, 150], ["cardiac", "ANATOMY", 237, 244], ["surgery", "OBSERVATION", 245, 252], ["increased", "OBSERVATION_MODIFIER", 276, 285], ["morbidity", "OBSERVATION", 286, 295]]], ["The aim of this study is to identify predictors of RBC transfusion for patients undergoing cardiac surgery, emphasizing the use of bioelectrical impedance analysis (BIA).Conclusions:Methods: This was a retrospective study of patients who underwent elective cardiac surgery between years 2013 and 2014 in a tertiary reference center.", [["RBC", "ANATOMY", 51, 54], ["cardiac", "ANATOMY", 91, 98], ["cardiac", "ANATOMY", 257, 264], ["RBC", "CELL", 51, 54], ["patients", "ORGANISM", 71, 79], ["cardiac", "ORGAN", 91, 98], ["patients", "ORGANISM", 225, 233], ["cardiac", "ORGAN", 257, 264], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 225, 233], ["this study", "TEST", 11, 21], ["RBC transfusion", "TREATMENT", 51, 66], ["cardiac surgery", "TREATMENT", 91, 106], ["bioelectrical impedance analysis", "TEST", 131, 163], ["a retrospective study", "TEST", 200, 221], ["elective cardiac surgery", "TREATMENT", 248, 272], ["cardiac", "ANATOMY", 91, 98], ["surgery", "OBSERVATION", 99, 106], ["cardiac", "ANATOMY", 257, 264], ["surgery", "OBSERVATION", 265, 272]]], ["Patients' demographic and clinical variables, preoperative BIA measurements and postoperative data were analyzed.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["preoperative BIA measurements", "TEST", 46, 75], ["postoperative data", "TEST", 80, 98]]], ["The univariate and multivariate logistic regression analyses were used to identify the predictors of postoperative RBC transfusion.", [["RBC", "ANATOMY", 115, 118], ["RBC", "CELL", 115, 118], ["multivariate logistic regression analyses", "TEST", 19, 60], ["postoperative RBC transfusion", "TREATMENT", 101, 130], ["postoperative RBC transfusion", "OBSERVATION", 101, 130]]], ["All of the calculations were performed with IBM SPSS v. 24.", [["the calculations", "TEST", 7, 23]]], ["Introduction: Red blood cells (RBC) transfusion is a common intervention in cardiac surgery and is associated with higher mortality rates and predisposes serious adverse events.", [["Red blood cells", "ANATOMY", 14, 29], ["RBC", "ANATOMY", 31, 34], ["cardiac", "ANATOMY", 76, 83], ["Red blood cells", "CELL", 14, 29], ["RBC", "CELL", 31, 34], ["cardiac", "ORGAN", 76, 83], ["Red blood cells", "CELL_TYPE", 14, 29], ["RBC", "CELL_TYPE", 31, 34], ["Red blood cells", "TEST", 14, 29], ["RBC) transfusion", "TREATMENT", 31, 47], ["a common intervention", "TREATMENT", 51, 72], ["cardiac surgery", "TREATMENT", 76, 91], ["higher mortality rates", "PROBLEM", 115, 137], ["serious adverse events", "PROBLEM", 154, 176], ["cardiac", "ANATOMY", 76, 83], ["surgery", "OBSERVATION", 84, 91]]], ["The aim of this study was to determine whether red blood cells (RBC) transfusion is linked to long-term results after cardiac surgery.Conclusions:Methods: This observational retrospective study included all of the patients who underwent any of the STS defined elective cardiac surgery types from 2013 to 2014.", [["red blood cells", "ANATOMY", 47, 62], ["RBC", "ANATOMY", 64, 67], ["cardiac", "ANATOMY", 118, 125], ["cardiac", "ANATOMY", 269, 276], ["red blood cells", "CELL", 47, 62], ["RBC", "CELL", 64, 67], ["cardiac", "ORGAN", 118, 125], ["patients", "ORGANISM", 214, 222], ["red blood cells", "CELL_TYPE", 47, 62], ["RBC", "CELL_TYPE", 64, 67], ["patients", "SPECIES", 214, 222], ["this study", "TEST", 11, 21], ["red blood cells", "TEST", 47, 62], ["RBC", "TEST", 64, 67], ["transfusion", "TREATMENT", 69, 80], ["cardiac surgery", "TREATMENT", 118, 133], ["This observational retrospective study", "TEST", 155, 193], ["elective cardiac surgery", "TREATMENT", 260, 284], ["cardiac", "ANATOMY", 118, 125], ["surgery", "OBSERVATION", 126, 133], ["cardiac", "ANATOMY", 269, 276], ["surgery", "OBSERVATION", 277, 284]]], ["We evaluated 3-5 year all-cause mortality rates and secondary postoperative outcomes defined by the STS risk prediction model.", [["mortality rates", "PROBLEM", 32, 47], ["secondary postoperative outcomes", "PROBLEM", 52, 84]]], ["Patients were categorized according to whether they received RBC transfusions postoperatively; long-term results were compared using Cox-regression analysis and Kaplan-Meier method.", [["RBC", "ANATOMY", 61, 64], ["Patients", "ORGANISM", 0, 8], ["RBC", "CELL", 61, 64], ["Patients", "SPECIES", 0, 8], ["RBC transfusions", "TREATMENT", 61, 77], ["Cox-regression analysis", "TEST", 133, 156]]], ["Introduction: Transfusion of packed red cells (PRCs) is an important treatment option for patients requiring intensive care but, like all treatments, it is not without risk.", [["red cells", "ANATOMY", 36, 45], ["PRCs", "ANATOMY", 47, 51], ["packed red cells", "CELL", 29, 45], ["PRCs", "CELL", 47, 51], ["patients", "ORGANISM", 90, 98], ["packed red cells", "CELL_TYPE", 29, 45], ["PRCs", "CELL_TYPE", 47, 51], ["patients", "SPECIES", 90, 98], ["Transfusion of packed red cells (PRCs", "TREATMENT", 14, 51], ["an important treatment option", "TREATMENT", 56, 85], ["intensive care", "TREATMENT", 109, 123], ["all treatments", "TREATMENT", 134, 148], ["not without", "UNCERTAINTY", 156, 167]]], ["These patients, although may be more sensitive to anaemia, are also at increased risk of transfusionrelated complications.", [["anaemia", "DISEASE", 50, 57], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["anaemia", "PROBLEM", 50, 57], ["transfusionrelated complications", "PROBLEM", 89, 121], ["anaemia", "OBSERVATION", 50, 57], ["transfusionrelated complications", "OBSERVATION", 89, 121]]], ["We conducted an audit of blood prescribing and administering practices in our intensive care unit.", [["blood", "ANATOMY", 25, 30], ["blood", "ORGANISM_SUBSTANCE", 25, 30]]], ["Methods: Audit proformas were placed in blood prescribing forms for a 1-month period.", [["blood", "ANATOMY", 40, 45], ["blood", "ORGANISM_SUBSTANCE", 40, 45], ["Audit proformas", "TREATMENT", 9, 24]]], ["All transfusions of PRCs were logged over this time, and transfusion triggers, post-transfusion Haemoglobin (Hb) and whether Hb was checked between units was recorded, in addition to other supplementary information.Conclusions:Results: Over a 1-month period, 25 transfusion events were recorded, with an average age of the transfused patients of 60 years old (range 35 -87 years).", [["Haemoglobin", "SIMPLE_CHEMICAL", 96, 107], ["Hb", "SIMPLE_CHEMICAL", 109, 111], ["Hb", "GENE_OR_GENE_PRODUCT", 125, 127], ["patients", "ORGANISM", 334, 342], ["Haemoglobin", "PROTEIN", 96, 107], ["Hb", "PROTEIN", 109, 111], ["Hb", "PROTEIN", 125, 127], ["patients", "SPECIES", 334, 342], ["All transfusions of PRCs", "TREATMENT", 0, 24], ["transfusion triggers", "TREATMENT", 57, 77], ["post-transfusion Haemoglobin", "TEST", 79, 107], ["Hb", "TEST", 109, 111], ["Hb", "TEST", 125, 127], ["25 transfusion events", "PROBLEM", 259, 280], ["transfusions", "OBSERVATION", 4, 16]]], ["76% of transfusion events were for low Hb, 8% for bleeding and in 16% of cases the indication was not documented.", [["bleeding", "DISEASE", 50, 58], ["transfusion events", "PROBLEM", 7, 25], ["low Hb", "PROBLEM", 35, 41], ["bleeding", "PROBLEM", 50, 58]]], ["For patients transfused for a low Hb, the mean transfusion trigger was 75 g/L (range: 66 g/L -86 g/L).", [["patients", "ORGANISM", 4, 12], ["Hb", "GENE_OR_GENE_PRODUCT", 34, 36], ["Hb", "PROTEIN", 34, 36], ["patients", "SPECIES", 4, 12], ["a low Hb", "PROBLEM", 28, 36], ["the mean transfusion trigger", "TEST", 38, 66]]], ["Only 12% had a transfusion trigger of 70g/L or less, and a further 12% who were transfused for a low Hb had a Hb of 80g/L or more.", [["Hb", "GENE_OR_GENE_PRODUCT", 101, 103], ["Hb", "PROTEIN", 101, 103], ["Hb", "PROTEIN", 110, 112], ["a transfusion trigger", "TREATMENT", 13, 34], ["a low Hb", "PROBLEM", 95, 103], ["a Hb", "TEST", 108, 112]]], ["36% of transfusion events involved transfusing 2 or more units and, in only 22% of these cases the Hb was checked between units.", [["Hb", "GENE_OR_GENE_PRODUCT", 99, 101], ["Hb", "PROTEIN", 99, 101], ["transfusion events", "PROBLEM", 7, 25], ["the Hb", "TEST", 95, 101]]], ["Excluding the two bleeding patients, the mean increase in Hb following a single unit transfusion was 11.4 g/L (range 2 g/L -18 g/L), whilst in patients transfused two units, the average increase in Hb was 10 g/L per unit transfused (range 7 g/L -14.5 g/L), suggesting single unit transfusions may have greater Hb yields.", [["bleeding", "DISEASE", 18, 26], ["patients", "ORGANISM", 27, 35], ["Hb", "GENE_OR_GENE_PRODUCT", 58, 60], ["patients", "ORGANISM", 143, 151], ["Hb", "GENE_OR_GENE_PRODUCT", 198, 200], ["Hb", "SIMPLE_CHEMICAL", 310, 312], ["Hb", "PROTEIN", 58, 60], ["Hb", "PROTEIN", 198, 200], ["Hb", "PROTEIN", 310, 312], ["patients", "SPECIES", 27, 35], ["patients", "SPECIES", 143, 151], ["the two bleeding", "PROBLEM", 10, 26], ["a single unit transfusion", "TREATMENT", 71, 96], ["Hb", "TEST", 198, 200], ["single unit transfusions", "TREATMENT", 268, 292], ["greater Hb yields", "PROBLEM", 302, 319], ["two", "OBSERVATION_MODIFIER", 14, 17], ["bleeding", "OBSERVATION", 18, 26], ["mean", "OBSERVATION_MODIFIER", 41, 45], ["increase", "OBSERVATION_MODIFIER", 46, 54], ["average", "OBSERVATION_MODIFIER", 178, 185], ["increase", "OBSERVATION_MODIFIER", 186, 194]]], ["Conclusions: Our audit demonstrated variability in transfusion triggers and progress needed with administering practices when transfusing multiple units of blood in the non-bleeding patient.", [["blood", "ANATOMY", 156, 161], ["blood", "ORGANISM_SUBSTANCE", 156, 161], ["patient", "ORGANISM", 182, 189], ["patient", "SPECIES", 182, 189], ["transfusion triggers", "TREATMENT", 51, 71], ["administering practices", "TREATMENT", 97, 120], ["multiple units of blood", "TREATMENT", 138, 161]]], ["We have since implemented measures to meet guidelines in both prescribing PRCs with restrictive triggers and in the administration and assessment of Hb between units, and will be re-auditing.", [["Hb", "GENE_OR_GENE_PRODUCT", 149, 151], ["Hb", "PROTEIN", 149, 151], ["restrictive triggers", "TREATMENT", 84, 104], ["assessment", "TEST", 135, 145]]], ["Introduction: There is a perceived increased risk of bleeding in cirrhosis patients undergoing invasive procedures.", [["bleeding", "DISEASE", 53, 61], ["cirrhosis", "DISEASE", 65, 74], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["bleeding in cirrhosis", "PROBLEM", 53, 74], ["invasive procedures", "TREATMENT", 95, 114], ["bleeding", "OBSERVATION", 53, 61], ["cirrhosis", "OBSERVATION", 65, 74]]], ["This lead to a high rate of empirical prophylactic transfusion, which has been associated to increased complications and cost.", [["empirical prophylactic transfusion", "TREATMENT", 28, 62], ["increased complications", "PROBLEM", 93, 116], ["increased", "OBSERVATION_MODIFIER", 93, 102], ["complications", "OBSERVATION", 103, 116]]], ["The best strategy to guide transfusion in these patients remains unclear.", [["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["guide transfusion", "TREATMENT", 21, 38]]], ["Our aim was to compare three strategies to guide blood component transfusion prior to central venous catheterization (CVC) in critically ill cirrhosis patients.P363Methods: Single center, randomized, double-blinded, controlled clinical trial conducted in Brazil [1] .", [["blood", "ANATOMY", 49, 54], ["central venous", "ANATOMY", 86, 100], ["critically ill", "DISEASE", 126, 140], ["cirrhosis", "DISEASE", 141, 150], ["blood", "ORGANISM_SUBSTANCE", 49, 54], ["central venous", "MULTI-TISSUE_STRUCTURE", 86, 100], ["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 151, 159], ["blood component transfusion", "TREATMENT", 49, 76], ["central venous catheterization", "TREATMENT", 86, 116], ["critically ill cirrhosis", "PROBLEM", 126, 150], ["double-blinded", "TREATMENT", 200, 214], ["central", "ANATOMY_MODIFIER", 86, 93], ["venous", "ANATOMY", 94, 100], ["catheterization", "OBSERVATION", 101, 116], ["ill", "OBSERVATION_MODIFIER", 137, 140], ["cirrhosis", "OBSERVATION", 141, 150]]], ["All cirrhosis patients admitted to the ICU with indication for a CVC were eligible.", [["cirrhosis", "DISEASE", 4, 13], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["All cirrhosis", "PROBLEM", 0, 13], ["a CVC", "TREATMENT", 63, 68], ["cirrhosis", "OBSERVATION", 4, 13]]], ["Participants were randomized 1:1:1 to three transfusion strategies based on: (1) standard coagulation tests (SCT), (2) rotational thromboelastometry (ROTEM) and (3) restrictive.", [["Participants", "SPECIES", 0, 12], ["three transfusion strategies", "TREATMENT", 38, 66], ["standard coagulation tests", "TEST", 81, 107], ["SCT", "TEST", 109, 112], ["rotational thromboelastometry (ROTEM)", "TEST", 119, 156]]], ["The primary outcome was proportion of transfusion of any blood component prior to CVC.", [["blood", "ANATOMY", 57, 62], ["blood", "ORGANISM_SUBSTANCE", 57, 62], ["any blood component", "PROBLEM", 53, 72], ["CVC", "TEST", 82, 85]]], ["Secondary outcomes were incidence of major and minor bleeding, ICU length of stay (LOS), and 28-day mortality.", [["bleeding", "DISEASE", 53, 61], ["major and minor bleeding", "PROBLEM", 37, 61], ["minor", "OBSERVATION_MODIFIER", 47, 52], ["bleeding", "OBSERVATION", 53, 61]]], ["Analysis was intention-to-treat.", [["Analysis", "TEST", 0, 8]]], ["Results: 57 participants (19 in each group) were enrolled between September 2014 and December 2016.", [["participants", "ORGANISM", 12, 24], ["participants", "SPECIES", 12, 24]]], ["Most were male (64.9%) and listed for liver transplantation.", [["liver", "ANATOMY", 38, 43], ["liver", "ORGAN", 38, 43], ["liver transplantation", "TREATMENT", 38, 59], ["liver", "ANATOMY", 38, 43], ["transplantation", "OBSERVATION", 44, 59]]], ["The study ended after reaching efficacy in first interim analysis.", [["The study", "TEST", 0, 9], ["first interim analysis", "TEST", 43, 65]]], ["There was no significant difference in baseline characteristics among groups.", [["significant difference in baseline characteristics among groups", "PROBLEM", 13, 76], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35]]], ["Regarding primary endpoint, there was 14 (73.7%), 13 (68.4%), and 3 (15.8%) events in SCT, ROTEM and restrictive groups, respectively (p <0.001).", [["SCT", "TEST", 86, 89], ["ROTEM", "TEST", 91, 96], ["restrictive", "OBSERVATION_MODIFIER", 101, 112]]], ["There was no difference between SCT and ROTEM groups (p >0.99).", [["SCT", "TEST", 32, 35], ["ROTEM groups", "TEST", 40, 52], ["p", "TEST", 54, 55], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23]]], ["There was no major bleeding.", [["bleeding", "DISEASE", 19, 27], ["major bleeding", "PROBLEM", 13, 27], ["no", "UNCERTAINTY", 10, 12], ["major", "OBSERVATION_MODIFIER", 13, 18], ["bleeding", "OBSERVATION", 19, 27]]], ["Overall minor bleeding occurred in 10.53% with no difference between groups.P363Conclusions: A restrictive strategy is safe and effective in reducing the need of blood component transfusion prior to CVC in critically ill cirrhosis patients.", [["blood", "ANATOMY", 162, 167], ["bleeding", "DISEASE", 14, 22], ["critically ill", "DISEASE", 206, 220], ["cirrhosis", "DISEASE", 221, 230], ["blood", "ORGANISM_SUBSTANCE", 162, 167], ["patients", "ORGANISM", 231, 239], ["patients", "SPECIES", 231, 239], ["Overall minor bleeding", "PROBLEM", 0, 22], ["A restrictive strategy", "TREATMENT", 93, 115], ["blood component transfusion", "TREATMENT", 162, 189], ["CVC", "TREATMENT", 199, 202], ["critically ill cirrhosis", "PROBLEM", 206, 230], ["minor", "OBSERVATION_MODIFIER", 8, 13], ["bleeding", "OBSERVATION", 14, 22], ["restrictive", "OBSERVATION", 95, 106], ["critically ill", "OBSERVATION_MODIFIER", 206, 220], ["cirrhosis", "OBSERVATION", 221, 230]]], ["A ROTEM-based strategy was no different from transfusion guided by SCT.", [["A ROTEM", "TEST", 0, 7]]], ["Introduction: Desmopressin (DDAVP) is a vasopressin analogue which improves platelet function.", [["platelet", "ANATOMY", 76, 84], ["Desmopressin", "CHEMICAL", 14, 26], ["DDAVP", "CHEMICAL", 28, 33], ["vasopressin", "CHEMICAL", 40, 51], ["Desmopressin", "CHEMICAL", 14, 26], ["DDAVP", "CHEMICAL", 28, 33], ["vasopressin", "CHEMICAL", 40, 51], ["Desmopressin", "SIMPLE_CHEMICAL", 14, 26], ["DDAVP", "SIMPLE_CHEMICAL", 28, 33], ["vasopressin", "SIMPLE_CHEMICAL", 40, 51], ["platelet", "CELL", 76, 84], ["Desmopressin (DDAVP)", "TREATMENT", 14, 34], ["a vasopressin analogue", "TREATMENT", 38, 60], ["platelet function", "TEST", 76, 93], ["platelet function", "OBSERVATION", 76, 93]]], ["Its general use as a haemostatic agent is still controversial.", [["a haemostatic agent", "TREATMENT", 19, 38]]], ["The aim of study was to evaluate the effect of prophylactic desmopressin in blood coagulation in patients undergoing heart valve surgery.", [["blood", "ANATOMY", 76, 81], ["heart valve", "ANATOMY", 117, 128], ["desmopressin", "CHEMICAL", 60, 72], ["blood coagulation", "DISEASE", 76, 93], ["desmopressin", "CHEMICAL", 60, 72], ["desmopressin", "SIMPLE_CHEMICAL", 60, 72], ["blood", "ORGANISM_SUBSTANCE", 76, 81], ["patients", "ORGANISM", 97, 105], ["heart valve", "MULTI-TISSUE_STRUCTURE", 117, 128], ["patients", "SPECIES", 97, 105], ["study", "TEST", 11, 16], ["prophylactic desmopressin", "TREATMENT", 47, 72], ["blood coagulation", "TREATMENT", 76, 93], ["heart valve surgery", "TREATMENT", 117, 136], ["heart valve", "ANATOMY", 117, 128], ["surgery", "OBSERVATION", 129, 136]]], ["Methods: Prospective, randomized, double-blind clinical trial performed at the Heart Institute of the University of S\u00e3o Paulo.", [["Heart", "ANATOMY", 79, 84]]], ["A total of 108 adult patients undergoing heart valve surgery were enrolled from February 2015 to November 2016.", [["heart valve", "ANATOMY", 41, 52], ["patients", "ORGANISM", 21, 29], ["heart", "ORGAN", 41, 46], ["patients", "SPECIES", 21, 29], ["heart valve surgery", "TREATMENT", 41, 60], ["heart valve", "ANATOMY", 41, 52]]], ["Immediately after cardiopulmonary bypass weaning and heparin reversal, patients were randomized in ratio 1:1 to intervention group: DDAVP (0.3 \u03bcg/kg) or control group.", [["cardiopulmonary", "ANATOMY", 18, 33], ["heparin", "CHEMICAL", 53, 60], ["DDAVP", "CHEMICAL", 132, 137], ["DDAVP", "CHEMICAL", 132, 137], ["heparin", "SIMPLE_CHEMICAL", 53, 60], ["patients", "ORGANISM", 71, 79], ["DDAVP", "SIMPLE_CHEMICAL", 132, 137], ["patients", "SPECIES", 71, 79], ["cardiopulmonary bypass weaning", "TREATMENT", 18, 48], ["heparin reversal", "TREATMENT", 53, 69], ["DDAVP", "TREATMENT", 132, 137], ["cardiopulmonary", "ANATOMY", 18, 33], ["bypass", "OBSERVATION", 34, 40]]], ["Blood samples were drawn at three different times, at baseline (T0), 2 hours (T1) and 24 hours (T2) after study medication.", [["Blood samples", "ANATOMY", 0, 13], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["Blood samples", "TEST", 0, 13], ["study medication", "TREATMENT", 106, 122]]], ["Blood coagulation and perioperative bleeding were analysed using laboratorial tests and thromboelastometry, chest tube drainage and requirement of allogenic transfusion within 48 hours.P363Results: A total of 54 patients were allocated to intervention and 54 to control group.", [["Blood", "ANATOMY", 0, 5], ["chest tube", "ANATOMY", 108, 118], ["Blood coagulation", "DISEASE", 0, 17], ["bleeding", "DISEASE", 36, 44], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["chest tube", "MULTI-TISSUE_STRUCTURE", 108, 118], ["patients", "ORGANISM", 212, 220], ["patients", "SPECIES", 212, 220], ["Blood coagulation", "TEST", 0, 17], ["perioperative bleeding", "PROBLEM", 22, 44], ["laboratorial tests", "TEST", 65, 83], ["thromboelastometry", "TEST", 88, 106], ["chest tube drainage", "TREATMENT", 108, 127], ["allogenic transfusion", "TREATMENT", 147, 168], ["intervention", "TREATMENT", 239, 251], ["perioperative bleeding", "OBSERVATION", 22, 44], ["chest", "ANATOMY", 108, 113], ["tube drainage", "OBSERVATION", 114, 127]]], ["Blood levels of factor VIII at T2 (236.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["factor VIII", "GENE_OR_GENE_PRODUCT", 16, 27], ["factor VIII", "PROTEIN", 16, 27], ["Blood levels", "TEST", 0, 12], ["factor VIII", "TEST", 16, 27]]], ["5 Conclusions: Prophylactic use of desmopressin in heart valve surgery does not influence coagulation and thromboelastometric parameters.P366Identifying the impact of hemostatic resuscitation on development of multiple organ failure using factor analysis: results from a randomized trial using first-line coagulation factor concentrates or fresh-frozen plasma in major trauma (RETIC study) P Innerhofer 1 Introduction: to clarify how hemostatic resuscitation affects occurrence of multiple organ failure.", [["heart valve", "ANATOMY", 51, 62], ["organ", "ANATOMY", 219, 224], ["plasma", "ANATOMY", 353, 359], ["organ", "ANATOMY", 490, 495], ["desmopressin", "CHEMICAL", 35, 47], ["multiple organ failure", "DISEASE", 210, 232], ["trauma", "DISEASE", 369, 375], ["organ failure", "DISEASE", 490, 503], ["desmopressin", "CHEMICAL", 35, 47], ["desmopressin", "SIMPLE_CHEMICAL", 35, 47], ["heart", "ORGAN", 51, 56], ["organ", "ORGAN", 219, 224], ["plasma", "ORGANISM_SUBSTANCE", 353, 359], ["organ", "ORGAN", 490, 495], ["coagulation factor", "PROTEIN", 305, 323], ["desmopressin in heart valve surgery", "TREATMENT", 35, 70], ["thromboelastometric parameters", "TEST", 106, 136], ["hemostatic resuscitation", "TREATMENT", 167, 191], ["multiple organ failure", "PROBLEM", 210, 232], ["factor analysis", "TEST", 239, 254], ["a randomized trial", "TREATMENT", 269, 287], ["first-line coagulation factor concentrates", "TREATMENT", 294, 336], ["fresh-frozen plasma", "TREATMENT", 340, 359], ["major trauma", "PROBLEM", 363, 375], ["RETIC study", "TEST", 377, 388], ["hemostatic resuscitation", "TREATMENT", 434, 458], ["multiple organ failure", "PROBLEM", 481, 503], ["heart valve", "ANATOMY", 51, 62], ["multiple", "OBSERVATION_MODIFIER", 210, 218], ["organ", "ANATOMY", 219, 224], ["failure", "OBSERVATION", 225, 232], ["multiple", "OBSERVATION_MODIFIER", 481, 489], ["organ", "ANATOMY", 490, 495], ["failure", "OBSERVATION", 496, 503]]], ["Methods: analysis of secondary endpoints of the RETIC study [1] (coagulation factors, activated protein C (APC), thrombin generation, ROTEM parameters, syndecan-1, thrombomodulin (TM) and D-Dimer) measured at randomization, and after patients had received FFP or coagulation factor concentrates (CFC) at admission to ICU, 24 and 48 hours thereafter.", [["coagulation factors", "GENE_OR_GENE_PRODUCT", 65, 84], ["protein C", "GENE_OR_GENE_PRODUCT", 96, 105], ["APC", "GENE_OR_GENE_PRODUCT", 107, 110], ["thrombin", "GENE_OR_GENE_PRODUCT", 113, 121], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 152, 162], ["thrombomodulin", "GENE_OR_GENE_PRODUCT", 164, 178], ["D-Dimer", "GENE_OR_GENE_PRODUCT", 188, 195], ["patients", "ORGANISM", 234, 242], ["FFP", "SIMPLE_CHEMICAL", 256, 259], ["coagulation factors", "PROTEIN", 65, 84], ["activated protein C", "PROTEIN", 86, 105], ["APC", "PROTEIN", 107, 110], ["thrombin", "PROTEIN", 113, 121], ["ROTEM", "PROTEIN", 134, 139], ["syndecan-1", "PROTEIN", 152, 162], ["thrombomodulin", "PROTEIN", 164, 178], ["TM", "PROTEIN", 180, 182], ["D-Dimer", "PROTEIN", 188, 195], ["FFP", "PROTEIN", 256, 259], ["coagulation factor", "PROTEIN", 263, 281], ["patients", "SPECIES", 234, 242], ["the RETIC study", "TEST", 44, 59], ["coagulation factors", "TEST", 65, 84], ["activated protein C (APC)", "TREATMENT", 86, 111], ["thrombin generation", "TEST", 113, 132], ["ROTEM parameters", "TEST", 134, 150], ["syndecan", "TEST", 152, 160], ["thrombomodulin (TM", "TEST", 164, 182], ["D-Dimer", "TEST", 188, 195], ["FFP", "TREATMENT", 256, 259], ["coagulation factor concentrates", "TREATMENT", 263, 294]]], ["We used factor analysis to reduce the highly interrelated variables to a few main underlying factors and analysed their relation to MOF before and after hemostatic therapy.P366Results: The factors Concentration, Clot and Hypoperfusion representing trauma-induced coagulopathy (Table 1) were comparable between groups at baseline (Fig. 1) and only high Hypoperfusionscore predicted MOF, while after therapy a low Clot-score also predicted MOF.", [["MOF", "DISEASE", 132, 135], ["Hypoperfusion", "DISEASE", 221, 234], ["trauma", "DISEASE", 248, 254], ["coagulopathy", "DISEASE", 263, 275], ["MOF", "DISEASE", 381, 384], ["MOF", "DISEASE", 438, 441], ["Clot", "PROTEIN", 412, 416], ["factor analysis", "TEST", 8, 23], ["hemostatic therapy", "TREATMENT", 153, 171], ["Clot", "PROBLEM", 212, 216], ["Hypoperfusion", "PROBLEM", 221, 234], ["trauma", "PROBLEM", 248, 254], ["induced coagulopathy", "PROBLEM", 255, 275], ["high Hypoperfusionscore predicted MOF", "PROBLEM", 347, 384], ["therapy", "TREATMENT", 398, 405], ["a low Clot", "PROBLEM", 406, 416], ["Clot", "OBSERVATION", 212, 216], ["Hypoperfusion", "OBSERVATION_MODIFIER", 221, 234], ["trauma", "OBSERVATION", 248, 254], ["coagulopathy", "OBSERVATION", 263, 275], ["low", "OBSERVATION_MODIFIER", 408, 411], ["Clot", "OBSERVATION", 412, 416]]], ["Only the changes of the Clot-score independently affected occurrence of MOF (p=0.0002, adjusted OR 3.40, CI 2.46-4.71), while changes of Concentration (p= 0.8979, adjusted OR 0.96, CI 0.68-1.34) and Hypoperfusion (p=0.8098, adjusted OR 1.06, CI 0.84-1.33) did not.", [["MOF", "DISEASE", 72, 75], ["Hypoperfusion", "DISEASE", 199, 212], ["the Clot", "PROBLEM", 20, 28], ["CI", "TEST", 105, 107], ["CI", "TEST", 181, 183], ["Hypoperfusion", "TEST", 199, 212], ["CI", "TEST", 242, 244], ["Clot", "OBSERVATION", 24, 28], ["Hypoperfusion", "OBSERVATION", 199, 212]]], ["A lower Clot-score occurred after FFP transfusion than use of CFC, mainly through persistent thrombocytopenia (platelet count R2-4 FFP vs CFC p<0.02) (Fig. 2) .", [["platelet", "ANATOMY", 111, 119], ["thrombocytopenia", "DISEASE", 93, 109], ["platelet", "CELL", 111, 119], ["A lower Clot-score", "PROBLEM", 0, 18], ["FFP transfusion", "TREATMENT", 34, 49], ["CFC", "TREATMENT", 62, 65], ["persistent thrombocytopenia", "PROBLEM", 82, 109], ["platelet count", "TEST", 111, 125], ["R2", "TEST", 126, 128], ["FFP", "TEST", 131, 134], ["CFC p", "TEST", 138, 143], ["lower", "OBSERVATION_MODIFIER", 2, 7], ["Clot", "OBSERVATION", 8, 12], ["persistent", "OBSERVATION_MODIFIER", 82, 92], ["thrombocytopenia", "OBSERVATION", 93, 109]]], ["The higher Concentration-score after FFP did not affect MOF and FFP had no beneficial effect on fibrinolysis, syndecan-1, TM or APC.", [["MOF", "DISEASE", 56, 59], ["FFP", "SIMPLE_CHEMICAL", 64, 67], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 110, 120], ["TM", "GENE_OR_GENE_PRODUCT", 122, 124], ["APC", "GENE_OR_GENE_PRODUCT", 128, 131], ["syndecan-1", "PROTEIN", 110, 120], ["TM", "PROTEIN", 122, 124], ["APC", "CELL_TYPE", 128, 131], ["FFP", "TREATMENT", 37, 40], ["MOF", "PROBLEM", 56, 59], ["FFP", "TREATMENT", 64, 67], ["fibrinolysis", "TEST", 96, 108], ["syndecan", "TEST", 110, 118], ["APC", "PROBLEM", 128, 131]]], ["Conclusions: Hemostatic resuscitation should augment the factor Clot, which is feasible with early fibrinogen administration but not with FFP.", [["fibrinogen", "GENE_OR_GENE_PRODUCT", 99, 109], ["FFP", "SIMPLE_CHEMICAL", 138, 141], ["fibrinogen", "PROTEIN", 99, 109], ["FFP", "PROTEIN", 138, 141], ["Hemostatic resuscitation", "TREATMENT", 13, 37], ["the factor Clot", "PROBLEM", 53, 68], ["early fibrinogen administration", "TREATMENT", 93, 124], ["FFP", "TREATMENT", 138, 141], ["Clot", "OBSERVATION", 64, 68]]], ["The found platelet-saving effect of early fibrinogen administration is important as platelets play a major role in inflammation and transfusion of platelets did not correct thrombocytopenia.", [["platelet", "ANATOMY", 10, 18], ["platelets", "ANATOMY", 84, 93], ["platelets", "ANATOMY", 147, 156], ["inflammation", "DISEASE", 115, 127], ["thrombocytopenia", "DISEASE", 173, 189], ["platelet", "CELL", 10, 18], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 42, 52], ["platelets", "CELL", 84, 93], ["platelets", "CELL", 147, 156], ["fibrinogen", "PROTEIN", 42, 52], ["platelets", "CELL_TYPE", 84, 93], ["platelets", "CELL_TYPE", 147, 156], ["platelet", "TEST", 10, 18], ["early fibrinogen administration", "TREATMENT", 36, 67], ["inflammation", "PROBLEM", 115, 127], ["transfusion of platelets", "TREATMENT", 132, 156], ["thrombocytopenia", "PROBLEM", 173, 189], ["platelet", "OBSERVATION", 10, 18], ["fibrinogen", "OBSERVATION", 42, 52], ["inflammation", "OBSERVATION", 115, 127], ["thrombocytopenia", "OBSERVATION", 173, 189]]], ["Introduction: The Trauma Induced Coagulopathy Clinical Score (TICCS) was developed to be calculable on the site of injury with the objective to discriminate between trauma patients with or without the need for Damage Control Resuscitation (DCR) and thus transfusion [1] .", [["Trauma", "DISEASE", 18, 24], ["trauma", "DISEASE", 165, 171], ["patients", "ORGANISM", 172, 180], ["patients", "SPECIES", 172, 180], ["The Trauma Induced Coagulopathy", "PROBLEM", 14, 45], ["injury", "PROBLEM", 115, 121], ["trauma", "PROBLEM", 165, 171], ["Damage Control Resuscitation", "TREATMENT", 210, 238], ["injury", "OBSERVATION", 115, 121]]], ["This early alert could then be translated to in-hospital parameters at patient arrival.", [["patient", "ORGANISM", 71, 78], ["patient", "SPECIES", 71, 78]]], ["Base excess (BE) and ultrasound (FAST) are known to be predictive parameters for emergent transfusion.", [["Base excess", "PROBLEM", 0, 11], ["ultrasound", "TEST", 21, 31], ["emergent transfusion", "TREATMENT", 81, 101], ["excess", "OBSERVATION", 5, 11]]], ["We emphasize that adding this two parameters to the TICCS could improve its predictability.", [["TICCS", "DNA", 52, 57]]], ["Methods: A retrospective study was conducted in the University Hospital of Li\u00e8ge.", [["A retrospective study", "TEST", 9, 30]]], ["Based on the available data in the register (from January 1st 2015 to December 31st 2016), the TICCS was calculated for every patient.", [["patient", "ORGANISM", 126, 133], ["patient", "SPECIES", 126, 133]]], ["BE and FAST results were recorded and points were added to the TICCS according to the TICCS.BE definition (+3 points if BE < -5 and + 3 points in case of a positive FAST).", [["TICCS", "DNA", 86, 91]]], ["Emergent transfusion was defined as the use of at least one blood product in the resuscitation room.", [["blood", "ANATOMY", 60, 65], ["blood", "ORGANISM_SUBSTANCE", 60, 65], ["Emergent transfusion", "TREATMENT", 0, 20], ["transfusion", "OBSERVATION", 9, 20]]], ["The capacity of the TICCS, the TICCS.BE and the Trauma Associated Severe Hemorrhage (TASH) to predict emergent transfusion were assessed.", [["BE", "CHEMICAL", 37, 39], ["Trauma", "DISEASE", 48, 54], ["Hemorrhage", "DISEASE", 73, 83], ["TASH", "DISEASE", 85, 89], ["TICCS", "DNA", 31, 36], ["the Trauma", "PROBLEM", 44, 54], ["Severe Hemorrhage (TASH)", "PROBLEM", 66, 90], ["emergent transfusion", "TREATMENT", 102, 122], ["capacity", "OBSERVATION_MODIFIER", 4, 12], ["Severe", "OBSERVATION_MODIFIER", 66, 72], ["Hemorrhage", "OBSERVATION", 73, 83]]], ["Results: A total of 328 patients were included in the analysis.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["the analysis", "TEST", 50, 62]]], ["46 (14 %) needed emergent transfusion.", [["emergent transfusion", "TREATMENT", 17, 37]]], ["The probability for emergent transfusion grows with the TICCS.BE value (Fig. 1) .", [["BE", "CHEMICAL", 62, 64], ["emergent transfusion grows", "TREATMENT", 20, 46], ["the TICCS", "TREATMENT", 52, 61]]], ["Positive Predictive Values (PPV) and Negative Predictive Values (NPV) of the three scores are displayed in Table 1 .", [["PPV", "TEST", 28, 31], ["NPV", "TEST", 65, 68]]], ["Conclusions: Our results confirm that BE and FAST results are relevant parameters that can be added to the TICCS for better prediction of the need for emergent transfusion after trauma.", [["BE", "CHEMICAL", 38, 40], ["trauma", "DISEASE", 178, 184], ["emergent transfusion", "TREATMENT", 151, 171], ["trauma", "PROBLEM", 178, 184]]], ["Probability for emergent transfusion with TICCS.BE values.", [["BE", "CHEMICAL", 48, 50], ["emergent transfusion with TICCS", "TREATMENT", 16, 47]]], ["Boxplots show available measurements of extrinsically activated clot firmness at 10 min (ExA10), fibrin polymerization at 10 min (FibA10) and platelet count at baseline (R1) and after therapy at admission to ICU, 24 and 48 hours thereafter (R2 to R4) for the CFC (blue, n=46) and the FFP (yellow, n=42) group as well as for patients without (white, n=40) and with (grey, n=48) multiple organ failure.", [["clot", "ANATOMY", 64, 68], ["platelet", "ANATOMY", 142, 150], ["organ", "ANATOMY", 386, 391], ["organ failure", "DISEASE", 386, 399], ["clot", "TISSUE", 64, 68], ["fibrin", "GENE_OR_GENE_PRODUCT", 97, 103], ["platelet", "CELL", 142, 150], ["patients", "ORGANISM", 324, 332], ["organ", "ORGAN", 386, 391], ["fibrin", "PROTEIN", 97, 103], ["patients", "SPECIES", 324, 332], ["extrinsically activated clot firmness", "PROBLEM", 40, 77], ["fibrin polymerization", "PROBLEM", 97, 118], ["platelet count", "TEST", 142, 156], ["therapy", "TREATMENT", 184, 191], ["the CFC (blue", "TEST", 255, 268], ["the FFP", "TEST", 280, 287], ["yellow", "TEST", 289, 295], ["grey", "TEST", 365, 369], ["multiple organ failure", "PROBLEM", 377, 399], ["clot", "OBSERVATION", 64, 68], ["fibrin", "OBSERVATION", 97, 103], ["organ", "ANATOMY", 386, 391], ["failure", "OBSERVATION", 392, 399]]], ["Table 1 ) for the CFC (blue, n=46) and the FFP (yellow, n=42) group, as well as for patients without (white, n=40) and with (grey, n=48) multiple organ failure.", [["organ", "ANATOMY", 146, 151], ["organ failure", "DISEASE", 146, 159], ["patients", "ORGANISM", 84, 92], ["organ", "ORGAN", 146, 151], ["patients", "SPECIES", 84, 92], ["the CFC (blue", "TREATMENT", 14, 27], ["the FFP (yellow", "TREATMENT", 39, 54], ["multiple organ failure", "PROBLEM", 137, 159], ["organ", "ANATOMY", 146, 151], ["failure", "OBSERVATION", 152, 159]]], ["Each factor is given at the measurement time point baseline (R1) and following haemostatic resuscitation at admission to ICU, 24 and 48 hours thereafter (R2 to R4).", [["haemostatic resuscitation", "TREATMENT", 79, 104]]], ["Introduction: The management of the critically ill polytrauma patient is complex and is often a challenge for the intensive care team.", [["critically ill", "DISEASE", 36, 50], ["polytrauma", "DISEASE", 51, 61], ["patient", "ORGANISM", 62, 69], ["patient", "SPECIES", 62, 69], ["the critically ill polytrauma", "PROBLEM", 32, 61]]], ["The objectives of this study is to analyze the oxidative stress expression in polytrauma cases as well as to evaluate the impact of antioxidant therapy on outcomes.P366Methods: This prospective study was carried out in the Clinic for Anaesthesia and Intensive Care \"Casa Austria\", form the \"Pius Br\u00eenzeu\" Emergency County Hospital, Timisoara, Romania, with the approval of the hospital's Ethics Committee.", [["polytrauma", "DISEASE", 78, 88], ["this study", "TEST", 18, 28], ["the oxidative stress expression in polytrauma cases", "PROBLEM", 43, 94], ["antioxidant therapy", "TREATMENT", 132, 151], ["This prospective study", "TEST", 177, 199], ["Anaesthesia", "TREATMENT", 234, 245]]], ["The patients' selection criteria included an Injury Severity Score (ISS) of 16 or higher, and age of 18 or higher.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["an Injury Severity Score", "TEST", 42, 66], ["ISS", "TEST", 68, 71], ["Injury", "OBSERVATION", 45, 51]]], ["67 patients were eligible for the study.", [["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["the study", "TEST", 30, 39]]], ["They were divided in two groups, group A (antioxidant free, control, N=32), and group B (antioxidant therapy, study group, N=35).", [["group B (antioxidant therapy", "TREATMENT", 80, 108]]], ["The antioxidant therapy consisted in continuous IV administration of 7500 mg/24 h of vitamin C until discharge from ICU.Results:The patients included in the study presented with similar characteristics, and no statistically significant differences were shown between group A and B regarding age (p > 0.05), sex (p > 0.05), ISS upon admission (p > 0.05), percentage of patients admitted in the ICU more than 24 hour post-trauma (p > 0.05), and associated trauma (p > 0.05).", [["vitamin C", "CHEMICAL", 85, 94], ["trauma", "DISEASE", 420, 426], ["trauma", "DISEASE", 454, 460], ["vitamin C", "CHEMICAL", 85, 94], ["vitamin C", "SIMPLE_CHEMICAL", 85, 94], ["patients", "ORGANISM", 132, 140], ["patients", "ORGANISM", 368, 376], ["patients", "SPECIES", 132, 140], ["patients", "SPECIES", 368, 376], ["The antioxidant therapy", "TREATMENT", 0, 23], ["continuous IV administration", "TREATMENT", 37, 65], ["vitamin C", "TREATMENT", 85, 94], ["the study", "TEST", 153, 162], ["ISS", "TEST", 323, 326], ["trauma", "PROBLEM", 420, 426], ["associated trauma", "PROBLEM", 443, 460]]], ["Among patients in group B statistically significant differences were identified regarding the incidence of sepsis (p < 0.05), multiple organ dysfunction syndrome (p < 0.05), mechanical ventilation time (p < 0.05), and mortality (p < 0.05).", [["organ", "ANATOMY", 135, 140], ["sepsis", "DISEASE", 107, 113], ["organ dysfunction syndrome", "DISEASE", 135, 161], ["patients", "ORGANISM", 6, 14], ["organ", "ORGAN", 135, 140], ["patients", "SPECIES", 6, 14], ["sepsis", "PROBLEM", 107, 113], ["multiple organ dysfunction syndrome", "PROBLEM", 126, 161], ["mechanical ventilation time", "TREATMENT", 174, 201], ["sepsis", "OBSERVATION", 107, 113], ["multiple", "OBSERVATION_MODIFIER", 126, 134], ["organ", "ANATOMY", 135, 140], ["dysfunction", "OBSERVATION", 141, 152]]], ["No statistically significant differences were shown regarding the time spent in the ICU (p > 0.05).", [["statistically", "OBSERVATION_MODIFIER", 3, 16], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["differences", "OBSERVATION", 29, 40]]], ["Conclusions: Following this study we can state that the administration of substances with a strong antioxidant character has positive influences on the outcome of critically ill patients, decreasing the incidence of secondary pathologies as well as mortality rates.", [["critically ill", "DISEASE", 163, 177], ["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 178, 186], ["this study", "TEST", 23, 33], ["the administration of substances", "TREATMENT", 52, 84], ["secondary pathologies", "PROBLEM", 216, 237], ["mortality rates", "TEST", 249, 264]]], ["ICC increased by 22.62%, ICD increased by 17.57%, slightly increased MA, and IRCL was nearly in the normal range.Results:Conclusions: Rapid and accurate diagnosis of the coagulation system by LPTEG method at different stages of traumatic disease allows for more accurate selection and adjustment of the therapy, which allows improving the prognosis of the disease.Results:Introduction: Evidence for tranexamic acid (TXA) in the pharmacologic management of trauma is largely derived from data in adults [1] .", [["traumatic disease", "DISEASE", 228, 245], ["tranexamic acid", "CHEMICAL", 399, 414], ["TXA", "CHEMICAL", 416, 419], ["trauma", "DISEASE", 456, 462], ["tranexamic acid", "CHEMICAL", 399, 414], ["TXA", "CHEMICAL", 416, 419], ["tranexamic acid", "SIMPLE_CHEMICAL", 399, 414], ["TXA", "SIMPLE_CHEMICAL", 416, 419], ["ICD", "TREATMENT", 25, 28], ["slightly increased MA", "PROBLEM", 50, 71], ["IRCL", "TEST", 77, 81], ["the coagulation system", "TEST", 166, 188], ["LPTEG method", "TEST", 192, 204], ["traumatic disease", "PROBLEM", 228, 245], ["the therapy", "TREATMENT", 299, 310], ["the disease", "PROBLEM", 352, 363], ["tranexamic acid (TXA", "TREATMENT", 399, 419], ["the pharmacologic management", "TREATMENT", 424, 452], ["trauma", "PROBLEM", 456, 462], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["slightly", "OBSERVATION_MODIFIER", 50, 58], ["increased", "OBSERVATION_MODIFIER", 59, 68], ["normal range", "OBSERVATION", 100, 112], ["traumatic disease", "OBSERVATION", 228, 245], ["disease", "OBSERVATION", 356, 363]]], ["Guidance on the use of TXA in pediatric patients comes from studies evaluating its use in cardiac and orthopedic surgery.", [["cardiac", "ANATOMY", 90, 97], ["TXA", "CHEMICAL", 23, 26], ["TXA", "CHEMICAL", 23, 26], ["TXA", "SIMPLE_CHEMICAL", 23, 26], ["patients", "ORGANISM", 40, 48], ["cardiac", "ANATOMICAL_SYSTEM", 90, 97], ["patients", "SPECIES", 40, 48], ["TXA", "TREATMENT", 23, 26], ["cardiac and orthopedic surgery", "TREATMENT", 90, 120], ["cardiac", "ANATOMY", 90, 97]]], ["There is minimal data describing TXA safety and efficacy in pediatric trauma.", [["TXA", "CHEMICAL", 33, 36], ["trauma", "DISEASE", 70, 76], ["TXA", "CHEMICAL", 33, 36], ["TXA", "SIMPLE_CHEMICAL", 33, 36], ["TXA safety", "TREATMENT", 33, 43], ["pediatric trauma", "PROBLEM", 60, 76], ["minimal", "OBSERVATION_MODIFIER", 9, 16]]], ["The purpose of this study is to describe the use of TXA in the management of pediatric trauma and evaluate efficacy and safety endpoints.Results:Methods: This retrospective, observational analysis of pediatric trauma admissions at Hennepin County Medical Center from August 2011 to November 2017 compares patients who did and did not receive TXA.", [["TXA", "CHEMICAL", 52, 55], ["trauma", "DISEASE", 87, 93], ["trauma", "DISEASE", 210, 216], ["TXA", "CHEMICAL", 342, 345], ["TXA", "CHEMICAL", 52, 55], ["TXA", "CHEMICAL", 342, 345], ["TXA", "SIMPLE_CHEMICAL", 52, 55], ["patients", "ORGANISM", 305, 313], ["TXA", "SIMPLE_CHEMICAL", 342, 345], ["patients", "SPECIES", 305, 313], ["this study", "TEST", 15, 25], ["TXA", "TREATMENT", 52, 55], ["pediatric trauma", "TREATMENT", 77, 93], ["TXA", "TREATMENT", 342, 345]]], ["Secondary endpoints include surgical intervention, transfusion requirements, length of stay, thrombosis, and TXA dose administered.", [["thrombosis", "DISEASE", 93, 103], ["TXA", "CHEMICAL", 109, 112], ["TXA", "SIMPLE_CHEMICAL", 109, 112], ["Secondary endpoints", "PROBLEM", 0, 19], ["surgical intervention", "TREATMENT", 28, 49], ["transfusion requirements", "TREATMENT", 51, 75], ["thrombosis", "PROBLEM", 93, 103], ["TXA dose", "TREATMENT", 109, 117], ["surgical", "OBSERVATION", 28, 36], ["thrombosis", "OBSERVATION", 93, 103]]], ["Results: There were 35 patients [<=] 16 years old identified for inclusion using a massive transfusion protocol order.", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["a massive transfusion protocol", "TREATMENT", 81, 111]]], ["Twenty patients (57%) received TXA.", [["TXA", "CHEMICAL", 31, 34], ["TXA", "CHEMICAL", 31, 34], ["patients", "ORGANISM", 7, 15], ["TXA", "SIMPLE_CHEMICAL", 31, 34], ["patients", "SPECIES", 7, 15], ["TXA", "TREATMENT", 31, 34]]], ["Patients receiving TXA were more likely to be older, but there was no difference in injury type or injury severity score (ISS) at baseline (Table 1) .", [["TXA", "CHEMICAL", 19, 22], ["TXA", "CHEMICAL", 19, 22], ["Patients", "ORGANISM", 0, 8], ["TXA", "SIMPLE_CHEMICAL", 19, 22], ["Patients", "SPECIES", 0, 8], ["TXA", "TREATMENT", 19, 22], ["injury type", "PROBLEM", 84, 95], ["injury severity score", "PROBLEM", 99, 120], ["ISS", "TEST", 122, 125], ["no", "UNCERTAINTY", 67, 69], ["injury", "OBSERVATION", 84, 90]]], ["There was no difference in survival to discharge, need for surgical intervention, or thrombosis (Table 2) .", [["thrombosis", "DISEASE", 85, 95], ["surgical intervention", "TREATMENT", 59, 80], ["thrombosis", "PROBLEM", 85, 95], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23], ["thrombosis", "OBSERVATION", 85, 95]]], ["Patients who did not receive TXA had numerically higher transfusion requirements and longer length of stay, but these did not reach significance.Results:Conclusions: TXA was utilized in 57% of pediatric trauma admissions at a single level I trauma center, more commonly in older patients.", [["TXA", "CHEMICAL", 29, 32], ["TXA", "CHEMICAL", 166, 169], ["trauma", "DISEASE", 203, 209], ["trauma", "DISEASE", 241, 247], ["TXA", "CHEMICAL", 29, 32], ["Patients", "ORGANISM", 0, 8], ["TXA", "SIMPLE_CHEMICAL", 29, 32], ["TXA", "SIMPLE_CHEMICAL", 166, 169], ["patients", "ORGANISM", 279, 287], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 279, 287], ["TXA", "TREATMENT", 29, 32], ["numerically higher transfusion requirements", "PROBLEM", 37, 80], ["TXA", "TREATMENT", 166, 169]]], ["Though limited by observational design, we found patients receiving TXA had no difference in mortality or thrombosis.", [["TXA", "CHEMICAL", 68, 71], ["thrombosis", "DISEASE", 106, 116], ["TXA", "CHEMICAL", 68, 71], ["patients", "ORGANISM", 49, 57], ["TXA", "SIMPLE_CHEMICAL", 68, 71], ["patients", "SPECIES", 49, 57], ["TXA", "TREATMENT", 68, 71], ["difference in mortality", "PROBLEM", 79, 102], ["thrombosis", "PROBLEM", 106, 116], ["thrombosis", "OBSERVATION", 106, 116]]], ["Introduction: The risk of venous thromboembolism (VTE) in trauma is greatly increased and one of the leading causes of morbidity and mortality after an accident [1] .", [["venous", "ANATOMY", 26, 32], ["venous thromboembolism", "DISEASE", 26, 48], ["VTE", "DISEASE", 50, 53], ["trauma", "DISEASE", 58, 64], ["venous", "MULTI-TISSUE_STRUCTURE", 26, 32], ["venous thromboembolism", "PROBLEM", 26, 48], ["VTE", "PROBLEM", 50, 53], ["trauma", "PROBLEM", 58, 64], ["morbidity", "PROBLEM", 119, 128], ["venous", "ANATOMY", 26, 32], ["thromboembolism", "OBSERVATION", 33, 48], ["increased", "OBSERVATION_MODIFIER", 76, 85]]], ["Prophylactic measures to prevent VTE primarily consist of anticoagulants.", [["VTE", "DISEASE", 33, 36], ["Prophylactic measures", "TREATMENT", 0, 21], ["VTE", "PROBLEM", 33, 36], ["anticoagulants", "TREATMENT", 58, 72]]], ["In instances in which anticoagulation is contraindicated or inadequate, inferior vena cava (IVC) filters can be used [2] .", [["inferior vena cava", "ANATOMY", 72, 90], ["IVC", "ANATOMY", 92, 95], ["inferior vena cava", "MULTI-TISSUE_STRUCTURE", 72, 90], ["IVC", "MULTI-TISSUE_STRUCTURE", 92, 95], ["anticoagulation", "TREATMENT", 22, 37], ["inferior vena cava (IVC) filters", "TREATMENT", 72, 104], ["inferior vena cava", "ANATOMY", 72, 90], ["IVC", "ANATOMY", 92, 95]]], ["However, insertion of IVC filter as a prophylactic measure is controversial as filter-related complications are well documented and increase with treatment time [3] .", [["IVC", "MULTI-TISSUE_STRUCTURE", 22, 25], ["IVC filter", "TREATMENT", 22, 32], ["a prophylactic measure", "TREATMENT", 36, 58], ["complications", "PROBLEM", 94, 107], ["IVC", "ANATOMY", 22, 25], ["filter", "OBSERVATION", 26, 32]]], ["The objectives of our study were to evaluate IVC filter insertion indications and filter related complications in pelvic trauma patients.Results:Methods: 250 patients with pelvic fractures were operated during the study period 1/01/2011-31/12/2015.", [["pelvic", "ANATOMY", 114, 120], ["pelvic", "ANATOMY", 172, 178], ["pelvic trauma", "DISEASE", 114, 127], ["pelvic fractures", "DISEASE", 172, 188], ["pelvic", "ORGANISM_SUBDIVISION", 114, 120], ["patients", "ORGANISM", 128, 136], ["patients", "ORGANISM", 158, 166], ["pelvic", "ORGAN", 172, 178], ["patients", "SPECIES", 128, 136], ["patients", "SPECIES", 158, 166], ["our study", "TEST", 18, 27], ["IVC filter insertion indications", "TREATMENT", 45, 77], ["filter related complications in pelvic trauma", "PROBLEM", 82, 127], ["pelvic fractures", "PROBLEM", 172, 188], ["the study", "TEST", 210, 219], ["IVC", "ANATOMY", 45, 48], ["filter", "OBSERVATION", 49, 55], ["pelvic", "ANATOMY", 114, 120], ["trauma", "OBSERVATION", 121, 127], ["pelvic", "ANATOMY", 172, 178], ["fractures", "OBSERVATION", 179, 188]]], ["All patients who received IVC filter during the period were included into analysis.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["IVC filter", "TREATMENT", 26, 36], ["analysis", "TEST", 74, 82], ["IVC", "ANATOMY", 26, 29], ["filter", "OBSERVATION", 30, 36]]], ["Relevant data was collected from electronic patient journal.Results:Results: Thirty four patients received retrievable filters during the study period (22 males and 12 females) ( Table 1) .", [["patient", "ORGANISM", 44, 51], ["patients", "ORGANISM", 89, 97], ["patient", "SPECIES", 44, 51], ["patients", "SPECIES", 89, 97], ["retrievable filters", "TREATMENT", 107, 126], ["the study", "TEST", 134, 143]]], ["Median age of patients was 59 years (range, 21-80).", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["The predominant indication (79%) was prophylactic insertion.", [["prophylactic insertion", "TREATMENT", 37, 59], ["predominant", "OBSERVATION_MODIFIER", 4, 15]]], ["Despite IVC filter insertion one patient experienced lung embolism and another -DVT.", [["lung", "ANATOMY", 53, 57], ["lung embolism", "DISEASE", 53, 66], ["DVT", "DISEASE", 80, 83], ["IVC filter", "MULTI-TISSUE_STRUCTURE", 8, 18], ["patient", "ORGANISM", 33, 40], ["lung", "ORGAN", 53, 57], ["patient", "SPECIES", 33, 40], ["IVC filter insertion", "TREATMENT", 8, 28], ["lung embolism", "PROBLEM", 53, 66], ["DVT", "PROBLEM", 80, 83], ["IVC", "ANATOMY", 8, 11], ["filter", "OBSERVATION", 12, 18], ["lung", "ANATOMY", 53, 57], ["embolism", "OBSERVATION", 58, 66], ["DVT", "OBSERVATION", 80, 83]]], ["In eleven cases IVC filters were tried to be removed at the treating hospital.", [["IVC filters", "TREATMENT", 16, 27], ["IVC", "ANATOMY", 16, 19], ["filters", "OBSERVATION", 20, 27]]], ["In two cases filter extraction was unsuccessful and in another two cases filters were left in place due to IVC thrombosis.", [["IVC", "ANATOMY", 107, 110], ["thrombosis", "DISEASE", 111, 121], ["IVC", "MULTI-TISSUE_STRUCTURE", 107, 110], ["two cases filter extraction", "TREATMENT", 3, 30], ["another two cases filters", "TREATMENT", 55, 80], ["IVC thrombosis", "PROBLEM", 107, 121], ["filter", "OBSERVATION", 13, 19], ["IVC", "ANATOMY", 107, 110], ["thrombosis", "OBSERVATION", 111, 121]]], ["Conclusions: Majority of IVC filters were inserted outside guidelines [4] and proportion of prophylactic indications is significantly higher (80% vs 24%) than seen in registry studies [5] .", [["IVC", "ANATOMY", 25, 28], ["IVC filters", "TREATMENT", 25, 36], ["prophylactic indications", "TREATMENT", 92, 116], ["registry studies", "TEST", 167, 183], ["IVC", "ANATOMY", 25, 28], ["filters", "OBSERVATION", 29, 36], ["significantly", "OBSERVATION_MODIFIER", 120, 133], ["higher", "OBSERVATION_MODIFIER", 134, 140]]], ["Filter related complications were observed in 18% of patients.", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["Filter related complications", "PROBLEM", 0, 28], ["complications", "OBSERVATION", 15, 28]]], ["More restrictive approach to prophylactic IVC insertion should be exercised.P373The impact of preinjury antiplatelet and anticoagulant pharmacotherapy on outcomes in patients with major trauma admitted to intensive care unit ( Conclusions: Patients on preinjury anticoagulants and antiplatelet agents showed an increased mortality; this may be the result of the greater incidence of bleeding, the older age and more comorbidities in this groups.P374Is enzymatic debridement better in critically burned patients?", [["IVC", "ANATOMY", 42, 45], ["major trauma", "DISEASE", 180, 192], ["bleeding", "DISEASE", 383, 391], ["IVC", "MULTI-TISSUE_STRUCTURE", 42, 45], ["P373", "GENE_OR_GENE_PRODUCT", 76, 80], ["patients", "ORGANISM", 166, 174], ["Patients", "ORGANISM", 240, 248], ["P374", "GENE_OR_GENE_PRODUCT", 445, 449], ["patients", "ORGANISM", 502, 510], ["patients", "SPECIES", 166, 174], ["Patients", "SPECIES", 240, 248], ["patients", "SPECIES", 502, 510], ["More restrictive approach", "TREATMENT", 0, 25], ["prophylactic IVC insertion", "TREATMENT", 29, 55], ["preinjury antiplatelet", "TREATMENT", 94, 116], ["anticoagulant pharmacotherapy", "TREATMENT", 121, 150], ["preinjury anticoagulants", "TREATMENT", 252, 276], ["antiplatelet agents", "TREATMENT", 281, 300], ["an increased mortality", "PROBLEM", 308, 330], ["bleeding", "PROBLEM", 383, 391], ["more comorbidities in this groups", "PROBLEM", 411, 444], ["enzymatic debridement", "TREATMENT", 452, 473], ["restrictive", "OBSERVATION_MODIFIER", 5, 16], ["IVC", "ANATOMY", 42, 45], ["increased", "OBSERVATION_MODIFIER", 311, 320], ["mortality", "OBSERVATION", 321, 330], ["greater", "OBSERVATION_MODIFIER", 362, 369], ["bleeding", "OBSERVATION", 383, 391], ["debridement", "OBSERVATION", 462, 473]]], ["Introduction: Early debridement of burned tissue reduces infection rate, ICU stay and mortality.", [["tissue", "ANATOMY", 42, 48], ["infection", "DISEASE", 57, 66], ["tissue", "TISSUE", 42, 48], ["Early debridement", "TREATMENT", 14, 31], ["burned tissue", "PROBLEM", 35, 48], ["infection rate", "PROBLEM", 57, 71], ["debridement", "OBSERVATION", 20, 31], ["burned tissue", "OBSERVATION_MODIFIER", 35, 48], ["reduces", "OBSERVATION_MODIFIER", 49, 56], ["infection", "OBSERVATION", 57, 66]]], ["The use of proteolytic enzymes such as bromelain allows a faster, more effective and selective debridement of denatured tissue, preserving and exposing healthy tissues, reducing debridement times compared to standard of care.P374Methods: Retrospective observational study performed in the Critical Burn Unit (March 2016 to September 2017) including 27 patients >18 years old with a total body surface area (TBSA) burned > 15% and < 75%, or > 65 years old with a TBSA burned > 10%, who underwent enzymatic debridement.", [["tissue", "ANATOMY", 120, 126], ["tissues", "ANATOMY", 160, 167], ["body surface area", "ANATOMY", 388, 405], ["tissue", "TISSUE", 120, 126], ["tissues", "TISSUE", 160, 167], ["patients", "ORGANISM", 352, 360], ["body", "ORGANISM_SUBDIVISION", 388, 392], ["proteolytic enzymes", "PROTEIN", 11, 30], ["patients", "SPECIES", 352, 360], ["proteolytic enzymes", "TEST", 11, 30], ["bromelain", "TREATMENT", 39, 48], ["selective debridement of denatured tissue", "TREATMENT", 85, 126], ["reducing debridement", "TREATMENT", 169, 189], ["Retrospective observational study", "TEST", 238, 271], ["a total body surface area", "TREATMENT", 380, 405], ["TBSA", "TEST", 407, 411], ["a TBSA burned", "PROBLEM", 460, 473], ["enzymatic debridement", "TREATMENT", 495, 516], ["selective", "OBSERVATION_MODIFIER", 85, 94], ["debridement", "OBSERVATION", 95, 106], ["denatured tissue", "OBSERVATION", 110, 126], ["healthy tissues", "OBSERVATION", 152, 167], ["debridement", "OBSERVATION", 178, 189], ["body", "ANATOMY_MODIFIER", 388, 392], ["surface", "ANATOMY_MODIFIER", 393, 400], ["debridement", "OBSERVATION", 505, 516]]], ["Mean and standard deviation were used for normal quantitative variables and median and interquartile range in the opposite case.", [["Mean", "TEST", 0, 4], ["standard deviation", "OBSERVATION", 9, 27]]], ["Qualitative variables were presented by absolute and relative frequencies.", [["Qualitative variables", "PROBLEM", 0, 21]]], ["Results: Mean age was 47.6 \u00b1 17.8 years old, 74% males, APACHE II 11 (RI 5-18), ABSI 7 (RI 5-9).", [["Mean age", "TEST", 9, 17], ["APACHE II", "TEST", 56, 65], ["RI", "TEST", 70, 72], ["ABSI", "TEST", 80, 84], ["RI", "TEST", 88, 90]]], ["Median TBSA burned was 29% (RI 18-50%), 21% (RI 16-39) were deep dermal or full thickness.", [["dermal", "ANATOMY", 65, 71], ["dermal", "TISSUE", 65, 71], ["Median TBSA burned", "TEST", 0, 18], ["RI", "TEST", 28, 30], ["RI", "TEST", 45, 47], ["deep", "ANATOMY_MODIFIER", 60, 64], ["dermal", "ANATOMY", 65, 71], ["full thickness", "OBSERVATION", 75, 89]]], ["Time until debridement was 21 hours (RI 8-35).", [["debridement", "TREATMENT", 11, 22], ["RI", "TEST", 37, 39]]], ["7.4% (n=2) had incomplete debridement after first application, 33% (n=9) received regional anesthesia, 91% (n=25) didn't need blood transfusion.", [["blood", "ANATOMY", 126, 131], ["blood", "ORGANISM_SUBSTANCE", 126, 131], ["incomplete debridement", "TREATMENT", 15, 37], ["regional anesthesia", "TREATMENT", 82, 101], ["blood transfusion", "TREATMENT", 126, 143], ["debridement", "OBSERVATION", 26, 37]]], ["25% of patients who didn't have vasopressors prior debridement, needed the use of it with a mean dose of 0,6mcg/Kg/min.", [["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["vasopressors prior debridement", "TREATMENT", 32, 62], ["a mean dose", "TREATMENT", 90, 101], ["debridement", "OBSERVATION", 51, 62]]], ["25% of patients with vasopressors prior treatment, required an increase of dose by a mean of 0.9 mcg/Kg/min.", [["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["vasopressors prior treatment", "TREATMENT", 21, 49], ["an increase of dose", "TREATMENT", 60, 79]]], ["Mortality was 22%.P374Conclusions: Topical bromelain allows a fast start of tissue debridement with a low rate of failure.", [["tissue", "ANATOMY", 76, 82], ["tissue", "TISSUE", 76, 82], ["Mortality", "TEST", 0, 9], ["Topical bromelain", "TREATMENT", 35, 52], ["tissue debridement", "TREATMENT", 76, 94], ["a low rate of failure", "PROBLEM", 100, 121], ["debridement", "OBSERVATION", 83, 94], ["failure", "OBSERVATION", 114, 121]]], ["The need for fasciotomy and blood transfusion was very low.", [["blood", "ANATOMY", 28, 33], ["blood", "ORGANISM_SUBSTANCE", 28, 33], ["fasciotomy", "TREATMENT", 13, 23], ["blood transfusion", "TEST", 28, 45], ["fasciotomy", "OBSERVATION", 13, 23]]], ["Topical treatment involved a fast and simultaneous debridement of the TBSA burned, generating an inflammatory response that in some cases required vasopressors.", [["TBSA", "SIMPLE_CHEMICAL", 70, 74], ["Topical treatment", "TREATMENT", 0, 17], ["simultaneous debridement", "TREATMENT", 38, 62], ["the TBSA burned", "PROBLEM", 66, 81], ["an inflammatory response", "PROBLEM", 94, 118], ["vasopressors", "TREATMENT", 147, 159], ["inflammatory response", "OBSERVATION", 97, 118]]], ["The BChE activity was measured by using point-ofcare-test system (Securetec Detektions-Systeme AG, Neubiberg, Germany).", [["BChE", "GENE_OR_GENE_PRODUCT", 4, 8], ["BChE", "PROTEIN", 4, 8], ["The BChE activity", "TEST", 0, 17], ["test system", "TEST", 53, 64]]], ["Levels of the routine inflammation biomarkers, i.e. C-reactive protein (CRP) and the white blood cell count (WBCC), were measured during the initial treatment period.", [["white blood cell", "ANATOMY", 85, 101], ["WBCC", "ANATOMY", 109, 113], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 52, 70], ["CRP", "GENE_OR_GENE_PRODUCT", 72, 75], ["white blood cell", "CELL", 85, 101], ["C-reactive protein", "PROTEIN", 52, 70], ["CRP", "PROTEIN", 72, 75], ["the routine inflammation biomarkers", "TEST", 10, 45], ["C-reactive protein", "TEST", 52, 70], ["CRP", "TEST", 72, 75], ["the white blood cell count", "TEST", 81, 107], ["WBCC", "TEST", 109, 113]]], ["Injury Severity Score (ISS) was used to assess the trauma severity.P374Results: The observed reduction in the BChE activity was in accordance with the change in the CRP concentration and the WBCC.", [["Injury", "DISEASE", 0, 6], ["trauma", "DISEASE", 51, 57], ["BChE", "GENE_OR_GENE_PRODUCT", 110, 114], ["CRP", "GENE_OR_GENE_PRODUCT", 165, 168], ["BChE", "PROTEIN", 110, 114], ["CRP", "PROTEIN", 165, 168], ["the trauma severity", "PROBLEM", 47, 66], ["The observed reduction", "TREATMENT", 80, 102], ["the BChE activity", "PROBLEM", 106, 123], ["the CRP concentration", "TEST", 161, 182], ["the WBCC", "TEST", 187, 195], ["reduction", "OBSERVATION_MODIFIER", 93, 102]]], ["The BChE activity measured at the hospital admission negatively correlated with the length of the ICU stay in patients with polytrauma (r = -0.5, Spearman's rank correlation coefficient).P374Conclusions: The BChE activity might be used as an early indicator for the magnitude of the systemic inflammation following polytrauma.", [["polytrauma", "DISEASE", 124, 134], ["inflammation", "DISEASE", 292, 304], ["polytrauma", "DISEASE", 315, 325], ["BChE", "GENE_OR_GENE_PRODUCT", 4, 8], ["patients", "ORGANISM", 110, 118], ["BChE", "GENE_OR_GENE_PRODUCT", 208, 212], ["BChE", "PROTEIN", 4, 8], ["BChE", "PROTEIN", 208, 212], ["patients", "SPECIES", 110, 118], ["The BChE activity", "TEST", 0, 17], ["polytrauma", "PROBLEM", 124, 134], ["The BChE activity", "TEST", 204, 221], ["the systemic inflammation", "PROBLEM", 279, 304], ["polytrauma", "PROBLEM", 315, 325], ["polytrauma", "OBSERVATION", 124, 134], ["systemic", "OBSERVATION_MODIFIER", 283, 291], ["inflammation", "OBSERVATION", 292, 304], ["polytrauma", "OBSERVATION", 315, 325]]], ["Moreover, the BChE activity, measured at the hospital admission, might predict the patient outcome and therefore prove useful in early identification of the high-risk patients.P376Pharmacological interventions for agitation in traumatic brain injury: a systematic review Introduction: Among TBI complications, agitation is a frequent behavioural problem [1] .", [["brain", "ANATOMY", 237, 242], ["agitation", "DISEASE", 214, 223], ["traumatic brain injury", "DISEASE", 227, 249], ["TBI", "DISEASE", 291, 294], ["agitation", "DISEASE", 310, 319], ["BChE", "GENE_OR_GENE_PRODUCT", 14, 18], ["patient", "ORGANISM", 83, 90], ["patients", "ORGANISM", 167, 175], ["brain", "ORGAN", 237, 242], ["BChE", "PROTEIN", 14, 18], ["patient", "SPECIES", 83, 90], ["patients", "SPECIES", 167, 175], ["the BChE activity", "TEST", 10, 27], ["P376Pharmacological interventions", "TREATMENT", 176, 209], ["agitation", "PROBLEM", 214, 223], ["traumatic brain injury", "PROBLEM", 227, 249], ["TBI complications", "PROBLEM", 291, 308], ["agitation", "PROBLEM", 310, 319], ["a frequent behavioural problem", "PROBLEM", 323, 353], ["brain", "ANATOMY", 237, 242]]], ["Agitation causes potential harm to patients and caregivers, interferes with treatments, leads to unnecessary chemical and physical restraints, increases hospital length of stay, delays rehabilitation, and impedes functional independence.", [["Agitation", "DISEASE", 0, 9], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["Agitation", "PROBLEM", 0, 9], ["treatments", "TREATMENT", 76, 86], ["chemical and physical restraints", "TREATMENT", 109, 141], ["delays rehabilitation", "TREATMENT", 178, 199]]], ["Pharmacological treatments are often considered for agitation management following TBI.", [["agitation", "DISEASE", 52, 61], ["TBI", "DISEASE", 83, 86], ["Pharmacological treatments", "TREATMENT", 0, 26], ["agitation management", "TREATMENT", 52, 72], ["TBI", "PROBLEM", 83, 86]]], ["However, the benefit and safety of these agents in TBI patients as well as their differential effects and interactions are uncertain.", [["TBI", "DISEASE", 51, 54], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["these agents", "TREATMENT", 35, 47], ["TBI patients", "TREATMENT", 51, 63]]], ["We included all randomized controlled, quasi-experimental, and observational studies with control groups.", [["observational studies", "TEST", 63, 84]]], ["The population of interest was all patients, including children and adults, who have suffered a TBI.", [["TBI", "DISEASE", 96, 99], ["patients", "ORGANISM", 35, 43], ["children", "ORGANISM", 55, 63], ["patients", "SPECIES", 35, 43], ["children", "SPECIES", 55, 63], ["a TBI", "PROBLEM", 94, 99], ["TBI", "OBSERVATION", 96, 99]]], ["Studies in which agitation was the presenting symptom or one of the presenting symptoms, studies where agitation was not the presenting symptom but was measured as an outcome variable and studies assessing the safety of these pharmacological interventions in TBI patients were included.", [["agitation", "DISEASE", 17, 26], ["agitation", "DISEASE", 103, 112], ["TBI", "DISEASE", 259, 262], ["patients", "ORGANISM", 263, 271], ["patients", "SPECIES", 263, 271], ["Studies", "TEST", 0, 7], ["agitation", "PROBLEM", 17, 26], ["the presenting symptom", "PROBLEM", 31, 53], ["the presenting symptoms", "PROBLEM", 64, 87], ["agitation", "PROBLEM", 103, 112], ["the presenting symptom", "PROBLEM", 121, 143], ["studies", "TEST", 188, 195], ["these pharmacological interventions", "TREATMENT", 220, 255], ["TBI patients", "TREATMENT", 259, 271]]], ["Two authors screened 12 899 after removal of duplicates.", [["removal", "TREATMENT", 34, 41]]], ["Eleven studies in which agitation or an associated behavior was the presenting symptom, 11 studies where agitation was not the presenting symptom but was measured as an outcome variable, and 3 studies assessing the safety of these pharmacological interventions were identified.", [["agitation", "DISEASE", 24, 33], ["agitation", "DISEASE", 105, 114], ["Eleven studies", "TEST", 0, 14], ["agitation", "PROBLEM", 24, 33], ["an associated behavior", "PROBLEM", 37, 59], ["the presenting symptom", "PROBLEM", 64, 86], ["11 studies", "TEST", 88, 98], ["agitation", "PROBLEM", 105, 114], ["the presenting symptom", "PROBLEM", 123, 145], ["3 studies", "TEST", 191, 200], ["these pharmacological interventions", "TREATMENT", 225, 260]]], ["Overall, the quality of studies was weak.", [["weak", "PROBLEM", 36, 40]]], ["In studies directly addressing agitation, pindolol and propranolol may reduce assaults and agitation episodes.", [["agitation", "DISEASE", 31, 40], ["pindolol", "CHEMICAL", 42, 50], ["propranolol", "CHEMICAL", 55, 66], ["agitation", "DISEASE", 91, 100], ["pindolol", "CHEMICAL", 42, 50], ["propranolol", "CHEMICAL", 55, 66], ["pindolol", "SIMPLE_CHEMICAL", 42, 50], ["propranolol", "SIMPLE_CHEMICAL", 55, 66], ["agitation", "PROBLEM", 31, 40], ["pindolol", "TREATMENT", 42, 50], ["propranolol", "TREATMENT", 55, 66], ["assaults", "PROBLEM", 78, 86], ["agitation episodes", "PROBLEM", 91, 109]]], ["Amantadine and olanzapine may reduce aggression, whereas valproic acid may reduce agitated behavior.P376Conclusions: There is weak evidence to support the use of pharmacological agents for the management of agitation in TBI.P377Impact of decompressive craniectomy on neurological functional outcome in critically ill adult patients with severe traumatic brain injury: a systematic review and meta-analysis P Bonaventure, JA Jamous, F Lauzier, R Zarychanski, C Francoeur, A Turgeon CHU de Qu\u00e9bec -Universit\u00e9 Laval, Qu\u00e9bec, Canada Critical Care 2018, 22(Suppl 1):P377P377Introduction: Severe traumatic brain injury is associated with high mortality and functional disability.", [["neurological", "ANATOMY", 267, 279], ["brain", "ANATOMY", 354, 359], ["brain", "ANATOMY", 600, 605], ["Amantadine", "CHEMICAL", 0, 10], ["olanzapine", "CHEMICAL", 15, 25], ["aggression", "DISEASE", 37, 47], ["valproic acid", "CHEMICAL", 57, 70], ["agitation", "DISEASE", 207, 216], ["TBI", "DISEASE", 220, 223], ["critically ill", "DISEASE", 302, 316], ["traumatic brain injury", "DISEASE", 344, 366], ["traumatic brain injury", "DISEASE", 590, 612], ["functional disability", "DISEASE", 651, 672], ["Amantadine", "CHEMICAL", 0, 10], ["olanzapine", "CHEMICAL", 15, 25], ["valproic acid", "CHEMICAL", 57, 70], ["Amantadine", "SIMPLE_CHEMICAL", 0, 10], ["olanzapine", "SIMPLE_CHEMICAL", 15, 25], ["valproic acid", "SIMPLE_CHEMICAL", 57, 70], ["patients", "ORGANISM", 323, 331], ["brain", "ORGAN", 354, 359], ["brain", "ORGAN", 600, 605], ["patients", "SPECIES", 323, 331], ["Amantadine", "TREATMENT", 0, 10], ["olanzapine", "TREATMENT", 15, 25], ["aggression", "PROBLEM", 37, 47], ["valproic acid", "TREATMENT", 57, 70], ["agitated behavior", "PROBLEM", 82, 99], ["pharmacological agents", "TREATMENT", 162, 184], ["the management", "TREATMENT", 189, 203], ["agitation", "PROBLEM", 207, 216], ["TBI", "PROBLEM", 220, 223], ["decompressive craniectomy", "TREATMENT", 238, 263], ["severe traumatic brain injury", "PROBLEM", 337, 366], ["meta-analysis", "TEST", 392, 405], ["Severe traumatic brain injury", "PROBLEM", 583, 612], ["high mortality and functional disability", "PROBLEM", 632, 672], ["decompressive", "OBSERVATION_MODIFIER", 238, 251], ["craniectomy", "OBSERVATION", 252, 263], ["brain", "ANATOMY", 354, 359], ["injury", "OBSERVATION", 360, 366], ["Severe", "OBSERVATION_MODIFIER", 583, 589], ["traumatic", "OBSERVATION", 590, 599], ["brain", "ANATOMY", 600, 605], ["injury", "OBSERVATION", 606, 612]]], ["Several interventions are commonly used to control the intracranial pressure to prevent secondary cerebral injuries.", [["intracranial", "ANATOMY", 55, 67], ["cerebral", "ANATOMY", 98, 106], ["cerebral injuries", "DISEASE", 98, 115], ["cerebral", "ORGAN", 98, 106], ["Several interventions", "TREATMENT", 0, 21], ["the intracranial pressure", "TEST", 51, 76], ["secondary cerebral injuries", "PROBLEM", 88, 115], ["cerebral", "ANATOMY", 98, 106], ["injuries", "OBSERVATION", 107, 115]]], ["Among them, decompressive craniectomy (DC) is widely performed; however, its impact on functional outcome is still under debate.", [["DC", "ANATOMY", 39, 41], ["decompressive craniectomy", "TREATMENT", 12, 37], ["decompressive", "OBSERVATION_MODIFIER", 12, 25], ["craniectomy", "OBSERVATION", 26, 37]]], ["Our objective was to assess the efficacy and safety of this procedure in adult patients with severe traumatic brain injury.", [["brain", "ANATOMY", 110, 115], ["traumatic brain injury", "DISEASE", 100, 122], ["patients", "ORGANISM", 79, 87], ["brain", "ORGAN", 110, 115], ["patients", "SPECIES", 79, 87], ["this procedure", "TREATMENT", 55, 69], ["severe traumatic brain injury", "PROBLEM", 93, 122], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["traumatic", "OBSERVATION", 100, 109], ["brain", "ANATOMY", 110, 115], ["injury", "OBSERVATION", 116, 122]]], ["Methods: We systematically searched in MEDLINE, EMBASE, CEN-TRAL, Web of Science, conference proceedings and databases of ongoing trials for eligible trials.", [["ongoing trials", "TREATMENT", 122, 136], ["eligible trials", "TREATMENT", 141, 156]]], ["We included randomized controlled trials of adult patients with severe traumatic brain injury, comparing DC to any other intervention.", [["brain", "ANATOMY", 81, 86], ["DC", "ANATOMY", 105, 107], ["traumatic brain injury", "DISEASE", 71, 93], ["patients", "ORGANISM", 50, 58], ["brain", "ORGAN", 81, 86], ["DC", "CELL_TYPE", 105, 107], ["patients", "SPECIES", 50, 58], ["severe traumatic brain injury", "PROBLEM", 64, 93], ["any other intervention", "TREATMENT", 111, 133], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["traumatic", "OBSERVATION_MODIFIER", 71, 80], ["brain", "ANATOMY", 81, 86], ["injury", "OBSERVATION", 87, 93]]], ["Our primary outcome was the neurological function based on the Glasgow Outcome Scale.", [["neurological", "ANATOMY", 28, 40]]], ["Secondary outcomes were mortality, intensive care unit (ICU) and hospital length of stay, intracranial pressure control, and complications.", [["intracranial", "ANATOMY", 90, 102], ["intracranial pressure control", "TREATMENT", 90, 119], ["complications", "PROBLEM", 125, 138]]], ["We used random effect models to conduct our analyses and the I2 index to assess heterogeneity.", [["random effect models", "PROBLEM", 8, 28], ["our analyses", "TEST", 40, 52], ["the I2 index", "TEST", 57, 69], ["heterogeneity", "PROBLEM", 80, 93]]], ["Results: We identified 5360 citations, from which we included 3 trials for a total of 573 patients.", [["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98]]], ["Univariate logistic regression analyses were performed to identify predictors associated with the decision for ICP monitoring.P377Results: A total of 857 adult patients were included (Tables 1 and 2 ).", [["patients", "ORGANISM", 160, 168], ["patients", "SPECIES", 160, 168], ["Univariate logistic regression analyses", "TEST", 0, 39], ["ICP monitoring", "TEST", 111, 125]]], ["The risk of poor outcome estimated by the IMPACT model was associated to the decision to monitor ICP (Fig. 1) .", [["poor outcome", "PROBLEM", 12, 24], ["ICP", "TEST", 97, 100]]], ["ICP was more often monitored in patients with severe TBI, with one dilated pupil at admission and positive CT findings (in particular, high Marshall scores).P377Conclusions: According to our results, the clinician follows a multifactorial reasoning: the main determinants for the decision to monitor ICP are GCS, pupils' abnormalities and, above all, CT findings.", [["pupil", "ANATOMY", 75, 80], ["TBI", "DISEASE", 53, 56], ["GCS", "DISEASE", 308, 311], ["patients", "ORGANISM", 32, 40], ["pupil", "MULTI-TISSUE_STRUCTURE", 75, 80], ["patients", "SPECIES", 32, 40], ["ICP", "TEST", 0, 3], ["severe TBI", "PROBLEM", 46, 56], ["one dilated pupil", "PROBLEM", 63, 80], ["positive CT findings", "PROBLEM", 98, 118], ["ICP", "TEST", 300, 303], ["GCS", "TEST", 308, 311], ["pupils' abnormalities", "PROBLEM", 313, 334], ["CT findings", "TEST", 351, 362], ["more often", "OBSERVATION_MODIFIER", 8, 18], ["severe", "OBSERVATION_MODIFIER", 46, 52], ["TBI", "OBSERVATION", 53, 56], ["dilated", "OBSERVATION", 67, 74]]], ["Future studies will be needed to clarify specific indications for the clinicians in the identification of patients who would benefit from invasive monitoring.P379Trajectories of early secondary insults after traumatic brain injury: a new approach to evaluate impact on outcome.", [["brain", "ANATOMY", 218, 223], ["traumatic brain injury", "DISEASE", 208, 230], ["patients", "ORGANISM", 106, 114], ["brain", "ORGAN", 218, 223], ["patients", "SPECIES", 106, 114], ["Future studies", "TEST", 0, 14], ["invasive monitoring", "TEST", 138, 157], ["early secondary insults", "PROBLEM", 178, 201], ["traumatic brain injury", "PROBLEM", 208, 230], ["a new approach", "TREATMENT", 232, 246], ["early", "OBSERVATION_MODIFIER", 178, 183], ["secondary insults", "OBSERVATION", 184, 201], ["traumatic", "OBSERVATION_MODIFIER", 208, 217], ["brain", "ANATOMY", 218, 223], ["injury", "OBSERVATION", 224, 230]]], ["Introduction: Secondary insults (SI) occur frequently after traumatic brain injury (TBI).", [["brain", "ANATOMY", 70, 75], ["Secondary insults", "DISEASE", 14, 31], ["traumatic brain injury", "DISEASE", 60, 82], ["TBI", "DISEASE", 84, 87], ["brain", "ORGAN", 70, 75], ["Secondary insults", "PROBLEM", 14, 31], ["traumatic brain injury", "PROBLEM", 60, 82], ["brain", "ANATOMY", 70, 75], ["injury", "OBSERVATION", 76, 82]]], ["Their presence is associated with a worse outcome.", [["a worse outcome", "PROBLEM", 34, 49]]], ["We examined the early trajectories of hypotension (SBP<90mmHg), hypoxia (SpO2<90%) and pupillary abnormalities from the prehospital settings to the Emergency Department (ED), and their relationship with 6-months outcome.", [["hypotension", "DISEASE", 38, 49], ["hypoxia", "DISEASE", 64, 71], ["pupillary abnormalities", "DISEASE", 87, 110], ["hypotension", "PROBLEM", 38, 49], ["SBP", "TEST", 51, 54], ["hypoxia", "PROBLEM", 64, 71], ["SpO2", "TEST", 73, 77], ["pupillary abnormalities", "PROBLEM", 87, 110], ["hypotension", "OBSERVATION", 38, 49], ["pupillary", "OBSERVATION_MODIFIER", 87, 96], ["abnormalities", "OBSERVATION", 97, 110]]], ["Methods: In this retrospective, observational study we included all TBI patients admitted to our Neuro Intensive Care Unit (NICU) from January 1997 to December 2016.", [["TBI", "DISEASE", 68, 71], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["observational study", "TEST", 32, 51]]], ["We defined the trajectories of SI:P379-\"sustained\" if present on the scene of accident and at hospital admission, -\"resolved\" if present on the scene but resolved in ED, -\"new event\" if absent on the scene and present in ED, -\"none\" if no insults were recorded.P379We investigated the association of SI trajectories with 6-months dichotomized outcome (Glasgow Outcome Scale (GOS); favorable=4-5; unfavorable=1-3).", [["insults", "PROBLEM", 239, 246]]], ["Results: 967 patients were enrolled in the final analysis.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["the final analysis", "TEST", 39, 57]]], ["Hypoxia and hypotension were related with unfavourable outcome when Introduction: Guidelines for management of pediatric traumatic brain injury recommend maintaining intracranial pressure (ICP) <20 mmHg [1] .", [["brain", "ANATOMY", 131, 136], ["intracranial", "ANATOMY", 166, 178], ["Hypoxia", "DISEASE", 0, 7], ["hypotension", "DISEASE", 12, 23], ["traumatic brain injury", "DISEASE", 121, 143], ["brain", "ORGAN", 131, 136], ["Hypoxia", "PROBLEM", 0, 7], ["hypotension", "PROBLEM", 12, 23], ["management", "TREATMENT", 97, 107], ["pediatric traumatic brain injury", "PROBLEM", 111, 143], ["intracranial pressure", "TEST", 166, 187], ["hypotension", "OBSERVATION", 12, 23], ["brain", "ANATOMY", 131, 136], ["injury", "OBSERVATION", 137, 143], ["intracranial", "ANATOMY", 166, 178]]], ["Use of 23.4% sodium chloride (NaCl) is considered safe and effective for management of ICP in adults, but evidence for concentrations >3% in pediatrics is limited.", [["sodium chloride", "CHEMICAL", 13, 28], ["NaCl", "CHEMICAL", 30, 34], ["sodium chloride", "CHEMICAL", 13, 28], ["NaCl", "CHEMICAL", 30, 34], ["sodium chloride", "SIMPLE_CHEMICAL", 13, 28], ["NaCl", "SIMPLE_CHEMICAL", 30, 34], ["% sodium chloride (NaCl)", "TREATMENT", 11, 35], ["management", "TREATMENT", 73, 83], ["ICP in adults", "PROBLEM", 87, 100], ["concentrations", "TEST", 119, 133]]], ["This study will describe the safety and efficacy of 23.4% NaCl in reducing ICP among pediatric patients.P379Methods: This retrospective study evaluated patients <=18 years old who received 23.4% NaCl and had continuous ICP monitoring.", [["NaCl", "CHEMICAL", 58, 62], ["NaCl", "CHEMICAL", 195, 199], ["NaCl", "CHEMICAL", 58, 62], ["NaCl", "CHEMICAL", 195, 199], ["patients", "ORGANISM", 95, 103], ["patients", "ORGANISM", 152, 160], ["patients", "SPECIES", 95, 103], ["patients", "SPECIES", 152, 160], ["This study", "TEST", 0, 10], ["23.4% NaCl", "TREATMENT", 52, 62], ["This retrospective study", "TEST", 117, 141], ["23.4% NaCl", "TREATMENT", 189, 199], ["continuous ICP monitoring", "TEST", 208, 233]]], ["Cerebral perfusion pressure (CPP), mean arterial pressure (MAP), ICP, and brain tissue oxygenation (PbtO2) were recorded hourly and were compared to baseline for 6 hours after each dose.", [["Cerebral", "ANATOMY", 0, 8], ["arterial", "ANATOMY", 40, 48], ["brain tissue", "ANATOMY", 74, 86], ["Cerebral", "MULTI-TISSUE_STRUCTURE", 0, 8], ["arterial", "MULTI-TISSUE_STRUCTURE", 40, 48], ["brain tissue", "TISSUE", 74, 86], ["Cerebral perfusion pressure", "TEST", 0, 27], ["CPP", "TEST", 29, 32], ["mean arterial pressure", "TEST", 35, 57], ["MAP", "TEST", 59, 62], ["ICP", "TEST", 65, 68], ["brain tissue oxygenation", "TEST", 74, 98], ["PbtO2", "TEST", 100, 105], ["pressure", "OBSERVATION_MODIFIER", 19, 27], ["brain tissue", "ANATOMY", 74, 86], ["oxygenation", "OBSERVATION_MODIFIER", 87, 98]]], ["Safety outcomes included peak serum sodium, peak serum chloride, and the incidence of stage 1 acute kidney injury (AKI) (serum creatinine elevation >=0.3 mg/dL or >=50%) [2] .", [["serum", "ANATOMY", 30, 35], ["serum", "ANATOMY", 49, 54], ["kidney", "ANATOMY", 100, 106], ["serum", "ANATOMY", 121, 126], ["sodium", "CHEMICAL", 36, 42], ["chloride", "CHEMICAL", 55, 63], ["acute kidney injury", "DISEASE", 94, 113], ["AKI", "DISEASE", 115, 118], ["creatinine", "CHEMICAL", 127, 137], ["sodium", "CHEMICAL", 36, 42], ["chloride", "CHEMICAL", 55, 63], ["creatinine", "CHEMICAL", 127, 137], ["serum", "ORGANISM_SUBSTANCE", 30, 35], ["sodium", "SIMPLE_CHEMICAL", 36, 42], ["serum", "ORGANISM_SUBSTANCE", 49, 54], ["chloride", "SIMPLE_CHEMICAL", 55, 63], ["kidney", "ORGAN", 100, 106], ["serum", "ORGANISM_SUBSTANCE", 121, 126], ["peak serum sodium", "TEST", 25, 42], ["peak serum chloride", "TEST", 44, 63], ["stage 1 acute kidney injury", "PROBLEM", 86, 113], ["AKI", "TEST", 115, 118], ["serum creatinine elevation", "TEST", 121, 147], ["acute", "OBSERVATION_MODIFIER", 94, 99], ["kidney", "ANATOMY", 100, 106], ["injury", "OBSERVATION", 107, 113]]], ["Results: Between August 2007 and July 2017, 45 eligible pediatric patients received 235 doses of 23.4% NaCl; 215 doses were included in the analysis of perfusion parameters.", [["NaCl", "CHEMICAL", 103, 107], ["NaCl", "CHEMICAL", 103, 107], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["23.4% NaCl", "TREATMENT", 97, 107], ["perfusion parameters", "TEST", 152, 172]]], ["Mean age was 11.6 +/-6 years (2 months to 18 years), and the median initial Glasgow Coma Scale score was 4.", [["Coma", "DISEASE", 84, 88], ["Mean age", "TEST", 0, 8], ["the median initial Glasgow Coma Scale score", "TEST", 57, 100]]], ["Subjects received a median of four 23.4% NaCl boluses, with a mean dose of 0.5 +/-0.18 mL/kg.", [["NaCl", "CHEMICAL", 41, 45], ["NaCl", "CHEMICAL", 41, 45], ["Subjects", "ORGANISM", 0, 8], ["four 23.4% NaCl boluses", "TREATMENT", 30, 53]]], ["Significantly lower ICP and higher CPP (p<0.001) were observed at all post-treatment time points (Fig. 1) ; PbtO2 was also significantly increased during 3 of the 6 hours recorded (p<0.05).", [["PbtO2", "CHEMICAL", 108, 113], ["PbtO2", "SIMPLE_CHEMICAL", 108, 113], ["Significantly lower ICP", "PROBLEM", 0, 23], ["higher CPP", "TEST", 28, 38], ["Fig", "TEST", 98, 101], ["PbtO2", "TEST", 108, 113], ["lower", "OBSERVATION_MODIFIER", 14, 19], ["ICP", "OBSERVATION", 20, 23], ["higher", "OBSERVATION_MODIFIER", 28, 34], ["CPP", "OBSERVATION_MODIFIER", 35, 38]]], ["There was no difference in MAP.", [["difference in MAP", "PROBLEM", 13, 30], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23]]], ["Peak post-treatment serum sodium and chloride were 157 +/-6 mEq/L and 122 +/-7 mEq/L, respectively (Fig. 2) .", [["serum", "ANATOMY", 20, 25], ["sodium", "CHEMICAL", 26, 32], ["chloride", "CHEMICAL", 37, 45], ["sodium", "CHEMICAL", 26, 32], ["chloride", "CHEMICAL", 37, 45], ["serum", "ORGANISM_SUBSTANCE", 20, 25], ["sodium", "SIMPLE_CHEMICAL", 26, 32], ["chloride", "SIMPLE_CHEMICAL", 37, 45], ["Peak", "TEST", 0, 4], ["serum sodium", "TEST", 20, 32], ["chloride", "TEST", 37, 45]]], ["Stage 1 AKI was observed in 15.6% of patients, and in-hospital mortality was 24.4%.", [["AKI", "DISEASE", 8, 11], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["Stage 1 AKI", "PROBLEM", 0, 11], ["AKI", "OBSERVATION", 8, 11]]], ["Conclusions: Our data suggests that 23.4% NaCl is a safe and effective therapy for elevated ICP in pediatric patients.", [["NaCl", "CHEMICAL", 42, 46], ["NaCl", "CHEMICAL", 42, 46], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["Our data", "TEST", 13, 21], ["NaCl", "TREATMENT", 42, 46], ["effective therapy", "TREATMENT", 61, 78], ["elevated ICP", "PROBLEM", 83, 95]]], ["Methods: We performed a prospective study in adult patients with mild head trauma (GCS 14 and 15) qualified for acquisition of urgent head CT scan.", [["head", "ANATOMY", 70, 74], ["head", "ANATOMY", 134, 138], ["head trauma", "DISEASE", 70, 81], ["GCS", "DISEASE", 83, 86], ["patients", "ORGANISM", 51, 59], ["head", "ORGANISM_SUBDIVISION", 70, 74], ["head", "ORGANISM_SUBDIVISION", 134, 138], ["patients", "SPECIES", 51, 59], ["a prospective study", "TEST", 22, 41], ["mild head trauma", "PROBLEM", 65, 81], ["GCS", "TEST", 83, 86], ["urgent head CT scan", "TEST", 127, 146], ["mild", "OBSERVATION_MODIFIER", 65, 69], ["head", "ANATOMY", 70, 74], ["trauma", "OBSERVATION", 75, 81]]], ["The clinical symptoms potentially related to intracranial lesion including abnormal vitals, vomiting, headache, persistent dizziness were recorded.", [["intracranial lesion", "ANATOMY", 45, 64], ["intracranial lesion", "DISEASE", 45, 64], ["abnormal vitals", "DISEASE", 75, 90], ["vomiting", "DISEASE", 92, 100], ["headache", "DISEASE", 102, 110], ["dizziness", "DISEASE", 123, 132], ["intracranial lesion", "PATHOLOGICAL_FORMATION", 45, 64], ["The clinical symptoms", "PROBLEM", 0, 21], ["intracranial lesion", "PROBLEM", 45, 64], ["abnormal vitals", "PROBLEM", 75, 90], ["vomiting", "PROBLEM", 92, 100], ["headache", "PROBLEM", 102, 110], ["persistent dizziness", "PROBLEM", 112, 132], ["intracranial", "ANATOMY", 45, 57], ["lesion", "OBSERVATION", 58, 64]]], ["ONS as well as head CT were then performed.", [["head", "ANATOMY", 15, 19], ["head", "ORGAN", 15, 19], ["head CT", "TEST", 15, 22], ["head", "ANATOMY", 15, 19]]], ["All ONS examinations were executed by an experienced sonographer to eliminating interrater bias.", [["All ONS examinations", "TEST", 0, 20]]], ["Head CT findings were dichotomized as positive or negative finding for ICH based on formal radiology reports.", [["ICH", "DISEASE", 71, 74], ["Head CT", "TEST", 0, 7], ["ICH", "PROBLEM", 71, 74]]], ["The patients' disposition including admission, surgery and safe discharge were followed.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["surgery", "TREATMENT", 47, 54]]], ["Results: 78 patients were enrolled for the survey.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["16 patients had at least one symptom related to potential intracranial lesion (20.5%).", [["intracranial lesion", "ANATOMY", 58, 77], ["intracranial lesion", "DISEASE", 58, 77], ["patients", "ORGANISM", 3, 11], ["intracranial lesion", "PATHOLOGICAL_FORMATION", 58, 77], ["patients", "SPECIES", 3, 11], ["one symptom", "PROBLEM", 25, 36], ["potential intracranial lesion", "PROBLEM", 48, 77], ["intracranial", "ANATOMY", 58, 70], ["lesion", "OBSERVATION", 71, 77]]], ["The mean ONSD was 44\u00b19mm.", [["The mean ONSD", "TEST", 0, 13], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["44\u00b19mm", "OBSERVATION_MODIFIER", 18, 24]]], ["25 patients were found to have ICH and 6 underwent neurosurgery thereafter.", [["ICH", "DISEASE", 31, 34], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["ICH", "PROBLEM", 31, 34], ["ICH", "OBSERVATION", 31, 34]]], ["No significant difference of ONSD was found between the groups with and without ICH, as well as the group receiving surgery or conservative treatment.", [["ICH", "DISEASE", 80, 83], ["ONSD", "CANCER", 29, 33], ["ONSD", "PROBLEM", 29, 33], ["ICH", "PROBLEM", 80, 83], ["surgery", "TREATMENT", 116, 123], ["conservative treatment", "TREATMENT", 127, 149], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION_MODIFIER", 15, 25], ["without", "UNCERTAINTY", 72, 79], ["ICH", "OBSERVATION", 80, 83]]], ["With introducing a conventional 5mm threshold of ONSD, the sensitivity, specificity, PPV and NPV was 0.36, 0.83, 0.50 and 0.73, respectively.", [["ONSD", "TEST", 49, 53], ["the sensitivity", "TEST", 55, 70], ["specificity", "TEST", 72, 83], ["PPV", "TEST", 85, 88], ["NPV", "TEST", 93, 96]]], ["While incorporating occurrance of at least one positive clinical symptom with the ONSD measurement greater than 5mm as a composite threshold, the sensitivity, specificity, PPV and NPV was 0.32, 1.00, 1.00 and 0.76, respectively.", [["positive clinical symptom", "PROBLEM", 47, 72], ["the ONSD measurement", "TEST", 78, 98], ["a composite threshold", "TEST", 119, 140], ["the sensitivity", "TEST", 142, 157], ["specificity", "TEST", 159, 170], ["PPV", "TEST", 172, 175], ["NPV", "TEST", 180, 183]]], ["Conclusions: The diagnostic value of ONS in mild head trauma is defective.", [["head", "ANATOMY", 49, 53], ["head trauma", "DISEASE", 49, 60], ["head", "ORGANISM_SUBDIVISION", 49, 53], ["mild head trauma", "PROBLEM", 44, 60], ["mild", "OBSERVATION_MODIFIER", 44, 48], ["head", "ANATOMY", 49, 53], ["trauma", "OBSERVATION", 54, 60], ["defective", "OBSERVATION", 64, 73]]], ["Nevertheless, with the supplemental aid of recognition of clinical symptoms relevant to potential intracranial lesion, the overall accuracy would improve.P382A correlation between YKL-40 concentrations in cerebrospinal fluid and Marshall classification in traumatic brain injurypreliminary results G Pavlov 1 , M Kazakova 1 , P Timonov 1 , K Simitchiev 2 , C Stefanov 1 , V Sarafian 1 1 Medical University -Plovdiv, Plovdiv, Bulgaria, 2 University of Plovdiv, Plovdiv, Bulgaria Critical Care 2018, 22(Suppl 1):P382P382Introduction: Establishment of prognostic models in traumatic brain injury (TBI) would improve the classification based on predictive risks and will better define treatment options [1] .", [["intracranial lesion", "ANATOMY", 98, 117], ["cerebrospinal fluid", "ANATOMY", 205, 224], ["brain", "ANATOMY", 266, 271], ["brain", "ANATOMY", 580, 585], ["intracranial lesion", "DISEASE", 98, 117], ["YKL-40", "CHEMICAL", 180, 186], ["traumatic brain injury", "DISEASE", 570, 592], ["TBI", "DISEASE", 594, 597], ["intracranial lesion", "PATHOLOGICAL_FORMATION", 98, 117], ["P382A", "GENE_OR_GENE_PRODUCT", 154, 159], ["YKL-40", "GENE_OR_GENE_PRODUCT", 180, 186], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 205, 224], ["brain", "ORGAN", 266, 271], ["brain", "ORGAN", 580, 585], ["P382A", "PROTEIN", 154, 159], ["YKL", "PROTEIN", 180, 183], ["clinical symptoms", "PROBLEM", 58, 75], ["potential intracranial lesion", "PROBLEM", 88, 117], ["YKL", "TEST", 180, 183], ["cerebrospinal fluid", "TEST", 205, 224], ["Kazakova", "TREATMENT", 313, 321], ["Timonov", "TEST", 328, 335], ["V Sarafian", "TREATMENT", 372, 382], ["traumatic brain injury", "PROBLEM", 570, 592], ["TBI", "PROBLEM", 594, 597], ["treatment options", "TREATMENT", 681, 698], ["intracranial", "ANATOMY", 98, 110], ["lesion", "OBSERVATION", 111, 117], ["cerebrospinal", "ANATOMY", 205, 218], ["fluid", "OBSERVATION", 219, 224], ["brain", "ANATOMY", 266, 271], ["brain", "ANATOMY", 580, 585], ["injury", "OBSERVATION", 586, 592]]], ["In recent years, one of the most intensively studied glycoprotein is YKL-40.", [["YKL-40", "CHEMICAL", 69, 75], ["YKL-40", "GENE_OR_GENE_PRODUCT", 69, 75], ["glycoprotein", "PROTEIN", 53, 65], ["YKL-40", "PROTEIN", 69, 75]]], ["It is expressed as a consequence of broad spectrum of inflammatory and malignant diseases [2] .", [["malignant diseases", "DISEASE", 71, 89], ["inflammatory and malignant diseases", "PROBLEM", 54, 89], ["inflammatory", "OBSERVATION_MODIFIER", 54, 66], ["malignant", "OBSERVATION", 71, 80]]], ["This is study aimed to investigate the level of YKL-40 in TBI patients and its relationship with several clinical models.", [["YKL-40", "CHEMICAL", 48, 54], ["TBI", "DISEASE", 58, 61], ["YKL-40", "GENE_OR_GENE_PRODUCT", 48, 54], ["patients", "ORGANISM", 62, 70], ["YKL-40", "PROTEIN", 48, 54], ["patients", "SPECIES", 62, 70]]], ["Methods: We determined plasma and cerebrospinal fluid (CSF) YKL-40 levels in six (6) patientson the 24th and 96th hour after the TBI.", [["plasma", "ANATOMY", 23, 29], ["cerebrospinal fluid", "ANATOMY", 34, 53], ["TBI", "DISEASE", 129, 132], ["plasma", "ORGANISM_SUBSTANCE", 23, 29], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 34, 53], ["CSF", "ORGANISM_SUBSTANCE", 55, 58], ["YKL-40", "GENE_OR_GENE_PRODUCT", 60, 66], ["plasma and cerebrospinal fluid (CSF) YKL", "TEST", 23, 63], ["the TBI", "PROBLEM", 125, 132], ["cerebrospinal", "ANATOMY", 34, 47], ["fluid", "OBSERVATION", 48, 53]]], ["Each patient was examined by physical and instrumental methods for somatic and neurological status, clinical assessment and prognostic scales (GCS, Marshall Classification, APACHE III).", [["neurological", "ANATOMY", 79, 91], ["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12], ["somatic and neurological status", "PROBLEM", 67, 98], ["clinical assessment", "TEST", 100, 119], ["prognostic scales", "TEST", 124, 141], ["GCS", "TEST", 143, 146]]], ["Routine haematological and biochemical tests were also performed.", [["Routine haematological and biochemical tests", "TEST", 0, 44]]], ["As control served the CSF of age-matched suddenly deceased healthy individuals (n = 11), which was examined post mortem for YKL-40 levels.P382Results: We found no significant difference between plasma YKL-40 levels till 24th and 96th in all patients (mean difference \u00b1 SD: 57 \u00b1 237 ng/ml 1 ) and calculated Cerebral Autoregulation (AR) as correlation coefficients (Pearson) for each IH Wave.", [["plasma", "ANATOMY", 194, 200], ["Cerebral", "ANATOMY", 307, 315], ["YKL-40", "GENE_OR_GENE_PRODUCT", 124, 130], ["plasma", "ORGANISM_SUBSTANCE", 194, 200], ["YKL-40", "GENE_OR_GENE_PRODUCT", 201, 207], ["patients", "ORGANISM", 241, 249], ["AR", "PROTEIN", 332, 334], ["patients", "SPECIES", 241, 249], ["YKL", "TEST", 124, 127], ["plasma YKL", "TEST", 194, 204], ["SD", "TEST", 269, 271], ["calculated Cerebral Autoregulation (AR", "PROBLEM", 296, 334], ["no", "UNCERTAINTY", 160, 162], ["significant", "OBSERVATION_MODIFIER", 163, 174], ["Cerebral", "ANATOMY", 307, 315]]], ["Z-Ratios were divided according to binary AR outcome and correlation calculated with intracranial pressure before, during and after the IH waves.P382Results: Our preliminary analysis demonstrated a negative correlation between Intracranial pressure and Z-Ratio in the grouped 6 IH waves with preserved AR, but no correlation in the grouped 9 IH waves with impaired AR (Table 2 and Fig. 2 ).", [["intracranial", "ANATOMY", 85, 97], ["Intracranial", "ANATOMY", 227, 239], ["AR", "GENE_OR_GENE_PRODUCT", 302, 304], ["AR", "PROTEIN", 42, 44], ["AR", "PROTEIN", 302, 304], ["AR", "PROTEIN", 365, 367], ["Z-Ratios", "TEST", 0, 8], ["intracranial pressure", "TEST", 85, 106], ["Our preliminary analysis", "TEST", 158, 182], ["Intracranial pressure", "TEST", 227, 248], ["Z-Ratio", "TEST", 253, 260], ["impaired AR", "PROBLEM", 356, 367], ["preserved AR", "OBSERVATION", 292, 304], ["impaired", "OBSERVATION", 356, 364]]], ["This indicates a decrease in power in the EEG low frequencies (0-7Hz) and/or an increase in the EEG high frequencies (7-30Hz) for increased values of intracranial pressure when AR is preserved.P382Conclusions: Features of IH waves differ depending on the ability of the injured brain to autoregulate cerebral blood flow.", [["intracranial", "ANATOMY", 150, 162], ["brain", "ANATOMY", 278, 283], ["cerebral", "ANATOMY", 300, 308], ["blood", "ANATOMY", 309, 314], ["intracranial", "MULTI-TISSUE_STRUCTURE", 150, 162], ["AR", "GENE_OR_GENE_PRODUCT", 177, 179], ["brain", "ORGAN", 278, 283], ["cerebral blood", "MULTI-TISSUE_STRUCTURE", 300, 314], ["AR", "PROTEIN", 177, 179], ["a decrease in power in the EEG low frequencies", "PROBLEM", 15, 61], ["an increase in the EEG high frequencies", "PROBLEM", 77, 116], ["increased values of intracranial pressure", "PROBLEM", 130, 171], ["IH waves", "PROBLEM", 222, 230], ["cerebral blood flow", "TEST", 300, 319], ["decrease", "OBSERVATION_MODIFIER", 17, 25], ["power", "OBSERVATION_MODIFIER", 29, 34], ["increase", "OBSERVATION_MODIFIER", 80, 88], ["intracranial pressure", "ANATOMY", 150, 171], ["preserved", "OBSERVATION", 183, 192], ["injured", "OBSERVATION", 270, 277], ["cerebral blood", "ANATOMY", 300, 314]]], ["These features might include different signature of EEG frequency changes.", [["EEG frequency changes", "PROBLEM", 52, 73]]], ["The causative links and clinical significance of the different EEG patterns remain unexplored and might represent a signature of neurovascular coupling.", [["neurovascular", "ANATOMY", 129, 142], ["neurovascular", "MULTI-TISSUE_STRUCTURE", 129, 142], ["the different EEG patterns", "PROBLEM", 49, 75], ["neurovascular coupling", "PROBLEM", 129, 151], ["neurovascular coupling", "OBSERVATION", 129, 151]]], ["Introduction: Targeted temperature management of patients who have suffered a traumatic brain injury is often used in the hope of preventing further insult to the brain; however, there is no uniform approach to managing temperature either locally, nationally or internationally, and maintenance of goal temperature in this patient population is often challenging due to hypothalamic injury.", [["brain", "ANATOMY", 88, 93], ["brain", "ANATOMY", 163, 168], ["brain injury", "DISEASE", 88, 100], ["insult to the brain", "DISEASE", 149, 168], ["hypothalamic injury", "DISEASE", 370, 389], ["patients", "ORGANISM", 49, 57], ["brain", "ORGAN", 88, 93], ["brain", "ORGAN", 163, 168], ["patient", "ORGANISM", 323, 330], ["hypothalamic", "MULTI-TISSUE_STRUCTURE", 370, 382], ["patients", "SPECIES", 49, 57], ["patient", "SPECIES", 323, 330], ["Targeted temperature management", "TREATMENT", 14, 45], ["a traumatic brain injury", "PROBLEM", 76, 100], ["further insult to the brain", "PROBLEM", 141, 168], ["hypothalamic injury", "PROBLEM", 370, 389], ["traumatic", "OBSERVATION", 78, 87], ["brain", "ANATOMY", 88, 93], ["injury", "OBSERVATION", 94, 100], ["brain", "ANATOMY", 163, 168], ["no", "UNCERTAINTY", 188, 190], ["uniform", "OBSERVATION_MODIFIER", 191, 198], ["hypothalamic injury", "OBSERVATION", 370, 389]]], ["We sought to evaluate the feasibility and safety of an esophageal heat transfer device (EnsoETM, Attune Medical, Chicago, IL) to perform temperature management of patients suffering from traumatic brain injury.P382Methods: This was an IRB-approved prospective study of patients undergoing temperature management after traumatic brain injury.", [["esophageal", "ANATOMY", 55, 65], ["brain", "ANATOMY", 197, 202], ["brain", "ANATOMY", 328, 333], ["traumatic brain injury", "DISEASE", 187, 209], ["traumatic brain injury", "DISEASE", 318, 340], ["esophageal", "ORGAN", 55, 65], ["patients", "ORGANISM", 163, 171], ["brain", "ORGAN", 197, 202], ["patients", "ORGANISM", 269, 277], ["brain", "ORGAN", 328, 333], ["patients", "SPECIES", 163, 171], ["patients", "SPECIES", 269, 277], ["an esophageal heat transfer device", "TREATMENT", 52, 86], ["temperature management", "TREATMENT", 137, 159], ["traumatic brain injury", "PROBLEM", 187, 209], ["prospective study", "TEST", 248, 265], ["temperature management", "TREATMENT", 289, 311], ["traumatic brain injury", "PROBLEM", 318, 340], ["esophageal", "ANATOMY", 55, 65], ["traumatic brain injury", "OBSERVATION", 187, 209], ["brain", "ANATOMY", 328, 333], ["injury", "OBSERVATION", 334, 340]]], ["Patients were treated with an esophageal heat transfer device connected to an external heater-cooler, and maintained at target temperature for at least 24 hours.", [["esophageal", "ANATOMY", 30, 40], ["Patients", "ORGANISM", 0, 8], ["esophageal", "ORGAN", 30, 40], ["Patients", "SPECIES", 0, 8], ["an esophageal heat transfer device", "TREATMENT", 27, 61], ["an external heater", "TREATMENT", 75, 93], ["esophageal", "ANATOMY", 30, 40]]], ["Patient temperature obtained via Foley catheter was recorded hourly, and the deviation from goal temperature during treatment reported.P382Results: A total of 12 patients were treated from August 2015 to May 2016.", [["patients", "ORGANISM", 162, 170], ["Patient", "SPECIES", 0, 7], ["patients", "SPECIES", 162, 170], ["Patient temperature", "TEST", 0, 19], ["Foley catheter", "TREATMENT", 33, 47], ["the deviation", "PROBLEM", 73, 86], ["treatment", "TREATMENT", 116, 125], ["catheter", "OBSERVATION", 39, 47]]], ["Temperature targets during treatment ranged from 34.0 to 36.8 degrees C. Maintenance of target temperature was successful, with 85% of readings within +/-1 degrees C of target, and 75% of readings within +/-0.5 degrees C of target.", [["Temperature targets", "TEST", 0, 19], ["treatment", "TEST", 27, 36], ["target temperature", "TEST", 88, 106], ["target", "TEST", 169, 175]]], ["One patient developed a small hydrothorax, not attributed to device use.", [["hydrothorax", "DISEASE", 30, 41], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["a small hydrothorax", "PROBLEM", 22, 41], ["small", "OBSERVATION_MODIFIER", 24, 29], ["hydrothorax", "OBSERVATION", 30, 41], ["not attributed to", "UNCERTAINTY", 43, 60], ["device", "OBSERVATION", 61, 67]]], ["All patients survived to discharge from the ICU, with median CPC of 2 (range 1 to 4).", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["median CPC", "TEST", 54, 64]]], ["Conclusions: Targeted temperature management of patients with traumatic brain injury using an esophageal heat transfer device was feasible and safe, providing a tight maintenance of goal temperature in this challenging patient population.", [["brain", "ANATOMY", 72, 77], ["esophageal", "ANATOMY", 94, 104], ["traumatic brain injury", "DISEASE", 62, 84], ["patients", "ORGANISM", 48, 56], ["brain", "ORGAN", 72, 77], ["esophageal", "ORGAN", 94, 104], ["patient", "ORGANISM", 219, 226], ["patients", "SPECIES", 48, 56], ["patient", "SPECIES", 219, 226], ["Targeted temperature management", "TREATMENT", 13, 44], ["traumatic brain injury", "PROBLEM", 62, 84], ["an esophageal heat transfer device", "TREATMENT", 91, 125], ["this challenging patient population", "TREATMENT", 202, 237], ["brain", "ANATOMY", 72, 77], ["injury", "OBSERVATION", 78, 84], ["esophageal", "ANATOMY", 94, 104]]], ["Introduction: Traumatic brain injury (TBI) represents a serious problem in Europe.", [["brain", "ANATOMY", 24, 29], ["Traumatic brain injury", "DISEASE", 14, 36], ["TBI", "DISEASE", 38, 41], ["brain", "ORGAN", 24, 29], ["Traumatic brain injury", "PROBLEM", 14, 36], ["TBI", "PROBLEM", 38, 41], ["a serious problem", "PROBLEM", 54, 71], ["Traumatic", "OBSERVATION_MODIFIER", 14, 23], ["brain", "ANATOMY", 24, 29], ["injury", "OBSERVATION", 30, 36], ["serious", "OBSERVATION_MODIFIER", 56, 63]]], ["It still is the principal cause of death in US and Europe.", [["death", "DISEASE", 35, 40], ["death", "PROBLEM", 35, 40], ["death", "OBSERVATION", 35, 40]]], ["Every year in Italy 250 people on 100,000 suffers of TBI and 17 on 100,000 dies.", [["TBI", "DISEASE", 53, 56], ["people", "ORGANISM", 24, 30], ["people", "SPECIES", 24, 30], ["TBI", "PROBLEM", 53, 56]]], ["Disability and incapacity from TBI provides \"strong ethicals, medicals, social and health economy imperative to motivate a concerted effort to improve treatment and preventions\" Methods: Our hospital is the hub for Modena's county for TBI and we took part in the past 3 year on European project CREACTIVE (Collaborative ResearcE on ACute Traumatic brain Injury in intensiVe Care medicine in Europa) as branch of Italian group GIVITI (Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva).", [["brain", "ANATOMY", 348, 353], ["TBI", "DISEASE", 31, 34], ["TBI", "DISEASE", 235, 238], ["Traumatic brain Injury", "DISEASE", 338, 360], ["GIVITI", "CHEMICAL", 426, 432], ["brain", "ORGAN", 348, 353], ["Disability", "PROBLEM", 0, 10], ["incapacity", "PROBLEM", 15, 25], ["TBI", "PROBLEM", 31, 34], ["treatment", "TREATMENT", 151, 160], ["TBI", "PROBLEM", 235, 238], ["ACute Traumatic brain Injury", "PROBLEM", 332, 360], ["Italian group GIVITI", "TREATMENT", 412, 432], ["la Valutazione degli Interventi", "TREATMENT", 454, 485], ["incapacity", "OBSERVATION", 15, 25], ["ACute", "OBSERVATION_MODIFIER", 332, 337], ["Traumatic", "OBSERVATION_MODIFIER", 338, 347], ["brain", "ANATOMY", 348, 353], ["Injury", "OBSERVATION", 354, 360]]], ["Our study concerned about patients with TBI dismissed from ICU that \"personally\" or by the family will accepted the consensus to be included in our follow up conducted after 6 months from the dismissal.", [["TBI", "DISEASE", 40, 43], ["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["Our study", "TEST", 0, 9], ["TBI", "PROBLEM", 40, 43]]], ["We collected clinical data from the admission to the dismissale and measured impact of TBI on all day life with GOS-E and QOLIBRI-OS using telephonical interview.", [["TBI", "DISEASE", 87, 90], ["TBI", "PROBLEM", 87, 90]]], ["Results: We collected data about 63 patients, 33 answered to the telephonical follow-up and only 10 compilated the QOLIBRI-OS.", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44]]], ["We found out that patients admitted with lower GCS has worst outcome in terms of quality of life.", [["GCS", "DISEASE", 47, 50], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["lower GCS", "PROBLEM", 41, 50]]], ["It also appears that anisocoria during ICU staying represents an odds ratio for death and is connected with worst quality of life after 6 months from the dismissal (Tables 1 & 2) .", [["anisocoria", "DISEASE", 21, 31], ["death", "DISEASE", 80, 85], ["anisocoria", "PROBLEM", 21, 31], ["death", "PROBLEM", 80, 85], ["anisocoria", "OBSERVATION", 21, 31]]], ["Inability to re-start a normal work-activity appeared to be the most important factor on the perception that our patient have of their new lives.", [["patient", "ORGANISM", 113, 120], ["patient", "SPECIES", 113, 120]]], ["Conclusions: Anisocoria seems to be an indicator of severe brain damage.", [["brain", "ANATOMY", 59, 64], ["brain damage", "DISEASE", 59, 71], ["brain", "ORGAN", 59, 64], ["Anisocoria", "PROBLEM", 13, 23], ["severe brain damage", "PROBLEM", 52, 71], ["Anisocoria", "OBSERVATION", 13, 23], ["severe", "OBSERVATION_MODIFIER", 52, 58], ["brain", "ANATOMY", 59, 64], ["damage", "OBSERVATION", 65, 71]]], ["GCS, despite it's simplicity, still represent the best and easiest way to score TBI.", [["GCS", "DISEASE", 0, 3], ["TBI", "DISEASE", 80, 83], ["GCS", "TEST", 0, 3], ["TBI", "PROBLEM", 80, 83]]], ["Work impairment appear to be the most important disability to determine subjective perception of quality of life after TBI, so efforts have to be made to improve work rehabilitation after the dismissal from hospital.", [["Work impairment", "DISEASE", 0, 15], ["TBI", "DISEASE", 119, 122], ["Work impairment", "PROBLEM", 0, 15], ["TBI", "PROBLEM", 119, 122], ["work rehabilitation", "TREATMENT", 162, 181]]], ["Introduction: Hyperventilation (HV) reduces elevated intracranial pressure (ICP) by changing autoregulatory functions connected to cerebrovascular CO2 reactivity.", [["intracranial", "ANATOMY", 53, 65], ["cerebrovascular", "ANATOMY", 131, 146], ["Hyperventilation", "DISEASE", 14, 30], ["CO2", "CHEMICAL", 147, 150], ["CO2", "CHEMICAL", 147, 150], ["intracranial", "IMMATERIAL_ANATOMICAL_ENTITY", 53, 65], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 131, 146], ["CO2", "SIMPLE_CHEMICAL", 147, 150], ["Hyperventilation (HV)", "TREATMENT", 14, 35], ["elevated intracranial pressure", "PROBLEM", 44, 74], ["changing autoregulatory functions", "PROBLEM", 84, 117], ["cerebrovascular CO2 reactivity", "TEST", 131, 161], ["intracranial pressure", "OBSERVATION", 53, 74], ["cerebrovascular", "ANATOMY", 131, 146], ["CO2 reactivity", "OBSERVATION", 147, 161]]], ["Criticism to HV is due to the possibility of developing cerebral ischemia and tissue hypoxia because of hypocapnia-induced vasoconstriction.", [["cerebral", "ANATOMY", 56, 64], ["tissue", "ANATOMY", 78, 84], ["cerebral ischemia", "DISEASE", 56, 73], ["hypoxia", "DISEASE", 85, 92], ["hypocapnia", "DISEASE", 104, 114], ["cerebral", "ORGAN", 56, 64], ["tissue", "TISSUE", 78, 84], ["developing cerebral ischemia", "PROBLEM", 45, 73], ["tissue hypoxia", "PROBLEM", 78, 92], ["hypocapnia", "PROBLEM", 104, 114], ["vasoconstriction", "PROBLEM", 123, 139], ["due to the possibility of", "UNCERTAINTY", 19, 44], ["cerebral", "ANATOMY", 56, 64], ["ischemia", "OBSERVATION", 65, 73], ["tissue", "OBSERVATION_MODIFIER", 78, 84], ["hypoxia", "OBSERVATION", 85, 92], ["hypocapnia", "OBSERVATION", 104, 114], ["vasoconstriction", "OBSERVATION", 123, 139]]], ["We aimed to investigate the potential adverse effects of moderate HV of short duration in the acute phase in patients with severe traumatic brain injury (TBI), using concomitant monitoring of cerebral metabolism, continuous brain tissue oxygen tension (PbrO2), and cerebral hemodynamic with transcranial color-coded duplex sonography (TCCD).", [["brain", "ANATOMY", 140, 145], ["cerebral", "ANATOMY", 192, 200], ["brain tissue", "ANATOMY", 224, 236], ["cerebral", "ANATOMY", 265, 273], ["traumatic brain injury", "DISEASE", 130, 152], ["TBI", "DISEASE", 154, 157], ["oxygen", "CHEMICAL", 237, 243], ["oxygen", "CHEMICAL", 237, 243], ["patients", "ORGANISM", 109, 117], ["brain", "ORGAN", 140, 145], ["cerebral", "MULTI-TISSUE_STRUCTURE", 192, 200], ["brain tissue", "TISSUE", 224, 236], ["oxygen", "SIMPLE_CHEMICAL", 237, 243], ["cerebral", "ORGAN", 265, 273], ["patients", "SPECIES", 109, 117], ["moderate HV of short duration", "PROBLEM", 57, 86], ["severe traumatic brain injury", "PROBLEM", 123, 152], ["concomitant monitoring", "TEST", 166, 188], ["cerebral metabolism", "PROBLEM", 192, 211], ["continuous brain tissue oxygen tension", "TREATMENT", 213, 251], ["transcranial color", "TEST", 291, 309], ["coded duplex sonography", "TEST", 310, 333], ["moderate HV", "OBSERVATION_MODIFIER", 57, 68], ["short duration", "OBSERVATION_MODIFIER", 72, 86], ["acute phase", "OBSERVATION_MODIFIER", 94, 105], ["severe", "OBSERVATION_MODIFIER", 123, 129], ["traumatic", "OBSERVATION_MODIFIER", 130, 139], ["brain", "ANATOMY", 140, 145], ["injury", "OBSERVATION", 146, 152], ["cerebral metabolism", "ANATOMY", 192, 211], ["oxygen tension", "OBSERVATION", 237, 251]]], ["Methods: A prospective trial was conducted between May 2014 and May 2017 at the University Hospital of Zurich.", [["A prospective trial", "TREATMENT", 9, 28]]], ["Adults (>18 years), with non-penetrating TBI, first GCS < 9, ICP-monitoring, PbrO2 and/or microdialysis (MD)-probes were included within 36 hours after injury.", [["TBI", "DISEASE", 41, 44], ["GCS", "DISEASE", 52, 55], ["Adults", "ORGANISM", 0, 6], ["PbrO2", "SIMPLE_CHEMICAL", 77, 82], ["Adults", "SPECIES", 0, 6], ["non-penetrating TBI", "PROBLEM", 25, 44], ["first GCS", "TEST", 46, 55], ["ICP", "TEST", 61, 64], ["PbrO2", "TREATMENT", 77, 82], ["injury", "PROBLEM", 152, 158]]], ["Data collection and TCCD measurements took place at baseline (A), at the begin of moderate HV (PaCO2 4-4.7 kPa) (C), after 50 minutes of moderate HV (PaCO2 4-4.7 kPa) (D), and after return to baseline (E) (Fig. 1) .", [["Data collection", "TEST", 0, 15], ["TCCD measurements", "TEST", 20, 37], ["PaCO2", "TEST", 95, 100], ["PaCO2", "TEST", 150, 155]]], ["Repeated measures ANOVA was used to compare variables at the different time points followed by post hoc analysis with Bonferroni adjustment as appropriate.", [["Repeated measures ANOVA", "TREATMENT", 0, 23], ["hoc analysis", "TEST", 100, 112], ["Bonferroni adjustment", "TREATMENT", 118, 139]]], ["P-value < .05 was considered significant.", [["P", "TEST", 0, 1]]], ["Results: Eleven patients were included (64% males, mean age 36 \u00b1 14 years).", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24]]], ["First GCS was 7 (3-8: median and interquartile range).", [["GCS", "DISEASE", 6, 9], ["First GCS", "TEST", 0, 9]]], ["Data concerning PaCO2, ICP, PbrO2, mean flow velocity (MFV) in the middle cerebral artery, and MD values are presented in Table 1 .", [["middle cerebral artery", "ANATOMY", 67, 89], ["PbrO2", "SIMPLE_CHEMICAL", 28, 33], ["cerebral artery", "MULTI-TISSUE_STRUCTURE", 74, 89], ["PaCO2", "TEST", 16, 21], ["ICP", "TEST", 23, 26], ["PbrO2", "TEST", 28, 33], ["mean flow velocity", "TEST", 35, 53], ["MD values", "TEST", 95, 104], ["mean", "OBSERVATION", 35, 39], ["flow velocity", "OBSERVATION", 40, 53], ["middle cerebral artery", "ANATOMY", 67, 89]]], ["During HV, ICP and MFV decreased significantly.", [["ICP", "TEST", 11, 14], ["MFV", "TEST", 19, 22], ["MFV", "OBSERVATION_MODIFIER", 19, 22], ["decreased", "OBSERVATION_MODIFIER", 23, 32], ["significantly", "OBSERVATION_MODIFIER", 33, 46]]], ["PbrO2 presented a trend of reduction.", [["PbrO2", "CHEMICAL", 0, 5], ["PbrO2", "SIMPLE_CHEMICAL", 0, 5], ["reduction", "OBSERVATION_MODIFIER", 27, 36]]], ["Glucose, lactate and pyruvate did not change significantly ( Table 2) .", [["Glucose", "CHEMICAL", 0, 7], ["lactate", "CHEMICAL", 9, 16], ["pyruvate", "CHEMICAL", 21, 29], ["Glucose", "CHEMICAL", 0, 7], ["lactate", "CHEMICAL", 9, 16], ["pyruvate", "CHEMICAL", 21, 29], ["Glucose", "SIMPLE_CHEMICAL", 0, 7], ["lactate", "SIMPLE_CHEMICAL", 9, 16], ["pyruvate", "SIMPLE_CHEMICAL", 21, 29], ["Glucose", "TEST", 0, 7], ["lactate", "TEST", 9, 16], ["pyruvate", "TEST", 21, 29]]], ["Conclusions: Short episodes of moderate HV have a potent effect on the cerebral blood flow, as assessed by TCCD, reduce ICP and PbrO2, and do not induce significant changes in cerebral metabolism.P387Outcome of pediatric patients six months after moderate to severe TBI -results of CREACTKids study from three PICU in Israel PaCO2 arterial partial pressure of CO2, CPP cerebral perfusion pressure (mmHg), ICP intracranial pressure (mmHg), PbrO2 brain tissue oxygen tension (mmHg), MFV mean flow velocity in the middle cerebral artery Introduction: Delirium is a major cause of complications in postoperative patient in ICU.", [["cerebral blood", "ANATOMY", 71, 85], ["cerebral", "ANATOMY", 176, 184], ["arterial", "ANATOMY", 331, 339], ["cerebral", "ANATOMY", 369, 377], ["intracranial", "ANATOMY", 409, 421], ["brain tissue", "ANATOMY", 445, 457], ["middle cerebral artery", "ANATOMY", 511, 533], ["TBI", "DISEASE", 266, 269], ["CO2", "CHEMICAL", 360, 363], ["oxygen", "CHEMICAL", 458, 464], ["Delirium", "DISEASE", 548, 556], ["CO2", "CHEMICAL", 360, 363], ["oxygen", "CHEMICAL", 458, 464], ["cerebral blood", "MULTI-TISSUE_STRUCTURE", 71, 85], ["TCCD", "SIMPLE_CHEMICAL", 107, 111], ["PbrO2", "SIMPLE_CHEMICAL", 128, 133], ["cerebral", "ORGAN", 176, 184], ["patients", "ORGANISM", 221, 229], ["arterial", "MULTI-TISSUE_STRUCTURE", 331, 339], ["CO2", "SIMPLE_CHEMICAL", 360, 363], ["cerebral", "MULTI-TISSUE_STRUCTURE", 369, 377], ["brain tissue", "TISSUE", 445, 457], ["oxygen", "SIMPLE_CHEMICAL", 458, 464], ["cerebral artery", "MULTI-TISSUE_STRUCTURE", 518, 533], ["patient", "ORGANISM", 608, 615], ["patients", "SPECIES", 221, 229], ["patient", "SPECIES", 608, 615], ["moderate HV", "PROBLEM", 31, 42], ["the cerebral blood flow", "TEST", 67, 90], ["ICP", "TEST", 120, 123], ["PbrO2", "TREATMENT", 128, 133], ["significant changes in cerebral metabolism", "PROBLEM", 153, 195], ["moderate to severe TBI", "PROBLEM", 247, 269], ["CREACTKids study", "TEST", 282, 298], ["Israel PaCO2", "TEST", 318, 330], ["CO2", "TEST", 360, 363], ["CPP cerebral perfusion pressure", "TEST", 365, 396], ["mmHg", "TEST", 398, 402], ["ICP intracranial pressure", "TEST", 405, 430], ["mmHg", "TEST", 432, 436], ["PbrO2 brain tissue oxygen tension", "TEST", 439, 472], ["mmHg", "TEST", 474, 478], ["MFV mean flow velocity", "TEST", 481, 503], ["Delirium", "PROBLEM", 548, 556], ["complications", "PROBLEM", 577, 590], ["moderate", "OBSERVATION_MODIFIER", 31, 39], ["HV", "OBSERVATION", 40, 42], ["potent", "OBSERVATION_MODIFIER", 50, 56], ["cerebral blood", "ANATOMY", 71, 85], ["cerebral metabolism", "OBSERVATION", 176, 195], ["pressure", "OBSERVATION_MODIFIER", 348, 356], ["pressure", "OBSERVATION_MODIFIER", 422, 430], ["oxygen tension", "OBSERVATION", 458, 472], ["flow velocity", "OBSERVATION", 490, 503], ["middle cerebral artery", "ANATOMY", 511, 533], ["Delirium", "OBSERVATION", 548, 556], ["complications", "OBSERVATION", 577, 590]]], ["Risk factors for delirium include poor cerebral hemodynamics and peri-operative cerebral desaturations.", [["cerebral", "ANATOMY", 39, 47], ["cerebral", "ANATOMY", 80, 88], ["delirium", "DISEASE", 17, 25], ["cerebral desaturations", "DISEASE", 80, 102], ["cerebral", "MULTI-TISSUE_STRUCTURE", 39, 47], ["cerebral", "ORGAN", 80, 88], ["Risk factors", "PROBLEM", 0, 12], ["delirium", "PROBLEM", 17, 25], ["poor cerebral hemodynamics", "PROBLEM", 34, 60], ["peri-operative cerebral desaturations", "PROBLEM", 65, 102], ["cerebral", "ANATOMY", 80, 88], ["desaturations", "OBSERVATION", 89, 102]]], ["Intraoperative target cerebral oximetry monitoring may decrease the incidence of postoperative delirium in elective major abdominal surgery patients.P387Methods: A single-blinded, randomised controlled trial in patients undergo elective major abdominal surgery who received postoperative care in surgical ICU with age more than 65 years were randomised into two groups.", [["cerebral", "ANATOMY", 22, 30], ["abdominal", "ANATOMY", 122, 131], ["abdominal", "ANATOMY", 243, 252], ["postoperative delirium", "DISEASE", 81, 103], ["cerebral", "MULTI-TISSUE_STRUCTURE", 22, 30], ["abdominal", "ORGANISM_SUBDIVISION", 122, 131], ["patients", "ORGANISM", 140, 148], ["patients", "ORGANISM", 211, 219], ["abdominal", "ORGAN", 243, 252], ["patients", "SPECIES", 140, 148], ["patients", "SPECIES", 211, 219], ["Intraoperative target cerebral oximetry monitoring", "TEST", 0, 50], ["postoperative delirium", "PROBLEM", 81, 103], ["elective major abdominal surgery", "TREATMENT", 107, 139], ["randomised controlled trial", "TREATMENT", 180, 207], ["elective major abdominal surgery", "TREATMENT", 228, 260], ["postoperative care", "TREATMENT", 274, 292], ["cerebral", "ANATOMY", 22, 30], ["postoperative delirium", "OBSERVATION", 81, 103], ["abdominal", "ANATOMY", 122, 131], ["surgery", "OBSERVATION", 132, 139], ["abdominal", "ANATOMY", 243, 252], ["surgery", "OBSERVATION", 253, 260]]], ["The intervention group was received intra-operative target cerebral oxygen monitoring using cerebral oximetry whereas the control group was not.", [["cerebral", "ANATOMY", 59, 67], ["cerebral", "ANATOMY", 92, 100], ["oxygen", "CHEMICAL", 68, 74], ["oxygen", "CHEMICAL", 68, 74], ["cerebral", "ORGAN", 59, 67], ["oxygen", "SIMPLE_CHEMICAL", 68, 74], ["cerebral", "ORGAN", 92, 100], ["intra-operative target cerebral oxygen monitoring", "TREATMENT", 36, 85], ["cerebral oximetry", "TEST", 92, 109]]], ["Delirium was assessed in both group at 24, 48, 72 hour postoperatively.", [["Delirium", "DISEASE", 0, 8], ["Delirium", "PROBLEM", 0, 8]]], ["Other risk factors for delirium, mechanical ventilator day, length of ICU stay, length of hospital stay and post-operative complication were recorded.P387Results: From August 2015-March 2016, 37 patients who met the criteria were randomised to 19 patients in intervention group and 18 patients in control group.", [["delirium", "DISEASE", 23, 31], ["patients", "ORGANISM", 195, 203], ["patients", "ORGANISM", 247, 255], ["patients", "ORGANISM", 285, 293], ["patients", "SPECIES", 195, 203], ["patients", "SPECIES", 247, 255], ["patients", "SPECIES", 285, 293], ["delirium", "PROBLEM", 23, 31], ["mechanical ventilator", "TREATMENT", 33, 54], ["post-operative complication", "PROBLEM", 108, 135]]], ["Overall incidence of delirium was 27.03% (Intervention 21.05% VS Control 33.34%, p=0.401).", [["delirium", "DISEASE", 21, 29], ["delirium", "PROBLEM", 21, 29], ["Intervention", "TEST", 42, 54], ["Control", "TEST", 65, 72], ["p", "TEST", 81, 82], ["delirium", "OBSERVATION", 21, 29]]], ["Baseline cerebral oxygen in intervention group was 66.79 \u00b1 3.11%.", [["cerebral", "ANATOMY", 9, 17], ["oxygen", "CHEMICAL", 18, 24], ["oxygen", "CHEMICAL", 18, 24], ["cerebral", "ORGAN", 9, 17], ["oxygen", "SIMPLE_CHEMICAL", 18, 24], ["Baseline cerebral oxygen in intervention", "TREATMENT", 0, 40], ["cerebral", "ANATOMY", 9, 17], ["oxygen", "OBSERVATION_MODIFIER", 18, 24]]], ["Desaturation below 10% from baseline was found in 8 from19 patients (42.1%) and was the only significant risk factor associated with delirium (p=.008, odd ratio 1.68).", [["delirium", "DISEASE", 133, 141], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["Desaturation", "TEST", 0, 12], ["delirium", "PROBLEM", 133, 141], ["odd ratio", "TEST", 151, 160]]], ["There was no significant different in mechanical ventilator day, ICU length of stay, hospital length of stay and postoperative complication between both groups.", [["postoperative complication", "PROBLEM", 113, 139], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["different", "OBSERVATION_MODIFIER", 25, 34], ["mechanical ventilator", "OBSERVATION", 38, 59]]], ["There was no complication associated with application of the cerebral oximetry probe in the intervention group.P387Conclusions: From this preliminary report can not demonstrated the significant different of intra-operative target cerebral oxygen monitoring by using cerebral oximetry in prevention of delirium.", [["cerebral", "ANATOMY", 61, 69], ["cerebral", "ANATOMY", 230, 238], ["cerebral", "ANATOMY", 266, 274], ["oxygen", "CHEMICAL", 239, 245], ["delirium", "DISEASE", 301, 309], ["oxygen", "CHEMICAL", 239, 245], ["cerebral", "ORGAN", 61, 69], ["cerebral", "ORGAN", 230, 238], ["oxygen", "SIMPLE_CHEMICAL", 239, 245], ["cerebral", "MULTI-TISSUE_STRUCTURE", 266, 274], ["complication", "PROBLEM", 13, 25], ["the cerebral oximetry probe", "TREATMENT", 57, 84], ["intra-operative target cerebral oxygen monitoring", "TREATMENT", 207, 256], ["cerebral oximetry", "TEST", 266, 283], ["delirium", "PROBLEM", 301, 309], ["no", "UNCERTAINTY", 10, 12], ["complication", "OBSERVATION", 13, 25], ["cerebral", "ANATOMY", 61, 69], ["cerebral oxygen", "OBSERVATION", 230, 245], ["delirium", "OBSERVATION", 301, 309]]], ["However the reduction of cerebral oxygen more than 10% from baseline in intervention group showed significantly associated with delirium postoperatively.P390The SET score as a predictor of ICU length of stay and the need for tracheotomy in stroke patients who need mechanical ventilation Introduction: SET score was initially developed as an in-house screening tool based on tracheotomy predictors identified in several retrospective studies.", [["cerebral", "ANATOMY", 25, 33], ["oxygen", "CHEMICAL", 34, 40], ["delirium", "DISEASE", 128, 136], ["stroke", "DISEASE", 240, 246], ["oxygen", "CHEMICAL", 34, 40], ["cerebral", "ORGAN", 25, 33], ["oxygen", "SIMPLE_CHEMICAL", 34, 40], ["P390", "GENE_OR_GENE_PRODUCT", 153, 157], ["SET", "GENE_OR_GENE_PRODUCT", 161, 164], ["patients", "ORGANISM", 247, 255], ["P390", "PROTEIN", 153, 157], ["SET", "PROTEIN", 161, 164], ["patients", "SPECIES", 247, 255], ["cerebral oxygen", "TREATMENT", 25, 40], ["delirium", "PROBLEM", 128, 136], ["tracheotomy", "TREATMENT", 225, 236], ["mechanical ventilation", "TREATMENT", 265, 287], ["tracheotomy predictors", "TREATMENT", 375, 397], ["several retrospective studies", "TEST", 412, 441], ["reduction", "OBSERVATION_MODIFIER", 12, 21], ["cerebral", "OBSERVATION_MODIFIER", 25, 33], ["oxygen", "OBSERVATION_MODIFIER", 34, 40]]], ["It combined the categories of neurological function, neurological lesions, and general organ function/ procedure, and weighed by allocation of certain point values [1] .", [["neurological", "ANATOMY", 30, 42], ["neurological lesions", "ANATOMY", 53, 73], ["organ", "ANATOMY", 87, 92], ["neurological lesions", "DISEASE", 53, 73], ["lesions", "PATHOLOGICAL_FORMATION", 66, 73], ["organ", "ORGAN", 87, 92], ["neurological function", "PROBLEM", 30, 51], ["neurological lesions", "PROBLEM", 53, 73], ["procedure", "TREATMENT", 103, 112], ["lesions", "OBSERVATION", 66, 73]]], ["In our study it was very interesting to us to find a tool to judge application of early tracheotomy, and as we have a good culprit number from stroke cases so we decided to try to apply this score in our ICU after discussion with the inventor of this score.", [["stroke", "DISEASE", 143, 149], ["our study", "TEST", 3, 12], ["early tracheotomy", "TREATMENT", 82, 99], ["tracheotomy", "OBSERVATION", 88, 99]]], ["Methods: 164 stroke patients were prospectively included in the study as they were ventilated or were very little potential for ventilation and assessed by the stroke-related early tracheotomy score (SET score, Table 1 ) within the first 24 h of admission (Table 2) .", [["stroke", "DISEASE", 13, 19], ["stroke", "DISEASE", 160, 166], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["the study", "TEST", 60, 69], ["ventilation", "TREATMENT", 128, 139]]], ["Endpoints were length of stay and ventilation time (VT) after doing early tracheotomy.", [["ventilation time", "TEST", 34, 50], ["early tracheotomy", "TREATMENT", 68, 85], ["tracheotomy", "OBSERVATION", 74, 85]]], ["We examined the correlation of these variables with the SET score using standard analytical methods.P390Results: The SET score with a value cutoff point of 8 had a significant effect on decision of making tracheotomy and hence decreasing ventilation time and length of stay in ICU, which affected outcome (Figs.", [["SET", "GENE_OR_GENE_PRODUCT", 56, 59], ["SET", "GENE_OR_GENE_PRODUCT", 117, 120], ["SET", "PROTEIN", 56, 59], ["SET", "PROTEIN", 117, 120], ["standard analytical methods", "TREATMENT", 72, 99], ["The SET score", "TEST", 113, 126], ["a value cutoff", "TEST", 132, 146], ["tracheotomy", "TREATMENT", 205, 216], ["tracheotomy", "OBSERVATION", 205, 216]]], ["Conclusions: All efforts must be exhausted in neuro intensie care to decrease the secondary changes of brain injury after stroke,early tracheotomy is a good tool to decrease length of stay in ICU and ventilation time in these patients.Inventing a tool to judge these decisions of doing tracheotomy was a challenge.", [["brain", "ANATOMY", 103, 108], ["brain injury", "DISEASE", 103, 115], ["stroke", "DISEASE", 122, 128], ["brain", "ORGAN", 103, 108], ["patients", "ORGANISM", 226, 234], ["patients", "SPECIES", 226, 234], ["neuro intensie care", "TREATMENT", 46, 65], ["brain injury", "PROBLEM", 103, 115], ["stroke", "PROBLEM", 122, 128], ["early tracheotomy", "TREATMENT", 129, 146], ["ventilation", "TREATMENT", 200, 211], ["tracheotomy", "TREATMENT", 286, 297], ["brain", "ANATOMY", 103, 108], ["injury", "OBSERVATION", 109, 115], ["tracheotomy", "OBSERVATION", 135, 146]]], ["SET score proved to be valuable.Further multi center trials are needed.", [["SET", "GENE_OR_GENE_PRODUCT", 0, 3], ["SET", "PROTEIN", 0, 3], ["SET score", "TEST", 0, 9], ["Further multi center trials", "TREATMENT", 32, 59]]], ["Specificity for the cutoff point of SET SCORE.", [["SET", "GENE_OR_GENE_PRODUCT", 36, 39], ["SET", "PROTEIN", 36, 39], ["Specificity", "TEST", 0, 11]]], ["Cut point of 9 is the best to predict tracheostomy with sensitivity of 85.0% and specificity of 80.4%.", [["tracheostomy", "TREATMENT", 38, 50], ["sensitivity", "TEST", 56, 67], ["specificity", "TEST", 81, 92]]], ["Cut point of 9 is the best to predict early tracheostomy with sensitivity of 86.1% and specificity of 81.5%.", [["early tracheostomy", "TREATMENT", 38, 56], ["sensitivity", "TEST", 62, 73], ["specificity", "TEST", 87, 98], ["tracheostomy", "OBSERVATION", 44, 56]]], ["Since no patients had score 9 so the previous analysis that consider cut-point of 8 should remain the same but just change the number in the text to 9 contraindication for pharmacological VTE prophylaxis (65.4%).", [["VTE", "DISEASE", 188, 191], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["the previous analysis", "TEST", 33, 54], ["cut-point", "TEST", 69, 78], ["pharmacological VTE prophylaxis", "TREATMENT", 172, 203]]], ["Overall, NCC patients were more likely to receive mechanical (90.3% ICU days) than pharmacological VTE prophylaxis (74.1% ICU days), however pharmacologic was more likely among younger patients with lower APACHE II scores.", [["VTE", "DISEASE", 99, 102], ["patients", "ORGANISM", 13, 21], ["patients", "ORGANISM", 185, 193], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 185, 193], ["pharmacological VTE prophylaxis", "TREATMENT", 83, 114], ["lower APACHE II scores", "PROBLEM", 199, 221]]], ["Guideline concordant care varied by recommendation; lower for pharmacological and higher for mechanical VTE prophylaxis.P391Conclusions: NCC patients uncommonly receive guideline concordant pharmacological VTE prophylaxis.", [["VTE", "DISEASE", 104, 107], ["VTE", "DISEASE", 206, 209], ["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 141, 149], ["pharmacological", "TREATMENT", 62, 77], ["mechanical VTE prophylaxis", "TREATMENT", 93, 119], ["guideline", "TREATMENT", 169, 178], ["pharmacological VTE prophylaxis", "TREATMENT", 190, 221], ["pharmacological VTE", "OBSERVATION", 190, 209]]], ["Collectively, our findings suggest that current VTE prophylaxis prescribing practices may reflect uncertainty around risks associated with VTE prophylaxis among NCC patients.", [["VTE", "DISEASE", 48, 51], ["VTE", "DISEASE", 139, 142], ["patients", "ORGANISM", 165, 173], ["patients", "SPECIES", 165, 173], ["current VTE prophylaxis", "TREATMENT", 40, 63], ["VTE prophylaxis", "TREATMENT", 139, 154]]], ["Methods: We retrospectively analysed prospectively collected data from 134 consecutive ICH patients that received DVT prophylaxis in a tertiary hospital.", [["ICH", "DISEASE", 87, 90], ["DVT", "CHEMICAL", 114, 117], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["DVT prophylaxis", "TREATMENT", 114, 129], ["DVT", "OBSERVATION", 114, 117]]], ["HE was defined as an increase of >6mL measured using the ABC/2 method or the semiautomatic software based volumetric approach.", [["the ABC/2 method", "TREATMENT", 53, 69], ["the semiautomatic software based volumetric approach", "TREATMENT", 73, 125], ["increase", "OBSERVATION_MODIFIER", 21, 29]]], ["Using multivariate analysis, we analysed risk factors including early DVT prophylaxis for HE>24h, hospital mortality and poor 3-month functional outcome (3m modified Rankin Score>3).P391Results: Patients presented with a median GCS of 14 (IQR 10-15), hematoma volume of 11mL (IQR 5-24) and were 71y old (IQR 61-76).", [["hematoma", "ANATOMY", 251, 259], ["DVT", "DISEASE", 70, 73], ["HE", "DISEASE", 90, 92], ["hematoma", "DISEASE", 251, 259], ["Patients", "ORGANISM", 195, 203], ["hematoma", "PATHOLOGICAL_FORMATION", 251, 259], ["Patients", "SPECIES", 195, 203], ["multivariate analysis", "TEST", 6, 27], ["early DVT prophylaxis", "TREATMENT", 64, 85], ["Rankin Score", "TEST", 166, 178], ["a median GCS", "TEST", 219, 231], ["IQR", "TEST", 239, 242], ["hematoma volume", "TEST", 251, 266], ["IQR", "TEST", 276, 279], ["IQR", "TEST", 304, 307], ["DVT", "OBSERVATION", 70, 73], ["hematoma", "OBSERVATION", 251, 259]]], ["56% received early DVT prophylaxis, 37% late DVT prophylaxis and 6% had unclear bleeding onset.", [["DVT", "DISEASE", 19, 22], ["DVT", "DISEASE", 45, 48], ["bleeding", "DISEASE", 80, 88], ["early DVT prophylaxis", "TREATMENT", 13, 34], ["late DVT prophylaxis", "TREATMENT", 40, 60], ["unclear bleeding onset", "PROBLEM", 72, 94], ["DVT", "OBSERVATION", 19, 22], ["bleeding", "OBSERVATION", 80, 88]]], ["Hematoma volume was smaller in the early DVT prophylaxis group with 9.5mL (IQR 4-18.5) vs 17.5mL (IQR 8-29) in the late prophylaxis group (p=0.038) without any other significant differences in disease severity.", [["Hematoma", "ANATOMY", 0, 8], ["DVT", "ANATOMY", 41, 44], ["Hematoma", "DISEASE", 0, 8], ["DVT", "DISEASE", 41, 44], ["Hematoma", "CANCER", 0, 8], ["Hematoma volume", "PROBLEM", 0, 15], ["the early DVT prophylaxis", "TREATMENT", 31, 56], ["IQR", "TEST", 75, 78], ["IQR", "TEST", 98, 101], ["any other significant differences in disease severity", "PROBLEM", 156, 209], ["volume", "OBSERVATION", 9, 15], ["smaller", "OBSERVATION_MODIFIER", 20, 27], ["early", "OBSERVATION_MODIFIER", 35, 40], ["DVT", "OBSERVATION", 41, 44], ["significant", "OBSERVATION_MODIFIER", 166, 177], ["differences", "OBSERVATION", 178, 189], ["disease", "OBSERVATION", 193, 200]]], ["Delayed HE (N=5/134, 3.7%) was associated with higher initial hematoma volume (p=0.02) and lower thrombocyte count (p=0.03) but not with early DVT prophylaxis (p=0.36) in a multivariate analysis adjusted for known risk factors.", [["hematoma", "ANATOMY", 62, 70], ["thrombocyte", "ANATOMY", 97, 108], ["HE", "DISEASE", 8, 10], ["hematoma", "DISEASE", 62, 70], ["DVT", "DISEASE", 143, 146], ["hematoma", "PATHOLOGICAL_FORMATION", 62, 70], ["thrombocyte", "CELL", 97, 108], ["higher initial hematoma volume", "PROBLEM", 47, 77], ["lower thrombocyte count", "TEST", 91, 114], ["early DVT prophylaxis", "TREATMENT", 137, 158], ["a multivariate analysis", "TEST", 171, 194], ["known risk factors", "PROBLEM", 208, 226], ["hematoma", "OBSERVATION", 62, 70], ["lower", "ANATOMY", 91, 96], ["thrombocyte count", "OBSERVATION", 97, 114], ["DVT", "OBSERVATION", 143, 146]]], ["Early DVT prophylaxis was not independently associated with 3m outcome.", [["DVT", "DISEASE", 6, 9], ["Early DVT prophylaxis", "TREATMENT", 0, 21], ["DVT", "OBSERVATION", 6, 9]]], ["Conclusions: Although limited by the retrospective design, our data suggest that early DVT prophylaxis (<48h) may be safe in patients presenting with primary ICH, which supports the recommendations given by the Neurocritical Care Society.", [["DVT", "DISEASE", 87, 90], ["ICH", "DISEASE", 158, 161], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["our data", "TEST", 59, 67], ["early DVT prophylaxis", "TREATMENT", 81, 102], ["primary ICH", "PROBLEM", 150, 161], ["early", "OBSERVATION_MODIFIER", 81, 86], ["DVT", "OBSERVATION", 87, 90]]], ["Introduction: There is a paucity of literature describing the relationship between clevidipine and its impact on intracranial pressure (ICP).", [["intracranial", "ANATOMY", 113, 125], ["clevidipine", "CHEMICAL", 83, 94], ["clevidipine", "CHEMICAL", 83, 94], ["clevidipine", "SIMPLE_CHEMICAL", 83, 94], ["intracranial", "ORGANISM_SUBDIVISION", 113, 125], ["clevidipine", "TREATMENT", 83, 94], ["intracranial pressure", "TEST", 113, 134]]], ["The safety of clevidipine in patients with intracranial hemorrhage is often extrapolated from studies using nicardipine, which has demonstrated a neutral effect on ICP [1] .", [["intracranial", "ANATOMY", 43, 55], ["clevidipine", "CHEMICAL", 14, 25], ["intracranial hemorrhage", "DISEASE", 43, 66], ["nicardipine", "CHEMICAL", 108, 119], ["clevidipine", "CHEMICAL", 14, 25], ["nicardipine", "CHEMICAL", 108, 119], ["clevidipine", "SIMPLE_CHEMICAL", 14, 25], ["patients", "ORGANISM", 29, 37], ["nicardipine", "SIMPLE_CHEMICAL", 108, 119], ["patients", "SPECIES", 29, 37], ["clevidipine", "TREATMENT", 14, 25], ["intracranial hemorrhage", "PROBLEM", 43, 66], ["nicardipine", "TREATMENT", 108, 119], ["a neutral effect on ICP", "PROBLEM", 144, 167], ["intracranial", "ANATOMY", 43, 55], ["hemorrhage", "OBSERVATION", 56, 66]]], ["The objective of this study was to determine if there was a relationship between clevidipine initiation and changes to cerebral hemodynamic parameters.P391Methods: This study was a retrospective analysis of adults admitted to Hennepin County Medical Center between July 2012 and July 2017.", [["cerebral", "ANATOMY", 119, 127], ["clevidipine", "CHEMICAL", 81, 92], ["clevidipine", "CHEMICAL", 81, 92], ["clevidipine", "SIMPLE_CHEMICAL", 81, 92], ["cerebral", "ORGAN", 119, 127], ["adults", "ORGANISM", 207, 213], ["this study", "TEST", 17, 27], ["clevidipine initiation", "TREATMENT", 81, 103], ["cerebral hemodynamic parameters", "TEST", 119, 150]]], ["Individuals were included if they had intracranial bleeding and ICP data recorded prior to initiation of a clevidipine infusion.", [["intracranial", "ANATOMY", 38, 50], ["intracranial bleeding", "DISEASE", 38, 59], ["clevidipine", "CHEMICAL", 107, 118], ["clevidipine", "CHEMICAL", 107, 118], ["clevidipine", "SIMPLE_CHEMICAL", 107, 118], ["intracranial bleeding", "PROBLEM", 38, 59], ["ICP data", "TEST", 64, 72], ["a clevidipine infusion", "TREATMENT", 105, 127], ["bleeding", "OBSERVATION", 51, 59]]], ["Baseline demographic data was collected, including age, gender, type of injury, and initial Glasgow Coma Score (GCS Introduction: Aneurysmal subarachnoid hemorrhage (SAH) is an acute cerebrovascular event with high mortality and is an important cause of neurologic disability among survivors.", [["cerebrovascular", "ANATOMY", 183, 198], ["neurologic", "ANATOMY", 254, 264], ["Coma", "DISEASE", 100, 104], ["Aneurysmal subarachnoid hemorrhage", "DISEASE", 130, 164], ["SAH", "DISEASE", 166, 169], ["neurologic disability", "DISEASE", 254, 275], ["Baseline demographic data", "TEST", 0, 25], ["injury", "PROBLEM", 72, 78], ["initial Glasgow Coma Score", "TEST", 84, 110], ["Aneurysmal subarachnoid hemorrhage", "PROBLEM", 130, 164], ["SAH", "PROBLEM", 166, 169], ["an acute cerebrovascular event", "PROBLEM", 174, 204], ["high mortality", "PROBLEM", 210, 224], ["neurologic disability", "PROBLEM", 254, 275], ["injury", "OBSERVATION", 72, 78], ["Aneurysmal", "OBSERVATION_MODIFIER", 130, 140], ["subarachnoid", "ANATOMY", 141, 153], ["hemorrhage", "OBSERVATION", 154, 164], ["acute", "OBSERVATION_MODIFIER", 177, 182], ["cerebrovascular", "OBSERVATION", 183, 198], ["high mortality", "OBSERVATION", 210, 224]]], ["Many complications in the course of SAH, such as hydrocephalus, also play a role in the poor outcome.", [["SAH", "DISEASE", 36, 39], ["hydrocephalus", "DISEASE", 49, 62], ["Many complications", "PROBLEM", 0, 18], ["SAH", "PROBLEM", 36, 39], ["hydrocephalus", "PROBLEM", 49, 62], ["complications", "OBSERVATION", 5, 18], ["SAH", "OBSERVATION", 36, 39], ["hydrocephalus", "OBSERVATION", 49, 62]]], ["The aim of the study was to describe the characteristics of patients with SAH admitted to the ICU to evaluate the factors associated with outcome.", [["SAH", "DISEASE", 74, 77], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["the study", "TEST", 11, 20], ["SAH", "PROBLEM", 74, 77]]], ["Methods: This study was conducted in two reference centersone in Rio de Janeiro and one in Porto Alegre.", [["This study", "TEST", 9, 19]]], ["From July 2015 to September 2017, every adult patient admitted to the ICU with aneurysmal SAH was enrolled in the study.", [["aneurysmal SAH", "DISEASE", 79, 93], ["patient", "ORGANISM", 46, 53], ["patient", "SPECIES", 46, 53], ["aneurysmal SAH", "PROBLEM", 79, 93], ["the study", "TEST", 110, 119], ["aneurysmal", "OBSERVATION_MODIFIER", 79, 89], ["SAH", "OBSERVATION", 90, 93]]], ["Dichotomous variables were analyzed using two-tailed Fisher's exact test.", [["Dichotomous variables", "TEST", 0, 21], ["Fisher's exact test", "TEST", 53, 72]]], ["Results: A total of 261 patients were included.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32]]], ["Frequency of clinical and neurological complications are presented in Table 2 .", [["neurological", "ANATOMY", 26, 38], ["clinical and neurological complications", "PROBLEM", 13, 52]]], ["In univariate analysis, factors most frequently seen in patients with unfavorable outcome were seizure (17% vs 3%, p=0.0003), hydrocephalus (51% vs 17%, p<0.0001), meningitis (30% vs 12%, p=0.0004), rebleeding (17% vs 4%, p= 0.0008), vasospasm (46% vs 26%, p=0.001), pneumonia (37% vs 7%, p<0.0001), sepsis/septic shock (21% vs 4%, p<0.0001), postsurgical neurological deterioration (37% vs 18%, p=0.001) and delayed cerebral ischemia (37% vs 12%, p<0.0001).", [["neurological", "ANATOMY", 356, 368], ["cerebral", "ANATOMY", 417, 425], ["seizure", "DISEASE", 95, 102], ["hydrocephalus", "DISEASE", 126, 139], ["meningitis", "DISEASE", 164, 174], ["rebleeding", "DISEASE", 199, 209], ["vasospasm", "DISEASE", 234, 243], ["pneumonia", "DISEASE", 267, 276], ["sepsis", "DISEASE", 300, 306], ["septic shock", "DISEASE", 307, 319], ["neurological deterioration", "DISEASE", 356, 382], ["cerebral ischemia", "DISEASE", 417, 434], ["patients", "ORGANISM", 56, 64], ["cerebral", "ORGAN", 417, 425], ["patients", "SPECIES", 56, 64], ["univariate analysis", "TEST", 3, 22], ["seizure", "PROBLEM", 95, 102], ["p", "TEST", 115, 116], ["hydrocephalus", "PROBLEM", 126, 139], ["p", "TEST", 153, 154], ["meningitis", "PROBLEM", 164, 174], ["p", "TEST", 188, 189], ["rebleeding", "PROBLEM", 199, 209], ["p", "TEST", 222, 223], ["vasospasm", "PROBLEM", 234, 243], ["p", "TEST", 257, 258], ["pneumonia", "PROBLEM", 267, 276], ["p", "TEST", 289, 290], ["sepsis", "PROBLEM", 300, 306], ["septic shock", "PROBLEM", 307, 319], ["p", "TEST", 332, 333], ["postsurgical neurological deterioration", "PROBLEM", 343, 382], ["vs", "TEST", 388, 390], ["p", "TEST", 396, 397], ["delayed cerebral ischemia", "PROBLEM", 409, 434], ["p", "TEST", 448, 449], ["hydrocephalus", "OBSERVATION", 126, 139], ["meningitis", "OBSERVATION", 164, 174], ["rebleeding", "OBSERVATION", 199, 209], ["vasospasm", "OBSERVATION", 234, 243], ["pneumonia", "OBSERVATION", 267, 276], ["sepsis", "OBSERVATION", 300, 306], ["septic shock", "OBSERVATION", 307, 319], ["cerebral", "ANATOMY", 417, 425], ["ischemia", "OBSERVATION", 426, 434]]], ["At 12 months, out of 74 patients with follow-up, 40% had poor outcome.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32]]], ["Conclusions: SAH is associated with high morbidity.", [["SAH", "DISEASE", 13, 16], ["SAH", "PROBLEM", 13, 16], ["high morbidity", "PROBLEM", 36, 50], ["SAH", "OBSERVATION", 13, 16], ["high", "OBSERVATION_MODIFIER", 36, 40], ["morbidity", "OBSERVATION", 41, 50]]], ["Both neurological complications as clinical complications were associated with unfavorable outcomes.", [["neurological", "ANATOMY", 5, 17], ["neurological complications", "DISEASE", 5, 31], ["Both neurological complications", "PROBLEM", 0, 31], ["clinical complications", "PROBLEM", 35, 57], ["neurological", "OBSERVATION_MODIFIER", 5, 17], ["complications", "OBSERVATION", 18, 31]]], ["Therapeutic interventions to prevent those may have an impact on clinical outcomes.", [["Therapeutic interventions", "TREATMENT", 0, 25]]], ["Introduction: Brain tissue hypoxia (brain tissue oxygen tension, PbtO2<20mmHg) is common after subarachnoid hemorrhage (SAH) and associated with poor outcome.", [["Brain tissue", "ANATOMY", 14, 26], ["brain tissue", "ANATOMY", 36, 48], ["subarachnoid", "ANATOMY", 95, 107], ["hypoxia", "DISEASE", 27, 34], ["oxygen", "CHEMICAL", 49, 55], ["subarachnoid hemorrhage", "DISEASE", 95, 118], ["SAH", "DISEASE", 120, 123], ["oxygen", "CHEMICAL", 49, 55], ["Brain tissue", "TISSUE", 14, 26], ["brain tissue", "TISSUE", 36, 48], ["oxygen", "SIMPLE_CHEMICAL", 49, 55], ["Brain tissue hypoxia", "PROBLEM", 14, 34], ["brain tissue oxygen tension", "TREATMENT", 36, 63], ["PbtO2", "TEST", 65, 70], ["subarachnoid hemorrhage", "PROBLEM", 95, 118], ["SAH", "PROBLEM", 120, 123], ["Brain tissue", "ANATOMY", 14, 26], ["hypoxia", "OBSERVATION", 27, 34], ["oxygen tension", "OBSERVATION", 49, 63], ["subarachnoid", "ANATOMY", 95, 107], ["hemorrhage", "OBSERVATION", 108, 118]]], ["Recent data suggest that brain oxygen optimization is feasible and may reduce the time with brain tissue hypoxia to 15% in patients with severe traumatic brain injury [1] .", [["brain", "ANATOMY", 25, 30], ["brain tissue", "ANATOMY", 92, 104], ["brain", "ANATOMY", 154, 159], ["oxygen", "CHEMICAL", 31, 37], ["hypoxia", "DISEASE", 105, 112], ["traumatic brain injury", "DISEASE", 144, 166], ["oxygen", "CHEMICAL", 31, 37], ["brain", "ORGAN", 25, 30], ["oxygen", "SIMPLE_CHEMICAL", 31, 37], ["brain tissue", "TISSUE", 92, 104], ["patients", "ORGANISM", 123, 131], ["brain", "ORGAN", 154, 159], ["patients", "SPECIES", 123, 131], ["Recent data", "TEST", 0, 11], ["brain oxygen optimization", "TREATMENT", 25, 50], ["brain tissue hypoxia", "PROBLEM", 92, 112], ["severe traumatic brain injury", "PROBLEM", 137, 166], ["severe", "OBSERVATION_MODIFIER", 137, 143], ["traumatic", "OBSERVATION_MODIFIER", 144, 153], ["brain", "ANATOMY", 154, 159], ["injury", "OBSERVATION", 160, 166]]], ["Little is known about the effectiveness of protocolized treatment approaches in poor-grade SAH patients.", [["SAH", "DISEASE", 91, 94], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["protocolized treatment approaches", "TREATMENT", 43, 76], ["poor-grade SAH patients", "PROBLEM", 80, 103]]], ["Methods: We present a retrospective analysis of prospectively collected data of 105 poor-grade SAH patients admitted to 2 tertiary care centers where PbtO2<20mmHg was treated using an institutional protocol.", [["SAH", "DISEASE", 95, 98], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["a retrospective analysis", "TEST", 20, 44], ["prospectively collected data", "TEST", 48, 76], ["poor-grade SAH", "PROBLEM", 84, 98], ["PbtO2", "TEST", 150, 155], ["an institutional protocol", "TREATMENT", 181, 206], ["SAH", "OBSERVATION", 95, 98]]], ["Treatment options were left to the discretion of the treating neuro-intensivists including augmentation of cerebral perfusion pressure (CPP) using vasopressors if necessary, treatment of anemia and targeting normocapnia, euvolemia and normothermia.", [["cerebral", "ANATOMY", 107, 115], ["anemia", "DISEASE", 187, 193], ["euvolemia", "DISEASE", 221, 230], ["cerebral", "ORGAN", 107, 115], ["Treatment options", "TREATMENT", 0, 17], ["the treating neuro-intensivists", "TREATMENT", 49, 80], ["augmentation of cerebral perfusion pressure", "TREATMENT", 91, 134], ["vasopressors", "TREATMENT", 147, 159], ["anemia", "PROBLEM", 187, 193], ["targeting normocapnia", "PROBLEM", 198, 219], ["euvolemia", "PROBLEM", 221, 230], ["normothermia", "PROBLEM", 235, 247], ["cerebral perfusion", "ANATOMY", 107, 125], ["anemia", "OBSERVATION", 187, 193]]], ["The dataset used for analysis was based on routine blood gas analysis for hemoglobin data matched to 2 hourly averaged data of continuous CPP, PbtO2, temperature and cerebral microdialysis (CMD) samples over the first 10 days of admission.", [["blood", "ANATOMY", 51, 56], ["cerebral", "ANATOMY", 166, 174], ["PbtO2", "CHEMICAL", 143, 148], ["blood", "ORGANISM_SUBSTANCE", 51, 56], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 74, 84], ["PbtO2", "SIMPLE_CHEMICAL", 143, 148], ["hemoglobin", "PROTEIN", 74, 84], ["analysis", "TEST", 21, 29], ["routine blood gas analysis", "TEST", 43, 69], ["hemoglobin data", "TEST", 74, 89], ["continuous CPP", "TEST", 127, 141], ["PbtO2", "TEST", 143, 148], ["cerebral microdialysis (CMD) samples", "PROBLEM", 166, 202], ["cerebral", "ANATOMY", 166, 174]]], ["Results: Patients were admitted with a GCS of 3 (IQR 3-4) and were 58 (IQR 48-66) years old.", [["GCS", "DISEASE", 39, 42], ["Patients", "ORGANISM", 9, 17], ["Patients", "SPECIES", 9, 17], ["a GCS", "TEST", 37, 42], ["IQR", "TEST", 49, 52], ["IQR", "TEST", 71, 74]]], ["Overall incidence of brain tissue hypoxia was 25%.", [["brain tissue", "ANATOMY", 21, 33], ["hypoxia", "DISEASE", 34, 41], ["brain tissue", "MULTI-TISSUE_STRUCTURE", 21, 33], ["brain tissue hypoxia", "PROBLEM", 21, 41], ["brain tissue", "ANATOMY", 21, 33], ["hypoxia", "OBSERVATION", 34, 41]]], ["During this time we identified associated episodes of CPP<70mmHg (27%), hyperglycolysis (CMD-lacta-te>4mmol/L, CMD-pyruvate>120\u03bcmol/L; 26%), pCO2<35mmHg (19%), metabolic distress (CMD-lactate-to-pyruvate-ratio>40; 18%), PaO2<80mmHg (14%), Hb<9g/dL (10%), and temperature>38.3\u00b0C (4%) (Fig. 1 ).", [["hyperglycolysis", "DISEASE", 72, 87], ["CMD", "DISEASE", 89, 92], ["pyruvate", "CHEMICAL", 115, 123], ["metabolic distress", "DISEASE", 160, 178], ["lactate", "CHEMICAL", 184, 191], ["pyruvate", "CHEMICAL", 195, 203], ["pyruvate", "CHEMICAL", 115, 123], ["lactate", "CHEMICAL", 184, 191], ["pyruvate", "CHEMICAL", 195, 203], ["pyruvate", "SIMPLE_CHEMICAL", 115, 123], ["lactate", "SIMPLE_CHEMICAL", 184, 191], ["pyruvate", "SIMPLE_CHEMICAL", 195, 203], ["CPP", "TEST", 54, 57], ["hyperglycolysis", "TEST", 72, 87], ["CMD", "TEST", 89, 92], ["lacta", "TEST", 93, 98], ["te", "TEST", 99, 101], ["CMD", "TEST", 111, 114], ["pyruvate", "TEST", 115, 123], ["pCO2", "TEST", 141, 145], ["metabolic distress", "PROBLEM", 160, 178], ["CMD", "TEST", 180, 183], ["lactate", "TEST", 184, 191], ["pyruvate", "TEST", 195, 203], ["ratio", "TEST", 204, 209], ["PaO2", "TEST", 220, 224], ["Hb", "TEST", 239, 241], ["temperature", "TEST", 259, 270], ["\u00b0C", "TEST", 275, 277], ["metabolic distress", "OBSERVATION", 160, 178]]], ["Of these variables only hyperglycolysis was significantly more common (37%) during episodes of normal PbtO2 (75% of episodes).", [["hyperglycolysis", "DISEASE", 24, 39], ["episodes", "PROBLEM", 116, 124], ["normal", "OBSERVATION", 95, 101]]], ["Conclusions: Underutilization of IVT despite the overwhelming evidence that support the effectiveness of such therapy can be partly attributed to the fear of hemorrhagic complications.", [["hemorrhagic", "DISEASE", 158, 169], ["IVT", "TREATMENT", 33, 36], ["such therapy", "TREATMENT", 105, 117], ["hemorrhagic complications", "PROBLEM", 158, 183], ["hemorrhagic", "OBSERVATION_MODIFIER", 158, 169], ["complications", "OBSERVATION", 170, 183]]], ["The estrangement of the emergency medicine community regarding IVT and the domination of stroke experts in decision making is also a barrier.P402Regional wall motion abnormalities and reduced global longitudinal strain is common in patients with subarachnoid hemorrhage and associated with markedly elevated troponin K Dalla Sahlgrenska University Hospital, Gothenburg, Sweden Critical Care 2018, 22(Suppl 1):P402P402Introduction: Stress-induced cardiomyopathy after subarachnoid hemorrhage (SAH) is a life-threating condition associated with poor outcome.", [["wall", "ANATOMY", 154, 158], ["subarachnoid", "ANATOMY", 246, 258], ["subarachnoid", "ANATOMY", 467, 479], ["stroke", "DISEASE", 89, 95], ["reduced global longitudinal strain", "DISEASE", 184, 218], ["subarachnoid hemorrhage", "DISEASE", 246, 269], ["K", "CHEMICAL", 317, 318], ["cardiomyopathy", "DISEASE", 446, 460], ["subarachnoid hemorrhage", "DISEASE", 467, 490], ["SAH", "DISEASE", 492, 495], ["patients", "ORGANISM", 232, 240], ["patients", "SPECIES", 232, 240], ["IVT", "TREATMENT", 63, 66], ["stroke", "PROBLEM", 89, 95], ["P402Regional wall motion abnormalities", "PROBLEM", 141, 179], ["reduced global longitudinal strain", "PROBLEM", 184, 218], ["subarachnoid hemorrhage", "PROBLEM", 246, 269], ["markedly elevated troponin", "PROBLEM", 290, 316], ["Stress-induced cardiomyopathy", "PROBLEM", 431, 460], ["subarachnoid hemorrhage", "PROBLEM", 467, 490], ["SAH", "PROBLEM", 492, 495], ["poor outcome", "PROBLEM", 543, 555], ["stroke", "OBSERVATION", 89, 95], ["wall", "ANATOMY_MODIFIER", 154, 158], ["motion abnormalities", "OBSERVATION", 159, 179], ["reduced", "OBSERVATION_MODIFIER", 184, 191], ["global", "OBSERVATION_MODIFIER", 192, 198], ["longitudinal strain", "OBSERVATION", 199, 218], ["subarachnoid", "ANATOMY", 246, 258], ["hemorrhage", "OBSERVATION", 259, 269], ["subarachnoid", "ANATOMY", 467, 479], ["hemorrhage", "OBSERVATION", 480, 490]]], ["Regional wall motion abnormalities (RWMA) is a frequent finding, however, assessment of RWMA is known to be difficult.", [["wall", "ANATOMY", 9, 13], ["wall motion abnormalities", "DISEASE", 9, 34], ["RWMA", "DISEASE", 36, 40], ["RWMA", "DISEASE", 88, 92], ["wall", "MULTI-TISSUE_STRUCTURE", 9, 13], ["Regional wall motion abnormalities", "PROBLEM", 0, 34], ["assessment of RWMA", "TEST", 74, 92], ["wall", "ANATOMY_MODIFIER", 9, 13], ["motion abnormalities", "OBSERVATION", 14, 34]]], ["In the present study we hypothesized that global and regional longitudinal strain (GLS and RLS) assessed with speckle tracking echocardiography can detect myocardial dysfunction indicated by increased levels of the cardiac biomarker troponin (TnT).P402Methods: This prospective study comprised 71 patients with SAH.", [["myocardial", "ANATOMY", 155, 165], ["cardiac", "ANATOMY", 215, 222], ["RLS", "DISEASE", 91, 94], ["myocardial dysfunction", "DISEASE", 155, 177], ["SAH", "DISEASE", 311, 314], ["myocardial", "MULTI-TISSUE_STRUCTURE", 155, 165], ["cardiac", "ORGAN", 215, 222], ["troponin", "GENE_OR_GENE_PRODUCT", 233, 241], ["TnT", "GENE_OR_GENE_PRODUCT", 243, 246], ["patients", "ORGANISM", 297, 305], ["troponin", "PROTEIN", 233, 241], ["TnT", "PROTEIN", 243, 246], ["patients", "SPECIES", 297, 305], ["the present study", "TEST", 3, 20], ["global and regional longitudinal strain (GLS and RLS)", "PROBLEM", 42, 95], ["speckle tracking echocardiography", "TEST", 110, 143], ["myocardial dysfunction", "PROBLEM", 155, 177], ["increased levels", "PROBLEM", 191, 207], ["the cardiac biomarker troponin", "TEST", 211, 241], ["This prospective study", "TEST", 261, 283], ["SAH", "PROBLEM", 311, 314], ["global", "OBSERVATION_MODIFIER", 42, 48], ["cardiac", "ANATOMY", 215, 222], ["SAH", "OBSERVATION", 311, 314]]], ["The TnT was followed daily from the admission up to 3 days postadmission and elevated TnT was defined as > 80 ng/l.", [["TnT", "GENE_OR_GENE_PRODUCT", 4, 7], ["TnT", "GENE_OR_GENE_PRODUCT", 86, 89], ["TnT", "PROTEIN", 4, 7], ["TnT", "PROTEIN", 86, 89], ["The TnT", "TEST", 0, 7], ["elevated TnT", "PROBLEM", 77, 89]]], ["A transthoracic echocardiography examination was performed within 48 hours after the hospitalization.", [["A transthoracic echocardiography examination", "TEST", 0, 44]]], ["The peak GLS was determined using the three apical projections and presented as the mean of the 18 segments.", [["The peak GLS", "TEST", 0, 12], ["18 segments", "ANATOMY_MODIFIER", 96, 107]]], ["Reduced GLS was defined as > -15% and reduced RLS was considered present when segmental strain was > -15% in > 2 adjacent segments.", [["RLS", "DISEASE", 46, 49], ["Reduced GLS", "TEST", 0, 11], ["reduced RLS", "PROBLEM", 38, 49], ["segmental strain", "PROBLEM", 78, 94], ["segments", "ANATOMY_MODIFIER", 122, 130]]], ["Introduction: Deviations from strict eligibility criteria for intravenous thrombolysis (IVT) in ischemic strokes regarding either license contraindications to alteplase or relative contraindications to thrombolysis have been reported in international literature, with conflicting results on patients' outcome.The aim of our study was to evaluate safety and efficacy for patients receiving IVT outside standard inclusion criteria.", [["intravenous", "ANATOMY", 62, 73], ["ischemic strokes", "DISEASE", 96, 112], ["alteplase", "CHEMICAL", 159, 168], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 62, 73], ["patients", "ORGANISM", 291, 299], ["patients", "ORGANISM", 370, 378], ["patients", "SPECIES", 291, 299], ["patients", "SPECIES", 370, 378], ["intravenous thrombolysis", "TREATMENT", 62, 86], ["IVT)", "TREATMENT", 88, 92], ["ischemic strokes", "PROBLEM", 96, 112], ["alteplase", "TREATMENT", 159, 168], ["thrombolysis", "TREATMENT", 202, 214], ["our study", "TEST", 320, 329], ["ischemic", "OBSERVATION_MODIFIER", 96, 104], ["strokes", "OBSERVATION", 105, 112]]], ["Methods: Retrospective analysis of our department's thrombolysis database.We compared 83 patients with strict protocol adherence (strict protocol group) [mean age 63 years and National Institutes of Health Stroke Scale (NIHSS) at admission 12/range 5-28] and 41 patients with protocol deviations (off-label group) [mean age 68 years and NIHSS at admission 10/range 2-24],in particular 10 patients >80 years old, 13 patients with mild stroke-NIHSS< 5,and 22 with symptom-to-needle time 3-4.5 hours (4 patients had 2 deviations).", [["Stroke", "DISEASE", 206, 212], ["stroke", "DISEASE", 434, 440], ["patients", "ORGANISM", 89, 97], ["patients", "ORGANISM", 262, 270], ["patients", "ORGANISM", 388, 396], ["patients", "ORGANISM", 415, 423], ["patients", "ORGANISM", 500, 508], ["patients", "SPECIES", 89, 97], ["patients", "SPECIES", 262, 270], ["patients", "SPECIES", 388, 396], ["patients", "SPECIES", 415, 423], ["patients", "SPECIES", 500, 508], ["thrombolysis database", "TEST", 52, 73], ["strict protocol adherence", "TREATMENT", 103, 128], ["NIHSS", "TEST", 220, 225], ["NIHSS", "TEST", 337, 342], ["mild stroke", "PROBLEM", 429, 440], ["NIHSS", "TEST", 441, 446], ["symptom", "TEST", 462, 469], ["mild", "OBSERVATION_MODIFIER", 429, 433], ["stroke", "OBSERVATION", 434, 440]]], ["Results: Patients in the off-label group were older but had no difference in baseline severity scores (SAPSII, NIHSS).", [["Patients", "ORGANISM", 9, 17], ["Patients", "SPECIES", 9, 17], ["baseline severity scores", "PROBLEM", 77, 101]]], ["They had no statistically significant difference on short-term (NIHSS at 7 days, need for critical care support, primary adverse event) and long-term (mortality,functional outcome at 3 months) outcome measures when compared to standard protocol patients.", [["patients", "ORGANISM", 245, 253], ["patients", "SPECIES", 245, 253], ["critical care support", "TREATMENT", 90, 111], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["difference", "OBSERVATION", 38, 48]]], ["Conclusions: In accordance with international literature,off-label thrombolysis is save and equally effective to standard protocol thrombolysis.Thrombolysis strict protocol needs expansion of inclusion criteria.", [["label thrombolysis", "TREATMENT", 61, 79], ["standard protocol thrombolysis", "TREATMENT", 113, 143], ["Thrombolysis strict protocol", "TREATMENT", 144, 172], ["expansion of inclusion criteria", "TEST", 179, 210]]], ["Introduction: Most scales (GCS,NIHSS) don't consider the pathway of secondary acute brain failure (sABF).", [["brain", "ANATOMY", 84, 89], ["acute brain failure", "DISEASE", 78, 97], ["brain", "ORGAN", 84, 89], ["GCS", "TEST", 27, 30], ["secondary acute brain failure", "PROBLEM", 68, 97], ["acute", "OBSERVATION_MODIFIER", 78, 83], ["brain", "ANATOMY", 84, 89], ["failure", "OBSERVATION", 90, 97]]], ["Neuron-specific-enolase (NSE) could be usefull in diagnostic and treatment pts. with sABF [1, 2] .", [["Neuron-specific-enolase", "GENE_OR_GENE_PRODUCT", 0, 23], ["NSE", "GENE_OR_GENE_PRODUCT", 25, 28], ["Neuron-specific-enolase", "PROTEIN", 0, 23], ["NSE", "PROTEIN", 25, 28]]], ["Methods: Prospective study incl.", [["Prospective study", "TEST", 9, 26]]], ["35 pts. with ABF.", [["ABF", "PROTEIN", 13, 16]]], ["In main group, NSE examed and choline alfoscerate was used, pts. was divided into 2 subgroups Ia (n=12) with acute ischemic stroke(AIS) and Ib (n=10) pts. with posthypoxic encephalopathy.", [["choline", "CHEMICAL", 30, 37], ["acute ischemic stroke", "DISEASE", 109, 130], ["AIS", "DISEASE", 131, 134], ["encephalopathy", "DISEASE", 172, 186], ["choline", "CHEMICAL", 30, 37], ["NSE", "GENE_OR_GENE_PRODUCT", 15, 18], ["choline alfoscerate", "SIMPLE_CHEMICAL", 30, 49], ["NSE", "PROTEIN", 15, 18], ["NSE examed", "TEST", 15, 25], ["choline alfoscerate", "TREATMENT", 30, 49], ["acute ischemic stroke", "PROBLEM", 109, 130], ["AIS", "PROBLEM", 131, 134], ["posthypoxic encephalopathy", "PROBLEM", 160, 186], ["acute", "OBSERVATION_MODIFIER", 109, 114], ["ischemic", "OBSERVATION_MODIFIER", 115, 123], ["stroke", "OBSERVATION", 124, 130], ["posthypoxic encephalopathy", "OBSERVATION", 160, 186]]], ["The control group (n=13) pts. with AIS treated by Loc.Protocol \u2116602.", [["AIS", "DISEASE", 35, 38], ["AIS", "PROBLEM", 35, 38]]], ["Clinical, laboratory, and imaging variables were fully compared.", [["imaging variables", "TEST", 26, 43]]], ["Pts. examed by ABCDE algorithm, GCS and NIHSS.", [["GCS", "TEST", 32, 35], ["NIHSS", "TEST", 40, 45]]], ["Brain CT, Carotid Doppler performed.", [["Brain", "ANATOMY", 0, 5], ["Carotid", "ANATOMY", 10, 17], ["Carotid", "MULTI-TISSUE_STRUCTURE", 10, 17], ["Brain CT", "TEST", 0, 8], ["Carotid Doppler", "TEST", 10, 25], ["Carotid", "ANATOMY", 10, 17]]], ["Considering criteria:NSE(days 1,3,5), neurological status, length of stay in ICU (ICU LOS).", [["neurological", "ANATOMY", 38, 50]]], ["Results: The baseline NSE was higher and correlated to NIHSS (16.3 \u00b12.2, \u00f72=1.08) in all pts.", [["NSE", "GENE_OR_GENE_PRODUCT", 22, 25], ["NSE", "PROTEIN", 22, 25], ["The baseline NSE", "TEST", 9, 25], ["NIHSS", "TEST", 55, 60]]], ["In Ia, Ib sbgroups NSE decreased for 3-5 days vs. control group 10-12days (\u00f72=7.93) and correlated with regression neurological deficit.", [["neurological", "ANATOMY", 115, 127], ["neurological deficit", "DISEASE", 115, 135], ["Ib sbgroups NSE", "GENE_OR_GENE_PRODUCT", 7, 22], ["NSE", "PROTEIN", 19, 22], ["regression neurological deficit", "PROBLEM", 104, 135]]], ["ICU LOS in main group was 3.8\u00b10.9 days vs. control group 5.9\u00b10.9 days.", [["ICU LOS", "TEST", 0, 7], ["LOS", "OBSERVATION_MODIFIER", 4, 7]]], ["Sensitivity and specificity of NSE as a marker of brain injury in pts. with AIS were 65 and 83% and in posthypoxic pts. were 90 and 90%, respectively, which showed NSE as eligible diagnostic criterion of posthypoxic cerebral edema.", [["brain", "ANATOMY", 50, 55], ["cerebral", "ANATOMY", 216, 224], ["brain injury", "DISEASE", 50, 62], ["AIS", "DISEASE", 76, 79], ["cerebral edema", "DISEASE", 216, 230], ["NSE", "GENE_OR_GENE_PRODUCT", 31, 34], ["brain", "ORGAN", 50, 55], ["NSE", "GENE_OR_GENE_PRODUCT", 164, 167], ["cerebral edema", "PATHOLOGICAL_FORMATION", 216, 230], ["NSE", "PROTEIN", 31, 34], ["NSE", "PROTEIN", 164, 167], ["Sensitivity", "TEST", 0, 11], ["brain injury", "PROBLEM", 50, 62], ["AIS", "TEST", 76, 79], ["posthypoxic cerebral edema", "PROBLEM", 204, 230], ["brain", "ANATOMY", 50, 55], ["injury", "OBSERVATION", 56, 62], ["posthypoxic", "OBSERVATION_MODIFIER", 204, 215], ["cerebral", "ANATOMY", 216, 224], ["edema", "OBSERVATION", 225, 230]]], ["In Ia (AIS) pts. and Ib (posthypoxic edema) were confirmed by increasing NSE in 4fold and 9-fold respectively more vs. pts. who had only Brain CT at first day.", [["edema", "ANATOMY", 37, 42], ["edema", "DISEASE", 37, 42], ["edema", "PATHOLOGICAL_FORMATION", 37, 42], ["NSE", "GENE_OR_GENE_PRODUCT", 73, 76], ["NSE", "PROTEIN", 73, 76], ["Ib (posthypoxic edema", "PROBLEM", 21, 42], ["increasing NSE in 4fold", "PROBLEM", 62, 85], ["Brain CT", "TEST", 137, 145], ["posthypoxic", "OBSERVATION_MODIFIER", 25, 36], ["edema", "OBSERVATION", 37, 42], ["increasing", "OBSERVATION_MODIFIER", 62, 72], ["Brain", "ANATOMY", 137, 142]]], ["NSE also correlated with regression neurological deficit and improving of the neurological status.", [["neurological", "ANATOMY", 36, 48], ["neurological", "ANATOMY", 78, 90], ["neurological deficit", "DISEASE", 36, 56], ["NSE", "GENE_OR_GENE_PRODUCT", 0, 3], ["NSE", "PROTEIN", 0, 3], ["regression neurological deficit", "PROBLEM", 25, 56]]], ["In IIb group died with NSE 150-220 \u00ecg/ml Conclusions: 1.", [["NSE", "TEST", 23, 26]]], ["NSE is an effective marker of the severity of damages even in the sABF, and shoved efficacy efficacy of treatment.", [["NSE", "GENE_OR_GENE_PRODUCT", 0, 3], ["NSE", "PROTEIN", 0, 3], ["damages", "PROBLEM", 46, 53], ["treatment", "TREATMENT", 104, 113], ["damages", "OBSERVATION", 46, 53]]], ["Negative outcome can be in pts. with sABF and more 3-fold increasing NSE and increasing up to 150-220 \u00ecg/ml is a mortality predictor.", [["sABF", "GENE_OR_GENE_PRODUCT", 37, 41], ["NSE", "GENE_OR_GENE_PRODUCT", 69, 72], ["sABF", "PROTEIN", 37, 41], ["NSE", "PROTEIN", 69, 72], ["sABF and more 3-fold increasing NSE", "PROBLEM", 37, 72], ["more 3-fold", "OBSERVATION_MODIFIER", 46, 57], ["increasing", "OBSERVATION_MODIFIER", 58, 68]]], ["We included NSE in local protocols P405 N-terminal pro-brain natriuretic peptide as a bio-marker of the acute brain injury Introduction: The detection of biomarkers levels facilitates an early diagnosis of brain tissues damage, allows assessing the prognosis of the disease and its outcome, and performs the monitoring of the patient treatment.", [["brain", "ANATOMY", 110, 115], ["brain tissues", "ANATOMY", 206, 219], ["brain injury", "DISEASE", 110, 122], ["brain tissues damage", "DISEASE", 206, 226], ["N", "CHEMICAL", 40, 41], ["NSE", "GENE_OR_GENE_PRODUCT", 12, 15], ["brain", "ORGAN", 110, 115], ["brain tissues", "TISSUE", 206, 219], ["patient", "ORGANISM", 326, 333], ["NSE", "PROTEIN", 12, 15], ["patient", "SPECIES", 326, 333], ["terminal pro-brain natriuretic peptide", "TREATMENT", 42, 80], ["the acute brain injury", "PROBLEM", 100, 122], ["biomarkers levels", "TEST", 154, 171], ["brain tissues damage", "PROBLEM", 206, 226], ["the disease", "PROBLEM", 262, 273], ["the monitoring", "TEST", 304, 318], ["the patient treatment", "TREATMENT", 322, 343], ["acute", "OBSERVATION_MODIFIER", 104, 109], ["brain", "ANATOMY", 110, 115], ["injury", "OBSERVATION", 116, 122], ["brain tissues", "ANATOMY", 206, 219]]], ["Methods: We studied 64 patients (36 m, 28 f.).", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31]]], ["1st group comprised 12 patients with severe brain trauma: 1asurvivors with good outcome (on Glasgow outcome scale groups I-II) (n=8), 1bdead or severely disabled (on Glasgow outcome scale groups III-V) (n=4).", [["brain", "ANATOMY", 44, 49], ["brain trauma", "DISEASE", 44, 56], ["patients", "ORGANISM", 23, 31], ["brain", "ORGAN", 44, 49], ["patients", "SPECIES", 23, 31], ["severe brain trauma", "PROBLEM", 37, 56], ["severely disabled", "PROBLEM", 144, 161], ["brain", "ANATOMY", 44, 49], ["trauma", "OBSERVATION", 50, 56]]], ["2nd group comprises 37 patients with intracranial and sub-arachnoid hemorrhages: Assignment to groups 2a (n=14), 2b (n=22) was done using the same criteria as group 1.", [["intracranial", "ANATOMY", 37, 49], ["intracranial and sub-arachnoid hemorrhages", "DISEASE", 37, 79], ["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["intracranial and sub-arachnoid hemorrhages", "PROBLEM", 37, 79], ["intracranial", "ANATOMY", 37, 49], ["sub", "OBSERVATION_MODIFIER", 54, 57], ["arachnoid", "ANATOMY", 58, 67], ["hemorrhages", "OBSERVATION", 68, 79]]], ["3rd group comprises 16 patients operated in conjunction with brain tumor.", [["brain tumor", "ANATOMY", 61, 72], ["brain tumor", "DISEASE", 61, 72], ["patients", "ORGANISM", 23, 31], ["brain tumor", "CANCER", 61, 72], ["patients", "SPECIES", 23, 31], ["brain tumor", "PROBLEM", 61, 72], ["brain", "ANATOMY", 61, 66], ["tumor", "OBSERVATION", 67, 72]]], ["We tested the level of N-terminal Pro-Brain natriuretic peptide in blood (0-125 pg/ml) between 1st and 3rd days after severe brain injury and then every 2-12 days for the total duration of 21 days.", [["blood", "ANATOMY", 67, 72], ["brain", "ANATOMY", 125, 130], ["brain injury", "DISEASE", 125, 137], ["Pro-Brain natriuretic peptide", "GENE_OR_GENE_PRODUCT", 34, 63], ["blood", "ORGANISM_SUBSTANCE", 67, 72], ["brain", "ORGAN", 125, 130], ["N-terminal Pro-Brain natriuretic peptide", "TREATMENT", 23, 63], ["severe brain injury", "PROBLEM", 118, 137], ["brain", "ANATOMY", 125, 130], ["injury", "OBSERVATION", 131, 137]]], ["Results: : Statistical analysis failed to demonstrate noticeable difference in the level of NTproBNP between groups 1,2,3.", [["NTproBNP", "SIMPLE_CHEMICAL", 92, 100], ["NTproBNP", "PROTEIN", 92, 100], ["Statistical analysis", "TEST", 11, 31], ["noticeable difference", "PROBLEM", 54, 75], ["NTproBNP", "TEST", 92, 100]]], ["Patients from groups 1a,2a,3a (n=28) NTproBNP level stayed below 700 pg/ml in 20 cases (71%), in the 8 cases (29%) the level was above 700 pg/ml, but by 14-21th day decreased to the normal values.", [["Patients", "ORGANISM", 0, 8], ["NTproBNP", "GENE_OR_GENE_PRODUCT", 37, 45], ["Patients", "SPECIES", 0, 8], ["NTproBNP level", "TEST", 37, 51], ["the level", "TEST", 115, 124], ["normal", "OBSERVATION", 182, 188]]], ["For patients in subgroups 1b,2b,3b (n=36) in 28 cases (78%) NTproBNP level was above 700 pg/ml at least once, in 8 cases (12%) level stayed below 700 pg/ ml but remain high for the entire duration of the study without significant decrease.", [["patients", "ORGANISM", 4, 12], ["NTproBNP", "GENE_OR_GENE_PRODUCT", 60, 68], ["NTproBNP", "PROTEIN", 60, 68], ["patients", "SPECIES", 4, 12], ["NTproBNP level", "TEST", 60, 74], ["level", "TEST", 127, 132], ["the study", "TEST", 200, 209], ["significant decrease", "PROBLEM", 218, 238], ["high", "OBSERVATION", 168, 172], ["significant", "OBSERVATION_MODIFIER", 218, 229], ["decrease", "OBSERVATION", 230, 238]]], ["Conclusions: All the patients with acute brain injury show the increased level of NTproBNP above normal values, irrespective of ethiology of injury.", [["brain", "ANATOMY", 41, 46], ["brain injury", "DISEASE", 41, 53], ["patients", "ORGANISM", 21, 29], ["brain", "ORGAN", 41, 46], ["NTproBNP", "GENE_OR_GENE_PRODUCT", 82, 90], ["NTproBNP", "PROTEIN", 82, 90], ["patients", "SPECIES", 21, 29], ["acute brain injury", "PROBLEM", 35, 53], ["NTproBNP", "TEST", 82, 90], ["injury", "PROBLEM", 141, 147], ["brain", "ANATOMY", 41, 46], ["injury", "OBSERVATION", 47, 53], ["increased", "OBSERVATION_MODIFIER", 63, 72], ["injury", "OBSERVATION", 141, 147]]], ["In case when NTproBNP level increases above 700 pg/ml and/or does not decrease to the normal values it is possible to predict a negative outcome.", [["NTproBNP", "CHEMICAL", 13, 21], ["NTproBNP", "GENE_OR_GENE_PRODUCT", 13, 21], ["NTproBNP", "PROTEIN", 13, 21], ["NTproBNP level", "TEST", 13, 27], ["negative", "OBSERVATION", 128, 136]]], ["Introduction: Cerebrovascular and coronary artery diseases share many of the same risk factors [1] .", [["Cerebrovascular", "ANATOMY", 14, 29], ["coronary artery", "ANATOMY", 34, 49], ["Cerebrovascular and coronary artery diseases", "DISEASE", 14, 58], ["Cerebrovascular", "MULTI-TISSUE_STRUCTURE", 14, 29], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 34, 49], ["Cerebrovascular and coronary artery diseases", "PROBLEM", 14, 58], ["Cerebrovascular", "ANATOMY", 14, 29], ["coronary artery", "ANATOMY", 34, 49]]], ["Cardiac mortality accounts for 20% of deaths and is the second commonest cause of death in the acute stroke population, second only to neurologic deaths as a direct result of the incident stroke.", [["Cardiac", "ANATOMY", 0, 7], ["neurologic", "ANATOMY", 135, 145], ["Cardiac mortality", "DISEASE", 0, 17], ["deaths", "DISEASE", 38, 44], ["death", "DISEASE", 82, 87], ["stroke", "DISEASE", 101, 107], ["deaths", "DISEASE", 146, 152], ["stroke", "DISEASE", 188, 194], ["Cardiac", "ORGAN", 0, 7], ["death", "PROBLEM", 82, 87], ["the acute stroke population", "PROBLEM", 91, 118], ["the incident stroke", "PROBLEM", 175, 194], ["mortality", "OBSERVATION", 8, 17], ["acute", "OBSERVATION_MODIFIER", 95, 100], ["stroke", "OBSERVATION", 101, 107], ["stroke", "OBSERVATION", 188, 194]]], ["Methods: This is a prospective observational study from July 2015 to April 2016 done on 80 adult patients (groupI: 50 pts acute ischemic strokes & group II:30 pts as control) in Kafr-Elsheikh general hospital ICU.", [["ischemic strokes", "DISEASE", 128, 144], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["acute ischemic strokes", "PROBLEM", 122, 144]]], ["Inclusion criteria: All patients with acute ischemic stroke while Exclusion criteria: Patients with heart or renal failure/sepsis&septic shock/Ischemic heart disease or Hemorrhagic stroke,full clinical examination&labs including admission quantitative serum cardiac Troponin I ELISA immunoassay,ECG,2D echocardiography&CT brain on day 0&3,Alberta stroke program (ASP) early CT (ASPECT) to predict neurological outcomes and mortality in patient with acute ischemic stroke within 28 days so survivors Vs non-survivors in group 1 were divided to G1A & G1B respectively.", [["heart", "ANATOMY", 100, 105], ["renal", "ANATOMY", 109, 114], ["heart", "ANATOMY", 152, 157], ["serum", "ANATOMY", 252, 257], ["brain", "ANATOMY", 322, 327], ["neurological", "ANATOMY", 397, 409], ["ischemic stroke", "DISEASE", 44, 59], ["heart or renal failure", "DISEASE", 100, 122], ["shock", "DISEASE", 137, 142], ["Ischemic heart disease", "DISEASE", 143, 165], ["Hemorrhagic stroke", "DISEASE", 169, 187], ["stroke", "DISEASE", 347, 353], ["acute ischemic stroke", "DISEASE", 449, 470], ["patients", "ORGANISM", 24, 32], ["Patients", "ORGANISM", 86, 94], ["heart", "ORGAN", 100, 105], ["renal", "ORGAN", 109, 114], ["heart", "ORGAN", 152, 157], ["serum", "ORGANISM_SUBSTANCE", 252, 257], ["Troponin I", "GENE_OR_GENE_PRODUCT", 266, 276], ["brain", "ORGAN", 322, 327], ["patient", "ORGANISM", 436, 443], ["patients", "SPECIES", 24, 32], ["Patients", "SPECIES", 86, 94], ["patient", "SPECIES", 436, 443], ["acute ischemic stroke", "PROBLEM", 38, 59], ["renal failure", "PROBLEM", 109, 122], ["sepsis&septic shock", "PROBLEM", 123, 142], ["Ischemic heart disease", "PROBLEM", 143, 165], ["Hemorrhagic stroke", "PROBLEM", 169, 187], ["full clinical examination&labs", "TEST", 188, 218], ["serum cardiac", "TEST", 252, 265], ["ELISA immunoassay", "TEST", 277, 294], ["ECG", "TEST", 295, 298], ["2D echocardiography&CT brain", "TEST", 299, 327], ["Alberta stroke program", "TREATMENT", 339, 361], ["early CT", "TEST", 368, 376], ["acute ischemic stroke", "PROBLEM", 449, 470], ["non-survivors in group 1", "PROBLEM", 502, 526], ["acute", "OBSERVATION_MODIFIER", 38, 43], ["ischemic", "OBSERVATION_MODIFIER", 44, 52], ["stroke", "OBSERVATION", 53, 59], ["heart", "ANATOMY", 100, 105], ["renal", "ANATOMY", 109, 114], ["failure", "OBSERVATION", 115, 122], ["sepsis&septic shock", "OBSERVATION", 123, 142], ["Ischemic", "OBSERVATION_MODIFIER", 143, 151], ["heart", "ANATOMY", 152, 157], ["disease", "OBSERVATION", 158, 165], ["Hemorrhagic", "OBSERVATION_MODIFIER", 169, 180], ["stroke", "OBSERVATION", 181, 187], ["acute", "OBSERVATION_MODIFIER", 449, 454], ["ischemic", "OBSERVATION_MODIFIER", 455, 463], ["stroke", "OBSERVATION", 464, 470]]], ["Results: Dyslipidemia, hypertension, diabetes mellitus were significant comorbidities in all ischemic stroke pts.TLC, Urea, INR and Troponin were significantly higher in case group Vs control group.GCS was found to be lower in non-survivors at day 0&at 3rd day follow up while ASPECT was significantly lower only at 3rd day follow up.Troponin level was significantly higher in non-survivors G1B, it was also higher in patents who developed convulsion later during their ICU stay& it was significantly inversely correlated to GCS and ASP. troponin had sensitivity 53% and specificity 87% (ROC curve analysis) Conclusions: Troponin level was predictor for mortality in patient with acute ischemic stroke.it is well correlated to GCS and ASP on admission.it was a predictor for occurence of convulsions later in ICU stay.", [["Dyslipidemia", "DISEASE", 9, 21], ["hypertension", "DISEASE", 23, 35], ["diabetes mellitus", "DISEASE", 37, 54], ["ischemic stroke", "DISEASE", 93, 108], ["GCS", "DISEASE", 198, 201], ["convulsion", "DISEASE", 440, 450], ["GCS", "DISEASE", 525, 528], ["acute ischemic stroke", "DISEASE", 680, 701], ["GCS", "DISEASE", 727, 730], ["convulsions", "DISEASE", 788, 799], ["Urea", "CHEMICAL", 118, 122], ["Urea", "SIMPLE_CHEMICAL", 118, 122], ["Troponin", "GENE_OR_GENE_PRODUCT", 132, 140], ["Troponin", "GENE_OR_GENE_PRODUCT", 334, 342], ["troponin", "GENE_OR_GENE_PRODUCT", 538, 546], ["Troponin", "GENE_OR_GENE_PRODUCT", 621, 629], ["patient", "ORGANISM", 667, 674], ["INR", "PROTEIN", 124, 127], ["Troponin", "PROTEIN", 132, 140], ["Troponin", "PROTEIN", 334, 342], ["troponin", "PROTEIN", 538, 546], ["Troponin", "PROTEIN", 621, 629], ["patient", "SPECIES", 667, 674], ["Dyslipidemia", "PROBLEM", 9, 21], ["hypertension", "PROBLEM", 23, 35], ["diabetes mellitus", "PROBLEM", 37, 54], ["significant comorbidities", "PROBLEM", 60, 85], ["all ischemic stroke", "PROBLEM", 89, 108], ["TLC", "TEST", 113, 116], ["Urea", "TEST", 118, 122], ["INR", "TEST", 124, 127], ["Troponin", "TEST", 132, 140], ["GCS", "TEST", 198, 201], ["Troponin level", "TEST", 334, 348], ["convulsion", "PROBLEM", 440, 450], ["GCS", "TEST", 525, 528], ["ASP", "TEST", 533, 536], ["troponin", "TEST", 538, 546], ["sensitivity", "TEST", 551, 562], ["specificity", "TEST", 571, 582], ["ROC curve analysis", "TEST", 588, 606], ["Troponin level", "TEST", 621, 635], ["acute ischemic stroke", "PROBLEM", 680, 701], ["GCS", "TEST", 727, 730], ["ASP", "TEST", 735, 738], ["convulsions", "PROBLEM", 788, 799], ["Dyslipidemia", "OBSERVATION", 9, 21], ["hypertension", "OBSERVATION", 23, 35], ["significant", "OBSERVATION_MODIFIER", 60, 71], ["comorbidities", "OBSERVATION", 72, 85], ["ischemic", "OBSERVATION_MODIFIER", 93, 101], ["stroke", "OBSERVATION", 102, 108], ["higher", "OBSERVATION_MODIFIER", 408, 414], ["acute", "OBSERVATION_MODIFIER", 680, 685], ["ischemic", "OBSERVATION_MODIFIER", 686, 694], ["stroke", "OBSERVATION", 695, 701]]], ["Introduction: Based on examination and treatment of hyperkinetic disorder in patients with UWS and MCS, we supposed that hyperkinesis manifesting the formation of the generator of pathologically enhanced excitation in cerebral cortex, basal ganglia, which subsequently causes the formation of hyperkinesis.", [["cerebral cortex", "ANATOMY", 218, 233], ["basal ganglia", "ANATOMY", 235, 248], ["hyperkinetic disorder", "DISEASE", 52, 73], ["UWS", "DISEASE", 91, 94], ["hyperkinesis", "DISEASE", 121, 133], ["hyperkinesis", "DISEASE", 293, 305], ["patients", "ORGANISM", 77, 85], ["cerebral cortex", "MULTI-TISSUE_STRUCTURE", 218, 233], ["basal ganglia", "MULTI-TISSUE_STRUCTURE", 235, 248], ["patients", "SPECIES", 77, 85], ["examination", "TEST", 23, 34], ["hyperkinetic disorder", "PROBLEM", 52, 73], ["MCS", "TEST", 99, 102], ["hyperkinesis", "PROBLEM", 121, 133], ["pathologically enhanced excitation in cerebral cortex, basal ganglia", "PROBLEM", 180, 248], ["hyperkinesis", "PROBLEM", 293, 305], ["hyperkinetic disorder", "OBSERVATION", 52, 73], ["hyperkinesis", "OBSERVATION", 121, 133], ["pathologically", "OBSERVATION_MODIFIER", 180, 194], ["enhanced excitation", "OBSERVATION", 195, 214], ["cerebral cortex", "ANATOMY", 218, 233], ["basal", "ANATOMY_MODIFIER", 235, 240], ["ganglia", "ANATOMY", 241, 248], ["hyperkinesis", "OBSERVATION", 293, 305]]], ["Halogencontaining anesthetic sevoflurane had a good clinical effect in patients with prolonged impairment of consciousness.", [["sevoflurane", "CHEMICAL", 29, 40], ["impairment of consciousness", "DISEASE", 95, 122], ["sevoflurane", "CHEMICAL", 29, 40], ["sevoflurane", "SIMPLE_CHEMICAL", 29, 40], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["Halogencontaining anesthetic sevoflurane", "TREATMENT", 0, 40], ["prolonged impairment of consciousness", "PROBLEM", 85, 122]]], ["Methods: The study included 5 patients with UWS (4 -hypoxia, 1 -encephalitis) and 3 patients with MCS (2 -hypoxia, 1-encephalitis).", [["UWS", "DISEASE", 44, 47], ["hypoxia", "DISEASE", 52, 59], ["encephalitis", "DISEASE", 64, 76], ["MCS", "DISEASE", 98, 101], ["hypoxia", "DISEASE", 106, 113], ["encephalitis", "DISEASE", 117, 129], ["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 84, 92], ["The study", "TEST", 9, 18], ["UWS", "TEST", 44, 47], ["hypoxia", "PROBLEM", 52, 59], ["encephalitis", "PROBLEM", 64, 76], ["MCS", "TEST", 98, 101], ["hypoxia", "PROBLEM", 106, 113], ["encephalitis", "PROBLEM", 117, 129], ["encephalitis", "OBSERVATION", 117, 129]]], ["Hyperkinetic disorder presenting as permanent myoclonus of arms and legs, face.", [["legs", "ANATOMY", 68, 72], ["Hyperkinetic disorder", "DISEASE", 0, 21], ["myoclonus", "DISEASE", 46, 55], ["legs", "ORGANISM_SUBDIVISION", 68, 72], ["Hyperkinetic disorder", "PROBLEM", 0, 21], ["permanent myoclonus of arms and legs, face", "PROBLEM", 36, 78], ["disorder", "OBSERVATION", 13, 21], ["permanent", "OBSERVATION_MODIFIER", 36, 45], ["myoclonus", "OBSERVATION", 46, 55], ["arms", "ANATOMY", 59, 63], ["legs", "ANATOMY", 68, 72], ["face", "ANATOMY", 74, 78]]], ["All patients were performed head MRI and EEG (before, during and after anesthesia), CRS-R assessment, 3 patients -[18F]-FGD PET.", [["head", "ANATOMY", 28, 32], ["[18F]-FGD", "CHEMICAL", 114, 123], ["patients", "ORGANISM", 4, 12], ["head", "ORGANISM_SUBDIVISION", 28, 32], ["patients", "ORGANISM", 104, 112], ["[18F]-FGD", "SIMPLE_CHEMICAL", 114, 123], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 104, 112], ["head MRI", "TEST", 28, 36], ["EEG", "TEST", 41, 44], ["anesthesia", "TREATMENT", 71, 81], ["CRS", "TEST", 84, 87], ["R assessment", "TEST", 88, 100], ["FGD PET", "TEST", 120, 127]]], ["Initial anesthesia: propofol 2-3 mg/kg, rocuronium bromide (Esmeron) 0, 6 mg/kg, fentanyl 3-5 mg/kg and clonidine (clophelin) 0.5-0.7 mg/kg.", [["propofol", "CHEMICAL", 20, 28], ["rocuronium bromide", "CHEMICAL", 40, 58], ["Esmeron", "CHEMICAL", 60, 67], ["fentanyl", "CHEMICAL", 81, 89], ["clonidine", "CHEMICAL", 104, 113], ["clophelin", "CHEMICAL", 115, 124], ["propofol", "CHEMICAL", 20, 28], ["rocuronium bromide", "CHEMICAL", 40, 58], ["Esmeron", "CHEMICAL", 60, 67], ["fentanyl", "CHEMICAL", 81, 89], ["clonidine", "CHEMICAL", 104, 113], ["clophelin", "CHEMICAL", 115, 124], ["propofol", "SIMPLE_CHEMICAL", 20, 28], ["rocuronium bromide", "SIMPLE_CHEMICAL", 40, 58], ["Esmeron", "SIMPLE_CHEMICAL", 60, 67], ["fentanyl", "SIMPLE_CHEMICAL", 81, 89], ["clonidine", "SIMPLE_CHEMICAL", 104, 113], ["clophelin", "SIMPLE_CHEMICAL", 115, 124], ["Initial anesthesia", "TREATMENT", 0, 18], ["propofol", "TREATMENT", 20, 28], ["rocuronium bromide (Esmeron)", "TREATMENT", 40, 68], ["fentanyl", "TREATMENT", 81, 89], ["clonidine (clophelin)", "TREATMENT", 104, 125]]], ["Maintenance of anesthesia is carried out due to the following scheme: inhalation anesthesia using Sevoflurane (2.0-3.0 vol%, MAC 0.8-0.9).", [["Sevoflurane", "CHEMICAL", 98, 109], ["Sevoflurane", "CHEMICAL", 98, 109], ["Sevoflurane", "SIMPLE_CHEMICAL", 98, 109], ["anesthesia", "TREATMENT", 15, 25], ["inhalation anesthesia", "TREATMENT", 70, 91], ["Sevoflurane", "TREATMENT", 98, 109], ["MAC", "TEST", 125, 128]]], ["Additionally, during the 2nd -4th hours of medical anesthesia was prescribed the intravenous injection using Ketamine 1-2 mg/kg/hr.", [["intravenous", "ANATOMY", 81, 92], ["Ketamine", "CHEMICAL", 109, 117], ["Ketamine", "CHEMICAL", 109, 117], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 81, 92], ["Ketamine", "SIMPLE_CHEMICAL", 109, 117], ["medical anesthesia", "TREATMENT", 43, 61], ["the intravenous injection", "TREATMENT", 77, 102], ["Ketamine", "TREATMENT", 109, 117]]], ["The anesthesia is used during 24 hours.", [["The anesthesia", "TREATMENT", 0, 14]]], ["The patients were nurtured by balanced mixtures through nasogastric tube.", [["patients", "ORGANISM", 4, 12], ["nasogastric tube", "MULTI-TISSUE_STRUCTURE", 56, 72], ["patients", "SPECIES", 4, 12], ["nasogastric tube", "TREATMENT", 56, 72], ["nasogastric tube", "OBSERVATION", 56, 72]]], ["After 24 hours the patients were gradually transferred to the autonomous breathing.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["autonomous breathing", "OBSERVATION", 62, 82]]], ["The control clinical and instrumental studies to evaluate the therapy effectiveness (EEG, CRS-R) were performed.", [["instrumental studies", "TEST", 25, 45], ["the therapy effectiveness", "TREATMENT", 58, 83], ["EEG", "TEST", 85, 88], ["CRS", "TEST", 90, 93]]], ["Results: In 5 patients (2 MCS, 3 UWS) was observed the hyperkinetic disorder regression as decrease of hyperkinesis manifestation, 3 patients didn't have a significant dynamics.", [["hyperkinetic disorder", "DISEASE", 55, 76], ["hyperkinesis", "DISEASE", 103, 115], ["patients", "ORGANISM", 14, 22], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 133, 141], ["the hyperkinetic disorder regression", "PROBLEM", 51, 87], ["hyperkinesis manifestation", "PROBLEM", 103, 129], ["hyperkinetic disorder", "OBSERVATION", 55, 76], ["hyperkinesis", "OBSERVATION", 103, 115]]], ["Conclusions: The artificially formed \"pharmacological dominant\" (using sevoflurane and Ketamine) may decrease the activity of pathological system of the brain, which clinically presented as significant decrease of hyperkinesis manifestation in 5 out 8 patients.P40815-year experience of using benzodiazepines in predicting outcomes and targeted treatment of patients in unresponsive wakefulness syndrome (UWS).", [["brain", "ANATOMY", 153, 158], ["sevoflurane", "CHEMICAL", 71, 82], ["Ketamine", "CHEMICAL", 87, 95], ["hyperkinesis", "DISEASE", 214, 226], ["benzodiazepines", "CHEMICAL", 293, 308], ["wakefulness syndrome", "DISEASE", 383, 403], ["UWS", "DISEASE", 405, 408], ["sevoflurane", "CHEMICAL", 71, 82], ["Ketamine", "CHEMICAL", 87, 95], ["benzodiazepines", "CHEMICAL", 293, 308], ["sevoflurane", "SIMPLE_CHEMICAL", 71, 82], ["Ketamine", "SIMPLE_CHEMICAL", 87, 95], ["brain", "ORGAN", 153, 158], ["patients", "ORGANISM", 252, 260], ["patients", "ORGANISM", 358, 366], ["patients", "SPECIES", 252, 260], ["patients", "SPECIES", 358, 366], ["sevoflurane", "TREATMENT", 71, 82], ["Ketamine", "TREATMENT", 87, 95], ["hyperkinesis manifestation", "PROBLEM", 214, 240], ["benzodiazepines", "TREATMENT", 293, 308], ["targeted treatment", "TREATMENT", 336, 354], ["unresponsive wakefulness syndrome", "PROBLEM", 370, 403], ["brain", "ANATOMY", 153, 158], ["significant", "OBSERVATION_MODIFIER", 190, 201], ["decrease", "OBSERVATION_MODIFIER", 202, 210], ["hyperkinesis", "OBSERVATION", 214, 226]]], ["Introduction: We accepted a hypothesis that in some patients UWS is a consequence of a pathologic system (PS), that limits the brain functional activity.", [["brain", "ANATOMY", 127, 132], ["UWS", "DISEASE", 61, 64], ["patients", "ORGANISM", 52, 60], ["brain", "ORGAN", 127, 132], ["patients", "SPECIES", 52, 60], ["functional activity", "OBSERVATION", 133, 152]]], ["Identification of a PS allow to predict consciousness recovery.", [["a PS", "TREATMENT", 18, 22]]], ["EEG registration under benzodiazepines test (BT) has become the method of PS identifying in UWS patients.", [["benzodiazepines", "CHEMICAL", 23, 38], ["UWS", "DISEASE", 92, 95], ["benzodiazepines", "CHEMICAL", 23, 38], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["EEG registration", "TEST", 0, 16], ["benzodiazepines test", "TEST", 23, 43], ["the method of PS", "TREATMENT", 60, 76]]], ["Methods: We examined 145 UWS patients (74 -traumatic, 71 -non traumatic).", [["UWS", "DISEASE", 25, 28], ["traumatic", "DISEASE", 43, 52], ["traumatic", "DISEASE", 62, 71], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37]]], ["CRS scales assessment, EEG with BT, MRI of brain were performed for all patients.", [["brain", "ANATOMY", 43, 48], ["brain", "ORGAN", 43, 48], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["CRS scales assessment", "TEST", 0, 21], ["EEG", "TEST", 23, 26], ["BT", "TEST", 32, 34], ["MRI of brain", "TEST", 36, 48], ["brain", "ANATOMY", 43, 48]]], ["The midazolamum was administered iv 0.04 mg/kg,.In 3-4 min after BZD was recorded EEG for 15 min.", [["midazolamum", "CHEMICAL", 4, 15], ["midazolamum", "CHEMICAL", 4, 15], ["BZD", "CHEMICAL", 65, 68], ["midazolamum", "SIMPLE_CHEMICAL", 4, 15], ["BZD", "SIMPLE_CHEMICAL", 65, 68], ["The midazolamum", "TREATMENT", 0, 15], ["BZD", "TREATMENT", 65, 68], ["EEG", "TEST", 82, 85]]], ["The test was considered to be positive if against the background of BZD EEG pattern restructuring was observed: the low-amplitude EEG activity was rebuilt with the advent of alpha-and beta-spectrum.In patients with slowwave activity of theta-and delta-spectrum appeared stable fast forms, and in patients with baseline polymorphic EEG pattern was recorded prevalence of alpha activity and (or) the alpha rhythm.", [["patients", "ORGANISM", 201, 209], ["patients", "ORGANISM", 296, 304], ["alpha", "GENE_OR_GENE_PRODUCT", 370, 375], ["alpha", "PROTEIN", 174, 179], ["patients", "SPECIES", 201, 209], ["patients", "SPECIES", 296, 304], ["The test", "TEST", 0, 8], ["BZD EEG pattern restructuring", "PROBLEM", 68, 97], ["slowwave activity of theta", "PROBLEM", 215, 241], ["baseline polymorphic EEG pattern", "PROBLEM", 310, 342], ["alpha activity", "PROBLEM", 370, 384], ["the alpha rhythm", "TEST", 394, 410], ["stable", "OBSERVATION", 270, 276]]], ["In order to confirm the correlation between the BZD effect and EEG pattern restructuring, Flumazenil was administrated at rate of 0.1 mg every 1 to 2 minutes until the original EEG pattern has been registered again.", [["Flumazenil", "CHEMICAL", 90, 100], ["Flumazenil", "CHEMICAL", 90, 100], ["Flumazenil", "SIMPLE_CHEMICAL", 90, 100], ["the BZD effect", "TEST", 44, 58], ["EEG pattern", "TEST", 63, 74], ["Flumazenil", "TREATMENT", 90, 100], ["the original EEG pattern", "TEST", 164, 188]]], ["Results: The BT was true positive (recovery consciousness in 3-12 month later) in 22 traumatic and 19 non traumatic patients.", [["traumatic", "DISEASE", 85, 94], ["traumatic", "DISEASE", 106, 115], ["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 116, 124], ["The BT", "TEST", 9, 15], ["22 traumatic and 19 non traumatic patients", "PROBLEM", 82, 124]]], ["True negative (permanent UWS 12 month later) in 27 traumatic and 43 non traumatic patients.", [["traumatic", "DISEASE", 51, 60], ["traumatic", "DISEASE", 72, 81], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["negative", "OBSERVATION", 5, 13], ["non traumatic", "OBSERVATION_MODIFIER", 68, 81]]], ["False positive -11 traumatic, 4 non traumatic.", [["traumatic", "DISEASE", 19, 28], ["traumatic", "DISEASE", 36, 45], ["False positive", "PROBLEM", 0, 14], ["traumatic", "PROBLEM", 19, 28], ["traumatic", "PROBLEM", 36, 45], ["11 traumatic", "OBSERVATION_MODIFIER", 16, 28], ["non traumatic", "OBSERVATION_MODIFIER", 32, 45]]], ["False negative 14 traumatic, 5 non traumatic patients.", [["traumatic", "DISEASE", 18, 27], ["traumatic", "DISEASE", 35, 44], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["False", "TEST", 0, 5], ["traumatic", "PROBLEM", 18, 27], ["5 non traumatic patients", "PROBLEM", 29, 53], ["negative", "OBSERVATION_MODIFIER", 6, 14], ["14 traumatic", "OBSERVATION_MODIFIER", 15, 27]]], ["Sensitivity BT to VS/UWS = 74.6% Sensitivity to MCS = 43.1% Conclusions: Our data confirmed the correctness of hypothesis that a PS limits the activity of the brain in patients in a UWS.", [["brain", "ANATOMY", 159, 164], ["UWS", "DISEASE", 182, 185], ["brain", "ORGAN", 159, 164], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 168, 176], ["Sensitivity BT", "TEST", 0, 14], ["VS", "TEST", 18, 20], ["UWS", "TEST", 21, 24], ["Sensitivity", "TEST", 33, 44], ["MCS", "TEST", 48, 51], ["Our data", "TEST", 73, 81], ["a PS", "TEST", 127, 131], ["brain", "ANATOMY", 159, 164]]], ["We proposed diagnostic method of a PS activity and suppression.", [["a PS activity", "TREATMENT", 33, 46]]], ["Apparently, BZD are the drugs of first stage examination choice in the treatment of UWS patients.P409Early identification of sepsis-associated encephalopathy with EEG is not associated with short-term cognitive dysfunction Introduction: Septic-associated encephalopathy (SAE) affects approximately 75% of septic patients.", [["UWS", "DISEASE", 84, 87], ["sepsis", "DISEASE", 125, 131], ["encephalopathy", "DISEASE", 143, 157], ["cognitive dysfunction", "DISEASE", 201, 222], ["encephalopathy", "DISEASE", 255, 269], ["SAE", "DISEASE", 271, 274], ["septic", "DISEASE", 305, 311], ["BZD", "CHEMICAL", 12, 15], ["BZD", "SIMPLE_CHEMICAL", 12, 15], ["patients", "ORGANISM", 88, 96], ["patients", "ORGANISM", 312, 320], ["patients", "SPECIES", 88, 96], ["patients", "SPECIES", 312, 320], ["first stage examination", "TEST", 33, 56], ["sepsis", "PROBLEM", 125, 131], ["associated encephalopathy", "PROBLEM", 132, 157], ["EEG", "TEST", 163, 166], ["short-term cognitive dysfunction", "PROBLEM", 190, 222], ["Septic-associated encephalopathy", "PROBLEM", 237, 269], ["septic patients", "PROBLEM", 305, 320], ["sepsis", "OBSERVATION", 125, 131], ["encephalopathy", "OBSERVATION", 143, 157], ["Septic", "OBSERVATION", 237, 243], ["encephalopathy", "OBSERVATION", 255, 269], ["septic", "OBSERVATION", 305, 311]]], ["Recent studies showed SAE is associated with short-term mortality and long-term cognitive disability.", [["SAE", "DISEASE", 22, 25], ["cognitive disability", "DISEASE", 80, 100], ["Recent studies", "TEST", 0, 14], ["SAE", "PROBLEM", 22, 25], ["short-term mortality", "PROBLEM", 45, 65], ["long-term cognitive disability", "PROBLEM", 70, 100]]], ["However, diagnosis of SAE is one of exclusion and its association with short-term cognitive deficit is uncertain.", [["SAE", "DISEASE", 22, 25], ["cognitive deficit", "DISEASE", 82, 99], ["SAE", "PROBLEM", 22, 25], ["short-term cognitive deficit", "PROBLEM", 71, 99]]], ["The aim of this study is to evaluate the sensitivity of clinical examination in detecting SAE.", [["SAE", "DISEASE", 90, 93], ["this study", "TEST", 11, 21], ["clinical examination", "TEST", 56, 76]]], ["The association between SAE and short-term cognitive impairment is also assessed.", [["SAE", "DISEASE", 24, 27], ["cognitive impairment", "DISEASE", 43, 63], ["short-term cognitive impairment", "PROBLEM", 32, 63], ["SAE", "OBSERVATION_MODIFIER", 24, 27], ["short-term", "OBSERVATION_MODIFIER", 32, 42]]], ["Methods: Prospective observational study enrolling adult septic patients admitted to a mixed ICU.", [["septic", "DISEASE", 57, 63], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["septic", "OBSERVATION", 57, 63]]], ["Exclusion criteria were: encephalopathy from another cause, history of psychiatric/neurologic disease, cardiac surgery.", [["neurologic", "ANATOMY", 83, 93], ["cardiac", "ANATOMY", 103, 110], ["encephalopathy", "DISEASE", 25, 39], ["psychiatric", "DISEASE", 71, 82], ["neurologic disease", "DISEASE", 83, 101], ["cardiac", "ORGAN", 103, 110], ["encephalopathy", "PROBLEM", 25, 39], ["psychiatric/neurologic disease", "PROBLEM", 71, 101], ["cardiac surgery", "TREATMENT", 103, 118], ["encephalopathy", "OBSERVATION", 25, 39], ["neurologic disease", "OBSERVATION", 83, 101], ["cardiac", "ANATOMY", 103, 110], ["surgery", "OBSERVATION", 111, 118]]], ["All patients received continuous EEG monitoring and were assessed for SAE for up to 7 days after inclusion.", [["SAE", "DISEASE", 70, 73], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["continuous EEG monitoring", "TEST", 22, 47]]], ["We performed a comprehensive consciousness assessment twice daily during the ICU (GCS; Full Outline of UnResponsiveness, FOUR; Coma Recovery Scale-Revised, CRS-R; Reaction Level Scale 85, RLS85; Confusion Assessment Method for the ICU, CAM-ICU).", [["Coma", "DISEASE", 127, 131], ["Confusion", "DISEASE", 195, 204], ["a comprehensive consciousness assessment", "TEST", 13, 53], ["UnResponsiveness", "PROBLEM", 103, 119], ["Coma Recovery Scale", "TEST", 127, 146], ["CRS", "TEST", 156, 159], ["Reaction Level Scale", "TEST", 163, 183]]], ["We defined altered brain function as GCS<15, No correlation between cognitive function at hospital discharge and severity of EEG alteration was found.P409Conclusions: EEG was more sensitive than clinical assessment in detecting SAE.", [["brain", "ANATOMY", 19, 24], ["SAE", "DISEASE", 228, 231], ["brain", "ORGAN", 19, 24], ["altered brain function", "PROBLEM", 11, 33], ["GCS", "TEST", 37, 40], ["EEG alteration", "PROBLEM", 125, 139], ["EEG", "TEST", 167, 170], ["clinical assessment", "TEST", 195, 214]]], ["Altered EEG was not associated with short-term cognitive function.P410Analysis of the training needs in Italian centers that use brain ultrasound in their daily practices: a descriptive, multicenter study R Aspide 1 Introduction: As mission of SIAARTI Neuroanesthesia and NeuroICU group of study, we are mapping out the Brain Ultrasound training needs in our Centers.", [["brain", "ANATOMY", 129, 134], ["brain", "ORGAN", 129, 134], ["EEG", "PROTEIN", 8, 11], ["Altered EEG", "PROBLEM", 0, 11], ["short-term cognitive function", "PROBLEM", 36, 65], ["the training", "TREATMENT", 82, 94], ["brain ultrasound", "TEST", 129, 145], ["SIAARTI Neuroanesthesia", "TREATMENT", 244, 267], ["the Brain Ultrasound training", "TREATMENT", 316, 345]]], ["Although Brain Ultrasound is widely used to study the intracranial vessels and other issues, it is still not clear the homogeneity of the skills required in both Neuro and General ICU in Italy.", [["Brain", "ANATOMY", 9, 14], ["intracranial vessels", "ANATOMY", 54, 74], ["Brain", "ORGAN", 9, 14], ["intracranial vessels", "MULTI-TISSUE_STRUCTURE", 54, 74], ["Brain Ultrasound", "TEST", 9, 25], ["intracranial vessels", "ANATOMY", 54, 74]]], ["The aim of this study is to explore the use of US-TCD and validate a collection of criterea which would prove useful in any future national wide survey.", [["this study", "TEST", 11, 21], ["US", "TEST", 47, 49], ["TCD", "TEST", 50, 53], ["a collection of criterea", "PROBLEM", 67, 91]]], ["Methods: Starting from Sept. 2017 the seven Center involved (Bologna, Catania, Pisa, Verona, Bergamo, Cesena, Roma) collected clinical and sonographic data, basing on a CRF of twenty criteria such as: kind of hospital and ICU, number of beds and neuro-patients/year, the physicians specialization trained to perform US-TCD, the kind of US doppler device used and the kind of training course followed.", [["CRF", "DISEASE", 169, 172], ["sonographic data", "TEST", 139, 155], ["US", "TEST", 316, 318], ["US doppler device", "TEST", 336, 353], ["training course", "TREATMENT", 375, 390]]], ["Results: The result is a ready list of 20 items, an available tool for all the participant Centers, that are going to start with an internal test survey for a final validation.", [["an internal test survey", "TEST", 129, 152]]], ["Conclusions: There is more than one path to train a physician on Brain US in Italy and there are new possible applications, even outside of the Neuro sub-speciality.", [["Brain US", "TEST", 65, 73], ["new", "OBSERVATION_MODIFIER", 97, 100]]], ["The main aim is the production of a validated criterea collection, available for eventually future national survey, useful to help map out the real national training needs in Italy on US Brain.P411Perinatal neurosurgical admissions to intensive care C Nestor, R Hollingsworth, K Sweeney, R Dwyer Beaumont Hospital, Dublin, Ireland Critical Care 2018, 22(Suppl 1):P411 Introduction: Beaumont Hospital is the Neurosurgical centre for Ireland serving a population of 3.6 million.", [["Brain", "ANATOMY", 187, 192], ["Brain", "ORGAN", 187, 192], ["a validated criterea collection", "PROBLEM", 34, 65], ["main", "OBSERVATION_MODIFIER", 4, 8], ["Brain", "ANATOMY", 187, 192]]], ["We present data on all perinatal patients who required ICU admission for Neurosurgical conditions over an 8 year period.", [["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["Neurosurgical conditions", "TREATMENT", 73, 97]]], ["Our data presents an insight into the incidence and outcome of Neurosurgical conditions during pregnancy Methods: Searching our database identified 11 pregnant and 8 recently pregnant patients admitted to ICU with neurosurgical conditions.", [["patients", "ORGANISM", 184, 192], ["patients", "SPECIES", 184, 192], ["Neurosurgical conditions", "PROBLEM", 63, 87], ["neurosurgical conditions", "TREATMENT", 214, 238]]], ["Patient data was collected retrospectively by review of charts and of an electronic database.", [["Patient", "SPECIES", 0, 7], ["an electronic database", "TEST", 70, 92]]], ["A further 12 pregnant patients were admitted for Neurosurgical intervention but did not require critical care.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["Neurosurgical intervention", "TREATMENT", 49, 75], ["critical care", "TREATMENT", 96, 109]]], ["Results: Intracranial haemorrhage was the most common diagnosis (5 subarachnoid haemorrhage and 5 had intra-cerebral haemorrhage).", [["Intracranial", "ANATOMY", 9, 21], ["subarachnoid", "ANATOMY", 67, 79], ["intra-cerebral", "ANATOMY", 102, 116], ["Intracranial haemorrhage", "DISEASE", 9, 33], ["subarachnoid haemorrhage", "DISEASE", 67, 91], ["intra-cerebral haemorrhage", "DISEASE", 102, 128], ["Intracranial haemorrhage", "PROBLEM", 9, 33], ["5 subarachnoid haemorrhage", "PROBLEM", 65, 91], ["intra-cerebral haemorrhage", "PROBLEM", 102, 128], ["Intracranial", "ANATOMY", 9, 21], ["haemorrhage", "OBSERVATION", 22, 33], ["subarachnoid", "ANATOMY", 67, 79], ["haemorrhage", "OBSERVATION", 80, 91], ["haemorrhage", "OBSERVATION", 117, 128]]], ["6 patients presented with intracranial tumours and 1 patient had a traumatic brain injury.", [["intracranial tumours", "ANATOMY", 26, 46], ["brain", "ANATOMY", 77, 82], ["intracranial tumours", "DISEASE", 26, 46], ["traumatic brain injury", "DISEASE", 67, 89], ["patients", "ORGANISM", 2, 10], ["intracranial tumours", "CANCER", 26, 46], ["patient", "ORGANISM", 53, 60], ["brain", "ORGAN", 77, 82], ["patients", "SPECIES", 2, 10], ["patient", "SPECIES", 53, 60], ["intracranial tumours", "PROBLEM", 26, 46], ["a traumatic brain injury", "PROBLEM", 65, 89], ["intracranial", "ANATOMY", 26, 38], ["tumours", "OBSERVATION", 39, 46], ["traumatic", "OBSERVATION", 67, 76], ["brain", "ANATOMY", 77, 82], ["injury", "OBSERVATION", 83, 89]]], ["1 patient was admitted post spinal tumour resection.", [["spinal tumour", "ANATOMY", 28, 41], ["tumour", "DISEASE", 35, 41], ["patient", "ORGANISM", 2, 9], ["spinal tumour", "CANCER", 28, 41], ["patient", "SPECIES", 2, 9], ["spinal tumour resection", "TREATMENT", 28, 51], ["spinal", "ANATOMY", 28, 34], ["tumour resection", "OBSERVATION", 35, 51]]], ["1 patient was referred with an ischemic stroke after iatrogenic injury to the carotid and vertebral artery.", [["carotid", "ANATOMY", 78, 85], ["vertebral artery", "ANATOMY", 90, 106], ["ischemic stroke", "DISEASE", 31, 46], ["injury to the carotid and vertebral artery", "DISEASE", 64, 106], ["patient", "ORGANISM", 2, 9], ["carotid", "MULTI-TISSUE_STRUCTURE", 78, 85], ["vertebral artery", "MULTI-TISSUE_STRUCTURE", 90, 106], ["patient", "SPECIES", 2, 9], ["an ischemic stroke", "PROBLEM", 28, 46], ["iatrogenic injury to the carotid and vertebral artery", "PROBLEM", 53, 106], ["ischemic", "OBSERVATION_MODIFIER", 31, 39], ["stroke", "OBSERVATION", 40, 46], ["iatrogenic", "OBSERVATION_MODIFIER", 53, 63], ["injury", "OBSERVATION", 64, 70], ["carotid", "ANATOMY", 78, 85], ["vertebral artery", "ANATOMY", 90, 106]]], ["The requirement for organ support in this cohort of patients was high; 64% required ventilation and 45% inotropes.", [["organ", "ANATOMY", 20, 25], ["organ", "ORGAN", 20, 25], ["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["organ support", "TREATMENT", 20, 33], ["ventilation", "TREATMENT", 84, 95], ["45% inotropes", "TREATMENT", 100, 113]]], ["13 patients underwent neurosurgical intervention & 6 medical treatment.", [["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["neurosurgical intervention", "TREATMENT", 22, 48], ["6 medical treatment", "TREATMENT", 51, 70]]], ["2 maternal deaths occurred at 16 & 37 weeks gestation.", [["deaths", "DISEASE", 11, 17], ["2 maternal deaths", "PROBLEM", 0, 17]]], ["The modified Rankin Score (mRS) on discharge from hospital was <= 2 for 9 of the 17 surviving patients (median=3).", [["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102]]], ["Of the 11 pregnancies (all singleton) there were 3 foetal deaths.", [["deaths", "DISEASE", 58, 64], ["3 foetal deaths", "PROBLEM", 49, 64]]], ["1 patient miscarried spontaneously at 4 weeks, 1 had a medical termination of pregnancy at 12 weeks to facilitate chemotherapy and 1 foetus died after maternal death at 16 weeks.", [["death", "DISEASE", 160, 165], ["patient", "ORGANISM", 2, 9], ["patient", "SPECIES", 2, 9], ["chemotherapy", "TREATMENT", 114, 126], ["maternal death", "PROBLEM", 151, 165]]], ["The 8 remaining patients delivered normal babies.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24]]], ["Conclusions: Neurosurgical disease requiring ICU admission during pregnancy is rare; our data suggest an incidence of 1 case per 2 million population.", [["Neurosurgical disease", "PROBLEM", 13, 34]]], ["Maternal outcomes were mixed with more than half having a mRS>2 on discharge.", [["a mRS", "TEST", 56, 61]]], ["Foetal outcomes were good with only one miscarriage and good neurological outcome in all surviving infants.", [["Foetal", "ANATOMY", 0, 6], ["neurological", "ANATOMY", 61, 73], ["miscarriage", "DISEASE", 40, 51], ["Foetal", "ORGAN", 0, 6], ["infants", "ORGANISM", 99, 106], ["infants", "SPECIES", 99, 106]]], ["Results: Prehospital ALS (adjusted OR, 1.63; 95%CI, 1.38-1.93) but not good-quality of bystander-performed CCs (1.02, 0.84-1.26) was associated with sustained return of circulation (ROSC).", [["ALS", "DISEASE", 21, 24], ["CI", "TEST", 48, 50], ["CCs", "TEST", 107, 110], ["circulation", "OBSERVATION_MODIFIER", 169, 180]]], ["Neither provison of good-quality CCs nor prehospital ALS was a major factor associated with on-month survival.", [["ALS", "DISEASE", 53, 56], ["prehospital ALS", "PROBLEM", 41, 56], ["good", "OBSERVATION_MODIFIER", 20, 24]]], ["However, good-quality of bystanderperformed CCs (2.44, 1.81-5.00) in addition to shockable rhythm (13.3; 8.70-20.4) and bystander-witnessed OHCA (4.79; 2.98-8.00) were associated with higher chances of neurologically favourable one-year survival, whereas prehospital ALS (0.21; 0.10-0.39) and elderly OHCA (0.47; 0.31-0.73) were associated with lower chances of the survival (Fig. 1) .", [["ALS", "DISEASE", 267, 270], ["OHCA", "DISEASE", 301, 305], ["CCs", "MULTI-TISSUE_STRUCTURE", 44, 47], ["bystanderperformed CCs", "TEST", 25, 47], ["shockable rhythm", "TEST", 81, 97], ["OHCA", "TEST", 140, 144], ["prehospital ALS", "TEST", 255, 270], ["OHCA", "TEST", 301, 305]]], ["The impact of good quality CCs on survival were preserved in bystander-witnessed OHCAs with shockable initial rhythm.", [["good", "OBSERVATION_MODIFIER", 14, 18]]], ["Noncentral region (adjusted OR for good-quality, 0.46; 95%CI, 0.39-0.54), lack of BLS training experience (0.47; 0.36-0.62), elderly-only rescuers (0.53; 0.44-0.65), CC initiation following dispatcher-assisted cardiopulmonary resuscitation (0.71; 0.55-0.91), and female-only rescuer (0.77; 0.65-0.90) were associated with poor-quality CCs.", [["cardiopulmonary", "ANATOMY", 210, 225], ["CC", "CHEMICAL", 166, 168], ["CI", "TEST", 58, 60], ["rescuers", "TEST", 138, 146], ["dispatcher-assisted cardiopulmonary resuscitation", "TREATMENT", 190, 239], ["rescuer", "TEST", 275, 282], ["cardiopulmonary", "ANATOMY", 210, 225]]], ["CC quality in athome OHCAs remained low throughout the day, whereas that in outof-home OHCAs decreased during night-time.P411Conclusions: Provision of good-quality CCs before EMS arrival but not prehospital ALS was essential for neurologically favourable survival.P413New protocol for start of chest compressions before definitive cardiac arrest improved survival from out-of-hospital cardiac arrest witnessed by emergency medical service Introduction: Healthcare providers including emergency medical service (EMS) personnel usually confirm absence of carotid pulse before starting chest compressions.", [["chest", "ANATOMY", 294, 299], ["cardiac", "ANATOMY", 331, 338], ["cardiac", "ANATOMY", 385, 392], ["carotid", "ANATOMY", 553, 560], ["chest", "ANATOMY", 583, 588], ["CC", "CHEMICAL", 0, 2], ["ALS", "DISEASE", 207, 210], ["cardiac arrest", "DISEASE", 331, 345], ["cardiac arrest", "DISEASE", 385, 399], ["chest", "ORGANISM_SUBDIVISION", 294, 299], ["cardiac", "ORGAN", 385, 392], ["carotid", "MULTI-TISSUE_STRUCTURE", 553, 560], ["chest", "ORGANISM_SUBDIVISION", 583, 588], ["CC quality", "TEST", 0, 10], ["prehospital ALS", "PROBLEM", 195, 210], ["New protocol", "TREATMENT", 268, 280], ["chest compressions", "TREATMENT", 294, 312], ["definitive cardiac arrest", "PROBLEM", 320, 345], ["carotid pulse", "PROBLEM", 553, 566], ["chest compressions", "TREATMENT", 583, 601], ["low", "OBSERVATION", 36, 39], ["chest", "ANATOMY", 294, 299], ["cardiac", "ANATOMY", 331, 338], ["arrest", "OBSERVATION", 339, 345], ["cardiac", "ANATOMY", 385, 392], ["arrest", "OBSERVATION", 393, 399], ["carotid", "ANATOMY", 553, 560], ["chest", "ANATOMY", 583, 588]]], ["At the end of 2011, Ishikawa Medical Control Council implemented new criteria for start of chest compressions encouraging EMS to start chest compressions when carotid pulse was week and/or <50/min in comatose adult patient with respiratory arrest or agonal breathing.", [["chest", "ANATOMY", 91, 96], ["chest", "ANATOMY", 135, 140], ["carotid", "ANATOMY", 159, 166], ["respiratory", "ANATOMY", 228, 239], ["comatose", "DISEASE", 200, 208], ["respiratory arrest", "DISEASE", 228, 246], ["chest", "ORGANISM_SUBDIVISION", 91, 96], ["chest", "ORGANISM_SUBDIVISION", 135, 140], ["carotid", "MULTI-TISSUE_STRUCTURE", 159, 166], ["patient", "ORGANISM", 215, 222], ["patient", "SPECIES", 215, 222], ["chest compressions", "TREATMENT", 91, 109], ["chest compressions", "TEST", 135, 153], ["carotid pulse", "TEST", 159, 172], ["respiratory arrest", "PROBLEM", 228, 246], ["agonal breathing", "PROBLEM", 250, 266], ["chest", "ANATOMY", 91, 96], ["chest", "ANATOMY", 135, 140], ["carotid", "ANATOMY", 159, 166], ["respiratory arrest", "OBSERVATION", 228, 246], ["agonal breathing", "OBSERVATION", 250, 266]]], ["Methods: Data were prospectively collected for out-of-hospital cardiac and respiratory arrests during the period of 2008-2015.", [["cardiac", "ANATOMY", 63, 70], ["respiratory", "ANATOMY", 75, 86], ["cardiac and respiratory arrests", "DISEASE", 63, 94], ["cardiac", "ORGAN", 63, 70], ["respiratory arrests", "OBSERVATION", 75, 94]]], ["Definitive cardiac arrest was recorded when loss of carotid pulse was confirmed by pulse checks performed every 2 min after the early start of chest compressions.", [["cardiac", "ANATOMY", 11, 18], ["carotid", "ANATOMY", 52, 59], ["chest", "ANATOMY", 143, 148], ["cardiac arrest", "DISEASE", 11, 25], ["cardiac", "ORGAN", 11, 18], ["carotid", "MULTI-TISSUE_STRUCTURE", 52, 59], ["chest", "ORGANISM_SUBDIVISION", 143, 148], ["Definitive cardiac arrest", "PROBLEM", 0, 25], ["loss of carotid pulse", "PROBLEM", 44, 65], ["pulse checks", "TEST", 83, 95], ["chest compressions", "TREATMENT", 143, 161], ["cardiac", "ANATOMY", 11, 18], ["arrest", "OBSERVATION", 19, 25], ["carotid", "ANATOMY", 52, 59], ["chest", "ANATOMY", 143, 148]]], ["The effect of early chest compressions on the proportions of definitive cardiac arrest was analysed in 243 cases with respiratory arrest and circulatory depression in initial patient evaluation.", [["chest", "ANATOMY", 20, 25], ["cardiac", "ANATOMY", 72, 79], ["respiratory", "ANATOMY", 118, 129], ["cardiac arrest", "DISEASE", 72, 86], ["respiratory arrest", "DISEASE", 118, 136], ["circulatory depression", "DISEASE", 141, 163], ["chest", "ORGANISM_SUBDIVISION", 20, 25], ["cardiac", "ORGAN", 72, 79], ["patient", "ORGANISM", 175, 182], ["patient", "SPECIES", 175, 182], ["early chest compressions", "TREATMENT", 14, 38], ["definitive cardiac arrest", "PROBLEM", 61, 86], ["respiratory arrest", "PROBLEM", 118, 136], ["circulatory depression", "PROBLEM", 141, 163], ["initial patient evaluation", "TEST", 167, 193], ["chest", "ANATOMY", 20, 25], ["cardiac", "ANATOMY", 72, 79], ["arrest", "OBSERVATION", 80, 86], ["respiratory arrest", "OBSERVATION", 118, 136], ["circulatory depression", "OBSERVATION", 141, 163]]], ["Before/after comparison of neurologically favourable 1-Y survival was performed in 619 cases with EMS-witnessed OHCA.", [["OHCA", "DISEASE", 112, 116]]], ["Results: The early start of chest compressions did not significantly prevent definitive cardiac arrest that followed respiratory arrest with circulatory depression in the initial patient evaluation (Fig. 1) .", [["chest", "ANATOMY", 28, 33], ["cardiac", "ANATOMY", 88, 95], ["respiratory", "ANATOMY", 117, 128], ["cardiac arrest", "DISEASE", 88, 102], ["respiratory arrest", "DISEASE", 117, 135], ["circulatory depression", "DISEASE", 141, 163], ["chest", "ORGANISM_SUBDIVISION", 28, 33], ["cardiac", "ORGAN", 88, 95], ["patient", "ORGANISM", 179, 186], ["patient", "SPECIES", 179, 186], ["chest compressions", "TREATMENT", 28, 46], ["definitive cardiac arrest", "PROBLEM", 77, 102], ["respiratory arrest", "PROBLEM", 117, 135], ["circulatory depression", "PROBLEM", 141, 163], ["the initial patient evaluation", "TEST", 167, 197], ["chest", "ANATOMY", 28, 33], ["cardiac", "ANATOMY", 88, 95], ["arrest", "OBSERVATION", 96, 102], ["respiratory arrest", "OBSERVATION", 117, 135], ["circulatory depression", "OBSERVATION", 141, 163]]], ["Time interval between start of chest compressions and definitive cardiac arrest confirmation (median; IQR) was 2; 1.5-3 min.", [["chest", "ANATOMY", 31, 36], ["cardiac", "ANATOMY", 65, 72], ["cardiac arrest", "DISEASE", 65, 79], ["chest", "ORGANISM_SUBDIVISION", 31, 36], ["chest compressions", "TREATMENT", 31, 49], ["definitive cardiac arrest", "TREATMENT", 54, 79], ["chest", "ANATOMY", 31, 36], ["cardiac", "ANATOMY", 65, 72], ["arrest", "OBSERVATION", 73, 79]]], ["The survival rate of all EMS-witnessed OHCAs after the implementation of new criteria was significantly higher than that before the implementation: adjusted OR; 95% CI, 1.86; 1.02-3.40 (Fig. 2) .", [["OHCAs", "DISEASE", 39, 44], ["EMS", "CHEMICAL", 25, 28], ["CI", "TEST", 165, 167]]], ["No complications related to early chest compressions were reported during the study period.", [["chest", "ANATOMY", 34, 39], ["chest", "ORGANISM_SUBDIVISION", 34, 39], ["complications", "PROBLEM", 3, 16], ["early chest compressions", "TREATMENT", 28, 52], ["the study", "TEST", 74, 83], ["complications", "OBSERVATION", 3, 16], ["chest", "ANATOMY", 34, 39], ["compressions", "OBSERVATION", 40, 52]]], ["Conclusions: Start of chest compressions before definitive cardiac arrest improved survival from out-of-hospital cardiac arrest witnessed by emergency medical service.", [["chest", "ANATOMY", 22, 27], ["cardiac", "ANATOMY", 59, 66], ["cardiac", "ANATOMY", 113, 120], ["cardiac arrest", "DISEASE", 59, 73], ["cardiac arrest", "DISEASE", 113, 127], ["chest", "ORGAN", 22, 27], ["cardiac", "ORGAN", 113, 120], ["chest compressions", "TREATMENT", 22, 40], ["definitive cardiac arrest", "PROBLEM", 48, 73], ["chest", "ANATOMY", 22, 27], ["cardiac", "ANATOMY", 59, 66], ["arrest", "OBSERVATION", 67, 73], ["cardiac", "ANATOMY", 113, 120], ["arrest", "OBSERVATION", 121, 127]]], ["Healthcare providers including EMS personnel should be encouraged to provide chest compressions on cases with respiratory arrest and severe cardiovascular depression.", [["chest", "ANATOMY", 77, 82], ["respiratory", "ANATOMY", 110, 121], ["cardiovascular", "ANATOMY", 140, 154], ["respiratory arrest", "DISEASE", 110, 128], ["cardiovascular depression", "DISEASE", 140, 165], ["chest", "ORGANISM_SUBDIVISION", 77, 82], ["chest compressions", "TREATMENT", 77, 95], ["respiratory arrest", "PROBLEM", 110, 128], ["severe cardiovascular depression", "PROBLEM", 133, 165], ["chest", "ANATOMY", 77, 82], ["respiratory arrest", "OBSERVATION", 110, 128], ["severe", "OBSERVATION_MODIFIER", 133, 139], ["cardiovascular depression", "OBSERVATION", 140, 165]]], ["Introduction: Our study sought to determine if there is a difference in time to tracheal intubation between direct and video laryngoscopy during cardiac compressions.", [["tracheal", "ANATOMY", 80, 88], ["cardiac", "ANATOMY", 145, 152], ["tracheal", "ORGAN", 80, 88], ["cardiac", "ORGAN", 145, 152], ["Our study", "TEST", 14, 23], ["tracheal intubation", "TREATMENT", 80, 99], ["direct and video laryngoscopy", "TEST", 108, 137], ["cardiac compressions", "TREATMENT", 145, 165], ["tracheal", "ANATOMY", 80, 88], ["intubation", "OBSERVATION", 89, 99], ["cardiac", "ANATOMY", 145, 152], ["compressions", "OBSERVATION", 153, 165]]], ["Guidelines suggest no more than 5 seconds should be taken to perform intubation to minimise any delay in compressions [1, 2] .", [["intubation", "TREATMENT", 69, 79]]], ["It is unclear if use of video laryngoscopes results in faster intubation times during cardiac arrest.", [["cardiac", "ANATOMY", 86, 93], ["cardiac arrest", "DISEASE", 86, 100], ["video laryngoscopes", "TEST", 24, 43], ["faster intubation", "TREATMENT", 55, 72], ["cardiac arrest", "PROBLEM", 86, 100], ["cardiac", "ANATOMY", 86, 93], ["arrest", "OBSERVATION", 94, 100]]], ["Participants' baseline data obtained by questionnaire.", [["Participants", "SPECIES", 0, 12]]], ["Resusci-Anne\u2122 manikin with Airway Trainer\u2122 head [Laerdal] with grade 1 airway was utilised.", [["head", "ANATOMY", 43, 47], ["airway", "ANATOMY", 71, 77], ["airway", "MULTI-TISSUE_STRUCTURE", 71, 77], ["Resusci-", "TREATMENT", 0, 8], ["Airway", "ANATOMY", 27, 33], ["airway", "ANATOMY", 71, 77]]], ["Participants intubated the manikin 3 times, once with each of: MacIntosh size 3 blade, C-Mac video laryngoscope (Karl Storz, Germany) with size 3 blade and portable McGrath MAC enhanced video laryngoscope (Medtronic, USA) with size 3 blade.", [["Participants", "SPECIES", 0, 12], ["C-Mac video laryngoscope", "TREATMENT", 87, 111], ["size 3 blade", "TREATMENT", 139, 151], ["size 3 blade", "TREATMENT", 227, 239], ["Mac", "ANATOMY", 89, 92]]], ["Order of laryngoscopes was randomised by computer generated sequence.", [["laryngoscopes", "TREATMENT", 9, 22]]], ["Continuous cardiac compressions were performed throughout attempts.", [["cardiac", "ANATOMY", 11, 18], ["cardiac", "ORGAN", 11, 18], ["Continuous cardiac compressions", "TREATMENT", 0, 31], ["cardiac", "ANATOMY", 11, 18], ["compressions", "OBSERVATION", 19, 31]]], ["Results: Total 54 participants.", [["participants", "SPECIES", 18, 30]]], ["There was a statistically significant difference in time to intubation between the 3 devices using Friedman test (p<0.01).", [["intubation", "TREATMENT", 60, 70], ["the 3 devices", "TREATMENT", 79, 92], ["Friedman test", "TEST", 99, 112], ["statistically", "OBSERVATION_MODIFIER", 12, 25], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["difference", "OBSERVATION_MODIFIER", 38, 48]]], ["Wilcox signed-rank test demonstrated time to intubation with videolaryngoscopy was longer, C-Mac (p=0.032) andP413McGrath (p=0.011) compared with direct laryngoscopy.", [["intubation", "TREATMENT", 45, 55], ["videolaryngoscopy", "TEST", 61, 78], ["direct laryngoscopy", "TEST", 146, 165]]], ["There was no significant difference between the two videolaryngoscopes (p = 0.401).", [["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35]]], ["When controlled for participants level of seniority and previous experience with device, direct laryngoscopy was still significantly faster than C-Mac (p = 0.009) and McGrath (p = 0.017) Conclusions: Our study showed a disadvantage of video laryngoscopy during cardiac compressions.", [["cardiac", "ANATOMY", 261, 268], ["cardiac", "ORGAN", 261, 268], ["participants", "SPECIES", 20, 32], ["device", "TREATMENT", 81, 87], ["direct laryngoscopy", "TEST", 89, 108], ["Our study", "TEST", 200, 209], ["video laryngoscopy", "TEST", 235, 253], ["cardiac compressions", "TREATMENT", 261, 281], ["cardiac", "ANATOMY", 261, 268], ["compressions", "OBSERVATION", 269, 281]]], ["Faster intubation times with direct laryngoscopy could result in less pause in compressions and decrease periods without perfusion.", [["Faster intubation", "TREATMENT", 0, 17], ["direct laryngoscopy", "TEST", 29, 48], ["compressions", "TREATMENT", 79, 91], ["less", "OBSERVATION_MODIFIER", 65, 69], ["pause", "OBSERVATION", 70, 75], ["decrease", "OBSERVATION_MODIFIER", 96, 104]]], ["Direct laryngoscopy is an appropriate first choice for tracheal intubation during cardiac arrest.", [["tracheal", "ANATOMY", 55, 63], ["cardiac", "ANATOMY", 82, 89], ["cardiac arrest", "DISEASE", 82, 96], ["tracheal", "ORGAN", 55, 63], ["Direct laryngoscopy", "TEST", 0, 19], ["tracheal intubation", "TREATMENT", 55, 74], ["cardiac arrest", "PROBLEM", 82, 96], ["tracheal", "ANATOMY", 55, 63], ["intubation", "OBSERVATION", 64, 74], ["cardiac", "ANATOMY", 82, 89], ["arrest", "OBSERVATION", 90, 96]]], ["Introduction: The aim of this study was to describe the coronary angiographic findings in relation to specific ECG changes and comorbidity in survivors after cardiac arrest.P413Methods: A retrospective cohort study of out-of-hospital cardiac arrest patients with data retrieved between 2008-2013 from national registries in Sweden.", [["coronary", "ANATOMY", 56, 64], ["cardiac", "ANATOMY", 158, 165], ["cardiac", "ANATOMY", 234, 241], ["cardiac arrest", "DISEASE", 158, 172], ["cardiac arrest", "DISEASE", 234, 248], ["coronary", "MULTI-TISSUE_STRUCTURE", 56, 64], ["patients", "ORGANISM", 249, 257], ["patients", "SPECIES", 249, 257], ["this study", "TEST", 25, 35], ["comorbidity", "PROBLEM", 127, 138], ["cardiac arrest", "PROBLEM", 158, 172], ["A retrospective cohort study", "TEST", 186, 214], ["coronary", "ANATOMY", 56, 64], ["cardiac", "ANATOMY", 158, 165], ["arrest", "OBSERVATION", 166, 172], ["cardiac", "ANATOMY", 234, 241], ["arrest", "OBSERVATION", 242, 248]]], ["Unconscious patients with coronary angiography performed within 28 days after return of spontaneous circulation and available ECG were included (Fig. 1) .P413Results: After exclusion, 1133 patients were analyzed (Fig. 1) , (Table 1) .", [["coronary", "ANATOMY", 26, 34], ["patients", "ORGANISM", 12, 20], ["coronary", "MULTI-TISSUE_STRUCTURE", 26, 34], ["patients", "ORGANISM", 189, 197], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 189, 197], ["coronary angiography", "TEST", 26, 46], ["ECG", "TEST", 126, 129], ["coronary", "ANATOMY", 26, 34]]], ["249 (22%) were women and mean age were 64 years.", [["women", "ORGANISM", 15, 20], ["women", "SPECIES", 15, 20]]], ["Patients without ST-elevation were separated into groups with specified ECG changes and comorbidities.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["ST-elevation", "PROBLEM", 17, 29], ["comorbidities", "PROBLEM", 88, 101], ["elevation", "OBSERVATION", 20, 29]]], ["Differences were observed in the incidence of any significant stenosis, total occlusion and PCI performed, between the specified ECG changes, as well as between the comorbidity groups ( Introduction: Fewer women after return of spontaneous circulation from Out-of-Hospital Cardiac Arrest (OHCA) are undergoing coronary angiography (CAG) with possible Percutaneous Coronary Intervention (PCI).", [["Cardiac", "ANATOMY", 273, 280], ["coronary", "ANATOMY", 310, 318], ["Coronary", "ANATOMY", 364, 372], ["stenosis", "DISEASE", 62, 70], ["OHCA", "DISEASE", 289, 293], ["women", "ORGANISM", 206, 211], ["coronary", "MULTI-TISSUE_STRUCTURE", 310, 318], ["Coronary", "MULTI-TISSUE_STRUCTURE", 364, 372], ["women", "SPECIES", 206, 211], ["any significant stenosis", "PROBLEM", 46, 70], ["total occlusion", "TREATMENT", 72, 87], ["PCI", "TREATMENT", 92, 95], ["coronary angiography", "TEST", 310, 330], ["CAG", "TEST", 332, 335], ["Percutaneous Coronary Intervention", "TREATMENT", 351, 385], ["PCI", "TREATMENT", 387, 390], ["significant", "OBSERVATION_MODIFIER", 50, 61], ["stenosis", "OBSERVATION", 62, 70], ["total", "OBSERVATION_MODIFIER", 72, 77], ["occlusion", "OBSERVATION", 78, 87], ["PCI", "OBSERVATION", 92, 95], ["Cardiac", "ANATOMY", 273, 280], ["Arrest", "OBSERVATION", 281, 287], ["coronary", "ANATOMY", 310, 318], ["Coronary", "ANATOMY", 364, 372]]], ["The aim was to investigate gender differences in comorbidity, CAG findings and outcome after OHCA in comatose patients with a shockable first ECG rhythm.", [["OHCA", "DISEASE", 93, 97], ["comatose", "DISEASE", 101, 109], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["comorbidity", "PROBLEM", 49, 60], ["CAG findings", "PROBLEM", 62, 74], ["a shockable first ECG rhythm", "PROBLEM", 124, 152]]], ["Methods: A retrospective cohort study of out-of-hospital cardiac arrest patients with data retrieved between 2008-2013 from national registries in Sweden (Fig. 1) .", [["cardiac", "ANATOMY", 57, 64], ["cardiac arrest", "DISEASE", 57, 71], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["A retrospective cohort study", "TEST", 9, 37], ["cardiac", "ANATOMY", 57, 64], ["arrest", "OBSERVATION", 65, 71]]], ["Results: There was no difference in age or comorbidity except for men having more ischemic heart disease, 21.5 vs 15.0% (p=0.006).", [["heart", "ANATOMY", 91, 96], ["ischemic heart disease", "DISEASE", 82, 104], ["men", "ORGANISM", 66, 69], ["heart", "ORGAN", 91, 96], ["men", "SPECIES", 66, 69], ["comorbidity", "PROBLEM", 43, 54], ["more ischemic heart disease", "PROBLEM", 77, 104], ["no", "UNCERTAINTY", 19, 21], ["ischemic", "OBSERVATION_MODIFIER", 82, 90], ["heart", "ANATOMY", 91, 96], ["disease", "OBSERVATION", 97, 104]]], ["Rates of previous myocardial infarction did not differ, 8.2 vs 6.3%.", [["myocardial", "ANATOMY", 18, 28], ["myocardial infarction", "DISEASE", 18, 39], ["myocardial", "MULTI-TISSUE_STRUCTURE", 18, 28], ["previous myocardial infarction", "PROBLEM", 9, 39], ["myocardial", "ANATOMY", 18, 28], ["infarction", "OBSERVATION", 29, 39]]], ["No difference was seen in rates of ECG indicating prompt CAG according to guidelines.", [["ECG", "TEST", 35, 38], ["prompt CAG", "TREATMENT", 50, 60], ["difference", "OBSERVATION_MODIFIER", 3, 13]]], ["Still, more men underwent CAG but no difference in numbers of CAG leading to PCI was seen (Table 1) .", [["men", "ORGANISM", 12, 15], ["men", "SPECIES", 12, 15], ["CAG", "TREATMENT", 26, 29], ["CAG", "PROBLEM", 62, 65], ["PCI", "TREATMENT", 77, 80], ["no", "UNCERTAINTY", 34, 36]]], ["Furthermore, in patients with ST elevation or LBBB, no gender difference in CAG and subsequent PCI was found.", [["LBBB", "DISEASE", 46, 50], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["ST elevation", "PROBLEM", 30, 42], ["LBBB", "PROBLEM", 46, 50], ["gender difference in CAG", "PROBLEM", 55, 79], ["subsequent PCI", "TREATMENT", 84, 98], ["LBBB", "ANATOMY", 46, 50], ["no", "UNCERTAINTY", 52, 54], ["PCI", "OBSERVATION", 95, 98]]], ["Men had lower rates of normal CAG findings but more triple vessel and left main coronary artery disease ( Table 2) .", [["vessel", "ANATOMY", 59, 65], ["left main coronary artery", "ANATOMY", 70, 95], ["coronary artery disease", "DISEASE", 80, 103], ["vessel", "MULTI-TISSUE_STRUCTURE", 59, 65], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 80, 95], ["Men", "SPECIES", 0, 3], ["normal CAG findings", "PROBLEM", 23, 42], ["left main coronary artery disease", "PROBLEM", 70, 103], ["normal CAG", "OBSERVATION", 23, 33], ["vessel", "ANATOMY", 59, 65], ["left main coronary artery", "ANATOMY", 70, 95], ["disease", "OBSERVATION", 96, 103]]], ["Conclusions: Our study suggests, that despite no gender differences in rate of ECG findings indicating a prompt CAG, men seems to have a more severe coronary artery disease while women have more frequently normal angiograms.", [["coronary artery", "ANATOMY", 149, 164], ["coronary artery disease", "DISEASE", 149, 172], ["men", "ORGANISM", 117, 120], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 149, 164], ["women", "ORGANISM", 179, 184], ["men", "SPECIES", 117, 120], ["women", "SPECIES", 179, 184], ["Our study", "TEST", 13, 22], ["ECG findings", "TEST", 79, 91], ["a prompt CAG", "PROBLEM", 103, 115], ["a more severe coronary artery disease", "PROBLEM", 135, 172], ["severe", "OBSERVATION_MODIFIER", 142, 148], ["coronary artery", "ANATOMY", 149, 164], ["disease", "OBSERVATION", 165, 172]]], ["Introduction: The circadian clock influences a number of cardiovascular physiological processes.", [["cardiovascular", "ANATOMY", 57, 71], ["cardiovascular", "ANATOMICAL_SYSTEM", 57, 71]]], ["A time-of-day variation in infarct size has recently been shown in patients with ST segment elevation myocardial infarction.", [["infarct", "ANATOMY", 27, 34], ["myocardial", "ANATOMY", 102, 112], ["infarct", "DISEASE", 27, 34], ["myocardial infarction", "DISEASE", 102, 123], ["patients", "ORGANISM", 67, 75], ["myocardial", "MULTI-TISSUE_STRUCTURE", 102, 112], ["patients", "SPECIES", 67, 75], ["infarct size", "PROBLEM", 27, 39], ["ST segment elevation myocardial infarction", "PROBLEM", 81, 123], ["infarct", "OBSERVATION", 27, 34], ["size", "OBSERVATION_MODIFIER", 35, 39], ["segment", "ANATOMY_MODIFIER", 84, 91], ["elevation myocardial", "ANATOMY", 92, 112], ["infarction", "OBSERVATION", 113, 123]]], ["However, there is no clinical evidence of circadian variation in patients with out-of-hospital cardiac arrest (OHCA) of cardiac etiology.", [["cardiac", "ANATOMY", 95, 102], ["cardiac", "ANATOMY", 120, 127], ["cardiac arrest", "DISEASE", 95, 109], ["OHCA", "DISEASE", 111, 115], ["cardiac etiology", "DISEASE", 120, 136], ["patients", "ORGANISM", 65, 73], ["cardiac", "ORGAN", 120, 127], ["patients", "SPECIES", 65, 73], ["circadian variation", "PROBLEM", 42, 61], ["hospital cardiac arrest", "PROBLEM", 86, 109], ["no clinical evidence of", "UNCERTAINTY", 18, 41], ["circadian variation", "OBSERVATION", 42, 61], ["cardiac", "ANATOMY", 95, 102], ["arrest", "OBSERVATION", 103, 109], ["cardiac", "ANATOMY", 120, 127], ["etiology", "OBSERVATION", 128, 136]]], ["Methods: We performed retrospective analysis using data from Japan's nationwide OHCA registry from January 2005 through December 2012, which includes all OHCA patients presented with ventricular fibrillation as first documented rhythm, and consequently confirmed cardiac etiology.", [["ventricular", "ANATOMY", 183, 194], ["cardiac", "ANATOMY", 263, 270], ["OHCA", "DISEASE", 154, 158], ["ventricular fibrillation", "DISEASE", 183, 207], ["cardiac etiology", "DISEASE", 263, 279], ["patients", "ORGANISM", 159, 167], ["ventricular", "MULTI-TISSUE_STRUCTURE", 183, 194], ["cardiac", "ORGAN", 263, 270], ["patients", "SPECIES", 159, 167], ["retrospective analysis", "TEST", 22, 44], ["ventricular fibrillation", "PROBLEM", 183, 207], ["ventricular", "ANATOMY", 183, 194], ["fibrillation", "OBSERVATION", 195, 207], ["cardiac", "ANATOMY", 263, 270], ["etiology", "OBSERVATION", 271, 279]]], ["In order to eliminate the night and weekend effects, we enrolled only patients suffered OHCA in the morning We conduct a retrospective cohort study focusing on the association between OHCA outcome and ICU bed availability.", [["OHCA", "DISEASE", 88, 92], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["a retrospective cohort study", "TEST", 119, 147]]], ["The OHCA data was acquired from a regional emergency operation center, and the ICU bed information was obtained from a regional sur it exceeds physiological levels in order to avoid insufficient oxygenation [1] .", [["The OHCA data", "TEST", 0, 13]]], ["Hyperoxia has been associated with increased in-hospital mortality, though uncertainty remains about this association.", [["Hyperoxia", "DISEASE", 0, 9], ["Hyperoxia", "PROBLEM", 0, 9], ["increased", "OBSERVATION_MODIFIER", 35, 44]]], ["Multiwave pulse co-oximetry has safely been studied intraoperatively as a guide to monitor hyper-and hypoxia by calculating an oxygen reserve index (ORI) which could add information to pulse oximetry measures when SpO2 is >98% [2] .P413Methods: This is a monocentric prospective study including 12 patients with successful resuscitation following OHCA.", [["hypoxia", "DISEASE", 101, 108], ["oxygen", "CHEMICAL", 127, 133], ["OHCA", "DISEASE", 347, 351], ["oxygen", "CHEMICAL", 127, 133], ["oxygen", "SIMPLE_CHEMICAL", 127, 133], ["patients", "ORGANISM", 298, 306], ["patients", "SPECIES", 298, 306], ["Multiwave pulse co-oximetry", "TEST", 0, 27], ["hyper", "PROBLEM", 91, 96], ["hypoxia", "PROBLEM", 101, 108], ["an oxygen reserve index", "TEST", 124, 147], ["pulse oximetry measures", "TEST", 185, 208], ["SpO2", "TEST", 214, 218], ["a monocentric prospective study", "TEST", 253, 284], ["successful resuscitation", "TREATMENT", 312, 336]]], ["The aim of our study is to evaluate the feasibility and assess the availability of novel non invasive oxygen and hemodynamic variables.", [["oxygen", "CHEMICAL", 102, 108], ["oxygen", "CHEMICAL", 102, 108], ["oxygen", "SIMPLE_CHEMICAL", 102, 108], ["our study", "TEST", 11, 20], ["novel non invasive oxygen", "TREATMENT", 83, 108], ["hemodynamic variables", "TEST", 113, 134]]], ["Collected data principally concern blood oxygen and circulation such as ORI, SpO2, total Hb, perfusion index and pulse rates.", [["blood", "ANATOMY", 35, 40], ["oxygen", "CHEMICAL", 41, 47], ["oxygen", "CHEMICAL", 41, 47], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["oxygen", "SIMPLE_CHEMICAL", 41, 47], ["Hb", "SIMPLE_CHEMICAL", 89, 91], ["Collected data", "TEST", 0, 14], ["blood oxygen", "TEST", 35, 47], ["ORI", "TEST", 72, 75], ["SpO2", "TEST", 77, 81], ["total Hb", "TEST", 83, 91], ["perfusion index", "TEST", 93, 108], ["pulse rates", "TEST", 113, 124]]], ["Recording is ideally started at time of ROSC.", [["ROSC", "TEST", 40, 44], ["ROSC", "OBSERVATION", 40, 44]]], ["Results: We monitored 12 consecutive patients for a total time of 456.8 min during transport from OHCA place to the ER.", [["ER", "ANATOMY", 116, 118], ["patients", "ORGANISM", 37, 45], ["ER", "GENE_OR_GENE_PRODUCT", 116, 118], ["ER", "PROTEIN", 116, 118], ["patients", "SPECIES", 37, 45]]], ["SpO2 signal was present for 82.3% of transport time.Oxygen Reserve Index signal was present for 58.5% of the total transport time.", [["Oxygen", "CHEMICAL", 52, 58], ["Oxygen", "SIMPLE_CHEMICAL", 52, 58], ["SpO2 signal", "TEST", 0, 11], ["Oxygen Reserve Index signal", "TEST", 52, 79]]], ["Pleth variability index (PVI) signal was present 59.8% of the total transport time.", [["Pleth variability index", "TEST", 0, 23], ["PVI) signal", "TEST", 25, 36]]], ["SpHb signal was present 44.7% of total time from ROSC to hospital.", [["SpHb", "GENE_OR_GENE_PRODUCT", 0, 4], ["SpHb", "PROTEIN", 0, 4], ["SpHb signal", "TEST", 0, 11]]], ["The confidence interval for each variable is given in Fig. 1 .P413Conclusions: Our pilot study shows that noninvasive measurements of hyperoxia, fluid responsiveness and hemoglobin are readily available from the prehospital phase of post-ROSC care allowing for early tailored and goal directed interventions. increase in SOFA score was associated with 170\u20ac (95% CI 150-180\u20ac) increase in the cost per day alive in the first 12 months after CA.Conclusions:The SOFA score is a good indicator of disease severity but the overlap between outcome groups does not allow its use for early prognostication in CA patients.", [["fluid", "ORGANISM_SUBSTANCE", 145, 150], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 170, 180], ["patients", "ORGANISM", 603, 611], ["hemoglobin", "PROTEIN", 170, 180], ["patients", "SPECIES", 603, 611], ["The confidence interval", "TREATMENT", 0, 23], ["Our pilot study", "TEST", 79, 94], ["noninvasive measurements", "TEST", 106, 130], ["hyperoxia", "PROBLEM", 134, 143], ["fluid responsiveness", "TEST", 145, 165], ["hemoglobin", "TEST", 170, 180], ["post-ROSC care", "TREATMENT", 233, 247], ["goal directed interventions", "TREATMENT", 280, 307], ["SOFA score", "TEST", 321, 331], ["The SOFA score", "TEST", 454, 468], ["disease severity", "PROBLEM", 492, 508], ["hyperoxia", "OBSERVATION", 134, 143], ["fluid responsiveness", "OBSERVATION", 145, 165], ["SOFA score", "OBSERVATION", 321, 331], ["disease", "OBSERVATION", 492, 499]]], ["The association of SOFA and its sub-scores with 12-month outcome and healthcare costs highlights that in addition to neurologic damage the full spectrum of multiple organ failure affects the survival and morbidity of CA patients.P424Public opinion on cardiopulmonary resuscitation decision and outcome in out-of-hospital cardiac arrest patientsquestionnaire study TY Li 1 Introduction: Metabolomics is a novel approach that can characterize small molecules (metabolites) and has the potential to explore genotype-phenotype and genotype-environment interactions, delivering an accurate snapshot of the subject's metabolic status.", [["neurologic", "ANATOMY", 117, 127], ["organ", "ANATOMY", 165, 170], ["cardiopulmonary", "ANATOMY", 251, 266], ["cardiac", "ANATOMY", 321, 328], ["neurologic damage", "DISEASE", 117, 134], ["organ failure", "DISEASE", 165, 178], ["cardiac arrest", "DISEASE", 321, 335], ["Li", "CHEMICAL", 367, 369], ["organ", "ORGAN", 165, 170], ["patients", "ORGANISM", 220, 228], ["patients", "SPECIES", 220, 228], ["SOFA", "TEST", 19, 23], ["neurologic damage", "PROBLEM", 117, 134], ["multiple organ failure", "PROBLEM", 156, 178], ["cardiopulmonary resuscitation", "TREATMENT", 251, 280], ["a novel approach", "TREATMENT", 402, 418], ["genotype-phenotype", "PROBLEM", 504, 522], ["multiple", "OBSERVATION_MODIFIER", 156, 164], ["organ", "ANATOMY", 165, 170], ["failure", "OBSERVATION", 171, 178], ["cardiopulmonary", "ANATOMY", 251, 266], ["cardiac", "ANATOMY", 321, 328], ["arrest", "OBSERVATION", 329, 335]]], ["In this context, the aim of metabolomics is to improve early diagnosis, classification, and prediction over the development of a pathological condition.", [["a pathological condition", "PROBLEM", 127, 151]]], ["To this end, metabolomics have not been used in the characterisation of cardiac arrest (CA), cardiopulmonary resuscitation (CPR) and return of spontaneous resuscitation (ROSC).", [["cardiac", "ANATOMY", 72, 79], ["cardiac arrest", "DISEASE", 72, 86], ["cardiac", "ORGAN", 72, 79], ["cardiac arrest", "PROBLEM", 72, 86], ["cardiopulmonary resuscitation", "TREATMENT", 93, 122], ["CPR", "TREATMENT", 124, 127], ["spontaneous resuscitation", "TREATMENT", 143, 168], ["cardiac", "ANATOMY", 72, 79], ["arrest", "OBSERVATION", 80, 86], ["cardiopulmonary", "ANATOMY", 93, 108]]], ["The aim of the present study was to explore whether metabolomics can characterize the CA versus ROSC in a swine model of ventricular fibrillation (VF).", [["ventricular", "ANATOMY", 121, 132], ["ventricular fibrillation", "DISEASE", 121, 145], ["VF", "DISEASE", 147, 149], ["CA", "GENE_OR_GENE_PRODUCT", 86, 88], ["ventricular", "MULTI-TISSUE_STRUCTURE", 121, 132], ["swine", "SPECIES", 106, 111], ["the present study", "TEST", 11, 28], ["the CA", "PROBLEM", 82, 88], ["ROSC", "PROBLEM", 96, 100], ["ventricular fibrillation", "PROBLEM", 121, 145], ["ventricular", "ANATOMY", 121, 132], ["fibrillation", "OBSERVATION", 133, 145]]], ["Methods: Ten animals were intubated and instrumented and VF was induced with the use of a cadmium battery.", [["VF", "DISEASE", 57, 59], ["cadmium", "CHEMICAL", 90, 97], ["cadmium", "CHEMICAL", 90, 97], ["animals", "ORGANISM", 13, 20], ["cadmium", "SIMPLE_CHEMICAL", 90, 97], ["intubated", "TREATMENT", 26, 35], ["VF", "PROBLEM", 57, 59], ["a cadmium battery", "TREATMENT", 88, 105]]], ["VF was left untreated for 6min and the animals were then resuscitated according to the 2010 guidelines.", [["VF", "PROBLEM", 0, 2], ["left", "ANATOMY_MODIFIER", 7, 11], ["untreated", "OBSERVATION", 12, 21]]], ["Defibrillation was attempted in all animals.", [["Defibrillation", "TREATMENT", 0, 14]]], ["Venous blood was drown at baseline, 2 min, 4 min, 6 min during untreated CA and finally at 2min, 30min, 2h, 6h after ROSC in order to determine the metabolomic profile during CA and during the early post-resuscitation period.", [["Venous blood", "ANATOMY", 0, 12], ["Venous blood", "ORGANISM_SUBSTANCE", 0, 12], ["Venous blood", "TEST", 0, 12], ["ROSC", "TREATMENT", 117, 121], ["blood", "ANATOMY", 7, 12]]], ["ROSC was defined as the presence of an organized cardiac rhythm with a mean arterial pressure of at least 50 mmHg for >5 min.", [["cardiac", "ANATOMY", 49, 56], ["arterial", "ANATOMY", 76, 84], ["cardiac", "ORGAN", 49, 56], ["arterial", "MULTI-TISSUE_STRUCTURE", 76, 84], ["ROSC", "PROBLEM", 0, 4], ["a mean arterial pressure", "TEST", 69, 93], ["cardiac", "ANATOMY", 49, 56], ["rhythm", "OBSERVATION", 57, 63], ["mean arterial pressure", "OBSERVATION", 71, 93]]], ["Blood was centrifuged and serum was analysed by high resolution 1H-NMR spectroscopy.", [["Blood", "ANATOMY", 0, 5], ["serum", "ANATOMY", 26, 31], ["1H", "CHEMICAL", 64, 66], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 26, 31], ["Blood", "TEST", 0, 5], ["serum", "TEST", 26, 31], ["NMR spectroscopy", "TEST", 67, 83]]], ["NMR spectral data were submitted to multivariate discriminant analysis.P424Results: Eight animals survived the experiment and were included in the analysis.", [["NMR spectral data", "TEST", 0, 17], ["multivariate discriminant analysis", "TEST", 36, 70], ["the analysis", "TEST", 143, 155]]], ["Metabolites upregulated in the immediate ROSC versus CA were succinate, hypoxanthine, choline and lactate.", [["succinate", "CHEMICAL", 61, 70], ["hypoxanthine", "CHEMICAL", 72, 84], ["choline", "CHEMICAL", 86, 93], ["lactate", "CHEMICAL", 98, 105], ["succinate", "CHEMICAL", 61, 70], ["hypoxanthine", "CHEMICAL", 72, 84], ["choline", "CHEMICAL", 86, 93], ["lactate", "CHEMICAL", 98, 105], ["CA", "GENE_OR_GENE_PRODUCT", 53, 55], ["succinate", "SIMPLE_CHEMICAL", 61, 70], ["hypoxanthine", "SIMPLE_CHEMICAL", 72, 84], ["choline", "SIMPLE_CHEMICAL", 86, 93], ["lactate", "SIMPLE_CHEMICAL", 98, 105], ["CA", "TEST", 53, 55], ["hypoxanthine, choline and lactate", "TEST", 72, 105]]], ["Metabolites upregulated in the 2 hour ROSC versus CA were ornithine and alanine.", [["ornithine", "CHEMICAL", 58, 67], ["alanine", "CHEMICAL", 72, 79], ["ornithine", "CHEMICAL", 58, 67], ["alanine", "CHEMICAL", 72, 79], ["CA", "GENE_OR_GENE_PRODUCT", 50, 52], ["ornithine", "SIMPLE_CHEMICAL", 58, 67], ["alanine", "AMINO_ACID", 72, 79], ["CA", "PROBLEM", 50, 52], ["alanine", "TEST", 72, 79]]], ["The 3 measured phases are shown in Fig. 1 Introduction: Early outcome prognostication in successfully resuscitated out-of-hospital cardiac arrest (OHCA) patients remains challenging.", [["cardiac", "ANATOMY", 131, 138], ["cardiac arrest", "DISEASE", 131, 145], ["OHCA", "DISEASE", 147, 151], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 153, 161], ["cardiac arrest", "PROBLEM", 131, 145], ["cardiac", "ANATOMY", 131, 138], ["arrest", "OBSERVATION", 139, 145]]], ["Prediction models supporting the early decision to continue with full supportive treatment could be of major interest following OHCA.", [["full supportive treatment", "TREATMENT", 65, 90]]], ["We constructed prognostic models able to predict good neurologic outcome within 48 hours after ICU admission.", [["neurologic", "ANATOMY", 54, 64]]], ["Methods: Upon ICU admission, targeted temperature management at 33\u00b0C, hemodynamic and neuromonitoring (cerebral oxygen saturation measured with near-infrared spectroscopy and bispectral index (BIS)) was initiated.", [["cerebral", "ANATOMY", 103, 111], ["oxygen", "CHEMICAL", 112, 118], ["oxygen", "CHEMICAL", 112, 118], ["cerebral", "ORGAN", 103, 111], ["oxygen", "SIMPLE_CHEMICAL", 112, 118], ["targeted temperature management", "TREATMENT", 29, 60], ["neuromonitoring (cerebral oxygen saturation", "TEST", 86, 129], ["infrared spectroscopy", "TEST", 149, 170]]], ["Prediction models for good neurologic outcome at 180 days post-CA were constructed at hour 1, 12, 24 and 48 after admission using variables easily collectable and known to be predictive for outcome.", [["neurologic", "ANATOMY", 27, 37], ["Prediction models", "TEST", 0, 17]]], ["After multiple imputation, variables were selected using the elastic-net method.", [["the elastic-net method", "TREATMENT", 57, 79]]], ["Each imputed dataset was divided into training and validation sets (80% and 20% of patients, respectively).", [["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["validation sets", "TEST", 51, 66]]], ["Cut-off probabilities yielding a sensitivity above 90% were determined and performance of all logistic regression models was assessed using misclassification rates.", [["a sensitivity", "TEST", 31, 44], ["all logistic regression models", "TEST", 90, 120], ["misclassification rates", "TEST", 140, 163]]], ["Introduction: In many venues, EMS crews limit on-scene care for pediatric out-hospital cardiac arrest (POHCA), attempting treatment during transport.", [["cardiac", "ANATOMY", 87, 94], ["cardiac arrest", "DISEASE", 87, 101], ["POHCA", "DISEASE", 103, 108], ["treatment", "TREATMENT", 122, 131], ["cardiac", "ANATOMY", 87, 94], ["arrest", "OBSERVATION", 95, 101]]], ["Hypothesizing that neuro-intact survival can be improved by prioritizing on-site care, strategies were effected to expedite on-scene drug delivery and intubation (with controlled ventilation).", [["scene drug delivery", "TREATMENT", 127, 146], ["intubation", "TREATMENT", 151, 161], ["controlled ventilation", "TREATMENT", 168, 190]]], ["Methods: From 1/1/2012 to 4/30/2017, data for POHCA cases were collected.", [["POHCA cases", "TEST", 46, 57]]], ["In 2014, new training prioritized on-site resuscitation (Phase I) using expedited drug delivery and intubation with controlled ventilation (~6 breaths/min).", [["-site resuscitation", "TREATMENT", 36, 55], ["expedited drug delivery", "TREATMENT", 72, 95], ["intubation", "TREATMENT", 100, 110], ["controlled ventilation", "TREATMENT", 116, 138]]], ["In 2016, drugs were prepared while responding (Phase II).", [["drugs", "TREATMENT", 9, 14]]], ["2010 American Heart Association guidelines were used throughout and no other modifications were made.", [["Heart", "ANATOMY", 14, 19]]], ["Results: Over the 5.33-years, EMS faced 143 consecutive POHCA cases.", [["POHCA", "DISEASE", 56, 61], ["EMS", "CHEMICAL", 30, 33]]], ["The great majority presented in asystole throughout.", [["asystole", "DISEASE", 32, 40], ["asystole", "PROBLEM", 32, 40], ["great", "OBSERVATION_MODIFIER", 4, 9], ["majority", "OBSERVATION_MODIFIER", 10, 18], ["asystole", "OBSERVATION", 32, 40]]], ["In those resuscitated, mean time from on-scene arrival to the 1st epinephrine infusion fell from 16.5 min (2012-13) to 7.3 min (Phase I) and 5.0 min (Phase II).", [["epinephrine", "CHEMICAL", 66, 77], ["epinephrine", "CHEMICAL", 66, 77], ["epinephrine", "SIMPLE_CHEMICAL", 66, 77], ["the 1st epinephrine infusion", "TREATMENT", 58, 86]]], ["By 2017, it was 2 min. for resuscitated patients and 3.33 min. for all patients.", [["patients", "ORGANISM", 40, 48], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 71, 79]]], ["Intubation and intraosseous insertion occurred more frequently in Phase I/II, but there were no significant differences in age, sex, etiology, response times, bystander CPR or drug sequencing.", [["intraosseous", "ANATOMY", 15, 27], ["Intubation", "TREATMENT", 0, 10], ["intraosseous insertion", "TREATMENT", 15, 37], ["bystander CPR", "TREATMENT", 159, 172], ["drug sequencing", "TREATMENT", 176, 191], ["intraosseous insertion", "OBSERVATION", 15, 37], ["no", "UNCERTAINTY", 93, 95], ["significant", "OBSERVATION_MODIFIER", 96, 107], ["differences", "OBSERVATION_MODIFIER", 108, 119]]], ["Neuro-intact survival improved significantly from 0/38 in 2012-13 to 23.2% (13/56) in Phase I and 34.7% (17/49) in Phase II (p < 0.0001; 2-tailed Fisher's exact test) (Fig. 1) .", [["Phase I", "TEST", 86, 93], ["Fisher's exact test", "TEST", 146, 165]]], ["Conclusions: Although historically-controlled, the sudden appearance of neuro-intact survivors following a renewed focus on rapid on-site care was profound, immediate and sustained.", [["neuro-intact survivors", "PROBLEM", 72, 94], ["rapid on-site care", "TREATMENT", 124, 142]]], ["Effecting neurologically-intact survival for children with out-of-hospital cardiac arrest P430 Improved outcomes with a bundled resuscitation technique to enhance venous return out of the brain and into the heart during cardiopulmonary resuscitation PE Pepe 1 , KA Scheppke 2 , PM Antevy 2 , D Millstone 2 , C Coyle 2 , C Prusansky 2 , S Garay 2 , JC Moore Introduction: Lowering intracranial pressure to improve brain perfusion during CPR has become a focus for our team.", [["cardiac", "ANATOMY", 75, 82], ["venous", "ANATOMY", 163, 169], ["brain", "ANATOMY", 188, 193], ["heart", "ANATOMY", 207, 212], ["cardiopulmonary", "ANATOMY", 220, 235], ["intracranial", "ANATOMY", 380, 392], ["brain", "ANATOMY", 413, 418], ["cardiac arrest", "DISEASE", 75, 89], ["children", "ORGANISM", 45, 53], ["venous", "MULTI-TISSUE_STRUCTURE", 163, 169], ["brain", "ORGAN", 188, 193], ["heart", "ORGAN", 207, 212], ["intracranial", "MULTI-TISSUE_STRUCTURE", 380, 392], ["brain", "ORGAN", 413, 418], ["children", "SPECIES", 45, 53], ["a bundled resuscitation technique", "TREATMENT", 118, 151], ["venous return", "TEST", 163, 176], ["cardiopulmonary resuscitation", "TREATMENT", 220, 249], ["Pepe", "TEST", 253, 257], ["KA Scheppke", "TREATMENT", 262, 273], ["D Millstone", "TREATMENT", 292, 303], ["C Coyle 2", "TREATMENT", 308, 317], ["Lowering intracranial pressure", "TREATMENT", 371, 401], ["CPR", "TREATMENT", 436, 439], ["venous", "ANATOMY", 163, 169], ["brain", "ANATOMY", 188, 193], ["heart", "ANATOMY", 207, 212], ["cardiopulmonary", "ANATOMY", 220, 235], ["PE", "OBSERVATION", 250, 252], ["intracranial pressure", "OBSERVATION", 380, 401]]], ["Combined with devices that enhance venous return out of the brain and into the thorax during CPR, outcomes have improved using head/chest elevation in the laboratory (Fig. 1) .", [["venous", "ANATOMY", 35, 41], ["brain", "ANATOMY", 60, 65], ["thorax", "ANATOMY", 79, 85], ["head", "ANATOMY", 127, 131], ["chest", "ANATOMY", 132, 137], ["venous", "MULTI-TISSUE_STRUCTURE", 35, 41], ["brain", "ORGAN", 60, 65], ["thorax", "ORGAN", 79, 85], ["head", "ORGANISM_SUBDIVISION", 127, 131], ["chest", "ORGANISM_SUBDIVISION", 132, 137], ["devices", "TREATMENT", 14, 21], ["CPR", "TREATMENT", 93, 96], ["head/chest elevation", "TEST", 127, 147], ["venous", "ANATOMY", 35, 41], ["return", "OBSERVATION", 42, 48], ["brain", "ANATOMY", 60, 65], ["thorax", "ANATOMY", 79, 85], ["chest", "ANATOMY", 132, 137]]], ["This study's purpose was to confirm the safety/clinical feasibility of this new approach involving mechanical CPR at an angle.", [["This study's purpose", "TEST", 0, 20], ["this new approach", "TREATMENT", 71, 88], ["mechanical CPR", "TREATMENT", 99, 113]]], ["Methods: 2,285 consecutive out-of-hospital cardiac arrest (OOHCA) cases (all rhythms) were studied for 3.5 years (1/1/14 to 30/6/17) in an expansive, socio-economically-diverse U.S. county (pop.", [["cardiac", "ANATOMY", 43, 50], ["cardiac arrest", "DISEASE", 43, 57], ["OOHCA", "DISEASE", 59, 64], ["arrest", "OBSERVATION", 51, 57], ["expansive", "OBSERVATION_MODIFIER", 139, 148]]], ["In 2014, EMS crews used the Lucas\u00a9 and impedance threshold (ITD) devices on such patients, but, after April 2015, they also: 1) applied O2 and deferred +-pressure ventilation several min; 2) raised the backboard~20\u00b0; and 3) solidified a pit-crew approach to expedite Lucas\u00a9 placement.", [["O2", "CHEMICAL", 136, 138], ["O2", "CHEMICAL", 136, 138], ["patients", "ORGANISM", 81, 89], ["O2", "SIMPLE_CHEMICAL", 136, 138], ["Lucas\u00a9", "SIMPLE_CHEMICAL", 267, 273], ["patients", "SPECIES", 81, 89], ["the Lucas\u00a9 and impedance threshold (ITD) devices", "TREATMENT", 24, 72], ["O2", "TREATMENT", 136, 138], ["deferred +-pressure ventilation", "TREATMENT", 143, 174], ["a pit-crew approach", "TREATMENT", 235, 254], ["expedite Lucas\u00a9 placement", "TREATMENT", 258, 283]]], ["Neuro-intact survival was not recorded until 2015, so resuscitation by EMS to hospital admission was used for consistency.", [["resuscitation", "TREATMENT", 54, 67]]], ["Quarterly reports were run to identify any periodic variations or incremental effects during protocol transition (Quarter 2, 2015).", [["any periodic variations", "PROBLEM", 39, 62]]], ["Results: No problems were observed with head/torso-up positioning (n=1,319), but rates of resuscitation rose steadily during the transition period with an ensuing sustained doubling (Fig. 2 ) over the ensuing 2 years when compared to those studied (n=806) prior to the head-up approach (mean 35.2%; range 30-40% vs. 17.9%, range 15-20%; p < 0.0001).", [["head", "ANATOMY", 40, 44], ["head", "ANATOMY", 269, 273], ["head", "ORGANISM_SUBDIVISION", 40, 44], ["problems", "PROBLEM", 12, 20], ["head/torso", "TEST", 40, 50], ["resuscitation", "TREATMENT", 90, 103], ["the head-up approach", "TEST", 265, 285], ["mean", "TEST", 287, 291], ["range", "TEST", 299, 304], ["range", "TEST", 323, 328], ["torso", "ANATOMY", 45, 50], ["head", "ANATOMY", 269, 273]]], ["Response intervals, indications for attempting CPR and bystander CPR rates were unchanged.", [["CPR", "TREATMENT", 47, 50], ["bystander CPR rates", "TEST", 55, 74], ["unchanged", "OBSERVATION_MODIFIER", 80, 89]]], ["Resuscitation rates in 2015-17 remained proportional to neuro-intact survival.", [["Resuscitation rates", "TEST", 0, 19]]], ["Conclusions: The head/torso-up CPR bundle was not only feasible, but also associated with an immediate, steady rise in resuscitation rates during the transition phase with a sustained doubling of resuscitation rates, making a compelling case that this bundled technique may improve OOHCA outcomes in future clinical trials.", [["head", "ANATOMY", 17, 21], ["head", "ORGANISM_SUBDIVISION", 17, 21], ["The head/torso", "TEST", 13, 27], ["resuscitation rates", "TREATMENT", 196, 215], ["this bundled technique", "TREATMENT", 247, 269], ["head", "ANATOMY", 17, 21], ["torso", "ANATOMY", 22, 27], ["steady", "OBSERVATION_MODIFIER", 104, 110], ["rise", "OBSERVATION_MODIFIER", 111, 115]]], ["Introduction: Cardiac arrest (CA) often requires intensive care unit (ICU) treatment, which is costly.", [["Cardiac", "ANATOMY", 14, 21], ["Cardiac arrest", "DISEASE", 14, 28], ["Cardiac arrest", "PROBLEM", 14, 28], ["ICU) treatment", "TREATMENT", 70, 84], ["Cardiac", "ANATOMY", 14, 21], ["arrest", "OBSERVATION", 22, 28]]], ["While there are plenty of data regarding post-CA outcomes, knowledge of cardiac arrest associated healthcare costs is virtually non-existent.", [["cardiac", "ANATOMY", 72, 79], ["cardiac arrest", "DISEASE", 72, 86], ["cardiac", "ORGAN", 72, 79], ["cardiac arrest", "PROBLEM", 72, 86], ["cardiac", "ANATOMY", 72, 79], ["arrest", "OBSERVATION", 80, 86]]], ["Methods: We performed a single-center registry-based study to determine expenditure data for ICU-treated CA patients between 2005 and 2013.", [["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["based study", "TEST", 47, 58]]], ["Healthcare cost evaluation included costs from the initial hospital treatment, rehabilitation costs and social security costs up to one year post-CA.", [["Healthcare cost evaluation", "TEST", 0, 26], ["the initial hospital treatment", "TREATMENT", 47, 77], ["rehabilitation costs", "TREATMENT", 79, 99]]], ["We calculated mean healthcare costs for one year survivors and for hospital survivors who died within the first year after cardiac arrest.", [["cardiac", "ANATOMY", 123, 130], ["cardiac arrest", "DISEASE", 123, 137], ["cardiac arrest", "PROBLEM", 123, 137], ["cardiac", "ANATOMY", 123, 130], ["arrest", "OBSERVATION", 131, 137]]], ["We calculated effective costs per independent survivor (ECPIS) as an indicator of cost-effectiveness.", [["effective", "OBSERVATION_MODIFIER", 14, 23]]], ["Results: We identified 1,314 CA patients eligible for the analyses.P424At one year after CA 52% of the patients were alive and 40% were alive and independent in daily activities.", [["patients", "ORGANISM", 32, 40], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 103, 111], ["the analyses", "TEST", 54, 66], ["CA", "TEST", 89, 91]]], ["One year survival stratified by cardiac arrest location group was 59% for out-ofhospital CA patients, 47% for in-hospital CA patients and 27% for in-ICU CA patients.", [["cardiac", "ANATOMY", 32, 39], ["cardiac arrest", "DISEASE", 32, 46], ["cardiac", "ORGAN", 32, 39], ["patients", "ORGANISM", 92, 100], ["patients", "ORGANISM", 125, 133], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 92, 100], ["patients", "SPECIES", 125, 133], ["patients", "SPECIES", 156, 164], ["cardiac", "ANATOMY", 32, 39], ["arrest", "OBSERVATION", 40, 46]]], ["For the whole study population, mean healthcare costs were 50,211\u20ac per patient.", [["patient", "ORGANISM", 71, 78], ["patient", "SPECIES", 71, 78], ["the whole study", "TEST", 4, 19]]], ["Healthcare costs for hospital survivors were 67,928\u20ac per patient and for hospital non-survivors 22,100\u20ac per patient.", [["patient", "ORGANISM", 57, 64], ["patient", "ORGANISM", 108, 115], ["patient", "SPECIES", 57, 64], ["patient", "SPECIES", 108, 115]]], ["Healthcare costs for those who survived to hospital discharge but died within the first year were 56,490\u20ac per patient, while for one year survivors they were 70,148\u20ac per patient.", [["patient", "ORGANISM", 110, 117], ["patient", "ORGANISM", 170, 177], ["patient", "SPECIES", 110, 117], ["patient", "SPECIES", 170, 177]]], ["Healthcare costs stratified by CA location are presented in Fig. 1 .", [["CA", "GENE_OR_GENE_PRODUCT", 31, 33]]], ["Mean ECPIS were 65,684\u20ac.", [["Mean ECPIS", "TEST", 0, 10]]], ["Conclusions: For ICU-treated cardiac arrest patients, the mean ECPIS were close to 65,000\u20ac.", [["cardiac", "ANATOMY", 29, 36], ["cardiac arrest", "DISEASE", 29, 43], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["cardiac arrest", "PROBLEM", 29, 43], ["the mean ECPIS", "TEST", 54, 68], ["cardiac", "ANATOMY", 29, 36], ["arrest", "OBSERVATION", 37, 43]]], ["The best prognosis and the lowest costs were observed for out-of-hospital CA patients.", [["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85]]], ["Introduction: In Lithuania the incidence of out-of-hospital cardiac arrest (OHCA) is unknown, as there is no official coding for OHCA as a cause of death in the national death registry.", [["cardiac", "ANATOMY", 60, 67], ["cardiac arrest", "DISEASE", 60, 74], ["OHCA", "DISEASE", 76, 80], ["OHCA", "DISEASE", 129, 133], ["death", "DISEASE", 148, 153], ["death", "DISEASE", 170, 175], ["OHCA", "PROBLEM", 129, 133], ["death", "PROBLEM", 148, 153], ["cardiac", "ANATOMY", 60, 67], ["arrest", "OBSERVATION", 68, 74]]], ["We sought to describe the epidemiology and outcomes from OHCA in Kaunas, the second largest Lithuanian city.", [["OHCA", "DISEASE", 57, 61], ["largest", "OBSERVATION_MODIFIER", 84, 91]]], ["Methods: The incidence, demographics and outcomes of patients who were treated for an OHCA between 1st January 2016 and 31st December 2016 in Kaunas EMS, serving a population of almost 0.3 million, were collected and are reported in accordance with 2014 Utstein recommendations.", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61]]], ["Results: In total, 313 OHCA cases of EMS treated cardiac arrests were reported (105 per 100.000 of resident population).", [["cardiac", "ANATOMY", 49, 56], ["OHCA", "DISEASE", 23, 27], ["EMS", "DISEASE", 37, 40], ["cardiac arrests", "DISEASE", 49, 64], ["EMS", "CHEMICAL", 37, 40], ["cardiac arrests", "PROBLEM", 49, 64]]], ["The mean age was 67.7 (SD=15.7) years and 64.9% were male.", [["The mean age", "TEST", 0, 12], ["SD", "TEST", 23, 25]]], ["70% OHCA cases occurred at home and 52.7% were witnessed by either EMS or a bystander.", [["OHCA", "DISEASE", 4, 8]]], ["In non-EMS witnessed cases, 43.8% received bystander CPR, whilst public access defibrillation was not used.", [["bystander CPR", "TREATMENT", 43, 56], ["public access defibrillation", "TREATMENT", 65, 93]]], ["Medical dispatcher identified OHCA in 71.3% of all cases and provided over-the-phone CPR instructions in 60.2% of them.", [["OHCA", "DISEASE", 30, 34]]], ["Cardiac aetiology was the leading cause of cardiac arrest (84.3%).", [["Cardiac", "ANATOMY", 0, 7], ["cardiac", "ANATOMY", 43, 50], ["Cardiac aetiology", "DISEASE", 0, 17], ["cardiac arrest", "DISEASE", 43, 57], ["Cardiac", "ORGAN", 0, 7], ["cardiac", "ORGAN", 43, 50], ["cardiac arrest", "PROBLEM", 43, 57], ["cardiac", "ANATOMY", 43, 50], ["arrest", "OBSERVATION", 51, 57]]], ["The initial rhythm was shockable (VF or pVT) in 26% and non-shockable (asystole or EMD) in 70.5% of all cases.", [["VF", "DISEASE", 34, 36], ["asystole", "DISEASE", 71, 79], ["shockable", "PROBLEM", 23, 32], ["VF", "PROBLEM", 34, 36], ["pVT", "PROBLEM", 40, 43], ["asystole", "PROBLEM", 71, 79]]], ["Return of spontaneous circulation (ROSC) at hospital transfer was evident in 24.9% and survival to hospital discharge was 8.6%.", [["spontaneous", "OBSERVATION_MODIFIER", 10, 21], ["circulation", "OBSERVATION_MODIFIER", 22, 33]]], ["Conclusions: ROSC and survival to hospital discharge in Kaunas were similar to those reported in United Kingdom in 2014 [1] .", [["ROSC", "PROBLEM", 13, 17]]], ["Routine OHCA data collection and analysis will allow us to track the efficiency of service improvements and should become a standard practice in all Lithuanian regions.P433Outcomes of patients admitted to intensive care following cardiac arrest J McLoughlin, E Landymore, P Morgan East Surrey Hospital, Surrey, UK Critical Care 2018, 22(Suppl 1):P433 Introduction: Patients who have return of spontaneous circulation following a cardiac arrest are haemodynamically unstable and require critical care input.", [["cardiac", "ANATOMY", 230, 237], ["cardiac", "ANATOMY", 429, 436], ["cardiac arrest", "DISEASE", 230, 244], ["cardiac arrest", "DISEASE", 429, 443], ["patients", "ORGANISM", 184, 192], ["Patients", "ORGANISM", 365, 373], ["patients", "SPECIES", 184, 192], ["Patients", "SPECIES", 365, 373], ["Routine OHCA data collection", "TEST", 0, 28], ["analysis", "TEST", 33, 41], ["a standard practice", "TREATMENT", 122, 141], ["spontaneous circulation", "PROBLEM", 393, 416], ["a cardiac arrest", "PROBLEM", 427, 443], ["haemodynamically unstable", "PROBLEM", 448, 473], ["cardiac", "ANATOMY", 230, 237], ["arrest", "OBSERVATION", 238, 244], ["cardiac", "ANATOMY", 429, 436], ["arrest", "OBSERVATION", 437, 443]]], ["Outcomes are often poor, with unadjusted survival to hospital discharge at 18.4%, following an in hospital cardiac arrest [1] .", [["cardiac", "ANATOMY", 107, 114], ["cardiac arrest", "DISEASE", 107, 121]]], ["The aim of the study was to assess the survival of patients admitted to intensive care following a cardiac arrest, reviewing whether age and gender impacted on their outcome.", [["cardiac", "ANATOMY", 99, 106], ["cardiac arrest", "DISEASE", 99, 113], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["the study", "TEST", 11, 20], ["a cardiac arrest", "TREATMENT", 97, 113], ["cardiac", "ANATOMY", 99, 106], ["arrest", "OBSERVATION", 107, 113]]], ["Since 1993, 519 patients were admitted following a cardiac arrest (both in and out of hospital).", [["cardiac", "ANATOMY", 51, 58], ["cardiac arrest", "DISEASE", 51, 65], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["a cardiac arrest", "PROBLEM", 49, 65], ["cardiac", "ANATOMY", 51, 58], ["arrest", "OBSERVATION", 59, 65]]], ["Results: 210 female patients and 309 male patients of varying ages were admitted to our ICU following a cardiac arrest.", [["cardiac", "ANATOMY", 104, 111], ["cardiac arrest", "DISEASE", 104, 118], ["patients", "ORGANISM", 20, 28], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 42, 50], ["a cardiac arrest", "PROBLEM", 102, 118], ["cardiac", "ANATOMY", 104, 111], ["arrest", "OBSERVATION", 112, 118]]], ["The mortality for both genders increased with increasing age.", [["increased", "OBSERVATION_MODIFIER", 31, 40]]], ["Overall survival to the time of ICU discharge following a cardiac arrest was similar for both females (44.3%) and males (48.5%).", [["cardiac", "ANATOMY", 58, 65], ["cardiac arrest", "DISEASE", 58, 72], ["a cardiac arrest", "PROBLEM", 56, 72], ["cardiac", "ANATOMY", 58, 65], ["arrest", "OBSERVATION", 66, 72]]], ["Figures 1 (female) and 2 (male) below show the number of patients who survived or died on ICU discharge, by age and gender.", [["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65]]], ["Mortality rates increased when reviewing hospital outcome, as some patients died following discharge to the ward.", [["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["Mortality rates", "TEST", 0, 15]]], ["Conclusions: Overall mortality in our ICU following a cardiac arrest at any age is at least 50%, with the general trend appearing to rise with increasing age.", [["cardiac", "ANATOMY", 54, 61], ["cardiac arrest", "DISEASE", 54, 68], ["a cardiac arrest", "PROBLEM", 52, 68], ["Overall", "OBSERVATION_MODIFIER", 13, 20], ["mortality", "OBSERVATION", 21, 30], ["cardiac", "ANATOMY", 54, 61], ["arrest", "OBSERVATION", 62, 68]]], ["More male patients were admitted to ICU following a cardiac arrest than female, with similar survival rates for both male and female patients.", [["cardiac", "ANATOMY", 52, 59], ["cardiac arrest", "DISEASE", 52, 66], ["patients", "ORGANISM", 10, 18], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 10, 18], ["patients", "SPECIES", 133, 141], ["a cardiac arrest", "PROBLEM", 50, 66], ["cardiac", "ANATOMY", 52, 59], ["arrest", "OBSERVATION", 60, 66]]], ["More research could be undertaken to assess whether survival rates following a cardiac arrest have improved since 1993 and also to compare outcomes following either an in or out of hospital arrest.", [["cardiac", "ANATOMY", 79, 86], ["cardiac arrest", "DISEASE", 79, 93], ["a cardiac arrest", "PROBLEM", 77, 93], ["cardiac", "ANATOMY", 79, 86], ["arrest", "OBSERVATION", 87, 93]]], ["Introduction: Raw simplified EEG tracings obtained by a bispectral index (BIS) device significantly correlate with standard EEG [1] .", [["Raw simplified EEG tracings", "TEST", 14, 41], ["a bispectral index", "TEST", 54, 72], ["standard EEG", "TEST", 115, 127]]], ["This study aimed to investigate whether simplified BIS EEG tracings can predict poor neurologic outcome after cardiac arrest (CA).", [["neurologic", "ANATOMY", 85, 95], ["cardiac", "ANATOMY", 110, 117], ["cardiac arrest", "DISEASE", 110, 124], ["This study", "TEST", 0, 10], ["simplified BIS EEG tracings", "TEST", 40, 67], ["poor neurologic outcome", "PROBLEM", 80, 103], ["cardiac arrest", "PROBLEM", 110, 124], ["cardiac", "ANATOMY", 110, 117], ["arrest", "OBSERVATION", 118, 124]]], ["Methods: Bilateral BIS monitoring (BIS VISTATM, Aspect Medical Systems, Inc. Norwood, USA) was started following ICU admission.", [["Bilateral BIS monitoring", "TEST", 9, 33], ["Bilateral", "ANATOMY_MODIFIER", 9, 18]]], ["Six, 12, 18, 24, 36 and 48hrs after targeted temperature management (TTM) at 33\u00b0C was started, raw simplified BIS EEG tracings were extracted and reviewed by two neurophysiologists for the presence of burst suppression, cerebral inactivity and epileptic activity.", [["cerebral", "ANATOMY", 220, 228], ["cerebral inactivity", "DISEASE", 220, 239], ["epileptic", "DISEASE", 244, 253], ["cerebral", "ORGAN", 220, 228], ["targeted temperature management", "TREATMENT", 36, 67], ["TTM", "TEST", 69, 72], ["BIS EEG tracings", "TEST", 110, 126], ["burst suppression", "PROBLEM", 201, 218], ["cerebral inactivity", "PROBLEM", 220, 239], ["epileptic activity", "PROBLEM", 244, 262], ["burst suppression", "OBSERVATION", 201, 218], ["cerebral", "ANATOMY", 220, 228], ["inactivity", "OBSERVATION", 229, 239], ["epileptic activity", "OBSERVATION", 244, 262]]], ["At 180 days post-CA, neurologic outcome was determined using the CPC scale, where a CPC1-2 and CPC3-5 corresponded to good and poor neurologic outcome, respectively.", [["neurologic", "ANATOMY", 21, 31], ["neurologic", "ANATOMY", 132, 142], ["CPC1-2", "GENE_OR_GENE_PRODUCT", 84, 90], ["CPC3-5", "GENE_OR_GENE_PRODUCT", 95, 101], ["CPC3-5", "DNA", 95, 101], ["the CPC scale", "TEST", 61, 74], ["a CPC1", "TEST", 82, 88], ["CPC3", "TEST", 95, 99]]], ["Results: Of the 75 enrolled CA-patients enrolled, 40 had good and 35 poor neurologic outcome.", [["neurologic", "ANATOMY", 74, 84], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["enrolled CA", "TEST", 19, 30], ["poor neurologic outcome", "PROBLEM", 69, 92]]], ["With a positive predictive value (PPV) of 1.000 and a negative predictive value (NPV) of 0.606, epileptic activity within 6-12hrs predicted a CPC3-5 with the highest accuracy.", [["epileptic", "DISEASE", 96, 105], ["CPC3-5", "DNA", 142, 148], ["PPV", "TEST", 34, 37], ["NPV", "TEST", 81, 84], ["epileptic activity", "PROBLEM", 96, 114], ["a CPC3", "TEST", 140, 146]]], ["Epileptic activity within time frames 18-24hrs and 36-48hrs showed a PPV for poor outcome of 0.917 and 0.938, respectively.", [["Epileptic", "DISEASE", 0, 9], ["Epileptic activity", "PROBLEM", 0, 18], ["a PPV", "TEST", 67, 72]]], ["Cerebral inactivity within 6-12hrs had a poor predictive power (PPV=0.545, NPV=0.566).", [["Cerebral", "ANATOMY", 0, 8], ["Cerebral inactivity", "DISEASE", 0, 19], ["Cerebral", "MULTI-TISSUE_STRUCTURE", 0, 8], ["Cerebral inactivity", "PROBLEM", 0, 19], ["PPV", "TEST", 64, 67], ["NPV", "TEST", 75, 78]]], ["In contrast, cerebral inactivity between 36-48hrs predicted a CPC3-5 with a PPV of 1.000 and a NPV of 0.597.", [["cerebral", "ANATOMY", 13, 21], ["cerebral inactivity", "DISEASE", 13, 32], ["cerebral", "ORGAN", 13, 21], ["CPC3", "PROTEIN", 62, 66], ["cerebral inactivity", "PROBLEM", 13, 32], ["a CPC3", "TEST", 60, 66], ["a PPV", "TEST", 74, 79], ["a NPV", "TEST", 93, 98], ["cerebral", "ANATOMY", 13, 21]]], ["The pattern with the worst predictive power at any time point was burst suppression with a PPV of 0.363, 0.529 and 0.500 at 6-12hrs, at 18-24hrs and at 36-48hrs, respectively.P433Conclusions: Based on simplified EEG derived from a BIS device, both the presence of epileptic activity at any time as well as cerebral inactivity after the end of TTM can be used to assist with poor outcome prognostication in successfully resuscitated CA patients.P436The helicopter as first response tool -Rio de Janeiro Fire Department experience. (interquartile range=28) min, followed by TIH with 552 flights (34%) and median time of 65 (IQR=70) min, and 270 (17%) were NEO missions with median time of 120 (IQR=92) min.", [["cerebral", "ANATOMY", 306, 314], ["epileptic", "DISEASE", 264, 273], ["cerebral inactivity", "DISEASE", 306, 325], ["cerebral", "ORGAN", 306, 314], ["patients", "ORGANISM", 435, 443], ["P436", "GENE_OR_GENE_PRODUCT", 444, 448], ["patients", "SPECIES", 435, 443], ["burst suppression", "PROBLEM", 66, 83], ["a PPV", "TEST", 89, 94], ["simplified EEG", "TEST", 201, 215], ["a BIS device", "TREATMENT", 229, 241], ["epileptic activity", "PROBLEM", 264, 282], ["cerebral inactivity", "PROBLEM", 306, 325], ["NEO missions", "TREATMENT", 654, 666], ["burst suppression", "OBSERVATION", 66, 83], ["epileptic activity", "OBSERVATION", 264, 282], ["cerebral", "ANATOMY", 306, 314], ["inactivity", "OBSERVATION", 315, 325]]], ["Total time of aircraft usage was higher for TIH (39%), followed by NEO (32%).", [["TIH", "DISEASE", 44, 47], ["NEO", "TREATMENT", 67, 70]]], ["EVAM was the most frequent mission, however it accounted for 29% of aircraft utilization time, where most victims had traumatic brain injury (TBI) followed by other traumatic injuries (216 and 187 cases respectively).", [["brain", "ANATOMY", 128, 133], ["EVAM", "DISEASE", 0, 4], ["traumatic brain injury", "DISEASE", 118, 140], ["TBI", "DISEASE", 142, 145], ["traumatic injuries", "DISEASE", 165, 183], ["brain", "ORGAN", 128, 133], ["traumatic brain injury", "PROBLEM", 118, 140], ["TBI", "PROBLEM", 142, 145], ["other traumatic injuries", "PROBLEM", 159, 183], ["traumatic", "OBSERVATION_MODIFIER", 118, 127], ["brain", "ANATOMY", 128, 133], ["injury", "OBSERVATION", 134, 140], ["traumatic", "OBSERVATION_MODIFIER", 165, 174], ["injuries", "OBSERVATION", 175, 183]]], ["TBI victims were predominantly males (83%) with a median age of 30(IQR=23) years.", [["TBI", "DISEASE", 0, 3], ["TBI victims", "PROBLEM", 0, 11]]], ["Most commonly, TBI is a consequence of transportation accident (75%), where a motorcycle was involved in 31%, car collision in 24% and pedestrian run over 24% of the cases.", [["TBI", "DISEASE", 15, 18], ["TBI", "PROBLEM", 15, 18]]], ["Conclusions: GOA utilizes the air ambulance helicopter as a first response tool in 49% of total missions, where respect for the Trauma Golden Hour is paramount.", [["Trauma", "DISEASE", 128, 134]]], ["Traumatic brain injury is the most prevalent diagnosis at the scene of event.", [["brain", "ANATOMY", 10, 15], ["Traumatic brain injury", "DISEASE", 0, 22], ["brain", "ORGAN", 10, 15], ["Traumatic brain injury", "PROBLEM", 0, 22], ["brain", "ANATOMY", 10, 15], ["injury", "OBSERVATION", 16, 22], ["most prevalent", "OBSERVATION_MODIFIER", 30, 44]]], ["Therefore, GOA training and equipment must be tailored to meet this demand, which translates in stabilization of critical patients outside hospital environment with limited resources.", [["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["GOA training", "TREATMENT", 11, 23], ["equipment", "TREATMENT", 28, 37]]], ["Introduction: The intra-hospital transport of critical patients is associated with adverse events and worse outcomes.", [["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["adverse events", "PROBLEM", 83, 97]]], ["The objective of this study was to evaluate the safety profile of intrahospital transport after the creation of a specific group for this purpose.", [["this study", "TEST", 17, 27], ["intrahospital transport", "TREATMENT", 66, 89]]], ["Methods: Evaluated all the transports of critical patients from October 2016 to September 2017, in a large hospital, after the creation of a group consisting of intensive care physician, nurse and physiotherapist.", [["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58]]], ["Clinical and non-clinical complications related to the transport and outcome of the patients were evaluated.", [["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["Clinical and non-clinical complications", "PROBLEM", 0, 39]]], ["Results: A total of 1,559 transports were performed, 54.7% of the male patients and 60.9% of the patients being hospitalized.", [["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 97, 105]]], ["10.6% were under mechanical ventilation and 19.8% under vasoactive drugs.", [["mechanical ventilation", "TREATMENT", 17, 39], ["vasoactive drugs", "TREATMENT", 56, 72], ["mechanical ventilation", "OBSERVATION", 17, 39]]], ["At the time of transport, 78.8% were clinically stable.", [["stable", "OBSERVATION_MODIFIER", 48, 54]]], ["During transport, 7.5% presented clinical complications, being more frequent hemodynamic instability (43 patients) and respiratory failure (21 patients).", [["respiratory", "ANATOMY", 119, 130], ["hemodynamic instability", "DISEASE", 77, 100], ["respiratory failure", "DISEASE", 119, 138], ["patients", "ORGANISM", 105, 113], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 105, 113], ["patients", "SPECIES", 143, 151], ["clinical complications", "PROBLEM", 33, 55], ["frequent hemodynamic instability", "PROBLEM", 68, 100], ["respiratory failure", "PROBLEM", 119, 138], ["respiratory", "ANATOMY", 119, 130], ["failure", "OBSERVATION", 131, 138]]], ["Non-clinical complications occurred in 125 patients (8.0%), and communication failures were responsible for 79.2% of the occurrences.", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["Non-clinical complications", "PROBLEM", 0, 26], ["communication failures", "PROBLEM", 64, 86]]], ["In 29 cases (1.9%) there was worsening of the clinical conditions during transportation, and in only one case this worsening resulted in an increase in the length of stay in the ICU and in the hospital, with no correlation with deaths.", [["deaths", "DISEASE", 228, 234], ["the clinical conditions", "PROBLEM", 42, 65], ["worsening", "OBSERVATION_MODIFIER", 29, 38], ["increase", "OBSERVATION_MODIFIER", 140, 148], ["length", "OBSERVATION_MODIFIER", 156, 162]]], ["Conclusions: The implantation of a group specialized in critical patients to carry out in-hospital transport made the process safer with complications rates lower than literature and guarantee better quality of care.P438Clinical profile of patients admitted to ICU due to acute poisoning MP Benitez Moreno 1 , E Curiel Balsera 1 , MC Mart\u00ednez Gonz\u00e1lez 1 , S Jimenez Jimenez 2 1Intensive Care Unit, Hospital Regional Universitario Carlos Haya, Malaga, Spain; 2 Hospital Regional Universitario Carlos Haya, M\u00e1laga, Spain Critical Care 2018, 22(Suppl 1):P438 Introduction: Patients suffering from acute intoxication, whether voluntarily for autolytic or accidental purposes, often require life support in intensive care units.", [["poisoning", "DISEASE", 278, 287], ["MP", "DISEASE", 288, 290], ["patients", "ORGANISM", 65, 73], ["patients", "ORGANISM", 240, 248], ["Patients", "ORGANISM", 570, 578], ["patients", "SPECIES", 65, 73], ["patients", "SPECIES", 240, 248], ["Patients", "SPECIES", 570, 578], ["The implantation", "TREATMENT", 13, 29], ["complications rates", "PROBLEM", 137, 156], ["acute poisoning", "PROBLEM", 272, 287], ["Moreno", "TEST", 299, 305], ["acute intoxication", "PROBLEM", 594, 612], ["autolytic", "PROBLEM", 638, 647], ["life support", "TREATMENT", 686, 698], ["acute", "OBSERVATION_MODIFIER", 594, 599], ["intoxication", "OBSERVATION", 600, 612]]], ["Methods: Retrospective observational study of all patients admitted for acute intoxication who required admission to the ICU of the Regional Hospital of Malaga between January 2012 and August 2016, older than 14 years with admission to the ICU for intoxication of any kind.", [["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["Retrospective observational study", "TEST", 9, 42], ["acute intoxication", "PROBLEM", 72, 90], ["intoxication", "PROBLEM", 248, 260], ["acute", "OBSERVATION_MODIFIER", 72, 77], ["intoxication", "OBSERVATION", 78, 90]]], ["We study patient characteristics in terms of age, sex and medical history, type of toxicity, severity and evolution in our unit.", [["toxicity", "DISEASE", 83, 91], ["patient", "ORGANISM", 9, 16], ["patient", "SPECIES", 9, 16], ["type of toxicity", "PROBLEM", 75, 91], ["severity", "PROBLEM", 93, 101]]], ["Results: We found 70 cases of patients who required admission to the ICU due to acute intoxication, of which 55.6% were women.", [["patients", "ORGANISM", 30, 38], ["women", "ORGANISM", 120, 125], ["patients", "SPECIES", 30, 38], ["women", "SPECIES", 120, 125], ["acute intoxication", "PROBLEM", 80, 98], ["acute", "OBSERVATION_MODIFIER", 80, 85], ["intoxication", "OBSERVATION", 86, 98]]], ["54.2% of patients had a psychiatric history.", [["psychiatric", "DISEASE", 24, 35], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17]]], ["As other background highlights, 19.4% were addicted to illegal drugs and 25% were hypertensive.", [["hypertensive", "DISEASE", 82, 94], ["illegal drugs", "TREATMENT", 55, 68], ["hypertensive", "PROBLEM", 82, 94]]], ["Most patients took more than one toxic 83.3% and intoxication was voluntary in 84.7% versus accidental in 12.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13]]], ["The toxic was known in 68%.", [["toxic", "OBSERVATION_MODIFIER", 4, 9]]], ["The most used benzodiazepines in 26.4% of the total.", [["benzodiazepines", "CHEMICAL", 14, 29], ["benzodiazepines", "CHEMICAL", 14, 29], ["benzodiazepines", "TREATMENT", 14, 29]]], ["The main cause of admission to the ICU was due to neurological deterioration in 49 of the cases registered and mechanical ventilation was necessary in 44 patients.", [["neurological", "ANATOMY", 50, 62], ["neurological deterioration", "DISEASE", 50, 76], ["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 154, 162], ["neurological deterioration", "PROBLEM", 50, 76], ["mechanical ventilation", "TREATMENT", 111, 133], ["main", "OBSERVATION_MODIFIER", 4, 8], ["mechanical ventilation", "OBSERVATION", 111, 133]]], ["The maximum time in mechanical ventilation was 34 days.", [["mechanical ventilation", "TREATMENT", 20, 42], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["mechanical ventilation", "OBSERVATION", 20, 42]]], ["The infection occurred in 24.3%, with the majority being respiratory infection.", [["respiratory", "ANATOMY", 57, 68], ["infection", "DISEASE", 4, 13], ["respiratory infection", "DISEASE", 57, 78], ["The infection", "PROBLEM", 0, 13], ["respiratory infection", "PROBLEM", 57, 78], ["infection", "OBSERVATION", 4, 13], ["respiratory", "ANATOMY", 57, 68], ["infection", "OBSERVATION", 69, 78]]], ["Conclusions: The profile of a patient admitted to the ICU due to acute intoxication is that of a woman of middle age and psychiatric history, with voluntary intoxication of several toxic substances and requiring mechanical ventilation for a low level of consciousness for an average of 3 days.", [["psychiatric", "DISEASE", 121, 132], ["patient", "ORGANISM", 30, 37], ["woman", "ORGANISM", 97, 102], ["patient", "SPECIES", 30, 37], ["woman", "SPECIES", 97, 102], ["acute intoxication", "PROBLEM", 65, 83], ["several toxic substances", "PROBLEM", 173, 197], ["mechanical ventilation", "TREATMENT", 212, 234], ["a low level of consciousness", "PROBLEM", 239, 267], ["acute", "OBSERVATION_MODIFIER", 65, 70], ["intoxication", "OBSERVATION", 71, 83]]], ["The survival is very high and it would be necessary to analyze the possible relapses of these patients.P438AMushroom that break hearts: a case report E Karakoc, K Demirtas, S Ekemen, A Ayyildiz, B Yelken Eskisehir Osmangazi University, Eskisehir, Turkey Critical Care 2018, 22(Suppl 1):P438A Introduction: Because of the high mortality and morbidity mushroom poisoning is a significiant medical emergency [1] .", [["hearts", "ANATOMY", 128, 134], ["mushroom poisoning", "DISEASE", 350, 368], ["patients", "ORGANISM", 94, 102], ["hearts", "ORGAN", 128, 134], ["patients", "SPECIES", 94, 102], ["the high mortality", "PROBLEM", 317, 335]]], ["Amanita phalloides (A. phalloides) is responsible for the 20% of the mortality in adults caused by mushroom poisoning.", [["Amanita phalloides", "DISEASE", 0, 18], ["mushroom poisoning", "DISEASE", 99, 117], ["Amanita phalloides", "ORGANISM", 0, 18], ["A. phalloides", "ORGANISM", 20, 33], ["Amanita phalloides", "SPECIES", 0, 18], ["A. phalloides", "SPECIES", 20, 33], ["Amanita phalloides", "SPECIES", 0, 18], ["A. phalloides", "SPECIES", 20, 33], ["Amanita phalloides", "PROBLEM", 0, 18], ["mushroom poisoning", "PROBLEM", 99, 117]]], ["It causes damage in liver, kidneys and rarely pancreas, causing encephalopathic coma, disseminated intravascular coagulation, hemorrhage, hypovolemic shock and death but its effect on cardiac functions has not been established yet.", [["liver", "ANATOMY", 20, 25], ["kidneys", "ANATOMY", 27, 34], ["pancreas", "ANATOMY", 46, 54], ["intravascular", "ANATOMY", 99, 112], ["cardiac", "ANATOMY", 184, 191], ["damage in liver, kidneys and rarely pancreas", "DISEASE", 10, 54], ["coma", "DISEASE", 80, 84], ["disseminated intravascular coagulation", "DISEASE", 86, 124], ["hemorrhage", "DISEASE", 126, 136], ["hypovolemic shock", "DISEASE", 138, 155], ["death", "DISEASE", 160, 165], ["liver", "ORGAN", 20, 25], ["kidneys", "ORGAN", 27, 34], ["pancreas", "ORGAN", 46, 54], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 99, 112], ["cardiac", "ORGAN", 184, 191], ["damage in liver, kidneys and rarely pancreas", "PROBLEM", 10, 54], ["encephalopathic coma", "PROBLEM", 64, 84], ["disseminated intravascular coagulation", "PROBLEM", 86, 124], ["hemorrhage", "PROBLEM", 126, 136], ["hypovolemic shock", "PROBLEM", 138, 155], ["death", "PROBLEM", 160, 165], ["cardiac functions", "TEST", 184, 201], ["damage", "OBSERVATION", 10, 16], ["liver", "ANATOMY", 20, 25], ["kidneys", "ANATOMY", 27, 34], ["rarely", "ANATOMY_MODIFIER", 39, 45], ["pancreas", "ANATOMY", 46, 54], ["encephalopathic", "OBSERVATION_MODIFIER", 64, 79], ["disseminated", "OBSERVATION_MODIFIER", 86, 98], ["intravascular coagulation", "OBSERVATION", 99, 124], ["hemorrhage", "OBSERVATION", 126, 136], ["hypovolemic shock", "OBSERVATION", 138, 155]]], ["There are three main groups of toxins;phallotoxins, virotoxins and amatoxins;amatoxin is the common responsible toxin from the fatality.", [["amatoxin", "CHEMICAL", 77, 85], ["fatality", "DISEASE", 127, 135], ["amatoxin", "CHEMICAL", 77, 85], ["phallotoxins", "SIMPLE_CHEMICAL", 38, 50], ["virotoxins", "SIMPLE_CHEMICAL", 52, 62], ["amatoxins", "SIMPLE_CHEMICAL", 67, 76], ["amatoxin", "SIMPLE_CHEMICAL", 77, 85], ["toxins", "TREATMENT", 31, 37], ["phallotoxins", "TREATMENT", 38, 50], ["virotoxins", "TREATMENT", 52, 62], ["amatoxins", "TREATMENT", 67, 76], ["amatoxin", "TREATMENT", 77, 85]]], ["We aimed to present a 44-year-old woman poisoned by mushroom complicated with hepatic,renal and cardiac toxicity Methods: Patient with nausea and vomiting started 48 hours after mushroom eating,creatine kinase MB 2.73 ng/mL and cardiac troponin I 0.02 ng/mL Her blood urea nitrogen, creatinine levels and liver enzymes were higher than upper limits in lab tests (Table 1) ; she was admitted to ICU, treated for acute renal failure by hemodialysis.Plasmapheresis was applied against potent mushroom toxins.", [["mushroom", "ANATOMY", 52, 60], ["hepatic", "ANATOMY", 78, 85], ["renal", "ANATOMY", 86, 91], ["cardiac", "ANATOMY", 96, 103], ["mushroom", "ANATOMY", 178, 186], ["cardiac", "ANATOMY", 228, 235], ["blood", "ANATOMY", 262, 267], ["liver", "ANATOMY", 305, 310], ["renal", "ANATOMY", 417, 422], ["hepatic,renal and cardiac toxicity", "DISEASE", 78, 112], ["nausea and vomiting", "DISEASE", 135, 154], ["creatine", "CHEMICAL", 194, 202], ["blood urea nitrogen", "CHEMICAL", 262, 281], ["creatinine", "CHEMICAL", 283, 293], ["acute renal failure", "DISEASE", 411, 430], ["creatine", "CHEMICAL", 194, 202], ["urea", "CHEMICAL", 268, 272], ["nitrogen", "CHEMICAL", 273, 281], ["creatinine", "CHEMICAL", 283, 293], ["woman", "ORGANISM", 34, 39], ["hepatic", "ORGAN", 78, 85], ["renal", "ORGAN", 86, 91], ["cardiac", "ORGAN", 96, 103], ["Patient", "ORGANISM", 122, 129], ["creatine kinase MB", "GENE_OR_GENE_PRODUCT", 194, 212], ["blood", "ORGANISM_SUBSTANCE", 262, 267], ["urea", "SIMPLE_CHEMICAL", 268, 272], ["creatinine", "SIMPLE_CHEMICAL", 283, 293], ["liver", "ORGAN", 305, 310], ["renal", "ORGAN", 417, 422], ["liver enzymes", "PROTEIN", 305, 318], ["woman", "SPECIES", 34, 39], ["Patient", "SPECIES", 122, 129], ["hepatic,renal and cardiac toxicity", "PROBLEM", 78, 112], ["nausea", "PROBLEM", 135, 141], ["vomiting", "PROBLEM", 146, 154], ["creatine kinase MB", "TEST", 194, 212], ["cardiac troponin I", "TEST", 228, 246], ["Her blood urea nitrogen", "TEST", 258, 281], ["creatinine levels", "TEST", 283, 300], ["liver enzymes", "TEST", 305, 318], ["lab tests", "TEST", 352, 361], ["acute renal failure", "PROBLEM", 411, 430], ["hemodialysis", "TREATMENT", 434, 446], ["Plasmapheresis", "TREATMENT", 447, 461], ["hepatic", "ANATOMY", 78, 85], ["renal", "ANATOMY", 86, 91], ["cardiac", "ANATOMY", 96, 103], ["toxicity", "OBSERVATION", 104, 112], ["cardiac", "ANATOMY", 228, 235], ["liver", "ANATOMY", 305, 310], ["acute", "OBSERVATION_MODIFIER", 411, 416], ["renal", "ANATOMY", 417, 422], ["failure", "OBSERVATION", 423, 430], ["hemodialysis", "OBSERVATION", 434, 446]]], ["At 5.day in ICU, hypoxemia and severe swelling resistant to ultrafiltration was evaluated as a global left ventricular hypokinesia with ejection fraction(EF) 20%, end-diastolic diameter of 5.9 cm, and systolic pulmonary artery pressure (SPAP) of 40 mmHg.", [["left ventricular", "ANATOMY", 102, 118], ["pulmonary artery", "ANATOMY", 210, 226], ["hypoxemia", "DISEASE", 17, 26], ["swelling", "DISEASE", 38, 46], ["left ventricular hypokinesia", "DISEASE", 102, 130], ["ventricular", "MULTI-TISSUE_STRUCTURE", 107, 118], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 210, 226], ["hypoxemia", "PROBLEM", 17, 26], ["severe swelling", "PROBLEM", 31, 46], ["ultrafiltration", "TREATMENT", 60, 75], ["a global left ventricular hypokinesia", "PROBLEM", 93, 130], ["ejection fraction", "TEST", 136, 153], ["EF", "TEST", 154, 156], ["end-diastolic diameter", "TEST", 163, 185], ["systolic pulmonary artery pressure", "TEST", 201, 235], ["SPAP", "TEST", 237, 241], ["hypoxemia", "OBSERVATION", 17, 26], ["severe", "OBSERVATION_MODIFIER", 31, 37], ["swelling", "OBSERVATION", 38, 46], ["left ventricular", "ANATOMY", 102, 118], ["hypokinesia", "OBSERVATION", 119, 130], ["ejection fraction", "OBSERVATION", 136, 153], ["diastolic", "OBSERVATION_MODIFIER", 167, 176], ["diameter", "OBSERVATION_MODIFIER", 177, 185], ["5.9 cm", "OBSERVATION", 189, 195], ["systolic", "ANATOMY_MODIFIER", 201, 209], ["pulmonary artery", "ANATOMY", 210, 226], ["pressure", "OBSERVATION_MODIFIER", 227, 235]]], ["Oxygen was administrated to treatment.Urine output improved at 6.day, three more plasmapheresis sessions were performed. hypoxemia was recovered,liver enzymes and creatinin levels decreased Results: At control EF measured was 44%, end-diastolic diameter of 4.9 cm, SPAP of 25 mmHg.than at the 15.day patient discharged from the ICU.After a year follow up assessment she has no complaints Conclusions: One of the major problems for amanita poisoning is diagnosis.", [["Urine", "ANATOMY", 38, 43], ["liver", "ANATOMY", 145, 150], ["Oxygen", "CHEMICAL", 0, 6], ["hypoxemia", "DISEASE", 121, 130], ["poisoning", "DISEASE", 439, 448], ["Oxygen", "CHEMICAL", 0, 6], ["creatinin", "CHEMICAL", 163, 172], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["Urine", "ORGANISM_SUBSTANCE", 38, 43], ["liver", "ORGAN", 145, 150], ["creatinin", "SIMPLE_CHEMICAL", 163, 172], ["patient", "ORGANISM", 300, 307], ["amanita", "ORGANISM", 431, 438], ["liver enzymes", "PROTEIN", 145, 158], ["patient", "SPECIES", 300, 307], ["Oxygen", "TREATMENT", 0, 6], ["treatment", "TREATMENT", 28, 37], ["Urine output", "TEST", 38, 50], ["plasmapheresis sessions", "TREATMENT", 81, 104], ["hypoxemia", "PROBLEM", 121, 130], ["liver enzymes", "TEST", 145, 158], ["creatinin levels", "TEST", 163, 179], ["EF", "TEST", 210, 212], ["end-diastolic diameter", "TEST", 231, 253], ["SPAP", "TEST", 265, 269], ["follow up assessment", "TEST", 345, 365], ["amanita poisoning", "PROBLEM", 431, 448], ["output", "OBSERVATION_MODIFIER", 44, 50], ["improved", "OBSERVATION_MODIFIER", 51, 59], ["liver", "ANATOMY", 145, 150], ["diastolic", "OBSERVATION_MODIFIER", 235, 244], ["diameter", "OBSERVATION_MODIFIER", 245, 253], ["4.9 cm", "OBSERVATION", 257, 263]]], ["Patients who had mushroom poisoning should also be evaluated especially in terms of cardiac dysfunction with clinic signs, ECG, cardiac enzyme tests and ECO Introduction: The characterization of clinical and/or biological variables found in the emergency room predictive of a secondary admission in ICU would help to improve the identification of patients at risk of aggravation in order to avoid the associated consequences, such as, an increased mortality and increased hospital stay.", [["mushroom", "ANATOMY", 17, 25], ["cardiac", "ANATOMY", 84, 91], ["cardiac", "ANATOMY", 128, 135], ["mushroom poisoning", "DISEASE", 17, 35], ["cardiac dysfunction", "DISEASE", 84, 103], ["Patients", "ORGANISM", 0, 8], ["cardiac", "ORGAN", 84, 91], ["patients", "ORGANISM", 347, 355], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 347, 355], ["mushroom poisoning", "PROBLEM", 17, 35], ["cardiac dysfunction", "PROBLEM", 84, 103], ["clinic signs", "TEST", 109, 121], ["ECG", "TEST", 123, 126], ["cardiac enzyme tests", "TEST", 128, 148], ["aggravation", "PROBLEM", 367, 378], ["an increased mortality", "PROBLEM", 435, 457], ["cardiac", "ANATOMY", 84, 91], ["dysfunction", "OBSERVATION", 92, 103], ["increased", "OBSERVATION_MODIFIER", 438, 447], ["mortality", "OBSERVATION", 448, 457], ["increased", "OBSERVATION_MODIFIER", 462, 471]]], ["Methods: This is a retrospective monocentric study of 3 years with patients admitted secondarily to a medical ICU within 48 hours of admission to the general wards from the emergency department in the Piti\u00e9-Salp\u00eatri\u00e8re hospital in Paris.", [["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75]]], ["Results: 319 patients, of whom 107 were cases and 212 controls were studied.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21]]], ["Pneumonia is the diagnosis the most frequent in cases followed by sepsis (in 23 and 16%, respectively).", [["Pneumonia", "DISEASE", 0, 9], ["sepsis", "DISEASE", 66, 72], ["Pneumonia", "PROBLEM", 0, 9], ["sepsis", "PROBLEM", 66, 72], ["most frequent", "OBSERVATION_MODIFIER", 31, 44], ["sepsis", "OBSERVATION", 66, 72]]], ["6 Conclusions: The risk of being admitted secondarily to intensive care is higher if patients consult for dyspnea or fever, if they are old smokers, if they have a high IGS2 score, if an arterial blood gas is requested and if an ICU medical advice is taken.", [["arterial blood", "ANATOMY", 187, 201], ["dyspnea", "DISEASE", 106, 113], ["fever", "DISEASE", 117, 122], ["patients", "ORGANISM", 85, 93], ["arterial", "MULTI-TISSUE_STRUCTURE", 187, 195], ["blood", "ORGANISM_SUBSTANCE", 196, 201], ["patients", "SPECIES", 85, 93], ["dyspnea", "PROBLEM", 106, 113], ["fever", "PROBLEM", 117, 122], ["a high IGS2 score", "PROBLEM", 162, 179], ["an arterial blood gas", "TEST", 184, 205]]], ["The MEDS score under 7 and being an active smoker seems to be protects for the unexpected transfer.", [["The MEDS score", "TEST", 0, 14], ["active", "OBSERVATION_MODIFIER", 36, 42], ["smoker", "OBSERVATION", 43, 49]]], ["Introduction: Managing the special needs of patients who present with agitation or psychosis can pose a greater challenge to an already busy emergency department as their symptoms can escalate rapidly.", [["agitation", "DISEASE", 70, 79], ["psychosis", "DISEASE", 83, 92], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["agitation", "PROBLEM", 70, 79], ["psychosis", "PROBLEM", 83, 92], ["their symptoms", "PROBLEM", 165, 179]]], ["Traditional antipsychotics used in the ED, such as haloperidol or ziprasidone often do not fully relieve patient's symptoms and may require administration of repeat doses or additional medications such as benzodiazepines to achieve effective results.", [["haloperidol", "CHEMICAL", 51, 62], ["ziprasidone", "CHEMICAL", 66, 77], ["benzodiazepines", "CHEMICAL", 205, 220], ["haloperidol", "CHEMICAL", 51, 62], ["ziprasidone", "CHEMICAL", 66, 77], ["benzodiazepines", "CHEMICAL", 205, 220], ["haloperidol", "SIMPLE_CHEMICAL", 51, 62], ["ziprasidone", "SIMPLE_CHEMICAL", 66, 77], ["patient", "ORGANISM", 105, 112], ["patient", "SPECIES", 105, 112], ["Traditional antipsychotics", "TREATMENT", 0, 26], ["haloperidol", "TREATMENT", 51, 62], ["ziprasidone", "TREATMENT", 66, 77], ["patient's symptoms", "PROBLEM", 105, 123], ["repeat doses", "TREATMENT", 158, 170], ["additional medications", "TREATMENT", 174, 196], ["benzodiazepines", "TREATMENT", 205, 220]]], ["This can induce excess sedation which can lead to longer length of stay in the ED and requires additional time at the bedside by the ED physicians and staff to manage these patients.", [["patients", "ORGANISM", 173, 181], ["patients", "SPECIES", 173, 181], ["excess sedation", "TREATMENT", 16, 31]]], ["Adasuve\u00ae is an antipsychotic drug that works in a single-use device providing an aerosol form of Loxapine that is rapidly absorbed by the lungs which may offer faster symptom relief, allowing subsequent earlier psychiatric evaluation and disposition.P438AMethods: To test this hypothesis, data including time of physician assignment and time physician documented discharge disposition and number of hours physician was assigned to the patients was retrospectively collected from 407 patients who arrived to the emergency department presenting with agitation or psychosis that received Adasuve or other types of antipsychotic medication such as ziprasidone, haloperidol and benzodiazepines or a combination of the three.", [["lungs", "ANATOMY", 138, 143], ["Adasuve\u00ae", "CHEMICAL", 0, 8], ["Loxapine", "CHEMICAL", 97, 105], ["psychiatric", "DISEASE", 211, 222], ["agitation", "DISEASE", 548, 557], ["psychosis", "DISEASE", 561, 570], ["Adasuve", "CHEMICAL", 585, 592], ["ziprasidone", "CHEMICAL", 644, 655], ["haloperidol", "CHEMICAL", 657, 668], ["benzodiazepines", "CHEMICAL", 673, 688], ["Loxapine", "CHEMICAL", 97, 105], ["ziprasidone", "CHEMICAL", 644, 655], ["haloperidol", "CHEMICAL", 657, 668], ["benzodiazepines", "CHEMICAL", 673, 688], ["Adasuve\u00ae", "SIMPLE_CHEMICAL", 0, 8], ["Loxapine", "SIMPLE_CHEMICAL", 97, 105], ["lungs", "ORGAN", 138, 143], ["patients", "ORGANISM", 435, 443], ["patients", "ORGANISM", 483, 491], ["ziprasidone", "SIMPLE_CHEMICAL", 644, 655], ["haloperidol", "SIMPLE_CHEMICAL", 657, 668], ["benzodiazepines", "SIMPLE_CHEMICAL", 673, 688], ["patients", "SPECIES", 435, 443], ["patients", "SPECIES", 483, 491], ["an antipsychotic drug", "TREATMENT", 12, 33], ["device", "TREATMENT", 61, 67], ["Loxapine", "TREATMENT", 97, 105], ["faster symptom relief", "PROBLEM", 160, 181], ["psychiatric evaluation", "TEST", 211, 233], ["agitation", "PROBLEM", 548, 557], ["psychosis", "PROBLEM", 561, 570], ["Adasuve", "TREATMENT", 585, 592], ["antipsychotic medication", "TREATMENT", 611, 635], ["ziprasidone", "TREATMENT", 644, 655], ["haloperidol", "TREATMENT", 657, 668], ["benzodiazepines", "TREATMENT", 673, 688], ["lungs", "ANATOMY", 138, 143]]], ["Results: We found that physicians who administered Adasuve spent an average of 8.30 hours assigned to their patient compared to 11.42 hours when the physician administered any other type of antipsychotic medication.", [["patient", "ORGANISM", 108, 115], ["patient", "SPECIES", 108, 115], ["antipsychotic medication", "TREATMENT", 190, 214]]], ["This resulted in a significant 3.12-hour difference (p < 0.002) between the two groups.P438AConclusions: In conclusion, less time spent assigned to a patient that received Adasuve can be attributed to faster symptom relief which allowed the physicians to complete their psychological evaluations and develop dispositions more rapidly than with patients that received other antipsychotic agents.P446Clinical work in language-discordant Emergency Department Introduction: Emergency residents are particularly vulnerable to sleep deprivation due to persistent conflicts between work schedule and the biological clock.", [["patient", "ORGANISM", 150, 157], ["patients", "ORGANISM", 344, 352], ["patient", "SPECIES", 150, 157], ["patients", "SPECIES", 344, 352], ["faster symptom relief", "PROBLEM", 201, 222], ["their psychological evaluations", "TEST", 264, 295], ["other antipsychotic agents", "TREATMENT", 367, 393], ["work schedule", "TREATMENT", 575, 588], ["significant", "OBSERVATION_MODIFIER", 19, 30]]], ["Recent approaches to address fatiguerelated risk mainly focused on reducing work hours and ensuring sufficient recuperation time.", [["fatiguerelated risk", "PROBLEM", 29, 48]]], ["Dawson & McCulloch (2005) introduced the notion of proofing as a complementary approach to manage fatigue-related risk [1] .", [["fatigue", "DISEASE", 98, 105], ["fatigue", "PROBLEM", 98, 105]]], ["Fatigue proofing strategies (FPS) aim to reduce the likelihood a fatigued operator will make an error, in contrast of reduction strategies (FRS) aiming to reduce the likelihood a fatigued operator is working.", [["Fatigue", "DISEASE", 0, 7], ["Fatigue", "PROBLEM", 0, 7], ["a fatigued operator", "PROBLEM", 63, 82], ["reduction strategies", "TREATMENT", 118, 138]]], ["In this study, we aim to 1) identify informal reduction and proofing strategies used by residents and 2) to investigate how they relate to fatigue-related risk indicators.", [["fatigue", "DISEASE", 139, 146], ["this study", "TEST", 3, 13], ["informal reduction and proofing strategies", "TREATMENT", 37, 79], ["fatigue", "PROBLEM", 139, 146]]], ["Methods: First, we organized 4 focus-group with a total of 25 residents in order to identify informal strategies used to manage fatigue-related risk.", [["fatigue", "DISEASE", 128, 135], ["informal strategies", "TREATMENT", 93, 112], ["fatigue", "PROBLEM", 128, 135]]], ["Introduction: This randomized controlled study assessed the impact of a 3-hour intravenous medication safety simulation-based learning (SBL) on self-efficacy, stress, knowledge and skills of nursing students.", [["intravenous", "ANATOMY", 79, 90], ["This randomized controlled study", "TEST", 14, 46], ["a 3-hour intravenous medication safety simulation", "TREATMENT", 70, 119]]], ["Medication administration error is a worldwide concern [1], that has been linked with a lack of knowledge and skills in safe medication administration among new graduate and student nurses [2] [3] [4] .", [["safe medication administration", "TREATMENT", 120, 150]]], ["Preventing medication errors could therefore involve training through simulation.", [["medication errors", "PROBLEM", 11, 28]]], ["Methods: Participants (n=99) were randomly assigned either to the control group (CG, n=50) or the experimental group (EG, n=49).", [["Participants", "SPECIES", 9, 21], ["CG", "TEST", 81, 83]]], ["While CG and EG both had a traditional clinical internship, EG beneficiated in addition the 3-hour SBL, using standardized patients in the context of an intensive care unit.", [["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131]]], ["The two groups were assessed twice: at T0 and T1 (four weeks later), through an Objective Structured Clinical Examination (OSCE) and questionnaires.", [["Clinical Examination", "TEST", 101, 121]]], ["Two blinded experts rated the students OSCE with an evaluation grid.", [["an evaluation grid", "TEST", 49, 67]]], ["Results: Mean participants age was 21,2.", [["participants", "ORGANISM", 14, 26], ["participants", "SPECIES", 14, 26]]], ["There were no statistically differences between groups at T0.", [["no", "UNCERTAINTY", 11, 13], ["statistically", "OBSERVATION_MODIFIER", 14, 27], ["differences", "OBSERVATION_MODIFIER", 28, 39]]], ["Compared to the CG (0%), the EG increased its self-efficacy (+19.35%) with a significantly difference (p<0.001) at T1.", [["the CG", "TEST", 12, 18], ["the EG", "TEST", 25, 31], ["a significantly difference (p<0.001) at T1", "PROBLEM", 75, 117], ["increased", "OBSERVATION_MODIFIER", 32, 41], ["significantly", "OBSERVATION_MODIFIER", 77, 90], ["difference", "OBSERVATION_MODIFIER", 91, 101]]], ["The SBL conducted to a greater increase of knowledge and skills in the EG (respectively +150%, +128%) than in the CG (respectively +46% and +47%), with a statistically significant difference (p<0.0001).", [["the EG", "TEST", 67, 73], ["the CG", "TEST", 110, 116], ["a statistically significant difference", "PROBLEM", 152, 190], ["greater", "OBSERVATION_MODIFIER", 23, 30], ["increase", "OBSERVATION_MODIFIER", 31, 39], ["significant", "OBSERVATION_MODIFIER", 168, 179], ["difference", "OBSERVATION_MODIFIER", 180, 190]]], ["Conclusions: Results reinforce the interest of a short SBL using standardized patients to improve medication administration.", [["SBL", "CANCER", 55, 58], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["a short SBL", "PROBLEM", 47, 58], ["standardized patients", "TREATMENT", 65, 86], ["medication administration", "TREATMENT", 98, 123]]], ["Clinical impact of these observations requires further evaluation to determine potential transfer in clinical settings and retention over time.", [["further evaluation", "TEST", 47, 65]]], ["Introduction: Medication errors occur frequently in the intensive care unit (ICU) and during care transitions.", [["Medication errors", "PROBLEM", 14, 31]]], ["Medication reconciliation by a pharmacist could be useful to prevent such errors.", [["Medication reconciliation", "TREATMENT", 0, 25]]], ["Therefore, the aim of this study was to determine the effect of medication reconciliation at the ICU.", [["this study", "TEST", 22, 32], ["medication reconciliation", "TREATMENT", 64, 89]]], ["Methods: A prospective 8-month intervention study with a pre-and post-phase was performed in Haga Teaching Hospital (2013) and Erasmus University Medical Center (2014).", [["intervention study", "TEST", 31, 49]]], ["The intervention consisted of medication reconciliation by pharmacists at ICU admission and discharge.", [["medication reconciliation", "TREATMENT", 30, 55]]], ["The severity of potential harm of the medication transfer errors (MTE) (pADE=0; 0.01; 0.1; 0.4; 0.6) was scored.", [["pADE", "TEST", 72, 76]]], ["Primary outcome measures were the proportions of patients with >= 1 MTE at ICU admission and ICU discharge.", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57]]], ["Secondary outcome measures were the proportions of patients with a pADE score >= 0.01, the severity of the pADEs and a cost-benefit analysis.", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["a pADE score", "TEST", 65, 77], ["a cost-benefit analysis", "TEST", 117, 140]]], ["Odds ratio and 95% confidence intervals were calculated.", [["Odds ratio", "TEST", 0, 10]]], ["Results: Table 1 shows patient characteristics.", [["patient", "ORGANISM", 23, 30], ["patient", "SPECIES", 23, 30]]], ["Figure 1 shows the primary outcome measures (ORadj admission =0.18 [95% CI 0.11-0.30] and ORadj discharge = 0.24 [95% CI 0.15-0.37]).", [["CI", "TEST", 72, 74], ["ORadj", "TEST", 90, 95], ["CI", "TEST", 118, 120]]], ["The proportion of patients with a pADE >=0.01 at ICU admission reduced from 34.8% to 8.0% and after ICU discharge from 69.5% to 36.2%.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["a pADE", "TEST", 32, 38]]], ["The pADE reduction resulted in a potential net cost benefit of \u20ac 103 per patient.", [["pADE", "CHEMICAL", 4, 8], ["patient", "ORGANISM", 73, 80], ["patient", "SPECIES", 73, 80], ["The pADE reduction", "TREATMENT", 0, 18]]], ["Conclusions: Medication reconciliation by pharmacists at ICU transfers is an effective safety intervention, leading to a significant decrease in the number of errors and a cost effective reduction of potential adverse drug events.", [["Medication reconciliation", "TREATMENT", 13, 38], ["an effective safety intervention", "TREATMENT", 74, 106], ["a significant decrease", "PROBLEM", 119, 141], ["a cost effective reduction", "TREATMENT", 170, 196], ["potential adverse drug events", "PROBLEM", 200, 229], ["significant", "OBSERVATION_MODIFIER", 121, 132], ["decrease", "OBSERVATION_MODIFIER", 133, 141]]], ["Introduction: In intensive care unit, administration of numerous drugs in ICU patients via a central venous catheter provide a high risk of drugs incompatibilities.", [["venous", "ANATOMY", 101, 107], ["patients", "ORGANISM", 78, 86], ["venous catheter", "MULTI-TISSUE_STRUCTURE", 101, 116], ["patients", "SPECIES", 78, 86], ["numerous drugs", "TREATMENT", 56, 70], ["a central venous catheter", "TREATMENT", 91, 116], ["drugs incompatibilities", "PROBLEM", 140, 163], ["central", "ANATOMY_MODIFIER", 93, 100], ["venous", "ANATOMY", 101, 107], ["catheter", "OBSERVATION", 108, 116]]], ["It has been reported in experimental studies [1] that particles issued of drug incompatibilities could induce thrombogenesis, microcirculation impairment and inflammatory response which could aggravate the occurrence of organ dysfunctions [2] .", [["organ", "ANATOMY", 220, 225], ["thrombogenesis", "DISEASE", 110, 124], ["microcirculation impairment", "DISEASE", 126, 153], ["organ dysfunctions", "DISEASE", 220, 238], ["organ", "ORGAN", 220, 225], ["experimental studies", "TEST", 24, 44], ["drug incompatibilities", "PROBLEM", 74, 96], ["thrombogenesis", "PROBLEM", 110, 124], ["microcirculation impairment", "PROBLEM", 126, 153], ["inflammatory response", "PROBLEM", 158, 179], ["organ dysfunctions", "PROBLEM", 220, 238], ["thrombogenesis", "OBSERVATION", 110, 124], ["inflammatory", "OBSERVATION_MODIFIER", 158, 170]]], ["The objective of this study was to evaluate the occurrence of particles by reproducing in vitro the intravenous system and the drugs combination used in ICU for patients suffering either septic shock or Acute Respiratory distress Syndrome (ARDS).", [["intravenous", "ANATOMY", 100, 111], ["septic shock", "DISEASE", 187, 199], ["Respiratory distress Syndrome", "DISEASE", 209, 238], ["ARDS", "DISEASE", 240, 244], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 100, 111], ["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 161, 169], ["this study", "TEST", 17, 27], ["vitro the intravenous system", "TREATMENT", 90, 118], ["the drugs", "TREATMENT", 123, 132], ["septic shock", "PROBLEM", 187, 199], ["Acute Respiratory distress Syndrome", "PROBLEM", 203, 238], ["ARDS", "PROBLEM", 240, 244], ["septic shock", "OBSERVATION", 187, 199], ["Acute", "OBSERVATION_MODIFIER", 203, 208], ["Respiratory distress", "OBSERVATION", 209, 229]]], ["Methods: First, we registered during a period of 6 months the most common central venous catheter system used in patients admitted for septic shock or ARDS in three University Hospital in Lille.", [["venous", "ANATOMY", 82, 88], ["septic shock", "DISEASE", 135, 147], ["ARDS", "DISEASE", 151, 155], ["central venous", "MULTI-TISSUE_STRUCTURE", 74, 88], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["the most common central venous catheter system", "TREATMENT", 58, 104], ["septic shock", "PROBLEM", 135, 147], ["ARDS", "PROBLEM", 151, 155], ["central", "ANATOMY_MODIFIER", 74, 81], ["venous", "ANATOMY", 82, 88], ["catheter", "OBSERVATION", 89, 97], ["septic shock", "OBSERVATION", 135, 147], ["ARDS", "OBSERVATION", 151, 155]]], ["The second part of the study was to reproduce in vitro the previous infusion system in order to quantify the amount of particles generated during a simulated period of 8 hours infusion.", [["the study", "TEST", 19, 28], ["vitro the previous infusion system", "TREATMENT", 49, 83], ["particles", "OBSERVATION", 119, 128]]], ["The egress of the IV line was connected to a dynamic particle counter QicPIC analyser (Sympatec Inc ; Clausthal Zellerfeld, Germany) (Fig. 1) .", [["the IV line", "TREATMENT", 14, 25], ["a dynamic particle counter QicPIC analyser", "TREATMENT", 43, 85], ["Sympatec Inc", "TREATMENT", 87, 99], ["Clausthal Zellerfeld", "TREATMENT", 102, 122], ["egress", "OBSERVATION_MODIFIER", 4, 10], ["IV line", "OBSERVATION", 18, 25]]], ["Results: The most common intravenous system observed was a three lumen central catheter.", [["intravenous", "ANATOMY", 25, 36], ["lumen", "ANATOMY", 65, 70], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 25, 36], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 65, 70], ["The most common intravenous system", "TREATMENT", 9, 43], ["a three lumen central catheter", "TREATMENT", 57, 87], ["three lumen", "OBSERVATION", 59, 70], ["central catheter", "OBSERVATION", 71, 87]]], ["The proximal lumen was dedicated for vasoactive agents, the medial lumen for sedation and the distal lumen for the other drugs infused continuously and discontinuously..Among the drugs infused via the distal lumen of the central venous catheter, Introduction: Insufficient identification of possible organ donors in the ICU is one of the main factors contributing to the loss of donors after brain death [1] .", [["proximal lumen", "ANATOMY", 4, 18], ["medial lumen", "ANATOMY", 60, 72], ["distal lumen", "ANATOMY", 94, 106], ["distal lumen", "ANATOMY", 201, 213], ["central venous", "ANATOMY", 221, 235], ["organ", "ANATOMY", 300, 305], ["brain", "ANATOMY", 392, 397], ["brain death", "DISEASE", 392, 403], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 13, 18], ["medial lumen", "MULTI-TISSUE_STRUCTURE", 60, 72], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 101, 106], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 208, 213], ["central venous", "MULTI-TISSUE_STRUCTURE", 221, 235], ["organ", "ORGAN", 300, 305], ["donors", "ORGANISM", 379, 385], ["brain", "ORGAN", 392, 397], ["vasoactive agents", "TREATMENT", 37, 54], ["the medial lumen", "TREATMENT", 56, 72], ["sedation", "TREATMENT", 77, 85], ["the distal lumen", "TREATMENT", 90, 106], ["the other drugs", "TREATMENT", 111, 126], ["the drugs", "TREATMENT", 175, 184], ["the distal lumen", "TREATMENT", 197, 213], ["the central venous catheter", "TREATMENT", 217, 244], ["organ donors", "TREATMENT", 300, 312], ["the loss of donors", "PROBLEM", 367, 385], ["brain death", "PROBLEM", 392, 403], ["proximal", "ANATOMY_MODIFIER", 4, 12], ["lumen", "ANATOMY_MODIFIER", 13, 18], ["medial lumen", "OBSERVATION", 60, 72], ["distal lumen", "OBSERVATION", 94, 106], ["distal", "ANATOMY_MODIFIER", 201, 207], ["lumen", "ANATOMY_MODIFIER", 208, 213], ["central", "ANATOMY_MODIFIER", 221, 228], ["venous", "ANATOMY", 229, 235], ["catheter", "OBSERVATION", 236, 244]]], ["Up to 50% of potential donors might not be identified [2] .", [["donors", "ORGANISM", 23, 29], ["potential donors", "TREATMENT", 13, 29]]], ["The aim of this study was to evaluate how active search of possible brain dead donors affect the potential deceased donor pool.", [["brain", "ANATOMY", 68, 73], ["brain", "ORGAN", 68, 73], ["donors", "ORGANISM", 79, 85], ["this study", "TEST", 11, 21], ["brain dead donors", "PROBLEM", 68, 85]]], ["Donor coordinator visited all ICUs every day and selected patients who met possible brain dead donor criteria: 1) GCS <= 5; 2) severe brain injury.", [["brain", "ANATOMY", 84, 89], ["brain", "ANATOMY", 134, 139], ["GCS", "DISEASE", 114, 117], ["brain injury", "DISEASE", 134, 146], ["patients", "ORGANISM", 58, 66], ["brain", "ORGAN", 84, 89], ["brain", "ORGAN", 134, 139], ["patients", "SPECIES", 58, 66], ["GCS", "TEST", 114, 117], ["severe brain injury", "PROBLEM", 127, 146], ["severe", "OBSERVATION_MODIFIER", 127, 133], ["brain", "ANATOMY", 134, 139], ["injury", "OBSERVATION", 140, 146]]], ["All data registered in original color coded follow-up system according to the patient status.P446Results: A total of 237 patients were identified as possible donors.", [["patient", "ORGANISM", 78, 85], ["patients", "ORGANISM", 121, 129], ["donors", "ORGANISM", 158, 164], ["patient", "SPECIES", 78, 85], ["patients", "SPECIES", 121, 129]]], ["There was no significant difference of potential donor numbers in study period comparing to previous year (32 vs 31).", [["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35]]], ["Main causes of brain death remain intracranial hemorrhage and subarachnoid hemorrhage.", [["brain", "ANATOMY", 15, 20], ["intracranial", "ANATOMY", 34, 46], ["subarachnoid", "ANATOMY", 62, 74], ["brain death", "DISEASE", 15, 26], ["intracranial hemorrhage", "DISEASE", 34, 57], ["subarachnoid hemorrhage", "DISEASE", 62, 85], ["brain", "ORGAN", 15, 20], ["intracranial hemorrhage", "PATHOLOGICAL_FORMATION", 34, 57], ["subarachnoid hemorrhage", "PATHOLOGICAL_FORMATION", 62, 85], ["brain death", "PROBLEM", 15, 26], ["intracranial hemorrhage", "PROBLEM", 34, 57], ["subarachnoid hemorrhage", "PROBLEM", 62, 85], ["brain", "ANATOMY", 15, 20], ["death", "OBSERVATION", 21, 26], ["intracranial", "ANATOMY", 34, 46], ["hemorrhage", "OBSERVATION", 47, 57], ["subarachnoid", "OBSERVATION_MODIFIER", 62, 74], ["hemorrhage", "OBSERVATION", 75, 85]]], ["The length of hospital stay of potential donors was significantly longer in study period comparing to previous year (4\u00b14.86 vs 2.29\u00b12.2, P=0.004).", [["donors", "ORGANISM", 41, 47], ["potential donors", "PROBLEM", 31, 47], ["vs", "TEST", 124, 126], ["P", "TEST", 137, 138], ["length", "OBSERVATION_MODIFIER", 4, 10]]], ["There was no significant difference of donor's demographic data, conversion rates to actual donor or frequency of family refusals and medical contraindications.P446Conclusions: Active search of brain dead donors neither increased total number of potential donors nor increased conversion rates and did not change a donor profile in our donor center.", [["brain", "ANATOMY", 194, 199], ["brain", "ORGAN", 194, 199], ["donors", "ORGANISM", 205, 211], ["donors", "ORGANISM", 256, 262], ["increased conversion rates", "PROBLEM", 267, 293], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["Active", "OBSERVATION_MODIFIER", 177, 183], ["increased", "OBSERVATION_MODIFIER", 220, 229]]], ["Longer observational period and more sophisticated follow-up system might be required.P461A fast hug bid a day keeps the patient ok!", [["patient", "ORGANISM", 121, 128], ["patient", "SPECIES", 121, 128]]], ["E Sousa, T Leonor, R Pinho Centro Hospitalar de Entre Douro e Vouga, Santa Maria da Feira, Portugal Critical Care 2018, 22(Suppl 1):P461P461Introduction: Regardless the underlying diagnose, providing meticulous supportive care is essential to critically ill patients management.P461In 2005, Vincent JL introduced the FAST HUG (Feeding, Analgesia, Sedation, Thromboembolic prophylaxis, Head of bed elevation, Ulcer prevention, Glucose control) mnemonic for recalling what he considered the key issues to review in daily clinical practice.", [["critically ill", "DISEASE", 243, 257], ["Ulcer", "DISEASE", 408, 413], ["Glucose", "CHEMICAL", 426, 433], ["Glucose", "CHEMICAL", 426, 433], ["patients", "ORGANISM", 258, 266], ["Glucose", "SIMPLE_CHEMICAL", 426, 433], ["patients", "SPECIES", 258, 266], ["E", "SPECIES", 0, 1], ["meticulous supportive care", "TREATMENT", 200, 226], ["critically ill patients management", "TREATMENT", 243, 277], ["the FAST HUG (Feeding", "TREATMENT", 313, 334], ["Analgesia", "TREATMENT", 336, 345], ["Sedation", "TREATMENT", 347, 355], ["Thromboembolic prophylaxis", "TREATMENT", 357, 383], ["Head of bed elevation", "TREATMENT", 385, 406], ["Ulcer prevention", "TREATMENT", 408, 424], ["Glucose control", "TREATMENT", 426, 441], ["Ulcer", "OBSERVATION", 408, 413]]], ["Our Intensive Care Unit (ICU) decided to add BID (Bowel regimen; Indwelling catheter removal; De-escalation of antibiotics) indicators following some published data.", [["BID", "CHEMICAL", 45, 48], ["Bowel regimen", "TREATMENT", 50, 63], ["Indwelling catheter removal", "TREATMENT", 65, 92], ["De-escalation of antibiotics", "TREATMENT", 94, 122], ["Bowel", "ANATOMY", 50, 55]]], ["Since 2013, the adequate use of this mnemonic became an instrument for quality of care evaluation.", [["this mnemonic", "TREATMENT", 32, 45], ["care evaluation", "TEST", 82, 97]]], ["Objectives for each variable were designed; regular annual audits done.", [["regular annual audits", "TEST", 44, 65]]], ["The present study aims to audit the use of this mnemonic in a portuguese tertiary hospital ICU, in 2017.P461Methods: A prospective observational study was performed.", [["A prospective observational study", "TEST", 117, 150]]], ["The predictable global FAST HUG BID assessment was 1086 entries [one per each full day (00h00-23h59) in the unit, per patient].", [["patient", "ORGANISM", 118, 125], ["patient", "SPECIES", 118, 125], ["The predictable global FAST HUG BID assessment", "TEST", 0, 46], ["predictable", "OBSERVATION_MODIFIER", 4, 15], ["global", "OBSERVATION_MODIFIER", 16, 22]]], ["The target thresholds were considered as achieved in 95% of entries (concordance equal or superior to 80%).", [["concordance", "TEST", 69, 80]]], ["Looking to individual variables, the best performance was achieved in H and U; worse performance was seen in S.Conclusions:The daily use of this mnemonic aims to revisit important intervention sectors in critical patient.", [["patient", "ORGANISM", 213, 220], ["patient", "SPECIES", 213, 220]]], ["Applying the \"Plan-Do-Check-Act\" policy, this study allowed us to identify growth opportunities, reviewing or creating protocols, adopting more frequent training measures and seeking to take this model to other hospital areas.P462Impact of incidents and adverse events in intensive care unit and its characteristics on outcomes E Siqueira, L Taniguchi, J Vieira Junior Hospital S\u00edrio LIban\u00eas, Sao Paulo, Brazil Critical Care 2018, 22(Suppl 1):P462P462Introduction: Critically ill patients are usually exposed to adverse events (AE) due to acuity and complexity of care.", [["Critically ill", "DISEASE", 465, 479], ["patients", "ORGANISM", 480, 488], ["patients", "SPECIES", 480, 488], ["this study", "TEST", 41, 51], ["creating protocols", "TREATMENT", 110, 128], ["frequent training measures", "TREATMENT", 144, 170], ["adverse events", "PROBLEM", 512, 526]]], ["AE might potentially result in disability or death, and increase in length of stay.", [["disability", "DISEASE", 31, 41], ["death", "DISEASE", 45, 50], ["death", "PROBLEM", 45, 50], ["increase", "OBSERVATION_MODIFIER", 56, 64], ["length", "OBSERVATION_MODIFIER", 68, 74]]], ["All consecutive patients who were admitted to the ICU and all incidents and AE reported in the study period were evaluated.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24]]], ["Univariate and multivariate analysis were used to identify risk factors associated with hospital mortality.", [["Univariate", "TEST", 0, 10], ["multivariate analysis", "TEST", 15, 36]]], ["Results: Between May to November 2016 we studied 890 patients and 533 reported incidents and AE.", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61]]], ["Overall, 267 patients (30%) experienced some incident or AE during ICU stay.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21]]], ["We found higher severity of illness (SAPS3 of 48 versus 44; p<0.001), mechanical ventilation (MV), use of vascular lines, drains and catheters, physical restraints, delirium and also an increased length of ICU (4 vs 2 days; p<0.001) and hospital stay (20 vs 11 days; p<0.001) and hospital mortality (24% vs 11%; p<0.001) among patients who experienced any incident or AE.", [["vascular lines", "ANATOMY", 106, 120], ["illness", "DISEASE", 28, 35], ["delirium", "DISEASE", 165, 173], ["vascular lines", "CELL", 106, 120], ["patients", "ORGANISM", 327, 335], ["patients", "SPECIES", 327, 335], ["MV", "SPECIES", 94, 96], ["illness", "PROBLEM", 28, 35], ["SAPS3", "TEST", 37, 42], ["mechanical ventilation", "TREATMENT", 70, 92], ["vascular lines", "TREATMENT", 106, 120], ["drains", "TREATMENT", 122, 128], ["catheters", "TREATMENT", 133, 142], ["physical restraints", "TREATMENT", 144, 163], ["delirium", "PROBLEM", 165, 173], ["higher severity", "OBSERVATION_MODIFIER", 9, 24], ["mechanical ventilation", "OBSERVATION", 70, 92], ["vascular", "ANATOMY", 106, 114], ["lines", "OBSERVATION", 115, 120], ["drains", "OBSERVATION", 122, 128], ["catheters", "OBSERVATION", 133, 142]]], ["Independent risk factors for hospital mortality in our logistic model were: higher SAPS3, MV and at least one adverse event during the ICU stay.", [["MV", "SPECIES", 90, 92]]], ["Mortality was higher among patients who experienced late AE (>48 hours after ICU admission) compared to patients who experienced early AE (37% vs 19%; p<0.003).", [["patients", "ORGANISM", 27, 35], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 27, 35], ["patients", "SPECIES", 104, 112], ["late AE", "PROBLEM", 52, 59], ["early AE", "PROBLEM", 129, 137]]], ["SAPS3, SOFA and MV were predictors of moderate and/or severe AE and a negative correlation between these events and ICU occupancy rate was found.P462Conclusions: Patients who experienced incident or adverse event during ICU stay had poorer outcome.", [["SAPS3", "GENE_OR_GENE_PRODUCT", 0, 5], ["Patients", "ORGANISM", 162, 170], ["SAPS3", "PROTEIN", 0, 5], ["Patients", "SPECIES", 162, 170], ["MV", "SPECIES", 16, 18], ["SAPS3", "TEST", 0, 5], ["SOFA", "TEST", 7, 11], ["MV", "TEST", 16, 18], ["moderate and/or severe AE", "PROBLEM", 38, 63], ["ICU occupancy rate", "TEST", 116, 134], ["adverse event", "PROBLEM", 199, 212], ["moderate", "OBSERVATION_MODIFIER", 38, 46]]], ["AE, mainly moderate or severe, MV and severity of illness were independent risk factors to mortality.", [["illness", "DISEASE", 50, 57], ["MV", "SPECIES", 31, 33], ["illness", "PROBLEM", 50, 57], ["moderate", "OBSERVATION_MODIFIER", 11, 19], ["severe", "OBSERVATION_MODIFIER", 23, 29]]], ["There was a negative correlation between moderate or severe adverse event and ICU occupancy rate.P463Monte Carlo modelling of patient flow can aid complex intensive care bed and workforce capacity planning.", [["patient", "ORGANISM", 126, 133], ["patient", "SPECIES", 126, 133], ["moderate or severe adverse event", "PROBLEM", 41, 73], ["ICU occupancy rate", "TEST", 78, 96], ["workforce capacity planning", "TREATMENT", 178, 205], ["moderate", "OBSERVATION_MODIFIER", 41, 49], ["severe", "OBSERVATION_MODIFIER", 53, 59]]], ["Introduction: Models for ICU populations based on the Queuing model use arrival rate, length of stay, and bed number [1, 2] .", [["ICU populations", "TREATMENT", 25, 40]]], ["These models lack the complexity of specialised ICUs with different admission types, and patient subpopulations.", [["patient", "ORGANISM", 89, 96], ["patient", "SPECIES", 89, 96], ["complexity", "OBSERVATION_MODIFIER", 22, 32]]], ["Results: >98% of patients reported satisfaction on all areas except noise, patient facilities for hand hygiene and being informed about timing of operations.", [["hand", "ANATOMY", 98, 102], ["patients", "ORGANISM", 17, 25], ["patient", "ORGANISM", 75, 82], ["hand", "ORGANISM_SUBDIVISION", 98, 102], ["patients", "SPECIES", 17, 25], ["patient", "SPECIES", 75, 82], ["hand hygiene", "TREATMENT", 98, 110]]], ["Staff survey results revealed confusion regarding the interventions that are provided.", [["confusion", "DISEASE", 30, 39], ["Staff survey", "TEST", 0, 12], ["confusion", "PROBLEM", 30, 39], ["the interventions", "TREATMENT", 50, 67]]], ["Baseline capacity for new patients was 53%, bed occupancy varied between 1 and 12 per day (overflow to recovery) with overall capacity at 93.5% and mean length of stay (LOS) was 1.3 days (SD=0.7, n=481, =range 1-5).", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["Baseline capacity", "PROBLEM", 0, 17], ["overall capacity", "TEST", 118, 134], ["SD", "TEST", 188, 190], ["new", "OBSERVATION_MODIFIER", 22, 25]]], ["Following intervention, the LOS was reduced to 1.18 days (SD=0.4, n=112, range 1-3).", [["intervention", "TREATMENT", 10, 22], ["the LOS", "TEST", 24, 31], ["SD", "TEST", 58, 60]]], ["New patient capacity was increased to 62% with a bed occupancy range 1-8.P463Introduction: In clinical practice, when harm or potential harm occurs to patients, this can adversely impact upon the morale of staff involved and thereby affect clinical care delivered to subsequent patients.", [["patient", "ORGANISM", 4, 11], ["patients", "ORGANISM", 151, 159], ["patients", "ORGANISM", 278, 286], ["patient", "SPECIES", 4, 11], ["patients", "SPECIES", 151, 159], ["patients", "SPECIES", 278, 286], ["New patient capacity", "PROBLEM", 0, 20], ["capacity", "OBSERVATION_MODIFIER", 12, 20]]], ["The personal narratives behind clinical incidents contain learning opportunities and individuals involved may reflect on the course of events and make changes to their practice to avoid recurrence.", [["recurrence", "PROBLEM", 186, 196]]], ["The aim of this study was to evaluate whether sessions enabling trainees to discuss their mistakes in a confidential environment improved trainee morale and safe clinical practice in an anaesthetic trainee cohort.P463Methods: We conducted a survey amongst anaesthetic trainees in a London teaching hospital before and after a monthly, hour long, confidential, semi-structured, trainee lead \"confession session\" was introduced.P463Results: Initial results demonstrated that 68% of respondents (N=30) had made a mistake resulting in patient harm with 84% of these individuals describing negative feelings about themselves as a consequence.", [["patient", "ORGANISM", 531, 538], ["patient", "SPECIES", 531, 538], ["this study", "TEST", 11, 21], ["an anaesthetic trainee cohort", "TREATMENT", 183, 212]]], ["A follow-up survey identified that 100% of respondents (N=13) agreed that the session had the potential to improve clinical practice and trainee morale with 77% agreeing that their own clinical practice had improved from attending the sessions.P463Conclusions: Clinical mistakes leading to harm and \"near misses\" are common and provide opportunities to improve care.", [["Clinical mistakes", "PROBLEM", 261, 278]]], ["This trainee lead \"confession session\" appears to improve trainee morale and may improve patient care by encouraging trainees to engage in a process that seeks to understand error through sharing stories in a non-judgmental setting.P466Funnel plots for quality control of the Swiss ICU -minimal data set Introduction: A clinical database should be representative of the labelled population and guarantee completeness and accuracy of collected data.", [["patient", "ORGANISM", 89, 96], ["patient", "SPECIES", 89, 96], ["collected data", "TEST", 433, 447]]], ["Without explicit permission of the patients, Swiss laws regarding data protection do not allow external audits based on periodic checks of random samples, supposed to give a general pattern of accuracy.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["data protection", "TREATMENT", 66, 81], ["external audits", "TEST", 95, 110], ["periodic checks", "TEST", 120, 135], ["random samples", "TEST", 139, 153]]], ["To test alternative methods for quality control we introduced the principles of statistical process control to derive funnel plots from the Swiss ICU -Minimal Data Set (MDSi).Methods:The MDSi from all certified adult Swiss ICUs (2014 and 2015) was subjected to quality assessment (completeness and accuracy).", [["quality control", "TREATMENT", 32, 47], ["statistical process control", "TREATMENT", 80, 107], ["quality assessment", "TEST", 261, 279], ["accuracy", "TEST", 298, 306]]], ["For the analysis of accuracy, a list of logical rules and cross-checks was developed as e.g. range of SAPS II according to age.", [["SAPS II", "PROTEIN", 102, 109], ["accuracy", "TEST", 20, 28], ["logical rules", "TEST", 40, 53], ["cross-checks", "TEST", 58, 70]]], ["Errors were classified in coding errors (e.g. NEMS score > 56 points) or implausible data (NEMS without basic monitoring).", [["NEMS score", "TEST", 46, 56], ["basic monitoring", "TEST", 104, 120]]], ["We also checked for ICUs producing significantly more errors -outliers -(> mean \u00b1 3 standard deviations [SD] or > 99.8% confidence interval [CI] of an adapted version of the funnel plots, which allows the presence of trends depending of the ICU's size.Methods:Results: A total of 164'415 patient MDSi (31 items/patient; 32 items for trauma patients) from the 77 certified ICUs.were investigated.", [["trauma", "DISEASE", 333, 339], ["patient", "ORGANISM", 288, 295], ["patient", "ORGANISM", 311, 318], ["patients", "ORGANISM", 340, 348], ["patient", "SPECIES", 288, 295], ["patient", "SPECIES", 311, 318], ["patients", "SPECIES", 340, 348], ["CI", "TEST", 141, 143], ["the funnel plots", "TEST", 170, 186], ["funnel plots", "OBSERVATION", 174, 186], ["size", "OBSERVATION_MODIFIER", 247, 251]]], ["We detected 15'572 patients (9.5%) with an overall sum of 3121 coding errors and 31'265 implausible situations.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27]]], ["Implausible situations related to supposedly inaccurate definitions (diagnostic and patient's provenance prior to ICU admission) and discrepancies in the logical rules between diagnostics and treatments.", [["patient", "ORGANISM", 84, 91], ["patient", "SPECIES", 84, 91], ["Implausible situations", "PROBLEM", 0, 22], ["treatments", "TREATMENT", 192, 202]]], ["Figure 1 is an example for imprecise coding of the diagnostic: 11 ICUs declared having treated 14-61% of their patients without a defined diagnosis.Methods:Conclusions: Accuracy of data in MDSi needs further improvement.", [["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119]]], ["Funnel plots may be useful for meaningful interpretation of data quality and permit to identify ICUs disproportionately generating inaccurate and/or implausible data.", [["Funnel plots", "TEST", 0, 12]]], ["Introduction: Lung cancer is the leading cause of intensive care unit (ICU) admission in patients with the advanced solid tumors.", [["Lung cancer", "ANATOMY", 14, 25], ["solid tumors", "ANATOMY", 116, 128], ["Lung cancer", "DISEASE", 14, 25], ["tumors", "DISEASE", 122, 128], ["Lung cancer", "CANCER", 14, 25], ["patients", "ORGANISM", 89, 97], ["solid tumors", "CANCER", 116, 128], ["patients", "SPECIES", 89, 97], ["Lung cancer", "PROBLEM", 14, 25], ["the advanced solid tumors", "PROBLEM", 103, 128], ["Lung", "ANATOMY", 14, 18], ["cancer", "OBSERVATION", 19, 25], ["tumors", "OBSERVATION", 122, 128]]], ["This study was aimed to elucidate the clinical factors associated with ICU mortality of advanced lung cancer patients and the effect of intensivist's contribution on their clinical outcomes.", [["lung cancer", "ANATOMY", 97, 108], ["lung cancer", "DISEASE", 97, 108], ["lung cancer", "CANCER", 97, 108], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["This study", "TEST", 0, 10], ["advanced lung cancer", "PROBLEM", 88, 108], ["lung", "ANATOMY", 97, 101], ["cancer", "OBSERVATION", 102, 108]]], ["Methods: We included patients with advanced lung cancer including non-small cell lung cancer (NSCLC) with stage IIIB or IV and small cell lung cancer (SCLC) with extensive stage who admitted to ICU from 2005 to 2016.", [["lung cancer", "ANATOMY", 44, 55], ["non-small cell lung cancer", "ANATOMY", 66, 92], ["NSCLC", "ANATOMY", 94, 99], ["small cell lung cancer", "ANATOMY", 127, 149], ["SCLC", "ANATOMY", 151, 155], ["lung cancer", "DISEASE", 44, 55], ["non-small cell lung cancer", "DISEASE", 66, 92], ["NSCLC", "DISEASE", 94, 99], ["small cell lung cancer", "DISEASE", 127, 149], ["SCLC", "DISEASE", 151, 155], ["patients", "ORGANISM", 21, 29], ["lung cancer", "CANCER", 44, 55], ["non-small cell lung cancer", "CANCER", 66, 92], ["NSCLC", "CANCER", 94, 99], ["small cell lung cancer", "CANCER", 127, 149], ["SCLC", "CANCER", 151, 155], ["patients", "SPECIES", 21, 29], ["advanced lung cancer", "PROBLEM", 35, 55], ["non-small cell lung cancer", "PROBLEM", 66, 92], ["NSCLC", "PROBLEM", 94, 99], ["stage IIIB or IV and small cell lung cancer", "PROBLEM", 106, 149], ["lung", "ANATOMY", 44, 48], ["cancer", "OBSERVATION", 49, 55], ["non-small cell", "OBSERVATION", 66, 80], ["lung", "ANATOMY", 81, 85], ["cancer", "OBSERVATION", 86, 92], ["NSCLC", "OBSERVATION", 94, 99], ["stage IIIB", "OBSERVATION_MODIFIER", 106, 116], ["small", "OBSERVATION_MODIFIER", 127, 132], ["cell", "OBSERVATION", 133, 137], ["lung", "ANATOMY", 138, 142], ["cancer", "OBSERVATION", 143, 149], ["SCLC", "OBSERVATION", 151, 155]]], ["Multivariate logistic regression analysis was performed to find the variables associated with ICU mortality and in-hospital mortality.", [["Multivariate logistic regression analysis", "TEST", 0, 41]]], ["Results: Among total 264 patients with advanced lung cancer, 85 patients (32.2%) were admitted ICU before introduction of organized intensive care at 2011, and 179 (67.8%) were admitted after 2011 (Fig. 1) .", [["lung cancer", "ANATOMY", 48, 59], ["lung cancer", "DISEASE", 48, 59], ["patients", "ORGANISM", 25, 33], ["lung cancer", "CANCER", 48, 59], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 25, 33], ["patients", "SPECIES", 64, 72], ["advanced lung cancer", "PROBLEM", 39, 59], ["advanced", "OBSERVATION_MODIFIER", 39, 47], ["lung", "ANATOMY", 48, 52], ["cancer", "OBSERVATION", 53, 59]]], ["The leading cause of admission was the respiratory failure (77.7%) and cancer-related event (34.5%) in terms of intensivist's and oncologist's perspective.", [["respiratory", "ANATOMY", 39, 50], ["cancer", "ANATOMY", 71, 77], ["respiratory failure", "DISEASE", 39, 58], ["cancer", "DISEASE", 71, 77], ["cancer", "CANCER", 71, 77], ["the respiratory failure", "PROBLEM", 35, 58], ["cancer", "PROBLEM", 71, 77], ["respiratory failure", "OBSERVATION", 39, 58]]], ["Before and after 2011, the 30-day ICU mortality rate was 43.5% and 40.2% (p = 0.610), and the hospital mortality rate changed from 82.4% to 65.9% (p = 0.006) (Fig. 2) Introduction: Decisions when to refer and to admit patients to the intensive care unit (ICU) care are very challenging.", [["patients", "ORGANISM", 218, 226], ["patients", "SPECIES", 218, 226], ["mortality rate", "TEST", 38, 52], ["the hospital mortality rate", "TEST", 90, 117]]], ["Demand typically exceeds supply in ICU beds, which results in a constant need for evaluation of the processes involved in ICU referral and admission with a view to optimising resource allocation and patient outcomes.", [["patient", "ORGANISM", 199, 206], ["patient", "SPECIES", 199, 206], ["evaluation", "TEST", 82, 92]]], ["The aim of this study was to evaluate the theoretical impact of a newly designed triage tool for ICU referrals on a cohort of patients referred to ICU (Fig. 1) .", [["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["this study", "TEST", 11, 21]]], ["Methods: We reviewed all patients consecutively referred to our ICU, whether admitted or not, in February 2017.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33]]], ["Demographics, referring speciality, role of the referrer, comorbidities, the presence of advanced disease or terminal illness, the presence of acute organ failure, DNR status, reason for not admitting, and ICU mortality were recorded.", [["organ", "ANATOMY", 149, 154], ["acute organ failure", "DISEASE", 143, 162], ["DNR", "CHEMICAL", 164, 167], ["organ", "ORGAN", 149, 154], ["advanced disease", "PROBLEM", 89, 105], ["terminal illness", "PROBLEM", 109, 125], ["acute organ failure", "PROBLEM", 143, 162], ["advanced", "OBSERVATION_MODIFIER", 89, 97], ["disease", "OBSERVATION", 98, 105], ["terminal", "OBSERVATION_MODIFIER", 109, 117], ["illness", "OBSERVATION", 118, 125], ["acute", "OBSERVATION_MODIFIER", 143, 148], ["organ", "ANATOMY", 149, 154], ["failure", "OBSERVATION", 155, 162]]], ["A retrospective analysis of ICU referrals using a pilot triage tool was carried out independently by three authors.", [["a pilot triage tool", "TEST", 48, 67]]], ["Results: Forty-six patients were referred to our ICU over the study period.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27]]], ["Patients were declined ICU if their admission was deemed unnecessary (50%), futile (33%), or were transferred due to bed shortage (16%).", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Of the patients referred, 25 (54%) had an advanced disease or a terminal illness.", [["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["an advanced disease", "PROBLEM", 39, 58], ["a terminal illness", "PROBLEM", 62, 80], ["advanced", "OBSERVATION_MODIFIER", 42, 50], ["disease", "OBSERVATION", 51, 58], ["terminal", "OBSERVATION_MODIFIER", 64, 72], ["illness", "OBSERVATION", 73, 80]]], ["Of those, 18 (72%) were admitted, DNR status was unclear in 22 (88%), family was involved in 12 (48%) and their ICU mortality was 48%.", [["DNR", "CHEMICAL", 34, 37]]], ["DNR status and family involvement would have been clarified in all patients with advanced disease or terminal illness before ICU referral.", [["DNR", "CHEMICAL", 0, 3], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["advanced disease", "PROBLEM", 81, 97], ["terminal illness", "PROBLEM", 101, 117]]], ["Kappa score for inter-rater agreement was 0.78.", [["Kappa score", "TEST", 0, 11]]], ["In this study, we evaluated the effect of implementing a decision-aid tool for ICU triage on ICU admission decisions.", [["this study", "TEST", 3, 13]]], ["Our primary outcome was the proportion of potentially inappropriate ICU referrals (defined as priority 4B or 5 patients, as described by the 1999 or 2016 Society of Critical Care Medicine [SCCM] guidelines) that were admitted to the ICU in 48 hours following referral.", [["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119]]], ["We conducted multivariate analyses to adjust for potential confounders, and evaluated the interaction between phase and triage priorities to assess for differential effects in each priority strata.", [["multivariate analyses", "TEST", 13, 34], ["triage priorities", "TEST", 120, 137]]], ["Results: Of 2374 urgent ICU referrals, 110 (5%), 161 (7%), 284 (13%), 726 (33%) and 928 (42%) were categorized as priorities 4B, 4A, 3, 2 and 1 (SCCM 1999) or 110 (4.6%), 115 (4.8%), 887 (37%), 169 (7%) and 928 (39%) were categorized as priorities 5, 4, 3, 2 and 1 (SCCM 2016), respectively.", [["4A", "TEST", 129, 131], ["SCCM", "TEST", 145, 149], ["SCCM", "TEST", 266, 270]]], ["Overall, 1184 (54%) patients were admitted to the ICU in 48 hours following referral.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28]]], ["There was no difference on hospital mortality for the overall cohort between phase 1 and phase 2.", [["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23]]], ["Conclusions: The implementation of a decision-aid tool for ICU triage was associated with a reduction of potentially inappropriate ICU admissions.", [["ICU triage", "TEST", 59, 69]]], ["Introduction: The aim was analyze the ICU bed rotation pattern, the epidemiological characteristics of patients and to correlate them with prognostic score after software implementation Methods: This is an epidemiological and retrospective study.", [["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["the ICU bed rotation pattern", "TREATMENT", 34, 62], ["retrospective study", "TEST", 226, 245]]], ["Authorization for collection and use of data was granted by the institution.", [["collection", "PROBLEM", 18, 28]]], ["All patients hospitalized in the period were included regardless of other exclusion criteria.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["Results: During the period evaluated, there were 1.011 new hospitalizations, 649 men (64.19%) and 362 women (35.81%).", [["men", "ORGANISM", 81, 84], ["women", "ORGANISM", 102, 107], ["men", "SPECIES", 81, 84], ["women", "SPECIES", 102, 107]]], ["46.38% (469) were in the age group of 18 to 44 years, followed by 28.28% of the patients (286), who were between 45 and 64.", [["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88]]], ["The mean duration of hospitalization in our unit was approximately 8,45 days.", [["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["During the period covered, 1.009 exits occurred: 701 patients (69.47%) were Introduction: Early debriefing after stressful events holds great value in reflection on both an individual and team-based level.", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["stressful events", "PROBLEM", 113, 129]]], ["Methods: 100% of junior doctors (n=10, pre-implementation questionnaire) on the intensive care unit expressed a need for regular debriefing sessions to discuss challenging and complex cases.", [["regular debriefing sessions", "TREATMENT", 121, 148]]], ["Desired outcomes included assessment of team performance, identification of key learning points and psychological support.", [["assessment of team performance", "TEST", 26, 56], ["psychological support", "TREATMENT", 100, 121]]], ["Common themes in perceived benefits included improved team communication and creation of an open environment to address concerns.", [["an open environment", "TREATMENT", 89, 108]]], ["Methods: Retrospective cohort study in 129,680 (68% medical) patients admitted to 93 medical-surgical ICUs during 2014-15.", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["Retrospective cohort study", "TEST", 9, 35]]], ["We retrieved patients' data from an ICU registry (Epimed Monitor System) and surveyed participating ICUs about characteristics related to ICU organization.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21]]], ["We used multilevel logistic regression analysis to identify factors associated with hospital mortality.", [["multilevel logistic regression analysis", "TREATMENT", 8, 47]]], ["We evaluated efficiency in resource use using standardized mortality rates (SMR) and resource use (SRU) based on SAPS 3.", [["standardized mortality rates", "TREATMENT", 46, 74]]], ["Results: SAPS 3 score was 44 (34-54) points and hospital mortality was 18.2%.", [["SAPS 3 score", "TEST", 9, 21], ["hospital mortality", "TEST", 48, 66]]], ["Median bed/ nurse ratio was 5.8 (4.2-7.3) and at least the chief nurse was boardcertified in critical care (BCCC) in 47% ICUs.", [["Median bed/ nurse ratio", "TEST", 0, 23]]], ["Bed/nurse technicians ratio was 1.9 (1.8-2.1).", [["Bed/nurse technicians ratio", "TEST", 0, 27]]], ["Adjusting for relevant characteristics at patientlevel (age, admission type, SOFA, performance status, comorbidities, hospital days before ICU) and ICU-level (hospital type, checklist use, 24/7 intensivist, protocols), bed/nurse ratio was not associated with mortality [OR=0.99 (95% CI, 0.95-1.03)].", [["CI", "TEST", 283, 285]]], ["However, mortality was lower in ICUs with at least the chief nurse BCCC [OR=0.78 (0.65-0.74)].", [["BCCC", "DISEASE", 67, 71]]], ["In multivariate analysis, bed/nurse ratios <=6 [OR=3.53 (1.19-10.53)] and having the chief nurse BCCC [OR=6.36 (2.13-19.02)] were associated with higher efficiency.", [["BCCC", "DISEASE", 97, 101], ["multivariate analysis", "TEST", 3, 24], ["bed/nurse ratios", "TEST", 26, 42], ["higher efficiency", "PROBLEM", 146, 163], ["higher efficiency", "OBSERVATION", 146, 163]]], ["However, having at least the nurse chief BCCC was associated with higher survival.", [["BCCC", "CANCER", 41, 45]]], ["The methodological quality of the included studies was rated using the Newcastle Ottawa scale (NOS).", [["NOS", "GENE_OR_GENE_PRODUCT", 95, 98]]], ["Twenty comparative cohort studies were identified which compared non-physicians with either residents or fellows.", [["Twenty comparative cohort studies", "TEST", 0, 33]]], ["All studies comprised adult intensive care.", [["All studies", "TEST", 0, 11]]], ["Most of the included studies were moderate to good quality.", [["the included studies", "TEST", 8, 28], ["moderate", "OBSERVATION_MODIFIER", 34, 42]]], ["A random effects meta-analysis from all studies regarding length of stay and mortality showed no differences between non-physicians and physicians, although there was a trend to better survival when implementing acute non-physician providers in the ICU (Figs.", [["A random effects meta-analysis", "PROBLEM", 0, 30], ["all studies", "TEST", 36, 47]]], ["Mean difference for length of stay on the ICU was 0.36 (95% CI -0.07 -0.79; I2=88%) and for in hospital -0.15 (95% CI = -0.90 -0.61; I2=83%); while the odds ratio for ICU mortality was 0.94 (95% CI = 0.73 -1.20; I2=60%) and for hospital mortality 0.94 (95% CI 0.89 -1.00; I2=0).", [["CI", "TEST", 60, 62], ["I2", "TEST", 76, 78], ["CI", "TEST", 115, 117], ["I2", "TEST", 133, 135], ["the odds ratio", "TEST", 148, 162], ["ICU mortality", "TEST", 167, 180], ["CI", "TEST", 195, 197], ["I2", "TEST", 212, 214], ["hospital mortality", "TEST", 228, 246], ["CI", "TEST", 257, 259], ["I2", "TEST", 272, 274], ["length", "OBSERVATION_MODIFIER", 20, 26]]], ["Conclusions: The acute care non-physician provider in the ICU seems a promising clinician on the ICU with regard to quality and continuity of care.", [["acute", "OBSERVATION_MODIFIER", 17, 22]]], ["Their role in Europe remains to be elucidated.P479Burnout and depression in ICU staff members N Bahgat Menoufia University hospital, Shibin Elkom, Egypt Critical Care 2018, 22(Suppl 1):P479 Introduction: Family and success in work are the most important sources of person satisfaction in life, Chronic prolonged exposure to stressful high workload in intensive care units (ICU), create a bad psychological state named burnout syndrome in which person is depressed, exhausted and thinks to leave job.", [["depression", "DISEASE", 62, 72], ["burnout syndrome", "DISEASE", 418, 434], ["depressed", "DISEASE", 454, 463], ["person", "SPECIES", 265, 271], ["person", "SPECIES", 444, 450], ["depression", "PROBLEM", 62, 72], ["Chronic prolonged exposure", "PROBLEM", 294, 320], ["burnout syndrome", "PROBLEM", 418, 434], ["depressed", "PROBLEM", 454, 463], ["depression", "OBSERVATION", 62, 72], ["burnout syndrome", "OBSERVATION", 418, 434]]], ["In this study we made a survey on ICUs staff members in Egypt Menoufia university hospital to explore and find risk factors increase depression and burnout among nurses and doctor.", [["depression", "DISEASE", 133, 143], ["burnout", "DISEASE", 148, 155], ["depression", "PROBLEM", 133, 143]]], ["Methods: Questionnaires were given to all intensive care staff for estimating the prevalence and associated risk factors of burnout using Maslach Burnout Inventory (MBI) with its three subscales emotional exhaustion (EE), lack of accomplishment (LA), and depersonalization (DP).", [["burnout", "DISEASE", 124, 131], ["EE", "CHEMICAL", 217, 219], ["depersonalization", "DISEASE", 255, 272]]], ["Depressive symptoms using the Beck Depression Inventory Scale.", [["Depressive symptoms", "DISEASE", 0, 19], ["Depressive symptoms", "PROBLEM", 0, 19], ["the Beck Depression Inventory Scale", "PROBLEM", 26, 61]]], ["Blood sample was taken for assessing depression biomarkers including IL-6, tumor necrosis factor (TNF)-alpha, and coenzyme Q10 (CoQ10), which appears to be one of the most reliable peripheral biomarkers.", [["Blood sample", "ANATOMY", 0, 12], ["depression", "DISEASE", 37, 47], ["necrosis", "DISEASE", 81, 89], ["coenzyme Q10", "CHEMICAL", 114, 126], ["CoQ10", "CHEMICAL", 128, 133], ["Q10", "CHEMICAL", 123, 126], ["CoQ10", "CHEMICAL", 128, 133], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["IL-6", "GENE_OR_GENE_PRODUCT", 69, 73], ["tumor necrosis factor (TNF)-alpha", "GENE_OR_GENE_PRODUCT", 75, 108], ["coenzyme Q10", "SIMPLE_CHEMICAL", 114, 126], ["CoQ10", "SIMPLE_CHEMICAL", 128, 133], ["peripheral", "TISSUE", 181, 191], ["IL-6", "PROTEIN", 69, 73], ["tumor necrosis factor (TNF)-alpha", "PROTEIN", 75, 108], ["Blood sample", "TEST", 0, 12], ["depression biomarkers", "TEST", 37, 58], ["IL", "TEST", 69, 71], ["tumor necrosis factor", "PROBLEM", 75, 96], ["TNF", "TEST", 98, 101], ["alpha", "TREATMENT", 103, 108], ["coenzyme", "TREATMENT", 114, 122], ["tumor", "OBSERVATION_MODIFIER", 75, 80], ["necrosis", "OBSERVATION", 81, 89]]], ["Results: 100 participants were respond in our survey from 127 ICU members the response rate was 78.7%, The depression symptoms found increased in nurses more than physicians in ICU with more desire to leave the job.", [["depression", "DISEASE", 107, 117], ["participants", "ORGANISM", 13, 25], ["participants", "SPECIES", 13, 25], ["the response rate", "TEST", 74, 91], ["The depression symptoms", "PROBLEM", 103, 126], ["depression", "OBSERVATION", 107, 117], ["increased", "OBSERVATION_MODIFIER", 133, 142]]], ["There was strong correlation between the degree of depression symptoms and decrease percent of personal accomplishment.", [["depression", "DISEASE", 51, 61], ["depression symptoms", "PROBLEM", 51, 70], ["depression", "OBSERVATION", 51, 61], ["decrease", "OBSERVATION_MODIFIER", 75, 83]]], ["Impaired personal relationships at work and increased night shifts were major risk factors of burnout syndrome.", [["burnout syndrome", "DISEASE", 94, 110], ["increased night shifts", "PROBLEM", 44, 66], ["burnout syndrome", "PROBLEM", 94, 110], ["burnout syndrome", "OBSERVATION", 94, 110]]], ["Levels of the proinflammatory cytokine (IL6 and TNF alpha) were elevated in members who recorded sever degree of depression score with decrease in concentration of Co-enzyme Q10.", [["depression", "DISEASE", 113, 123], ["Co-enzyme Q10", "CHEMICAL", 164, 177], ["IL6", "GENE_OR_GENE_PRODUCT", 40, 43], ["TNF alpha", "GENE_OR_GENE_PRODUCT", 48, 57], ["proinflammatory cytokine", "PROTEIN", 14, 38], ["IL6", "PROTEIN", 40, 43], ["TNF alpha", "PROTEIN", 48, 57], ["Levels", "TEST", 0, 6], ["the proinflammatory cytokine", "TEST", 10, 38], ["IL6 and TNF alpha)", "TEST", 40, 58], ["depression score", "PROBLEM", 113, 129], ["Co-enzyme Q10", "TREATMENT", 164, 177], ["proinflammatory", "OBSERVATION_MODIFIER", 14, 29], ["depression", "OBSERVATION", 113, 123]]], ["Conclusions: The health workers in ICU had high liability for depression and burnout syndrome.", [["depression", "DISEASE", 62, 72], ["burnout syndrome", "DISEASE", 77, 93], ["depression", "PROBLEM", 62, 72], ["burnout syndrome", "PROBLEM", 77, 93], ["burnout syndrome", "OBSERVATION", 77, 93]]], ["IL6, co-enzyme Q10 and TNF alpha concentrations had god correlation with degree of severity of symptoms.P480Impact of a tailored multicomponent program to reduce discomfort in the ICU on post-traumatic stress disorder: a casecontrol study P Kalfon 1 , M Alessandrini 2 , M Boucekine 2 , M Geantot 3 , S Renoult 4 , S Deparis-Dusautois 5 , O Mimoz 6 , J Amour 7 , E Azoulay 8 , C Martin 9 , T Sharshar 10 , M Garrouste-Orgeas 11 , K Baumstarck 2 , P Auquier 2 Introduction: Reducing discomfort during the ICU stay should be beneficial on long-term outcomes.", [["post-traumatic stress disorder", "DISEASE", 187, 217], ["IL6", "GENE_OR_GENE_PRODUCT", 0, 3], ["co-enzyme Q10", "GENE_OR_GENE_PRODUCT", 5, 18], ["TNF alpha", "GENE_OR_GENE_PRODUCT", 23, 32], ["IL6", "PROTEIN", 0, 3], ["co-enzyme Q10", "PROTEIN", 5, 18], ["TNF alpha", "PROTEIN", 23, 32], ["IL6", "TEST", 0, 3], ["co-enzyme Q10", "TREATMENT", 5, 18], ["TNF alpha concentrations", "TREATMENT", 23, 47], ["severity of symptoms", "PROBLEM", 83, 103], ["a tailored multicomponent program", "TREATMENT", 118, 151], ["discomfort", "PROBLEM", 162, 172], ["post-traumatic stress disorder", "PROBLEM", 187, 217], ["a casecontrol study", "TREATMENT", 219, 238], ["Kalfon", "TREATMENT", 241, 247], ["Reducing discomfort", "PROBLEM", 473, 492]]], ["The aim of this study was to assess the impact of the implementation of a tailored multicomponent program to reduce discomfort in the ICU [1] on the occurrence of posttraumatic stress disorder (PTSD) 12 months after discharge from the ICU.", [["posttraumatic stress disorder", "DISEASE", 163, 192], ["PTSD", "DISEASE", 194, 198], ["this study", "TEST", 11, 21], ["a tailored multicomponent program", "TREATMENT", 72, 105], ["discomfort", "PROBLEM", 116, 126], ["posttraumatic stress disorder", "PROBLEM", 163, 192]]], ["Methods: Design: case-control study; the cases were patients hospitalized in the ICUs which implemented the tailored multicomponent program; the controls were patients hospitalized in the ICUs which did not implement the program.", [["patients", "ORGANISM", 52, 60], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 159, 167]]], ["Exposition: the tailored multicomponent program consisted of assessment of ICU-related self-perceived discomforts by using the IPREA questionnaire, immediate and monthly feedback to healthcare teams, and tailored site-targeted measures under control of a duo of local champions.", [["assessment", "TEST", 61, 71], ["tailored site", "TREATMENT", 204, 217]]], ["General procedure: eligible patients were recalled 12 months after the ICU stay.", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36]]], ["Data collection: sociodemographics, clinical data related to the ICU stay, discomfort's levels assessed the day of discharge from the ICU, life situation (home/care center), PSTD (IES-R) and anxiety-depression symptoms (HADS) 12 months after the ICU discharge.", [["anxiety-depression", "DISEASE", 191, 209], ["HADS", "DISEASE", 220, 224], ["discomfort's levels", "TEST", 75, 94], ["anxiety", "PROBLEM", 191, 198], ["depression symptoms", "PROBLEM", 199, 218]]], ["Results: From the 617 eligible cases and 847 eligible controls, 344 cases and 475 controls were included (reason for exclusion: deaths after discharge from the ICU, lost to follow-up, patient refusal, cognitive incapacity).", [["deaths", "DISEASE", 128, 134], ["cognitive incapacity", "DISEASE", 201, 221], ["patient", "ORGANISM", 184, 191], ["patient", "SPECIES", 184, 191]]], ["A total of 6.1% of the cases and 12.2% of the controls presented certain symptoms of PTSD at12 months (p=0.004).", [["PTSD", "DISEASE", 85, 89], ["the cases", "TEST", 19, 28], ["PTSD", "PROBLEM", 85, 89]]], ["After adjustment for age, gender, IPREA score, McCabe score, presence of invasive devices during the ICU stay and considering anxietydepression symptoms at 12 months, cases are less likely to have PTSD symptoms than controls.", [["anxietydepression", "DISEASE", 126, 143], ["PTSD", "DISEASE", 197, 201], ["invasive devices", "TREATMENT", 73, 89], ["anxietydepression symptoms", "PROBLEM", 126, 152], ["PTSD symptoms", "PROBLEM", 197, 210], ["invasive devices", "OBSERVATION", 73, 89]]], ["Conclusions: Our tailored multicomponent program for discomfort reduction in the ICU can reduce long-term outcomes as PTSD.", [["PTSD", "DISEASE", 118, 122], ["discomfort reduction", "TREATMENT", 53, 73], ["PTSD", "PROBLEM", 118, 122]]], ["Diffusion of such a program should be enhanced in the ICUs paving the way for a new strategy in care management.P480Introduction: Cognitive dysfunction is a major factor leading to disability and poor quality of life in ICU survivors.", [["Cognitive dysfunction", "DISEASE", 130, 151], ["disability", "DISEASE", 181, 191], ["a new strategy in care management", "TREATMENT", 78, 111], ["Cognitive dysfunction", "PROBLEM", 130, 151]]], ["In order to identify patients at risk for developing cognitive dysfunction due to critical illness or ICU treatment, one has to discriminate between patients with pre-existing cognitive dysfunction and those developing new cognitive dysfunction or worsening of cognitive function during ICU treatment.", [["cognitive dysfunction", "DISEASE", 53, 74], ["illness", "DISEASE", 91, 98], ["cognitive dysfunction", "DISEASE", 176, 197], ["cognitive dysfunction", "DISEASE", 223, 244], ["patients", "ORGANISM", 21, 29], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 149, 157], ["developing cognitive dysfunction", "PROBLEM", 42, 74], ["critical illness", "PROBLEM", 82, 98], ["ICU treatment", "TREATMENT", 102, 115], ["pre-existing cognitive dysfunction", "PROBLEM", 163, 197], ["new cognitive dysfunction", "PROBLEM", 219, 244], ["worsening of cognitive function", "PROBLEM", 248, 279], ["ICU treatment", "TREATMENT", 287, 300], ["worsening", "OBSERVATION_MODIFIER", 248, 257]]], ["We investigated the incidence of pre-existing cognitive dysfunction in ICU patients using the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) and its relation with delirium during ICU treatment.", [["cognitive dysfunction", "DISEASE", 46, 67], ["Cognitive Decline", "DISEASE", 121, 138], ["delirium", "DISEASE", 185, 193], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["pre-existing cognitive dysfunction", "PROBLEM", 33, 67], ["Cognitive Decline", "PROBLEM", 121, 138], ["delirium", "PROBLEM", 185, 193], ["ICU treatment", "TREATMENT", 201, 214], ["cognitive dysfunction", "OBSERVATION", 46, 67]]], ["Methods: Patients relatives were asked to fill in the IQCODE on admission.", [["Patients", "ORGANISM", 9, 17], ["Patients", "SPECIES", 9, 17]]], ["An overall score on cognitive dysfunction was calculated by the average of the score on each item of the questionnaire.", [["cognitive dysfunction", "DISEASE", 20, 41], ["cognitive dysfunction", "PROBLEM", 20, 41], ["overall", "OBSERVATION_MODIFIER", 3, 10], ["score", "OBSERVATION_MODIFIER", 11, 16]]], ["The incidence of delirium was based on the CAM-ICU score.", [["delirium", "DISEASE", 17, 25], ["delirium", "PROBLEM", 17, 25], ["delirium", "OBSERVATION", 17, 25]]], ["Statistical analysis was performed using the Fisher's exact test.", [["Statistical analysis", "TEST", 0, 20], ["the Fisher's exact test", "TEST", 41, 64]]], ["P-values of less then 0.05 were deemed significant.", [["P-values", "TEST", 0, 8]]], ["Results: In total 452 consecutive patients admitted to our ICU were analyzed, of whom 47.8% (n=216) showed decline in cognitive function prior to ICU admission.", [["decline in cognitive function", "DISEASE", 107, 136], ["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["decline in cognitive function", "PROBLEM", 107, 136]]], ["Cognitive function was divided in four groups; no change 52.2% (n=236), slight decline 34.1% (n=154), moderate decline 9.7% (n=44) and severe decline 4.0% (n=18) (Fig. 1 ).", [["Cognitive function", "TEST", 0, 18], ["slight decline", "PROBLEM", 72, 86], ["moderate decline", "PROBLEM", 102, 118], ["severe decline", "PROBLEM", 135, 149], ["slight", "OBSERVATION_MODIFIER", 72, 78], ["moderate", "OBSERVATION_MODIFIER", 102, 110], ["severe", "OBSERVATION_MODIFIER", 135, 141]]], ["Incidence of delirium is shown in Fig. 2 .", [["delirium", "DISEASE", 13, 21], ["delirium", "PROBLEM", 13, 21], ["delirium", "OBSERVATION", 13, 21]]], ["Patients with moderate to severe cognitive dysfunction showed significant more delirium during ICU treatment than patients with no change in cognition (44.2% and 21.1% respectively, (p=0.023)).", [["cognitive dysfunction", "DISEASE", 33, 54], ["delirium", "DISEASE", 79, 87], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 114, 122], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 114, 122], ["moderate to severe cognitive dysfunction", "PROBLEM", 14, 54], ["significant more delirium", "PROBLEM", 62, 87], ["ICU treatment", "TREATMENT", 95, 108], ["change in cognition", "PROBLEM", 131, 150], ["moderate", "OBSERVATION_MODIFIER", 14, 22], ["severe", "OBSERVATION_MODIFIER", 26, 32], ["significant", "OBSERVATION_MODIFIER", 62, 73], ["more", "OBSERVATION_MODIFIER", 74, 78], ["delirium", "OBSERVATION", 79, 87], ["no", "UNCERTAINTY", 128, 130], ["change", "OBSERVATION_MODIFIER", 131, 137]]], ["Conclusions: Almost half of the patients admitted to the ICU have cognitive dysfunction prior to ICU admission.", [["cognitive dysfunction", "DISEASE", 66, 87], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["cognitive dysfunction", "PROBLEM", 66, 87]]], ["To assess ones cognitive function after ICU treatment one has to take in to account the patients pre-existing cognitive functioning.", [["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["ICU treatment", "TREATMENT", 40, 53]]], ["Patients with a moderate to severe pre-existing cognitive dysfunction develop significantly more delirium during ICU treatment.", [["cognitive dysfunction", "DISEASE", 48, 69], ["delirium", "DISEASE", 97, 105], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["a moderate to severe pre-existing cognitive dysfunction", "PROBLEM", 14, 69], ["significantly more delirium", "PROBLEM", 78, 105], ["ICU treatment", "TREATMENT", 113, 126], ["moderate", "OBSERVATION_MODIFIER", 16, 24], ["severe", "OBSERVATION_MODIFIER", 28, 34], ["cognitive dysfunction", "OBSERVATION", 48, 69], ["significantly more", "OBSERVATION_MODIFIER", 78, 96], ["delirium", "OBSERVATION", 97, 105]]], ["Introduction: Our aim was to identify and analyse patients treated for POCD admitted to a thoracics/urology intensive care unit at University College London, UK.", [["POCD", "DISEASE", 71, 75], ["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["POCD", "TREATMENT", 71, 75], ["thoracics", "ANATOMY", 90, 99]]], ["POCD is rising in the ageing high-risk surgical patient.", [["POCD", "DISEASE", 0, 4], ["patient", "ORGANISM", 48, 55], ["patient", "SPECIES", 48, 55], ["POCD", "PROBLEM", 0, 4], ["rising", "OBSERVATION_MODIFIER", 8, 14], ["surgical patient", "OBSERVATION", 39, 55]]], ["Early identification of those at risk and timely intervention could help reduce associated morbidity and mortality [1] .", [["timely intervention", "TREATMENT", 42, 61], ["associated morbidity", "PROBLEM", 80, 100]]], ["Methods: We identified patients treated with haloperidol, midazolam, lorazepam, olanzapine, clonidine or chlordiazepoxide from our electronic data system.", [["haloperidol", "CHEMICAL", 45, 56], ["midazolam", "CHEMICAL", 58, 67], ["lorazepam", "CHEMICAL", 69, 78], ["olanzapine", "CHEMICAL", 80, 90], ["clonidine", "CHEMICAL", 92, 101], ["chlordiazepoxide", "CHEMICAL", 105, 121], ["haloperidol", "CHEMICAL", 45, 56], ["midazolam", "CHEMICAL", 58, 67], ["lorazepam", "CHEMICAL", 69, 78], ["olanzapine", "CHEMICAL", 80, 90], ["clonidine", "CHEMICAL", 92, 101], ["chlordiazepoxide", "CHEMICAL", 105, 121], ["patients", "ORGANISM", 23, 31], ["haloperidol", "SIMPLE_CHEMICAL", 45, 56], ["midazolam", "SIMPLE_CHEMICAL", 58, 67], ["lorazepam", "SIMPLE_CHEMICAL", 69, 78], ["olanzapine", "SIMPLE_CHEMICAL", 80, 90], ["clonidine", "SIMPLE_CHEMICAL", 92, 101], ["chlordiazepoxide", "SIMPLE_CHEMICAL", 105, 121], ["patients", "SPECIES", 23, 31], ["haloperidol", "TREATMENT", 45, 56], ["midazolam", "TREATMENT", 58, 67], ["lorazepam", "TREATMENT", 69, 78], ["olanzapine", "TREATMENT", 80, 90], ["clonidine", "TREATMENT", 92, 101], ["chlordiazepoxide", "TREATMENT", 105, 121]]], ["These pharmacological interventions were used as surrogate markers of primarily hyperactive POCD, acknowledging other forms of delirium may be unaccounted for.", [["POCD", "DISEASE", 92, 96], ["delirium", "DISEASE", 127, 135], ["These pharmacological interventions", "TREATMENT", 0, 35], ["hyperactive POCD", "PROBLEM", 80, 96], ["delirium", "PROBLEM", 127, 135], ["hyperactive POCD", "OBSERVATION", 80, 96]]], ["Patients were excluded if the drugs had been used for other indications.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["the drugs", "TREATMENT", 26, 35]]], ["Prevalence of known POCD risk factors were then detailed.", [["POCD risk factors", "PROTEIN", 20, 37], ["known POCD risk factors", "PROBLEM", 14, 37], ["POCD", "OBSERVATION", 20, 24]]], ["On these data we performed a cluster analysis using R. Results: Of the 58 patients (7.17%) suitable for analysis, the mean age was 72.", [["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["a cluster analysis", "TEST", 27, 45], ["analysis", "TEST", 104, 112], ["the mean age", "TEST", 114, 126]]], ["41 patients underwent elective procedures.", [["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["elective procedures", "TREATMENT", 22, 41]]], ["75% patients had thoracic surgery.", [["thoracic", "ANATOMY", 17, 25], ["patients", "ORGANISM", 4, 12], ["thoracic", "ORGAN", 17, 25], ["patients", "SPECIES", 4, 12], ["thoracic surgery", "TREATMENT", 17, 33], ["thoracic", "ANATOMY", 17, 25], ["surgery", "OBSERVATION", 26, 33]]], ["The mean pain score in the first 24 hours post-op was 1.6 (SD=1.1), (with 0= no pain, 4= very severe pain).", [["pain", "DISEASE", 9, 13], ["pain", "DISEASE", 80, 84], ["pain", "DISEASE", 101, 105], ["The mean pain score", "TEST", 0, 19], ["pain", "PROBLEM", 80, 84], ["very severe pain", "PROBLEM", 89, 105], ["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["62% had evidence of poor sleep and 14% evidence of anxiety.", [["anxiety", "DISEASE", 51, 58], ["poor sleep", "PROBLEM", 20, 30], ["anxiety", "PROBLEM", 51, 58]]], ["In the 24 hours prior to evidence of POCD, the mean pain score remained 1.6 (SD=0.99), 76% had evidence of poor sleep and 22% had evidence of anxiety.", [["POCD", "DISEASE", 37, 41], ["pain", "DISEASE", 52, 56], ["anxiety", "DISEASE", 142, 149], ["POCD", "PROBLEM", 37, 41], ["the mean pain score", "TEST", 43, 62], ["SD", "TEST", 77, 79], ["poor sleep", "PROBLEM", 107, 117], ["anxiety", "PROBLEM", 142, 149], ["POCD", "OBSERVATION", 37, 41], ["anxiety", "OBSERVATION", 142, 149]]], ["66% of our population was septic during their ITU admission.", [["septic", "DISEASE", 26, 32], ["septic", "PROBLEM", 26, 32], ["septic", "OBSERVATION", 26, 32]]], ["Conclusions: Our analysis demonstrates POCD is highly prevalent in male patients over 70 undergoing thoracic procedures.", [["thoracic", "ANATOMY", 100, 108], ["POCD", "CANCER", 39, 43], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["Our analysis", "TEST", 13, 25], ["POCD", "PROBLEM", 39, 43], ["thoracic procedures", "TREATMENT", 100, 119], ["POCD", "OBSERVATION", 39, 43], ["thoracic", "ANATOMY", 100, 108]]], ["We will now develop a POCD pathway targeting improved postoperative management of pain, sleep, anxiety and infection in this patient population.P480Introduction: Our objective was to determine the feasibility of employing family-administered tools to detect delirium in the critically ill.", [["pain", "DISEASE", 82, 86], ["anxiety", "DISEASE", 95, 102], ["infection", "DISEASE", 107, 116], ["delirium", "DISEASE", 258, 266], ["critically ill", "DISEASE", 274, 288], ["patient", "ORGANISM", 125, 132], ["patient", "SPECIES", 125, 132], ["a POCD pathway", "TREATMENT", 20, 34], ["postoperative management", "TREATMENT", 54, 78], ["pain", "PROBLEM", 82, 86], ["sleep", "PROBLEM", 88, 93], ["anxiety", "PROBLEM", 95, 102], ["infection", "PROBLEM", 107, 116], ["delirium", "PROBLEM", 258, 266], ["infection", "OBSERVATION", 107, 116]]], ["The use of family-administered delirium detection tools has not been assessed in the ICU where patients are critically ill and frequently intubated.", [["delirium", "DISEASE", 31, 39], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["delirium detection tools", "PROBLEM", 31, 55], ["critically ill", "PROBLEM", 108, 122]]], ["Family members may be able to detect changes in patient cognition and behavior from pre-illness levels earlier than unfamiliar providers.", [["patient", "ORGANISM", 48, 55], ["patient", "SPECIES", 48, 55], ["changes in patient cognition", "PROBLEM", 37, 65], ["pre-illness levels", "TEST", 84, 102]]], ["Methods: Consecutive patients and family members (dyads) in the largest adult ICU in Calgary, Canada were recruited (Aug. 9-Sept.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29]]], ["Inclusion criteria were: patients with a Richmond Agitation Sedation Scale (RASS) >=-3; no primary brain injury and Glasgow Coma Scale score of <9; ability to provide informed consent (patient/ surrogate); and remain in ICU for 24 hours.", [["brain", "ANATOMY", 99, 104], ["Agitation", "DISEASE", 50, 59], ["primary brain injury", "DISEASE", 91, 111], ["Coma", "DISEASE", 124, 128], ["patients", "ORGANISM", 25, 33], ["brain", "ORGAN", 99, 104], ["patient", "ORGANISM", 185, 192], ["patients", "SPECIES", 25, 33], ["patient", "SPECIES", 185, 192], ["a Richmond Agitation Sedation Scale", "TREATMENT", 39, 74], ["RASS", "TEST", 76, 80], ["primary brain injury", "PROBLEM", 91, 111], ["Glasgow Coma Scale score", "TEST", 116, 140], ["brain", "ANATOMY", 99, 104], ["injury", "OBSERVATION", 105, 111]]], ["Family-administered delirium assessments were completed once daily (Family Confusion Assessment Method & Sour Seven).", [["delirium", "DISEASE", 20, 28], ["Confusion", "DISEASE", 75, 84], ["delirium assessments", "TEST", 20, 40]]], ["To assess feasibility, we assessed proportion of eligible patients and percent family member enrollment.", [["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66]]], ["Results: Of 99 admitted patients with family, 37 (37%) met inclusion criteria and 17 (46%) dyads consented.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32]]], ["20% of admitted patients did not have family and were thus ineligible.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24]]], ["73% of enrolled dyads assessed delirium at least once, with a median of 5 (of 10 total) assessments.", [["delirium", "DISEASE", 31, 39], ["delirium", "PROBLEM", 31, 39]]], ["Barriers with nursing staff were encountered, including not providing access to patients and patient exclusion.", [["patients", "ORGANISM", 80, 88], ["patient", "ORGANISM", 93, 100], ["patients", "SPECIES", 80, 88], ["patient", "SPECIES", 93, 100]]], ["Conclusions: These data suggest that employing family-administered delirium detection tools in the ICU is feasible for a subset of the population.", [["delirium", "DISEASE", 67, 75], ["These data", "TEST", 13, 23], ["delirium detection tools", "PROBLEM", 67, 91]]], ["Future studies will validate the use of these tools in the ICU, decrease modifiable barriers to enrollment, and test strategies to overcome attitudinal barriers towards employing these tools.", [["Future studies", "TEST", 0, 14], ["test strategies", "TREATMENT", 112, 127], ["attitudinal barriers", "TREATMENT", 140, 160]]], ["Introduction: Psychological impact of critical illness and ICU stay on patients can be severe and frequently results in acute distress as well as psychological morbidity after discharge [1] .", [["critical illness", "DISEASE", 38, 54], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["critical illness", "PROBLEM", 38, 54], ["acute distress", "PROBLEM", 120, 134]]], ["However, the stressful experience in ICU and its influence on patient recovery, remain relatively understudied.", [["patient", "ORGANISM", 62, 69], ["patient", "SPECIES", 62, 69]]], ["We assessed patients in ICU for acute distress and psychological symptoms with validated tools.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["acute distress", "PROBLEM", 32, 46], ["psychological symptoms", "PROBLEM", 51, 73]]], ["Methods: We conducted an observational study in a group of awake ICU adult patients admitted in a tertiary centre for at least 48 hours, from January 2017 until October 2017, with mixed diagnosis on admission.", [["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["an observational study", "TEST", 22, 44]]], ["We collected demographic factors, SAPS II at admission, mechanical ventilation, day of sedation, history of psychopathological disorder.", [["psychopathological disorder", "DISEASE", 108, 135], ["SAPS II", "PROTEIN", 34, 41], ["mechanical ventilation", "TREATMENT", 56, 78], ["sedation", "TREATMENT", 87, 95], ["psychopathological disorder", "PROBLEM", 108, 135], ["mechanical ventilation", "OBSERVATION", 56, 78]]], ["Un-sedated and alert, critical care patients were assessed with tools such as Intensive Care Delirium Screening Checklist (ICDSC), Hospital Anxiety and Depression Scale (HADS) and Intensive Care Psychological Assessment Tool (IPAT).", [["Delirium", "DISEASE", 93, 101], ["Anxiety and Depression", "DISEASE", 140, 162], ["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["sedated", "TREATMENT", 3, 10], ["Depression Scale (HADS)", "TREATMENT", 152, 175]]], ["Results: 68 patients were recruited, (mean age 51.2\u00b117.9 years, 66.2% males).", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["SAPS II at admission was 32.2\u00b116.7, 60.3% was mechanically ventilated (mean duration 6.1\u00b114), mean duration of sedation was 2.8\u00b13.9 days and a rate of 22.05% had an history of psychopatological disorder.", [["psychopatological disorder", "DISEASE", 176, 202], ["SAPS II", "PROTEIN", 0, 7], ["SAPS II", "TEST", 0, 7], ["mean duration", "TEST", 71, 84], ["mean duration", "TEST", 94, 107], ["sedation", "TEST", 111, 119], ["a rate", "TEST", 141, 147], ["psychopatological disorder", "PROBLEM", 176, 202], ["psychopatological disorder", "OBSERVATION", 176, 202]]], ["10.3% of the sample had clinical delirium (ICSDC>3) and was not assessed with others tools, 20.6% had subclinical delirium (ICSDC <=3).", [["delirium", "DISEASE", 33, 41], ["delirium", "DISEASE", 114, 122], ["the sample", "TEST", 9, 19], ["clinical delirium", "PROBLEM", 24, 41], ["ICSDC", "TEST", 43, 48], ["subclinical delirium", "PROBLEM", 102, 122]]], ["Regarding psychological outcomes, 26.2 % (mean score 6.1\u00b12.5) reported a score (>=8) on HADS that indicates a possible diagnosis of anxiety and 54.1% (mean score 7.9 \u00b1 3.7) of depression.", [["anxiety", "DISEASE", 132, 139], ["depression", "DISEASE", 176, 186], ["psychological outcomes", "TEST", 10, 32], ["mean score", "TEST", 42, 52], ["a score", "TEST", 71, 78], ["HADS", "TEST", 88, 92], ["anxiety", "PROBLEM", 132, 139], ["mean score", "TEST", 151, 161], ["depression", "PROBLEM", 176, 186]]], ["A rate of 24.6% reported a score >= 7 on IPAT suggesting an acute distress.", [["A rate", "TEST", 0, 6], ["a score", "TEST", 25, 32], ["an acute distress", "PROBLEM", 57, 74], ["acute", "OBSERVATION_MODIFIER", 60, 65], ["distress", "OBSERVATION", 66, 74]]], ["Conclusions: The study's key finding was that acute psychological distress was high in awake ICU patients.", [["acute psychological distress", "DISEASE", 46, 74], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["The study", "TEST", 13, 22], ["acute psychological distress", "PROBLEM", 46, 74]]], ["Further work is needed to determine the efficacy of early psychological interventions to reduce the incidence of acute distress and psychological outcomes after ICU stay.", [["early psychological interventions", "TREATMENT", 52, 85], ["acute distress", "PROBLEM", 113, 127], ["acute", "OBSERVATION_MODIFIER", 113, 118], ["distress", "OBSERVATION", 119, 127]]], ["Introduction: A high percentage of polytrauma patients require surgery within the first 24 hours to stabilize primary traumatic injuries.", [["polytrauma", "DISEASE", 35, 45], ["traumatic injuries", "DISEASE", 118, 136], ["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["polytrauma", "PROBLEM", 35, 45], ["surgery", "TREATMENT", 63, 70], ["primary traumatic injuries", "PROBLEM", 110, 136], ["polytrauma", "OBSERVATION", 35, 45], ["traumatic", "OBSERVATION_MODIFIER", 118, 127], ["injuries", "OBSERVATION", 128, 136]]], ["One of the main intraoperative complications in this type of patients is due to hemodynamic instability [1] .", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["the main intraoperative complications", "PROBLEM", 7, 44], ["hemodynamic instability", "PROBLEM", 80, 103], ["main", "OBSERVATION_MODIFIER", 11, 15], ["intraoperative", "OBSERVATION_MODIFIER", 16, 30], ["complications", "OBSERVATION", 31, 44]]], ["Thus, it is necessary to implement multimodal monitoring involving both hemodynamic monitoring and monitoring of general anesthesia.", [["multimodal monitoring", "TEST", 35, 56], ["both hemodynamic monitoring", "TEST", 67, 94], ["general anesthesia", "TREATMENT", 113, 131]]], ["The objectives of this study were to identify the possible implications of Entropy monitoring on hemodynamic stability in critically ill polytrauma patients.", [["critically ill", "DISEASE", 122, 136], ["polytrauma", "DISEASE", 137, 147], ["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 148, 156], ["this study", "TEST", 18, 28], ["Entropy monitoring", "TEST", 75, 93]]], ["There were two groups, Group A (N = 37), in which the depth of hypnosis was monitored through Entropy (GE Healthcare, Helsinki, Finland) and Group B (N = 35).", [["hypnosis", "PROBLEM", 63, 71], ["hypnosis", "OBSERVATION", 63, 71]]], ["Results: The incidence of hypotension and tachycardia episodes was statistically significantly lower in Group A, unlike the control group (p <0.05).", [["hypotension", "DISEASE", 26, 37], ["tachycardia", "DISEASE", 42, 53], ["hypotension", "PROBLEM", 26, 37], ["tachycardia episodes", "PROBLEM", 42, 62], ["hypotension", "OBSERVATION", 26, 37]]], ["Moreover, a statistically significant (p <0.05) consumption of inhaled anesthetic agent was recorded in Group A compared with Group B. Consumption of vasopressor was also lower in Group A (p <0.0001, difference between means 0.960 \u00b1 0.063, 95% confidence interval 0.8334 -1.0866) Conclusions: Deploying monitoring for the depth of hypnosis in general anesthesia using Entropy can significantly increase the hemodynamic stability of critically ill polytrauma patients.P480Introduction: The use of methadone as a potent analgesic has been gaining ground in the intensive care setting, such as where it is possible to properly select the group of patients who will benefit from the drug, as well as monitoring of possible complications.", [["critically ill", "DISEASE", 432, 446], ["polytrauma", "DISEASE", 447, 457], ["methadone", "CHEMICAL", 496, 505], ["methadone", "CHEMICAL", 496, 505], ["patients", "ORGANISM", 458, 466], ["methadone", "SIMPLE_CHEMICAL", 496, 505], ["patients", "ORGANISM", 644, 652], ["patients", "SPECIES", 458, 466], ["patients", "SPECIES", 644, 652], ["inhaled anesthetic agent", "TREATMENT", 63, 87], ["vasopressor", "TREATMENT", 150, 161], ["means", "TEST", 219, 224], ["Deploying monitoring", "TEST", 293, 313], ["hypnosis", "PROBLEM", 331, 339], ["general anesthesia", "TREATMENT", 343, 361], ["Entropy", "TREATMENT", 368, 375], ["critically ill polytrauma", "PROBLEM", 432, 457], ["methadone", "TREATMENT", 496, 505], ["a potent analgesic", "TREATMENT", 509, 527], ["the drug", "TREATMENT", 675, 683], ["complications", "PROBLEM", 719, 732], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["hypnosis", "OBSERVATION", 331, 339], ["hemodynamic stability", "OBSERVATION", 407, 428]]], ["The objective of this study is to evaluate the safety of the use of methadone in critically ill patients in a large hospital.", [["methadone", "CHEMICAL", 68, 77], ["critically ill", "DISEASE", 81, 95], ["methadone", "CHEMICAL", 68, 77], ["methadone", "SIMPLE_CHEMICAL", 68, 77], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["this study", "TEST", 17, 27], ["methadone", "TREATMENT", 68, 77]]], ["Methods: A retrospective analysis of all patients who used methadone in a neurological intensive care unit for a period of four months and the results were evaluated.", [["methadone", "CHEMICAL", 59, 68], ["methadone", "CHEMICAL", 59, 68], ["patients", "ORGANISM", 41, 49], ["methadone", "SIMPLE_CHEMICAL", 59, 68], ["patients", "SPECIES", 41, 49], ["A retrospective analysis", "TEST", 9, 33], ["methadone", "TREATMENT", 59, 68]]], ["Results: In the four-month period, 52 patients used methadone during intensive care.", [["methadone", "CHEMICAL", 52, 61], ["methadone", "CHEMICAL", 52, 61], ["patients", "ORGANISM", 38, 46], ["methadone", "SIMPLE_CHEMICAL", 52, 61], ["patients", "SPECIES", 38, 46], ["methadone", "TREATMENT", 52, 61], ["intensive care", "TREATMENT", 69, 83]]], ["65 % of the patients were male, with a medical age of 59.7 \u00b1 17.4 years.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["The main indication for the use of the medication was for analgesia in patients who were weaned from mechanical ventilation.", [["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["the medication", "TREATMENT", 35, 49], ["analgesia", "TREATMENT", 58, 67], ["mechanical ventilation", "TREATMENT", 101, 123], ["main", "OBSERVATION_MODIFIER", 4, 8], ["mechanical ventilation", "OBSERVATION", 101, 123]]], ["In all cases evaluated, analgesia was effective, with methadone being used alone or in combination with other drugs, according to an institutional protocol.", [["methadone", "CHEMICAL", 54, 63], ["methadone", "CHEMICAL", 54, 63], ["methadone", "SIMPLE_CHEMICAL", 54, 63], ["analgesia", "TREATMENT", 24, 33], ["methadone", "TREATMENT", 54, 63], ["other drugs", "TREATMENT", 104, 115], ["an institutional protocol", "TREATMENT", 130, 155]]], ["Among the complications found, 20 patients presented hypotension (38 %); 20 presented bradycardia (38 %); 15 presented constipation (29%); 4 had excessive sedation (8 %) and 7 had other complications.", [["hypotension", "DISEASE", 53, 64], ["bradycardia", "DISEASE", 86, 97], ["constipation", "DISEASE", 119, 131], ["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["the complications", "PROBLEM", 6, 23], ["hypotension", "PROBLEM", 53, 64], ["bradycardia", "PROBLEM", 86, 97], ["constipation", "PROBLEM", 119, 131], ["excessive sedation", "TREATMENT", 145, 163], ["other complications", "PROBLEM", 180, 199], ["complications", "OBSERVATION", 186, 199]]], ["All complications were reversible.", [["All complications", "PROBLEM", 0, 17], ["complications", "OBSERVATION", 4, 17]]], ["10 patients of the studied population died, however, without correlation with the use of methadone.", [["methadone", "CHEMICAL", 89, 98], ["methadone", "CHEMICAL", 89, 98], ["patients", "ORGANISM", 3, 11], ["methadone", "SIMPLE_CHEMICAL", 89, 98], ["patients", "SPECIES", 3, 11], ["methadone", "TREATMENT", 89, 98]]], ["Conclusions: The use of methadone, in the studied group, was effective in the control of analgesia, with no impact on patient safety when used in a monitored way.", [["methadone", "CHEMICAL", 24, 33], ["methadone", "CHEMICAL", 24, 33], ["methadone", "SIMPLE_CHEMICAL", 24, 33], ["patient", "ORGANISM", 118, 125], ["patient", "SPECIES", 118, 125], ["methadone", "TREATMENT", 24, 33], ["analgesia", "TREATMENT", 89, 98]]], ["Introduction: Renal colic is a common disorder which presents with dramatic acute pain.", [["Renal colic", "ANATOMY", 14, 25], ["Renal colic", "DISEASE", 14, 25], ["pain", "DISEASE", 82, 86], ["Renal", "ORGAN", 14, 19], ["Renal colic", "PROBLEM", 14, 25], ["a common disorder", "PROBLEM", 29, 46], ["dramatic acute pain", "PROBLEM", 67, 86], ["Renal colic", "ANATOMY", 14, 25], ["dramatic", "OBSERVATION_MODIFIER", 67, 75], ["acute", "OBSERVATION_MODIFIER", 76, 81], ["pain", "OBSERVATION", 82, 86]]], ["Providing rapid relief, using effective pain control medications is the clinical priority to treat the patients.", [["pain", "DISEASE", 40, 44], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["rapid relief", "TREATMENT", 10, 22], ["effective pain control medications", "TREATMENT", 30, 64]]], ["This study aims to compare the effect of IV Ketorolac versus Morphine in releasing renal colic pain by measuring pain severity and duration and also the need for additional doses.", [["renal colic", "ANATOMY", 83, 94], ["Ketorolac", "CHEMICAL", 44, 53], ["Morphine", "CHEMICAL", 61, 69], ["renal colic pain", "DISEASE", 83, 99], ["pain", "DISEASE", 113, 117], ["Ketorolac", "CHEMICAL", 44, 53], ["Morphine", "CHEMICAL", 61, 69], ["Ketorolac", "SIMPLE_CHEMICAL", 44, 53], ["Morphine", "SIMPLE_CHEMICAL", 61, 69], ["renal", "ORGAN", 83, 88], ["This study", "TEST", 0, 10], ["IV Ketorolac", "TREATMENT", 41, 53], ["Morphine", "TREATMENT", 61, 69], ["releasing renal colic pain", "PROBLEM", 73, 99], ["measuring pain severity", "PROBLEM", 103, 126], ["additional doses", "TREATMENT", 162, 178], ["renal colic", "ANATOMY", 83, 94]]], ["Methods: We performed a clinical pilot cohort study from during 2014 on patients with the clinical diagnosis of renal colic who recruited from the emergency department (ED) of Rasool-e-Akram Hospital and Firoozgar Hospital.", [["renal colic", "ANATOMY", 112, 123], ["renal colic", "DISEASE", 112, 123], ["patients", "ORGANISM", 72, 80], ["renal", "ORGAN", 112, 117], ["patients", "SPECIES", 72, 80], ["a clinical pilot cohort study", "TEST", 22, 51], ["renal colic", "PROBLEM", 112, 123], ["renal colic", "ANATOMY", 112, 123]]], ["Participants who were candidate to receive either Morphine or Ketorolac were divided into two groups who received either 30 mg Ketorolac IV or 5 mg Morphine.", [["Morphine", "CHEMICAL", 50, 58], ["Ketorolac", "CHEMICAL", 62, 71], ["Ketorolac IV", "CHEMICAL", 127, 139], ["Morphine", "CHEMICAL", 148, 156], ["Morphine", "CHEMICAL", 50, 58], ["Ketorolac", "CHEMICAL", 62, 71], ["Ketorolac IV", "CHEMICAL", 127, 139], ["Morphine", "CHEMICAL", 148, 156], ["Morphine", "SIMPLE_CHEMICAL", 50, 58], ["Ketorolac", "SIMPLE_CHEMICAL", 62, 71], ["Morphine", "SIMPLE_CHEMICAL", 148, 156], ["Participants", "SPECIES", 0, 12], ["Morphine", "TREATMENT", 50, 58], ["Ketorolac", "TREATMENT", 62, 71], ["30 mg Ketorolac IV", "TREATMENT", 121, 139], ["Morphine", "TREATMENT", 148, 156]]], ["The pain was evaluated using the visual analog scale (VAS) at four time points: before drug injection (VAS-1), 20 minutes (VAS-2), 40 minutes (VAS-3), and 60 minutes (VAS-4) after injection.", [["pain", "DISEASE", 4, 8], ["The pain", "PROBLEM", 0, 8], ["the visual analog scale", "TEST", 29, 52], ["VAS", "TEST", 103, 106], ["VAS", "TEST", 123, 126], ["VAS", "TEST", 143, 146], ["VAS", "TEST", 167, 170], ["injection", "TREATMENT", 180, 189]]], ["In cases when the pain was not controlled with the first injection of drug beyond 60 minutes; additional doses (rescue) were injected.", [["pain", "DISEASE", 18, 22], ["the pain", "PROBLEM", 14, 22], ["drug", "TREATMENT", 70, 74], ["additional doses (rescue)", "TREATMENT", 94, 119]]], ["Statistical analyses were performed using SPSS 21.", [["Statistical analyses", "TEST", 0, 20], ["SPSS", "TEST", 42, 46]]], ["Results: One-hundred-fifty patients treated with Morphine and 150 ones with Ketorolac were studiedThe group treated with Morphine scored on average 9.91 before the injection, which was roughly 2.4 points higher than Ketorolac.", [["Morphine", "CHEMICAL", 49, 57], ["Ketorolac", "CHEMICAL", 76, 85], ["Morphine", "CHEMICAL", 121, 129], ["Ketorolac", "CHEMICAL", 216, 225], ["Morphine", "CHEMICAL", 49, 57], ["Ketorolac", "CHEMICAL", 76, 85], ["Morphine", "CHEMICAL", 121, 129], ["Ketorolac", "CHEMICAL", 216, 225], ["patients", "ORGANISM", 27, 35], ["Morphine", "SIMPLE_CHEMICAL", 49, 57], ["Ketorolac", "SIMPLE_CHEMICAL", 76, 85], ["Morphine", "SIMPLE_CHEMICAL", 121, 129], ["Ketorolac", "SIMPLE_CHEMICAL", 216, 225], ["patients", "SPECIES", 27, 35], ["Morphine", "TREATMENT", 49, 57], ["Ketorolac", "TREATMENT", 76, 85], ["Morphine", "TREATMENT", 121, 129], ["Ketorolac", "TREATMENT", 216, 225]]], ["Morphine reduced patients' VAS scores more intensely (median: 10, IQR: 0 versus median: 6, IQR: 1; p value<0.001).", [["Morphine", "CHEMICAL", 0, 8], ["Morphine", "CHEMICAL", 0, 8], ["Morphine", "SIMPLE_CHEMICAL", 0, 8], ["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["Morphine", "TREATMENT", 0, 8]]], ["In general, patients treated with Morphine were more likely to need a second (rescue) dose, when compared to Ketorolac group (38.6% vs 20%, p value= 0.001).", [["Morphine", "CHEMICAL", 34, 42], ["Ketorolac", "CHEMICAL", 109, 118], ["Morphine", "CHEMICAL", 34, 42], ["Ketorolac", "CHEMICAL", 109, 118], ["patients", "ORGANISM", 12, 20], ["Morphine", "SIMPLE_CHEMICAL", 34, 42], ["Ketorolac", "SIMPLE_CHEMICAL", 109, 118], ["patients", "SPECIES", 12, 20], ["Morphine", "TREATMENT", 34, 42], ["a second (rescue) dose", "TREATMENT", 68, 90], ["Ketorolac group", "TEST", 109, 124], ["p value", "TEST", 140, 147]]], ["Conclusions: Morphine is a better option for pain release in cases of renal colic.", [["renal", "ANATOMY", 70, 75], ["Morphine", "CHEMICAL", 13, 21], ["pain", "DISEASE", 45, 49], ["renal colic", "DISEASE", 70, 81], ["Morphine", "CHEMICAL", 13, 21], ["Morphine", "SIMPLE_CHEMICAL", 13, 21], ["renal", "ORGAN", 70, 75], ["Morphine", "TREATMENT", 13, 21], ["pain release", "TREATMENT", 45, 57], ["renal colic", "PROBLEM", 70, 81], ["renal", "ANATOMY", 70, 75], ["colic", "OBSERVATION", 76, 81]]], ["Ketorolac released the pain to an acceptable level; but, because of its slower action time, we recommend it in cases with moderate than severe pains.P493Effect of analgesics on cardiovascular and hormonal response to operative trauma D Loncar Stojiljkovic, MP Stojiljkovic SGH, 11000, Serbia Critical Care 2018, 22(Suppl 1):P493P493Introduction: Objective of this study was to compare the effects of two analgesic regimens, one opioid and one non-opioid, on cardiovascular and hormonal reaction of patients undergoing elective surgery under general endotracheal anaesthesia.", [["cardiovascular", "ANATOMY", 177, 191], ["cardiovascular", "ANATOMY", 458, 472], ["endotracheal", "ANATOMY", 549, 561], ["Ketorolac", "CHEMICAL", 0, 9], ["pain", "DISEASE", 23, 27], ["pains", "DISEASE", 143, 148], ["trauma", "DISEASE", 227, 233], ["cardiovascular and hormonal reaction", "DISEASE", 458, 494], ["Ketorolac", "CHEMICAL", 0, 9], ["Ketorolac", "SIMPLE_CHEMICAL", 0, 9], ["cardiovascular", "ANATOMICAL_SYSTEM", 177, 191], ["cardiovascular", "ANATOMICAL_SYSTEM", 458, 472], ["patients", "ORGANISM", 498, 506], ["patients", "SPECIES", 498, 506], ["Ketorolac", "TREATMENT", 0, 9], ["the pain", "PROBLEM", 19, 27], ["moderate than severe pains", "PROBLEM", 122, 148], ["analgesics", "TREATMENT", 163, 173], ["this study", "TEST", 359, 369], ["two analgesic regimens", "TREATMENT", 400, 422], ["one opioid", "TREATMENT", 424, 434], ["cardiovascular and hormonal reaction", "TREATMENT", 458, 494], ["elective surgery", "TREATMENT", 518, 534], ["general endotracheal anaesthesia", "TREATMENT", 541, 573], ["moderate", "OBSERVATION_MODIFIER", 122, 130], ["severe", "OBSERVATION_MODIFIER", 136, 142], ["pains", "OBSERVATION", 143, 148], ["endotracheal anaesthesia", "OBSERVATION", 549, 573]]], ["Methods: A total of 40 elderly patients, ASA 2, scheduled for elective abdominal surgery were assigned to receive on induction a single dose of either fentanyl (0.2 mg, +0.1mg) or a fix combination of etodolac and carbamazepine (Novocomb, dose 100mg+100mg iv bolus).", [["abdominal", "ANATOMY", 71, 80], ["fentanyl", "CHEMICAL", 151, 159], ["etodolac", "CHEMICAL", 201, 209], ["carbamazepine", "CHEMICAL", 214, 227], ["Novocomb", "CHEMICAL", 229, 237], ["fentanyl", "CHEMICAL", 151, 159], ["etodolac", "CHEMICAL", 201, 209], ["carbamazepine", "CHEMICAL", 214, 227], ["Novocomb", "CHEMICAL", 229, 237], ["patients", "ORGANISM", 31, 39], ["abdominal", "ORGAN", 71, 80], ["fentanyl", "SIMPLE_CHEMICAL", 151, 159], ["etodolac", "SIMPLE_CHEMICAL", 201, 209], ["carbamazepine", "SIMPLE_CHEMICAL", 214, 227], ["Novocomb", "SIMPLE_CHEMICAL", 229, 237], ["patients", "SPECIES", 31, 39], ["ASA", "TREATMENT", 41, 44], ["elective abdominal surgery", "TREATMENT", 62, 88], ["fentanyl", "TREATMENT", 151, 159], ["etodolac", "TREATMENT", 201, 209], ["carbamazepine", "TREATMENT", 214, 227], ["Novocomb", "TREATMENT", 229, 237], ["abdominal", "ANATOMY", 71, 80]]], ["Haemodynamic parameters and concentrations of prolactin cortisol and growth hormone (GH) [1] were determined at critical points and 24 h after operation.", [["cortisol", "CHEMICAL", 56, 64], ["cortisol", "CHEMICAL", 56, 64], ["prolactin cortisol", "GENE_OR_GENE_PRODUCT", 46, 64], ["growth hormone", "GENE_OR_GENE_PRODUCT", 69, 83], ["GH", "GENE_OR_GENE_PRODUCT", 85, 87], ["Haemodynamic parameters", "TEST", 0, 23], ["prolactin cortisol", "TEST", 46, 64]]], ["Results: Both fentanyl and Novocomb blocked the hypertensivetachycardic response to surgical trauma.", [["fentanyl", "CHEMICAL", 14, 22], ["Novocomb", "CHEMICAL", 27, 35], ["trauma", "DISEASE", 93, 99], ["fentanyl", "CHEMICAL", 14, 22], ["Novocomb", "CHEMICAL", 27, 35], ["fentanyl", "SIMPLE_CHEMICAL", 14, 22], ["Novocomb", "SIMPLE_CHEMICAL", 27, 35], ["Both fentanyl", "TREATMENT", 9, 22], ["Novocomb", "TREATMENT", 27, 35], ["the hypertensivetachycardic response", "TREATMENT", 44, 80], ["surgical trauma", "PROBLEM", 84, 99], ["surgical trauma", "OBSERVATION", 84, 99]]], ["Cortisol was a more appropriate endocrine marker of stress than prolactin or GH since fentanyl as an opioid analgesic increased secretion of prolactin [2] , while carbamazepine from Novocomb did the same with GH [3] (Figs.", [["endocrine", "ANATOMY", 32, 41], ["fentanyl", "CHEMICAL", 86, 94], ["carbamazepine", "CHEMICAL", 163, 176], ["Cortisol", "CHEMICAL", 0, 8], ["fentanyl", "CHEMICAL", 86, 94], ["carbamazepine", "CHEMICAL", 163, 176], ["Cortisol", "SIMPLE_CHEMICAL", 0, 8], ["prolactin", "GENE_OR_GENE_PRODUCT", 64, 73], ["GH", "GENE_OR_GENE_PRODUCT", 77, 79], ["fentanyl", "SIMPLE_CHEMICAL", 86, 94], ["opioid", "SIMPLE_CHEMICAL", 101, 107], ["prolactin", "GENE_OR_GENE_PRODUCT", 141, 150], ["carbamazepine", "SIMPLE_CHEMICAL", 163, 176], ["Novocomb", "SIMPLE_CHEMICAL", 182, 190], ["GH [3]", "GENE_OR_GENE_PRODUCT", 209, 215], ["Cortisol", "TEST", 0, 8], ["prolactin", "TREATMENT", 64, 73], ["GH", "TREATMENT", 77, 79], ["fentanyl", "TREATMENT", 86, 94], ["an opioid analgesic increased secretion of prolactin", "TREATMENT", 98, 150], ["carbamazepine", "TREATMENT", 163, 176]]], ["Conclusions: Cortisol plasma concentration correlates positively with cardiovascular parameters in patients undergoing elective abdominal surgery who received fentanyl or Novocomb as intraoperative analgesic.", [["plasma", "ANATOMY", 22, 28], ["cardiovascular", "ANATOMY", 70, 84], ["abdominal", "ANATOMY", 128, 137], ["Cortisol", "CHEMICAL", 13, 21], ["fentanyl", "CHEMICAL", 159, 167], ["Novocomb", "CHEMICAL", 171, 179], ["Cortisol", "CHEMICAL", 13, 21], ["fentanyl", "CHEMICAL", 159, 167], ["Novocomb", "CHEMICAL", 171, 179], ["Cortisol", "GENE_OR_GENE_PRODUCT", 13, 21], ["plasma", "ORGANISM_SUBSTANCE", 22, 28], ["cardiovascular", "ANATOMICAL_SYSTEM", 70, 84], ["patients", "ORGANISM", 99, 107], ["abdominal", "ORGANISM_SUBDIVISION", 128, 137], ["fentanyl", "SIMPLE_CHEMICAL", 159, 167], ["Novocomb", "SIMPLE_CHEMICAL", 171, 179], ["patients", "SPECIES", 99, 107], ["Cortisol plasma concentration", "TEST", 13, 42], ["cardiovascular parameters", "TEST", 70, 95], ["elective abdominal surgery", "TREATMENT", 119, 145], ["fentanyl", "TREATMENT", 159, 167], ["Novocomb", "TREATMENT", 171, 179], ["intraoperative analgesic", "TREATMENT", 183, 207], ["abdominal", "ANATOMY", 128, 137], ["surgery", "OBSERVATION", 138, 145]]], ["Its suppression is better marker of analgesia than prolactin and GH.P494Volatile anaesthetic consumption and recovery times after long term inhalative sedation using the mirus system -an automated delivery system for isoflurane, sevoflurane and desflurane Introduction: The new MIRUS system as well as the AnaConDa uses a reflector to conserve volatile anaesthetics (VA) [1, 2] .", [["isoflurane", "CHEMICAL", 217, 227], ["sevoflurane", "CHEMICAL", 229, 240], ["desflurane", "CHEMICAL", 245, 255], ["AnaConDa", "CHEMICAL", 306, 314], ["isoflurane", "CHEMICAL", 217, 227], ["sevoflurane", "CHEMICAL", 229, 240], ["desflurane", "CHEMICAL", 245, 255], ["prolactin", "GENE_OR_GENE_PRODUCT", 51, 60], ["GH.P494", "GENE_OR_GENE_PRODUCT", 65, 72], ["isoflurane", "SIMPLE_CHEMICAL", 217, 227], ["sevoflurane", "SIMPLE_CHEMICAL", 229, 240], ["desflurane", "SIMPLE_CHEMICAL", 245, 255], ["analgesia than prolactin", "TREATMENT", 36, 60], ["Volatile anaesthetic consumption", "TREATMENT", 72, 104], ["long term inhalative sedation", "TREATMENT", 130, 159], ["the mirus system", "TREATMENT", 166, 182], ["an automated delivery system", "TREATMENT", 184, 212], ["isoflurane", "TREATMENT", 217, 227], ["sevoflurane", "TREATMENT", 229, 240], ["desflurane", "TREATMENT", 245, 255], ["The new MIRUS system", "TREATMENT", 270, 290], ["a reflector", "TREATMENT", 320, 331], ["volatile anaesthetics", "TREATMENT", 344, 365]]], ["Both systems can be paired with ICU ventilators, but MIRUS features an automated control of end-tidal VA concentrations (etVA).", [["ICU ventilators", "TREATMENT", 32, 47], ["end-tidal VA concentrations", "TREATMENT", 92, 119]]], ["We compare feasibility and recovery times for inhalational long term sedation with isoflurane (ISO), sevoflurane (SEVO) or desflurane (DES).", [["isoflurane", "CHEMICAL", 83, 93], ["ISO", "CHEMICAL", 95, 98], ["sevoflurane", "CHEMICAL", 101, 112], ["SEVO", "CHEMICAL", 114, 118], ["desflurane", "CHEMICAL", 123, 133], ["DES", "CHEMICAL", 135, 138], ["isoflurane", "CHEMICAL", 83, 93], ["ISO", "CHEMICAL", 95, 98], ["sevoflurane", "CHEMICAL", 101, 112], ["SEVO", "CHEMICAL", 114, 118], ["desflurane", "CHEMICAL", 123, 133], ["DES", "CHEMICAL", 135, 138], ["isoflurane", "SIMPLE_CHEMICAL", 83, 93], ["sevoflurane", "SIMPLE_CHEMICAL", 101, 112], ["SEVO", "SIMPLE_CHEMICAL", 114, 118], ["desflurane", "SIMPLE_CHEMICAL", 123, 133], ["inhalational long term sedation", "TREATMENT", 46, 77], ["isoflurane (ISO)", "TREATMENT", 83, 99], ["sevoflurane", "TREATMENT", 101, 112], ["desflurane (DES", "TREATMENT", 123, 138]]], ["Methods: 30 ASA II-IV patients undergoing elective or emergency surgery under general anaesthesia were included.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["ASA II", "TREATMENT", 12, 18], ["emergency surgery", "TREATMENT", 54, 71], ["general anaesthesia", "TREATMENT", 78, 97]]], ["Patients were randomized into three equal groups ISO, SEVO and DES.", [["ISO", "CHEMICAL", 49, 52], ["SEVO", "CHEMICAL", 54, 58], ["DES", "CHEMICAL", 63, 66], ["ISO", "CHEMICAL", 49, 52], ["SEVO", "CHEMICAL", 54, 58], ["DES", "CHEMICAL", 63, 66], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["SEVO and DES", "TREATMENT", 54, 66]]], ["The MIRUS system was started with a targeted etVA of 0.5 MAC.", [["The MIRUS system", "TREATMENT", 0, 16]]], ["We used the Puritan Bennett 840 ICU ventilator and performed a spontaneous breathing trial.", [["the Puritan Bennett 840 ICU ventilator", "TREATMENT", 8, 46], ["a spontaneous breathing trial", "TREATMENT", 61, 90]]], ["Results: Patients were comparable in demographics, tidal volume, respiratory rate and sedation time (total 696h: ISO 19\u00b19h; SEVO 22 \u00b119h; DES 29\u00b129h; p=0.55).", [["respiratory", "ANATOMY", 65, 76], ["DES", "CHEMICAL", 138, 141], ["Patients", "ORGANISM", 9, 17], ["tidal", "ORGANISM_SUBDIVISION", 51, 56], ["Patients", "SPECIES", 9, 17], ["tidal volume", "TEST", 51, 63], ["respiratory rate", "TEST", 65, 81], ["sedation time", "TEST", 86, 99], ["ISO", "TEST", 113, 116], ["SEVO", "TEST", 124, 128], ["DES", "TEST", 138, 141], ["p", "TEST", 150, 151]]], ["In all patients, a MAC of 0.5 was reached.", [["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["a MAC", "TREATMENT", 17, 22]]], ["Conclusions: MIRUS could automatically control end-tidal VA concentrations in ventilated and spontaneously breathing patients.", [["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["tidal VA", "OBSERVATION", 51, 59], ["ventilated", "OBSERVATION", 78, 88]]], ["The recovery times are only prolonged in the ISO group and could be shortened by removing the reflector.", [["ISO", "CHEMICAL", 45, 48], ["ISO", "CHEMICAL", 45, 48], ["prolonged", "OBSERVATION_MODIFIER", 28, 37]]], ["The higher etVA required for a 0.5 MAC using DES and SEVO were associated with an increased VA consumption.P494Introduction: Intranasal analgesia is increasingly used in order to relieve pain in the emergency department.", [["DES", "CHEMICAL", 45, 48], ["SEVO", "CHEMICAL", 53, 57], ["P494Introduction", "CHEMICAL", 107, 123], ["pain", "DISEASE", 187, 191], ["DES", "CHEMICAL", 45, 48], ["SEVO", "CHEMICAL", 53, 57], ["SEVO", "SIMPLE_CHEMICAL", 53, 57], ["a 0.5 MAC using DES", "TREATMENT", 29, 48], ["SEVO", "TREATMENT", 53, 57], ["an increased VA consumption", "PROBLEM", 79, 106], ["Intranasal analgesia", "TREATMENT", 125, 145], ["pain", "PROBLEM", 187, 191], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["increased", "OBSERVATION_MODIFIER", 82, 91], ["VA", "OBSERVATION", 92, 94]]], ["This non-invasive approach avoids discomfort, stress and risks related to the parenteral route of administration.", [["parenteral", "ANATOMY", 78, 88], ["discomfort", "PROBLEM", 34, 44], ["stress and risks", "PROBLEM", 46, 62], ["the parenteral route of administration", "TREATMENT", 74, 112]]], ["The objective is to compare intranasal (IN) fentanyl versus any parenteral opioid (intravenous, subcutaneous, intramuscular) for the effectiveness of acute pain relief in an adult population.", [["parenteral", "ANATOMY", 64, 74], ["intravenous", "ANATOMY", 83, 94], ["subcutaneous", "ANATOMY", 96, 108], ["fentanyl", "CHEMICAL", 44, 52], ["pain", "DISEASE", 156, 160], ["fentanyl", "CHEMICAL", 44, 52], ["fentanyl", "SIMPLE_CHEMICAL", 44, 52], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 83, 94], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 110, 123], ["intranasal", "TREATMENT", 28, 38], ["fentanyl", "TREATMENT", 44, 52], ["any parenteral opioid (intravenous, subcutaneous, intramuscular)", "TREATMENT", 60, 124], ["acute pain relief", "PROBLEM", 150, 167]]], ["The research of articles was conducted through Embase, Central, and Medline databases.", [["Central", "OBSERVATION_MODIFIER", 55, 62]]], ["Randomized clinical trials comparing the effectiveness of IN fentanyl to any parenteral opioid for acute pain relief (<= 7 days) in an adult population (>= 18 years old) were considered for inclusion.", [["fentanyl", "CHEMICAL", 61, 69], ["pain", "DISEASE", 105, 109], ["fentanyl", "CHEMICAL", 61, 69], ["IN", "ORGANISM", 58, 60], ["fentanyl", "SIMPLE_CHEMICAL", 61, 69], ["clinical trials", "TREATMENT", 11, 26], ["fentanyl", "TREATMENT", 61, 69], ["any parenteral opioid", "TREATMENT", 73, 94], ["acute pain relief", "PROBLEM", 99, 116]]], ["Studies on breakthrough cancer pain were excluded.", [["cancer", "ANATOMY", 24, 30], ["cancer pain", "DISEASE", 24, 35], ["cancer", "CANCER", 24, 30], ["breakthrough cancer pain", "PROBLEM", 11, 35], ["cancer", "OBSERVATION", 24, 30]]], ["The main outcome was the difference between pain levels before and after analgesia.", [["pain", "DISEASE", 44, 48], ["pain levels", "TEST", 44, 55], ["analgesia", "TREATMENT", 73, 82], ["main", "OBSERVATION_MODIFIER", 4, 8], ["outcome", "OBSERVATION_MODIFIER", 9, 16]]], ["The effect size was approximated using the inverse of variance of standardized mean differences, based on a random-effect model.", [["effect", "OBSERVATION_MODIFIER", 4, 10], ["size", "OBSERVATION_MODIFIER", 11, 15]]], ["Heterogeneity was quantified using a test of I2.", [["a test of I2", "TEST", 35, 47]]], ["Results: Eight randomized clinical trials with 11 cohorts and a total of 613 patients were selected (320 IN fentanyl vs 293 control group).", [["fentanyl", "CHEMICAL", 108, 116], ["fentanyl", "CHEMICAL", 108, 116], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["fentanyl", "TREATMENT", 108, 116]]], ["Selected articles contained a low risk of bias.", [["low risk", "OBSERVATION_MODIFIER", 30, 38]]], ["There is no significant difference between the average levels of pain before and after analgesia comparing the two groups (SMD 0.12 [IC 95% -0.04 \u00e0 0.28], p=0.14; I2 = 0%) (Fig. 1) .", [["pain", "DISEASE", 65, 69], ["pain", "PROBLEM", 65, 69], ["analgesia", "TREATMENT", 87, 96], ["SMD", "TEST", 123, 126], ["IC", "TEST", 133, 135], ["p", "TEST", 155, 156], ["I2", "TEST", 163, 165], ["no", "UNCERTAINTY", 9, 11], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["difference", "OBSERVATION_MODIFIER", 24, 34]]], ["Conclusions: IN fentanyl is as effective as other parenteral opioid to relieve pain during the first hour of treatment.", [["fentanyl", "CHEMICAL", 16, 24], ["pain", "DISEASE", 79, 83], ["fentanyl", "CHEMICAL", 16, 24], ["IN fentanyl", "SIMPLE_CHEMICAL", 13, 24], ["fentanyl", "TREATMENT", 16, 24], ["other parenteral opioid", "TREATMENT", 44, 67], ["pain", "PROBLEM", 79, 83], ["treatment", "TREATMENT", 109, 118]]], ["Introduction: The aim of this study is to underline the importance of sedation protocol when performing the PEGJ procedure in advanced Parkinson's Disease (PD) patients.", [["Parkinson's Disease", "DISEASE", 135, 154], ["PD", "DISEASE", 156, 158], ["patients", "ORGANISM", 160, 168], ["patients", "SPECIES", 160, 168], ["this study", "TEST", 25, 35], ["sedation protocol", "TREATMENT", 70, 87], ["the PEGJ procedure", "TREATMENT", 104, 122], ["advanced Parkinson's Disease", "PROBLEM", 126, 154]]], ["Research about the use of sedation in endoscopy is getting more and more widespread as to answer to the increasing grade of complexity and duration of endoscopic procedures as to offer comfort to the patient in terms of analgesia, tolerability, and amnesia.", [["amnesia", "DISEASE", 249, 256], ["patient", "ORGANISM", 200, 207], ["patient", "SPECIES", 200, 207], ["sedation", "TREATMENT", 26, 34], ["endoscopy", "TREATMENT", 38, 47], ["endoscopic procedures", "TREATMENT", 151, 172], ["comfort", "TREATMENT", 185, 192], ["analgesia", "TREATMENT", 220, 229], ["amnesia", "PROBLEM", 249, 256]]], ["Sedation is also a way to assure quality and safety examination and to improve its outcome [1] .", [["Sedation", "TREATMENT", 0, 8], ["safety examination", "TEST", 45, 63]]], ["Methods: This observational retrospective study includes 40 PD patients scheduled for PEGJ procedure (Fig. 1 ) in order to start therapy with Duodopa gel.", [["PD", "DISEASE", 60, 62], ["patients", "ORGANISM", 63, 71], ["Duodopa", "SIMPLE_CHEMICAL", 142, 149], ["patients", "SPECIES", 63, 71], ["This observational retrospective study", "TEST", 9, 47], ["PEGJ procedure", "TREATMENT", 86, 100], ["therapy", "TREATMENT", 129, 136], ["Duodopa gel", "TREATMENT", 142, 153]]], ["We propose an anesthetic technique (Table 1) to support PEGJ with both local anesthesia and moderate sedation so as to provide analgesia and patient's comfort.", [["patient", "ORGANISM", 141, 148], ["patient", "SPECIES", 141, 148], ["an anesthetic technique", "TREATMENT", 11, 34], ["PEGJ", "TREATMENT", 56, 60], ["both local anesthesia", "TREATMENT", 66, 87], ["moderate sedation", "TREATMENT", 92, 109], ["analgesia", "TREATMENT", 127, 136]]], ["This technique ensures Mean duration of PEGJ procedure was 35'\u00b15'.", [["This technique", "TREATMENT", 0, 14], ["PEGJ procedure", "TREATMENT", 40, 54]]], ["Compared to our old experience, we collected lack of patient's discomfort, anxiety, and memory, high procedure compliance and improvement of the quality of procedure without use of opioids.P494Conclusions: Based on our experience, we consider this sedation protocol effective for different reasons: to relieve or abolish patient's discomfort, anxiety, and memory, to ensure compliance with the procedure, to ensure patient's analgesia and patient's safety and, finally to assure procedure's quality and rapid discharge.", [["anxiety", "DISEASE", 75, 82], ["anxiety", "DISEASE", 343, 350], ["patient", "ORGANISM", 53, 60], ["patient", "ORGANISM", 321, 328], ["patient", "ORGANISM", 415, 422], ["patient", "ORGANISM", 439, 446], ["patient", "SPECIES", 53, 60], ["patient", "SPECIES", 321, 328], ["patient", "SPECIES", 415, 422], ["patient", "SPECIES", 439, 446], ["patient's discomfort", "PROBLEM", 53, 73], ["anxiety", "PROBLEM", 75, 82], ["high procedure compliance", "TREATMENT", 96, 121], ["procedure", "TREATMENT", 156, 165], ["opioids", "TREATMENT", 181, 188], ["this sedation protocol", "TREATMENT", 243, 265], ["patient's discomfort", "PROBLEM", 321, 341], ["anxiety", "PROBLEM", 343, 350], ["the procedure", "TREATMENT", 390, 403], ["patient's analgesia", "TREATMENT", 415, 434], ["procedure's quality", "TREATMENT", 479, 498]]], ["Anyways, a multicentric study should be done to test our protocol.P494Introduction: Studies have shown that ICU survivors exhibit longterm neurocognitive impairment and perceived reduction in quality of life after ICU discharge, but studies examining sleep architecture and sleep disordered breathing (SDB) in ICU survivors after ICU discharge are scanty.", [["neurocognitive impairment", "DISEASE", 139, 164], ["sleep disordered breathing", "DISEASE", 274, 300], ["SDB", "DISEASE", 302, 305], ["a multicentric study", "TEST", 9, 29], ["longterm neurocognitive impairment", "PROBLEM", 130, 164], ["sleep architecture", "PROBLEM", 251, 269], ["sleep disordered breathing", "PROBLEM", 274, 300]]], ["The aim of our study was to assess sleep architecture and SBD in ICU survivors.", [["SBD", "DISEASE", 58, 61], ["our study", "TEST", 11, 20]]], ["Methods: ICU survivors were screened for eligibility.", [["survivors", "ORGANISM", 13, 22]]], ["Inclusion criteria were: age 18 -80 yrs, mechanical ventilation >= 48 hours, GCS of 15 at the time of hospital discharge.", [["mechanical ventilation", "TREATMENT", 41, 63], ["GCS", "TEST", 77, 80]]], ["Patients with a history of SBD, chronic neuromuscular disorders, chronic restrictive lung disease, congestive heart failure and respiratory failure at hospital discharge were excluded.", [["neuromuscular", "ANATOMY", 40, 53], ["lung", "ANATOMY", 85, 89], ["heart", "ANATOMY", 110, 115], ["respiratory", "ANATOMY", 128, 139], ["SBD", "DISEASE", 27, 30], ["chronic neuromuscular disorders", "DISEASE", 32, 63], ["restrictive lung disease", "DISEASE", 73, 97], ["congestive heart failure", "DISEASE", 99, 123], ["respiratory failure", "DISEASE", 128, 147], ["Patients", "ORGANISM", 0, 8], ["lung", "ORGAN", 85, 89], ["heart", "ORGAN", 110, 115], ["Patients", "SPECIES", 0, 8], ["SBD", "PROBLEM", 27, 30], ["chronic neuromuscular disorders", "PROBLEM", 32, 63], ["chronic restrictive lung disease", "PROBLEM", 65, 97], ["congestive heart failure", "PROBLEM", 99, 123], ["respiratory failure", "PROBLEM", 128, 147], ["chronic", "OBSERVATION_MODIFIER", 32, 39], ["neuromuscular", "ANATOMY", 40, 53], ["chronic", "OBSERVATION_MODIFIER", 65, 72], ["restrictive", "OBSERVATION_MODIFIER", 73, 84], ["lung", "ANATOMY", 85, 89], ["disease", "OBSERVATION", 90, 97], ["congestive", "OBSERVATION_MODIFIER", 99, 109], ["heart", "ANATOMY", 110, 115], ["failure", "OBSERVATION", 116, 123], ["respiratory failure", "OBSERVATION", 128, 147]]], ["Patients were evaluated within one week after hospital discharge and 6 months later.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["At both visits patients completed health related quality of life questionnaires (SF36 and Epworth Sleepiness Scale), underwent a physical examination, lung function tests including maximum inspiratory and expiratory mouth pressures, and an overnight full polysomnography (PSG).P494Results: Sleep quality at 7 days of hospital discharge is poor, characterized by severe disruption of sleep architecture and excessive SDB, mainly of obstructive type which in 76% of patients was classified as moderate or severe.", [["lung", "ANATOMY", 151, 155], ["mouth", "ANATOMY", 216, 221], ["disruption of sleep architecture", "DISEASE", 369, 401], ["SDB", "DISEASE", 416, 419], ["obstructive type", "DISEASE", 431, 447], ["patients", "ORGANISM", 15, 23], ["lung", "ORGAN", 151, 155], ["patients", "ORGANISM", 464, 472], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 464, 472], ["a physical examination", "TEST", 127, 149], ["lung function tests", "TEST", 151, 170], ["maximum inspiratory", "TEST", 181, 200], ["expiratory mouth pressures", "TEST", 205, 231], ["an overnight full polysomnography", "TEST", 237, 270], ["severe disruption of sleep architecture", "PROBLEM", 362, 401], ["excessive SDB", "PROBLEM", 406, 419], ["obstructive type", "PROBLEM", 431, 447], ["lung", "ANATOMY", 151, 155], ["severe", "OBSERVATION_MODIFIER", 362, 368], ["disruption", "OBSERVATION", 369, 379], ["sleep architecture", "OBSERVATION", 383, 401], ["excessive", "OBSERVATION_MODIFIER", 406, 415], ["SDB", "OBSERVATION", 416, 419], ["obstructive", "OBSERVATION_MODIFIER", 431, 442], ["moderate", "OBSERVATION_MODIFIER", 491, 499], ["severe", "OBSERVATION_MODIFIER", 503, 509]]], ["Although at six months after hospital discharge sleep quality remained relatively poor, significant improvement in N3 stage and AHI was observed, with more patients to be classified as normal or mild SDB.", [["SDB", "DISEASE", 200, 203], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 156, 164], ["N3 stage", "PROBLEM", 115, 123], ["AHI", "PROBLEM", 128, 131], ["mild SDB", "PROBLEM", 195, 203], ["significant", "OBSERVATION_MODIFIER", 88, 99], ["improvement", "OBSERVATION_MODIFIER", 100, 111], ["N3 stage", "OBSERVATION_MODIFIER", 115, 123], ["normal", "OBSERVATION", 185, 191], ["mild", "OBSERVATION_MODIFIER", 195, 199], ["SDB", "OBSERVATION", 200, 203]]], ["Both at hospital discharge and 6 months later quality of life was reduced but there was no relationship between the health related quality of life and sleep disturbances.P494Conclusions: ICU survivors experience significant deterioration in their quality of life status with minor improvement 6 months later and a variety of sleep disturbances that seems to start getting better 6 months later.", [["sleep disturbances", "DISEASE", 151, 169], ["sleep disturbances", "DISEASE", 325, 343], ["sleep disturbances", "PROBLEM", 151, 169], ["significant deterioration", "PROBLEM", 212, 237], ["sleep disturbances", "PROBLEM", 325, 343], ["significant", "OBSERVATION_MODIFIER", 212, 223], ["deterioration", "OBSERVATION", 224, 237]]], ["Introduction: Disrupted sleep in critically ill patients may be associated with delirium, prolonged stay in ICU and increased mortality.", [["critically ill", "DISEASE", 33, 47], ["delirium", "DISEASE", 80, 88], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["delirium", "PROBLEM", 80, 88], ["increased mortality", "PROBLEM", 116, 135], ["increased", "OBSERVATION_MODIFIER", 116, 125], ["mortality", "OBSERVATION", 126, 135]]], ["Polysomnography (PSG), the criterion standard method of sleep monitoring, is challenging in ICU due to interpretation difficulties, as the patterns defined by the standard classification for scoring sleep are absent in many critically ill patients.", [["critically ill", "DISEASE", 224, 238], ["patients", "ORGANISM", 239, 247], ["patients", "SPECIES", 239, 247], ["Polysomnography", "TEST", 0, 15], ["sleep monitoring", "TEST", 56, 72], ["interpretation difficulties", "PROBLEM", 103, 130], ["scoring sleep", "PROBLEM", 191, 204]]], ["The aim of this study was to investigate if the presence of atypical patterns in critically ill patients' PSG is associated with poor outcome measured by 90-days mortality in conscious critically ill patients on mechanical ventilation.", [["critically ill", "DISEASE", 81, 95], ["critically ill", "DISEASE", 185, 199], ["patients", "ORGANISM", 96, 104], ["patients", "ORGANISM", 200, 208], ["patients", "SPECIES", 96, 104], ["patients", "SPECIES", 200, 208], ["this study", "TEST", 11, 21], ["atypical patterns in critically ill patients' PSG", "PROBLEM", 60, 109], ["mechanical ventilation", "TREATMENT", 212, 234], ["atypical", "OBSERVATION_MODIFIER", 60, 68], ["mechanical ventilation", "OBSERVATION", 212, 234]]], ["Methods: 70 PSGs (median duration 20 hours) recorded in conscious critically ill mechanically ventilated patients were scored by an expert in sleep medicine blinded to patient characteristics.", [["PSGs", "ANATOMY", 12, 16], ["PSGs", "CANCER", 12, 16], ["patients", "ORGANISM", 105, 113], ["patient", "ORGANISM", 168, 175], ["patients", "SPECIES", 105, 113], ["patient", "SPECIES", 168, 175], ["sleep medicine", "TREATMENT", 142, 156]]], ["Otherwise, modified classification for scoring sleep in critically ill patients proposed by Watson et al. was applied [1] .", [["critically ill", "DISEASE", 56, 70], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79]]], ["The association of sleep patterns (normal or atypical) and micro-sleep phenomena (sleep spindles and Kcomplexes) with 90 days mortality was assessed using Weibull model by calculation of Hazard Ratios (HR).", [["sleep patterns", "PROBLEM", 19, 33], ["micro-sleep phenomena (sleep spindles", "PROBLEM", 59, 96]]], ["Results: HR analysis showed twice as high mortality risk in case of atypical sleep compared to normal sleep; this was however not significant (HR 2.5; 95% CI 0.95-4.44; p=0.08).", [["HR analysis", "TEST", 9, 20], ["atypical sleep", "PROBLEM", 68, 82], ["HR", "TEST", 143, 145], ["CI", "TEST", 155, 157], ["p", "TEST", 169, 170]]], ["The presence of sleep spindles in PSG significantly reduced mortality risk to 1/3 (HR 0.33; 95% CI 0.13-0.86; p=0.02).", [["sleep spindles", "PROBLEM", 16, 30], ["PSG significantly reduced mortality risk", "PROBLEM", 34, 74], ["HR", "TEST", 83, 85], ["CI", "TEST", 96, 98], ["p", "TEST", 110, 111], ["sleep spindles", "OBSERVATION", 16, 30]]], ["The presence of K-complexes in PSG reduced mortality risk to \u00bd, though not significantly (HR 0.52; 95% CI 0.24-1.12; p=0.1).P494Conclusions: The absence of normal sleep characteristics in PSG in conscious critically ill patients on mechanical ventilation is associated with poor short-term outcome.P499Antipsychotics (APs) prescribing in critically ill delirious patients, the reported versus the perceived practice E Almehairi 1 , G Davies 1 , D Taylor Introduction: APs are the most commonly prescribed drugs in hyperactive/mixed delirium and agitation in critical care (CC) [1] .", [["critically ill", "DISEASE", 205, 219], ["P499Antipsychotics", "CHEMICAL", 298, 316], ["APs", "CHEMICAL", 318, 321], ["critically ill delirious", "DISEASE", 338, 362], ["hyperactive", "DISEASE", 514, 525], ["delirium", "DISEASE", 532, 540], ["agitation", "DISEASE", 545, 554], ["CC", "CHEMICAL", 573, 575], ["P499Antipsychotics", "CHEMICAL", 298, 316], ["patients", "ORGANISM", 220, 228], ["P499Antipsychotics", "SIMPLE_CHEMICAL", 298, 316], ["APs", "SIMPLE_CHEMICAL", 318, 321], ["patients", "ORGANISM", 363, 371], ["K-complexes", "PROTEIN", 16, 27], ["patients", "SPECIES", 220, 228], ["patients", "SPECIES", 363, 371], ["K-complexes in PSG reduced mortality risk", "PROBLEM", 16, 57], ["HR", "TEST", 90, 92], ["CI", "TEST", 103, 105], ["p", "TEST", 117, 118], ["mechanical ventilation", "TREATMENT", 232, 254], ["poor short-term outcome", "PROBLEM", 274, 297], ["hyperactive/mixed delirium", "PROBLEM", 514, 540], ["agitation", "PROBLEM", 545, 554], ["PSG reduced", "OBSERVATION", 31, 42], ["mechanical ventilation", "OBSERVATION", 232, 254]]], ["Yet evidence in CC is scant, there are known adverse effects (ADE) and prescription is out with the European license.", [["CC", "CHEMICAL", 16, 18], ["known adverse effects", "PROBLEM", 39, 60], ["scant", "OBSERVATION", 22, 27], ["adverse", "OBSERVATION_MODIFIER", 45, 52]]], ["Meticulous observation of AP selection, prescribing and safety, alongside delirium assessment/plan is essential to gain new knowledge and patients.", [["delirium", "DISEASE", 74, 82], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["AP selection", "TREATMENT", 26, 38], ["delirium assessment", "TEST", 74, 93]]], ["When accompanied by prescribing clinicians perspective of delirium AP treatment results are more interpretable.", [["delirium", "DISEASE", 58, 66], ["delirium", "PROBLEM", 58, 66]]], ["We conducted a two-part single centre cohort study that aimed to describe/compare real to perceived delirium assessment/plan, APs prescribing and safety in CC adult patients at GSTT.", [["delirium", "DISEASE", 100, 108], ["CC", "CHEMICAL", 156, 158], ["patients", "ORGANISM", 165, 173], ["patients", "SPECIES", 165, 173], ["cohort study", "TEST", 38, 50], ["perceived delirium assessment", "TEST", 90, 119], ["APs prescribing", "TREATMENT", 126, 141]]], ["Methods: Part 1: a prospective survey, of CC prescribing clinician's beliefs and attitudes to delirium assessment/plan, APs prescribing and safety over previous 12 months.", [["CC", "CHEMICAL", 42, 44], ["delirium", "DISEASE", 94, 102], ["delirium assessment", "TEST", 94, 113]]], ["Part 2: a meticulous audit of APs prescribing and safety and delirium/agitation assessment and plan, over period of 4 months.", [["delirium", "DISEASE", 61, 69], ["agitation", "DISEASE", 70, 79], ["APs prescribing", "TREATMENT", 30, 45], ["delirium", "PROBLEM", 61, 69], ["agitation assessment", "TEST", 70, 90]]], ["88% of reported using APs to treat delirium, with 83% selecting atypical APs as first option.", [["delirium", "DISEASE", 35, 43], ["APs", "TREATMENT", 22, 25], ["delirium", "PROBLEM", 35, 43]]], ["There were 2400 admissions to CC.", [["CC", "CHEMICAL", 30, 32]]], ["APs were prescribed in 6.4% (188 prescription), 3.8% (113 prescription) were in delirium/agitation patients (Table 1) .", [["delirium", "DISEASE", 80, 88], ["agitation", "DISEASE", 89, 98], ["APs", "SIMPLE_CHEMICAL", 0, 3], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["delirium", "PROBLEM", 80, 88], ["agitation", "PROBLEM", 89, 98]]], ["Survey (vs.) audit: In the survey 67% reported daily delirium screening whereas only 12.3% undertook daily screening in audit (Fig. 1) .", [["delirium", "DISEASE", 53, 61], ["delirium screening", "TEST", 53, 71]]], ["Higher quetiapine and lower IV haloperidol maximum daily dose were prescribed in audit in comparison with survey reported doses ( Table 2) .", [["quetiapine", "CHEMICAL", 7, 17], ["haloperidol", "CHEMICAL", 31, 42], ["quetiapine", "CHEMICAL", 7, 17], ["haloperidol", "CHEMICAL", 31, 42], ["quetiapine", "SIMPLE_CHEMICAL", 7, 17], ["haloperidol", "SIMPLE_CHEMICAL", 31, 42], ["Higher quetiapine", "TREATMENT", 0, 17], ["lower IV haloperidol", "TREATMENT", 22, 42]]], ["12 Lead ECG was used to monitor AP ADE.", [["12 Lead ECG", "TEST", 0, 11]]], ["In survey 34% reported assessing ECG once or more daily.", [["ECG", "TEST", 33, 36]]], ["Audit revealed only 19% actually did so (Fig. 2) .", [["Audit", "TEST", 0, 5]]], ["Major differences were in delirium assessment/plan and safety monitoring sedation practices in Turkish ICUs, the aim was to provide knowledge on this matter.", [["delirium", "DISEASE", 26, 34], ["delirium assessment", "TEST", 26, 45], ["safety monitoring sedation practices", "TREATMENT", 55, 91]]], ["First part of the form included questions about demographics, and choices and routines of sedation administration.", [["sedation administration", "TREATMENT", 90, 113]]], ["This part mostly contained multiple choice questions, which more than one choice could be indicated.", [["multiple", "OBSERVATION_MODIFIER", 27, 35]]], ["Sedation was generally applied by the physicians (96%).", [["Sedation", "TREATMENT", 0, 8]]], ["The indications were mechanical ventilation (94%), agitation (87%), seizures (77%), anxiety (61%), delirium (59%).", [["agitation", "DISEASE", 51, 60], ["seizures", "DISEASE", 68, 76], ["anxiety", "DISEASE", 84, 91], ["delirium", "DISEASE", 99, 107], ["mechanical ventilation", "TREATMENT", 21, 43], ["agitation", "PROBLEM", 51, 60], ["seizures", "PROBLEM", 68, 76], ["anxiety", "PROBLEM", 84, 91], ["delirium", "PROBLEM", 99, 107], ["mechanical ventilation", "OBSERVATION", 21, 43]]], ["Sedation level was evaluated daily by 73% of respondents, mostly using Ramsay Scale (57%).", [["Sedation level", "TEST", 0, 14], ["Ramsay Scale", "TEST", 71, 83]]], ["Daily established sedation level was indicated in 63.8%, and daily interruption of sedation was indicated in 71.4% answers.", [["sedation level", "TEST", 18, 32], ["sedation", "TREATMENT", 83, 91]]], ["Sedation protocol was not used in 62.7% of the answers.", [["Sedation protocol", "TREATMENT", 0, 17]]], ["Analgesics applied commonly, while 63% routinely evaluated pain and visual analogue scale (VAS) was the preferred method in 69% of the answers.", [["pain", "DISEASE", 59, 63], ["Analgesics", "TREATMENT", 0, 10], ["pain", "PROBLEM", 59, 63], ["visual analogue scale", "TEST", 68, 89]]], ["77.2% of physicians indicated routine use of neuromuscular blockers.", [["neuromuscular", "ANATOMY", 45, 58], ["neuromuscular blockers", "SIMPLE_CHEMICAL", 45, 67], ["neuromuscular blockers", "TREATMENT", 45, 67]]], ["In 50.5% answers routine evaluation for delirium was indicated, mostly using CAM-ICU.When the knowledge of 2013 SCCM guideline pain, agitation and delirium management, 38% indicated a positive answer.The respondents indicated their opinion for some comments on sedation, the answers are shown in the Table 2 .P499Conclusions: It may be concluded sedation practices may need to be improved by increasing awareness on novel concepts in this area.", [["delirium", "DISEASE", 40, 48], ["pain", "DISEASE", 127, 131], ["agitation", "DISEASE", 133, 142], ["delirium", "DISEASE", 147, 155], ["routine evaluation", "TEST", 17, 35], ["delirium", "PROBLEM", 40, 48], ["SCCM guideline pain", "PROBLEM", 112, 131], ["agitation", "PROBLEM", 133, 142], ["delirium management", "TREATMENT", 147, 166], ["sedation", "TREATMENT", 261, 269], ["sedation practices", "TREATMENT", 346, 364]]], ["The prediction-corrected VPC plots for dexmedetomidine PK.", [["dexmedetomidine", "CHEMICAL", 39, 54], ["dexmedetomidine", "CHEMICAL", 39, 54], ["dexmedetomidine PK", "GENE_OR_GENE_PRODUCT", 39, 57], ["The prediction", "TEST", 0, 14], ["dexmedetomidine PK", "TREATMENT", 39, 57]]], ["The VPC plots show the simulation-based 95% confidence intervals around the 10th, 50th, and 90th percentiles of the PK data in the form of blue (50th) and gray (10th and 90th) areas.", [["The VPC plots", "TEST", 0, 13], ["the simulation", "TEST", 19, 33], ["the PK data", "TEST", 112, 123]]], ["The corresponding percentiles from the prediction corrected observed data are plotted in black color Methods: A prospective multinational cohort study was performed in 10 ICUs in Sweden, Denmark and The Netherlands.", [["A prospective multinational cohort study", "TEST", 110, 150]]], ["All adult patients with an ICU stay >= 12 hours were screened for inclusion.", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18]]], ["Primary outcome was psychological problems three months after discharge from the ICU, assessed with the questionnaires Hospital Anxiety and Depression Scale (HADS) and Post-Traumatic Stress Symptoms Checklist-14 (PTSS-14).", [["Anxiety and Depression", "DISEASE", 128, 150], ["Depression Scale (HADS)", "PROBLEM", 140, 163], ["Post-Traumatic Stress Symptoms", "PROBLEM", 168, 198], ["Checklist", "TEST", 199, 208], ["PTSS", "TEST", 213, 217]]], ["A subscale score >10 in the HADS and a score >45 in the PTSS-14 part B indicate clinically significant symptoms of depression, anxiety and PTS and was considered an adverse outcome.", [["PTSS", "DISEASE", 56, 60], ["depression", "DISEASE", 115, 125], ["anxiety", "DISEASE", 127, 134], ["PTS", "DISEASE", 139, 142], ["A subscale score", "TEST", 0, 16], ["the HADS", "TEST", 24, 32], ["a score", "TEST", 37, 44], ["clinically significant symptoms", "PROBLEM", 80, 111], ["depression", "PROBLEM", 115, 125], ["anxiety", "PROBLEM", 127, 134], ["an adverse outcome", "PROBLEM", 162, 180], ["depression", "OBSERVATION", 115, 125]]], ["We collected data on 21 known risk factors for psychological problems post-ICU.", [["psychological problems", "PROBLEM", 47, 69]]], ["Univariable and multivariable logistic regression modelling of risk factors was performed in order to create an instrument to be used bedside, predicting individual risk for adverse psychological outcome.", [["risk factors", "PROBLEM", 63, 75], ["adverse psychological outcome", "PROBLEM", 174, 203]]], ["Results: 573 patients were included and 404 (71%) returned follow-up questionnaires.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21]]], ["14% of patients scored above the predefined cut-offs having symptoms of depression, anxiety or PTS.P499Age, lack of social support, depressive symptoms and traumatic memories at discharge remained significant after multivariable modelling and constituted the screening instrument ( Table 1) .", [["depression", "DISEASE", 72, 82], ["anxiety", "DISEASE", 84, 91], ["PTS", "DISEASE", 95, 98], ["depressive symptoms", "DISEASE", 132, 151], ["traumatic memories", "DISEASE", 156, 174], ["patients", "ORGANISM", 7, 15], ["P499Age", "GENE_OR_GENE_PRODUCT", 99, 106], ["patients", "SPECIES", 7, 15], ["symptoms", "PROBLEM", 60, 68], ["depression", "PROBLEM", 72, 82], ["anxiety", "PROBLEM", 84, 91], ["depressive symptoms", "PROBLEM", 132, 151], ["traumatic memories", "PROBLEM", 156, 174], ["the screening instrument", "TEST", 255, 279]]], ["The predictive value of the instrument was fairly good with an area under the receiver operating characteristics curve (AUROC) of 75% (Fig. 1) .Conclusions:We developed an instrument to be used at ICU discharge, predicting individual patients' risk for psychological problems three months post-ICU.", [["patients", "ORGANISM", 234, 242], ["patients", "SPECIES", 234, 242], ["AUROC", "TEST", 120, 125], ["an instrument", "TREATMENT", 169, 182], ["psychological problems", "PROBLEM", 253, 275]]], ["The instrument can be used as a screening tool for ICU follow-up and enable early rehabilitation.P508Improving the patients hospitalization experience in an intensive care unit by contact with nature W Yacov 1 , Y Polishuk 2 , A Geal-dor 2 , G Yosef-hay 2 1 Kaplan Medical Center, Rehovot, Israel; 2 Kaplan medical center, Rehovot, Israel Critical Care 2018, 22(Suppl 1):P508 Introduction: The intensive care unit is characterized by a noisy and threatening work environment using multi tecnologic equipment.the staff works very intensively caring for very complicated and unstable patients.whilst caring for the patients physical needs one must not forget the patients mentally needs.the improvement of the patients hospitalization experience by changing the environment improves the mood and responsiveness to treatment gives hope for healing to the patient and family.P508Methods: a quality questionare with open questions relating to the subjective sensory experience of the patients and their families. the patients were transferred to the \"sun balcony\" for a period of 30-60 minutes having their families alongside. music was transmitted and the patients were offered food and drinks if their condition allowed.", [["patients", "ORGANISM", 115, 123], ["patients", "ORGANISM", 582, 590], ["patients", "ORGANISM", 613, 621], ["patients", "ORGANISM", 661, 669], ["patients", "ORGANISM", 708, 716], ["patient", "ORGANISM", 852, 859], ["patients", "ORGANISM", 979, 987], ["patients", "ORGANISM", 1012, 1020], ["patients", "ORGANISM", 1152, 1160], ["patients", "SPECIES", 115, 123], ["patients", "SPECIES", 582, 590], ["patients", "SPECIES", 613, 621], ["patients", "SPECIES", 661, 669], ["patients", "SPECIES", 708, 716], ["patient", "SPECIES", 852, 859], ["patients", "SPECIES", 979, 987], ["patients", "SPECIES", 1012, 1020], ["patients", "SPECIES", 1152, 1160], ["a screening tool", "TEST", 30, 46], ["early rehabilitation", "TREATMENT", 76, 96], ["multi tecnologic equipment", "TREATMENT", 481, 507], ["treatment", "TREATMENT", 812, 821], ["improvement", "OBSERVATION_MODIFIER", 689, 700]]], ["Results: the patients reported a significant improvement of hospilizaton experience following their exposure to the \"nature environment\". patients described the sensory experience as a positive, pleasant, quiet and relaxing experience. the contact with the sun, wind, sky and grass and being outside on the \"sun balcony\" allows a disconnection from the threatening ICU environment.", [["patients", "ORGANISM", 13, 21], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 138, 146], ["significant", "OBSERVATION_MODIFIER", 33, 44], ["improvement", "OBSERVATION_MODIFIER", 45, 56]]], ["Conclusions: The \"sun balcony\" gave the patients a sense of hope and wish for healing. mobilizing complicated patients to the \"sun balcony\" is a big challenge which requires planning and preparation by the staff. yet by the proactive and creative thinking of the staff the patients are tranferred to the \"sun balcony\" to give them encouragement, a feeling of well being and hope for recovering.", [["patients", "ORGANISM", 40, 48], ["patients", "ORGANISM", 110, 118], ["patients", "ORGANISM", 273, 281], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 110, 118], ["patients", "SPECIES", 273, 281], ["healing", "PROBLEM", 78, 85], ["a big challenge", "TREATMENT", 143, 158]]], ["This intervention is costless and a routine procedure in the intensive care unit.", [["This intervention", "TREATMENT", 0, 17], ["a routine procedure", "TREATMENT", 34, 53]]], ["Introduction: Long-term psychological outcomes of patients(pts) discharged from ICU represent an emergent relevant matter of concern.Systematic reviews refer prevalence of 23%-48% for anxiety,17%-43% for depression and 8%-35% for posttraumatic symptoms in ARDS patients.The onset of psychiatric symptoms after discharge, might be associated with patient's competence to process memories related with hospitalization and with memories.", [["anxiety", "DISEASE", 184, 191], ["depression", "DISEASE", 204, 214], ["posttraumatic symptoms", "DISEASE", 230, 252], ["ARDS", "DISEASE", 256, 260], ["psychiatric", "DISEASE", 283, 294], ["patients", "ORGANISM", 50, 58], ["patients", "ORGANISM", 261, 269], ["patient", "ORGANISM", 346, 353], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 261, 269], ["patient", "SPECIES", 346, 353], ["anxiety", "TEST", 184, 191], ["depression", "PROBLEM", 204, 214], ["posttraumatic symptoms", "PROBLEM", 230, 252], ["ARDS", "PROBLEM", 256, 260], ["psychiatric symptoms", "PROBLEM", 283, 303], ["ARDS", "OBSERVATION", 256, 260]]], ["Methods: We selected 35 ARDS pts in ICU of a tertiary centre (Jan 2014-Dec 2016) at least 72 hour, for 6 months follow-up and 26 pts for 12 months follow-up after discharge.", [["ARDS", "DISEASE", 24, 28]]], ["The psychopathological assessment was performed using scale as: Impact Event Scale-Revised (IES-R), Hospital Anxiety and Depression Scale (HADS), ICU Memory Tool (ICU-MT).P508Results: Mean age was 53.11\u00b114.32 at 6 months follow-up and 51,19\u00b114,83 at 12 months.", [["Anxiety and Depression", "DISEASE", 109, 131], ["The psychopathological assessment", "TEST", 0, 33], ["Hospital Anxiety", "PROBLEM", 100, 116], ["Depression Scale (HADS", "PROBLEM", 121, 143], ["Mean age", "TEST", 184, 192]]], ["PTSD symptoms was fund respectively in 24% and 34.6% pts at 6 and 12 months; anxiety symptoms 24% and 23.1% of pts;depression symptoms in 24% and 30.8%.", [["PTSD", "DISEASE", 0, 4], ["anxiety", "DISEASE", 77, 84], ["depression", "DISEASE", 115, 125], ["PTSD symptoms", "PROBLEM", 0, 13], ["anxiety symptoms", "PROBLEM", 77, 93], ["depression symptoms", "PROBLEM", 115, 134]]], ["Significant correlations were fund between psychopathology at 6 months and memories of ICU: HADS anxiety with delusion memories (r 0.45,p<0.01); HADS depression with factual (r 0.46,p<0.05), feeling (r 0.49,p<0.01) and delusion memories (r= 0.59,p<0.01); feeling (r 0.45,p<0.05).", [["psychopathology", "DISEASE", 43, 58], ["anxiety", "DISEASE", 97, 104], ["delusion memories", "DISEASE", 110, 127], ["HADS depression", "DISEASE", 145, 160], ["delusion memories", "DISEASE", 219, 236], ["HADS anxiety", "PROBLEM", 92, 104], ["delusion memories", "PROBLEM", 110, 127], ["HADS depression", "PROBLEM", 145, 160], ["delusion memories", "PROBLEM", 219, 236]]], ["At 12 months significant correlations was fund between HADS anxiety and feeling memories (r 0.48,p<0.05); IES-R and factual (r 0.45,p<0.01), feeling (r 0.68,p<0.01) and delusion memories (r 0.64,p<0.01).Conclusions:The results of the study confirmed the importance of assessing psychopathology after discharge from ICU.", [["anxiety", "DISEASE", 60, 67], ["delusion memories", "DISEASE", 169, 186], ["psychopathology", "DISEASE", 278, 293], ["HADS anxiety", "PROBLEM", 55, 67], ["IES", "TEST", 106, 109], ["delusion memories", "TEST", 169, 186], ["the study", "TEST", 230, 239]]], ["The onset of these symptoms appeared to be mediated by specific traumatic memories related with ICU hospitalization.", [["traumatic memories", "DISEASE", 64, 82], ["these symptoms", "PROBLEM", 13, 27], ["specific traumatic memories", "PROBLEM", 55, 82], ["ICU hospitalization", "TREATMENT", 96, 115]]], ["The main clinical recommendation emerging from this study is to investigate psychiatric history and develop psychological strategies to manage frightening or delusional experiences during ICU stay.", [["psychiatric", "DISEASE", 76, 87], ["delusional", "DISEASE", 158, 168], ["this study", "TEST", 47, 57], ["psychological strategies", "TREATMENT", 108, 132], ["delusional experiences", "PROBLEM", 158, 180], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["The subgroup of very old (>= 80 years (ys)) is the one that increases the most rapidly.", [["most", "OBSERVATION_MODIFIER", 74, 78], ["rapidly", "OBSERVATION_MODIFIER", 79, 86]]], ["Intensive Care Unit (ICU) admission of these patients is an ongoing discussion worldwide.", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53]]], ["The purpose of this first analysis is to evaluate specifically the group of very old patients (VOLDs) admitted to a tertiary Portuguese hospital ICU.", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["this first analysis", "TEST", 15, 34]]], ["Methods: Retrospective observational study was preformed, included all VOLDs admitted in ICU during 15 years (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) .", [["VOLDs", "DISEASE", 71, 76], ["Retrospective observational study", "TEST", 9, 42]]], ["Demographic data, admission diagnosis, severity scores, Charlson comorbidity index, length of stay and outcomes were considered.", [["severity scores", "PROBLEM", 39, 54], ["Charlson comorbidity index", "PROBLEM", 56, 82]]], ["Data analysis used SPSS software.", [["Data analysis", "TEST", 0, 13], ["SPSS software", "TEST", 19, 32]]], ["The median age was 83.0 ys with IQR 4; Mostly male with medical admission diagnosis (sepsis and respiratory failure due to infection).", [["respiratory", "ANATOMY", 96, 107], ["sepsis", "DISEASE", 85, 91], ["respiratory failure", "DISEASE", 96, 115], ["infection", "DISEASE", 123, 132], ["sepsis", "PROBLEM", 85, 91], ["respiratory failure", "PROBLEM", 96, 115], ["infection", "PROBLEM", 123, 132], ["sepsis", "OBSERVATION", 85, 91], ["respiratory failure", "OBSERVATION", 96, 115], ["infection", "OBSERVATION", 123, 132]]], ["There was a median Acute Physiology and Chronic Health Evaluation II of 18 (IQR 8) and Simplified Acute Physiology Score II of 49 (IQR 16).", [["a median Acute Physiology", "PROBLEM", 10, 35], ["Chronic Health Evaluation II", "TEST", 40, 68], ["Simplified Acute Physiology Score II", "TEST", 87, 123], ["median", "OBSERVATION_MODIFIER", 12, 18], ["Acute", "OBSERVATION_MODIFIER", 19, 24], ["Physiology", "OBSERVATION", 25, 35], ["Chronic", "OBSERVATION_MODIFIER", 40, 47], ["Acute", "OBSERVATION_MODIFIER", 98, 103]]], ["Median Charlson comorbidity index was 6.0 (IQR 2).", [["Median Charlson comorbidity index", "TEST", 0, 33]]], ["Median length of stay was 3.9 days (IQR 8.2).", [["IQR", "TEST", 36, 39]]], ["Identified as predictors of intra-hospital mortality the use of mechanical ventilation (p < 0.001), urgent surgical admission or medical admission versus schedule surgical admission (p < 0.001) and the absence of oncologic disease (p = 0.024).", [["mechanical ventilation", "TREATMENT", 64, 86], ["oncologic disease", "PROBLEM", 213, 230], ["mechanical ventilation", "OBSERVATION", 64, 86], ["oncologic disease", "OBSERVATION", 213, 230]]], ["On multivariate analysis, only mechanical ventilation (p = 0.002, HR 0.35, 95% C.I. 0.18-0.68) and urgent surgical admission versus schedule surgical admission (p = 0.002, HR 0.29, 95% C.I. 0.14-0.63) remain significant.Conclusions:Conclusions: Recognizing the need to understand what is the biologic|funcional age (opposed to chronologic age) would be beneficial in the selection of VOLDs to ICU admission.P515Organ failure and return to work after intensive care S Riddersholm 1 , S Christensen 2 , K Kragholm 1 , CF Christiansen 2 , BS Rasmussen 1 1 Aalborg university hospital, Aalborg, Denmark; 2 Aarhus Univeristy hsopital, Aarhus, Denmark Critical Care 2018, 22(Suppl 1):P515P515Introduction: Organ failure is associated with an unfavorable prognosis.", [["Organ", "ANATOMY", 700, 705], ["Organ failure", "DISEASE", 700, 713], ["multivariate analysis", "TEST", 3, 24], ["mechanical ventilation", "TREATMENT", 31, 53], ["p", "TEST", 55, 56], ["HR", "TEST", 66, 68], ["C.I.", "TEST", 79, 83], ["HR", "TEST", 172, 174], ["C.I.", "TEST", 185, 189], ["P515Organ failure", "PROBLEM", 407, 424], ["Organ failure", "PROBLEM", 700, 713], ["an unfavorable prognosis", "PROBLEM", 733, 757], ["mechanical ventilation", "OBSERVATION", 31, 53], ["significant", "OBSERVATION_MODIFIER", 208, 219], ["Organ", "ANATOMY", 700, 705], ["failure", "OBSERVATION", 706, 713], ["unfavorable", "OBSERVATION_MODIFIER", 736, 747]]], ["Therefore, we investigated the association between organ support therapy as a proxy for organ failure and return to work in a nationwide cohort of ICU survivors.", [["organ", "ANATOMY", 51, 56], ["organ", "ANATOMY", 88, 93], ["organ failure", "DISEASE", 88, 101], ["organ", "ORGAN", 51, 56], ["organ", "ORGAN", 88, 93], ["organ support therapy", "TREATMENT", 51, 72], ["organ failure", "PROBLEM", 88, 101], ["failure", "OBSERVATION", 94, 101]]], ["Methods: We linked Danish registry-data on ICU-and hospitalsurvivors working prior to hospital admission during 2005-2014, 18-65 years of age, with an ICU length of stay > 24 hours and not previously treated with dialysis, to data on return to work.", [["dialysis", "TREATMENT", 213, 221]]], ["We reported cumulative incidences (chance) of return to work with death as competing risk, and compared rate of return to work in adjusted Cox regression-models by number of organ support therapies including renal replacement therapy, cardiovascular support and mechanical ventilation and stratified on primary hospital-admission diagnosis.P515Results: Of 24,795 patients 18-65 years of age, 35% (8,660) survived to hospital discharge (Tables 1 and 2 ).", [["organ", "ANATOMY", 174, 179], ["renal", "ANATOMY", 208, 213], ["cardiovascular", "ANATOMY", 235, 249], ["death", "DISEASE", 66, 71], ["organ", "ORGAN", 174, 179], ["renal", "ORGAN", 208, 213], ["patients", "ORGANISM", 363, 371], ["patients", "SPECIES", 363, 371], ["organ support therapies", "TREATMENT", 174, 197], ["renal replacement therapy", "TREATMENT", 208, 233], ["cardiovascular support", "TREATMENT", 235, 257], ["mechanical ventilation", "TREATMENT", 262, 284], ["renal", "ANATOMY", 208, 213], ["replacement", "OBSERVATION", 214, 225], ["mechanical ventilation", "OBSERVATION", 262, 284]]], ["Among these, the chance of return to work was 72.2% (95% CI [71.3-73.2]) within two years (Fig. 1 (Fig. 2) .", [["CI", "TEST", 57, 59]]], ["When stratified an increasing number of organ support was associated with a decreased chance of return to work among patients with infection, respiratory failure or trauma but not among patients with neoplasms or endocrine, gastrointestinal and cardiovascular diagnoses.", [["organ", "ANATOMY", 40, 45], ["respiratory", "ANATOMY", 142, 153], ["neoplasms", "ANATOMY", 200, 209], ["endocrine", "ANATOMY", 213, 222], ["gastrointestinal", "ANATOMY", 224, 240], ["cardiovascular", "ANATOMY", 245, 259], ["infection", "DISEASE", 131, 140], ["respiratory failure", "DISEASE", 142, 161], ["trauma", "DISEASE", 165, 171], ["neoplasms", "DISEASE", 200, 209], ["endocrine, gastrointestinal and cardiovascular diagnoses", "DISEASE", 213, 269], ["organ", "ORGAN", 40, 45], ["patients", "ORGANISM", 117, 125], ["patients", "ORGANISM", 186, 194], ["neoplasms", "CANCER", 200, 209], ["endocrine", "ANATOMICAL_SYSTEM", 213, 222], ["gastrointestinal", "ORGAN", 224, 240], ["patients", "SPECIES", 117, 125], ["patients", "SPECIES", 186, 194], ["organ support", "TREATMENT", 40, 53], ["infection", "PROBLEM", 131, 140], ["respiratory failure", "PROBLEM", 142, 161], ["trauma", "PROBLEM", 165, 171], ["neoplasms", "PROBLEM", 200, 209], ["endocrine, gastrointestinal and cardiovascular diagnoses", "PROBLEM", 213, 269], ["increasing", "OBSERVATION_MODIFIER", 19, 29], ["infection", "OBSERVATION", 131, 140], ["respiratory", "ANATOMY", 142, 153], ["failure", "OBSERVATION", 154, 161], ["neoplasms", "OBSERVATION", 200, 209], ["gastrointestinal", "ANATOMY", 224, 240], ["cardiovascular", "ANATOMY", 245, 259]]], ["Introduction: Mortality rates among people with moderate to severe learning disabilities (LD) are 3 times higher than in the general population [1] [2] [3] .", [["learning disabilities", "DISEASE", 67, 88], ["people", "ORGANISM", 36, 42], ["people", "SPECIES", 36, 42], ["moderate to severe learning disabilities", "PROBLEM", 48, 88]]], ["This study was designed to examine Critical Care admissions with learning disabilities in terms of mortality, demographics and reason for admission.P515Methods: Data was retrieved for adult patients (>16 years old) between Sept 1993 and 2016.", [["learning disabilities", "DISEASE", 65, 86], ["patients", "ORGANISM", 190, 198], ["patients", "SPECIES", 190, 198], ["This study", "TEST", 0, 10]]], ["The Ward Watcher database for ICUs within Surrey and Sussex Healthcare NHS Trust was interrogated using search words including, learning disability, cerebral palsy, Down's syndrome and autism.P515Results: There were 154 episodes (1.4% of all admissions) of patients admitted with LD.", [["cerebral", "ANATOMY", 149, 157], ["learning disability", "DISEASE", 128, 147], ["cerebral palsy", "DISEASE", 149, 163], ["Down's syndrome", "DISEASE", 165, 180], ["autism", "DISEASE", 185, 191], ["cerebral", "ORGAN", 149, 157], ["patients", "ORGANISM", 257, 265], ["patients", "SPECIES", 257, 265], ["cerebral palsy", "PROBLEM", 149, 163], ["Down's syndrome", "PROBLEM", 165, 180], ["autism", "PROBLEM", 185, 191], ["cerebral", "ANATOMY", 149, 157], ["palsy", "OBSERVATION", 158, 163]]], ["10% of the LD patients had more than 1 admission.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["Respiratory is the most common system affected (46%).", [["most common", "OBSERVATION_MODIFIER", 19, 30]]], ["Logistic regression suggests survival is highest in those with a neurological reason for admission (p=0.007).", [["survival", "OBSERVATION", 29, 37], ["highest", "OBSERVATION_MODIFIER", 41, 48]]], ["Proportionally LD patients were young compared to the total population (Fig. 1) .", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26]]], ["We found that mortality appears to increase rapidly in those over 60 years of age and overall mortality is greater in those with LD (Fig. 2) .", [["mortality", "OBSERVATION", 14, 23], ["increase", "OBSERVATION_MODIFIER", 35, 43], ["rapidly", "OBSERVATION_MODIFIER", 44, 51], ["greater", "OBSERVATION_MODIFIER", 107, 114]]], ["Conclusions: From April 2018 all UK Trusts will be required to complete a detailed review for patients with LD who die whilst in hospital care.", [["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102]]], ["This follows MENCAP's report 'Death by Indifference' which exposed deficiencies in the care of 6 people with LDs who died whilst in NHS care and the subsequent Confidential Inquiry into premature deaths of people with learning disabilities.", [["Death", "DISEASE", 30, 35], ["deaths", "DISEASE", 196, 202], ["learning disabilities", "DISEASE", 218, 239], ["people", "ORGANISM", 97, 103], ["people", "ORGANISM", 206, 212], ["people", "SPECIES", 97, 103], ["people", "SPECIES", 206, 212]]], ["In our population, LD patients have an earlier death than the general population and the overall mortality from critical illness is greater.P519A multidisciplinary approach at the emergency department to admit potential organ donors for Introduction: The aim of the present study is to improve the recognition of potential organ donors by implementing a multidisciplinary approach for organ donation at the emergency department (ED) [1] .", [["organ", "ANATOMY", 220, 225], ["organ", "ANATOMY", 323, 328], ["organ", "ANATOMY", 385, 390], ["death", "DISEASE", 47, 52], ["patients", "ORGANISM", 22, 30], ["organ", "ORGAN", 220, 225], ["organ", "ORGAN", 323, 328], ["donors", "ORGANISM", 329, 335], ["organ", "ORGAN", 385, 390], ["patients", "SPECIES", 22, 30], ["an earlier death", "PROBLEM", 36, 52], ["critical illness", "PROBLEM", 112, 128], ["illness", "OBSERVATION", 121, 128], ["greater", "OBSERVATION_MODIFIER", 132, 139]]], ["Methods: In a prospective intervention study, we implemented this approach in six hospitals in the Netherlands.", [["a prospective intervention study", "TEST", 12, 44]]], ["When the decision to withdraw life sustaining treatment was made at the ED in patients with a devastating brain injury without contra indications for organ donation, an Intensive Care Unit (ICU) admission for end-of-life care was considered.", [["brain", "ANATOMY", 106, 111], ["organ", "ANATOMY", 150, 155], ["brain injury", "DISEASE", 106, 118], ["patients", "ORGANISM", 78, 86], ["brain", "ORGAN", 106, 111], ["organ", "ORGAN", 150, 155], ["patients", "SPECIES", 78, 86], ["life sustaining treatment", "TREATMENT", 30, 55], ["a devastating brain injury", "PROBLEM", 92, 118], ["organ donation", "TREATMENT", 150, 164], ["end-of-life care", "TREATMENT", 209, 225], ["brain", "ANATOMY", 106, 111], ["injury", "OBSERVATION", 112, 118]]], ["Every ICU admission for end-of-life care was evaluated.", [["end-of-life care", "TREATMENT", 24, 40]]], ["This interview focused on medical decisions that were made and difficulties arising during hospitalization.P519Results: From 1 January 2016 to November 2017 data were collected on the number of patients admitted to the ED with acute brain injury.", [["brain", "ANATOMY", 233, 238], ["brain injury", "DISEASE", 233, 245], ["patients", "ORGANISM", 194, 202], ["brain", "ORGAN", 233, 238], ["patients", "SPECIES", 194, 202], ["acute brain injury", "PROBLEM", 227, 245], ["acute", "OBSERVATION_MODIFIER", 227, 232], ["brain", "ANATOMY", 233, 238], ["injury", "OBSERVATION", 239, 245]]], ["In total, 50 potential organ donors were admitted to the ICU for end-of-life care.", [["organ", "ANATOMY", 23, 28], ["organ", "ORGAN", 23, 28], ["donors", "ORGANISM", 29, 35], ["end-of-life care", "TREATMENT", 65, 81]]], ["This led to 21 successful organ transplantations.", [["organ", "ANATOMY", 26, 31], ["organ", "ORGAN", 26, 31], ["21 successful organ transplantations", "TREATMENT", 12, 48], ["organ", "ANATOMY", 26, 31], ["transplantations", "OBSERVATION", 32, 48]]], ["In four of these 21 patients family consent was obtained to intubate them solely for the purpose of organ donation.", [["organ", "ANATOMY", 100, 105], ["patients", "ORGANISM", 20, 28], ["organ", "ORGAN", 100, 105], ["patients", "SPECIES", 20, 28], ["organ donation", "TREATMENT", 100, 114]]], ["The most important points raised during the interviews were: explaining the non-therapeutic ICU admission to the family, the location where donation should be requested (ED/ICU) and utility of ICU resources.P519Conclusions: A close collaboration between the ED, neurology department and ICU is necessary and achievable in order not to miss potential organ donors in patients with acute brain injury with a futile prognosis in the ED.", [["organ", "ANATOMY", 350, 355], ["brain", "ANATOMY", 386, 391], ["brain injury", "DISEASE", 386, 398], ["organ", "ORGAN", 350, 355], ["donors", "ORGANISM", 356, 362], ["patients", "ORGANISM", 366, 374], ["brain", "ORGAN", 386, 391], ["patients", "SPECIES", 366, 374], ["ICU resources", "TREATMENT", 193, 206], ["acute brain injury", "PROBLEM", 380, 398], ["brain", "ANATOMY", 386, 391], ["injury", "OBSERVATION", 392, 398]]], ["Introduction: There is a relationships between Intensive care patients losing the ability to speak and negative emotions [1] .", [["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70]]], ["Nursing care is challenging when patients are unable to verbalise and factors like pain and comfort are misjudged..", [["pain", "DISEASE", 83, 87], ["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["pain", "PROBLEM", 83, 87]]], ["Our Intensive Care Unit has introduced a communication tool Intelligaze grid 3 which enables patients with primary motoric disorders to communicate their needs.", [["primary motoric disorders", "DISEASE", 107, 132], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["primary motoric disorders", "PROBLEM", 107, 132]]], ["A quality improvement study reviewed the methods of communication and interactions that our nurses use for patients who are ventilated.", [["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["A quality improvement study", "TEST", 0, 27]]], ["The objective of the study was to promote areas of improvement with communication in the ICU.", [["the study", "TEST", 17, 26]]], ["Methods: We used a mixed-methods qualitative and quantitative study to evaluate the communication tools used by our nursing staff to interact with ventilated patients.", [["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 158, 166], ["quantitative study", "TEST", 49, 67]]], ["The study has been approved as a Quality Assurance project by the Human Research Ethics Committee of Nepean Hospital.P519Results: Sixty registered nurses (66%) participated in the study.", [["Human", "ORGANISM", 66, 71], ["Human", "SPECIES", 66, 71], ["The study", "TEST", 0, 9], ["the study", "TEST", 176, 185]]], ["The most common communication tool used with patients was closed YES/NO questions(27%), followed by hand gestures(21%), magnetic writing board(19.8%), lip reading(14.4%) and alphabet board(7.2%).P519The descriptive analysis identified challenges were levels of sedation, weakness, non-English speaking patients and delirium.", [["hand", "ANATOMY", 100, 104], ["lip", "ANATOMY", 151, 154], ["NO", "CHEMICAL", 69, 71], ["weakness", "DISEASE", 271, 279], ["delirium", "DISEASE", 315, 323], ["NO", "CHEMICAL", 69, 71], ["patients", "ORGANISM", 45, 53], ["hand", "ORGANISM_SUBDIVISION", 100, 104], ["lip", "ORGAN", 151, 154], ["patients", "ORGANISM", 302, 310], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 302, 310], ["magnetic writing board", "TEST", 120, 142], ["lip reading", "TEST", 151, 162], ["The descriptive analysis", "TEST", 199, 223], ["sedation", "TREATMENT", 261, 269], ["weakness", "PROBLEM", 271, 279], ["delirium", "PROBLEM", 315, 323], ["lip", "ANATOMY", 151, 154]]], ["A significant finding was that only 6% of nurses identified the patients message being understood and 5% acknowledged listening as effective communication.P519Conclusions: Communication is a vital aspect of ICU nursing and is achieved through dialogue and specialised skills.", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["significant", "OBSERVATION_MODIFIER", 2, 13]]], ["The study concluded that ICU nurses find it difficult to communicate effectively with ventilated patients.", [["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["The study", "TEST", 0, 9], ["ICU nurses", "TREATMENT", 25, 35]]], ["The introduction of Intelligaze Grid 3 has improved patient communication and promotes holistic nursing care.P519P525 Withdrawn Introduction: Substantial variability in EOLP occurs around the world [1] .", [["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59], ["Intelligaze Grid", "TREATMENT", 20, 36], ["holistic nursing care", "TREATMENT", 87, 108], ["Substantial", "OBSERVATION_MODIFIER", 142, 153], ["variability", "OBSERVATION_MODIFIER", 154, 165]]], ["Differences in EOLP were previously reported in Europe in the Ethicus I study [2] .", [["EOLP", "DNA", 15, 19]]], ["Consecutive admitted ICU patients who died or had treatments limitations during a 6 month period from 1.9.2015 to 30.9.16 were prospectively studied.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33]]], ["Regions included North, Central and Southern Europe (NE, CE, SE), North and Latin America (NA, LA), Asia (As), Australia (Au) and Africa (Af).", [["SE", "DISEASE", 61, 63], ["LA", "CHEMICAL", 95, 97], ["Africa (Af", "PROBLEM", 130, 140], ["North", "OBSERVATION_MODIFIER", 17, 22], ["Central", "OBSERVATION_MODIFIER", 24, 31]]], ["Results: 199 ICUs in 36 countries participated enrolling 12,857 patients.", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72]]], ["Figure 1 shows differences in EOLP by region and Figure 2 in patient competency by region.P519Conclusions: Worldwide differences included more CPR in Af, LA, and SE and less CPR in NE, Au and NA.", [["LA", "CHEMICAL", 154, 156], ["SE", "DISEASE", 162, 164], ["NE", "CHEMICAL", 181, 183], ["Au", "CHEMICAL", 185, 187], ["NA", "CHEMICAL", 192, 194], ["Au", "CHEMICAL", 185, 187], ["patient", "ORGANISM", 61, 68], ["NE", "SIMPLE_CHEMICAL", 181, 183], ["NE", "PROTEIN", 181, 183], ["patient", "SPECIES", 61, 68], ["CPR", "TEST", 143, 146], ["Af", "PROBLEM", 150, 152], ["LA", "TEST", 154, 156]]], ["There was more withdrawing (WD) in NE and Au and less WD in LA and Af.", [["Au", "CHEMICAL", 42, 44], ["WD", "DISEASE", 54, 56], ["LA", "CHEMICAL", 60, 62], ["Au", "CHEMICAL", 42, 44], ["NE", "PROTEIN", 35, 37]]], ["More patients were competent in Au and NE and less were competent in Af, SE and LA.P519Introduction: The decision of end-of-life care in the ICU is very tough issue because the law, ethics, traditions and futility should be concerned involving family's will.", [["Au", "CHEMICAL", 32, 34], ["NE", "CHEMICAL", 39, 41], ["SE", "DISEASE", 73, 75], ["LA", "CHEMICAL", 80, 82], ["Au", "CHEMICAL", 32, 34], ["patients", "ORGANISM", 5, 13], ["Au", "GENE_OR_GENE_PRODUCT", 32, 34], ["patients", "SPECIES", 5, 13], ["LA", "ANATOMY", 80, 82]]], ["Especially, stop or withdraw therapy is a quite difficult operation in Japan because of our traditions.", [["therapy", "TREATMENT", 29, 36]]], ["Recently there are few legal issues due to some guidelines.", [["few legal issues", "PROBLEM", 19, 35], ["few", "OBSERVATION_MODIFIER", 19, 22]]], ["Our hypothesis is some difference over time exists in thoughts about end-of-life care in the ICU.", [["end-of-life care", "TREATMENT", 69, 85], ["some", "OBSERVATION_MODIFIER", 18, 22], ["difference", "OBSERVATION_MODIFIER", 23, 33]]], ["The purpose of this study is to know changing Methods: A questionnaire survey, which consists of 11 questions with 5 optional answers related to the thoughts of participants about end-of-life care of hopeless or brain death patients, was performed to nurses and doctors in our ICU.", [["brain", "ANATOMY", 212, 217], ["brain death", "DISEASE", 212, 223], ["brain", "ORGAN", 212, 217], ["patients", "ORGANISM", 224, 232], ["participants", "SPECIES", 161, 173], ["patients", "SPECIES", 224, 232], ["this study", "TEST", 15, 25]]], ["The questions were; whether accept to withdraw therapy or not and with family's will, whether positive or not to donate of organs from brain death patient, necessary of ICU care for brain death patient, feel guilty and stress for doing stop or withdraw therapy.", [["organs", "ANATOMY", 123, 129], ["brain", "ANATOMY", 135, 140], ["brain", "ANATOMY", 182, 187], ["brain death", "DISEASE", 135, 146], ["brain death", "DISEASE", 182, 193], ["organs", "ORGAN", 123, 129], ["brain", "ORGAN", 135, 140], ["patient", "ORGANISM", 147, 154], ["brain", "ORGAN", 182, 187], ["patient", "ORGANISM", 194, 201], ["patient", "SPECIES", 147, 154], ["patient", "SPECIES", 194, 201], ["therapy", "TREATMENT", 47, 54], ["ICU care", "TREATMENT", 169, 177], ["brain death", "PROBLEM", 182, 193], ["withdraw therapy", "TREATMENT", 244, 260]]], ["It was guaranteed to be anonymous for them in the data analysis.", [["the data analysis", "TEST", 46, 63]]], ["Patient mental compentency by region", [["Patient", "SPECIES", 0, 7]]]], "8ede4c87afcf5faeb93614270669e256135c5748": [["IntroductionIn 2003, Hong Kong experienced an outbreak of SARS.", [["SARS", "DISEASE", 58, 62]]], ["The outbreak incurred huge economical and social losses.", [["huge", "OBSERVATION_MODIFIER", 22, 26], ["economical", "OBSERVATION_MODIFIER", 27, 37], ["social losses", "OBSERVATION", 42, 55]]], ["SARS mainly presents as pneumonia-like symptoms and the lungs are pathologically the most affected organs.", [["lungs", "ANATOMY", 56, 61], ["organs", "ANATOMY", 99, 105], ["SARS", "DISEASE", 0, 4], ["pneumonia", "DISEASE", 24, 33], ["lungs", "ORGAN", 56, 61], ["organs", "ORGAN", 99, 105], ["SARS", "PROBLEM", 0, 4], ["pneumonia", "PROBLEM", 24, 33], ["symptoms", "PROBLEM", 39, 47], ["pneumonia", "OBSERVATION", 24, 33], ["lungs", "ANATOMY", 56, 61], ["pathologically", "OBSERVATION", 66, 80]]], ["Immunohistochemistry and in situ hybridization of organs from SARS patients who died revealed that the virus was found not only in the lungs and intestines, but also in the liver, distal convoluted renal tubules, sweat glands, parathyroid, pituitary glands, pancreas, adrenal gland, and cerebrum.", [["organs", "ANATOMY", 50, 56], ["lungs", "ANATOMY", 135, 140], ["intestines", "ANATOMY", 145, 155], ["liver", "ANATOMY", 173, 178], ["distal convoluted renal tubules", "ANATOMY", 180, 211], ["sweat glands", "ANATOMY", 213, 225], ["parathyroid", "ANATOMY", 227, 238], ["pituitary glands", "ANATOMY", 240, 256], ["pancreas", "ANATOMY", 258, 266], ["adrenal gland", "ANATOMY", 268, 281], ["cerebrum", "ANATOMY", 287, 295], ["SARS", "DISEASE", 62, 66], ["organs", "ORGAN", 50, 56], ["patients", "ORGANISM", 67, 75], ["lungs", "ORGAN", 135, 140], ["intestines", "ORGAN", 145, 155], ["liver", "ORGAN", 173, 178], ["distal convoluted renal tubules", "TISSUE", 180, 211], ["sweat glands", "ORGAN", 213, 225], ["parathyroid", "ORGAN", 227, 238], ["pituitary glands", "ORGAN", 240, 256], ["pancreas", "ORGAN", 258, 266], ["adrenal gland", "ORGAN", 268, 281], ["cerebrum", "ORGAN", 287, 295], ["patients", "SPECIES", 67, 75], ["Immunohistochemistry", "TEST", 0, 20], ["the virus", "PROBLEM", 99, 108], ["distal convoluted renal tubules, sweat glands, parathyroid, pituitary glands, pancreas, adrenal gland, and cerebrum", "PROBLEM", 180, 295], ["organs", "ANATOMY", 50, 56], ["virus", "OBSERVATION", 103, 108], ["lungs", "ANATOMY", 135, 140], ["intestines", "ANATOMY", 145, 155], ["liver", "ANATOMY", 173, 178], ["distal", "ANATOMY_MODIFIER", 180, 186], ["convoluted", "ANATOMY_MODIFIER", 187, 197], ["renal", "ANATOMY", 198, 203], ["tubules", "ANATOMY_MODIFIER", 204, 211], ["sweat glands", "ANATOMY", 213, 225], ["parathyroid", "ANATOMY", 227, 238], ["pituitary glands", "ANATOMY", 240, 256], ["pancreas", "ANATOMY", 258, 266], ["adrenal gland", "ANATOMY", 268, 281], ["cerebrum", "ANATOMY", 287, 295]]], ["The etiological agent for this disease is a novel member of the coronavirus (SARS-CoV) family with limited sequence homology to other coronaviruses [1] [2] [3] [4] [5] [6] [7] [8] .", [["coronavirus", "ORGANISM", 64, 75], ["SARS-CoV", "ORGANISM", 77, 85], ["[1] [2] [3] [4] [5] [6] [7] [8]", "SIMPLE_CHEMICAL", 148, 179], ["coronavirus (SARS-CoV) family", "PROTEIN", 64, 93], ["SARS-CoV", "SPECIES", 77, 85], ["this disease", "PROBLEM", 26, 38], ["the coronavirus", "PROBLEM", 60, 75]]], ["Coronaviruses are enveloped, plus-stranded RNA viruses that lead to respiratory diseases such as the avian coronavirus, Infectious Bronchitis Virus (IBV).", [["respiratory", "ANATOMY", 68, 79], ["respiratory diseases", "DISEASE", 68, 88], ["avian coronavirus", "DISEASE", 101, 118], ["Infectious Bronchitis Virus", "DISEASE", 120, 147], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["avian coronavirus", "ORGANISM", 101, 118], ["Infectious Bronchitis Virus", "ORGANISM", 120, 147], ["IBV", "ORGANISM", 149, 152], ["avian coronavirus", "SPECIES", 101, 118], ["Infectious Bronchitis Virus", "SPECIES", 120, 147], ["avian coronavirus", "SPECIES", 101, 118], ["Infectious Bronchitis Virus", "SPECIES", 120, 147], ["IBV", "SPECIES", 149, 152], ["Coronaviruses", "PROBLEM", 0, 13], ["stranded RNA viruses", "PROBLEM", 34, 54], ["respiratory diseases", "PROBLEM", 68, 88], ["the avian coronavirus", "PROBLEM", 97, 118], ["Infectious Bronchitis Virus", "PROBLEM", 120, 147], ["RNA viruses", "OBSERVATION", 43, 54], ["respiratory diseases", "OBSERVATION", 68, 88], ["Infectious", "OBSERVATION_MODIFIER", 120, 130]]], ["SARS-CoV encodes 23 putative proteins including four typical structural proteins: the spike (S), nucleocapsid (N), membrane (M), and envelope (E) proteins [4, 7] .", [["membrane", "ANATOMY", 115, 123], ["SARS", "DISEASE", 0, 4], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 97, 113], ["membrane", "CELLULAR_COMPONENT", 115, 123], ["envelope (E) proteins", "GENE_OR_GENE_PRODUCT", 133, 154], ["SARS-CoV encodes 23 putative proteins", "PROTEIN", 0, 37], ["structural proteins", "PROTEIN", 61, 80], ["spike (S)", "PROTEIN", 86, 95], ["nucleocapsid (N), membrane (M)", "PROTEIN", 97, 127], ["envelope (E) proteins", "PROTEIN", 133, 154], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV encodes 23 putative proteins", "PROBLEM", 0, 37], ["the spike (S", "TEST", 82, 94], ["nucleocapsid (N), membrane (M)", "TEST", 97, 127], ["envelope (E) proteins", "TEST", 133, 154]]], ["These four proteins contribute to generating the host's immune response, as has been observed in many other transmissible viruses, such as gastroenteritis coronavirus, bronchitis virus, porcine respiratory coronavirus, and mouse hepatitis virus.", [["gastroenteritis coronavirus", "DISEASE", 139, 166], ["bronchitis virus", "DISEASE", 168, 184], ["porcine respiratory coronavirus", "DISEASE", 186, 217], ["mouse hepatitis virus", "DISEASE", 223, 244], ["gastroenteritis coronavirus", "ORGANISM", 139, 166], ["bronchitis virus", "ORGANISM", 168, 184], ["porcine respiratory coronavirus", "ORGANISM", 186, 217], ["mouse hepatitis virus", "ORGANISM", 223, 244], ["gastroenteritis coronavirus", "SPECIES", 139, 166], ["bronchitis virus", "SPECIES", 168, 184], ["porcine respiratory coronavirus", "SPECIES", 186, 217], ["mouse", "SPECIES", 223, 228], ["hepatitis virus", "SPECIES", 229, 244], ["gastroenteritis coronavirus", "SPECIES", 139, 166], ["bronchitis virus", "SPECIES", 168, 184], ["porcine respiratory coronavirus", "SPECIES", 186, 217], ["mouse hepatitis virus", "SPECIES", 223, 244], ["many other transmissible viruses", "PROBLEM", 97, 129], ["gastroenteritis coronavirus", "PROBLEM", 139, 166], ["bronchitis virus", "PROBLEM", 168, 184], ["porcine respiratory coronavirus", "PROBLEM", 186, 217], ["mouse hepatitis virus", "PROBLEM", 223, 244], ["viruses", "OBSERVATION", 122, 129], ["gastroenteritis coronavirus", "OBSERVATION", 139, 166], ["bronchitis", "OBSERVATION", 168, 178], ["respiratory coronavirus", "OBSERVATION", 194, 217], ["hepatitis virus", "OBSERVATION", 229, 244]]], ["In addition to the structural proteins, replicase 1a ORF, replicase 1b ORF and eight novel ORFs have been identified.IntroductionAlthough the sequence of the SARS-CoV has now been characterized, the pathogenesis of the virus, the host's response to the viral infection, and the mechanism of the disease remain largely elusive.", [["SARS", "DISEASE", 158, 162], ["viral infection", "DISEASE", 253, 268], ["replicase 1a", "GENE_OR_GENE_PRODUCT", 40, 52], ["replicase 1b", "GENE_OR_GENE_PRODUCT", 58, 70], ["SARS-CoV", "ORGANISM", 158, 166], ["structural proteins", "PROTEIN", 19, 38], ["replicase 1a ORF", "DNA", 40, 56], ["replicase 1b ORF", "DNA", 58, 74], ["ORFs", "DNA", 91, 95], ["SARS-CoV", "SPECIES", 158, 166], ["replicase 1a ORF", "TREATMENT", 40, 56], ["replicase 1b ORF", "TREATMENT", 58, 74], ["eight novel ORFs", "PROBLEM", 79, 95], ["the SARS-CoV", "PROBLEM", 154, 166], ["the virus", "PROBLEM", 215, 224], ["the viral infection", "PROBLEM", 249, 268], ["the disease", "PROBLEM", 291, 302], ["viral", "OBSERVATION_MODIFIER", 253, 258], ["infection", "OBSERVATION", 259, 268], ["disease", "OBSERVATION", 295, 302]]], ["Viruses are known to utilize their own proteins to influence host cells.", [["cells", "ANATOMY", 66, 71], ["host cells", "CELL", 61, 71], ["host cells", "CELL_TYPE", 61, 71], ["Viruses", "PROBLEM", 0, 7]]], ["Apoptosis is a physiological mechanism to control cell numbers during development and to respond to foreign infections, including bacterial and viral infections [9] .", [["cell", "ANATOMY", 50, 54], ["infections", "DISEASE", 108, 118], ["bacterial and viral infections", "DISEASE", 130, 160], ["cell", "CELL", 50, 54], ["foreign infections", "PROBLEM", 100, 118], ["bacterial and viral infections", "PROBLEM", 130, 160], ["viral infections", "OBSERVATION", 144, 160]]], ["Viruses have evolved strategies either to inhibit or stimulate host cell apoptosis, depending on particular virushost interactions.", [["cell", "ANATOMY", 68, 72], ["host cell", "CELL", 63, 72], ["Viruses", "PROBLEM", 0, 7], ["host cell apoptosis", "PROBLEM", 63, 82], ["host cell apoptosis", "OBSERVATION", 63, 82]]], ["Many viruses encode either pro-apoptotic or antiapoptotic proteins, such as BRLF-A and LMP-1 of the Epstein-Barr virus, Crm of the poxvirus, p35 of the baculovirus, and E1A which can specifically inhibit or delay apoptotic pathways, resulting in increased virus production [10, 11] .", [["BRLF-A", "GENE_OR_GENE_PRODUCT", 76, 82], ["LMP-1", "GENE_OR_GENE_PRODUCT", 87, 92], ["Epstein-Barr virus", "ORGANISM", 100, 118], ["Crm", "GENE_OR_GENE_PRODUCT", 120, 123], ["poxvirus", "ORGANISM", 131, 139], ["p35", "GENE_OR_GENE_PRODUCT", 141, 144], ["baculovirus", "ORGANISM", 152, 163], ["E1A", "GENE_OR_GENE_PRODUCT", 169, 172], ["pro-apoptotic or antiapoptotic proteins", "PROTEIN", 27, 66], ["BRLF", "PROTEIN", 76, 80], ["LMP", "PROTEIN", 87, 90], ["p35", "PROTEIN", 141, 144], ["baculovirus", "PROTEIN", 152, 163], ["E1A", "PROTEIN", 169, 172], ["Epstein-Barr virus", "SPECIES", 100, 118], ["baculovirus", "SPECIES", 152, 163], ["Many viruses", "PROBLEM", 0, 12], ["antiapoptotic proteins", "PROBLEM", 44, 66], ["BRLF", "TEST", 76, 80], ["LMP", "TEST", 87, 90], ["the Epstein", "TEST", 96, 107], ["Barr virus", "PROBLEM", 108, 118], ["the poxvirus", "PROBLEM", 127, 139], ["the baculovirus", "TREATMENT", 148, 163], ["E1A", "TREATMENT", 169, 172], ["delay apoptotic pathways", "PROBLEM", 207, 231], ["increased virus production", "PROBLEM", 246, 272], ["viruses", "OBSERVATION", 5, 12], ["pro-apoptotic", "OBSERVATION_MODIFIER", 27, 40], ["antiapoptotic proteins", "OBSERVATION", 44, 66], ["Barr virus", "OBSERVATION", 108, 118], ["increased", "OBSERVATION_MODIFIER", 246, 255], ["virus", "OBSERVATION", 256, 261]]], ["Apoptosis in later stages of infection may also be advantageous in facilitating virus dissemination and limiting the host's inflammatory response.", [["Apoptosis", "DISEASE", 0, 9], ["infection", "DISEASE", 29, 38], ["Apoptosis", "PROBLEM", 0, 9], ["infection", "PROBLEM", 29, 38], ["facilitating virus dissemination", "PROBLEM", 67, 99], ["the host's inflammatory response", "PROBLEM", 113, 145], ["infection", "OBSERVATION", 29, 38], ["may also be", "UNCERTAINTY", 39, 50], ["virus", "OBSERVATION", 80, 85]]], ["Apoptosis usually shows typical morphological changes such as cell blebbing nuclei condensation and DNA fragmentation and involves the activation of caspases, which cleave a variety of cellular substrates.", [["cell", "ANATOMY", 62, 66], ["nuclei", "ANATOMY", 76, 82], ["cellular", "ANATOMY", 185, 193], ["cell", "CELL", 62, 66], ["nuclei", "CELLULAR_COMPONENT", 76, 82], ["DNA", "CELLULAR_COMPONENT", 100, 103], ["caspases", "GENE_OR_GENE_PRODUCT", 149, 157], ["cellular", "CELL", 185, 193], ["caspases", "PROTEIN", 149, 157], ["Apoptosis", "TEST", 0, 9], ["typical morphological changes", "PROBLEM", 24, 53], ["cell blebbing nuclei condensation", "PROBLEM", 62, 95], ["DNA fragmentation", "PROBLEM", 100, 117], ["caspases", "PROBLEM", 149, 157], ["cell", "OBSERVATION", 62, 66], ["blebbing nuclei condensation", "OBSERVATION", 67, 95], ["DNA fragmentation", "OBSERVATION", 100, 117], ["variety", "OBSERVATION_MODIFIER", 174, 181], ["cellular substrates", "OBSERVATION", 185, 204]]], ["Caspases are synthesized as precursors and activated upon induction by apoptotic signals.", [["Caspases", "GENE_OR_GENE_PRODUCT", 0, 8], ["Caspases", "PROTEIN", 0, 8], ["Caspases", "TREATMENT", 0, 8], ["apoptotic signals", "TEST", 71, 88]]], ["Mitochondria play a crucial role in the activation of caspases, leading to the activation of caspase-9 [12] .", [["Mitochondria", "ANATOMY", 0, 12], ["Mitochondria", "CELLULAR_COMPONENT", 0, 12], ["caspases", "GENE_OR_GENE_PRODUCT", 54, 62], ["caspase-9", "GENE_OR_GENE_PRODUCT", 93, 102], ["caspases", "PROTEIN", 54, 62], ["caspase", "PROTEIN", 93, 100], ["caspases", "PROBLEM", 54, 62], ["caspase", "TEST", 93, 100]]], ["The Bcl-2 family proteins play an important role in regulating cytochrome c releases, while proapoptotic members such as Bax, Bak, Bid and Bik promote cytochrome c release [13] .IntroductionApart from mitochondria, endoplasmic reticulum (ER) also plays an important role in apoptosis.", [["mitochondria", "ANATOMY", 201, 213], ["endoplasmic reticulum", "ANATOMY", 215, 236], ["ER", "ANATOMY", 238, 240], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 4, 9], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 63, 75], ["Bax", "GENE_OR_GENE_PRODUCT", 121, 124], ["Bak", "GENE_OR_GENE_PRODUCT", 126, 129], ["Bid", "GENE_OR_GENE_PRODUCT", 131, 134], ["Bik", "GENE_OR_GENE_PRODUCT", 139, 142], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 151, 163], ["mitochondria", "CELLULAR_COMPONENT", 201, 213], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 215, 236], ["ER", "GENE_OR_GENE_PRODUCT", 238, 240], ["Bcl-2 family proteins", "PROTEIN", 4, 25], ["cytochrome c", "PROTEIN", 63, 75], ["proapoptotic members", "PROTEIN", 92, 112], ["Bax", "PROTEIN", 121, 124], ["Bak", "PROTEIN", 126, 129], ["Bid", "PROTEIN", 131, 134], ["Bik", "PROTEIN", 139, 142], ["cytochrome c", "PROTEIN", 151, 163], ["ER", "PROTEIN", 238, 240], ["Bak", "TREATMENT", 126, 129], ["Bik promote cytochrome c release", "TREATMENT", 139, 171], ["endoplasmic reticulum", "OBSERVATION", 215, 236], ["apoptosis", "OBSERVATION", 274, 283]]], ["Functions of the ER are affected by various intra-cellular and extra-cellular stimuli, so called ER stress, which includes inhibition of glycosylation, reduction of disulfide bonds, calcium depletion from the ER lumen, impairment of protein transport to the Golgi, and expression of mutated proteins in the ER.", [["ER", "ANATOMY", 17, 19], ["intra-cellular", "ANATOMY", 44, 58], ["ER lumen", "ANATOMY", 209, 217], ["Golgi", "ANATOMY", 258, 263], ["ER", "ANATOMY", 307, 309], ["calcium", "CHEMICAL", 182, 189], ["disulfide", "CHEMICAL", 165, 174], ["calcium", "CHEMICAL", 182, 189], ["ER", "GENE_OR_GENE_PRODUCT", 17, 19], ["intra-cellular", "IMMATERIAL_ANATOMICAL_ENTITY", 44, 58], ["ER", "GENE_OR_GENE_PRODUCT", 97, 99], ["calcium", "SIMPLE_CHEMICAL", 182, 189], ["ER", "GENE_OR_GENE_PRODUCT", 209, 211], ["Golgi", "CELLULAR_COMPONENT", 258, 263], ["ER", "GENE_OR_GENE_PRODUCT", 307, 309], ["ER", "PROTEIN", 17, 19], ["ER", "PROTEIN", 97, 99], ["ER", "PROTEIN", 209, 211], ["mutated proteins", "PROTEIN", 283, 299], ["ER", "PROTEIN", 307, 309], ["extra-cellular stimuli", "TEST", 63, 85], ["inhibition of glycosylation", "TREATMENT", 123, 150], ["reduction of disulfide bonds", "TREATMENT", 152, 180], ["calcium depletion", "PROBLEM", 182, 199], ["the ER lumen", "TREATMENT", 205, 217], ["impairment of protein transport", "PROBLEM", 219, 250], ["mutated proteins", "PROBLEM", 283, 299], ["extra-cellular stimuli", "OBSERVATION", 63, 85], ["disulfide bonds", "OBSERVATION", 165, 180], ["calcium depletion", "OBSERVATION", 182, 199], ["lumen", "ANATOMY_MODIFIER", 212, 217]]], ["Under ER stress, unfolded proteins accumulate in the lumen of the ER, which eventually induces conflicting cellular activities; survival and apoptosis.", [["lumen", "ANATOMY", 53, 58], ["ER", "ANATOMY", 66, 68], ["cellular", "ANATOMY", 107, 115], ["ER", "GENE_OR_GENE_PRODUCT", 6, 8], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 53, 58], ["ER", "GENE_OR_GENE_PRODUCT", 66, 68], ["cellular", "CELL", 107, 115], ["ER", "PROTEIN", 6, 8], ["unfolded proteins", "PROTEIN", 17, 34], ["ER", "PROTEIN", 66, 68], ["unfolded proteins", "PROBLEM", 17, 34], ["apoptosis", "PROBLEM", 141, 150], ["stress", "OBSERVATION", 9, 15], ["unfolded", "OBSERVATION_MODIFIER", 17, 25], ["proteins accumulate", "OBSERVATION", 26, 45], ["lumen", "ANATOMY_MODIFIER", 53, 58], ["cellular activities", "OBSERVATION", 107, 126]]], ["When misfolded proteins accumulate in the ER, cells activate a self-protective mechanism, termed the ER-stress response, to survive ER-stress conditions.", [["ER", "ANATOMY", 42, 44], ["cells", "ANATOMY", 46, 51], ["ER", "GENE_OR_GENE_PRODUCT", 42, 44], ["cells", "CELL", 46, 51], ["ER", "GENE_OR_GENE_PRODUCT", 101, 103], ["ER", "GENE_OR_GENE_PRODUCT", 132, 134], ["misfolded proteins", "PROTEIN", 5, 23], ["ER", "PROTEIN", 42, 44], ["ER", "PROTEIN", 101, 103], ["ER", "PROTEIN", 132, 134], ["misfolded proteins accumulate", "PROBLEM", 5, 34]]], ["The ER-stress responses of eukaryotic cells consist of three different mechanisms: translational attenuation to reduce accumulation of misfolded proteins [14] , transcriptional activation of gene encoding ER-resident chaperones [15] and ERassociated degradation (ERAD) [16] .", [["cells", "ANATOMY", 38, 43], ["ER", "GENE_OR_GENE_PRODUCT", 4, 6], ["eukaryotic cells", "CELL", 27, 43], ["ER-resident chaperones [15]", "GENE_OR_GENE_PRODUCT", 205, 232], ["ER", "PROTEIN", 4, 6], ["eukaryotic cells", "CELL_TYPE", 27, 43], ["misfolded proteins", "PROTEIN", 135, 153], ["ER", "PROTEIN", 205, 207], ["resident chaperones", "PROTEIN", 208, 227], ["ERAD", "PROTEIN", 263, 267], ["eukaryotic cells", "PROBLEM", 27, 43], ["translational attenuation", "PROBLEM", 83, 108], ["misfolded proteins", "PROBLEM", 135, 153], ["ERassociated degradation", "PROBLEM", 237, 261], ["eukaryotic cells", "OBSERVATION", 27, 43], ["translational attenuation", "OBSERVATION_MODIFIER", 83, 108]]], ["The ER-stress response is initiated by three types of ER membrane receptors, ATF6, IRE1 and PERK.", [["ER membrane", "ANATOMY", 54, 65], ["ER", "GENE_OR_GENE_PRODUCT", 4, 6], ["ER membrane receptors", "GENE_OR_GENE_PRODUCT", 54, 75], ["ATF6", "GENE_OR_GENE_PRODUCT", 77, 81], ["IRE1", "GENE_OR_GENE_PRODUCT", 83, 87], ["PERK", "GENE_OR_GENE_PRODUCT", 92, 96], ["ER", "PROTEIN", 4, 6], ["ER membrane receptors", "PROTEIN", 54, 75], ["ATF6", "PROTEIN", 77, 81], ["IRE1", "PROTEIN", 83, 87], ["PERK", "PROTEIN", 92, 96], ["ER membrane receptors", "TREATMENT", 54, 75], ["stress response", "OBSERVATION", 7, 22]]], ["If the adaptive responses are not sufficient to relieve cells from ER stress, cells undergo apoptosis to destroy the ER-stress-damaged cells.IntroductionEight SARS-CoV-encoded proteins have been shown to induce apoptosis [17] .", [["cells", "ANATOMY", 56, 61], ["cells", "ANATOMY", 78, 83], ["cells", "ANATOMY", 135, 140], ["cells", "CELL", 56, 61], ["ER", "GENE_OR_GENE_PRODUCT", 67, 69], ["cells", "CELL", 78, 83], ["ER", "GENE_OR_GENE_PRODUCT", 117, 119], ["cells", "CELL", 135, 140], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 159, 167], ["ER", "PROTEIN", 67, 69], ["ER", "PROTEIN", 117, 119], ["damaged cells", "CELL_TYPE", 127, 140], ["SARS-CoV-encoded proteins", "PROTEIN", 159, 184], ["SARS-CoV", "SPECIES", 159, 167], ["cells", "PROBLEM", 56, 61], ["ER stress", "PROBLEM", 67, 76], ["apoptosis", "PROBLEM", 92, 101], ["stress-damaged cells", "PROBLEM", 120, 140], ["damaged cells", "OBSERVATION", 127, 140]]], ["These data suggest that apoptosis may indeed play an important role in helping with virus dissemination in vivo, minimizing inflammatory reaction and evasion of the host's defense mechanisms.", [["apoptosis", "PROBLEM", 24, 33], ["virus dissemination", "TREATMENT", 84, 103], ["inflammatory reaction", "PROBLEM", 124, 145]]], ["Importantly, pathological studies have revealed diffuse alveolar damage as the most notable feature in patients who died of SARS.", [["alveolar", "ANATOMY", 56, 64], ["alveolar damage", "DISEASE", 56, 71], ["SARS", "DISEASE", 124, 128], ["alveolar", "TISSUE", 56, 64], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["pathological studies", "TEST", 13, 33], ["diffuse alveolar damage", "PROBLEM", 48, 71], ["SARS", "PROBLEM", 124, 128], ["diffuse", "OBSERVATION_MODIFIER", 48, 55], ["alveolar damage", "OBSERVATION", 56, 71], ["most notable", "OBSERVATION_MODIFIER", 79, 91]]], ["It is reasonable to believe that apoptosis occurs in the alveolar epithelia cells in SARS patients.", [["alveolar epithelia cells", "ANATOMY", 57, 81], ["SARS", "DISEASE", 85, 89], ["alveolar epithelia cells", "CELL", 57, 81], ["patients", "ORGANISM", 90, 98], ["alveolar epithelia cells", "CELL_TYPE", 57, 81], ["patients", "SPECIES", 90, 98], ["apoptosis", "PROBLEM", 33, 42], ["apoptosis", "OBSERVATION", 33, 42], ["alveolar epithelia cells", "OBSERVATION", 57, 81]]], ["Three accessory proteins of SARS-CoV have been shown to induce apoptosis, ORF-3a (also known as U274, SARS X1, or ORF-3), ORF-3b (also known as ORF-4) and ORF-7a (also known as U122, SARS X4, or ORF-8) [18, 19] .", [["SARS-CoV", "ORGANISM", 28, 36], ["ORF-3a", "GENE_OR_GENE_PRODUCT", 74, 80], ["U274", "GENE_OR_GENE_PRODUCT", 96, 100], ["SARS X1", "GENE_OR_GENE_PRODUCT", 102, 109], ["ORF-3", "GENE_OR_GENE_PRODUCT", 114, 119], ["ORF-3b", "GENE_OR_GENE_PRODUCT", 122, 128], ["ORF-4", "GENE_OR_GENE_PRODUCT", 144, 149], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 155, 161], ["SARS X4", "GENE_OR_GENE_PRODUCT", 183, 190], ["ORF-8", "GENE_OR_GENE_PRODUCT", 195, 200], ["accessory proteins", "PROTEIN", 6, 24], ["CoV", "PROTEIN", 33, 36], ["ORF-3a", "DNA", 74, 80], ["U274", "DNA", 96, 100], ["SARS X1", "DNA", 102, 109], ["ORF-3", "DNA", 114, 119], ["ORF-3b", "DNA", 122, 128], ["ORF-4", "DNA", 144, 149], ["ORF-7a", "DNA", 155, 161], ["U122", "DNA", 177, 181], ["SARS X4", "DNA", 183, 190], ["ORF-8", "DNA", 195, 200], ["SARS-CoV", "SPECIES", 28, 36], ["SARS", "PROBLEM", 28, 32], ["CoV", "PROBLEM", 33, 36], ["apoptosis", "PROBLEM", 63, 72], ["SARS", "PROBLEM", 102, 106], ["SARS", "PROBLEM", 183, 187], ["SARS", "OBSERVATION", 28, 32], ["3b", "ANATOMY", 126, 128]]], ["ORF-3a protein is ER and Golgi apparatus localized protein.", [["Golgi apparatus", "ANATOMY", 25, 40], ["ORF-3a", "GENE_OR_GENE_PRODUCT", 0, 6], ["ER", "GENE_OR_GENE_PRODUCT", 18, 20], ["Golgi", "CELLULAR_COMPONENT", 25, 30], ["ORF-3a protein", "PROTEIN", 0, 14], ["ER", "PROTEIN", 18, 20], ["Golgi apparatus localized protein", "PROTEIN", 25, 58], ["ORF", "TEST", 0, 3], ["localized protein", "OBSERVATION", 41, 58]]], ["It has been shown to upregulate expression of all three subunits (A\u03b1, B\u03b2 and \u03b3) of fibrinogen in lung epithelial cells and induce chromatin condensation and DNA fragmentation [20, 21] .", [["lung epithelial cells", "ANATOMY", 97, 118], ["chromatin", "ANATOMY", 130, 139], ["A\u03b1", "GENE_OR_GENE_PRODUCT", 66, 68], ["B\u03b2", "GENE_OR_GENE_PRODUCT", 70, 72], ["\u03b3", "GENE_OR_GENE_PRODUCT", 77, 78], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 83, 93], ["lung epithelial cells", "CELL", 97, 118], ["chromatin", "CELLULAR_COMPONENT", 130, 139], ["DNA", "CELLULAR_COMPONENT", 157, 160], ["A\u03b1", "PROTEIN", 66, 68], ["B\u03b2", "PROTEIN", 70, 72], ["\u03b3", "PROTEIN", 77, 78], ["fibrinogen", "PROTEIN", 83, 93], ["lung epithelial cells", "CELL_TYPE", 97, 118], ["chromatin", "DNA", 130, 139], ["A\u03b1", "TEST", 66, 68], ["B\u03b2", "TEST", 70, 72], ["fibrinogen in lung epithelial cells", "PROBLEM", 83, 118], ["chromatin condensation", "PROBLEM", 130, 152], ["DNA fragmentation", "PROBLEM", 157, 174], ["fibrinogen", "OBSERVATION", 83, 93], ["lung", "ANATOMY", 97, 101], ["epithelial cells", "OBSERVATION", 102, 118], ["chromatin condensation", "OBSERVATION", 130, 152], ["DNA fragmentation", "OBSERVATION", 157, 174]]], ["ORF-3b is predominantly localized in the nucleolus and partially in the mitochondria.", [["nucleolus", "ANATOMY", 41, 50], ["mitochondria", "ANATOMY", 72, 84], ["ORF-3b", "GENE_OR_GENE_PRODUCT", 0, 6], ["nucleolus", "CELLULAR_COMPONENT", 41, 50], ["mitochondria", "CELLULAR_COMPONENT", 72, 84], ["ORF-3b", "DNA", 0, 6], ["3b", "ANATOMY_MODIFIER", 4, 6], ["predominantly", "OBSERVATION_MODIFIER", 10, 23], ["localized", "OBSERVATION", 24, 33], ["nucleolus", "OBSERVATION", 41, 50], ["mitochondria", "ANATOMY", 72, 84]]], ["ORF-3b also induces G0/G1 arrest and apoptosis in transfected cells [22, 23] .", [["cells", "ANATOMY", 62, 67], ["ORF-3b", "GENE_OR_GENE_PRODUCT", 0, 6], ["cells", "CELL", 62, 67], ["ORF-3b", "DNA", 0, 6], ["transfected cells", "CELL_LINE", 50, 67], ["ORF", "TEST", 0, 3], ["G0/G1 arrest", "PROBLEM", 20, 32], ["apoptosis in transfected cells", "PROBLEM", 37, 67], ["G1 arrest", "OBSERVATION", 23, 32]]], ["ORF-7a is an ER-localized protein.", [["ORF-7a", "GENE_OR_GENE_PRODUCT", 0, 6], ["ER", "GENE_OR_GENE_PRODUCT", 13, 15], ["ORF-7a", "DNA", 0, 6], ["ER-localized protein", "PROTEIN", 13, 33]]], ["It has been shown to have a signal peptide at the N-terminus and a typical ER retrieval motif at the C-terminus [24] .", [["ER", "ANATOMY", 75, 77], ["N", "CHEMICAL", 50, 51], ["ER", "GENE_OR_GENE_PRODUCT", 75, 77], ["N-terminus", "PROTEIN", 50, 60], ["ER retrieval motif", "PROTEIN", 75, 93], ["a signal peptide", "PROBLEM", 26, 42], ["a typical ER retrieval motif", "TREATMENT", 65, 93]]], ["Moreover, overexpression of ORF-7a induces apoptosis via the caspase-dependent pathway [19] .", [["ORF-7a", "GENE_OR_GENE_PRODUCT", 28, 34], ["caspase", "GENE_OR_GENE_PRODUCT", 61, 68], ["ORF", "DNA", 28, 31], ["caspase", "PROTEIN", 61, 68], ["apoptosis", "PROBLEM", 43, 52]]], ["However, the signaling pathway for ORF-3a, ORF-3b and ORF-7a induced apoptosis remains elusive.IntroductionThis study reports the characterization of another SARS-CoV group-specific gene product encoded by ORF-6 (also known as X3, ORF-7).", [["ORF-3a", "GENE_OR_GENE_PRODUCT", 35, 41], ["ORF-3b", "GENE_OR_GENE_PRODUCT", 43, 49], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 54, 60], ["ORF-6", "GENE_OR_GENE_PRODUCT", 206, 211], ["ORF-7", "GENE_OR_GENE_PRODUCT", 231, 236], ["ORF", "DNA", 35, 38], ["ORF", "DNA", 43, 46], ["ORF", "DNA", 54, 57], ["SARS-CoV group-specific gene product", "PROTEIN", 158, 194], ["ORF-6", "DNA", 206, 211], ["X3", "DNA", 227, 229], ["ORF-7", "DNA", 231, 236], ["SARS-CoV", "SPECIES", 158, 166], ["ORF", "TEST", 35, 38], ["ORF", "TEST", 43, 46], ["ORF", "TEST", 54, 57], ["apoptosis", "PROBLEM", 69, 78], ["This study", "TEST", 107, 117], ["the characterization", "TEST", 126, 146], ["another SARS", "PROBLEM", 150, 162]]], ["ORF-6 (nucleotide 27,074-27,265 in Tor2 genome sequence [4] ) contains 63 amino acids and has no significant sequence homology to other proteins.", [["nucleotide 27,074-27,265", "CHEMICAL", 7, 31], ["amino acids", "CHEMICAL", 74, 85], ["nucleotide", "CHEMICAL", 7, 17], ["amino acids", "CHEMICAL", 74, 85], ["ORF-6", "GENE_OR_GENE_PRODUCT", 0, 5], ["amino acids", "AMINO_ACID", 74, 85], ["ORF-6", "DNA", 0, 5], ["nucleotide 27,074-27,265", "DNA", 7, 31], ["Tor2 genome sequence", "DNA", 35, 55], ["ORF", "TEST", 0, 3], ["nucleotide", "TEST", 7, 17], ["amino acids", "TEST", 74, 85], ["significant sequence homology", "PROBLEM", 97, 126]]], ["It has been shown to accelerate replication of a related mouse virus and interact with nonstructural protein (nsp8), which may be involved in virus replication [25, 26] .", [["mouse", "ORGANISM", 57, 62], ["nonstructural protein", "GENE_OR_GENE_PRODUCT", 87, 108], ["nsp8", "GENE_OR_GENE_PRODUCT", 110, 114], ["nonstructural protein", "PROTEIN", 87, 108], ["nsp8", "PROTEIN", 110, 114], ["mouse", "SPECIES", 57, 62], ["mouse virus", "SPECIES", 57, 68], ["a related mouse virus", "PROBLEM", 47, 68], ["replication", "OBSERVATION", 32, 43], ["mouse virus", "OBSERVATION", 57, 68]]], ["Recently, ORF-6 has been identified as an ER/Golgi membrane localized protein [27] .", [["ER/Golgi membrane", "ANATOMY", 42, 59], ["ORF-6", "GENE_OR_GENE_PRODUCT", 10, 15], ["ER", "GENE_OR_GENE_PRODUCT", 42, 44], ["Golgi membrane", "CELLULAR_COMPONENT", 45, 59], ["ORF-6", "DNA", 10, 15], ["ER", "PROTEIN", 42, 44], ["Golgi membrane localized protein", "PROTEIN", 45, 77], ["ORF", "TEST", 10, 13]]], ["Here, we show that first; overexpression of ORF-6 induces apoptosis.", [["ORF-6", "GENE_OR_GENE_PRODUCT", 44, 49], ["ORF-6", "DNA", 44, 49], ["ORF", "TEST", 44, 47], ["apoptosis", "PROBLEM", 58, 67]]], ["Second, caspase-3 was activated in the present of ORF-6.", [["caspase-3", "GENE_OR_GENE_PRODUCT", 8, 17], ["caspase-3", "PROTEIN", 8, 17], ["ORF-6", "DNA", 50, 55], ["caspase", "TREATMENT", 8, 15]]], ["Third, apoptosis induced by ORF-6 and ORF-7a was blocked by caspase-3 inhibitor, z-DEVD, and JNK(c-Jun N-terminal kinase) inhibitor.", [["N", "CHEMICAL", 103, 104], ["ORF-6", "GENE_OR_GENE_PRODUCT", 28, 33], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 38, 44], ["caspase-3", "GENE_OR_GENE_PRODUCT", 60, 69], ["z-DEVD", "SIMPLE_CHEMICAL", 81, 87], ["JNK", "GENE_OR_GENE_PRODUCT", 93, 96], ["c-Jun N-terminal kinase", "GENE_OR_GENE_PRODUCT", 97, 120], ["ORF-6", "DNA", 28, 33], ["ORF", "DNA", 38, 41], ["JNK(c-Jun N-terminal kinase", "PROTEIN", 93, 120], ["ORF", "TEST", 28, 31], ["ORF", "TEST", 38, 41], ["caspase", "TEST", 60, 67], ["z-DEVD", "TEST", 81, 87], ["JNK", "TEST", 93, 96], ["c-Jun N-terminal kinase) inhibitor", "TREATMENT", 97, 131]]], ["Finally, ORF-6 and ORF-7a up-regulates ER chaperone protein, 94 kDa glucose-regulated protein (GRP94), protein levels.", [["glucose", "CHEMICAL", 68, 75], ["glucose", "CHEMICAL", 68, 75], ["ORF-6", "GENE_OR_GENE_PRODUCT", 9, 14], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 19, 25], ["ER", "GENE_OR_GENE_PRODUCT", 39, 41], ["glucose-regulated protein", "GENE_OR_GENE_PRODUCT", 68, 93], ["GRP94", "GENE_OR_GENE_PRODUCT", 95, 100], ["ORF-6", "DNA", 9, 14], ["ORF-7a", "DNA", 19, 25], ["ER chaperone protein", "PROTEIN", 39, 59], ["94 kDa glucose-regulated protein", "PROTEIN", 61, 93], ["GRP94", "PROTEIN", 95, 100], ["ORF", "TEST", 9, 12], ["ORF", "TEST", 19, 22], ["ER chaperone protein", "TEST", 39, 59], ["kDa glucose", "TEST", 64, 75], ["protein", "TEST", 86, 93], ["GRP94", "TEST", 95, 100], ["protein levels", "TEST", 103, 117]]], ["All these data suggest that in addition to ORF-3a, ORF-3b and ORF-7a, ORF-6 is a new player involved in SARS-CoV-induced apoptosis and both ORF-6 and ORF-7a share a similar pathway to induce apoptosis.Cell cultureHuman embryonic kidney cells HEK293T, Cercopithecus aethiops kidney cells COS-7 and C. aethiops kidney cells Vero E6 were grown in Dulbecco's modified minimal essential medium (DMEM), supplemented with 10% heat-inactivated fetal bovine serum and 2 mM glutamine, 100 U/ml of penicillin and 100 \u03bcg/ml of streptomycin in a humidified incubator with 5% (v/v) carbon dioxide at 37\u00b0C.Construction of plasmidsORF-6 and ORF-7a cDNA was kindly provided by Dr. Zhanguo Wu (Department of Biochemistry, HKUST).", [["Cell", "ANATOMY", 201, 205], ["embryonic kidney cells HEK293T", "ANATOMY", 219, 249], ["kidney cells COS-7", "ANATOMY", 274, 292], ["kidney cells", "ANATOMY", 309, 321], ["serum", "ANATOMY", 449, 454], ["glutamine", "CHEMICAL", 464, 473], ["penicillin", "CHEMICAL", 487, 497], ["streptomycin", "CHEMICAL", 515, 527], ["carbon dioxide", "CHEMICAL", 568, 582], ["glutamine", "CHEMICAL", 464, 473], ["penicillin", "CHEMICAL", 487, 497], ["streptomycin", "CHEMICAL", 515, 527], ["carbon dioxide", "CHEMICAL", 568, 582], ["ORF-3a", "GENE_OR_GENE_PRODUCT", 43, 49], ["ORF-3b", "GENE_OR_GENE_PRODUCT", 51, 57], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 62, 68], ["ORF-6", "GENE_OR_GENE_PRODUCT", 70, 75], ["SARS-CoV", "ORGANISM", 104, 112], ["ORF-6", "GENE_OR_GENE_PRODUCT", 140, 145], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 150, 156], ["Cell", "CELL", 201, 205], ["embryonic kidney cells HEK293T", "CELL", 219, 249], ["Cercopithecus", "ORGANISM", 251, 264], ["aethiops", "ORGANISM", 265, 273], ["kidney cells COS-7", "CELL", 274, 292], ["aethiops", "ORGANISM", 300, 308], ["kidney cells", "CELL", 309, 321], ["Vero E6", "ORGANISM", 322, 329], ["bovine", "ORGANISM", 442, 448], ["serum", "ORGANISM_SUBSTANCE", 449, 454], ["glutamine", "AMINO_ACID", 464, 473], ["penicillin", "SIMPLE_CHEMICAL", 487, 497], ["streptomycin", "SIMPLE_CHEMICAL", 515, 527], ["v/v) carbon dioxide", "SIMPLE_CHEMICAL", 563, 582], ["plasmidsORF-6", "GENE_OR_GENE_PRODUCT", 607, 620], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 625, 631], ["ORF", "DNA", 43, 46], ["ORF-3b", "DNA", 51, 57], ["ORF-7a", "DNA", 62, 68], ["ORF-6", "DNA", 70, 75], ["ORF-6", "DNA", 140, 145], ["ORF-7a", "DNA", 150, 156], ["Cell cultureHuman embryonic kidney cells HEK293T", "CELL_LINE", 201, 249], ["Cercopithecus aethiops kidney cells COS-7", "CELL_LINE", 251, 292], ["C. aethiops kidney cells Vero E6", "CELL_LINE", 297, 329], ["plasmidsORF-6 and ORF-7a cDNA", "DNA", 607, 636], ["Cercopithecus aethiops", "SPECIES", 251, 273], ["C. aethiops", "SPECIES", 297, 308], ["bovine", "SPECIES", 442, 448], ["SARS-CoV", "SPECIES", 104, 112], ["Cercopithecus aethiops", "SPECIES", 251, 273], ["C. aethiops", "SPECIES", 297, 308], ["Vero E6", "SPECIES", 322, 329], ["bovine", "SPECIES", 442, 448], ["ORF", "TEST", 51, 54], ["ORF", "TEST", 70, 73], ["SARS", "PROBLEM", 104, 108], ["induced apoptosis", "PROBLEM", 113, 130], ["apoptosis", "PROBLEM", 191, 200], ["Cell cultureHuman embryonic kidney cells", "TEST", 201, 241], ["HEK293T", "TEST", 242, 249], ["Cercopithecus aethiops kidney cells", "TEST", 251, 286], ["COS", "TEST", 287, 290], ["C. aethiops kidney cells", "TEST", 297, 321], ["Vero E6", "TEST", 322, 329], ["Dulbecco", "TEST", 344, 352], ["fetal bovine serum", "TEST", 436, 454], ["2 mM glutamine", "TREATMENT", 459, 473], ["penicillin", "TREATMENT", 487, 497], ["streptomycin", "TREATMENT", 515, 527], ["a humidified incubator", "TREATMENT", 531, 553], ["v/v) carbon dioxide", "TREATMENT", 563, 582], ["plasmidsORF", "TEST", 607, 618], ["apoptosis", "OBSERVATION", 191, 200], ["kidney", "ANATOMY", 229, 235], ["cells HEK293T", "OBSERVATION", 236, 249], ["kidney", "ANATOMY", 309, 315]]], ["ORF-6 and ORF-7a were amplified by PCR and restriction sites BamHI and XhoI were introduced at 5\u2032 and 3\u2032 end, respectively.", [["ORF-6", "GENE_OR_GENE_PRODUCT", 0, 5], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 10, 16], ["BamHI", "GENE_OR_GENE_PRODUCT", 61, 66], ["XhoI", "GENE_OR_GENE_PRODUCT", 71, 75], ["ORF-6", "DNA", 0, 5], ["ORF-7a", "DNA", 10, 16], ["restriction sites", "DNA", 43, 60], ["XhoI", "DNA", 71, 75], ["5\u2032 and 3\u2032 end", "DNA", 95, 108], ["ORF", "TEST", 0, 3], ["ORF", "TEST", 10, 13], ["PCR", "TEST", 35, 38], ["restriction sites BamHI and XhoI", "TREATMENT", 43, 75]]], ["The fragments ORF-6 and ORF-7a were sub-cloned into mammalian expression vector GFP-N1.Drug treatmentVero E6 cells or COS-7 cells were pre-incubated with 50 \u03bcM of z-DEVD-fmk (Calbiochem) or 40 \u03bcM of JNK inhibitor or DimethylTransfection and Western blotTransfection was performed by using calcium chloride or Lipofectamine Transfection Reagent (Invitrogen) according to the manufacturer's instructions.", [["fragments", "ANATOMY", 4, 13], ["Vero E6 cells", "ANATOMY", 101, 114], ["COS-7 cells", "ANATOMY", 118, 129], ["z-DEVD-fmk", "CHEMICAL", 163, 173], ["calcium chloride", "CHEMICAL", 289, 305], ["calcium chloride", "CHEMICAL", 289, 305], ["ORF-6", "GENE_OR_GENE_PRODUCT", 14, 19], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 24, 30], ["GFP-N1", "GENE_OR_GENE_PRODUCT", 80, 86], ["Vero E6 cells", "CELL", 101, 114], ["COS-7 cells", "CELL", 118, 129], ["z-DEVD-fmk", "SIMPLE_CHEMICAL", 163, 173], ["Calbiochem", "SIMPLE_CHEMICAL", 175, 185], ["JNK", "GENE_OR_GENE_PRODUCT", 199, 202], ["calcium chloride", "SIMPLE_CHEMICAL", 289, 305], ["fragments ORF-6", "DNA", 4, 19], ["ORF-7a", "DNA", 24, 30], ["mammalian expression vector GFP-N1", "DNA", 52, 86], ["Vero E6 cells", "CELL_LINE", 101, 114], ["COS-7 cells", "CELL_LINE", 118, 129], ["JNK", "PROTEIN", 199, 202], ["Vero E6", "SPECIES", 101, 108], ["The fragments ORF", "TEST", 0, 17], ["ORF", "TEST", 24, 27], ["Drug treatment", "TREATMENT", 87, 101], ["Vero E6 cells", "TEST", 101, 114], ["COS", "TEST", 118, 121], ["z-DEVD", "TEST", 163, 169], ["JNK inhibitor", "TREATMENT", 199, 212], ["DimethylTransfection", "TREATMENT", 216, 236], ["Western blotTransfection", "TREATMENT", 241, 265], ["calcium chloride", "TREATMENT", 289, 305], ["Lipofectamine Transfection Reagent (Invitrogen)", "TREATMENT", 309, 356], ["fragments", "OBSERVATION_MODIFIER", 4, 13], ["E6 cells", "OBSERVATION", 106, 114]]], ["For the Western blot, 24 h after transfection, cells were lysed with 300 \u03bcl cold lysis buffer [20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM \u03b2-glycerolphosphate, 1 mM sodium orthovanadate, 1 \u03bcg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride] and were scrapped into 1.5 ml Eppendorf tubes.", [["cells", "ANATOMY", 47, 52], ["Tris-HCl", "CHEMICAL", 101, 109], ["NaCl", "CHEMICAL", 126, 130], ["EGTA", "CHEMICAL", 148, 152], ["sodium pyrophosphate", "CHEMICAL", 172, 192], ["\u03b2-glycerolphosphate", "CHEMICAL", 199, 218], ["sodium orthovanadate", "CHEMICAL", 225, 245], ["phenylmethylsulfonyl fluoride", "CHEMICAL", 271, 300], ["Tris-HCl", "CHEMICAL", 101, 109], ["NaCl", "CHEMICAL", 126, 130], ["EDTA", "CHEMICAL", 137, 141], ["EGTA", "CHEMICAL", 148, 152], ["sodium pyrophosphate", "CHEMICAL", 172, 192], ["\u03b2-glycerolphosphate", "CHEMICAL", 199, 218], ["sodium orthovanadate", "CHEMICAL", 225, 245], ["leupeptin", "CHEMICAL", 255, 264], ["phenylmethylsulfonyl fluoride", "CHEMICAL", 271, 300], ["cells", "CELL", 47, 52], ["Tris-HCl", "SIMPLE_CHEMICAL", 101, 109], ["EDTA", "SIMPLE_CHEMICAL", 137, 141], ["EGTA", "SIMPLE_CHEMICAL", 148, 152], ["Triton", "SIMPLE_CHEMICAL", 157, 163], ["sodium pyrophosphate", "SIMPLE_CHEMICAL", 172, 192], ["\u03b2-glycerolphosphate", "SIMPLE_CHEMICAL", 199, 218], ["sodium orthovanadate", "SIMPLE_CHEMICAL", 225, 245], ["leupeptin", "SIMPLE_CHEMICAL", 255, 264], ["phenylmethylsulfonyl fluoride", "SIMPLE_CHEMICAL", 271, 300], ["cold lysis buffer", "TREATMENT", 76, 93], ["Tris", "TEST", 101, 105], ["HCl", "TEST", 106, 109], ["pH", "TEST", 111, 113], ["NaCl", "TEST", 126, 130], ["EDTA", "TEST", 137, 141], ["EGTA", "TEST", 148, 152], ["1% Triton", "TREATMENT", 154, 163], ["2.5 mM sodium pyrophosphate", "TREATMENT", 165, 192], ["glycerolphosphate", "TREATMENT", 201, 218], ["1 mM sodium orthovanadate", "TREATMENT", 220, 245], ["leupeptin", "TREATMENT", 255, 264], ["1 mM phenylmethylsulfonyl fluoride", "TREATMENT", 266, 300]]], ["The lysates were exposed to sonication and cleaned by centrifugation at 15,000 \u00d7g for 30 min.", [["lysates", "ANATOMY", 4, 11], ["lysates", "ORGANISM_SUBSTANCE", 4, 11], ["The lysates", "TREATMENT", 0, 11]]], ["The supernatant was collected and the protein concentration was measured and adjusted to a concentration of 2 mg/ml by the lysis buffer.", [["supernatant", "ANATOMY", 4, 15], ["The supernatant", "TREATMENT", 0, 15], ["the protein concentration", "TEST", 34, 59], ["the lysis buffer", "TREATMENT", 119, 135]]], ["Sample buffer was added and the samples were subjected to SDS-PAGE and were transferred onto PVDF membranes (Hybond).", [["samples", "ANATOMY", 32, 39], ["membranes", "ANATOMY", 98, 107], ["PVDF", "CHEMICAL", 93, 97], ["membranes", "CELLULAR_COMPONENT", 98, 107], ["Sample buffer", "TREATMENT", 0, 13], ["the samples", "TEST", 28, 39]]], ["The membranes were blotted with 5% non-fat milk for an hour and then immunoblotted by using appropriate primary and secondary antibodies.", [["membranes", "ANATOMY", 4, 13], ["fat milk", "ANATOMY", 39, 47], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["fat milk", "ORGANISM_SUBSTANCE", 39, 47], ["primary and secondary antibodies", "PROTEIN", 104, 136], ["5% non-fat milk", "TREATMENT", 32, 47], ["secondary antibodies", "OBSERVATION", 116, 136]]], ["The specific protein bands were visualized by SuperSignal West Pico Luminol (PIERCE) and exposed on Fuji Medical X-ray film (Fujifilm).Measurement of cell deathAfter 24 h of transfection, 1 \u03bcM Hoechst 33324 (Sigma) was applied to the cells for 10 min.", [["cell", "ANATOMY", 150, 154], ["cells", "ANATOMY", 234, 239], ["Luminol", "CHEMICAL", 68, 75], ["Hoechst 33324", "CHEMICAL", 193, 206], ["Hoechst 33324", "CHEMICAL", 193, 206], ["cell", "CELL", 150, 154], ["Hoechst 33324", "SIMPLE_CHEMICAL", 193, 206], ["cells", "CELL", 234, 239], ["The specific protein bands", "PROBLEM", 0, 26], ["SuperSignal West Pico Luminol (PIERCE)", "TREATMENT", 46, 84], ["Fuji Medical X-ray film", "TEST", 100, 123], ["transfection", "TEST", 174, 186], ["protein bands", "OBSERVATION", 13, 26]]], ["Apoptotic cells were characterized by counting condensed and fragmented nuclei under a fluorescent microscope.", [["cells", "ANATOMY", 10, 15], ["nuclei", "ANATOMY", 72, 78], ["Apoptotic cells", "CELL", 0, 15], ["nuclei", "CELLULAR_COMPONENT", 72, 78], ["Apoptotic cells", "CELL_TYPE", 0, 15], ["Apoptotic cells", "PROBLEM", 0, 15], ["a fluorescent microscope", "TEST", 85, 109], ["fragmented", "OBSERVATION_MODIFIER", 61, 71], ["nuclei", "OBSERVATION_MODIFIER", 72, 78]]], ["The numbers of GFP-expressed cells and GFP-expressed apoptotic cells were counted.", [["cells", "ANATOMY", 29, 34], ["cells", "ANATOMY", 63, 68], ["GFP", "GENE_OR_GENE_PRODUCT", 15, 18], ["cells", "CELL", 29, 34], ["GFP", "GENE_OR_GENE_PRODUCT", 39, 42], ["cells", "CELL", 63, 68], ["GFP", "PROTEIN", 15, 18], ["GFP", "PROTEIN", 39, 42], ["apoptotic cells", "CELL_TYPE", 53, 68], ["GFP", "TEST", 15, 18], ["expressed cells", "PROBLEM", 19, 34], ["GFP", "TEST", 39, 42], ["expressed apoptotic cells", "PROBLEM", 43, 68], ["apoptotic cells", "OBSERVATION", 53, 68]]], ["At least three hundred cells were counted each time and each experiment was repeated three times.Overexpression of ORF-6 protein induces apoptosisIn a search for SARS proteins that could induce apoptosis, the SARS protein, ORF-6 was tagged with GFP at the N-terminus and was transfected into Vero E6 and COS-7 cells.", [["cells", "ANATOMY", 23, 28], ["Vero", "ANATOMY", 292, 296], ["COS-7 cells", "ANATOMY", 304, 315], ["N", "CHEMICAL", 256, 257], ["cells", "CELL", 23, 28], ["ORF-6", "GENE_OR_GENE_PRODUCT", 115, 120], ["ORF-6", "GENE_OR_GENE_PRODUCT", 223, 228], ["GFP", "GENE_OR_GENE_PRODUCT", 245, 248], ["Vero E6", "CELL", 292, 299], ["COS-7 cells", "CELL", 304, 315], ["ORF-6 protein", "PROTEIN", 115, 128], ["SARS proteins", "PROTEIN", 162, 175], ["SARS protein", "PROTEIN", 209, 221], ["ORF-6", "DNA", 223, 228], ["GFP", "PROTEIN", 245, 248], ["N-terminus", "PROTEIN", 256, 266], ["Vero E6", "CELL_LINE", 292, 299], ["COS-7 cells", "CELL_LINE", 304, 315], ["Vero E6", "SPECIES", 292, 299], ["Overexpression of ORF", "PROBLEM", 97, 118], ["apoptosis", "PROBLEM", 137, 146], ["SARS proteins", "PROBLEM", 162, 175], ["apoptosis", "PROBLEM", 194, 203], ["the SARS protein", "TEST", 205, 221], ["ORF", "TEST", 223, 226], ["GFP", "TEST", 245, 248], ["Vero E6", "TEST", 292, 299], ["hundred cells", "OBSERVATION", 15, 28], ["apoptosis", "OBSERVATION_MODIFIER", 137, 146]]], ["We observed that ORF-6 was able to induce apoptosis when overexpressed in Vero E6 and COS-7 cells (Fig. 1A and B) .", [["Vero E6", "ANATOMY", 74, 81], ["COS-7 cells", "ANATOMY", 86, 97], ["ORF-6", "GENE_OR_GENE_PRODUCT", 17, 22], ["Vero E6", "CELL", 74, 81], ["COS-7 cells", "CELL", 86, 97], ["Fig. 1A", "CELL", 99, 106], ["B", "CELL", 111, 112], ["ORF-6", "DNA", 17, 22], ["Vero E6", "CELL_LINE", 74, 81], ["COS-7 cells", "CELL_LINE", 86, 97], ["Vero E6", "SPECIES", 74, 81], ["ORF", "TEST", 17, 20], ["apoptosis", "PROBLEM", 42, 51], ["Vero E6", "TEST", 74, 81], ["COS", "TEST", 86, 89]]], ["Approximately one third of the cells died when 2 \u03bcg of ORF-6 DNA was transfected into cells.", [["cells", "ANATOMY", 31, 36], ["cells", "ANATOMY", 86, 91], ["cells", "CELL", 31, 36], ["ORF-6", "GENE_OR_GENE_PRODUCT", 55, 60], ["DNA", "CELLULAR_COMPONENT", 61, 64], ["cells", "CELL", 86, 91], ["ORF-6 DNA", "DNA", 55, 64], ["ORF", "TEST", 55, 58]]], ["The number of apoptotic cells was increased when more ORF-6 DNA was transfected into the cells (Fig. 1 ).", [["cells", "ANATOMY", 24, 29], ["cells", "ANATOMY", 89, 94], ["cells", "CELL", 24, 29], ["DNA", "CELLULAR_COMPONENT", 60, 63], ["cells", "CELL", 89, 94], ["apoptotic cells", "CELL_TYPE", 14, 29], ["ORF-6 DNA", "DNA", 54, 63], ["apoptotic cells", "PROBLEM", 14, 29], ["ORF", "TEST", 54, 57], ["apoptotic cells", "OBSERVATION", 14, 29]]], ["The death rates were comparable to the rates caused by the overexpression of Bax, a well-known pro-apoptotic member of the Bcl-family, and ORF-7a, a SARS protein that has been shown to induce apoptosis [19] .", [["death", "DISEASE", 4, 9], ["Bax", "GENE_OR_GENE_PRODUCT", 77, 80], ["Bcl-family", "GENE_OR_GENE_PRODUCT", 123, 133], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 139, 145], ["Bax", "PROTEIN", 77, 80], ["pro-apoptotic member", "PROTEIN", 95, 115], ["Bcl-family", "PROTEIN", 123, 133], ["ORF-7a", "PROTEIN", 139, 145], ["SARS protein", "PROTEIN", 149, 161], ["The death rates", "PROBLEM", 0, 15], ["a SARS protein", "PROBLEM", 147, 161]]], ["GFP-N1 served as the negative control, as the transfection of 5 \u03bcg of GFP-N1 DNA could not induce apoptosis.", [["GFP-N1", "GENE_OR_GENE_PRODUCT", 0, 6], ["GFP", "GENE_OR_GENE_PRODUCT", 70, 73], ["DNA", "CELLULAR_COMPONENT", 77, 80], ["GFP", "PROTEIN", 0, 3], ["N1", "DNA", 4, 6], ["GFP-N1 DNA", "DNA", 70, 80], ["GFP", "TEST", 0, 3], ["the transfection", "TEST", 42, 58], ["GFP", "TEST", 70, 73], ["N1 DNA", "PROBLEM", 74, 80], ["apoptosis", "PROBLEM", 98, 107], ["apoptosis", "OBSERVATION", 98, 107]]], ["These results showed that the ORF-6 protein does induce apoptosis.Overexpression of ORF-6-induced apoptosis is caspase-3 dependentORF-7a induces apoptosis via a caspase-3 dependent pathway [19] .", [["ORF-6", "GENE_OR_GENE_PRODUCT", 30, 35], ["ORF-6", "GENE_OR_GENE_PRODUCT", 84, 89], ["caspase-3", "GENE_OR_GENE_PRODUCT", 111, 120], ["dependentORF-7a", "GENE_OR_GENE_PRODUCT", 121, 136], ["caspase-3", "GENE_OR_GENE_PRODUCT", 161, 170], ["ORF-6 protein", "PROTEIN", 30, 43], ["ORF-6", "DNA", 84, 89], ["caspase-3 dependentORF-7a", "PROTEIN", 111, 136], ["the ORF", "TEST", 26, 33], ["apoptosis", "PROBLEM", 56, 65], ["ORF", "TEST", 84, 87], ["caspase", "TEST", 111, 118], ["apoptosis", "PROBLEM", 145, 154], ["a caspase-3 dependent pathway", "TREATMENT", 159, 188], ["apoptosis", "OBSERVATION", 56, 65]]], ["To determine if cell death induced by ORF-6 is also caspase-3 dependent, a caspase-3-specific inhibitor, z-DEVD, was used to block the caspase-3 activation in the cells.", [["cell", "ANATOMY", 16, 20], ["cells", "ANATOMY", 163, 168], ["death", "DISEASE", 21, 26], ["cell", "CELL", 16, 20], ["ORF-6", "GENE_OR_GENE_PRODUCT", 38, 43], ["caspase-3", "GENE_OR_GENE_PRODUCT", 52, 61], ["caspase-3", "GENE_OR_GENE_PRODUCT", 75, 84], ["z-DEVD", "SIMPLE_CHEMICAL", 105, 111], ["caspase-3", "GENE_OR_GENE_PRODUCT", 135, 144], ["cells", "CELL", 163, 168], ["ORF", "DNA", 38, 41], ["caspase-3", "PROTEIN", 135, 144], ["cell death", "PROBLEM", 16, 26], ["ORF", "TEST", 38, 41], ["caspase", "TEST", 52, 59], ["a caspase", "TREATMENT", 73, 82], ["specific inhibitor", "TREATMENT", 85, 103], ["z-DEVD", "TREATMENT", 105, 111], ["the caspase", "TREATMENT", 131, 142], ["cells", "ANATOMY", 163, 168]]], ["In the absence of z-DEVD, approximately 60% of cells underwent apoptosis when ORF-6 and ORF-7a were transiently transfected into the Vero E6 cells; however, when ORF-6 or ORF-7a were overexpressed in z-DEVD pre-treated cells, the percentage of apoptotic cells was significantly decreased to approximately 20% ( Fig. 2A) .", [["cells", "ANATOMY", 47, 52], ["Vero E6 cells", "ANATOMY", 133, 146], ["z-DEVD", "ANATOMY", 200, 206], ["cells", "ANATOMY", 219, 224], ["cells", "ANATOMY", 254, 259], ["cells", "CELL", 47, 52], ["ORF-6", "GENE_OR_GENE_PRODUCT", 78, 83], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 88, 94], ["Vero E6 cells", "CELL", 133, 146], ["ORF-6", "GENE_OR_GENE_PRODUCT", 162, 167], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 171, 177], ["z-DEVD", "CELL", 200, 206], ["cells", "CELL", 219, 224], ["cells", "CELL", 254, 259], ["z-DEVD", "PROTEIN", 18, 24], ["ORF-6", "DNA", 78, 83], ["ORF-7a", "DNA", 88, 94], ["Vero E6 cells", "CELL_LINE", 133, 146], ["ORF-6", "DNA", 162, 167], ["ORF-7a", "DNA", 171, 177], ["z-DEVD pre-treated cells", "CELL_LINE", 200, 224], ["apoptotic cells", "CELL_TYPE", 244, 259], ["Vero E6", "SPECIES", 133, 140], ["apoptosis", "PROBLEM", 63, 72], ["ORF", "TEST", 78, 81], ["ORF", "TEST", 88, 91], ["ORF", "TEST", 162, 165], ["ORF", "TEST", 171, 174], ["z-DEVD pre-treated cells", "PROBLEM", 200, 224], ["apoptotic cells", "PROBLEM", 244, 259], ["Vero", "ANATOMY", 133, 137], ["E6 cells", "OBSERVATION", 138, 146], ["apoptotic cells", "OBSERVATION", 244, 259], ["decreased", "OBSERVATION_MODIFIER", 278, 287]]], ["In parallel, Caspase-3 activities were also monitored when the Vero E6 cells were transfected with ORF-6.", [["Vero E6 cells", "ANATOMY", 63, 76], ["Caspase-3", "GENE_OR_GENE_PRODUCT", 13, 22], ["Vero E6 cells", "CELL", 63, 76], ["ORF-6", "GENE_OR_GENE_PRODUCT", 99, 104], ["Caspase-3", "PROTEIN", 13, 22], ["Vero E6 cells", "CELL_LINE", 63, 76], ["ORF-6", "DNA", 99, 104], ["Vero E6", "SPECIES", 63, 70], ["Caspase", "TREATMENT", 13, 20], ["the Vero E6 cells", "TREATMENT", 59, 76]]], ["The activity of Caspase-3 can be detected by the amount of the 17 kD active form of Caspase-3 in cells by using Caspase-3 specific antibodies.", [["cells", "ANATOMY", 97, 102], ["Caspase-3", "GENE_OR_GENE_PRODUCT", 16, 25], ["Caspase-3", "GENE_OR_GENE_PRODUCT", 84, 93], ["cells", "CELL", 97, 102], ["Caspase-3", "GENE_OR_GENE_PRODUCT", 112, 121], ["Caspase-3", "PROTEIN", 16, 25], ["Caspase-3", "PROTEIN", 84, 93], ["Caspase-3 specific antibodies", "PROTEIN", 112, 141], ["Caspase", "TREATMENT", 16, 23], ["Caspase", "TREATMENT", 84, 91], ["Caspase", "TEST", 112, 119]]], ["Fig. 2B showed that both ORF-6 and ORF-7a induced Caspase-3 activation, as the 17 kD active form of Caspase-3 was detected in both.", [["ORF-6", "GENE_OR_GENE_PRODUCT", 25, 30], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 35, 41], ["Caspase-3", "GENE_OR_GENE_PRODUCT", 50, 59], ["Caspase-3", "GENE_OR_GENE_PRODUCT", 100, 109], ["ORF-6", "DNA", 25, 30], ["ORF", "DNA", 35, 38], ["Caspase-3", "PROTEIN", 50, 59], ["Caspase-3", "PROTEIN", 100, 109], ["ORF", "TEST", 25, 28], ["ORF", "TEST", 35, 38], ["Caspase", "TEST", 50, 57], ["Caspase", "TREATMENT", 100, 107]]], ["Cells without any treatment served as a negative control and cells treated with Staurosporine (STS) served as a positive control.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 61, 66], ["Staurosporine", "CHEMICAL", 80, 93], ["STS", "CHEMICAL", 95, 98], ["Staurosporine", "CHEMICAL", 80, 93], ["STS", "CHEMICAL", 95, 98], ["Cells", "CELL", 0, 5], ["cells", "CELL", 61, 66], ["Staurosporine", "SIMPLE_CHEMICAL", 80, 93], ["STS", "SIMPLE_CHEMICAL", 95, 98], ["any treatment", "TREATMENT", 14, 27], ["Staurosporine (STS)", "TREATMENT", 80, 99], ["a positive control", "TREATMENT", 110, 128]]], ["Similar results were obtained when using 293T or COS-7 cells (data not shown).", [["293T", "ANATOMY", 41, 45], ["COS-7 cells", "ANATOMY", 49, 60], ["293T", "CELL", 41, 45], ["COS-7 cells", "CELL", 49, 60], ["293T", "CELL_LINE", 41, 45], ["COS-7 cells", "CELL_LINE", 49, 60], ["COS", "TEST", 49, 52]]], ["Our observation suggests that overexpression of ORF-6 induced apoptosis via a Caspase-3-dependent pathway.JNK inhibitor blocks ORF-6 and ORF-7a-induced apoptosisOne of the possible mechanisms for SARS protein-induced cell death is via the JNK pathway.", [["cell", "ANATOMY", 217, 221], ["SARS", "DISEASE", 196, 200], ["death", "DISEASE", 222, 227], ["ORF-6", "GENE_OR_GENE_PRODUCT", 48, 53], ["Caspase-3", "GENE_OR_GENE_PRODUCT", 78, 87], ["JNK", "GENE_OR_GENE_PRODUCT", 106, 109], ["ORF-6", "GENE_OR_GENE_PRODUCT", 127, 132], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 137, 143], ["cell", "CELL", 217, 221], ["JNK", "GENE_OR_GENE_PRODUCT", 239, 242], ["ORF-6", "DNA", 48, 53], ["Caspase-3", "PROTEIN", 78, 87], ["JNK", "PROTEIN", 106, 109], ["ORF-6", "DNA", 127, 132], ["ORF-7a", "DNA", 137, 143], ["SARS protein", "PROTEIN", 196, 208], ["JNK", "PROTEIN", 239, 242], ["Our observation", "TEST", 0, 15], ["overexpression of ORF", "PROBLEM", 30, 51], ["a Caspase-3-dependent pathway", "TREATMENT", 76, 105], ["JNK inhibitor blocks ORF", "TEST", 106, 130], ["ORF", "TEST", 137, 140], ["SARS protein", "PROBLEM", 196, 208], ["induced cell death", "PROBLEM", 209, 227], ["cell death", "OBSERVATION", 217, 227]]], ["Previous studies have shown that JNK is phosphorylated in SARS-CoV-infected Vero E6 cells and JNK inhibitor (SP600125) can block SARS-CoV-infected Vero E6 cells-induced apoptosis.", [["Vero E6 cells", "ANATOMY", 76, 89], ["Vero E6 cells", "ANATOMY", 147, 160], ["SP600125", "CHEMICAL", 109, 117], ["SP600125", "CHEMICAL", 109, 117], ["JNK", "GENE_OR_GENE_PRODUCT", 33, 36], ["SARS-CoV", "ORGANISM", 58, 66], ["Vero E6 cells", "CELL", 76, 89], ["JNK", "GENE_OR_GENE_PRODUCT", 94, 97], ["SP600125", "SIMPLE_CHEMICAL", 109, 117], ["SARS-CoV", "ORGANISM", 129, 137], ["Vero E6 cells", "CELL", 147, 160], ["JNK", "PROTEIN", 33, 36], ["SARS-CoV-infected Vero E6 cells", "CELL_LINE", 58, 89], ["JNK", "PROTEIN", 94, 97], ["Vero E6 cells", "CELL_LINE", 147, 160], ["SARS-CoV", "SPECIES", 58, 66], ["Vero E6", "SPECIES", 76, 83], ["SARS-CoV", "SPECIES", 129, 137], ["Vero E6", "SPECIES", 147, 154], ["Previous studies", "TEST", 0, 16], ["JNK", "TEST", 33, 36], ["phosphorylated", "PROBLEM", 40, 54], ["SARS", "PROBLEM", 58, 62], ["CoV", "TEST", 63, 66], ["infected Vero E6 cells", "PROBLEM", 67, 89], ["JNK inhibitor", "TREATMENT", 94, 107], ["block SARS", "PROBLEM", 123, 133], ["CoV", "TEST", 134, 137], ["infected Vero E6 cells", "PROBLEM", 138, 160], ["apoptosis", "PROBLEM", 169, 178], ["Vero E6 cells", "OBSERVATION", 76, 89], ["infected", "OBSERVATION_MODIFIER", 138, 146], ["Vero E6 cells", "OBSERVATION", 147, 160], ["apoptosis", "OBSERVATION_MODIFIER", 169, 178]]], ["We investigated whether JNK inhibitor could block ORF-6-and ORF-7a-induced apoptosis in Vero E6 cells.", [["Vero E6 cells", "ANATOMY", 88, 101], ["ORF-7a", "CHEMICAL", 60, 66], ["JNK", "GENE_OR_GENE_PRODUCT", 24, 27], ["ORF-6", "GENE_OR_GENE_PRODUCT", 50, 55], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 60, 66], ["Vero E6 cells", "CELL", 88, 101], ["JNK", "PROTEIN", 24, 27], ["ORF-6", "DNA", 50, 55], ["ORF", "DNA", 60, 63], ["Vero E6 cells", "CELL_LINE", 88, 101], ["Vero E6", "SPECIES", 88, 95], ["JNK inhibitor", "PROBLEM", 24, 37], ["ORF", "TEST", 50, 53], ["ORF", "TEST", 60, 63], ["apoptosis in Vero E6 cells", "PROBLEM", 75, 101], ["Vero E6 cells", "OBSERVATION", 88, 101]]], ["Interestingly, apoptosis induced by ORF-6 and ORF-7a was blocked by the JNK inhibitor.", [["ORF-6", "GENE_OR_GENE_PRODUCT", 36, 41], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 46, 52], ["JNK", "GENE_OR_GENE_PRODUCT", 72, 75], ["ORF-6", "DNA", 36, 41], ["ORF-7a", "DNA", 46, 52], ["JNK", "PROTEIN", 72, 75], ["ORF", "TEST", 36, 39], ["ORF", "TEST", 46, 49], ["the JNK inhibitor", "TREATMENT", 68, 85]]], ["The blocking efficiency was similar to that of z-DEVD as only approximately 10% of cells underwent apoptosis (Fig. 2C ).", [["cells", "ANATOMY", 83, 88], ["cells", "CELL", 83, 88], ["z-DEVD", "PROTEIN", 47, 53], ["The blocking efficiency", "PROBLEM", 0, 23], ["apoptosis", "PROBLEM", 99, 108], ["blocking efficiency", "OBSERVATION", 4, 23]]], ["JNK inhibitor also was able to block ORF-6 and ORF-7a in 293T and COS-7 cells (data not shown).", [["293T", "ANATOMY", 57, 61], ["COS-7 cells", "ANATOMY", 66, 77], ["JNK", "GENE_OR_GENE_PRODUCT", 0, 3], ["ORF-6", "GENE_OR_GENE_PRODUCT", 37, 42], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 47, 53], ["293T", "CELL", 57, 61], ["COS-7 cells", "CELL", 66, 77], ["JNK", "PROTEIN", 0, 3], ["ORF-6", "DNA", 37, 42], ["ORF-7a", "DNA", 47, 53], ["293T", "CELL_LINE", 57, 61], ["COS-7 cells", "CELL_LINE", 66, 77], ["JNK inhibitor", "TEST", 0, 13], ["block ORF", "TEST", 31, 40], ["ORF", "TEST", 47, 50], ["COS", "TEST", 66, 69]]], ["These results suggest that the JNK inhibitor is able to block overexpression of ORF-6-or ORF-7a-induced apoptosis.ORF-6 and ORF-7a induce ER stressA recent report showed that ORF-6 is localized in ER/Golgi membrane [27] which is consistent with our immunostaining result of ORF-6 and ORF-7a in COS-7 cells (data not shown).", [["ER/Golgi membrane", "ANATOMY", 197, 214], ["COS-7 cells", "ANATOMY", 294, 305], ["JNK", "GENE_OR_GENE_PRODUCT", 31, 34], ["ORF-6", "GENE_OR_GENE_PRODUCT", 80, 85], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 89, 95], ["ORF-6", "GENE_OR_GENE_PRODUCT", 114, 119], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 124, 130], ["ER", "GENE_OR_GENE_PRODUCT", 138, 140], ["ORF-6", "GENE_OR_GENE_PRODUCT", 175, 180], ["ER", "GENE_OR_GENE_PRODUCT", 197, 199], ["Golgi membrane", "CELLULAR_COMPONENT", 200, 214], ["ORF-6", "GENE_OR_GENE_PRODUCT", 274, 279], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 284, 290], ["COS-7 cells", "CELL", 294, 305], ["JNK", "PROTEIN", 31, 34], ["ORF-6", "DNA", 80, 85], ["ORF", "DNA", 89, 92], ["ORF-6", "DNA", 114, 119], ["ORF-7a", "DNA", 124, 130], ["ER", "PROTEIN", 138, 140], ["ORF-6", "DNA", 175, 180], ["ER", "PROTEIN", 197, 199], ["ORF-6", "DNA", 274, 279], ["ORF-7a", "DNA", 284, 290], ["COS-7 cells", "CELL_LINE", 294, 305], ["the JNK inhibitor", "TREATMENT", 27, 44], ["ORF", "TEST", 80, 83], ["ORF", "PROBLEM", 89, 92], ["apoptosis", "PROBLEM", 104, 113], ["ORF", "TEST", 114, 117], ["ORF", "TEST", 175, 178], ["our immunostaining", "TEST", 245, 263], ["ORF", "TEST", 274, 277], ["ORF", "TEST", 284, 287], ["apoptosis", "OBSERVATION", 104, 113], ["consistent with", "UNCERTAINTY", 229, 244]]], ["Since both ORF-6 and ORF-7a are ER-localized, we suspected that they induce apoptosis through the ER-stress pathway.", [["ORF-6", "GENE_OR_GENE_PRODUCT", 11, 16], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 21, 27], ["ER", "GENE_OR_GENE_PRODUCT", 32, 34], ["ER", "GENE_OR_GENE_PRODUCT", 98, 100], ["ORF-6", "DNA", 11, 16], ["ORF-7a", "DNA", 21, 27], ["ER", "PROTEIN", 32, 34], ["ER", "PROTEIN", 98, 100]]], ["GRP94 is an ER-resident molecular chaperone protein which the expression level is increased upon ER-stress [28] .", [["GRP94", "GENE_OR_GENE_PRODUCT", 0, 5], ["ER", "GENE_OR_GENE_PRODUCT", 12, 14], ["ER", "GENE_OR_GENE_PRODUCT", 97, 99], ["GRP94", "PROTEIN", 0, 5], ["ER", "PROTEIN", 12, 14], ["chaperone protein", "PROTEIN", 34, 51], ["ER", "PROTEIN", 97, 99], ["increased", "OBSERVATION_MODIFIER", 82, 91]]], ["We compared the protein level of GRP94 in order to check whether ER stress occurred in cells transfected with ORF-6 and ORF-7a.", [["cells", "ANATOMY", 87, 92], ["GRP94", "GENE_OR_GENE_PRODUCT", 33, 38], ["ER", "GENE_OR_GENE_PRODUCT", 65, 67], ["cells", "CELL", 87, 92], ["ORF-6", "GENE_OR_GENE_PRODUCT", 110, 115], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 120, 126], ["GRP94", "PROTEIN", 33, 38], ["ER", "PROTEIN", 65, 67], ["ORF-6", "DNA", 110, 115], ["ORF-7a", "DNA", 120, 126], ["the protein level", "TEST", 12, 29], ["ER stress", "PROBLEM", 65, 74], ["ORF", "TEST", 110, 113]]], ["Results in Fig. 3a showed that in cells transfected with either ORF-6 or ORF-7a, the GRP94 protein level is increased compared to cells without transfection; however, the protein level is lower than that of the cells treated with 1 \u03bcM Thapsigargin, a chemical specific for induction of ER stress.", [["cells", "ANATOMY", 34, 39], ["cells", "ANATOMY", 130, 135], ["cells", "ANATOMY", 211, 216], ["Thapsigargin", "CHEMICAL", 235, 247], ["Thapsigargin", "CHEMICAL", 235, 247], ["cells", "CELL", 34, 39], ["ORF-6", "GENE_OR_GENE_PRODUCT", 64, 69], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 73, 79], ["GRP94", "GENE_OR_GENE_PRODUCT", 85, 90], ["cells", "CELL", 130, 135], ["cells", "CELL", 211, 216], ["Thapsigargin", "SIMPLE_CHEMICAL", 235, 247], ["ER", "GENE_OR_GENE_PRODUCT", 286, 288], ["ORF-6", "DNA", 64, 69], ["ORF", "DNA", 73, 76], ["GRP94", "PROTEIN", 85, 90], ["ER", "PROTEIN", 286, 288], ["ORF", "TEST", 64, 67], ["ORF", "TEST", 73, 76], ["the GRP94 protein level", "TEST", 81, 104], ["transfection", "PROBLEM", 144, 156], ["the protein level", "TEST", 167, 184], ["ER stress", "PROBLEM", 286, 295], ["increased", "OBSERVATION_MODIFIER", 108, 117]]], ["In parallel, we conducted dose dependent experiments by transfecting different amounts of ORF-6 and ORF-7a into cells.", [["cells", "ANATOMY", 112, 117], ["ORF-6", "GENE_OR_GENE_PRODUCT", 90, 95], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 100, 106], ["cells", "CELL", 112, 117], ["ORF-6", "DNA", 90, 95], ["ORF-7a", "DNA", 100, 106], ["dose dependent experiments", "TREATMENT", 26, 52], ["ORF", "TEST", 90, 93]]], ["Consistently, the endogenous GRP94 protein level was increased when the amount of ORF-6 or ORF-7 increased ( Fig. 3B and C).", [["GRP94", "GENE_OR_GENE_PRODUCT", 29, 34], ["ORF-6", "GENE_OR_GENE_PRODUCT", 82, 87], ["ORF-7", "GENE_OR_GENE_PRODUCT", 91, 96], ["GRP94", "PROTEIN", 29, 34], ["ORF-6", "DNA", 82, 87], ["ORF-7", "DNA", 91, 96], ["the endogenous GRP94 protein level", "TEST", 14, 48], ["ORF", "TEST", 82, 85], ["ORF", "TEST", 91, 94]]], ["Our observation suggests that overexpression of ORF-6 and ORF-7a could induce apoptosis via ER-stress pathway.DiscussionWe report here that ORF-6 is the fourth SARS accessory protein that can induce apoptosis.", [["ORF-6", "GENE_OR_GENE_PRODUCT", 48, 53], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 58, 64], ["ER", "GENE_OR_GENE_PRODUCT", 92, 94], ["ORF-6", "GENE_OR_GENE_PRODUCT", 140, 145], ["ORF-6", "DNA", 48, 53], ["ORF", "DNA", 58, 61], ["ER", "PROTEIN", 92, 94], ["ORF-6", "DNA", 140, 145], ["SARS accessory protein", "PROTEIN", 160, 182], ["Our observation", "TEST", 0, 15], ["overexpression of ORF", "PROBLEM", 30, 51], ["apoptosis", "PROBLEM", 78, 87], ["ORF", "TEST", 140, 143], ["the fourth SARS accessory protein", "PROBLEM", 149, 182], ["apoptosis", "PROBLEM", 199, 208]]], ["Apoptosis induced by ORF-6 is Caspase-3 dependent.", [["Apoptosis", "DISEASE", 0, 9], ["ORF-6", "GENE_OR_GENE_PRODUCT", 21, 26], ["Caspase-3", "GENE_OR_GENE_PRODUCT", 30, 39], ["ORF", "DNA", 21, 24], ["Caspase-3", "PROTEIN", 30, 39], ["Apoptosis", "PROBLEM", 0, 9], ["ORF", "TEST", 21, 24]]], ["Moreover, we identified that ORF-6-and ORF-7a-induced apoptosis is via JNK-dependent pathway.", [["ORF-6", "GENE_OR_GENE_PRODUCT", 29, 34], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 39, 45], ["JNK", "GENE_OR_GENE_PRODUCT", 71, 74], ["ORF-6", "DNA", 29, 34], ["ORF", "DNA", 39, 42], ["JNK", "PROTEIN", 71, 74], ["ORF", "TEST", 29, 32], ["ORF", "TEST", 39, 42]]], ["Finally, these two ERlocalized proteins induce ER stress when overexpressed in cells.", [["cells", "ANATOMY", 79, 84], ["ER", "GENE_OR_GENE_PRODUCT", 47, 49], ["cells", "CELL", 79, 84], ["ERlocalized proteins", "PROTEIN", 19, 39], ["ER", "PROTEIN", 47, 49], ["ER stress", "PROBLEM", 47, 56], ["overexpressed in cells", "PROBLEM", 62, 84]]], ["By searching through the database in NCBI (National Center for Biotechnology Information), we found that there is no significant homology between ORF-6 and other known proteins.", [["ORF-6", "GENE_OR_GENE_PRODUCT", 146, 151], ["ORF-6", "DNA", 146, 151], ["significant homology between ORF", "PROBLEM", 117, 149], ["proteins", "OBSERVATION", 168, 176]]], ["Interestingly, we found that the molecular pathway for ORF-6-induced apoptosis is similar to that of ORF-7a.DiscussionSARS-CoV encodes 23 putative proteins and 8 novel ORFs have been identified.", [["ORF-6", "GENE_OR_GENE_PRODUCT", 55, 60], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 101, 107], ["DiscussionSARS-CoV", "GENE_OR_GENE_PRODUCT", 108, 126], ["ORF-6", "DNA", 55, 60], ["ORF", "DNA", 101, 104], ["CoV", "DNA", 123, 126], ["ORFs", "DNA", 168, 172], ["ORF", "TEST", 55, 58], ["induced apoptosis", "PROBLEM", 61, 78], ["putative proteins", "TEST", 138, 155], ["8 novel ORFs", "PROBLEM", 160, 172]]], ["Five of these, ORF-3a, ORF-3b, ORF-6, ORF-7a and ORF-8a, induce apoptosis when they are overexpressed in cells [18] [19] [20] 23, 29] .", [["cells", "ANATOMY", 105, 110], ["ORF-3a", "GENE_OR_GENE_PRODUCT", 15, 21], ["ORF-3b", "GENE_OR_GENE_PRODUCT", 23, 29], ["ORF-6", "GENE_OR_GENE_PRODUCT", 31, 36], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 38, 44], ["ORF-8a", "GENE_OR_GENE_PRODUCT", 49, 55], ["cells", "CELL", 105, 110], ["ORF", "DNA", 15, 18], ["ORF-3b", "DNA", 23, 29], ["ORF-6", "DNA", 31, 36], ["ORF-7a", "DNA", 38, 44], ["ORF-8a", "DNA", 49, 55], ["ORF", "TEST", 15, 18], ["ORF", "TEST", 23, 26], ["ORF", "TEST", 31, 34], ["ORF", "TEST", 38, 41], ["ORF", "TEST", 49, 52], ["apoptosis", "PROBLEM", 64, 73]]], ["However, the signaling pathway responsible for ORF-3a, ORF-3b, ORF-6 and ORF-7a induced apoptosis remains elusive.", [["ORF-3a", "GENE_OR_GENE_PRODUCT", 47, 53], ["ORF-3b", "GENE_OR_GENE_PRODUCT", 55, 61], ["ORF-6", "GENE_OR_GENE_PRODUCT", 63, 68], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 73, 79], ["ORF-3a, ORF-3b", "DNA", 47, 61], ["ORF-6", "DNA", 63, 68], ["ORF", "DNA", 73, 76], ["the signaling pathway", "TEST", 9, 30], ["ORF", "TEST", 47, 50], ["ORF", "TEST", 55, 58], ["ORF", "TEST", 63, 66], ["ORF", "TEST", 73, 76], ["apoptosis", "PROBLEM", 88, 97]]], ["It has been shown that in SARS-CoV-infected Vero E6 cells, JNK is phosphorylated and apoptosis was inhibited by both JNK and PI3K inhibitors [30] .", [["cells", "ANATOMY", 52, 57], ["SARS-CoV", "ORGANISM", 26, 34], ["Vero E6 cells", "CELL", 44, 57], ["JNK", "GENE_OR_GENE_PRODUCT", 59, 62], ["JNK", "GENE_OR_GENE_PRODUCT", 117, 120], ["PI3K", "GENE_OR_GENE_PRODUCT", 125, 129], ["SARS-CoV-infected Vero E6 cells", "CELL_LINE", 26, 57], ["JNK", "PROTEIN", 59, 62], ["JNK", "PROTEIN", 117, 120], ["PI3K", "PROTEIN", 125, 129], ["SARS-CoV", "SPECIES", 26, 34], ["Vero E6", "SPECIES", 44, 51], ["SARS", "PROBLEM", 26, 30], ["CoV", "TEST", 31, 34], ["infected Vero E6 cells", "PROBLEM", 35, 57], ["phosphorylated", "PROBLEM", 66, 80], ["apoptosis", "PROBLEM", 85, 94], ["PI3K inhibitors", "TEST", 125, 140], ["infected", "OBSERVATION_MODIFIER", 35, 43], ["Vero E6 cells", "OBSERVATION", 44, 57]]], ["We identified that JNK inhibitor inhibits both ORF-6and ORF-7a-induced apoptosis; therefore, we determined that ORF-6 and ORF-7a in SARS-CoV may be responsible for inducing phosphorylation of JNK, which leads to apoptosis.DiscussionER is an organelle that is responsible for protein synthesis; proteins are modified in the ER to form their proper tertiary structure and are then translocated to the outer cell membrane [31] .", [["ER", "ANATOMY", 323, 325], ["outer cell membrane", "ANATOMY", 399, 418], ["ORF-6and ORF-7a", "CHEMICAL", 47, 62], ["SARS", "DISEASE", 132, 136], ["JNK", "GENE_OR_GENE_PRODUCT", 19, 22], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 56, 62], ["ORF-6", "GENE_OR_GENE_PRODUCT", 112, 117], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 122, 128], ["SARS-CoV", "ORGANISM", 132, 140], ["JNK", "GENE_OR_GENE_PRODUCT", 192, 195], ["organelle", "CELLULAR_COMPONENT", 241, 250], ["ER", "GENE_OR_GENE_PRODUCT", 323, 325], ["outer cell membrane", "CELLULAR_COMPONENT", 399, 418], ["JNK", "PROTEIN", 19, 22], ["ORF-6and ORF-7a", "DNA", 47, 62], ["ORF-6", "DNA", 112, 117], ["ORF-7a", "DNA", 122, 128], ["JNK", "PROTEIN", 192, 195], ["DiscussionER", "PROTEIN", 222, 234], ["ER", "PROTEIN", 323, 325], ["SARS-CoV", "SPECIES", 132, 140], ["JNK inhibitor", "TEST", 19, 32], ["ORF", "TEST", 47, 50], ["ORF", "TEST", 56, 59], ["apoptosis", "PROBLEM", 71, 80], ["ORF", "TEST", 112, 115], ["ORF", "TEST", 122, 125], ["SARS", "PROBLEM", 132, 136], ["CoV", "PROBLEM", 137, 140], ["inducing phosphorylation of JNK", "PROBLEM", 164, 195], ["apoptosis", "PROBLEM", 212, 221], ["protein synthesis", "PROBLEM", 275, 292], ["tertiary structure", "OBSERVATION", 347, 365], ["outer", "ANATOMY_MODIFIER", 399, 404], ["cell membrane", "OBSERVATION", 405, 418]]], ["Particular proteins in an organelle require signals that retain the protein in the correct location.", [["organelle", "ANATOMY", 26, 35], ["organelle", "CELLULAR_COMPONENT", 26, 35], ["Particular proteins", "PROBLEM", 0, 19], ["protein", "OBSERVATION", 68, 75]]], ["A tetrapeptide sequence, Lys-Asp-Glu-Leu (KDEL), is a general sequence that has been identified for ER-resident proteins [32] ; however, evaluating the amino acid sequence of ORF-6 and ORF-7a, we found that neither of them do have KDEL sequences.", [["Lys-Asp-Glu-Leu", "CHEMICAL", 25, 40], ["amino acid", "CHEMICAL", 152, 162], ["tetrapeptide", "CHEMICAL", 2, 14], ["Lys-Asp-Glu-Leu", "CHEMICAL", 25, 40], ["amino acid", "CHEMICAL", 152, 162], ["Lys-Asp-Glu-Leu", "GENE_OR_GENE_PRODUCT", 25, 40], ["KDEL", "GENE_OR_GENE_PRODUCT", 42, 46], ["ER", "GENE_OR_GENE_PRODUCT", 100, 102], ["amino acid", "AMINO_ACID", 152, 162], ["ORF-6", "GENE_OR_GENE_PRODUCT", 175, 180], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 185, 191], ["KDEL", "GENE_OR_GENE_PRODUCT", 231, 235], ["KDEL", "PROTEIN", 42, 46], ["ER", "PROTEIN", 100, 102], ["resident proteins", "PROTEIN", 103, 120], ["amino acid sequence", "PROTEIN", 152, 171], ["ORF-6 and ORF-7a", "DNA", 175, 191], ["KDEL", "PROTEIN", 231, 235], ["A tetrapeptide sequence", "TEST", 0, 23], ["Lys-Asp", "TEST", 25, 32], ["a general sequence", "TEST", 52, 70], ["the amino acid sequence", "TEST", 148, 171], ["KDEL sequences", "TEST", 231, 245]]], ["It has been shown that ORF-7a C-terminal KRKTE is crucial for ER localization whereas ORF-6 C-terminal mutants are still localized in ER/Golgi membrane [27] .", [["ER", "ANATOMY", 62, 64], ["ER/Golgi membrane", "ANATOMY", 134, 151], ["C", "CHEMICAL", 92, 93], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 23, 29], ["KRKTE", "GENE_OR_GENE_PRODUCT", 41, 46], ["ER", "GENE_OR_GENE_PRODUCT", 62, 64], ["ORF-6", "GENE_OR_GENE_PRODUCT", 86, 91], ["ER", "GENE_OR_GENE_PRODUCT", 134, 136], ["Golgi membrane", "CELLULAR_COMPONENT", 137, 151], ["ORF", "DNA", 23, 26], ["KRKTE", "PROTEIN", 41, 46], ["ER", "PROTEIN", 62, 64], ["ORF-6 C-terminal mutants", "DNA", 86, 110], ["ER", "PROTEIN", 134, 136], ["ORF", "TEST", 23, 26], ["ER localization", "TEST", 62, 77], ["ORF", "TEST", 86, 89], ["terminal mutants", "PROBLEM", 94, 110]]], ["Further mapping is needed in order to determine which region is important for ORF-6 ER localization.DiscussionOne of the possible causes of ORF-6 inducing ER stress is that ORF-6 blocks STAT1 translocation to the nucleus and sequesters host nuclear import factor KPNA2 into rough ER/Golgi membrane.", [["nucleus", "ANATOMY", 213, 220], ["nuclear", "ANATOMY", 241, 248], ["ER/Golgi membrane", "ANATOMY", 280, 297], ["ORF-6", "GENE_OR_GENE_PRODUCT", 78, 83], ["ER", "GENE_OR_GENE_PRODUCT", 84, 86], ["ORF-6", "GENE_OR_GENE_PRODUCT", 140, 145], ["ER", "GENE_OR_GENE_PRODUCT", 155, 157], ["ORF-6", "GENE_OR_GENE_PRODUCT", 173, 178], ["STAT1", "GENE_OR_GENE_PRODUCT", 186, 191], ["nucleus", "CELLULAR_COMPONENT", 213, 220], ["KPNA2", "GENE_OR_GENE_PRODUCT", 263, 268], ["ER", "GENE_OR_GENE_PRODUCT", 280, 282], ["Golgi membrane", "CELLULAR_COMPONENT", 283, 297], ["ORF", "DNA", 78, 81], ["ER", "PROTEIN", 84, 86], ["ORF", "DNA", 140, 143], ["ER", "PROTEIN", 155, 157], ["ORF-6", "DNA", 173, 178], ["STAT1", "PROTEIN", 186, 191], ["nuclear import factor", "PROTEIN", 241, 262], ["KPNA2", "PROTEIN", 263, 268], ["ER", "PROTEIN", 280, 282], ["Further mapping", "TEST", 0, 15], ["ER localization", "TEST", 84, 99], ["ORF", "PROBLEM", 140, 143], ["ER stress", "PROBLEM", 155, 164], ["ORF", "PROBLEM", 173, 176], ["6 blocks STAT1 translocation", "PROBLEM", 177, 205], ["Golgi membrane", "OBSERVATION", 283, 297]]], ["This may cause the overloading of protein in the ER and affect its homeostasis of ER.", [["ER", "ANATOMY", 49, 51], ["ER", "ANATOMY", 82, 84], ["ER", "GENE_OR_GENE_PRODUCT", 49, 51], ["ER", "GENE_OR_GENE_PRODUCT", 82, 84], ["ER", "PROTEIN", 49, 51], ["ER", "PROTEIN", 82, 84], ["the overloading of protein", "PROBLEM", 15, 41], ["overloading", "OBSERVATION", 19, 30]]], ["However, it is still unclear whether Caspase-3 activation in ORF-6 and ORF-7a overexpressed cells is via Caspase-12 or not, as we failed to detect Caspase-12 cleavage products in Thapsigargin treated Vero E6 cells (positive control) and ORF-6 and ORF-7a transfected Vero E6 cells (data not shown).", [["cells", "ANATOMY", 92, 97], ["cells", "ANATOMY", 208, 213], ["Vero E6 cells", "ANATOMY", 266, 279], ["Thapsigargin", "CHEMICAL", 179, 191], ["Thapsigargin", "CHEMICAL", 179, 191], ["Caspase-3", "GENE_OR_GENE_PRODUCT", 37, 46], ["ORF-6", "GENE_OR_GENE_PRODUCT", 61, 66], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 71, 77], ["cells", "CELL", 92, 97], ["Caspase-12", "GENE_OR_GENE_PRODUCT", 105, 115], ["Caspase-12", "GENE_OR_GENE_PRODUCT", 147, 157], ["Thapsigargin", "SIMPLE_CHEMICAL", 179, 191], ["Vero E6 cells", "CELL", 200, 213], ["ORF-6", "GENE_OR_GENE_PRODUCT", 237, 242], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 247, 253], ["Vero E6 cells", "CELL", 266, 279], ["Caspase-3", "PROTEIN", 37, 46], ["ORF", "DNA", 61, 64], ["ORF", "DNA", 71, 74], ["Caspase-12", "PROTEIN", 105, 115], ["Caspase-12 cleavage products", "PROTEIN", 147, 175], ["Thapsigargin treated Vero E6 cells", "CELL_LINE", 179, 213], ["ORF", "DNA", 237, 240], ["ORF", "DNA", 247, 250], ["Vero E6 cells", "CELL_LINE", 266, 279], ["Vero E6", "SPECIES", 200, 207], ["Caspase", "TEST", 37, 44], ["ORF", "TEST", 61, 64], ["ORF", "TEST", 71, 74], ["Caspase", "TEST", 105, 112], ["Caspase", "TEST", 147, 154], ["cleavage products", "TREATMENT", 158, 175], ["Thapsigargin", "TREATMENT", 179, 191], ["Vero E6 cells", "TREATMENT", 200, 213], ["ORF", "TEST", 237, 240], ["ORF", "TEST", 247, 250], ["Vero E6 cells", "TEST", 266, 279], ["E6 cells", "OBSERVATION", 271, 279]]], ["Also, ER stress can activate JNK through IRE1, TRAF2 and ASK1 pathways.", [["ER", "GENE_OR_GENE_PRODUCT", 6, 8], ["JNK", "GENE_OR_GENE_PRODUCT", 29, 32], ["IRE1", "GENE_OR_GENE_PRODUCT", 41, 45], ["TRAF2", "GENE_OR_GENE_PRODUCT", 47, 52], ["ASK1", "GENE_OR_GENE_PRODUCT", 57, 61], ["ER", "PROTEIN", 6, 8], ["JNK", "PROTEIN", 29, 32], ["IRE1", "PROTEIN", 41, 45], ["TRAF2", "PROTEIN", 47, 52], ["ASK1", "PROTEIN", 57, 61], ["IRE1", "TEST", 41, 45]]], ["Since both ORF-6 and ORF-7a are ERlocalized proteins, we hypothesized that ER stress induced by these two proteins will lead to Caspase-3 and JNK activation.DiscussionActivation of effector Caspases, Caspases-3, -6 and -7, causes apoptosis as they cleave a variety of proteins.", [["ORF-6", "GENE_OR_GENE_PRODUCT", 11, 16], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 21, 27], ["ERlocalized", "GENE_OR_GENE_PRODUCT", 32, 43], ["ER", "GENE_OR_GENE_PRODUCT", 75, 77], ["Caspase-3", "GENE_OR_GENE_PRODUCT", 128, 137], ["JNK", "GENE_OR_GENE_PRODUCT", 142, 145], ["Caspases", "GENE_OR_GENE_PRODUCT", 190, 198], ["Caspases-3", "GENE_OR_GENE_PRODUCT", 200, 210], ["-6", "GENE_OR_GENE_PRODUCT", 212, 214], ["-7", "GENE_OR_GENE_PRODUCT", 219, 221], ["ORF-6", "DNA", 11, 16], ["ORF-7a", "DNA", 21, 27], ["ERlocalized proteins", "PROTEIN", 32, 52], ["ER", "PROTEIN", 75, 77], ["Caspase-3", "PROTEIN", 128, 137], ["JNK", "PROTEIN", 142, 145], ["effector Caspases", "PROTEIN", 181, 198], ["Caspases-3, -6 and -7", "PROTEIN", 200, 221], ["ORF", "TEST", 11, 14], ["ER stress", "PROBLEM", 75, 84], ["these two proteins", "PROBLEM", 96, 114], ["Caspase", "TEST", 128, 135], ["JNK activation", "PROBLEM", 142, 156], ["effector Caspases", "TREATMENT", 181, 198], ["Caspases", "TEST", 200, 208], ["apoptosis", "PROBLEM", 230, 239]]], ["To date, over 200 Caspase substrates have been discovered [33] .", [["Caspase", "GENE_OR_GENE_PRODUCT", 18, 25]]], ["Caspase activation for the treatment of insufficient apoptosis, such as in cancer, is challenging whereas Caspase inhibition for the treatment of excessive apoptosis, such as in neurodegeneration, appears to be easier with the use of classical small-molecule inhibitors.", [["cancer", "ANATOMY", 75, 81], ["cancer", "DISEASE", 75, 81], ["neurodegeneration", "DISEASE", 178, 195], ["Caspase", "GENE_OR_GENE_PRODUCT", 0, 7], ["cancer", "CANCER", 75, 81], ["Caspase", "GENE_OR_GENE_PRODUCT", 106, 113], ["Caspase", "PROTEIN", 0, 7], ["Caspase", "PROTEIN", 106, 113], ["Caspase activation", "TREATMENT", 0, 18], ["insufficient apoptosis", "PROBLEM", 40, 62], ["Caspase inhibition", "TREATMENT", 106, 124], ["excessive apoptosis", "PROBLEM", 146, 165], ["neurodegeneration", "PROBLEM", 178, 195], ["classical small-molecule inhibitors", "TREATMENT", 234, 269], ["insufficient", "OBSERVATION_MODIFIER", 40, 52], ["apoptosis", "OBSERVATION", 53, 62], ["cancer", "OBSERVATION", 75, 81], ["excessive", "OBSERVATION_MODIFIER", 146, 155], ["apoptosis", "OBSERVATION", 156, 165]]], ["Preliminary experiments in animal models using non-selective Caspase inhibitors such as z-VAD (OMe)-CH 2 F have shown in vivo efficacy in ischemic and hypoxic brain injury, traumatic and excitotoxic brain damage.", [["brain", "ANATOMY", 159, 164], ["brain", "ANATOMY", 199, 204], ["z-VAD", "CHEMICAL", 88, 93], ["OMe", "CHEMICAL", 95, 98], ["ischemic and hypoxic brain injury", "DISEASE", 138, 171], ["traumatic", "DISEASE", 173, 182], ["brain damage", "DISEASE", 199, 211], ["z-VAD", "CHEMICAL", 88, 93], ["CH 2 F", "CHEMICAL", 100, 106], ["Caspase", "GENE_OR_GENE_PRODUCT", 61, 68], ["z-VAD", "SIMPLE_CHEMICAL", 88, 93], ["OMe)-CH 2 F", "SIMPLE_CHEMICAL", 95, 106], ["brain", "ORGAN", 159, 164], ["brain", "ORGAN", 199, 204], ["non-selective Caspase inhibitors", "TREATMENT", 47, 79], ["z-VAD (OMe)", "TREATMENT", 88, 99], ["ischemic", "PROBLEM", 138, 146], ["hypoxic brain injury", "PROBLEM", 151, 171], ["traumatic", "PROBLEM", 173, 182], ["excitotoxic brain damage", "PROBLEM", 187, 211], ["ischemic", "OBSERVATION", 138, 146], ["hypoxic brain injury", "OBSERVATION", 151, 171], ["excitotoxic brain damage", "OBSERVATION", 187, 211]]], ["The same approach may be applied to SARS-infected cells to identify for therapy [34] [35] [36] as two SARS proteins, ORF-6 and ORF-7a, seem to activate proapoptotic pathways via the Caspase-3 dependent pathway.DiscussionSARS is an infectious disease that is transmissible and fatal.", [["cells", "ANATOMY", 50, 55], ["SARS-infected", "DISEASE", 36, 49], ["infectious disease", "DISEASE", 231, 249], ["cells", "CELL", 50, 55], ["[34] [35] [36]", "SIMPLE_CHEMICAL", 80, 94], ["ORF-6", "GENE_OR_GENE_PRODUCT", 117, 122], ["ORF-7a", "GENE_OR_GENE_PRODUCT", 127, 133], ["Caspase-3", "GENE_OR_GENE_PRODUCT", 182, 191], ["SARS-infected cells", "CELL_TYPE", 36, 55], ["SARS proteins", "PROTEIN", 102, 115], ["ORF-6 and ORF-7a", "DNA", 117, 133], ["Caspase-3", "PROTEIN", 182, 191], ["The same approach", "TREATMENT", 0, 17], ["SARS", "PROBLEM", 36, 40], ["infected cells", "PROBLEM", 41, 55], ["therapy", "TREATMENT", 72, 79], ["two SARS proteins", "TEST", 98, 115], ["ORF", "TEST", 117, 120], ["the Caspase", "TREATMENT", 178, 189], ["an infectious disease", "PROBLEM", 228, 249], ["infectious", "OBSERVATION", 231, 241]]], ["SARS-CoV is a previously unknown coronavirus.", [["SARS", "DISEASE", 0, 4], ["coronavirus", "DISEASE", 33, 44], ["SARS-CoV", "ORGANISM", 0, 8], ["coronavirus", "ORGANISM", 33, 44], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["a previously unknown coronavirus", "PROBLEM", 12, 44]]], ["To date, there is no drug specifically targeting the control of SARS-CoV.", [["SARS", "DISEASE", 64, 68], ["SARS-CoV", "ORGANISM", 64, 72], ["SARS-CoV", "SPECIES", 64, 72], ["no", "UNCERTAINTY", 18, 20]]], ["The exact mechanism whereby SARS proteins induce apoptosis must be identified in order to begin to develop SARS targeted drugs.", [["SARS", "DISEASE", 28, 32], ["SARS", "DISEASE", 107, 111], ["SARS proteins", "PROTEIN", 28, 41], ["SARS proteins", "PROBLEM", 28, 41], ["apoptosis", "PROBLEM", 49, 58], ["SARS targeted drugs", "TREATMENT", 107, 126]]]], "a8290b10160619efec2c44fcdec582b8d37abc3e": [["IntroductionApple and Google have adopted a decentralized approach to mobile contact tracing that prioritizes individual privacy [1] .", [["a decentralized approach", "TREATMENT", 42, 66]]], ["Under the Apple-Google Exposure Notification (AGEN) protocol (see Fig. 1 ), individual phones determine if the user has been exposed, without revealing the identity of the infected individual and where the contact event took place The AGEN protocol is related to contemporaneously proposed protocols including PACT and DP-3t [2, 3] .", [["DP-3t", "CHEMICAL", 319, 324], ["PACT", "PROTEIN", 310, 314], ["The AGEN protocol", "TREATMENT", 231, 248], ["DP", "TEST", 319, 321]]], ["Like these other protocols, the AGEN protocol does not use location information.", [["the AGEN protocol", "TREATMENT", 28, 45]]], ["With these goals in mind, governments advocate for a centralized approach, whether national or regional, where they maintain records of each persons locations and interactions.", [["a centralized approach", "TREATMENT", 51, 73]]], ["This allows governments to determine exposures and notify people directly, as timeliness reduces spread.", [["people", "ORGANISM", 58, 64], ["people", "SPECIES", 58, 64]]], ["While centralized contact tracing may offer utility critical to re-opening the worlds economy, it raises profound concerns for civil liberties and personal privacy.", [["centralized contact tracing", "TEST", 6, 33]]], ["Government efforts that avoid reliance on the industrial Exposure Notification offerings have run into a host of failings, including reliability, power drain, interoperability, and participation.IntroductionApple and Google have taken an unprecedented position -essentially dictating public policy, not just by requiring the decentralized approach, but also by prohibiting contact tracing apps from collecting location information.", [["power drain", "TREATMENT", 146, 157], ["the decentralized approach", "TREATMENT", 321, 347]]], ["Meanwhile, governments contact tracing apps have failed due to restrictions imposed by AGEN.How Contact Tracing WorksIn this article, we present two simple measures that enable the AGEN protocol to support manual contact tracing efforts, provide visibility into the spread of disease, and return authority to local communities all while preserving privacy within the Apple and Google framework.How Contact Tracing Works1.", [["AGEN", "PROTEIN", 87, 91], ["the AGEN protocol", "TREATMENT", 177, 194], ["manual contact tracing", "TEST", 206, 228], ["disease", "PROBLEM", 276, 283]]], ["Treat places as people.", [["people", "ORGANISM", 16, 22], ["people", "SPECIES", 16, 22]]], ["Endow public places with the same privacy-preserving technology we used to monitor exposure for individuals.How Contact Tracing Works2.", [["individuals", "PROBLEM", 96, 107]]], ["Nation-scale data, not apps and processes.", [["Nation-scale data", "TEST", 0, 17]]], ["Build a common backend for the AGEN protocol that spans apps and governmental boundaries.How Contact Tracing WorksIn the rest of this article, we describe these two simple measures and how they both improve contact tracing while also preserving individual privacy.Lighthouse: Treat Places as PeopleIf we treat public places as people, we can use the AGEN protocol to (a) understand COVID-19 exposures across space, (b) integrate with manual contact tracing, and (c) do so with the same privacy-sensitive protocol.", [["People", "ORGANISM", 292, 298], ["people", "ORGANISM", 327, 333], ["People", "SPECIES", 292, 298], ["people", "SPECIES", 327, 333], ["the AGEN protocol", "TREATMENT", 27, 44], ["the AGEN protocol", "TREATMENT", 346, 363], ["COVID", "TEST", 382, 387], ["manual contact tracing", "TEST", 434, 456]]], ["To treat places as people in AGEN, simply attach mobile phones or specialized low-cost beacons to publicly accessible places (e.g., county services, stores, buses).", [["people", "ORGANISM", 19, 25], ["people", "SPECIES", 19, 25]]], ["Like a lighthouse, these devices help communicate risk associated with places.", [["these devices", "TREATMENT", 19, 32]]], ["Well-positioned, they can offer robust proximity detection, can detect their exposure, and the can convey aspects the risk that represents.Lighthouse: Treat Places as PeopleBy choosing to share their locally computed exposure risk with public health authorities through the AGEN protocol, owners of publicly-accessible places can aid in mitigating virus spread.", [["the AGEN protocol", "TREATMENT", 270, 287], ["mitigating virus spread", "PROBLEM", 337, 360], ["virus spread", "OBSERVATION", 348, 360]]], ["Alternatively, if a place is identified through traditional, manual contact tracing, the place can still anonymously participate in the AGEN protocol, notifying others without revealing where they were exposed.", [["manual contact tracing", "TEST", 61, 83], ["the AGEN protocol", "TEST", 132, 149]]], ["Treating places as people empowers stewards of public spaces to collaborate with public health authorities to help mitigate the spread of disease without jeopardizing the privacy of patrons or the reputation of the public spaces.", [["people", "ORGANISM", 19, 25], ["people", "SPECIES", 19, 25], ["disease", "PROBLEM", 138, 145], ["public spaces", "ANATOMY", 215, 228]]], ["This procedure can facilitate detection of exposure from a non-participating individual while improving anonymity over manual contactCOVID Commons: A Nation-scale Data BackendRather than one app per nation, a better solution would be to provide a common privacy-preserving data exchange across apps and administrative boundaries a Commons.", [["This procedure", "TREATMENT", 0, 14]]], ["It is very likely that participation will be greatest if the apps are available through local organizations (e.g., tribal organization, university campus) that individuals trust.", [["very likely", "UNCERTAINTY", 6, 17]]], ["A common privacy-preserving data exchange is already compatible with the AGEN protocol.", [["the AGEN protocol", "TEST", 69, 86]]], ["When an individual tests positive and they engage in a conventional contact tracing interview with a public health professional, the professional obtains an authorization so the individual, on an opt-in basis, can share their anonymous exposure information.", [["an individual tests", "TEST", 5, 24]]], ["Public health professionals serve to protect the integrity of the information in the Commons without exposing any patient data or medical data.COVID Commons: A Nation-scale Data BackendTheir actions are quite similar to publishing counts of cases, statistics and demographic information, as is done today.", [["patient", "ORGANISM", 114, 121], ["patient", "SPECIES", 114, 121], ["medical data", "TEST", 130, 142]]], ["We have organized each section to be relatively self-contained.Background on Privacy-Sensitive Mobile Contact TracingThe key building block for Privacy-Sensitive Mobile Contact Tracing (PS-MCT) is a subtle combination of radio protocols, cryptography, and risk-calculation.", [["Privacy", "TEST", 144, 151], ["radio protocols", "TREATMENT", 221, 236], ["cryptography", "TEST", 238, 250]]], ["The PS-MCT protocols leverages this short-range background broadcast to resolve nearby individuals.Background on Privacy-Sensitive Mobile Contact TracingIn the Apple-Google Exposure Notification (AGEN) protocol, each phone generates a daily secret key called a Temporary Exposure Key (TEK).", [["The PS", "TEST", 0, 6]]], ["The RPI sequence is generated using a crytographic hash function and it therefore caries no information about the source individual.", [["RPI sequence", "DNA", 4, 16], ["The RPI sequence", "TEST", 0, 16]]], ["The current RPI is then continuously broadcast every few hundered milliseconds.", [["RPI", "PROTEIN", 12, 15]]], ["All phones log the RPIs they hear for future exposure analysis.", [["future exposure analysis", "TEST", 38, 62]]], ["Because the RPI is continuously changing, it also cannot be easily tracked.Background on Privacy-Sensitive Mobile Contact TracingWhen someone tests positive they can anonymously publish the daily keys (TEKs) from the days when they were contagious.", [["RPI", "PROTEIN", 12, 15], ["someone tests", "TEST", 134, 147]]], ["The confirmed positive collection of TEKs is called a Diagnosis Key in the AGEN protocol.", [["TEKs", "DISEASE", 37, 41], ["TEKs", "CANCER", 37, 41], ["the AGEN protocol", "TREATMENT", 71, 88], ["positive", "OBSERVATION_MODIFIER", 14, 22], ["collection", "OBSERVATION", 23, 33]]], ["The Diagnois Keys are published by sharing them with a trusted and server whcich publishes the TEKs for download.", [["TEKs", "DNA", 95, 99]]], ["Others can obtain these keys and use the same cryptographic hash functions to recreate the sequence of RPIs and determine if they encountered any infected individuals.", [["RPIs", "CANCER", 103, 107], ["the sequence of RPIs", "TEST", 87, 107], ["any infected individuals", "PROBLEM", 142, 166]]], ["The AGEN protocol (and the extensions proposed in this paper) provide a mechanism to detect and notify users about exposure risk, but it is up to public health authorities to define what constitutes an exposure.", [["The AGEN protocol", "TREATMENT", 0, 17]]], ["Of course, manual contact tracing does not have this issue and remains the gold standard.", [["manual contact tracing", "TEST", 11, 33]]], ["Finally, bluetooth contact detection is limited in range and time; it cannot detect many important forms of transmission like surfaces or HVAC systems [5] .Treating Places as PeopleThere is a simple extension to mobile contact tracing that can help address these issues.", [["bluetooth contact detection", "TEST", 9, 36], ["HVAC systems", "PROBLEM", 138, 150]]], ["It is this second form of beacon, the lighthouse, that is needed to address several of the key limitations in privacy-sensitive mobile contact tracing.What is an Exposure Notification Lighthouse?A privacy-sensitive exposure notification lighthouse is a device (e.g., a mobile phone or even a smart sticker) deployed in a public space following the same privacy sensitive mechanisms as individuals.", [["a smart sticker)", "TREATMENT", 290, 306]]], ["Much like the maritime lighthouse, contact tracing lighthouses can be used to inform others of potential exposures associated with public spaces discovered through manual contact tracing.", [["manual contact tracing", "TEST", 164, 186]]], ["A contact tracing lighthouse can also log passing beacons to inform owners and public health authorities of exposure risks.", [["A contact tracing", "TEST", 0, 17]]], ["Moreover, by installing contact tracing lighthouses in participating public spaces ranging from stores and restaurants to schools and buses, we introduce a privacy sensitive mechanism to bridge manual contact tracing with mobile contact tracing while also giving public health authorities the ability to gain visibility into the spread of disease while preserving individual privacy.What is an Exposure Notification Lighthouse?(a) Existing Devices: Easily deployed immediately but expensive to deploy to new places.", [["disease", "PROBLEM", 339, 346]]], ["They can also be unreliable when unattended. wikimedia commons Travelarz CC-ASA 3.0 (b) Dedicated Devices: Cheap and reliable.", [["CC", "CHEMICAL", 73, 75], ["ASA", "TREATMENT", 76, 79], ["Cheap", "TREATMENT", 107, 112]]], ["They will require new development and can be tricky to place correctly.42ABC17(c) No Device: Allows those without the app or even a mobile device to participate.", [["a mobile device", "TREATMENT", 130, 145]]], ["Let's explore some of these benefits in more detail.Bridging Place and MobileThe contact tracing lighthouse empowers stewards of public spaces (e.g., shop owners, school administrators) to collaborate with public health authorities to help mitigate the spread of disease without jeopardizing the privacy of patrons or the reputation of the public spaces.", [["The contact tracing", "TEST", 77, 96], ["disease", "PROBLEM", 263, 270], ["Mobile", "OBSERVATION_MODIFIER", 71, 77], ["public spaces", "ANATOMY", 340, 353]]], ["A place, unlike an individual, has a large set of explicit relationships with its institutional environment -business license, health department approvals, chamber of commerce, etc. The interview process routinely seeks to gather information about places.", [["large", "OBSERVATION_MODIFIER", 37, 42]]], ["With its lighthouse, it has a very simple way to provide assistance without undue impact on its reputation.", [["undue impact", "PROBLEM", 76, 88]]], ["Just like a person, it can check its own potential exposures.", [["person", "SPECIES", 12, 18]]], ["And, like a person, it can anonymously publish its own random numbers as COVID positive so that people can use them for detecting their exposure risk.", [["people", "ORGANISM", 96, 102], ["person", "SPECIES", 12, 18], ["people", "SPECIES", 96, 102]]], ["Unlike a persons phone, stationary lighthouses can be carefully positioned to avoid issues like weak or unreliable broadcast that mobile phones can face.", [["persons", "SPECIES", 9, 16]]], ["Finally, the public place may also take other measures in assisting its local health authority in detecting hot spots, such as informing them of the exposure risk that it observes.Indirect TransmissionThe lighthouse can be used to address forms of indirect transmission that are not captured in the existing privacysensitive mobile contact tracing efforts.", [["hot spots", "PROBLEM", 108, 117]]], ["If a COVID-positive individual enters a bus and touches or sneezes on several surfaces they could potentially infect others over the next several hours, long after they have left the bus.", [["COVID", "GENE_OR_GENE_PRODUCT", 5, 10], ["COVID", "PROTEIN", 5, 10], ["a COVID", "TEST", 3, 10], ["left", "ANATOMY_MODIFIER", 174, 178]]], ["Air conditioning systems have also been implicated in spreading the virus over large distances [5] .", [["Air conditioning systems", "PROBLEM", 0, 24]]], ["Existing wireless protocols will fail to capture these forms of transmission since they rely on close, contemporaneous radio proximity with the positive individual.", [["Existing wireless protocols", "TREATMENT", 0, 27]]], ["Simple lighthouse codes might be included on printed receipts or handed to customers so that a person without contact tracing on their phone might use such code they have received to privately check for exposure on public websites somewhat like they would if they used such an app.Lighthouse PrivacyThere are legitimate privacy interests for places, as there are for people.", [["people", "ORGANISM", 367, 373], ["person", "SPECIES", 95, 101], ["people", "SPECIES", 367, 373]]], ["Businesses may fear irrational boycotts or loss of reputation, and there are risks of perpetuating prejudice or stigma against neighborhoods or ethnic groups (already a growing problem [6] ).", [["loss of reputation", "DISEASE", 43, 61]]], ["The good news is that lighthouses inherit the privacy protecting characteristics of the AGEN protocol.", [["the AGEN protocol", "TREATMENT", 84, 101], ["good", "OBSERVATION_MODIFIER", 4, 8]]], ["In their simplest form, they are phones running ordinary apps, different only because they live in a fixed place rather than in purse or pocket.Lighthouse PrivacyLighthouses can complement manual contact tracing by offering greater confidentiality in situations where people cross paths in stigmatized locations.", [["people", "ORGANISM", 268, 274], ["people", "SPECIES", 268, 274], ["manual contact tracing", "TEST", 189, 211]]], ["Lighthouses can fill such gaps without requiring or relying on anyone, even an affected person, to disclose their location history.Lighthouse PrivacyA potential concern about lighthouses is that internal state, if combined and aggregated, could be used to undermine some of the privacy guarantees of AGEN.", [["AGEN", "GENE_OR_GENE_PRODUCT", 300, 304], ["AGEN", "PROTEIN", 300, 304], ["person", "SPECIES", 88, 94]]], ["Indeed, with a sufficiently large deployment of lighthouses and centralized collection of recieved RPIs, it would be possible to resolve the locations of all the COVID positive individuals.", [["a sufficiently large deployment of lighthouses", "PROBLEM", 13, 59], ["RPIs", "TREATMENT", 99, 103], ["large", "OBSERVATION_MODIFIER", 28, 33], ["deployment", "OBSERVATION", 34, 44], ["centralized", "OBSERVATION_MODIFIER", 64, 75], ["collection", "OBSERVATION_MODIFIER", 76, 86]]], ["We therefore stress that each lighthouse must follow the existing decentralized protocol for risk assessment in which only risk is aggregated and not the underlying RPIs.Lighthouse PrivacyTo address some of these security concerns, it is possible to deploy transmit only (passive) lighthouses which could be used to anonymously notify others of exposure without listening for RPIs.", [["RPIs", "CANCER", 165, 169], ["risk assessment", "TEST", 93, 108], ["the underlying RPIs", "PROBLEM", 150, 169], ["RPIs", "TEST", 376, 380]]], ["This eliminates the risk of resolving COVID positive individuals locations but also limits visibility into where the disease is spreading.Covid Commons: Unified Contact Tracing With Many AppsStandardizing on an exposure notification protocol such as AGEN is crucial to achieving the critical mass of participation required to make such an approach effective (estimated to be at least 80% for a city of 1 million individuals [8] ) and privacy preserving.", [["resolving COVID positive individuals locations", "PROBLEM", 28, 74], ["the disease", "PROBLEM", 113, 124], ["an exposure notification protocol", "TREATMENT", 208, 241], ["resolving", "OBSERVATION_MODIFIER", 28, 37], ["positive", "OBSERVATION_MODIFIER", 44, 52], ["individuals", "OBSERVATION", 53, 64], ["disease", "OBSERVATION", 117, 124], ["spreading", "OBSERVATION_MODIFIER", 128, 137], ["mass", "OBSERVATION", 292, 296]]], ["Apple and Google, as producers of the two dominant smartphone OSes, are uniquely positioned to bring these capabilities to nearly every smartphone and have engineered the AGEN protocol to that end.", [["the AGEN protocol", "TREATMENT", 167, 184]]], ["Providing an implementation of the protocol through an OS upgrade would eliminate the fragmentation of the protocol preventing sufficient adoption.", [["the protocol", "TREATMENT", 31, 43], ["an OS upgrade", "TREATMENT", 52, 65], ["the protocol", "TREATMENT", 103, 115]]], ["However, the public health authorities responsible for testing and tracing often operate at a more local level [10, 11] .Covid Commons: Unified Contact Tracing With Many AppsThe fundamental issue with this policy is a failure to distinguish between ownership of the required repository of \"diagnosis keys\" and the applications that produce and utilize them.", [["testing", "TEST", 55, 62], ["tracing", "TEST", 67, 74], ["a failure", "PROBLEM", 216, 225]]], ["The repository contains keys that correspond to times when diagnosed individuals may have interacted with others and must therefore be publicfacing so that individuals, via AGEN-compatible apps, can download the keys and determine their own exposure risk.", [["individuals", "ORGANISM", 69, 80]]], ["The keys uploaded to the repository must be limited to those that have been authorized by a public health authority through some testing and interview process.", [["some testing", "TEST", 124, 136]]], ["In the U.S., public health measures such as contact tracing and case reporting are carried out at a county or city level through individually executed processes, in coordination with state and national law and policy.", [["contact tracing", "TEST", 44, 59]]], ["However, health authorities do not generally have the technical, human or financial resources to produce the required app and also stand up and maintain such a public-facing data service.", [["human", "ORGANISM", 65, 70], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 65, 70]]], ["This is even less tenable during a pandemic, when such resources are already strained.", [["less tenable", "OBSERVATION_MODIFIER", 13, 25]]], ["Indeed, there are already efforts to combine contact tracing efforts and data across the administrative boundaries established by industry's policy around AGEN [12] .A Path to Nation-scale DataA solution to this issue is the creation of a privacy-preserving data exchange shared and accessible across apps and administrative boundaries -a Commons.", [["Nation-scale DataA solution", "TREATMENT", 176, 203], ["a privacy", "TREATMENT", 237, 246]]], ["The Commons may be hosted and maintained by governmental authorities, foundations or other appropriate institutional entities.A Path to Nation-scale DataThe Commons requires no change to the EN protocols.", [["the EN protocols", "TREATMENT", 187, 203]]], ["Each individual participates in the proximity detection using daily TEKs and the RPIs generated from them without change.", [["daily TEKs", "TREATMENT", 62, 72]]], ["Just as in the current decentralized protocol, an individual who tests positive -i.e. a confirmed case -and participates in contact tracing with a specific public health authority is asked to voluntarily submit their TEKs for the past period over which they are likely to have been contagious.", [["an individual who tests", "TEST", 47, 70]]], ["The AGEN protocol does not stipulate how that request is formulated or how that submission is performed, but the introduction of the Commons allows us to answer that question precisely.The PHA Experience: Federating Access to the CommonsA Commons is utilized by a well-defined set of public health authorities that are registered with it.", [["PHA", "PROTEIN", 189, 192], ["The AGEN protocol", "TREATMENT", 0, 17]]], ["As part of requesting a patient to submit their diagnosis keys to the Commons, the professional requests a one-time authorization (OTA) from the Commons.", [["patient", "ORGANISM", 24, 31], ["patient", "SPECIES", 24, 31]]], ["The OTA authorizes the upload of TEKs corresponding to the extent of time during which the patient is likely to have been contagious; this will involve some days prior to the diagnosis and extend to several days or weeks following.", [["OTA", "DISEASE", 4, 7], ["TEKs", "GENE_OR_GENE_PRODUCT", 33, 37], ["patient", "ORGANISM", 91, 98], ["patient", "SPECIES", 91, 98], ["contagious", "OBSERVATION", 122, 132]]], ["The OTA is provided to the patient to authorize the submission of their keys to the Commons; the upload is opt-in, as under the usual AGEN protocol.The PHA Experience: Federating Access to the CommonsBecause the OTA corresponds to a single interaction between a healthcare professional and a patient, it is a natural key on which helpful metadata can be associated.", [["OTA", "CHEMICAL", 4, 7], ["OTA", "DISEASE", 212, 215], ["patient", "ORGANISM", 27, 34], ["patient", "ORGANISM", 292, 299], ["PHA", "PROTEIN", 152, 155], ["patient", "SPECIES", 27, 34], ["patient", "SPECIES", 292, 299]]], ["The authorizing PHA may want their identity to be associated with the submitted diagnosis keys so that the provenance of the diagnosis is preserved.", [["PHA", "CELL", 16, 19], ["PHA", "PROTEIN", 16, 19], ["preserved", "OBSERVATION", 138, 147]]], ["This identity, realized by the TLS public key of the PHA, can be associated with generated OTAs in the Commons.", [["PHA", "PROTEIN", 53, 56]]], ["This provides no more information than having each PHA host their own exposure key store, as currently envisioned.", [["PHA", "CHEMICAL", 51, 54], ["PHA", "PROTEIN", 51, 54]]], ["As we will discuss below, the PHA identity can also be used to filter which diagnosis keys are considered in the matching process on an individual's phone.The PHA Experience: Federating Access to the CommonsThe OTA itself is also a useful piece of metadata when associated with the uploaded keys in the Commons.", [["PHA", "PROTEIN", 30, 33], ["PHA", "PROTEIN", 159, 162]]], ["The authorizing professional will likely want to be able to determine whether the patient has in fact contributed their keys as requested to determine if follow-up is necessary.", [["patient", "ORGANISM", 82, 89], ["patient", "SPECIES", 82, 89]]], ["Associating the OTA with the uploaded keys places no new information in the Commons: the professional knows what they know about those they interview and they know what authorizations they have requested.", [["OTA", "DISEASE", 16, 19], ["new", "OBSERVATION_MODIFIER", 53, 56]]], ["Each such confirmed case can be expected to have generated some authorization request, but that information, along with all other aspects of the contact tracing process, is under the purview of the PHA.", [["PHA", "CHEMICAL", 198, 201], ["PHA", "SIMPLE_CHEMICAL", 198, 201], ["PHA", "PROTEIN", 198, 201]]], ["Counts of confirmed cases and other aggregate information are already regularly reported to the public.The PHA Experience: Federating Access to the CommonsThe Commons is able to provide this functionality despite no patient data -indeed, no health or medical data of any kind -ever being entered into the Commons.", [["patient", "ORGANISM", 216, 223], ["PHA", "PROTEIN", 107, 110], ["patient", "SPECIES", 216, 223], ["patient data", "TEST", 216, 228]]], ["The Commons also takes no position on which parts of the contact tracing process are automated and which are manual.", [["no", "UNCERTAINTY", 23, 25], ["position", "OBSERVATION_MODIFIER", 26, 34]]], ["It integrates cleanly with the existing processes established by PHAs for interviewing patients, deciding which diagnosis keys are appropiate to share, and so on.", [["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95]]], ["The Commons merely provides a means of carrying out the result of these decisions in a way that does not require individuals to be using the same phone app.The User Experience: Federating Downloads from the CommonsThe current draft of the AGEN protocol says very little about how exposure notification information will be transmitted or relayed among the different instances of the diagnosis key repository.", [["the AGEN protocol", "TREATMENT", 235, 252]]], ["A unified Commons immediately addresses this issue -all diagnosis keys are uploaded and downloaded from the shared repository.The User Experience: Federating Downloads from the CommonsHowever, under a federated regime, it is necessary to address how exposure notification and uploaded keys can be routed across instances of the Commons.The User Experience: Federating Downloads from the CommonsConsider a scenario where an individual is diagnosed by one PHA but may travel or may have traveled to regions covered by different PHAs.", [["PHA", "CHEMICAL", 454, 457], ["PHA", "PROTEIN", 454, 457], ["Federating Downloads", "TREATMENT", 147, 167], ["Federating Downloads", "TREATMENT", 357, 377]]], ["Individuals in those other regions should be able to obtain the TEKs for the diagnosed individual, even though the diagnosis was performed by a remote PHA.", [["PHA", "CHEMICAL", 151, 154], ["TEKs", "CANCER", 64, 68], ["PHA", "PROTEIN", 151, 154], ["a remote PHA", "PROBLEM", 142, 154]]], ["A PHA professional can \"tag\" a requested OTA with public keys or other metadata identifying relevant remote PHAs, using information acquired as part of the interaction with the individual.", [["PHA", "PROTEIN", 2, 5], ["public keys", "TREATMENT", 50, 61]]], ["The process of uploading diagnosis keys authorized by that OTA to the Commons can then incorporate a simple forwarding mechanism that replicates those keys to the federated instances of the Commons managed by those other PHAs.", [["a simple forwarding mechanism", "PROBLEM", 99, 128]]], ["Additionally, an individual may subscribe to Commons for surrounding regions.The User Experience: Federating Downloads from the CommonsRegardless of whether the Commons is realized as an administratively centralized server or a federated mesh, the Commons must provide some mechanism for filtering or scoping the download of diagnosis keys onto an individual's device.", [["Federating Downloads", "TREATMENT", 98, 118], ["a federated mesh", "TREATMENT", 226, 242], ["an individual's device", "TREATMENT", 345, 367], ["mesh", "OBSERVATION", 238, 242]]], ["The number of keys downloaded from the Commons will grow with the adoption of AGENbased apps, improvements in testing, and the spread of COVID-19.", [["COVID-19", "CHEMICAL", 137, 145], ["testing", "TEST", 110, 117], ["COVID", "TEST", 137, 142]]], ["Without the ability to filter the set of keys down to a reasonable and relevant set that is still large enough to maintain the privacy-preserving properties of AGEN, the bandwidth requirements and compute requirements (for deriving the thousands of RPIs used for the matching process) may grow to be untenable.Extending the CommonsOnce this basic separation of key repository has been established, along with the method for authorizing submissions and routing them to queries, it becomes possible to meaningfully entertain the question of including earlier stages.", [["AGEN", "PROTEIN", 160, 164], ["RPIs", "PROTEIN", 249, 253], ["the bandwidth requirements", "TREATMENT", 166, 192], ["RPIs", "TREATMENT", 249, 253]]], ["Especially with testing being scarce, confirmation occurs late and involves the contact tracing processes of public health authorities.", [["testing", "TEST", 16, 23]]], ["Associated with each stage is a process, an (increasingly large) set of principals who might authorize a submission, and a reduced significance in conveying exposure.", [["a process", "PROBLEM", 30, 39], ["large", "OBSERVATION_MODIFIER", 58, 63]]], ["The privacy-sensitive protocol could access these, as well as the Confirmed Keys referred to as Diagnosis Keys in the EN protocol.", [["The privacy-sensitive protocol", "TREATMENT", 0, 30]]], ["The protocol permits the distinction to be reflected in metadata carried along with the keys.", [["The protocol", "TREATMENT", 0, 12]]], ["Thus they might factor in, perhaps with lesser weight, into the risk score.ConclusionWith these two simple innovations, we can move past the conflicts and controversy and on to utilizing privacysensitive mobile contact tracing to improve the efficacy of public health measures -thereby saving lives and unnecessary suffering -while respecting civil liberty.", [["public health measures", "TREATMENT", 254, 276], ["two", "OBSERVATION_MODIFIER", 96, 99], ["simple", "OBSERVATION_MODIFIER", 100, 106], ["innovations", "OBSERVATION", 107, 118]]], ["The technology can assist the contact tracing process, but should not be dictating it or replacing the human relationship of the patient and the health professionals performing interviews and care.", [["human", "ORGANISM", 103, 108], ["patient", "ORGANISM", 129, 136], ["human", "SPECIES", 103, 108], ["patient", "SPECIES", 129, 136], ["human", "SPECIES", 103, 108]]]]}